0.35228625.11157409.html.plaintext.txt	0	Apolipoprotein E Genotypes Incidence Alzheimers Disease among Persons Aged 75 Years Older Variation Use Antihypertensive Medication Zhenchao Guo Laura Fratiglioni Matti Viitanen Lars Lannfelt Hans Basun Johan Fastbom Bengt Winblad
0.35228625.11157409.html.plaintext.txt	1	From Stockholm Gerontology Research Center Department Geriatric Medicine Karolinska Institute Stockholm Sweden
0.35228625.11157409.html.plaintext.txt	2	ABSTRACT TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES The authors examined impact apolipoprotein E APOE4 allele Alzheimers disease incidence relation use antihypertensive medication
0.35228625.11157409.html.plaintext.txt	3	A population based Kungsholmen Project cohort 985 nondemented Swedish subjects aged 75 years followed average 3 years 1990 1992 164 dementia 122 Alzheimers disease cases identified
0.35228625.11157409.html.plaintext.txt	4	Compared 33 APOE4 allele increased risk developing dementia relative risk RR 1
0.35228625.11157409.html.plaintext.txt	5	5 95 confidence interval CI 1
0.35228625.11157409.html.plaintext.txt	6	1 Alzheimers disease RR 1
0.35228625.11157409.html.plaintext.txt	7	Subjects using antihypertensive medication baseline n 432 80 used diuretics decreased risk dementia RR 0
0.35228625.11157409.html.plaintext.txt	8	9 Alzheimers disease RR 0
0.35228625.11157409.html.plaintext.txt	9	8 adjustment several variables including APOE
0.35228625.11157409.html.plaintext.txt	10	The effect antihypertensive medication use pronounced among 4 carriers
0.35228625.11157409.html.plaintext.txt	11	For using antihypertensive medication relative risks dementia Alzheimers disease carriers 2
0.35228625.11157409.html.plaintext.txt	12	The corresponding relative risks using antihypertensive medication 0
0.35228625.11157409.html.plaintext.txt	13	The APOE4 allele important predictor dementia Alzheimers disease incidence
0.35228625.11157409.html.plaintext.txt	14	Further studies needed clarify whether use antihypertensive medication especially diuretics modifies effect allele
0.35228625.11157409.html.plaintext.txt	15	Alzheimer disease apolipoproteins E dementia diuretics genotype incidence
0.35228625.11157409.html.plaintext.txt	16	Abbreviations APOE apolipoprotein E genotype ATC Anatomical Therapeutic Chemical CI confidence interval MMSE Mini Mental State Examination RR relative risk
0.35228625.11157409.html.plaintext.txt	17	INTRODUCTION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Increasing evidence indicates apolipoprotein E APOE4 allele major genetic risk factor late onset Alzheimers disease 1 2
0.35228625.11157409.html.plaintext.txt	18	An increased frequency 4 allele consistently found familial sporadic Alzheimers disease cases different ethnic samples 3 17
0.35228625.11157409.html.plaintext.txt	19	APOE4 related global cognitive decline general elderly population 18 21 also increases risk developing Alzheimers disease memory impaired persons 22 23
0.35228625.11157409.html.plaintext.txt	20	A community based prospective study provided strong evidence supporting APOE4 allele risk factor Alzheimers disease also suggested previous family case control studies may overestimated contribution 24
0.35228625.11157409.html.plaintext.txt	21	Indeed 4 alone neither necessary sufficient development disease 11 considerable proportion 4 carriers escape disease 9
0.35228625.11157409.html.plaintext.txt	22	Several studies also noted lack significant association 4 Alzheimers disease 25 26
0.35228625.11157409.html.plaintext.txt	23	A recent study 27 found evidence supporting previous view APOE4 allele significant risk factor Alzheimers disease among African Americans Hispanics
0.35228625.11157409.html.plaintext.txt	24	It argued effect APOE4 may mediated genetic factors may modified environmental exposures 28 29
0.35228625.11157409.html.plaintext.txt	25	The Kungsholmen Project community based longitudinal study aging dementia people aged 75 years older 30
0.35228625.11157409.html.plaintext.txt	26	In previous analysis found use antihypertensive medication 80 percent diuretics related lower prevalence dementia decreased risk developing dementia slower cognitive decline among patients dementia 31
0.35228625.11157409.html.plaintext.txt	27	We therefore examined effect APOE4 allele incidence dementia Alzheimers disease considering use drugs
0.35228625.11157409.html.plaintext.txt	28	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Study population The study population consisted 1310 subjects free dementia baseline participated first follow Kungsholmen Project
0.35228625.11157409.html.plaintext.txt	29	Of subjects 985 APOE genotyping included analysis
0.35228625.11157409.html.plaintext.txt	30	The Kungsholmen Project longitudinal study aging dementia targeted inhabitants Kungsholmen district Stockholm Sweden aged 75 years older October 1 1987 30
0.35228625.11157409.html.plaintext.txt	31	To detect prevalent cases dementia baseline Mini Mental State Examination MMSE administered 1810 participants 32
0.35228625.11157409.html.plaintext.txt	32	Those MMSE score 24 n 314 random sample subjects MMSE score 24 n 354 examined clinically 33
0.35228625.11157409.html.plaintext.txt	33	Of 1475 baseline participants free dementia diagnosed means two phase design 174 excluded follow refused participate moved away Stockholm
0.35228625.11157409.html.plaintext.txt	34	Thus 1301 subjects remained follow assessment incident dementia cases 1301 subjects 985 agreed provide blood sample APOE genotyping
0.35228625.11157409.html.plaintext.txt	35	Identification dementia Of 985 subjects provided blood sample 840 administered comprehensive clinical examination November 1990 April 1992
0.35228625.11157409.html.plaintext.txt	36	A total 145 subjects died follow examination medical records death certificates subjects reviewed physicians
0.35228625.11157409.html.plaintext.txt	37	Diagnostic Statistical Manual Mental Disorders third edition revised diagnostic criteria 34 used define dementia
0.35228625.11157409.html.plaintext.txt	38	A diagnosis Alzheimers disease requires gradual onset progressive deterioration lack specific causes dementia
0.35228625.11157409.html.plaintext.txt	39	Our criteria identifying Alzheimers disease similar used National Institute Neurological Communicative Disorders Stroke Alzheimers Disease Related Disorders Association NINCDS ADRDA 35 probable Alzheimers disease
0.35228625.11157409.html.plaintext.txt	40	Three steps used diagnosis
0.35228625.11157409.html.plaintext.txt	41	First examining physician made preliminary diagnosis
0.35228625.11157409.html.plaintext.txt	42	Second cases reviewed independently neurologist second preliminary diagnosis made
0.35228625.11157409.html.plaintext.txt	43	In event agreement first second diagnoses second diagnosis considered final event disagreement third opinion requested concordant diagnosis accepted
0.35228625.11157409.html.plaintext.txt	44	Details clinical examination diagnostic procedure primary results data age sex specific incidence dementia presented elsewhere 36
0.35228625.11157409.html.plaintext.txt	45	Data collection The baseline examination conducted October 1987 December 1989
0.35228625.11157409.html.plaintext.txt	46	Arterial blood pressure measured using mercury sphygmomanometer subject seated position 5 minute rest 37
0.35228625.11157409.html.plaintext.txt	47	A standard polymerase chain reaction procedure used APOE genotyping 38 39 DNA prepared peripheral blood samples
0.35228625.11157409.html.plaintext.txt	48	Information regarding medical history participant derived computerized inpatient register covers hospitals Stockholm area
0.35228625.11157409.html.plaintext.txt	49	Heart disease myocardial infarction cardiac dysrhythmia heart failure stroke treated two potential confounders
0.35228625.11157409.html.plaintext.txt	50	Information drug use prescription nonprescription collected 2 weeks preceding baseline interview 40 41 drug containers prescription forms inspected verify information
0.35228625.11157409.html.plaintext.txt	51	Antihypertensive drugs included medicines potentially used lower blood pressure Anatomical Therapeutic Chemical ATC classification system 42 codes C02 C03 C07
0.35228625.11157409.html.plaintext.txt	52	For analysis first divided whole sample two groups according use antihypertensive medication
0.35228625.11157409.html.plaintext.txt	53	We divided whole sample two groups use diuretics ATC code C03 regardless antihypertensive medication
0.35228625.11157409.html.plaintext.txt	54	Finally sample divided three groups group receiving diuretic monotherapy group using antihypertensive medications ATC codes C02 C07 group using antihypertensive medications
0.35228625.11157409.html.plaintext.txt	55	Among participated first follow Kungsholmen Project n 1310 drugs used 20 subjects baseline included diuretics bendroflumethiazide hydrochlorothiazide furosemide spironolactone amiloride hydrochloride calcium channel antagonists verapamil nifedipine diltiazem ss blockers metoprolol tartrate propranolol hydrochloride alprenolol hydrochloride atenolol
0.35228625.11157409.html.plaintext.txt	56	Among bendroflumethiazide furosemide amiloride hydrochloride verapamil used 100 subjects
0.35228625.11157409.html.plaintext.txt	57	Statistical analysis Frequencies variables groups examined using chi square method
0.35228625.11157409.html.plaintext.txt	58	Incidence rates calculated dividing number events number person years follow
0.35228625.11157409.html.plaintext.txt	59	The follow time nondemented subjects determined date baseline interview date follow examination death
0.35228625.11157409.html.plaintext.txt	60	For demented subjects half time assumed
0.35228625.11157409.html.plaintext.txt	61	We used Cox proportional hazards regression model calculate relative risks developing dementia relation APOE genotypes according use antihypertensive medication
0.35228625.11157409.html.plaintext.txt	62	Because limited numbers treated 24 34 44 group labeled 4 compared 33
0.35228625.11157409.html.plaintext.txt	63	We considered age years sex female vs
0.35228625.11157409.html.plaintext.txt	64	8 years systolic blood pressure two dummy variables 130 160 compared 130 160 mmHg heart disease yes vs
0.35228625.11157409.html.plaintext.txt	65	covariates models
0.35228625.11157409.html.plaintext.txt	66	When age dementia onset used time scale Cox proportional hazards regression model suggested Korn et al
0.35228625.11157409.html.plaintext.txt	67	43 similar results obtained
0.35228625.11157409.html.plaintext.txt	68	Therefore paper presents results models follow time used
0.35228625.11157409.html.plaintext.txt	69	RESULTS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Among 1301 subjects participated follow evaluation 224 diagnosed demented 164 Alzheimers disease 41 vascular dementia 19 dementias
0.35228625.11157409.html.plaintext.txt	70	The mean follow interval cohort 36
0.35228625.11157409.html.plaintext.txt	71	7 months maximum 63
0.35228625.11157409.html.plaintext.txt	72	Use antihypertensive medication related significantly reduced risk dementias relative risk RR 0
0.35228625.11157409.html.plaintext.txt	73	7 95 percent confidence interval CI 0
0.35228625.11157409.html.plaintext.txt	74	9 Alzheimers disease RR 0
0.35228625.11157409.html.plaintext.txt	75	APOE genotyping available 75
0.35228625.11157409.html.plaintext.txt	76	7 percent n 985 1301 subjects
0.35228625.11157409.html.plaintext.txt	77	Among without APOE genotyping compared APOE genotyping slightly significant subjects became demented follow period dementias 19
0.35228625.11157409.html.plaintext.txt	78	4 percent Alzheimers disease 13
0.35228625.11157409.html.plaintext.txt	79	Among 985 subjects APOE genotyping available 162 dementia cases 122 Alzheimers disease 40 vascular dementias identified 3 year follow
0.35228625.11157409.html.plaintext.txt	80	Compared develop dementia subjects developed Alzheimers disease older aged 83
0.35228625.11157409.html.plaintext.txt	81	001 less education 8 years 69
0.35228625.11157409.html.plaintext.txt	82	001 likely female 88
0.35228625.11157409.html.plaintext.txt	83	001 likely stroke 18
0.35228625.11157409.html.plaintext.txt	84	001 less likely use antihypertensive medication 34
0.35228625.11157409.html.plaintext.txt	85	More Alzheimers disease patients without dementia carried least one APOE4 allele 36
0.35228625.11157409.html.plaintext.txt	86	All differences patients without dementia remained significant adjusted age using logistic regression
0.35228625.11157409.html.plaintext.txt	87	Subjects used antihypertensive medication baseline n 432 likely female p 0
0.35228625.11157409.html.plaintext.txt	88	002 history heart disease p 0
0.35228625.11157409.html.plaintext.txt	89	001 using antihypertensive medication table 1
0.35228625.11157409.html.plaintext.txt	90	There significant differences age education systolic blood pressure APOE genotypes two groups
0.35228625.11157409.html.plaintext.txt	91	The incidence dementias Alzheimers disease lower among subjects using versus using antihypertensive medication
0.35228625.11157409.html.plaintext.txt	92	The adjusted relative risks dementias Alzheimers disease associated use antihypertensive medication 0
0.35228625.11157409.html.plaintext.txt	93	Characteristics subjects according use antihypertensive medication community based population aged 75 years older first follow Kungsholmen Project Stockholm Sweden 1990 1992
0.35228625.11157409.html.plaintext.txt	94	The APOE4 allele compared 33 significantly increased risk dementia RR 1
0.35228625.11157409.html.plaintext.txt	95	1 Alzheimers disease RR 1
0.35228625.11157409.html.plaintext.txt	96	The population attributable risks 44 APOE4 12
0.35228625.11157409.html.plaintext.txt	97	9 percent dementias 16
0.35228625.11157409.html.plaintext.txt	98	4 percent Alzheimers disease
0.35228625.11157409.html.plaintext.txt	99	Among using antihypertensive medication 4 carriers twofold higher risk dementia Alzheimers disease compared 33 carriers table 2
0.35228625.11157409.html.plaintext.txt	100	Carriers 2 allele lower risk dementia finding significant
0.35228625.11157409.html.plaintext.txt	101	Among used antihypertensive medication significant difference found incidence dementia Alzheimers disease 4 carriers 33 carriers table 2
0.35228625.11157409.html.plaintext.txt	102	Incidence number cases relative risks RR 95 confidence intervals CI dementias according apolipoprotein E genotypes use antihypertensive medication first follow Kungsholmen Project Stockholm Sweden 1990 1992
0.35228625.11157409.html.plaintext.txt	103	The simultaneous effect APOE4 antihypertensive medication examined considering reference group persons carry 4 allele use antihypertensive medication table 3
0.35228625.11157409.html.plaintext.txt	104	The risk dementia Alzheimers disease associated APOE4 allele differed according use antihypertensive medication
0.35228625.11157409.html.plaintext.txt	105	We divided entire sample three groups according APOE genotypes
0.35228625.11157409.html.plaintext.txt	106	A significantly reduced risk dementia associated use antihypertensive medication found APOE4 carriers relative risks 0
0.35228625.11157409.html.plaintext.txt	107	Relative risks RR 95 confidence intervals CI dementia according apolipoprotein E 4 allele use antihypertensive medication first follow Kungsholmen Project Stockholm Sweden 1990 1992
0.35228625.11157409.html.plaintext.txt	108	The analyses performed subjects baseline MMSE score 23 n 938 participated follow clinical examination n 840
0.35228625.11157409.html.plaintext.txt	109	All analyses produced similar results concerning relation APOE4 dementia
0.35228625.11157409.html.plaintext.txt	110	There significant differences baseline use estrogens nonsteroidal anti inflammatory drugs salicylic acid agents used use antihypertensive medication
0.35228625.11157409.html.plaintext.txt	111	Inclusion variables drugs analyses change results significantly
0.35228625.11157409.html.plaintext.txt	112	Among subjects using antihypertensive medication 80 percent used diuretics 55 percent diuretic monotherapy
0.35228625.11157409.html.plaintext.txt	113	Among using antihypertensive drugs 50 percent used calcium channel antagonists 45 percent used ss blockers
0.35228625.11157409.html.plaintext.txt	114	Table 4 shows results population divided two groups use diuretics regardless antihypertensive medications
0.35228625.11157409.html.plaintext.txt	115	The population divided three groups group receiving diuretic monotherapy group using antihypertensive medications group using antihypertensive medication
0.35228625.11157409.html.plaintext.txt	116	APOE4 carriers diuretic monotherapy n 242 relative risks 0
0.35228625.11157409.html.plaintext.txt	117	9 Alzheimers disease carriers using antihypertensive medications n 190 relative risks 1
0.35228625.11157409.html.plaintext.txt	118	Relative risks RR 95 confidence intervals CI dementia according apolipoprotein E genotypes use diuretics first follow Kungsholmen Project Stockholm Sweden 1990 1992
0.35228625.11157409.html.plaintext.txt	119	DISCUSSION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES In large community based cohort persons aged 75 years older significantly increased incidence dementia Alzheimers disease associated APOE4 allele among using antihypertensive medication baseline increased incidence found among used antihypertensive medication
0.35228625.11157409.html.plaintext.txt	120	The latter group significantly decreased risk dementia Alzheimers disease
0.35228625.11157409.html.plaintext.txt	121	These results derived analyses age sex education systolic blood pressure heart disease stroke considered
0.35228625.11157409.html.plaintext.txt	122	Our study may shed new light relation APOE4 Alzheimers disease
0.35228625.11157409.html.plaintext.txt	123	First large scale prospective data general population confirm link APOE4 Alzheimers disease
0.35228625.11157409.html.plaintext.txt	124	However estimated 12
0.35228625.11157409.html.plaintext.txt	125	9 percent incident dementia cases 16
0.35228625.11157409.html.plaintext.txt	126	4 percent Alzheimers disease cases could accounted 4 allele
0.35228625.11157409.html.plaintext.txt	127	This result similar recent study concluding 13
0.35228625.11157409.html.plaintext.txt	128	5 percent incident Alzheimers disease may explained 4 24
0.35228625.11157409.html.plaintext.txt	129	The lower population attributable risk could due decreased relative risk Alzheimers disease associated APOE4 allele age 70 years 45 46 lower frequency APOE4 allele old
0.35228625.11157409.html.plaintext.txt	130	In meta analysis risk Alzheimers disease associated APOE4 allele increased age 60 years 34 44 carriers age 70 years 24 carriers diminished thereafter 14
0.35228625.11157409.html.plaintext.txt	131	Second finding lack significant association 4 Alzheimers disease among using antihypertensive medication supports previous view effect APOE4 allele uniform modifiable suggested several studies 25 27
0.35228625.11157409.html.plaintext.txt	132	Third antihypertensive medication use significantly decreased incidence dementia effect pronounced subjects APOE4 allele
0.35228625.11157409.html.plaintext.txt	133	The probable explanation results antihypertensive medication significantly reduce number cerebrovascular events lesions believed important pathogenesis Alzheimers disease vascular dementia may interaction cerebrovascular disease APOE4 dementia 47 48
0.35228625.11157409.html.plaintext.txt	134	A recent clinical trial showed antihypertensive treatment reduced incidence dementia 50 percent 49
0.35228625.11157409.html.plaintext.txt	135	It unlikely lower risk associated use antihypertensive medication due potential protective effect 2 allele 50 found differences frequencies APOE genotypes two groups
0.35228625.11157409.html.plaintext.txt	136	If assume 4 carriers using antihypertensive medication risk Alzheimers disease 4 carriers using antihypertensive medication would difference incidence Alzheimers disease two groups
0.35228625.11157409.html.plaintext.txt	137	Subjects use antihypertensive medication may differ many aspects including genetic factors use drugs
0.35228625.11157409.html.plaintext.txt	138	Use drugs may marker unknown factor factors modify effect APOE4 thereby reduce incidence Alzheimers disease
0.35228625.11157409.html.plaintext.txt	139	However significant differences baseline use estrogens nonsteroidal anti inflammatory drugs salicylic acid agents use antihypertensive medication
0.35228625.11157409.html.plaintext.txt	140	We also examined several drugs including cardiovascular agents find drugs could account results
0.35228625.11157409.html.plaintext.txt	141	In study diagnosis dementia based clinical data
0.35228625.11157409.html.plaintext.txt	142	No neuroimaging andor pathologic data available diagnosis dementia Alzheimers disease
0.35228625.11157409.html.plaintext.txt	143	We could distinguish definite Alzheimers disease probable Alzheimers disease
0.35228625.11157409.html.plaintext.txt	144	Misclassification dementia dementia types may occurred leading decreased power detecting small effects
0.35228625.11157409.html.plaintext.txt	145	However unlikely differential misclassification occurred
0.35228625.11157409.html.plaintext.txt	146	In fact classified Alzheimers disease patients non Alzheimers disease patients group used antihypertensive medication likely heart disease stroke would expected excess non Alzheimers disease cases associated 4 group
0.35228625.11157409.html.plaintext.txt	147	However case
0.35228625.11157409.html.plaintext.txt	148	Importantly results consistent dementias Alzheimers disease
0.35228625.11157409.html.plaintext.txt	149	The first limitation study 24 percent eligible subjects undergo APOE genotyping
0.35228625.11157409.html.plaintext.txt	150	Although dropout rate lower study previous studies caution necessary interpreting results
0.35228625.11157409.html.plaintext.txt	151	However significant difference cumulative incidence dementia Alzheimers disease without APOE genotyping
0.35228625.11157409.html.plaintext.txt	152	Also among subjects without APOE genotyping use antihypertensive medication associated lower incidence dementia Alzheimers disease although finding significant
0.35228625.11157409.html.plaintext.txt	153	The second limitation use two phase design initial survey prevalent cases
0.35228625.11157409.html.plaintext.txt	154	We estimated 26 patients might missing screening test 51 thereby possibly included cohort 1301 participants follow assessment
0.35228625.11157409.html.plaintext.txt	155	This problem may led overestimation total incidence dementia
0.35228625.11157409.html.plaintext.txt	156	However reason think may significantly biased results relation APOE4 Alzheimers disease
0.35228625.11157409.html.plaintext.txt	157	The third limitation groups using antihypertensive medication relatively small
0.35228625.11157409.html.plaintext.txt	158	This problem might reduced power detect difference risk 33 4 resulted wide range confidence intervals occurred
0.35228625.11157409.html.plaintext.txt	159	Some confidence intervals overlapped 4 carriers use antihypertensive medication different references used table 2
0.35228625.11157409.html.plaintext.txt	160	However little overlap reference used tables 3 4
0.35228625.11157409.html.plaintext.txt	161	Furthermore among using antihypertensive medication 80 percent used diuretics
0.35228625.11157409.html.plaintext.txt	162	Although results associated use antihypertensive medication mostly due use diuretics similar trend dementias also found use antihypertensive medications
0.35228625.11157409.html.plaintext.txt	163	However seemed use antihypertensive medications mainly affected relation APOE4 vascular dementias
0.35228625.11157409.html.plaintext.txt	164	Alternatively finding could due misclassification types dementia group using antihypertensive drugs
0.35228625.11157409.html.plaintext.txt	165	The fourth limitation lack information duration drug use
0.35228625.11157409.html.plaintext.txt	166	Generally limitation may decreased power detect given association led underestimation association
0.35228625.11157409.html.plaintext.txt	167	We performed Cox regression analyses using age onset time scale produced similar results
0.35228625.11157409.html.plaintext.txt	168	Finally unlike clinical trial study designed specifically assess effects antihypertensive medication
0.35228625.11157409.html.plaintext.txt	169	In cohort group using antihypertensive medication may differed many ways group using antihypertensive medication
0.35228625.11157409.html.plaintext.txt	170	Although adjusted number variables including drugs reported protect Alzheimers disease cannot rule possibility results biased factors examine
0.35228625.11157409.html.plaintext.txt	171	In conclusion large scale prospective data support view APOE4 allele important risk factor late onset dementia Alzheimers disease
0.35228625.11157409.html.plaintext.txt	172	However allele may account less 20 percent incident cases people aged 75 years older
0.35228625.11157409.html.plaintext.txt	173	Furthermore significant association APOE4 allele dementia Alzheimers disease found among using antihypertensive medication 80 percent used diuretics
0.35228625.11157409.html.plaintext.txt	174	Use drugs related significantly reduced incidence dementia Alzheimers disease pronounced among APOE4 carriers
0.35228625.11157409.html.plaintext.txt	175	Further studies needed clarify whether drugs especially diuretics modify effect APOE4 allele
0.35228625.11157409.html.plaintext.txt	176	At time antihypertensive drugs prescribed treat prevent dementia
0.35228625.11157409.html.plaintext.txt	177	ACKNOWLEDGMENTS This study supported grants Swedish Medical Research Council Swedish Council Social Research Swedish Municipal Pension Institute National Corporation Swedish Pharmacies Fund Research Studies Health Economics Social Pharmaceutics Torsten Ragnar Soderbergs Foundation Foundation Medical Research Stiftelsen Hjalp till Medicin Forskning
0.35228625.11157409.html.plaintext.txt	178	The authors thank Kungsholmen Project workers collecting managing data
0.35228625.11157409.html.plaintext.txt	179	They also thank Lena Lilius Benita Engvall Inga Volkmann invaluable technical assistance
0.35228625.11157409.html.plaintext.txt	180	NOTES Reprint requests Dr
0.35228625.11157409.html.plaintext.txt	181	Zhenchao Guo Stockholm Gerontology Research Center Box 6401 S 113 82 Stockholm Sweden e mail Li
0.35228625.11157409.html.plaintext.txt	182	REFERENCES TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Breitner JCS Welsh KA
0.35228625.11157409.html.plaintext.txt	183	Genes recent developments epidemiology Alzheimers disease related dementia
0.35228625.11157409.html.plaintext.txt	184	Epidemiol Rev 19951739 47
0.35228625.11157409.html.plaintext.txt	185	ISIMedline Strittmatter WJ Roses AD
0.35228625.11157409.html.plaintext.txt	186	Apolipoprotein E Alzheimer disease
0.35228625.11157409.html.plaintext.txt	187	Proc Natl Acad Sci U S A 1995924725 7
0.35228625.11157409.html.plaintext.txt	188	Abstract Saunders AM Strittmatter WJ Schmechel D et al
0.35228625.11157409.html.plaintext.txt	189	Association apolipoprotein E allele 4 late onset familial sporadic Alzheimers disease
0.35228625.11157409.html.plaintext.txt	190	Abstract Poirier J Davignon J Bouthillier D et al
0.35228625.11157409.html.plaintext.txt	191	Apolipoprotein E polymorphism Alzheimers disease
0.35228625.11157409.html.plaintext.txt	192	ISIMedline Corder EH Saunders AM Strittmatter WJ et al
0.35228625.11157409.html.plaintext.txt	193	Gene dose apolipoprotein E type 4 allele risk Alzheimers disease late onset families
0.35228625.11157409.html.plaintext.txt	194	ISIMedline Yoshizawa T Yamakawa Kobayashi K Komatsuzaki Y et al
0.35228625.11157409.html.plaintext.txt	195	Dose dependent association apolipoprotein E allele 4 late onset sporadic Alzheimers disease
0.35228625.11157409.html.plaintext.txt	196	ISIMedline Kuusisto J Koivisto K Kervinen K et al
0.35228625.11157409.html.plaintext.txt	197	Association apolipoprotein E genotypes late onset Alzheimers disease population based study
0.35228625.11157409.html.plaintext.txt	198	AbstractFree Full Text Nalbantoglu J Gilfix BM Bertrand P et al
0.35228625.11157409.html.plaintext.txt	199	Predictive value apolipoprotein E genotyping Alzheimers disease results autopsy series analysis several combined studies
0.35228625.11157409.html.plaintext.txt	200	ISIMedline Mayers RH Schaefer EJ Wilson PWF et al
0.35228625.11157409.html.plaintext.txt	201	Apolipoprotein E 4 association dementia population based study Framingham Study
0.35228625.11157409.html.plaintext.txt	202	Abstract Mak YT Chiu H Woo J et al
0.35228625.11157409.html.plaintext.txt	203	Apolipoprotein E genotype Alzheimers disease Hong Kong elderly Chinese
0.35228625.11157409.html.plaintext.txt	204	Abstract Payami H Zareparsi S Montee KR et al
0.35228625.11157409.html.plaintext.txt	205	Gender difference apolipoprotein E associated risk familial Alzheimer disease possible clue higher incidence Alzheimer disease women
0.35228625.11157409.html.plaintext.txt	206	Am J Hum Genet 199658803 11
0.35228625.11157409.html.plaintext.txt	207	ISIMedline Bickeboller H Campion D Brice A et al
0.35228625.11157409.html.plaintext.txt	208	Apolipoprotein E Alzheimer disease genotype specific risks age sex
0.35228625.11157409.html.plaintext.txt	209	Am J Hum Genet 199760439 46
0.35228625.11157409.html.plaintext.txt	210	ISIMedline Katzman R Zhang MY Chen PJ et al
0.35228625.11157409.html.plaintext.txt	211	Effects apolipoprotein E dementia aging Shanghai Survey Dementia
0.35228625.11157409.html.plaintext.txt	212	Abstract Farrer LA Cupples LA Haines JL et al
0.35228625.11157409.html.plaintext.txt	213	Effects age sex ethnicity association apolipoprotein E genotype Alzheimer disease meta analysis
0.35228625.11157409.html.plaintext.txt	214	Abstract Slooter AJC Cruts M Kalmijn S et al
0.35228625.11157409.html.plaintext.txt	215	Risk estimates dementia apolipoprotein E genotypes population based incidence study Rotterdam Study
0.35228625.11157409.html.plaintext.txt	216	AbstractFree Full Text Quiroga P Calvo C Albala C et al
0.35228625.11157409.html.plaintext.txt	217	Apolipoprotein E polymorphism elderly Chilean people Alzheimers disease
0.35228625.11157409.html.plaintext.txt	218	Neuroepidemiology 19991848 52
0.35228625.11157409.html.plaintext.txt	219	ISIMedline Breitner JCS Wyse BW Anthony JC et al
0.35228625.11157409.html.plaintext.txt	220	APOE 4 count predicts age prevalence AD increases declines Cache County Study
0.35228625.11157409.html.plaintext.txt	221	AbstractFree Full Text Feskens EJM Havekes LM Kalmijn S et al
0.35228625.11157409.html.plaintext.txt	222	Apolipoprotein 4 allele cognitive decline elderly men
0.35228625.11157409.html.plaintext.txt	223	AbstractFree Full Text Hyman BT Gomez Isla T Briggs M et al
0.35228625.11157409.html.plaintext.txt	224	Apolipoprotein E cognitive change elderly population
0.35228625.11157409.html.plaintext.txt	225	Medline Yaffe K Cauley J Sands L et al
0.35228625.11157409.html.plaintext.txt	226	Apolipoprotein E phenotype cognitive decline prospective study elderly community women
0.35228625.11157409.html.plaintext.txt	227	Arch Neurol 1997541110 14
0.35228625.11157409.html.plaintext.txt	228	Abstract Jonker C Schmand B Lindeboom J et al
0.35228625.11157409.html.plaintext.txt	229	Association apolipoprotein E 4 rate cognitive decline community dwelling elderly individuals without dementia
0.35228625.11157409.html.plaintext.txt	230	AbstractFree Full Text Petersen RC Smith GE Ivnik RJ et al
0.35228625.11157409.html.plaintext.txt	231	Apolipoprotein E status predictor development Alzheimers disease memory impaired individuals
0.35228625.11157409.html.plaintext.txt	232	Abstract Tierney MC Szalai JP Snow WG et al
0.35228625.11157409.html.plaintext.txt	233	A prospective study clinical utility ApoE genotype prediction outcome patients memory impairment
0.35228625.11157409.html.plaintext.txt	234	Abstract Evans DA Beckett LA Field TS et al
0.35228625.11157409.html.plaintext.txt	235	Apolipoprotein E 4 incidence Alzheimers disease community population older persons
0.35228625.11157409.html.plaintext.txt	236	Abstract Sobel E Louhija J Sulkava R et al
0.35228625.11157409.html.plaintext.txt	237	Lack association apolipoprotein E allele 4 late onset Alzheimers disease among Finnish centenarians
0.35228625.11157409.html.plaintext.txt	238	Abstract Osuntokun BO Sahota A Ogunniyi AO et al
0.35228625.11157409.html.plaintext.txt	239	Lack association apolipoprotein E epsilon 4 Alzheimers disease elderly Nigerians
0.35228625.11157409.html.plaintext.txt	240	ISIMedline Tang MX Stern Y Marder K et al
0.35228625.11157409.html.plaintext.txt	241	The APOE 4 allele risk Alzheimer disease among African Americans Whites Hispanics
0.35228625.11157409.html.plaintext.txt	242	AbstractFree Full Text Jarvik GP Larson EB Goddard K et al
0.35228625.11157409.html.plaintext.txt	243	Influence apolipoprotein E genotype transmission Alzheimer disease community based sample
0.35228625.11157409.html.plaintext.txt	244	Am J Hum Genet 199658191 200
0.35228625.11157409.html.plaintext.txt	245	ISIMedline Mui S Briggs M Chung H et al
0.35228625.11157409.html.plaintext.txt	246	A newly identified polymorphism apolipoprotein E enhancer gene region associated Alzheimers disease strongly 4 allele
0.35228625.11157409.html.plaintext.txt	247	Abstract Fratiglioni L Viitanen M Bockman L et al
0.35228625.11157409.html.plaintext.txt	248	Occurrence dementia advanced age study design Kungsholmen Project
0.35228625.11157409.html.plaintext.txt	249	Neuroepidemiology 199211suppl 129 36
0.35228625.11157409.html.plaintext.txt	250	Guo Z Fratiglioni L Zhu L et al
0.35228625.11157409.html.plaintext.txt	251	Occurrence progression dementia community population aged 75 years older relationship antihypertensive medication use
0.35228625.11157409.html.plaintext.txt	252	AbstractFree Full Text Folstein MF Folstein SE McHugh PR
0.35228625.11157409.html.plaintext.txt	253	Mini mental state practical method grading cognitive state patients clinician
0.35228625.11157409.html.plaintext.txt	254	J Psychiatr Res 197512189 98
0.35228625.11157409.html.plaintext.txt	255	ISIMedline Fratiglioni L Grut M Forsell Y et al
0.35228625.11157409.html.plaintext.txt	256	Prevalence Alzheimers disease dementias elderly urban population relationship age sex education
0.35228625.11157409.html.plaintext.txt	257	Abstract American Psychiatric Association
0.35228625.11157409.html.plaintext.txt	258	Diagnostic statistical manual mental disorders DSM III R
0.35228625.11157409.html.plaintext.txt	259	Washington DC American Psychiatric Association 1987
0.35228625.11157409.html.plaintext.txt	260	McKhann G Drachman D Folstein M et al
0.35228625.11157409.html.plaintext.txt	261	Clinical diagnosis Alzheimers disease report NINCDS ADRDA Work Group auspices Department Health Human Services Task Force Alzheimers disease
0.35228625.11157409.html.plaintext.txt	262	Abstract Fratiglioni L Viitanen M von Strauss E et al
0.35228625.11157409.html.plaintext.txt	263	Very old women highest risk dementia Alzheimers disease incidence data Kungsholmen Project Stockholm
0.35228625.11157409.html.plaintext.txt	264	Abstract Guo Z Fratiglioni L Winblad B et al
0.35228625.11157409.html.plaintext.txt	265	Blood pressure performance Mini Mental State Examination old cross sectional longitudinal data Kungsholmen Project
0.35228625.11157409.html.plaintext.txt	266	Am J Epidemiol 19971451106 13
0.35228625.11157409.html.plaintext.txt	267	Abstract Wenham PR Price WH Blundell G
0.35228625.11157409.html.plaintext.txt	268	Apolipoprotein E genotyping one stage PCR
0.35228625.11157409.html.plaintext.txt	269	Medline Basun H Corder EH Guo Z et al
0.35228625.11157409.html.plaintext.txt	270	Apolipoprotein E polymorphism stroke population sample aged 75 years
0.35228625.11157409.html.plaintext.txt	271	AbstractFree Full Text Wills P Fastbom J Claesson CB et al
0.35228625.11157409.html.plaintext.txt	272	Use cardiovascular drugs older Swedish population
0.35228625.11157409.html.plaintext.txt	273	J Am Geriatr Soc 19964454 60
0.35228625.11157409.html.plaintext.txt	274	ISIMedline Guo Z Wills P Viitanen M et al
0.35228625.11157409.html.plaintext.txt	275	Cognitive impairment drug use risk hip fracture old prospective study
0.35228625.11157409.html.plaintext.txt	276	Am J Epidemiol 1998148887 92
0.35228625.11157409.html.plaintext.txt	277	Abstract Guidelines ATC classification
0.35228625.11157409.html.plaintext.txt	278	Uppsala Sweden Nordic Council Medicines 1985
0.35228625.11157409.html.plaintext.txt	279	Korn EL Graubard BI Midthune D
0.35228625.11157409.html.plaintext.txt	280	Time event analysis longitudinal follow survey choice time scale
0.35228625.11157409.html.plaintext.txt	281	Am J Epidemiol 199714572 80
0.35228625.11157409.html.plaintext.txt	282	Abstract Kelsey JL Thompson WD Evans AS
0.35228625.11157409.html.plaintext.txt	283	Methods observational epidemiology
0.35228625.11157409.html.plaintext.txt	284	New York NY Oxford University Press 1986
0.35228625.11157409.html.plaintext.txt	285	Rebeck GW Perls TT West HL et al
0.35228625.11157409.html.plaintext.txt	286	Reduced apolipoprotein 4 allele frequency oldest old Alzheimers patients cognitively normal individuals
0.35228625.11157409.html.plaintext.txt	287	Abstract Blaker D Haines JL Rodes L et al
0.35228625.11157409.html.plaintext.txt	288	ApoE 4 age onset Alzheimer disease NIMH genetic initiative
0.35228625.11157409.html.plaintext.txt	289	Abstract Kalmijn S Feskens EJM Launer LJ et al
0.35228625.11157409.html.plaintext.txt	290	Cerebrovascular disease apolipoprotein e4 allele cognitive decline community based study elderly men
0.35228625.11157409.html.plaintext.txt	291	AbstractFree Full Text Zhu L Fratiglioni L Guo Z et al
0.35228625.11157409.html.plaintext.txt	292	Incidence dementia relation stroke apolipoprotein E 4 allele old findings population based longitudinal study
0.35228625.11157409.html.plaintext.txt	293	AbstractFree Full Text Forette F Seux ML Staessen JA et al
0.35228625.11157409.html.plaintext.txt	294	Prevention dementia randomised double blind placebo controlled systolic hypertension Europe Syst Eur trial
0.35228625.11157409.html.plaintext.txt	295	ISIMedline Corder EH Saunders AM Risch NJ et al
0.35228625.11157409.html.plaintext.txt	296	Protective effect apolipoprotein E type 2 allele late onset Alzheimer disease
0.35228625.11157409.html.plaintext.txt	297	Guo Z Viitanen M Fratiglioni L et al
0.35228625.11157409.html.plaintext.txt	298	Low blood pressure dementia elderly people Kungsholmen project
0.35228625.11157409.html.plaintext.txt	299	AbstractFree Full Text Received publication July 8 1999
0.35228625.11157409.html.plaintext.txt	300	Accepted publication March 31 2000
0.41210636.11136203.html.plaintext.txt	0	Genetic risk Alzheimers disease advising relatives M
0.41210636.11136203.html.plaintext.txt	1	Department Psychological Medicine University Wales College Medicine Cardiff
0.41210636.11136203.html.plaintext.txt	2	Institute Psychiatry London
0.41210636.11136203.html.plaintext.txt	3	Department Psychological Medicine University Wales College Medicine Cardiff
0.41210636.11136203.html.plaintext.txt	4	Liddell Department Psychological Medicine University Wales College Medicine Heath Park Cardiff CF14 4xN UK
0.41210636.11136203.html.plaintext.txt	5	ABSTRACT TOP ABSTRACT INTRODUCTION AUTOSOMAL DOMINANT FAMILIAL
0.41210636.11136203.html.plaintext.txt	6	THE APOLIPOPROTEIN E EFFECT CLINICAL SIGNIFICANCE OF
0.41210636.11136203.html.plaintext.txt	7	RECOMMENDATIONS Clinical Implications
0.41210636.11136203.html.plaintext.txt	8	ACKNOWLEDGMENTS REFERENCES Background Clinicians increasingly asked relatives patients Alzheimers disease advise genetic risk developing Alzheimers disease later life
0.41210636.11136203.html.plaintext.txt	9	Many clinicians find difficult question answer
0.41210636.11136203.html.plaintext.txt	10	Aims To provide information old age psychiatrists wishing advise relatives risk developing Alzheimers disease
0.41210636.11136203.html.plaintext.txt	11	Method A selective review key literature genetic epidemiology Alzheimers disease
0.41210636.11136203.html.plaintext.txt	12	Results Currently DNA diagnosis attainable 70 families autosomal dominant Alzheimers disease
0.41210636.11136203.html.plaintext.txt	13	In first degree relatives cases risk increased three four fold relative controls one third realised average life span
0.41210636.11136203.html.plaintext.txt	14	Apolipoprotein E genotyping cannot used predictive test confers minimal diagnostic benefit
0.41210636.11136203.html.plaintext.txt	15	Conclusions Pedigrees familial Alzheimers disease referred Regional Centre Medical Genetics
0.41210636.11136203.html.plaintext.txt	16	Accurate risk prediction possible vast majority pedigrees Alzheimers disease although possible psychiatrist give rough estimate risk reasonably couched reassuring terms
0.41210636.11136203.html.plaintext.txt	17	INTRODUCTION TOP ABSTRACT INTRODUCTION AUTOSOMAL DOMINANT FAMILIAL
0.41210636.11136203.html.plaintext.txt	18	THE APOLIPOPROTEIN E EFFECT CLINICAL SIGNIFICANCE OF
0.41210636.11136203.html.plaintext.txt	19	RECOMMENDATIONS Clinical Implications
0.41210636.11136203.html.plaintext.txt	20	ACKNOWLEDGMENTS REFERENCES Eighty per cent typical old age psychiatrists time spent assessment management dementia
0.41210636.11136203.html.plaintext.txt	21	Most due Alzheimers disease combination Alzheimers disease vascular dementia
0.41210636.11136203.html.plaintext.txt	22	Because increased public awareness advances genetics efforts advocacy groups explaining latest research findings relatives people Alzheimers disease increasingly asking question What risk childrens risk developing Alzheimers disease
0.41210636.11136203.html.plaintext.txt	23	The aim article summarise relevant research suggest ways answered
0.41210636.11136203.html.plaintext.txt	24	AUTOSOMAL DOMINANT FAMILIAL ALZHEIMERS DISEASE TOP ABSTRACT INTRODUCTION AUTOSOMAL DOMINANT FAMILIAL
0.41210636.11136203.html.plaintext.txt	25	THE APOLIPOPROTEIN E EFFECT CLINICAL SIGNIFICANCE OF
0.41210636.11136203.html.plaintext.txt	26	RECOMMENDATIONS Clinical Implications
0.41210636.11136203.html.plaintext.txt	27	ACKNOWLEDGMENTS REFERENCES Most highly publicised advances genetics Alzheimers disease concerned rare families autosomal dominant forms disease called familial Alzheimers disease FAD kindred 50 generation regardless gender succumb Alzheimers disease usually early mid life reviewed Selkoe 1999
0.41210636.11136203.html.plaintext.txt	28	The identification causative mutations within amyloid precursor protein APP presenilin genes PSEN1 PSEN2 probably overinflated publics perception role genes causing far common forms Alzheimers disease show autosomal dominant transmission
0.41210636.11136203.html.plaintext.txt	29	Yet important able recognise FAD possible offer kindreds definitive genetic counselling provided causative mutation identified
0.41210636.11136203.html.plaintext.txt	30	Furthermore study Campion et al 1999 suggests FAD may occur frequency around 40 per 100 000 persons risk implies 600 affected individuals found England Wales number suggests psychiatrist neurologist encounter individual FAD pedigree time working life
0.41210636.11136203.html.plaintext.txt	31	SUGGESTED APPROACH FOR HIGHLY FAMILIAL FORMS OF ALZHEIMERS DISEASE TOP ABSTRACT INTRODUCTION AUTOSOMAL DOMINANT FAMILIAL
0.41210636.11136203.html.plaintext.txt	32	THE APOLIPOPROTEIN E EFFECT CLINICAL SIGNIFICANCE OF
0.41210636.11136203.html.plaintext.txt	33	RECOMMENDATIONS Clinical Implications
0.41210636.11136203.html.plaintext.txt	34	ACKNOWLEDGMENTS REFERENCES The function psychiatrist straight forward
0.41210636.11136203.html.plaintext.txt	35	The first step confirm diagnosis actually one Alzheimers disease one often familial dementias Huntingtons disease frontal temporal dementias Creutzfeldt Jakob disease CJD cerebral autosomal dominant arteriopathy subcortical infarcts leukoencephalopathy CADASIL
0.41210636.11136203.html.plaintext.txt	36	Next clinician take detailed family history possible order try determine whether sufferer comes pedigree autosomal dominant FAD occurrence numerous individuals early onset disease 55 years several generations highly suggestive
0.41210636.11136203.html.plaintext.txt	37	The presence many affected individuals one generation may also raise suspicion forgotten early death causes might prevent manifestation disorder carriers disease gene
0.41210636.11136203.html.plaintext.txt	38	In practice recommend families containing three members history early onset Alzheimers disease occurring age 60 years request advice referred clinical geneticist
0.41210636.11136203.html.plaintext.txt	39	Some forms FAD linked PSEN2 mutations occur age 65 years psychiatrist low threshold discussing pedigree clinical geneticist
0.41210636.11136203.html.plaintext.txt	40	Predictive prenatal testing potentially feasible families FAD depend upon availability DNA least one affected individual order establish mutation causing disease family
0.41210636.11136203.html.plaintext.txt	41	It worth stating genetic counselling highly specialised area strongly recommended psychiatrists involve without appropriate training
0.41210636.11136203.html.plaintext.txt	42	The study Campion et al 1999 analysed DNA 34 families FAD obtained France causative mutations
0.41210636.11136203.html.plaintext.txt	43	Probably pathogenic mutations found PSEN1 gene 19 families mutations within APP gene another 5 mutations PSEN1 PSEN2 APP genes remaining 10 families
0.41210636.11136203.html.plaintext.txt	44	Thus individuals FAD pedigrees need informed 30 chance current state knowledge causative mutation found
0.41210636.11136203.html.plaintext.txt	45	If mutation found pedigree strongly suggestive autosomal dominant disorder geneticist may choose go search mutations genes associated similar conditions prion protein PrP CJD tau frontal temporal dementias example
0.41210636.11136203.html.plaintext.txt	46	Yet another factor consider one report apparent non penetrance PSEN1 mutation healthy 68 year old member FAD pedigree Rossor et al 1996
0.41210636.11136203.html.plaintext.txt	47	Notwithstanding caveats absence preventive treatment take predictive testing likely low case Huntingtons disease Binedell et al 1998
0.41210636.11136203.html.plaintext.txt	48	SUGGESTED APPROACH FOR NON MENDELIAN ALZHEIMERS DISEASE TOP ABSTRACT INTRODUCTION AUTOSOMAL DOMINANT FAMILIAL
0.41210636.11136203.html.plaintext.txt	49	THE APOLIPOPROTEIN E EFFECT CLINICAL SIGNIFICANCE OF
0.41210636.11136203.html.plaintext.txt	50	RECOMMENDATIONS Clinical Implications
0.41210636.11136203.html.plaintext.txt	51	ACKNOWLEDGMENTS REFERENCES The great majority cases Alzheimers disease result disease causing mutations single gene
0.41210636.11136203.html.plaintext.txt	52	Here inheritance follow simple Mendelian ratios appears reflect presence number different genetic risk factors together environmental factors
0.41210636.11136203.html.plaintext.txt	53	When faced someone worried risk developing Alzheimers disease often worth pointing risk developing Alzheimers disease provided live long enough
0.41210636.11136203.html.plaintext.txt	54	The large Rotterdam study suggests risk age 55 years developing dementia following 35 years 0
0.41210636.11136203.html.plaintext.txt	55	In study 73 dementia wholly partially attributable Alzheimers disease
0.41210636.11136203.html.plaintext.txt	56	The large continuing Framingham study yields somewhat lower lifetime risks Alzheimers disease age 65 years 6
0.41210636.11136203.html.plaintext.txt	57	3 men 12 women corresponding risk dementia 10
0.41210636.11136203.html.plaintext.txt	58	9 19 respectively Seshadri et al 1997
0.41210636.11136203.html.plaintext.txt	59	Many epidemiological studies suggest women increased risk Alzheimers disease
0.41210636.11136203.html.plaintext.txt	60	The reasons clear increased longevity compared men increased survival disease increase intrinsic vulnerability probably play part
0.41210636.11136203.html.plaintext.txt	61	Prevalence studies tell us dementia doubles every 5 years age 65 years age around 85 years time rate increase appears slow Heeren et al 1991 Skoog et al 1993 Ritchie Kildea 1995 Breitner et al 1999 von Strauss et al 1999
0.41210636.11136203.html.plaintext.txt	62	It likely slowing due old people living long dementia younger sufferers although also possible survivors late old age relatively resistant developing dementia Drachman 1994
0.41210636.11136203.html.plaintext.txt	63	Prevalence data summarised Table 1
0.41210636.11136203.html.plaintext.txt	64	View table Table 1 Prevalence dementia age Ritchie Kildea 1995 permission
0.41210636.11136203.html.plaintext.txt	65	In fact two nearly completely ascertained community based studies one Japan one The Netherlands found prevalence dementia centenarians high 70 Japanese 88 Dutch sample Asada et al 1996 Blansjaar et al 2000
0.41210636.11136203.html.plaintext.txt	66	Asada et al 1996 attributed 76 dementia Alzheimers disease demonstrated 6 month mortality rate 27 centenarians dementia whereas none non demented centenarians died
0.41210636.11136203.html.plaintext.txt	67	Thus prevalence figures dementia tell us many us risk developing dementia provided live long enough
0.41210636.11136203.html.plaintext.txt	68	This obviously simplistic people expect live mid 90s much reasonable question What chance developing Alzheimers disease age 85 years
0.41210636.11136203.html.plaintext.txt	69	Family studies Alzheimers disease go way towards allowing us answer question relatives affected individuals
0.41210636.11136203.html.plaintext.txt	70	FAMILY STUDIES AND RISK OF DEMENTIA TOP ABSTRACT INTRODUCTION AUTOSOMAL DOMINANT FAMILIAL
0.41210636.11136203.html.plaintext.txt	71	THE APOLIPOPROTEIN E EFFECT CLINICAL SIGNIFICANCE OF
0.41210636.11136203.html.plaintext.txt	72	RECOMMENDATIONS Clinical Implications
0.41210636.11136203.html.plaintext.txt	73	ACKNOWLEDGMENTS REFERENCES In 1980s early 1990s number family studies attempted identify inheritance pattern Alzheimers disease quantify risk first degree relatives families history Alzheimers disease comparison family members control individuals summarised McGuffin et al 1994
0.41210636.11136203.html.plaintext.txt	74	There also studies based representative community samples
0.41210636.11136203.html.plaintext.txt	75	Overall findings studies based memory clinics likely centres secondary referral suggest 30 48 probands Alzheimers disease history affected first degree relatives compared 13 19 controls
0.41210636.11136203.html.plaintext.txt	76	This translates 6 14 relatives patients Alzheimers disease history Alzheimers disease compared 3
0.41210636.11136203.html.plaintext.txt	77	5 7 first degree relatives healthy controls
0.41210636.11136203.html.plaintext.txt	78	Kaplan Meier life table analysis used studies infer cumulative risk dementia age 90 varies 30 50 compared 10 23 control relatives
0.41210636.11136203.html.plaintext.txt	79	However pointed Breitner owing competing causes death one third theoretical familial predisposition Alzheimers disease realised usual life span
0.41210636.11136203.html.plaintext.txt	80	This translates actual predicted risk developing Alzheimers disease first degree relatives probands Alzheimers disease 15 19 compared 5 controls Breitner et al 1988 Breitner 1991
0.41210636.11136203.html.plaintext.txt	81	The latest systematically ascertained twin studies heritability Alzheimers disease also tend support estimates familial risk derived family studies
0.41210636.11136203.html.plaintext.txt	82	Probandwise concordance rates 40 84 respectively seen fraternal identical twins Bergem et al 1997
0.41210636.11136203.html.plaintext.txt	83	Because fraternal twins genetically equivalent ordinary first degree relatives observed morbid risk developing Alzheimers disease similar estimated first degree relatives family studies
0.41210636.11136203.html.plaintext.txt	84	A study Silverman et al 1994 suggested large measure familial component risk relatives probands Alzheimers disease expended end ninth decade time risk similar controls
0.41210636.11136203.html.plaintext.txt	85	A number family history studies suggested familial factors prominent onset earlier McGuffin et al 1994
0.41210636.11136203.html.plaintext.txt	86	Thus much Alzheimers disease late old age may considered familial merely expression one ways ageing process manifested survivors late old age
0.41210636.11136203.html.plaintext.txt	87	The findings family studies used advise relatives broadest terms
0.41210636.11136203.html.plaintext.txt	88	One little say balance risk first degree relatives patients Alzheimers disease developed disorder time age 85 years increased threefold fourfold relative risk controls
0.41210636.11136203.html.plaintext.txt	89	This would seem translate risk developing Alzheimers disease one five one six although improvement risk one two still rather frightening
0.41210636.11136203.html.plaintext.txt	90	In order put risk better perspective help allay clients anxiety may preferable present risk estimates graphical form done Fig
0.41210636.11136203.html.plaintext.txt	91	If done clients see even 78 years age greatest risk actual predicted risk 3 cumulative risk half area curve fx Sx age 65 78 probably less 10
0.41210636.11136203.html.plaintext.txt	92	In experience many tell us reassuring partly worries getting Alzheimers disease fifties familial Alzheimers disease happens sixtiesseventies thus preventing enjoying retirement
0.41210636.11136203.html.plaintext.txt	93	View larger version 15K Fig
0.41210636.11136203.html.plaintext.txt	94	1 fx represents probability hypothetical relative patient Alzheimers disease developing Alzheimers disease age x absence competing form mortality
0.41210636.11136203.html.plaintext.txt	95	Sx represents actuarial probability surviving age x
0.41210636.11136203.html.plaintext.txt	96	The product fx Sx represents probability relative surviving age x developing Alzheimers disease
0.41210636.11136203.html.plaintext.txt	97	Adapted Breitner et al 1988
0.41210636.11136203.html.plaintext.txt	98	In case patients Alzheimers disease became demented late old age say 80s relatives probably run 30 50 risk developing dementia anyone else lives age 90 years beyond
0.41210636.11136203.html.plaintext.txt	99	Of course possible genes confer longevity may also increase risk developing Alzheimers disease
0.41210636.11136203.html.plaintext.txt	100	Like disorders reflect combined action several genes risk relatives drops rapidly degree genetic relatedness falls
0.41210636.11136203.html.plaintext.txt	101	Data limited risk second degree relatives grand children probably less twice population levels Heston et al 1981
0.41210636.11136203.html.plaintext.txt	102	THE APOLIPOPROTEIN E EFFECT TOP ABSTRACT INTRODUCTION AUTOSOMAL DOMINANT FAMILIAL
0.41210636.11136203.html.plaintext.txt	103	THE APOLIPOPROTEIN E EFFECT CLINICAL SIGNIFICANCE OF
0.41210636.11136203.html.plaintext.txt	104	RECOMMENDATIONS Clinical Implications
0.41210636.11136203.html.plaintext.txt	105	ACKNOWLEDGMENTS REFERENCES Apolipoprotein E apoE protein roles lipid metabolism tissue repair
0.41210636.11136203.html.plaintext.txt	106	Its primary site biosynthesis liver second major site synthesis brain
0.41210636.11136203.html.plaintext.txt	107	Like APP synthesis apoE regulated nervous system damaged
0.41210636.11136203.html.plaintext.txt	108	There three commonly occurring polymorphic forms apoE known apoE2 apoE3 apoE4 originate APOE 2 APOE 3 APOE 4 alleles gene
0.41210636.11136203.html.plaintext.txt	109	The key observation originally made Strittmatter et al 1993 frequency APOE 4 patients Alzheimers disease namely 0
0.41210636.11136203.html.plaintext.txt	110	5 greater APOE 4 frequency 0
0.41210636.11136203.html.plaintext.txt	111	15 age matched population controls
0.41210636.11136203.html.plaintext.txt	112	Some studies suggest APOE 2 allele represented Alzheimers disease may inference protective reviewed Farrer et al 1997
0.41210636.11136203.html.plaintext.txt	113	Consistent idea finding healthy centenarians higher APOE 2 frequency general population controls Schachter et al 1994 Kehoe et al 1999
0.41210636.11136203.html.plaintext.txt	114	The APOE 4 association Alzheimers disease replicated many laboratories around world
0.41210636.11136203.html.plaintext.txt	115	A meta analysis summarised data demonstrated association found people European African American American Hispanic Japanese origin Farrer et al 1997
0.41210636.11136203.html.plaintext.txt	116	Exactly APOE 4 apoE4 protein influence pathophysiology Alzheimers disease still unknown bearers risk allele appear get Alzheimers disease earlier develop heavier amyloid burden
0.41210636.11136203.html.plaintext.txt	117	CLINICAL SIGNIFICANCE OF APOLIPOPROTEIN E GENOTYPE TOP ABSTRACT INTRODUCTION AUTOSOMAL DOMINANT FAMILIAL
0.41210636.11136203.html.plaintext.txt	118	THE APOLIPOPROTEIN E EFFECT CLINICAL SIGNIFICANCE OF
0.41210636.11136203.html.plaintext.txt	119	RECOMMENDATIONS Clinical Implications
0.41210636.11136203.html.plaintext.txt	120	ACKNOWLEDGMENTS REFERENCES Most studies show patients Alzheimers disease APOE 4 deteriorate rapidly without allele Corder et al 1995 Growdon et al 1996 Holmes et al 1996 Kurz et al 1996 Stern et al 1997
0.41210636.11136203.html.plaintext.txt	121	It possible APOE 4 marker poor response treatment acetylcholinesterese inhibitors particularly perhaps women Poirer et al 1995 Farlow et al 1998
0.41210636.11136203.html.plaintext.txt	122	The consensus opinion appears APOE genotype determines rather whether one succumbs Alzheimers disease
0.41210636.11136203.html.plaintext.txt	123	For example Cache County study Meyer et al 1998 Breitner et al 1999 elderly population almost 5000 found 22 cases Alzheimers disease among 141 APOE 4 homozygotes 118 among 1452 APOE 4 heterozygotes 80 among 3339 bearing APOE 4 allele
0.41210636.11136203.html.plaintext.txt	124	There appeared plateau groups survival curve beyond new cases Alzheimers disease seen
0.41210636.11136203.html.plaintext.txt	125	For APOE 4 homozygotes new cases seen age 84 years nine individuals surviving without Alzheimers disease combined total 37 years
0.41210636.11136203.html.plaintext.txt	126	For APOE 4 heterozygotes last onset Alzheimers disease 99 years four long term survivors
0.41210636.11136203.html.plaintext.txt	127	The last onset dementia individuals without APOE 4 allele age 95 years 31 surviving free dementia combined total 100 years thereafter
0.41210636.11136203.html.plaintext.txt	128	This differential effect APOE genotype age maximum risk Alzheimers disease also suggested APOE meta analysis Farrer et al 1997 also study Asada et al 1996
0.41210636.11136203.html.plaintext.txt	129	A Bayesian analysis used Seshadri et al 1995 relate APOE genotype lifetime risk developing Alzheimers disease
0.41210636.11136203.html.plaintext.txt	130	When estimates dementia risk derived Framingham study Seshadri et al 1997 substituted analysis somewhat lower risk estimates stratified according gender obtained Table 2
0.41210636.11136203.html.plaintext.txt	131	View table Table 2 Remaining lifetime risk age 65 years developing Alzheimers disease according gender apolipoprotein E APOE status
0.41210636.11136203.html.plaintext.txt	132	These estimates suggest 50 APOE 4 homozygotes develop Alzheimers disease within lifetime
0.41210636.11136203.html.plaintext.txt	133	These predictions agree well general population based study Henderson et al 1995 suggested risk developing dementia age 90 years APOE 4 homozygotes 50
0.41210636.11136203.html.plaintext.txt	134	POSSIBLE CLINICAL USES OF APOE GENOTYPING IN ALZHEIMERS DISEASE TOP ABSTRACT INTRODUCTION AUTOSOMAL DOMINANT FAMILIAL
0.41210636.11136203.html.plaintext.txt	135	THE APOLIPOPROTEIN E EFFECT CLINICAL SIGNIFICANCE OF
0.41210636.11136203.html.plaintext.txt	136	RECOMMENDATIONS Clinical Implications
0.41210636.11136203.html.plaintext.txt	137	ACKNOWLEDGMENTS REFERENCES From foregoing obvious knowledge persons APOE genotype little use predicting chances succumbing Alzheimers disease knowledge family history dementia
0.41210636.11136203.html.plaintext.txt	138	It seems even individuals APOE 4APOE 4 genotype average greater 50 chance escaping disease
0.41210636.11136203.html.plaintext.txt	139	Therefore APOE genotyping currently role predicting risk developing Alzheimers disease
0.41210636.11136203.html.plaintext.txt	140	Some claims made APOE genotyping may aid diagnosing Alzheimers disease
0.41210636.11136203.html.plaintext.txt	141	The study Mayeux et al 1998 suggested patients referred specialised assessment centres Alzheimers disease APOE genotyping used combination clinical criteria might improve specificity diagnosis
0.41210636.11136203.html.plaintext.txt	142	The data show whereas demonstration one APOE 4 allele person suspected suffering dementia slightly increases accuracy clinical diagnosis Alzheimers disease absence APOE 4 allele little value either endorsing refuting clinical diagnosis Alzheimers disease
0.41210636.11136203.html.plaintext.txt	143	Thus even selected group patients presumably high priori chance Alzheimers disease APOE genotyping seems confer negligible diagnostic benefit
0.41210636.11136203.html.plaintext.txt	144	GENETIC COUNSELLING AND ALZHEIMERS DISEASE TOP ABSTRACT INTRODUCTION AUTOSOMAL DOMINANT FAMILIAL
0.41210636.11136203.html.plaintext.txt	145	THE APOLIPOPROTEIN E EFFECT CLINICAL SIGNIFICANCE OF
0.41210636.11136203.html.plaintext.txt	146	RECOMMENDATIONS Clinical Implications
0.41210636.11136203.html.plaintext.txt	147	ACKNOWLEDGMENTS REFERENCES A number groups UK USA formulated consensus guidelines regarding genetic testing genetic counselling Alzheimers disease including Alzheimers Disease International Brodaty et al 1996 American College Medical GeneticsAmerican Society Human Genetics Working Group APOE Alzheimers Disease Farrer et al 1995 Alzheimers AssociationNational Institute Aging Davies et al 1998
0.41210636.11136203.html.plaintext.txt	148	In UK Alzheimers Disease Genetics Consortium meets regularly discuss issues surrounding clinical use genetics Alzheimers disease
0.41210636.11136203.html.plaintext.txt	149	These issues include whether test counsel patients issues regarding confidentiality consent research ethics concerns regarding insurance Tunstall Lovestone 1999
0.41210636.11136203.html.plaintext.txt	150	The various groups drawn following consensus guidelines generally one mind regard clinical response growing understanding genetics Alzheimers disease
0.41210636.11136203.html.plaintext.txt	151	Families evidence FAD indeed familial early onset dementia referred specialist centre UK regional genetics department
0.41210636.11136203.html.plaintext.txt	152	Counselling families follow process established Huntingtons disease
0.41210636.11136203.html.plaintext.txt	153	For late onset Alzheimers disease groups agreed role APOE genotyping prediction risk assessment
0.41210636.11136203.html.plaintext.txt	154	RECOMMENDATIONS TOP ABSTRACT INTRODUCTION AUTOSOMAL DOMINANT FAMILIAL
0.41210636.11136203.html.plaintext.txt	155	THE APOLIPOPROTEIN E EFFECT CLINICAL SIGNIFICANCE OF
0.41210636.11136203.html.plaintext.txt	156	RECOMMENDATIONS Clinical Implications
0.41210636.11136203.html.plaintext.txt	157	ACKNOWLEDGMENTS REFERENCES Apparent FAD Early onset familial dementia straight forward refer regional genetics department
0.41210636.11136203.html.plaintext.txt	158	Late onset Alzheimers disease For late onset Alzheimers disease wide agreement genetic test available genetic testing genetic counselling
0.41210636.11136203.html.plaintext.txt	159	The absence test mean relatives denied information opportunity discuss concerns
0.41210636.11136203.html.plaintext.txt	160	So asked I likely get Alzheimers disease relative patient late onset Alzheimers disease one answer In cases Alzheimers disease possible advise relatives risk broadest terms
0.41210636.11136203.html.plaintext.txt	161	Extrapolating family history studies possible say risk children region one five one six one prepared illustrate means easy understand graphical form
0.41210636.11136203.html.plaintext.txt	162	We believe permissible broad estimate risk imparted consultant doctor specifically trained genetic counselling
0.41210636.11136203.html.plaintext.txt	163	Occasionally psychiatrists encounter families several siblings affected late onset Alzheimers disease history dementia previous generations
0.41210636.11136203.html.plaintext.txt	164	Such families almost certainly exhibit high genetic loading reliable data whether extent risk increases number affected relatives although studies common disorders suggest likely case
0.41210636.11136203.html.plaintext.txt	165	However borne mind number affected relatives may well depend factors affecting longevity well degree genetic loading Alzheimers disease may advisable possible base discussion risk estimates increased several relatives affected late old age
0.41210636.11136203.html.plaintext.txt	166	There also preliminary evidence substantially increased risk offspring parents diagnosis Alzheimers disease Bird et al 1993
0.41210636.11136203.html.plaintext.txt	167	In pedigrees relatives request information may worth taking detailed family history consulting clinical geneticist
0.41210636.11136203.html.plaintext.txt	168	Clinical Implications Limitations TOP ABSTRACT INTRODUCTION AUTOSOMAL DOMINANT FAMILIAL
0.41210636.11136203.html.plaintext.txt	169	THE APOLIPOPROTEIN E EFFECT CLINICAL SIGNIFICANCE OF
0.41210636.11136203.html.plaintext.txt	170	RECOMMENDATIONS Clinical Implications
0.41210636.11136203.html.plaintext.txt	171	ACKNOWLEDGMENTS REFERENCES CLINICAL IMPLICATIONS The taking family history look cases dementia first degree relatives part every routine dementia diagnostic process
0.41210636.11136203.html.plaintext.txt	172	A clinician able recognise possible familial Alzheimers disease able refer family regional genetics centre members family request genetic counselling
0.41210636.11136203.html.plaintext.txt	173	A clinician able advise relatives less highly genetically loaded pedigrees Alzheimers disease risk broad terms seek advice regional genetics centre clarification required
0.41210636.11136203.html.plaintext.txt	174	LIMITATIONS In interests space clarity citation literature selective
0.41210636.11136203.html.plaintext.txt	175	Estimates risk instances approximate may need modified light future work
0.41210636.11136203.html.plaintext.txt	176	Few data relating vascular mixed forms dementia available
0.41210636.11136203.html.plaintext.txt	177	ACKNOWLEDGMENTS TOP ABSTRACT INTRODUCTION AUTOSOMAL DOMINANT FAMILIAL
0.41210636.11136203.html.plaintext.txt	178	THE APOLIPOPROTEIN E EFFECT CLINICAL SIGNIFICANCE OF
0.41210636.11136203.html.plaintext.txt	179	RECOMMENDATIONS Clinical Implications
0.41210636.11136203.html.plaintext.txt	180	ACKNOWLEDGMENTS REFERENCES Our work supported Medical Research Council cooperative group grant
0.41210636.11136203.html.plaintext.txt	181	REFERENCES TOP ABSTRACT INTRODUCTION AUTOSOMAL DOMINANT FAMILIAL
0.41210636.11136203.html.plaintext.txt	182	THE APOLIPOPROTEIN E EFFECT CLINICAL SIGNIFICANCE OF
0.41210636.11136203.html.plaintext.txt	183	RECOMMENDATIONS Clinical Implications
0.41210636.11136203.html.plaintext.txt	184	ACKNOWLEDGMENTS REFERENCES Asada T
0.41210636.11136203.html.plaintext.txt	185	et al 1996 Prevalence dementia distribution ApoE alleles Japanese centenarians almost complete survey Yamanashi Prefecture Japan
0.41210636.11136203.html.plaintext.txt	186	Journal American Geriatrics Society 44 151 155
0.41210636.11136203.html.plaintext.txt	187	1997 The role heredity late onset Alzheimers disease vascular dementia
0.41210636.11136203.html.plaintext.txt	188	Archives General Psychiatry 54 264 270
0.41210636.11136203.html.plaintext.txt	189	1998 Predictive testing Huntingtons disease I
0.41210636.11136203.html.plaintext.txt	190	Predictors uptake South Wales
0.41210636.11136203.html.plaintext.txt	191	Clinical Genetics 54 477 488
0.41210636.11136203.html.plaintext.txt	192	1993 Conjugal Alzheimers disease increased risk offspring Annals Neurology 34 396 399
0.41210636.11136203.html.plaintext.txt	193	2000 Prevalence dementia centenarians
0.41210636.11136203.html.plaintext.txt	194	International Journal Geriatric Society 15 219 225
0.41210636.11136203.html.plaintext.txt	195	1991 Clinical genetics genetic counselling Alzheimers disease
0.41210636.11136203.html.plaintext.txt	196	Annals Internal Medicine 115 601 606
0.41210636.11136203.html.plaintext.txt	197	et al 1988 Age dependent expression familial risk Alzheimers disease
0.41210636.11136203.html.plaintext.txt	198	American Journal Epidemiology 128 536 548
0.41210636.11136203.html.plaintext.txt	199	et al 1999 APOE 4 count predicts age prevalence AD increases declines Cache County Study
0.41210636.11136203.html.plaintext.txt	200	et al 1996 Medical scientific committee Alzheimers Disease International consensus statement predictive testing
0.41210636.11136203.html.plaintext.txt	201	Alzheimers Disease Associated Disorders 9 182 187
0.41210636.11136203.html.plaintext.txt	202	et al 1999 Early onset autosomal dominant Alzheimers disease prevalence genetic heterogeneity mutation spectrum
0.41210636.11136203.html.plaintext.txt	203	American Journal Human Genetics 65 664 670
0.41210636.11136203.html.plaintext.txt	204	et al 1995 Apolipoprotein E survival Alzheimers disease patients competing risks death Alzheimers disease
0.41210636.11136203.html.plaintext.txt	205	1994 If live long enough demented Neurology 44 1563 1565
0.41210636.11136203.html.plaintext.txt	206	et al 1998 Consensus report working group Molecular Biochemical Markers Alzheimers Disease
0.41210636.11136203.html.plaintext.txt	207	Neurobiology Aging 19 109 116
0.41210636.11136203.html.plaintext.txt	208	et al 1998 Treatment outcome tacrine therapy depends apolipoprotein genotype gender subjects Alzheimers disease
0.41210636.11136203.html.plaintext.txt	209	et al 1995 The American College Medical Genetics American Society Human Genetics statement use apolipoprotein E testing Alzheimers disease
0.41210636.11136203.html.plaintext.txt	210	Journal American Medical Association 274 1627 1629
0.41210636.11136203.html.plaintext.txt	211	et al 1997 Effects age sex ethnicity association apolipoprotein E genotype Alzheimers disease meta analysis
0.41210636.11136203.html.plaintext.txt	212	Journal American Medical Association 278 1349 1356
0.41210636.11136203.html.plaintext.txt	213	et al 1996 Apolipoprotein E genotype influence rates cognitive decline Alzheimers disease
0.41210636.11136203.html.plaintext.txt	214	et al 1991 Prevalence dementia oldest old Dutch community
0.41210636.11136203.html.plaintext.txt	215	Journal American Geriatrics Society 39 755 759
0.41210636.11136203.html.plaintext.txt	216	et al 1995 Apolipoprotein E allele 4 dementia cognitive decline population sample
0.41210636.11136203.html.plaintext.txt	217	et al 1981 Dementia Alzheimer type clinical genetics natural history associated conditions
0.41210636.11136203.html.plaintext.txt	218	Archives General Psychiatry 38 1085 1090
0.41210636.11136203.html.plaintext.txt	219	et al 1996 Apolipoprotein E clinical features late onset Alzheimers disease
0.41210636.11136203.html.plaintext.txt	220	Journal Neurology Neurosurgery Psychiatry 61 580 583
0.41210636.11136203.html.plaintext.txt	221	et al 1999 Variation DCP I encoding ACE associated susceptibility Alzheimers disease
0.41210636.11136203.html.plaintext.txt	222	et al 1996 Apolipoprotein E 4 allele cognitive decline deterioration everyday performance Alzheimers disease
0.41210636.11136203.html.plaintext.txt	223	et al 1998 Utility apolipoprotein E genotype diagnosis Alzheimers disease
0.41210636.11136203.html.plaintext.txt	224	New England Journal Medicine 338 506 511
0.41210636.11136203.html.plaintext.txt	225	et al 1998 APOE genotype predicts whether one predisposed develop Alzheimers disease
0.41210636.11136203.html.plaintext.txt	226	et al 1994 Seminars Psychiatric Genetics
0.41210636.11136203.html.plaintext.txt	227	et al 1998 Incidence risk dementia Rotterdam study
0.41210636.11136203.html.plaintext.txt	228	American Journal Epidemiology 147 574 580
0.41210636.11136203.html.plaintext.txt	229	et al 1995 Apolipoprotein E4 alleles predictor cholinergic deficits treatment outcome Alzheimers disease
0.41210636.11136203.html.plaintext.txt	230	Proceedings National Academy Sciences USA 92 1260 1264
0.41210636.11136203.html.plaintext.txt	231	1995 Is senile dementia age related ageing related Evidence meta analysis dementia prevalence oldest old
0.41210636.11136203.html.plaintext.txt	232	et al 1996 Incomplete penetrance familial Alzheimers disease pedigree novel presenilin I gene mutation
0.41210636.11136203.html.plaintext.txt	233	et al 1994 Genetic associations human longevity APOE ACE loci
0.41210636.11136203.html.plaintext.txt	234	1999 Translating cell biology therapeutic advances Alzheimers disease
0.41210636.11136203.html.plaintext.txt	235	1995 Apolipoprotein E 4 allele lifetime risk Alzheimers disease physicians know know
0.41210636.11136203.html.plaintext.txt	236	Archives Neurology 52 1074 1079
0.41210636.11136203.html.plaintext.txt	237	et al 1997 Lifetime risk dementia Alzheimers disease impact mortality risk estimates Framingham study
0.41210636.11136203.html.plaintext.txt	238	et al 1994 Patterns risk first degree relatives patients Alzheimers disease
0.41210636.11136203.html.plaintext.txt	239	Archives General Psychiatry 51 577 586
0.41210636.11136203.html.plaintext.txt	240	et al 1993 A population based study dementia 85 year olds
0.41210636.11136203.html.plaintext.txt	241	New England Journal Medicine 328 153 158
0.41210636.11136203.html.plaintext.txt	242	et al 1997 The absence apolipoprotein 4 allele associated aggressive form Alzheimers disease
0.41210636.11136203.html.plaintext.txt	243	Annals Neurology 41 615 620
0.41210636.11136203.html.plaintext.txt	244	et al 1993 Apolipoprotein E high avidity binding ss amyloid increased frequency type 4 allele late onset familial Alzheimers disease
0.41210636.11136203.html.plaintext.txt	245	Proceedings National Academy Sciences USA 90 1977 1981
0.41210636.11136203.html.plaintext.txt	246	1999 The UK Alzheimers disease genetics consortium
0.41210636.11136203.html.plaintext.txt	247	International Journal Geriatric Psychiatry 14 789 791
0.41210636.11136203.html.plaintext.txt	248	CO2 VlinktypeDOICrossRefMedline
0.41210636.11136203.html.plaintext.txt	249	et al 1999 Ageing occurrence dementia findings population based cohort large sample nonagenarians
0.41210636.11136203.html.plaintext.txt	250	Archives Neurology 56 587 592
0.41210636.11136203.html.plaintext.txt	251	Received publication February 14 2000
0.41210636.11136203.html.plaintext.txt	252	Revision received June 26 2000
0.41210636.11136203.html.plaintext.txt	253	Accepted publication June 28 2000
0.35414052.11005793.html.plaintext.txt	0	Transcriptional regulation Alzheimer disease genes implications susceptibility Jessie Theuns Christine Van Broeckhoven
0.35414052.11005793.html.plaintext.txt	1	Flanders Interuniversity Institute Biotechnology VIB Born Bunge Foundation BBS University Antwerp UIA Department Biochemistry Universiteitsplein 1 B 2610 Antwerpen Belgium
0.35414052.11005793.html.plaintext.txt	2	Received 19 June 2000 Accepted 6 July 2000
0.35414052.11005793.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION GENE EXPRESSION AND REGULATION
0.35414052.11005793.html.plaintext.txt	4	CONCLUSIONS REFERENCES In recent years important progress made uncovering genes implicated Alzheimer disease AD
0.35414052.11005793.html.plaintext.txt	5	Three causal genes identified mutations cause familial presenile AD amyloid precursor protein gene presenilin 1 2 genes
0.35414052.11005793.html.plaintext.txt	6	Additionally 4 allele apolipoprotein E gene shown major risk factor AD
0.35414052.11005793.html.plaintext.txt	7	Despite genetic heterogeneity genes work common mechanism
0.35414052.11005793.html.plaintext.txt	8	increasing amount deposition amyloid ss peptide Ass brain triggering AD related neuronal degeneration
0.35414052.11005793.html.plaintext.txt	9	Therefore levels Ass factors involved production deposition important neuropathogenesis AD
0.35414052.11005793.html.plaintext.txt	10	Regulation transcription AD genes might therefore important player neurodegenerative process
0.35414052.11005793.html.plaintext.txt	11	In review describe major features transcriptional regulation known AD genes implications variable expression levels susceptibility AD
0.35414052.11005793.html.plaintext.txt	12	INTRODUCTION TOP ABSTRACT INTRODUCTION GENE EXPRESSION AND REGULATION
0.35414052.11005793.html.plaintext.txt	13	CONCLUSIONS REFERENCES Alzheimer disease AD neurodegenerative disorder brain characterized neuronal loss extensive deposition amyloid ss peptide Ass brain parenchyma vessel walls appearance neuronal inclusions abnormally phosphorylated tau
0.35414052.11005793.html.plaintext.txt	14	The regions affected hippocampus cerebral cortex
0.35414052.11005793.html.plaintext.txt	15	Clinically AD patients show gradually progressive decline memory cognitive functions diagnosed neurological examination neuropsychological testing neuroimaging
0.35414052.11005793.html.plaintext.txt	16	Among dementias AD frequent 70 cases affected
0.35414052.11005793.html.plaintext.txt	17	The prevalence AD increases age 40 population older 85 years affected 1
0.35414052.11005793.html.plaintext.txt	18	Apart aging per se two well defined risk factors gender family history AD 2
0.35414052.11005793.html.plaintext.txt	19	The genetic etiology AD complex genetic environmental factors influencing expression phenotype
0.35414052.11005793.html.plaintext.txt	20	Nevertheless small percentage 1 AD cases disease inherited fully penetrant monogenic trait autosomal dominant manner
0.35414052.11005793.html.plaintext.txt	21	In cases disease onset age 65 years
0.35414052.11005793.html.plaintext.txt	22	presenile AD early onset AD EOAD
0.35414052.11005793.html.plaintext.txt	23	These monogenic AD families instrumental identification AD genes using positional cloning approach
0.35414052.11005793.html.plaintext.txt	24	At least four genetic loci confer inherited susceptibility identified date
0.35414052.11005793.html.plaintext.txt	25	Characteristics genes summarized Table 1
0.35414052.11005793.html.plaintext.txt	26	The first causative gene identified EOAD amyloid precursor protein gene APP 3 chromosome 21q21
0.35414052.11005793.html.plaintext.txt	27	2 4 encoding single membrane spanning protein 5 9
0.35414052.11005793.html.plaintext.txt	28	Full length APP metabolized rapidly two major pathways cells
0.35414052.11005793.html.plaintext.txt	29	In many cells prominent pathway constitutive pathway secretase cleaves Ass sequence 10 producing N truncated Ass peptides
0.35414052.11005793.html.plaintext.txt	30	Neurons however intrinsic tendency metabolize APP along amyloidogenic pathway 11 13 sequential cleavage ss secretases releases full length Ass peptides
0.35414052.11005793.html.plaintext.txt	31	Whereas ss secretase cleaves highly specifically secretase cleaves less specifically leading either 40 amino acid peptide Ass40 42 amino acid isoform Ass42 1415
0.35414052.11005793.html.plaintext.txt	32	All eight AD related APP mutations detected date located near secretase cleavage sites demonstrated interfere APP processing leading increased secretion Ass42
0.35414052.11005793.html.plaintext.txt	33	This Ass42 peptide shown least vitro aggregate rapidly fibrils 16 claimed earliest abundant Ass peptide amyloid deposits 17 19
0.35414052.11005793.html.plaintext.txt	34	Recent theories propose Ass deposits partially aggregated soluble Ass trigger neurotoxic cascade thereby causing neurodegeneration AD 2021
0.35414052.11005793.html.plaintext.txt	35	As result Ass particular Ass42 assigned pivotal role AD pathogenesis
0.35414052.11005793.html.plaintext.txt	36	AD genes The frequently mutated EOAD gene presenilin 1 PSEN1 located chromosome 14q24
0.35414052.11005793.html.plaintext.txt	37	Based homology studies third causal EOAD gene presenilin 2 PSEN2 isolated mapped chromosome 1q42
0.35414052.11005793.html.plaintext.txt	38	The PSEN genes encode highly homologous integral membrane proteins eight putative transmembrane domains 27 30
0.35414052.11005793.html.plaintext.txt	39	To date 60 PSEN1 4 PSEN2 mutations identified EOAD patients scattered entire coding region genes httpmolgen www
0.35414052.11005793.html.plaintext.txt	40	Both vitro vivo PSEN mutations lead increased Ass42 production suggesting role PSEN processing APP 31 45
0.35414052.11005793.html.plaintext.txt	41	Together findings led hypothesis gain function mutant PSEN 20 provided evidence central role Ass42 AD pathogenesis
0.35414052.11005793.html.plaintext.txt	42	PSENs also shown death substrates undergoing caspase cleavage apoptosis 46 48
0.35414052.11005793.html.plaintext.txt	43	Although role apoptosis neuronal cell death AD remains proven AD linked PSEN mutations well decreased expression PSEN1 overexpression PSEN2 46 result apoptosis 49
0.35414052.11005793.html.plaintext.txt	44	However homology SEL 12 Caenorhabditis elegans suggested possible role PSEN NOTCH signaling 50
0.35414052.11005793.html.plaintext.txt	45	Further evidence provided study embryonically lethal PSEN1 deficient mice show abnormal somite segmentation phenotype shared NOTCH1 deficient mice 5152
0.35414052.11005793.html.plaintext.txt	46	Moreover mutations genes involved NOTCH signaling also lead central nervous system CNS disorders onset ages adulthood 53
0.35414052.11005793.html.plaintext.txt	47	In addition three causative genes 4 allele apolipoprotein E gene APOE chromosome 19 identified genetic risk factor EOAD 5455 late onset AD LOAD 56 58
0.35414052.11005793.html.plaintext.txt	48	The risk associated 4 allele dose dependent reflected increased risk decreased onset age number 4 alleles 59
0.35414052.11005793.html.plaintext.txt	49	Several observations indicated APOE 4 also involved increased Ass deposition
0.35414052.11005793.html.plaintext.txt	50	It shown APOE promotes Ass fibril formation vitro 60
0.35414052.11005793.html.plaintext.txt	51	Also APOE 4 higher binding affinity Ass APOE 3 5661 possibly making Ass insoluble therefore prone deposition
0.35414052.11005793.html.plaintext.txt	52	Although vitro data controversial AD patients homozygous APOE 4 indeed shown Ass deposits APOE 3 homozygotes 62
0.35414052.11005793.html.plaintext.txt	53	Also shown APOE 4 influences onset age EOAD patients carrying AD related APP mutation PSEN1 mutation carriers 63
0.35414052.11005793.html.plaintext.txt	54	Since mutations causal EOAD genes explain 1 APOE 4 20 AD cases 226465 clear genetic factors involved AD pathogenesis
0.35414052.11005793.html.plaintext.txt	55	Variation regulatory regions APP 6667 PSEN1 226869 APOE 70 73 suggested contribute susceptibility AD
0.35414052.11005793.html.plaintext.txt	56	In review discuss importance expression levels known AD genes implications variations regulatory regions susceptibility AD
0.35414052.11005793.html.plaintext.txt	57	GENE EXPRESSION AND REGULATION OF TRANSCRIPTION TOP ABSTRACT INTRODUCTION GENE EXPRESSION AND REGULATION
0.35414052.11005793.html.plaintext.txt	58	CONCLUSIONS REFERENCES APP expressed variety tissues highest expression neuronal cells CNS 674 77
0.35414052.11005793.html.plaintext.txt	59	APP expression induced variety agents growth hormones cytokines 91178 86 stress conditions 87 89
0.35414052.11005793.html.plaintext.txt	60	Up regulation 9091 APP promoter activity corroborates mRNA expression studies 8292 suggesting major role APP promoter specific APP expression
0.35414052.11005793.html.plaintext.txt	61	The control mechanisms APP gene expression subject extensive studies
0.35414052.11005793.html.plaintext.txt	62	The APP promoter contains numerous putative binding sites regulatory transcription factors Table 2 93 97
0.35414052.11005793.html.plaintext.txt	63	However deletion mapping APP promoter demonstrated 100 bp upstream transcriptional start site TSS sufficient high levels expression numerous cell types 98 100
0.35414052.11005793.html.plaintext.txt	64	This proximal promoter region devoid functional TATA box transcription initiation regulated strong initiator element Inr surrounding major TSS 1 Fig
0.35414052.11005793.html.plaintext.txt	65	Mutations within immediately upstream Inr lead altered use multiple TSSs reduce transcriptional activity
0.35414052.11005793.html.plaintext.txt	66	Both Inr upstream element UE associated DNase I protected domains suggesting sequence specific binding nuclear factors 101
0.35414052.11005793.html.plaintext.txt	67	Functional promoter elements AD genes
0.35414052.11005793.html.plaintext.txt	68	Boxes represent consensus sequences binding TFs
0.35414052.11005793.html.plaintext.txt	69	DNA binding proteins presented brackets
0.35414052.11005793.html.plaintext.txt	70	Transcription start sites TSSs represented black arrows
0.35414052.11005793.html.plaintext.txt	71	A Functional elements APP proximal promoter sequence GenBank accession
0.35414052.11005793.html.plaintext.txt	72	B Functional elements PSEN1 proximal promoter sequence GenBank accession
0.35414052.11005793.html.plaintext.txt	73	Numbering according upstream TSS exon 1A P1 131
0.35414052.11005793.html.plaintext.txt	74	Other TSSs found 2 P2 131 16 Rt1 27 Rt2 129
0.35414052.11005793.html.plaintext.txt	75	C Functional elements 5 flanking region APOE
0.35414052.11005793.html.plaintext.txt	76	Shaded boxes represent enhancer elements
0.35414052.11005793.html.plaintext.txt	77	APP promoter activation covered mainly two GC rich elements Table 2 Fig
0.35414052.11005793.html.plaintext.txt	78	The 93 82 fragment APBss contributes least 70 APP promoter activity neuronal non neuronal cells shown bind CCCTC binding factor CTCF known regulator c myc expression implicated promotion apoptosis Table 2 Fig
0.35414052.11005793.html.plaintext.txt	79	The remaining APP promoter activity accounted mainly 65 41 fragment APB mediated binding stimulating protein 1 SP1 upstream stimulatory factor USF member c Myc related family DNA binding proteins 99104 106
0.35414052.11005793.html.plaintext.txt	80	Recently interaction model APP transcriptional activity based DNA looping presented
0.35414052.11005793.html.plaintext.txt	81	In model novel SP1 like protein forms homodimer tethering USF 5 flanking SP1 sites upstream AP 1 site flanking GC rich motif Fig
0.35414052.11005793.html.plaintext.txt	82	View larger version 25K Figure 2
0.35414052.11005793.html.plaintext.txt	83	Model APP transcription activation interaction near upstream downstream proximal GC rich elements
0.35414052.11005793.html.plaintext.txt	84	Speckled boxes SP1 like binding protein complex open boxes homologous DNA sequences shared domains hatched box SP1 site black box AP 1 site
0.35414052.11005793.html.plaintext.txt	85	Transcriptional activation APP also mediated heat shock factor 1 HSF 1 binding heat shock element HSE position 317 Table 2 Fig
0.35414052.11005793.html.plaintext.txt	86	HSF 1 activation induced numerous stress factors including hypoxia decreased pH elevated Ca2 decreased ATP exposure reactive species
0.35414052.11005793.html.plaintext.txt	87	It also reported recently members NF BRel family specifically recognize two identical sequences 1837 1822 2250 2241 distal promoter region APP referred APPB sites 108
0.35414052.11005793.html.plaintext.txt	88	These sites shown interact specifically complex containing p50 subunit NF B family constitutively expressed neurons acts positive regulator gene expression cells neuronal origin 109
0.35414052.11005793.html.plaintext.txt	89	The distal APP promoter also harbors least one negative regulator transcription upstream regulatory element URE 2257 2234 binding unknown transcription factor TF expressed restricted number cell types different regions human brain 110111
0.35414052.11005793.html.plaintext.txt	90	Not structure expression pattern APP highly conserved species 112113 promoter regions rodents primates also highly homologous human APP 80 9394114
0.35414052.11005793.html.plaintext.txt	91	They high GC content lack typical TATA CAAT boxes share nearly described TF binding sites Table 2 suggesting major role TFs APP regulation vivo 939499114
0.35414052.11005793.html.plaintext.txt	92	Like APP PSENs ubiquitously expressed although display markedly tissue specific transcriptional differences
0.35414052.11005793.html.plaintext.txt	93	In brain PSEN1 transcripts 2
0.35414052.11005793.html.plaintext.txt	94	5 kb present relatively high levels whereas one PSEN2 transcript 2
0.35414052.11005793.html.plaintext.txt	95	3 kb detected relatively low levels 2426 115116
0.35414052.11005793.html.plaintext.txt	96	Both PSENs expressed primarily neurons lesser extent glial cells 117 127
0.35414052.11005793.html.plaintext.txt	97	The PSEN1 5 untranslated region UTR contained within four exons first two exons 1A 1B alternatively transcribed Table 1 128129
0.35414052.11005793.html.plaintext.txt	98	Multiple TSSs reported date major exon 1A TSSs designated 1P1 P2 Fig
0.35414052.11005793.html.plaintext.txt	99	Deletion mapping PSEN1 promoter delineated active fragment 118 178 relative 1P1 neuronal non neuronal cells 131
0.35414052.11005793.html.plaintext.txt	100	The sequence region contains 70 GC lacks TATA box contains transcriptionally active GC boxes around positions 70 50 20 Fig
0.35414052.11005793.html.plaintext.txt	101	The crucial PSEN1 promoter element located 22 6 controls 90 PSEN1 promoter activity
0.35414052.11005793.html.plaintext.txt	102	This region contains binding motif Ets proteins 12 Fig
0.35414052.11005793.html.plaintext.txt	103	1B altering core sequence results drastic decrease promoter activity interfering TF binding
0.35414052.11005793.html.plaintext.txt	104	In neuronal cells PSEN1 promoter binds Ets 12 protein
0.35414052.11005793.html.plaintext.txt	105	Both Ets 1 Ets 2 widely expressed different tissues differentially regulated 132133
0.35414052.11005793.html.plaintext.txt	106	Ets 2 present high levels adult brain including post mitotic neurons
0.35414052.11005793.html.plaintext.txt	107	Ets 1 particularly abundant CNS specific developmental stages 133
0.35414052.11005793.html.plaintext.txt	108	Another Ets family member Elk 1 also shown expressed brain localized exclusively neurons 134
0.35414052.11005793.html.plaintext.txt	109	Which members Ets family able activate PSEN1 transcription vivo clear
0.35414052.11005793.html.plaintext.txt	110	Sequences 107 178 downstream TSS also contain major cis elements controlling 80 total PSEN1 promoter activity
0.35414052.11005793.html.plaintext.txt	111	Collectively data indicate sequences upstream downstream TSS control 80 promoter activity indicating importance protein protein interactions TFs binding upstream downstream cis elements
0.35414052.11005793.html.plaintext.txt	112	Preliminary data murine PSEN1 promoter activity situ hybridization suggest PSEN1 expressed transcribed preferentially neurons
0.35414052.11005793.html.plaintext.txt	113	The structure expression PSEN1 highly conserved mice human
0.35414052.11005793.html.plaintext.txt	114	Multiple mRNA transcripts originating TSSs alternatively transcribed first exons reported species
0.35414052.11005793.html.plaintext.txt	115	Reporter gene analysis showed TSSs probably controlled one single promoter spanning 1 position exon 1A 130
0.35414052.11005793.html.plaintext.txt	116	In human one exon 1B transcript reported far therefore difficult conceive exon 1B transcription driven promoter abundant exon 1A transcripts described mouse transcripts
0.35414052.11005793.html.plaintext.txt	117	Hence possible transcription human exon 1B controlled promoter least exon 1B specific cis elements possibly located downstream 178
0.35414052.11005793.html.plaintext.txt	118	Until data functional cis elements controlling transcription human PSEN1 exon 1B reported
0.35414052.11005793.html.plaintext.txt	119	In regulatory region maximal similarity found 39117 sequence mouse PSEN1 promoter region
0.35414052.11005793.html.plaintext.txt	120	The 20 GC box SP1 12 Ets motif strictly conserved reporter gene analysis indicated region contributes neuron preferred promoter activity 130
0.35414052.11005793.html.plaintext.txt	121	The mouse sequence upstream position 39 differs significantly human sequences
0.35414052.11005793.html.plaintext.txt	122	Absence long stretches sequence homology one main problems promoter recognition conceivable functional cis elements although located corresponding positions shared mouse human PSEN1 promoter
0.35414052.11005793.html.plaintext.txt	123	Furthermore sequences 22 178 confer 80 human PSEN1 promoter activity coincide region high homology mouse promoter
0.35414052.11005793.html.plaintext.txt	124	Also major human 1 TSS located eight nucleotides downstream mouse TSS 130131 emphasizing importance region function promoter species
0.35414052.11005793.html.plaintext.txt	125	Despite striking similarities PSEN2 PSEN1 genomic structure alternative transcripts use multiple TSSs 116135136 little homology 5 flanking region first two exons PSEN2 although alternatively transcribed mutually exclusive 116
0.35414052.11005793.html.plaintext.txt	126	There two distinct cis elements regulating transcription predicted TSS
0.35414052.11005793.html.plaintext.txt	127	PSEN2 basal promoter activity resides 403 13 TATA less GC rich region containing numerous putative AP 2 SP1 sites 137
0.35414052.11005793.html.plaintext.txt	128	In region functional nerve growth factor NGF responsive element mediates PSEN2 promoter activation following NGF treatment also resides
0.35414052.11005793.html.plaintext.txt	129	The observed 2 fold regulation NGF confirmed predicted involvement PSENs neuronal differentiation 138
0.35414052.11005793.html.plaintext.txt	130	Whether AP 2 SP1 sites clustered region another yet unidentified cis element responsible NGF responsiveness yet clear
0.35414052.11005793.html.plaintext.txt	131	Further deletion analysis provided evidence existence second PSEN2 promoter located intron 1 directing transcription start sites exon 2 though functional elements identified far
0.35414052.11005793.html.plaintext.txt	132	APOE expressed variety tissues cell types expression highly regulated nutritional hormonal tissue cell specific factors intracellular cholesterol levels 139140
0.35414052.11005793.html.plaintext.txt	133	In contrast causal AD genes 5 flanking sequence APOE harbors functional TATA box 141
0.35414052.11005793.html.plaintext.txt	134	Multiple general specific cis elements mapped APOE promoter Table 2 Fig
0.35414052.11005793.html.plaintext.txt	135	The proximal GC box binds SP1 required maximum transcriptional activity 142
0.35414052.11005793.html.plaintext.txt	136	Three non specific enhancer elements active neuronal non neuronal cells 143 identified
0.35414052.11005793.html.plaintext.txt	137	Two upstream regulatory elements 1 URE1 2 URE2 reside proximal promoter region one resides first intron intron regulatory element 1 IRE1
0.35414052.11005793.html.plaintext.txt	138	The dominant regulatory sequence URE1 located 161 141 termed positive element transcription PET
0.35414052.11005793.html.plaintext.txt	139	This fragment binds least two TFs one SP1
0.35414052.11005793.html.plaintext.txt	140	Although SP1 protein required enhancer activity PET second yet unknown protein competes SP1 way possibly negatively regulating APOE expression 142
0.35414052.11005793.html.plaintext.txt	141	A fourth regulatory domain APOE promoter URE3 binds 300 kDa URE3 binding protein needs characterization 144
0.35414052.11005793.html.plaintext.txt	142	In astrocytic cells activity proximal promoter APOE regulated synergistically cAMP retinoic acid RA mediated two AP 2 sites located proximal promoter 145
0.35414052.11005793.html.plaintext.txt	143	cAMP mimics changes occurring reactive gliosis 146147 RA potent morphogenetic agent developing nervous system known regulator AP 2 expression 148
0.35414052.11005793.html.plaintext.txt	144	It therefore reasonable presume observed synergistic effect cAMP RA APOE promoter probably due RA promoted increase AP 2 followed post transcriptional activation AP 2 mediated cAMP 148149
0.35414052.11005793.html.plaintext.txt	145	More tissue specific cis elements identified present seem reside downstream APOE potential brain specific transcriptional activator APOE APOCI intergenic region 150 154
0.35414052.11005793.html.plaintext.txt	146	The 5 upstream region rodent APOE homologous human APOE 200 bp upstream TSS 155156 TATA box proximal GC box URE3 corresponding positions Table 2 141156157
0.35414052.11005793.html.plaintext.txt	147	PROMOTER VARIATIONS AND TRANSCRIPTIONAL ACTIVITY TOP ABSTRACT INTRODUCTION GENE EXPRESSION AND REGULATION
0.35414052.11005793.html.plaintext.txt	148	CONCLUSIONS REFERENCES Screening mutations 802268 APP promoter fragment sporadic familial EOAD LOAD cases reveal AD specific mutation 158 161
0.35414052.11005793.html.plaintext.txt	149	However CG transversion detected position 209 affected unaffected subjects Table 3 161
0.35414052.11005793.html.plaintext.txt	150	Although variation unique AD may effect APP transcriptional activity associated AD
0.35414052.11005793.html.plaintext.txt	151	Since number patients controls small individual analyses covered parts APP promoter one cannot yet exclude existence AD related variations APP promoter altering transcriptional activity
0.35414052.11005793.html.plaintext.txt	152	Recent sib pair analyses suggested genetic variability APP locus may contribute risk LOAD 6667
0.35414052.11005793.html.plaintext.txt	153	It obvious systematic screening APP regulatory sequences extended AD populations necessary
0.35414052.11005793.html.plaintext.txt	154	Promoter variations AD genes Besides amount full length APP available amount activity APP processing factors also influence production amyloidogenic Ass42
0.35414052.11005793.html.plaintext.txt	155	Since PSENs assigned pivotal role APP processing altered PSEN expression due variations regulatory regions considered risk factor AD
0.35414052.11005793.html.plaintext.txt	156	Genetic association studies population based EOAD case control sample showed association single nucleotide polymorphism SNP 48CT EOAD Table 3 68
0.35414052.11005793.html.plaintext.txt	157	Systematic screening 3 kb PSEN1 upstream region population revealed addition 48CT 22 four novel polymorphisms 1789GA 2154GA 2319Tn 2823ID two 2154GA 2823ID also shown associated increased risk EOAD Table 3
0.35414052.11005793.html.plaintext.txt	158	Linkage disequilibrium allowed identification EOAD risk haplotype 48C 2154G 2823D
0.35414052.11005793.html.plaintext.txt	159	Additionally two potentially AD related mutations 280CG 2818AG identified Table 3 69
0.35414052.11005793.html.plaintext.txt	160	The effect 280CG 48CT transcriptional activity PSEN1 studied transient transfection system
0.35414052.11005793.html.plaintext.txt	161	Luciferase reporter gene analysis demonstrated neuron specific 30 decrease promoter activity 280G mutant neuron specific 50 decrease promoter activity 48C risk allele homozygous individuals lead critical decrease PSEN1 expression
0.35414052.11005793.html.plaintext.txt	162	Notably genetic association 48C EOAD explained representation CC genotype EOAD patients
0.35414052.11005793.html.plaintext.txt	163	These studies provide evidence increased risk EOAD associated PSEN1 may result genetic variations regulatory region leading altered expression levels PSEN1 neuronal cells due differential binding nuclear proteins 69162163
0.35414052.11005793.html.plaintext.txt	164	These data suggest increased risk EOAD associated PSEN1 may result decreased expression levels PSEN1 protein
0.35414052.11005793.html.plaintext.txt	165	Although PSEN2 also shown involved APP processing changes expression levels might important AD pathology association found AD PSEN2 promoter variations reported date
0.35414052.11005793.html.plaintext.txt	166	It shown relative APOE 4 mRNA level increased AD compared controls suggested genetic variability neuronal expression APOE contributes disease risk 70
0.35414052.11005793.html.plaintext.txt	167	Multiple studies suggested genetic variability regulatory region APOE may modulate risk associated APOE 4 isoform
0.35414052.11005793.html.plaintext.txt	168	The first variation detected APOE regulatory region CG transversion position 113 intron 1 enhancer element IE1 although statistically significant association independent APOE 4 could detected Table 3 164
0.35414052.11005793.html.plaintext.txt	169	In population based study three SNPs 491AT 427TC 219TG alias Th1E47cs two heterozygous mutations 557CT 456CT identified Table 3 7173
0.35414052.11005793.html.plaintext.txt	170	Reporter gene analysis electrophoretic mobility shift assays EMSAs demonstrated three SNPs alter transcriptional activity APOE promoter due differential binding TFs 7172
0.35414052.11005793.html.plaintext.txt	171	For three SNPs genetic association AD independent APOE 4 reported 71 73
0.35414052.11005793.html.plaintext.txt	172	Although several studies attempted confirm association reported either absence association association due linkage disequilibrium APOE 4 114165 172
0.35414052.11005793.html.plaintext.txt	173	However population based differences APOE 4 frequencies giving rise differences relative risk AD documented previously 173174
0.35414052.11005793.html.plaintext.txt	174	It therefore conceivable wide variation relative risk AD associated APOE promoter polymorphisms
0.35414052.11005793.html.plaintext.txt	175	In vivo studies demonstrated deleterious effect disease risk 219T 491A risk alleles correlated increased expression 4 allele brain 175
0.35414052.11005793.html.plaintext.txt	176	Later shown 491AA risk genotype associated increased levels APOE plasma independently APOE 4 AD status though pronounced AD patients 176
0.35414052.11005793.html.plaintext.txt	177	These data provide evidence addition qualitative effect APOE 234 isoforms risk AD quantitative variation expression isoforms due functional APOE promoter variations key determinant AD development
0.35414052.11005793.html.plaintext.txt	178	IMPLICATIONS OF VARIABLE GENE EXPRESSION ON AD PATHOGENESIS TOP ABSTRACT INTRODUCTION GENE EXPRESSION AND REGULATION
0.35414052.11005793.html.plaintext.txt	179	CONCLUSIONS REFERENCES The favored hypothesis suggests pivotal role increased Ass42 secretion AD pathology
0.35414052.11005793.html.plaintext.txt	180	Since amount APP factors involved processing crucial elevation conceivable transcriptional regulation genes plays important role AD pathology
0.35414052.11005793.html.plaintext.txt	181	A number studies indicate amount APP mRNA indeed increased AD brains 177 181
0.35414052.11005793.html.plaintext.txt	182	Moreover trisomy 21 Down syndrome DS patients leads 4 5 fold overexpression APP resulting 50 year decrease onset age AD DS patients compared normal population 182
0.35414052.11005793.html.plaintext.txt	183	These results imply fundamental component molecular etiology AD may lie expression APP biogenesis turnover since induction pathway leading Ass production depend amount APP present
0.35414052.11005793.html.plaintext.txt	184	Since overlapping cis elements known important differential gene expression 183 185 presence overlapping SP1 USF binding sites APP promoter suggests two different independent regulatory pathways APP expression might exist one mediated SP1 USF 104
0.35414052.11005793.html.plaintext.txt	185	SP1 shown ubiquitously expressed however substantial variation different cell types development 186
0.35414052.11005793.html.plaintext.txt	186	The low levels SP1 detected different brain regions suggest USF might also contribute substantially high expression APP neuronal cells confirmed EMSA nuclear extracts rat brain showing binding USF SP1
0.35414052.11005793.html.plaintext.txt	187	A number factors reported able influence SP1 activity certain cell types way leading preferred usage one pathway 187188
0.35414052.11005793.html.plaintext.txt	188	Therefore deregulated overexpression APP brain might simply caused local increase SP1 activity
0.35414052.11005793.html.plaintext.txt	189	Additionally AD brains exhibit numerous features indicate neurons affected AD exist conditions stress
0.35414052.11005793.html.plaintext.txt	190	Since APP expression regulated stress factors one speculate APP may one genes coordinately modulated brain response situations require defensive reaction
0.35414052.11005793.html.plaintext.txt	191	Stress induced overexpression APP lead increased Ass production
0.35414052.11005793.html.plaintext.txt	192	It therefore conceivable imbalance different regulatory pathways APP expression caused variation functional cis element altered expression levels TFs specific brain regions might risk factor AD
0.35414052.11005793.html.plaintext.txt	193	During aging expression PSENs decreases 120 even significant decrease PSEN reported neurons brain areas adversely affected AD 189190
0.35414052.11005793.html.plaintext.txt	194	In contrast astrocytes reacting neurodegeneration express elevated levels PSEN 189191
0.35414052.11005793.html.plaintext.txt	195	Several lines evidence indicate PSEN1 closely linked secretase processing APP decreased expression 50 mutations PSEN1 lead increased secretion Ass42 20192
0.35414052.11005793.html.plaintext.txt	196	Small changes PSEN expression levels major implications APP processing AD pathology
0.35414052.11005793.html.plaintext.txt	197	Additionally PSENs shown death substrates undergoing caspase cleavage apoptosis 46 48193
0.35414052.11005793.html.plaintext.txt	198	Although role apoptosis neuronal cell death AD remains proven interesting PSEN2 overexpression AD linked mutations PSENs shift conventional PSEN cleavage towards caspase cleavage 46 whereas reduction PSEN1 results apoptosis 49
0.35414052.11005793.html.plaintext.txt	199	Regardless hypothesis AD pathology clear expression PSENs highly regulated mutations variations leading altered expression easily imagined major effects PSEN functioning
0.35414052.11005793.html.plaintext.txt	200	APOE suggested involved repair process following nerve injury
0.35414052.11005793.html.plaintext.txt	201	It shown APOE effect neurite morphogenesis cultured neurons APOE 3 reduces amount neurite branching promotes neurite extension whereas APOE 4 194195
0.35414052.11005793.html.plaintext.txt	202	In brain APOE synthesis takes place astrocytes 196197 increased dramatically nerve injury 198 200
0.35414052.11005793.html.plaintext.txt	203	The reactive gliosis AD brains involves series morphological biochemical changes activated astrocytes 201 including regulation APOE mRNA levels mediated AP 2 202
0.35414052.11005793.html.plaintext.txt	204	Further determination molecular mechanisms involved regulation APOE synthesis brain matter greatest importance considering possible roles protein processes repair pathogenesis AD 5659
0.35414052.11005793.html.plaintext.txt	205	Here special attention needs drawn mechanisms differential expression different APOE isoforms
0.35414052.11005793.html.plaintext.txt	206	Although clear expression levels AD genes important AD etiology little known specific regulation
0.35414052.11005793.html.plaintext.txt	207	Studying effect variations regulatory elements corresponding TFs contribute understanding disease process
0.35414052.11005793.html.plaintext.txt	208	CONCLUSIONS TOP ABSTRACT INTRODUCTION GENE EXPRESSION AND REGULATION
0.35414052.11005793.html.plaintext.txt	209	CONCLUSIONS REFERENCES The promoters three causal EOAD genes APP PSEN12 show characteristics promoters housekeeping genes
0.35414052.11005793.html.plaintext.txt	210	All lack functional TATA box show high GC content presenting multiple potential SP1 sites known involved transcription initiation regulation TATA less promoters 137
0.35414052.11005793.html.plaintext.txt	211	APP PSEN1 PSEN2 ubiquitously expressed though tightly controlled differential regulation depending tissue cell type developmental stage environmental factors
0.35414052.11005793.html.plaintext.txt	212	Interestingly proteins synthesized predominantly neurons CNS
0.35414052.11005793.html.plaintext.txt	213	This highly controlled regulation implicates presence specific regulatory elements mediating transcriptional activity though described date
0.35414052.11005793.html.plaintext.txt	214	The regulation APOE extremely complex multiple general specific positive negative cis elements
0.35414052.11005793.html.plaintext.txt	215	In brain APOE expressed astrocytes probably involved neuronal regeneration processes
0.35414052.11005793.html.plaintext.txt	216	It well documented single nucleotide changes promoter region may affect transcriptional activity mediated TFs 203204 either directly altering TF binding site changing structure DNA thereby affecting access TFs
0.35414052.11005793.html.plaintext.txt	217	Multiple studies provided evidence altered expression levels APP PSENs different isoforms APOE involved AD pathology suggesting role transcriptional regulation disease process
0.35414052.11005793.html.plaintext.txt	218	Variations functional regulatory elements therefore considered risk factors AD altering gene expression
0.35414052.11005793.html.plaintext.txt	219	To date promoter variations PSEN1 APOE shown associated increased risk AD
0.35414052.11005793.html.plaintext.txt	220	Functional data suggested increased risk AD could explained effect promoter variations transcriptional levels genes either decreasing levels total expression PSEN1 differentially influencing expression levels different isoforms APOE
0.35414052.11005793.html.plaintext.txt	221	Further analysis transcriptional regulation AD genes variations regulatory regions lead insight AD etiology
0.35414052.11005793.html.plaintext.txt	222	Multiple factors genetic environmental underlie etiology complex diseases like AD
0.35414052.11005793.html.plaintext.txt	223	It therefore conceivable interplay discrete transcriptional changes different genes influence disease processes
0.35414052.11005793.html.plaintext.txt	224	Analysis regulatory regions disease genes effect variations gene regulation therefore important elucidation complex disease processes
0.35414052.11005793.html.plaintext.txt	225	FOOTNOTES To correspondence addressed
0.35414052.11005793.html.plaintext.txt	226	Tel 32 3 8202601 Fax 32 3 8202541 Email cvbroeckuia
0.35414052.11005793.html.plaintext.txt	227	REFERENCES TOP ABSTRACT INTRODUCTION GENE EXPRESSION AND REGULATION
0.35414052.11005793.html.plaintext.txt	228	CONCLUSIONS REFERENCES 1 Breteler M
0.35414052.11005793.html.plaintext.txt	229	1992 Epidemiology Alzheimer disease
0.35414052.11005793.html.plaintext.txt	230	1991 Frequency distribution Alzheimer disease Europe collaborative study 1980 1990 prevalence findings
0.35414052.11005793.html.plaintext.txt	231	1991 Segregation missense mutation amyloid precursor protein gene familial Alzheimer disease
0.35414052.11005793.html.plaintext.txt	232	1987 The precursor Alzheimer disease amyloid A4 protein resembles cell surface receptor
0.35414052.11005793.html.plaintext.txt	233	1988 A new A4 amyloid mRNA contains domain homologous serine proteinase inhibitors
0.35414052.11005793.html.plaintext.txt	234	1988 Protease inhibitor domain encoded amyloid protein precursor mRNA associated Alzheimer disease
0.35414052.11005793.html.plaintext.txt	235	1992 Identification differential expression novel alternative splice isoform ssA4 amyloid precursor protein APP mRNA leukocytes brain microglial cells
0.35414052.11005793.html.plaintext.txt	236	1994 ssA4 amyloid protein precursor mRNA isoforms without exon 15 ubiquitously expressed rat tissues including brain neurons
0.35414052.11005793.html.plaintext.txt	237	1990 Genomic organization human amyloid ss protein precursor gene
0.35414052.11005793.html.plaintext.txt	238	1990 Cleavage amyloid ss peptide constitutive processing precursor
0.35414052.11005793.html.plaintext.txt	239	1992 Increased expression ss amyloid precursor protein neuronal differentiation accompanied secretory cleavage
0.35414052.11005793.html.plaintext.txt	240	1995 Production intracellular amyloid containing fragments hippocampal neurons expressing human amyloid precursor protein protection amyloidogenesis subtle amino acid substitutions rodent sequence
0.35414052.11005793.html.plaintext.txt	241	1996 Amyloidogenic processing human amyloid precursor protein primary cultures rat hippocampal neurons
0.35414052.11005793.html.plaintext.txt	242	1996 Evidence 42 40 amino acid forms amyloid ss protein generated ss amyloid precursor protein different protease activities
0.35414052.11005793.html.plaintext.txt	243	1996 The carboxyl termini ss amyloid peptides 1 40 1 42 generated distinct secretase activities
0.35414052.11005793.html.plaintext.txt	244	1993 Seeding one demensional crystallization amyloid pathogenic mechanism Alzheimer disease scrapie Cell 73 1055 1058
0.35414052.11005793.html.plaintext.txt	245	1994 Visualization Ass4243 Ass40 senile plaques end specific Ass monoclonals evidence initially deposited species Ass4243
0.35414052.11005793.html.plaintext.txt	246	1996 Diffuse plaques cerebellum corpus striatum Down syndrome contain amyloid ss protein Ass form Ass 4243
0.35414052.11005793.html.plaintext.txt	247	Neurodegeneration 5 115 120
0.35414052.11005793.html.plaintext.txt	248	1995 Amyloid ss protein Ass Alzheimer disease brain
0.35414052.11005793.html.plaintext.txt	249	Biochemical immunocytochemical analysis antibodies specific forms ending Ass40 Ass4243
0.35414052.11005793.html.plaintext.txt	250	1997 Amyloid presenilins Alzheimer disease
0.35414052.11005793.html.plaintext.txt	251	1996 The role APP processing trafficking pathways formation amyloid ss protein
0.35414052.11005793.html.plaintext.txt	252	1998 Estimation genetic contribution presenilin 1 2 mutations population based study presenile Alzheimer disease
0.35414052.11005793.html.plaintext.txt	253	1992 Mapping gene predisposing early onset Alzheimer disease chromosome 14q24
0.35414052.11005793.html.plaintext.txt	254	1995 Cloning gene bearing mis sense mutations early onset familial Alzheimer disease
0.35414052.11005793.html.plaintext.txt	255	1995 A familial Alzheimer disease locus chromosome 1
0.35414052.11005793.html.plaintext.txt	256	1995 Candidate gene chromosome 1 familial Alzheimer disease locus
0.35414052.11005793.html.plaintext.txt	257	1996 Protein topology presenilin 1
0.35414052.11005793.html.plaintext.txt	258	1996 Membrane topology C
0.35414052.11005793.html.plaintext.txt	259	1997 Phosphorylation subcellular localization membrane orientation Alzheimer disease associated presenilins
0.35414052.11005793.html.plaintext.txt	260	1998 Additional evidence eight transmembrane domain topology Caenorhabditis elegans human presenilins
0.35414052.11005793.html.plaintext.txt	261	1996 Secreted amyloid ss protein similar senile plaques Alzheimer disease increased vivo presenilin 1 2 APP mutations linked familial Alzheimer disease
0.35414052.11005793.html.plaintext.txt	262	1996 Familial Alzheimer disease linked presenilin 1 variants elevate Ass1 421 40 ratio vitro vivo
0.35414052.11005793.html.plaintext.txt	263	1997 Mutant presenilins Alzheimer disease increase production 42 residue amyloid ss protein transfected cells transgenic mice
0.35414052.11005793.html.plaintext.txt	264	1997 Enhanced production oligomerization 42 residue amyloid ss protein Chinese hamster ovary cells stably expressing mutant presenilins
0.35414052.11005793.html.plaintext.txt	265	1998 Increased plasma amyloid ss protein 1 42 levels Down syndrome
0.35414052.11005793.html.plaintext.txt	266	1999 Enhancement amyloid ss42 secretion 28 different presenilin 1 mutations familial Alzheimer disease
0.35414052.11005793.html.plaintext.txt	267	1996 Increased amyloid ss4243 brains mice expressing mutant presenilin 1
0.35414052.11005793.html.plaintext.txt	268	1998 Mutant presenilin 2 transgenic mouse effect age dependent increase amyloid ss protein 42 brain
0.35414052.11005793.html.plaintext.txt	269	1996 The E280A presenilin 1 Alzheimer mutation produces increased Ass42 deposition severe cerebellar pathology
0.35414052.11005793.html.plaintext.txt	270	1996 Amyloid ss protein Ass deposition chromosome 14 linked Alzheimer disease predominance Ass4243
0.35414052.11005793.html.plaintext.txt	271	1997 A novel presenilin 1 mutation increased ss amyloid neurofibrillary changes
0.35414052.11005793.html.plaintext.txt	272	1997 Proteolytic processing presenilin 1 PS 1 associated Alzheimer disease without PS 1 mutations
0.35414052.11005793.html.plaintext.txt	273	1998 Deficiency presenilin 1 inhibits normal cleavage amyloid precursor protein
0.35414052.11005793.html.plaintext.txt	274	1998 An Alzheimer disease linked PS1 variant rescues developmental abnormalities PS1 deficient embryos
0.35414052.11005793.html.plaintext.txt	275	1998 Mutant human presenilin 1 protects presenilin 1 null mouse embryonic lethality elevates Ass1 4243 expression
0.35414052.11005793.html.plaintext.txt	276	1997 Endoproteolytic cleavage proteasomal degradation presenilin 2 transfected cells
0.35414052.11005793.html.plaintext.txt	277	1998 Alzheimer disease associated presenilin 1 holoprotein 18 20 kDa C terminal fragment death substrates proteases caspase family
0.35414052.11005793.html.plaintext.txt	278	Biochemistry 37 2263 2270
0.35414052.11005793.html.plaintext.txt	279	1997 Presenilins processed caspase type proteases
0.35414052.11005793.html.plaintext.txt	280	1998 Inhibition presenilin 1 expression promoted p53 p21WAF 1 results apoptosis tumor suppression
0.35414052.11005793.html.plaintext.txt	281	1995 Facilitation lin 12 mediated signalling sel 12 Caenorhabditis elegans S182 Alzheimer disease gene
0.35414052.11005793.html.plaintext.txt	282	1997 Skeletal CNS defects presenilin 1 deficient mice
0.35414052.11005793.html.plaintext.txt	283	1997 Presenilin 1 required Notch1 DII1 expression paraxial mesoderm
0.35414052.11005793.html.plaintext.txt	284	1996 Notch3 mutations CADASIL hereditary adult onset condition causing stroke dementia
0.35414052.11005793.html.plaintext.txt	285	1994 Apolipoprotein E4 allele population based study early onset Alzheimer disease
0.35414052.11005793.html.plaintext.txt	286	1994 Apolipoprotein E affects rate Alzheimer disease expression ss amyloid burden secondary consequence dependent APOE genotype duration disease
0.35414052.11005793.html.plaintext.txt	287	1993 Apolipoprotein E high avidity binding ss amyloid increased frequency type 4 allele late onset familial Alzheimer disease
0.35414052.11005793.html.plaintext.txt	288	1991 Linkage studies familial Alzheimer disease evidence chromosome 19 linkage
0.35414052.11005793.html.plaintext.txt	289	1998 Risk estimates dementia apolipoprotein E genotypes population based incidence study Rotterdam study
0.35414052.11005793.html.plaintext.txt	290	1993 Gene dose apolipoprotein E type 4 allele risk Alzheimer disease late onset families
0.35414052.11005793.html.plaintext.txt	291	1994 Amyloid associated proteins 1 antichymotrypsin apolipoprotein E promote assembly Alzheimer ss protein filaments
0.35414052.11005793.html.plaintext.txt	292	1996 Alzheimer amyloid ss peptide forms denaturant resistant complex type 3 type 4 isoform native apolipoprotein E
0.35414052.11005793.html.plaintext.txt	293	1995 Genetic susceptibility Alzheimer disease
0.35414052.11005793.html.plaintext.txt	294	1993 Confirmation apolipoprotein E E4 allele associated late onset familial Alzheimer disease
0.35414052.11005793.html.plaintext.txt	295	Neurodegeneration 2 283 286
0.35414052.11005793.html.plaintext.txt	296	1995 Molecular genetics Alzheimer disease identification genes gene mutations
0.35414052.11005793.html.plaintext.txt	297	1997 Effects age sex ethnicity association apolipoprotein E genotype Alzheimer disease
0.35414052.11005793.html.plaintext.txt	298	APOE Alzheimer Disease Meta Analysis Consortium
0.35414052.11005793.html.plaintext.txt	299	1999 Genetic variability amyloid ss precursor protein locus may contribute risk late onset Alzheimer disease
0.35414052.11005793.html.plaintext.txt	300	1999 A full genome scan late onset Alzheimer disease
0.35414052.11005793.html.plaintext.txt	301	1999 Genetic association presenilin 1 regulatory region early onset Alzheimer disease population based sample
0.35414052.11005793.html.plaintext.txt	302	2000 Genetic variability regulatory region presenilin 1 associated risk Alzheimer disease variable expression
0.35414052.11005793.html.plaintext.txt	303	1997 Distortion allelic expression apolipoprotein E Alzheimer disease
0.35414052.11005793.html.plaintext.txt	304	1998 Allelic polymorphisms transcriptional regulatory region apolipoprotein E gene
0.35414052.11005793.html.plaintext.txt	305	1998 A polymorphism regulatory region APOE associated risk Alzheimer dementia
0.35414052.11005793.html.plaintext.txt	306	1998 A new polymorphism APOE promoter associated risk developing Alzheimer disease
0.35414052.11005793.html.plaintext.txt	307	1987 Localization amyloid bss protein messenger RNA brains patients Alzheimer disease
0.35414052.11005793.html.plaintext.txt	308	1987 Neuronal localization amyloid ss protein precursor mRNA normal human brain Alzheimer disease
0.35414052.11005793.html.plaintext.txt	309	1988 Alzheimer disease amyloidogenic glycoprotein expression pattern rat brain suggests role cell contact
0.35414052.11005793.html.plaintext.txt	310	1988 Localization putative precursor Alzheimer disease specific amyloid nuclear envelopes adult human muscle
0.35414052.11005793.html.plaintext.txt	311	1988 Nerve growth factor increases mRNA levels prion protein ss amyloid protein precursor developing hamster brain
0.35414052.11005793.html.plaintext.txt	312	1989 Interleukin 1 regulates synthesis amyloid ss protein precursor mRNA human endothelial cells
0.35414052.11005793.html.plaintext.txt	313	1990 Fibroblast growth factor induces ss amyloid precursor mRNA glial neuronal cultured cells
0.35414052.11005793.html.plaintext.txt	314	1992 Expression amyloid precursor protein mRNAs endothelial neuronal glial cells modulation interleukin 1
0.35414052.11005793.html.plaintext.txt	315	1995 Promoter activity gene encoding ss amyloid precursor protein regulated growth factors phorbol ester retinoic acid interleukin 1
0.35414052.11005793.html.plaintext.txt	316	1990 Retinoic acid induced differentiated neuroblastoma cells show increased expression ssA4 amyloid gene Alzheimer disease altered splicing pattern
0.35414052.11005793.html.plaintext.txt	317	1993 Induction ss amyloid precursor protein isoform mRNAs bFGF astrocytes
0.35414052.11005793.html.plaintext.txt	318	1990 Synthesis secretion Alzheimer amyloid ssA4 precursor protein stimulated human peripheral blood leucocytes
0.35414052.11005793.html.plaintext.txt	319	1991 Increased gene expression Alzheimer disease ss amyloid precursor protein senescent cultured fibroblasts
0.35414052.11005793.html.plaintext.txt	320	1995 Transcriptional activation Alzheimer ss amyloid precursor protein gene stress
0.35414052.11005793.html.plaintext.txt	321	1996 Heat shock factor 1 mediates transcriptional activation Alzheimer ss amyloid precursor protein gene response stress
0.35414052.11005793.html.plaintext.txt	322	1991 Induction amyloid precursor protein mRNA heat shock cultured human lymphoblastoid cells
0.35414052.11005793.html.plaintext.txt	323	1989 Expression ss amyloid precursor protein reactive astrocytes following neuronal damage
0.35414052.11005793.html.plaintext.txt	324	1993 Increased levels Kunitz protease inhibitor containing ss APP mRNAs rat brain following neurotoxic damage
0.35414052.11005793.html.plaintext.txt	325	1991 Regulatory region human amyloid precursor protein APP gene promotes neuron specific gene expression CNS transgenic mice
0.35414052.11005793.html.plaintext.txt	326	1993 Structural features 5 upstream regulatory region gene encoding rat amyloid precursor protein
0.35414052.11005793.html.plaintext.txt	327	1992 Positive negative regulatory elements expression Alzheimer disease amyloid precursor encoding gene mouse
0.35414052.11005793.html.plaintext.txt	328	1989 Characterization 5 end region first two exons ss protein precursor gene
0.35414052.11005793.html.plaintext.txt	329	1995 Molecular analysis promoter region gene encoding ss amyloid precursor protein
0.35414052.11005793.html.plaintext.txt	330	1988 The promoter Alzheimer disease amyloid A4 precursor gene
0.35414052.11005793.html.plaintext.txt	331	1991 The promoter activity gene encoding Alzheimer ss amyloid precursor protein APP regulated two blocks upstream sequences
0.35414052.11005793.html.plaintext.txt	332	1992 The amyloid ss protein precursor promoter
0.35414052.11005793.html.plaintext.txt	333	A region essential transcriptional activity contains nuclear factor binding domain
0.35414052.11005793.html.plaintext.txt	334	1992 The expression amyloid precursor protein APP regulated two GC elements promoter
0.35414052.11005793.html.plaintext.txt	335	1996 The initiator element proximal upstream sequences affect transcriptional activity start site selection amyloid ss protein precursor promoter
0.35414052.11005793.html.plaintext.txt	336	1994 Two nuclear factor binding domains activate expression human amyloid ss protein precursor promoter
0.35414052.11005793.html.plaintext.txt	337	1997 The zinc finger protein CTCF binds APBss domain amyloid ss protein precursor promoter
0.35414052.11005793.html.plaintext.txt	338	Evidence role transcriptional activation
0.35414052.11005793.html.plaintext.txt	339	1993 Overlapping binding sites two different transcription factors promoter human gene Alzheimer amyloid precursor protein
0.35414052.11005793.html.plaintext.txt	340	1995 The upstream stimulatory factor functionally interacts Alzheimer amyloid ss protein precursor gene
0.35414052.11005793.html.plaintext.txt	341	1995 USF binds APB sequence promoter amyloid ss protein precursor gene
0.35414052.11005793.html.plaintext.txt	342	1999 Enhancer function novel DNA binding protein activity near upstream ssAPP gene promoter
0.35414052.11005793.html.plaintext.txt	343	1995 Identification characterization BRel binding site regulatory region amyloid precursor protein gene
0.35414052.11005793.html.plaintext.txt	344	1996 Interleukin 1ss glutamate activate NF BRel binding site regulatory region amyloid precursor protein gene primary neuronal cultures
0.35414052.11005793.html.plaintext.txt	345	1998 An region upstream gene promoter ss amyloid precursor protein interacts proteins nuclear extracts human brain PC12 cells
0.35414052.11005793.html.plaintext.txt	346	1999 Promoter activity ss amyloid precursor protein gene negatively modulated upstream regulatory element
0.35414052.11005793.html.plaintext.txt	347	1989 Structure expression alternatively spliced forms mRNA mouse homolog Alzheimer disease amyloid ss protein precursor
0.35414052.11005793.html.plaintext.txt	348	1987 Complementary DNA mouse homolog human amyloid ss protein precursor
0.35414052.11005793.html.plaintext.txt	349	1998 Functional identification promoter gene encoding Rhesus monkey ss amyloid precursor protein
0.35414052.11005793.html.plaintext.txt	350	1995 Familial Alzheimer disease kindreds missense mutations gene chromosome 1 related Alzheimer disease type 3 gene
0.35414052.11005793.html.plaintext.txt	351	1998 Cloning characterization presenilin 2 gene promoter
0.35414052.11005793.html.plaintext.txt	352	1996 Widespread neuronal expression presenilin 1 early onset Alzheimer disease gene murine brain
0.35414052.11005793.html.plaintext.txt	353	1996 Alzheimer associated presenilins 1 2 neuronal expression brain localization intracelllular membranes mammalian cells
0.35414052.11005793.html.plaintext.txt	354	1996 Identification neuron specific expression S182presenilin I protein human rodent brains
0.35414052.11005793.html.plaintext.txt	355	1996 Expression presenilin 1 2 PS1 PS2 human murine tissues
0.35414052.11005793.html.plaintext.txt	356	1996 Widespread immunoreactivity presenilin neurons normal Alzheimer disease brains double labeling immunohistochemical study
0.35414052.11005793.html.plaintext.txt	357	1997 Presenilin 1 protein expression familial sporadic Alzheimer disease
0.35414052.11005793.html.plaintext.txt	358	1997 Regional cellular localization presenilin 2 RNA rat human brain
0.35414052.11005793.html.plaintext.txt	359	1997 Immunoreactivity presenilin 1 human rat mouse brain
0.35414052.11005793.html.plaintext.txt	360	1997 Neuronal localization presenilin 1 association amyloid plaques neurofibrillary tangles Alzheimer disease
0.35414052.11005793.html.plaintext.txt	361	1997 Neuronal expression intracellular localization presenilins normal Alzheimer disease brains
0.35414052.11005793.html.plaintext.txt	362	1998 Immunoreactivity presenilin 1 tau Alzheimer disease brain
0.35414052.11005793.html.plaintext.txt	363	1995 The structure presenilin 1 S182 gene identification six novel mutations early onset AD families
0.35414052.11005793.html.plaintext.txt	364	1997 Analysis 5 sequence genomic structure alternative splicing presenilin 1 gene PSEN1 associated early onset Alzheimer disease
0.35414052.11005793.html.plaintext.txt	365	1997 Transcriptional regulation mouse presenilin 1 gene
0.35414052.11005793.html.plaintext.txt	366	1999 An upstream element containing ETS binding site crucial transcription human presenilin 1 gene
0.35414052.11005793.html.plaintext.txt	367	1990 Reciprocal expression human ETS1 ETS2 genes T cell activation regulatory role protooncogene ETS1
0.35414052.11005793.html.plaintext.txt	368	1994 Differential expression ets 1 ets 2 proto oncogenes murine embryogenesis
0.35414052.11005793.html.plaintext.txt	369	1998 In vivo expression regulation Elk 1 target extracellular regulated kinase signaling pathway adult rat brain
0.35414052.11005793.html.plaintext.txt	370	1996 Genomic structure expression STM2 chromosome 1 familial Alzheimer disease gene
0.35414052.11005793.html.plaintext.txt	371	1996 Structure alternative splicing presenilin 2 gene
0.35414052.11005793.html.plaintext.txt	372	1991 Transcription TATA less promoter requires multisubunit TFIID complex
0.35414052.11005793.html.plaintext.txt	373	1999 Contrasting role presenilin 1 presenilin 2 neuronal differentiation vitro
0.35414052.11005793.html.plaintext.txt	374	1990 The apolipoprotein gene family organization upstream elements regulation gene expression
0.35414052.11005793.html.plaintext.txt	375	1988 Expression human apolipoprotein E gene regulated multiple positive negative elements
0.35414052.11005793.html.plaintext.txt	376	1985 Nucleotide sequence structure human apolipoprotein E gene
0.35414052.11005793.html.plaintext.txt	377	1990 Characterization human apolipoprotein E gene enhancer element associated protein factors
0.35414052.11005793.html.plaintext.txt	378	1988 Identification characterization transcriptional regulatory regions associated expression human apolipoprotein E gene
0.35414052.11005793.html.plaintext.txt	379	1995 Characterization upstream regulatory element human apolipoprotein E gene purification binding protein human placenta
0.35414052.11005793.html.plaintext.txt	380	1996 Transcription factor AP 2 regulates human apolipoprotein E gene expression astrocytoma cells
0.35414052.11005793.html.plaintext.txt	381	Similarity astrocytes form presence dBcAMP cultures reactive astrocytes vivo
0.35414052.11005793.html.plaintext.txt	382	1987 Transient increase intracellular concentration adenosine 35 cyclic monophosphate results morphological biochemical differentiation C6 glioma cells culture
0.35414052.11005793.html.plaintext.txt	383	1989 Regulation transcription factor AP 2 morphogen retinoic acid second messengers
0.35414052.11005793.html.plaintext.txt	384	1987 Transcription factor AP 2 mediates induction two different signal transduction pathways protein kinase C cAMP
0.35414052.11005793.html.plaintext.txt	385	1990 Downstream regulatory elements stimulate expression human apolipoprotein E gene liver suppress expression kidney transgenic mice
0.35414052.11005793.html.plaintext.txt	386	1990 In absence downstream element apolipoprotein E gene expressed high levels kidneys transgenic mice
0.35414052.11005793.html.plaintext.txt	387	1991 Multiple tissue specific elements control apolipoprotein EC I gene locus transgenic mice
0.35414052.11005793.html.plaintext.txt	388	1993 A far downstream hepatocyte specific control region directs expression linked human apolipoprotein E C I genes transgenic mice
0.35414052.11005793.html.plaintext.txt	389	1995 Structure hepatic control region human apolipoprotein EC I gene locus
0.35414052.11005793.html.plaintext.txt	390	1989 Structure expression mouse apolipoprotein E gene
0.35414052.11005793.html.plaintext.txt	391	1986 Structure expression rat apolipoprotein E gene
0.35414052.11005793.html.plaintext.txt	392	1986 Complete nucleotide sequence gene encoding rat apolipoprotein E
0.35414052.11005793.html.plaintext.txt	393	1992 Screening mutations open reading frame promoter ss amyloid precursor protein gene familial Alzheimer disease identification family APP717 ValIle
0.35414052.11005793.html.plaintext.txt	394	1992 Screening promoter ss amyloid sequence APP gene polymorphisms families late onset Alzheimer disease
0.35414052.11005793.html.plaintext.txt	395	Neurodegeneration 1 237 240
0.35414052.11005793.html.plaintext.txt	396	1993 Analysis c fos gene chromosome 14 promoter amyloid precursor protein gene familial Alzheimer disease
0.35414052.11005793.html.plaintext.txt	397	1995 No evidence common allelic variation Amyloid precursor protein APP gene confers susceptibility Alzheimer disease
0.35414052.11005793.html.plaintext.txt	398	1999 DGGE method mutational analysis coding proximal promoter regions Alzheimer disease presenilin 1 gene two novel mutations
0.35414052.11005793.html.plaintext.txt	399	2000 Variable neuron specific presenilin 1 transcription increases risk Alzheimer disease
0.35414052.11005793.html.plaintext.txt	400	1996 A newly identified polymorphism apolipoprotein E enhancer gene region associated Alzheimer disease strongly 4 allele
0.35414052.11005793.html.plaintext.txt	401	1998 The 491AT apolipoprotein E promoter polymorphism association Alzheimer disease independent risk linkage disequilibrium known APOE polymorphism
0.35414052.11005793.html.plaintext.txt	402	1998 The 491 AT polymorphism regulatory region apolipoprotein E gene early onset Alzheimer disease
0.35414052.11005793.html.plaintext.txt	403	1999 Apolipoprotein E promoter polymorphism sporadic Alzheimer disease Japanese population
0.35414052.11005793.html.plaintext.txt	404	1999 Promoter polymorphism 491AT APOE gene Finnish Alzheimer disease patients control individuals
0.35414052.11005793.html.plaintext.txt	405	1999 Apolipoprotein E promoter 2 macroglobulin polymorphisms genetically associated Chinese late onset Alzheimer disease
0.35414052.11005793.html.plaintext.txt	406	1999 Polymorphisms human apolipoprotein E promoter bleomycin hydrolase gene risk factors Alzheimer dementia Neurosci
0.35414052.11005793.html.plaintext.txt	407	1999 Apolipoprotein E 1 antichymotrypsin allele polymorphism sporadic familial Alzheimer disease
0.35414052.11005793.html.plaintext.txt	408	1999 The 491AT polymorphism apolipoprotein E gene associated ApoE4 allele Alzheimer disease
0.35414052.11005793.html.plaintext.txt	409	1997 Pattern gradient apolipoprotein E allele 4 frequencies western Europe
0.35414052.11005793.html.plaintext.txt	410	1992 Apolipoprotein E polymorphism Danish population compared findings 45 study populations around world
0.35414052.11005793.html.plaintext.txt	411	1998 Pronounced impact Th1E47cs mutation compared 491 AT mutation neural APOE gene expression risk developing Alzheimer disease
0.35414052.11005793.html.plaintext.txt	412	1999 The 491AA polymorphism APOE gene associated increased plasma apoE levels Alzheimer disease
0.35414052.11005793.html.plaintext.txt	413	1988 In situ hybridization nucleus basalis neurons shows increased ss amyloid mRNA Alzheimer disease
0.35414052.11005793.html.plaintext.txt	414	1989 Expression neuronal mRNAs Alzheimer type degeneration nervous system
0.35414052.11005793.html.plaintext.txt	415	1989 Increasing amyloid peptide precursor production impact Alzheimer disease
0.35414052.11005793.html.plaintext.txt	416	1988 Differential regulation amyloid ss protein mRNA expression within hippocampal neuronal subpopulations Alzheimer disease
0.35414052.11005793.html.plaintext.txt	417	1988 Distribution precursor amyloid ss protein messenger RNA human cerebral cortex relationship neurofibrillary tangles neuritic plaques
0.35414052.11005793.html.plaintext.txt	418	1989 Amyloid A4 protein precursor Down syndrome Alzheimer disease
0.35414052.11005793.html.plaintext.txt	419	1990 Jun Fos receptors vitamins A D recognize common response element human osteocalcin gene
0.35414052.11005793.html.plaintext.txt	420	1990 Sp1 displace GHF 1 distal binding site stimulate transcription growth hormone gene promoter
0.35414052.11005793.html.plaintext.txt	421	1992 Competition overlapping sites regulatory region Drosophila gene Kruppel
0.35414052.11005793.html.plaintext.txt	422	1991 Developmental expression Sp1 mouse
0.35414052.11005793.html.plaintext.txt	423	1990 SV40 stimulates expression transacting factor Sp1 mRNA level
0.35414052.11005793.html.plaintext.txt	424	1990 GC box binding induces phosphorylation Sp1 DNA dependent protein kinase
0.35414052.11005793.html.plaintext.txt	425	1997 Expression presenilin 1 2 mRNAs rat Alzheimer disease brains
0.35414052.11005793.html.plaintext.txt	426	1996 Neuronal expression STM2 mRNA human brain reduced Alzheimer disease
0.35414052.11005793.html.plaintext.txt	427	1996 Injury induces presenilin 1 gene expression mouse brain
0.35414052.11005793.html.plaintext.txt	428	1999 Antisense induced reduction presenilin 1 expression selectively increases production amyloid ss42 transfected cells
0.35414052.11005793.html.plaintext.txt	429	1999 Identification caspases cleave presenilin 1 presenilin 2
0.35414052.11005793.html.plaintext.txt	430	Five presenilin 1 PS1 mutations alter sensitivity PS1 caspases
0.35414052.11005793.html.plaintext.txt	431	1994 Differential effects apolipoproteins E3 E4 neuronal growth vitro
0.35414052.11005793.html.plaintext.txt	432	1992 Effects apolipoprotein E ss low density lipoproteins cholesterol extension neurites rabbit dorsal root ganglion neurons vitro
0.35414052.11005793.html.plaintext.txt	433	1985 Apolipoprotein E associated astrocytic glia central nervous system nonmyelinating glia peripheral nervous system
0.35414052.11005793.html.plaintext.txt	434	1987 Astrocytes synthesize apolipoprotein E metabolize apolipoprotein E containing lipoproteins
0.35414052.11005793.html.plaintext.txt	435	1989 A role apolipoprotein E apolipoprotein A I low density lipoprotein receptors cholesterol transport regeneration remyelination rat sciatic nerve
0.35414052.11005793.html.plaintext.txt	436	1986 Expression apolipoprotein E nerve degeneration regeneration
0.35414052.11005793.html.plaintext.txt	437	1986 Nerve injury stimulates secretion apolipoprotein E nonneuronal cells
0.35414052.11005793.html.plaintext.txt	438	1991 Astrocytic apolipoprotein E mRNA GFAP mRNA hippocampus ento rhinal cortex lesioning
0.35414052.11005793.html.plaintext.txt	439	1991 Neuropathological changes scrapie Alzheimer disease associated increased expression apolipoprotein E cathepsin D astrocytes
0.35414052.11005793.html.plaintext.txt	440	1992 Single base pair substitutions within HLA DRA gene promoter separate functions X1 X2 boxes
0.35414052.11005793.html.plaintext.txt	441	1994 A polymorphism GA transition 78 position apolipoprotein A I promoter increases transcription efficiency
0.35414052.11005793.html.plaintext.txt	442	1997 Conserved elements 5 regulatory region amyloid precursor protein gene primates
0.35414052.11005793.html.plaintext.txt	443	1995 Characterization upstream regulatory sequence binding protein mouse apolipoprotein E gene
0.35414052.11005793.html.plaintext.txt	444	1999 Determination genomic organization human presenilin 1 fiber FISH analysis restriction mapping cloned DNA
0.31481948.7615568.html.plaintext.txt	0	1995 The American Society Biochemistry Molecular Biology Inc
0.31481948.7615568.html.plaintext.txt	1	Apolipoprotein E Carboxyl terminal Fragments Are Complexed Amyloids A L IMPLICATIONS FOR AMYLOIDOGENESIS AND ALZHEIMERS DISEASE
0.31481948.7615568.html.plaintext.txt	2	Received publication February 21 1995 revised form May 1 1995
0.31481948.7615568.html.plaintext.txt	3	Castao Frances Prelli Mordechai Pras 1 Blas Frangione
0.31481948.7615568.html.plaintext.txt	4	From Department Pathology New York University Medical Center New York New York 10016 Heller Institute Medical Research Sheba Medical Center Tel Hashomer Israel ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION FOOTNOTES REFERENCES
0.31481948.7615568.html.plaintext.txt	5	Apolipoprotein E ApoE immunoreactivity consistently present senile plaques neurofibrillary tangles Alzheimers disease AD brain
0.31481948.7615568.html.plaintext.txt	6	In vitro apoE particular apoE4 isoform bind promote fibrillogenesis amyloid A peptide main constituent senile plaques
0.31481948.7615568.html.plaintext.txt	7	These findings together strong genetic association late onset AD E4 allele apoE strengthened hypothesis apoE may central role pathogenesis AD modulating A cerebral accumulation
0.31481948.7615568.html.plaintext.txt	8	However apoE immunoreactivity present cerebral systemic amyloidoses tested tryptic apoE fragments identified association amyloid A AA
0.31481948.7615568.html.plaintext.txt	9	In order elucidate interaction apoE amyloids purified AA amyloid L AL fibrils patients familial Mediterranean fever primary amyloidosis respectively studied association apoE AA AL proteins
0.31481948.7615568.html.plaintext.txt	10	In case apoE fragments detected Western blot co purified amyloid fibrils
0.31481948.7615568.html.plaintext.txt	11	Microsequencing analysis identified COOH terminal fragments apoE similar 10 kDa fragment produced thrombin digestion contains purported binding region A
0.31481948.7615568.html.plaintext.txt	12	In vitro co incubation AA purified human apoE resulted formation SDS resistant AAapoE complex higher degree polymerization AA peptide
0.31481948.7615568.html.plaintext.txt	13	These findings similar results obtained AD senile plaques suggest 1 carboxyl terminal fragment apoE complexed amyloid fibrils resists proteolysis vivo 2 apoE may promote amyloidogenesis conformation dependent interaction regardless primary structure amyloid precursors
0.31481948.7615568.html.plaintext.txt	14	Amyloidosis disorder protein conformation low molecular weight proteins soluble physiological conditions become deposited accumulate either intact partially digested diverse tissues organs insoluble amyloid fibrils
0.31481948.7615568.html.plaintext.txt	15	In spite biochemical diversity amyloid proteins adopt common secondary structure pleated sheet form fibrils similar morphology
0.31481948.7615568.html.plaintext.txt	16	These fibrils characteristically long straight filaments 5 12 nm wide share tinctorial properties green birefringence Congo red staining specific affinity fluorescent dyes Thioflavine S T
0.31481948.7615568.html.plaintext.txt	17	In addition features shared types amyloids several factors consistently associated pathological condition viewed part biochemical setting amyloid deposition arises develops
0.31481948.7615568.html.plaintext.txt	18	These include elevated concentration amyloid precursors fluids tissues invariable presence certain amyloid associated proteins amyloid P component AP1 2 sulfated proteoglycans 3 4 5 apolipoprotein E apoE 6 7 apolipoprotein J 8 notorious
0.31481948.7615568.html.plaintext.txt	19	Whether amyloid associated proteins play active role promoting inhibiting amyloidogenesis inert bystanders present unknown
0.31481948.7615568.html.plaintext.txt	20	ApoE 34 kDa exchangeable apolipoprotein present types lipoprotein particles involved cholesterol transport well less defined functions nerve regeneration injury9 10 11 12
0.31481948.7615568.html.plaintext.txt	21	The recently reported association certain apoE genetic isoforms Alzheimers disease AD condition characterized massive deposition brain 39 44 residue amyloid protein A13 14 15 16 17 18 strengthened hypothesis apolipoprotein may directly involved pathogenesis cerebral amyloidosis19 20
0.31481948.7615568.html.plaintext.txt	22	Moreover vitro binding experiments using human apoE isolated plasma recombinant human apoE synthetic peptides homologous A shown two proteins form SDS resistant complex A promote A fibril formation vitro21 22 23 24
0.31481948.7615568.html.plaintext.txt	23	These lines evidence together immunohistochemical colocalization apoE A senile plaques presence intraneuronal amyloid neurofibrillary tangles6 suggest apoE may play active role pathogenesis AD promoting fibrillogenesis
0.31481948.7615568.html.plaintext.txt	24	However immunohistochemical studies shown apoE tightly associated types cerebral amyloidosis including Down syndrome related A hereditary cerebral amyloid angiopathy Icelandic type related cystatin C variant spongiform encephalopathies Creutzfeldt Jakob kuru Gerstmann Straussler Scheinker disease associated prion amyloid6 7 25
0.31481948.7615568.html.plaintext.txt	25	Furthermore apoE immunohistochemically identified within amyloid deposits systemic forms disease secondary amyloidosis familial Mediterranean fever related amyloid A immunoglobulin related primary amyloidosis AL familial amyloidotic polyneuropathy due deposition transthyretin genetic variants7
0.31481948.7615568.html.plaintext.txt	26	Noteworthy apoE rarely detected nonfibrillar monoclonal deposits light chain deposition disease light heavy chain deposition disease may considered preamyloid forms AL disease26
0.31481948.7615568.html.plaintext.txt	27	This widespread association apoE biochemically clinically diverse types amyloidoses suggests apoE may participate general manner process amyloid formation
0.31481948.7615568.html.plaintext.txt	28	In order gain insight biochemistry association apoE amyloid proteins characterized Western blot amino terminal sequence analysis apoE fragments co purified amyloid subunits cases systemic amyloidosis AA AL
0.31481948.7615568.html.plaintext.txt	29	We also studied vitro binding human apoE isolated plasma amyloid proteins
0.31481948.7615568.html.plaintext.txt	30	Protein PurificationAmyloid A AL fibrils isolated method Pras et al
0.31481948.7615568.html.plaintext.txt	31	27 spleen tissue patients familial Mediterranean fever COH primary amyloidosis RAM
0.31481948.7615568.html.plaintext.txt	32	Briefly 20 g spleen tissue homogenized 0
0.31481948.7615568.html.plaintext.txt	33	15 M sodium chloride centrifuged 8000 g 30 min 4 degrees C supernatant discarded
0.31481948.7615568.html.plaintext.txt	34	This procedure repeated supernatant absorbance less 0
0.31481948.7615568.html.plaintext.txt	35	Then insoluble residue homogenized distilled water centrifuged 8000 g 4 degrees C 1 h
0.31481948.7615568.html.plaintext.txt	36	The amyloid fibrils appear mucoid mass upper layer dialyzed water lyophilized
0.31481948.7615568.html.plaintext.txt	37	After lyophilization AA protein purified high performance liquid chromatography HPLC see
0.31481948.7615568.html.plaintext.txt	38	AL fibrils solubilized 3 ml 6 M guanidine hydrochloride 0
0.31481948.7615568.html.plaintext.txt	39	2 stirred 48 h room temperature
0.31481948.7615568.html.plaintext.txt	40	Then 1 ml 2 M guanidine hydrochloride 4 M acetic acid added solution applied column 2
0.31481948.7615568.html.plaintext.txt	41	5 180 cm consisting 11 wt Sephadex G 75 Sephadex G 100 Pharmacia Biotech Inc
0.31481948.7615568.html.plaintext.txt	42	equilibrated 5 M guanidine hydrochloride 1 M acetic acid
0.31481948.7615568.html.plaintext.txt	43	AL amyloid fragments isolated size exclusion chromatography AA fibrils subjected reverse phase chromatography Deltapak C column 0
0.31481948.7615568.html.plaintext.txt	44	78 30 cm Waters gradient 30 80 acetonitrile 0
0.31481948.7615568.html.plaintext.txt	45	1 vv trifluoroacetic acid pH 2
0.31481948.7615568.html.plaintext.txt	46	The column eluents monitored 214 nm protein peaks pooled lyophilized
0.31481948.7615568.html.plaintext.txt	47	Crude amyloid fibrils fractions obtained gel filtration HPLC subjected 12
0.31481948.7615568.html.plaintext.txt	48	5 Tricine sodium dodecyl sulfate polyacrylamide gel electrophoresis SDS PAGE28 proteins electrophoretically transferred 1 h 400 mA 4 degrees C polyvinylidene difluoride membranes Immobilon Millipore using 10 mM CAPS buffer pH 11 containing 10 methanol
0.31481948.7615568.html.plaintext.txt	49	The membranes blocked 5 nonfat dry milk 10 mM Tris HCl 150 mM sodium chloride 0
0.31481948.7615568.html.plaintext.txt	50	6 2 h room temperature incubated overnight 4 degrees C following antibodies rabbit polyclonal antibodies amyloid A29 light chain Dako Corp
0.31481948.7615568.html.plaintext.txt	51	goat anti human apolipoprotein E Fitzgerald monoclonal antibodies ID7 6C5 raised residues 142 158 1 15 apoE respectively generous gift Dr Y
0.31481948.7615568.html.plaintext.txt	52	Horseradish peroxidase conjugated sheep anti mouse Amersham Corp
0.31481948.7615568.html.plaintext.txt	53	goat anti rabbit rabbit anti goat IgG Biosource International used second antibody dilution 15000
0.31481948.7615568.html.plaintext.txt	54	Immunoblots visualized ECL chemiluminescence kit Amersham Corp
0.31481948.7615568.html.plaintext.txt	55	according manufacturers specifications
0.31481948.7615568.html.plaintext.txt	56	Anti apoE antiserum adsorbed incubating 15 microg purified human apoE anti apoE diluted 1100 0
0.31481948.7615568.html.plaintext.txt	57	3 bovine serum albumin BSA Tris buffered saline pH 7
0.31481948.7615568.html.plaintext.txt	58	Protein Sequence AnalysisAutomated Edman degradation sequence analysis carried 477A ProteinPeptide Sequenator resulting phenylthiohydantoin amino acid derivatives identified using line 120A PTH Analyzer Applied Biosystems Foster City CA
0.31481948.7615568.html.plaintext.txt	59	In Vitro Incubation ApoE Amyloid PeptidesHuman ApoE purchased Cortex Biochem bovine ubiquitin BSA purchased Sigma
0.31481948.7615568.html.plaintext.txt	60	The purity 95 proteins assessed SDS PAGE NH terminal sequence analysis
0.31481948.7615568.html.plaintext.txt	61	Since human pooled apoE used seems likely major isoform apoE3 according statistical distribution normal population
0.31481948.7615568.html.plaintext.txt	62	Stock solutions amyloid peptides prepared 0
0.31481948.7615568.html.plaintext.txt	63	1 trifluoroacetic acid 50 acetonitrile quantitated amino acid analysis using Pico Tag analyzer Waters using microbicinchoninic acid assay kit Pierce
0.31481948.7615568.html.plaintext.txt	64	ApoE stock solution made 0
0.31481948.7615568.html.plaintext.txt	65	4 aliquots stored 20 degrees C
0.31481948.7615568.html.plaintext.txt	66	Aliquots stock solutions lyophilized used co incubation experiments described21
0.31481948.7615568.html.plaintext.txt	67	5 microg apoE incubated 10 microg AA 15 microg AL 12 microl 0
0.31481948.7615568.html.plaintext.txt	68	4 indicated time room temperature
0.31481948.7615568.html.plaintext.txt	69	After incubation 15 microl 4 SDS sample buffer added mixture run 12
0.31481948.7615568.html.plaintext.txt	70	5 SDS Tricine gels nondenaturing 7
0.31481948.7615568.html.plaintext.txt	71	5 polyacrylamide gels without SDS
0.31481948.7615568.html.plaintext.txt	72	Proteins transferred Immobilon P detected using polyclonal anti apoE anti AA anti AL antibodies described
0.31481948.7615568.html.plaintext.txt	73	As control co incubation experiments ubiquitin molecular mass 8 kDa BSA used instead amyloid peptides apoE respectively
0.31481948.7615568.html.plaintext.txt	74	ImmunohistochemistrySections spleen tissue cases amyloid A COH AL RAM deparaffinized xylene rehydrated ethanol Tris buffered saline
0.31481948.7615568.html.plaintext.txt	75	After rehydration endogenous peroxidase quenched incubation 0
0.31481948.7615568.html.plaintext.txt	76	3 hydrogen peroxide methanol 30 min
0.31481948.7615568.html.plaintext.txt	77	After blocking 3 BSA Tris buffered saline sections incubated goat anti human apoE Fitzgerald 1100 dilution overnight 4 degrees C rabbit anti goat labeled horseradish peroxidase Biosource International 11000 1 h
0.31481948.7615568.html.plaintext.txt	78	The reaction detected using 0
0.31481948.7615568.html.plaintext.txt	79	03 33 diaminobenzidine tetrachloride 0
0.31481948.7615568.html.plaintext.txt	80	01 hydrogen peroxide 50 mM Tris pH 7
0.31481948.7615568.html.plaintext.txt	81	Anti apoE antiserum adsorbed purified human apoE described
0.31481948.7615568.html.plaintext.txt	82	Immunohistochemistry spleen sections patients COH RAM showed polyclonal anti human apoE labeled amyloid deposits described previously7
0.31481948.7615568.html.plaintext.txt	83	This immunoreactivity completely abolished adsorption purified human apoE indicating specificity Fig
0.31481948.7615568.html.plaintext.txt	84	Figure 1 Immunohistochemistry spleen sections patient COH amyloid A
0.31481948.7615568.html.plaintext.txt	85	anti apoE antibody labels amyloid laden vessels
0.31481948.7615568.html.plaintext.txt	86	b adjacent section adsorption anti apoE human purified apoE
0.31481948.7615568.html.plaintext.txt	87	Amyloid L patient RAM purified procedure saline water extraction gel chromatography Sephadex G 100 equilibrated 5 M guanidine
0.31481948.7615568.html.plaintext.txt	88	SDS PAGE fractions revealed main amyloid subunit molecular mass 12 13 kDa amino terminal sequence analysis showed homology III IV Ig light chain Fig
0.31481948.7615568.html.plaintext.txt	89	HPLC separation RAM AL yielded broad peak 45 73 solvent B
0.31481948.7615568.html.plaintext.txt	90	This peak divided four fractions A B C D rechromatographed Fig
0.31481948.7615568.html.plaintext.txt	91	Figure 3 Microsequence Analysis
0.31481948.7615568.html.plaintext.txt	92	Amino terminal sequence amyloid L amyloid A proteins apoE peptides co purified
0.31481948.7615568.html.plaintext.txt	93	Figure 2 Purification RAM Amyloid L
0.31481948.7615568.html.plaintext.txt	94	reverse phase HPLC RAM amyloid L Deltapak C column 0
0.31481948.7615568.html.plaintext.txt	95	78 30 cm using 30 80 linear gradient acetonitrile 0
0.31481948.7615568.html.plaintext.txt	96	RAM amyloid L eluted broad peak 45 73 solvent B
0.31481948.7615568.html.plaintext.txt	97	5 Tricine SDS PAGE RAM AL fibrils F HPLC fractions A B C D
0.31481948.7615568.html.plaintext.txt	98	RAM amyloid L subunit mass 12 13 kDa K present fractions together minor dimeric component 26 kDa
0.31481948.7615568.html.plaintext.txt	99	The 8 9 kDa band present fraction C carboxyl terminal truncated fragment AL
0.31481948.7615568.html.plaintext.txt	100	c Western blot analysis HPLC fractions A B C D using antibody human apoE developed chemoluminescence showed major 8 9 kDa band minor 18 kDa band fraction D
0.31481948.7615568.html.plaintext.txt	101	The approximate yield apoE fragment obtained RAM amyloid estimated follows
0.31481948.7615568.html.plaintext.txt	102	The ratio amyloid apoE fraction D determined densitometry Coomassie Blue stained 12 13 kDa 26 kDa AL bands 8 9 kDa apoE band PDI optical densitometer
0.31481948.7615568.html.plaintext.txt	103	This ratio applied area fraction D HPLC profile
0.31481948.7615568.html.plaintext.txt	104	Then proportional area fraction D total area HPLC profile determined
0.31481948.7615568.html.plaintext.txt	105	SDS PAGE analysis fractions revealed addition major AL subunit 12 13 kDa 26 kDa component seen fractions
0.31481948.7615568.html.plaintext.txt	106	The latter probably corresponded dimer AL subunit since recognized anti chain antibody shown
0.31481948.7615568.html.plaintext.txt	107	In addition minor bands approximately 8 9 kDa present fractions C D Fig
0.31481948.7615568.html.plaintext.txt	108	Western blot analysis fractions using anti apoE antibody visualized chemiluminescence detection revealed major band 8 9 kDa minor 24 kDa component fraction D Fig
0.31481948.7615568.html.plaintext.txt	109	The failure detect apoE direct amino terminal sequence analysis RAM fraction D despite positive apoE immunoreactivity fraction indicated present low concentration
0.31481948.7615568.html.plaintext.txt	110	Therefore HPLC fractions A B C D run SDS Tricine gels transferred Immobilon membrane bands excised subjected amino terminal sequence analysis
0.31481948.7615568.html.plaintext.txt	111	Amino terminal sequence 8 9 kDa component fraction C revealed fragment AL starting position 1 shown
0.31481948.7615568.html.plaintext.txt	112	The 8 9 kDa band HPLC fraction D yielded two major fragments apoE starting positions 225 227 minor one starting position 216 addition amyloid protein Fig
0.31481948.7615568.html.plaintext.txt	113	The estimated relative yield apoE carboxyl fragment extracted amyloid deposits approximately 150 molar ratio apoEamyloid
0.31481948.7615568.html.plaintext.txt	114	Purification amyloid A subunits COH performed saline water extraction followed separation HPLC Fig
0.31481948.7615568.html.plaintext.txt	115	This procedure yielded broad ill defined peaks eluted 60 78 solvent B pooled four fractions A B C D rechromatographed analyzed SDS PAGE
0.31481948.7615568.html.plaintext.txt	116	A major protein band 6 8 kDa present fractions minor 16 kDa component may polymer 6 8 kDa peptide detected fractions B C Fig
0.31481948.7615568.html.plaintext.txt	117	Amino terminal sequence analysis HPLC fractions revealed one residue per cycle
0.31481948.7615568.html.plaintext.txt	118	The sequence identical serum amyloid A protein Fig
0.31481948.7615568.html.plaintext.txt	119	No additional sequences identified
0.31481948.7615568.html.plaintext.txt	120	When fractions subjected Western blot using anti apoE antibody fluorogram revealed broad band 8 9 kDa fraction D Fig
0.31481948.7615568.html.plaintext.txt	121	Immunoreactivity band completely suppressed adsorption antiserum purified human apoE reflecting specificity reaction
0.31481948.7615568.html.plaintext.txt	122	There band corresponding intact apoE 34 kDa suggesting small fragments apoE associated amyloid A subunit
0.31481948.7615568.html.plaintext.txt	123	Figure 4 Purification COH amyloid A proteins
0.31481948.7615568.html.plaintext.txt	124	reverse phase HPLC COH amyloid A Deltapak C column 0
0.31481948.7615568.html.plaintext.txt	125	78 30 cm using 30 80 linear gradient acetonitrile 0
0.31481948.7615568.html.plaintext.txt	126	COH amyloid A eluted broad peak 60 78 solvent B
0.31481948.7615568.html.plaintext.txt	127	5 Tricine SDS PAGE HPLC fractions A B C D
0.31481948.7615568.html.plaintext.txt	128	A major COH amyloid A subunit 6 8 kDa K present fractions
0.31481948.7615568.html.plaintext.txt	129	A minor 16 kDa component possibly polymer former detected fractions B C
0.31481948.7615568.html.plaintext.txt	130	c Western blot analysis HPLC fractions A B C D using antibody human apoE developed chemiluminescence revealed broad 8 9 kDa component fraction D
0.31481948.7615568.html.plaintext.txt	131	The failure detect apoE direct amino terminal sequence analysis COH fraction D despite positive apoE immunoreactivity indicated present low concentration
0.31481948.7615568.html.plaintext.txt	132	Therefore similar approach RAM AL used proteins separated SDS Tricine gels transferred Immobilon membrane
0.31481948.7615568.html.plaintext.txt	133	The upper portion 6 8 kDa band HPLC fraction D yielded two sequences corresponding N terminus amyloid A apoE fragment starting position 199 respectively Fig
0.31481948.7615568.html.plaintext.txt	134	In order investigate whether intact apoE present crude A L amyloid fibril fraction HPLC separation performed Western blots using monoclonal antibodies ID7 6C5 specific amino terminal domain apoE
0.31481948.7615568.html.plaintext.txt	135	A band corresponding 34 kDa intact apoE observed association COH fibrils
0.31481948.7615568.html.plaintext.txt	136	5 micrograms purified human apoE incubated 10 microg purified COH amyloid A 6 h room temperature 0
0.31481948.7615568.html.plaintext.txt	137	4 novel component approximately 44 kDa detected Western immunoblot analysis using anti apoE Fig
0.31481948.7615568.html.plaintext.txt	138	5a anti AA antibodies shown indicating apoE amyloid complex partially resistant SDS formed
0.31481948.7615568.html.plaintext.txt	139	Under nondenaturing conditions 7
0.31481948.7615568.html.plaintext.txt	140	5 polyacrylamide gels complex resulted shift electrophoretic mobility apoE Fig
0.31481948.7615568.html.plaintext.txt	141	No complex formation detected apoE incubated 20 microg ubiquitin
0.31481948.7615568.html.plaintext.txt	142	The influence apoE upon AA polymerization evaluated detection apoE AA incubation mixture anti AA antibody Western blots
0.31481948.7615568.html.plaintext.txt	143	AA alone incubated 6 h room temperature 0
0.31481948.7615568.html.plaintext.txt	144	4 showed mainly monomeric forms minor polymeric components SDS PAGE
0.31481948.7615568.html.plaintext.txt	145	In contrast AA co incubated apoE 185 molar ratio apoEamyloid conditions resulted appearance gel higher amount AA dimers trimers tetramers higher molecular weight components Fig
0.31481948.7615568.html.plaintext.txt	146	AA co incubated BSA showed increment polymerization compared AA alone shown
0.31481948.7615568.html.plaintext.txt	147	When experiment done using RAM AL additional bands present
0.31481948.7615568.html.plaintext.txt	148	However amyloid apoE incubation mixture remained top stacking running gels high molecular weight components shown
0.31481948.7615568.html.plaintext.txt	149	This result consistent higher degree aggregation amyloid AL subunits presence apoE resisted denaturation SDS treatment
0.31481948.7615568.html.plaintext.txt	150	Figure 5 In vitro co incubation amyloid A apoE
0.31481948.7615568.html.plaintext.txt	151	5 microg amyloid A 10 microg incubated 0
0.31481948.7615568.html.plaintext.txt	152	The incubation stopped addition 2 Laemmli sample buffer samples run 12
0.31481948.7615568.html.plaintext.txt	153	After transferring Immobilon P proteins detected anti apoE antibody
0.31481948.7615568.html.plaintext.txt	154	Lane1 apoE alone lane2 apoE incubated amyloid A
0.31481948.7615568.html.plaintext.txt	155	Leftmargin indicates molecular mass kilodaltons kD
0.31481948.7615568.html.plaintext.txt	156	E apoE EA apoE amyloid A complex
0.31481948.7615568.html.plaintext.txt	157	b apoE amyloid A incubated described run nondenaturing 7
0.31481948.7615568.html.plaintext.txt	158	Proteins detected Western blots anti apoE antibody
0.31481948.7615568.html.plaintext.txt	159	A shift electrophoretic mobility apoE reflects formation amyloid apoE complex
0.31481948.7615568.html.plaintext.txt	160	Lane1 apoE alone lane2 apoE incubated amyloid A
0.31481948.7615568.html.plaintext.txt	161	c amyloid A incubated alone apoE described
0.31481948.7615568.html.plaintext.txt	162	5 SDS Tricine PAGE transferred Immobilon P membranes
0.31481948.7615568.html.plaintext.txt	163	Proteins detected anti AA antibody
0.31481948.7615568.html.plaintext.txt	164	A higher degree polymerization amyloid A peptide present upon incubation apoE
0.31481948.7615568.html.plaintext.txt	165	Lane1 amyloid A alone lane2 amyloid A incubated apoE
0.31481948.7615568.html.plaintext.txt	166	Leftmargin indicates molecular mass kDa
0.31481948.7615568.html.plaintext.txt	167	Apo E two domain protein modeled two major fragments thrombin digestion
0.31481948.7615568.html.plaintext.txt	168	The 22 kDa amino terminal domain residues 1 191 stable globular structure containing sequence mediates low density lipoprotein receptor binding9 30
0.31481948.7615568.html.plaintext.txt	169	In contrast 10 kDa carboxyl terminal fragment less stable binds lipoproteins mediates lipid free apoE tetramerization aqueous solutions31
0.31481948.7615568.html.plaintext.txt	170	Previously published finding tryptic fragment apolipoprotein E corresponding residues 270 278 association two amyloid A proteins29
0.31481948.7615568.html.plaintext.txt	171	Our present data extend observation
0.31481948.7615568.html.plaintext.txt	172	Three fragments apoE located within thrombolytic carboxyl fragment apoE co purified RAM amyloid L
0.31481948.7615568.html.plaintext.txt	173	A slightly larger fragment apoE starting region connecting thrombolytic amino terminal carboxyl terminal domains apoE co purified COH amyloid A Fig
0.31481948.7615568.html.plaintext.txt	174	Similar apoE fragments recently obtained AD senile plaques 32
0.31481948.7615568.html.plaintext.txt	175	Figure 6 Schematic representation structural domains apolipoprotein E modeled thrombin proteolytic cleavage31
0.31481948.7615568.html.plaintext.txt	176	Alignment apoE carboxyl terminal peptides associated AL AA proteins shown well representation purported apoE binding domain A b20
0.31481948.7615568.html.plaintext.txt	177	We propose apoE fragments co purify AA AL bound amyloid proteins vivo
0.31481948.7615568.html.plaintext.txt	178	The remainder apoE molecule cleaved thrombin andor serine proteases situ either amyloid apoE complex formed
0.31481948.7615568.html.plaintext.txt	179	Alternatively cannot rule apoE partially degraded purification
0.31481948.7615568.html.plaintext.txt	180	Intact apoE apoE fragments determined Western blot analysis present crude AA AL fibril fractions HPLC
0.31481948.7615568.html.plaintext.txt	181	However purification carboxyl terminal apoE fragment co purifies AA AL amyloids
0.31481948.7615568.html.plaintext.txt	182	The question whether apoE amyloid association precedes tissue deposition remains addressed
0.31481948.7615568.html.plaintext.txt	183	It likely initial formation stable apoE amyloid complexes requires interaction amino carboxyl terminal domains apoE
0.31481948.7615568.html.plaintext.txt	184	Binding low density lipoprotein receptor amino terminal domain apoE requires lipid association largely mediated carboxyl end molecule31
0.31481948.7615568.html.plaintext.txt	185	The interdependence domains apoE reflected effect amino acid substitutions within amino terminal region association apoE diverse lipoprotein classes
0.31481948.7615568.html.plaintext.txt	186	Such association known mediated carboxyl terminus apoE 9
0.31481948.7615568.html.plaintext.txt	187	The apoE3 isoform Cys position 112 preferentially binds high density lipoproteins whereas presence Arg position favors binding low density intermediate density lipoproteins33 34
0.31481948.7615568.html.plaintext.txt	188	A cooperation domains unique apoE isoform postulated explain selective lipoprotein distribution35
0.31481948.7615568.html.plaintext.txt	189	Whether similar mechanism account higher avidity apoE4 isoform A AD remains tested
0.31481948.7615568.html.plaintext.txt	190	ApoE capable binding synthetic A strong interaction resistant SDS21
0.31481948.7615568.html.plaintext.txt	191	A similar interaction apoE A Dutch variant cerebral amyloid angiopathy rare form familial AD also documented 36 details apoE A binding published elsewhere
0.31481948.7615568.html.plaintext.txt	192	By using set truncated recombinants purported binding region A located within carboxyl end apoE amino acids 244 272 21
0.31481948.7615568.html.plaintext.txt	193	Our findings suggest binding region A specific peptide rather reflects hydrophobic interaction apoE carboxyl end common conformation shared different amyloids
0.31481948.7615568.html.plaintext.txt	194	Secondary structure predictions indicate putative amphipathic helix high affinity lipids 37 located within region co purifies amyloid peptides
0.31481948.7615568.html.plaintext.txt	195	Possibly exchangeable apolipoproteins sharing similar amphipathic helices also amyloid apolipoprotein interactions
0.31481948.7615568.html.plaintext.txt	196	It noteworthy genetic variants apoAI form amyloid certain hereditary forms human amyloidosis 38 39 SAA precursor AA apolipoprotein associated high density lipoprotein40
0.31481948.7615568.html.plaintext.txt	197	We recently found apoAI bind A promote A fibrillogenesis vitro
0.31481948.7615568.html.plaintext.txt	198	Presumably way large number amyloidogenic precursor proteins end insoluble amyloid fibrils also group amyloidogenic apolipoproteins acute phase reactants actively participate process either constituents fibrils modulators fibrillogenesis
0.31481948.7615568.html.plaintext.txt	199	Our finding higher degree polymerization AA AL native peptides upon incubation apoE together previous work using synthetic A 22 23 24 36 points general role apoE amyloidogenesis
0.31481948.7615568.html.plaintext.txt	200	The molar ratios apoE AA used vitro experiments opposite found plasma normal conditions apoE SAA
0.31481948.7615568.html.plaintext.txt	201	However SAA acute phase reactant concentration plasma capable rising 1000 fold tissue injury inflammation41
0.31481948.7615568.html.plaintext.txt	202	AL turn derived monoclonal light chains known high levels circulation cases
0.31481948.7615568.html.plaintext.txt	203	Therefore believe concentrations used vitro resemble closely pathological conditions amyloidosis develops physiological levels apoE amyloid precursors
0.31481948.7615568.html.plaintext.txt	204	ApoE may act one group pathological chaperones promote aggregation amyloidogenic precursors diverse primary structure pleated sheet conformation amyloid fibrils
0.31481948.7615568.html.plaintext.txt	205	The absence apoE AP nonfibrillar Congo red negative monoclonal deposits light chain deposition disease light heavy chain deposition disease considered preamyloid forms AL disease26 suggests apoE AP may essential catalysts modulation amyloid generation process
0.31481948.7615568.html.plaintext.txt	206	The interaction apoE amyloids may also influenced local acute phase reactants proteoglycans amyloid precursors apoE known bind42 43
0.31481948.7615568.html.plaintext.txt	207	In spite putative widespread role apoE amyloid formation seems likely certain specificity exists amyloid precursors apoE genetic isoforms
0.31481948.7615568.html.plaintext.txt	208	Thus far preferential associations systemic amyloidoses apoE isoforms reported however genetic association AD apoE4 vitro higher avidity isoform A may reflect specificity19 21
0.31481948.7615568.html.plaintext.txt	209	Alternatively apoE4 isoform may participate pathogenesis AD different pathway unrelated A formation deposition
0.31481948.7615568.html.plaintext.txt	210	Recently reported apoE inhibit A aggregation vitro concentrations similar found normally biological fluids44
0.31481948.7615568.html.plaintext.txt	211	This apparent discrepancy previous studies could due different experimental conditions22 23 24 36
0.31481948.7615568.html.plaintext.txt	212	However raises intriguing possibility apoE may dual effect upon fibrillogenesis vivo depending local concentrations apoE amyloid precursors sites amyloid formation
0.31481948.7615568.html.plaintext.txt	213	Within physiological levels apoE may protective role amyloid formation sequestering soluble amyloid precursors postulated A44
0.31481948.7615568.html.plaintext.txt	214	However A appears associated apolipoproteins
0.31481948.7615568.html.plaintext.txt	215	apolipoprotein J biological fluids vivo45
0.31481948.7615568.html.plaintext.txt	216	Yet tissues local membrane repair lipid turnover increased cell injury apoE overexpressed reach higher concentrations found normally circulation10 11 12 46
0.31481948.7615568.html.plaintext.txt	217	Under circumstances apoE may substantially different effect upon association amyloid precursors
0.31481948.7615568.html.plaintext.txt	218	In pathological setting several factors may affect apoE behavior state oxidation lipid association presence amyloidapoE binding proteins stage amyloid process47
0.31481948.7615568.html.plaintext.txt	219	The abnormal amyloid response individual determined finally complex process involving critical concentrations amyloid precursors set amyloid associated proteins apoE apolipoproteins AP antichymotrypsin 22 proteoglycans
0.31481948.7615568.html.plaintext.txt	220	These may act conjunction yet undefined tissue specific factors modulate conformational transition soluble protein insoluble fibril
0.31481948.7615568.html.plaintext.txt	221	A better understanding complex interactions amyloids factors modulate formation may open novel strategies treatment systemic cerebral amyloid related diseases
0.31481948.7615568.html.plaintext.txt	222	This work supported National Institutes Health Grants AR02594 MERIT AG10953 LEAD AG05891 Metropolitan Life Foundation Award Medical Research 1993
0.31481948.7615568.html.plaintext.txt	223	Part work presented 1994 Annual Meeting Society Neuroscience Miami Beach Florida
0.31481948.7615568.html.plaintext.txt	224	The costs publication article defrayed part payment page charges
0.31481948.7615568.html.plaintext.txt	225	This article must therefore hereby marked advertisement accordance 18 U
0.31481948.7615568.html.plaintext.txt	226	Section 1734 solely indicate fact
0.31481948.7615568.html.plaintext.txt	227	To correspondence addressed Dept
0.31481948.7615568.html.plaintext.txt	228	Pathology New York University Medical Center 550 First Ave
0.31481948.7615568.html.plaintext.txt	229	212 263 5775 Fax 212 263 6751
0.31481948.7615568.html.plaintext.txt	230	The abbreviations used AP amyloid P component HPLC high performance liquid chromatography AL amyloid L SAA serum amyloid A precursor AA amyloid A AD Alzheimers disease CAPS 3 cyclohexylaminopropanesulfonic acid BSA bovine serum albumin PAGE polyacrylamide gel electrophoresis
0.31481948.7615568.html.plaintext.txt	231	Castao unpublished observations
0.31481948.7615568.html.plaintext.txt	232	58 454 458 Medline Order article via Infotrieve Duong T
0.31481948.7615568.html.plaintext.txt	233	78 429 437 Medline Order article via Infotrieve Snow A
0.31481948.7615568.html.plaintext.txt	234	56 120 123 Medline Order article via Infotrieve Snow A
0.31481948.7615568.html.plaintext.txt	235	78 202 209 Medline Order article via Infotrieve Namba Y
0.31481948.7615568.html.plaintext.txt	236	541 163 166 CrossRefMedline Order article via Infotrieve Wisniewski T
0.31481948.7615568.html.plaintext.txt	237	135 235 238 CrossRefMedline Order article via Infotrieve Choi Miura N
0.31481948.7615568.html.plaintext.txt	238	83 260 264 Medline Order article via Infotrieve Mahley R
0.31481948.7615568.html.plaintext.txt	239	1988Science 240 622 630 Medline Order article via Infotrieve Boyles J
0.31481948.7615568.html.plaintext.txt	240	83 1015 1031 Medline Order article via Infotrieve Leblanc A
0.31481948.7615568.html.plaintext.txt	241	25 162 171 Medline Order article via Infotrieve Poirer J
0.31481948.7615568.html.plaintext.txt	242	55 81 90 CrossRefMedline Order article via Infotrieve Glenner G
0.31481948.7615568.html.plaintext.txt	243	122 1131 1135 Medline Order article via Infotrieve Masters C
0.31481948.7615568.html.plaintext.txt	244	82 4245 4249 Abstract Wong C
0.31481948.7615568.html.plaintext.txt	245	82 8729 8732 Abstract Miller D
0.31481948.7615568.html.plaintext.txt	246	301 41 52 CrossRefMedline Order article via Infotrieve Selkoe D
0.31481948.7615568.html.plaintext.txt	247	35 245 246 Medline Order article via Infotrieve Corder E
0.31481948.7615568.html.plaintext.txt	248	1993 Science 261 921 923 Medline Order article via Infotrieve Strittmatter W
0.31481948.7615568.html.plaintext.txt	249	90 1977 1981 Abstract Strittmatter W
0.31481948.7615568.html.plaintext.txt	250	90 8098 8102 AbstractFree Full Text Ma J
0.31481948.7615568.html.plaintext.txt	251	1995Nature 372 92 94 Wisniewski T
0.31481948.7615568.html.plaintext.txt	252	145 1030 1035 Abstract Sanan D
0.31481948.7615568.html.plaintext.txt	253	94 860 869 Medline Order article via Infotrieve Bugiani O
0.31481948.7615568.html.plaintext.txt	254	145 526 530 Abstract Pras M
0.31481948.7615568.html.plaintext.txt	255	47 924 933 Medline Order article via Infotrieve Schagger H
0.31481948.7615568.html.plaintext.txt	256	166 368 379 Medline Order article via Infotrieve Prelli F
0.31481948.7615568.html.plaintext.txt	257	33 783 786 Medline Order article via Infotrieve Wilson C
0.31481948.7615568.html.plaintext.txt	258	1991 Science 252 1817 1822 Medline Order article via Infotrieve Wetterau J
0.31481948.7615568.html.plaintext.txt	259	263 6240 6248 AbstractFree Full Text Wisniewski T
0.31481948.7615568.html.plaintext.txt	260	1995 Lancet 345 956 958 CrossRefMedline Order article via Infotrieve Gregg R
0.31481948.7615568.html.plaintext.txt	261	78 815 821 Medline Order article via Infotrieve Steinmetz A
0.31481948.7615568.html.plaintext.txt	262	1989 Arteriosclerosis 9 405 411 Abstract Weisgraber K
0.31481948.7615568.html.plaintext.txt	263	31 1503 1511 Abstract Castao E
0.31481948.7615568.html.plaintext.txt	264	306 599 604 Medline Order article via Infotrieve Segrest J
0.31481948.7615568.html.plaintext.txt	265	33 141 166 Abstract Nichols W
0.31481948.7615568.html.plaintext.txt	266	156 762 768 Medline Order article via Infotrieve Soutar A
0.31481948.7615568.html.plaintext.txt	267	89 7389 7393 Abstract Benditt E
0.31481948.7615568.html.plaintext.txt	268	76 4092 4096 Abstract McAdam K
0.31481948.7615568.html.plaintext.txt	269	144 1121 1127 Abstract Stenstad T
0.31481948.7615568.html.plaintext.txt	270	94 189 195 Medline Order article via Infotrieve Weisgraber K
0.31481948.7615568.html.plaintext.txt	271	261 2068 2076 AbstractFree Full Text Evans K
0.31481948.7615568.html.plaintext.txt	272	92 763 767 Abstract Ghiso J
0.31481948.7615568.html.plaintext.txt	273	293 27 30 Medline Order article via Infotrieve Snipes G
0.31481948.7615568.html.plaintext.txt	274	83 1130 1134 Abstract LaDu M
0.31481948.7615568.html.plaintext.txt	275	269 23403 23406 AbstractFree Full Text 1995 The American Society Biochemistry Molecular Biology Inc
0.30876386.9218423.html.plaintext.txt	0	Targeted Replacement Mouse Apolipoprotein E Gene Common Human APOE3 Allele Enhances Diet induced Hypercholesterolemia Atherosclerosis
0.30876386.9218423.html.plaintext.txt	1	Received publication December 19 1996 revised form April 24 1997
0.30876386.9218423.html.plaintext.txt	2	Sullivan Hafid Mezdour Yasuaki Aratani Chris Knouff Jamila Najib Robert L
0.30876386.9218423.html.plaintext.txt	3	From Department Pathology Laboratory Medicine University North Carolina Chapel Hill North Carolina 27599 7525 Institut Pasteur de Lille U 235 Lille France Department Medicine Durham VA Hospital Duke University Medical Center Durham North Carolina 27705 ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION FOOTNOTES ACKNOWLEDGEMENTS REFERENCES
0.30876386.9218423.html.plaintext.txt	4	Apolipoprotein apo E constituent several lipoproteins ligand low density lipoprotein receptor interaction important maintaining cholesterol triglyceride homeostasis
0.30876386.9218423.html.plaintext.txt	5	We used gene replacement strategy generate mice express human apoE3 isoform place mouse protein
0.30876386.9218423.html.plaintext.txt	6	The levels apoE mRNA various tissues virtually human apoE3 homozygous 33 mice littermates wild type mouse allele
0.30876386.9218423.html.plaintext.txt	7	Total cholesterol triglyceride levels fasted plasma 33 mice different mice maintained normal low fat chow diet
0.30876386.9218423.html.plaintext.txt	8	We found however notable differences distribution plasma lipoproteins apolipoprotein E two groups migrating lipoproteins plasma apoB100 levels decreased 33 mice apoE distribution shifted high density lipoproteins larger lipoprotein particles
0.30876386.9218423.html.plaintext.txt	9	In addition fractional catabolic rate exogenously administered remnant particles without apoE 6 fold slower 33 mice compared mice
0.30876386.9218423.html.plaintext.txt	10	When 33 animals fed high fathigh cholesterol diet 33 animals responded dramatic increase 5 fold total cholesterol compared mice 1
0.30876386.9218423.html.plaintext.txt	11	5 fold 12 weeks diet 33 animals developed significantly least 13 fold larger atherosclerotic plaques aortic sinus area animals
0.30876386.9218423.html.plaintext.txt	12	Thus structural differences human APOE3 mouse ApoE proteins sufficient cause increased susceptibility dietary induced hypercholesterolemia atherosclerosis 33 mice
0.30876386.9218423.html.plaintext.txt	13	Apolipoprotein apo1 E important transport cholesterol triglyceride throughout body
0.30876386.9218423.html.plaintext.txt	14	It amphipathic protein stabilizes structure lipoprotein particles via ability bind lipid functions ligand lipoprotein receptors low density lipoprotein receptor LDLR low density lipoprotein receptor related protein 1 3
0.30876386.9218423.html.plaintext.txt	15	ApoE major protein component chylomicron remnants low density lipoproteins VLDL intermediate density lipoproteins IDL present low density lipoproteins LDL
0.30876386.9218423.html.plaintext.txt	16	ApoE also enriched subclass high density lipoproteins HDL functions effective ligand binding LDLR 4
0.30876386.9218423.html.plaintext.txt	17	The human APOE gene located chromosome 19 5 part apolipoprotein cluster also includes genes encoding APOCI APOCII APOCIV 6
0.30876386.9218423.html.plaintext.txt	18	Multiple tissue specific enhancers negative elements identified region proximal gene 7
0.30876386.9218423.html.plaintext.txt	19	A distal enhancer hepatic control region required liver expression located 15 kb downstream gene 8 9
0.30876386.9218423.html.plaintext.txt	20	The liver synthesizes approximately 70 apoE found body 20 found brain remainder synthesized several tissues including spleen lung heart ovary testis kidney skin 10 11
0.30876386.9218423.html.plaintext.txt	21	Three major APOE alleles 2 3 4 occur humans frequencies 7
0.30876386.9218423.html.plaintext.txt	22	These three alleles distinguished coding differences positions 112 158 13
0.30876386.9218423.html.plaintext.txt	23	The common isoform apoE3 cysteine position 112 arginine position 158 apoE2 isoform cysteine positions whereas apoE4 isoform arginine positions
0.30876386.9218423.html.plaintext.txt	24	Functionally three isoforms differ affinity LDLR apoE3 E4 exhibiting 100 binding apoE2 displaying 1 normal binding affinity 14
0.30876386.9218423.html.plaintext.txt	25	Despite lower affinity apoE2 LDLR individuals homozygous 2 typically lower normal plasma cholesterol levels except fraction homozygotes 5 10 develop type III hyperlipoproteinemia 15
0.30876386.9218423.html.plaintext.txt	26	Individuals homozygous 4 higher total plasma cholesterol LDL cholesterol compared 3 homozygotes increased risk developing coronary artery disease 16
0.30876386.9218423.html.plaintext.txt	27	The 4 allele also associated development Alzheimers disease 17 18
0.30876386.9218423.html.plaintext.txt	28	ApoE isoform specific effects important etiology atherosclerosis diseases appropriate animal models rigorously investigate effects currently lacking
0.30876386.9218423.html.plaintext.txt	29	To date transgenic animals made pronuclear injection human DNA used study effects method produces mice varying levels transgene expression due differences chromosomal location copy number expression endogenous mouse apoE complicates interpretation data 19 24 47
0.30876386.9218423.html.plaintext.txt	30	To overcome difficulties used targeted gene replacement generate mice express human apoE3 isoform levels physiological range
0.30876386.9218423.html.plaintext.txt	31	In mice coding sequences mouse apoE replaced sequences coding human APOE3 without disturbing known regulatory sequences
0.30876386.9218423.html.plaintext.txt	32	This replacement results animals expression human apoE mRNA identical tissue distribution levels mouse apoE mRNA wild type animals
0.30876386.9218423.html.plaintext.txt	33	We describe essentially normal cholesterol triglyceride levels mice homozygous human apoE3 33 maintained normal low fat mouse chow diet show markedly susceptible diet induced atherosclerosis wild type littermates
0.30876386.9218423.html.plaintext.txt	34	The targeting construct made inserting pPNT vector 25 4
0.30876386.9218423.html.plaintext.txt	35	1 kb SacI human genomic fragment isolated plasmid pHEG 1 20 kindly provided Dr
0.30876386.9218423.html.plaintext.txt	36	John Taylor University California San Francisco
0.30876386.9218423.html.plaintext.txt	37	This fragment contains 3 part intron 1 723 base pairs exons 2 4 human APOE3 gene 1
0.30876386.9218423.html.plaintext.txt	38	3 kb EcoRI SacI strain 129 mouse genomic fragment containing sequences upstream mouse apoE gene including exon 1 5 part intron 1 376 base pairs inserted 5 human APOE3 fragment
0.30876386.9218423.html.plaintext.txt	39	4 kb PvuI KpnI strain 129 mouse genomic fragment containing 3 half exon 4 3 flanking sequence inserted downstream neomycin resistant gene pPNT see Fig
0.30876386.9218423.html.plaintext.txt	40	Replacement mouse apoE gene human APOE3 gene
0.30876386.9218423.html.plaintext.txt	41	A genomic organization mouse apoE gene containing exons 1 4 black boxes
0.30876386.9218423.html.plaintext.txt	42	B apoE3 targeting construct containing 5 3 arms mouse homology black line boxes interrupted human apoE3 gene hatched boxes 2 3 4 labeled huE3
0.30876386.9218423.html.plaintext.txt	43	The neomycin resistant Neo thymidine kinase TK genes selection targeted ES cells pPNT plasmid vector
0.30876386.9218423.html.plaintext.txt	44	C resulting chimeric gene encoding human apoE3
0.30876386.9218423.html.plaintext.txt	45	The mouse exon 4 probe Probe used detect targeted allele
0.30876386.9218423.html.plaintext.txt	46	Sizes diagnostic fragments shown dashed lines
0.30876386.9218423.html.plaintext.txt	47	Sites follows E EcoRI S SacI H HindIII P PvuI K KpnI X XbaI B BamHI
0.30876386.9218423.html.plaintext.txt	48	View Larger Version Image 20K GIF file
0.30876386.9218423.html.plaintext.txt	49	Generation Homozygous Human apoE3 Mice
0.30876386.9218423.html.plaintext.txt	50	A subclone BK4 mouse strain 129 embryonic stem ES cell line E14TG2a cultured electroporated human apoE3 targeting construct described previously 26
0.30876386.9218423.html.plaintext.txt	51	Targeted ES cell clones identified Southern blot analysis
0.30876386.9218423.html.plaintext.txt	52	Chimeras generated mated C57BL6J B6 mice
0.30876386.9218423.html.plaintext.txt	53	F2 generation mice used experiments described
0.30876386.9218423.html.plaintext.txt	54	Mice kept normal low fat chow diet consisting 5 ww fat 0
0.30876386.9218423.html.plaintext.txt	55	022 ww cholesterol Prolab RMH 3000 number 5P76 St
0.30876386.9218423.html.plaintext.txt	56	Louis MO atherogenic diet contains 15
0.30876386.9218423.html.plaintext.txt	57	5 ww sodium cholate TK 88051 Teklad Premier Madison WI
0.30876386.9218423.html.plaintext.txt	58	All lipid measurements performed mice age 8 20 weeks
0.30876386.9218423.html.plaintext.txt	59	Animals fasted overnight approximately 16 h anesthetized Avertin 150 microl blood collected retro orbital sinus tubes containing 8 mM EDTA 1 microgml aprotinin Boehringer Mannheim 1 microgml gentamycin stored ice
0.30876386.9218423.html.plaintext.txt	60	Plasma removed centrifugation 8000 x g 10 min 4 degrees C total cholesterol HDL cholesterol measured using diagnostic CII kits Wako Richmond VA according manufacturers instructions
0.30876386.9218423.html.plaintext.txt	61	Triglyceride levels measured using enzymatic kit Sigma
0.30876386.9218423.html.plaintext.txt	62	Within 1 h blood collection 1 microl plasma electrophoresed precast 1 agarose gels Ciba Corning Diagnostics Corp
0.30876386.9218423.html.plaintext.txt	63	Palo Alto CA neutral lipids visualized Fat Red 7B staining Sigma
0.30876386.9218423.html.plaintext.txt	64	One ml pooled plasma 10 mice 100 microl separated sequential density ultracentrifugation seven fractions ranging densities 1
0.30876386.9218423.html.plaintext.txt	65	21 gml using procedure described de Silva et al
0.30876386.9218423.html.plaintext.txt	66	Total lipoproteins isolated plasma density 1
0.30876386.9218423.html.plaintext.txt	67	Lipoprotein fractions dialyzed 10 mM Tris pH 7
0.30876386.9218423.html.plaintext.txt	68	4 1 mM EDTA 150 mM NaCl electrophoresis 3 20 denaturing SDS PAGE gel 27
0.30876386.9218423.html.plaintext.txt	69	Plasma 100 microl either individual pooled samples separated gel filtration chromatography using Superose 6 HR1030 column Pharmacia Biotech Inc
0.30876386.9218423.html.plaintext.txt	70	Immunoblot analysis FPLC fractions 2 microl electrophoresed precast 1 agarose gels performed antibodies described
0.30876386.9218423.html.plaintext.txt	71	Total RNA extracted several tissues according method Chomczynski Sacchi 28 using RNAzolTM B Tel test Friendswood TX
0.30876386.9218423.html.plaintext.txt	72	Total RNA 20 microg electrophoresed 1 agarose gel denaturation glyoxalMe2SO mixture 29
0.30876386.9218423.html.plaintext.txt	73	RNA transferred Hybond membrane Amersham Corp
0.30876386.9218423.html.plaintext.txt	74	hybridized overnight 42 degrees C 50 formamide 5 x SSC 1 x Denhardts solution 100 microg salmon sperm DNA 30 mM sodium phosphate pH 6
0.30876386.9218423.html.plaintext.txt	75	5 10 dextran sulfate probe mouse exon 4 DNA fragment labeled 32PdCTP
0.30876386.9218423.html.plaintext.txt	76	The blot washed 3 x SSC 0
0.30876386.9218423.html.plaintext.txt	77	1 SDS 10 min 37 degrees C 0
0.30876386.9218423.html.plaintext.txt	78	1 SDS 10 min 65 degrees C
0.30876386.9218423.html.plaintext.txt	79	The blot exposed preflashed Kodak XAR film 20 h
0.30876386.9218423.html.plaintext.txt	80	ApoE Enzyme linked Immunosorbent Assay
0.30876386.9218423.html.plaintext.txt	81	Human APOE mouse plasma measured sandwich type enzyme linked immunosorbent assay ELISA essentially described 30
0.30876386.9218423.html.plaintext.txt	82	A mouse anti human apoE monoclonal antibody E01 huE m 30 used capture antibody goat anti human apoE antibody huE p Calbiochem detecting antibody
0.30876386.9218423.html.plaintext.txt	83	The huE p antibody cross reacts mouse apoE low level
0.30876386.9218423.html.plaintext.txt	84	The huE m antibody shown react human APOE classes lipoprotein particles 30 cross react mouse ApoE
0.30876386.9218423.html.plaintext.txt	85	Values determined standard curve made pooled human plasma whose apoE levels determined purified recombinant human apoE3 number 178475 Calbiochem validated international calibrator Dr
0.30876386.9218423.html.plaintext.txt	86	Rifai Childrens Hospital Boston MA
0.30876386.9218423.html.plaintext.txt	87	Mouse ApoE measured similar manner using purified rabbit anti mouse apoE antibody muE m 10 microgml raised mouse apoE peptide residues 179 241 capture antibody
0.30876386.9218423.html.plaintext.txt	88	The antibody conjugated horseradish peroxidase used detection chromagen
0.30876386.9218423.html.plaintext.txt	89	The mouse peptide residues 179 241 used standard determining concentration mouse ApoE
0.30876386.9218423.html.plaintext.txt	90	Fasted whole plasma 1 microl electrophoresed 4 20 denaturing SDS PAGE gel 1 agarose gel transferred Immobilon P membrane Millipore Corp
0.30876386.9218423.html.plaintext.txt	91	Bedford MA reacted three anti apoE antibodies described
0.30876386.9218423.html.plaintext.txt	92	Immunoreactive proteins visualized horseradish peroxidase conjugate using enhanced chemiluminescence kit Amersham Corp
0.30876386.9218423.html.plaintext.txt	93	Western blots analysis apoB made similarly using 4 SDS PAGE rabbit anti mouse apoB sera gift Dr
0.30876386.9218423.html.plaintext.txt	94	Steven Young University California San Francisco
0.30876386.9218423.html.plaintext.txt	95	Four apoE mice injected 20 microg free cholesterol containing 2
0.30876386.9218423.html.plaintext.txt	96	5 microCi 4 14C labeled cholesterol dispersed egg lecithinfree cholesterol 11 molar ratio mesophase
0.30876386.9218423.html.plaintext.txt	97	The apoE VLDL fraction isolated 36 h later centrifugation 1
0.30876386.9218423.html.plaintext.txt	98	More 72 tracer cholesterol ester fraction 31
0.30876386.9218423.html.plaintext.txt	99	Three mice group apoE 33 injected labeled apoE VLDL
0.30876386.9218423.html.plaintext.txt	100	The fractional catabolic rates variances determined 4 h described previously 31
0.30876386.9218423.html.plaintext.txt	101	Evaluation Atherosclerotic Lesions
0.30876386.9218423.html.plaintext.txt	102	Female mice fed high fat diet 3 months sacrificed Avertin overdose 16 h fast
0.30876386.9218423.html.plaintext.txt	103	The thoracic cavity opened heart vascular system perfused 4 paraformaldehyde phosphate buffered saline pH 7
0.30876386.9218423.html.plaintext.txt	104	4 physiological pressure
0.30876386.9218423.html.plaintext.txt	105	Segments proximal aorta aortic sinus embedded sectioned stained described previously 32
0.30876386.9218423.html.plaintext.txt	106	Morphometric evaluations lesion size made using NIH image version 1
0.30876386.9218423.html.plaintext.txt	107	The significance differences means tested using two tailed unpaired Student test nonparametric Mann Whitney U test
0.30876386.9218423.html.plaintext.txt	108	Replacement Mouse apoE Gene Human APOE3 Allele
0.30876386.9218423.html.plaintext.txt	109	The targeting strategy used replace mouse apoE coding exons 2 4 human counterpart illustrated Fig
0.30876386.9218423.html.plaintext.txt	110	Homologous recombination targeting construct Fig
0.30876386.9218423.html.plaintext.txt	111	1B endogenous mouse apoE locus Fig
0.30876386.9218423.html.plaintext.txt	112	1A results chimeric gene Fig
0.30876386.9218423.html.plaintext.txt	113	1C mouse coding sequences replaced sequences coding human APOE3
0.30876386.9218423.html.plaintext.txt	114	This chimeric locus retains normal mouse regulatory sequences addition non coding mouse exon one
0.30876386.9218423.html.plaintext.txt	115	Identification correctly modified embryonic stem ES cells Southern blot analysis mouse exon 1 exon 4 probe data shown ES cell DNA digested EcoRI hybridized mouse exon 1 probe revealed 8
0.30876386.9218423.html.plaintext.txt	116	8 kb targeted band confirming correct modification 5 region ES cell DNA digested HindIII hybridized mouse exon 4 probe revealed 7
0.30876386.9218423.html.plaintext.txt	117	5 kb endogenous band 15 kb targeted band confirming correct modification 3 region
0.30876386.9218423.html.plaintext.txt	118	The modified locus transmitted F1 generation chimeras made one targeted cell lines
0.30876386.9218423.html.plaintext.txt	119	All F1 matings produced normal litter sizes normal Mendelian segregation pattern modified locus
0.30876386.9218423.html.plaintext.txt	120	Genotypes F2 animals determined using Southern blot analysis tail DNA digested BamHI Fig
0.30876386.9218423.html.plaintext.txt	121	The nucleotide sequence codon 112 TGC codon 158 CGC 33 mouse confirmed using allele specific PCR 33 tail DNA
0.30876386.9218423.html.plaintext.txt	122	Southern Western blot analysis
0.30876386.9218423.html.plaintext.txt	123	A Southern analysis mouse exon 4 probe identify F2 mice carrying targeted allele
0.30876386.9218423.html.plaintext.txt	124	2 kb hybridizing BamHI fragment indicates presence human APOE3 allele
0.30876386.9218423.html.plaintext.txt	125	8 kb hybridizing BamHI fragment indicates presence mouse apoE allele
0.30876386.9218423.html.plaintext.txt	126	B fasted whole plasma 1 microl electrophoresed 4 20 denaturing SDS PAGE gel proteins transferred Immobilon P membrane incubated either anti human apoE antisera huE p weakly cross reacts mouse apoE top panel anti mouse apoE antibody muE m middle panel anti human apoE monoclonal antibody huE m bottom panel cross react mouse apoE
0.30876386.9218423.html.plaintext.txt	127	C fasted whole plasma 1 microl electrophoresed 4 20 SDS PAGE gel proteins transferred Immobilon P membrane incubated huE p antiserum presence absence mercaptoethanol
0.30876386.9218423.html.plaintext.txt	128	The abbreviations used Hu human sample 33 sample homozygous human apoE3 mouse 3 heterozygous sample wild type sample
0.30876386.9218423.html.plaintext.txt	129	View Larger Version Image 59K GIF file
0.30876386.9218423.html.plaintext.txt	130	Human apoE3 Levels Whole Plasma
0.30876386.9218423.html.plaintext.txt	131	To confirm presence human APOE protein mice plasma 1 microl 33 3 mice human hu electrophoresed 4 20 gradient denaturing SDS PAGE gel
0.30876386.9218423.html.plaintext.txt	132	Western blot analysis anti human apoE antisera huE p slightly cross reacts mouse ApoE showed human APOE 34 200 Da 33 plasma migrates rate apoE human plasma slightly slower mouse apoE 32 600 Da plasma Fig
0.30876386.9218423.html.plaintext.txt	133	The absence mouse ApoE 33 plasma confirmed Western blot analysis anti mouse apoE antibody mu m shows mouse ApoE present 3 samples 33 plasma
0.30876386.9218423.html.plaintext.txt	134	In contrast anti human apoE monoclonal antibody huE m cross react mouse ApoE shows human APOE present 33 3 human plasma plasma Fig
0.30876386.9218423.html.plaintext.txt	135	Western blotting plasma two 33 mice 4 20 nonreducing SDS PAGE gel showed human APOE3 homodimer present less 5 monomeric E3 Fig
0.30876386.9218423.html.plaintext.txt	136	The concentration apoE 33 plasma 1
0.30876386.9218423.html.plaintext.txt	137	47 mgdl determined ELISA similar levels 1
0.30876386.9218423.html.plaintext.txt	138	23 mgdl found plasma see Table I
0.30876386.9218423.html.plaintext.txt	139	Plasma lipid profiles apoE concentration mice fed normal high fat diet
0.30876386.9218423.html.plaintext.txt	140	Data means plus minus S
0.30876386.9218423.html.plaintext.txt	141	fasted mice receiving chow C high fat HF diet
0.30876386.9218423.html.plaintext.txt	142	Parentheses show number mice
0.30876386.9218423.html.plaintext.txt	143	Genotype Diet TC TG HDL cholesterol Human apoE3 Mouse apoE mgdl mgdl mgdl mgdl mgdl Females 33 C 67 plus minus 18 30 35 plus minus 12 26 46 plus minus 11 26 1
0.30876386.9218423.html.plaintext.txt	144	47 10 HF 350 plus minus 207 17a 29 plus minus 22 15 22 plus minus 11 14 10
0.30876386.9218423.html.plaintext.txt	145	60 8a C 73 plus minus 20 30 43 plus minus 15 26 53 plus minus 15 23 1
0.30876386.9218423.html.plaintext.txt	146	23 6 HF 111 plus minus 44 17b 21 plus minus 7 14 23 plus minus 15 13 1
0.30876386.9218423.html.plaintext.txt	147	34 5 Males 33 C 104 plus minus 22 15c 39 plus minus 16 13 54 plus minus 19 7 C 95 plus minus 16 15 41 plus minus 17 14 52 plus minus 15 7 p 0
0.30876386.9218423.html.plaintext.txt	148	001 versus 33 females high fat
0.30876386.9218423.html.plaintext.txt	149	Tissue Distribution apoE mRNA
0.30876386.9218423.html.plaintext.txt	150	Total RNA extracted several tissues including skin Sk spleen Sp kidney Ki small intestine Si stomach St heart He testis Te muscle Mu lung Lu liver Li submandibular gland Su brain Br 33 male mouse wild type male mouse
0.30876386.9218423.html.plaintext.txt	151	Northern blot analysis mouse exon 4 probe used compare levels apoE mRNA two types animal Fig
0.30876386.9218423.html.plaintext.txt	152	This probe hybridizes equally well human gene mouse gene conditions used
0.30876386.9218423.html.plaintext.txt	153	A actin probe hybridized blot removal apoE probe lower panels Fig
0.30876386.9218423.html.plaintext.txt	154	3 assess amount mRNA loaded group
0.30876386.9218423.html.plaintext.txt	155	In agreement previous reports 10 11 apoE mRNA expression highest liver second brain lesser amounts tissues
0.30876386.9218423.html.plaintext.txt	156	No apoE mRNA detected muscle
0.30876386.9218423.html.plaintext.txt	157	The expression apoE mRNA 33 animals essentially indistinguishable tissues analyzed exception small intestine reduced levels apoE mRNA 33 animals compared mice
0.30876386.9218423.html.plaintext.txt	158	This Northern blot analysis clearly demonstrates modified locus containing human apoE3 coding sequences wild type mouse gene expressed virtually identical levels tissues
0.30876386.9218423.html.plaintext.txt	159	Northern blot analysis total RNA various tissues
0.30876386.9218423.html.plaintext.txt	160	Total RNA 20 microg electrophoresed 1 gel blotted hybridized mouse apoE exon 4 probe indicated
0.30876386.9218423.html.plaintext.txt	161	The filter rehybridized actin probe
0.30876386.9218423.html.plaintext.txt	162	3 identifies lanes containing RNA human apoE3 mice identifies lanes containing RNA wild type mice Sk skin Sp spleen Ki Kidney Si small intestine St stomach He heart Te testis Mu muscle Lu lung Li liver Su submandibular gland Br brain
0.30876386.9218423.html.plaintext.txt	163	View Larger Version Image 116K GIF file
0.30876386.9218423.html.plaintext.txt	164	Plasma Lipids Lipoproteins Mice Fed Normal Chow
0.30876386.9218423.html.plaintext.txt	165	The levels total cholesterol TC triglycerides HDL cholesterol female mice fed normal low fat chow diet determined plasma obtained 16 h fast Table I
0.30876386.9218423.html.plaintext.txt	166	There difference TC levels 33 mice 67 plus minus 18 mgdl n 30 controls 73 plus minus 20 mgdl n 30 striking contrast total cholesterol levels previously found apoE deficient mice diet 541 plus minus 220 mgdl 32
0.30876386.9218423.html.plaintext.txt	167	The TC levels males higher females p 0
0.30876386.9218423.html.plaintext.txt	168	0001 differences 33 group
0.30876386.9218423.html.plaintext.txt	169	Triglyceride HDL cholesterol levels 33 mice mice also similar Table I
0.30876386.9218423.html.plaintext.txt	170	Fasted wild type plasma lipoproteins migrate three distinct bands designated HDL LDL pre VLDL using agarose gel electrophoresis Fig
0.30876386.9218423.html.plaintext.txt	171	Plasma fasted 33 mice hand showed increase pre band absence migrating lipoproteins relative samples
0.30876386.9218423.html.plaintext.txt	172	These differences observed plasma male female 33 mice
0.30876386.9218423.html.plaintext.txt	173	The amount migrating particles 33 mice
0.30876386.9218423.html.plaintext.txt	174	These results suggest 33 mice slightly increased amounts VLDLIDL remnants reduction LDL particles
0.30876386.9218423.html.plaintext.txt	175	Analysis plasma lipoproteins
0.30876386.9218423.html.plaintext.txt	176	A fasted plasma 1 microl males females maintained normal low fat chow diet electrophoresed 1 agarose gel stained Fat Red 7B
0.30876386.9218423.html.plaintext.txt	177	The positions pre lipoproteins indicated
0.30876386.9218423.html.plaintext.txt	178	B Western analysis fasted plasma 1 microl female mice using denaturing 4 SDS PAGE gel anti apoB antisera
0.30876386.9218423.html.plaintext.txt	179	The positions apoB100 48 proteins indicated
0.30876386.9218423.html.plaintext.txt	180	Samples 33 homozygous human apoE3 mice wild type mice
0.30876386.9218423.html.plaintext.txt	181	C total lipoproteins density 1
0.30876386.9218423.html.plaintext.txt	182	21 gml pooled five female 33 four mice electrophoresed 3 20 SDS PAGE gel stained Coomassie Brilliant Blue
0.30876386.9218423.html.plaintext.txt	183	The positions apolipoproteins indicated
0.30876386.9218423.html.plaintext.txt	184	View Larger Version Image 59K GIF file
0.30876386.9218423.html.plaintext.txt	185	To determine amount apoB100 relative apoB48 equal amounts whole plasma 33 female mouse separated 4 SDS PAGE gel blotted reacted anti mouse apoB sera Fig
0.30876386.9218423.html.plaintext.txt	186	A densitometric scan autoradiograph showed 33 sample B100B48 ratio 13 compared B100B48 ratio 10
0.30876386.9218423.html.plaintext.txt	187	In separate experiment total lipoproteins density 1
0.30876386.9218423.html.plaintext.txt	188	21 gml isolated pooled plasma five female 33 mice four mice electrophoresed 3 20 SDS PAGE gel
0.30876386.9218423.html.plaintext.txt	189	Coomassie Brilliant Blue staining gel Fig
0.30876386.9218423.html.plaintext.txt	190	4C showed plasma apoB100 levels 33 mice greatly reduced compared mice apoB48 levels higher 33 mice compared mice
0.30876386.9218423.html.plaintext.txt	191	Different Distribution Human Mouse Apolipoprotein E
0.30876386.9218423.html.plaintext.txt	192	Individual plasma samples pooled n 10 plasma samples separated gel filtration chromatography Superose 6B column determination cholesterol triglyceride apoE distribution
0.30876386.9218423.html.plaintext.txt	193	The distribution cholesterol solid circles Fig
0.30876386.9218423.html.plaintext.txt	194	5 A B nearly identical 33 mice except small decrease fractions 21 24 33 group
0.30876386.9218423.html.plaintext.txt	195	This decrease LDL cholesterol agrees agarose gel electrophoresis results described
0.30876386.9218423.html.plaintext.txt	196	Triglyceride distribution essentially groups data shown largest percentage triglyceride present fractions 14 16
0.30876386.9218423.html.plaintext.txt	197	Distribution cholesterol apoE mice fed normal chow
0.30876386.9218423.html.plaintext.txt	198	A B pooled plasma 10 mice fractionated gel filtration chromatography Superose 6B column
0.30876386.9218423.html.plaintext.txt	199	5 ml fractions collected cholesterol measured microgfraction
0.30876386.9218423.html.plaintext.txt	200	ApoE microgfraction measured using ELISA antibodies specific human huE m A mouse apoE muE m B
0.30876386.9218423.html.plaintext.txt	201	C D Western blot analysis FPLC fractions C 33 D electrophoresed 1 agarose gels incubated huE p antiserum cross reacts mouse apoE
0.30876386.9218423.html.plaintext.txt	202	View Larger Version Image 39K GIF file
0.30876386.9218423.html.plaintext.txt	203	Contrary identical distribution lipids distribution apoE open circles Fig
0.30876386.9218423.html.plaintext.txt	204	5 A B 33 mice markedly different determined ELISA mouse human specific antibodies
0.30876386.9218423.html.plaintext.txt	205	The majority apoE mice present HDL region fractions 26 31 minor amount present VLDL fractions 14 17 IDL LDL regions fractions 18 25 Fig
0.30876386.9218423.html.plaintext.txt	206	Western blot analysis FPLC fractions electrophoresed agarose gel using huE p antisera support results obtained ELISA Fig
0.30876386.9218423.html.plaintext.txt	207	However 33 mice majority apoE present two distinct peaks VLDL fractions 14 17 IDL species fractions 18 21 typically elute Fig
0.30876386.9218423.html.plaintext.txt	208	Western blots agarose gel FPLC fraction agreement apoE3 distribution determined ELISA Fig
0.30876386.9218423.html.plaintext.txt	209	SDS PAGE gel electrophoresis lipoproteins fractionated sequential density ultracentrifugation Fig
0.30876386.9218423.html.plaintext.txt	210	6A showed apoE3 33 mice found predominantly lower density fractions d 1
0.30876386.9218423.html.plaintext.txt	211	No major differences detectable distributions apolipoproteins AI 33 samples apoCs SDS PAGE fractions separated sequential density ultracentrifugation Fig
0.30876386.9218423.html.plaintext.txt	212	Distribution apolipoproteins mice fed either normal high fat diet
0.30876386.9218423.html.plaintext.txt	213	A pooled plasma 10 mice fed normal chow fractionated sequential density ultracentrifugation fraction electrophoresed denaturing SDS PAGE 3 20 gradient gel stained Coomassie Brilliant Blue
0.30876386.9218423.html.plaintext.txt	214	B except mice fed high fat diet 3 months
0.30876386.9218423.html.plaintext.txt	215	View Larger Version Image 75K GIF file
0.30876386.9218423.html.plaintext.txt	216	The IDL like peak 33 plasma particularly noteworthy since cholesterol triglyceride fractions low
0.30876386.9218423.html.plaintext.txt	217	These IDL like particles enriched apoE3 likely represent VLDLchylomicron remnants since agarose gel electrophoresis FPLC fractions followed Western blotting huE p antisera demonstrated majority apoE3 associated particles migrating pre position association apoE3 large HDL particles position minimal Fig
0.30876386.9218423.html.plaintext.txt	218	FPLC analysis plasma immunoprecipitation anti mouse apoB antibody confirms IDL like particles contain apoB data shown
0.30876386.9218423.html.plaintext.txt	219	Interestingly FPLC analysis plasma mice heterozygous human apoE3 3 showed shift second apoE3 peak fractions 21 25 suggesting co presence mouse ApoE reduces size remnant particles apoE3 accumulates data shown
0.30876386.9218423.html.plaintext.txt	220	An increase mouse ApoE associated larger particles also evident heterozygote although approximately half mouse ApoE still found associated HDL
0.30876386.9218423.html.plaintext.txt	221	Response Atherogenic Diet
0.30876386.9218423.html.plaintext.txt	222	The 33 n 12 n 12 female mice used measure lipid profiles normal chow fed atherogenic diet 8 weeks assess change response diet two groups
0.30876386.9218423.html.plaintext.txt	223	One animal showed significant weight loss yellow colored plasma diet study excluded
0.30876386.9218423.html.plaintext.txt	224	The 33 mice responded 5 fold increase cholesterol 350 plus minus 207 versus 67 plus minus 18 mgdl whereas cholesterol control mice increased 1
0.30876386.9218423.html.plaintext.txt	225	5 fold 111 plus minus 44 versus 73 plus minus 20 mgdl Table I
0.30876386.9218423.html.plaintext.txt	226	Triglyceride levels 33 mice reduced 18 50 respectively
0.30876386.9218423.html.plaintext.txt	227	HDL cholesterol levels reduced groups mice extent approximately 50
0.30876386.9218423.html.plaintext.txt	228	Agarose gel electrophoresis plasma types animals showed decrease migrating particles increase pre migrating particles consistent total lipid measurements data shown
0.30876386.9218423.html.plaintext.txt	229	These results suggest marked increase remnant particles concurrent reduction HDL response atherogenic diet types mice extent increase 33 mice much larger
0.30876386.9218423.html.plaintext.txt	230	The elution profile Superose 6 gel filtration column 33 plasma Fig
0.30876386.9218423.html.plaintext.txt	231	7A showed majority highly elevated cholesterol VLDL IDL fractions whereas group modestly increased cholesterol distributed equally VLDL HDL fractions Fig
0.30876386.9218423.html.plaintext.txt	232	As expected mice distribution apoE followed cholesterol Fig
0.30876386.9218423.html.plaintext.txt	233	The apoE distribution pattern 33 animals highly unusual similar seen animals fed normal chow diet two distinct classes lipoproteins VLDL IDL range associated human APOE Fig
0.30876386.9218423.html.plaintext.txt	234	There large increase plasma apoE 33 animals 10
0.30876386.9218423.html.plaintext.txt	235	47 mgdl compared increase animals 1
0.30876386.9218423.html.plaintext.txt	236	23 mgdl two diets Table I
0.30876386.9218423.html.plaintext.txt	237	Distribution cholesterol apoE mice high fat HF diet
0.30876386.9218423.html.plaintext.txt	238	A B plasma 10 mice pooled group lipoproteins fractionated gel filtration chromatography Superose 6B column
0.30876386.9218423.html.plaintext.txt	239	5 ml fractions collected cholesterol measured microgfraction
0.30876386.9218423.html.plaintext.txt	240	ApoE microgfraction measured using ELISA antibodies specific human huE m A mouse apoE muE m B
0.30876386.9218423.html.plaintext.txt	241	View Larger Version Image 17K GIF file
0.30876386.9218423.html.plaintext.txt	242	The distributions several plasma apolipoproteins also different 33 mice fed high fat diet Fig
0.30876386.9218423.html.plaintext.txt	243	A comparison apolipoprotein distribution among density fractions SDS PAGE Fig
0.30876386.9218423.html.plaintext.txt	244	6 A normal chow B high fat revealed marked increase high fat diet apoE AI AIV mainly 1
0.30876386.9218423.html.plaintext.txt	245	04 gml fractions mice
0.30876386.9218423.html.plaintext.txt	246	In contrast 33 mice showed increases proteins whole density range
0.30876386.9218423.html.plaintext.txt	247	Of particular interest increase apoAI 1
0.30876386.9218423.html.plaintext.txt	248	04 fraction apoAIV 1
0.30876386.9218423.html.plaintext.txt	249	The amount apoB48 increased 33 mice compared mice distribution different
0.30876386.9218423.html.plaintext.txt	250	Delayed Clearance apoE deficient VLDL 33 Mice
0.30876386.9218423.html.plaintext.txt	251	The marked increase cholesterol rich remnant particles seen 33 animals response atherogenic diet suggests human apoE3 effective murine homologue clearance particles mice
0.30876386.9218423.html.plaintext.txt	252	To test possibility injected 14C radiolabeled remnant particles 72 cholesterol ester VLDL flotation range prepared apoE deficient mice mice fed normal chow measured decay label 4 h period
0.30876386.9218423.html.plaintext.txt	253	The decay 14Ccholesterol rapid mice virtually complete 15 min Fig
0.30876386.9218423.html.plaintext.txt	254	The fractional catabolic rate mice based single compartment system 0
0.30876386.9218423.html.plaintext.txt	255	Clearance lipoproteins apoE mice considerably slower fractional catabolic rate 0
0.30876386.9218423.html.plaintext.txt	256	0003min 6 fold slower mice rapid apoE mice
0.30876386.9218423.html.plaintext.txt	257	Note however within 2 h amount label remaining 33 mice decreased levels seen mice
0.30876386.9218423.html.plaintext.txt	258	The plasma clearance ApoE remnant particles controls 33 mice
0.30876386.9218423.html.plaintext.txt	259	Three mice group ApoE deficient mice E 33 injected radiolabeled apoE remnant particles clearance measured 4 h
0.30876386.9218423.html.plaintext.txt	260	Each data point shows mean plus minus S
0.30876386.9218423.html.plaintext.txt	261	Abbreviations 33 homozygous human apoE3 mice wild type mice E apoE deficient mice
0.30876386.9218423.html.plaintext.txt	262	View Larger Version Image 18K GIF file
0.30876386.9218423.html.plaintext.txt	263	Morphometric Evaluations Aortic Lesions
0.30876386.9218423.html.plaintext.txt	264	After 3 months atherogenic diet 33 animals females evaluated atherosclerotic lesions
0.30876386.9218423.html.plaintext.txt	265	All measurements made sections proximal aorta near aortic valve attachment sites
0.30876386.9218423.html.plaintext.txt	266	All six 33 animals developed substantial atherosclerotic lesions logarithmic mean area 6
0.30876386.9218423.html.plaintext.txt	267	4 x 104 microm2 ranging 2
0.30876386.9218423.html.plaintext.txt	268	In contrast four five animals developed fatty streak lesions small logarithmic mean area 5
0.30876386.9218423.html.plaintext.txt	269	1 x 103 microm2 ranging 2
0.30876386.9218423.html.plaintext.txt	270	These observations clearly demonstrate 33 mice much susceptible diet induced atherosclerosis mice
0.30876386.9218423.html.plaintext.txt	271	Morphometric evaluation atherosclerotic lesions mice fed atherogenic diet
0.30876386.9218423.html.plaintext.txt	272	All mice F2 females kept atherogenic diet 12 weeks sacrifice
0.30876386.9218423.html.plaintext.txt	273	Measurements animal made single section proximal aorta near aortic valve attachment site
0.30876386.9218423.html.plaintext.txt	274	The logarithmic means lesion areas six 33 mice four five mice indicated p 0
0.30876386.9218423.html.plaintext.txt	275	View Larger Version Image 17K GIF file
0.30876386.9218423.html.plaintext.txt	276	We successfully replaced coding sequence mouse apoE gene equivalent human APOE3 coding region without altering known endogenous regulatory sequences
0.30876386.9218423.html.plaintext.txt	277	Expression human apoE mRNA liver brain tissues parallels found normally wild type mice
0.30876386.9218423.html.plaintext.txt	278	Thus human APOE3 protein functional expressed physiological levels modified mice thereby providing model studying function human APOE3 vivo
0.30876386.9218423.html.plaintext.txt	279	To date pronuclear injection DNA used generate transgenic animals expressing various forms human APOE study role lipid metabolism 19 24 47
0.30876386.9218423.html.plaintext.txt	280	There three severe limitations approach follows number copies transgene vary wide ranges marked uncontrolled differences expression transgenes different chromosomal locations presence endogenous mouse protein complicates interpretation results
0.30876386.9218423.html.plaintext.txt	281	Most importantly rigorous comparisons different isoforms possible variable expression inherent conventional transgenic animals
0.30876386.9218423.html.plaintext.txt	282	Mice made replacement endogenous mouse coding region equivalent region human gene retain natural chromosomal context apoE locus
0.30876386.9218423.html.plaintext.txt	283	Thus locus specific sequences enhancers altered except possible intragenic control sequences differ mice humans
0.30876386.9218423.html.plaintext.txt	284	Therefore expected tissue specific expression human replacement APOE3 gene would closely parallel endogenous mouse apoE gene
0.30876386.9218423.html.plaintext.txt	285	Our mRNA studies show expectation indeed fulfilled exception intestinal apoE mRNA slightly reduced 33 mice compared mice
0.30876386.9218423.html.plaintext.txt	286	The significance reduction intestinal expression clear considering intestinal apoE expression low compared tissues chylomicrons originating small intestine known contain little apoE 34 35
0.30876386.9218423.html.plaintext.txt	287	Differences 33 mice consequently highly informative far function apolipoprotein concerned
0.30876386.9218423.html.plaintext.txt	288	Thus gene replacement demonstrates advantages pronuclear injection generating transgenic animals
0.30876386.9218423.html.plaintext.txt	289	The lipid profiles 33 mice similar mice maintained chow low fat diet fasting levels total cholesterol triglyceride HDL cholesterol essentially identical two animals
0.30876386.9218423.html.plaintext.txt	290	However mice fed high fat diet 33 animals responded 5 fold increase total cholesterol compared 1
0.30876386.9218423.html.plaintext.txt	291	5 fold increase animals
0.30876386.9218423.html.plaintext.txt	292	Second 3 months high fat diet atherosclerotic plaques seen 33 animals 13 fold larger observed wild type controls
0.30876386.9218423.html.plaintext.txt	293	Third 6 fold slower clearance rate remnant lipoprotein particles 33 animals
0.30876386.9218423.html.plaintext.txt	294	The accumulation cholesterol delayed clearance remnant particles observed 33 animals likely causes increased susceptibility lesion development
0.30876386.9218423.html.plaintext.txt	295	The dramatic delay clearance remnant particles 33 mice unexpected since previous studies using transgenic mice expressing human APOE revealed normal enhanced clearance kinetics 22 36
0.30876386.9218423.html.plaintext.txt	296	One possible explanation observed delay clearance human APOE3 protein lower affinity mouse LDLR andor receptors mouse ApoE species differences structures
0.30876386.9218423.html.plaintext.txt	297	Mouse human apoE differ 30 amino acid sequences differences amino carboxyl termini 1
0.30876386.9218423.html.plaintext.txt	298	The receptor binding domain residues 136 160 highly conserved mouse human apoE since 21 25 residues identical region including seven residues designated critical receptor binding 37 38
0.30876386.9218423.html.plaintext.txt	299	The residues differ conservative substitutions e
0.30876386.9218423.html.plaintext.txt	300	methionine leucine affect net charge hydrophobicity protein would predicted substantial effects protein conformation 39
0.30876386.9218423.html.plaintext.txt	301	Thus must ascribed differences outside receptor binding domain affinity receptor differs mouse human apoE proteins
0.30876386.9218423.html.plaintext.txt	302	Species differences receptors interact apoE LDLR low density lipoprotein receptor related protein could also contribute lower affinity
0.30876386.9218423.html.plaintext.txt	303	A dysfunctional interaction human APOE3 mouse heparan sulfate proteoglycans HSPG may also contribute delay clearance
0.30876386.9218423.html.plaintext.txt	304	It postulated HSPGs involved initial sequestration process enhances uptake apoE containing lipoproteins 40 41
0.30876386.9218423.html.plaintext.txt	305	The interaction apoE HSPGs thought occur mainly via electrostatic attraction 42
0.30876386.9218423.html.plaintext.txt	306	Human APOE3 cysteine position 112 mouse protein arginine equivalent position mouse apoE residue 104
0.30876386.9218423.html.plaintext.txt	307	This charge difference could significant even though residue 112 outside known heparin binding domain
0.30876386.9218423.html.plaintext.txt	308	The delayed clearance could also due protein protein interactions involving receptors
0.30876386.9218423.html.plaintext.txt	309	Several proteins known interact apoE play role lipid metabolism
0.30876386.9218423.html.plaintext.txt	310	For example interaction apoE hepatic lipoprotein lipases mediatesor enhances catabolism lipoproteins 41
0.30876386.9218423.html.plaintext.txt	311	Lipoprotein particles containing human APOE3 may less efficient type interaction mouse ApoE
0.30876386.9218423.html.plaintext.txt	312	This would important consequences remodeling processing phase lipoprotein catabolism
0.30876386.9218423.html.plaintext.txt	313	Another consideration clearance experiment exogenously introduced remnant particles acquire apoE prior removal receptors
0.30876386.9218423.html.plaintext.txt	314	In mice plasma apoE associated HDL particles presumably source apoE used clear exogenously added remnants
0.30876386.9218423.html.plaintext.txt	315	In 33 animals however majority plasma apoE3 associated large lipoproteins may transfer easily exogenously added particles
0.30876386.9218423.html.plaintext.txt	316	In support others 27 noted distributions apoE among mouse plasma lipoproteins analyzed FPLC ultracentrifugation always agree apoE associated HDL readily lost ultracentrifugation
0.30876386.9218423.html.plaintext.txt	317	Although capacity apoE3 exchange different classes lipoproteins documented decreased ability apoE3 transfer large lipoproteins may important implications
0.30876386.9218423.html.plaintext.txt	318	The association apoE3 larger lipoproteins mice Fig
0.30876386.9218423.html.plaintext.txt	319	5 A C different observations made humans demonstrate preference apoE3 HDL 1 43
0.30876386.9218423.html.plaintext.txt	320	It unlikely difference result mutation unexpectedly introduced APOE3 gene manipulation work2 observed transgenic apoE3 mice endogenous apoE background virtually identical apoE3 distribution pattern seen 33 replacement mice
0.30876386.9218423.html.plaintext.txt	321	These mice made pronuclear injection human cosmid clone isolated different individual one used make mice 24
0.30876386.9218423.html.plaintext.txt	322	Similar findings also reported Taylor et al
0.30876386.9218423.html.plaintext.txt	323	44 transgenic apoE3 mice also express mouse apoE showed majority human APOE3 resided larger lipoprotein particles using SDS PAGE immunoblot analysis fractions separated sequential density ultracentrifugation
0.30876386.9218423.html.plaintext.txt	324	In work authors also found mouse ApoE human APOE co distributed among lipoproteins
0.30876386.9218423.html.plaintext.txt	325	This different results FPLC analysis 3 heterozygote plasma shows approximately half mouse ApoE minor fraction human APOE3 associated HDL data shown
0.30876386.9218423.html.plaintext.txt	326	It known whether observed differences work Taylor et al
0.30876386.9218423.html.plaintext.txt	327	result different techniques used fractionate plasma lipoproteins result different levels human APOE mouse ApoE expression two types mice
0.30876386.9218423.html.plaintext.txt	328	Further characterization large apoE3 rich lipoprotein particles required understand observed delay clearance 33 animals
0.30876386.9218423.html.plaintext.txt	329	The reduced clearance rate remnant particles 33 mice whatever cause eventually proves sufficient cause alteration fasted plasma cholesterol levels animals relative littermates animals normal chow diet
0.30876386.9218423.html.plaintext.txt	330	The 33 mice however much susceptible diet induced hyperlipidemia atherosclerosis littermates
0.30876386.9218423.html.plaintext.txt	331	Possibly high fat diet postprandial accumulation VLDLs occurs leads development atherosclerosis suggested Zilversmit 45
0.30876386.9218423.html.plaintext.txt	332	In human APOE2 homozygous individuals type III hyperlipoproteinemia abnormal accumulation remnant particles suggested cause accelerated coronary peripheral vascular disease 46
0.30876386.9218423.html.plaintext.txt	333	Even small changes lipid metabolism decrease clearance efficiency lipoproteins likely dramatic effects development atherosclerosis thus 33 animals give us opportunity investigate changes important
0.30876386.9218423.html.plaintext.txt	334	In conclusion demonstrated use targeted gene replacement generate mice expressing common human isoform APOE3 physiological levels
0.30876386.9218423.html.plaintext.txt	335	These mice allow us document behavior human APOE3 isoform vivo mice without co expression mouse apoE
0.30876386.9218423.html.plaintext.txt	336	Future experiments comparing mice mice expressing human apoE2 E4 isoforms created identical manner prove invaluable studying diseases related different human apoE isoforms
0.30876386.9218423.html.plaintext.txt	337	This work supported National Institute Health Grant HL42630
0.30876386.9218423.html.plaintext.txt	338	The costs publication article defrayed part payment page charges
0.30876386.9218423.html.plaintext.txt	339	The article must therefore hereby marked advertisement accordance 18 U
0.30876386.9218423.html.plaintext.txt	340	Section 1734 solely indicate fact
0.30876386.9218423.html.plaintext.txt	341	Supported part fellowships ARCOL France Uehara Memorial Foundation Japan respectively
0.30876386.9218423.html.plaintext.txt	342	Current address Yokohama City University Kihara Institute Biological Research Yokohama 244 Japan
0.30876386.9218423.html.plaintext.txt	343	Pathology University Texas San Antonio TX 78284 7750
0.30876386.9218423.html.plaintext.txt	344	To correspondence addressed
0.30876386.9218423.html.plaintext.txt	345	919 966 6916 Fax 919 966 8800
0.30876386.9218423.html.plaintext.txt	346	1 The abbreviations used apo apolipoprotein LDLR low density lipoprotein receptor VLDL low density lipoprotein IDL intermediate density lipoprotein LDL low density lipoprotein R receptor HDL high density lipoprotein HSPG heparan sulfate proteoglycans 33 mice homozygous human apoE3 allele 3 mice heterozygous human apoE3 mice homozygous wild type mouse apoE allele kb kilobase ES cell embryonic stem cell TC total cholesterol ELISA enzyme linked immunosorbent assay hu human FPLC fast protein liquid chromatography PAGE polyacrylamide gel electrophoresis
0.30876386.9218423.html.plaintext.txt	347	Maeda unpublished observations
0.30876386.9218423.html.plaintext.txt	348	Masahiko Watanabe help building targeting construct Daniel Throckmorton Brian Oswald Denise Lee Kim Kluckman technical help
0.30876386.9218423.html.plaintext.txt	349	Taylor apoE3 plasmid Dr
0.30876386.9218423.html.plaintext.txt	350	Fruchart E01 antibody Dr
0.30876386.9218423.html.plaintext.txt	351	Young anti mouse ApoB sera Dr
0.30876386.9218423.html.plaintext.txt	352	Rifai validation human apoE standard Dr
0.30876386.9218423.html.plaintext.txt	353	Kirby reviewing manuscript
0.30876386.9218423.html.plaintext.txt	354	45 249 302 Medline Order article via Infotrieve Herz J
0.30876386.9218423.html.plaintext.txt	355	7 4119 4127 Abstract Mahley R
0.30876386.9218423.html.plaintext.txt	356	252 3980 3986 Abstract Mahley R
0.30876386.9218423.html.plaintext.txt	357	1978 Disturbances Lipid Lipoprotein Metabolism Dietschy J
0.30876386.9218423.html.plaintext.txt	358	181 197 American Physiological Society Bethesda Olaisen B
0.30876386.9218423.html.plaintext.txt	359	62 233 Medline Order article via Infotrieve Kardassis D
0.30876386.9218423.html.plaintext.txt	360	1996 Hypertension 27 980 1008 Free Full Text Paik Y
0.30876386.9218423.html.plaintext.txt	361	263 13340 13349 AbstractFree Full Text Smith J
0.30876386.9218423.html.plaintext.txt	362	263 8300 8308 AbstractFree Full Text Simonet W
0.30876386.9218423.html.plaintext.txt	363	268 8221 8229 AbstractFree Full Text Blue M
0.30876386.9218423.html.plaintext.txt	364	80 283 287 Abstract Basu S
0.30876386.9218423.html.plaintext.txt	365	257 9788 9795 Free Full Text Hallman D
0.30876386.9218423.html.plaintext.txt	366	49 338 349 Medline Order article via Infotrieve Rall S
0.30876386.9218423.html.plaintext.txt	367	257 4171 4178 Free Full Text Weisgraber K
0.30876386.9218423.html.plaintext.txt	368	257 2518 2521 Free Full Text Utermann G
0.30876386.9218423.html.plaintext.txt	369	90 9649 9653 Abstract Saunders A
0.30876386.9218423.html.plaintext.txt	370	1993 Neurology 43 1467 1472 Abstract Smith J
0.30876386.9218423.html.plaintext.txt	371	265 14709 14712 AbstractFree Full Text Simonet W
0.30876386.9218423.html.plaintext.txt	372	265 10809 10812 AbstractFree Full Text Fazio S
0.30876386.9218423.html.plaintext.txt	373	35 408 416 Abstract Mortimer B
0.30876386.9218423.html.plaintext.txt	374	14 1542 1552 Abstract van den Maagdenberg A
0.30876386.9218423.html.plaintext.txt	375	268 10540 10545 AbstractFree Full Text Xu P
0.30876386.9218423.html.plaintext.txt	376	3 229 245 CrossRefMedline Order article via Infotrieve Tybulewicz V
0.30876386.9218423.html.plaintext.txt	377	1991 Cell 65 1153 1163 Medline Order article via Infotrieve Koller B
0.30876386.9218423.html.plaintext.txt	378	88 10730 10734 Abstract de Silva H
0.30876386.9218423.html.plaintext.txt	379	35 1297 1310 Abstract Chomczynski P
0.30876386.9218423.html.plaintext.txt	380	162 156 159 CrossRefMedline Order article via Infotrieve Thomas P
0.30876386.9218423.html.plaintext.txt	381	77 5201 5205 Abstract Leroy A
0.30876386.9218423.html.plaintext.txt	382	Immunoassay 9 309 334 Medline Order article via Infotrieve Quarfordt S
0.30876386.9218423.html.plaintext.txt	383	36 1227 1235 Abstract Zhang S
0.30876386.9218423.html.plaintext.txt	384	94 937 945 Medline Order article via Infotrieve Green E
0.30876386.9218423.html.plaintext.txt	385	37 1263 1268 AbstractFree Full Text Robinson S
0.30876386.9218423.html.plaintext.txt	386	Acta 541 492 503 Medline Order article via Infotrieve Imaizumi K
0.30876386.9218423.html.plaintext.txt	387	19 712 722 Abstract de Silva H
0.30876386.9218423.html.plaintext.txt	388	269 2324 2335 AbstractFree Full Text Yang Y
0.30876386.9218423.html.plaintext.txt	389	32 469 475 Medline Order article via Infotrieve Wardell M
0.30876386.9218423.html.plaintext.txt	390	80 483 490 Medline Order article via Infotrieve Lalazar A
0.30876386.9218423.html.plaintext.txt	391	263 3542 3545 AbstractFree Full Text Landis B
0.30876386.9218423.html.plaintext.txt	392	Acta 575 81 91 Medline Order article via Infotrieve Weisgraber K
0.30876386.9218423.html.plaintext.txt	393	31 1503 1511 Abstract Taylor J
0.30876386.9218423.html.plaintext.txt	394	1979 Circulation 60 473 485 Abstract Slyper A
0.30876386.9218423.html.plaintext.txt	395	1992 Lancet 340 289 291 Medline Order article via Infotrieve van Vlijmen B
0.30876386.9218423.html.plaintext.txt	396	271 30595 30602 AbstractFree Full Text 1997 The American Society Biochemistry Molecular Biology Inc
0.28076172.12042316.html.plaintext.txt	0	Apolipoprotein E ApoE Isoform dependent Lipid Release Astrocytes Prepared Human ApoE3 ApoE4 Knock Mice Jian Sheng Gong Mariko Kobayashi Hideki Hayashi Kun Zou Naoya Sawamura Shinobu C
0.28076172.12042316.html.plaintext.txt	1	Fujita Katsuhiko Yanagisawa Makoto Michikawa
0.28076172.12042316.html.plaintext.txt	2	From Department Dementia Research National Institute Longevity Sciences 36 3 Gengo Morioka Obu Aichi 474 8522 Japan Organization Pharmaceutical Safety Research Japan Tokyo 100 0013 Japan Mitsubishi Kagaku Institute Life Sciences 11 Minamiooya Machida Tokyo 194 8511 Japan Japan Society Promotion Science JSPS Tokyo 102 8471 Japan
0.28076172.12042316.html.plaintext.txt	3	Received publication April 23 2002 revised form May 31 2002
0.28076172.12042316.html.plaintext.txt	4	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.28076172.12042316.html.plaintext.txt	5	We reported previously Michikawa M
0.28076172.12042316.html.plaintext.txt	6	74 1008 1016 exogenously added recombinant human apolipoprotein E apoE promotes cholesterol release isoform dependent manner
0.28076172.12042316.html.plaintext.txt	7	However molecular mechanism underlying isoform dependent promotion cholesterol release remains undetermined
0.28076172.12042316.html.plaintext.txt	8	In study demonstrate cholesterol release mediated endogenously synthesized secreted apoE isoforms clarify mechanism underlying apoE isoform dependent cholesterol release using cultured astrocytes prepared human apoE3 apoE4 knock mice
0.28076172.12042316.html.plaintext.txt	9	Cholesterol phospholipids released culture media resulting generation two types high density lipoprotein HDL like particles one associated apoE apoJ
0.28076172.12042316.html.plaintext.txt	10	The amount cholesterol released culture media apoE3 expressing astrocytes 2
0.28076172.12042316.html.plaintext.txt	11	5 fold greater apoE4 expressing astrocytes
0.28076172.12042316.html.plaintext.txt	12	In contrast amount apoE3 released association HDL like particles similar apoE4 sizes HDL like particles released apoE3 apoE4 expressing astrocytes similar
0.28076172.12042316.html.plaintext.txt	13	The molar ratios cholesterol apoE HDL fraction culture media apoE3 apoE4 expressing astrocytes 250 plus minus 6
0.28076172.12042316.html.plaintext.txt	14	These data indicate apoE3 ability generate similarly sized lipid particles less number apoE molecules apoE4 suggesting apoE3 expressing astrocytes supply cholesterol neurons apoE4 expressing astrocytes
0.28076172.12042316.html.plaintext.txt	15	These findings provide new insight issue concerning putative alteration apoE related cholesterol metabolism Alzheimers disease
0.28076172.12042316.html.plaintext.txt	16	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.28076172.12042316.html.plaintext.txt	17	Previous epidemiological studies show elevated serum cholesterol level risk factor development Alzheimers disease AD1 1 3 statin therapy reduces frequency AD 4 dementia 5
0.28076172.12042316.html.plaintext.txt	18	The decreased levels cellular cholesterol shown reduce A production vitro 6 vivo 7
0.28076172.12042316.html.plaintext.txt	19	Previous studies also shown association cholesterol accumulation mature senile plaques 8 neurofibrillary tangle bearing neurons 9
0.28076172.12042316.html.plaintext.txt	20	Additionally recent study 10 suggested increased cholesterol level membrane facilitates amyloid fibril formation formation GM1 ganglioside bound A putative endogenous seed
0.28076172.12042316.html.plaintext.txt	21	These findings suggest increased cellular cholesterol levels induce high amyloid protein A production subsequent AD development
0.28076172.12042316.html.plaintext.txt	22	However several studies 11 14 shown opposing evidence indicating cholesterol levels serum cell membranes brains cerebrospinal fluid decreased AD patients compared controls
0.28076172.12042316.html.plaintext.txt	23	Previous studies shown increased dietary cholesterol levels reduce A secretion 15 increased cellular cholesterol levels inhibit A mediated cell toxicity 16 17
0.28076172.12042316.html.plaintext.txt	24	On hand effect A cellular cholesterol metabolism also investigated 18
0.28076172.12042316.html.plaintext.txt	25	Our recent studies shown monomeric oligomeric A affects cholesterol metabolism 19 eventually reduces cellular cholesterol levels 20
0.28076172.12042316.html.plaintext.txt	26	In addition cholesterol deficiency shown promote tau phosphorylation vitro 21 22 vivo 23
0.28076172.12042316.html.plaintext.txt	27	These findings suggest involvement cholesterol pathogenesis AD dualistic
0.28076172.12042316.html.plaintext.txt	28	The elevated levels cellular cholesterol contribute AD development elevating A secretion however increasing amount oligomerized A reduces cellular cholesterol levels turn may promote progression AD pathologies
0.28076172.12042316.html.plaintext.txt	29	ApoE one major apolipoproteins central nervous system regulating lipid metabolisms 24 27
0.28076172.12042316.html.plaintext.txt	30	Astrocytes microglia known synthesize apoE 28 29 generates HDL like particles cellular lipids cerebrospinal fluid CSF culture media 25 26 30 31
0.28076172.12042316.html.plaintext.txt	31	These apoE lipid particles assumed supply cholesterol neurons apoE receptor mediated manner 32 33
0.28076172.12042316.html.plaintext.txt	32	Previously reported 34 exogenously added recombinant human apoE promotes cholesterol release isoform dependent manner
0.28076172.12042316.html.plaintext.txt	33	However mechanism underlying isoform dependent cholesterol release mediated apoE remains undetermined
0.28076172.12042316.html.plaintext.txt	34	It known majority apoE CSF conditioned culture media associated lipids 31 35 characteristics lipid particles generated addition exogenous apolipoprotein generated endogenous apolipoprotein different
0.28076172.12042316.html.plaintext.txt	35	HDL like particles generated addition exogenous apolipoprotein AI apoAI 36 apoE 34 low amount cholesterol whereas HDL like particles formed endogenous apoE cholesterol rich 37
0.28076172.12042316.html.plaintext.txt	36	These lines evidence led us determine whether endogenous apoE mediated cholesterol release cultured astrocytes isoform specific case characterize molecular mechanism underlying isoform dependent lipid release
0.28076172.12042316.html.plaintext.txt	37	In study investigated endogenous apoE mediated cholesterol release astrocytes isolated human apoE3 apoE4 knock mouse brains
0.28076172.12042316.html.plaintext.txt	38	We found apoE3 ability generate similarly sized HDL like particles less amount apoE apoE4
0.28076172.12042316.html.plaintext.txt	39	These findings may provide basis studies relate cholesterol AD pathogenesis
0.28076172.12042316.html.plaintext.txt	40	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.28076172.12042316.html.plaintext.txt	41	Animals Mice expressing human apoE4 place mouse apoE generated gene targeting technique taking advantage homologous recombination embryonic stem cells knock described previously 38
0.28076172.12042316.html.plaintext.txt	42	ApoE3 knock mice produced manner except transgene carried apoE3 cDNA place apoE4 cDNA
0.28076172.12042316.html.plaintext.txt	43	The details generation apoE3 mice described elsewhere
0.28076172.12042316.html.plaintext.txt	44	Postnatal day 2 mice possess homozygous 3 33 4 44 allele correctly expressing human apoE3 apoE4 proteins respectively used study
0.28076172.12042316.html.plaintext.txt	45	Cell Culture Highly astrocyte rich cultures prepared according method described previously 39 40
0.28076172.12042316.html.plaintext.txt	46	In brief brains postnatal day 2 mice removed anesthesia
0.28076172.12042316.html.plaintext.txt	47	The cerebral cortices mouse brains dissected freed meninges diced small pieces cortical fragments incubated 0
0.28076172.12042316.html.plaintext.txt	48	25 trypsin 20 mgml DNase I phosphate buffered saline PBS 8
0.28076172.12042316.html.plaintext.txt	49	5 mM KH2PO4 137 mM NaCl 2
0.28076172.12042316.html.plaintext.txt	50	The fragments dissociated single cells pipetting
0.28076172.12042316.html.plaintext.txt	51	The dissociated cells seeded 75 cm2 dishes cell density 1 x 107 DMEM containing 10 FBS
0.28076172.12042316.html.plaintext.txt	52	After 10 days incubation vitro astrocytes monolayer trypsinized 0
0.28076172.12042316.html.plaintext.txt	53	1 reseeded onto 6 well dishes
0.28076172.12042316.html.plaintext.txt	54	The astrocyte rich cultures maintained DMEM containing 10 FBS use
0.28076172.12042316.html.plaintext.txt	55	Neuron rich cultures prepared rat cerebral cortices described previously 19
0.28076172.12042316.html.plaintext.txt	56	The dissociated cells suspended feeding medium plated onto poly D lysine coated 6 well plates cell density 2 x 105cm2
0.28076172.12042316.html.plaintext.txt	57	The feeding medium consisted Dulbeccos modified Eagles medium nutrient mixture DMEMF 12 5050 N2 supplements
0.28076172.12042316.html.plaintext.txt	58	More 99 cultured cells identified neurons immunocytochemical analysis using monoclonal antibody microtubule associated protein 2 neuron specific marker day 3 culture 41
0.28076172.12042316.html.plaintext.txt	59	Quantification Released Intracellular Cholesterols Phosphatidylcholines The astrocytes 6 well plates washed DMEM three times incubated 2 ml DMEM 1 3 5 days 37 degrees C
0.28076172.12042316.html.plaintext.txt	60	The conditioned culture media removed processed lipid extraction
0.28076172.12042316.html.plaintext.txt	61	The astrocytes monolayer washed PBS three times air dried room temperature
0.28076172.12042316.html.plaintext.txt	62	Lipids conditioned culture media extracted according methods reported previously 34 41 modifications
0.28076172.12042316.html.plaintext.txt	63	0 ml conditioned culture media transferred clean glass tubes containing 4
0.28076172.12042316.html.plaintext.txt	64	0 ml chloroformmethanol 21 vv
0.28076172.12042316.html.plaintext.txt	65	The organic phase separated aqueous phase washed twice vigorous mixing 3 ml water re separated aqueous phase centrifugation dried N2 gas
0.28076172.12042316.html.plaintext.txt	66	For extraction intracellular lipids dried cells incubated hexaneisopropyl alcohol 32 vv 1 h room temperature
0.28076172.12042316.html.plaintext.txt	67	The solvent plate removed dried N2 gas
0.28076172.12042316.html.plaintext.txt	68	The organic phases redissolved 400 microl chloroform 150 microl sample transferred onto 96 well polypropylene plates Corning Glass dried air flow
0.28076172.12042316.html.plaintext.txt	69	The dried lipids dissolved 20 microl isopropyl alcohol contents cholesterol phospholipids determined using cholesterol Wako Osaka Japan phospholipid Kyowa Medix Tokyo Japan determiner kits respectively
0.28076172.12042316.html.plaintext.txt	70	Determination Amount 14CAcetate Incorporated Cholesterol Phosphatidylcholine Astrocytes cultured DMEM plus 10 FBS washed PBS three times recultured DMEM
0.28076172.12042316.html.plaintext.txt	71	The cultures treated 37 kBqml 14Cacetate PerkinElmer Life Sciences 1 3 5 days
0.28076172.12042316.html.plaintext.txt	72	At indicated time points culture medium quickly removed cells washed three times cold PBS dried room temperature
0.28076172.12042316.html.plaintext.txt	73	5 ml conditioned culture media transferred clean glass tubes containing 2
0.28076172.12042316.html.plaintext.txt	74	5 ml chloroformmethanol 21 vv
0.28076172.12042316.html.plaintext.txt	75	For extraction intracellular lipids dried cells incubated hexaneisopropyl alcohol 32 vv 1 h room temperature
0.28076172.12042316.html.plaintext.txt	76	The solvent plate removed dried N2 gas
0.28076172.12042316.html.plaintext.txt	77	The organic phases redissolved 50 microl chloroform 10 microl sample spotted activated silica gel high performance thin layer chromatography plates Merck lipids separated sequential one dimensional chromatography using chloroformmethanolacetic acidwater 251542 vv followed another run hexanediethyl etheracetic acid 80301
0.28076172.12042316.html.plaintext.txt	78	14CCholesterol 14Cphosphatidylcholine used standards
0.28076172.12042316.html.plaintext.txt	79	The chromatography plates exposed radiosensitive films lipid visualized quantified BAS2500 Fuji Film Tokyo Japan
0.28076172.12042316.html.plaintext.txt	80	For determination protein concentration astrocytes cultured 1 ml distilled water containing 0
0.28076172.12042316.html.plaintext.txt	81	1 NaOH 1 h 10 microl sample processed determination protein concentration using BCA kit
0.28076172.12042316.html.plaintext.txt	82	Density Gradient Ultracentrifugation After incubation DMEM 5 days astrocyte culture medium collected centrifuged 1600 x g 15 min 50 ml plastic tube exclude cell debris adjusted discontinuous sucrose gradient
0.28076172.12042316.html.plaintext.txt	83	A discontinuous sucrose gradient prepared 14 x 89 mm ultracentrifuge tube Ultraclear Beckman Instruments Palo Alto CA bottom top 2 ml sucrose density 1
0.28076172.12042316.html.plaintext.txt	84	The sample sucrose gradient centrifuged SW41 Ti swing rotor Beckman Instruments Palo Alto CA 4 degrees C 48 h 160000 x gav
0.28076172.12042316.html.plaintext.txt	85	Following density gradient centrifugation 12 1
0.28076172.12042316.html.plaintext.txt	86	0 ml fractions collected micropipette top gradient
0.28076172.12042316.html.plaintext.txt	87	The densities fractions determined measuring weight 100 microl fraction using micropipette
0.28076172.12042316.html.plaintext.txt	88	The final fraction stirred resuspend pellet
0.28076172.12042316.html.plaintext.txt	89	The lipid content fraction determined described
0.28076172.12042316.html.plaintext.txt	90	The density fraction determined using density meter DMA35N Anton Paar Graz Austria
0.28076172.12042316.html.plaintext.txt	91	Immunoblot Analysis Samples fraction dissolved sampling buffer consisting 100 mM Tris HCl pH 7
0.28076172.12042316.html.plaintext.txt	92	4 10 glycerol 4 SDS 10 mercaptoethanol 0
0.28076172.12042316.html.plaintext.txt	93	01 bromphenol blue analyzed 12
0.28076172.12042316.html.plaintext.txt	94	5 TrisTricine SDS PAGE reported previously 42
0.28076172.12042316.html.plaintext.txt	95	The separated proteins transferred onto Immobilon membranes semidry electrophoretic transfer apparatus Nihon Eido Tokyo Japan using transfer buffer 0
0.28076172.12042316.html.plaintext.txt	96	192 M glycine 20 methanol
0.28076172.12042316.html.plaintext.txt	97	Blots probed 4 h room temperature goat anti apoE polyclonal antibody AB947 12000 Chemicon Temecula CA goat anti apoJ antibody 1 2000 Rockland Gilbertsville PA
0.28076172.12042316.html.plaintext.txt	98	Band detection carried ECL kit Amersham Biosciences
0.28076172.12042316.html.plaintext.txt	99	For determination concentration apoE released culture medium signals corresponding apoE sample immunoblot membrane quantified densitometry NIH image software varying concentrations synthetic apoE protein Wako Tokyo Japan standards
0.28076172.12042316.html.plaintext.txt	100	Standard signals demonstrated linear range apoE protein amounts 0 2 microg per lane
0.28076172.12042316.html.plaintext.txt	101	The apoE concentrations conditioned culture media within range used analysis
0.28076172.12042316.html.plaintext.txt	102	For detection oligomeric apoE protein conditioned culture media Western blot analysis performed nonreducing conditions
0.28076172.12042316.html.plaintext.txt	103	Aliquots conditioned culture medium apoE3 apoE4 expressing astrocytes mixed volume 2 x nonreducing Laemmli buffer consisting 100 mM Tris HCl pH 7
0.28076172.12042316.html.plaintext.txt	104	4 10 glycerol 4 SDS 0
0.28076172.12042316.html.plaintext.txt	105	01 bromphenol blue mercaptoethanol analyzed Western blotting described
0.28076172.12042316.html.plaintext.txt	106	Size Determination Lipoprotein Particles The conditioned culture media astrocytes expressing human apoE3 apoE4 concentrated 5 fold using Centriprep YM10 tube Millipore Bedford MA centrifugation JA 12 rotor using Beckman J 25I ultracentrifuge 4 degrees C 40 min 3000 x g
0.28076172.12042316.html.plaintext.txt	107	After centrifugation sample subjected density gradient ultracentrifugation discontinuous sucrose gradient described
0.28076172.12042316.html.plaintext.txt	108	Two milliliters HDL fraction fraction number 4 Centricon YM10 tube Millipore concentrated 200 microl JA 20
0.28076172.12042316.html.plaintext.txt	109	1 rotor using Beckman J 25I ultracentrifuge 4 degrees C 2 h 5000 x g
0.28076172.12042316.html.plaintext.txt	110	The concentrated conditioned culture medium subjected nondenaturing 4 20 TBE pH 8
0.28076172.12042316.html.plaintext.txt	111	3 buffered PAGE evaluate particle size heterogeneity apoE fractions
0.28076172.12042316.html.plaintext.txt	112	Ten microliters apoE lipid particles unboiled nonreduced containing 10 sucrose 0
0.28076172.12042316.html.plaintext.txt	113	02 bromphenol blue applied onto 4 20 gradient gel
0.28076172.12042316.html.plaintext.txt	114	Native high molecular weight protein standards Amersham Biosciences used size standards 43
0.28076172.12042316.html.plaintext.txt	115	Electrophoresis performed 4 degrees C prerun 15 min 125 V entry samples stacking gel followed migration 100 V 8 h
0.28076172.12042316.html.plaintext.txt	116	The separated apoE migrated lipid apoE complex transferred onto Immobilon membrane semidry electrophoretic transfer apparatus Nihon Eido Tokyo Japan using transfer buffer 0
0.28076172.12042316.html.plaintext.txt	117	192 M glycine 20 methanol
0.28076172.12042316.html.plaintext.txt	118	Separated proteins probed 4 h room temperature goat anti apoE polyclonal antibody AB947 Chemicon Temecula CA 12000
0.28076172.12042316.html.plaintext.txt	119	ApoE protein detected using ECL kit Amersham Biosciences
0.28076172.12042316.html.plaintext.txt	120	The mean apoE lipid particle size obtained based migration size standards stained 0
0.28076172.12042316.html.plaintext.txt	121	5 Ponceau S Sigma 1 acetic acid distilled water
0.28076172.12042316.html.plaintext.txt	122	Statistical Analysis StatView computer software Macintosh used statistical analysis
0.28076172.12042316.html.plaintext.txt	123	Statistical significance differences samples evaluated Students test
0.28076172.12042316.html.plaintext.txt	124	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.28076172.12042316.html.plaintext.txt	125	The apoE3 apoE4 expressing astrocytes became confluent 7 days replating appeared morphologically comparable
0.28076172.12042316.html.plaintext.txt	126	The time dependent curves release cholesterol phospholipids cultured astrocytes expressing human apoE3 apoE4 shown Fig
0.28076172.12042316.html.plaintext.txt	127	We found amounts cholesterol Fig
0.28076172.12042316.html.plaintext.txt	128	1b released cells genotypes increased time dependent manner amounts lipids released apoE3 expressing astrocytes significantly higher apoE4 expressing astrocytes days 3 5 compared basis cellular protein
0.28076172.12042316.html.plaintext.txt	129	In contrast levels 14Cacetate incorporation cholesterol phosphatidylcholine apoE3 apoE4 expressing astrocytes similar time point Fig
0.28076172.12042316.html.plaintext.txt	130	Similarly total amounts cellular cholesterol phospholipids genotypes astrocytes similar time point Fig
0.28076172.12042316.html.plaintext.txt	131	View larger version 35K Fig
0.28076172.12042316.html.plaintext.txt	132	Characterization lipid metabolism cultured astrocytes prepared human apoE3 apoE4 knock mouse brains
0.28076172.12042316.html.plaintext.txt	133	Astrocyte rich cultures prepared described Experimental Procedures
0.28076172.12042316.html.plaintext.txt	134	Three week cultured astrocytes washed three times DMEM incubated DMEM
0.28076172.12042316.html.plaintext.txt	135	At time points indicated lipids released medium intracellular lipids extracted analyzed described Experimental Procedures b e f
0.28076172.12042316.html.plaintext.txt	136	For determination synthesis rates cholesterol phospholipids cultured astrocytes washed three times DMEM followed incubation 14Cacetate 2 h 37 degrees C
0.28076172.12042316.html.plaintext.txt	137	The cells washed cold PBS three times amount 14Cacetate incorporated cholesterol phosphatidylcholine determined described Experimental Procedures c d
0.28076172.12042316.html.plaintext.txt	138	The amounts cholesterol phospholipids b apoE3 expressing astrocytes significantly greater apoE4 expressing astrocytes respectively significant differences cellular cholesterolphospholipids concentrations e f rate cholesterolphosphatidylcholine synthesis c d apoE3 apoE4 expressing astrocytes
0.28076172.12042316.html.plaintext.txt	139	Data means plus minus S
0.28076172.12042316.html.plaintext.txt	140	001 versus apoE4 expressing astrocytes
0.28076172.12042316.html.plaintext.txt	141	Six independent experiments show similar results
0.28076172.12042316.html.plaintext.txt	142	We next determined amounts apoE3 apoE4 released culture medium
0.28076172.12042316.html.plaintext.txt	143	Western blot analysis conditioned culture media apoE3 apoE4 expressing astrocytes culture days 1 3 5 shows total amount apoE released culture media apoE3 apoE4 expressing astrocytes increased culture time Fig
0.28076172.12042316.html.plaintext.txt	144	The densitometric analysis signals shows comparative amounts apoE released apoE3 apoE4 expressing astrocytes Fig
0.28076172.12042316.html.plaintext.txt	145	View larger version 26K Fig
0.28076172.12042316.html.plaintext.txt	146	Amount apoE protein released conditioned culture media apoE3 apoE4 expressing astrocytes
0.28076172.12042316.html.plaintext.txt	147	Astrocyte rich cultures prepared described Experimental Procedures
0.28076172.12042316.html.plaintext.txt	148	Before experiments cells washed three times DMEM cultured DMEM
0.28076172.12042316.html.plaintext.txt	149	At time points indicated lipids released medium extracted analyzed described Experimental Procedures
0.28076172.12042316.html.plaintext.txt	150	The aliquots 5 microl sample subjected immunoblot analysis using polyclonal anti apoE antibody AB947 primary antibody
0.28076172.12042316.html.plaintext.txt	151	The intensity band quantified densitometric analysis using NIH imaging software Macintosh b
0.28076172.12042316.html.plaintext.txt	152	The amount apoE released culture media apoE3 expressing astrocytes similar apoE4 expressing astrocytes
0.28076172.12042316.html.plaintext.txt	153	Four independent experiments show similar results
0.28076172.12042316.html.plaintext.txt	154	The characteristics lipid particles released serum free media cultured astrocytes examined
0.28076172.12042316.html.plaintext.txt	155	The results density gradient ultracentrifugation cultured media apoE3 apoE4 expressing astrocytes shown Fig
0.28076172.12042316.html.plaintext.txt	156	3 indicate lipid distribution sample contains two peaks
0.28076172.12042316.html.plaintext.txt	157	They show cholesterol phospholipids distributed similarly fractions densities 1
0.28076172.12042316.html.plaintext.txt	158	They also show smaller amounts cholesterol phospholipids distributed fractions densities 1
0.28076172.12042316.html.plaintext.txt	159	These results show major parts cholesterol phospholipids present lighter density fractions 3 5 minor parts lipids present heavier density fractions 8 9 densities corresponded HDL
0.28076172.12042316.html.plaintext.txt	160	Next performed immunoblot analysis fraction using anti apoE anti apoJ antibodies
0.28076172.12042316.html.plaintext.txt	161	ApoE3 apoE4 detected mainly fractions 4 5 sample conditioned culture media apoE3 apoE4 expressing astrocytes consistent major peak lipid distribution shown Fig
0.28076172.12042316.html.plaintext.txt	162	In contrast apoJ sample conditioned culture media apoE3 apoE4 expressing astrocytes detected fractions 6 11 distinct containing apoE Fig
0.28076172.12042316.html.plaintext.txt	163	The distributions apoE apoJ across fractions sample quantified densitometric analysis shown Fig
0.28076172.12042316.html.plaintext.txt	164	4c indicating difference distribution apoE apoJ
0.28076172.12042316.html.plaintext.txt	165	View larger version 29K Fig
0.28076172.12042316.html.plaintext.txt	166	Density gradient analysis lipid particles released astrocytes
0.28076172.12042316.html.plaintext.txt	167	Three week cultured astrocytes plated 6 well dishes maintained DMEM containing 10 FBS 324 microgml cholesterol
0.28076172.12042316.html.plaintext.txt	168	The astrocytes rinsed three times fresh DMEM incubated DMEM 5 days
0.28076172.12042316.html.plaintext.txt	169	The culture medium collected centrifuged 1600 x g 15 min exclude cell debris
0.28076172.12042316.html.plaintext.txt	170	The supernatant collected subjected initial discontinuous density gradient prepared sucrose solutions described Experimental Procedures
0.28076172.12042316.html.plaintext.txt	171	After centrifugation fractions collected analyzed cholesterol phospholipid b contents
0.28076172.12042316.html.plaintext.txt	172	The density fraction also determined using density meter DMA35N
0.28076172.12042316.html.plaintext.txt	173	apoE3 Ast apoE3 expressing astrocytes apoE4 Ast apoE4 expressing astrocytes
0.28076172.12042316.html.plaintext.txt	174	Six independent experiments showed similar results
0.28076172.12042316.html.plaintext.txt	175	View larger version 32K Fig
0.28076172.12042316.html.plaintext.txt	176	Distribution apoE3 apoE4 across fractions separated density gradient ultracentrifugation
0.28076172.12042316.html.plaintext.txt	177	Twelve fractions obtained culture media apoE3 apoE4 expressing astrocytes described Fig
0.28076172.12042316.html.plaintext.txt	178	3 used determination distribution apoE apoJ
0.28076172.12042316.html.plaintext.txt	179	Aliquots 10 microl fraction mixed volume sample buffer subjected SDS PAGE
0.28076172.12042316.html.plaintext.txt	180	The separated proteins culture media apoE3 apoE4 expressing astrocytes b immunoblotted anti apoE antibody anti apoJ antibody
0.28076172.12042316.html.plaintext.txt	181	To determine distribution pattern apoE apoJ across fractions immunoblot membranes subjected scanning intensity band determined densitometric analysis using computer software c
0.28076172.12042316.html.plaintext.txt	182	apoE3 Ast apoE3 expressing astrocytes apoE4 Ast apoE4 expressing astrocytes
0.28076172.12042316.html.plaintext.txt	183	Six independent experiments show similar results
0.28076172.12042316.html.plaintext.txt	184	In addition found neurons synthesize secrete apoJ form HDL like particles without secretion apoE characterized apoJ mediated lipid release neurons compare astrocytes
0.28076172.12042316.html.plaintext.txt	185	The apoJ mediated lipid release conditioned media cultured neurons found distributed across fractions densities 1
0.28076172.12042316.html.plaintext.txt	186	180 gml similar apoJ mediated lipid release astrocyte cultures Fig
0.28076172.12042316.html.plaintext.txt	187	The distribution peaks apoJ Fig
0.28076172.12042316.html.plaintext.txt	188	5c across fraction densities found identical 1
0.28076172.12042316.html.plaintext.txt	189	These results show apoJ containing lipoproteins conditioned media cultured neurons astrocytes heavier generated apoE conditioned media cultured astrocytes characteristics apoJ containing lipoproteins generated neurons astrocytes examined study comparable
0.28076172.12042316.html.plaintext.txt	190	View larger version 24K Fig
0.28076172.12042316.html.plaintext.txt	191	Comparison distribution pattern apolipoproteins lipids conditioned media cultured astrocytes neurons
0.28076172.12042316.html.plaintext.txt	192	Density gradient ultracentrifugation conditioned culture media neurons performed obtain 12 fractions
0.28076172.12042316.html.plaintext.txt	193	The neurons cultured serum free N2 supplemented DMEMF 12 medium N2 medium 2 days washed fresh DMEM incubated N2 medium another 2 days
0.28076172.12042316.html.plaintext.txt	194	The culture medium centrifuged 1600 x g 15 min supernatant collected subjected initial discontinuous density gradient analysis using sucrose solutions described Experimental Procedures
0.28076172.12042316.html.plaintext.txt	195	After centrifugation fractions collected analyzed cholesterol phospholipids contents
0.28076172.12042316.html.plaintext.txt	196	Aliquots 10 microl fraction mixed volume sample buffer subjected SDS PAGE
0.28076172.12042316.html.plaintext.txt	197	The separated proteins immunoblotted anti apoE antibody anti apoJ antibody
0.28076172.12042316.html.plaintext.txt	198	No apoE signal detected conditioned culture medium neurons
0.28076172.12042316.html.plaintext.txt	199	The intensities apoJ signals detected Western blotting determined densitometric analysis described Experimental Procedures
0.28076172.12042316.html.plaintext.txt	200	For comparison results distribution apoE3 lipids across fractions conditioned culture media astrocytes used
0.28076172.12042316.html.plaintext.txt	201	The values parameter expressed terms density fraction x axis
0.28076172.12042316.html.plaintext.txt	202	The distributions apoE3 apoJ across density conditioned culture medium astrocytes apoJ conditioned culture medium neurons shown
0.28076172.12042316.html.plaintext.txt	203	The distributions cholesterol phospholipids astrocyte culture medium shown open circles b c neuronal culture medium shown closed circles b c
0.28076172.12042316.html.plaintext.txt	204	Astro CM conditioned culture medium astrocytes Neuron CM conditioned culture medium neurons
0.28076172.12042316.html.plaintext.txt	205	These results indicate apoE lipid complexes isoform dependent stoichiometry lipids apoE
0.28076172.12042316.html.plaintext.txt	206	Thus next determined molar weight ratios cholesterol phospholipids apoE
0.28076172.12042316.html.plaintext.txt	207	The quantification apoE given fraction carried Western blot analysis followed densitometric analysis using recombinant human apoE3 apoE4 standards
0.28076172.12042316.html.plaintext.txt	208	As shown Table I molar ratio cholesterol apoE apoE3 lipid particles 2
0.28076172.12042316.html.plaintext.txt	209	1 fold greater apoE4 lipid particles
0.28076172.12042316.html.plaintext.txt	210	On hand weight ratio phospholipids apoE apoE3 lipid particles 2
0.28076172.12042316.html.plaintext.txt	211	3 fold greater apoE4 lipid particles
0.28076172.12042316.html.plaintext.txt	212	These values comparable difference amount lipids released apoE3 apoE4 expressing astrocytes Fig
0.28076172.12042316.html.plaintext.txt	213	View table Table I The molar weight ratios cholesterol phospholipids apoE associated lipid complex released cultured media The culture media astrocytes expressing human apoE3 apoE4 changed DMEM without serum
0.28076172.12042316.html.plaintext.txt	214	The cultures incubated 5 days conditioned media culture collected
0.28076172.12042316.html.plaintext.txt	215	The conditioned culture media fractionated density gradient ultracentrifugation amounts cholesterol phospholipids HDL fraction fraction number 4 determined described Experimental Procedures
0.28076172.12042316.html.plaintext.txt	216	The amount apoE fraction determined quantitative Western blot analysis described Experimental Procedures
0.28076172.12042316.html.plaintext.txt	217	These results show ability apoE3 form lipid particles greater apoE4 indicating lipid particles generated stable form apoE3 less number apoE molecules apoE4
0.28076172.12042316.html.plaintext.txt	218	We determined compared sizes particles associated apoE3 apoE4
0.28076172.12042316.html.plaintext.txt	219	The sizes apoE lipid particles HDL fraction 4 analyzed nondenaturing gradient gel electrophoresis
0.28076172.12042316.html.plaintext.txt	220	Each sample conditioned culture media apoE3 apoE4 expressing astrocytes separated electrophoresis subsequently analyzed apoE Western blotting Fig
0.28076172.12042316.html.plaintext.txt	221	Two populations prominent apoE lipid particles diameters 6
0.28076172.12042316.html.plaintext.txt	222	97 nm present fraction 4 conditioned culture medium apoE3 apoE4 expressing astrocytes
0.28076172.12042316.html.plaintext.txt	223	Equivalent amounts aliquots used Western blot analysis anti apoJ antibody signal detected data shown
0.28076172.12042316.html.plaintext.txt	224	The apoE lipid particle sizes determined calculation size band based size standards
0.28076172.12042316.html.plaintext.txt	225	The particle sizes apoE3 expressing astrocytes similar apoE4 expressing astrocytes Table II
0.28076172.12042316.html.plaintext.txt	226	View larger version 45K Fig
0.28076172.12042316.html.plaintext.txt	227	Native nondenaturing gradient gel electrophoresis apoE3 apoE4 expressing astrocyte lipoprotein particles followed Western blot analysis
0.28076172.12042316.html.plaintext.txt	228	ApoE rich fraction 4 conditioned culture media apoE3 apoE4 expressing astrocytes nondenaturing nonreducing conditions electrophoresed nondenaturing 4 20 TBE gradient gel followed Western blot analysis using anti apoE antibody
0.28076172.12042316.html.plaintext.txt	229	Amersham Biosciences native high molecular weight standards used hydrated diameter assessment
0.28076172.12042316.html.plaintext.txt	230	Lanes 1 2 samples fraction 4 different conditioned culture media apoE3 expressing astrocytes lanes 3 4 samples fraction 4 different conditioned culture media apoE4 expressing astrocytes
0.28076172.12042316.html.plaintext.txt	231	Four independent experiments showed similar results
0.28076172.12042316.html.plaintext.txt	232	View table Table II Particle size apoE lipid complex conditioned culture media mouse astrocytes expressing human apoE3 apoE4 The conditioned culture media astrocytes expressing human apoE3 apoE4 concentrated 5 fold using Centriprep 10 Millipore Bedford MA prior fractionation
0.28076172.12042316.html.plaintext.txt	233	Two milliliters HDL fraction fraction number 4 concentrated 200 microl using Centricon YM10 Millipore
0.28076172.12042316.html.plaintext.txt	234	The samples electrophoresed nondenaturing 4 20 gradient gel separated proteins transferred onto polyvinylidene difluoride membrane Millipore probed anti apoE antibody AB947
0.28076172.12042316.html.plaintext.txt	235	6 apoE associated HDL like particles visualized separated bands sizes determined comparison migration standard proteins known diameters HMW calibration kit Amersham Biosciences
0.28076172.12042316.html.plaintext.txt	236	There significant difference size lipid particles obtained apoE3 apoE4 expressing astrocytes
0.28076172.12042316.html.plaintext.txt	237	It suggested disulfide linked dimeric apoA II exhibits stronger ability promote lipid release monomeric apoA II increased number helical segments 44
0.28076172.12042316.html.plaintext.txt	238	Because apoE3 contains cysteine residue 112 apoE4 higher ability apoE3 promote lipid release may caused increased number helical segments due formation disulfide linked dimers
0.28076172.12042316.html.plaintext.txt	239	To examine possibility performed immunoblot analysis conditioned culture media apoE3 apoE4 expressing astrocytes reducing nonreducing conditions
0.28076172.12042316.html.plaintext.txt	240	In absence mercaptoethanol conditioned culture media apoE3 expressing astrocytes contained oligomers mainly dimers less amount tetramers addition monomers whereas apoE4 expressing astrocytes contained monomers Fig
0.28076172.12042316.html.plaintext.txt	241	Obviously band representing apoE3 dimer higher expected one Mr 68400
0.28076172.12042316.html.plaintext.txt	242	Because known serum apoE3 forms homodimers migrate anomalously SDS gel nonreducing conditions 45 may also case apoE3 dimer conditioned culture media
0.28076172.12042316.html.plaintext.txt	243	The oligomers found conditioned culture media apoE3 expressing astrocytes found monomers samples incubated 10 mercaptoethanol Fig
0.28076172.12042316.html.plaintext.txt	244	View larger version 59K Fig
0.28076172.12042316.html.plaintext.txt	245	Time course apoE release conditioned medium cultured apoE3 apoE4 expressing astrocytes
0.28076172.12042316.html.plaintext.txt	246	Shown results Western blot analysis nonreducing reducing conditions apoE3 apoE4 conditioned culture medium apoE3 apoE4 expressing astrocytes respectively
0.28076172.12042316.html.plaintext.txt	247	Oligomeric apoE mainly dimers less amount tetramers found samples apoE3 expressing astrocyte cultures apoE4 expressing astrocyte cultures
0.28076172.12042316.html.plaintext.txt	248	When samples incubated Laemmli buffer containing 10 mercaptoethanol ME oligomers detected samples b
0.28076172.12042316.html.plaintext.txt	249	Five independent experiments show similar results
0.28076172.12042316.html.plaintext.txt	250	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.28076172.12042316.html.plaintext.txt	251	Here demonstrate apoE isoform dependent lipid release cultured astrocytes prepared apoE3 apoE4 knock mice
0.28076172.12042316.html.plaintext.txt	252	Although found apoE isoform dependent differences size apoE3 apoE4 lipid particles total amount released apoE apoE3 apoE4 astrocytes apoE3 specific enhancement lipid release cells observed
0.28076172.12042316.html.plaintext.txt	253	These results indicate apoE3 higher ability generate apoE lipid particles less numbers apoE molecules per particle apoE4 suggesting apoE3 expressing astrocytes could supply cholesterol neurons apoE4 expressing astrocytes thereby supporting neuronal plasticity promoting neuronal regeneration
0.28076172.12042316.html.plaintext.txt	254	It reported apolipoproteins multiple helix segments 20 30 amino acid residues hydrophobic hydrophilic residues aligned opposite sides axis induce cholesterol efflux cells added culture medium 44 46 50
0.28076172.12042316.html.plaintext.txt	255	ApoE one apolipoproteins effects apoE cholesterol release examined various cell systems 51 54
0.28076172.12042316.html.plaintext.txt	256	This apolipoprotein mediated cholesterol release results generation pre HDL contains apolipoproteins cellular cholesterol phosphatidylcholine
0.28076172.12042316.html.plaintext.txt	257	Recent studies 31 37 demonstrated HDL like particles association exogenous endogenous apoE also generated cultured medium central nervous system cells astrocytes neurons
0.28076172.12042316.html.plaintext.txt	258	In addition found addition exogenous apoE promotes lipid release central nervous system cells generating HDL like particles apoE isoform dependent manner 34
0.28076172.12042316.html.plaintext.txt	259	Consistent previous findings using exogenous apoE present study also shows amount lipids released apoE3 apoE4 expressing astrocytes apoE isoform dependent order potency apoE3 apoE4
0.28076172.12042316.html.plaintext.txt	260	However mechanism underlying isoform dependent cholesterol release remains undetermined
0.28076172.12042316.html.plaintext.txt	261	Therefore next question addressed mechanism underlying apoE isoform dependent cholesterol release
0.28076172.12042316.html.plaintext.txt	262	We found amount lipids released apoE3 expressing astrocytes 2
0.28076172.12042316.html.plaintext.txt	263	5 fold greater apoE4 expressing astrocytes whereas amount apoE3 released similar apoE4
0.28076172.12042316.html.plaintext.txt	264	One possible explanation may particle contains equal amount apoE proteins however particles containing apoE3 contain 2
0.28076172.12042316.html.plaintext.txt	265	5 fold greater amounts lipids containing apoE4
0.28076172.12042316.html.plaintext.txt	266	Another possible explanation may particle contains equal amounts lipids apoE3 containing particles contain lower numbers apoE molecules apoE4 containing particles
0.28076172.12042316.html.plaintext.txt	267	This implies apoE3 ability form lipid particles lower number apoE molecules apoE4 thus generate 2
0.28076172.12042316.html.plaintext.txt	268	5 fold greater numbers apoE lipid particles apoE4 number apoE molecules
0.28076172.12042316.html.plaintext.txt	269	Between two possibilities experiment favors latter shown Fig
0.28076172.12042316.html.plaintext.txt	270	6 Table II sizes particles conditioned culture media apoE3 apoE4 expressing astrocytes similar
0.28076172.12042316.html.plaintext.txt	271	The apoE isoform dependent difference association lipoprotein particles may explained terms mechanism underlying apoE isoform specific formation apoE oligomers apoE3 protein forms dimers apoE4
0.28076172.12042316.html.plaintext.txt	272	This difference may apoE3 cysteine position 112 N terminal domain whereas apoE4 arginine position
0.28076172.12042316.html.plaintext.txt	273	Previous studies shown number length amphiphilic helices responsible determining ability given apolipoprotein promote lipid release 44 49 55
0.28076172.12042316.html.plaintext.txt	274	Interestingly human apoA II known form disulfide linked dimers exhibit stronger ability promote lipid release monomeric apoA II 44
0.28076172.12042316.html.plaintext.txt	275	These lines evidence allow us postulate higher ability apoE dimers apoE monomers promote lipid release may explain greater amounts lipids released conditioned culture media apoE3 expressing astrocytes apoE4 expressing astrocytes
0.28076172.12042316.html.plaintext.txt	276	Based assumption propose model isoform dependent association apoE lipid particles Fig
0.28076172.12042316.html.plaintext.txt	277	Consistent present results previous studies revealed conformational adaptability apoE N terminal domain function lipid availability 56 presence competitor apolipoproteins review see Ref
0.28076172.12042316.html.plaintext.txt	278	In studies model two possible conformations apoE spherical lipid particles proposed high apoE concentration N terminal domain displaced lipid surface form helix bundle closed conformation whereas low concentration surface four helix bundles N terminal domain open conformation helices contact lipid surface
0.28076172.12042316.html.plaintext.txt	279	Based lines evidence together findings apoE3 containing HDL like particle contains approximately one half number apoE molecules compared apoE4 containing particle may possible apoE isoform dependent conformational change occurs surface lipid particles N terminal domain apoE3 open conformation whereas apoE4 closed helix bundle conformation
0.28076172.12042316.html.plaintext.txt	280	View larger version 40K Fig
0.28076172.12042316.html.plaintext.txt	281	Model apoE lipid particles generated apoE3 apoE4 expressing astrocytes
0.28076172.12042316.html.plaintext.txt	282	The present data indicate apoE3 ability generate similarly sized apoE lipid particles less number apoE molecules apoE4
0.28076172.12042316.html.plaintext.txt	283	Based findings propose model showing one apoE4 containing lipid particle contains 2 fold numbers apoE molecules compared apoE3 containing lipid particle
0.28076172.12042316.html.plaintext.txt	284	Another possible explanation may preferential association apoE isoforms lipoproteins apoE4 preferentially associates low density lipoprotein whereas apoE3 associates HDL
0.28076172.12042316.html.plaintext.txt	285	This assumption based facts N terminal domain modulates lipid binding preference elicited C terminal domain 58 59 interaction N C terminal domains responsible isoform preference 60 61
0.28076172.12042316.html.plaintext.txt	286	It suggested apoE4 interaction arginine 61 glutamic acid 255 may stabilize extended helical structure carboxyl terminus best accommodated less curved low density lipoprotein surface whereas interaction exist apoE3 therefore lacks stability shorter helices preference HDL 61 62
0.28076172.12042316.html.plaintext.txt	287	Based lines evidence apoE3 may preferentially bind HDL particle lower number apoE molecules stabilize particle whereas apoE4 less binding efficacy HDL particle requires higher numbers apoE molecules stabilize particle
0.28076172.12042316.html.plaintext.txt	288	Because physical properties apoE assumed influence functions
0.28076172.12042316.html.plaintext.txt	289	associates lipid particles stabilizes apoE isoform dependent difference stability among 22 kDa N terminal fragments apoE 63 may involved isoform dependent binding efficacy apoE HDL particles
0.28076172.12042316.html.plaintext.txt	290	Previous studies 48 50 54 demonstrated various cells generate cholesterol rich HDL like particles exogenous apolipoproteins
0.28076172.12042316.html.plaintext.txt	291	However case astrocytes researchers found generation HDL endogenous apoE exogenous apoE differently regulated cultured astrocytes HDL like particles generated exogenous apolipoproteins low amounts cholesterol 34 37 whereas HDL like particles generated endogenous apoE cholesterol rich 37
0.28076172.12042316.html.plaintext.txt	292	In support findings present study shown apoE lipid particles generated endogenously synthesized released apoE cholesterol rich compared generated addition exogenous apoE 34
0.28076172.12042316.html.plaintext.txt	293	Because amount apoE free lipid particles cultured medium CSF detection limit see Ref
0.28076172.12042316.html.plaintext.txt	294	4 b results suggest physiological conditions cholesterol rich lipid particles associated endogenous apoE major cholesterol source neurons central nervous system
0.28076172.12042316.html.plaintext.txt	295	In regard interest note apoE3 expressing astrocytes could supply cholesterol form apoE lipid particles cells including neurons comparable levels apoE secretion apoE4 expressing astrocytes
0.28076172.12042316.html.plaintext.txt	296	Under steady state conditions lipid metabolisms central nervous system appear similar brains apoE3 apoE4 knock mice concentrations free esterified cholesterol postnuclear supernatant plasma membrane endoplasmic reticulum brain homogenate similar 64
0.28076172.12042316.html.plaintext.txt	297	However different conditions recovery phases brain injury cell damage endogenous apoE mediated generation HDL like particles could play critical role cholesterol delivery neurons essential material axonal regeneration synapse formation 65 68
0.28076172.12042316.html.plaintext.txt	298	Actually previous studies 69 70 demonstrated traumatic brain injury robust environmental risk factor development AD
0.28076172.12042316.html.plaintext.txt	299	These lines evidence may allow us postulate apoE isoform dependence development AD may explained apoE isoform dependent ability cholesterol supply neurons injury cell damage leading neuroregeneration
0.28076172.12042316.html.plaintext.txt	300	This work supported Research Grant Longevity Sciences 8A 1 Program Promotion Fundamental Studies Health Sciences Organization Pharmaceutical Safety Research Research Brain Science Ministry Health Welfare CREST Japan
0.28076172.12042316.html.plaintext.txt	301	The costs publication article defrayed part payment page charges
0.28076172.12042316.html.plaintext.txt	302	The article must therefore hereby marked advertisement accordance 18 U
0.28076172.12042316.html.plaintext.txt	303	Section 1734 solely indicate fact
0.28076172.12042316.html.plaintext.txt	304	To correspondence addressed Dept
0.28076172.12042316.html.plaintext.txt	305	Dementia Research National Institute Longevity Sciences 36 3 Gengo Morioka Obu Aichi 474 8522 Japan
0.28076172.12042316.html.plaintext.txt	306	81 562 46 2311 Fax 81 562 46 3157 E mail michinils
0.28076172.12042316.html.plaintext.txt	307	Published JBC Papers Press May 31 2002 DOI 10
0.28076172.12042316.html.plaintext.txt	308	The abbreviations used AD Alzheimers disease HDL high density lipoprotein apoE apolipoprotein E apoA II apolipoprotein A II CSF cerebrospinal fluid DMEM Dulbeccos modified Eagles medium FBS fetal bovine serum PBS phosphate buffered saline Tricine N 2 hydroxy 11 bishydroxymethylethylglycine A amyloid protein
0.28076172.12042316.html.plaintext.txt	309	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES 1
0.28076172.12042316.html.plaintext.txt	310	1995 Neurology 45 1092 1096Abstract 2
0.28076172.12042316.html.plaintext.txt	311	1998 Neuroepidemiology 17 14 20CrossRefMedline Order article via Infotrieve 3
0.28076172.12042316.html.plaintext.txt	312	2001 Neurology 56 1683 1689AbstractFree Full Text 4
0.28076172.12042316.html.plaintext.txt	313	57 1439 1443AbstractFree Full Text 5
0.28076172.12042316.html.plaintext.txt	314	2000 Lancet 356 1627 1631CrossRefMedline Order article via Infotrieve 6
0.28076172.12042316.html.plaintext.txt	315	95 6460 6464AbstractFree Full Text 7
0.28076172.12042316.html.plaintext.txt	316	98 5856 5861AbstractFree Full Text 8
0.28076172.12042316.html.plaintext.txt	317	60 778 785Medline Order article via Infotrieve 9
0.28076172.12042316.html.plaintext.txt	318	101 547 554Medline Order article via Infotrieve 10
0.28076172.12042316.html.plaintext.txt	319	276 24985 24990AbstractFree Full Text 11
0.28076172.12042316.html.plaintext.txt	320	61 21 26Medline Order article via Infotrieve 12
0.28076172.12042316.html.plaintext.txt	321	18 203 206CrossRefMedline Order article via Infotrieve 13
0.28076172.12042316.html.plaintext.txt	322	12 198 203Medline Order article via Infotrieve 14
0.28076172.12042316.html.plaintext.txt	323	Aging 13 413 419CrossRefMedline Order article via Infotrieve 15
0.28076172.12042316.html.plaintext.txt	324	273 16576 16582AbstractFree Full Text 16
0.28076172.12042316.html.plaintext.txt	325	311 723 734CrossRefMedline Order article via Infotrieve 17
0.28076172.12042316.html.plaintext.txt	326	277 6273 6279AbstractFree Full Text 18
0.28076172.12042316.html.plaintext.txt	327	95 13266 13271AbstractFree Full Text 19
0.28076172.12042316.html.plaintext.txt	328	21 7226 7235AbstractFree Full Text 20
0.28076172.12042316.html.plaintext.txt	329	76 391 400CrossRefMedline Order article via Infotrieve 22
0.28076172.12042316.html.plaintext.txt	330	15 1858 1860AbstractFree Full Text 23
0.28076172.12042316.html.plaintext.txt	331	276 10314 10319AbstractFree Full Text 24
0.28076172.12042316.html.plaintext.txt	332	262 14352 14360AbstractFree Full Text 26
0.28076172.12042316.html.plaintext.txt	333	Acta 1255 192 200Medline Order article via Infotrieve 27
0.28076172.12042316.html.plaintext.txt	334	5 110 116Medline Order article via Infotrieve 28
0.28076172.12042316.html.plaintext.txt	335	76 1501 1513Medline Order article via Infotrieve 29
0.28076172.12042316.html.plaintext.txt	336	211 41 44CrossRefMedline Order article via Infotrieve 30
0.28076172.12042316.html.plaintext.txt	337	Acta 917 148 161Medline Order article via Infotrieve 31
0.28076172.12042316.html.plaintext.txt	338	70 2070 2081Medline Order article via Infotrieve 32
0.28076172.12042316.html.plaintext.txt	339	27 119 142Medline Order article via Infotrieve 33
0.28076172.12042316.html.plaintext.txt	340	74 1008 1016CrossRefMedline Order article via Infotrieve 35
0.28076172.12042316.html.plaintext.txt	341	274 30001 30007AbstractFree Full Text 36
0.28076172.12042316.html.plaintext.txt	342	1993 Biochemistry 32 4597 4603Medline Order article via Infotrieve 37
0.28076172.12042316.html.plaintext.txt	343	72 2362 2369CrossRefMedline Order article via Infotrieve 38
0.28076172.12042316.html.plaintext.txt	344	9 353 361AbstractFree Full Text 39
0.28076172.12042316.html.plaintext.txt	345	266 129 132CrossRefMedline Order article via Infotrieve 40
0.28076172.12042316.html.plaintext.txt	346	162 51 60CrossRefMedline Order article via Infotrieve 41
0.28076172.12042316.html.plaintext.txt	347	72 2278 2285CrossRefMedline Order article via Infotrieve 42
0.28076172.12042316.html.plaintext.txt	348	1970 Nature 227 680 685Medline Order article via Infotrieve 43
0.28076172.12042316.html.plaintext.txt	349	1992 Lipids 27 302 304Medline Order article via Infotrieve 45
0.28076172.12042316.html.plaintext.txt	350	266 12029 12034AbstractFree Full Text 46
0.28076172.12042316.html.plaintext.txt	351	Acta 1392 1 15Medline Order article via Infotrieve 48
0.28076172.12042316.html.plaintext.txt	352	1992 Biochemistry 31 2040 2046Medline Order article via Infotrieve 49
0.28076172.12042316.html.plaintext.txt	353	1983 Science 219 871 873Medline Order article via Infotrieve 52
0.28076172.12042316.html.plaintext.txt	354	271 28641 28646AbstractFree Full Text 54
0.28076172.12042316.html.plaintext.txt	355	266 3080 3086AbstractFree Full Text 55
0.28076172.12042316.html.plaintext.txt	356	276 40949 40954AbstractFree Full Text 57
0.28076172.12042316.html.plaintext.txt	357	Acta 1483 15 36Medline Order article via Infotrieve 58
0.28076172.12042316.html.plaintext.txt	358	1992 Biochemistry 31 1065 1068Medline Order article via Infotrieve 59
0.28076172.12042316.html.plaintext.txt	359	1995 Biochemistry 34 10953 10966Medline Order article via Infotrieve 60
0.28076172.12042316.html.plaintext.txt	360	269 22358 22365AbstractFree Full Text 61
0.28076172.12042316.html.plaintext.txt	361	271 19053 19057AbstractFree Full Text 62
0.28076172.12042316.html.plaintext.txt	362	98 11587 11591AbstractFree Full Text 63
0.28076172.12042316.html.plaintext.txt	363	2000 Biochemistry 39 11657 11666CrossRefMedline Order article via Infotrieve 64
0.28076172.12042316.html.plaintext.txt	364	2002 Neuroreport 13 383 386CrossRefMedline Order article via Infotrieve 65
0.28076172.12042316.html.plaintext.txt	365	17 525 530CrossRefMedline Order article via Infotrieve 66
0.28076172.12042316.html.plaintext.txt	366	272 30766 30773AbstractFree Full Text 67
0.28076172.12042316.html.plaintext.txt	367	275 19883 19890AbstractFree Full Text 68
0.28076172.12042316.html.plaintext.txt	368	2001 Science 294 1354 1357AbstractFree Full Text 69
0.28076172.12042316.html.plaintext.txt	369	Psychiatry 53 373 378Abstract 70
0.28076172.12042316.html.plaintext.txt	370	1 135 137Medline Order article via Infotrieve
0.28076172.12042316.html.plaintext.txt	371	Copyright 2002 The American Society Biochemistry Molecular Biology Inc
0.54427505.15198969.html.plaintext.txt	0	Estrogen Alzheimer Disease The Apolipoprotein Connection Neil J
0.54427505.15198969.html.plaintext.txt	1	Center Reproductive Sciences Columbia University Medical Center New York New York 10032
0.54427505.15198969.html.plaintext.txt	2	Address correspondence requests reprints Dr
0.54427505.15198969.html.plaintext.txt	3	MacLusky Center Reproductive Sciences Columbia University Medical Center 630 West 168th Street New York New York 10032
0.54427505.15198969.html.plaintext.txt	4	The contribution estrogens prevention neurodegenerative disorders attracted considerable attention last years result conflicting data clinical trials shown protective effects postmenopausal estrogen based hormone replacement therapy HRT whereas others including recently concluded Women Health Initiative trial revealed significant benefit
0.54427505.15198969.html.plaintext.txt	5	Although reason apparently discrepant results remains subject heated debate growing body evidence suggests individual women may exhibit variable neuroprotective responses HRT part interactions known risk factors neurodegenerative disease
0.54427505.15198969.html.plaintext.txt	6	One risk factor modulates effects HRT rates cognitive decline aging women expression pattern allelic variants apolipoprotein E apoE
0.54427505.15198969.html.plaintext.txt	7	1 issue Endocrinology indicates may case
0.54427505.15198969.html.plaintext.txt	8	Trophic effects natural ovarian estrogen estradiol 17ss neurite growth cultured mouse cerebral cortical neurons reported critically dependent apoE expression
0.54427505.15198969.html.plaintext.txt	9	Moreover responses estradiol 17ss shown dependent type apoE present whereas estradiol 17ss neurotrophic presence human apoE 2 apoE 3 apoE 4 variant associated progression late onset Alzheimer disease support response
0.54427505.15198969.html.plaintext.txt	10	The concept HRT might beneficial effects aging brain evolved initially studies laboratory animals
0.54427505.15198969.html.plaintext.txt	11	Almost 3 decades ago estradiol 17ss shown exert neurotrophic effects tissue explants derived developing mouse hypothalamus preoptic area 2
0.54427505.15198969.html.plaintext.txt	12	Synaptogenic effects estradiol 17ss later demonstrated occur adult brain including regions brain hippocampus important cognitive function 3 4
0.54427505.15198969.html.plaintext.txt	13	In various models neuronal damage natural synthetic estrogens reported enhance cell survival 5 whereas estradiol 17ss treatment shown enhance nonamyloidogenic processing Alzheimer amyloid precursor protein 6
0.54427505.15198969.html.plaintext.txt	14	Estradiol 17ss also found positive effects maintenance neurotransmitter systems undergo degeneration Alzheimer disease 7 Parkinson disease 8
0.54427505.15198969.html.plaintext.txt	15	Taken together observations provided strong mechanistic support concept postmenopausal HRT might slow prevent neurodegenerative processes
0.54427505.15198969.html.plaintext.txt	16	Clinical trials general provided mixed support hypothesis simultaneously highlighting potential health risks long term postmenopausal HRT use 1 9 10 11
0.54427505.15198969.html.plaintext.txt	17	Part problem appears human beings unlike laboratory animals effects HRT may confounded variety factors modulate oppose actions hormones
0.54427505.15198969.html.plaintext.txt	18	One particularly important genetic factor appears expression pattern apoE
0.54427505.15198969.html.plaintext.txt	19	Expression different apoE alleles previously demonstrated affect risk atherosclerosis 12 well rate progression several human neurodegenerative diseases 13 14 including Alzheimer dementia 15
0.54427505.15198969.html.plaintext.txt	20	Intriguingly patterns apoE expression also found significantly influence responses HRT 16
0.54427505.15198969.html.plaintext.txt	21	The mechanism underlying interaction remained uncertain
0.54427505.15198969.html.plaintext.txt	22	One possibility might reflect known effects apoE expression atherosclerotic processes 12 cerebral vascular compromise secondarily affecting rate cognitive decline 16
0.54427505.15198969.html.plaintext.txt	23	An alternative hypothesis however suggested studies aimed elucidating effects estradiol 17ss apoE expression nerve cells
0.54427505.15198969.html.plaintext.txt	24	Studies mice demonstrated expression apoE different brain regions varied stage female reproductive cycle 17 consistent hypothesis estradiol 17ss might induce apoE expression brain already demonstrated apoE blood 18
0.54427505.15198969.html.plaintext.txt	25	Addition apoE 3 found produce effects like estradiol 17ss cultured neurons 19
0.54427505.15198969.html.plaintext.txt	26	Moreover neuroprotective effects estradiol 17ss abolished transgenic mice homozygous deletion apoE gene 20
0.54427505.15198969.html.plaintext.txt	27	These observations raised possibility apoE might represent integral component mechanisms mediating trophic responses neurons estrogen exposure
0.54427505.15198969.html.plaintext.txt	28	1 demonstrate indeed case
0.54427505.15198969.html.plaintext.txt	29	The growth promoting effects estradiol 17ss depend expression apoE also highly dependent nature apoE subtype
0.54427505.15198969.html.plaintext.txt	30	In cultured cells adult mouse cerebral cortex estradiol 17ss increased apoE levels neurite outgrowth
0.54427505.15198969.html.plaintext.txt	31	The hormone effect neurite outgrowth mice lacking apoE gene apoE 4 exogenously supplied
0.54427505.15198969.html.plaintext.txt	32	ApoE 2 apoE variant associated reduced risk Alzheimer disease increased age onset increased neurite length apoE 3 presence estradiol 17ss
0.54427505.15198969.html.plaintext.txt	33	Cultures mice transgenic human apoE 3 capable responding estradiol 17ss whereas mice expressing apoE 4 relatively insensitive
0.54427505.15198969.html.plaintext.txt	34	Similarly apoE 3 accumulated neurons greater extent apoE 4 effective facilitating neuronal uptake fatty acid
0.54427505.15198969.html.plaintext.txt	35	These data consistent hypothesis apoE may play integral role supporting neurotrophic effects estradiol 17ss patterns apoE expression may profound impact sensitivity brain estrogen action
0.54427505.15198969.html.plaintext.txt	36	These observations important implications future studies effects HRT
0.54427505.15198969.html.plaintext.txt	37	If expression specific apoE alleles required estrogen exert neurotrophic neuroprotective effects pattern apoE allele expression likely important determining effectiveness estrogen based HRT
0.54427505.15198969.html.plaintext.txt	38	Synergism apoE subtype expression effects HRT already demonstrated respect progression atherosclerosis postmenopausal women estrogen use appears particularly beneficial patients apoE 4 allele 12
0.54427505.15198969.html.plaintext.txt	39	The situation may well true effects neurodegenerative processes
0.54427505.15198969.html.plaintext.txt	40	16 administered cognitive function tests number years women either taking estrogen based HRT taken HRT time past never used HRT
0.54427505.15198969.html.plaintext.txt	41	In women express apoE 4 variant postmenopausal estrogen use reduced risk age related cognitive impairment almost 50 compared women never used estrogen
0.54427505.15198969.html.plaintext.txt	42	By contrast apoE 4 positive women show significant estrogen response 16
0.54427505.15198969.html.plaintext.txt	43	These data consistent hypothesis analysis apoE variant expression may predictive whether HRT likely long term beneficial cognitive effects
0.54427505.15198969.html.plaintext.txt	44	One key questions remains answered extent data presented Nathan et al
0.54427505.15198969.html.plaintext.txt	45	1 extrapolated normal brain
0.54427505.15198969.html.plaintext.txt	46	used cultures dispersed neuronal glial cells adult mouse cerebral cortex
0.54427505.15198969.html.plaintext.txt	47	It important future determine whether effects estrogens aging brain involve comparable apoE dependent mechanisms
0.54427505.15198969.html.plaintext.txt	48	Published evidence consistent view effects estradiol 17ss recovery mature brain injury require apoE
0.54427505.15198969.html.plaintext.txt	49	Thus mice enhancement synaptic sprouting estradiol 17ss response entorhinal cortex lesions dependent apoE expression 21
0.54427505.15198969.html.plaintext.txt	50	However neuronal damage perhaps including cellular damage inevitably incurred preparation primary cell cultures may result reexpression estrogen receptor mechanisms normally expressed development 22
0.54427505.15198969.html.plaintext.txt	51	Hence remains established whether findings extrapolated regulation neuronal growth survival uninjured brain
0.54427505.15198969.html.plaintext.txt	52	1 dementia trauma degeneration repair may dynamic balance cognitive decline occurring degenerative processes predominate
0.54427505.15198969.html.plaintext.txt	53	However significant trophic responses estradiol 17ss also observed conditions neurodegeneration probably minimal 3 4
0.54427505.15198969.html.plaintext.txt	54	These responses may contribute effects estrogens cognitive performance 23
0.54427505.15198969.html.plaintext.txt	55	It remains determined whether apoE involved trophic actions estradiol 17ss normal physiological opposed pathological conditions
0.54427505.15198969.html.plaintext.txt	56	A second question apoE regulated steroids estradiol 17ss
0.54427505.15198969.html.plaintext.txt	57	A wide range estrogens progestins used HRT postmenopausal women 10 11
0.54427505.15198969.html.plaintext.txt	58	It remains determined different steroids affect apoE expression
0.54427505.15198969.html.plaintext.txt	59	The question specificity apoE response critical possibility combinations hormonal agents could abrogate beneficial effects natural estrogens
0.54427505.15198969.html.plaintext.txt	60	For example Nilsen Brinton 24 reported whereas progesterone 19 norprogesterone potentiate neuroprotective effects estradiol 17ss opposite effect observed medroxyprogesterone acetate synthetic progestin used Women Health Initiative trial
0.54427505.15198969.html.plaintext.txt	61	Whether apoE expression affected steroids also important fact estradiol 17ss hormonal steroid neuroprotective neurotrophic properties
0.54427505.15198969.html.plaintext.txt	62	Recent work suggests androgens may confer protection neurodegenerative processes
0.54427505.15198969.html.plaintext.txt	63	Men higher free testosterone levels appear lower risk developing Alzheimer disease 25 whereas reduced levels principal adrenal androgen dehydroepiandrosterone reported Alzheimer disease patients 26
0.54427505.15198969.html.plaintext.txt	64	In laboratory studies androgens progestins reported elicit neurotrophic neuroprotective effects variety experimental conditions 24 27 28
0.54427505.15198969.html.plaintext.txt	65	Although cases effects may involve either interactions estrogen intermediate estrogen biosynthesis others clearly 27
0.54427505.15198969.html.plaintext.txt	66	An intriguing hypothesis future study apoE expression may represent common link steroid activated neurotrophic responses
0.54427505.15198969.html.plaintext.txt	67	If effects androgens like estrogens may influenced apoE genotype
0.54427505.15198969.html.plaintext.txt	68	Interestingly possibility already raised preliminary clinical studies demonstrated interactions testosterone apoE 4 expression men Alzheimer disease well association apoE 4 circulating testosterone levels men without disease 29
0.54427505.15198969.html.plaintext.txt	69	These observations raise possibility relationship apoE expression gonadal steroids may multifactorial apoE 4 allele directly affecting risk neurodegenerative disease via effects neuronal growth survival well indirectly via reductions testicular androgen secretion
0.54427505.15198969.html.plaintext.txt	70	Perhaps intriguing aspect observations Nathan et al
0.54427505.15198969.html.plaintext.txt	71	1 however potential development novel strategies replacement therapy designed directly target regulation neural apoE expression
0.54427505.15198969.html.plaintext.txt	72	The adverse effects conventional HRT primarily associated responses involve brain including alterations coagulation factors enhancing risk stroke well trophic effects reproductive organs resulting increased risks breast endometrial cancer 10 11
0.54427505.15198969.html.plaintext.txt	73	If regulation apoE expression indeed critical component mechanisms mediating neuroprotective responses estradiol 17ss direct targeting apoE regulation brain might mimic beneficial central effects hormone without adverse risks associated conventional HRT
0.54427505.15198969.html.plaintext.txt	74	Such approach seems least potentially feasible receptor systems mediating effects estrogens central apoE synthesis may well different found nonneural estrogen target organs
0.54427505.15198969.html.plaintext.txt	75	Thus estradiol 17 estrogen weak systemic hormonal activity fully capable inducing apoE synthesis release mouse cerebral cortex cultured glial cells 30 31
0.54427505.15198969.html.plaintext.txt	76	As better understanding molecular mechanisms underlying effects estrogen apoE expression evolves may possible identify agents selectively regulate apoE expression brain significant adverse effects tissues elsewhere body
0.54427505.15198969.html.plaintext.txt	77	Footnotes Abbreviations apoE Apolipoprotein E HRT hormone replacement therapy
0.54427505.15198969.html.plaintext.txt	78	Accepted publication April 7 2004
0.54427505.15198969.html.plaintext.txt	79	References Top References Nathan BP Barsukova AG Shen F McAsey M Struble RG 2004 Estrogen facilitates neurite extension via apolipoprotein E cultured adult mouse cortical neurons
0.54427505.15198969.html.plaintext.txt	80	Endocrinology 1453065 3073AbstractFree Full Text Toran Allerand CD 1976 Sex steroids development newborn mouse hypothalamus preoptic area vitro Implication sexual differentiation
0.54427505.15198969.html.plaintext.txt	81	Brain Res 189413 427CrossRef Woolley CS McEwen BS 1992 Estradiol mediates fluctuation hippocampal synapse density estrous cycle adult rat
0.54427505.15198969.html.plaintext.txt	82	J Neurosci 122549 2554Abstract Hao J Janssen WG Tang Y Roberts JA McKay H Lasley B Allen PB Greengard P Rapp PR Kordower JH Hof PR Morrison JH 2003 Estrogen increases number spinophilin immunoreactive spines hippocampus young aged female rhesus monkeys
0.54427505.15198969.html.plaintext.txt	83	J Comp Neurol 465540 550CrossRefMedline Green PS Simpkins JW 2000 Neuroprotective effects estrogens potential mechanisms action
0.54427505.15198969.html.plaintext.txt	84	Int J Dev Neurosci 18347 358CrossRefMedline Jaffe AB Toran Allerand CD Greengard P Gandy SE 1994 Estrogen regulates metabolism Alzheimer amyloid ss precursor protein
0.54427505.15198969.html.plaintext.txt	85	J Biol Chem 26913065 13068AbstractFree Full Text Luine VN 1985 Estradiol increases choline acetyltransferase activity specific basal forebrain nuclei projection areas female rats
0.54427505.15198969.html.plaintext.txt	86	Exp Neurol 89484 490Medline Leranth C Roth RH Elsworth JD Naftolin F Horvath TL Redmond Jr DE 2000 Estrogen essential maintaining nigrostriatal dopamine neurons primates implications Parkinson disease memory
0.54427505.15198969.html.plaintext.txt	87	J Neurosci 208604 8609AbstractFree Full Text Shumaker SA Legault C Rapp SR Thal L Wallace RB Ockene JK Hendrix SL Jones BN 3rd Assaf AR Jackson RD Kotchen JM Wassertheil Smoller S Wactawski Wende J WHIMS Investigators 2003 Estrogen plus progestin incidence dementia mild cognitive impairment postmenopausal women Women Health Initiative Memory Study randomized controlled trial
0.54427505.15198969.html.plaintext.txt	88	JAMA 2892651 2662AbstractFree Full Text Beral V 2003 Breast cancer hormone replacement therapy Million Women Study
0.54427505.15198969.html.plaintext.txt	89	Lancet 362419 427CrossRefMedline Nelson HD Humphrey LL Nygren P Teutsch SM Allan JD 2002 Postmenopausal hormone replacement therapy scientific review
0.54427505.15198969.html.plaintext.txt	90	JAMA 288872 881AbstractFree Full Text Lehtimaki T Dastidar P Jokela H Koivula T Lehtinen S Ehnholm C Punnonen R 2002 Effect long term hormone replacement therapy atherosclerosis progression postmenopausal women relates functional apolipoprotein E genotype
0.54427505.15198969.html.plaintext.txt	91	J Clin Endocrinol Metab 874147 4153AbstractFree Full Text Fazekas F Strasser Fuchs S Kollegger HBerger T Kristoferitsch W Schmidt H Enzinger C Schiefermeier M Schwarz C Kornek B Reindl M Huber K Grass R Wimmer G Vass K Pfeiffer KH Hartung HP Schmidt R 2001 Apolipoprotein E 4 associated rapid progression multiple sclerosis
0.54427505.15198969.html.plaintext.txt	92	Neurology 57853 857AbstractFree Full Text Tang G Xie H Xu L Hao Y Lin D Ren D 2002 Genetic study apolipoprotein E gene 1 antichymotrypsin gene sporadic Parkinson disease
0.54427505.15198969.html.plaintext.txt	93	Am J Med Genet 114446 449CrossRefMedline Corder EH Saunders AM Strittmatter WJ Schmechel DE Gaskell PC Small GW Roses AD Haines JL Pericak Vance MA 1993 Gene dose apolipoprotein E type 4 allele risk Alzheimer disease late onset families
0.54427505.15198969.html.plaintext.txt	94	Science 261921 923Medline Yaffe K Haan M Byers A Tangen C Kuller L 2000 Estrogen use APOE cognitive decline evidence gene environment interaction
0.54427505.15198969.html.plaintext.txt	95	Neurology 541949 1954AbstractFree Full Text Struble RG Rosario ER Kircher MLLudwig SM McAdamis PJ Watabe K McAsey ME Cady C Nathan BP 2003 Regionally specific modulation brain apolipoprotein E mouse estrous cycle exogenous 17ss estradiol
0.54427505.15198969.html.plaintext.txt	96	Exp Neurol 183638 644CrossRefMedline Srivastava RA Krul ES Lin RC Schonfeld G 1997 Regulation lipoprotein metabolism estrogen inbred strains mice occurs primarily posttranscriptional mechanisms
0.54427505.15198969.html.plaintext.txt	97	Mol Cell Biochem 173161 168CrossRefMedline Nathan BP Jiang Y Wong GK Shen F Brewer GJ Struble RG 2002 Apolipoprotein E4 inhibits apolipoprotein E3 promotes neurite outgrowth cultured adult mouse cortical neurons low density lipoprotein receptor related protein
0.54427505.15198969.html.plaintext.txt	98	Brain Res 92896 105CrossRefMedline Horsburgh K Macrae IM Carswell H 2002 Estrogen neuroprotective via apolipoprotein E dependent mechanism mouse model global ischemia
0.54427505.15198969.html.plaintext.txt	99	J Cereb Blood Flow Metab 221189 1195CrossRefMedline Stone DJ Rozovsky I Morgan TE Anderson CP Finch CE 1998 Increased synaptic sprouting response estrogen via apolipoprotein E dependent mechanism implications Alzheimer disease
0.54427505.15198969.html.plaintext.txt	100	J Neurosci 183180 3185AbstractFree Full Text Toran Allerand CD Guan X MacLusky NJ Horvath TL Diano S Singh M Connolly Jr ES Nethrapalli IS Tinnikov AA 2002 ER X novel plasma membrane associated putative estrogen receptor regulated development ischemic brain injury
0.54427505.15198969.html.plaintext.txt	101	J Neurosci 228391 8401AbstractFree Full Text Sandstrom NJ Williams CL 2004 Spatial memory retention enhanced acute continuous estradiol replacement
0.54427505.15198969.html.plaintext.txt	102	Horm Behav 45128 135CrossRefMedline Nilsen J Brinton RD 2002 Impact progestins estrogen induced neuroprotection synergy progesterone 19 norprogesterone antagonism medroxyprogesterone acetate
0.54427505.15198969.html.plaintext.txt	103	Endocrinology 143205 212AbstractFree Full Text Moffat SD Zonderman AB Metter EJ Kawas C Blackman MR Harman SM Resnick SM 2004 Free testosterone risk Alzheimer disease older men
0.54427505.15198969.html.plaintext.txt	104	Neurology 62188 193AbstractFree Full Text Sunderland T Merril CR Harrington MG Lawlor BA Molchan SE Martinez R Murphy DL 1989 Reduced plasma dehydroepiandrosterone concentrations Alzheimer disease
0.54427505.15198969.html.plaintext.txt	105	Lancet 2570Medline Leranth C Hajszan T MacLusky NJ 2004 Androgens increase spine synapse density CA1 hippocampal subfield ovariectomized female rats
0.54427505.15198969.html.plaintext.txt	106	J Neurosci 24495 499AbstractFree Full Text Bastianetto S Ramassamy C Poirier J Quirion R 1999 Dehydroepiandrosterone DHEA protects hippocampal cells oxidative stress induced damage
0.54427505.15198969.html.plaintext.txt	107	Brain Res Mol Brain Res 6635 41Medline Hogervorst E Lehmann DJ Warden DR McBroom J Smith AD 2002 Apolipoprotein E 4 testosterone interact risk Alzheimer disease men
0.54427505.15198969.html.plaintext.txt	108	Int J Geriatr Psychiatry 17938 940CrossRefMedline Levin Allerhand J McEwen BS Lominska CE Lubahn DB Korach KS Smith JD 2001 Brain region specific regulation mouse apolipoprotein E pharmacological estrogen treatments
0.54427505.15198969.html.plaintext.txt	109	J Neurochem 79796 803CrossRefMedline Rozovsky I Hoving S Anderson CP O Callaghan J Finch CE 2002 Equine estrogens induce apolipoprotein E glial fibrillary acidic protein mixed glial cultures
0.54427505.15198969.html.plaintext.txt	110	Neurosci Lett 323191 194CrossRefMedline
0.29569125.7721816.html.plaintext.txt	0	1995 The American Society Biochemistry Molecular Biology Inc
0.29569125.7721816.html.plaintext.txt	1	Purification Apolipoprotein E Attenuates Isoform specific Binding Amyloid
0.29569125.7721816.html.plaintext.txt	2	From 1 From Neuroscience Discovery Pharmaceutical Products Division Abbott Laboratories Abbott Park Illinois 60064 2 Department Pathology University Chicago Chicago Illinois 60637 ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS AND DISCUSSION FOOTNOTES ACKNOWLEDGEMENTS REFERENCES
0.29569125.7721816.html.plaintext.txt	3	Apolipoprotein E apoE particularly e4 allele genetically linked incidence Alzheimers disease
0.29569125.7721816.html.plaintext.txt	4	In vitro apoE shown bind amyloid A amyloidogenic peptide aggregates form primary component senile plaques
0.29569125.7721816.html.plaintext.txt	5	In previous work demonstrated apoE3 tissue culture medium binds A greater avidity apoE4 LaDu M
0.29569125.7721816.html.plaintext.txt	6	This contrast data using purified apoE isoforms substrate A Strittmatter W
0.29569125.7721816.html.plaintext.txt	7	Here resolve apparent discrepancy demonstrating preferential binding A apoE3 attenuated even abolished purification process includes delipidation denaturation
0.29569125.7721816.html.plaintext.txt	8	We compared A binding capacity unpurified apoE isoforms tissue culture medium intact human low density lipoproteins apoE purified two sources
0.29569125.7721816.html.plaintext.txt	9	The interaction human A 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 peptide apoE analyzed nonreducing SDS polyacrylamide gel electrophoresis followed Western immunoblotting either A apoE immunoreactivity
0.29569125.7721816.html.plaintext.txt	10	While level apoE3A complex 20 fold greater compared apoE4A complex unpurified conditioned medium apoE3 apoE4 purified medium bound A comparable avidity
0.29569125.7721816.html.plaintext.txt	11	Moreover using endogenous apoE low density lipoproteins plasma apoE33 apoE44 homozygotes apoE3 better substrate A apoE4
0.29569125.7721816.html.plaintext.txt	12	However apoE purified plasma lipoproteins exhibited little isoform specificity binding A
0.29569125.7721816.html.plaintext.txt	13	These results suggest native preparations apoE may physiologically relevant substrate A binding purified apoE underscore importance subtle differences apoE conformation biological activity
0.29569125.7721816.html.plaintext.txt	14	Apolipoprotein E apoE component several classes lipoproteins acts ligand lipoprotein receptors thus regulating lipid transport clearance
0.29569125.7721816.html.plaintext.txt	15	ApoE also expressed brain 1 response injury peripheral 2 central nervous 3 systems
0.29569125.7721816.html.plaintext.txt	16	In humans apoE three major isoforms E2 Cys Cys E3 Cys Arg E4 Arg Arg products three alleles single gene locus
0.29569125.7721816.html.plaintext.txt	17	The presence cysteine apoE2 apoE3 allow isoforms form disulfide linked dimers
0.29569125.7721816.html.plaintext.txt	18	Recently demonstrated apoE e4 allele present increased frequency patients sporadic 4 late onset familial 5 Alzheimers disease AD
0.29569125.7721816.html.plaintext.txt	19	Due primarily genetic linkage role apoE pathogenesis AD actively pursued
0.29569125.7721816.html.plaintext.txt	20	A major neuropathological feature AD presence extracellular senile plaques composed predominantly aggregated amyloid peptide A
0.29569125.7721816.html.plaintext.txt	21	The physiological mechanism apoE contributes AD pathology may means isoform specific interaction A
0.29569125.7721816.html.plaintext.txt	22	ApoE A colocalize senile plaques 6 synthetic A peptides bind vitro apoE tissue culture medium 7 cerebrospinal fluid 5 8 9 well purified apoE 9 10
0.29569125.7721816.html.plaintext.txt	23	However studies involving apoE isoform specificity binding A limited contradictory
0.29569125.7721816.html.plaintext.txt	24	In previous work demonstrated apoE3 tissue culture medium binds A greater avidity apoE4 7
0.29569125.7721816.html.plaintext.txt	25	This contrast data Strittmatter et al
0.29569125.7721816.html.plaintext.txt	26	10 used apoE isoforms purified human plasma substrate A
0.29569125.7721816.html.plaintext.txt	27	Here resolve apparent discrepancy studies demonstrating previously observed preferential association A apoE3 attenuated abolished purification process includes delipidation denaturation
0.29569125.7721816.html.plaintext.txt	28	Expression Human ApoE Cultured Cells Human apoE3 apoE4 expressed HEK 293 cells stably transfected human apoE3 apoE4 products e3 e4 alleles respectively cDNA described previously 7
0.29569125.7721816.html.plaintext.txt	29	Conditioned medium containing apoE concentrated Centriprep Amicon Inc
0.29569125.7721816.html.plaintext.txt	30	50 fold prior binding reactions purification
0.29569125.7721816.html.plaintext.txt	31	Purification ApoE Human plasma screened apoE genotype using modification method Hixson Vernier 11
0.29569125.7721816.html.plaintext.txt	32	Intermediate low density lipoprotein VLDL particles d 1
0.29569125.7721816.html.plaintext.txt	33	02 gml isolated 12 plasma individuals homozygous apoE3 apoE4
0.29569125.7721816.html.plaintext.txt	34	Unpurified preparations VLDL used within 2 weeks isolation
0.29569125.7721816.html.plaintext.txt	35	Purification apoE lipoprotein fraction concentrated conditioned medium carried according standard procedures 13
0.29569125.7721816.html.plaintext.txt	36	Briefly conditioned medium lipoproteins dialyzed 0
0.29569125.7721816.html.plaintext.txt	37	01 EDTA lyophilized delipidated CHClMeOH 21
0.29569125.7721816.html.plaintext.txt	38	Delipidated proteins pelleted MeOH solubilized 6 M guanidine 0
0.29569125.7721816.html.plaintext.txt	39	Proteins fractionated Sephacryl S 300 column Pharmacia Biotech Inc
0.29569125.7721816.html.plaintext.txt	40	equilibrated 4 M guanidine 0
0.29569125.7721816.html.plaintext.txt	41	Fractions containing apoE dialyzed 5 m M NHHCO lyophilized resuspended 0
0.29569125.7721816.html.plaintext.txt	42	Unpurified purified apoE proteins quantified SDS polyacrylamide gel electrophoresis protein staining densitometry Molecular Dynamics Inc
0.29569125.7721816.html.plaintext.txt	43	serial dilutions apoE containing samples using purified apoE standard
0.29569125.7721816.html.plaintext.txt	44	ApoEA Complex Formation Detection For binding reactions synthetic human A 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 peptide purified high performance liquid chromatography resuspended 5 m M 100 MeSO
0.29569125.7721816.html.plaintext.txt	45	ApoE 25 microgml 700 n M incubated 2 h except noted legend Fig
0.29569125.7721816.html.plaintext.txt	46	4 room temperature 250 micro M A pH 7
0.29569125.7721816.html.plaintext.txt	47	Control reactions without A contained 5 MeSO
0.29569125.7721816.html.plaintext.txt	48	Reactions stopped addition 2 nonreducing Laemmli buffer 14 4 SDS 2 mercaptoethanol frozen 20 degrees C
0.29569125.7721816.html.plaintext.txt	49	Samples boiled 5 min electrophoresed 10 20 SDS Tricine gels transferred Immobilon P membranes Millipore Corp
0.29569125.7721816.html.plaintext.txt	50	probed antibodies A apoE 11000 dilution
0.29569125.7721816.html.plaintext.txt	51	Monoclonal antibody 4G8 amino acids 17 24 A provided Drs
0.29569125.7721816.html.plaintext.txt	52	ApoE antiserum obtained immunizing rabbits apoE purified human serum
0.29569125.7721816.html.plaintext.txt	53	Proteins Western blots visualized enhanced chemiluminescence Amersham Corp
0.29569125.7721816.html.plaintext.txt	54	quantified densitometry
0.29569125.7721816.html.plaintext.txt	55	Figure 4 Time course A binding apoE isoforms purified human plasma
0.29569125.7721816.html.plaintext.txt	56	Shown Western blots apoEA binding reactions assayed conditions described legend Fig
0.29569125.7721816.html.plaintext.txt	57	1 probed 4G8 antibody A apoE antiserum B
0.29569125.7721816.html.plaintext.txt	58	ApoE purified human plasma apoE33 lanes 1 6 apoE44 lanes 7 12 homozygotes
0.29569125.7721816.html.plaintext.txt	59	Lanes 1 7 apoE alone lanes 2 6 8 12 apoE A 2 min 10 min 2 h 8 h 24 h respectively
0.29569125.7721816.html.plaintext.txt	60	Genetic data defined presence e4 allele apoE major risk factor occurrence sporadic 4 late onset familial 5 Alzheimers disease
0.29569125.7721816.html.plaintext.txt	61	However physiological mechanism apoE isoform specificity contributes pathogenesis disease unknown
0.29569125.7721816.html.plaintext.txt	62	Previously using unpurified apoE conditioned medium showed amount apoE3A complex much greater compared apoE4A complex 7
0.29569125.7721816.html.plaintext.txt	63	These results contrast data published Strittmatter et al
0.29569125.7721816.html.plaintext.txt	64	Using apoE purified human plasma reported apoE4 binds A rapidly apoE3
0.29569125.7721816.html.plaintext.txt	65	However level A binding apoE3 apoE4 several hours incubation comparable
0.29569125.7721816.html.plaintext.txt	66	The major differences two studies source apoE plasma versus secreted cultured cells whether apoE protein purified prior use binding assays
0.29569125.7721816.html.plaintext.txt	67	In study examined whether differences could account discrepancy two reports regarding apoE isoform specific binding A
0.29569125.7721816.html.plaintext.txt	68	We compared A binding capacity unpurified apoE conditioned medium intact human VLDL plasma apoE33 apoE44 homozygotes A binding capacity apoE purified two sources
0.29569125.7721816.html.plaintext.txt	69	The purification procedure 13 used used Strittmatter et al
0.29569125.7721816.html.plaintext.txt	70	We first examined effect purification apoE conditioned medium formation apoEA complexes
0.29569125.7721816.html.plaintext.txt	71	ApoE3 apoE4 purified medium transfected HEK 293 cells binding material A compared binding unpurified apoE medium Fig
0.29569125.7721816.html.plaintext.txt	72	Prior purification amount apoE3A complex Fig
0.29569125.7721816.html.plaintext.txt	73	1 A B lane 2 20 fold greater compared apoE4A complex lane 4
0.29569125.7721816.html.plaintext.txt	74	These results consistent previous data demonstrated preferential binding A apoE3 maintained time pH range concentration apoE A 7
0.29569125.7721816.html.plaintext.txt	75	Purification apoE isoforms medium resulted decrease A binding apoE3 Fig
0.29569125.7721816.html.plaintext.txt	76	1 A B lane 6 increase A binding apoE4 lane 8
0.29569125.7721816.html.plaintext.txt	77	To determine whether auxiliary component influences isoform specificity apoE binding A present medium HEK 293 cells reconstituted purified apoE mock transfected conditioned medium
0.29569125.7721816.html.plaintext.txt	78	The isoform specificity apoE binding A restored pre purification levels indicating purification remove component present medium confers preferential binding A apoE3 compare Figs
0.29569125.7721816.html.plaintext.txt	79	Figure 1 ApoEA binding effect purifying apoE isoforms conditioned medium
0.29569125.7721816.html.plaintext.txt	80	Shown Western blots binding reactions using 25 microgml apoE 700 n M incubated lanes 2 4 6 8 without lanes 1 3 5 7 250 micro M A 1 40 peptide 2 h room temperature
0.29569125.7721816.html.plaintext.txt	81	Sources apoE follows conditioned medium transfected cells apoE3 lanes 1 2 apoE4 lanes 3 4 purified conditioned medium apoE3 lanes 5 6 apoE4 lanes 7 8
0.29569125.7721816.html.plaintext.txt	82	Samples run nonreducing Laemmli buffer 10 20 SDS Tricine gels transferred Immobilon P membrane probed 4G8 antibody A apoE antiserum B
0.29569125.7721816.html.plaintext.txt	83	To examine binding A unpurified plasma apoE isoforms VLDL isolated plasma apoE33 apoE44 homozygotes used binding reactions A
0.29569125.7721816.html.plaintext.txt	84	Similar results using unpurified apoE conditioned medium observed 20 fold difference amount apoE3A complex Fig
0.29569125.7721816.html.plaintext.txt	85	3 A B lane 2 compared apoE4A complex lane 4 using intact VLDL particles source apoE
0.29569125.7721816.html.plaintext.txt	86	As purification apoE medium purification apoE VLDL fraction human plasma attenuated preferential binding apoE3 A Fig
0.29569125.7721816.html.plaintext.txt	87	The level A binding apoE4 apoE3 dimer increased purification apoE plasma
0.29569125.7721816.html.plaintext.txt	88	In apoE33 plasma apoE immunoreactive species migrating slightly higher apoEA complex 55 kDa apoE3 apolipoprotein A II heterodimer Fig
0.29569125.7721816.html.plaintext.txt	89	The autoradiographs shown Figs
0.29569125.7721816.html.plaintext.txt	90	1 3 representative several experiments similar results using different apoE containing preparations
0.29569125.7721816.html.plaintext.txt	91	While variation purification mediated loss preferential apoE3 binding A observed general purification apoE medium plasma abolished isoform specific binding A
0.29569125.7721816.html.plaintext.txt	92	Figure 3 ApoEA binding effect purifying apoE isoforms human plasma
0.29569125.7721816.html.plaintext.txt	93	Shown Western blots apoEA binding reactions assayed conditions described legend Fig
0.29569125.7721816.html.plaintext.txt	94	Sources apoE follows intact VLDL apoE33 lanes 1 2 apoE44 lanes 3 4 homozygotes purified VLDL apoE33 lanes 5 6 apoE44 lanes 7 8 homozygotes
0.29569125.7721816.html.plaintext.txt	95	Samples run described legend Fig
0.29569125.7721816.html.plaintext.txt	96	1 probed 4G8 antibody A apoE antiserum B
0.29569125.7721816.html.plaintext.txt	97	For apoE3 VLDL total protein 95 ng microl triglyceride 600 ng microl
0.29569125.7721816.html.plaintext.txt	98	For apoE4 VLDL total protein 110 ng microl triglyceride 400 ng microl
0.29569125.7721816.html.plaintext.txt	99	10 used apoE purified plasma show A binds apoE4 monomer faster rate apoE3 monomer
0.29569125.7721816.html.plaintext.txt	100	However contribution apoE3 A complex time course data difficult discern since blots probed apoE A immunoreactivity simultaneously 10
0.29569125.7721816.html.plaintext.txt	101	Therefore repeated time course study using purified plasma apoE isoforms probed A Fig
0.29569125.7721816.html.plaintext.txt	102	4 B immunoreactivity individually
0.29569125.7721816.html.plaintext.txt	103	Similar results obtained Strittmatter et al
0.29569125.7721816.html.plaintext.txt	104	10 apoE4 monomer form complex A faster rate compared apoE3 monomer
0.29569125.7721816.html.plaintext.txt	105	However apoE3 dimer A complex taken account total binding A apoE3 apoE4 remained comparable across time
0.29569125.7721816.html.plaintext.txt	106	There several possibilities could account loss isoform specificity binding purified apoE A
0.29569125.7721816.html.plaintext.txt	107	Purification may result change oxidative state apoE influences binding A
0.29569125.7721816.html.plaintext.txt	108	Although apoE isoforms subject conditions undergoing purification oxidation could specific Cysin apoE3
0.29569125.7721816.html.plaintext.txt	109	This could affect conformation dependent binding apoE A either directly via interaction amino acids residue
0.29569125.7721816.html.plaintext.txt	110	However apoE3 dimer particularly purified form readily binds A indicating least oxidation cysteine seem adversely affect apoE3 A complex formation
0.29569125.7721816.html.plaintext.txt	111	In addition oxidation provides obvious explanation increase A binding purified apoE4 monomer
0.29569125.7721816.html.plaintext.txt	112	Another likely explanation apoE acquires conformation lipid associated confers isoform specific binding A
0.29569125.7721816.html.plaintext.txt	113	Purification includes delipidation may increase binding A apoE3 dimer apoE4 monomer disrupting endogenous conformation apoE species
0.29569125.7721816.html.plaintext.txt	114	In unpurified preparations used apoE lipid associated
0.29569125.7721816.html.plaintext.txt	115	ApoE human plasma VLDL fraction majority apoE conditioned medium high density lipid fraction
0.29569125.7721816.html.plaintext.txt	116	Purified apoE shown require lipid restore biological activity assay systems presumably allowing denatured protein refold functional conformation
0.29569125.7721816.html.plaintext.txt	117	These apoE activity assays include diverse functions receptor binding modulation neuritic growth
0.29569125.7721816.html.plaintext.txt	118	While purified apoE unable displace I labeled low density lipoprotein LDL LDL receptors 16 high affinity binding restored apoE added presence variety lipid particles including phospholipid vesicles 17
0.29569125.7721816.html.plaintext.txt	119	Similarly binding purified apoE LDL receptor related protein enhanced addition migrating VLDL 18
0.29569125.7721816.html.plaintext.txt	120	In primary dorsal root ganglia cultures purified apoE3 apoE4 effect neuritic growth
0.29569125.7721816.html.plaintext.txt	121	However added presence migrating VLDL apoE isoforms affect neuritic growth apoE3 increasing neuritic extension decreasing branching apoE4 decreasing branching extension 19
0.29569125.7721816.html.plaintext.txt	122	Experiments progress using assay system described determine nature interaction A lipid associated apoE using endogenous lipoproteins reconstituted lipid vesicles
0.29569125.7721816.html.plaintext.txt	123	The data presented consistent function apoE pathogenesis AD sequestering A
0.29569125.7721816.html.plaintext.txt	124	Avid binding apoE3 soluble A neuropil could lead enhanced clearance altered fibril formation could prevent conversion A neurotoxic species
0.29569125.7721816.html.plaintext.txt	125	Since lipid associated apoE3 apoE4 bind LDL receptor LDL receptor related protein equal affinity 18 efficient uptake clearance A may depend preferential binding apoE3
0.29569125.7721816.html.plaintext.txt	126	Alternatively purified apoE3 apoE4 known differ respect effect A fibril formation 20 21 22 suggesting native apoE may play even greater isoform specific role extracellular aggregation A due differences A binding characteristics
0.29569125.7721816.html.plaintext.txt	127	Finally evidence A induced toxicity hippocampal neurons attenuated addition rabbit apoE 23 leading intriguing possibility human apoE may contribute A induced toxicity isoform specific manner
0.29569125.7721816.html.plaintext.txt	128	In summary using unpurified apoE tissue culture medium intact VLDL particles apoE3A complex 20 fold abundant apoE4A complex
0.29569125.7721816.html.plaintext.txt	129	This isoform specificity attenuated abolished apoE purified two sources used binding reactions A
0.29569125.7721816.html.plaintext.txt	130	ApoE apolipoprotein endogenous conformation requires lipid
0.29569125.7721816.html.plaintext.txt	131	It therefore surprising type apoE preparation used affect results
0.29569125.7721816.html.plaintext.txt	132	The avidity A binding apoE3 compared apoE4 demonstrated may involved isoform specific effect underlying genetic correlation apoE e4 allele AD
0.29569125.7721816.html.plaintext.txt	133	The physiological relevance complex plaque formation neurodegeneration awaits investigation
0.29569125.7721816.html.plaintext.txt	134	This work supported part National Institutes Health Grant HL15062 Specialized Center Research Atherosclerosis Abbott Laboratories
0.29569125.7721816.html.plaintext.txt	135	The costs publication article defrayed part payment page charges
0.29569125.7721816.html.plaintext.txt	136	This article must therefore hereby marked advertisement accordance 18 U
0.29569125.7721816.html.plaintext.txt	137	Section 1734 solely indicate fact
0.29569125.7721816.html.plaintext.txt	138	Supported National Institutes Health Grant 1F32 HL08833 01
0.29569125.7721816.html.plaintext.txt	139	To correspondence addressed Dept
0.29569125.7721816.html.plaintext.txt	140	Pathology MC 6079 University Chicago 5841 S
0.29569125.7721816.html.plaintext.txt	141	312 702 1273 Fax 312 702 3778
0.29569125.7721816.html.plaintext.txt	142	Present address Womens Health Research Inst
0.29569125.7721816.html.plaintext.txt	143	Wyeth Ayerst Research 145 King Prussia Rd
0.29569125.7721816.html.plaintext.txt	144	The abbreviations used apoE apolipoprotein E AD Alzheimers disease A amyloid VLDL low density lipoprotein Tricine N 2 hydroxy 11 bishydroxymethylethylglycine LDL low density lipoprotein
0.29569125.7721816.html.plaintext.txt	145	Falduto unpublished observations
0.29569125.7721816.html.plaintext.txt	146	Reardon unpublished observations
0.29569125.7721816.html.plaintext.txt	147	We thank Warren Wade Richard Perner synthesis A peptides Randy Metzger genotyping plasma sources John Lukens lipoprotein isolation
0.29569125.7721816.html.plaintext.txt	148	We also thank Brad Hyman Bill Rebeck helpful discussions providing apoE44 plasma
0.29569125.7721816.html.plaintext.txt	149	82 203 207 Abstract Boyles J
0.29569125.7721816.html.plaintext.txt	150	83 1015 1031 Medline Order article via Infotrieve Snipes G
0.29569125.7721816.html.plaintext.txt	151	83 1130 1134 Abstract Saunders A
0.29569125.7721816.html.plaintext.txt	152	1993 Neurology 43 1467 1472 Abstract Strittmatter W
0.29569125.7721816.html.plaintext.txt	153	90 1977 1981 Abstract Wisniewski T
0.29569125.7721816.html.plaintext.txt	154	135 235 238 CrossRefMedline Order article via Infotrieve LaDu M
0.29569125.7721816.html.plaintext.txt	155	269 23403 23406 AbstractFree Full Text Ghiso J
0.29569125.7721816.html.plaintext.txt	156	293 27 30 Medline Order article via Infotrieve Wisniewski T
0.29569125.7721816.html.plaintext.txt	157	192 359 365 CrossRefMedline Order article via Infotrieve Strittmatter W
0.29569125.7721816.html.plaintext.txt	158	90 8098 8102 AbstractFree Full Text Hixson J
0.29569125.7721816.html.plaintext.txt	159	31 545 548 Abstract Weisgraber K
0.29569125.7721816.html.plaintext.txt	160	129 145 166 Medline Order article via Infotrieve Rall S
0.29569125.7721816.html.plaintext.txt	161	128 273 287 Medline Order article via Infotrieve Laemmli U
0.29569125.7721816.html.plaintext.txt	162	1970 Nature 227 680 685 Medline Order article via Infotrieve Kim K
0.29569125.7721816.html.plaintext.txt	163	1978 Biochemistry 17 1440 1447 Medline Order article via Infotrieve Innerarity T
0.29569125.7721816.html.plaintext.txt	164	129 542 565 Medline Order article via Infotrieve Kowal R
0.29569125.7721816.html.plaintext.txt	165	265 10771 10779 AbstractFree Full Text Nathan B
0.29569125.7721816.html.plaintext.txt	166	1994 Science 264 850 852 Medline Order article via Infotrieve Ma J
0.29569125.7721816.html.plaintext.txt	167	1994 Nature 372 92 94 CrossRefMedline Order article via Infotrieve Sanan D
0.29569125.7721816.html.plaintext.txt	168	94 860 869 Medline Order article via Infotrieve Wisniewski T
0.29569125.7721816.html.plaintext.txt	169	145 1030 1035 Abstract Whitson J
0.29569125.7721816.html.plaintext.txt	170	199 163 170 CrossRefMedline Order article via Infotrieve 1995 The American Society Biochemistry Molecular Biology Inc
0.37510666.12551940.html.plaintext.txt	0	Hepatocyte derived ApoE Is More Effective Non hepatocyte derived ApoE Remnant Lipoprotein Clearance Robert L
0.37510666.12551940.html.plaintext.txt	1	Hasty Yuwei Wang Shelley E
0.37510666.12551940.html.plaintext.txt	2	Linton Sergio Fazio Karl H
0.37510666.12551940.html.plaintext.txt	3	From Gladstone Institutes Cardiovascular Disease Neurological Disease San Francisco California 94141 9100 Cardiovascular Research Institute Department Pathology University California San Francisco California 94143 Department Medicine Vanderbilt University Nashville Tennessee 37232
0.37510666.12551940.html.plaintext.txt	4	Received publication December 18 2002 revised form January 23 2003
0.37510666.12551940.html.plaintext.txt	5	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.37510666.12551940.html.plaintext.txt	6	The importance hepatocyte derived apolipoprotein apo E clearance remnant lipoproteins liver controversial
0.37510666.12551940.html.plaintext.txt	7	To address controversy compared remnant clearance two mouse models apoE primarily derived either hepatocytes extrahepatic source
0.37510666.12551940.html.plaintext.txt	8	Hypomorphic apoE mice universally express reduced levels apoE tissues liver remaining primary source apoE
0.37510666.12551940.html.plaintext.txt	9	This mouse model hepatocyte derived apoE compared Apoe mice transplanted mouse bone marrow model primarily non hepatocyte derived apoE
0.37510666.12551940.html.plaintext.txt	10	Immunohistochemical analysis liver sections revealed hepatocyte derived apoE model detectable levels apoE hepatic sinusoidal surfaces
0.37510666.12551940.html.plaintext.txt	11	The non hepatocyte derived apoE model plasma apoE levels similar hepatocyte derived model 2 fold total plasma cholesterol 4 fold total plasma triglycerides 8 fold higher levels apoB48 similar Apoe mice
0.37510666.12551940.html.plaintext.txt	12	Both hepatocyte derived non hepatocyte derived apoE models delayed clearance infused bolus 125I labeled remnants compared wild type mice
0.37510666.12551940.html.plaintext.txt	13	However 3 h plasma remnants reached wild type levels hepatocyte derived apoE model accumulated 70 plus minus 5 wild type levels remnants liver non hepatocyte derived apoE model accumulated 38 plus minus 4
0.37510666.12551940.html.plaintext.txt	14	These results demonstrate existence role hepatically derived localized apoE remnant clearance
0.37510666.12551940.html.plaintext.txt	15	This role likely represents enrichment remnants sequestered hepatocyte hepatocyte derived apoE facilitating receptor mediated internalization
0.37510666.12551940.html.plaintext.txt	16	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.37510666.12551940.html.plaintext.txt	17	Plasma remnant lipoproteins metabolic end products intestine derived chylomicrons hepatocyte derived low density lipoprotein 1 3
0.37510666.12551940.html.plaintext.txt	18	Apolipoprotein apo1 E mediates uptake remnants liver binding LDL receptor LDLR LDLR related protein LRP heparan sulfate proteoglycans HSPG 4 7
0.37510666.12551940.html.plaintext.txt	19	Inefficient clearance leads accumulation remnants plasma contributes premature atherosclerosis 8 9
0.37510666.12551940.html.plaintext.txt	20	The liver major source plasma apoE extrahepatic tissues primarily macrophages contribute 10 plasma levels 10
0.37510666.12551940.html.plaintext.txt	21	Hepatocyte derived apoE proposed promote remnant clearance uptake two step process referred secretion capture 3 11 12
0.37510666.12551940.html.plaintext.txt	22	In first step portion newly secreted apoE interacts HSPG remains bound hepatocyte cell surfaces remainder released space Disse serves enrich lipoproteins 11 13
0.37510666.12551940.html.plaintext.txt	23	The presence apoE hepatocytes thought promote trapping sequestration remnants 6 11
0.37510666.12551940.html.plaintext.txt	24	In support mechanism distinct dynamic pools apoE hepatocyte cell surfaces recently reported vitro 14
0.37510666.12551940.html.plaintext.txt	25	In second step sequestered remnants enriched hepatocyte derived apoE internalized hepatocytes processes mediated receptors including LDLR LRP 7 15 19 interactions HSPG alone 11 20 21
0.37510666.12551940.html.plaintext.txt	26	When apoEHSPG interactions disrupted vivo intravenous heparinase infusion remnant clearance severely inhibited supporting importance secretion capture role apoE remnant clearance 22 23
0.37510666.12551940.html.plaintext.txt	27	The importance hepatically synthesized localized apoE thus secretion capture role apoE recently questioned 24
0.37510666.12551940.html.plaintext.txt	28	Moreover evidence mouse models expressing apoE exclusively extrahepatic sources suggests hepatic apoE expression absolutely required remnant clearance normal plasma cholesterol levels 25 27
0.37510666.12551940.html.plaintext.txt	29	Finally clear whether hepatic apoE expression required remnant clearance mice lacking LDLR 24 28 29
0.37510666.12551940.html.plaintext.txt	30	We previously reported 30 generation hypomorphic apoE hypoE mice express reduced levels Arg 61 apoE similar human apoE4 displays apoE4 domain interaction
0.37510666.12551940.html.plaintext.txt	31	The reduction apoE levels caused neomycin neo cassette flanked loxP sites Apoe intron 3
0.37510666.12551940.html.plaintext.txt	32	However expression pattern hypomorphic allele remains normal liver producing majority apoE mice 30
0.37510666.12551940.html.plaintext.txt	33	Excision neo cassette Cre mediated gene repair restores normal expression allele tissues 31
0.37510666.12551940.html.plaintext.txt	34	Despite 2 5 wild type plasma apoE levels hypoE mice display nearly normal lipoprotein profile
0.37510666.12551940.html.plaintext.txt	35	However Apoe mice similar plasma apoE levels transplantation varying amounts wild type bone marrow remnants accumulate 32
0.37510666.12551940.html.plaintext.txt	36	It plasma apoE levels exceeded 10 wild type levels remnant levels approached normal
0.37510666.12551940.html.plaintext.txt	37	The efficient remnant clearance hypoE mice suggests importance hepatocyte derived apoE secretion capture role apoE
0.37510666.12551940.html.plaintext.txt	38	This study designed address controversy concerning importance hepatically derived localized apoE remnant clearance vivo models
0.37510666.12551940.html.plaintext.txt	39	To end remnant clearance assessed hypoE mice model hepatocyte derived apoE Apoe mice expressing similar levels Arg 61 apoE bone marrow transplantation model non hepatocyte derived apoE
0.37510666.12551940.html.plaintext.txt	40	Our results demonstrate remnant clearance efficient hepatocyte derived apoE model provide vivo evidence importance hepatically derived localized apoE remnant clearance
0.37510666.12551940.html.plaintext.txt	41	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.37510666.12551940.html.plaintext.txt	42	Hepatocyte derived ApoE Mouse Model The generation hypoE mice hepatocyte derived apoE model previously described 30
0.37510666.12551940.html.plaintext.txt	43	Briefly neo cassette flanked loxP sites inserted Apoe intron 3 gene targeting embryonic stem cells help follow replacement human equivalent Thr 61 arginine aimed creating model apoE4 31
0.37510666.12551940.html.plaintext.txt	44	The presence neo cassette Apoe intron 3 results reduced apoE mRNA levels tissues organs 30
0.37510666.12551940.html.plaintext.txt	45	The apoE mRNA levels liver brain spleen targeted mice 5 wild type mice resulting plasma apoE levels equal 0
0.37510666.12551940.html.plaintext.txt	46	12 mgdl 2 5 wild type levels determined Western blot analysis using mouse apoE standards liver remaining primary source apoE
0.37510666.12551940.html.plaintext.txt	47	However following Cre mediated excision neo cassette targeted mice normal expression Arg 61 Apoe allele restored
0.37510666.12551940.html.plaintext.txt	48	The mice weaned 21 days age housed barrier facility 12 h light12 h dark cycle fed chow diet containing 4
0.37510666.12551940.html.plaintext.txt	49	Non hepatocyte derived ApoE Mouse Model Mice expressing Arg 61 apoE primarily peripheral source generated transplanting Cre deleted Arg 61 mouse bone marrow lethally irradiated Apoe mice
0.37510666.12551940.html.plaintext.txt	50	Bone marrow collected flushing femurs tibias RPMI 1640 containing 2 fetal bovine serum 10 unitsml heparin Sigma
0.37510666.12551940.html.plaintext.txt	51	Cells washed counted resuspended RPMI used immediately transplantation lethally irradiated Apoe recipient mice
0.37510666.12551940.html.plaintext.txt	52	The cells 5 x 106 volume 300 microl injected tail vein 4 h irradiation 900 rads cesium gamma source
0.37510666.12551940.html.plaintext.txt	53	Immunohistochemistry Mice fasted 4 h anesthetized avertin flush perfused PBS pH 7
0.37510666.12551940.html.plaintext.txt	54	2 3 paraformaldehyde PBS pH 7
0.37510666.12551940.html.plaintext.txt	55	2 room temperature 5 min
0.37510666.12551940.html.plaintext.txt	56	Hardened liver lobes cut slices 2 3 mm thick fixed overnight immersion 3 paraformaldehyde PBS pH 7
0.37510666.12551940.html.plaintext.txt	57	Slices briefly washed PBS pH 7
0.37510666.12551940.html.plaintext.txt	58	2 drained placed molds Tissue Tek compound Sakura Finetek Torrance CA frozen liquid nitrogen
0.37510666.12551940.html.plaintext.txt	59	Blocks held 70 degrees C cut 6 8 microm thick sections Leica Frigocut 2800 cryostat mounted glass slides
0.37510666.12551940.html.plaintext.txt	60	Slides immunostained follows room temperature unless otherwise indicated
0.37510666.12551940.html.plaintext.txt	61	Sections incubated sequence rabbit polyclonal anti mouse apoE antiserum 31 11000 overnight 4 degrees C biotinylated goat anti rabbit IgG Zymed Laboratories Inc
0.37510666.12551940.html.plaintext.txt	62	South San Francisco CA 0
0.37510666.12551940.html.plaintext.txt	63	4 microgml streptavidin horseradish peroxidase conjugate tyramide signal amplification kit TSA Fluorescein System NEL 701 PerkinElmer Life Sciences 1500 finally fluorescein tyramide kit 1100
0.37510666.12551940.html.plaintext.txt	64	Slides coverslipped application Vectashield anti fade mounting medium Vector H 1000 Vector Laboratories Burlingame CA imaged epifluorescence using Nikon E600 microscope equipped SPOT 2 digital camera Diagnostic Instruments Sterling Heights MI
0.37510666.12551940.html.plaintext.txt	65	Lipid Lipoprotein Determination Lipids lipoproteins measured age matched male mice fasted 4 h anesthetized bled retro orbital puncture
0.37510666.12551940.html.plaintext.txt	66	Lipoproteins fractionated fast performance liquid chromatography FPLC Superose 6 column Amersham Biosciences plasma lipoprotein fractions examined agarose gel electrophoresis Universal Gel8 Helena Laboratories Beaumont TX
0.37510666.12551940.html.plaintext.txt	67	Cholesterol triglyceride levels plasma FPLC fractions determined colorimetric assays Spectrum Abbott Irving TX Triglycerides Roche Molecular Biochemicals respectively
0.37510666.12551940.html.plaintext.txt	68	The statistical significance differences lipid levels determined Students test
0.37510666.12551940.html.plaintext.txt	69	ApoE ApoB Quantitation Fasted mouse plasma subjected SDS PAGE 10 20 4 15 gels transferred nitrocellulose
0.37510666.12551940.html.plaintext.txt	70	Western blotting performed rabbit antiserum mouse apoE 31 apoB 30
0.37510666.12551940.html.plaintext.txt	71	Western blots incubated primary antibodies 12000 bound primary antibodies detected horseradish peroxidase conjugated anti rabbit antibody Invitrogen
0.37510666.12551940.html.plaintext.txt	72	Signals generated incubating membranes chemiluminescent reagent Amersham Biosciences exposing x ray film Kodak Rochester NY
0.37510666.12551940.html.plaintext.txt	73	Signals quantified phosphorimaging quantification software Quantity One Bio Rad
0.37510666.12551940.html.plaintext.txt	74	Remnant Lipoprotein Clearance Study Remnant lipoproteins prepared plasma adjusted density d 1
0.37510666.12551940.html.plaintext.txt	75	04 gml fasted Apoe mice
0.37510666.12551940.html.plaintext.txt	76	Plasma centrifuged Beckman ultracentrifuge TL 100
0.37510666.12551940.html.plaintext.txt	77	3 rotor 80000 rpm 16 h 8 degrees C
0.37510666.12551940.html.plaintext.txt	78	Remnants isolated recentrifuged two additional 16 h periods d 1
0.37510666.12551940.html.plaintext.txt	79	04 gml ensure removal plasma albumin
0.37510666.12551940.html.plaintext.txt	80	The purity remnant preparation examined SDS PAGE staining Coomassie Blue revealed apoB48 major protein component followed apoAI apoB100 present trace amounts
0.37510666.12551940.html.plaintext.txt	81	Remnants labeled Na125I Amersham Biosciences modification iodine monochloride method first described McFarlane 33
0.37510666.12551940.html.plaintext.txt	82	125I labeled remnants extensively dialyzed PBS pH 7
0.37510666.12551940.html.plaintext.txt	83	2 adjusted specific activity 65000 cpm microg protein
0.37510666.12551940.html.plaintext.txt	84	Labeled remnants 24 microg protein volume 400 microl PBS injected tail vein recipient mice wild type hepatocyte derived apoE model non hepatocyte derived apoE model Apoe mice n 3group
0.37510666.12551940.html.plaintext.txt	85	Blood 50 microl collected retro orbital venous plexus heparinized tubes 1 5 15 30 60 180 min injection 125I labeled remnants
0.37510666.12551940.html.plaintext.txt	86	Aliquots plasma analyzed radioactivity gamma counter Packard
0.37510666.12551940.html.plaintext.txt	87	Total counts calculated assuming plasma represents 3
0.37510666.12551940.html.plaintext.txt	88	At 180 min mice anesthetized avertin flush perfused PBS pH 7
0.37510666.12551940.html.plaintext.txt	89	Whole livers collected amount 125I liver determined
0.37510666.12551940.html.plaintext.txt	90	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.37510666.12551940.html.plaintext.txt	91	Detection ApoE Hepatocyte Cell Surfaces Liver The impact tissue source apoE remnant clearance assessed studying two mouse models expressing low levels plasma apoE derived primarily liver hepatocytes primarily peripheral source
0.37510666.12551940.html.plaintext.txt	92	We first examined liver associated apoE mouse models
0.37510666.12551940.html.plaintext.txt	93	Like wild type mice hepatocyte derived apoE model detectable levels apoE bound hepatic sinusoidal surfaces although reduced levels Fig
0.37510666.12551940.html.plaintext.txt	94	In contrast similar Apoe mice non hepatocyte derived apoE model little detectable apoE bound hepatic sinusoidal surfaces
0.37510666.12551940.html.plaintext.txt	95	However unlike Apoe mice non hepatocyte derived apoE model apoE immunoreactive cells liver sections likely represent macrophage derived Kupfer cells expressing apoE cells taken apoE circulation
0.37510666.12551940.html.plaintext.txt	96	Thus enrichment apoE hepatic sinusoidal surfaces required local apoE expression present hepatocyte derived apoE model
0.37510666.12551940.html.plaintext.txt	97	View larger version 145K Fig
0.37510666.12551940.html.plaintext.txt	98	Localization apoE mouse liver
0.37510666.12551940.html.plaintext.txt	99	Livers wild type hepatocyte derived apoE model non hepatocyte derived apoE model Apoe mice perfused saline fixed paraformadehyde prepared cryosectioning
0.37510666.12551940.html.plaintext.txt	100	ApoE detected immunofluorescence viewed inverted light microscope
0.37510666.12551940.html.plaintext.txt	101	Plasma ApoE Levels Hepatocyte derived Non hepatocyte derived ApoE Models Despite different levels liver associated apoE hepatocyte derived non hepatocyte derived apoE models expressed similarly low levels apoE plasma corresponding 2 5 wild type apoE levels hepatocyte derived apoE model 2 fold non hepatocyte derived apoE model Fig
0.37510666.12551940.html.plaintext.txt	102	View larger version 16K Fig
0.37510666.12551940.html.plaintext.txt	103	Relative levels apoE mouse plasma
0.37510666.12551940.html.plaintext.txt	104	Plasma 1 microl fasted mice resolved SDS PAGE apoE detected Western blotting
0.37510666.12551940.html.plaintext.txt	105	Lane 1 recombinant mouse apoE lanes 2 3 plasma two hepatocyte derived apoE mice lanes 4 5 plasma two non hepatocyte derived apoE mice
0.37510666.12551940.html.plaintext.txt	106	Plasma Lipid Lipoprotein Levels Hepatocyte derived Non hepatocyte derived ApoE Models The tissue source apoE resulted marked difference plasma lipid lipoprotein levels
0.37510666.12551940.html.plaintext.txt	107	Plasma cholesterol levels non hepatocyte derived apoE model 2 fold higher hepatocyte derived apoE model 230 plus minus 50 versus 98 plus minus 18 mgdl n 6 p 0
0.37510666.12551940.html.plaintext.txt	108	02 plasma triglyceride levels 4 fold higher non hepatocyte derived apoE model hepatocyte derived apoE model 176 plus minus 27 versus 45 plus minus 12 mgdl n 6 p 0
0.37510666.12551940.html.plaintext.txt	109	Fractionation mouse plasma showed marked difference lipoprotein profiles Fig
0.37510666.12551940.html.plaintext.txt	110	The non hepatocyte derived apoE mice transported 60 80 plasma cholesterol remnant lipoproteins
0.37510666.12551940.html.plaintext.txt	111	In contrast hepatocyte derived apoE mice transported 30 40 plasma cholesterol remnant lipoproteins 30 like wild type mice transport majority plasma cholesterol high density lipoprotein 17
0.37510666.12551940.html.plaintext.txt	112	Thus non hepatocyte derived apoE model transports 2 3 fold remnant lipoprotein associated cholesterol less high density lipoprotein cholesterol hepatocyte derived model
0.37510666.12551940.html.plaintext.txt	113	Agarose gel electrophoresis mouse plasma confirmed normal lipoprotein profile hepatocyte derived apoE model accumulation remnants non hepatocyte derived model data shown
0.37510666.12551940.html.plaintext.txt	114	View larger version 17K Fig
0.37510666.12551940.html.plaintext.txt	115	Plasma lipoprotein profiles hepatocyte derived non hepatocyte derived apoE models
0.37510666.12551940.html.plaintext.txt	116	Plasma 100 microl four fasted mice pooled fractionated FPLC
0.37510666.12551940.html.plaintext.txt	117	Fractions corresponding remnant high density lipoprotein distribution plasma cholesterol levels indicated
0.37510666.12551940.html.plaintext.txt	118	The distribution apoE among classes plasma lipoproteins mouse models determined pooling plasma FPLC fractions lipoprotein classes followed Western blotting
0.37510666.12551940.html.plaintext.txt	119	4 apoE present remnant fractions mouse models demonstrates distribution pattern apoE among plasma lipoprotein classes mouse models identical
0.37510666.12551940.html.plaintext.txt	120	View larger version 29K Fig
0.37510666.12551940.html.plaintext.txt	121	Distribution apoE various lipoprotein classes hepatocyte derived non hepatocyte derived apoE models
0.37510666.12551940.html.plaintext.txt	122	Plasma 100 microl four fasted mice pooled separated lipoprotein classes FPLC low density lipoprotein fractions 5 8 intermediate density lipoprotein IDL fractions 9 12 LDL fractions 13 16 HDL fractions 17 24 see Fig
0.37510666.12551940.html.plaintext.txt	123	ApoE detected SDS PAGE Western blotting
0.37510666.12551940.html.plaintext.txt	124	SDS PAGE Western blot analysis mouse plasma demonstrated models accumulate apoB48
0.37510666.12551940.html.plaintext.txt	125	The non hepatocyte derived apoE model 8 fold plasma apoB48 hepatocyte derived apoE model models similar levels plasma apoB100 lower wild type mice Fig
0.37510666.12551940.html.plaintext.txt	126	These results consistent rapid removal apoB48 containing remnants hepatocyte derived apoE model non hepatocyte derived apoE model
0.37510666.12551940.html.plaintext.txt	127	Taken together results demonstrate remnant clearance effective hepatocyte derived apoE model non hepatocyte derived model due hepatically derived localized apoE
0.37510666.12551940.html.plaintext.txt	128	View larger version 53K Fig
0.37510666.12551940.html.plaintext.txt	129	Relative levels apoB100 apoB48 mouse plasma
0.37510666.12551940.html.plaintext.txt	130	Plasma 1 microl fasted mice resolved SDS PAGE apoB detected Western blotting
0.37510666.12551940.html.plaintext.txt	131	Lane 1 wild type mouse plasma lane 2 Apoe mouse plasma lanes 3 4 plasma two hepatocyte derived apoE mice lanes 5 7 plasma three non hepatocyte derived apoE mice
0.37510666.12551940.html.plaintext.txt	132	Uptake I125 labeled Remnant Lipoproteins Mice The importance source apoE synthesis remnant uptake assessed measuring plasma clearance liver uptake 125I labeled apoE deficient mouse remnants Fig
0.37510666.12551940.html.plaintext.txt	133	Although hepatocyte derived apoE model non hepatocyte derived apoE model overall delay remnant clearance relative wild type mice hepatocyte derived apoE model reached wild type levels 3 h
0.37510666.12551940.html.plaintext.txt	134	Moreover livers hepatocyte derived apoE model n 3 contained 70 plus minus 5 total radioactivity found wild type mouse livers whereas livers non hepatocyte derived apoE model n 3 contained 38 plus minus 4 3 h
0.37510666.12551940.html.plaintext.txt	135	View larger version 15K Fig
0.37510666.12551940.html.plaintext.txt	136	Clearance apoE deficient remnants mice
0.37510666.12551940.html.plaintext.txt	137	A 125I labeled apoE deficient mouse remnants injected mice via tail vein blood samples collected various time points
0.37510666.12551940.html.plaintext.txt	138	The presence remnants plasma presented percentage injected dose remaining plasma
0.37510666.12551940.html.plaintext.txt	139	Values represent mean plus minus S
0.37510666.12551940.html.plaintext.txt	140	three mice time point
0.37510666.12551940.html.plaintext.txt	141	B experiment performed hepatocyte derived apoE model well Apoe wild type mice
0.37510666.12551940.html.plaintext.txt	142	Contrary wild type mice initial rates remnant clearance hepatocyte derived apoE apoE null mice identical indicating initial rates models affected levels hepatically localized apoE number apoE molecules per remnant Fig
0.37510666.12551940.html.plaintext.txt	143	Rather difference rate remnant clearance two models apparent later time points diverging first 30 min
0.37510666.12551940.html.plaintext.txt	144	These results demonstrate apoE synthesized liver hepatocytes favors overall greater capacity liver mediated remnant uptake apoE synthesized extrahepatic tissue
0.37510666.12551940.html.plaintext.txt	145	Moreover results support role apoE enrichment remnants sequestered surface hepatocytes consistent plasma lipoprotein profiles fasted mice show significant accumulation remnants non hepatocyte derived apoE model hepatocyte derived apoE model Fig
0.37510666.12551940.html.plaintext.txt	146	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.37510666.12551940.html.plaintext.txt	147	This study presents vivo evidence demonstrates site apoE synthesis significantly influences remnant clearance consequently plasma cholesterol triglyceride levels mice
0.37510666.12551940.html.plaintext.txt	148	Hepatically derived localized apoE hepatocyte derived apoE model found effective macrophage derived apoE non hepatocyte derived apoE model promoting plasma clearance liver uptake apoB48 containing remnants
0.37510666.12551940.html.plaintext.txt	149	Moreover low levels hepatically derived localized apoE hepatocyte derived apoE model influenced late initial part remnant clearance
0.37510666.12551940.html.plaintext.txt	150	Because hepatocyte derived apoE model expresses Arg 61 apoE non hepatocyte derived apoE model generated using Cre deleted Arg 61 bone marrow allow direct comparison hepatocyte derived apoE model
0.37510666.12551940.html.plaintext.txt	151	In mice Cre mediated excision neo cassette Apoe intron 3 results normal apoE expression levels tissues including macrophages 31
0.37510666.12551940.html.plaintext.txt	152	The normal lipid lipoprotein levels Cre deleted Arg 61 mice suggest Arg 61 apoE wild type apoE equally effective remnant clearance 31
0.37510666.12551940.html.plaintext.txt	153	Immunohistochemical analysis liver sections demonstrated hepatocyte derived apoE model contained significant levels hepatically localized apoE whereas non hepatocyte derived apoE model
0.37510666.12551940.html.plaintext.txt	154	The hepatically localized apoE hepatocyte derived apoE model likely originated mostly hepatocytes expression pattern hypomorphic Apoe allele hepatocyte derived apoE model normal liver producing majority apoE mice 30
0.37510666.12551940.html.plaintext.txt	155	However cannot exclude possibility hepatically localized apoE hepatocyte derived apoE model originated periphery
0.37510666.12551940.html.plaintext.txt	156	The higher plasma lipid lipoprotein levels non hepatocyte derived apoE model relative hepatocyte derived apoE model despite similarly low apoE plasma levels consistent efficient clearance remnants hepatocyte derived model
0.37510666.12551940.html.plaintext.txt	157	The non hepatocyte derived apoE model accumulated 2 fold plasma cholesterol 4 fold plasma triglycerides hepatocyte derived apoE model
0.37510666.12551940.html.plaintext.txt	158	The 8 fold greater accumulation apoB48 containing remnants non hepatocyte derived apoE model also consistent site apoE synthesis influencing remnant clearance despite models similar levels plasma apoE
0.37510666.12551940.html.plaintext.txt	159	In hepatocyte derived apoE model low levels hepatic apoE synthesis overcome significant degree deficiency remnant clearance seen non hepatocyte derived apoE model
0.37510666.12551940.html.plaintext.txt	160	In contrast wild type mice similar Apoe mice models equally low levels plasma apoB100
0.37510666.12551940.html.plaintext.txt	161	The low levels plasma apoE two models apparently failed sufficiently enrich apoB48 containing remnants apoE causing become poor competitors apoB100 containing LDL binding LDLR
0.37510666.12551940.html.plaintext.txt	162	Alternatively reduced levels apoB100 models may result decreased apoB100 secretion liver
0.37510666.12551940.html.plaintext.txt	163	However hepatic apoE expression reported influence production rate apoB48 apoB100 mice 35
0.37510666.12551940.html.plaintext.txt	164	The finding levels apoB48 far greater non hepatocyte derived apoE model hepatocyte derived apoE model emphasizes importance hepatically derived localized apoE remnant clearance non hepatocyte derived apoE model likely secretes reduced levels apoB48 similar Apoe mice 35
0.37510666.12551940.html.plaintext.txt	165	Thus direct assessment apoB secretion rates models necessary confirm possibility
0.37510666.12551940.html.plaintext.txt	166	Lastly remnant clearance models may influenced recently described recycling pathway apoE liver hepatocytes 36
0.37510666.12551940.html.plaintext.txt	167	However 6 internalized apoE reported re secreted hepatocytes pathway likely plays minor role mediating remnant clearance models low levels plasma apoE
0.37510666.12551940.html.plaintext.txt	168	Directly comparing remnant clearance hepatocyte derived non hepatocyte derived apoE models confirmed conclusions drawn steady state plasma lipid lipoprotein levels indicate hepatocyte derived apoE effective non hepatocyte derived apoE remnant clearance
0.37510666.12551940.html.plaintext.txt	169	When compared wild type mice initial phase remnant clearance similarly reduced mouse models comparable apoE null mice
0.37510666.12551940.html.plaintext.txt	170	As initial phase likely reflects binding sequestration remnants hepatocyte cell surfaces space Disse levels apoE molecules per remnant well levels hepatically localized apoE hepatocyte derived apoE model appear contribute significantly process
0.37510666.12551940.html.plaintext.txt	171	Moreover differences lipoprotein pool sizes models affect rapid initial clearance remnants
0.37510666.12551940.html.plaintext.txt	172	However near normal level remnant clearance 3 h hepatocyte derived apoE model suggests hepatically derived localized apoE contribute substantially slower component remnant clearance likely represents liver uptake
0.37510666.12551940.html.plaintext.txt	173	Indeed livers hepatocyte derived apoE model contained 70 plus minus 5 normal 125I levels whereas livers non hepatocyte derived apoE model contained 38 plus minus 4
0.37510666.12551940.html.plaintext.txt	174	In hepatocyte derived apoE model apoE poor remnants sequestered hepatocytes likely become enriched newly secreted apoE space Disse passive exchange existing hepatically localized apoE allowing accelerated receptor mediated internalization LDLR LRP HSPG alone
0.37510666.12551940.html.plaintext.txt	175	However non hepatocyte derived apoE model large proportion sequestered apoE poor remnants likely redistribute accumulate circulation due absence apoE enrichment space Disse inefficient receptor mediated uptake
0.37510666.12551940.html.plaintext.txt	176	Studies remnant clearance isolated mouse liver perfusion model recently questioned importance hepatic synthesis localization apoE thus importance secretion capture role apoE remnant clearance 24
0.37510666.12551940.html.plaintext.txt	177	Livers Apoe mice cleared infused bolus apoE containing rat chylomicron remnants efficiently wild type mice unlike livers Apoe mice abundant levels apoE localized hepatocyte cell surfaces 24
0.37510666.12551940.html.plaintext.txt	178	More recent data model suggested apoEHSPG interactions hepatocyte cell surfaces required efficient remnant uptake 29
0.37510666.12551940.html.plaintext.txt	179	Rather apoELRP interactions proposed mediate direct sequestration internalization remnants
0.37510666.12551940.html.plaintext.txt	180	Interestingly parallel results observed mouse liver perfusion model 24 absence hepatically localized apoE non hepatocyte derived apoE model Apoe mice influence early phase remnant clearance relative hepatocyte derived apoE model
0.37510666.12551940.html.plaintext.txt	181	Indeed three mouse models displayed similarly delayed initial rates remnant clearance relative wild type mice
0.37510666.12551940.html.plaintext.txt	182	However shortcoming liver perfusion model results cannot necessarily extrapolated explain steady state levels remnants mice
0.37510666.12551940.html.plaintext.txt	183	For example apoE null mice perfused liver effectively cleared infused bolus remnants whereas steady state mice accumulate remnants plasma
0.37510666.12551940.html.plaintext.txt	184	In contrast vivo models directly focus steady state levels remnants mice
0.37510666.12551940.html.plaintext.txt	185	In conclusion vivo study mice expressing apoE hepatic versus extrahepatic sources demonstrates underscores importance hepatically derived localized apoE efficient remnant clearance liver
0.37510666.12551940.html.plaintext.txt	186	Because remnant clearance operates close sub optimal level hepatocyte derived apoE model model informative revealing relative contributions LDLR LRP remnant clearance context low levels plasma apoE
0.37510666.12551940.html.plaintext.txt	187	The hepatocyte derived apoE model also serve determine contribution proteins known ligands remnant clearance hepatic lipase 37 38
0.37510666.12551940.html.plaintext.txt	188	We also thank Dale Newland help histological analysis Brian Auerbach manuscript preparation Gary Howard Stephen Ordway editorial assistance Jack Hull John Carroll graphics
0.37510666.12551940.html.plaintext.txt	189	This work supported part NIH Grant HL47660 K
0.37510666.12551940.html.plaintext.txt	190	Grant 10KT 0318 University California Tobacco Related Disease Research Program fellowship Heart Stroke Foundation Canada R
0.37510666.12551940.html.plaintext.txt	191	NIH Grants 57986 S
0.37510666.12551940.html.plaintext.txt	192	The costs publication article defrayed part payment page charges
0.37510666.12551940.html.plaintext.txt	193	The article must therefore hereby marked advertisement accordance 18 U
0.37510666.12551940.html.plaintext.txt	194	Section 1734 solely indicate fact
0.37510666.12551940.html.plaintext.txt	195	To correspondence addressed Gladstone Inst
0.37510666.12551940.html.plaintext.txt	196	Box 419100 San Francisco CA 94141 9100
0.37510666.12551940.html.plaintext.txt	197	415 826 7500 Fax 415 285 5632 E mail kweisgrabergladstone
0.37510666.12551940.html.plaintext.txt	198	Published JBC Papers Press January 27 2003 DOI 10
0.37510666.12551940.html.plaintext.txt	199	The abbreviations used apo apolipoprotein hypoE hypomorphic apoE neo neomycin FPLC fast performance liquid chromatography HSPG heparan sulfate proteoglycans LDL low density lipoprotein LDLR LDL receptor LRP LDLR related protein PBS phosphate buffered saline
0.37510666.12551940.html.plaintext.txt	200	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES 1
0.37510666.12551940.html.plaintext.txt	201	1988 Science 240 622 630Medline Order article via Infotrieve 2
0.37510666.12551940.html.plaintext.txt	202	40 1 16AbstractFree Full Text 4
0.37510666.12551940.html.plaintext.txt	203	1989 Nature 341 162 164CrossRefMedline Order article via Infotrieve 5
0.37510666.12551940.html.plaintext.txt	204	268 10160 10167AbstractFree Full Text 7
0.37510666.12551940.html.plaintext.txt	205	1979 Circulation 60 473 485Abstract 9
0.37510666.12551940.html.plaintext.txt	206	2001 The Metabolic Molecular Bases Inherited Disease Scriver C
0.37510666.12551940.html.plaintext.txt	207	2835 2862 McGraw Hill New York 10
0.37510666.12551940.html.plaintext.txt	208	88 270 281Medline Order article via Infotrieve 11
0.37510666.12551940.html.plaintext.txt	209	269 2764 2772AbstractFree Full Text 12
0.37510666.12551940.html.plaintext.txt	210	93 2215 2223Medline Order article via Infotrieve 13
0.37510666.12551940.html.plaintext.txt	211	42 1413 1420AbstractFree Full Text 15
0.37510666.12551940.html.plaintext.txt	212	88 1173 1181Medline Order article via Infotrieve 16
0.37510666.12551940.html.plaintext.txt	213	268 15804 15811AbstractFree Full Text 17
0.37510666.12551940.html.plaintext.txt	214	101 689 695AbstractFree Full Text 20
0.37510666.12551940.html.plaintext.txt	215	267 13284 13292AbstractFree Full Text 21
0.37510666.12551940.html.plaintext.txt	216	105 1807 1818AbstractFree Full Text 22
0.37510666.12551940.html.plaintext.txt	217	1996 Hepatology 24 344 351Medline Order article via Infotrieve 24
0.37510666.12551940.html.plaintext.txt	218	41 1715 1727AbstractFree Full Text 25
0.37510666.12551940.html.plaintext.txt	219	1995 Science 267 1034 1037Medline Order article via Infotrieve 26
0.37510666.12551940.html.plaintext.txt	220	96 1118 1124Medline Order article via Infotrieve 27
0.37510666.12551940.html.plaintext.txt	221	20 1939 1945AbstractFree Full Text 28
0.37510666.12551940.html.plaintext.txt	222	101 1726 1736AbstractFree Full Text 29
0.37510666.12551940.html.plaintext.txt	223	107 1387 1394AbstractFree Full Text 30
0.37510666.12551940.html.plaintext.txt	224	277 11064 11068AbstractFree Full Text 31
0.37510666.12551940.html.plaintext.txt	225	98 11587 11591AbstractFree Full Text 32
0.37510666.12551940.html.plaintext.txt	226	40 1529 1538AbstractFree Full Text 33
0.37510666.12551940.html.plaintext.txt	227	266 13936 13940AbstractFree Full Text 35
0.37510666.12551940.html.plaintext.txt	228	41 1673 1679AbstractFree Full Text 36
0.37510666.12551940.html.plaintext.txt	229	276 22965 22970AbstractFree Full Text 37
0.37510666.12551940.html.plaintext.txt	230	42 201 210AbstractFree Full Text
0.37510666.12551940.html.plaintext.txt	231	Copyright 2003 The American Society Biochemistry Molecular Biology Inc
0.34268814.15576362.html.plaintext.txt	0	Generation Recombinant Apolipoprotein E Variant Improved Biological Functions HYDROPHOBIC RESIDUES LEU 261 TRP 264 PHE 265 LEU 268 VAL 269 OF apoE CAN ACCOUNT FOR THE apoE INDUCED HYPERTRIGLYCERIDEMIA Kyriakos E
0.34268814.15576362.html.plaintext.txt	1	From Molecular Genetics Department Medicine Boston University School Medicine Boston Massachusetts 02118 Department Human Genetics Leiden University Medical Center 2333AL Leiden The Netherlands Department General Internal Medicine Leiden University Medical Center 2333AL Leiden The Netherlands TNO Preventie en Gezondheid Prevention Health Gaubius Laboratory Leiden 2333CK The Netherlands Department Cardiology Leiden University Medical Center 2333AL Leiden The Netherlands Department Biochemistry Institute Molecular Biology Biotechnology University Crete Medical School Heraklion Crete 71110 Greece
0.34268814.15576362.html.plaintext.txt	2	Received publication November 30 2004
0.34268814.15576362.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES To identify residues carboxyl terminal region 260 299 human apolipoprotein E apoE contribute hypertriglyceridemia two sets conserved hydrophobic amino acids residues 261 283 mutated alanines recombinant adenoviruses expressing apoE mutants generated
0.34268814.15576362.html.plaintext.txt	4	Adenovirus mediated gene transfer apoE4 mut1 apoE4 L261A W264A F265A L268A V269A apoE deficient mice apoE corrected plasma cholesterol levels cause hypertriglyceridemia
0.34268814.15576362.html.plaintext.txt	5	In contrast gene transfer apoE4 mut2 apoE4 W276A L279A V280A V283A correct hypercholesterolemia induced mild hypertriglyceridemia
0.34268814.15576362.html.plaintext.txt	6	ApoE induced hyperlipidemia corrected co infection recombinant adenovirus expressing human lipoprotein lipase
0.34268814.15576362.html.plaintext.txt	7	Both apoE4 mutants caused small increase hepatic low density lipoprotein triglyceride secretion
0.34268814.15576362.html.plaintext.txt	8	Density gradient ultracentrifugation analysis plasma electron microscopy showed wild type apoE4 apoE4 mut2 displaced apoA I high density lipoprotein HDL region promoted formation discoidal HDL whereas apoE4 mut1 displace apoA I HDL promoted formation spherical HDL
0.34268814.15576362.html.plaintext.txt	9	The findings indicate residues Leu 261 Trp 264 Phe 265 Leu 268 Val 269 apoE responsible hypertriglyceridemia also interfere formation HDL
0.34268814.15576362.html.plaintext.txt	10	Substitutions residues alanine provide recombinant apoE form improved biological functions
0.34268814.15576362.html.plaintext.txt	11	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES ApoE1 polymorphic protein humans 1
0.34268814.15576362.html.plaintext.txt	12	In vitro vivo studies shown apoE mutants prevent binding apoE containing lipoproteins LDL receptor associated high plasma cholesterol levels cause premature atherosclerosis humans experimental animals 2 4
0.34268814.15576362.html.plaintext.txt	13	ApoE promotes cholesterol efflux 5 6 thus may contribute cell tissue cholesterol homeostasis protection atherosclerosis 7 8
0.34268814.15576362.html.plaintext.txt	14	ApoE also risk factor Alzheimers disease 9 10 may contribute lipid homeostasis brain 11
0.34268814.15576362.html.plaintext.txt	15	A series recent studies used adenoviruses expressing full length truncated genomic apoE sequences correct high cholesterol profile apoE deficient apoE mice
0.34268814.15576362.html.plaintext.txt	16	It shown overexpression full length apoE infection mice 1 2 x 109 pfu correct high cholesterol levels apoE mice contrast increased VLDL triglyceride secretion induced hypertriglyceridemia 12 16
0.34268814.15576362.html.plaintext.txt	17	Overexpression apoE3 apoE4 also aggravated hypercholesterolemia apoE2 knock mice 17
0.34268814.15576362.html.plaintext.txt	18	However high cholesterol profile apoE mice apoE2 knock mice corrected infection truncated apoE forms lacking different segments carboxyl terminal domain 12 17
0.34268814.15576362.html.plaintext.txt	19	The hypertriglyceridemia induced full length apoE independent apoE phenotype mouse strain could corrected overexpression lipoprotein lipase 15
0.34268814.15576362.html.plaintext.txt	20	In normal C57BL6 mice overexpression full length apoE induced combined hyperlipidemia characterized high cholesterol high triglycerides levels whereas truncated apoE forms change plasma lipid lipoprotein levels mice 13
0.34268814.15576362.html.plaintext.txt	21	Finally truncated apoE forms could correct high cholesterol profiles apoE x LDLr double deficient mice induce hypertriglyceridemia indicating carboxyl terminal region apoE responsible hypertriglyceridemia 15 16
0.34268814.15576362.html.plaintext.txt	22	Use series apoE deletion mutants extending amino acid 1 amino acids 185 202 229 259 mapped region responsible hypertriglyceridemia amino acids 260 299 apoE 12 17
0.34268814.15576362.html.plaintext.txt	23	This region contains two hydrophobic stretches amino acids residues 261 269 276 283
0.34268814.15576362.html.plaintext.txt	24	In present study hydrophobic residues regions mutated alanines functions mutant apoE forms studied vivo using adenovirus mediated gene transfer
0.34268814.15576362.html.plaintext.txt	25	This analysis showed residues Leu 261 Trp 264 Phe 265 Leu 268 Ala 269 account apoE induced hypertriglyceridemia
0.34268814.15576362.html.plaintext.txt	26	Furthermore 261 269 apoE sequence responsible displacing apoA I HDL region leading reduction plasma apoA I HDL levels
0.34268814.15576362.html.plaintext.txt	27	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Construction Recombinant Adenoviruses Expressing Wild type Mutant Forms ApoE4 Two apoE4 mutants generated apoE4 mut1 apoE4 L261A W264A F265A L268A V269A apoE4 mut2 apoE4 W276A L279A V280A V283A using mutagenesis kit QuikChange XL Stratagene
0.34268814.15576362.html.plaintext.txt	28	The mutagenic primers used apoE4 mut1 5 GCC TTC CAG GCC CGC GCC AAG AGC GCG GCC GAG CCC GCG GCG GAA GAC ATG CAG CGC 3 apoE4 mut1 5 GCG CTG CAT GTC TTC CGC CGC GGG CTC GGC CGC GCT CTT GGC GCG GGC CTG GAA GGC 3 apoE4 mut2 5 GAC ATG CAG CGC CAG GCG GCC GGG GCG GCG GAG AAG GCG CAG GCT GCC GT 3 apoE4 mut2 5 GCC CAC GGC AGC CTG CGC CTT CTC CGC CGC CCC GGC CGC CTG GCG CTG CA 3
0.34268814.15576362.html.plaintext.txt	29	The nucleotides mutated various codons shown bold
0.34268814.15576362.html.plaintext.txt	30	In mutagenic reactions vector pGEM7 apoE4 14 containing Exons II III IV human apoE used template
0.34268814.15576362.html.plaintext.txt	31	Following 18 cycles PCR amplification template DNA PCR product treated DpnI digest plasmids containing methylated DNA one strands
0.34268814.15576362.html.plaintext.txt	32	The reaction product consisting plasmids containing newly synthesized DNA carrying mutations interest used transform competent XL 10 blue bacteria cells Stratagene
0.34268814.15576362.html.plaintext.txt	33	Ampicillin resistant clones selected plasmid DNA isolated clones subjected sequencing confirm presence point mutations
0.34268814.15576362.html.plaintext.txt	34	The recombinant adenoviruses constructed described 14 using Ad Easy 1 system adenovirus construct generated bacteria BJ 5183 cells 18
0.34268814.15576362.html.plaintext.txt	35	Correct clones propagated RecA DH5 cells
0.34268814.15576362.html.plaintext.txt	36	The recombinant adenoviral vectors linearized PacI used infect 911 cells 19
0.34268814.15576362.html.plaintext.txt	37	Following large scale infection human embryonic kidney 293 cell cultures recombinant adenoviruses purified two consecutive CsCl ultracentrifugation steps dialyzed titrated 14
0.34268814.15576362.html.plaintext.txt	38	Usually titers 2 5 x 1010 pfuml obtained
0.34268814.15576362.html.plaintext.txt	39	Cell Culture Studies Human HTB13 cells SW1783 human astrocytoma grown confluence medium containing 10 fetal calf serum infected AdGFP E4 adenoviruses expressing mutant apoE forms AdGFP E4 mut1 AdGFP E4 mut2 multiplicity infection 5
0.34268814.15576362.html.plaintext.txt	40	Twenty four hours postinfection cell washed twice phosphate buffered saline fresh serum free medium added
0.34268814.15576362.html.plaintext.txt	41	After 24 h incubation medium collected analyzed enzyme linked immunosorbent assay ELISA SDS PAGE apoE expression
0.34268814.15576362.html.plaintext.txt	42	Animal Studies Female apoE deficient mice 4 6 weeks old used studies
0.34268814.15576362.html.plaintext.txt	43	Groups 8 10 female mice injected intravenously tail vein dose 2 x 109 pfu
0.34268814.15576362.html.plaintext.txt	44	Blood obtained tail vein 4 h fast preceding adenoviral injection 2 3 4 5 6 days postinfection
0.34268814.15576362.html.plaintext.txt	45	Aliquots plasma stored 4 20 degrees C
0.34268814.15576362.html.plaintext.txt	46	RNA Analysis To assess expression apoE4 apoE4 mut1 apoE4 mut2 infected mice least 3 mice group sacrificed 5 days postinfection
0.34268814.15576362.html.plaintext.txt	47	Livers collected individual animals frozen liquid nitrogen stored 80 degrees C
0.34268814.15576362.html.plaintext.txt	48	Total RNA isolated livers analyzed apoE mRNA expression Northern blotting quantitated phosphorimaging 13
0.34268814.15576362.html.plaintext.txt	49	FPLC Analysis Lipid Determination For FPLC analysis serum samples 12 microl serum diluted 15 phosphate buffered saline loaded onto Superose 6 column SMART micro FPLC system Amersham Biosciences eluted phosphate buffered saline
0.34268814.15576362.html.plaintext.txt	50	A total 25 fractions 50 microl volume collected analysis
0.34268814.15576362.html.plaintext.txt	51	Triglycerides cholesterol determined using GPO Trinder Kit Sigma CHOL MPR3 kit Roche Applied Science according manufacturers instructions
0.34268814.15576362.html.plaintext.txt	52	The triglyceride cholesterol concentrations serum FPLC fractions determined spectrophotometrically 540 492 nm respectively described previously 14
0.34268814.15576362.html.plaintext.txt	53	Quantification Human ApoE Human apoE concentrations measured using sandwich ELISA 12 15
0.34268814.15576362.html.plaintext.txt	54	Rate VLDL Triglyceride Production C57BL6 Mice Infected Different ApoE Forms VLDL triglyceride secretion determined following infection C57BL6 mice 2 x 109 pfu adenoviruses expressing either WT apoE4 apoE4 mut1 control AdGFP adenovirus
0.34268814.15576362.html.plaintext.txt	55	Four days postinfection mice fasted 4 h injected Triton WR 1339 dose 500 mgkg body weight using 15 solution wv 0
0.34268814.15576362.html.plaintext.txt	56	9 NaCl Triton WR 1339 shown completely inhibit VLDL catabolism 20
0.34268814.15576362.html.plaintext.txt	57	Serum samples isolated 20 40 60 90 min injection Triton WR 1339
0.34268814.15576362.html.plaintext.txt	58	Serum triglycerides measured rate VLDL triglyceride secretion expressed mgdlmin determined described 14
0.34268814.15576362.html.plaintext.txt	59	Statistical Analysis Comparison data two groups mice performed using Students test
0.34268814.15576362.html.plaintext.txt	60	Density Gradient Ultracentrifugation To assess ability WT mutant apoE forms associate different lipoproteins 0
0.34268814.15576362.html.plaintext.txt	61	3 ml serum mice infected either control adenovirus AdGFP adenoviruses expressing WT apoE4 apoE4 mut1 apoE4 mut2 brought volume 0
0.34268814.15576362.html.plaintext.txt	62	5 ml phosphate buffered saline adjusted density 1
0.34268814.15576362.html.plaintext.txt	63	This solution overlaid 1 ml 1
0.34268814.15576362.html.plaintext.txt	64	The mixture centrifuged 22 h SW 41 rotor 30000 rpm
0.34268814.15576362.html.plaintext.txt	65	Following ultracentrifugation 10 fractions 0
0.34268814.15576362.html.plaintext.txt	66	5 ml collected analyzed SDS PAGE
0.34268814.15576362.html.plaintext.txt	67	Electron Microscopy Aliquots fractions equilibrium density gradient centrifugation dialysis ammonium acetate carbonate buffer stained sodium phosphotungstate visualized Phillips CM 120 electron microscopy Phillips Electron Optics Eindhoven Netherlands photographed described previously 11
0.34268814.15576362.html.plaintext.txt	68	The photomicrographs taken x75000 magnification enlarged three times
0.34268814.15576362.html.plaintext.txt	69	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES The Full length ApoE4 Mutant ApoE Forms ApoE4 mut1 ApoE4 mut2 Are Secreted Efficiently HTB 13 Cells To test expression relative levels secretion mutant apoE4 forms apoE4 mut1 apoE4 mut2 comparison wild type apoE4 HTB 13 cells synthesize endogenous apoE infected recombinant adenoviruses expressing apoE4 apoE4 mut1 apoE4 mut2 control adenovirus AdGFP multiplicity infection 5
0.34268814.15576362.html.plaintext.txt	70	Analysis culture medium SDS PAGE Fig
0.34268814.15576362.html.plaintext.txt	71	1 sandwich ELISA showed apoE4 apoE4 mut1 apoE4 mut2 secreted efficiently comparable levels ranges 130 170 microg apoEml respectively 24 h postinfection
0.34268814.15576362.html.plaintext.txt	72	View larger version 55K FIG
0.34268814.15576362.html.plaintext.txt	73	SDS PAGE analysis culture medium HTB 13 cells infected control adenoviruses adenoviruses expressing WT apoE4 apoE4 mut1 apoE4 mut2
0.34268814.15576362.html.plaintext.txt	74	M indicates protein markers different molecular mass New England Biolabs
0.34268814.15576362.html.plaintext.txt	75	ApoE levels assessed comparison intensity bands samples containing 0
0.34268814.15576362.html.plaintext.txt	76	5 5 microg bovine serum albumin
0.34268814.15576362.html.plaintext.txt	77	Residues Leu 261 Trp 264 Phe 265 Leu 268 Val 269 Are Responsible ApoE induced Hypertriglyceridemia We used adenovirus mediated gene transfer apoE mice assess effects wild type apoE4 two mutants apoE4 mut1 apoE4 mut2 forms induction hyperlipidemia vivo
0.34268814.15576362.html.plaintext.txt	78	The apoE mice infected either control adenovirus AdGFP recombinant adenoviruses expressing wild type apoE4 mutant forms apoE4 mut1 contains point mutations L261A W264A F265A L268A V269A apoE4 mut2 contains point mutations W276A L279A V280A V283A blood samples collected 4 5 days postinfection analyzed plasma lipids levels
0.34268814.15576362.html.plaintext.txt	79	This analysis showed infection mice 2 x 109 pfu recombinant adenovirus expressing apoE4 apoE4 mut2 alter significantly plasma cholesterol levels 4 5 days postinfection induced hypertriglyceridemia compared mice infected control virus Fig
0.34268814.15576362.html.plaintext.txt	80	2 non infected mice data shown
0.34268814.15576362.html.plaintext.txt	81	ApoE4 mut2 overexpression resulted mild hypertriglyceridemia compared wild type apoE4 Fig
0.34268814.15576362.html.plaintext.txt	82	In contrast infection mice recombinant adenovirus expressing apoE4 mut1 dose 2 x 109 greatly reduced plasma cholesterol levels 4 5 days postinfection cause hypertriglyceridemia Fig
0.34268814.15576362.html.plaintext.txt	83	View larger version 22K FIG
0.34268814.15576362.html.plaintext.txt	84	Plasma cholesterol triglyceride apoE levels apoE mice infected recombinant adenoviruses expressing apoE4 apoE4 mut1 apoE4 mut2 control AdGFP virus
0.34268814.15576362.html.plaintext.txt	85	Mice infected least triplicate indicated doses recombinant virus serum samples isolated analyzed cholesterol A triglyceride levels B indicated days postinfection described Experimental Procedures
0.34268814.15576362.html.plaintext.txt	86	ApoE levels determined day 5 postinfection
0.34268814.15576362.html.plaintext.txt	87	The expression apoE4 apoE4 mut1 apoE4 mut2 assessed mice group 5 days postinfection Northern blotting apoE mRNA quantitated phosphorimaging
0.34268814.15576362.html.plaintext.txt	88	This analysis showed apoE mRNA levels three groups similar Fig
0.34268814.15576362.html.plaintext.txt	89	However apoE4 mut1 cleared efficiently cholesterol apoE deficient mice without induction hypertriglyceridemia whereas full length apoE4 apoE4 mut2 correct cholesterol levels apoE mice induced hypertriglyceridemia Fig
0.34268814.15576362.html.plaintext.txt	90	View larger version 20K FIG
0.34268814.15576362.html.plaintext.txt	91	Steady state hepatic apoE mRNA levels livers individual mice infected adenoviruses expressing apoE4 apoE4 mut2 apoE4 mut1
0.34268814.15576362.html.plaintext.txt	92	Total RNA isolated livers infected mice 5 days postinfection analyzed Northern blotting phosphorimaging expression apoE glyceraldehyde 3 phosphate dehydrogenase GAPDH mRNA
0.34268814.15576362.html.plaintext.txt	93	A representative autoradiograms Northern blot analysis total RNA isolated livers individual mice infected indicated dose recombinant adenoviruses expressing apoE4 2 apoE4 mut1 WT apoE4
0.34268814.15576362.html.plaintext.txt	94	B apoE mRNA levels quantified PhosphorImager using ImageQuant program version 4
0.34268814.15576362.html.plaintext.txt	95	2A normalized glyceraldehyde 3 phosphate dehydrogenase mRNA levels reported format bar graph mouse
0.34268814.15576362.html.plaintext.txt	96	ApoE4 ApoE4 mut2 Overexpression Results Accumulation Triglyceride rich VLDL Particles Whereas Overexpression ApoE4 mut1 Clears VLDL FPLC analysis plasma adenovirus infected mice showed mice expressing apoE4 apoE4 mut1 5 days postinfection cholesterol triglyceride levels high distributed predominantly VLDL region Fig
0.34268814.15576362.html.plaintext.txt	97	In contrast mice infected AdGFP E4 mut1 cholesterol triglycerides low distributed lipoprotein fractions Fig
0.34268814.15576362.html.plaintext.txt	98	As additional control infection mice 2 x 109 pfu control virus AdGFP result change cholesterol triglyceride profiles apoE mice data shown
0.34268814.15576362.html.plaintext.txt	99	View larger version 21K FIG
0.34268814.15576362.html.plaintext.txt	100	FPLC profiles serum cholesterol A C triglycerides D F adenovirus infected mice
0.34268814.15576362.html.plaintext.txt	101	Serum samples obtained uninfected apoE deficient mice mice infected 2 x 109 pfu recombinant adenoviruses expressing WT apo E4 A D apoE4 mut1 B E apoE4 mut2 C F 5 days postinfection fractionated FPLC
0.34268814.15576362.html.plaintext.txt	102	The cholesterol levels A C triglyceride levels D F FPLC fraction determined described Experimental Procedures
0.34268814.15576362.html.plaintext.txt	103	ApoE4 mut1 ApoE4 mut2 Have Modest Effect Rate Hepatic VLDL Triglyceride Secretion The rate hepatic VLDL triglyceride secretion plasma determined following injection Triton WR 1339 5 days infection recombinant adenoviruses
0.34268814.15576362.html.plaintext.txt	104	It found consistent previous findings 12 16 rate triglyceride secretion increased 6
0.34268814.15576362.html.plaintext.txt	105	5 fold mice infected adenoviruses expressing WT apoE4 compared mice infected AdGFP control
0.34268814.15576362.html.plaintext.txt	106	In mice infected adenoviruses expressing either apoE mut1 apoE4 mut2 rate VLDL triglyceride secretion increased 1
0.34268814.15576362.html.plaintext.txt	107	9 fold compared mice infected control adenoviruses 27 rate VLDL secretion observed mice infected apoE4 expressing adenovirus Fig
0.34268814.15576362.html.plaintext.txt	108	The findings suggest residues Leu 261 Trp 264 Phe 265 Leu 268 Val 269 residues Trp 276 Leu 279 Val 280 Val 283 human apoE major effect secretion hepatic triglycerides altered less hydrophobic alanines rate triglyceride secretion diminished
0.34268814.15576362.html.plaintext.txt	109	View larger version 13K FIG
0.34268814.15576362.html.plaintext.txt	110	Hepatic VLDL triglyceride TG secretion analysis mice infected either control AdGFP adenovirus recombinant adenoviruses expressing WT apoE4 apoE4 mut1 apoE4 mut2
0.34268814.15576362.html.plaintext.txt	111	Triton WR 1339 500 mgkg body weight injected 3 fasted micevirus group
0.34268814.15576362.html.plaintext.txt	112	Serum samples collected 20 40 60 90 min injection detergent
0.34268814.15576362.html.plaintext.txt	113	Control serum samples isolated 1 min immediately injection detergent
0.34268814.15576362.html.plaintext.txt	114	Serum triglyceride levels determined linear graph serum triglyceride concentration versus time generated
0.34268814.15576362.html.plaintext.txt	115	The rate VLDL triglyceride secretion expressed mgdlmin calculated slope linear graph individual mouse
0.34268814.15576362.html.plaintext.txt	116	individual rates VLDL triglyceride secretionvirus group presented form bar graphs
0.34268814.15576362.html.plaintext.txt	117	Co expression Full length ApoE4 ApoE4 mut2 Lipoprotein Lipase Normalizes Lipid Levels ApoE Mice To test potential insufficiency activity lipoprotein lipase induction hypertriglyceridemia apoE mice co infected 2 x 109 pfu adenovirus expressing apoE4 apoE4 mut1 apoE4 mut2 5 x 108 pfu adenovirus expressing human lipoprotein lipase
0.34268814.15576362.html.plaintext.txt	118	This treatment corrected hypertriglyceridemia hypercholesterolemia occurs mice treated apoE4 apoE4 mut2 alone Fig
0.34268814.15576362.html.plaintext.txt	119	Co infection apoE4 mut1 adenovirus expressing human lipoprotein lipase decreased slightly plasma cholesterol levels significant effect plasma triglyceride levels Fig
0.34268814.15576362.html.plaintext.txt	120	These findings indicated conditions overexpression apoE4 apoE4 mut2 endogenous lipoprotein lipase activity rate limiting lipolysis clearance VLDL
0.34268814.15576362.html.plaintext.txt	121	6 D E suggest apoE4 mut1 reduces plasma lipid levels apoE mice affect significantly hepatic VLDL triglyceride secretion negative effect activity lipoprotein lipase
0.34268814.15576362.html.plaintext.txt	122	View larger version 18K FIG
0.34268814.15576362.html.plaintext.txt	123	Plasma cholesterol triglyceride apoE levels apoE mice infected recombinant adenoviruses expressing either full length apoE4 apoE4 mut2 apoE4 mut1 alone mixture apoE4 apoE4 mut2 apoE4 mut1 human lipoprotein lipase determined 2 6 days postinfection
0.34268814.15576362.html.plaintext.txt	124	Mice infected indicated doses recombinant adenoviruses serum samples isolated analyzed plasma cholesterol A D G triglyceride B E H apoE levels C F I days 0 2 3 4 5 6 postinfection described Experimental Procedures
0.34268814.15576362.html.plaintext.txt	125	Effects Overexpression Lipoprotein Lipase Plasma ApoE Levels Mice Infected Adenoviruses Expressing ApoE4 ApoE4 mut2 ApoE4 mut1 The lipoprotein lipase treatment different effect plasma apoE levels mice treated apoE4 compared mice treated either apoE4 mut2 apoE4 mut1 Fig
0.34268814.15576362.html.plaintext.txt	126	Thus apoE levels reduced average value 125 mgdl mice infected apoE4 expressing adenovirus 2 6 days postinfection average value 10 mgdl mice infected apoE4 lipoprotein lipase expressing adenoviruses Fig
0.34268814.15576362.html.plaintext.txt	127	The lipoprotein lipase treatment reduced apoE levels average value 150 mgdl mice treated apoE4 mut2 alone average value 40 mgdl mice treated apoE4 mut2 lipoprotein lipase Fig
0.34268814.15576362.html.plaintext.txt	128	It interesting greatest levels apoE days 2 3 postinfection apoE4 mut2 expressing adenovirus associated mild hypertriglyceridemia Fig
0.34268814.15576362.html.plaintext.txt	129	In contrast apoE levels apoE4 mut1 remained high average value 170 mgdl without treatment LpL expressing adenovirus Fig
0.34268814.15576362.html.plaintext.txt	130	ApoE4 ApoE4 mut2 Not ApoE4 mut1 Displace ApoA I HDL Region Promote Formation Discoidal HDL Particles To establish ability apoE4 apoE4 mut1 apoE4 mut2 associate different lipoproteins 300 microl serum mice infected either recombinant adenoviruses expressing apoE4 apoE4 mut1 apoE4 mut2 fractionated density gradient ultracentrifugation
0.34268814.15576362.html.plaintext.txt	131	Fractions different densities isolated analyzed SDS PAGE followed either staining Coomassie Brilliant Blue stain Western blotting using anti apoE antibodies
0.34268814.15576362.html.plaintext.txt	132	It found full length apoE4 apoE4 mut1 apoE4 mut2 mutants associate lipoproteins float HDL region lesser extent particles LDL IDL VLDL regions
0.34268814.15576362.html.plaintext.txt	133	Remarkably however overexpression WT apoE4 apoE4 mut2 resulted displacement apoA I HDL whereas overexpression apoE4 mut1 displace apoA I HDL density region Fig
0.34268814.15576362.html.plaintext.txt	134	We estimated based SDS PAGE analysis apoA I levels mice infected apoE4 mut1 appear similar apoE mice 90 apoA I found HDL following density gradient ultracentrifugation Fig
0.34268814.15576362.html.plaintext.txt	135	View larger version 26K FIG
0.34268814.15576362.html.plaintext.txt	136	Distribution apoE different lipoprotein fractions following density gradient ultracentrifugation
0.34268814.15576362.html.plaintext.txt	137	Plasma obtained apoE mice expressing WT apoE4 apoE4 mut1 apoE4 mut2 mice infected control adenoviruses fractionated density gradient ultracentrifugation analyzed SDS PAGE described Experimental Procedures
0.34268814.15576362.html.plaintext.txt	138	A analysis plasma obtained mice infected control adenovirus AdGFP
0.34268814.15576362.html.plaintext.txt	139	B C analyses plasma obtained apoE mice infected WT apoE4
0.34268814.15576362.html.plaintext.txt	140	The concentrations plasma apoE E mice analyzed B C 60 233 mgdl respectively
0.34268814.15576362.html.plaintext.txt	141	The fraction numbers density fraction positions apoA I apoE shown panel
0.34268814.15576362.html.plaintext.txt	142	M indicates protein markers different Mrs
0.34268814.15576362.html.plaintext.txt	143	Note depending levels apoE expression apoA I AI either drastically reduced B totally displaced C HDL
0.34268814.15576362.html.plaintext.txt	144	D E analyses apoE mice infected apoE4 mut2 apoE4 mut1 respectively
0.34268814.15576362.html.plaintext.txt	145	Electron microscopy analysis fraction 6 8 containing apoA I showed overexpression WT apoE4 apoE4 mut2 associated formation discoidal HDL particles whereas expression apoE4 mut1 similar levels associated formation spherical HDL particles Fig
0.34268814.15576362.html.plaintext.txt	146	The differences biogenesis catabolism VLDL HDL apoE mice overexpress apoE4 apoE4 mut2 apoE4mut1 summarized Fig
0.34268814.15576362.html.plaintext.txt	147	View larger version 153K FIG
0.34268814.15576362.html.plaintext.txt	148	Electron microscopy analysis HDL fractions obtained plasma mice infected control adenovirus AdGFP A adenoviruses expressing WT apoE4 B apoE4 mut2 C apoE4 mut1 D
0.34268814.15576362.html.plaintext.txt	149	Pooled HDL fractions 6 8 shown Fig
0.34268814.15576362.html.plaintext.txt	150	7 A C D E used electron microscopy analyses
0.34268814.15576362.html.plaintext.txt	151	View larger version 26K FIG
0.34268814.15576362.html.plaintext.txt	152	Schematic representation summarizing differences biosynthesis catabolism VLDL HDL apoE mice overexpressing WT apoE4 A two mutants apoE4 mut2 B apoE4 mut1 C
0.34268814.15576362.html.plaintext.txt	153	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Previous vitro experiments shown residues 260 269 apoE important binding apoE lipids lipoproteins 11
0.34268814.15576362.html.plaintext.txt	154	Deletion residues diminished greatly ability truncated apoE solubilize multilamellar dimyristoyl L phosphatidylcholine vesicles
0.34268814.15576362.html.plaintext.txt	155	Further deletion residues 230 299 203 299 166 299 eliminated completely ability apoE solubilize multilamellar dimyristoyl L phosphatidylcholine vesicles 11
0.34268814.15576362.html.plaintext.txt	156	Thus possible carboxyl terminal 260 299 amino acids apoE may involved initial association apoE phospholipid process may required formation apoE containing lipoproteins
0.34268814.15576362.html.plaintext.txt	157	Whether association apoE phospholipids vivo requires participation ABCA1 remains established
0.34268814.15576362.html.plaintext.txt	158	Once apoE lipoprotein bound may taken LDL receptor
0.34268814.15576362.html.plaintext.txt	159	The apoE LDL receptor interactions control plasma cholesterol levels confer protection atherosclerosis 2
0.34268814.15576362.html.plaintext.txt	160	The contribution receptors LDL receptor clearance apoE containing lipoprotein remnants previously assessed studies apoE x LDLr double deficient mice 15
0.34268814.15576362.html.plaintext.txt	161	These studies shown neither full length apoE2 apoE4 truncated apoE2 202 apoE4 202 corrected high cholesterol profiles apoE x LDLr double deficient mice 15
0.34268814.15576362.html.plaintext.txt	162	These data observations full length apoE2 suggest strongly apoE mediated lipoprotein clearance mice carried mainly LDL receptor 15
0.34268814.15576362.html.plaintext.txt	163	In absence receptor lipoprotein receptor related protein apoE recognizing lipoprotein receptors heparan sulfate proteoglycans 22 23 sufficient clear lipoprotein remnants accumulate plasma double deficient mice 15
0.34268814.15576362.html.plaintext.txt	164	In addition role apoE cholesterol homeostasis circulation plasma apoE levels correlate plasma triglyceride levels humans 24
0.34268814.15576362.html.plaintext.txt	165	Hypertriglyceridemia also induced mice overexpression human apoE 12 15 25
0.34268814.15576362.html.plaintext.txt	166	However recent studies shown hypertriglyceridemia occur mice infected adenoviruses expressing truncated apoE forms lacking 260 299 carboxyl terminal domain 12 16
0.34268814.15576362.html.plaintext.txt	167	This set experiments also showed truncated apoE forms co expressed full length apoE forms dominant effect normalized cholesterol levels apoE mice 15
0.34268814.15576362.html.plaintext.txt	168	These findings suggested full length apoE bound triglyceride rich VLDL particles receptor binding domain may masked thus preventing direct apoE mediated clearance VLDL particles prior lipolysis
0.34268814.15576362.html.plaintext.txt	169	In contrast truncated apoE bound triglyceride rich VLDL particles receptor binding domain may exposed may allow direct clearance VLDL particle 15
0.34268814.15576362.html.plaintext.txt	170	The current study designed map residues carboxyl terminal region apoE responsible hypertriglyceridemia
0.34268814.15576362.html.plaintext.txt	171	The rationale identification residues may lead generation recombinant apoE form improved biological functions
0.34268814.15576362.html.plaintext.txt	172	We focused two regions apoE residues 260 299 contain hydrophobic amino acids
0.34268814.15576362.html.plaintext.txt	173	The first region includes amino acids Leu 261 Trp 264 Phe 265 Leu 268 Val 269 second region includes amino acids Trp 276 Leu 279 Val 280 Val 283
0.34268814.15576362.html.plaintext.txt	174	A BLAST search NCBI data base www
0.34268814.15576362.html.plaintext.txt	175	gov showed regions highly conserved among mammalian species
0.34268814.15576362.html.plaintext.txt	176	An vivo adenovirus mediated gene transfer two apoE mutants established unequivocally hydrophobic residues apoE amino acids 261 269 account large extent induction hypertriglyceridemia
0.34268814.15576362.html.plaintext.txt	177	Hypertriglyceridemia occur mice infected adenovirus expressing apoE4 mut1 residues changed alanines
0.34268814.15576362.html.plaintext.txt	178	In contrast infection mice adenovirus expressing apoE4 mut2 hydrophobic residues amino acids 276 283 substituted alanines resulted milder hypertriglyceridemia compared mice infected apoE4 expressing adenovirus
0.34268814.15576362.html.plaintext.txt	179	It appears hydrophobic residues within 261 269 well 276 283 regions affect secretion VLDL triglycerides
0.34268814.15576362.html.plaintext.txt	180	Mutations residues alanines reduced rate hepatic VLDL triglyceride secretion 27 caused wild type apoE4
0.34268814.15576362.html.plaintext.txt	181	Our data also showed increase levels plasma lipoprotein lipase co infection recombinant adenoviruses expressing human lipoprotein lipase corrected apoE induced dyslipidemia apoE mice overexpress full length apoE4
0.34268814.15576362.html.plaintext.txt	182	This finding suggests condition apoE overexpression activity lipoprotein lipase becomes rate limiting clearance hypertriglyceridemic VLDL
0.34268814.15576362.html.plaintext.txt	183	Substantial less severe hypertriglyceridemia also observed overexpression apoE4 mut2 also corrected co infection lipoprotein lipase expressing adenovirus
0.34268814.15576362.html.plaintext.txt	184	The difference severity hypertriglyceridemia WT apoE4 apoE4 mut2 may related increased VLDL triglyceride secretion caused WT apoE4
0.34268814.15576362.html.plaintext.txt	185	An important clue nature hypertriglyceridemic lipoprotein particles accumulate plasma mice provided clearance apoE mice co infected wild type mutant forms apoE LpL expressing adenoviruses
0.34268814.15576362.html.plaintext.txt	186	ApoE cleared mice treated apoE4 LpL partially cleared mice treated apoE4 mut2 LpL unaffected mice treated apoE4 mut1 LpL
0.34268814.15576362.html.plaintext.txt	187	The average apoE levels without treatment lipoprotein lipase 2 6 days postinfection changed 125 mgdl 10 mgdl apoE4 150 mgdl 40 mgdl apoE4 mut2 remained 170 mgdl apoE4 mut1
0.34268814.15576362.html.plaintext.txt	188	The findings indicate wild type apoE4 resides triglyceride rich lipoprotein particles following hydrolysis triglycerides particles LpL apoE4 recognized cleared component remnant particles LDL receptor
0.34268814.15576362.html.plaintext.txt	189	It appears majority mutant apoE4 mut1 may reside another population triglyceride poor particles cleared LDL receptor
0.34268814.15576362.html.plaintext.txt	190	Finally apoE4 mut2 may partitioned triglyceride rich particles processed LpL cleared LDL receptor triglyceride poor particles cleared LDL receptor
0.34268814.15576362.html.plaintext.txt	191	It possible mutations introduced apoE4 mut1 lesser extent apoE4 mut2 may promoted formation triglyceride poor apoE containing lipoprotein particles accumulate HDL region mice
0.34268814.15576362.html.plaintext.txt	192	A significant finding study apoE4 apoE4 mut2 W276A L279A V280A V283A displaced apoA I HDL promoted formation discoidal HDL
0.34268814.15576362.html.plaintext.txt	193	In contrast apoE mut1 L261A W264A F265A L268A V269A displace apoA I HDL region affect formation spherical HDL particles
0.34268814.15576362.html.plaintext.txt	194	The findings suggest WT apoE4 apoE4 mut2 overexpressed may influence formation stability HDL
0.34268814.15576362.html.plaintext.txt	195	The effect apoE mutations biosynthesis catabolism VLDL HDL summarized Fig
0.34268814.15576362.html.plaintext.txt	196	At present time clear whether apoE overexpression interferes biogenesis HDL pathway involves ABCA1 transporter whether affects stability displacing apoA I surface HDL
0.34268814.15576362.html.plaintext.txt	197	Both processes expected reduce levels HDL
0.34268814.15576362.html.plaintext.txt	198	The undesirable property WT apoE reduce plasma HDL levels overcome recombinant apoE4 mut1 hydrophobic residues 261 269 region mutated alanines
0.34268814.15576362.html.plaintext.txt	199	The ability recombinant apoE forms apoE4 mut1 clear cholesterol without inducing hypertriglyceridemia interfering formation spherical HDL makes attractive therapeutic agents correct remnant removal disorders
0.34268814.15576362.html.plaintext.txt	200	Therapeutic forms apoE may involve pure recombinant protein associated liposomes potential gene therapy future
0.34268814.15576362.html.plaintext.txt	201	FOOTNOTES This work supported Grant HL68216 National Institutes Health Kos Pharmaceuticals Grant LST
0.34268814.15576362.html.plaintext.txt	202	Grant MCIF 2000 02051 European Union Fifth Framework Program K
0.34268814.15576362.html.plaintext.txt	203	The costs publication article defrayed part payment page charges
0.34268814.15576362.html.plaintext.txt	204	This article must therefore hereby marked advertisement accordance 18 U
0.34268814.15576362.html.plaintext.txt	205	Section 1734 solely indicate fact
0.34268814.15576362.html.plaintext.txt	206	To correspondence addressed Section Molecular Genetics Whitaker Cardiovascular Institute Dept
0.34268814.15576362.html.plaintext.txt	207	Medicine Boston University School Medicine 700 Albany St
0.34268814.15576362.html.plaintext.txt	208	W 509 Boston Massachusetts 02118
0.34268814.15576362.html.plaintext.txt	209	617 638 5085 Fax 617 638 5141 E mail vzannisatbu
0.34268814.15576362.html.plaintext.txt	210	1 The abbreviations used ApoE apolipoprotein E apoA I apolipoprotein A I Ad adenovirus ELISA enzyme linked immunosorbent assay FPLC fast pressure liquid chromatography GFP green fluorescence protein HDL high density lipoprotein VLDL low density lipoprotein LpL lipoprotein lipase pfu plaque forming unit WT wild type IDL intermediate density lipoprotein apoE apoE deficient LDLr LDL receptor deficient
0.34268814.15576362.html.plaintext.txt	211	Zannis unpublished observations
0.34268814.15576362.html.plaintext.txt	212	ACKNOWLEDGMENTS We thank Anne Plunkett manuscript preparation Adelina Shkodrani Gayle Forbes Andre van der Zee technical assistance course experiments
0.34268814.15576362.html.plaintext.txt	213	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Zannis V
0.34268814.15576362.html.plaintext.txt	214	33 11 24Medline Order article via Infotrieve Plump A
0.34268814.15576362.html.plaintext.txt	215	1992 Cell 71 343 353Medline Order article via Infotrieve Schaefer E
0.34268814.15576362.html.plaintext.txt	216	78 1206 1219Medline Order article via Infotrieve Reddick R
0.34268814.15576362.html.plaintext.txt	217	14 141 147Abstract Huang Y
0.34268814.15576362.html.plaintext.txt	218	91 1834 1838AbstractFree Full Text Huang Y
0.34268814.15576362.html.plaintext.txt	219	17 2010 2019AbstractFree Full Text Linton M
0.34268814.15576362.html.plaintext.txt	220	1995 Science 267 1034 1037Medline Order article via Infotrieve Shimano H
0.34268814.15576362.html.plaintext.txt	221	95 469 476Medline Order article via Infotrieve Myers R
0.34268814.15576362.html.plaintext.txt	222	1996 Neurology 46 673 677Abstract Zannis V
0.34268814.15576362.html.plaintext.txt	223	1998 NATO ASI Series Life Sciences
0.34268814.15576362.html.plaintext.txt	224	179 209 Plenum Press New York Li X
0.34268814.15576362.html.plaintext.txt	225	2003 Biochemistry 42 10406 10417CrossRefMedline Order article via Infotrieve Kypreos K
0.34268814.15576362.html.plaintext.txt	226	15 1598 1600AbstractFree Full Text Kypreos K
0.34268814.15576362.html.plaintext.txt	227	2001 Biochemistry 40 6027 6035CrossRefMedline Order article via Infotrieve Kypreos K
0.34268814.15576362.html.plaintext.txt	228	276 19778 19786AbstractFree Full Text Kypreos K
0.34268814.15576362.html.plaintext.txt	229	2003 Biochemistry 42 9841 9853CrossRefMedline Order article via Infotrieve Zannis V
0.34268814.15576362.html.plaintext.txt	230	15 151 166CrossRefMedline Order article via Infotrieve Gerritsen G
0.34268814.15576362.html.plaintext.txt	231	44 408 414AbstractFree Full Text He T
0.34268814.15576362.html.plaintext.txt	232	95 2509 2514AbstractFree Full Text Fallaux F
0.34268814.15576362.html.plaintext.txt	233	7 215 222Medline Order article via Infotrieve Aalto Setala K
0.34268814.15576362.html.plaintext.txt	234	90 1889 1900Medline Order article via Infotrieve Nolte R
0.34268814.15576362.html.plaintext.txt	235	63 1221 1239Abstract Saito H
0.34268814.15576362.html.plaintext.txt	236	278 14782 14787AbstractFree Full Text Ji Z
0.34268814.15576362.html.plaintext.txt	237	269 2764 2772AbstractFree Full Text Havel R
0.34268814.15576362.html.plaintext.txt	238	66 1351 1362Medline Order article via Infotrieve Huang Y
0.34268814.15576362.html.plaintext.txt	239	273 26388 26393AbstractFree Full Text
0.30761042.15010453.html.plaintext.txt	0	Defective Endoplasmic Reticulum resident Membrane Protein CLN6 Affects Lysosomal Degradation Endocytosed Arylsulfatase A Claudia Heine Bettina Koch Stephan Storch Alfried Kohlschutter David N
0.30761042.15010453.html.plaintext.txt	1	From Department Biochemistry Childrens Hospital University Hamburg D 20246 Hamburg Germany Animal Food Science Division Lincoln University Canterbury 8150 New Zealand
0.30761042.15010453.html.plaintext.txt	2	Received publication January 20 2004 revised form March 8 2004
0.30761042.15010453.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Variant late infantile neuronal ceroid lipofuscinosis lysosomal storage disorder characterized progressive mental deterioration blindness caused mutations polytopic membrane protein CLN6 unknown intracellular localization function
0.30761042.15010453.html.plaintext.txt	4	In study transient transfection BHK21 cells CLN6 cDNA immunoblot analysis using peptide specific CLN6 antibodies demonstrated expression 27 kDa protein undergo proteolytic processing
0.30761042.15010453.html.plaintext.txt	5	Cross linking experiments revealed presence CLN6 dimers
0.30761042.15010453.html.plaintext.txt	6	Using double immunofluorescence microscopy epitope tagged CLN6 shown retained endoplasmic reticulum ER colocalization cis Golgi lysosomal markers
0.30761042.15010453.html.plaintext.txt	7	The translocation ER proper folding confirmed N linked glycosylation mutant CLN6 polypeptide
0.30761042.15010453.html.plaintext.txt	8	Pulse chase labeling fibroblasts CLN6 patients sheep OCL6 mouse nclf models disease followed immunoprecipitation cathepsin D indicated neither synthesis sorting proteolytic processing lysosomal enzyme affected CLN6 defective cells
0.30761042.15010453.html.plaintext.txt	9	However degradation endocytosed index protein arylsulfatase A strongly reduced mutant CLN6 cell lines compared controls
0.30761042.15010453.html.plaintext.txt	10	These data suggest defects ER resident CLN6 protein lead lysosomal dysfunctions may result lysosomal accumulation storage material
0.30761042.15010453.html.plaintext.txt	11	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Neuronal ceroid lipofuscinoses NCLs1 also collectively called Batten disease group autosomal recessively inherited neurodegenerative diseases affect children adults
0.30761042.15010453.html.plaintext.txt	12	The clinical features include loss vision seizures mental motor deterioration
0.30761042.15010453.html.plaintext.txt	13	Depending affected gene clinical signs become visible various developmental stages 1
0.30761042.15010453.html.plaintext.txt	14	Currently eight forms human NCLs CLN1 8 differentiated six underlying genes identified 2
0.30761042.15010453.html.plaintext.txt	15	CLN1 CLN2 encode soluble lysosomal enzymes palmitoyl protein thioesterase 1 tripeptidylpeptidase 1 respectively 3 5
0.30761042.15010453.html.plaintext.txt	16	CLN3 CLN5 CLN6 CLN8 represent transmembrane proteins still unknown function 6 10
0.30761042.15010453.html.plaintext.txt	17	Although nature CLN genes differs defects lead massive storage autofluorescent material lysosomes identified subunit c mitochondrial ATP synthase 2 11 12
0.30761042.15010453.html.plaintext.txt	18	Newly synthesized palmitoyl protein thioesterase 1 tripeptidylpeptidase 1 transported lysosome Man 6 P dependent manner 3 5
0.30761042.15010453.html.plaintext.txt	19	Binding Man 6 P specific receptors MPR46 MPR300 allows segregation secretory pathway transport trans Golgi network endosomal compartment
0.30761042.15010453.html.plaintext.txt	20	Because low pH receptor ligand complexes dissociate enzymes delivered lysosome
0.30761042.15010453.html.plaintext.txt	21	Soluble enzymes escape binding MPR trans Golgi network secreted partially endocytosed binding MPR localized cell surface transported lysosome 13
0.30761042.15010453.html.plaintext.txt	22	CLN3 CLN5 CLN8 localized lysosomes endoplasmic reticulum ERER Golgi intermediate compartment respectively 14 16
0.30761042.15010453.html.plaintext.txt	23	The subcellular localization CLN6 known
0.30761042.15010453.html.plaintext.txt	24	The transport lysosomal membrane proteins requires tyrosine dileucine based sorting signals 17
0.30761042.15010453.html.plaintext.txt	25	Recently lysosomal targeting motifs identified CLN3 protein 18 whereas localization CLN8 ER mediated KKXX ER retrieval signal 16
0.30761042.15010453.html.plaintext.txt	26	The CLN6 gene encodes highly conserved 311 amino acid protein six seven predicted membrane spanning domains
0.30761042.15010453.html.plaintext.txt	27	The deduced amino acid sequence contains putative N glycosylation sites classical lysosomal sorting signals
0.30761042.15010453.html.plaintext.txt	28	Furthermore sequence homologies proteins described 9 10
0.30761042.15010453.html.plaintext.txt	29	Various mutations CLN6 gene identified leading variant late infantile form NCL 9 10 19 21
0.30761042.15010453.html.plaintext.txt	30	Naturally occurring NCLs South Hampshire Merino sheep OCL6 nclf mice localized CLN6 22 24
0.30761042.15010453.html.plaintext.txt	31	The severe progressive neurodegeneration cerebral cortex accompanied astrocytosis elevated expression radical scavenger protein Mn SOD 24 25
0.30761042.15010453.html.plaintext.txt	32	Furthermore differences fatty acid profiles brain phosphatidylethanolamine observed OCL6 affected sheep 26
0.30761042.15010453.html.plaintext.txt	33	In study expressed human CLN6 BHK21 cells investigate subcellular localization
0.30761042.15010453.html.plaintext.txt	34	Furthermore transport lysosomal enzymes via biosynthetic endocytic pathway examined fibroblasts CLN6 patients OCL6 nclf mice
0.30761042.15010453.html.plaintext.txt	35	The data indicate CLN6 ER resident protein
0.30761042.15010453.html.plaintext.txt	36	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Materials Sodium 125I 15 Cimg iodine 35Smethionine 1000 Cimmol RainbowTM colored protein molecular mass marker obtained Amersham Biosciences
0.30761042.15010453.html.plaintext.txt	37	Opti MEM LipofectAMINETM 2000 antibiotics penicillinstreptomycin purchased Invitrogen
0.30761042.15010453.html.plaintext.txt	38	Protease inhibitor mixture P 2714 transferrin protein A agarose 2 mercaptoethanesulfonic acid MESNA Man 6 P obtained Sigma
0.30761042.15010453.html.plaintext.txt	39	Bradford reagent Trans Blot nitrocellulose membrane 0
0.30761042.15010453.html.plaintext.txt	40	2 microm purchased Bio Rad bissulfosuccinimidylsuberate BS3 disuccinimidylsuberate DSS sulfosuccinimidyl 2 biotinamidoethyl 13 dithio propionate IODO GEN obtained Pierce
0.30761042.15010453.html.plaintext.txt	41	Restriction endonucleases T4 DNA ligase molecular biology reagents Invitrogen New England Biolabs Qiagen Stratagene La Jolla CA
0.30761042.15010453.html.plaintext.txt	42	Recombinant human arylsulfatase A ASA purified ASA overexpressing mouse embryonic fibroblasts deficient MPRs 27 kindly provided Dr
0.30761042.15010453.html.plaintext.txt	43	Dierks University Gottingen Gottingen Germany
0.30761042.15010453.html.plaintext.txt	44	CLN6 Cloning Full length CLN6 cDNA amplified using forward primer 5 CGGGATCCGCGATGGAGGCGACGCGGAGG 3 reverse primer 5 CCCAAGCTTGGGGTGCCGACTGCTGACGTG 3 IMAGE clone IMAG p998E179643 template vector pCMVSPORT6
0.30761042.15010453.html.plaintext.txt	45	The PCR product subcloned frame C terminal Myc His tag vector pcDNA3
0.30761042.15010453.html.plaintext.txt	46	1Myc His A Invitrogen BamHIHindIII restriction sites
0.30761042.15010453.html.plaintext.txt	47	The untagged CLN6 wild type construct amplified reverse primer 5 CCCAAGCTTGGGTCAGTGCCGACTGCTGAC 3
0.30761042.15010453.html.plaintext.txt	48	For expression glutathione S transferase CLN6 fusion protein cDNAs coding aa 137 181 amplified primers 137 181for 5 GGAATTCCTGCTCTTCAGTGGCTAC 3 137 181rev 5 GGAATTCCTCACCACATGCAGTGACCCAG 3 subcloned EcoRI restriction sites vector pGEX 4T 1 Amersham Biosciences
0.30761042.15010453.html.plaintext.txt	49	Ile153Ser introduced PCR using Quick Change site directed mutagenesis kit Stratagene primers Ile153Serfor 5 GAGAACCCCAGCATCAAGAAT 3 Ile153Serrev 5 ATTCTTGATGCTGGGGTTCTC 3
0.30761042.15010453.html.plaintext.txt	50	All clones sequenced rule PCR introduced mutations verify reading frames fusion proteins
0.30761042.15010453.html.plaintext.txt	51	Antibodies Polyclonal antibodies mouse CtsD human CtsD purified mouse liver human placenta human MPR300 raised rabbits 28 30
0.30761042.15010453.html.plaintext.txt	52	The polyclonal anti Myc antibody obtained Santa Cruz Biotechnology Ors Santa Cruz CA
0.30761042.15010453.html.plaintext.txt	53	The monoclonal anti Myc antibody gift J
0.30761042.15010453.html.plaintext.txt	54	Blanz ZMNH Hamburg Germany produced hybridoma cell lines purchased LGC Promochem Teddington United Kingdom monoclonal antibody protein disulfide isomerase PDI purchased Stressgene Biotechnologies Corp
0.30761042.15010453.html.plaintext.txt	55	Victoria British Columbia Canada
0.30761042.15010453.html.plaintext.txt	56	The polyclonal anti CLN6 antibody raised rabbits peptide sequences 155 168 281 293 Eurogentech Seraing Belgium purified sequential affinity chromatography glutathione S transferase glutathione S transferase CLN6 137 181 fusion protein matrix
0.30761042.15010453.html.plaintext.txt	57	Anti mouse IgG Cy3 anti rabbit IgG fluorescein isothiocyanate conjugates obtained Sigma peroxidase conjugated goat anti rabbit IgG Jackson ImmunoResearch Laboratories West Grove PA
0.30761042.15010453.html.plaintext.txt	58	Isolation Culture Mouse Fibroblasts CLN6 defective mice B6
0.30761042.15010453.html.plaintext.txt	59	Cg nclf obtained The Jackson Laboratory Bar Harbor ME
0.30761042.15010453.html.plaintext.txt	60	Age matched C57BL6 mice served controls
0.30761042.15010453.html.plaintext.txt	61	The animals maintained killed according institutional guidelines animal facilities University Hospital Hamburg Eppendorf
0.30761042.15010453.html.plaintext.txt	62	Fibroblasts prepared lung biopsies 3 month old mice described previously 31
0.30761042.15010453.html.plaintext.txt	63	Cell Cultures Cell Transfection Skin fibroblasts affected South Hampshire age matched control sheep well CLN6 patients described previously 25
0.30761042.15010453.html.plaintext.txt	64	The cells cultured Dulbeccos modified Eagles medium Invitrogen containing 10 fetal calf serum PAA Laboratories Linz Austria 1 penicillinstreptomycin humidified atmosphere containing 5 CO2 95 O2 37 degrees C
0.30761042.15010453.html.plaintext.txt	65	BHK21 cells cultured conditions DMEMfetal calf serum transiently transfected described previously 32
0.30761042.15010453.html.plaintext.txt	66	Control cells transfected pcDNA3
0.30761042.15010453.html.plaintext.txt	67	Metabolic Labelings Immunoprecipitation Cells labeled 35Smethionine 150 microCiml 1 h followed chase indicated time
0.30761042.15010453.html.plaintext.txt	68	CtsD immunoprecipitated cell extracts media described previously 33 analyzed SDS PAGE fluorography
0.30761042.15010453.html.plaintext.txt	69	Cell Surface Biotinylation MPR300 Immunoprecipitation Cell surface proteins biotinylated sulfo NHS SS biotin 4 degrees C described previously 34
0.30761042.15010453.html.plaintext.txt	70	After washing cells incubated presence absence 50 mM MESNA 50 mM Tris buffer pH 8
0.30761042.15010453.html.plaintext.txt	71	6 containing 100 mM NaCl 1 mM MgCl2 0
0.30761042.15010453.html.plaintext.txt	72	1 mM CaCl2 followed immunoprecipitation MPR300 cell extracts described previously 29
0.30761042.15010453.html.plaintext.txt	73	Ligand Internalization Internalization 125IASA examined described previously 33
0.30761042.15010453.html.plaintext.txt	74	The internalized 125Itransferrin determined 3 h incubation 37 degrees C
0.30761042.15010453.html.plaintext.txt	75	Cells washed cell surface bound 125Itransferrin displaced acidic wash 35
0.30761042.15010453.html.plaintext.txt	76	Cells solubilized analyzed SDS PAGE autoradiography
0.30761042.15010453.html.plaintext.txt	77	SDS PAGE Western Blotting Solubilized proteins transfected non transfected cells separated SDS PAGE transferred nitrocellulose membrane examined CLN6 Myc immunoreactivity described previously 25
0.30761042.15010453.html.plaintext.txt	78	Cross link Experiments CLN6 overexpressing BHK21 cells permeabilized 0
0.30761042.15010453.html.plaintext.txt	79	25 saponin 50 mM MES buffer pH 6
0.30761042.15010453.html.plaintext.txt	80	5 containing 150 mM NaCl 0
0.30761042.15010453.html.plaintext.txt	81	5 bovine serum albumin 40 min 4 degrees C cross linked BS3 DSS indicated concentrations
0.30761042.15010453.html.plaintext.txt	82	The proteins analyzed Western blotting 36 37
0.30761042.15010453.html.plaintext.txt	83	Other Methods Protein concentrations determined using Bradford protein assay bovine serum albumin standard
0.30761042.15010453.html.plaintext.txt	84	5 1 microg iodinated IODO GEN described previously 38
0.30761042.15010453.html.plaintext.txt	85	For deglycosylation experiments total BHK21 extracts solubilized incubated presence absence 1 milliunit peptide N glycosidase F PNGase F 5 milliunits endoglycosidase H endo H Roche Applied Science according manufacturers protocol
0.30761042.15010453.html.plaintext.txt	86	The samples separated SDS PAGE followed Western blot analysis
0.30761042.15010453.html.plaintext.txt	87	Double immunofluorescence microscopy performed transfected BHK21 cells described previously 25 using anti Myc 150 anti PDI 1300 anti mouse CtsD antibodies 150 indicated
0.30761042.15010453.html.plaintext.txt	88	Hexosaminidase ASA activities determined described previously 39 40
0.30761042.15010453.html.plaintext.txt	89	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Expression Wild Type Myc tagged CLN6 Wild type C terminally Myc tagged CLN6 transiently expressed BHK21 cells
0.30761042.15010453.html.plaintext.txt	90	1 vector transfected BHK21 cells used controls
0.30761042.15010453.html.plaintext.txt	91	Western blot analysis using peptide specific anti CLN6 antibody revealed single prominent immunoreactive band 27 kDa cell extracts wild type CLN6 transfected cells Fig
0.30761042.15010453.html.plaintext.txt	92	No specific cross reacting material found cells transfected vector
0.30761042.15010453.html.plaintext.txt	93	An immunoreactive band 30 kDa observed cells expressing CLN6Myc construct
0.30761042.15010453.html.plaintext.txt	94	After stripping nitrocellulose membrane reprobing anti Myc antibodies 30 kDa Myc tagged CLN6 detectable
0.30761042.15010453.html.plaintext.txt	95	View larger version 23K FIG
0.30761042.15010453.html.plaintext.txt	96	Overexpression CLN6 BHK21 cells
0.30761042.15010453.html.plaintext.txt	97	A cell extracts vector transfected wild type CLN6 wild type CLN6MycHis tag expressing BHK21 cells separated SDS PAGE transferred nitrocellulose membrane analyzed peptide specific CLN6 antibody
0.30761042.15010453.html.plaintext.txt	98	B Western blot analysis carried nitrocellulose using antibodies Myc tag
0.30761042.15010453.html.plaintext.txt	99	The positions molecular mass markers kDa indicated
0.30761042.15010453.html.plaintext.txt	100	CLN6 Is ER resident Protein The deduced amino acid sequence predicted protein structure CLN6 revealed neither potential N glycosylation site sequences NXST X amino acid classical lysosomal sorting motifs
0.30761042.15010453.html.plaintext.txt	101	On hand N terminal RRR sequence amino acids residues 5 7 detected ER type II membrane protein glucosidase I 41 whereas N terminal segment CLN6 encoded exon 1 amino acids residues 1 28 suggested function putative targeting signal mitochondria 10
0.30761042.15010453.html.plaintext.txt	102	To investigate subcellular localization N glycosylation site introduced predicted second luminal loop
0.30761042.15010453.html.plaintext.txt	103	Ile residue 153 substituted Ser p
0.30761042.15010453.html.plaintext.txt	104	Ile153Ser site directed mutagenesis CLN6 cDNA changing sequence Asn X Ile Asn X Ser
0.30761042.15010453.html.plaintext.txt	105	Ile153Ser expressed BHK21 cells Western blot analysis revealed additional band 33 kDa disappeared deglycosylation PNGase F endo H Fig
0.30761042.15010453.html.plaintext.txt	106	These data demonstrate nascent CLN6 polypeptide translocated lumen ER became accessible glycosylation machinery
0.30761042.15010453.html.plaintext.txt	107	This confirmed double immunofluorescence microscopy
0.30761042.15010453.html.plaintext.txt	108	The CLN6Myc protein colocalized ER marker protein PDI lysosomal marker enzyme cathepsin D Fig
0.30761042.15010453.html.plaintext.txt	109	View larger version 34K FIG
0.30761042.15010453.html.plaintext.txt	110	A extracts BHK21 cells overexpressing either wild type mutant CLN6 p
0.30761042.15010453.html.plaintext.txt	111	Ile153Ser vector transfected cells incubated presence absence PNGase F endo H 16 h 37 degrees C
0.30761042.15010453.html.plaintext.txt	112	The samples separated SDS PAGE analyzed Western blot using anti Myc antibodies
0.30761042.15010453.html.plaintext.txt	113	The positions molecular mass marker proteins kDa indicated
0.30761042.15010453.html.plaintext.txt	114	B BHK21 cells transfected CLN6 wild type fixed permeabilized 24 h transfection
0.30761042.15010453.html.plaintext.txt	115	The cells double stained Myc green PDI b red Myc d red CtsD e green
0.30761042.15010453.html.plaintext.txt	116	The red green channels merged adjustment fluorescence signals similar levels c f
0.30761042.15010453.html.plaintext.txt	117	CLN6 Forms Dimers The capability CLN6 form oligomeric structures membranes examined cross linkage experiments
0.30761042.15010453.html.plaintext.txt	118	Semi intact BHK21 cells overexpressing CLN6 cross linked non cleavable reagents BS3 DSS
0.30761042.15010453.html.plaintext.txt	119	Immunoblot analysis showed amounts 60 kDa immunoreactive band increased cross linkage concentration dependent manner whereas intensity 30 kDa CLN6 band decreased Fig
0.30761042.15010453.html.plaintext.txt	120	These results indicate CLN6 partially exists dimer vivo
0.30761042.15010453.html.plaintext.txt	121	View larger version 42K FIG
0.30761042.15010453.html.plaintext.txt	122	Chemical cross linkage overexpressed CLN6 DSS BS3
0.30761042.15010453.html.plaintext.txt	123	CLN6Myc fusion protein overexpressing BHK21 cells permeabilized treated indicated concentrations cross linker BS3 DSS
0.30761042.15010453.html.plaintext.txt	124	The cell extracts separated SDS PAGE followed Western blot analysis using anti Myc antibodies
0.30761042.15010453.html.plaintext.txt	125	Defective CLN6 Mice Do Not Impair Sorting Processing Newly Synthesized Cathepsin D To examine whether CLN6 critical transport processing Man 6 P containing lysosomal proteins secretion proteolytic modifications newly synthesized CtsD determined fibroblasts CLN6 patients OCL6 sheep nclf mice corresponding control cells
0.30761042.15010453.html.plaintext.txt	126	In human fibroblasts CtsD synthesized 53 kDa precursor form 28
0.30761042.15010453.html.plaintext.txt	127	A small fraction CtsD precursor study BORDER03 total secreted Fig
0.30761042.15010453.html.plaintext.txt	128	The majority precursor protein binds MPRs trans Golgi network transported prelysosomalendosomal compartments processed 47 kDa intermediate form within 2 h synthesis 42
0.30761042.15010453.html.plaintext.txt	129	The intermediate CtsD forms delivered lysosomes processed mature 31 14 kDa forms within 6 h synthesis Fig
0.30761042.15010453.html.plaintext.txt	130	When South Hampshire sheep fibroblasts labeled 1 h 35Smethionine 45 kDa polypeptide immunoprecipitated anti human CtsD antibody Fig
0.30761042.15010453.html.plaintext.txt	131	After chase period 6 h 13 16 total CtsD recovered 30 kDa mature form cells 48 kDa form media respectively Fig
0.30761042.15010453.html.plaintext.txt	132	After metabolic labeling primary mouse fibroblasts followed immunoprecipitation anti mouse CtsD antibody predominant 45 kDa polypeptide observed 32
0.30761042.15010453.html.plaintext.txt	133	Small amounts 9 total synthesized CtsD detected 51 48 kDa band media Fig
0.30761042.15010453.html.plaintext.txt	134	4C suggesting variable extent glycosylation
0.30761042.15010453.html.plaintext.txt	135	These results show sorting processing newly synthesized CtsD affected fibroblasts CLN6 patient OCL6 sheep nclf mice
0.30761042.15010453.html.plaintext.txt	136	Additionally specific activities two lysosomal enzymes hexosaminidase ASA comparable control human sheep mouse CLN6 defective cells
0.30761042.15010453.html.plaintext.txt	137	View larger version 31K FIG
0.30761042.15010453.html.plaintext.txt	138	Immunoprecipitation CtsD affected fibroblasts
0.30761042.15010453.html.plaintext.txt	139	Fibroblasts control Co CLN6 patients A control OCL6 sheep fibroblasts B control nclf mouse fibroblasts C metabolically labeled 1 h 35Smethionine
0.30761042.15010453.html.plaintext.txt	140	CtsD immunoprecipitated cell extracts medium
0.30761042.15010453.html.plaintext.txt	141	The samples separated SDS PAGE visualized fluorography
0.30761042.15010453.html.plaintext.txt	142	The positions molecular mass markers kDa precursor p intermediate mature m CtsD forms indicated
0.30761042.15010453.html.plaintext.txt	143	Accumulation Endocytosed Arylsulfatase A CLN6 defective Fibroblasts To examine whether defective CLN6 affect endocytic pathway lysosome fibroblasts CLN6 patients OCL6 sheep nclf mice respective controls incubated 125IASA 16 h
0.30761042.15010453.html.plaintext.txt	144	Because MPR46 function endocytosis lysosomal enzymes 43 uptake ASA mediated MPR300
0.30761042.15010453.html.plaintext.txt	145	The ASA uptake specific shown complete inhibition presence excess Man 6 P Fig
0.30761042.15010453.html.plaintext.txt	146	The densitometric evaluation autoradiographs several experiments n 3 4 showed average amount 125IASA detectable human CLN6 OCL6 nclf cells 2 51 2 fold higher respectively control cells
0.30761042.15010453.html.plaintext.txt	147	This effect specific MPR300 mediated uptake amounts internalized 125Itransferrin comparable control CLN6 defective cells Fig
0.30761042.15010453.html.plaintext.txt	148	View larger version 41K FIG
0.30761042.15010453.html.plaintext.txt	149	Man 6 P M6P dependent uptake 125I labeled proteins
0.30761042.15010453.html.plaintext.txt	150	A fibroblasts affected human CLN6 mouse nclf sheep OCL6 fibroblasts corresponding controls Co incubated 125IASA 200000 cpmplate 16 h 37 degrees C presence absence 10 mM Man 6 P
0.30761042.15010453.html.plaintext.txt	151	After removal medium displacement cell surface bound material Man 6 P cells solubilized separated SDS PAGE
0.30761042.15010453.html.plaintext.txt	152	The internalized 125IASA visualized autoradiography
0.30761042.15010453.html.plaintext.txt	153	Densitometric evaluation represented autoradiograph revealed 4
0.30761042.15010453.html.plaintext.txt	154	6 mouse 27 ovine fold increased amounts 125IASA CLN6 defective cells
0.30761042.15010453.html.plaintext.txt	155	B CLN6 defective cells controls incubated 125I labeled transferrin 3 h 37 degrees C presence absence excess unlabeled transferrin
0.30761042.15010453.html.plaintext.txt	156	Cell surface bound material removed acidic wash followed solubilization cells SDS PAGE autoradiography
0.30761042.15010453.html.plaintext.txt	157	The increased intracellular amounts 125IASA CLN6 defective cells could result increased rate endocytosis 125IASA caused elevated concentrations MPR300 cell surface rapid MPR300 kinetics cycling decreased degradation endocytosed 125IASA
0.30761042.15010453.html.plaintext.txt	158	The concentration MPR300 cell surface control OCL6 sheep fibroblasts shown
0.30761042.15010453.html.plaintext.txt	159	This determined control affected sheep fibroblasts showing significant difference intracellular 125IASA content endocytosis cell surface biotinylation followed immunoprecipitation MPR300 Western blot analysis Fig
0.30761042.15010453.html.plaintext.txt	160	Even cells amounts MPR300 cell surface control OCL6 fibroblasts similar indicating increased amounts intracellular 125IASA OCL6 cells result increased concentrations MPR300 cell surface
0.30761042.15010453.html.plaintext.txt	161	The specificity procedure shown effect MESNA cleaved biotin label linkage
0.30761042.15010453.html.plaintext.txt	162	View larger version 81K FIG
0.30761042.15010453.html.plaintext.txt	163	Cell surface biotinylation MPR300
0.30761042.15010453.html.plaintext.txt	164	Control Co OCL6 sheep fibroblasts chilled 4 degrees C cell surface biotinylated followed incubation presence absence reducing agent MESNA
0.30761042.15010453.html.plaintext.txt	165	MPR300 immunoprecipitated cell extracts separated SDS PAGE 5 acrylamide transferred nitrocellulose membrane visualized streptavidin HRP enhanced chemiluminescence
0.30761042.15010453.html.plaintext.txt	166	To examine whether degradation endocytosed 125IASA inhibited CLN6 defective fibroblasts cells incubated 125IASA for3hat37 degrees C
0.30761042.15010453.html.plaintext.txt	167	After removal radioactive media cells either harvested chased 20 h
0.30761042.15010453.html.plaintext.txt	168	The solubilized cells analyzed SDS PAGE autoradiography Fig
0.30761042.15010453.html.plaintext.txt	169	Densitometry autoradiograph revealed amount intracellular 125IASA detected cells CLN6 patients 1
0.30761042.15010453.html.plaintext.txt	170	5 fold control cells 3 h endocytosis
0.30761042.15010453.html.plaintext.txt	171	During following chase period 20 h intracellular 125IASA remaining control cells reduced 32 whereas 96 remained fibroblasts CLN6 patients
0.30761042.15010453.html.plaintext.txt	172	These data indicate degradation endocytosed 125IASA strongly inhibited CLN6 defective cells
0.30761042.15010453.html.plaintext.txt	173	View larger version 34K FIG
0.30761042.15010453.html.plaintext.txt	174	Degradation endocytosed 125IASA reduced CLN6 defective fibroblasts
0.30761042.15010453.html.plaintext.txt	175	Fibroblasts control Co affected CLN6 patients incubated 125IASA 800000 cpmml 3 h 37 degrees C
0.30761042.15010453.html.plaintext.txt	176	After removal media cells either harvested chased additional 20 h 37 degrees C
0.30761042.15010453.html.plaintext.txt	177	The cells solubilized separated SDS PAGE internalized 125IASA visualized autoradiography
0.30761042.15010453.html.plaintext.txt	178	The autoradiograph quantified densitometric scanning expressed percentage total 125IASA detectable control cells
0.30761042.15010453.html.plaintext.txt	179	The experiment repeated twice similar results
0.30761042.15010453.html.plaintext.txt	180	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES In present study examined subcellular localization CLN6 protein
0.30761042.15010453.html.plaintext.txt	181	Mutations CLN6 gene cause accumulation storage material lysosomes clinical manifestation variant late infantile neuronal ceroid lipofuscinosis
0.30761042.15010453.html.plaintext.txt	182	Here report CLN6 ER resident protein capable forming dimers
0.30761042.15010453.html.plaintext.txt	183	Furthermore neither synthesis sorting transport newly synthesized CtsD lysosomal protease impaired CLN6 defective cells whereas degradation exogenous protein ASA reduced
0.30761042.15010453.html.plaintext.txt	184	Several lines evidence imply translocation localization CLN6 protein ER
0.30761042.15010453.html.plaintext.txt	185	First CLN6 antigenic sites found colocalize PDI established ER marker cis Golgi marker GM130 lysosomes stained CtsD
0.30761042.15010453.html.plaintext.txt	186	Secondly CLN6 protein undergo proteolytic processing steps
0.30761042.15010453.html.plaintext.txt	187	Thirdly although contains potential N glycosylation sites replacement residue isoleucine 153 serine located second proposed luminal loop amino acid residues 137 179 resulted addition oligosaccharide chain could removed PNGase F treatment
0.30761042.15010453.html.plaintext.txt	188	The mutant CLN6 also completely sensitive endo H removing high mannose ER type oligosaccharide chains complex Golgi type oligosaccharides
0.30761042.15010453.html.plaintext.txt	189	These data strongly support concept CLN6 residency ER
0.30761042.15010453.html.plaintext.txt	190	ER residency membrane proteins achieved retention andor retrieval mechanisms requiring signal structures targeting motifs within proteins
0.30761042.15010453.html.plaintext.txt	191	Thus ER resident type I transmembrane proteins contain dileucine motif C terminal cytoplasmic domain whereas arginine containing signal structure functions targeting signal type II membrane proteins 41 44 45
0.30761042.15010453.html.plaintext.txt	192	Recent studies revealed additional ER retention signals RXR R arginine X large neutral positively charged residue 46 48
0.30761042.15010453.html.plaintext.txt	193	Furthermore oligomerization proteins mediated transmembrane andor luminal domains forming large homodimeric heteromeric protein complexes might prevent package transport vesicles export ER 44 49 50
0.30761042.15010453.html.plaintext.txt	194	The signal structures responsible retention polytopic CLN6 ER known
0.30761042.15010453.html.plaintext.txt	195	Both N C terminal domain harbor potential RRR RKK retention motifs
0.30761042.15010453.html.plaintext.txt	196	However replacement motifs lysine leucine residues respectively alter ER localization mutant CLN6
0.30761042.15010453.html.plaintext.txt	197	2 It also possible dimerization reported study assembly CLN6 oligomeric complexes prevents export ER
0.30761042.15010453.html.plaintext.txt	198	The function CLN6 defined
0.30761042.15010453.html.plaintext.txt	199	However comparable rates synthesis sorting proteolytic processing CtsD CLN6 defective control cells well similar specific activities two lysosomal enzymes hexosaminidase ASA suggest CLN6 limit transport least three enzymes lysosome
0.30761042.15010453.html.plaintext.txt	200	On hand study shows capability degrade exogenous arylsulfatase A strikingly impaired CLN6 defective cells
0.30761042.15010453.html.plaintext.txt	201	Whereas half life newly synthesized ASA reported 40 days 51 internalized human ASA rapidly degraded Ref
0.30761042.15010453.html.plaintext.txt	202	It probable acidic pH dependent octamerization cannot completed endocytosed ASA resulting increased lysosomal instability 53
0.30761042.15010453.html.plaintext.txt	203	Taking endocytosed ASA index delayed degradation CLN6 defective cells results indicate either specific lysosomal proteases absent andor inactive lysosomal parameters pH presence cofactors affected
0.30761042.15010453.html.plaintext.txt	204	It interest incubation N1E
0.30761042.15010453.html.plaintext.txt	205	115 neuroblastoma cells amyloid protein fragments suspected neurotoxic mediator Alzheimers disease led increased expression acetylcholinesterase slowed lysosomal degradation
0.30761042.15010453.html.plaintext.txt	206	The data suggest lysosomal acidification impaired 54
0.30761042.15010453.html.plaintext.txt	207	Lysosomal dysfunction attributed defective ER resident membrane protein without precedent
0.30761042.15010453.html.plaintext.txt	208	CLN8 another polytopic ER membrane protein defective progressive epilepsy mental retardation belonging group NCL disorders 16
0.30761042.15010453.html.plaintext.txt	209	It remains investigated whether reduced capability lysosomal degradation proteins demonstrated study specific CLN6 common CLN6 CLN8 defective cells
0.30761042.15010453.html.plaintext.txt	210	FOOTNOTES This work supported Deutsche Forschungsgemeinschaft Grant BR 99010 2 Werner Otto Foundation Hamburg Germany National Institutes Health Grant NS40297 D
0.30761042.15010453.html.plaintext.txt	211	The costs publication article defrayed part payment page charges
0.30761042.15010453.html.plaintext.txt	212	This article must therefore hereby marked advertisement accordance 18 U
0.30761042.15010453.html.plaintext.txt	213	Section 1734 solely indicate fact
0.30761042.15010453.html.plaintext.txt	214	To correspondence addressed Childrens Hospital Biochemistry University Hospital Hamburg Martinistr
0.30761042.15010453.html.plaintext.txt	215	49 40 42803 4493 Fax 49 40 42803 8504 E mail braulkeatuke
0.30761042.15010453.html.plaintext.txt	216	1 The abbreviations used NCL neuronal ceroid lipofuscinosis MPR mannose 6 phosphate receptor ER endoplasmic reticulum OCL6 ovine NCL MESNA 2 mercaptoethanesulfonic acid BS3 bissulfosuccinimidyl suberate DSS disuccinimidylsuberate ASA arylsulfatase A CtsD cathepsin D PDI protein disulfide isomerase endo H endoglycosidase H MES 4 morpholineethanesulfonic acid PNGase F peptide N glycosidase F
0.30761042.15010453.html.plaintext.txt	217	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Goebel H
0.30761042.15010453.html.plaintext.txt	218	66 367 372CrossRefMedline Order article via Infotrieve Haltia M
0.30761042.15010453.html.plaintext.txt	219	62 1 13Medline Order article via Infotrieve Hellsten E
0.30761042.15010453.html.plaintext.txt	220	15 5240 5245Abstract Vines D
0.30761042.15010453.html.plaintext.txt	221	443 131 135CrossRefMedline Order article via Infotrieve Lin L
0.30761042.15010453.html.plaintext.txt	222	276 2249 2255AbstractFree Full Text Janes R
0.30761042.15010453.html.plaintext.txt	223	399 75 77CrossRefMedline Order article via Infotrieve Savukoski M
0.30761042.15010453.html.plaintext.txt	224	1998 Science 277 1802 1805 Ranta S
0.30761042.15010453.html.plaintext.txt	225	23 233 236CrossRefMedline Order article via Infotrieve Wheeler R
0.30761042.15010453.html.plaintext.txt	226	70 537 542CrossRefMedline Order article via Infotrieve Gao H
0.30761042.15010453.html.plaintext.txt	227	70 324 335CrossRefMedline Order article via Infotrieve Palmer D
0.30761042.15010453.html.plaintext.txt	228	42 561 567Medline Order article via Infotrieve Palmer D
0.30761042.15010453.html.plaintext.txt	229	1997 Neuropediatrics 28 45 48Medline Order article via Infotrieve Braulke T
0.30761042.15010453.html.plaintext.txt	230	1996 Subcellular Biochemistry Biology Lysosome Lloyd J
0.30761042.15010453.html.plaintext.txt	231	15 49 Plenum Press New York Jarvela I
0.30761042.15010453.html.plaintext.txt	232	8 1091 1098AbstractFree Full Text Isosomppi J
0.30761042.15010453.html.plaintext.txt	233	11 885 891AbstractFree Full Text Lonka L
0.30761042.15010453.html.plaintext.txt	234	9 1691 1697AbstractFree Full Text Bonifacino J
0.30761042.15010453.html.plaintext.txt	235	145 923 926Free Full Text Kyttala A
0.30761042.15010453.html.plaintext.txt	236	Cell 15 1313 1323AbstractFree Full Text Sharp J
0.30761042.15010453.html.plaintext.txt	237	22 35 42CrossRefMedline Order article via Infotrieve Teixeira C
0.30761042.15010453.html.plaintext.txt	238	250 661 667Medline Order article via Infotrieve Teixeira C
0.30761042.15010453.html.plaintext.txt	239	21 502 508CrossRefMedline Order article via Infotrieve Jolly R
0.30761042.15010453.html.plaintext.txt	240	66 376 380CrossRefMedline Order article via Infotrieve Bronson R
0.30761042.15010453.html.plaintext.txt	241	376 369 376CrossRefMedline Order article via Infotrieve Palmer D
0.30761042.15010453.html.plaintext.txt	242	Acta 834 159 163Medline Order article via Infotrieve Dierks T
0.30761042.15010453.html.plaintext.txt	243	94 11963 11968AbstractFree Full Text Hasilik A
0.30761042.15010453.html.plaintext.txt	244	255 4937 4945Free Full Text Korner C
0.30761042.15010453.html.plaintext.txt	245	270 287 295AbstractFree Full Text Claussen M
0.30761042.15010453.html.plaintext.txt	246	1997 Endocrinology 138 3797 3803AbstractFree Full Text Zwad O
0.30761042.15010453.html.plaintext.txt	247	510 211 215CrossRefMedline Order article via Infotrieve Partanen S
0.30761042.15010453.html.plaintext.txt	248	369 55 62CrossRefMedline Order article via Infotrieve Muschol N
0.30761042.15010453.html.plaintext.txt	249	368 845 853CrossRefMedline Order article via Infotrieve Meyer C
0.30761042.15010453.html.plaintext.txt	250	114 4469 4476Medline Order article via Infotrieve Damke H
0.30761042.15010453.html.plaintext.txt	251	281 225 229Medline Order article via Infotrieve Rosorius O
0.30761042.15010453.html.plaintext.txt	252	268 21470 21473AbstractFree Full Text Breuer P
0.30761042.15010453.html.plaintext.txt	253	Cell 8 567 576Abstract Parker K
0.30761042.15010453.html.plaintext.txt	254	1983 Biochemistry 22 1145 1153Medline Order article via Infotrieve Porter M
0.30761042.15010453.html.plaintext.txt	255	62 887 891Abstract von Figura K
0.30761042.15010453.html.plaintext.txt	256	111 15 21Medline Order article via Infotrieve Hardt B
0.30761042.15010453.html.plaintext.txt	257	2003 Glycobiology 13 159 168AbstractFree Full Text Gieselmann V
0.30761042.15010453.html.plaintext.txt	258	6 2677 2681Abstract Schutze M
0.30761042.15010453.html.plaintext.txt	259	13 1696 1705Abstract Cosson P
0.30761042.15010453.html.plaintext.txt	260	9 484 487CrossRefMedline Order article via Infotrieve Margeta Mitrovic M
0.30761042.15010453.html.plaintext.txt	261	2000 Neuron 27 97 106Medline Order article via Infotrieve Ren Z
0.30761042.15010453.html.plaintext.txt	262	23 6608 6616AbstractFree Full Text Scott D
0.30761042.15010453.html.plaintext.txt	263	21 3063 3072AbstractFree Full Text Maza J
0.30761042.15010453.html.plaintext.txt	264	Adhesion 10 319 322Medline Order article via Infotrieve Ren Z
0.30761042.15010453.html.plaintext.txt	265	278 52700 52709AbstractFree Full Text Steckel F
0.30761042.15010453.html.plaintext.txt	266	151 141 145Abstract Steckel F
0.30761042.15010453.html.plaintext.txt	267	151 147 152Abstract von Bulow R
0.30761042.15010453.html.plaintext.txt	268	277 9455 9461AbstractFree Full Text Hu W
0.30761042.15010453.html.plaintext.txt	269	86 470 478CrossRefMedline Order article via Infotrieve
0.32282493.12501252.html.plaintext.txt	0	Novel Role Apolipoprotein E Central Nervous System MODULATION OF SULFATIDE CONTENT Xianlin Han Hua Cheng John D
0.32282493.12501252.html.plaintext.txt	1	From Division Bioorganic Chemistry Molecular Pharmacology Department Internal Medicine Department Neurology Department Molecular Biology Pharmacology Center Study Nervous System Injury Washington University School Medicine St
0.32282493.12501252.html.plaintext.txt	2	Received publication December 4 2002 revised form December 20 2002
0.32282493.12501252.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.32282493.12501252.html.plaintext.txt	4	It long postulated apolipoprotein E apoE may play role lipid metabolism brain
0.32282493.12501252.html.plaintext.txt	5	However direct evidence apoE plays role lacking
0.32282493.12501252.html.plaintext.txt	6	We investigated whether apoE isoforms influence lipid content brain
0.32282493.12501252.html.plaintext.txt	7	We compared brains wild type mice apoE knockout human apoE3 apoE4 transgenic mice compared cerebrospinal fluid CSF humans different apoE isoforms
0.32282493.12501252.html.plaintext.txt	8	We found effect apoE content multiple phospholipids sphingolipids cholesterol
0.32282493.12501252.html.plaintext.txt	9	There however marked effect apoE sulfatide ST content brain CSF
0.32282493.12501252.html.plaintext.txt	10	The sulfatide mass hippocampus cortex apoE knockout mice found 61 114 mol higher wild type mice counterparts 12 months age
0.32282493.12501252.html.plaintext.txt	11	In contrast sulfatide content brain tissues human apoE4 expressing mice 60 less found wild type mice age
0.32282493.12501252.html.plaintext.txt	12	The ST mass human CSF significantly dependent APOE genotypes subjects
0.32282493.12501252.html.plaintext.txt	13	Examination potential sulfatide carriers human CSF demonstrated sulfatides specifically associated apoE containing high density lipoproteins suggesting sulfatide levels central nervous system CNS likely directly modulated metabolic pathways regulate levels apoE containing CNS lipoproteins
0.32282493.12501252.html.plaintext.txt	14	This novel role apoE CNS may provide new insights connection apoE Alzheimers disease poor recovery brain injury
0.32282493.12501252.html.plaintext.txt	15	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.32282493.12501252.html.plaintext.txt	16	Human apolipoprotein E apoE protein APOE gene1 34 kDa protein coded gene chromosome 19 plays prominent role transport metabolism plasma cholesterol triacylglycerides ability interact low density lipoprotein LDL receptor LDL receptor related protein 1 2
0.32282493.12501252.html.plaintext.txt	17	It postulated apoE may also play important role redistribution cholesterol phospholipids within central nervous system CNS 3 apoE expressed mainly astrocytes 4 5
0.32282493.12501252.html.plaintext.txt	18	In vitro vivo data suggest apoE play role neurite outgrowth sprouting 4 6 9 however whether due effects cholesterol lipid metabolism unclear
0.32282493.12501252.html.plaintext.txt	19	In addition role plasma lipid transport protein apoE participates pathobiological processes including Alzheimers disease AD 10
0.32282493.12501252.html.plaintext.txt	20	The effect apoE AD likely occur least part via interactions amyloid A peptide see Ref
0.32282493.12501252.html.plaintext.txt	21	To date mechanisms apoE involved biological processes completely clarified
0.32282493.12501252.html.plaintext.txt	22	There three common isoforms human apoE differ amino acids positions 112 158 1
0.32282493.12501252.html.plaintext.txt	23	The common isoform apoE3 cysteine position 112 arginine 158 whereas apoE2 cysteine positions apoE4 contains arginine positions
0.32282493.12501252.html.plaintext.txt	24	The isoforms encoded three alleles gene locus
0.32282493.12501252.html.plaintext.txt	25	ApoE4 shown risk factor AD cerebral amyloid angiopathy 10
0.32282493.12501252.html.plaintext.txt	26	Although role apoE pathogenesis AD entirely clear studies suggest apoE influences A deposition toxicity brain 12 15
0.32282493.12501252.html.plaintext.txt	27	Sulfatides ST represent class sulfated galactocerebrosides differ composition fatty acid residue acylates amino group sphingosine
0.32282493.12501252.html.plaintext.txt	28	Sulfatides mediate diverse biological processes including regulation cell growth protein trafficking signal transduction cell adhesion neuronal plasticity cell morphogenesis see Refs
0.32282493.12501252.html.plaintext.txt	29	Sulfatides almost exclusively synthesized oligodendrocytes CNS present predominantly myelin sheath surrounding axons thus present white matter gray matter 16
0.32282493.12501252.html.plaintext.txt	30	Altered levels ST human brain tissues involved pathogenesis various human diseases
0.32282493.12501252.html.plaintext.txt	31	Accumulation ST due sulfatidase deficiency responsible metachromatic leukodystrophy encephalopathy long tract signs degeneration myelin CNS 19
0.32282493.12501252.html.plaintext.txt	32	In contrast recent study demonstrated substantial ST deficiency occurs earliest stages AD although one causes deficiency remain unclear 20
0.32282493.12501252.html.plaintext.txt	33	Mice deficient ST galactocerebrosides GalC generated knocking ceramide galactosyltransferase generally die 3 months age demonstrate several abnormalities including abnormal axonal function dysmyelinosis loss axonal conduction velocity 21 24
0.32282493.12501252.html.plaintext.txt	34	Numerous studies demonstrated role apoE normal variation plasma lipids isoform dependent manner see Refs
0.32282493.12501252.html.plaintext.txt	35	Therefore long postulated apoE may also play role lipid metabolism brain
0.32282493.12501252.html.plaintext.txt	36	However direct evidence apoE plays role lacking
0.32282493.12501252.html.plaintext.txt	37	In study investigated whether apoE apoE isoforms influence lipid content CNS
0.32282493.12501252.html.plaintext.txt	38	We found significant effects apoE content multiple phospholipids sphingolipids cholesterol
0.32282493.12501252.html.plaintext.txt	39	In contrast apoE dramatic effect sulfatide content CNS
0.32282493.12501252.html.plaintext.txt	40	Furthermore potential mechanisms relationship apoE ST including ST assembly nascent apoE particles ST transport presence within cerebrospinal fluid CSF lipoproteins ST hydrolysis mediated apoE also investigated study
0.32282493.12501252.html.plaintext.txt	41	Collectively uncovered novel role apoE modulation ST content CNS
0.32282493.12501252.html.plaintext.txt	42	This finding may provide new insights roles apoE biological pathological processes CNS AD following brain injury
0.32282493.12501252.html.plaintext.txt	43	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.32282493.12501252.html.plaintext.txt	44	Materials Synthetic heptadecanoyl ceramide N170 Cer phospholipids including 12 dimyristoleoyl 3 phosphatidylcholine 141 141 PtdCho 12 dipentadecanoyl 3 phosphatidylethanolamine 150 150 PtdEtn 1 myristoyl 2 palmitoyl 3 phosphadylglycerol 140 160 PtdGro purchased Avanti Polar Lipids Inc
0.32282493.12501252.html.plaintext.txt	45	Semisynthetic N palmitoyl sulfatide N160 ST perdeuterated N stearoyl galactocerebroside D35 N180 GalC obtained Matreya Inc
0.32282493.12501252.html.plaintext.txt	46	The Amplex Red cholesterol assay kit obtained Molecular Probes Inc
0.32282493.12501252.html.plaintext.txt	47	Human recombinant apoE rhApoE isoforms rhApoE2 rhApoE3 rhApoE4 purchased Calbiochem Novabiochem Corp
0.32282493.12501252.html.plaintext.txt	48	All rhApoE isoforms determined ST free electrospray ionization mass spectrometry ESIMS
0.32282493.12501252.html.plaintext.txt	49	All cell culture supplies Invitrogen New York NY unless specified
0.32282493.12501252.html.plaintext.txt	50	Goat anti apoE anti apoJ antibodies purchased BioDesign Saco ME
0.32282493.12501252.html.plaintext.txt	51	Goat IgG control antibody purchased Sigma St
0.32282493.12501252.html.plaintext.txt	52	Protein G Sepharose obtained Pierce Rockford IL
0.32282493.12501252.html.plaintext.txt	53	Mouse Brain Tissues Wild type
0.32282493.12501252.html.plaintext.txt	54	apoE apoE transgenic mice studies C57BL6 background
0.32282493.12501252.html.plaintext.txt	55	Transgenic mice hemizygous GFAP apoE3 GFAP apoE4 transgene mouse apoE background produced described previously 26
0.32282493.12501252.html.plaintext.txt	56	GFAP refers glial fibrillary acidic protein promoter
0.32282493.12501252.html.plaintext.txt	57	The GFAP apoE3 apoE4 mice express apoE level
0.32282493.12501252.html.plaintext.txt	58	At indicated age mice anesthetized intraperitoneal pentobarbital 150 mgkg perfused transcardially 0
0.32282493.12501252.html.plaintext.txt	59	1 M phosphate buffered saline pH 7
0.32282493.12501252.html.plaintext.txt	60	Brain regions immediately dissected frozen powdered dry ice analysis
0.32282493.12501252.html.plaintext.txt	61	Human Cerebrospinal Fluid Astrocyte secreted Lipoproteins Human lumbar CSF samples collected previously described 27
0.32282493.12501252.html.plaintext.txt	62	Freshly frozen CSF samples 80 degrees C 0
0.32282493.12501252.html.plaintext.txt	63	5 1 ml subject used study ST content
0.32282493.12501252.html.plaintext.txt	64	Lumbar CSF samples obtained cognitively normal subjects clinical dementia rating score 0 non demented 28
0.32282493.12501252.html.plaintext.txt	65	A clinical dementia rating score assigned subjects experienced clinicians based extensive clinical neuropsychological evaluation described 28
0.32282493.12501252.html.plaintext.txt	66	Subjects genotypes apoE kindly provided laboratory Dr
0.32282493.12501252.html.plaintext.txt	67	Goate Washington University School Medicine
0.32282493.12501252.html.plaintext.txt	68	A total 16 subjects participated study apoE3E3 n 8 apoE3E4 n 6 apoE4E4 n 2 overall average age 70
0.32282493.12501252.html.plaintext.txt	69	Astrocyte secreted apoE3 apoE4 lipoproteins purified using immunoaffinity columns described 29
0.32282493.12501252.html.plaintext.txt	70	Briefly primary cultures forebrain astrocytes 95 pure prepared neonatal 1 2 day old wild type C57BL6 apoE GFAP apoE3 transgenic GFAP apoE4 transgenic mice grown confluence 10 14 days T75 flasks
0.32282493.12501252.html.plaintext.txt	71	Cultures incubated 5 ml serum free Dulbeccos modified Eagles mediumHams F 12 11 medium containing N2 supplement Invitrogen additional 72 h
0.32282493.12501252.html.plaintext.txt	72	Conditioned media collected apoE3 apoE4 lipoproteins purified corresponding conditioned media anti apoE immunoaffinity column
0.32282493.12501252.html.plaintext.txt	73	Preparation Quantitation Lipids Mouse Brain Tissues Human CSF Astrocyte secreted Lipoproteins Lipids individual mouse brain tissue prepared presence 141 141 PtdCho 20 nmolmg protein 150 150 PtdEtn 18 nmolmg protein 140 160 PtdGro 30 nmolmg protein D35 N180 GalC 35 nmolmg protein N170 Cer 5 nmolmg protein used internal standards quantification choline containing phospholipids ethanolamine containing phospholipids anionic lipids including PtdGro phosphatidylinositol PtdIns phosphatidylserine PtdSer ST GalC Cer respectively similarly prepared described previously 20 30 31
0.32282493.12501252.html.plaintext.txt	74	Lipids similarly extracted human CSF astrocyte secreted lipoproteins presence N160 ST 270 pmolmg CSF protein 2 nmolmg apoE respectively used internal standard quantification ST
0.32282493.12501252.html.plaintext.txt	75	ESIMS analyses lipids performed utilizing Finnigan TSQ 7000 spectrometer equipped electrospray ion source described 20 30 32
0.32282493.12501252.html.plaintext.txt	76	All molecular species directly quantitated comparisons individual ion peak intensities properly selected internal standard e
0.32282493.12501252.html.plaintext.txt	77	140 160 PtdGro anionic lipids including PtdIns PtdSer correction 13C isotope effects 33
0.32282493.12501252.html.plaintext.txt	78	For quantification cholesterol brain tissue samples tissue 10 mg homogenized 0
0.32282493.12501252.html.plaintext.txt	79	2 ml phosphate buffered saline
0.32282493.12501252.html.plaintext.txt	80	The cholesterol mass homogenates quantitated using enzymatic methodology Amplex Red cholesterol assay kit Molecular Probe Inc
0.32282493.12501252.html.plaintext.txt	81	Hydrolysis Assay Sulfatide Mediated Human Recombinant apoE Isoforms Hydrolysis ST mediated rhApoEs performed modification n sulfatidase assay described previously 34
0.32282493.12501252.html.plaintext.txt	82	Briefly rhApoE isoforms 50 microg incubated 1 ml final assay buffer 100 mM imidazole pH 7
0.32282493.12501252.html.plaintext.txt	83	5 micromol dissolved 50 microl Me2SO injected assay solution
0.32282493.12501252.html.plaintext.txt	84	5 1 2 4 h 37 degrees C aliquots 100 microl assay mixture pipetted lipids mixture immediately extracted modified Bligh Dyer technique 35 presence N170 Cer 5 nmol D35 N180 GalC 5 nmol internal standards used quantitation Cer GalC two products ST hydrolysis
0.32282493.12501252.html.plaintext.txt	85	The mass Cer GalC quantitated ESIMS described previously 20 31
0.32282493.12501252.html.plaintext.txt	86	Fractionation Immunoprecipitation Assays Human CSF Human CSF obtained fasted healthy subject via lumbar puncture L4L5 trained neurologist D
0.32282493.12501252.html.plaintext.txt	87	There blood contamination
0.32282493.12501252.html.plaintext.txt	88	CSF centrifuged 5 min 800 x g 4 degrees C pellet cellular elements
0.32282493.12501252.html.plaintext.txt	89	Twenty milliliters CSF concentrated 1 ml 4 degrees C using Centriplus 10 concentrators 10 kDa molecular mass Millipore Bedford MA prior fractionation via gel filtration chromatography BioLogic System Bio Rad Hercules CA using tandem Superose 6 HR 1030 columns Amersham Biosciences Piscataway NJ conditions physiological pH pH 7
0.32282493.12501252.html.plaintext.txt	90	Seventy fractions 400 microl collected
0.32282493.12501252.html.plaintext.txt	91	Lipids individual fractions extracted presence N160 ST 70 pmolfraction used internal standard ST quantitation using modified method Bligh Dyer 35 ST content fraction analyzed ESIMS described
0.32282493.12501252.html.plaintext.txt	92	Immunoprecipitation initiated incubating 1
0.32282493.12501252.html.plaintext.txt	93	7 ml pooled human CSF individual antibody final concentration 100 microgml 100 microl 50 protein G Sepharose slurry 3 h room temperature
0.32282493.12501252.html.plaintext.txt	94	The immunoprecipitation complexes pelleted briefly rinsed three times gently ice cooled phosphate buffered saline
0.32282493.12501252.html.plaintext.txt	95	Lipids extracted final immunoprecipitation pellets supernatants using modified Bligh Dyer method ST content lipid extracts analyzed ESIMS described
0.32282493.12501252.html.plaintext.txt	96	Miscellaneous Protein concentration determined utilizing bicinchoninic acid protein assay kit Pierce Rockford IL using bovine serum albumin standard
0.32282493.12501252.html.plaintext.txt	97	Quantitative data mouse brain samples normalized protein content tissues data presented means plus minus S
0.32282493.12501252.html.plaintext.txt	98	least three separate animals
0.32282493.12501252.html.plaintext.txt	99	Differences mean values determined ANOVA analysis followed Dunns test p 0
0.32282493.12501252.html.plaintext.txt	100	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.32282493.12501252.html.plaintext.txt	101	Altered Mass Sulfatides Not Other Examined Lipids Brain ApoE Mice To examine effects apoE mouse brain lipid homeostasis molecular species mass lipids including choline glycerophospholipids PC ethanolamine glycerophospholipids PE phosphatidylglycerol PtdGro phosphatidylinositol PtdIns phosphatidylserine PtdSer sphingomyelin SM galactocerebroside GalC ST cholesterol apoE apoE mouse brain regions analyzed either ESIMS fluorometric assay
0.32282493.12501252.html.plaintext.txt	102	Negative ion ESIMS analyses chloroform extracts wild type C57BL6 mice apoE mouse hippocampus 12 months age demonstrated multiple abundant ion peaks corresponding PE molecular species indicated Fig
0.32282493.12501252.html.plaintext.txt	103	These PE molecular species account total mass 320
0.32282493.12501252.html.plaintext.txt	104	6 nmolmg protein including 152
0.32282493.12501252.html.plaintext.txt	105	5 nmolmg protein ethanolamine plasmalogen
0.32282493.12501252.html.plaintext.txt	106	1B illustrates positive ion ESIMS spectrum identical lipid extract apoE mouse hippocampus 12 months age PC SM GalC molecular species identified quantitated
0.32282493.12501252.html.plaintext.txt	107	7 nmolmg protein PC SM GalC respectively obtained Table I
0.32282493.12501252.html.plaintext.txt	108	Negative ion ESIMS analyses identical chloroform extracts apoE mouse hippocampus without addition LiOH demonstrated multiple abundant ion peaks corresponding PtdIns PtdSer ST anionic lipid molecular species indicated Fig
0.32282493.12501252.html.plaintext.txt	109	2A total mass species tabulated Table I
0.32282493.12501252.html.plaintext.txt	110	3 nmolmg protein cholesterol hippocampus obtained using enzymatic methodology Amplex Red cholesterol assay kit
0.32282493.12501252.html.plaintext.txt	111	ESIMS analyses fluorometric assays lipids apoE mouse cortex cerebellum also performed results tabulated Table I
0.32282493.12501252.html.plaintext.txt	112	View larger version 29K Fig
0.32282493.12501252.html.plaintext.txt	113	Representative ESI mass spectra lipid extracts wild type mouse hippocampus
0.32282493.12501252.html.plaintext.txt	114	apoE mouse hippocampus 12 months age extracted modified method Bligh Dyer described Experimental Procedures
0.32282493.12501252.html.plaintext.txt	115	Negative ion A positive ion B ESIMS lipid extracts performed presence trace amount LiOH Experimental Procedures
0.32282493.12501252.html.plaintext.txt	116	All major individual molecular species indicated identified using tandem mass spectrometry
0.32282493.12501252.html.plaintext.txt	117	View table Table I Lipid content brain regions wild type apoE human apoE3 transgenic mice 12 months age Mouse brain tissue lipids extracted Bligh Dyer method 35
0.32282493.12501252.html.plaintext.txt	118	Phospholipids sphingolipids analyzed directly ESIMS described Experimental Procedures
0.32282493.12501252.html.plaintext.txt	119	Lipid molecular species identified ESI tandem mass spectrometry quantitated comparisons individual ion peak intensities properly selected internal standards corrections 13C isotope effects
0.32282493.12501252.html.plaintext.txt	120	Cholesterol contents determined flurometric technique
0.32282493.12501252.html.plaintext.txt	121	The results expressed nmolmg protein represent means plus minus S
0.32282493.12501252.html.plaintext.txt	122	least three separate animals
0.32282493.12501252.html.plaintext.txt	123	View larger version 26K Fig
0.32282493.12501252.html.plaintext.txt	124	Representative negative ion ESI mass spectra lipid extracts wild type apoE knockout mouse hippocampi
0.32282493.12501252.html.plaintext.txt	125	apoE panel A apoE knockout
0.32282493.12501252.html.plaintext.txt	126	apoE panel B mouse hippocampi 12 months age extracted modified method Bligh Dyer negative ion ESIMS lipid extracts without presence LiOH performed Experimental Procedures
0.32282493.12501252.html.plaintext.txt	127	All major individual molecular species indicated identified using tandem mass spectrometry
0.32282493.12501252.html.plaintext.txt	128	Asterisks indicate lower abundant ion peaks sulfatide molecular species present lipid extracts
0.32282493.12501252.html.plaintext.txt	129	2OH N241 ST represents 2 hydroxy N241 ST molecular species
0.32282493.12501252.html.plaintext.txt	130	Examination mass various lipid molecular species hippocampus cortex cerebellum apoE mice ESIMS analyses fluorometric assays demonstrated significant differences PC PE PtdIns PtdSer SM GalC cholesterol comparison obtained corresponding regions apoE mice Fig
0.32282493.12501252.html.plaintext.txt	131	Interestingly mass content ST hippocampus cortex cerebellum apoE mice increased 61 114 7 mol respectively relative found apoE mice age 12 months Figs
0.32282493.12501252.html.plaintext.txt	132	These results indicate apoE way regulates ST content CNS
0.32282493.12501252.html.plaintext.txt	133	Alterations Sulfatide Content Mediated apoE Dependence ApoE Isoform Age To examine effects human apoE isoforms modulation ST content mouse brain ST molecular species mass lipid extracts different brain regions transgenic mice expressing human apoE3 apoE4 specifically brain astrocytes compared apoE mice ESIMS analysis Fig
0.32282493.12501252.html.plaintext.txt	134	Importantly levels apoE3 apoE4 expression hemizygous transgenic mice indistinguishable 70 levels mouse apoE wild type mice 26 36
0.32282493.12501252.html.plaintext.txt	135	The levels ST mass hippocampus cortex apoE3 transgenic mice 12 months age 53 40 mol respectively found apoE mice statistically lower found apoE mice Fig
0.32282493.12501252.html.plaintext.txt	136	The levels ST mass cortex hippocampus apoE4 transgenic mice 28 37 mol respectively counterparts apoE mouse tissues 59 60 mol respectively found corresponding apoE mouse tissues 12 months age Fig
0.32282493.12501252.html.plaintext.txt	137	The ST mass levels brain regions apoE4 transgenic mice significantly lower found corresponding apoE3 transgenic mouse tissues p 0
0.32282493.12501252.html.plaintext.txt	138	3 demonstrating isoform specific regulation ST mass levels apoE
0.32282493.12501252.html.plaintext.txt	139	ApoE mice significantly higher ST content thalamus striatum septum compared present apoE mice even 6 months age Fig
0.32282493.12501252.html.plaintext.txt	140	In contrast significantly lower ST content brain regions demonstrated apoE3 transgenic mice relative wild type apoE mice Fig
0.32282493.12501252.html.plaintext.txt	141	The fact human apoE transgenic mice express apoE brain lower levels sulfatide wild type mice demonstrates regulation brain sulfatide levels via apoE produced brain
0.32282493.12501252.html.plaintext.txt	142	View larger version 16K Fig
0.32282493.12501252.html.plaintext.txt	143	Comparison sulfatide mass levels hippocampi cortices wild type apoE human apoE3 apoE4 transgenic mice 12 months age
0.32282493.12501252.html.plaintext.txt	144	Sulfatide mass lipid extracts hippocampus A cortex B wild type apoE apoE3 apoE4 transgenic mice 12 months age determined using negative ion ESIMS described Experimental Procedures
0.32282493.12501252.html.plaintext.txt	145	Data represent means plus minus S
0.32282493.12501252.html.plaintext.txt	146	least three separate animals
0.32282493.12501252.html.plaintext.txt	147	001 relative apoE mice
0.32282493.12501252.html.plaintext.txt	148	There also significant difference human apoE3 apoE4 transgenic mice p 0
0.32282493.12501252.html.plaintext.txt	149	01 hippocampus cortex
0.32282493.12501252.html.plaintext.txt	150	View larger version 42K Fig
0.32282493.12501252.html.plaintext.txt	151	The absence apoE results increase sulfatide mass levels several brain regions 6 months age
0.32282493.12501252.html.plaintext.txt	152	Total mass sulfatides lipid extracts thalamus striatum septum apoE unfilled apoE dot filled human apoE3 transgenic black filled mice 6 months age determined using negative ion ESIMS described Experimental Procedures
0.32282493.12501252.html.plaintext.txt	153	001 relative apoE mice
0.32282493.12501252.html.plaintext.txt	154	Further experiments performed examine effects age alterations ST content mediated mouse human apoE
0.32282493.12501252.html.plaintext.txt	155	Overall ST content brain regions wild type apoE mice relatively unchanged 6 months age Fig
0.32282493.12501252.html.plaintext.txt	156	However levels ST mass apoE mice 6 12 months age substantially increased relative apoE mice advanced age Fig
0.32282493.12501252.html.plaintext.txt	157	In contrast ST content examined regions apoE3 transgenic mice substantially lower compared found apoE mice ages 12 months older although ST content two types mice almost identical 6 months age Fig
0.32282493.12501252.html.plaintext.txt	158	It also found alterations ST mass mediated apoE smaller cerebellum found cortex hippocampus early ages Fig
0.32282493.12501252.html.plaintext.txt	159	View larger version 14K Fig
0.32282493.12501252.html.plaintext.txt	160	Age dependent regulation sulfatide mass levels hippocampus cortex cerebellum wild type apoE human apoE3 transgenic mice
0.32282493.12501252.html.plaintext.txt	161	Sulfatide mass levels lipid extracts hippocampus A cortex B cerebellum C apoE apoE human apoE3 transgenic mice determined using negative ion ESIMS described Experimental Procedures
0.32282493.12501252.html.plaintext.txt	162	Some error bars within symbols
0.32282493.12501252.html.plaintext.txt	163	Sulfatide Content Cultured Astrocyte secreted ApoE Particles Human CSF To investigate possible mechanisms apoE mediated alterations ST content CNS two experiments performed
0.32282493.12501252.html.plaintext.txt	164	First purified astrocyte secreted lipoproteins containing either apoE3 apoE4 prepared cultured astrocytes described Experimental Procedures
0.32282493.12501252.html.plaintext.txt	165	The ST content particles quantitated ESIMS
0.32282493.12501252.html.plaintext.txt	166	It found ST content particles negligible although apoE4 particles contained ST mass found apoE3 particles 731 plus minus 45 versus 562 plus minus 22 pmolmg apoE respectively
0.32282493.12501252.html.plaintext.txt	167	Second CSF contains CNS produced apoE containing lipoprotein particles samples collected age matched cognitively normal human subjects
0.32282493.12501252.html.plaintext.txt	168	The ST content CSF samples analyzed ESIMS
0.32282493.12501252.html.plaintext.txt	169	The ST mass nmolmg apoE apoE3E3 homozygous subjects 46
0.32282493.12501252.html.plaintext.txt	170	3 whereas level significantly higher subjects one two alleles apoE4 53
0.32282493.12501252.html.plaintext.txt	171	It noted ST content CSF samples subjects either heterozygous homozygous APOE4 34 44 indistinguishable study
0.32282493.12501252.html.plaintext.txt	172	Therefore concluded human CSF contains significant amount ST mass level ST human CSF apoE isoform dependent
0.32282493.12501252.html.plaintext.txt	173	View larger version 10K Fig
0.32282493.12501252.html.plaintext.txt	174	Relationship sulfatide mass human cerebrospinal fluid APOE genotypes subjects
0.32282493.12501252.html.plaintext.txt	175	Cerebrospinal fluid samples collected age matched 70
0.32282493.12501252.html.plaintext.txt	176	9 years cognitively normal human subjects lipids extracted modified method Bligh Dyer described Experimental Procedures
0.32282493.12501252.html.plaintext.txt	177	The mass ST lipid extracts human cerebrospinal fluid subjects homozygous apoE3 denotes average level sulfatide mass homozygous heterozygous apoE4 denotes average level sulfatide mass determined using negative ion ESIMS described Experimental Procedures
0.32282493.12501252.html.plaintext.txt	178	Identification ST Carriers Human CSF Examination mass levels ST cultured astrocyte secreted apoE particles human CSF see last subsection suggests two possibilities
0.32282493.12501252.html.plaintext.txt	179	First ST molecules acquired directly associate apoE particles CNS apoE particles secreted astrocytes
0.32282493.12501252.html.plaintext.txt	180	Alternatively ST molecules may influenced apoE indirect fashion directly associate interact apoE containing lipoproteins
0.32282493.12501252.html.plaintext.txt	181	Therefore understand one mechanisms apoE mediated alterations ST content CNS necessary identify carrier carriers ST molecules
0.32282493.12501252.html.plaintext.txt	182	The location ST molecules first investigated analyzing ST content human CSF fractions gel filtration chromatography
0.32282493.12501252.html.plaintext.txt	183	It found sulfatides co localized exactly HDL like lipoproteins present human CSF Fig
0.32282493.12501252.html.plaintext.txt	184	The two abundant apolipoproteins produced CNS apoE apoJ well several apolipoproteins present human CSF
0.32282493.12501252.html.plaintext.txt	185	Therefore experiments performed identify specific carriers ST human CSF immunoprecipitation see inset Fig
0.32282493.12501252.html.plaintext.txt	186	7B Western blots followed ESIMS quantitation ST content supernatants pellets
0.32282493.12501252.html.plaintext.txt	187	It found 80 mol ST molecules immunoprecipitated anti apoE antibodies whereas ST molecules specifically immunoprecipitated anti apoJ antibodies Fig
0.32282493.12501252.html.plaintext.txt	188	These results clearly demonstrated ST molecules specifically associated apoE containing HDL like lipoproteins CSF suggested apoE particles mainly acquired ST CNS secretion astrocytes
0.32282493.12501252.html.plaintext.txt	189	View larger version 22K Fig
0.32282493.12501252.html.plaintext.txt	190	Identification sulfatide carrier human cerebrospinal fluid
0.32282493.12501252.html.plaintext.txt	191	A quantitation sulfatide content human cerebrospinal fluid fractions gel filtration chromatography
0.32282493.12501252.html.plaintext.txt	192	Human cerebrospinal fluid fractionated employing tandem Superose 6 columns described Experimental Procedures
0.32282493.12501252.html.plaintext.txt	193	Seventy fractions 400 microl collected
0.32282493.12501252.html.plaintext.txt	194	Lipids individual fraction extracted presence N palmitoyl sulfatide 70 pmolfraction used internal standard sulfatide quantitation using modified Bligh Dyer method
0.32282493.12501252.html.plaintext.txt	195	Sulfatide content fraction quantitated ESIMS described Experimental Procedures
0.32282493.12501252.html.plaintext.txt	196	The x axis indicates fraction number known elution profile CSF lipoproteins reported previously 27
0.32282493.12501252.html.plaintext.txt	197	Quantitation sulfatide content immunoprecipitated lipoprotein particles B supernatants immunoprecipitation C initiated incubating 1
0.32282493.12501252.html.plaintext.txt	198	7 ml pooled human cerebrospinal fluids individual antibodies indicated described Experimental Procedures
0.32282493.12501252.html.plaintext.txt	199	Lipids immunoprecipitation pellet extracted presence N palmitoyl sulfatide 70 pmol
0.32282493.12501252.html.plaintext.txt	200	Sulfatide content lipid extracts quantitated ESIMS described Experimental Procedures
0.32282493.12501252.html.plaintext.txt	201	Data represent means plus minus S
0.32282493.12501252.html.plaintext.txt	202	least three separate experiments
0.32282493.12501252.html.plaintext.txt	203	The inset B shows typical Western blot using anti apoE anti apoJ antibodies analyze apoE apoJ content CSF samples prior Pre IP immunoprecipitation following Post IP
0.32282493.12501252.html.plaintext.txt	204	Following immunoprecipitation CSF pellet also analyzed apoE apoJ
0.32282493.12501252.html.plaintext.txt	205	Examination Hydrolysis Sulfatide Mediated ApoEs Because demonstrated human CSF apoE containing lipoproteins contain ST likely effects apoE ST via association apoE containing CNS lipoproteins subsequent apoE regulated metabolism
0.32282493.12501252.html.plaintext.txt	206	However possible one determinant apoE mediated ST content differences CNS might occur apoE catalyzed hydrolysis
0.32282493.12501252.html.plaintext.txt	207	Accordingly hydrolytic products ST
0.32282493.12501252.html.plaintext.txt	208	GalC Cer brain tissue samples wild type apoE human apoE transgenic mice determined ESIMS
0.32282493.12501252.html.plaintext.txt	209	There significant differences GalC content Table I Cer content data shown mice
0.32282493.12501252.html.plaintext.txt	210	Additionally neither GalC Cer detected lipid extracts sulfatide vesicles incubation type rhApoE isoforms vesicles 4 h
0.32282493.12501252.html.plaintext.txt	211	These results suggest differences ST content different apoE mice caused apoE mediated ST hydrolysis
0.32282493.12501252.html.plaintext.txt	212	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.32282493.12501252.html.plaintext.txt	213	The involvement apoE metabolism phospholipids cholesterol plasma well known 1 25
0.32282493.12501252.html.plaintext.txt	214	To investigate whether apoE influences mass distribution brain lipids systematically quantified distribution lipids including multiple phospholipids sphingolipids cholesterol different brain regions wild type apoE human apoE transgenic mice
0.32282493.12501252.html.plaintext.txt	215	We found significant effects apoE content examined lipids exception ST levels dramatically altered apoE knockout human apoE transgenic mice
0.32282493.12501252.html.plaintext.txt	216	Furthermore apoE mediated alteration ST content CNS regulated aging well apoE produced brain human apoE transgenic mice express apoE brain still markedly elevated plasma cholesterol 26
0.32282493.12501252.html.plaintext.txt	217	The results examination ST content astrocyte secreted apoE particles indicate apoE acquire small amount ST directly cells secrete apoE
0.32282493.12501252.html.plaintext.txt	218	However brain ST produced oligodendrocytes located myelin CNS likely majority ST apoE particles CNS acquired myelin apoE secretion expressed cells
0.32282493.12501252.html.plaintext.txt	219	The major effect mouse human apoE appears keeping ST levels brain lower level present absence apoE
0.32282493.12501252.html.plaintext.txt	220	This effect probably due apoE containing lipoproteins facilitating cellular clearance ST
0.32282493.12501252.html.plaintext.txt	221	Although hydrolysis ST directly catalyzed apoE observed study apoE associated ST hydrolysis vivo completely excluded
0.32282493.12501252.html.plaintext.txt	222	Because showed ST directly associates apoE containing lipoproteins CSF likely transport ST apoE particles brain interstitial fluid CSF endocytotic recycling apoE particles LDL receptor LDL receptor family members LDL receptor related proteins 37 major pathways apoE mediates ST metabolism CNS
0.32282493.12501252.html.plaintext.txt	223	The 4 allele APOE strong genetic risk factor AD cerebral amyloid angiopathy whereas 2 allele protective
0.32282493.12501252.html.plaintext.txt	224	Although several possible mechanisms associations exist strong evidence suggest interaction apoE A play important role effect apoE AD see Refs
0.32282493.12501252.html.plaintext.txt	225	For example transgenic animal models develop AD like amyloidosis neuritic plaques lack apoE results little fibrillar amyloid formation neuritic dystrophy 14 39 expression human apoE results isoform specific deposition amyloid within neuritic plaques effect order apoE4 E3 E2 15 40
0.32282493.12501252.html.plaintext.txt	226	These effects apoE A likely mediated interactions apoE containing HDL form apoE brain A
0.32282493.12501252.html.plaintext.txt	227	Given issues way sulfatide association apoE containing lipoproteins may involved apoE A interactions
0.32282493.12501252.html.plaintext.txt	228	It shown apoE interaction A markedly influenced presence lipids 41 43
0.32282493.12501252.html.plaintext.txt	229	However previous work 27 data presented shown quantitative difference amount phospholipids cholesterol present brain CSF lipoproteins presence absence apoE apoE isoforms
0.32282493.12501252.html.plaintext.txt	230	In contrast observed significant isoform specific difference ST levels E4 E3 human CSF lipoproteins
0.32282493.12501252.html.plaintext.txt	231	Although yet explored whether sulfatide levels apoE particles influence interactions A shown portion A co elutes apoE containing HDL particles shown also contain ST human CSF 27
0.32282493.12501252.html.plaintext.txt	232	In addition effect apoE apoE isoform risk AD substantial evidence apoE4 also risk factor poor outcome following certain CNS injuries head trauma multiple sclerosis possibly stroke see Ref
0.32282493.12501252.html.plaintext.txt	233	How apoE plays role processes remains unclear
0.32282493.12501252.html.plaintext.txt	234	It possible effect via isoform specific difference regeneration shown vitro vivo models see Ref
0.32282493.12501252.html.plaintext.txt	235	It also possible particularly case multiple sclerosis possibly stroke apoE somehow regulating CNS inflammatory processes cytokine production seen models e
0.32282493.12501252.html.plaintext.txt	236	Interestingly numerous studies shown sulfatides ligands family receptor proteins called selectins located activated vascular endothelial cells leukocytes activated platelets 45 51
0.32282493.12501252.html.plaintext.txt	237	Although relationship role apoE immunoregulation sulfatide ligand selectins unclear shown sulfatides potent anti inflammatory agents 52
0.32282493.12501252.html.plaintext.txt	238	This potential relationship likely indicates possible role ST apoE particles anti inflammatory immunomodulatory molecule
0.32282493.12501252.html.plaintext.txt	239	In sum although apoE brain play major role regulating brain phospholipid cholesterol levels data show apoE plays important role regulating brain sulfatide levels via apoE containing CNS lipoproteins serving extracellular ST carrier regulates metabolism
0.32282493.12501252.html.plaintext.txt	240	Further work understanding relationship apoE ST may provide important clues pathogenesis effects apoE AD following different CNS injuries
0.32282493.12501252.html.plaintext.txt	241	We grateful Washington University Mass Spectrometer Facility Center use electrospray ionization mass spectrometer
0.32282493.12501252.html.plaintext.txt	242	We thank Clinical Core Washington University Alzheimers Disease Research Center providing subject evaluations clinical dementia ratings Washington University General Clinical Research Center providing lumbar CSF samples
0.32282493.12501252.html.plaintext.txt	243	We also give special thanks Maia Parsadanian skillful assistance mouse brain dissection
0.32282493.12501252.html.plaintext.txt	244	This work supported NIA National Institutes Health NIH Grant P50 AG05681 NIH Grant AG 13956 NIH Grant M01 RR00036 Alzheimers Disease Related Disorders Program University Missouri System
0.32282493.12501252.html.plaintext.txt	245	The costs publication article defrayed part payment page charges
0.32282493.12501252.html.plaintext.txt	246	The article must therefore hereby marked advertisement accordance 18 U
0.32282493.12501252.html.plaintext.txt	247	Section 1734 solely indicate fact
0.32282493.12501252.html.plaintext.txt	248	To correspondence addressed Division Bioorganic Chemistry Molecular Pharmacology Dept
0.32282493.12501252.html.plaintext.txt	249	Internal Medicine Washington University School Medicine Box 8020 660 S
0.32282493.12501252.html.plaintext.txt	250	314 362 2690 Fax 314 362 1402 E mail xianlinpcg
0.32282493.12501252.html.plaintext.txt	251	Published JBC Papers Press December 24 2002 DOI 10
0.32282493.12501252.html.plaintext.txt	252	The abbreviations used apoE apolipoprotein E apoE3 apoE4 human apoE isoforms apoJ apolipoprotein J AD Alzheimers disease Cer ceramides CNS central nervous system CSF cerebrospinal fluid ESIMS electrospray ionization mass spectrometry GalC galactocerebrosides HDL high density lipoprotein LDL low density lipoprotein mn acyl chain containing m carbons n double bonds Nmn acyl amide m carbons n double bonds PC choline glycerophospholipids PE ethanolamine glycerophospholipids PtdCho phosphatidylcholine PtdEtn phosphatidylethanolamine PtdGro phosphatidylglycerols PtdIns phosphatidylinositols PtdSer phosphatidylserines rhApoE human recombinant apoE SM sphingomyelins ST sulfatides A amyloid peptide GFAP glial fibrillary acidic protein
0.32282493.12501252.html.plaintext.txt	253	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES 1
0.32282493.12501252.html.plaintext.txt	254	1988 Science 240 622 630Medline Order article via Infotrieve 2
0.32282493.12501252.html.plaintext.txt	255	45 249 302Medline Order article via Infotrieve 3
0.32282493.12501252.html.plaintext.txt	256	262 14352 14360AbstractFree Full Text 4
0.32282493.12501252.html.plaintext.txt	257	Acta 917 148 161Medline Order article via Infotrieve 6
0.32282493.12501252.html.plaintext.txt	258	1987 Science 236 959 962Medline Order article via Infotrieve 7
0.32282493.12501252.html.plaintext.txt	259	19 4867 4880AbstractFree Full Text 9
0.32282493.12501252.html.plaintext.txt	260	19 53 77CrossRefMedline Order article via Infotrieve 11
0.32282493.12501252.html.plaintext.txt	261	17 147 155CrossRefMedline Order article via Infotrieve 12
0.32282493.12501252.html.plaintext.txt	262	135 235 238CrossRefMedline Order article via Infotrieve 13
0.32282493.12501252.html.plaintext.txt	263	90 8098 8102AbstractFree Full Text 14
0.32282493.12501252.html.plaintext.txt	264	17 263 264Medline Order article via Infotrieve 15
0.32282493.12501252.html.plaintext.txt	265	97 2892 2897AbstractFree Full Text 16
0.32282493.12501252.html.plaintext.txt	266	Acta 1211 125 149Medline Order article via Infotrieve 17
0.32282493.12501252.html.plaintext.txt	267	142 208 225CrossRefMedline Order article via Infotrieve 18
0.32282493.12501252.html.plaintext.txt	268	36 245 319CrossRefMedline Order article via Infotrieve 19
0.32282493.12501252.html.plaintext.txt	269	1995 The Metabolic Basis Inherited Disease Scriver C
0.32282493.12501252.html.plaintext.txt	270	2693 2739 McGraw Hill New York 20
0.32282493.12501252.html.plaintext.txt	271	82 809 818CrossRefMedline Order article via Infotrieve 21
0.32282493.12501252.html.plaintext.txt	272	93 13280 13285AbstractFree Full Text 22
0.32282493.12501252.html.plaintext.txt	273	292 199 210CrossRefMedline Order article via Infotrieve 24
0.32282493.12501252.html.plaintext.txt	274	1996 Cell 86 209 219Medline Order article via Infotrieve 25
0.32282493.12501252.html.plaintext.txt	275	15 495 518CrossRefMedline Order article via Infotrieve 26
0.32282493.12501252.html.plaintext.txt	276	18 3261 3272AbstractFree Full Text 27
0.32282493.12501252.html.plaintext.txt	277	CO2 X 2 8linktypeDOI CrossRefMedline Order article via Infotrieve 40
0.32282493.12501252.html.plaintext.txt	278	9 305 318CrossRefMedline Order article via Infotrieve 41
0.32282493.12501252.html.plaintext.txt	279	269 23403 23406AbstractFree Full Text 42
0.32282493.12501252.html.plaintext.txt	280	270 9039 9042AbstractFree Full Text 43
0.32282493.12501252.html.plaintext.txt	281	348 359 365CrossRefMedline Order article via Infotrieve 44
0.32282493.12501252.html.plaintext.txt	282	76 70 74CrossRefMedline Order article via Infotrieve 45
0.32282493.12501252.html.plaintext.txt	283	190 426 434CrossRefMedline Order article via Infotrieve 47
0.32282493.12501252.html.plaintext.txt	284	1994 Biochemistry 33 1332 1339Medline Order article via Infotrieve 48
0.32282493.12501252.html.plaintext.txt	285	59 155 157Medline Order article via Infotrieve 49
0.32282493.12501252.html.plaintext.txt	286	2001 Biochemistry 40 5382 5391CrossRefMedline Order article via Infotrieve 51
0.32282493.12501252.html.plaintext.txt	287	2001 Circulation 104 2955 2960AbstractFree Full Text 52
0.32282493.12501252.html.plaintext.txt	288	40 3234 3247CrossRefMedline Order article via Infotrieve
0.32282493.12501252.html.plaintext.txt	289	Copyright 2003 The American Society Biochemistry Molecular Biology Inc
0.2925662.11304532.html.plaintext.txt	0	A Recycling Pathway Resecretion Internalized Apolipoprotein E Liver Cells Larry L
0.2925662.11304532.html.plaintext.txt	1	Major Klara Valyi Nagy MacRae F
0.2925662.11304532.html.plaintext.txt	2	From Departments Pathology Medicine Pharmacology Vanderbilt University School Medicine Nashville Tennessee 37232
0.2925662.11304532.html.plaintext.txt	3	Received publication January 9 2001 revised form March 29 2001
0.2925662.11304532.html.plaintext.txt	4	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.2925662.11304532.html.plaintext.txt	5	We investigated recycling apoE livers apoE mice transplanted wild type bone marrow apoE apoE model circulating apoE derived exclusively macrophages
0.2925662.11304532.html.plaintext.txt	6	Nascent Golgi lipoproteins recovered livers apoE apoE mice 8 weeks transplantation
0.2925662.11304532.html.plaintext.txt	7	ApoE identified nascent d 1
0.2925662.11304532.html.plaintext.txt	8	210 gml lipoproteins level 6 nascent lipoproteins C57BL6 mice
0.2925662.11304532.html.plaintext.txt	9	Hepatocytes apoE apoE mice isolated cultured media free exogenous apoE
0.2925662.11304532.html.plaintext.txt	10	ApoE found media primarily d 1
0.2925662.11304532.html.plaintext.txt	11	006 gml fraction indicating resecretion internalized apoprotein
0.2925662.11304532.html.plaintext.txt	12	Secretion apoE C57BL6 hepatocytes consistent constitutive production whereas majority apoE secreted apoE apoE hepatocytes recovered last 24 h culture
0.2925662.11304532.html.plaintext.txt	13	This suggests release may triggered accumulation acceptor low density lipoproteins media
0.2925662.11304532.html.plaintext.txt	14	In agreement vivo data total recovery apoE apoE apoE hepatocytes 6 apoE recovered C57BL6 hepatocytes
0.2925662.11304532.html.plaintext.txt	15	Since plasma apoE levels transplanted mice 10 control levels findings indicate 60 internalized apoE may reutilized physiologic conditions
0.2925662.11304532.html.plaintext.txt	16	These studies provide definitive evidence sparing apoE routing secretory pathway demonstrate internalized apoE resecreted quantitatively significant fashion
0.2925662.11304532.html.plaintext.txt	17	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.2925662.11304532.html.plaintext.txt	18	Apolipoprotein E apoE1 unique among plasma lipoprotein apoproteins many different functions metabolism lipids lipoproteins
0.2925662.11304532.html.plaintext.txt	19	Its role ligand receptor mediated endocytosis lipoproteins well established 1 3
0.2925662.11304532.html.plaintext.txt	20	Additionally apoE interacts lipoprotein lipase hepatic lipase modulate triglyceride hydrolysis 4 5
0.2925662.11304532.html.plaintext.txt	21	Even within cell apoE known serve biologically relevant roles
0.2925662.11304532.html.plaintext.txt	22	Studies suggest apoE directs intracellular routing internalized remnant lipoproteins smaller migrating low density lipoproteins VLDL particles routed perinuclear region mouse macrophage fashion similar low density lipoproteins LDL whereas larger VLDL remain closer plasma membrane 6 7
0.2925662.11304532.html.plaintext.txt	23	8 report apoE modulates intracellular lipid metabolism particular hydrolysis utilization triglyceride
0.2925662.11304532.html.plaintext.txt	24	ApoE also linked may regulator cholesterol efflux macrophages 9 11 effect significant repercussions vascular health process atherogenesis
0.2925662.11304532.html.plaintext.txt	25	Finally increasing evidence points role apoE hepatic lipoprotein assembly incorporation triglycerides newly forming VLDL 12 14
0.2925662.11304532.html.plaintext.txt	26	Due critical role number biological processes within cell apoE may follow unique pathways secretion internalization maximize impact cellular functions
0.2925662.11304532.html.plaintext.txt	27	Wong 15 among first suggest apoE may recirculated
0.2925662.11304532.html.plaintext.txt	28	He reported 62 66 intrahepatic apoE compared 7 10 intrahepatic apoB derived plasma
0.2925662.11304532.html.plaintext.txt	29	This suggested internalized apoE may undergo complete degradation may therefore follow unique intracellular routing pathway
0.2925662.11304532.html.plaintext.txt	30	We previously reported portion apoE component internalized lipoproteins spared degradation routed Golgi apparatus 16
0.2925662.11304532.html.plaintext.txt	31	After injection radioiodinated mouse d 1
0.2925662.11304532.html.plaintext.txt	32	019 gml lipoproteins C57BL6 mice radioactivity found Golgi apparatus rich fractions livers recipient mice almost exclusively due apoE although injected lipoproteins less 10 label associated apoE
0.2925662.11304532.html.plaintext.txt	33	The ratio apoEapoB48 Golgi fraction increased 10 fold relative serum traces apoB100 detected
0.2925662.11304532.html.plaintext.txt	34	Furthermore apoE recovered Golgi fraction part d 1
0.2925662.11304532.html.plaintext.txt	35	210 gml complex indicating association recycled apoE newly formed lipoproteins
0.2925662.11304532.html.plaintext.txt	36	Quantitatively similar results obtained labeled VLDL injected mice deficient either apoE LDL receptor indicating phenomenon apoE recycling influenced production endogenous apoE dependent presence LDL receptors
0.2925662.11304532.html.plaintext.txt	37	Although studies clearly demonstrated presence mechanism vivo apoE escapes degradation appearance internalized apoE within liver Golgi may influenced part bolus delivery apoE model
0.2925662.11304532.html.plaintext.txt	38	To address issue explore hepatic apoE recycling steady state completed experiments utilizing vivo model based bone marrow transplantation
0.2925662.11304532.html.plaintext.txt	39	Reconstitution lethally irradiated apoE mice wild type bone marrow results mouse model apoE present mouse derived macrophages
0.2925662.11304532.html.plaintext.txt	40	Our laboratory 17 shown within 3 weeks introduction normal macrophages apoE mouse serum apoE levels reach 10 normal resulting complete normalization plasma cholesterol levels virtue active hepatic clearance remnant lipoproteins
0.2925662.11304532.html.plaintext.txt	41	Since hepatocytes model produce endogenous apoE internalize apoE remnant lipoproteins approach provides excellent model investigating routing internalized apoE secretory pathway via Golgi apparatus absence endogenously produced apoE
0.2925662.11304532.html.plaintext.txt	42	The studies reported manuscript demonstrate clearly internalized apoE undergoes unique routing secretory pathway resecreted
0.2925662.11304532.html.plaintext.txt	43	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.2925662.11304532.html.plaintext.txt	44	Mice ApoE deficient apoE mice C57BL6 background obtained The Jackson Laboratory Bar Harbor ME
0.2925662.11304532.html.plaintext.txt	45	A colony C57BL6J mice established animal facility
0.2925662.11304532.html.plaintext.txt	46	All mice kept 12 h light12 h dark cycle fed normal mouse chow diet RP5015 PMI Feeds Inc
0.2925662.11304532.html.plaintext.txt	47	Food water available ad libitum
0.2925662.11304532.html.plaintext.txt	48	All animal procedures carried accordance institutional guidelines approval Animal Care Committee Vanderbilt University
0.2925662.11304532.html.plaintext.txt	49	Bone Marrow Transplantation BMT BMT carried described previously 17
0.2925662.11304532.html.plaintext.txt	50	One week 2 weeks BMT 100 mgliter neomycin 10 mgliter polymyxin B sulfate Sigma added water
0.2925662.11304532.html.plaintext.txt	51	Bone marrow collected donor mice flushing femurs RPMI 1640 media containing 2 fetal bovine serum 10 unitsml heparin Sigma
0.2925662.11304532.html.plaintext.txt	52	Recipient mice lethally irradiated 9 gray 4 h later 5 x 106 bone marrow cells 0
0.2925662.11304532.html.plaintext.txt	53	3 ml transplanted tail vein injection
0.2925662.11304532.html.plaintext.txt	54	Animals used studies 6 12 weeks transplantation
0.2925662.11304532.html.plaintext.txt	55	Isolation Golgi Apparatus rich Fractions Nascent Lipoproteins Golgi apparatus rich fractions prepared described previously 18
0.2925662.11304532.html.plaintext.txt	56	Golgi fractions isolated 4 5 mice total liver 5 6 g
0.2925662.11304532.html.plaintext.txt	57	Typically able isolate 200 300 microg Golgi protein 5 6 g liver
0.2925662.11304532.html.plaintext.txt	58	Nascent lipoproteins released Golgi apparatus using sodium carbonate treatment 19 lipoprotein classes isolated ultracentrifugation described
0.2925662.11304532.html.plaintext.txt	59	Preparation Culture Mouse Hepatocytes Hepatocytes isolated mouse livers described Horton et al
0.2925662.11304532.html.plaintext.txt	60	The mice anesthetized using ketaminexylazine mixture midline incision made
0.2925662.11304532.html.plaintext.txt	61	The portal vein cannulated 24 gauge plastic cannula liver perfused Ca2Mg2 free Honks Balanced Salt Solution containing glucose 10 mM HEPES 10 mM flow rate 3 mlmin 10 min
0.2925662.11304532.html.plaintext.txt	62	The perfusate switched liver digest medium containing collagenase Life Technologies Inc
0.2925662.11304532.html.plaintext.txt	63	perfusion continued another 10 min
0.2925662.11304532.html.plaintext.txt	64	The liver removed animal placed collagenase media culture dish minced gently scissors incubated 37 degrees C 4 min
0.2925662.11304532.html.plaintext.txt	65	The dissociated cells dispersed shaking followed filtration 100 microm nylon cell strainers Falcon cell strainer Becton Dickinson Franklin Lakes NJ
0.2925662.11304532.html.plaintext.txt	66	The liver capsule dish rinsed 10 15 ml low glucose Dulbeccos modified Eagles medium Life Technologies Inc
0.2925662.11304532.html.plaintext.txt	67	containing 1 bovine serum albumin 0
0.2925662.11304532.html.plaintext.txt	68	167 microgml insulin 4 milliunitsml 0
0.2925662.11304532.html.plaintext.txt	69	02 microgml dexamethasone 100 units penicillin 100 microg streptomycinml
0.2925662.11304532.html.plaintext.txt	70	The cells pelleted gravity sedimentation 5 min 4 degrees C
0.2925662.11304532.html.plaintext.txt	71	The media aspirated leaving 5 ml total volume fresh media added 20 ml
0.2925662.11304532.html.plaintext.txt	72	The cells resuspended viability assessed trypan blue exclusion
0.2925662.11304532.html.plaintext.txt	73	The yield hepatocytes ranged 3 x 106 6 x 106 cellsg liver viability consistently greater 85
0.2925662.11304532.html.plaintext.txt	74	The cells plated onto 60 mm mouse collagen IV coated dishes BioCoat Becton Dickinson density 1
0.2925662.11304532.html.plaintext.txt	75	2 x 106 viable cellsdish 2 ml medium
0.2925662.11304532.html.plaintext.txt	76	The media used isolation plating washing incubations contain serum avoid introduction exogenous apoE system
0.2925662.11304532.html.plaintext.txt	77	Media collected 4 21 45 h plating cells cell fragments pelleted centrifugation
0.2925662.11304532.html.plaintext.txt	78	Cells recovered end experiment 45 h time point washed phosphate buffered saline frozen
0.2925662.11304532.html.plaintext.txt	79	Isolation Lipoproteins Cell Cultures Golgi Fractions Lipoproteins adsorbed media using Liposorb PHM L Liposorb Calbiochem Novabiochem per manufacturers recommendations
0.2925662.11304532.html.plaintext.txt	80	5 ml normal saline 5 microl added 2 ml media
0.2925662.11304532.html.plaintext.txt	81	The samples gently mixed 30 min lipoproteins pelleted
0.2925662.11304532.html.plaintext.txt	82	In laboratory procedure shown adsorb 70 apoE hepatocyte media 100 apoE isolated lipoprotein fractions data shown
0.2925662.11304532.html.plaintext.txt	83	Furthermore apoE adsorbed large small lipoproteins equal efficiency
0.2925662.11304532.html.plaintext.txt	84	The adsorbed proteins solubilized lithium dodecyl sulfate solubilizing buffer separated SDS gels described
0.2925662.11304532.html.plaintext.txt	85	Intracellular lipoproteins recovered treating cells 0
0.2925662.11304532.html.plaintext.txt	86	1 M sodium carbonate 1 h 0 degrees C 19
0.2925662.11304532.html.plaintext.txt	87	The membranes cell debris pelleted centrifugation using Beckman Optima TLX ultracentrifuge Beckman Coulter 120
0.2925662.11304532.html.plaintext.txt	88	2 rotor 120000 rpm x 30 min
0.2925662.11304532.html.plaintext.txt	89	The supernatant dialyzed normal saline lipoproteins adsorbed using Liposorb described
0.2925662.11304532.html.plaintext.txt	90	Lipoproteins classes isolated Golgi contents hepatocyte culture media ultracentrifugation using Beckman tabletop ultracentrifuge
0.2925662.11304532.html.plaintext.txt	91	Golgi lipoprotein classes d 1
0.2925662.11304532.html.plaintext.txt	92	210 gml isolated described previously using 120
0.2925662.11304532.html.plaintext.txt	93	Lipoproteins culture media recovered using 100
0.2925662.11304532.html.plaintext.txt	94	006 gml lipoproteins isolated 6 h 100000 rpm recovered using tube slicing Beckman Centritube Slicer
0.2925662.11304532.html.plaintext.txt	95	The density infranatant raised 1
0.2925662.11304532.html.plaintext.txt	96	210 gml using solid KBr d 1
0.2925662.11304532.html.plaintext.txt	97	210 gml fraction isolated 13 h 100000 rpm recovered tube slicing
0.2925662.11304532.html.plaintext.txt	98	The fractions dialyzed lyophilized separation apoproteins SDS gel electrophoresis
0.2925662.11304532.html.plaintext.txt	99	Metabolic Labeling Mouse Hepatocytes Primary hepatocytes isolated cultured 16 h low glucose Dulbeccos modified Eagles medium containing 1 bovine serum albumin 0
0.2925662.11304532.html.plaintext.txt	100	Fresh media added cells pulsed 60 min Promix L 35S vitro cell labeling mix 100 microCiml Amersham Pharmacia Biotech
0.2925662.11304532.html.plaintext.txt	101	The media removed cells washed twice phosphate buffered saline chased 3 6 12 h media
0.2925662.11304532.html.plaintext.txt	102	ApoE immunoprecipitated media using anti human polyclonal antibody Biodesign International Saco ME Pansorbin Calbiochem Novabiochem described previously 21
0.2925662.11304532.html.plaintext.txt	103	The immunoprecipitates solubilized separated SDS PAGE described
0.2925662.11304532.html.plaintext.txt	104	The gels fixed watermethanolacetic acid 10101 vvv dried exposed Cyclone SR screen periods 46 h
0.2925662.11304532.html.plaintext.txt	105	ApoE visualized using Cyclone Storage Phosphor System OptiQuant software Packard Instrument Co
0.2925662.11304532.html.plaintext.txt	106	SDS Polyacrylamide Gel Electrophoresis Immunoblotting Proteins separated using NOVEX system Invitrogen Carlsbad CA NuPAGE bis tris gels 4 12 gradients
0.2925662.11304532.html.plaintext.txt	107	The samples solubilized NuPAGE lithium dodecyl sulfate sample buffer gels run using MOPS SDS running buffer
0.2925662.11304532.html.plaintext.txt	108	The proteins transferred nitrocellulose membranes using NOVEX system NuPAGE transfer buffer containing 10 methanol
0.2925662.11304532.html.plaintext.txt	109	The membranes blocked 5 nonfat milk incubated primary antibodies washed extensively incubated horseradish peroxidase conjugated secondary antibodies
0.2925662.11304532.html.plaintext.txt	110	Bands visualized using enhanced chemiluminescence Amersham Pharmacia Biotech
0.2925662.11304532.html.plaintext.txt	111	In Vivo Hepatic VLDL Triglyceride Production Hepatic VLDL triglyceride production measured using Triton WR1339
0.2925662.11304532.html.plaintext.txt	112	Mice fasted overnight anesthetized ketaminexylazine mixture injected via retro orbital plexus Triton WR1339 800 mgkg body weight
0.2925662.11304532.html.plaintext.txt	113	Triton Sigma dissolved normal saline concentration 25 mgdl
0.2925662.11304532.html.plaintext.txt	114	Preliminary studies laboratory demonstrated linear increase VLDL triglyceride 6 h period using concentration Triton providing strong evidence plasma VLDL clearance completely inhibited conditions
0.2925662.11304532.html.plaintext.txt	115	Blood samples 50 microl taken retro orbital plexus injection 0 h 1 2 3 4 h Triton injection
0.2925662.11304532.html.plaintext.txt	116	Plasma triglycerides measured using enzymatic assays adapted microtiter plates Raichem San Diego CA
0.2925662.11304532.html.plaintext.txt	117	Slopes lines determined GraphPad Prism v
0.2925662.11304532.html.plaintext.txt	118	Hepatic triglyceride production rates calculated slopes presented micromol triglyceride producedkgh assuming plasma volume 33 microlg 22
0.2925662.11304532.html.plaintext.txt	119	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.2925662.11304532.html.plaintext.txt	120	ApoE Recycling ApoE Mice Transplanted Bone Marrow C57BL6 Mice ApoE mice transplanted bone marrow C57BL6 mice apoE apoE 8 weeks post BMT hepatic Golgi apparatus rich fractions isolated
0.2925662.11304532.html.plaintext.txt	121	Previous studies laboratory show Golgi fractions enriched galactosyl transferase minimal contamination components endocytic compartment 18
0.2925662.11304532.html.plaintext.txt	122	Reconstitution apoE mice marrow C57BL6 mice leads appearance apoE plasma lipoproteins promoting clearance lipoprotein remnants normalization plasma cholesterol 17
0.2925662.11304532.html.plaintext.txt	123	In C57BL6 mice apoE easily detected d 1
0.2925662.11304532.html.plaintext.txt	124	1 relative distribution apoE among three fractions determined densitometric scanning 55 40 5 respectively
0.2925662.11304532.html.plaintext.txt	125	ApoE also found nascent Golgi lipoproteins apoE apoE mice Fig
0.2925662.11304532.html.plaintext.txt	126	1 distribution similar control C57BL6 preparations 50 d 1
0.2925662.11304532.html.plaintext.txt	127	No apoE detected d 1
0.2925662.11304532.html.plaintext.txt	128	210 gml fraction perhaps reflecting small amount total apoE recovered Golgi fractions
0.2925662.11304532.html.plaintext.txt	129	The apoE nascent hepatic Golgi lipoproteins apoE apoE animals normalized amount apoB48 6 found Golgi lipoproteins control animals
0.2925662.11304532.html.plaintext.txt	130	View larger version 47K Fig
0.2925662.11304532.html.plaintext.txt	131	Nascent hepatic Golgi lipoproteins C57BL6 mice apoE apoE mice
0.2925662.11304532.html.plaintext.txt	132	ApoE mice transplanted marrow C57BL6 mice 8 weeks post BMT hepatic Golgi apparatus rich fractions isolated nascent lipoproteins recovered
0.2925662.11304532.html.plaintext.txt	133	The apoproteins separated SDS PAGE blotted nitrocellulose probed apoB apoE
0.2925662.11304532.html.plaintext.txt	134	Ex Vivo Resecretion ApoE To determine apoE internalized resecreted primary hepatocytes isolated C57BL6 mice apoE apoE mice
0.2925662.11304532.html.plaintext.txt	135	2 presents micrograph cultured hepatocytes C57BL6 mice stained hematoxylin eosin
0.2925662.11304532.html.plaintext.txt	136	The cultures also immunostained presence Kupffer cells using monocyte macrophage marker MOMA 2
0.2925662.11304532.html.plaintext.txt	137	Cell counts numerous fields three different preparations showed less 1 2 contamination hepatocyte cultures Kupffer cells
0.2925662.11304532.html.plaintext.txt	138	3 shows results experiments media first two time points 4 21 h combined lipoproteins adsorbed using Liposorb
0.2925662.11304532.html.plaintext.txt	139	As seen apoE clearly present media apoE apoE mice
0.2925662.11304532.html.plaintext.txt	140	This suggests apoE internalized vivo routed secretory pathway resecreted hepatocytes culture
0.2925662.11304532.html.plaintext.txt	141	View larger version 99K Fig
0.2925662.11304532.html.plaintext.txt	142	Hepatocytes apoE apoE mice
0.2925662.11304532.html.plaintext.txt	143	Hepatocytes isolated described Experimental Procedures grown coverslips coated mouse type IV collagen fixed stained hematoxylin eosin A antibody MOMA 2 B macrophage marker
0.2925662.11304532.html.plaintext.txt	144	Less 1 2 cells stained MOMA 2
0.2925662.11304532.html.plaintext.txt	145	View larger version 23K Fig
0.2925662.11304532.html.plaintext.txt	146	Resecretion apoE hepatocytes apoE apoE mice
0.2925662.11304532.html.plaintext.txt	147	ApoE mice transplanted bone marrow C57BL6 mice 6 weeks post BMT hepatocytes isolated described Experimental Procedures
0.2925662.11304532.html.plaintext.txt	148	Hepatocytes nontransplanted C57BL6 mice served control
0.2925662.11304532.html.plaintext.txt	149	Media 4 21 h time points combined lipoproteins adsorbed using Liposorb
0.2925662.11304532.html.plaintext.txt	150	Apoproteins separated SDS PAGE blotted nitrocellulose probed apoE
0.2925662.11304532.html.plaintext.txt	151	The time course appearance apoE media hepatocytes C57BL6 mice apoE apoE mice shown Fig
0.2925662.11304532.html.plaintext.txt	152	ApoE present media C57BL6 hepatocytes time point
0.2925662.11304532.html.plaintext.txt	153	The mass apoE appeared proportional time culture
0.2925662.11304532.html.plaintext.txt	154	In addition apoE found cells end experiment
0.2925662.11304532.html.plaintext.txt	155	ApoE also observed media hepatocytes apoE apoE mice
0.2925662.11304532.html.plaintext.txt	156	At early time points little apoE detected later time points appeared greater release apoprotein
0.2925662.11304532.html.plaintext.txt	157	There little apoE detected cells apoE apoE mice end 45 h culture period
0.2925662.11304532.html.plaintext.txt	158	Furthermore cells appeared healthy 45 h culture period evidence massive cell death
0.2925662.11304532.html.plaintext.txt	159	In C57BL6 hepatocytes 10 total apoE secreted first 4 h 40 secreted next 17 h 49 secreted last 24 h Fig
0.2925662.11304532.html.plaintext.txt	160	This suggests constant production apoE throughout culture period
0.2925662.11304532.html.plaintext.txt	161	In contrast hepatocytes apoE mice transplanted C57BL6 marrow 1
0.2925662.11304532.html.plaintext.txt	162	7 total secreted apoE recovered media 4 h whereas 15
0.2925662.11304532.html.plaintext.txt	163	2 appeared next 17 h 83 recovered final 24 h incubation Fig
0.2925662.11304532.html.plaintext.txt	164	In two separate experiments total apoE secreted BMT hepatocytes 45 h period 6
0.2925662.11304532.html.plaintext.txt	165	5 apoE secreted C57BL6 hepatocytes period
0.2925662.11304532.html.plaintext.txt	166	View larger version 38K Fig
0.2925662.11304532.html.plaintext.txt	167	Time course resecretion apoE hepatocytes apoE apoE mice
0.2925662.11304532.html.plaintext.txt	168	Hepatocytes isolated apoE apoE mice cultured described Experimental Procedures
0.2925662.11304532.html.plaintext.txt	169	Media collected time point cells recovered end experiment
0.2925662.11304532.html.plaintext.txt	170	Cellular media lipoproteins adsorbed using Liposorb
0.2925662.11304532.html.plaintext.txt	171	Apoproteins separated SDS PAGE blotted nitrocellulose probed apoB apoE A
0.2925662.11304532.html.plaintext.txt	172	Hepatocytes nontransplanted C57BL6 mice served control
0.2925662.11304532.html.plaintext.txt	173	Blots scanned appearance apoE media expressed percent total secreted apoE B
0.2925662.11304532.html.plaintext.txt	174	Data expressed mean plus minus S
0.2925662.11304532.html.plaintext.txt	175	Synthesis Secretion ApoE Primary Cultures Mouse Hepatocytes The secretion radiolabeled apoE primary hepatocytes C57BL6 mice apoE apoE mice shown Fig
0.2925662.11304532.html.plaintext.txt	176	Newly synthesized apoE easily detected media C57BL6 hepatocytes detected hepatocyte cultures apoE apoE mice time points
0.2925662.11304532.html.plaintext.txt	177	As expected recycling unlabeled apoE observed time points data shown
0.2925662.11304532.html.plaintext.txt	178	These results demonstrate clearly apoE media hepatocytes apoE apoE mice derive contaminating Kupffer cells represents apoE internalized vivo subsequently resecreted culture
0.2925662.11304532.html.plaintext.txt	179	View larger version 20K Fig
0.2925662.11304532.html.plaintext.txt	180	Synthesis secretion apoE primary cultures mouse hepatocytes
0.2925662.11304532.html.plaintext.txt	181	ApoE mice transplanted bone marrow C57BL6 mice 25 day post BMT hepatocytes isolated described Experimental Procedures
0.2925662.11304532.html.plaintext.txt	182	Hepatocytes nontransplanted C57BL6 mice served control
0.2925662.11304532.html.plaintext.txt	183	The cells cultured 16 h Dulbeccos modified Eagles medium supplemented 0
0.2925662.11304532.html.plaintext.txt	184	The media replaced fresh media cells labeled 60 min Promix L 35S vitro cell labeling mix 100 microCiml
0.2925662.11304532.html.plaintext.txt	185	At end pulse media removed cells washed twice phosphate buffered saline chased 3 6 12 h media
0.2925662.11304532.html.plaintext.txt	186	ApoE immunoprecipitated media immunoprecipitates solubilized proteins separated SDS PAGE
0.2925662.11304532.html.plaintext.txt	187	The gels fixed watermethanolacetic acid 10101 vvv dried exposed Cyclone SR screen
0.2925662.11304532.html.plaintext.txt	188	ApoE visualized using Cyclone Storage Phosphor System
0.2925662.11304532.html.plaintext.txt	189	Lanes 1 3 5 C57BL6 lanes 2 4 6 apoE apoE
0.2925662.11304532.html.plaintext.txt	190	Density Distribution Resecreted ApoE In media C57BL6 hepatocytes apoE distributed approximately equally d 1
0.2925662.11304532.html.plaintext.txt	191	210 gml fractions whereas hepatocytes apoE apoE mice apoE found d 1
0.2925662.11304532.html.plaintext.txt	192	This may reflect affinity apoE triglyceride rich lipoproteins media apoE deficient may also suggest apoE deficient triglyceride rich lipoproteins media stimulate apoE release cells recycling apoE induces assembly triglyceride rich lipoproteins possibility investigated next set experiments
0.2925662.11304532.html.plaintext.txt	193	View larger version 49K Fig
0.2925662.11304532.html.plaintext.txt	194	Ultracentrifugal distribution apoE media hepatocytes apoE apoE mice
0.2925662.11304532.html.plaintext.txt	195	Hepatocytes isolated apoE apoE mice cultured described Experimental Procedures
0.2925662.11304532.html.plaintext.txt	196	Media collected 45 h time point dialyzed saline lipoproteins isolated using Beckman Optima TLX ultracentrifuge
0.2925662.11304532.html.plaintext.txt	197	Apoproteins fraction separated SDS PAGE blotted nitrocellulose probed apoB apoE
0.2925662.11304532.html.plaintext.txt	198	Hepatocytes nontransplanted C57BL6 mice served control
0.2925662.11304532.html.plaintext.txt	199	Hepatic Triglyceride Production Rate Hepatic triglyceride production rates using Triton method measured C57BL6 apoE mice apoE apoE mice apoE mice transplanted apoE marrow
0.2925662.11304532.html.plaintext.txt	200	The production rates groups linear time period r values 0
0.2925662.11304532.html.plaintext.txt	201	As shown previously 13 14 hepatic triglyceride production rates apoE mice 50 found C57BL6 mice Fig
0.2925662.11304532.html.plaintext.txt	202	Hepatic triglyceride production rates mice transplanted marrow either apoE apoE mice similar significantly different rates found apoE mice suggesting effect recycling apoE triglyceride production magnitude induce bulk increase lipoprotein accumulation
0.2925662.11304532.html.plaintext.txt	203	View larger version 9K Fig
0.2925662.11304532.html.plaintext.txt	204	Hepatic triglyceride TG production rates
0.2925662.11304532.html.plaintext.txt	205	Hepatic triglyceride production measured using Triton method C57BL6 mice C57BL6 apoE mice E apoE mice transplanted marrow C57BL6 mice E E apoE mice transplanted marrow apoE mice E E
0.2925662.11304532.html.plaintext.txt	206	Triglyceride secretion linear 4 h period hepatic triglyceride production rates calculated slopes lines using GraphPad Prism version 3
0.2925662.11304532.html.plaintext.txt	207	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.2925662.11304532.html.plaintext.txt	208	The present study explored recycling apoE livers apoE mice transplanted wild type bone marrow
0.2925662.11304532.html.plaintext.txt	209	In model apoE derives macrophages plasma apoE levels steady state production apoE macrophages internalization potential resecretion liver equilibrium
0.2925662.11304532.html.plaintext.txt	210	Therefore apoE appearing secretory pathway liver recovered media hepatocytes isolated mice derived internalized extrahepatic apoE
0.2925662.11304532.html.plaintext.txt	211	Using BMT model demonstrated presence apoE within nascent hepatic Golgi lipoproteins providing strong evidence least portion internalized extrahepatic apoE routed secretory pathway
0.2925662.11304532.html.plaintext.txt	212	Additional studies using primary hepatocytes apoE apoE mice confirmed routing internalized apoE secretory pathway also demonstrated resecretion internalized apoE
0.2925662.11304532.html.plaintext.txt	213	These results coupled earlier vivo studies 16 provide overwhelming support hypothesis portion apoE internalized lipoproteins completely degraded fact resecreted
0.2925662.11304532.html.plaintext.txt	214	The physiologic relevance reutilization recycling apoE unknown
0.2925662.11304532.html.plaintext.txt	215	Our studies show introduction apoE via BMT affect hepatic triglyceride production rates lack effect may simply reflect suboptimal concentrations intracellular recycling apoE
0.2925662.11304532.html.plaintext.txt	216	Alternatively functional role recycling apoE may linked effects independent subtle bulk secretion triglyceride rich lipoproteins
0.2925662.11304532.html.plaintext.txt	217	Our finding apoE nascent lipoproteins Golgi apparatus rich fractions apoE apoE mice present study Fig
0.2925662.11304532.html.plaintext.txt	218	1 provides definitive evidence routing internalized apoE secretory pathway physiologic conditions
0.2925662.11304532.html.plaintext.txt	219	The finding apoE within Golgi fractions due contamination preparations elements endocytic compartment studies laboratory established purity hepatic Golgi fractions technique 18
0.2925662.11304532.html.plaintext.txt	220	Contamination fractions Golgi Kupffer cells possible source apoE expected play role since engraftment Kupffer cells liver less 20 8 weeks 35 total macrophages 6 months transplantation 23
0.2925662.11304532.html.plaintext.txt	221	In addition unlikely Kupffer cell Golgi apparatus isolates hepatocyte Golgi apparatus Kupffer cells produce triglyceride rich lipoproteins contribute buoyancy hepatocyte derived organelle 24
0.2925662.11304532.html.plaintext.txt	222	Therefore appearance apoE hepatic Golgi fractions apoE apoE mice represents routing internalized apoE secretory pathway
0.2925662.11304532.html.plaintext.txt	223	The resecretion apoE primary cultures hepatocytes apoE apoE mice provided additional evidence apoE recycling
0.2925662.11304532.html.plaintext.txt	224	In contrast constitutive pattern secretion apoE hepatocytes C57BL6 mice majority apoE recovered media hepatocytes apoE apoE mice released last 24 h Fig
0.2925662.11304532.html.plaintext.txt	225	This release caused cell death cells control transplanted animals appeared healthy 45 h culture period
0.2925662.11304532.html.plaintext.txt	226	25 studying retroendocytosis apoE HepG2 cells report presence high density lipoproteins lipid emulsion media resulted significantly increased rate secretion intact protein compared media acceptor
0.2925662.11304532.html.plaintext.txt	227	26 also report high density lipoprotein seemed serve extracellular acceptor resecretion apoE fibroblasts
0.2925662.11304532.html.plaintext.txt	228	Although experiments media contain exogenous acceptor stimulate release apoE hepatocytes secrete apoE deficient VLDL Fig
0.2925662.11304532.html.plaintext.txt	229	1 may serve acceptor stimulator apoE release hepatocytes
0.2925662.11304532.html.plaintext.txt	230	A threshold concentration apoE deficient VLDL attainable 24 h culture period may required trigger release apoE
0.2925662.11304532.html.plaintext.txt	231	In regard important note apoE recovered media found mainly d 1
0.2925662.11304532.html.plaintext.txt	232	Although Kupffer cells hepatocyte cultures may contribute apoE recovered media data suggest contribution minimal
0.2925662.11304532.html.plaintext.txt	233	Immunocytochemical staining using antibody MOMA 2 established marker macrophages indicates less 1 2 cells culture macrophage origin
0.2925662.11304532.html.plaintext.txt	234	27 report Kupffer cells rat liver account less 1 0
0.2925662.11304532.html.plaintext.txt	235	7 total liver apoE mRNA level apoE mRNA Kupffer cells approximately one third hepatocytes
0.2925662.11304532.html.plaintext.txt	236	The total recovery apoE media hepatocytes apoE apoE mice 5 6 apoE recovered media C57BL6 hepatocytes
0.2925662.11304532.html.plaintext.txt	237	Assuming secretion apoE proportional apoE mRNA content Kupffer cells hepatocytes number Kupffer cells preparation cannot account mass apoE found media
0.2925662.11304532.html.plaintext.txt	238	In addition kinetics appearance apoE media consistent might predicted constitutively secreted apoprotein observed secretion apoE C57BL6 hepatocytes noted engraftment liver Kupffer cells mice BMT less 20 total tissue macrophages 8 weeks transplantation 23
0.2925662.11304532.html.plaintext.txt	239	Finally perhaps importantly newly synthesized apoE could detected hepatocyte cultures apoE apoE mice Fig
0.2925662.11304532.html.plaintext.txt	240	Therefore based mass apoE found media number cells identified Kupffer cells using immunocytochemistry secretion kinetics kinetics engraftment liver Kupffer cells absence newly synthesized apoE hepatocyte cultures apoE apoE mice conclude apoE recovered media derive Kupffer cells represents recycled apoE
0.2925662.11304532.html.plaintext.txt	241	The content apoE nascent hepatic Golgi VLDL apoE apoE mice 6 found control Golgi VLDL mass apoE released hepatocytes apoE apoE mice 6 apoE secreted hepatocytes C57BL6 mice
0.2925662.11304532.html.plaintext.txt	242	Since serum apoE levels apoE apoE mice 10 control levels 17 results suggest much 60 internalized apoE reutilized
0.2925662.11304532.html.plaintext.txt	243	Under normal conditions hepatocyte faced 10 times apoE amount apoE recycled may change
0.2925662.11304532.html.plaintext.txt	244	26 incubated radiolabeled apoE containing triglyceride rich lipoproteins Hep3b cells fibroblasts demonstrated 60 labeled apoprotein internalized cell released intact medium 90 min chase
0.2925662.11304532.html.plaintext.txt	245	The released apoproteins primarily apoE apoC
0.2925662.11304532.html.plaintext.txt	246	25 also report much 26 apoE taken triglyceride rich emulsions HepG2 cells released
0.2925662.11304532.html.plaintext.txt	247	Finally Takahashi Smith 28 estimate much 30 apoE internalized murine macrophage RAW 264 cell line resecreted
0.2925662.11304532.html.plaintext.txt	248	It seems clear process apoE sparing reutilization may variable among different cells simply limited liver quantitatively important
0.2925662.11304532.html.plaintext.txt	249	The physiologic relevance apoE reutilization resecretion unknown
0.2925662.11304532.html.plaintext.txt	250	Recycling may provide mechanism whereby impact apoE intracellular extracellular functions maximized
0.2925662.11304532.html.plaintext.txt	251	Accumulating evidence points critical role apoE VLDL assembly
0.2925662.11304532.html.plaintext.txt	252	Hepatic VLDL triglyceride production decreased nearly 50 apoE mice compared C57BL6 mice 13 14 reconstitution apoE expression via adenoviral transfer human apoE gene markedly increases hepatic VLDL triglyceride production 29
0.2925662.11304532.html.plaintext.txt	253	Our studies confirm hepatic triglyceride production rates decreased apoE mice compared C57BL6 mice Fig
0.2925662.11304532.html.plaintext.txt	254	However introduction apoE via BMT alter rate suggesting apoE routed site secretory pathway distal VLDL assembly triglyceride production
0.2925662.11304532.html.plaintext.txt	255	Alternatively introduction apoE via BMT intervention reconstitutes 10 total serum apoE may provide intracellular concentrations apoE needed affect hepatic triglyceride production VLDL secretion
0.2925662.11304532.html.plaintext.txt	256	Finally plausible recycling apoE may effects increasing remnant uptake secretion capture mechanism 30 32
0.2925662.11304532.html.plaintext.txt	257	In conclusion apoE internalized liver component lipoprotein particles escapes degradative pathway routed Golgi apparatus subsequently secreted quantitatively significant proportions
0.2925662.11304532.html.plaintext.txt	258	Further studies needed identify functional correlates newly described cellular process
0.2925662.11304532.html.plaintext.txt	259	This work supported National Institutes Health Grants HL57984 HL57986
0.2925662.11304532.html.plaintext.txt	260	The costs publication article defrayed part payment page charges
0.2925662.11304532.html.plaintext.txt	261	The article must therefore hereby marked advertisement accordance 18 U
0.2925662.11304532.html.plaintext.txt	262	Section 1734 solely indicate fact
0.2925662.11304532.html.plaintext.txt	263	To correspondence addressed Dept
0.2925662.11304532.html.plaintext.txt	264	Pathology Vanderbilt University School Medicine Nashville TN 37232 2561
0.2925662.11304532.html.plaintext.txt	265	615 343 2646 Fax 615 343 7023 E mail larry
0.2925662.11304532.html.plaintext.txt	266	Supported Vascular Biology Training Grant National Institutes Health Grant 5T32 HL07751 NHLBI
0.2925662.11304532.html.plaintext.txt	267	Established Investigator American Heart Association
0.2925662.11304532.html.plaintext.txt	268	Published JBC Papers Press April 13 2001 DOI 10
0.2925662.11304532.html.plaintext.txt	269	The abbreviations used apo apolipoprotein LDL low density lipoprotein VLDL LDL BMT bone marrow transplantation MOPS 4 morpholinepropanesulfonic acid PAGE polyacrylamide gel electrophoresis bis tris 2 bis2 hydroxyethylamino 2 hydroxymethylpropane 13 diol
0.2925662.11304532.html.plaintext.txt	270	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES 1
0.2925662.11304532.html.plaintext.txt	271	1989 Nature 341 162 164CrossRefMedline Order article via Infotrieve 2
0.2925662.11304532.html.plaintext.txt	272	258 12341 12347AbstractFree Full Text 3
0.2925662.11304532.html.plaintext.txt	273	271 14791 14799AbstractFree Full Text 5
0.2925662.11304532.html.plaintext.txt	274	16 934 940AbstractFree Full Text 6
0.2925662.11304532.html.plaintext.txt	275	270 1761 1769AbstractFree Full Text 9
0.2925662.11304532.html.plaintext.txt	276	6 22 27Medline Order article via Infotrieve 10
0.2925662.11304532.html.plaintext.txt	277	78 217 227CrossRefMedline Order article via Infotrieve 11
0.2925662.11304532.html.plaintext.txt	278	40 1618 1626AbstractFree Full Text 12
0.2925662.11304532.html.plaintext.txt	279	19 2952 2959AbstractFree Full Text 13
0.2925662.11304532.html.plaintext.txt	280	100 2915 2922AbstractFree Full Text 14
0.2925662.11304532.html.plaintext.txt	281	274 35711 35718AbstractFree Full Text 15
0.2925662.11304532.html.plaintext.txt	282	141 441 452Medline Order article via Infotrieve 16
0.2925662.11304532.html.plaintext.txt	283	274 8247 8253AbstractFree Full Text 17
0.2925662.11304532.html.plaintext.txt	284	1995 Science 267 1034 1037Medline Order article via Infotrieve 18
0.2925662.11304532.html.plaintext.txt	285	42 218 224AbstractFree Full Text 19
0.2925662.11304532.html.plaintext.txt	286	103 1067 1076AbstractFree Full Text 21
0.2925662.11304532.html.plaintext.txt	287	271 31491 31495AbstractFree Full Text 22
0.2925662.11304532.html.plaintext.txt	288	1975 Biology Laboratory Mouse Green E
0.2925662.11304532.html.plaintext.txt	289	337 350 Dover Publications Inc
0.2925662.11304532.html.plaintext.txt	290	1997 Blood 90 986 993AbstractFree Full Text 24
0.2925662.11304532.html.plaintext.txt	291	59 45 72AbstractFree Full Text 25
0.2925662.11304532.html.plaintext.txt	292	275 8564 8571AbstractFree Full Text 26
0.2925662.11304532.html.plaintext.txt	293	112 349 359AbstractFree Full Text 27
0.2925662.11304532.html.plaintext.txt	294	96 11358 11363AbstractFree Full Text 29
0.2925662.11304532.html.plaintext.txt	295	41 253 259AbstractFree Full Text 30
0.2925662.11304532.html.plaintext.txt	296	269 2764 2772AbstractFree Full Text 31
0.2925662.11304532.html.plaintext.txt	297	101 1726 1736AbstractFree Full Text 32
0.2925662.11304532.html.plaintext.txt	298	93 2215 2223Medline Order article via Infotrieve
0.2925662.11304532.html.plaintext.txt	299	Copyright 2001 The American Society Biochemistry Molecular Biology Inc
0.5179277.15126630.html.plaintext.txt	0	Cathepsin D involved regulation transglutaminase 1 epidermal differentiation Friederike Egberts1 Michael Heinrich2 Jens Michael Jensen1 Supandi Winoto Morbach2 Stephan Pfeiffer3 Marc Wickel2 Michael Schunck1 Judith Steude2 Paul Saftig4 Ehrhardt Proksch1 Stefan Schutze2
0.5179277.15126630.html.plaintext.txt	1	1 Department Dermatology University Hospital Schleswig Holstein Campus Kiel 24105 Kiel Germany 2 Institute Immunology University Hospital Schleswig Holstein Campus Kiel 24105 Kiel Germany 3 Central Microscopy Centrum Biology University Kiel 24118 Kiel Germany 4 Department Biochemistry University Kiel 24118 Kiel Germany
0.5179277.15126630.html.plaintext.txt	2	Author correspondence e mail schuetzeatimmunologie
0.5179277.15126630.html.plaintext.txt	3	Summary Top Summary Introduction Materials Methods Results Discussion References We previously demonstrated aspartate protease cathepsin D activated ceramide derived acid sphingomyelinase
0.5179277.15126630.html.plaintext.txt	4	Increased expression cathepsin D skin reported wound healing psoriasis skin tumors
0.5179277.15126630.html.plaintext.txt	5	We explored specific functions cathepsin D epidermal differentiation
0.5179277.15126630.html.plaintext.txt	6	Protein expression enzymatic activity cathepsin D increased differentiated keratinocytes stratified organotypic cultures mouse skin epidermal barrier repair
0.5179277.15126630.html.plaintext.txt	7	Treatment cultured keratinocytes exogenous cathepsin D increased activity transglutaminase 1 known cross link cornified envelope proteins involucrin loricrin epidermal differentiation
0.5179277.15126630.html.plaintext.txt	8	Inhibition cathepsin D pepstatin A suppressed activity transglutaminase 1
0.5179277.15126630.html.plaintext.txt	9	Cathepsin D deficient mice revealed reduced transglutaminase 1 activity reduced protein levels cornified envelope proteins involucrin loricrin
0.5179277.15126630.html.plaintext.txt	10	Also amount distribution cornified envelope proteins involucrin loricrin filaggrin keratins K1 K5 significantly altered cathepsin D deficient mice
0.5179277.15126630.html.plaintext.txt	11	Stratum corneum morphology cathepsin D deficient mice impaired increased numbers corneocyte layers faint staining cornified envelope similar human skin disease lamellar ichthyosis
0.5179277.15126630.html.plaintext.txt	12	Our findings suggest functional link cathepsin D activation transglutaminase 1 activity protein expression cornified envelope proteins epidermal differentiation
0.5179277.15126630.html.plaintext.txt	13	Key words Barrier function Cathepsin D Cornified envelope Epidermal differentiation Involucrin Loricrin Filaggrin Keratin Sphingomyelinase Transglutaminase
0.5179277.15126630.html.plaintext.txt	14	Introduction Top Summary Introduction Materials Methods Results Discussion References The goal epidermal differentiation form epidermal permeability barrier prevents excessive water loss entry harmful substances body
0.5179277.15126630.html.plaintext.txt	15	The barrier localized stratum corneum two compartment system protein enriched terminally differentiated keratinocytes corneocytes lipid enriched intercellular bilayers Elias Friend 1975 Downing 1992
0.5179277.15126630.html.plaintext.txt	16	The insoluble protein envelope located beneath plasma membrane keratinocytes cross linked cellular transglutaminase 1 TG1 terminal differentiation epidermis
0.5179277.15126630.html.plaintext.txt	17	Involucrin early marker terminal differentiation soluble protein precursor cross linked cornified envelope CE synthesized keratinocytes upper spinous layers Watt 1983 Eckert et al
0.5179277.15126630.html.plaintext.txt	18	1981 Rice Green 1979 Steinert Marekov 1997
0.5179277.15126630.html.plaintext.txt	19	In hyperproliferative diseases like psoriasis premature expression involucrin found lower spinous layers Thewes et al
0.5179277.15126630.html.plaintext.txt	20	Another main component CE loricrin
0.5179277.15126630.html.plaintext.txt	21	It expressed later stage differentiation Watt 1983 cross linked epidermal proteins cystatin elafin filaggrin
0.5179277.15126630.html.plaintext.txt	22	The extracellular lipids barrier predominantly ceramides synthesized keratinocytes stored epidermal lamellar bodies secreted intercellular space stratum corneum Elias 1983
0.5179277.15126630.html.plaintext.txt	23	Beside structural role ceramide known important intracellular signal mediator various cytokines particular tumor necrosis factor TNF Liu et al
0.5179277.15126630.html.plaintext.txt	24	1997 Perry Hannun 1998
0.5179277.15126630.html.plaintext.txt	25	TNF binding p55 TNF receptor TNF R55 results activation endolysosomal acid sphingomyelinase Wiegmann et al
0.5179277.15126630.html.plaintext.txt	26	Increase intracellular ceramide levels followed different cellular responses depending cell type degree activation differentiation proliferation programmed cell death apoptosis Kronke et al
0.5179277.15126630.html.plaintext.txt	27	1994 Kolesnick Golde 1994 Geilen et al
0.5179277.15126630.html.plaintext.txt	28	We suggested functional role TNF ceramide derived acid sphingomyelinase cutaneous permeability barrier repair experimentally induced injury skin
0.5179277.15126630.html.plaintext.txt	29	We detected high levels sphingomyelinase ceramides barrier disruption well significant delay barrier repair TNF R55 deficient mice Jensen et al
0.5179277.15126630.html.plaintext.txt	30	In understanding various biological effects ceramides important know direct intracellular targets
0.5179277.15126630.html.plaintext.txt	31	Recently found aspartatic protease cathepsin D CTSD novel specific intracellular binding protein ceramide derived acid sphingomyelinase Heinrich et al
0.5179277.15126630.html.plaintext.txt	32	Ceramide enhances proteolytic activity CTSD
0.5179277.15126630.html.plaintext.txt	33	CTSD main aspartatic protease endolysosomes
0.5179277.15126630.html.plaintext.txt	34	It synthesized translocated endoplasmic reticulum inactive pre proenzyme 52 kDa processed enzymatically active intermediate proenzyme 48 kDa finally converted mature form 32 kDa lysosomes Fujita et al
0.5179277.15126630.html.plaintext.txt	35	CTSD involved proteolytic activation well proteolytic degradation intracellular proteins Diment et al
0.5179277.15126630.html.plaintext.txt	36	Increased levels CTSD correlated tumor cell invasion metastasis malignant melanoma squamous cell carcinoma human breast cancer Kageshita et al
0.5179277.15126630.html.plaintext.txt	37	Reports suggest CTSD may play role metastasizing process malignant cells destructive effects extracellular matrix
0.5179277.15126630.html.plaintext.txt	38	Therefore CTSD activity used predict recurrence breast cancer Tandon et al
0.5179277.15126630.html.plaintext.txt	39	In HeLa cell cultures CTSD mediator programmed cell death induced various cytokines
0.5179277.15126630.html.plaintext.txt	40	Overexpression CTSD induced cell death without external stimuli CTSD inhibitor pepstatin A suppressed cell death system Deiss et al
0.5179277.15126630.html.plaintext.txt	41	Some findings supported vivo studies CTSD deficient mice generated gene targeting
0.5179277.15126630.html.plaintext.txt	42	These mice developed normally first 2 weeks
0.5179277.15126630.html.plaintext.txt	43	Afterwards exhibited progressive atrophy intestinal mucosa followed massive intestinal necrosis profound destruction lymphoid cells
0.5179277.15126630.html.plaintext.txt	44	The mice died state anorexia age 4 weeks though lysosomal bulk proteolysis maintained possibly due compensatory activation related lysosomal proteases Saftig et al
0.5179277.15126630.html.plaintext.txt	45	In skin CTSD plays role extracellular intracellular catabolism
0.5179277.15126630.html.plaintext.txt	46	In hyperproliferative skin disorders psoriasis increased expression mature form CTSD reported returning normal resolution psoriasis psoralen long wave ultraviolet radiation PUVA light treatment Kawada et al
0.5179277.15126630.html.plaintext.txt	47	It suggested CTSD may involved control cell differentiation normal development
0.5179277.15126630.html.plaintext.txt	48	found increased expression increased activity CTSD isoforms skin depending stage epidermal differentiation Horikoshi et al
0.5179277.15126630.html.plaintext.txt	49	CTSD enzyme active acid pH maximum pH 3 may work transition stratum granulosum stratum corneum stratum corneum produces acid environment pH 5
0.5179277.15126630.html.plaintext.txt	50	Despite results function cellular substrates CTSD epidermal differentiation still unknown
0.5179277.15126630.html.plaintext.txt	51	In present study explored functional role CTSD skin permeability barrier repair epidermal differentiation using keratinocyte cell culture wild type CTSD deficient mice
0.5179277.15126630.html.plaintext.txt	52	In particular examined functional role CTSD activation keratinocyte TG1 key enzyme processing CE proteins involucrin loricrin filaggrin epidermal differentiation
0.5179277.15126630.html.plaintext.txt	53	Materials Methods Top Summary Introduction Materials Methods Results Discussion References Mice cells Male hairless mice Crl hrhrBR 4 12 weeks age supplied Charles River Sulzfeld Germany
0.5179277.15126630.html.plaintext.txt	54	CTSD deficient mice C57BL6 obtained gene targeting described Saftig et al
0.5179277.15126630.html.plaintext.txt	55	Progeny heterozygous CTSD deficient mice genotyped PCR genomic DNA tail biopsies
0.5179277.15126630.html.plaintext.txt	56	The animals maintained conventionally standardized conditions
0.5179277.15126630.html.plaintext.txt	57	The study protocols approved University Kiel Committee Animal Care
0.5179277.15126630.html.plaintext.txt	58	Normal human keratinocytes stratified keratinocytes organotypic raft cultures obtained human foreskins
0.5179277.15126630.html.plaintext.txt	59	Primary keratinocytes maintained serum free keratinocyte growth medium KGM Clonetics San Diego USA supplemented 0
0.5179277.15126630.html.plaintext.txt	60	07 mM calcium grown 60 80 confluency
0.5179277.15126630.html.plaintext.txt	61	Also immortalized HaCaT keratinocytes used Boukamp et al
0.5179277.15126630.html.plaintext.txt	62	Human raft cultured epidermis prepared described previously Steude et al
0.5179277.15126630.html.plaintext.txt	63	Briefly primary dermal fibroblasts keratinocytes prepared foreskin grown described previously Mielke et al
0.5179277.15126630.html.plaintext.txt	64	Third passage fibroblasts 5 7x105 resuspended ice cold collagen solution containing 5
0.5179277.15126630.html.plaintext.txt	65	3 mg collagen type I 1x Dulbecco minimal Eagles medium DMEM Gibco BRL 2 mM L glutamine Gibco BRL 0
0.5179277.15126630.html.plaintext.txt	66	03 M NaOH submerge cultured DMEM 10 fetal bovine serum 5 days
0.5179277.15126630.html.plaintext.txt	67	Third passage keratinocytes 5x105 seeded onto collagen lattices submerge cultured 4 days keratinocyte growth medium KGM Bullet kit BioWhittaker Europe Belgium 5 fetal bovine serum
0.5179277.15126630.html.plaintext.txt	68	Raft cultures lifted air medium interphase incubated keratinocyte growth medium without bovine pituitary extract EGF additional 5 fetal bovine serum 1
0.5179277.15126630.html.plaintext.txt	69	Growth factors added medium
0.5179277.15126630.html.plaintext.txt	70	The medium including growth factors renewed every 2 3 days
0.5179277.15126630.html.plaintext.txt	71	Raft cultures harvested frozen 70 degrees C
0.5179277.15126630.html.plaintext.txt	72	Permeability barrier disruption Disruption permeability barrier induced hairless mice tape stripping Tesafilm Beiersdorf Hamburg Germany remove cells stratum corneum resulting superficial wound 20 30 fold increase transepidermal water loss TEWL marker barrier disruption achieved Meeco electronic water analyzer Meeco Inc
0.5179277.15126630.html.plaintext.txt	73	Warrington PA Spruit Malten 1966 Grubauer et al
0.5179277.15126630.html.plaintext.txt	74	Barrier recovery calculated follows Barrier recovery 100 xh baseline1000h baseline
0.5179277.15126630.html.plaintext.txt	75	xhTEWL x hours barrier disruption ohTEWL directly barrier disruption baselinenormal TEWL skin without barrier disruption
0.5179277.15126630.html.plaintext.txt	76	In hairy CTSD deficient mice fur carefully removed shaving prior barrier disruption
0.5179277.15126630.html.plaintext.txt	77	The shaving result irritation barrier disruption
0.5179277.15126630.html.plaintext.txt	78	For experiment least three animals treated least three animals served control
0.5179277.15126630.html.plaintext.txt	79	At different times barrier disruption 0 24 hours TEWL marker barrier repair measured skin samples 4 cm2 obtained
0.5179277.15126630.html.plaintext.txt	80	Measurements basal TEWL Measurements basal TEWL performed using Tewameter Courage Khazaka Germany described previously Jensen et al
0.5179277.15126630.html.plaintext.txt	81	The sensitivity Tewameter small changes TEWL seen basal conditions higher Meeco water analyzer
0.5179277.15126630.html.plaintext.txt	82	Topical application pepstatin A normal mouse skin Immediately barrier disruption 100 microl pepstatin A 0
0.5179277.15126630.html.plaintext.txt	83	1 propylene glycolisopropanol 73 vv applied topically
0.5179277.15126630.html.plaintext.txt	84	Vehicle application served control
0.5179277.15126630.html.plaintext.txt	85	TEWL determined different time points barrier disruption 0 24 hours skin samples 4 cm2 taken
0.5179277.15126630.html.plaintext.txt	86	Isolation epidermal samples acute barrier disruption Flank skin treated untreated sites excised immediately placed epidermal side onto covered Petri dish containing crushed ice
0.5179277.15126630.html.plaintext.txt	87	The skin pieces scraped scalpel blade remove subcutaneous fat immersed 37 degrees C 40 minutes 10 mM EDTA calcium magnesium free phosphate buffered saline PBS
0.5179277.15126630.html.plaintext.txt	88	Thereafter epidermis peeled dermis gentle scraping scalpel blade
0.5179277.15126630.html.plaintext.txt	89	15 20 mg epidermis disrupted 350 ml buffer H 150 mM KCl 5 mM NaF 1 mM phenylmethylsulfonylfluoride 20 microM pepstatin 20 microM leupeptin 20 microM antipain Boehringer Complete 1100 Hepes pH 7
0.5179277.15126630.html.plaintext.txt	90	4 electric glass homogenizer Potter S Braun Melsungen Germany 600 rpm 4 minutes
0.5179277.15126630.html.plaintext.txt	91	Cells homogenized passing 28 G needle followed sonication three times 10 seconds
0.5179277.15126630.html.plaintext.txt	92	To analyze involucrin loricrin expression entire skin sample excised subcutaneous fat removed skin disrupted Ultrathurrax IKA Labortechnik Staufen Germany Tris buffer 85 mM NaCl 50 mM Tris pH 7
0.5179277.15126630.html.plaintext.txt	93	4 homogenized Potter S described
0.5179277.15126630.html.plaintext.txt	94	Subsequently probes boiled 10 minutes lysates cleared centrifugation 5 minutes 20000 g
0.5179277.15126630.html.plaintext.txt	95	Isolation culture cells The keratinocyte culture cells harvested incubation trypsin EDTA scraped PBS pelleted centrifugation 5 minutes 800 g homogenized buffer H sonicated
0.5179277.15126630.html.plaintext.txt	96	After centrifugation supernatants stored 80 degrees C
0.5179277.15126630.html.plaintext.txt	97	Determination CTSD TG1 involucrin loricrin Protein concentration measured bicinchoninic acid protein assay Pierce Rockford USA
0.5179277.15126630.html.plaintext.txt	98	Equal protein samples electrophoresed 7
0.5179277.15126630.html.plaintext.txt	99	5 polyacrylamide gels transferred onto nitrocellulose filters 100 V 45 minutes Mini Transblot Biorad Munich Germany
0.5179277.15126630.html.plaintext.txt	100	CTSD cell cultures detected incubation 1 hour room temperature polyclonal rabbit anti human CTSD antibody dilution 11000 TBST Calbiochem Oncogene Science USA CTSD mice detected rabbit anti mouse CTSD antibody kindly provided R
0.5179277.15126630.html.plaintext.txt	101	Pohlmann University Munster Germany TG1 goat anti human polyclonal antibody kindly provided S
0.5179277.15126630.html.plaintext.txt	102	Steinert NIH Bethesda MD see Kim et al
0.5179277.15126630.html.plaintext.txt	103	1995 involucrin loricrin detected rabbit anti mouse antibodies PRB 142C PRB 145P respectively Covance Inc
0.5179277.15126630.html.plaintext.txt	104	CA USA distributed Hiss Diagnostics Freiburg Germany
0.5179277.15126630.html.plaintext.txt	105	Secondary antibody complexes visualized using chemiluminescent detection system ECL Amersham Braunschweig Germany quantified densitometry PC BAS TINA software
0.5179277.15126630.html.plaintext.txt	106	CTSD assay To estimate activity cellular CTSD assay performed using parathyroid hormone PTH specific substrate previously described Heinrich et al
0.5179277.15126630.html.plaintext.txt	107	Digestion PTH results cleavage hormone Phe34 Val35 yielding PTH 1 34 PTH 35 84 fragments
0.5179277.15126630.html.plaintext.txt	108	PTH proteolysis detected immunoblotting using monoclonal antibody could blocked aspartate protease inhibitor pepstatin A selective inhibitor CTSD
0.5179277.15126630.html.plaintext.txt	109	2 microg lysate protein incubated indicated times 50 ng PTH 37 degrees C volume 20 microl acidic buffer 100 mM sodium acetate 100 mM KCl pH 4
0.5179277.15126630.html.plaintext.txt	110	To demonstrate CTSD specificity reactions 0
0.5179277.15126630.html.plaintext.txt	111	5 microM pepstatin A added assay indicated
0.5179277.15126630.html.plaintext.txt	112	One sample containing PTH acidic buffer without lysate served control
0.5179277.15126630.html.plaintext.txt	113	Reactions stopped boiling samples 3 minutes Tris tricine SDS sample buffer 2 ss mercaptoethanol 12 glycerol 50 mM Tris pH 6
0.5179277.15126630.html.plaintext.txt	114	8 4 sodium dodecyl sulfate 0
0.5179277.15126630.html.plaintext.txt	115	Proteins separated 15 SDS PAGE transferred onto nitrocellulose filters
0.5179277.15126630.html.plaintext.txt	116	Immunoblotting performed using anti PTH mouse antibody specific fragment 1 34 Biogenesis anti mouse secondary horseradish peroxidase conjugate
0.5179277.15126630.html.plaintext.txt	117	Blots developed using ECL detection reagent Amersham
0.5179277.15126630.html.plaintext.txt	118	TG1 assay Mouse epidermis disrupted Ultrathurrax IKA Labortechnik Staufen Germany homogenized Potter S described buffer containing 20 mM sodium phosphate pH 7
0.5179277.15126630.html.plaintext.txt	119	5 mM EDTA 10 mM dithiothreitol 50 microgml phenylmethylsulfonylfluoride
0.5179277.15126630.html.plaintext.txt	120	Epidermal cells lysed buffer sonication
0.5179277.15126630.html.plaintext.txt	121	Epidermal TG1 activity measured described previously Hohl et al
0.5179277.15126630.html.plaintext.txt	122	Briefly 5 microg tissue extract added 95 microl solution containing 0
0.5179277.15126630.html.plaintext.txt	123	5 M sodium borate pH 9 5 microl 10 mM EDTA pH 8 5 microl 100 mM CaCl2 20 microl dimethylcasein 10 mgml 2
0.5179277.15126630.html.plaintext.txt	124	5 microl 10 Triton X 100 0
0.5179277.15126630.html.plaintext.txt	125	5 microl 1 M dithiotreitol 2
0.5179277.15126630.html.plaintext.txt	126	8 microl 100 microM putrescine 1 microl 14 n 3H putrescine dihydrochloride 1 mCiml 10 30 Cimmol NEN 48
0.5179277.15126630.html.plaintext.txt	127	After incubation 28 degrees C 30 minutes 80 microl applied cellulose filter papers Whatman washed sequentially 10 TCA 0
0.5179277.15126630.html.plaintext.txt	128	Radioactivity determined liquid scintillation counting
0.5179277.15126630.html.plaintext.txt	129	TG1 activity expressed pmol 3Hputrescine incorporated dimethylcaseine per hour mg protein
0.5179277.15126630.html.plaintext.txt	130	For evaluation effects CTSD TG1 activity membrane fractions prepared lysates homogenates centrifuged 25000 g 4 degrees C 30 minutes
0.5179277.15126630.html.plaintext.txt	131	The pellet re extracted sonication buffer supplemented 1 Triton X 100
0.5179277.15126630.html.plaintext.txt	132	After 10 minutes incubation 37 degrees C lysate centrifuged supernatant membrane fraction collected
0.5179277.15126630.html.plaintext.txt	133	TG1 activity membrane fraction measured described whole tissue extracts
0.5179277.15126630.html.plaintext.txt	134	Skin histology Chemical fixation embedding light electron microscopy follows
0.5179277.15126630.html.plaintext.txt	135	Skin samples prefixed overnight modified Karnovskys medium Elias Friend 1975 4 degrees C washed twice 0
0.5179277.15126630.html.plaintext.txt	136	2 M sodium cacodylate buffer 10 minutes postfixed 1 wv OsO4 0
0.5179277.15126630.html.plaintext.txt	137	133 M sodium cacodylate buffer containing 0
0.5179277.15126630.html.plaintext.txt	138	5 wv K4FeCN6 4 degrees C 45 minutes
0.5179277.15126630.html.plaintext.txt	139	Subsequently specimens dehydrated ethanol series embedded Epon 812 Luft 1961
0.5179277.15126630.html.plaintext.txt	140	Polymerization carried overnight 60 degrees C
0.5179277.15126630.html.plaintext.txt	141	Semi thin sections cut ultra microtome Leica UCT Leica Bensheim Germany staining investigated Zeiss Axioskop 40 Zeiss Gottingen Germany transmission mode
0.5179277.15126630.html.plaintext.txt	142	For electron microscopy ultra thin sections cut post stained according method Reynolds Reynolds 1963 subsequently investigated Philips CM 10 electron microscope
0.5179277.15126630.html.plaintext.txt	143	Immunohistochemistry Skin samples fixed formaldehyde embedded paraffin
0.5179277.15126630.html.plaintext.txt	144	5 microm sections incubated 3 H2O2 5 minutes block endogenous peroxidase activity rinsed microwave irradiated 650 W antigen detection according method Hazelbag et al
0.5179277.15126630.html.plaintext.txt	145	After blocking unspecific antibody binding incubation 20 pig serum DAKO Germany primary antibodies applied 30 minutes room temperature
0.5179277.15126630.html.plaintext.txt	146	The primary antibodies anti keratin K1 1500 anti keratin K5 11000 anti keratin K6 1500 anti involucrin 11000 anti loricrin 1500 anti filaggrin 11000 Hohl 1993 Rosenthal et al
0.5179277.15126630.html.plaintext.txt	147	All primary antibodies purchased Hiss Diagnostics Germany
0.5179277.15126630.html.plaintext.txt	148	A strep AB complexHRP used third antibody followed incubation diaminobenzidine substrate peroxidase
0.5179277.15126630.html.plaintext.txt	149	Results Top Summary Introduction Materials Methods Results Discussion References Increased protein levels activity CTSD differentiated keratinocyte cultures To investigate functional role CTSD epidermal differentiation first investigated amount enzyme activity CTSD primary undifferentiated keratinocytes differentiated stratified keratinocyte cell cultures Steude et al
0.5179277.15126630.html.plaintext.txt	150	1986 western blotting specific bioassay
0.5179277.15126630.html.plaintext.txt	151	In primary keratinocytes three known isoforms CTSD 52 kDa 48 kDa 32 kDa detected 48 kDa form main product
0.5179277.15126630.html.plaintext.txt	152	In 20 day old stratified cultures expressing various signature proteins keratinocyte cornification differentiation Steude et al
0.5179277.15126630.html.plaintext.txt	153	2002 found significant increase 52 kDa 48 kDa CTSD forms Fig
0.5179277.15126630.html.plaintext.txt	154	The 52 kDa protein represents enzymatically inactive pre pro CTSD form 48 kDa protein active membrane bound enzyme Fujita et al
0.5179277.15126630.html.plaintext.txt	155	View larger version 22K Fig
0.5179277.15126630.html.plaintext.txt	156	Increase protein expression activity CTSD differentiated keratinocyte cultures
0.5179277.15126630.html.plaintext.txt	157	A Protein expression CTSD isoforms primary differentiated keratinocytes determined cell lysates western blotting using anti CTSD antibodies
0.5179277.15126630.html.plaintext.txt	158	There increase prepro enzymatically active pro forms differentiated keratinocytes
0.5179277.15126630.html.plaintext.txt	159	B CTSD activity measured vitro enzyme assay keratinocyte lysates using parathyroid hormone PTH CTSD specific substrate
0.5179277.15126630.html.plaintext.txt	160	The amount PTH absence sample protein used control
0.5179277.15126630.html.plaintext.txt	161	The level PTH protein determined western blotting using anti PTH mAb peptide 1 34 quantified two dimensional laser scanning densitometry Molecular Dynamics Personal Densitometer
0.5179277.15126630.html.plaintext.txt	162	CTSD activity calculated amount PTH cleavedhour increased differentiated keratinocytes
0.5179277.15126630.html.plaintext.txt	163	The enzymatic activity CTSD primary differentiated keratinocytes correlated amount CTSD protein significantly enhanced 20 day stratified cultures estimated cleavage CTSD specific substrate PTH 84 amino acid polypeptide Heinrich et al
0.5179277.15126630.html.plaintext.txt	164	1999 resulting generation 34 amino acid fragment The amount PTH decreased upper part Fig
0.5179277.15126630.html.plaintext.txt	165	1B CTSD activity calculated amount PTH cleavedhour increased differentiated keratinocytes Fig
0.5179277.15126630.html.plaintext.txt	166	These results indicate CTSD protein enzymatic activity correlate stage keratinocyte differentiation vitro
0.5179277.15126630.html.plaintext.txt	167	Increased epidermal expression increased activity CTSD experimental injury skin hairless mice To evaluate possible role CTSD skin epidermal differentiation vivo determined protein levels activity CTSD epidermal barrier repair following experimental barrier disruption tape stripping
0.5179277.15126630.html.plaintext.txt	168	Following experimental skin injury expression active intermediate 48 kDa proenzyme Fig
0.5179277.15126630.html.plaintext.txt	169	2A black bars mature 32 kDa form Fig
0.5179277.15126630.html.plaintext.txt	170	2B black bars significantly increased 3 hours 5 hours 185 215 P 0
0.5179277.15126630.html.plaintext.txt	171	05 n4 48 kDa form 204 260 P 0
0.5179277.15126630.html.plaintext.txt	172	05 n4 32 kDa form respectively estimated western blotting
0.5179277.15126630.html.plaintext.txt	173	View larger version 25K Fig
0.5179277.15126630.html.plaintext.txt	174	Increased epidermal expression CTSD experimental skin injury
0.5179277.15126630.html.plaintext.txt	175	Acute disruption permeability barrier induced tape stripping
0.5179277.15126630.html.plaintext.txt	176	Immediately pepstatin A carrier solution applied skin samples obtained different times
0.5179277.15126630.html.plaintext.txt	177	The expression active intermediate A mature form B CTSD examined SDS PAGE western blotting using polyclonal anti CTSD antibody quantified two dimensional laser scanning densitometry
0.5179277.15126630.html.plaintext.txt	178	Inhibition CTSD topical application CTSD inhibitor pepstatin A suppressed increase amount intermediate mature enzyme barrier disruption Fig
0.5179277.15126630.html.plaintext.txt	179	The increase CTSD protein paralleled enhanced CTSD enzyme activity 3 hours 5 hours skin injury determined PTH cleavage assays Fig
0.5179277.15126630.html.plaintext.txt	180	Topical application pepstatin A resulted decrease enzymatic activity 6 hours treatment data shown
0.5179277.15126630.html.plaintext.txt	181	Together data demonstrate increased protein expression increased enzyme activity CTSD skin repair epidermal differentiation
0.5179277.15126630.html.plaintext.txt	182	View larger version 32K Fig
0.5179277.15126630.html.plaintext.txt	183	Increased activity CTSD experimental skin injury
0.5179277.15126630.html.plaintext.txt	184	Acute disruption permeability barrier induced tape stripping
0.5179277.15126630.html.plaintext.txt	185	Immediately barrier disruption pepstatin A carrier solution applied skin samples obtained directly tape stripping 0 hours 3 5 hours
0.5179277.15126630.html.plaintext.txt	186	CTSD activity measured specific parathyroid hormone PTH enzyme assays
0.5179277.15126630.html.plaintext.txt	187	The level PTH protein determined western blotting using anti PTH mAb peptide 1 34
0.5179277.15126630.html.plaintext.txt	188	The amount PTH assay starting point used control CTSD activity calculated amount PTH cleavedhour
0.5179277.15126630.html.plaintext.txt	189	TG1 activity stimulated exogenous CTSD keratinocytes culture During epidermal differentiation CE proteins involucrin loricrin filaggrin cross linked formation glutamyllysine isodipeptide bonds catalyzed TG1 Kim et al
0.5179277.15126630.html.plaintext.txt	190	In addition described TG1 catalyzes covalent ester binding hydroxyceramide involucrin Nemes et al
0.5179277.15126630.html.plaintext.txt	191	Thus enzyme mediates key functions epidermal differentiation
0.5179277.15126630.html.plaintext.txt	192	Since CTSD may involved regulation activity TG1 Negi et al
0.5179277.15126630.html.plaintext.txt	193	1990 investigated possible direct involvement CTSD proteolytic activation TG1
0.5179277.15126630.html.plaintext.txt	194	Since high molecular mass TG1 precursor protein membrane bound Chakravarty Rice 1989 Steinert et al
0.5179277.15126630.html.plaintext.txt	195	1996b upon terminal differentiation keratinocytes TG1 cleaved two sites leading active form Rice et al
0.5179277.15126630.html.plaintext.txt	196	1996b prepared membrane fraction lysates HaCaT cells starting material
0.5179277.15126630.html.plaintext.txt	197	The enzymatic activity TG1 measured membrane preparation addition exogenous CTSD absence presence pepstatin A vitro TG1 assay based cross linking 3Hputrescine dimethylcasein substrate Hohl et al
0.5179277.15126630.html.plaintext.txt	198	4 TG1 activity increased exogenous CTSD enzymatic activation blocked pepstatin A
0.5179277.15126630.html.plaintext.txt	199	This result suggests CTSD mediated proteolytic activation membrane bound TG1 precursor molecule leading enzymatically active TG1 fragments
0.5179277.15126630.html.plaintext.txt	200	This observation supports functional link CTSD TG1 activities
0.5179277.15126630.html.plaintext.txt	201	View larger version 15K Fig
0.5179277.15126630.html.plaintext.txt	202	CTSD stimulates transglutaminase 1 TG1 activity primary keratinocytes vitro
0.5179277.15126630.html.plaintext.txt	203	Isolated membranes HaCat cells left untreated black squares treated pepstatin A black circles purified CTSD absence black triangles presence pepstatin A white triangles 30 minutes subsequently measured TG1 enzymatic activity vitro enzyme assay using dimethylcasein 14n 3H putrescine substrates
0.5179277.15126630.html.plaintext.txt	204	Results three experiments performed triplicate shown mean plus minus
0.5179277.15126630.html.plaintext.txt	205	Topical application CTSD inhibitor pepstatin A TG inhibitor monodansyl cadaverin significantly delayed permeability barrier repair To investigate physiological significance CTSD epidermal differentiation next examined barrier recovery following experimental skin injury topical application CTSD inhibitor pepstatin A
0.5179277.15126630.html.plaintext.txt	206	At different times barrier disruption tape stripping 0 24 hours TEWL marker barrier repair measured Grubauer et al
0.5179277.15126630.html.plaintext.txt	207	After experimental barrier disruption endogenous barrier repair commenced
0.5179277.15126630.html.plaintext.txt	208	A rapid decrease TEWL leading 60 barrier recovery occurred hairless mice within 5 hours
0.5179277.15126630.html.plaintext.txt	209	This followed slower kinetics barrier recovery within next 24 hours
0.5179277.15126630.html.plaintext.txt	210	Topically application CTSD inhibitor pepstatin A immediately barrier disruption led significant delay barrier repair 1 3 5 7 24 hours treatment Fig
0.5179277.15126630.html.plaintext.txt	211	View larger version 17K Fig
0.5179277.15126630.html.plaintext.txt	212	Topical application CTSD inhibitor pepstatin A A TG inhibitor monodansyl cadaverin MDC B significantly delays permeability barrier repair
0.5179277.15126630.html.plaintext.txt	213	Acute disruption permeability barrier induced tape stripping 20 30 fold increase TEWL transepidermal water losstranscutaneous water loss occurred
0.5179277.15126630.html.plaintext.txt	214	Immediately barrier disruption pepstatin A monodansyl cadaverin carrier solution applied recovery TEWL determined different times treatment
0.5179277.15126630.html.plaintext.txt	215	Results three experiments performed triplicates shown
0.5179277.15126630.html.plaintext.txt	216	In addition functional role TG1 cutaneous differentiation permeability barrier repair examined topical application TG1 inhibitor monodansyl cadaverin experimental skin injury
0.5179277.15126630.html.plaintext.txt	217	At different times barrier disruption tape stripping TEWL determined marker barrier repair
0.5179277.15126630.html.plaintext.txt	218	After application monodansyl cadaverin found significant delay barrier repair 1 3 5 7 24 hours treatment Fig
0.5179277.15126630.html.plaintext.txt	219	These results show inhibition CTSD TG1 activity influences epidermal differentiation delays permeability barrier repair
0.5179277.15126630.html.plaintext.txt	220	Reduced TG1 enzymatic activity defective TG processing CTSD deficient mice Based observation CTSD able activate TG1 vitro Fig
0.5179277.15126630.html.plaintext.txt	221	4 next explored possible role CTSD regulation TG1 expression CTSD deficient mice vivo
0.5179277.15126630.html.plaintext.txt	222	Using specific TG1 enzyme assay found significantly decreased TG1 activity epidermis heterozygous CTSD mice reduced homozygous CTSD mice Fig
0.5179277.15126630.html.plaintext.txt	223	In order investigate whether decreased TG1 activity CTSD mice caused defective processing TG1 precursor molecule analyzed distribution TG1 protein western blotting using specific anti TG1 antibody
0.5179277.15126630.html.plaintext.txt	224	A strongly band approximately 35 kDa detected epidermis wild type mice band significantly decreased skins CTSD deficient heterozygous even homozygous mice Fig
0.5179277.15126630.html.plaintext.txt	225	In CTSD mice 150 kDa protein strongly expressed instead also seen CTSD mice completely absent wild type mice
0.5179277.15126630.html.plaintext.txt	226	These finding suggest defective processing 150 kDa TG1 precursor protein epidermis CTSD deficient mice points functional role CTSD maturation 150 kDa TG1 precursor enzymatic active 35 kDa form vivo
0.5179277.15126630.html.plaintext.txt	227	View larger version 14K Fig
0.5179277.15126630.html.plaintext.txt	228	Reduced transglutaminase 1 TG1 activity CTSD deficient mice
0.5179277.15126630.html.plaintext.txt	229	TG1 enzymatic activity determined epidermal lysates wild type heterozygous CTSD deficient mice vitro assay using dimethylcasein 14n 3H putrescine substrates
0.5179277.15126630.html.plaintext.txt	230	Results three experiments performed triplicate shown mean plus minus
0.5179277.15126630.html.plaintext.txt	231	View larger version 28K Fig
0.5179277.15126630.html.plaintext.txt	232	Absence 35 kDa TG1 protein CTSD deficient mice
0.5179277.15126630.html.plaintext.txt	233	TG1 protein levels determined epidermal samples wild type heterozygous homozygous CTSD deficient mice western blotting using anti TG1 antibody quantified densitometry
0.5179277.15126630.html.plaintext.txt	234	Reduced levels involucrin loricrin CTSD deficient mice We next investigated whether CTSD deficiency also results changes expression involucrin early marker loricrin late marker epidermal differentiation Watt 1983 Yoneda et al
0.5179277.15126630.html.plaintext.txt	235	1992 Steinert Marekov 1997
0.5179277.15126630.html.plaintext.txt	236	In epidermal samples wild type mice involucrin Fig
0.5179277.15126630.html.plaintext.txt	237	8B expressed 65 kDa 50 kDa proteins respectively estimated western blotting
0.5179277.15126630.html.plaintext.txt	238	In CTSD mice levels proteins clearly reduced CTSD mice completely absent suggesting crucial function CTSD appearance 65 kDa involucrin 50 kDa loricrin epidermis
0.5179277.15126630.html.plaintext.txt	239	View larger version 34K Fig
0.5179277.15126630.html.plaintext.txt	240	Reduced CE protein expression CTSD deficient mice
0.5179277.15126630.html.plaintext.txt	241	Skin sections wild type heterozygous homozygous CTSD deficient mice obtained
0.5179277.15126630.html.plaintext.txt	242	Expression involucrin A loricrin B determined epidermal samples western blotting using anti involucrin anti loricrin antibodies
0.5179277.15126630.html.plaintext.txt	243	Changes immunohistology differentiation related proteins CTSD mice To examine protein expression localization differentiation related epidermal proteins performed immunohistology using specific antibodies
0.5179277.15126630.html.plaintext.txt	244	9 keratin K1 staining healthy skin found suprabasal layers epidermis whereas keratin K5 expressed epidermal basal cells
0.5179277.15126630.html.plaintext.txt	245	In CTSD mice focal extension K1 staining basal layer
0.5179277.15126630.html.plaintext.txt	246	Staining K5 focally extended upper epidermal layers CTSD mice entire nucleated epidermis stained CTSD mice
0.5179277.15126630.html.plaintext.txt	247	Also thickness epidermis stratum granulosum stratum spinosum stratum basale reduced whereas thickening stratum corneum hyperkeratosis evident CTSD mice
0.5179277.15126630.html.plaintext.txt	248	These results show changes protein expression basal differentiation related keratins CTSD deficient mice
0.5179277.15126630.html.plaintext.txt	249	View larger version 118K Fig
0.5179277.15126630.html.plaintext.txt	250	Immunohistology revealed distinct changes expression keratins CE proteins CTSD deficient mice
0.5179277.15126630.html.plaintext.txt	251	Keratin K1 staining healthy skin found suprabasal layers epidermis whereas keratin K5 expressed epidermal basal cells
0.5179277.15126630.html.plaintext.txt	252	In CTSD mice focal extension K1 staining basal layer focal extension K5 upper epidermal layers
0.5179277.15126630.html.plaintext.txt	253	Keratin K6 faintly stained normal mouse skin CTSD CTSD mouse skin
0.5179277.15126630.html.plaintext.txt	254	Involucrin filaggrin antibodies showed strong staining upper stratum spinosum stratum granulosum whereas loricrin antibody showed staining stratum granulosum solely wild type mouse skin
0.5179277.15126630.html.plaintext.txt	255	For three antibodies staining intensity reduced CTSD mice even reduced CTSD mice
0.5179277.15126630.html.plaintext.txt	256	Keratin K6 known involved proliferation shows faint probably unspecific staining normal mouse skin
0.5179277.15126630.html.plaintext.txt	257	No staining found heterozygous homozygous mouse skin
0.5179277.15126630.html.plaintext.txt	258	This reveals abnormal cornification seen light microscopy CTSD mice related hyperproliferation
0.5179277.15126630.html.plaintext.txt	259	The involucrin antibody showed strong continuous staining upper stratum spinosum stratum granulosum wild type mice
0.5179277.15126630.html.plaintext.txt	260	In CTSD CTSD mice involucrin staining markedly reduced band like staining locally interrupted
0.5179277.15126630.html.plaintext.txt	261	The loricrin antibody produced strong staining stratum granulosum
0.5179277.15126630.html.plaintext.txt	262	In CTSD CTSD mice found focally reduced staining
0.5179277.15126630.html.plaintext.txt	263	Filaggrin similar involucrin stained strongly upper stratum spinosum stratum granulosum wild type mice
0.5179277.15126630.html.plaintext.txt	264	A slight reduction staining intensity found CTSD mice
0.5179277.15126630.html.plaintext.txt	265	Staining intensity clearly reduced staining focally absent CTSD mice
0.5179277.15126630.html.plaintext.txt	266	This reveals reduced expression CE proteins
0.5179277.15126630.html.plaintext.txt	267	These studies show functional link CTSD activity expression epidermal differentiation related proteins
0.5179277.15126630.html.plaintext.txt	268	Structural changes stratum corneum transition stratum granulosum stratum corneum changes TEWL CTSD deficient mice The biological consequences CTSD deficiency reduction TG1 activity alterations CE protein levels analyzed histological examination semi thin skin sections derived wild type CTSD mice
0.5179277.15126630.html.plaintext.txt	269	The epidermis wild type heterozygous mice data shown exhibited well known regular arrangement corneocytes stratum corneum
0.5179277.15126630.html.plaintext.txt	270	In contrast stratum corneum CTSD mice irregular structure
0.5179277.15126630.html.plaintext.txt	271	The different layers stratum corneum disrupted singular corneocytes undulated
0.5179277.15126630.html.plaintext.txt	272	Furthermore stratum corneum layers Fig
0.5179277.15126630.html.plaintext.txt	273	Part changes also evident Fig
0.5179277.15126630.html.plaintext.txt	274	The ultrastructure epidermis analyzed electron microscopy revealing distinct changes morphology stratum corneum transition stratum granulosum stratum corneum CTSD mice
0.5179277.15126630.html.plaintext.txt	275	In wild type mice found normal distances stratum corneum layers normal CE seen dark lines around corneocytes Fig
0.5179277.15126630.html.plaintext.txt	276	In CTSD mice distances stratum corneum layers broader faint staining CE thickened corneocytes axial direction Fig
0.5179277.15126630.html.plaintext.txt	277	Measurements TEWL basal conditions mice age 20 days CTSD mice life expectancy 28 days Tewameter revealed small increase significant TEWL CTSD mice 17 CTSD mice 11 wild type mice TEWL 10
0.5179277.15126630.html.plaintext.txt	278	7 gm 2h n13 CTSD TEWL 12
0.5179277.15126630.html.plaintext.txt	279	2 gm 2h n10 CTSD TEWL 12
0.5179277.15126630.html.plaintext.txt	280	Together results show increase thickness number stratum corneum layers ultrastructural changes CTSD mice
0.5179277.15126630.html.plaintext.txt	281	The ichthyotic skin phenotype CTSD mice largely compensates defect protein expression shown small increase basal TEWL
0.5179277.15126630.html.plaintext.txt	282	View larger version 97K Fig
0.5179277.15126630.html.plaintext.txt	283	CTSD deficient mice exhibited impaired stratum corneum morphology
0.5179277.15126630.html.plaintext.txt	284	Microscopic analysis semi thin skin sections CTSD wild type mice A revealed normal stratum corneum morphology
0.5179277.15126630.html.plaintext.txt	285	CTSD deficient mice B disrupted stratum corneum increased number corneocyte layers
0.5179277.15126630.html.plaintext.txt	286	View larger version 94K Fig
0.5179277.15126630.html.plaintext.txt	287	Ultrastructural changes stratum corneum transition stratum granulosum stratum corneum CTSD mice
0.5179277.15126630.html.plaintext.txt	288	Electron microscopy shows wild type mice A cornified envelope CE clearly visible dark lines around corneocytes arrow
0.5179277.15126630.html.plaintext.txt	289	In CTSD mice B broadening intercellular spaces stratum corneum SC faint staining CE arrow corneocytes thickened axial direction
0.5179277.15126630.html.plaintext.txt	290	Discussion Top Summary Introduction Materials Methods Results Discussion References Recently demonstrated activation TNF signal transduction pathway including TNF R55 acid sphingomyelinase second messenger ceramide skin permeability barrier repair Jensen et al
0.5179277.15126630.html.plaintext.txt	291	TNF acid sphingomyelinase involved cell signaling growth differentiation apoptosis Aggarwal Natarajan 1996
0.5179277.15126630.html.plaintext.txt	292	In vitro identified endolysosomal aspartate protease CTSD specific ceramide binding protein
0.5179277.15126630.html.plaintext.txt	293	Ceramide enhances CTSD proteolytic activity Heinrich et al
0.5179277.15126630.html.plaintext.txt	294	The existence CTSD skin shown previously function elucidated
0.5179277.15126630.html.plaintext.txt	295	Increased activity CTSD isoforms depending stage epidermal differentiation described Horikoshi et al
0.5179277.15126630.html.plaintext.txt	296	Also increased expression mature form CTSD reported Kawada et al
0.5179277.15126630.html.plaintext.txt	297	1997 psoriasis disease characterized addition inflammation epidermal hyperproliferation altered differentiation
0.5179277.15126630.html.plaintext.txt	298	Furthermore psoriasis premature expression CE protein involucrin known Thewes et al
0.5179277.15126630.html.plaintext.txt	299	We examined role specific targets CTSD epidermal differentiation
0.5179277.15126630.html.plaintext.txt	300	First performed vitro studies determining protein expression activity CTSD primary differentiated stratified organotypic cultured keratinocytes
0.5179277.15126630.html.plaintext.txt	301	We found significant increase CTSD protein levels increase enzymatic activity CTSD differentiated compared primary keratinocytes suggesting function CTSD epidermal differentiation vitro
0.5179277.15126630.html.plaintext.txt	302	To explore possible link CTSD epidermal differentiation vivo investigated epidermal expression enzymatic activity CTSD experimental skin injury permeability barrier repair wild type mice
0.5179277.15126630.html.plaintext.txt	303	We found significantly increased epidermal expression active intermediate well mature form CTSD 3 hours 5 hours permeability barrier disruption caused increased processing increased synthesis enzyme
0.5179277.15126630.html.plaintext.txt	304	In accordance noted significant increase epidermal CTSD enzyme activity different times skin injury
0.5179277.15126630.html.plaintext.txt	305	Topical application pepstatin A inhibitor CTSD Heinrich et al
0.5179277.15126630.html.plaintext.txt	306	1999 prevented increase protein expression activity CTSD significantly delayed permeability barrier repair experimental disruption
0.5179277.15126630.html.plaintext.txt	307	These results clearly show involvement CTSD epidermal repair process injury
0.5179277.15126630.html.plaintext.txt	308	The kinetics CTSD processing activation demonstrated increased expression 1 5 hours treatment corresponded activation sphingomyelinase amount epidermal ceramides barrier perturbation Jensen et al
0.5179277.15126630.html.plaintext.txt	309	In previous study significant increase acid sphingomyelinase activation elevated epidermal ceramide content 1 4 hours barrier disruption demonstrated Jensen et al
0.5179277.15126630.html.plaintext.txt	310	1999 thus acid sphingomyelinase derived ceramide may linked CTSD activity permeability barrier repair
0.5179277.15126630.html.plaintext.txt	311	The epidermis follows programmed transformation keratinocytes proliferating basal cells spinous granular horny layers permeability barrier resides finally desquamation occurs
0.5179277.15126630.html.plaintext.txt	312	Starting granular layer aspartatic proteinases CTSD activated lysosomes participate massive degradation process accompanying cornification
0.5179277.15126630.html.plaintext.txt	313	Recent observations identified CTSD located lamellar bodies within keratinocytes Ishida Yamamoto et al
0.5179277.15126630.html.plaintext.txt	314	Involucrin loricrin cross linked TG1 form insoluble rigid CE Steinert Marekov 1997
0.5179277.15126630.html.plaintext.txt	315	CTSD reported activate TG1 thereby contribute enzymatic processes cornification Negi et al
0.5179277.15126630.html.plaintext.txt	316	These findings supported extended vitro vivo results found CTSD dependent activation TG1 keratinocyte membrane preparation furthermore activity TG1 severely diminished epidermis CTSD mice compared wild type mice
0.5179277.15126630.html.plaintext.txt	317	The enzymatic activity TG1 correlated expression 35 kDa protein wild type mice detected immunoblotting
0.5179277.15126630.html.plaintext.txt	318	This 35 kDa protein undetectable epidermis CTSD mice observed expression 150 kDa TG1 protein instead
0.5179277.15126630.html.plaintext.txt	319	There less protein CTSD mice none wild type control mice
0.5179277.15126630.html.plaintext.txt	320	These observations suggest involvement CTSD processing higher molecular weight precursor generate enzymatically active 35 kDa TG1 form see model Fig
0.5179277.15126630.html.plaintext.txt	321	A recent report Iizuka et al
0.5179277.15126630.html.plaintext.txt	322	2003 studied proteolytically activated TG1 epidermis using cleavage site directed antibodies
0.5179277.15126630.html.plaintext.txt	323	A 33 kDa fragment identified western blotting mainly found cytosol keratinocytes differentiated cells stratum corneum skin Iizuka et al
0.5179277.15126630.html.plaintext.txt	324	A second fragment resided plasma membrane keratinocytes regions skin including suprabasal layer spinous layer granular layer stratum corneum
0.5179277.15126630.html.plaintext.txt	325	The differentiation related 33 kDa TG1 fragment study could protein 35 kDa fragment detected CTSD mice CTSD mice
0.5179277.15126630.html.plaintext.txt	326	View larger version 41K Fig
0.5179277.15126630.html.plaintext.txt	327	Model role CTSD epidermal differentiation
0.5179277.15126630.html.plaintext.txt	328	During epidermal differentiation aspartate protease CTSD stratum granulosum SG activated cleaves membrane bound 150 kDa precursor transglutaminase 1 TG1 producing active 35 kDa form
0.5179277.15126630.html.plaintext.txt	329	TG1 turn mediates cross linking cornified envelope CE proteins involucrin loricrin CE
0.5179277.15126630.html.plaintext.txt	330	SC stratum corneum SS stratum spinosum SB stratum basale
0.5179277.15126630.html.plaintext.txt	331	The functional significance TG1 epidermal homeostasis demonstrated delay permeability barrier repair inhibition TG1 monodansyl cadaverin
0.5179277.15126630.html.plaintext.txt	332	Similar effects observed inhibition CTSD pepstatin A inhibition acid sphingomyelinase imipramine Jensen et al
0.5179277.15126630.html.plaintext.txt	333	1999 suggesting importance possible associated function three enzymes barrier formation differentiation
0.5179277.15126630.html.plaintext.txt	334	Epidermal differentiation including formation CE proteins involucrin loricrin crucially involved permeability barrier repair Ekanayake Mudiyanselage et al
0.5179277.15126630.html.plaintext.txt	335	The soluble CE protein involucrin expressed spinous layer early stage keratinocyte differentiation
0.5179277.15126630.html.plaintext.txt	336	Loricrin insoluble CE precursor expressed later differentiation process intracellular granules
0.5179277.15126630.html.plaintext.txt	337	The link CTSD dependent activation keratinocyte TG1 expression CE proteins confirmed CTSD mice
0.5179277.15126630.html.plaintext.txt	338	In mice found significantly reduced involucrin loricrin protein levels experimental skin injury parallel reduced activity TG1
0.5179277.15126630.html.plaintext.txt	339	These results agreement effects observed application CTSD inhibitor pepstatin A data shown
0.5179277.15126630.html.plaintext.txt	340	Since high molecular mass TG1 precursor protein present CTSD wild type mice CTSD appears mediate proteolysis enzymatically inactive TG1 active enzyme
0.5179277.15126630.html.plaintext.txt	341	Thus deficient mice also reveal functional link CTSD expression maturation activation TG1 appearance involucrin loricrin epidermis
0.5179277.15126630.html.plaintext.txt	342	Morphologically CTSD mice exhibited epidermal hyperkeratosis sign disturbed epidermal differentiation
0.5179277.15126630.html.plaintext.txt	343	The skin symptoms may explained diminished ability corneocytes bind intercellular lipids caused reduced expression involucrin loricrin stratum corneum
0.5179277.15126630.html.plaintext.txt	344	Previously shown CE proteins particular involucrin covalently bind hydroxy ceramides
0.5179277.15126630.html.plaintext.txt	345	These ceramides form scaffold attachment free ceramides cholesterol free fatty acids provides stratum corneum lipid bilayers permeability barrier function Downing 1992 Steinert Marekov 1997
0.5179277.15126630.html.plaintext.txt	346	Morphological disruption corneocyte layers found CTSD mice Fig
0.5179277.15126630.html.plaintext.txt	347	These disruptions started interface stratum granulosumstratum corneum place normally lipid bilayers extrude lipids intercellular space
0.5179277.15126630.html.plaintext.txt	348	Ultrastructural analysis epidermis CTSD mice revealed broadening distances SC layers faint staining CE thickened corneocytes axial direction
0.5179277.15126630.html.plaintext.txt	349	This demonstrates influence CTSD corneocytes possibly lipid organization stratum corneum
0.5179277.15126630.html.plaintext.txt	350	Together morphological findings suggest important role CTSD epidermal differentiation
0.5179277.15126630.html.plaintext.txt	351	To evaluate consequences CTSD deficiency reduced TG1 activity detail analyzed distribution various epidermal keratins CE proteins immunohistology
0.5179277.15126630.html.plaintext.txt	352	An extended expression basal differentiation related keratins K5 K1 sign disturbed differentiation found CTSD deficient mice
0.5179277.15126630.html.plaintext.txt	353	In previous studies found expression differentiation marker K1 disturbed acute tape stripping chronic metabolic essential fatty acid deficient diet EFAD barrier disruption
0.5179277.15126630.html.plaintext.txt	354	However models also found increase expression proliferation associated keratin K6 also K16 Ekanayake Mudiyanselage et al
0.5179277.15126630.html.plaintext.txt	355	Expression K6 besides changes basal differentiation related keratins also known psoriasis Hagemann Proksch 1996
0.5179277.15126630.html.plaintext.txt	356	In CTSD mice K6 absent though thickening horny layer clearly visible
0.5179277.15126630.html.plaintext.txt	357	Therefore CTSD mice may similarities called retention hyperkeratosis ichthyosis called hyperproliferation associated keratosis psoriasis
0.5179277.15126630.html.plaintext.txt	358	In accordance mice heterozygous truncated keratin K10 model ichthyosis called epidermolytic hyperkeratosis caused point mutations suprabasal K1 K10 Cheng et al
0.5179277.15126630.html.plaintext.txt	359	2000 show K6K16 protein expression flank skin Porter et al
0.5179277.15126630.html.plaintext.txt	360	Ichthyosis group skin disorders different causes showing disturbed epidermal differentiation variable effects permeability barrier Lavrijsen et al
0.5179277.15126630.html.plaintext.txt	361	The expression involucrin loricrin well filaggrin significantly reduced heterozygote homozygote epidermis CTSD deficient mice
0.5179277.15126630.html.plaintext.txt	362	Filaggrin deficiency well known ichthyosis vulgaris Gunzel et al
0.5179277.15126630.html.plaintext.txt	363	Defective interaction keratin filaggrin also seen epidermolytic hyperkeratosis
0.5179277.15126630.html.plaintext.txt	364	Abnormal distribution loricrin detected genetic diseases involving loricrin loricrin keratoderma Vohwinkels syndrome Maestrini et al
0.5179277.15126630.html.plaintext.txt	365	Loricrin mutation Vohwinkels keratoderma unique variant ichthyosis Korge et al
0.5179277.15126630.html.plaintext.txt	366	Defects cross linking loricrin detected TG1 deficient mice animal model lamellar ichthyosis Matsuki et al
0.5179277.15126630.html.plaintext.txt	367	Evaluation barrier function CTSD mice measurements TEWL revealed constitutive defect
0.5179277.15126630.html.plaintext.txt	368	We suggest development ichthyosiform skin compensates defective stratum corneum morphology deficiency differentiation related proteins
0.5179277.15126630.html.plaintext.txt	369	Recently similar results reported mice lacking TG1 Matsuki et al
0.5179277.15126630.html.plaintext.txt	370	Skin TG1 deficient mice die neonates lacks normal insoluble CE impaired barrier function
0.5179277.15126630.html.plaintext.txt	371	Neonatal TG1 mouse skin taut erythrodermic transplanted TG1 mouse skin resembled seen severe ichthyosis epidermal hyperplasia marked hyperkeratosis
0.5179277.15126630.html.plaintext.txt	372	Abnormalities barrier structures remained TEWL decreased control levels ichthyosiform skin
0.5179277.15126630.html.plaintext.txt	373	The authors suggested ichthyosiform skin phenotype TG1 deficiency develops massive hyperkeratosis physical compensation defective cutaneous permeability barrier Kuramoto et al
0.5179277.15126630.html.plaintext.txt	374	A compensatory mechanisms maintaining skin barrier function absence major CE protein also described loricrin deficient mouse model Koch et al
0.5179277.15126630.html.plaintext.txt	375	Also targeted ablation murine involucrin gene show defects barrier function
0.5179277.15126630.html.plaintext.txt	376	These mice developed normally possessed apparently normal epidermis hair follicles generated CEs could distinguished wild type mice Djian et al
0.5179277.15126630.html.plaintext.txt	377	The complexity redundancy epithelial barrier function discussed Steinert Steinert 2000
0.5179277.15126630.html.plaintext.txt	378	Our CTSD mouse model broader impact skin morphology either involucrin loricrin deficiency
0.5179277.15126630.html.plaintext.txt	379	Notably similarities skin CTSD mice skin TG1 mice human skin disease lamellar ichthyosis
0.5179277.15126630.html.plaintext.txt	380	In lamellar ichthyosis mutation TG1 gene resulting reduction epidermal involucrin described Hohl et al
0.5179277.15126630.html.plaintext.txt	381	The similarities explained strongly reduced TG1 expression skin CTSD mice
0.5179277.15126630.html.plaintext.txt	382	In initial characterization CTSD deficient mice atopic changes ileal mucosa leading insufficient mucosal barrier observed
0.5179277.15126630.html.plaintext.txt	383	The limit epithelium central connective tissue normally formed basement membrane undetectable mice Saftig et al
0.5179277.15126630.html.plaintext.txt	384	Together results prove importance CTSD barrier function epithelial differentiation different organs
0.5179277.15126630.html.plaintext.txt	385	In summary vitro vivo results suggest crucial involvement aspartate protease CTSD activation keratinocyte TG1 regulation CE protein expression epidermal differentiation summarized model shown Fig
0.5179277.15126630.html.plaintext.txt	386	Our findings may important development new treatment modalities skin diseases altered epidermal differentiation pattern
0.5179277.15126630.html.plaintext.txt	387	Acknowledgments We greatly appreciate assistance Andrea Hethke Claudia Neumann Dr Xu Ping Wang
0.5179277.15126630.html.plaintext.txt	388	This work supported Deutsche Forschungsgemeinschaft Sonderforschungsbereich SFB 415 granted E
0.5179277.15126630.html.plaintext.txt	389	We wish thank Katherine Houghton reviewing text article
0.5179277.15126630.html.plaintext.txt	390	References Top Summary Introduction Materials Methods Results Discussion References
0.5179277.15126630.html.plaintext.txt	391	Tumor necrosis factor Developments last decade
0.5179277.15126630.html.plaintext.txt	392	Human epidermis reconstructed culture normal J
0.5179277.15126630.html.plaintext.txt	393	Normal keratinization spontaneously immortalized aneuploid human keratinocyte cell line
0.5179277.15126630.html.plaintext.txt	394	Acylation keratinocyte transglutaminase pamitic myristic acids membrane anchorage region
0.5179277.15126630.html.plaintext.txt	395	The genetic basis epidermolytic hyperkeratosis disorder differentiation specific epidermal keratin genes
0.5179277.15126630.html.plaintext.txt	396	response keratinocytes normal psoriatic epidermis interferon differs expression zinc 2 glycoprotein cathepsin D
0.5179277.15126630.html.plaintext.txt	397	A leucine proline mutation H1 subdomain keratin 1 causes epidermolytic hyperkeratosis
0.5179277.15126630.html.plaintext.txt	398	Cathepsin D protease mediates programmed cell death induced interferon gamma FasAPO 1 TNF alpha
0.5179277.15126630.html.plaintext.txt	399	Targeted ablation murine involucrin gene
0.5179277.15126630.html.plaintext.txt	400	Lipid protein structures permeability barrier mammalian epidermis
0.5179277.15126630.html.plaintext.txt	401	Cathepsin D membrane associated macrophage endosomes
0.5179277.15126630.html.plaintext.txt	402	Involucrin structure role envelope assembly
0.5179277.15126630.html.plaintext.txt	403	Expression epidermal keratins cornified envelope protein involucrin influenced permeability barrier disruption
0.5179277.15126630.html.plaintext.txt	404	The permeability barrier mammalian epidermis
0.5179277.15126630.html.plaintext.txt	405	Epidermal lipids barrier function desquamation
0.5179277.15126630.html.plaintext.txt	406	Isolation sequencing cDNA clone encoding rat liver lysosomal cathepsin D structure three forms mature enzymes
0.5179277.15126630.html.plaintext.txt	407	Ceramide signalling regulatory role cell proliferation differentiation apoptosis human epidermis
0.5179277.15126630.html.plaintext.txt	408	Transepidermal water loss signal recovery barrier structure function
0.5179277.15126630.html.plaintext.txt	409	Keratohyalin granules heterogeneous ridged non ridged human skin evidence anti filaggrin immunogold labelling normal skin skin autosomal dominant ichthyosis vulgaris patients
0.5179277.15126630.html.plaintext.txt	410	Topical treatment urea reduces epidermal hyperproliferation induces differentiation psoriasis
0.5179277.15126630.html.plaintext.txt	411	Immunostaining chain specific keratins formalin fixed paraffin embedded tissues comparison various antigen retrieval systems using microwave heating proteolytic pre treatments
0.5179277.15126630.html.plaintext.txt	412	Cathepsin D targeted acid sphingomyelinase derived ceramide
0.5179277.15126630.html.plaintext.txt	413	Expression patterns loricrin dermatological disorders
0.5179277.15126630.html.plaintext.txt	414	In vitro rapid situ transglutaminase assays congenital ichthyoses
0.5179277.15126630.html.plaintext.txt	415	Analysis cornified cell envelope lamellar ichthyosis
0.5179277.15126630.html.plaintext.txt	416	Isoforms cathepsin D human epidermal differentiation
0.5179277.15126630.html.plaintext.txt	417	Role endogenous cathepsin D like chymotrypsin like proteolysis human epidermal desquamation
0.5179277.15126630.html.plaintext.txt	418	Mutations keratinocyte transglutaminase lamellar ichthyosis
0.5179277.15126630.html.plaintext.txt	419	A novel approach detection proteolytically activated transglutaminase 1 epidermis using cleavage site directed antibodies
0.5179277.15126630.html.plaintext.txt	420	Decreased deiminated keratin K1 psoriatic hyperproliferative epidermis
0.5179277.15126630.html.plaintext.txt	421	Epidermal lamellar granules part branched tubular structures transport different cargoes distinct aggregates
0.5179277.15126630.html.plaintext.txt	422	Induction apoptotic DNA damage cell death activation sphingomyelin pathway
0.5179277.15126630.html.plaintext.txt	423	Role tumor necrosis factor receptor p55 sphingomyelinase cutaneous permeability barrier repair
0.5179277.15126630.html.plaintext.txt	424	Disturbed permeability barrier function transgenic involucrin deficient mice
0.5179277.15126630.html.plaintext.txt	425	Impaired cutaneous permeability barrier funcion skin hydration sphingomyelinase activity keratin 10 deficient mice
0.5179277.15126630.html.plaintext.txt	426	Biochemical immunohistochemical analysis cathepsins B H L D human melanocytic tumors
0.5179277.15126630.html.plaintext.txt	427	Involucrin expression keratinization disorders skin preliminary study
0.5179277.15126630.html.plaintext.txt	428	Expression Cathepsin D B invasion metastasis squamous cell carcinoma
0.5179277.15126630.html.plaintext.txt	429	Expression transglutaminase 1 human epidermis
0.5179277.15126630.html.plaintext.txt	430	Lessons loricrin deficient mice compensatory mechanisms maintaining skin barrier function absence major cornified envelope protein
0.5179277.15126630.html.plaintext.txt	431	The sphingomyelin pathway tumor necrosis factor interleukin 1 signaling
0.5179277.15126630.html.plaintext.txt	432	Loricrin mutation Vohwinkels keratoderma unique variant ichthyosis
0.5179277.15126630.html.plaintext.txt	433	Sphingomyelinases TNF induced apoptosis
0.5179277.15126630.html.plaintext.txt	434	Development ichthyosiform skin compensates defective permeability barrier function mice lacking transglutaminase 1
0.5179277.15126630.html.plaintext.txt	435	Barrier function parameters various keratinization disorders transepidermal water loss vascular response hexyl nicotinate
0.5179277.15126630.html.plaintext.txt	436	Cathepsin D rabbit skin immunoenzymic study
0.5179277.15126630.html.plaintext.txt	437	Sphingomyelinases cell regulation
0.5179277.15126630.html.plaintext.txt	438	Improvements epoxy resin embedding methods
0.5179277.15126630.html.plaintext.txt	439	A molecular defect loricrin major component cornified cell envelope underlies Vohwinkels syndrome
0.5179277.15126630.html.plaintext.txt	440	Defective stratum corneum early neonatal death mice lacking gene transglutaminase 1 keratinocyte transglutaminase
0.5179277.15126630.html.plaintext.txt	441	Detection neutrophil activating peptide NAPIL 8 NAPIL 8 mRNA human recombinant IL 1 alpha human recombinant tumor necrosis factor alpha stimulated human dermal fibroblasts
0.5179277.15126630.html.plaintext.txt	442	An immunocytochemical fluorescent situ hybridization study
0.5179277.15126630.html.plaintext.txt	443	A novel function transglutaminase 1 attatchment long chain omega hydroxyceramides involucrin ester bond formation
0.5179277.15126630.html.plaintext.txt	444	Mechanism human epidermal transglutaminase
0.5179277.15126630.html.plaintext.txt	445	Mechanism regulation human epidermal transglutaminase
0.5179277.15126630.html.plaintext.txt	446	In vivo studies concerning pH gradient human stratum corneum upper epidermis
0.5179277.15126630.html.plaintext.txt	447	The role ceramide cell signaling
0.5179277.15126630.html.plaintext.txt	448	cDNA cloning expression assembly characteristics mouse keratin 16
0.5179277.15126630.html.plaintext.txt	449	The use lead citrate high pH electron opaque stain electron microscopy
0.5179277.15126630.html.plaintext.txt	450	Presence human epidermal cells soluble protein precursor cross linked envelope activation cross linking calcium ions
0.5179277.15126630.html.plaintext.txt	451	Proteolytic release keratinocyte transglutaminase
0.5179277.15126630.html.plaintext.txt	452	Acute chronic topical retinoic acid treatment human skin vivo alters expression epidermal transglutaminase loricrin involucrin filaggrin keratins 6 13 keratins 1 10 14
0.5179277.15126630.html.plaintext.txt	453	Mutations rod domains keratins 1 10 epidermolytic hyperkeratosis
0.5179277.15126630.html.plaintext.txt	454	Mice deficient lysosomal proteinase cathepsin D exhibit progressive atrophy intestinal mucosa profound destruction lymphoid cells
0.5179277.15126630.html.plaintext.txt	455	Immunocytochemical localization lysosomal cysteine aspartatic proteinases ubiquitin rat epidermis
0.5179277.15126630.html.plaintext.txt	456	The regeneration rate water vapour loss heavily damaged skin
0.5179277.15126630.html.plaintext.txt	457	The complexity redundancy epithelial barrier function
0.5179277.15126630.html.plaintext.txt	458	Inactive zymogen highly active proteolytically processed membrane bound forms transglutaminase 1 enzyme human epidermal keratinocytes
0.5179277.15126630.html.plaintext.txt	459	The transglutaminase 1 enzyme variably acylated myristate palmitate differentiation epidermal keratinocytes
0.5179277.15126630.html.plaintext.txt	460	Direct evidence involucrin major early isopeptide cross linked keratinocyte cornified cell envelope
0.5179277.15126630.html.plaintext.txt	461	Interleukin 1 stimulated secretion interleukin 8 growth related oncogene alpha demonstrates greatly enhanced keratinocyte growth human raft cultured epidermis
0.5179277.15126630.html.plaintext.txt	462	A novel helix termination mutation keratin 10 annular epidermolytic ichthyosis variant bullous congenital ichthyosiform erythroderma
0.5179277.15126630.html.plaintext.txt	463	Transgenic mice expressing mutant form loricrin reveal molecular basis skin diseases Vohwinkel syndrome progressive symmetric erythrokeratoderma
0.5179277.15126630.html.plaintext.txt	464	Cathepsin D prognosis breast cancer
0.5179277.15126630.html.plaintext.txt	465	Normal psoriatic epidermis expression hyperproliferation associated keratins
0.5179277.15126630.html.plaintext.txt	466	Keratinocyte differentiation induced cell permeant ceramides proliferation promoted sphingosine
0.5179277.15126630.html.plaintext.txt	467	Involucrin markers keratinocyte terminal differentiation
0.5179277.15126630.html.plaintext.txt	468	Functional dichotomy neutral acidic spingomyelinases tumor necrosis factor signaling
0.5179277.15126630.html.plaintext.txt	469	An alanine proline mutation 1A rod domain keratin 10 chain epidermolytic hyperkeratosis
0.3697104.9700208.html.plaintext.txt	0	Pronounced impact Th1E47cs mutation compared 491 AT mutation neural APOE gene expression risk developing Alzheimers disease
0.3697104.9700208.html.plaintext.txt	1	Jean Charles Lambert Claudine Berr1 Florence Pasquier2 Andre Delacourte3 Bernard Frigard4 Dominique Cottel Jordi Perez Tur5 Vincent Mouroux Michel Mohr6 Danielle Cecyre7 Douglas Galasko8 Corinne Lendon9 Judes Poirier7 John Hardy5 David Mann10 Philippe Amouyel Marie Christine Chartier Harlin
0.3697104.9700208.html.plaintext.txt	2	INSERM CJF95 05 Institut Pasteur de Lille 1 rue du Professeur Calmette BP 245 59019 Lille Cedex France 1INSERM U360 Hopital de la Salpetriere 75651 Paris Cedex 13 France 2CHR et U de Lille Clinique Neurologique Centre de la Memoire Hopital Salengro 59037 Lille Cedex France 3INSERM U422 Place de Verdun 59045 Lille Cedex France 4Centre de Geriatrie de Wasquehal rue Salvador Allende BP 165 59444 Wasquehal France 5Birdsall Building Mayo Clinic Jacksonville 4500 San Pablo Road Jacksonville FL 32224 USA 6Institut de Pathologie 1 place de lHopital BP 22 67064 Strasbourg Cedex France 7McGill Centre Studies Aging 6875 La Salle Boulevard Verdun Quebec Canada H4H 1R3 8Department Neurosciences University California San Diego 3350 La Jolla Village Drive San Diego CA 9216 USA 9Departments Psychiatry Neurology Genetics Washington University School Medicine St Louis MO 63310 USA 10Department Pathological Sciences Stopford Building University Manchester Oxford Road Manchester M13 9PT UK
0.3697104.9700208.html.plaintext.txt	3	Received June 1 1998 Revised Accepted July 8 1998
0.3697104.9700208.html.plaintext.txt	4	Possession apolipoprotein E APOE epsis4 allele frequently associated genetic susceptibility factor Alzheimers disease AD
0.3697104.9700208.html.plaintext.txt	5	Recently new polymorphisms regulatory region APOE gene described
0.3697104.9700208.html.plaintext.txt	6	We analysed effects three mutations 491 AT 427 CT Th1E47cs disease risk large case control study tested impacts APOE allelic expression brain tissues
0.3697104.9700208.html.plaintext.txt	7	The Th1E47cs T allele associated increased risk occurrence AD 491 T allele associated decreased risk independently APOE epsis2epsis3epsis4 polymorphism effect
0.3697104.9700208.html.plaintext.txt	8	However impact Th1E47cs mutation strongest
0.3697104.9700208.html.plaintext.txt	9	The 427 CT polymorphism associated disease
0.3697104.9700208.html.plaintext.txt	10	In AD subjects heterozygous epsis4 allele analysis allelic expression showed relative expression levels epsis4 allele higher corresponding controls
0.3697104.9700208.html.plaintext.txt	11	Consistent epidemiological data relative level expression epsis4 allele modified accordingly presence absence two main promoter polymorphisms indicating vivo deleterious effect Th1E47cs T allele protective effect 491 T allele population
0.3697104.9700208.html.plaintext.txt	12	These data indicate addition qualitative effect APOE epsis2epsis3epsis4 polymorphisms AD occurrence quantitative variation expression alleles due functional APOE promoter mutations key determinant AD development
0.3697104.9700208.html.plaintext.txt	13	The presence least one apolipoprotein E APOE epsis4 allele major genetic susceptibility factor late onset familial sporadic Alzheimers disease AD
0.3697104.9700208.html.plaintext.txt	14	This risk factor accounts 45 60 cases 1
0.3697104.9700208.html.plaintext.txt	15	Indeed epsis4 allele associated increased risk AD allele dose dependant manner 23
0.3697104.9700208.html.plaintext.txt	16	Conversely epsis2 allele protects disease 45
0.3697104.9700208.html.plaintext.txt	17	The mechanisms apoE isoforms implicated human nervous system physiology influence pathogenesis AD fully understood 26 8
0.3697104.9700208.html.plaintext.txt	18	The effect APOE epsis2epsis3epsis4 alleles may due intrinsic biochemical properties isoforms coded alleles
0.3697104.9700208.html.plaintext.txt	19	Other genetic variants influencing APOE allele expression may account increase decrease level risk AD
0.3697104.9700208.html.plaintext.txt	20	This hypothesis supported firstly preliminary observations relative overexpression epsis4 allele compared epsis3 allele brain patients AD compared controls 9
0.3697104.9700208.html.plaintext.txt	21	Secondly Th1E47cs 491 AT polymorphisms located APOE promoter described associated AD risk 1011
0.3697104.9700208.html.plaintext.txt	22	Moreover effect two polymorphisms AD occurrence described separately case control studies
0.3697104.9700208.html.plaintext.txt	23	This prompted us analyse relative contribution two promoter polymorphisms also third located position 427 APOE promoter together epsis2epsis3epsis4 alleles towards AD risk large case control study 509 controls 573 AD cases
0.3697104.9700208.html.plaintext.txt	24	Furthermore investigated possible influences two main polymorphisms APOE epsis2epsis3epsis4 allelic relative expression brain tissues approach vivo functionality brain samples 49 AD cases 45 controls
0.3697104.9700208.html.plaintext.txt	25	As expected possession epsis4 allele strongly associated AD odds ratio OR 5
0.3697104.9700208.html.plaintext.txt	26	40 95 confidence interval CI 4
0.3697104.9700208.html.plaintext.txt	27	0001 presence epsis2 allele exhibited protective effect OR 0
0.3697104.9700208.html.plaintext.txt	28	The frequency Th1E47cs T allele increased AD cases compared controls chi2 23
0.3697104.9700208.html.plaintext.txt	29	The risk developing AD carriers least one T allele 2
0.3697104.9700208.html.plaintext.txt	30	Conversely frequency 491 T allele decreased patients compared controls chi2 9
0.3697104.9700208.html.plaintext.txt	31	The genotype allele frequencies 491 AT polymorphism similar observed North American population differed Spanish sample 11
0.3697104.9700208.html.plaintext.txt	32	The OR develop AD subjects bearing least one 491 T allele 0
0.3697104.9700208.html.plaintext.txt	33	No association disease detected 427 CT polymorphism
0.3697104.9700208.html.plaintext.txt	34	To eliminate possible confounding effects APOE epsis4 allele association Th1E47cs 491 AT polymorphisms AD controlled effects allele using logistic regression adjusted presence absence epsis4 allele
0.3697104.9700208.html.plaintext.txt	35	After adjustment risk associated possession least one Th1E47cs T allele persisted OR 1
0.3697104.9700208.html.plaintext.txt	36	004 risk associated 491 T allele OR 0
0.3697104.9700208.html.plaintext.txt	37	This observation suggested effect Th1E47cs T allele independent epsis4 allele 491 T allele
0.3697104.9700208.html.plaintext.txt	38	However since Th1E47cs G epsis2 alleles complete disequilibrium Table 2 also performed logistic regression including protective deleterious effects epsis2 epsis4 alleles respectively
0.3697104.9700208.html.plaintext.txt	39	The risk associated Th1E47cs T allele still persisted OR 1
0.3697104.9700208.html.plaintext.txt	40	If assume level expression APOE alleles increased decreased due cis mutations promoter region hypothesis two major implications promoter mutations may modulate expression APOE alleles leading increase decrease deleterious protective risk associated epsis4 epsis2 allele respectively ii given determines risk importance relative level expression alleles APOE suggested preliminary data 12 promoter mutations differential effects detectable mainly APOE epsis2epsis3epsis4 heterozygous individuals
0.3697104.9700208.html.plaintext.txt	41	To verify assumptions studied OR developing AD APOE heterozygous homozygous individuals using logistic regression adjusted age sex presence least one 491 T one Th1E47 T allele
0.3697104.9700208.html.plaintext.txt	42	In APOE epsis2epsis3epsis4 homozygotes effect found OR 1
0.3697104.9700208.html.plaintext.txt	43	44 Th1E47 T 491 T alleles respectively
0.3697104.9700208.html.plaintext.txt	44	Conversely APOE epsis2epsis3epsis4 heterozygotes individuals bearing least one Th1E47 T allele increased risk developing AD OR 3
0.3697104.9700208.html.plaintext.txt	45	0001 individuals bearing least one 491 T allele exhibited protective effect OR 0
0.3697104.9700208.html.plaintext.txt	46	014 consistent initial hypothesis
0.3697104.9700208.html.plaintext.txt	47	APOE Th1E47cs 491 AT allele genotype distributions Allele Genotype APOE epsis2 epsis3 epsis4 epsis2epsis2a epsis2epsis3 epsis2epsis4 epsis3epsis3 epsis3epsis4 epsis4epsis4 Controls 75 0
0.3697104.9700208.html.plaintext.txt	48	13 Th1Egr47cs G T GGa GT TT Controls 562 0
0.3697104.9700208.html.plaintext.txt	49	28 427 TCb T C TT TC CC Controls 874 0
0.3697104.9700208.html.plaintext.txt	50	00 491 AT A T AAc AT TT Controls 833 0
0.3697104.9700208.html.plaintext.txt	51	02 Allele genotype numbers frequencies presented
0.3697104.9700208.html.plaintext.txt	52	The genotypic distributions control population Hardy Weinberg equilibrium
0.3697104.9700208.html.plaintext.txt	53	Combination 491 AT Th1E47cs APOE polymorphism alleles controls AD cases APOE Th1E47cs polymorphism combination n epsis2epsis3a epsis3epsis3 epsis3epsis4 epsis4epsis4 epsis2epsis4 AD cases GG 103 5 60 30 3 5 GT 306 11 113 136 27 19 TT 139 49 70 43 n 571 16 222 236 73 24 Control cases GG 162 41 100 16 5 GT 238 20 170 40 2 5 TT 109 73 32 4 n 509 61 343 88 6 10 APOE 491 AT polymorphism combination n epsis2epsis3a epsis3epsis3 epsis3epsis4 epsis4epsis4 epsis2epsis4 AD cases AA 431 6 157 190 67 11 AT 128 8 58 44 6 12 TT 12 2 7 2 1 n 261 16 222 102 28 24 Control cases AA 342 24 242 65 5 6 AT 147 34 89 19 1 4 TT 20 3 12 4 n 509 61 343 88 6 10 Th1E47cs 491 AT polymorphism combination n AgrAgr AgrSigma SigmaSigma AD cases GG 103 79 22 2 GT 307 226 75 6 TT 162 127 31 4 n 572 432 128 12 Control cases GG 162 111 48 3 GT 238 162 67 9 TT 109 69 32 8 n 509 342 147 20 aThree individuals epsis2epsis2 control
0.3697104.9700208.html.plaintext.txt	54	The 491 A epsis4 alleles present degree linkage disequilibrium 26 75 control AD populations respectively
0.3697104.9700208.html.plaintext.txt	55	The Th1E47cs G epsis2 alleles complete linkage disequilibrium populations Th1E47cs T epsis4 alleles show linkage disequilibrium 44 populations
0.3697104.9700208.html.plaintext.txt	56	No linkage disequilibrium found 491 AT Th1E47cs polymorphisms
0.3697104.9700208.html.plaintext.txt	57	The location polymorphisms within regulatory region APOE gene potential effect vitro reported hepatoma cells suggested polymorphisms may play role control APOE expression levels brain
0.3697104.9700208.html.plaintext.txt	58	In order test hypothesis obtained 94 AD control brain tissues heterozygous APOE measured percentage expression level three APOE alleles
0.3697104.9700208.html.plaintext.txt	59	In controls epsis4 allele strongly underexpressed compared epsis3 epsis2 allele epsis3epsis4 epsis2epsis4 brain samples respectively epsis2 epsis3 expressions almost similar epsis2epsis3 samples Fig
0.3697104.9700208.html.plaintext.txt	60	As suggested preliminary data 9 clear consistent increase relative epsis4 allelic expression epsis3epsis4 patients epsis3epsis4 controls 34
0.3697104.9700208.html.plaintext.txt	61	A significant decrease relative epsis2 expression demonstrated epsis2epsis3 AD brains compared epsis2epsis3 controls 32
0.3697104.9700208.html.plaintext.txt	62	An increased expression epsis4 allele also detected epsis2epsis4 AD controls 46
0.3697104.9700208.html.plaintext.txt	63	Measured values epsis2epsis4 AD cases controls corresponded expected values estimated genotypes reinforcing observations see Materials Methods arrows Fig
0.3697104.9700208.html.plaintext.txt	64	Differential expression APOE mRNA three heterozygous genotypes AD control cases
0.3697104.9700208.html.plaintext.txt	65	The average level expression indicated bold line category
0.3697104.9700208.html.plaintext.txt	66	For brain sample RT PCR semi quantitation repeated least twice
0.3697104.9700208.html.plaintext.txt	67	Bold arrows indicate expected values epsis4 allele percentage epsis2epsis4 samples calculated epsis2 epsis4 percentage epsis2epsis3 epsis3epsis4 AD control cases respectively
0.3697104.9700208.html.plaintext.txt	68	The previous epidemiological data suggest 491 AT polymorphism Th1E47cs polymorphism may good candidates mediate allelic distortions
0.3697104.9700208.html.plaintext.txt	69	In particular estimation OR associated combination epsis4 Th1E47cs T allele chromosome indicate estimated increased risk 1
0.3697104.9700208.html.plaintext.txt	70	7 heterozygous epsis3epsis4 individuals presenting haplotype described previously 10
0.3697104.9700208.html.plaintext.txt	71	Thus epsis4 allele associated Th1E47cs T allele chromosome epsis3 allele associated Th1E47cs G allele relative epsis4epsis3 mRNA ratio significantly increased associated AD
0.3697104.9700208.html.plaintext.txt	72	Conversely epsis4 epsis3 alleles control Th1E47cs allele either G T level expression similar
0.3697104.9700208.html.plaintext.txt	73	Thus expected stronger distortion Th1E47cs heterozygotes homozygotes
0.3697104.9700208.html.plaintext.txt	74	This argument clearly illustrated experimental data Table 3
0.3697104.9700208.html.plaintext.txt	75	The approach valid 491 AT mutation
0.3697104.9700208.html.plaintext.txt	76	The influence polymorphisms relative mRNA expression level could observed cases Fig
0.3697104.9700208.html.plaintext.txt	77	Affected patients carrying Th1E47cs GT 491 AT genotypes highest lowest relative levels expression epsis4 expression respectively Fig
0.3697104.9700208.html.plaintext.txt	78	The difference levels expression cases pronounced Th1E47cs GT bearers 491 AT bearers 36
0.3697104.9700208.html.plaintext.txt	79	Differential expression epsis4 allele epsis3epsis4 AD control cases according Th1E47cs genotype
0.3697104.9700208.html.plaintext.txt	80	AD cases denoted triangles controls circles
0.3697104.9700208.html.plaintext.txt	81	Closed symbols open symbols correspond 491 AT AA genotypes respectively
0.3697104.9700208.html.plaintext.txt	82	The deleterious effect Th1E47cs T allele protective effect 491 T allele described recently 1011 confirmed large case control study
0.3697104.9700208.html.plaintext.txt	83	These effects obvious APOE heterozygous population homozygous population
0.3697104.9700208.html.plaintext.txt	84	These data surprising two reasons would expect APOE epsis4 homozygotes high expressing promoter alleles chromosomes higher risk developing AD epsis4 homozygotes low expressing promoter alleles
0.3697104.9700208.html.plaintext.txt	85	However small size epsis4epsis4 control population allow impact brought forward ii consequence measured OR epsis2epsis3epsis4 homozygous individuals mainly depended epsis3epsis3 population
0.3697104.9700208.html.plaintext.txt	86	No effect found latter population whatever studied promoter polymorphism
0.3697104.9700208.html.plaintext.txt	87	Furthermore apoE3 isoform considered isoform lesser effect AD pathology
0.3697104.9700208.html.plaintext.txt	88	Relative epsis4 allele expression according Th1E47cs 491 AT polymorphisms AD control brain samples n AD n Controlsa Th1E47cs GG 4 33
0.3697104.9700208.html.plaintext.txt	89	We confirm deleterious effect 491 AA genotype described epsis3epsis3 Spanish population 11
0.3697104.9700208.html.plaintext.txt	90	This discrepancy may explained significant difference 491 AT genotype distribution observed Spanish French American control populations
0.3697104.9700208.html.plaintext.txt	91	Since AD genotypic frequency similar three studied populations deleterious effect AA genotype epsis3epsis3 group may due distribution Spanish control population
0.3697104.9700208.html.plaintext.txt	92	When impacts two promoter polymorphisms APOE epsis4 allele studied simultaneously multiple logistic regression model demonstrated Th1E47cs T allele modified risk developing AD independently epsis4 allele suggesting 491 polymorphisms may play weaker role compared Th1E47cs development AD
0.3697104.9700208.html.plaintext.txt	93	The location polymorphisms regulatory region APOE gene effects transcriptional activity hepatoma cells 12 impacts AD population prompted us test hypothesis may modulate APOE expression levels brain therefore partly responsible marked allelic distortion APOE mRNA observed AD brain compared controls heterozygous genotypes
0.3697104.9700208.html.plaintext.txt	94	Indeed epsis4 allele overexpressed epsis3epsis4 epsis2epsis4 AD cases epsis2 allele underexpressed epsis2epsis3 AD cases compared respective controls
0.3697104.9700208.html.plaintext.txt	95	Consistent effects deduced case control study epsis4 allele expression AD brain also correlated polymorphisms regulatory region APOE Fig
0.3697104.9700208.html.plaintext.txt	96	2 Th1E47cs T allele may increase relative expression epsis4 allele AD 491 T allele may decrease
0.3697104.9700208.html.plaintext.txt	97	Because numerous studies reported contradictory findings brain cerebrospinal fluid CSF concerning apoE protein level difficult speculate link APOE mRNA apoE protein levels 13 17
0.3697104.9700208.html.plaintext.txt	98	However suggested Yamada et al
0.3697104.9700208.html.plaintext.txt	99	APOE expression may decreased epsis4 gene dosage AD epsis3 homozygous AD cases expressed APOE mRNA epsis4epsis4 AD cases epsis3epsis4 presenting intermediate mRNA level 18
0.3697104.9700208.html.plaintext.txt	100	A similar trend found proteins AD brains 14 plasma J
0.3697104.9700208.html.plaintext.txt	101	Poirier personal communication indicating protein mRNA levels may directly correlated disease
0.3697104.9700208.html.plaintext.txt	102	Underlining importance apoE level APOE expression shown correlate Abeta peptide deposition transgenic mice 1920
0.3697104.9700208.html.plaintext.txt	103	This observation may important since previous reports showed APOE gene expression increased 2 3 fold AD brains compared controls regardless APOE genotype 1821
0.3697104.9700208.html.plaintext.txt	104	In epsis3epsis4 AD cases epsis3 epsis4 alleles would overexpressed epsis4 allele due promoter mutations still overexpressed epsis3 allele
0.3697104.9700208.html.plaintext.txt	105	Exacerbation APOE epsis4 expression level may foster intrinsic deleterious effect apoE4 isoform AD instance promoting Abeta aggregation 2622
0.3697104.9700208.html.plaintext.txt	106	This expression level modulation may intended neurodegenerative disease also neural development
0.3697104.9700208.html.plaintext.txt	107	Indeed observed strong underexpression epsis4 allele compared epsis3 allele controls
0.3697104.9700208.html.plaintext.txt	108	Although role apoE maturation ageing completely understood yet fact apoE deficient homozygous mice exhibit reversible dendritic alterations significant learning deficits Morris water maze suggests neurotrophic capabilities apoE 23 25
0.3697104.9700208.html.plaintext.txt	109	However abilities isoform may different since apoE4 isoform effects apoE3 isoform neurite outgrowth 26
0.3697104.9700208.html.plaintext.txt	110	For instance apoE3 apoE4 may stabilize neuronal cytoskeleton 7
0.3697104.9700208.html.plaintext.txt	111	A global assessment modulation APOE expression difficult
0.3697104.9700208.html.plaintext.txt	112	Indeed date five polymorphisms described APOE promoter region 1012
0.3697104.9700208.html.plaintext.txt	113	Two three polymorphisms studied seem play role AD
0.3697104.9700208.html.plaintext.txt	114	The two remaining allelic frequencies 1 12 therefore cannot explain effects observed case control mRNA studies
0.3697104.9700208.html.plaintext.txt	115	However remains possible unknown polymorphisms modulate APOE mRNA level
0.3697104.9700208.html.plaintext.txt	116	These new mutations may far away promoter polymorphisms instance brain tissue specific element 2728
0.3697104.9700208.html.plaintext.txt	117	The interaction putative polymorphisms modifying APOE expression difficult model
0.3697104.9700208.html.plaintext.txt	118	Various combinations different mutations may confer large APOE expression heterogeneity two levels absolute level APOE expression ii percentage expression one allele compared heterozygous individuals adding complexity association APOE AD
0.3697104.9700208.html.plaintext.txt	119	Therefore variation APOE expression induced APOE promoter polymorphisms may partly explain heterogeneity impact epsis4 allele different ethnic groups 129
0.3697104.9700208.html.plaintext.txt	120	MATERIALS AND METHODS Populations
0.3697104.9700208.html.plaintext.txt	121	The AD control samples Caucasians originating France
0.3697104.9700208.html.plaintext.txt	122	Diagnoses probable AD established according DSM III R NINDCS ADRDA criteria n 573 age 73
0.3697104.9700208.html.plaintext.txt	123	The Caucasian controls defined subjects without DMS III R dementia criteria integrity cognitive functions n 509 age 74
0.3697104.9700208.html.plaintext.txt	124	Each individual relatives signed informed consent
0.3697104.9700208.html.plaintext.txt	125	These consisted 45 controls age 80
0.3697104.9700208.html.plaintext.txt	126	9 men 49 late onset AD cases age 76
0.3697104.9700208.html.plaintext.txt	127	4 men selected according APOE genotype
0.3697104.9700208.html.plaintext.txt	128	Eighty eight samples extracted frontal cortex six occipital cortex difference relative expressions observed regions
0.3697104.9700208.html.plaintext.txt	129	7 years AD cases genotyped epsis3epsis4 75
0.3697104.9700208.html.plaintext.txt	130	Diagnoses confirmed neuropathological examination
0.3697104.9700208.html.plaintext.txt	131	The 491 AT 427 CT Th1E47cs APOE genotypes produced PCR followed restriction enzyme digestion amplified DNA described 10 1232
0.3697104.9700208.html.plaintext.txt	132	Total RNA extraction brain tissues heterozygous APOE genotype performed described 33 using RNeasy Mini kit Qiagen Germany digested DNase Eurogentec Belgium
0.3697104.9700208.html.plaintext.txt	133	No DNA contamination observed DNase digestion detected PCR digested product
0.3697104.9700208.html.plaintext.txt	134	APOE mRNAs amplified RT PCR allele quantitation performed described previously 9 measuring ratio expression two alleles heterozygotes order avoid problems due post mortem delay agonal state cell population density
0.3697104.9700208.html.plaintext.txt	135	10 used SAS Institute Cary NC
0.3697104.9700208.html.plaintext.txt	136	Univariate analysis performed using Pearsons chi2 test
0.3697104.9700208.html.plaintext.txt	137	In multivariate analysis coded genotypes subject dummy variables according tested hypotheses least one Th1E47cs T allele TTTGGG least one 491 T allele TTATAA least one epsis4 allele
0.3697104.9700208.html.plaintext.txt	138	The effects variables disease assessed multiple logistic regression model adjusted age gender
0.3697104.9700208.html.plaintext.txt	139	Comparison allelic expression performed using Wilcoxon test
0.3697104.9700208.html.plaintext.txt	140	We calculated expected range values epsis4 percentage epsis2epsis4 AD control individuals using extreme values obtained epsis2 epsis4 percentages epsis3epsis4 epsis2epsis3 AD control samples respectively epsis3 allele used reference
0.3697104.9700208.html.plaintext.txt	141	recipient Ministere de lEnseignement Superieur et de la Recherche MESR
0.3697104.9700208.html.plaintext.txt	142	This work supported Institut National pour la Sante et la Recherche Medicale INSERM Institut Pasteur de Lille Conseil Regional du Nord Pas de Calais axe regional de recherche sur les maladies neurodegeneratives et le vieillissement cerebral M
0.3697104.9700208.html.plaintext.txt	143	Fondation pour la Recherche Medicale
0.3697104.9700208.html.plaintext.txt	144	1997 Effects age sex ethnicity association apolipoprotein E genotype Alzheimer disease
0.3697104.9700208.html.plaintext.txt	145	APOE Alzheimer Disease Meta Analysis Consortium
0.3697104.9700208.html.plaintext.txt	146	1993 Binding human apolipoprotein E synthetic amyloid beta peptide isoform specific effects implications late onset Alzheimer disease
0.3697104.9700208.html.plaintext.txt	147	1993 Gene dose apolipoprotein E type 4 allele risk Alzheimers disease late onset families
0.3697104.9700208.html.plaintext.txt	148	1994 Apolipoprotein E epsis4 allele major risk factor sporadic early late onset forms Alzheimers disease analysis 19q13
0.3697104.9700208.html.plaintext.txt	149	1994 Protective effect apolipoprotein E type 2 late onset Alzheimers disease
0.3697104.9700208.html.plaintext.txt	150	1995 Apolipoprotein E kinetic thermodynamic inhibitor amyloid formation implication pathogenesis treatment Alzheimers disease
0.3697104.9700208.html.plaintext.txt	151	1996 Apolipoprotein E allele specific antioxidant activity effects cytotoxicity oxidative insults beta amyloid peptides
0.3697104.9700208.html.plaintext.txt	152	1994 Hypotesis microtubule instability paired helical filament formation Alzheimer disease related Apolipoprotein E genotype
0.3697104.9700208.html.plaintext.txt	153	1997 Distortion allelic expression apolipoprotein E Alzheimers disease
0.3697104.9700208.html.plaintext.txt	154	1998 A new polymorphism APOE promoter associated risk developing Alzheimers Disease
0.3697104.9700208.html.plaintext.txt	155	1998 A polymorphism regulatory region APOE associated risk Alzheimers dementia
0.3697104.9700208.html.plaintext.txt	156	1998 Allelic polymorphisms transcriptional regulatory region apolipoprotein E gene
0.3697104.9700208.html.plaintext.txt	157	1996 Relevance quantification apolipoprotein E cerebrospinal fluid Alzheimers disease
0.3697104.9700208.html.plaintext.txt	158	1995 Association apolipoprotein E genotype brain levels apolipoprotein E apolipoprotein J clusterin Alzheimer disease
0.3697104.9700208.html.plaintext.txt	159	1996 Brain expression Apolipoprotein E J A I Alzheimers disease
0.3697104.9700208.html.plaintext.txt	160	1995 Apolipoprotein E apoE polymorphism influence ApoE concentrations cerebrospinal fluid Finnish patients Alzheimers disease
0.3697104.9700208.html.plaintext.txt	161	1997 Cerebrospinal fluid apolipoprotein E level increased late onset Alzheimers disease
0.3697104.9700208.html.plaintext.txt	162	1995 Apolipoprotein E mRNA brains patients Alzheimers disease
0.3697104.9700208.html.plaintext.txt	163	1997 Lack apolipoprotein E dramatically reduces amyloid beta peptide deposition
0.3697104.9700208.html.plaintext.txt	164	1997 Apolipoprotein E accumulates progression A beta deposition transgenic mice
0.3697104.9700208.html.plaintext.txt	165	1991 Neuropathological changes scrapie Alzheimers disease associated increased expression Apolipoprotein E Cathepsin D astrocytes
0.3697104.9700208.html.plaintext.txt	166	1994 Apolipoprotein E allele epsilon 4 linked increased deposition amyloid beta peptide A beta cases without Alzheimers disease
0.3697104.9700208.html.plaintext.txt	167	1995 Neurodegeneration central nervous system apoE deficient mice
0.3697104.9700208.html.plaintext.txt	168	1995 Memory deficits cholinergic impairments apolipoprotein E deficient mice
0.3697104.9700208.html.plaintext.txt	169	1997 Neurodegeneration cognitive impairment apoE deficient mice ameliorated infusion recombinant apoE
0.3697104.9700208.html.plaintext.txt	170	1996 Apolipoprotein E containing high density lipoprotein promotes neurite outgrowth ligand low density lipoprotein receptor related protein
0.3697104.9700208.html.plaintext.txt	171	1991 Multiple tissue specific elements control apolipoprotein EC I gene locus transgenic mice
0.3697104.9700208.html.plaintext.txt	172	1997 Apolipoprotein E gene complex biological interactions aging brain
0.3697104.9700208.html.plaintext.txt	173	1998 The APOE epsis4 allele risk Alzheimer Disease among African Americans whites Hispanics
0.3697104.9700208.html.plaintext.txt	174	American Psychiatric Association 1987 Diagnostic statistical manual mental disorders
0.3697104.9700208.html.plaintext.txt	175	Third edition revised DSM III R American Psychatric Association Washington DC
0.3697104.9700208.html.plaintext.txt	176	1984 Clinical diagnosis Alzheimers disease report NINCDS ADRDA work group Neurology 34 939 944
0.3697104.9700208.html.plaintext.txt	177	1991 Restriction isotyping human apolipoprotein E gene amplification cleavage HhaI
0.3697104.9700208.html.plaintext.txt	178	1972 Biosynthesis protamine trout testis
0.3697104.9700208.html.plaintext.txt	179	To correspondence addressed
0.3697104.9700208.html.plaintext.txt	180	Tel 33 3 20 87 72 28 Fax 33 3 20 87 78 94 Email marie christine
0.3697104.9700208.html.plaintext.txt	181	fr u d This page run Oxford University Press Great Clarendon Street Oxford OX2 6DP part OUP Journals Comments feedback www adminatoup
0.3697104.9700208.html.plaintext.txt	182	uk u d Last modification 12 Aug 1998 Copyright Oxford University Press 1998
0.30104497.11861652.html.plaintext.txt	0	Reconstituted Discoidal ApoE Phospholipid Particles Are Ligands Scavenger Receptor BI THE AMINO TERMINAL 1 165 DOMAIN OF ApoE SUFFICES FOR RECEPTOR BINDING Xiaoping Li Horng Yuan Kan Sophia Lavrentiadou Monty Krieger Vassilis Zannis
0.30104497.11861652.html.plaintext.txt	1	From Section Molecular Genetics Whitaker Cardiovascular Institute Departments Medicine Biochemistry Boston University School Medicine Boston Massachusetts 02118 Biology Department Massachusetts Institute Technology Cambridge Massachusetts 02139
0.30104497.11861652.html.plaintext.txt	2	Received publication January 22 2002 revised form February 19 2002
0.30104497.11861652.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.30104497.11861652.html.plaintext.txt	4	The high density lipoprotein receptor scavenger receptor class B type I SR BI recognizes lipid bound apolipoprotein A I apoA I apolipoproteins
0.30104497.11861652.html.plaintext.txt	5	Here used large scale cultures apoE expressing cells purify apoE prepare apoE containing reconstituted discoidal 1 palmitoyl 2 oleoyl L phosphatidylcholine POPC apoE particles
0.30104497.11861652.html.plaintext.txt	6	These particles used examine binding wild type mutant forms SR BI expressed transfected ldlA 7 cells
0.30104497.11861652.html.plaintext.txt	7	Specific binding SR BI determined subtracting total binding nonspecific values measured using either control untransfected ldlA 7 cells inhibiting SR BI mediated binding high titer antireceptor blocking antibody
0.30104497.11861652.html.plaintext.txt	8	POPC apoE particles generated using apoE2 apoE3 apoE4 carboxyl terminally truncated forms apoE165 apoE202 apoE229 apoE259 bound tightly wild type SR BI similar affinities Kd 35 45 microgml
0.30104497.11861652.html.plaintext.txt	9	Binding nearly abolished cell line expressing ldlA Q402RQ418R double mutant form SR BI unable bind native high density lipoprotein binds low density lipoprotein normally
0.30104497.11861652.html.plaintext.txt	10	The findings establish apoE ligand SR BI receptor binding domain located amino terminal 1 165 region protein
0.30104497.11861652.html.plaintext.txt	11	SR BI apoE interactions may contribute cholesterol homeostasis tissues cells expressing SR BI accessible apoE containing lipoproteins
0.30104497.11861652.html.plaintext.txt	12	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.30104497.11861652.html.plaintext.txt	13	Apolipoprotein E apoE1 299 amino acid long protein
0.30104497.11861652.html.plaintext.txt	14	ApoE constituent different lipoprotein particles serves ligand several cell receptors apoER2 LDL receptor LDL receptor related protein VLDL receptor promotes catabolism liver 1 5
0.30104497.11861652.html.plaintext.txt	15	ApoE may also involved cellular cholesterol efflux 6 9
0.30104497.11861652.html.plaintext.txt	16	These functions apoE contribute cell tissue cholesterol homeostasis 6 9 may explain expressed locally macrophages endothelial cells apoE protects atherosclerosis 9 11
0.30104497.11861652.html.plaintext.txt	17	Mutations apoE prevent binding apoE containing lipoprotein remnants LDL receptor possibly receptors well heparan sulfate proteoglycans associated type III hyperlipoproteinemia 12 18 premature atherosclerosis 17 19 20
0.30104497.11861652.html.plaintext.txt	18	SR BI binds high affinity HDL LDL discoidal reconstituted particles containing apoA I 21 24
0.30104497.11861652.html.plaintext.txt	19	On binding lipoproteins SR BI mediates selective cholesteryl ester uptake lipoprotein cells 24 28 bi directional unesterified cholesterol movement 28 32
0.30104497.11861652.html.plaintext.txt	20	In addition cholesteryl esters 25 SR BI mediate cellular uptake HDL free cholesterol 31 32 triglycerides 32 33 phospholipids 34 vitamin E 35 39
0.30104497.11861652.html.plaintext.txt	21	HDL reconstituted discoidal HDL particles also promote cholesterol efflux SR BI expressing cells 28 30 40
0.30104497.11861652.html.plaintext.txt	22	Inactivation SR BI gene reduces cholesterol levels steroidogenic tissues bile promote atherosclerosis despite associated increase plasma HDL cholesterol levels 41 42 thus demonstrating beneficial physiological functions receptor 41 42
0.30104497.11861652.html.plaintext.txt	23	Studies transgenic mice also corroborated role SR BI cholesterol bile acid homeostasis protection atherosclerosis 43 47
0.30104497.11861652.html.plaintext.txt	24	In current study focused SR BI binding discoidal POPC apoE particles containing natural apoE isoforms truncated apoE forms
0.30104497.11861652.html.plaintext.txt	25	The carboxyl terminal mutants apoE generated assess contribution carboxyl terminal domain apoE SR BI binding
0.30104497.11861652.html.plaintext.txt	26	Recent studies us established 1 185 region apoE suffices clearance apoE containing lipoprotein remnants vivo implying amino terminal domain apoE contains necessary determinants binding least apoE receptors 48 49
0.30104497.11861652.html.plaintext.txt	27	The current study establishes apoE ligand SR BI receptor binding domain found within amino terminal 1 165 residues
0.30104497.11861652.html.plaintext.txt	28	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Materials
0.30104497.11861652.html.plaintext.txt	29	The Klenow fragment DNA polymerase I T4 ligase polynucleotide kinase restriction enzymes purchased New England Biolabs
0.30104497.11861652.html.plaintext.txt	30	Calf intestinal alkaline phosphatase purchased Stratagene La Jolla CA Vent polymerase Promega
0.30104497.11861652.html.plaintext.txt	31	Other materials polymerase chain reaction obtained PerkinElmer Life Sciences
0.30104497.11861652.html.plaintext.txt	32	The Sequenase sequencing kit purchased U
0.30104497.11861652.html.plaintext.txt	33	The oligonucleotides purchased GIBCO Life Technologies Inc
0.30104497.11861652.html.plaintext.txt	34	Bacto tryptone bacto yeast extract obtained VWR Pittsburgh PA
0.30104497.11861652.html.plaintext.txt	35	Dulbeccos modified Eagles medium DMEM provided Invitrogen
0.30104497.11861652.html.plaintext.txt	36	Dextran sulfate epoxy activated Sepharose 6B purchased Pharmacia column BioRad iodo beads iodination reagent D salt dextran plastic desalting columns purchased Pierce
0.30104497.11861652.html.plaintext.txt	37	The sodium 125I purchased PerkinElmer Life Sciences
0.30104497.11861652.html.plaintext.txt	38	The bicinchoninic acid assay kit purchased Pierce
0.30104497.11861652.html.plaintext.txt	39	Other reagents sources fatty acid free bovine serum albumin cholesterol sodium cholate 1 palmitoyl 2 oleoyl L phosphatidylcholine POPC aprotinin benzamidine leupeptin phenylmethylsulfonyl fluoride Sigma dialysis tubing Spectrum Medical Industries Inc
0.30104497.11861652.html.plaintext.txt	40	Los Angeles CA Hams F 12 medium fetal bovine serum trypsinEDTA JRH Biosciences Lenexa KS penicillinstreptomycin glutamine G418 sulfate GIBCO Life Technologies Inc
0.30104497.11861652.html.plaintext.txt	41	All reagents purchased Sigma Bio Rad standard commercial sources previously described 22
0.30104497.11861652.html.plaintext.txt	42	The SR BI receptor blocking monoclonal antibody KKB 1 gift Karen Kozarsky
0.30104497.11861652.html.plaintext.txt	43	Plasmid Construction Generation Expression Vector Carrying ApoE Gene Derivatives Full length apoE cDNA derivatives cloned HindIII BamHI site pUC 19 plasmid 43 used generate three new sets plasmids I II III containing WT mutated apoE gene sequences Fig
0.30104497.11861652.html.plaintext.txt	44	Plasmid I pBlueEexIV contains EcoRI EcoRI apoE gene region consisting exon 4 part flanking introns cloned pBlueScript II KS plus minus vector
0.30104497.11861652.html.plaintext.txt	45	Plasmid II pBlueXapoEg contains entire apoE gene BamHI HindIII flanked two bioengineered XhoI sites cloned pBlueScript II KS plus minus vector
0.30104497.11861652.html.plaintext.txt	46	Plasmid III pBMT3XapoEg contains entire apoE gene cloned XhoI site pBMT3X bovine papilloma based vector front mouse metallothionein I promoter
0.30104497.11861652.html.plaintext.txt	47	Each three plasmids constructed apoE2 apoE3 apoE4 exon IV sequences mutated sequences
0.30104497.11861652.html.plaintext.txt	48	The following protocol utilized generation mutations
0.30104497.11861652.html.plaintext.txt	49	Mutations generated exon IV PCR amplification mutagenesis using pUCexIV apoE derivatives 50 template set two external primers spanning instance Sty BbsI region mutagenic primers covering region needs mutagenized
0.30104497.11861652.html.plaintext.txt	50	The primers used shown Table I
0.30104497.11861652.html.plaintext.txt	51	b The amplified mutant sequence digested StyI BbsI used replace corresponding apoE sequence pBlueEexIV derivative plasmid I
0.30104497.11861652.html.plaintext.txt	52	The mutated apoE sequence excised pBlueEexIV derivative EcoRI digestion used replace corresponding region pBluXapoEg derivative plasmid II
0.30104497.11861652.html.plaintext.txt	53	c The entire mutated apoE gene sequence excised XhoI digestion cloned XhoI site pBMT3X vector generate pBMT3XapoEg derivatives
0.30104497.11861652.html.plaintext.txt	54	Plasmids correct orientation selected sequenced verify mutations utilized
0.30104497.11861652.html.plaintext.txt	55	View table Table I Oligonucleotides used mutagenesis mutants created
0.30104497.11861652.html.plaintext.txt	56	Generation Characterization Permanent Cell Lines Expressing WT Variant ApoE Forms To generate stable cell lines expressing mutant genes C127 cells derived mouse mammary tumor 51 transfected different pBMT3XEg derivatives described previously 18
0.30104497.11861652.html.plaintext.txt	57	Cell clones expressing apoE2apoE3apoE4 labeled 35SMetCys mixture secreted protein immunoprecipitated analyzed two dimensional gel electrophoresis autoradiography verify known isoelectric point differences among apoE isoforms 18
0.30104497.11861652.html.plaintext.txt	58	ApoE Production Eukaryotic Expression Systems Using Permanent ApoE expressing Cell Lines To generate media isolation full length apoE isoforms cell clones highest efficiency production thawed placed two T 75 flasks DMEM containing 10 fetal calf serum 10 microM CdCl2
0.30104497.11861652.html.plaintext.txt	59	Within 5 7 days confluent flasks trypsinized cells placed 850 cm2 roller bottle
0.30104497.11861652.html.plaintext.txt	60	The bottle placed roller rack turning 1 rpm allow cells attach surface bottle
0.30104497.11861652.html.plaintext.txt	61	When cells grew 80 85 confluence 10 ml packed conditioned microcarriers beads added roller bottle speed roller rack increased 7 rpm
0.30104497.11861652.html.plaintext.txt	62	The beads prepared first autoclaving phosphate buffered saline solution subsequently incubating media containing 1 fetal calf serum overnight could absorb nutrients
0.30104497.11861652.html.plaintext.txt	63	The cells fed twice week 300 ml DMEM media containing 5 fetal calf serum 10 microM CdCl2
0.30104497.11861652.html.plaintext.txt	64	For collection media protein purification cells rinsed twice serum free media pre incubated media 2 h
0.30104497.11861652.html.plaintext.txt	65	After one additional rinse cells incubated serum free media overnight
0.30104497.11861652.html.plaintext.txt	66	The media collected stored 1 mM EDTA 0
0.30104497.11861652.html.plaintext.txt	67	01 NaN3 10 mM aprotinin 10 mM benzamidine
0.30104497.11861652.html.plaintext.txt	68	The media collected twice week period one month
0.30104497.11861652.html.plaintext.txt	69	Density gradient ultracentrifugation media analysis resulting fractions established 95 apoE2 apoE3 apoE4 secreted C127 cells found d 1
0.30104497.11861652.html.plaintext.txt	70	27 gml fraction conventionally defined lipid freelipid poor fraction
0.30104497.11861652.html.plaintext.txt	71	Following purification apoE complexed POPC used receptor binding experiments
0.30104497.11861652.html.plaintext.txt	72	ApoE Production Eukaryotic Expression Systems Using Adenoviral Infection Cells To generate media isolation truncated apoE forms human astrocytoma HTB 13 cells express apoE infected recombinant adenoviruses expressing apoE4 259 apoE4 229 apoE4 202 apoE2 202 48 49 serum free medium collected described previously
0.30104497.11861652.html.plaintext.txt	73	Purification Lipid free ApoE Ion Exchange Chromatography Using Dextran Sulfate Sepharose Column ApoE purified culture medium C127 cells expressing apoE2 apoE3 apoE4 genes media HTB 13 cells expressing truncated apoE forms
0.30104497.11861652.html.plaintext.txt	74	The purification scheme involved dextran sulfate Sepharose column fractionation
0.30104497.11861652.html.plaintext.txt	75	Briefly 30 ml dextran sulfate Sepharose column equilibrated 20 mM Tris HCl 0
0.30104497.11861652.html.plaintext.txt	76	A total 2 liters apoE containing culture medium concentrated 75 ml Amicon concentrator using membrane cutting molecular mass 10 kDa NaCl concentration adjusted 0
0.30104497.11861652.html.plaintext.txt	77	2 M loaded column flow rate 80 mlh
0.30104497.11861652.html.plaintext.txt	78	The column eluted 120 ml 0
0.30104497.11861652.html.plaintext.txt	79	0 M NaCl gradient 20 mM Tris HCl pH 7
0.30104497.11861652.html.plaintext.txt	80	4 flow rate fractions 3 ml collected
0.30104497.11861652.html.plaintext.txt	81	The pure protein fractions pooled dialyzed extensively 0
0.30104497.11861652.html.plaintext.txt	82	The protein yield 10 20 mgliter depending apoE variant
0.30104497.11861652.html.plaintext.txt	83	Preparation Discoidal Reconstituted HDL Particles Containing ApoE POPC ApoE POPC used prepare reconstituted discoidal POPC apoE particles employing sodium cholate dialysis method minor modifications 52
0.30104497.11861652.html.plaintext.txt	84	POPC ApoE particles prepared molar ratio 100101100 POPCcholesterolapoEsodium cholate
0.30104497.11861652.html.plaintext.txt	85	71 mg POPC placed glass tubes vortexed gently dried nitrogen
0.30104497.11861652.html.plaintext.txt	86	The dried lipid dissolved 10 mM Tris HCl pH 8 150 mM NaCl 1 mM NaN3 0
0.30104497.11861652.html.plaintext.txt	87	01 EDTA buffer vortexing 30 followed storage ice
0.30104497.11861652.html.plaintext.txt	88	The process repeated phospholipid completely suspended buffer
0.30104497.11861652.html.plaintext.txt	89	The sodium cholate added solution placed ice one hour
0.30104497.11861652.html.plaintext.txt	90	The apoE usually 1 mg added incubation ice continued another hour
0.30104497.11861652.html.plaintext.txt	91	To remove sodium cholate solution dialyzed 5 6 liters 10 mM Tris HCl pH 8 150 mM NaCl 1 mM NaN3 0
0.30104497.11861652.html.plaintext.txt	92	01 EDTA buffer 4 degrees C using tubing molecular mass cut 12 14 kDa
0.30104497.11861652.html.plaintext.txt	93	Finally gradient gel 8 25 run native conditions 15 degrees C Pharmacia Phast Gel system ascertain size particle used electron microscopy analysis described
0.30104497.11861652.html.plaintext.txt	94	The POPC apoE particles stored 4 degrees C nitrogen prevent oxidation lipids
0.30104497.11861652.html.plaintext.txt	95	Electron Microscopy EM POPC apoE particles prepared various mutant apoE forms described analyzed EM
0.30104497.11861652.html.plaintext.txt	96	To prepare sample EM 50 microg POPC apoE desalted three times using Amicon centrifugal filter devices Microcon
0.30104497.11861652.html.plaintext.txt	97	The final concentration 1 mgml deionized water
0.30104497.11861652.html.plaintext.txt	98	A 5 microl aliquot suspension vesicle applied 10 Formvar carbon coated 300 mesh copper grid
0.30104497.11861652.html.plaintext.txt	99	The carbon film surface made hydrophilic glow discharge Balzers Union CTA 010 glow discharge apparatus used immediately
0.30104497.11861652.html.plaintext.txt	100	Excess POPC apoE suspension removed blotting filter paper immediately replaced 5 microl droplet 1 sodium phosphotungstate pH 7
0.30104497.11861652.html.plaintext.txt	101	After seconds excess stain removed grid air dried
0.30104497.11861652.html.plaintext.txt	102	Fields particles photographed Philips CM12 electron microscope Philips Electron Optics Eindhoven The Netherlands
0.30104497.11861652.html.plaintext.txt	103	Iodination ApoE ApoE labeled 125I using Iodo Beads 53 iodination reagent Na125I PerkinElmer Life Sciences
0.30104497.11861652.html.plaintext.txt	104	Each reaction used one mCi 125I three beads 1 mg apoE
0.30104497.11861652.html.plaintext.txt	105	The reaction carried Tris HCl buffer 10 mM Tris HCl pH 8 150 mM NaCl 0
0.30104497.11861652.html.plaintext.txt	106	An aliquot 100 microl Tris HCl buffer added 125I container mixed
0.30104497.11861652.html.plaintext.txt	107	The diluted radioactive 125I solution transferred Eppendorf tube containing 1 2 mg apoE form POPC apoE particles Tris HCl salt buffer
0.30104497.11861652.html.plaintext.txt	108	The final volume adjusted 900 microl using Tris HCl salt buffer
0.30104497.11861652.html.plaintext.txt	109	The sample placed lead pig
0.30104497.11861652.html.plaintext.txt	110	Just prior use beads washed 500 microl Tris HCl salt buffer per bead dried filter paper
0.30104497.11861652.html.plaintext.txt	111	This washing step removes loose particles reagent beads
0.30104497.11861652.html.plaintext.txt	112	The beads added reaction solution kept room temperature 45 min mixing every 5 10 min
0.30104497.11861652.html.plaintext.txt	113	The reaction terminated removing solution reaction vessel
0.30104497.11861652.html.plaintext.txt	114	The 125I labeled apoE separated unincorparated Na125I gel filtration using Pierces Presto Desalting Columns Pierce Inc
0.30104497.11861652.html.plaintext.txt	115	5 ml collected 1 microl fraction used determination 125I counts
0.30104497.11861652.html.plaintext.txt	116	Ten microl fraction used measure protein concentration bicinchoninic acid protein assay 54
0.30104497.11861652.html.plaintext.txt	117	Another 10 microl fraction used PAGE gel analysis sample
0.30104497.11861652.html.plaintext.txt	118	The specific activity calculated based protein concentration 125I counts expressed cpmng protein
0.30104497.11861652.html.plaintext.txt	119	Specific activities 1000 1500 cpmng protein obtained
0.30104497.11861652.html.plaintext.txt	120	Radioreceptor Binding Assay ldlA 7 LDL receptor deficient Chinese hamster ovary cell mutant 55 56 expresses little SR BI protein HDL bindingselective uptake activity 25 57
0.30104497.11861652.html.plaintext.txt	121	The ldlA 7 cells ldlAmSR BI cells ldlA 7 cells stably transfected murine SR BI cDNA 25 57 maintained monolayer culture Hams F12 medium containing 5 fetal bovine serum 100 unitsml penicillin 100 unitsml streptomycin 2 mM glutamine
0.30104497.11861652.html.plaintext.txt	122	All incubations cells performed 37 degrees C humidified 5 CO2 95 air incubator
0.30104497.11861652.html.plaintext.txt	123	SR BI activity 37 4 degrees C assessed measuring cell association radiolabeled ligands
0.30104497.11861652.html.plaintext.txt	124	Briefly day 0 cells ldlA 7 ldlA mSR BI ldlA 7 ldlA Q402RQ418R 28 plated concentrations 4
0.30104497.11861652.html.plaintext.txt	125	5 5 x 104 cellswell 24 well dishes complete F12 medium
0.30104497.11861652.html.plaintext.txt	126	On day 2 monolayers washed twice Hams F12 medium refed 0
0.30104497.11861652.html.plaintext.txt	127	5 ml medium Hams F 12 containing 0
0.30104497.11861652.html.plaintext.txt	128	5 wv fatty acid free bovine serum albumin 100 unitsml penicillin 100 unitsml streptomycin 2 mM glutamine indicated radiolabeled ligands 125I POPC apoE
0.30104497.11861652.html.plaintext.txt	129	Eight different concentrations ranging 0
0.30104497.11861652.html.plaintext.txt	130	5 100 microgml used experiments performed duplicate
0.30104497.11861652.html.plaintext.txt	131	5 h incubation either 37 4 degrees C cells washed twice 4 degrees C buffer B 50 mM Tris HCl pH 7
0.30104497.11861652.html.plaintext.txt	132	15 M NaCl containing 2 mgml fatty acid free bovine serum albumin followed one rapid wash buffer B alone
0.30104497.11861652.html.plaintext.txt	133	The cells solubilized 0
0.30104497.11861652.html.plaintext.txt	134	1 N NaOH 300 microl well
0.30104497.11861652.html.plaintext.txt	135	Aliquots 200 microl used radioactivity determinations 25 microl used determination protein concentration using bicinchoninic acid assay
0.30104497.11861652.html.plaintext.txt	136	The specific binding obtained subtracting binding untransfected cells ldlA 7 binding receptor expressing cell lines ldlAmSR BI ldlA Q402RQ418R 28
0.30104497.11861652.html.plaintext.txt	137	Receptor binding studies untransfected transfected cells also performed presence absence SR BI blocking monoclonal antibody KKB 1 28
0.30104497.11861652.html.plaintext.txt	138	Receptor blocking experiments performed described previously 28
0.30104497.11861652.html.plaintext.txt	139	Binding parameters Kd Bmax determined basis specific binding curve using Prism program GraphPad Software Inc
0.30104497.11861652.html.plaintext.txt	140	The specific binding cell association values saturation curves expressed ng apoE complex associated cells per mg total cell protein
0.30104497.11861652.html.plaintext.txt	141	Immunoreceptor Assay Using ELISA For immunoreceptor association experiments Maxisorb 96 well plates coated anti human apoE polyclonal antibody 1 microgml Biodesign diluted 1800 phosphate buffered saline 100 microlwell stored 4 degrees C overnight
0.30104497.11861652.html.plaintext.txt	142	The coating solution aspirated well washed three times washing buffer 0
0.30104497.11861652.html.plaintext.txt	143	05 Tween 20 phosphate buffered saline 200 microlwell
0.30104497.11861652.html.plaintext.txt	144	Blocking buffer 10 nonfat dry milk washing buffer added 200 microlwell
0.30104497.11861652.html.plaintext.txt	145	The plates incubated room temperature 1
0.30104497.11861652.html.plaintext.txt	146	5 h washed three times washing buffer
0.30104497.11861652.html.plaintext.txt	147	Cell lysates diluted phosphate buffered saline total volume 100 microl added well incubated room temperature 1 h
0.30104497.11861652.html.plaintext.txt	148	To obtain standard curve POPC apoE particles containing different amounts apoE mixed 25 microg lysate blank cells ldlA 7 ldlAapoER 2 treated rHDL particles lipoprotein adjusted total volume 100 microl added different wells
0.30104497.11861652.html.plaintext.txt	149	After plates washed washing buffer three times secondary antibody rabbit anti human IgG peroxidase conjugated Biodesign diluted 1500 blocking buffer added 100 microlwell
0.30104497.11861652.html.plaintext.txt	150	The plates incubated room temperature 1 h washed washing buffer three times
0.30104497.11861652.html.plaintext.txt	151	An aliquot 200 microl o phenylenediamine dihydrochloride substrate o phenylenediamine dihydrochloride 0
0.30104497.11861652.html.plaintext.txt	152	4 mgml urea hydrogen peroxide 0
0.30104497.11861652.html.plaintext.txt	153	4 mgml phosphate citrate buffer 0
0.30104497.11861652.html.plaintext.txt	154	After 30 min incubation room temperature reaction terminated adding 50 microl 2 N H2SO4 per well
0.30104497.11861652.html.plaintext.txt	155	The absorbance measured 490 nm using microtiter plate reader
0.30104497.11861652.html.plaintext.txt	156	A polynomial second order regression used best fit standard curve
0.30104497.11861652.html.plaintext.txt	157	The specific binding obtained subtracting binding ldlA 7 cells binding apoER 2 expressing cells experimental point expressed ng cell associated POPC apoE particles per mg total cell protein
0.30104497.11861652.html.plaintext.txt	158	The cell associated ligands analyzed function concentration nonlinear regression program Prism using one site binding isotherm
0.30104497.11861652.html.plaintext.txt	159	Competition Assays Competition assays carried described direct association experiments except day 2 unlabeled competitor protein concentration range 0
0.30104497.11861652.html.plaintext.txt	160	5 100 microgml added addition labeled ligand
0.30104497.11861652.html.plaintext.txt	161	The average percent cell association competition assays calculated relative control values
0.30104497.11861652.html.plaintext.txt	162	The 100 value corresponds binding 5 microg 125I labeled HDL 5 microg 125I POPC apoE absence competitor
0.30104497.11861652.html.plaintext.txt	163	Two independent competition experiments performed duplicate
0.30104497.11861652.html.plaintext.txt	164	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.30104497.11861652.html.plaintext.txt	165	Expression Production Purification Characterization WT Variant ApoE Forms To characterize apoE isoforms mutant apoE forms cell clones expressing WT variant apoE genes labeled 35SMetCys immunoprecipitated analyzed one two dimensional polyacrylamide gel electrophoresis autoradiography using 10 microg VLDL subject apoE44 phenotype internal marker
0.30104497.11861652.html.plaintext.txt	166	The Coomassie Brilliant Blue stained gel obtained analysis showed position apoE4 included sample autoradiogram showed position newly synthesized apoE
0.30104497.11861652.html.plaintext.txt	167	Superimposition gel autoradiogram establishes charge size differences apoE4 newly synthesized variant apoE forms described previously data shown
0.30104497.11861652.html.plaintext.txt	168	1B shows SDS PAGE analysis full length truncated apoE forms
0.30104497.11861652.html.plaintext.txt	169	ApoE purified culture medium apoE expressing cells described Experimental Procedures
0.30104497.11861652.html.plaintext.txt	170	1C shows SDS PAGE analysis different purified apoE forms
0.30104497.11861652.html.plaintext.txt	171	View larger version 47K Fig
0.30104497.11861652.html.plaintext.txt	172	A C generation production purification WT mutant apoE forms
0.30104497.11861652.html.plaintext.txt	173	A apoE gene plasmids used express apoE mutant forms
0.30104497.11861652.html.plaintext.txt	174	Construction plasmids described Experimental Procedures
0.30104497.11861652.html.plaintext.txt	175	B SDS polyacrylamide gel electrophoresis media cells expressing WT truncated apoE forms
0.30104497.11861652.html.plaintext.txt	176	C SDS PAGE apoE purified media apoE expressing cells ion exchange chromatography
0.30104497.11861652.html.plaintext.txt	177	The media containing full length apoE obtained permanent C127 cell lines expressing different apoE isoforms
0.30104497.11861652.html.plaintext.txt	178	Lane M left indicates protein standards known molecular mass
0.30104497.11861652.html.plaintext.txt	179	The media containing truncated apoE forms obtained human astrocytoma HTB 13 cells following infection recombinant adenoviruses expressing corresponding apoE forms 48 49
0.30104497.11861652.html.plaintext.txt	180	Lane M right indicates protein standards used analysis truncated apoE forms
0.30104497.11861652.html.plaintext.txt	181	Generation Characterization EM Analysis Reconstituted POPC ApoE Particles The wild type different mutant apoE proteins reconstituted particles containing POPC cholesterol ratio 100101 POPCcholesterolapoE using sodium cholate dialysis method 52
0.30104497.11861652.html.plaintext.txt	182	The sodium cholate dialysis method allowed formation discoidal particles WT mutant apoE forms tested
0.30104497.11861652.html.plaintext.txt	183	The POPC apoE particles negatively stained potassium phosphotungstate overlaid carbon coated grids photographed Philips CM12 electron microscope
0.30104497.11861652.html.plaintext.txt	184	2 A G shows formation POPC apoE particles WT mutant apoE forms
0.30104497.11861652.html.plaintext.txt	185	Under negative staining conditions used particles form typical rouleaux indicating discoidal thickness phospholipid bilayer
0.30104497.11861652.html.plaintext.txt	186	The number rouleaux observed depends concentration sample carbon grid
0.30104497.11861652.html.plaintext.txt	187	In less concentrated samples large number round particles lie flat grid also observed
0.30104497.11861652.html.plaintext.txt	188	These particles seem pack hexagonally grid aggregation characteristic spherical structures providing evidence particles fact discoidal
0.30104497.11861652.html.plaintext.txt	189	To characterize size discoidal POPC apoE cross linking experiments performed particles isolated gel filtration using sodium suberimidate
0.30104497.11861652.html.plaintext.txt	190	This analysis showed presence two apoE2 apoE2 202 molecules per particle
0.30104497.11861652.html.plaintext.txt	191	The average size POPC particles determined EM pictures 174 plus minus 49 A data shown
0.30104497.11861652.html.plaintext.txt	192	View larger version 63K Fig
0.30104497.11861652.html.plaintext.txt	193	A G electron microscopy discoidal POPC apoE particles used ligands binding SR BI
0.30104497.11861652.html.plaintext.txt	194	A apoE2 B poE3 C apoE4 D apoE4 259 E apoE4 229 F apoE4 202 G apoE4 165
0.30104497.11861652.html.plaintext.txt	195	High Affinity Binding Discoidal Reconstituted POPC ApoE Particles SR BI Binding reduced SR BI mutant
0.30104497.11861652.html.plaintext.txt	196	HDL reconstituted discoidal HDL particles containing apoA I apoA II apoCIII bind high affinity SR BI whereas lipid free apoA I pre HDL poor ligands 22 23
0.30104497.11861652.html.plaintext.txt	197	In current study examined binding reconstituted POPC apoE particles SR BI
0.30104497.11861652.html.plaintext.txt	198	To determine specific binding POPC apoE ligands SR BI binding studies performed using SR BI expressing ldlA mSR BI transfected cells control untransfected cells ldlA 7
0.30104497.11861652.html.plaintext.txt	199	Both approaches necessary since SR BI dependent association particles control cells high high background clearly manifest transfected cells see
0.30104497.11861652.html.plaintext.txt	200	This presumably due presence cells apoE binding sites
0.30104497.11861652.html.plaintext.txt	201	The specific binding curve binding parameters Kd Bmax ldlA mSR BI cells determined subtracting binding values untransfected cells corresponding values transfected cells Fig
0.30104497.11861652.html.plaintext.txt	202	To ensure differences obtained reflected overexpression mSR BI transfected cells fortuitous increase expression endogenous mouse SR BI performed receptor binding studies untransfected transfected cells presence SR BI receptor blocking antibodies
0.30104497.11861652.html.plaintext.txt	203	Specific binding observed transfected cells Fig
0.30104497.11861652.html.plaintext.txt	204	The binding parameters obtained using SR BI receptor blocking antibodies subtracting binding curves untransfected mSR BI expressing cell line similar Fig
0.30104497.11861652.html.plaintext.txt	205	The ligand receptor specificity also assessed cells expressing mutant mSR BI double substitution arginines glutamines positions 402 418 designated ldlA Q402RQ418R 28
0.30104497.11861652.html.plaintext.txt	206	Even correction lower level mutant receptor expression ldlA Q402RQ418R cells relative wild type receptor expression ldlAmSR BI cells ability mutant bind native HDL dramatically reduced relative wild type receptor 28
0.30104497.11861652.html.plaintext.txt	207	We shown recently POPC apoA I particles bind tightly SR BI native HDL 22 23 binding particles mutant receptor readily detected binding native HDL
0.30104497.11861652.html.plaintext.txt	208	3D shows specific binding POPC apoE4 cells expressing WT mutant SR BI
0.30104497.11861652.html.plaintext.txt	209	We found binding affinity POPC apoE particles mutant clearly reduced Kd 185 microgml mutant SR BI compared wild type SR BI 38 microgml Table II
0.30104497.11861652.html.plaintext.txt	210	To establish whether iodination apoE changes binding properties SR BI determined receptor binding using ELISA assay
0.30104497.11861652.html.plaintext.txt	211	This control experiment showed binding parameters apoE2 apoE2 202 similar obtained iodinated apoE used binding studies Kd 45
0.30104497.11861652.html.plaintext.txt	212	Similar results obtained binding experiments apoE2 apoE4 apoE2 202 performed 4 degrees C Fig
0.30104497.11861652.html.plaintext.txt	213	It interesting nonspecific binding 4 degrees C reduced whereas SR BI specific binding altered considerably
0.30104497.11861652.html.plaintext.txt	214	View larger version 21K Fig
0.30104497.11861652.html.plaintext.txt	215	A G concentration dependent binding 125I POPC apoE4 complexes confluent monolayers ldlA mSR BI ldlA Q402RQ418R
0.30104497.11861652.html.plaintext.txt	216	A ldlA 7 cells ldlA mSR BI cells microtiter wells washed incubated various concentrations 125I POPC apoE4
0.30104497.11861652.html.plaintext.txt	217	Total binding ldlA mSR BI cells total binding untransfected ldlA 7 cells obtained experimentally
0.30104497.11861652.html.plaintext.txt	218	The specific binding determined subtracting values binding ldlA 7 cells corresponding values binding ldlA mSR BI cells
0.30104497.11861652.html.plaintext.txt	219	B C ldlA 7 cells ldlA mSR BI cells microtiter wells washed incubated various concentrations 125I POPC apoE4in presence absence receptor blocking monoclonal antibodies
0.30104497.11861652.html.plaintext.txt	220	Total binding ldlA mSR BI ldlA 7 cells obtained experimentally
0.30104497.11861652.html.plaintext.txt	221	The specific binding ldlA mSR BI cells B ldlA 7 cells C determined subtracting values binding two cell lines presence receptor blocking monoclonal antibodies values obtained absence SR BI receptor blocking monoclonal antibodies
0.30104497.11861652.html.plaintext.txt	222	Note specific binding ldlA mSR BI cells B ldlA cells C
0.30104497.11861652.html.plaintext.txt	223	D concentration dependent binding 125I POPC apoE4 complexes confluent monolayers ldlA cells expressing WT mouse SR BI designated ldlA mSR BI mutant mouse SR BI designated ldlA Q402RQ418R cells
0.30104497.11861652.html.plaintext.txt	224	Cells microtiter wells washed incubated various concentrations 125I POPC apoE4
0.30104497.11861652.html.plaintext.txt	225	Total binding ldlA mSR BI ldlA Q402RQ418R cells total binding untransfected ldlA 7 cells obtained experimentally
0.30104497.11861652.html.plaintext.txt	226	The specific binding WT mutant receptor determined subtracting values binding ldlA 7 cells corresponding values binding ldlA mSR BI ldlA Q402RQ418R cells
0.30104497.11861652.html.plaintext.txt	227	The specific activity 125I POPC apoE4 range 1000 1500 cpmng protein
0.30104497.11861652.html.plaintext.txt	228	The experiments A D performed radioreceptor assay 37 degrees C
0.30104497.11861652.html.plaintext.txt	229	E F G represent control experiments
0.30104497.11861652.html.plaintext.txt	230	In E binding 37 degrees C measured using ELISA assay described Experimental Procedures
0.30104497.11861652.html.plaintext.txt	231	Specific binding determined explained
0.30104497.11861652.html.plaintext.txt	232	In F G binding 4 degrees C measured using radioreceptor assay described A Experimental Procedures
0.30104497.11861652.html.plaintext.txt	233	Note binding parameters obtained different experimental conditions similar Table II
0.30104497.11861652.html.plaintext.txt	234	View table Table II Dissociation constants Kd Bmax ApoE mSR BI complexes involving different ApoE forms
0.30104497.11861652.html.plaintext.txt	235	We previously shown normal cell culture ligand binding conditions LDL relatively poor inhibitor HDL binding possibly SR BI exhibits multiple classes ligand binding sites 24 28
0.30104497.11861652.html.plaintext.txt	236	4 shows binding 125I labeled HDL SR BI effectively competed HDL less effectively POPC apoE4 much less effectively LDL
0.30104497.11861652.html.plaintext.txt	237	The findings consistent Kd values POPC apoE particles SR BI 22 Table II well reduced binding POPC apoE4 ldlA Q402RQ418R cells Fig
0.30104497.11861652.html.plaintext.txt	238	View larger version 27K Fig
0.30104497.11861652.html.plaintext.txt	239	Competition binding 125I HDL 125I POPC apoE excess HDL LDL POPC apoE
0.30104497.11861652.html.plaintext.txt	240	On day 2 plating ldlA mSR BI cells incubated 5 microgml 125I labeled HDL 0
0.30104497.11861652.html.plaintext.txt	241	5 100 microgml unlabeled LDL POPC apoE4 HDL explained Experimental Procedures
0.30104497.11861652.html.plaintext.txt	242	The binding obtained absence competitor set 100
0.30104497.11861652.html.plaintext.txt	243	The values represented average duplicate determinations
0.30104497.11861652.html.plaintext.txt	244	The specific activity 125I labeled HDL range 1000 1500 cpmng
0.30104497.11861652.html.plaintext.txt	245	The Natural ApoE Isoforms Mutant ApoE Forms Have Similar Affinities SR BI Receptor binding maintained carboxyl terminal residues 166 299 deleted
0.30104497.11861652.html.plaintext.txt	246	To address question whether specific domains residues apoE involved receptor binding generated several carboxyl terminally truncated apoE forms extending residues 259 229 202 165
0.30104497.11861652.html.plaintext.txt	247	The purpose mutations assess importance carboxyl terminal region apoE SR BI specific binding
0.30104497.11861652.html.plaintext.txt	248	Previous studies shown residue Arg 158 important binding apoE containing lipoproteins LDL receptor 58 61
0.30104497.11861652.html.plaintext.txt	249	Similarly vitro experiments shown residues 171 183 region apoE contribute directly indirectly LDL receptor binding 60
0.30104497.11861652.html.plaintext.txt	250	Analysis binding truncated variant apoE forms SR BI showed truncated apoE forms bind similar affinities Kd 35 45 microgml Fig
0.30104497.11861652.html.plaintext.txt	251	This indicates amino terminal residues 1 165 apoE contain determinant region binding SR BI
0.30104497.11861652.html.plaintext.txt	252	5H shows comparison binding POPC apoA I particles ldlA mSR BI cells determined immunoreceptor assay described previously 22
0.30104497.11861652.html.plaintext.txt	253	The affinity POPC apoA I particles 3
0.30104497.11861652.html.plaintext.txt	254	4 microg proteinml order magnitude greater POPC apoE particles
0.30104497.11861652.html.plaintext.txt	255	View larger version 21K Fig
0.30104497.11861652.html.plaintext.txt	256	A H concentration dependent binding 125I POPC apoE4 POPC apoA I complexes containing different apoE isoforms mutant truncated apoE forms apoA I confluent monolayers ldlA mSR BI cells
0.30104497.11861652.html.plaintext.txt	257	A G Cells microtiter wells washed incubated various concentrations 125I POPC apoE4
0.30104497.11861652.html.plaintext.txt	258	Total binding ldlA mSR BI cells total binding untransfected ldlA 7 cells obtained experimentally
0.30104497.11861652.html.plaintext.txt	259	The specific binding shown figure determined subtracting values binding ldlA 7 cells corresponding values binding ldlA mSR BI cells
0.30104497.11861652.html.plaintext.txt	260	The specific activity apoE range 1000 1500 cpmng
0.30104497.11861652.html.plaintext.txt	261	Two four independent experiments performed duplicate apoE form
0.30104497.11861652.html.plaintext.txt	262	The average Kd Bmax values thus determined shown Table II
0.30104497.11861652.html.plaintext.txt	263	The apoE forms used A apoE2 B apoE3 C apoE4 D apoE4 259 E apoE4 229 F apoE4 202 G apoE4 165
0.30104497.11861652.html.plaintext.txt	264	H shows specific binding curve non radiolabeled POPC apoA I ldlA mSR BI cells determined immunoreceptor assay described 22
0.30104497.11861652.html.plaintext.txt	265	The apoA I obtained using baculovirus expression system 22
0.30104497.11861652.html.plaintext.txt	266	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.30104497.11861652.html.plaintext.txt	267	Background In current study focused interactions SR BI another potential ligand apolipoprotein E plays important role cholesterol homeostasis circulation brain 6 9 62
0.30104497.11861652.html.plaintext.txt	268	Apolipoprotein E remarkable structural similarities apoA I
0.30104497.11861652.html.plaintext.txt	269	Both proteins contain 11 22 amino acid long repeats organized amphipathic helices
0.30104497.11861652.html.plaintext.txt	270	ApoE ligand several cell receptors serve deliver cholesterol cells 1 5
0.30104497.11861652.html.plaintext.txt	271	ApoE may also play important role cholesterol efflux 6 9
0.30104497.11861652.html.plaintext.txt	272	It shown initially apoE containing lipoprotein particles electrophoretic mobility Lp E effective removing excess cholesterol cholesterol loaded cell cultures 6
0.30104497.11861652.html.plaintext.txt	273	Plasma mice lacking apoE reduced capacity promote cholesterol efflux macrophages
0.30104497.11861652.html.plaintext.txt	274	However defect corrected selective expression apoE macrophages E mice 7
0.30104497.11861652.html.plaintext.txt	275	Cholesterol efflux may account protective role apoE atherosclerosis expressed locally arterial wall macrophages endothelial cells 9 11
0.30104497.11861652.html.plaintext.txt	276	Numerous studies also implicated SR BI cholesterol efflux vitro 28 30 40
0.30104497.11861652.html.plaintext.txt	277	It shown transiently transfected cells permanent cell lines overexpressing SR BI promote net cholesterol efflux cells HDL rHDL cholesterol acceptors lipid free apoA I 28 30
0.30104497.11861652.html.plaintext.txt	278	In variety cell lines studied rate cholesterol efflux correlates levels SR BI expression 30
0.30104497.11861652.html.plaintext.txt	279	Potential interactions apoE containing lipoproteins SR BI could contribute cholesterol ester delivery well cholesterol efflux cells express SR BI 63
0.30104497.11861652.html.plaintext.txt	280	Specific Binding Reconstituted POPC ApoE Particles SR BI Cells contain numerous apoE recognizing receptors
0.30104497.11861652.html.plaintext.txt	281	The prominent LDL receptor 1 2 64 LDL receptor related protein 3 VLDL receptor 5 apoE receptor 2 4
0.30104497.11861652.html.plaintext.txt	282	ldlA 7 LDL receptor 55 56 apoE recognizing receptors
0.30104497.11861652.html.plaintext.txt	283	We observed high background binding presumably due presence cells apoE recognizing receptors
0.30104497.11861652.html.plaintext.txt	284	To establish specific binding apoE containing lipoprotein particles SR BI necessary subtract background binding apoE receptors Chinese hamster ovary cell line overexpresses mouse SR BI ldlA mSR BI
0.30104497.11861652.html.plaintext.txt	285	Binding experiments using apoE4 established specific binding POPC apoE particles ldlA mSR BI occurs Kd 38 microgml Bmax 1700 ngmg cell protein
0.30104497.11861652.html.plaintext.txt	286	To ensure specific values determined valid measured SR BI dependent binding using SR BI receptor blocking antibodies
0.30104497.11861652.html.plaintext.txt	287	The specific binding curves binding parameters obtained procedures essentially identical Kd 39 microgml Bmax 1800 ngmg cell protein
0.30104497.11861652.html.plaintext.txt	288	Similar binding parameters obtained binding experiments performed 4 degrees C receptor binding determined ELISA
0.30104497.11861652.html.plaintext.txt	289	The binding POPC apoE4 affected double mutation SR BI eliminated binding HDL LDL 28
0.30104497.11861652.html.plaintext.txt	290	This observation suggests similarities modes binding apoA I containing native HDL POPC apoE4
0.30104497.11861652.html.plaintext.txt	291	This conclusion supported competition experiments suggesting recognition site apoE SR BI like site binds HDL site binds LDL
0.30104497.11861652.html.plaintext.txt	292	Effects ApoE Mutations Binding POPC ApoE Particles SR BI Binding apoE LDL receptor affected mutations residue 158 well substitutions charged residues 140 150 region apoE 58 60
0.30104497.11861652.html.plaintext.txt	293	In current study examined binding three naturally occurring apoE forms apoE2 C112C158 apoE3 C112R158 apoE4 R118R158 several truncated apoE forms
0.30104497.11861652.html.plaintext.txt	294	These truncations produced amino terminal segments apoE extend residues 259 229 202 165
0.30104497.11861652.html.plaintext.txt	295	In previous studies used cell lines expressing mouse SR BI determine ligand specificity receptor using ligands containing human apoA I 22
0.30104497.11861652.html.plaintext.txt	296	The use heterologous system present study offers advantage availability large number mouse SR BI human apoE mutations available human SR BI mouse apoE
0.30104497.11861652.html.plaintext.txt	297	Although mouse human apoE well mouse human SR BI considerable sequence similarities one exclude possibility species differences receptor ligand specificity due use heterologous system
0.30104497.11861652.html.plaintext.txt	298	5 A H Table II binding parameters POPC apoE particles SR BI similar WT apoE truncated apoE forms range Kd 35 45 microgml
0.30104497.11861652.html.plaintext.txt	299	The findings suggest amino terminal region 1 165 apoE contains necessary determinants recognition SR BI Arg 158 critical SR BI receptor binding
0.30104497.11861652.html.plaintext.txt	300	Similar studies LDL receptor shown previously Arg 158 well carboxyl terminal 171 183 apoE region important binding apoE containing liposomes LDL receptor 60
0.30104497.11861652.html.plaintext.txt	301	The receptor binding properties POPC apoE particles similar involving rHDL apoA I particles
0.30104497.11861652.html.plaintext.txt	302	In case apoA I deletion residues 186 243 affect binding POPC apoA I SR BI 22
0.30104497.11861652.html.plaintext.txt	303	The interactions SR BI HDL LDL associated selective lipid uptake 24 28 31 34 well cholesterol efflux 28 30 40
0.30104497.11861652.html.plaintext.txt	304	Recent studies indicated SR BI expressed astrocytes microglia brain 63 indicating interactions apoE containing lipoproteins SR BI may contribute brain cholesterol homeostasis
0.30104497.11861652.html.plaintext.txt	305	Reconstituted POPCapoE particles containing apoE ability deliver cholesteryl esters cells 32
0.30104497.11861652.html.plaintext.txt	306	The role apoE containing lipoproteins SR BI mediated cholesterol efflux selective lipid uptake brain impact apoE mutations processes remains determined
0.30104497.11861652.html.plaintext.txt	307	We thank Anne Plunkett secretarial assistance Pamela Morani Gayle Forbes technical assistance Markella Zanni editing manuscript Kalliopi Liadaki providing data Fig
0.30104497.11861652.html.plaintext.txt	308	We thank Karen Kozarsky generously providing KKB 1 antibody used studies
0.30104497.11861652.html.plaintext.txt	309	This work supported National Institutes Health Grants HL48739 HL68216 V
0.30104497.11861652.html.plaintext.txt	310	HL41484 HL52212 M
0.30104497.11861652.html.plaintext.txt	311	Alzheimers Association Grant IIRG 002220 V
0.30104497.11861652.html.plaintext.txt	312	The costs publication article defrayed part payment page charges
0.30104497.11861652.html.plaintext.txt	313	The article must therefore hereby marked advertisement accordance 18 U
0.30104497.11861652.html.plaintext.txt	314	Section 1734 solely indicate fact
0.30104497.11861652.html.plaintext.txt	315	To correspondence addressed
0.30104497.11861652.html.plaintext.txt	316	617 638 5085 Fax 617 638 5141 Email vzannisbu
0.30104497.11861652.html.plaintext.txt	317	Published JBC Papers Press February 22 2002 DOI 10
0.30104497.11861652.html.plaintext.txt	318	The abbreviations used apoE apolipoprotein E HDL high density lipoprotein LDL low density lipoprotein VLDL low density lipoprotein SR BI scavenger receptor class B type I apoA I apolipoprotein A I POPC 1 palmitoyl 2 oleoyl L phosphatidylcholine DMEM Dulbeccos modified Eagle medium WT wild type EM electron microscopy ELISA enzyme linked immunosorbent assay ldlA LDL receptor deficient Chinese hamster ovary cell line ldlAmSR BI cells mSR BI cells expressing ldlA cells mSR BI murine SR BI rHDL discoidal reconstituted HDL particles
0.30104497.11861652.html.plaintext.txt	319	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES 1
0.30104497.11861652.html.plaintext.txt	320	1978 Biochemistry 17 1440 1447Medline Order article via Infotrieve 2
0.30104497.11861652.html.plaintext.txt	321	6 97 103Medline Order article via Infotrieve 3
0.30104497.11861652.html.plaintext.txt	322	1989 Nature 341 162 164CrossRefMedline Order article via Infotrieve 4
0.30104497.11861652.html.plaintext.txt	323	271 8373 8380AbstractFree Full Text 5
0.30104497.11861652.html.plaintext.txt	324	95 7585 7590AbstractFree Full Text 8
0.30104497.11861652.html.plaintext.txt	325	101 1670 1677AbstractFree Full Text 9
0.30104497.11861652.html.plaintext.txt	326	1995 Science 267 1034 1037Medline Order article via Infotrieve 10
0.30104497.11861652.html.plaintext.txt	327	95 469 476Medline Order article via Infotrieve 12
0.30104497.11861652.html.plaintext.txt	328	3 718 722Medline Order article via Infotrieve 13
0.30104497.11861652.html.plaintext.txt	329	80 483 490Medline Order article via Infotrieve 14
0.30104497.11861652.html.plaintext.txt	330	83 1095 1101Medline Order article via Infotrieve 15
0.30104497.11861652.html.plaintext.txt	331	264 21205 21210AbstractFree Full Text 16
0.30104497.11861652.html.plaintext.txt	332	78 1206 1219Medline Order article via Infotrieve 18
0.30104497.11861652.html.plaintext.txt	333	262 2310 2315AbstractFree Full Text 19
0.30104497.11861652.html.plaintext.txt	334	1992 Cell 71 343 353Medline Order article via Infotrieve 20
0.30104497.11861652.html.plaintext.txt	335	68 523 558CrossRefMedline Order article via Infotrieve 22
0.30104497.11861652.html.plaintext.txt	336	275 21262 21271AbstractFree Full Text 23
0.30104497.11861652.html.plaintext.txt	337	275 9120 9130AbstractFree Full Text 25
0.30104497.11861652.html.plaintext.txt	338	1996 Science 271 518 520Abstract 26
0.30104497.11861652.html.plaintext.txt	339	98 984 995AbstractFree Full Text 27
0.30104497.11861652.html.plaintext.txt	340	273 26338 26348AbstractFree Full Text 28
0.30104497.11861652.html.plaintext.txt	341	275 29993 30001AbstractFree Full Text 29
0.30104497.11861652.html.plaintext.txt	342	275 36596 36604AbstractFree Full Text 30
0.30104497.11861652.html.plaintext.txt	343	272 20982 20985AbstractFree Full Text 31
0.30104497.11861652.html.plaintext.txt	344	274 32692 32698AbstractFree Full Text 32
0.30104497.11861652.html.plaintext.txt	345	276 43801 43808AbstractFree Full Text 33
0.30104497.11861652.html.plaintext.txt	346	276 4804 4811AbstractFree Full Text 34
0.30104497.11861652.html.plaintext.txt	347	275 33409 33415AbstractFree Full Text 35
0.30104497.11861652.html.plaintext.txt	348	27 882 890CrossRefMedline Order article via Infotrieve 36
0.30104497.11861652.html.plaintext.txt	349	276 1669 1672AbstractFree Full Text 37
0.30104497.11861652.html.plaintext.txt	350	97 13830 13834AbstractFree Full Text 38
0.30104497.11861652.html.plaintext.txt	351	76 498 508CrossRefMedline Order article via Infotrieve 39
0.30104497.11861652.html.plaintext.txt	352	132 443 449AbstractFree Full Text 40
0.30104497.11861652.html.plaintext.txt	353	40 575 580AbstractFree Full Text 41
0.30104497.11861652.html.plaintext.txt	354	94 12610 12615AbstractFree Full Text 42
0.30104497.11861652.html.plaintext.txt	355	96 9322 9327AbstractFree Full Text 43
0.30104497.11861652.html.plaintext.txt	356	273 32920 32926AbstractFree Full Text 44
0.30104497.11861652.html.plaintext.txt	357	1997 Nature 387 414 417CrossRefMedline Order article via Infotrieve 45
0.30104497.11861652.html.plaintext.txt	358	274 2366 2371AbstractFree Full Text 46
0.30104497.11861652.html.plaintext.txt	359	274 7165 7171AbstractFree Full Text 47
0.30104497.11861652.html.plaintext.txt	360	95 10194 10199AbstractFree Full Text 48
0.30104497.11861652.html.plaintext.txt	361	2001 Biochemistry 40 6027 6035CrossRefMedline Order article via Infotrieve 49
0.30104497.11861652.html.plaintext.txt	362	276 19778 19786AbstractFree Full Text 50
0.30104497.11861652.html.plaintext.txt	363	1997 Biochemistry 36 10571 10580CrossRefMedline Order article via Infotrieve 51
0.30104497.11861652.html.plaintext.txt	364	26 291 298Medline Order article via Infotrieve 52
0.30104497.11861652.html.plaintext.txt	365	257 4535 4540AbstractFree Full Text 53
0.30104497.11861652.html.plaintext.txt	366	125 427 432Medline Order article via Infotrieve 54
0.30104497.11861652.html.plaintext.txt	367	226 80 84CrossRefMedline Order article via Infotrieve 55
0.30104497.11861652.html.plaintext.txt	368	33 413 422CrossRefMedline Order article via Infotrieve 56
0.30104497.11861652.html.plaintext.txt	369	6 3268 3277Medline Order article via Infotrieve 57
0.30104497.11861652.html.plaintext.txt	370	269 21003 21009AbstractFree Full Text 58
0.30104497.11861652.html.plaintext.txt	371	263 3542 3545AbstractFree Full Text 60
0.30104497.11861652.html.plaintext.txt	372	264 8447 8450AbstractFree Full Text 61
0.30104497.11861652.html.plaintext.txt	373	19 2945 2951AbstractFree Full Text 62
0.30104497.11861652.html.plaintext.txt	374	1998 NATO ASI Series Life Sciences Catravas J
0.30104497.11861652.html.plaintext.txt	375	158 825 832AbstractFree Full Text 64
0.30104497.11861652.html.plaintext.txt	376	264 21682 21688AbstractFree Full Text
0.30104497.11861652.html.plaintext.txt	377	Copyright 2002 The American Society Biochemistry Molecular Biology Inc
0.3494895.15385439.html.plaintext.txt	0	Allelic expression APOE human brain effects epsilon status promoter haplotypes Nicholas J
0.3494895.15385439.html.plaintext.txt	1	Bray1 Luke Jehu1 Valentina Moskvina2 Joseph D
0.3494895.15385439.html.plaintext.txt	2	Buxbaum3 Stella Dracheva3 Vahram Haroutunian34 Julie Williams12 Paul R
0.3494895.15385439.html.plaintext.txt	3	1Department Psychological Medicine 2Biostatistics Bioinformatics Unit School Medicine Cardiff University Cardiff CF14 4XN UK 3Department Psychiatry Mount Sinai School Medicine New York NY 10021 USA 4Mental Illness Research Education Clinical Centres MIRECC Bronx Veterans Affairs Medical Centre Bronx New York NY 10468 USA
0.3494895.15385439.html.plaintext.txt	4	Received August 9 2004 Accepted September 11 2004
0.3494895.15385439.html.plaintext.txt	5	ABSTRACT TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES The 4 haplotype APOE undisputed genetic risk factor late onset Alzheimers disease LOAD
0.3494895.15385439.html.plaintext.txt	6	It proposed least two polymorphisms promoter APOE gene 219G T 491A T might also contribute disease susceptibility modulate impact structural changes ApoE protein altering expression
0.3494895.15385439.html.plaintext.txt	7	In order assess extent cis acting influences APOE expression human brain highly quantitative measures allele discrimination applied cortical RNA individuals heterozygous epsilon alleles
0.3494895.15385439.html.plaintext.txt	8	A small significant increase expression 4 allele observed relative 3 2 alleles P 0
0.3494895.15385439.html.plaintext.txt	9	Similar differences observed brain tissue confirmed LOAD subjects cortical regions BA10 frontopolar BA20 inferior temporal
0.3494895.15385439.html.plaintext.txt	10	Stratification 43 allelic expression ratios according heterozygosity 219G T promoter polymorphism revealed significantly lower relative expression haplotypes containing 219T allele P0
0.3494895.15385439.html.plaintext.txt	11	Our data indicate human brain cis acting variance APOE expression accounted 4 haplotype additional small cis acting influences associated promoter genotype
0.3494895.15385439.html.plaintext.txt	12	INTRODUCTION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Apolipoprotein E ApoE serves central role lipid metabolism major apolipoprotein synthesized brain 1
0.3494895.15385439.html.plaintext.txt	13	The ApoE protein exists three common isoforms designated ApoE2 ApoE3 ApoE4 resulting two non synonymous single nucleotide polymorphisms APOE gene
0.3494895.15385439.html.plaintext.txt	14	These isoforms differentially impact variety biological parameters including plasma cholesterol levels 2 neurite outgrowth 3 amyloid deposition 4
0.3494895.15385439.html.plaintext.txt	15	Possession 4 allele APOE gene encoding ApoE4 undisputed genetic risk factor common late onset form Alzheimers disease LOAD increasing risk dose dependent manner 56
0.3494895.15385439.html.plaintext.txt	16	However 4 allele neither necessary sufficient expression disease large proportion 4 homozygotes surviving 80 years show cognitive impairment 7
0.3494895.15385439.html.plaintext.txt	17	The 2 allele encoding ApoE2 confers protective effect 8
0.3494895.15385439.html.plaintext.txt	18	It postulated addition structural changes ApoE cis acting variation within APOE regulatory sequence might also contribute disease susceptibility influencing gene expression
0.3494895.15385439.html.plaintext.txt	19	Transgenic mouse models indicate APOE dosage significantly influence pathological hallmarks human Alzheimers disease including amyloid deposition neuritic degeneration 910
0.3494895.15385439.html.plaintext.txt	20	Furthermore cis acting regulatory variants human APOE potential influence LOAD susceptibilty suggested study variation quantitative measures peripheral lipid metabolism better explained considering genotype data additional polymorphic sites vicinity APOE rather 2 4 status alone 11
0.3494895.15385439.html.plaintext.txt	21	It however noted implications study Alzheimers disease unknown unclear aspects APOE function indexed peripheral lipid metabolism relevant LOAD pathogenesis
0.3494895.15385439.html.plaintext.txt	22	Moreover extent cis acting influences APOE expression human brain also currently unclear
0.3494895.15385439.html.plaintext.txt	23	A powerful method investigating cis acting influences gene expression involves comparing relative level mRNA transcript individuals heterozygous expressed polymorphism
0.3494895.15385439.html.plaintext.txt	24	This within subjects approach allow detection genuine cis acting effects whilst controlling trans acting factors confound measures total expression samples
0.3494895.15385439.html.plaintext.txt	25	One study using RFLP based assay reported evidence intrinsic effects epsilon status APOE mRNA expression brain 3 expression greatly increased relative 4 34 heterozygotes 12
0.3494895.15385439.html.plaintext.txt	26	Elevated 3 expression observed LOAD cases controls although former magnitude difference smaller
0.3494895.15385439.html.plaintext.txt	27	However findings replicated subsequent study potential methodological shortcomings RFLP based assays clearly demonstrated 13
0.3494895.15385439.html.plaintext.txt	28	Molecular genetic studies provide support association LOAD two polymorphisms promoter APOE denoted 491A T 219G T also known Th1E47cs 14 16
0.3494895.15385439.html.plaintext.txt	29	Both polymorphisms shown influence APOE expression vitro 17 raising possibility association direct result cis acting effects gene expression rather virtue linkage disequilibrium LD
0.3494895.15385439.html.plaintext.txt	30	Given importance APOE risk factor LOAD potential importance variation APOE expression undertaken thorough investigation allelic expression APOE human brain using highly quantitative measures allele discrimination 1819 large series heterozygous samples
0.3494895.15385439.html.plaintext.txt	31	Our objectives establish whether epsilon status influences APOE expression brain determine extent APOE expression subject cis acting influences particular effects promoter polymorphisms current interest Alzheimers disease research
0.3494895.15385439.html.plaintext.txt	32	RESULTS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES We analysed three sets samples comprising total 202 brain samples 142 unrelated individuals
0.3494895.15385439.html.plaintext.txt	33	Of initial set 60 non AD samples 15 34 heterozygotes 11 23 heterozygotes two 24 heterozygotes
0.3494895.15385439.html.plaintext.txt	34	Eleven 34 heterozygotes identified second sample 22 LOAD subjects 2 alleles observed
0.3494895.15385439.html.plaintext.txt	35	Thirteen third set 60 samples mixture psychiatric diagnosis used within subject comparisons brain regions 34 heterozygotes four 23 heterozygotes
0.3494895.15385439.html.plaintext.txt	36	Observed allele frequencies three groups shown Table 1
0.3494895.15385439.html.plaintext.txt	37	Observed allele frequencies genotyped polymorphisms sample groups Measures APOE allele specific expression performed using expressed SNPs 334T C 472C T
0.3494895.15385439.html.plaintext.txt	38	The 3 allele determined haplotype 334T 472C 2 allele 334T 472T 4 allele 334C 472C
0.3494895.15385439.html.plaintext.txt	39	The use polymorphisms within mRNA sequence permits discrimination alleles transcribed chromosome
0.3494895.15385439.html.plaintext.txt	40	Corrected cDNA ratios 34 23 heterozygotes shown Table 2
0.3494895.15385439.html.plaintext.txt	41	Analysis corrected cDNA ratios initial sample 15 34 heterozygotes showed small significant elevation C allele SNP 334T C 4 relative T allele 3 three replication experiments
0.3494895.15385439.html.plaintext.txt	42	Repeat assays showed good reproducibility individual cDNA allele ratios average co efficient variation SDmean 0
0.3494895.15385439.html.plaintext.txt	43	Combining data 15 individuals across experiments expression 4 allele increased cDNA average 14 relative 3 allele mean corrected ratio1
0.3494895.15385439.html.plaintext.txt	44	0001 individual ratios ranging 6 25 relative increase Fig
0.3494895.15385439.html.plaintext.txt	45	Comparison corrected genomic cDNA ratios assayed SNP 334T C 34 subjects
0.3494895.15385439.html.plaintext.txt	46	For individuals C allele determines 4 T allele determines 3
0.3494895.15385439.html.plaintext.txt	47	The ratio therefore expressed level 43
0.3494895.15385439.html.plaintext.txt	48	Column 2 shows cDNA data points non AD cases n15 column 3 shows cDNA data points confirmed LOAD cases n11
0.3494895.15385439.html.plaintext.txt	49	The data genomic DNA averages two measurements individual sample
0.3494895.15385439.html.plaintext.txt	50	The data cDNA averages six estimates individual sample
0.3494895.15385439.html.plaintext.txt	51	For non AD LOAD cases level 4 significantly greater 3 cDNA P 0
0.3494895.15385439.html.plaintext.txt	52	No differences observed extent allelic distortion non AD LOAD cases P0
0.3494895.15385439.html.plaintext.txt	53	Expression ratios derived 11 34 heterozygotes LOAD sample yielded similar pattern average 15 relative increase 4 compared 3 expression P 0
0.3494895.15385439.html.plaintext.txt	54	There good reproducibility individual cDNA ratios across assays SDmean0
0.3494895.15385439.html.plaintext.txt	55	04 averaged increases ranging 9 19 Fig
0.3494895.15385439.html.plaintext.txt	56	No significant differences observed ratios derived initial sample LOAD cases P0
0.3494895.15385439.html.plaintext.txt	57	Ratios obtained additional 13 34 heterozygotes tissue BA10 BA20 available showed significant increase expression 4 allele BA10 mean increase11 P 0
0.3494895.15385439.html.plaintext.txt	58	0001 BA20 mean increase10 P 0
0.3494895.15385439.html.plaintext.txt	59	Within subject comparisons two brain regions indicated significant differences extent allelic imbalance paired test P0
0.3494895.15385439.html.plaintext.txt	60	A smaller difference observed relative expression 2 3 alleles SNP 472C T initial sample 11 23 heterozygotes Fig
0.3494895.15385439.html.plaintext.txt	61	The average increase 472C 3 allele 472T 2 allele across experiments 4 ratio1
0.3494895.15385439.html.plaintext.txt	62	04 ranging equal expression ratio1 10 relative increase 3 allele ratio1
0.3494895.15385439.html.plaintext.txt	63	Although meets conventional criteria significance P0
0.3494895.15385439.html.plaintext.txt	64	04 increase relative 3 expression observed four 23 heterozygotes USA sample tissue derived either BA10 BA20 mean ratios1
0.3494895.15385439.html.plaintext.txt	65	Combining data 15 samples frontal cortex yielded mean 32 ratio 1
0.3494895.15385439.html.plaintext.txt	66	View larger version 12K Figure 2
0.3494895.15385439.html.plaintext.txt	67	Comparison corrected genomic cDNA ratios assayed SNP 472C T non AD 23 subjects n11
0.3494895.15385439.html.plaintext.txt	68	For individuals C allele determines 3 T allele determines 2
0.3494895.15385439.html.plaintext.txt	69	The ratio therefore expressed level 32
0.3494895.15385439.html.plaintext.txt	70	The data genomic DNA averages two measurements individual sample
0.3494895.15385439.html.plaintext.txt	71	The data cDNA averages six estimates individual sample
0.3494895.15385439.html.plaintext.txt	72	The level 3 allele slightly higher 2 cDNA P0
0.3494895.15385439.html.plaintext.txt	73	Two initial 60 samples 24 heterozygotes therefore heterozygous SNPs 334T C 472C T
0.3494895.15385439.html.plaintext.txt	74	This allowed comparison allele ratios derived two separate assays absence alternative splicing comparable despite amplified assayed using different primer sets
0.3494895.15385439.html.plaintext.txt	75	The cDNA ratios corrected average genomic assay 1
0.3494895.15385439.html.plaintext.txt	76	08 sample SNPs 334T C 472C T respectively
0.3494895.15385439.html.plaintext.txt	77	Thus cases calculated ratios differed 4 two independent assays
0.3494895.15385439.html.plaintext.txt	78	This sample small statistical analysis expected observations relative expression 4 3 32 4 allele expressed higher level 2 case
0.3494895.15385439.html.plaintext.txt	79	To investigate influence known promoter polymorphisms allelic expression 60 unrelated Caucasians 22 Caucasian LOAD cases genotyped promoter SNPs 491A T 219G T observed allele frequencies presented Table 1
0.3494895.15385439.html.plaintext.txt	80	Although variants potential regulatory significance exist e
0.3494895.15385439.html.plaintext.txt	81	427T C 113G C particular polymorphisms selected basis strongest prior evidence association LOAD 16
0.3494895.15385439.html.plaintext.txt	82	The sample used within subject comparisons brain regions included analysis ethnically heterogeneous
0.3494895.15385439.html.plaintext.txt	83	The use samples different genetic backgrounds potentially problematic calculating conditional diplotype probabilities diplotypes less likely follow Hardy Weinberg expectations
0.3494895.15385439.html.plaintext.txt	84	To determine variance relative 4 expression attributable heterozygosity promoter sites corrected cDNA ratios obtained analysis 34 heterozygotes SNP334T C stratified according whether individuals heterozygous homozygous two promoter loci
0.3494895.15385439.html.plaintext.txt	85	Ratios derived 13 219G T heterozygotes 13 219G T homozygotes compared using two factorial ANOVA LOAD diagnosis included factor
0.3494895.15385439.html.plaintext.txt	86	Of 13 219G T homozygotes nine homozygous 219T allele four homozygous 219G allele
0.3494895.15385439.html.plaintext.txt	87	The average increase 4 allele relative 3 12 219G T heterozygotes range 6 23 compared 16 219G T homozygotes range 9 25 Fig
0.3494895.15385439.html.plaintext.txt	88	A significant main effect heterozygosity versus homozygosity 219G T polymorphism observed P0
0.3494895.15385439.html.plaintext.txt	89	02 significant effect LOAD diagnosis P0
0.3494895.15385439.html.plaintext.txt	90	Knowledge phase required allow inference direction effect 219G T alleles
0.3494895.15385439.html.plaintext.txt	91	Diplotypes unambiguous respect individuals homozygous promoter polymorphism heterozygous assayed site
0.3494895.15385439.html.plaintext.txt	92	However given observed haplotype frequencies 219G T334T C double heterozygotes probability 219G nucleotide phase 334T 3 219T nucleotide phase 334C 4 0
0.3494895.15385439.html.plaintext.txt	93	As 219G T heterozygotes showed reduced relative increase 4 expression compared 219G T homozygotes case heterozygotes 219T allele predicted phase 4 allele 85 cases infer 219T allele associated reduced APOE expression compared 219G allele
0.3494895.15385439.html.plaintext.txt	94	View larger version 13K Figure 3
0.3494895.15385439.html.plaintext.txt	95	Comparison corrected 43 cDNA ratios 219G T homozygotes 219G T heterozygotes assayed SNP 334T C
0.3494895.15385439.html.plaintext.txt	96	Ratios derived 34 heterozygotes also heterozygous SNP 219G T show lower ratios 43 expression 34 heterozygotes homozygous SNP 219G T P0
0.3494895.15385439.html.plaintext.txt	97	Of 26 34 heterozygotes included analysis six heterozygous 491A T polymorphism one homozygous 491T allele 19 homozygous 491A allele
0.3494895.15385439.html.plaintext.txt	98	The average increase 4 allele relative 3 16 491A T heterozygotes range 9 25 compared 14 491A T homozygotes range 6 23 Fig
0.3494895.15385439.html.plaintext.txt	99	Differences allele ratio approach statistical significance P0
0.3494895.15385439.html.plaintext.txt	100	Again significant effect LOAD diagnosis P0
0.3494895.15385439.html.plaintext.txt	101	However given individual genotypes SNPs 334T C 219G T four six 491A T heterozygotes probability 491T nucleotide phase 334T 3 allele 491A nucleotide phase 334C 4 allele 0
0.3494895.15385439.html.plaintext.txt	102	As phase probability much greater chance likely phase reversed proportion cases distorting directional effect 4 expression
0.3494895.15385439.html.plaintext.txt	103	The 491A T heterozygote greatest phase certainty P0
0.3494895.15385439.html.plaintext.txt	104	99 predicted possess 491A nucleotide phase 219G 334C 4 491T nucleotide phase 219G 334T 3
0.3494895.15385439.html.plaintext.txt	105	This sample individual homozygous high expression 219G allele whereas heterozygous 491A T polymorphism showed greatest elevation relative 334C 4 expression assayed samples 25
0.3494895.15385439.html.plaintext.txt	106	View larger version 13K Figure 4
0.3494895.15385439.html.plaintext.txt	107	Comparison corrected 43 cDNA ratios 491A T homozygotes 491A T heterozygotes assayed SNP 334T C
0.3494895.15385439.html.plaintext.txt	108	No significant differences observed two groups P0
0.3494895.15385439.html.plaintext.txt	109	DISCUSSION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Using highly quantitative method allele discrimination 1819 compared relative expression APOE 2 3 4 alleles brain RNA individual heterozygotes
0.3494895.15385439.html.plaintext.txt	110	By comparing relative expression alleles within individuals assay perfect internal control variables RNA quality disease status exception multiplicative effects risk factors gene expression cell loss result degenerative changes trans acting effects loci environmental factors e
0.3494895.15385439.html.plaintext.txt	111	cause death drug treatment nutritional status etc
0.3494895.15385439.html.plaintext.txt	112	All variables expected influence allelic variant mRNA equally
0.3494895.15385439.html.plaintext.txt	113	The assay therefore permits detection small cis acting influences gene expression even background large inter individual variation total gene expression feature previously observed studies total APOE mRNA expression 20
0.3494895.15385439.html.plaintext.txt	114	A advantage assay robust secondary effects gene expression
0.3494895.15385439.html.plaintext.txt	115	For example possession allele influences disease result impaired protein function might trans acting homeostatic mechanisms result compensatory increase gene expression
0.3494895.15385439.html.plaintext.txt	116	We found increased expression 4 allele 3 allele 34 heterozygotes finding replicated two additional samples LOAD subjects mixed population subjects neuropsychiatric disorders
0.3494895.15385439.html.plaintext.txt	117	We also observed small increase relative 3 expression 23 individuals finding replicate small number neuropsychiatric patients genotype observed
0.3494895.15385439.html.plaintext.txt	118	Although comprehensive survey different brain regions analysis frontal temporal cortex yielded evidence differences neuroanatomical region
0.3494895.15385439.html.plaintext.txt	119	The relatively small difference allele ratio observed 34 heterozygotes study stark contrast findings previous study 12 RFLP based design used
0.3494895.15385439.html.plaintext.txt	120	In study large increase observed level 3 relative 4 mRNA control LOAD samples although smaller differences seen LOAD group
0.3494895.15385439.html.plaintext.txt	121	Our data compatible subsequent study 13 major differences expression two alleles found either control LOAD 34 heterozygotes
0.3494895.15385439.html.plaintext.txt	122	It also notable subsequent study 13 average 4 relative increase 4 expression found maximum 22
0.3494895.15385439.html.plaintext.txt	123	Using RFLP based design similar previous study also showed estimation allele ratio using method critically dependent number PCR cycles due digestion resistant heteroduplex formation suggesting former results due artefact
0.3494895.15385439.html.plaintext.txt	124	The primer extension method used present study unaffected problem thus present data likely provide accurate estimate relative allelic expression brain APOE
0.3494895.15385439.html.plaintext.txt	125	The small increase 4 expression observed study could possibly reflect intrinsic effect alleles transcription efficiency RNA stability
0.3494895.15385439.html.plaintext.txt	126	Alternatively finding may reflect strong LD 2 4 conferring haplotype untested regulatory variant may many 11
0.3494895.15385439.html.plaintext.txt	127	Increased representation 4 allele unlikely resulted differences PCR primer extension efficiency controlled corrected concurrent assay genomic DNA conditions
0.3494895.15385439.html.plaintext.txt	128	Although genomic control cannot applied limit potential confounding differential RT efficiency neither phenomenon likely explain observed differences 34 heterozygotes inter individual differences ratios largely preserved separate RT reactions
0.3494895.15385439.html.plaintext.txt	129	Our finding increased expression 4 allele RNA level consistent recent study encoded ApoE4 isoform found account elevated proportion total ApoE protein CSF 34 heterozygotes 21
0.3494895.15385439.html.plaintext.txt	130	This finding contrast measures ApoE4 plasma 221 associated lower protein expression suggesting important allele specific differences CNS periphery control synthesis andor degradation ApoE
0.3494895.15385439.html.plaintext.txt	131	The magnitude 4 expression found virtually identical initial sample sample confirmed LOAD cases
0.3494895.15385439.html.plaintext.txt	132	The initial sample selected specific control group LOAD sample although contain individual diagnosis AD possible individuals might developed disease survived old age
0.3494895.15385439.html.plaintext.txt	133	However differences observed sample confirmed LOAD cases consistent previous comparisons using age matched control groups terms relative 4 RNA expression 13 relative level ApoE4 protein 21 suggesting common risk factors LOAD influence risk disease altering APOE expression selectively interact markedly increase expression specific APOE mRNA species
0.3494895.15385439.html.plaintext.txt	134	Though significant influence cis acting polymorphisms steady state levels APOE mRNA cerebral cortex small maximum relative difference expression observed study 25
0.3494895.15385439.html.plaintext.txt	135	The 56 APOE heterozygotes assayed study provided 99 power detect effect distinct regulatory variant occurring general population frequency 0
0.3494895.15385439.html.plaintext.txt	136	05 almost 90 power detect effect one present frequency 0
0.3494895.15385439.html.plaintext.txt	137	This degree power effectively excludes existence even fairly rare polymorphisms around APOE exerting large direct effects net APOE mRNA expression
0.3494895.15385439.html.plaintext.txt	138	The third objective study determine APOE mRNA levels vivo influenced polymorphisms affect transcription activity vitro several studies associated LOAD
0.3494895.15385439.html.plaintext.txt	139	Stratification observed 43 allele ratios according heterozygosity promoter polymorphisms indicated small statistically significant effect 219G T polymorphism allelic expression consistent functional effect brain
0.3494895.15385439.html.plaintext.txt	140	The 219T allele previously associated reduced transcriptional activity vitro 17 reduced plasma ApoE vivo 22
0.3494895.15385439.html.plaintext.txt	141	The present finding reduced ratio 43 expression probability 4 allele phase 219T allele 3 allele phase 219G allele suggests 219T allele also decreases APOE expression brain
0.3494895.15385439.html.plaintext.txt	142	As measures total expression data allow us distinguish direct indirect association consistency finding vitro studies suggests direct effect
0.3494895.15385439.html.plaintext.txt	143	The conditional probabilities diplotypes suggest 15 219G T heterozygotes
0.3494895.15385439.html.plaintext.txt	144	two 13 higher expression 219G allele phase 4 34 individuals
0.3494895.15385439.html.plaintext.txt	145	As know individual diplotypes analysis misclassified cannot accurately assess impact estimate magnitude effect
0.3494895.15385439.html.plaintext.txt	146	However assume two heterozygotes displaying least reduction 43 ratio misclassified obtain estimate maximum possible size effect
0.3494895.15385439.html.plaintext.txt	147	Excluding analysis reveals mean net effect 219T allele 6 reduction relative 4 expression
0.3494895.15385439.html.plaintext.txt	148	We stress analysis provides guide maximum effect cannot conclude effect size compelling case exclude single individual analysis
0.3494895.15385439.html.plaintext.txt	149	The 491A allele 491A G promoter polymorphism reported show higher transcriptional activity vitro 17 associated increased measures total APOE expression plasma 23 brain 24
0.3494895.15385439.html.plaintext.txt	150	In present study heterozygosity site significantly influence relative 4 expression one direction
0.3494895.15385439.html.plaintext.txt	151	It noted however power detect small directional effect would diminished small sample size low predicted consistency phase
0.3494895.15385439.html.plaintext.txt	152	Interestingly although single observation assayed samples one showing greatest elevation relative 334C 4 expression 25 also sample high probability 0
0.3494895.15385439.html.plaintext.txt	153	99 491A high expression predicted vitro nucleotide phase 219G high expression vitro study 334C high expression study
0.3494895.15385439.html.plaintext.txt	154	Our study illustrates importance complementing vivo vitro work
0.3494895.15385439.html.plaintext.txt	155	In vitro work requires analysis effects variants alien genomic cellular contexts therefore findings must examined compatibility vivo
0.3494895.15385439.html.plaintext.txt	156	Nevertheless without vitro work associations observed impossible attribute vivo effects expression specific variants
0.3494895.15385439.html.plaintext.txt	157	This would require effect cis acting variants haplotype controlled effectively impossible task relevant variants could legion distributed across large genomic sequences
0.3494895.15385439.html.plaintext.txt	158	To summarize using relatively large series brain samples demonstrated common influences APOE expression attributable cis acting polymorphism small
0.3494895.15385439.html.plaintext.txt	159	We also effectively excluded existence even fairly rare cis acting haplotypes large effect
0.3494895.15385439.html.plaintext.txt	160	Of variance occur accounted 4 haplotype 4 allele APOE expressed significantly higher level 3
0.3494895.15385439.html.plaintext.txt	161	This highly reproducible appears independent AD status
0.3494895.15385439.html.plaintext.txt	162	We also shown 219G promoter allele associated higher expression APOE mRNA vivo finding compatible previous vitro studies
0.3494895.15385439.html.plaintext.txt	163	Our study provides important functional vivo plausibility existing body association data suggesting 219T promoter polymorphism may modulate risk AD independent APOE epsilon status 16
0.3494895.15385439.html.plaintext.txt	164	However though demonstration functionality enhances case strong genetic support samples larger currently available single group required force conclusion extremely small effects observed relevant LOAD susceptibility
0.3494895.15385439.html.plaintext.txt	165	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Samples Initial experiments performed using post mortem frontal temporal cortex 60 unrelated anonymized Caucasians 50 UK MRC London Neurodegenerative Diseases Brain Bank 10 Sweden Department Clinical Neuroscience Karolinska Institute Stockholm
0.3494895.15385439.html.plaintext.txt	166	All free diagnosis psychiatric neurological disorder time death
0.3494895.15385439.html.plaintext.txt	167	Of 15 34 heterozygotes 12M 3F mean age55 SD20 11 23 heterozygotes 9M 4F mean age61 SD18 two 24 heterozygotes 2F mean age65 SD35
0.3494895.15385439.html.plaintext.txt	168	The LOAD sample consisted post mortem temporal cortex 22 unrelated anonymized UK Caucasians neuropathological diagnosis late onset LOAD obtained MRC London Neurodegenerative Diseases Brain Bank
0.3494895.15385439.html.plaintext.txt	169	Of 11 34 heterozygotes 3M 8F mean age77 SD12 2 heterozygotes observed
0.3494895.15385439.html.plaintext.txt	170	Within subject comparisons expression brain regions made using sample 13 34 heterozygotes 10M 3F drawn additional 60 unrelated anonymized individuals mixed ethnicity mixed neuropsychiatric diagnoses USA The Mount Sinai School Medicine Department Psychiatry Alzheimers disease Schizophrenia Brain Bank also four 23 heterozygotes 2M 2F
0.3494895.15385439.html.plaintext.txt	171	Tissue available cortical regions BA10 frontopolar BA20 inferior temporal 60 individuals
0.3494895.15385439.html.plaintext.txt	172	For samples genomic DNA extracted using standard phenol chloroform procedures total RNA extracted using RNAwizTM isolation reagent Ambion
0.3494895.15385439.html.plaintext.txt	173	Total RNA treated DNase prior reverse transcription using random decamers RETROscriptTM kit Ambion
0.3494895.15385439.html.plaintext.txt	174	Genotyping Genotyping APOE 234 performed using RFLP based assay described previously 25
0.3494895.15385439.html.plaintext.txt	175	Genotyping SNP 491A T performed using SNaPshot primer extension amplification primers 5 GCCTAGCCCCACTTTCTTTT 3 5 CACAGTGGGCGAATCACTTA 3 extension primer 5 CGAATCACTTAAGGTCAGGAG 3
0.3494895.15385439.html.plaintext.txt	176	SNP 219G T genotyped using primers 5 AGAATGGAGGAGGGTGTCCG 3 5 ACTCAAGGATCCCAGACTTG 3 followed restriction digestion HpaII EcoN1
0.3494895.15385439.html.plaintext.txt	177	Allele expression assay Genomic DNA subjects initially genotyped described order identify heterozygotes SNPs 334T C 4 heterozygotes 472C T 2 heterozygotes
0.3494895.15385439.html.plaintext.txt	178	In individual allelic expression experiment cDNA heterozygotes assayed two separate RT reactions alongside duplicates corresponding genomic DNA samples
0.3494895.15385439.html.plaintext.txt	179	Each experiment repeated two separate occasions
0.3494895.15385439.html.plaintext.txt	180	DNase treated RNA samples yield detectable product absence RT step
0.3494895.15385439.html.plaintext.txt	181	For assays relative 4 expression 182 bp fragment containing SNP 334T C amplified cDNA genomic DNA using primers 5 GCCTACAAATCGGAACTGGA 3 5 AGCTCCTCGGTGCTCTGG 3
0.3494895.15385439.html.plaintext.txt	182	For assays relative 2 expression 67 bp fragment containing SNP 472C T amplified cDNA genomic DNA using primers 5 CTGCGTAAGCGGCTCCTC 3 5 CCCCGGCCTGGTACACTG 3
0.3494895.15385439.html.plaintext.txt	183	PCRs carried total reaction volume 12 microl containing either cDNA genomic DNA template 1xPCR buffer dNTPs 0
0.3494895.15385439.html.plaintext.txt	184	3 U Hot Star taq polymerase Qiagen 6 DMSO 35 cycles annealing temperature 60 degrees C
0.3494895.15385439.html.plaintext.txt	185	Amplified samples incubated 1 U shrimp alkaline phosphatase Amersham 2 U exonuclease I Amersham 45 min 37 degrees C 15 min 85 degrees C prior primer extension reactions
0.3494895.15385439.html.plaintext.txt	186	Primer extension carried using SNaPshot Multiplex Kit Applied Biosystems
0.3494895.15385439.html.plaintext.txt	187	The extension primer SNP 334T C 5 GCGCGGACATGGAGGACGTG 3
0.3494895.15385439.html.plaintext.txt	188	The extension primer SNP 472C T 5 CCGATGACCTGCAGAAG 3
0.3494895.15385439.html.plaintext.txt	189	Primer extension reactions performed total volume 10 microl containing 2 microl treated PCR product 4
0.3494895.15385439.html.plaintext.txt	190	5 microl water 1 pM extension primer
0.3494895.15385439.html.plaintext.txt	191	Primer extension thermocycling conditions consisted initial step 95 degrees C 2 min followed 25 cycles 95 degrees C 5 43 degrees C 5 60 degrees C 5
0.3494895.15385439.html.plaintext.txt	192	Following primer extension reaction products treated 0
0.3494895.15385439.html.plaintext.txt	193	5 U shrimp alkaline phosphatase Amersham 45 min 37 degrees C 15 min 85 degrees C
0.3494895.15385439.html.plaintext.txt	194	Aliquots 1 microl SNaPshot reaction product combined 9 microl Hi Di formamide loaded onto 3100 DNA sequencer Applied Biosystems
0.3494895.15385439.html.plaintext.txt	195	Products electrophoresed 36 cm capillary array 60 degrees C data processed using Genescan analysis version 3
0.3494895.15385439.html.plaintext.txt	196	7 software Applied Biosystems
0.3494895.15385439.html.plaintext.txt	197	Peak heights allele specific extended primers determined using Genotyper version 2
0.3494895.15385439.html.plaintext.txt	198	5 software Applied Biosystems ratios used index relative expression two alleles individual sample
0.3494895.15385439.html.plaintext.txt	199	The analytic conditions used genomic DNA cDNA average ratios observed genomic DNA experiment representing 1 1 ratio two alleles could used correct allelic ratios obtained cDNA analyses inequalities allelic representation specific assay 26
0.3494895.15385439.html.plaintext.txt	200	Statistical analysis Differences allelic expression tested comparing genomic ratios cDNA ratios heterozygous samples
0.3494895.15385439.html.plaintext.txt	201	All group comparisons analyzed test two tailed diagnosis included factor two factorial ANOVA
0.3494895.15385439.html.plaintext.txt	202	Predicted haplotype frequencies calculated using EH plus 27 formed basis calculation individual diplotype probabilities
0.3494895.15385439.html.plaintext.txt	203	We calculate probability individual carries specific diplotype first reconstructing possible combinations diplotypes individual given observed genotypes locus
0.3494895.15385439.html.plaintext.txt	204	We use expected distribution diplotype frequencies given observed haplotypes frequencies within specific sample identify probable diplotype individual
0.3494895.15385439.html.plaintext.txt	205	The probability diplotype within individual frequency diplotype divided sum frequencies possible diplotypes
0.3494895.15385439.html.plaintext.txt	206	Calculation power detect effects unknown regulatory variants based binomial distribution Hardy Weinberg equilibrium regulatory SNP LD marker SNP
0.3494895.15385439.html.plaintext.txt	207	The probability individual homozygous putative regulatory locus alleles Hardy Weinberg equilibrium p2q2 p q two allele frequencies
0.3494895.15385439.html.plaintext.txt	208	The probability n individuals homozygous therefore undetected assay regulatory polymorphism p2q2n
0.3494895.15385439.html.plaintext.txt	209	This also applies n individuals selected heterozygosity marker locus relationship
0.3494895.15385439.html.plaintext.txt	210	LD genotypes locus
0.3494895.15385439.html.plaintext.txt	211	The power detect least one heterozygote 1 p2q2n
0.3494895.15385439.html.plaintext.txt	212	If marker regulatory SNP LD higher proportion people selected heterozygosity marker also heterozygous regulatory SNP power increased
0.3494895.15385439.html.plaintext.txt	213	ACKNOWLEDGEMENTS We grateful MRC London Neurodegenerative Diseases Brain Bank UK Department Clinical Neuroscience Karolinska Institute Stockholm Sweden donating brain tissue
0.3494895.15385439.html.plaintext.txt	214	This work funded Medical Research Council UK
0.3494895.15385439.html.plaintext.txt	215	FOOTNOTES To correspondence addressed
0.3494895.15385439.html.plaintext.txt	216	Tel 44 2920743242 Fax 44 2920746554 Email odonovanmcatcardiff
0.3494895.15385439.html.plaintext.txt	217	REFERENCES TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Koch S
0.3494895.15385439.html.plaintext.txt	218	2001 Characterization four lipoprotein classes human cerebrospinal fluid
0.3494895.15385439.html.plaintext.txt	219	1988 Simultaneous effects apolipoprotein E polymorphism apolipoprotein E apolipoprotein B cholesterol metabolism
0.3494895.15385439.html.plaintext.txt	220	1994 Differential effects apolipoproteins E3 E4 neuronal growth vitro
0.3494895.15385439.html.plaintext.txt	221	1993 Apolipoprotein E sporadic Alzheimers disease allelic variation receptor interactions
0.3494895.15385439.html.plaintext.txt	222	1993 Apolipoprotein E high avidity binding beta amyloid increased frequency type 4 allele late onset familial Alzheimer disease
0.3494895.15385439.html.plaintext.txt	223	1993 Gene dose apolipoprotein E type 4 allele risk Alzheimers disease late onset families
0.3494895.15385439.html.plaintext.txt	224	1996 Apolipoprotein E cognitive change elderly population
0.3494895.15385439.html.plaintext.txt	225	1994 Protection Alzheimers disease apoE epsilon 2
0.3494895.15385439.html.plaintext.txt	226	1997 Lack apolipoprotein E dramatically reduces amyloid beta peptide deposition
0.3494895.15385439.html.plaintext.txt	227	2000 Apolipoprotein E isoform dependent amyloid deposition neuritic degeneration mouse model Alzheimers disease
0.3494895.15385439.html.plaintext.txt	228	2002 Contributions 18 additional DNA sequence variations gene encoding apolipoprotein E explaining variation quantitative measures lipid metabolism
0.3494895.15385439.html.plaintext.txt	229	1997 Distortion allelic expression apolipoprotein E Alzheimers disease
0.3494895.15385439.html.plaintext.txt	230	1999 Lack allelic imbalance APOE epsilon34 brain mRNA expression Alzheimers disease
0.3494895.15385439.html.plaintext.txt	231	1998 Polymorphism regulatory region APOE associated risk Alzheimers dementia
0.3494895.15385439.html.plaintext.txt	232	1998 A new polymorphism APOE promoter associated risk developing Alzheimers disease
0.3494895.15385439.html.plaintext.txt	233	2002 Contribution APOE promoter polymorphisms Alzheimers disease risk
0.3494895.15385439.html.plaintext.txt	234	1998 Allelic polymorphisms transcriptional regulatory region apolipoprotein E gene
0.3494895.15385439.html.plaintext.txt	235	2002 Allelic variation human gene expression
0.3494895.15385439.html.plaintext.txt	236	2003 A haplotype implicated schizophrenia susceptibility associated reduced COMT expression human brain
0.3494895.15385439.html.plaintext.txt	237	2001 High expression apolipoprotein E mRNA brains sporadic Alzheimers disease
0.3494895.15385439.html.plaintext.txt	238	2003 APOE epsilon 3epsilon 4 heterozygotes elevated proportion apolipoprotein E4 cerebrospinal fluid relative plasma independent Alzheimers disease diagnosis
0.3494895.15385439.html.plaintext.txt	239	2000 Independent association APOE gene promoter polymorphism increased risk myocardial infarction decreased APOE plasma concentrations ECTIM study
0.3494895.15385439.html.plaintext.txt	240	1999 The 491AA polymorphism APOE gene associated increased plasma apoE levels Alzheimers disease
0.3494895.15385439.html.plaintext.txt	241	2002 Variation APOE 491 promoter locus associated altered brain levels apolipoprotein E
0.3494895.15385439.html.plaintext.txt	242	1990 Restriction isotyping human apolipoprotein E gene amplification cleavage Hha1
0.3494895.15385439.html.plaintext.txt	243	2000 Cheap accurate rapid allele frequency estimation single nucleotide polymorphisms primer extension DHPLC DNA pools
0.3494895.15385439.html.plaintext.txt	244	2000 Model free analysis permutation tests allelic associations
0.29108343.15269218.html.plaintext.txt	0	Deficiency ABCA1 Impairs Apolipoprotein E Metabolism Brain Veronica Hirsch Reinshagen Steven Zhou Braydon L
0.29108343.15269218.html.plaintext.txt	1	Burgess Lise Bernier Sean A
0.29108343.15269218.html.plaintext.txt	2	From Department Pathology Laboratory Medicine University British Columbia Vancouver V5Z 4H4 Canada Clinical Research Institute Montreal Montreal H2W 1R7 Canada Centre Molecular Medicine Therapeutics University British Columbia Vancouver V5Z 4H4 Canada
0.29108343.15269218.html.plaintext.txt	3	Received publication July 14 2004
0.29108343.15269218.html.plaintext.txt	4	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES ABCA1 cholesterol transporter widely expressed throughout body
0.29108343.15269218.html.plaintext.txt	5	Outside central nervous system CNS ABCA1 functions biogenesis high density lipoprotein HDL mediates efflux cholesterol phospholipids apolipoprotein apo A I
0.29108343.15269218.html.plaintext.txt	6	Deficiency ABCA1 results lack circulating HDL greatly reduced levels apoA I
0.29108343.15269218.html.plaintext.txt	7	ABCA1 also expressed cells within CNS roles brain lipid metabolism yet fully understood
0.29108343.15269218.html.plaintext.txt	8	In brain glia synthesize apolipoproteins involved CNS lipid metabolism
0.29108343.15269218.html.plaintext.txt	9	Here demonstrate glial ABCA1 required cholesterol efflux apoA I plays key role facilitating cholesterol efflux apoE major apolipoprotein brain
0.29108343.15269218.html.plaintext.txt	10	In astrocytes microglia ABCA1 deficiency reduces lipid efflux exogenous apoE
0.29108343.15269218.html.plaintext.txt	11	The impaired ability efflux lipids ABCA1 glia results lipid accumulation astrocytes microglia normal culture conditions
0.29108343.15269218.html.plaintext.txt	12	Additionally apoE secretion compromised ABCA1 astrocytes microglia
0.29108343.15269218.html.plaintext.txt	13	In vivo deficiency ABCA1 results 65 decrease apoE levels whole brain 75 80 decrease apoE levels hippocampus striatum
0.29108343.15269218.html.plaintext.txt	14	Additionally effect ABCA1 apoE selective apoJ levels unchanged brains ABCA1 mice
0.29108343.15269218.html.plaintext.txt	15	Taken together results show glial ABCA1 key influence apoE metabolism CNS
0.29108343.15269218.html.plaintext.txt	16	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES ABCA1 member ATP binding cassette superfamily transporters transport substrates across membranes 1 3
0.29108343.15269218.html.plaintext.txt	17	A major biochemical function ABCA1 transport cholesterol phospholipids plasma membrane peripheral cells lipid free lipid poor apolipoprotein A I apoA I reverse cholesterol transport 1 process constitutes initial step biogenesis high density lipoproteins HDL1 peripheral circulation
0.29108343.15269218.html.plaintext.txt	18	Mutation one ABCA1 allele causes familial hypoalphalipoproteinemia FHA mild disorder lipid metabolism characterized reduced plasma HDL levels 4
0.29108343.15269218.html.plaintext.txt	19	Mutation alleles ABCA1 results Tangier Disease TD characterized nearly complete absence plasma HDL deposition intracellular cholesterol esters increased risk cardiovascular disease 4 6
0.29108343.15269218.html.plaintext.txt	20	Conversely overexpression ABCA1 mice increases plasma HDL protects atherosclerosis 7 9
0.29108343.15269218.html.plaintext.txt	21	ABCA1 abundant liver macrophages expression induced agonists liver X receptorretinoid X receptor LXRRXR pathways 10 16
0.29108343.15269218.html.plaintext.txt	22	ABCA1 also expressed glia neurons central nervous system CNS particularly abundant Purkinje cells large pyramidal cortical neurons 10 17 18
0.29108343.15269218.html.plaintext.txt	23	Similar non CNS cells ABCA1 induced LXRRXR stimulation primary neurons astrocytes microglia 18 20
0.29108343.15269218.html.plaintext.txt	24	The importance lipid homeostasis CNS underscored fact brain cholesterol rich organ body contains 25 total body cholesterol 2 total body weight 21
0.29108343.15269218.html.plaintext.txt	25	Nearly brain cholesterol synthesized situ quantitative analyses show essentially cholesterol crosses blood brain barrier 21
0.29108343.15269218.html.plaintext.txt	26	In contrast brain cannot degrade cholesterol excess cholesterol must delivered peripheral circulation eventual excretion via liver
0.29108343.15269218.html.plaintext.txt	27	Approximately 6 7 mg cholesterol leaves human brain day conversion 24S hydroxycholesterol easily traverses blood brain barrier 22 24
0.29108343.15269218.html.plaintext.txt	28	Glial cells play crucial roles regulating lipid homeostasis CNS
0.29108343.15269218.html.plaintext.txt	29	Astrocytes microglia cells within CNS synthesize secrete apolipoproteins transport lipids within brain cerebrospinal fluid CSF 25 27
0.29108343.15269218.html.plaintext.txt	30	Apolipoprotein E apoE major apolipoprotein brain also component several lipoproteins peripheral circulation including HDL low density lipoproteins VLDL chylomicrons 28 30
0.29108343.15269218.html.plaintext.txt	31	In humans apoE exists one three allelic variants contain either cysteine arginine residue amino acids 112 158 31
0.29108343.15269218.html.plaintext.txt	32	Liver transplantation experiments humans shown allelic variant apoE plasma converted donor whereas apoE CSF retains allelic identity recipient illustrating CNS non CNS apoE pools synthesized independently 32
0.29108343.15269218.html.plaintext.txt	33	Additionally brain perfusion experiments guinea pigs shown radiolabeled apoE administered peripheral circulation demonstrates low blood brain transport 33 providing additional support independent regulation CNS non CNS apoE pools
0.29108343.15269218.html.plaintext.txt	34	ApoJ second major CNS lipoprotein unlike apoE easily traverses blood brain barrier associates HDL periphery 26 33 34
0.29108343.15269218.html.plaintext.txt	35	ApoE apoJ synthesized secreted astrocytes microglia expression apoE apoJ induced response CNS injury disease 24 26
0.29108343.15269218.html.plaintext.txt	36	ApoE thought coordinate mobilization redistribution cholesterol repair maintenance neuronal membranes myelin 35 37 whereas apoJ may function cytoprotective extracellular chaperone 38
0.29108343.15269218.html.plaintext.txt	37	In contrast apoE apoJ apoA I primarily taken brain outside CNS believed involved maturation lipoprotein particles CSF 26 39
0.29108343.15269218.html.plaintext.txt	38	In 1993 apoE discovered important genetic risk factor Alzheimers disease AD finding replicated 100 studies
0.29108343.15269218.html.plaintext.txt	39	Inheritance apoE4 increases risk AD dosage specific manner may act decreasing age onset AD 40 41
0.29108343.15269218.html.plaintext.txt	40	In contrast inheritance apoE2 appears protect AD associated later age onset 42
0.29108343.15269218.html.plaintext.txt	41	Many hypotheses proposed explain apoE participates pathogenesis AD including roles apoE formation deposition clearance A peptides constitute amyloid plaques 43 51
0.29108343.15269218.html.plaintext.txt	42	For example apoE binds A vivo required amyloid deposition 50 53
0.29108343.15269218.html.plaintext.txt	43	Furthermore apoE affects deposition A isoform specific manner mice expressing human apoE4 develop least 2
0.29108343.15269218.html.plaintext.txt	44	5 fold A deposits mice expressing human apoE3 per unit area 45 49 53 54
0.29108343.15269218.html.plaintext.txt	45	Interestingly replacement murine apoE human apoE isoforms completely suppresses A deposition compared wild type mice expressing endogenous murine apoE 49 55 suggesting distinctions human murine apoE may play important roles A deposition andor clearance
0.29108343.15269218.html.plaintext.txt	46	Compared apoE role apoJ AD less well understood although known apoJ also binds A suggested play major role transporting A across blood brain barrier 33 34
0.29108343.15269218.html.plaintext.txt	47	Both ABCA1 apoE shown induced response LXRRXR stimulation 15 16 20 56 57 repressed ZN202 58 peripheral macrophages
0.29108343.15269218.html.plaintext.txt	48	Previous work demonstrated apoE robust acceptor lipids ABCA1 59 60 raising question whether ABCA1 mediated lipid efflux may play important roles brain apoE predominant apolipoprotein
0.29108343.15269218.html.plaintext.txt	49	Furthermore antisense inhibition ABCA1 observed inhibit secretion apoE monocyte derived macrophages 61 raising second question whether ABCA1 may also regulate apoE synthesis secretion apoE producing cells astrocytes microglia
0.29108343.15269218.html.plaintext.txt	50	To address two questions sought determine relationship ABCA1 cholesterol efflux apoE metabolism specifically glia
0.29108343.15269218.html.plaintext.txt	51	In study report ABCA1 deficient primary astrocytes microglia impaired ability efflux lipids exogenous apoE results lipid accumulation normal culture conditions
0.29108343.15269218.html.plaintext.txt	52	Furthermore lack ABCA1 expression decreases apoE secretion glial cells vitro
0.29108343.15269218.html.plaintext.txt	53	In vivo impairment apoE secretion astrocytes microglia results decrease apoE levels 65 whole brain lysates ABCA1 deficient mice hippocampus striatum severely affected regions
0.29108343.15269218.html.plaintext.txt	54	Our observations show ABCA1 plays key roles cholesterol transport apoE metabolism CNS
0.29108343.15269218.html.plaintext.txt	55	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Mice ABCA1 deficient mice generously provided Dr
0.29108343.15269218.html.plaintext.txt	56	Omar Francone Pfizer Global Research Development Groton
0.29108343.15269218.html.plaintext.txt	57	Wild type DBA1J C57Bl6 apoE deficient apoA I deficient mice obtained Jackson Laboratories
0.29108343.15269218.html.plaintext.txt	58	Animals maintained regular chow PMI Lab Diet experiments
0.29108343.15269218.html.plaintext.txt	59	All procedures involving experimental animals performed accordance protocols Canadian Council Animal Care University British Columbia Animal Care Committees
0.29108343.15269218.html.plaintext.txt	60	Animal Tissues Murine brains harvested immediately sacrifice dissected individual regions indicated stored 80 degrees C use
0.29108343.15269218.html.plaintext.txt	61	Tissues homogenized buffer containing 10 glycerol 1 Triton X 100 protease inhibitor Roche Applied Science phosphate buffered saline PBS
0.29108343.15269218.html.plaintext.txt	62	Protein concentration determined Lowry assay
0.29108343.15269218.html.plaintext.txt	63	Culture Primary Astrocytes Microglia Primary mixed glial cultures prepared postnatal day 1 2 mice
0.29108343.15269218.html.plaintext.txt	64	Brains individual animals placed ice cold Hanks Buffered Salt Solution Canadian Life Technologies containing 6 mgml glucose 10 mM HEPES
0.29108343.15269218.html.plaintext.txt	65	Meninges removed frontal cortices dissected cells dissociated repeated passage series wide fine bored pipettes
0.29108343.15269218.html.plaintext.txt	66	Dissociated cells plated Dulbeccos modified Eagles medium DMEM Canadian Life Technologies 10 fetal bovine serum 10 horse serum 2 mM L glutamine Canadian Life Technologies 100 unitsml penicillin streptomycin Canadian Life Technologies one T75 flask per mouse
0.29108343.15269218.html.plaintext.txt	67	Cells cultured presence 5 CO2 14 days 3 medium changes
0.29108343.15269218.html.plaintext.txt	68	After reaching confluence microglia isolated gently tapping culture flasks collecting medium detached cells
0.29108343.15269218.html.plaintext.txt	69	Subsequently attached microglia separated astrocytes mild trypsinization previously described 62 added previously isolated cells
0.29108343.15269218.html.plaintext.txt	70	Microglia enriched astrocytes reseeded needed
0.29108343.15269218.html.plaintext.txt	71	Immunofluorescence Cells seeded poly D lysine coated coverslips washed twice PBS fixed 4 paraformaldehyde PBS 20 min room temperature washed twice permeabilized 0
0.29108343.15269218.html.plaintext.txt	72	5 Triton X 100 PBS 5 min room temperature
0.29108343.15269218.html.plaintext.txt	73	After washing three times PBS cells blocked 4 normal goat serum PBS 30 min room temperature stained astrocyte marker GFAP Cy3 1250 Sigma microglial marker F480 1200 Serotec 1 h
0.29108343.15269218.html.plaintext.txt	74	F480 stained cells visualized incubation Alexa 488 conjugated secondary antibody Transduction Laboratories 30 min
0.29108343.15269218.html.plaintext.txt	75	Finally cell nuclei stained 46 diamidine 2 phenylindole dihydrochloride DAPI coverslips mounted Vectashield Vector Laboratories
0.29108343.15269218.html.plaintext.txt	76	The percentage stained cells determined least 200 cells
0.29108343.15269218.html.plaintext.txt	77	Cells viewed Zeiss Axioplan 2 microscope images captured using CCD camera equipped Metamorph Universal Imaging Corporation imaging software
0.29108343.15269218.html.plaintext.txt	78	Western Blotting Equal amounts protein electrophoresed 7
0.29108343.15269218.html.plaintext.txt	79	5 10 SDS polyacrylamide gels electrophoretically transferred polyvinylidene fluoride membrane Millipore immunodetected using monoclonal anti ABCA1 antibody raised second nucleotide binding domain NBD2 ABCA1 10 murine specific apoE antibody Santa Cruz Biotechnology 1500 polyclonal antibody murine apoJ 1250 generously provided Dr
0.29108343.15269218.html.plaintext.txt	80	David Holtzman Washington University School Medicine anti GAPDH antibody Chemicon 110000 loading control
0.29108343.15269218.html.plaintext.txt	81	Blots developed using enhanced chemiluminescence Amersham Biosciences according manufacturers recommendations
0.29108343.15269218.html.plaintext.txt	82	Bands quantitated densitometry using NIH Image J
0.29108343.15269218.html.plaintext.txt	83	Where applicable apoE apoJ ABCA1 levels normalized GAPDH levels control protein loading
0.29108343.15269218.html.plaintext.txt	84	Purification Recombinant apoE Proteins ApoE isoforms purified Escherichia coli harboring recombinant glutathione S transferase GST apoE2 apoE3 apoE4 fusion proteins described 63
0.29108343.15269218.html.plaintext.txt	85	Briefly logarithmic phase cells induced 0
0.29108343.15269218.html.plaintext.txt	86	5 mM isopropyl 1 thio D galactopyranoside 1 h harvested centrifugation lysed sonication 1
0.29108343.15269218.html.plaintext.txt	87	0 Triton X 100 10 glycerol PBS 200 microgml lysozyme cleared centrifugation
0.29108343.15269218.html.plaintext.txt	88	GST apoE fusion proteins cleared lysates purified glutathione Sepharose 4B beads eluted upon cleavage GST moiety Precision Protease Amersham Biosciences
0.29108343.15269218.html.plaintext.txt	89	Where indicated purified apoE proteins delipidated 6 M urea followed dialysis several changes PBS
0.29108343.15269218.html.plaintext.txt	90	Cholesterol Efflux Microglia enriched astrocytes seeded 50000 cellswell 96 well plates labeled 1 microCiml 3H cholesterol PerkinElmer Life Sciences 18 24 h
0.29108343.15269218.html.plaintext.txt	91	Labeled cells washed equilibrated DMEMF12 1 h 10 microgml lipid free apoA I Calbiochem recombinant apoE2 apoE3 apoE4 added 8 h
0.29108343.15269218.html.plaintext.txt	92	Media collected centrifuged 2000 rpm 5 min
0.29108343.15269218.html.plaintext.txt	93	Cells lysed addition 50 microl 0
0.29108343.15269218.html.plaintext.txt	94	2 SDS followed incubation room temperature 20 min
0.29108343.15269218.html.plaintext.txt	95	50 microl media cell lysate added scintillation vials quantified
0.29108343.15269218.html.plaintext.txt	96	Percent cholesterol efflux calculated total counts medium divided sum counts medium plus cell lysate previously described 64
0.29108343.15269218.html.plaintext.txt	97	Lipid Staining Cells seeded 24 well plates poly D lysine coated coverslips 100000 cellswell microglia 200000 cellswell astrocytes
0.29108343.15269218.html.plaintext.txt	98	After least 18 h DMEM containing 10 fetal bovine serum 10 horse serum cells air dried fixed neutral buffered formalin stained Oil red O
0.29108343.15269218.html.plaintext.txt	99	Nuclei counterstained hematoxylin
0.29108343.15269218.html.plaintext.txt	100	Cells photographed Zeiss Axioplan 2 microscope using CCD camera equipped Metamorph Universal Imaging Corporation imaging software
0.29108343.15269218.html.plaintext.txt	101	Measurement Apolipoprotein Secretion Microglia astrocytes seeded 96 well plates 50000 cellswell 100000 cellswell respectively
0.29108343.15269218.html.plaintext.txt	102	After 18 h cells washed PBS cultured serum free DMEMF12 Canadian Life Technologies 6 h microglia 8 h astrocytes
0.29108343.15269218.html.plaintext.txt	103	Conditioned medium collected centrifuged 2000 rpm 4 min supernatant stored 80 degrees C use
0.29108343.15269218.html.plaintext.txt	104	Cells scraped lysed buffer containing 10 glycerol 1 Triton X 100 protease inhibitor Roche Applied Science PBS centrifuged 9000 rpm 10 min
0.29108343.15269218.html.plaintext.txt	105	The supernatant stored 80 degrees C use
0.29108343.15269218.html.plaintext.txt	106	Media cell lysate samples analyzed apoE apoJ ABCA1 GAPDH expression Western blot described
0.29108343.15269218.html.plaintext.txt	107	Intracellular GAPDH levels used normalize measurements cellular secreted apoE
0.29108343.15269218.html.plaintext.txt	108	Statistical Analysis One way ANOVA Newman Keuls post test two tailed unpaired Students tests used statistical analyses
0.29108343.15269218.html.plaintext.txt	109	In Students test analyses Welchs correction unequal variances applied variances significantly different groups
0.29108343.15269218.html.plaintext.txt	110	Where indicated apoE ABCA1 levels correlated using linear regression analyses
0.29108343.15269218.html.plaintext.txt	111	All statistical analyses performed using Graphpad Prism version 3
0.29108343.15269218.html.plaintext.txt	112	0 Graphpad Software Science Inc
0.29108343.15269218.html.plaintext.txt	113	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Glial ABCA1 Mediates Cholesterol Efflux apoA I Facilitates Efflux apoE Several studies non CNS cells established ABCA1 promotes cholesterol phospholipid efflux lipid deficient apolipoproteins including apoA I apoE others 59 65 66
0.29108343.15269218.html.plaintext.txt	114	Whether ABCA1 functions similarly CNS cells yet completely understood
0.29108343.15269218.html.plaintext.txt	115	Previous work shown ABCA1 expressed glia neurons brain 10 17 LXRRXR stimulation primary glia promotes cholesterol efflux apoA I apoE3 18
0.29108343.15269218.html.plaintext.txt	116	However specific role ABCA1 promoting cholesterol efflux glial cells yet clear expression genes addition ABCA1 also induced LXRRXR treatment 56 67 68
0.29108343.15269218.html.plaintext.txt	117	To selectively address role ABCA1 cholesterol efflux glial cells primary cultures astrocytes microglia prepared ABCA1 mice wild type littermate controls maintained absence LXRRXR treatment cholesterol loading
0.29108343.15269218.html.plaintext.txt	118	The presence ABCA1 protein wild type ABCA1 cultures first confirmed using immunoblotting Fig
0.29108343.15269218.html.plaintext.txt	119	The purity astrocyte microglial cultures used experiments evaluated immunofluorescent staining using anti GFAP anti F480 specifically label astrocytes microglia respectively
0.29108343.15269218.html.plaintext.txt	120	Experimental cultures least 85 pure astrocytes 98 pure microglia data shown
0.29108343.15269218.html.plaintext.txt	121	View larger version 17K FIG
0.29108343.15269218.html.plaintext.txt	122	Cholesterol efflux impaired ABCA1 glial cells
0.29108343.15269218.html.plaintext.txt	123	A ABCA1 expression wild type ABCA1 primary astrocytes left microglia right first determined Western blotting using ABCA1 specific antibody
0.29108343.15269218.html.plaintext.txt	124	GAPDH lower panels served control equal protein loading
0.29108343.15269218.html.plaintext.txt	125	Efflux 8 h presence absence 10 microgml exogenous apoA1 apoE2 apoE3 apoE4 evaluated wild type ABCA1 astrocytes B microglia C
0.29108343.15269218.html.plaintext.txt	126	least two independent experiments least six individual mice per genotype
0.29108343.15269218.html.plaintext.txt	127	One way ANOVA Newman Keuls post test used determine significant increases cholesterol efflux baseline
0.29108343.15269218.html.plaintext.txt	128	The role glial ABCA1 cholesterol efflux exogenous apoA I apoE isoforms apoE2 apoE3 apoE4 determined primary wild type ABCA1 astrocytes microglia
0.29108343.15269218.html.plaintext.txt	129	Cholesterol efflux measured absence apolipoprotein acceptors presence recombinant human apoA I apoE2 apoE3 apoE4 8 h
0.29108343.15269218.html.plaintext.txt	130	Because preliminary experiments mixed glial cultures showed difference cholesterol efflux presence either native delipidated apoE3 data shown native apoE proteins used subsequent experiments
0.29108343.15269218.html.plaintext.txt	131	The effect different apolipoprotein acceptors cholesterol efflux wild type ABCA1 astrocytes microglia illustrated Fig
0.29108343.15269218.html.plaintext.txt	132	As expected ABCA1 required astrocytes efflux cholesterol exogenous apoA I
0.29108343.15269218.html.plaintext.txt	133	Under experimental conditions wild type astrocytes displayed 2
0.29108343.15269218.html.plaintext.txt	134	5 fold increase cholesterol efflux upon apoA I addition whereas ABCA1 astrocytes show higher efflux apoA I compared baseline p 0
0.29108343.15269218.html.plaintext.txt	135	In wild type astrocytes addition apoE2 apoE3 apoE4 resulted 2
0.29108343.15269218.html.plaintext.txt	136	6 fold increase cholesterol efflux similar magnitude elicited apoA I
0.29108343.15269218.html.plaintext.txt	137	In contrast cholesterol efflux elicited apoE isoform 30 less ABCA1 cells compared wild type astrocytes corrected differences baseline efflux Table I
0.29108343.15269218.html.plaintext.txt	138	These observations suggest ABCA1 astrocytes facilitates lipid efflux exogenous apoE
0.29108343.15269218.html.plaintext.txt	139	However ABCA1 absolutely required efflux cholesterol apoE residual efflux activity 1
0.29108343.15269218.html.plaintext.txt	140	8 fold remained absence ABCA1
0.29108343.15269218.html.plaintext.txt	141	These observations suggest genes addition ABCA1 also contribute cholesterol efflux astrocytes
0.29108343.15269218.html.plaintext.txt	142	Comparison among apoE isoforms suggested apoE2 less effective cholesterol acceptor apoE3 apoE4 wild type ABCA1 astrocytes whereas significant differences observed efflux apoE3 apoE4 Fig
0.29108343.15269218.html.plaintext.txt	143	Compared wild type astrocytes ABCA1 astrocytes significantly impaired ability efflux cholesterol apoA I apoE isoform p 0
0.29108343.15269218.html.plaintext.txt	144	View table TABLE I Cholesterol efflux different apolipoproteins WT ABCA1 glia
0.29108343.15269218.html.plaintext.txt	145	We noted fold increase cholesterol efflux apoA I consistently greater wild type astrocytes compared microglia cultured animals 2
0.29108343.15269218.html.plaintext.txt	146	Because experiments conducted absence LXRRXR stimulation order selectively examine effect ABCA1 cholesterol efflux possible conditions astrocytes express components pathway necessary efficient cholesterol efflux apoA I whereas additional factors may required elicit strong efflux response apoA I microglia
0.29108343.15269218.html.plaintext.txt	147	Although surprisingly low efflux exogenous apoA I 1
0.29108343.15269218.html.plaintext.txt	148	2 fold observed primary wild type microglia cells display significant cholesterol efflux apoE2 1
0.29108343.15269218.html.plaintext.txt	149	Wild type microglia showed poor efflux presence apoE4 1
0.29108343.15269218.html.plaintext.txt	150	5 fold reach statistical significance baseline Fig
0.29108343.15269218.html.plaintext.txt	151	Deficiency ABCA1 microglia blocked efflux apoA I impaired cholesterol efflux 15 apoE2 apoE3 p 0
0.29108343.15269218.html.plaintext.txt	152	05 compared wild type cells
0.29108343.15269218.html.plaintext.txt	153	Each apoE isoform still able elicit residual efflux activity 1
0.29108343.15269218.html.plaintext.txt	154	6 fold ABCA1 microglia Fig
0.29108343.15269218.html.plaintext.txt	155	1C Table I suggesting microglia also contain ABCA1 independent pathways efflux lipid apoE
0.29108343.15269218.html.plaintext.txt	156	For wild type ABCA1 microglia apoE3 tended best acceptor although statistically significant difference observed among apoE isoform tested
0.29108343.15269218.html.plaintext.txt	157	Taken together results suggest ABCA1 facilitates cholesterol efflux apoE required cholesterol efflux apoA I astrocytes microglia
0.29108343.15269218.html.plaintext.txt	158	Additionally astrocytes microglia appear contain ABCA1 independent pathways efflux cholesterol apoE
0.29108343.15269218.html.plaintext.txt	159	In astrocytes apoE good cholesterol acceptor apoA I whereas apoE appears preferred acceptor microglia
0.29108343.15269218.html.plaintext.txt	160	Lack ABCA1 Results Lipid Accumulation Astrocytes Microglia To determine elimination ABCA1 dependent efflux pathways results cellular lipid accumulation glia subjected wild type ABCA1 primary astrocytes microglia Oil Red O staining
0.29108343.15269218.html.plaintext.txt	161	Under normal culture conditions lipids accumulate efflux competent wild type astrocytes Fig
0.29108343.15269218.html.plaintext.txt	162	2A small lipid droplets observed wild type microglia Fig
0.29108343.15269218.html.plaintext.txt	163	In contrast ABCA1 astrocytes microglia accumulated numerous cytoplasmic lipid droplets particularly abundant microglia Fig
0.29108343.15269218.html.plaintext.txt	164	These observations suggest ABCA1 required prevent excessive accumulation lipids glial cells even absence cholesterol loading
0.29108343.15269218.html.plaintext.txt	165	View larger version 124K FIG
0.29108343.15269218.html.plaintext.txt	166	ABCA1 deficient glia accumulate lipids
0.29108343.15269218.html.plaintext.txt	167	Primary wild type WT ABCA1 astrocytes A B microglia C D stained Oil Red O reveal accumulated neutral lipids nuclei counterstained hematoxylin blue
0.29108343.15269218.html.plaintext.txt	168	Images taken x200 magnification
0.29108343.15269218.html.plaintext.txt	169	A B compared wild type astrocytes ABCA1 astrocytes show increased intracellular levels neutral lipids red droplets
0.29108343.15269218.html.plaintext.txt	170	C D microglia showing marked accumulation lipid droplets absence ABCA1 compared wild type cells
0.29108343.15269218.html.plaintext.txt	171	ABCA1 Facilitates apoE Secretion Astrocytes Microglia Antisense inhibition ABCA1 expression previously reported reduce apoE secretion peripheral macrophages 61
0.29108343.15269218.html.plaintext.txt	172	To assess role ABCA1 apoE secretion glial cells first determined levels intracellular apoE well levels apoE secreted conditioned medium
0.29108343.15269218.html.plaintext.txt	173	Initial experiments conducted using medium conditioned 72 h differences secreted apoE levels observed wild type ABCA1 glia data shown
0.29108343.15269218.html.plaintext.txt	174	Because astrocytes microglia express apoE receptors known take resecrete apoE hypothesized 72 h apoE medium may arisen newly synthesized apoE well resecreted apoE
0.29108343.15269218.html.plaintext.txt	175	We therefore examined apoE secretion astrocytes microglia 6 8 h respectively order minimize effect resecreted apoE
0.29108343.15269218.html.plaintext.txt	176	For well intracellular GAPDH levels used control small variations total number cells per well
0.29108343.15269218.html.plaintext.txt	177	Intracellular levels apoE equivalent wild type ABCA1 astrocytes Fig
0.29108343.15269218.html.plaintext.txt	178	In contrast ABCA1 conditioned media contained 50 less apoE wild type Fig
0.29108343.15269218.html.plaintext.txt	179	As well proportion total apoE released 8 h conditioned medium primary wild type ABCA1 astrocytes determined
0.29108343.15269218.html.plaintext.txt	180	This value defined apoE medium divided sum intracellular extracellular apoE thus correcting variations intracellular apoE levels
0.29108343.15269218.html.plaintext.txt	181	The proportion total apoE secreted conditioned medium reduced 30 ABCA1 compared wild type astrocytes Fig
0.29108343.15269218.html.plaintext.txt	182	View larger version 24K FIG
0.29108343.15269218.html.plaintext.txt	183	ABCA1 facilitates apoE secretion astrocytes
0.29108343.15269218.html.plaintext.txt	184	A ApoE levels conditioned medium upper panel whole cell lysates middle panel wild type ABCA1 primary astrocytes determined using polyclonal antibody murine apoE
0.29108343.15269218.html.plaintext.txt	185	Intracellular GAPDH lower panel detected control equal protein loading normalize small variations cell number measurement secreted apoE
0.29108343.15269218.html.plaintext.txt	186	Bands quantitated densitometry
0.29108343.15269218.html.plaintext.txt	187	Graphs illustrate four independent experiments N indicating number cultures prepared individual mice
0.29108343.15269218.html.plaintext.txt	188	apoE levels whole cell lysates B conditioned medium C astrocytes well proportion total apoE secreted medium D
0.29108343.15269218.html.plaintext.txt	189	Students test used determine significant differences apoE levels
0.29108343.15269218.html.plaintext.txt	190	Welchs correction applied necessary
0.29108343.15269218.html.plaintext.txt	191	ABCA1 pronounced effect apoE metabolism microglia
0.29108343.15269218.html.plaintext.txt	192	Compared wild type microglia deficiency ABCA1 resulted 35 decrease intracellular apoE levels Fig
0.29108343.15269218.html.plaintext.txt	193	06 90 decrease secreted apoE levels Fig
0.29108343.15269218.html.plaintext.txt	194	05 resulted 60 overall reduction proportion total apoE secreted conditioned media Fig
0.29108343.15269218.html.plaintext.txt	195	View larger version 22K FIG
0.29108343.15269218.html.plaintext.txt	196	ABCA1 microglia impaired apoE secretion
0.29108343.15269218.html.plaintext.txt	197	A ApoE levels conditioned medium upper panel whole cell lysates middle panel wild type ABCA1 primary microglia determined using polyclonal antibody murine apoE
0.29108343.15269218.html.plaintext.txt	198	Intracellular GAPDH lower panel detected control equal protein loading normalize variations total cell number measurements secreted apoE
0.29108343.15269218.html.plaintext.txt	199	Bands quantitated densitometry
0.29108343.15269218.html.plaintext.txt	200	Graphs illustrate least two independent experiments N indicates number cultures prepared individual mice
0.29108343.15269218.html.plaintext.txt	201	apoE levels microglial whole cell lysates B conditioned medium C well proportion total apoE secreted medium D
0.29108343.15269218.html.plaintext.txt	202	Students test used determine significant differences apoE levels
0.29108343.15269218.html.plaintext.txt	203	Welchs correction applied necessary
0.29108343.15269218.html.plaintext.txt	204	ApoE Secretion Wild type Microglia Correlates ABCA1 Expression Levels Despite consistent culture conditions noted wild type microglia cultured individual animals displayed surprisingly large variability apoE levels particularly apoE secreted medium
0.29108343.15269218.html.plaintext.txt	205	Because ABCA1 previously shown affect apoE secretion macrophages 61 hypothesized ABCA1 expression levels may influence extent apoE secreted microglia derived lineage peripheral macrophages
0.29108343.15269218.html.plaintext.txt	206	To assess possibility ABCA1 expression levels microglia determined immunoblotting
0.29108343.15269218.html.plaintext.txt	207	Basal ABCA1 protein levels wild type microglia found highly variable among equivalent amounts wild type microglia prepared individual mice
0.29108343.15269218.html.plaintext.txt	208	Furthermore ABCA1 levels correlated highly apoE secretion r2 0
0.29108343.15269218.html.plaintext.txt	209	5A apoE intracellular levels r2 0
0.29108343.15269218.html.plaintext.txt	210	In contrast microglia intracellular medium apoE levels ABCA1 expression levels far consistent among independent primary cultures wild type astrocytes
0.29108343.15269218.html.plaintext.txt	211	However slight variations levels ABCA1 protein positively correlated medium r2 0
0.29108343.15269218.html.plaintext.txt	212	Taken together results provide support role ABCA1 secretion apoE particularly microglia
0.29108343.15269218.html.plaintext.txt	213	Finally microglia showed far greater range ABCA1 apoE levels media cells compared astrocytes Fig
0.29108343.15269218.html.plaintext.txt	214	View larger version 24K FIG
0.29108343.15269218.html.plaintext.txt	215	ABCA1 expression correlated secreted intracellular apoE levels wild type glia
0.29108343.15269218.html.plaintext.txt	216	ABCA1 apoE levels wild type microglia A B astrocytes C D normalized intracellular GAPDH levels correlated using linear regression analysis
0.29108343.15269218.html.plaintext.txt	217	Graphs secreted A C intracellular B D apoE represent pooled data least three independent experiments N indicating number cultures prepared individual mice
0.29108343.15269218.html.plaintext.txt	218	ApoE Levels Are Reduced Brain ABCA1 deficient Mice The results presented led us hypothesize ABCA1 may play prominent role regulation apoE homeostasis murine brain
0.29108343.15269218.html.plaintext.txt	219	To assess impact ABCA1 deficiency apoE levels vivo first compared apoE protein levels whole brain extracts prepared age sex matched ABCA1 mice wild type littermate controls DBA1J genetic background
0.29108343.15269218.html.plaintext.txt	220	Because genetic strain profound effects murine lipids lipoproteins 69 70 whole brain extracts age sex matched apoE deficient wild type controls pure C57Bl6 genetic background also prepared additional controls
0.29108343.15269218.html.plaintext.txt	221	Western blot analysis showed apoE levels whole brains male ABCA1 mice reduced 65 compared wild type DBA1J littermate controls p 0
0.29108343.15269218.html.plaintext.txt	222	01 well age sex matched wild type C57Bl6 mice p 0
0.29108343.15269218.html.plaintext.txt	223	There significant differences total brain apoE levels wild type DBA1J C57Bl6 mice Fig
0.29108343.15269218.html.plaintext.txt	224	Identical results obtained mice evaluated 2
0.29108343.15269218.html.plaintext.txt	225	5 months well 6 months age data shown
0.29108343.15269218.html.plaintext.txt	226	Compared wild type mice ABCA1 mice also 75 less apoE plasma data shown similar results reported Warhle et al
0.29108343.15269218.html.plaintext.txt	227	View larger version 26K FIG
0.29108343.15269218.html.plaintext.txt	228	ApoE levels reduced brain ABCA1 deficient mice
0.29108343.15269218.html.plaintext.txt	229	A B male mice WT DBA1J ABCA1 DBA1J apoE C57Bl6 WT C57Bl6 sacrificed 2
0.29108343.15269218.html.plaintext.txt	230	Gels representative total protein lysates prepared whole brain two individual mice per genotype
0.29108343.15269218.html.plaintext.txt	231	Tissue blots immunodetected ABCA1 upper panel apoE second panel GAPDH third panel apoJ fourth panel
0.29108343.15269218.html.plaintext.txt	232	GAPDH levels used control equal protein loading
0.29108343.15269218.html.plaintext.txt	233	Bands quantitated densitometry graph represents pooled data least four mice per genotype measured duplicate
0.29108343.15269218.html.plaintext.txt	234	One way ANOVA Newman Keuls post test used determine significant differences brain apoE levels
0.29108343.15269218.html.plaintext.txt	235	ApoJ second major brain lipoprotein synthesized secreted astrocytes microglia
0.29108343.15269218.html.plaintext.txt	236	To assess whether loss ABCA1 also affected metabolism apoJ total brain extracts wild type ABCA1 mice immunoblotted apoJ
0.29108343.15269218.html.plaintext.txt	237	In contrast apoE apoJ levels indistinguishable among ABCA1 wild type DBA1J littermate controls well apoE deficient wild type littermate C57Bl6 controls Fig
0.29108343.15269218.html.plaintext.txt	238	6A lower panel demonstrating ABCA1 selectively influences apoE metabolism vivo
0.29108343.15269218.html.plaintext.txt	239	To determine ABCA1 affected apoE levels region specific manner individual brain regions age sex matched ABCA1 mice wild type littermate controls examined Fig
0.29108343.15269218.html.plaintext.txt	240	Lack ABCA1 affected apoE levels severely hippocampus striatum apoE levels reduced 76 79 respectively Fig
0.29108343.15269218.html.plaintext.txt	241	ApoE levels reduced 61 thalamus 41 cortex Fig
0.29108343.15269218.html.plaintext.txt	242	In contrast ABCA1 least impact cerebellum apoE levels reduced 35 ABCA1 compared wild type mice Fig
0.29108343.15269218.html.plaintext.txt	243	View larger version 31K FIG
0.29108343.15269218.html.plaintext.txt	244	ABCA1 deficiency affects brain apoE levels region specific manner
0.29108343.15269218.html.plaintext.txt	245	A male mice WT DBA1J ABCA1 DBA1J sacrificed 3 months age individual brain regions dissected
0.29108343.15269218.html.plaintext.txt	246	ABCA1 upper panels ApoE middle panels detected region Western blot quantitated densitometry normalized GAPDH lower panels internal protein loading control
0.29108343.15269218.html.plaintext.txt	247	B graph represents mean S
0.29108343.15269218.html.plaintext.txt	248	two micegenotype measured duplicate
0.29108343.15269218.html.plaintext.txt	249	Students test used determine significant differences regional apoE levels
0.29108343.15269218.html.plaintext.txt	250	Because ABCA1 mice used studies lack circulating HDL apoA I loss peripheral ABCA1 activity 71 formally possible changes apoE levels observed brains ABCA1 mice simply due loss HDL apoA I primarily taken brain peripheral circulation 26
0.29108343.15269218.html.plaintext.txt	251	To address possibility apoE levels compared total brain extracts prepared age sex matched wild type apoA I deficient mice model characterized absent HDL apoA I
0.29108343.15269218.html.plaintext.txt	252	Deficiency apoA I impact apoE levels brain Fig
0.29108343.15269218.html.plaintext.txt	253	8 demonstrating lack circulating HDL apoA I ABCA1 mice sufficient alter brain apoE levels vivo
0.29108343.15269218.html.plaintext.txt	254	View larger version 48K FIG
0.29108343.15269218.html.plaintext.txt	255	ApoE levels affected apoA I deficiency
0.29108343.15269218.html.plaintext.txt	256	Total brain lysates 2 month old male mice WT C57Bl6 ApoA1 C57Bl6 apoE C57Bl6 immunodetected apoE upper panel GAPDH lower panel control equal protein loading
0.29108343.15269218.html.plaintext.txt	257	Western blot representative two micegenotype single apoE control
0.29108343.15269218.html.plaintext.txt	258	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES The identification ABCA1 essential protein production HDL generated great interest understanding ABCA1 function particularly tissues liver macrophages relevant HDL metabolism atherosclerosis
0.29108343.15269218.html.plaintext.txt	259	However nearly ubiquitous expression ABCA1 suggests may also play roles lipid transport cell types tissues
0.29108343.15269218.html.plaintext.txt	260	Lipid metabolism CNS largely independent outside CNS although several points intersection may highly relevant neurodegenerative diseases particularly AD
0.29108343.15269218.html.plaintext.txt	261	In study provide evidence lack glial ABCA1 activity results 65 decrease apoE levels vivo likely due reduced apoE secretion astrocytes microglia diminished pool intracellular apoE microglia
0.29108343.15269218.html.plaintext.txt	262	Additionally show ABCA1 facilitates cholesterol efflux exogenous apoE primary astrocytes microglia efflux reduced absence ABCA1 cell types
0.29108343.15269218.html.plaintext.txt	263	However astrocytes microglia may also contain ABCA1 independent pathways efflux cholesterol apoE residual efflux remains ABCA1 cells
0.29108343.15269218.html.plaintext.txt	264	Our findings agreement previous studies showing macrophage ABCA1 facilitates cholesterol efflux exogenous apoE 60 72
0.29108343.15269218.html.plaintext.txt	265	Under experimental conditions used efflux studies observe marked apoE isoform specificity pattern consistent astrocyte microglial cultures
0.29108343.15269218.html.plaintext.txt	266	In astrocyte cultures apoE2 slightly less potent acceptor apoE3 apoE4 trend observed microglial cultures significant differences observed efflux among apoE isoforms
0.29108343.15269218.html.plaintext.txt	267	Our findings contrast previous study suggesting apoE2 elicits cholesterol efflux apoE3 apoE4 73
0.29108343.15269218.html.plaintext.txt	268	The reasons findings differ previous work clear may due subtle differences culture preparation efflux protocol
0.29108343.15269218.html.plaintext.txt	269	In study show ABCA1 plays critical role secretion apoE astrocytes microglia
0.29108343.15269218.html.plaintext.txt	270	These observations confirm extend previous study ABCA1 found facilitate apoE secretion human monocyte derived macrophages 61
0.29108343.15269218.html.plaintext.txt	271	We also demonstrate ABCA1 positively correlated steady state levels intracellular apoE well apoE secreted medium measures dynamic processes
0.29108343.15269218.html.plaintext.txt	272	Steady state intracellular apoE levels reflect balance apoE synthesis degradation newly synthesized recycled apoE whereas secreted apoE levels reflect balance apoE released cell coupled reuptake apoE apoE receptors expressed astrocytes microglia
0.29108343.15269218.html.plaintext.txt	273	Although mechanisms ABCA1 affect apoE metabolism glial cells yet understood clear lack ABCA1 impairs proportion total apoE secreted medium astrocytes microglia
0.29108343.15269218.html.plaintext.txt	274	There several potential mechanisms ABCA1 may affect apoE metabolism may may linked functionally lipid efflux
0.29108343.15269218.html.plaintext.txt	275	ABCA1 known cycle plasma membrane late endosomal compartments 74 addition plasma membrane suggested ABCA1 may efflux cholesterol late endosomes lysosomes 65
0.29108343.15269218.html.plaintext.txt	276	Moreover apoA I recently reported internalized resecreted ABCA1 mediated cholesterol efflux 75
0.29108343.15269218.html.plaintext.txt	277	An increasing body evidence indicates internalized apoE undergo complete degradation resecreted 75 77
0.29108343.15269218.html.plaintext.txt	278	For example nascent lipoproteins recovered livers apoE mice transplanted wild type bone marrow model circulating apoE derived exclusively macrophages showed 60 internalized apoE may reutilized physiological conditions 78
0.29108343.15269218.html.plaintext.txt	279	Recently HDL3 shown stimulate recycling internalized apoE act extracellular acceptor recycled apoE hepatoma cells 76
0.29108343.15269218.html.plaintext.txt	280	In study apoE recycling accompanied cholesterol efflux involved internalization HDL3 derived apoA I targeting endosomes containing cholesterol apoE 76
0.29108343.15269218.html.plaintext.txt	281	Taken together observations suggest possibility apoE secretion recycling may coupled cholesterol efflux ABCA1 may play role process
0.29108343.15269218.html.plaintext.txt	282	It also possible speculate ABCA1 could influence apoE secretion affecting trafficking secretory recycling pathways
0.29108343.15269218.html.plaintext.txt	283	In respect plasma membrane associated ABCA1 may distinct function compared intracytoplasmic ABCA1
0.29108343.15269218.html.plaintext.txt	284	For example plasma membrane associated ABCA1 may function transport cholesterol phospholipids various extracellular apolipoprotein acceptors whereas intracytoplasmic ABCA1 may primarily participate intracellular lipid trafficking
0.29108343.15269218.html.plaintext.txt	285	Additionally known apoE requires prenylation order efficiently secreted 79 suggesting possibility impact ABCA1 prenylation pathways might also affect apoE secretion
0.29108343.15269218.html.plaintext.txt	286	Although much remains learned results provide support role ABCA1 apoE secretion
0.29108343.15269218.html.plaintext.txt	287	reported nascent particles released conditioned medium ABCA1 astrocytes contain less cholesterol wild type particles suggesting ABCA1 affects secretion lipidation apoE CNS
0.29108343.15269218.html.plaintext.txt	288	In vivo total apoE levels reduced 65 whole brains ABCA1 compared wild type animals indicating critical role ABCA1 maintaining normal apoE homeostasis CNS physiological conditions
0.29108343.15269218.html.plaintext.txt	289	Loss ABCA1 affects apoE levels severely hippocampus striatum whereas cortex thalamus moderately affected ABCA1 deficiency
0.29108343.15269218.html.plaintext.txt	290	ApoE levels cerebellum minimally reduced ABCA1 mice compared wild type controls
0.29108343.15269218.html.plaintext.txt	291	We hypothesize defective secretion apoE astrocytes microglia key factor underlies reduced apoE levels vivo
0.29108343.15269218.html.plaintext.txt	292	In absence ABCA1 astrocytes microglia secrete less apoE intracellular pool microglial apoE available secretion also lower
0.29108343.15269218.html.plaintext.txt	293	Interestingly elimination ABCA1 effect apoJ levels suggesting ABCA1 selectively regulates apoE metabolism rather general effect brain derived apolipoproteins
0.29108343.15269218.html.plaintext.txt	294	To knowledge whether deficiency human ABCA1 results changes CNS CSF levels apoE determined
0.29108343.15269218.html.plaintext.txt	295	The vivo reduction brain apoE levels coupled reduced ability ABCA1 glia maintain normal levels cholesterol efflux apoE secretion vitro suggests ABCA1 deficiency may impair normal brain function particularly response injury disease
0.29108343.15269218.html.plaintext.txt	296	ApoE expression known induced glial cells response neuronal injury believed participate lipid transport processes involved repairing neuronal membranes 36 80
0.29108343.15269218.html.plaintext.txt	297	Because ABCA1 deficiency results region specific reductions apoE levels brain possible speculate ABCA1 may play role recovery variety neurological insults facilitating lipid mobilization via apoE
0.29108343.15269218.html.plaintext.txt	298	Our observation ABCA1 mice significant reduction apoE levels brain creates paradox predictions role ABCA1 AD
0.29108343.15269218.html.plaintext.txt	299	In study provide first direct evidence glial ABCA1 affects apoE metabolism vivo vitro
0.29108343.15269218.html.plaintext.txt	300	Reduced levels apoE ABCA1 brains may predict greater susceptibility neuronal injury due decreased lipid mediated repair pathways yet lower levels apoE may also delay amyloid deposition
0.29108343.15269218.html.plaintext.txt	301	In addition glial ABCA1 neuronal ABCA1 may also participate AD affecting A generation
0.29108343.15269218.html.plaintext.txt	302	At present controversial whether ABCA1 increases decreases A generation two vitro studies reported increased ABCA1 expression reduced A production 18 81 whereas third study reported opposite finding 19
0.29108343.15269218.html.plaintext.txt	303	Genetic variations ABCA1 reported alter susceptibility AD 82 83 although additional studies necessary fully validate results
0.29108343.15269218.html.plaintext.txt	304	Clearly understanding contributions ABCA1 AD require vivo studies contribution glial neuronal ABCA1 pathogenesis AD evaluated appropriate physiological context
0.29108343.15269218.html.plaintext.txt	305	In summary demonstrate glial ABCA1 key participant apoE metabolism
0.29108343.15269218.html.plaintext.txt	306	We show selective disruption ABCA1 reduces cholesterol efflux exogenous apoE impairs apoE secretion astrocytes microglia
0.29108343.15269218.html.plaintext.txt	307	As result ABCA1 glia accumulate lipids normal culture conditions
0.29108343.15269218.html.plaintext.txt	308	In vivo ABCA1 required maintain normal levels apoE brain
0.29108343.15269218.html.plaintext.txt	309	Further effect ABCA1 specific apoE independent HDL apoA I levels
0.29108343.15269218.html.plaintext.txt	310	Taken together observations provide clear direct link ABCA1 apoE metabolism brain
0.29108343.15269218.html.plaintext.txt	311	FOOTNOTES The costs publication article defrayed part payment page charges
0.29108343.15269218.html.plaintext.txt	312	This article must therefore hereby marked advertisement accordance 18 U
0.29108343.15269218.html.plaintext.txt	313	Section 1734 solely indicate fact
0.29108343.15269218.html.plaintext.txt	314	Supported British Columbia Research Institute Childrens Womens Health BCRICWH
0.29108343.15269218.html.plaintext.txt	315	Supported operating grant Canadian Institutes Health Research CIHR CIHRPfizer Investigator Salary Award
0.29108343.15269218.html.plaintext.txt	316	Holds Canada Research Chair Human Genetics supported grants Heart Stroke Foundation BC Yukon HSFBCY CIHR
0.29108343.15269218.html.plaintext.txt	317	Supported CIHR New Investigator Salary Award operating grants CIHR Alzheimers Society CanadaCIHRAstraZeneca
0.29108343.15269218.html.plaintext.txt	318	To correspondence addressed Dept
0.29108343.15269218.html.plaintext.txt	319	Pathology Laboratory Medicine University British Columbia 980 W
0.29108343.15269218.html.plaintext.txt	320	Vancouver BC V5Z 4H4 Canada
0.29108343.15269218.html.plaintext.txt	321	6825 Fax 604 875 3819 E mail cherylatcmmt
0.29108343.15269218.html.plaintext.txt	322	1 The abbreviations used HDL high density lipoprotein AD Alzheimers disease PBS phosphate buffered saline DMEM Dulbeccos modified Eagles medium GST glutathione S transferase ANOVA analysis variance GAPDH glyceraldehyde 3 phosphate dehydrogenase CNS central nervous system apoE apolipoprotein E WT wild type
0.29108343.15269218.html.plaintext.txt	323	ACKNOWLEDGMENTS We thank Omar Francone providing ABCA1 deficient mice Dave Holtzman John Cirrito apoJ antibody Anita Kwok Yu Zhou Yang Hayden laboratory ABCA1 antibody Leonardo Basso members research groups many insightful comments suggestions throughout course work
0.29108343.15269218.html.plaintext.txt	324	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Hayden M
0.29108343.15269218.html.plaintext.txt	325	11 117 122CrossRefMedline Order article via Infotrieve Broccardo C
0.29108343.15269218.html.plaintext.txt	326	Acta 1461 395 404Medline Order article via Infotrieve Dean M
0.29108343.15269218.html.plaintext.txt	327	42 1007 1017AbstractFree Full Text Brooks Wilson A
0.29108343.15269218.html.plaintext.txt	328	22 336 345CrossRefMedline Order article via Infotrieve Rust S
0.29108343.15269218.html.plaintext.txt	329	22 352 355CrossRefMedline Order article via Infotrieve Bodzioch M
0.29108343.15269218.html.plaintext.txt	330	22 347 351CrossRefMedline Order article via Infotrieve Singaraja R
0.29108343.15269218.html.plaintext.txt	331	276 33969 33979AbstractFree Full Text Singaraja R
0.29108343.15269218.html.plaintext.txt	332	110 35 42AbstractFree Full Text Vaisman B
0.29108343.15269218.html.plaintext.txt	333	108 303 309AbstractFree Full Text Wellington C
0.29108343.15269218.html.plaintext.txt	334	82 273 283CrossRefMedline Order article via Infotrieve Van Eck M
0.29108343.15269218.html.plaintext.txt	335	99 6298 6303AbstractFree Full Text Oram J
0.29108343.15269218.html.plaintext.txt	336	275 34508 34511AbstractFree Full Text Repa J
0.29108343.15269218.html.plaintext.txt	337	2000 Science 289 1524 1529AbstractFree Full Text Venkateswaran A
0.29108343.15269218.html.plaintext.txt	338	97 12097 12102AbstractFree Full Text Schwartz K
0.29108343.15269218.html.plaintext.txt	339	274 794 802CrossRefMedline Order article via Infotrieve Chawla A
0.29108343.15269218.html.plaintext.txt	340	Cell 7 161 171Medline Order article via Infotrieve Lawn R
0.29108343.15269218.html.plaintext.txt	341	21 378 385AbstractFree Full Text Koldamova R
0.29108343.15269218.html.plaintext.txt	342	278 13244 13256AbstractFree Full Text Fukumoto H
0.29108343.15269218.html.plaintext.txt	343	277 48508 48513AbstractFree Full Text Liang Y
0.29108343.15269218.html.plaintext.txt	344	88 623 634CrossRefMedline Order article via Infotrieve Dietschy J
0.29108343.15269218.html.plaintext.txt	345	12 105 112CrossRefMedline Order article via Infotrieve Bjorkhem I
0.29108343.15269218.html.plaintext.txt	346	273 30178 30184CrossRef Bjorkhem I
0.29108343.15269218.html.plaintext.txt	347	39 1594 1600AbstractFree Full Text Pitas R
0.29108343.15269218.html.plaintext.txt	348	Acta 917 148 161Medline Order article via Infotrieve Pitas R
0.29108343.15269218.html.plaintext.txt	349	262 14352 14360AbstractFree Full Text Ladu M
0.29108343.15269218.html.plaintext.txt	350	903 167 175AbstractFree Full Text Koch S
0.29108343.15269218.html.plaintext.txt	351	2000 Lipoproteins Brain New Frontier Lipids Vascular Disease Betteridge D
0.29108343.15269218.html.plaintext.txt	352	51 64 Martin Dunitz London Mahley R
0.29108343.15269218.html.plaintext.txt	353	1 507 537CrossRefMedline Order article via Infotrieve Mahley R
0.29108343.15269218.html.plaintext.txt	354	1998 Science 240 622 630CrossRef Curtiss L
0.29108343.15269218.html.plaintext.txt	355	11 243 251CrossRefMedline Order article via Infotrieve Strittmatter W
0.29108343.15269218.html.plaintext.txt	356	92 4725 4727Abstract Linton M
0.29108343.15269218.html.plaintext.txt	357	88 270 281Medline Order article via Infotrieve Zlokovic B
0.29108343.15269218.html.plaintext.txt	358	205 1431 1437CrossRefMedline Order article via Infotrieve Zlokovic B
0.29108343.15269218.html.plaintext.txt	359	93 4229 4234AbstractFree Full Text Ignatius M
0.29108343.15269218.html.plaintext.txt	360	83 1125 1129Abstract Ignatius M
0.29108343.15269218.html.plaintext.txt	361	71 177 184Medline Order article via Infotrieve Poon S
0.29108343.15269218.html.plaintext.txt	362	513 259 266CrossRefMedline Order article via Infotrieve Lakins J
0.29108343.15269218.html.plaintext.txt	363	2002 Biochemistry 41 282 291CrossRefMedline Order article via Infotrieve Ladu M
0.29108343.15269218.html.plaintext.txt	364	1993 Science 261 921 923Medline Order article via Infotrieve Strittmatter W
0.29108343.15269218.html.plaintext.txt	365	90 1977 1981Abstract Corder E
0.29108343.15269218.html.plaintext.txt	366	7 180 184Medline Order article via Infotrieve Selkoe D
0.29108343.15269218.html.plaintext.txt	367	43 545 584CrossRefMedline Order article via Infotrieve Fagan A
0.29108343.15269218.html.plaintext.txt	368	CO2 C 2 HlinktypeDOI CrossRefMedline Order article via Infotrieve Holtzman D
0.29108343.15269218.html.plaintext.txt	369	97 2892 2897AbstractFree Full Text Bales K
0.29108343.15269218.html.plaintext.txt	370	17 263 264Medline Order article via Infotrieve Bales K
0.29108343.15269218.html.plaintext.txt	371	96 15233 15238AbstractFree Full Text Irizarry M
0.29108343.15269218.html.plaintext.txt	372	920 171 178AbstractFree Full Text Bales K
0.29108343.15269218.html.plaintext.txt	373	Aging 21 427 432CrossRefMedline Order article via Infotrieve Carter D
0.29108343.15269218.html.plaintext.txt	374	50 468 475CrossRefMedline Order article via Infotrieve Holtzman D
0.29108343.15269218.html.plaintext.txt	375	103 R15 R21Medline Order article via Infotrieve Costet P
0.29108343.15269218.html.plaintext.txt	376	275 28240 28245AbstractFree Full Text Mak P
0.29108343.15269218.html.plaintext.txt	377	277 31900 31908AbstractFree Full Text Langmann T
0.29108343.15269218.html.plaintext.txt	378	44 968 977AbstractFree Full Text Remaley A
0.29108343.15269218.html.plaintext.txt	379	289 818 823CrossRef Bortnick A
0.29108343.15269218.html.plaintext.txt	380	275 28634 28640AbstractFree Full Text von Eckardstein A
0.29108343.15269218.html.plaintext.txt	381	15 1555 1561AbstractFree Full Text Saura J
0.29108343.15269218.html.plaintext.txt	382	2003 Glia 44 183 189CrossRefMedline Order article via Infotrieve Mabile L
0.29108343.15269218.html.plaintext.txt	383	90 766 776CrossRefMedline Order article via Infotrieve Wellington C
0.29108343.15269218.html.plaintext.txt	384	43 1939 1949AbstractFree Full Text Chen W
0.29108343.15269218.html.plaintext.txt	385	276 43564 43569AbstractFree Full Text Wang N
0.29108343.15269218.html.plaintext.txt	386	276 23742 23747AbstractFree Full Text Repa J
0.29108343.15269218.html.plaintext.txt	387	16 459 481CrossRefMedline Order article via Infotrieve Repa J
0.29108343.15269218.html.plaintext.txt	388	277 18793 18800AbstractFree Full Text Allayee H
0.29108343.15269218.html.plaintext.txt	389	23 1501 1509AbstractFree Full Text Paigen B
0.29108343.15269218.html.plaintext.txt	390	1985 Atheroscler 57 65 73 McNeish J
0.29108343.15269218.html.plaintext.txt	391	97 4245 4250AbstractFree Full Text Huang Z
0.29108343.15269218.html.plaintext.txt	392	21 2019 2025AbstractFree Full Text Michikawa M
0.29108343.15269218.html.plaintext.txt	393	74 1008 1016CrossRefMedline Order article via Infotrieve Neufeld E
0.29108343.15269218.html.plaintext.txt	394	276 27584 27590AbstractFree Full Text Takahashi Y
0.29108343.15269218.html.plaintext.txt	395	96 11358 11363AbstractFree Full Text Heeren J
0.29108343.15269218.html.plaintext.txt	396	278 14370 14378AbstractFree Full Text Fazio S
0.29108343.15269218.html.plaintext.txt	397	2000 TINS 10 23 30 Swift L
0.29108343.15269218.html.plaintext.txt	398	276 22965 22970AbstractFree Full Text Naidu A
0.29108343.15269218.html.plaintext.txt	399	958 100 111CrossRefMedline Order article via Infotrieve Poirier J
0.29108343.15269218.html.plaintext.txt	400	17 525 530CrossRefMedline Order article via Infotrieve Sun Y
0.29108343.15269218.html.plaintext.txt	401	278 27688 27694AbstractFree Full Text Wollmer M
0.29108343.15269218.html.plaintext.txt	402	Aging 24 421 426CrossRefMedline Order article via Infotrieve Katzov H
0.29108343.15269218.html.plaintext.txt	403	23 358 367CrossRefMedline Order article via Infotrieve Wahrle S
0.36174858.15888448.html.plaintext.txt	0	The Low Density Lipoprotein Receptor Regulates Level Central Nervous System Human Murine Apolipoprotein E Does Not Modify Amyloid Plaque Pathology PDAPP Mice John D
0.36174858.15888448.html.plaintext.txt	1	Sullivanf Maia Parsadaniana Guojun Bucg David M
0.36174858.15888448.html.plaintext.txt	2	From Departments aNeurologyh Molecular Biology Pharmacologyc Pediatrics gCell Biology Physiology iHope Center Neurological Disorders Washington University School Medicine St
0.36174858.15888448.html.plaintext.txt	3	Louis Missouri 63110 bNeuroscience Discovery Research Eli Lilly Co
0.36174858.15888448.html.plaintext.txt	4	Lilly Research Laboratories Indianapolis Indiana 46285 Departments ofd Pharmacology Toxicology ande Psychiatry Indiana University School Medicine Indianapolis Indiana 46285 fBryan Alzheimers Disease Research Center Division Neurology Department Medicine Duke University Medical Center Durham North Carolina 27710
0.36174858.15888448.html.plaintext.txt	5	Received publication February 24 2005 revised form April 25 2005
0.36174858.15888448.html.plaintext.txt	6	ABSTRACT TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Apolipoprotein E apoE chaperone amyloid A peptide regulates deposition structure A deposits brain Alzheimer disease AD
0.36174858.15888448.html.plaintext.txt	7	The primary apoE receptor regulates levels apoE brain unknown
0.36174858.15888448.html.plaintext.txt	8	We report low density lipoprotein receptor LDLR regulates cellular uptake central nervous system levels astrocyte derived apoE
0.36174858.15888448.html.plaintext.txt	9	Cells lacking LDLR unable appreciably endocytose astrocyte secreted apoE containing lipoprotein particles
0.36174858.15888448.html.plaintext.txt	10	Moreover cells overexpressing LDLR showed dramatic increase apoE endocytosis degradation
0.36174858.15888448.html.plaintext.txt	11	We also found LDLR knock Ldlr mice significant 50 increase level apoE cerebrospinal fluid extracellular pools brain
0.36174858.15888448.html.plaintext.txt	12	However PDAPP mouse model AD bred onto Ldlr background observe significant change brain A levels either onset A deposition
0.36174858.15888448.html.plaintext.txt	13	Interestingly human APOE3 APOE4 APOE2 knock mice bred Ldlr background 210 380 increase respectively level apoE cerebrospinal fluid
0.36174858.15888448.html.plaintext.txt	14	These results demonstrate central nervous system levels human murine apoE directly regulated LDLR
0.36174858.15888448.html.plaintext.txt	15	Although increase murine apoE caused LDLR deficiency sufficient affect A levels deposition 10 months age PDAPP mice remains possibility increase human apoE3 apoE4 levels caused LDLR deficiency affect process could hold promise therapeutic targets AD
0.36174858.15888448.html.plaintext.txt	16	INTRODUCTION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Alzheimer disease AD1 progressive neurodegenerative disease common cause dementia
0.36174858.15888448.html.plaintext.txt	17	One key pathological hallmarks AD deposition 39 43 amino acid amyloid A peptide form diffuse thioflavine SCongo red negative fibrillar thioflavine SCongo red positive plaques
0.36174858.15888448.html.plaintext.txt	18	An abundance data suggests conversion A soluble insoluble forms early event pathogenesis AD
0.36174858.15888448.html.plaintext.txt	19	The A peptide generated cleavage larger amyloid precursor protein APP predominant species A40 andto lesser extent A42 1
0.36174858.15888448.html.plaintext.txt	20	Although accounting 1 cases early onset autosomal dominant forms AD identified share common feature overall increase A levels relative elevation fibrillogenic A42 throughout life ultimately resulting early A deposition plaque formation
0.36174858.15888448.html.plaintext.txt	21	Identification familial AD cases led generation several APP transgenic mouse models recapitulate many aspects A deposition associated pathology 2
0.36174858.15888448.html.plaintext.txt	22	In 1993 4 allele apoE found genetic risk factor common form AD late onset AD well cerebral amyloid angiopathy whereas 2 allele shown protective 3
0.36174858.15888448.html.plaintext.txt	23	Abundant data suggest apoE linked AD cerebral amyloid angiopathy due ability act A chaperone 4 influence A metabolism
0.36174858.15888448.html.plaintext.txt	24	By acting A binding molecule apoE influences amount A deposition conformation A aggregates well A clearance toxicity vivo 5 8
0.36174858.15888448.html.plaintext.txt	25	Furthermore level apoE brain directly influences aforementioned processes 5 8
0.36174858.15888448.html.plaintext.txt	26	For example APP transgenic mice lacking apoE develop less A deposition virtually fibrillar A deposits 5 9 10
0.36174858.15888448.html.plaintext.txt	27	Thus understanding cellular events receptors regulate apoE levels brain may give important insights AD pathogenesis
0.36174858.15888448.html.plaintext.txt	28	ApoE expressed high levels liver central nervous system CNS present lipoprotein particles
0.36174858.15888448.html.plaintext.txt	29	Furthermore apoE CNS derived within CNS plasma 11
0.36174858.15888448.html.plaintext.txt	30	However CNS apoE containing lipoproteins differ found periphery amount sialation perhaps importantly type lipoprotein particle associates 12
0.36174858.15888448.html.plaintext.txt	31	In plasma apoE low density lipoproteins VLDLs subset high density lipoproteins also contain apoproteins
0.36174858.15888448.html.plaintext.txt	32	In contrast CNS apoE high density lipoprotein like lipoproteins secreted primarily astrocytes released cells contain apoE sole apolipoprotein constituent 12 13
0.36174858.15888448.html.plaintext.txt	33	Despite information whether specific apoE receptors regulate level apoE brain mediate apoE dependent clearance apoE binding proteins unknown
0.36174858.15888448.html.plaintext.txt	34	Nearly 20 years ago Brown Goldstein 14 elucidated role low density lipoprotein receptor LDLR receptor mediated endocytosis lipoproteins plasma including apoE
0.36174858.15888448.html.plaintext.txt	35	Subsequently members LDLR family identified
0.36174858.15888448.html.plaintext.txt	36	Many expressed brain shown vitro bind endocytose lipid rich lipoproteins contain apoE 15
0.36174858.15888448.html.plaintext.txt	37	To determine whether LDLR family members influence level CNS apoE A metabolism AD mouse model recently bred mice lacking 39 kDa receptor associated protein RAP 16
0.36174858.15888448.html.plaintext.txt	38	An increase A aggregation deposition found mice
0.36174858.15888448.html.plaintext.txt	39	RAP endoplasmic reticulum chaperone protein known influence folding level LDLR family members study levels LDLR related protein LRP LDLR examined found reduced brain mice lacking RAP 16
0.36174858.15888448.html.plaintext.txt	40	Additionally overexpression functional LRP mini receptor PDAPP model led increase levels soluble A advanced stages deposition detectable change A deposition measured histologically 17
0.36174858.15888448.html.plaintext.txt	41	Thus whether LDLR family members responsible brain apoE metabolism whether play role regulating A levels vivo remains unclear
0.36174858.15888448.html.plaintext.txt	42	Herein investigate role LDLR regulation CNS derived apoE well brain A levels mouse model AD
0.36174858.15888448.html.plaintext.txt	43	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES ApoE Labeling Vitro Assays The immunoaffinity purification astrocyte secreted apoE containing lipoprotein particles described previously 18
0.36174858.15888448.html.plaintext.txt	44	For apoE degradation studies astrocyte secreted apoE3 containing lipoprotein particles labeled 125I using IODO GEN kit Pierce
0.36174858.15888448.html.plaintext.txt	45	Chinese hamster ovary cells lack endogenous LRP LRP null used stably express LDLR LRP mini receptor apoER2 VLDL receptor 19
0.36174858.15888448.html.plaintext.txt	46	Degradation 125I labeled apoE3 measured radioactivity soluble 20 trichloroacetic acid cell culture supernatant previously described 19
0.36174858.15888448.html.plaintext.txt	47	1 microM unlabeled RAP used determine specificity concentration inhibits LDLR family members
0.36174858.15888448.html.plaintext.txt	48	For apoE endocytosis assays apoE lipoprotein particles labeled fluorescent hydrocarbon probe DiI previously described 20
0.36174858.15888448.html.plaintext.txt	49	Wild type mouse embryonic fibroblast cells mouse embryonic fibroblast cells lacking LDLR LRP receptors used DiI studies 21 22
0.36174858.15888448.html.plaintext.txt	50	DiI labeled apoE applied 1 h room temperature washed PBS fixed 4 paraformaldehyde
0.36174858.15888448.html.plaintext.txt	51	Animal Tissue Preparation For analysis tissue plasma cholesterol CSF apoE 3 month old Ldlr Ldlr mice identical C57BL6J background used 23
0.36174858.15888448.html.plaintext.txt	52	For analysis human apoE isoforms Ldlr mice first bred wild type SJL mice generate Ldlr mice mixed C57BL6J x SJL background
0.36174858.15888448.html.plaintext.txt	53	These mice bred human APOE expressing mice 24 maintained C57BL6J x SJL background mice analyzed human apoE experiments identical background
0.36174858.15888448.html.plaintext.txt	54	For A analysis utilized PDAPP mice overexpress human APP751 familial AD mutation position 717 APPV717F control neuron specific platelet derived growth factor promoter 25
0.36174858.15888448.html.plaintext.txt	55	We crossed PDAPP Ldlr mice Ldlr mice generate PDAPP Ldlr PDAPP Ldlr mice littermates mixed genetic background described previously 7
0.36174858.15888448.html.plaintext.txt	56	Hereafter mice referred PDAPP study hemizygous PDAPP transgene PDAPP
0.36174858.15888448.html.plaintext.txt	57	Animals anesthetized pentobarbital 150 mgkg intraperitoneal perfused transcardially 0
0.36174858.15888448.html.plaintext.txt	58	1 M PBS containing heparin 3 unitsml pH 7
0.36174858.15888448.html.plaintext.txt	59	One hemibrain immersion fixed PBS containing 4 paraformaldehyde overnight 4 degrees C
0.36174858.15888448.html.plaintext.txt	60	After fixation brain cryoprotected PBS containing 30 sucrose 4 degrees C
0.36174858.15888448.html.plaintext.txt	61	Brain regions hemisphere dissected frozen powdered dry ice analysis
0.36174858.15888448.html.plaintext.txt	62	Complete protease inhibitors Roche Applied Science used indicated
0.36174858.15888448.html.plaintext.txt	63	For PBS soluble A analysis tissue first Dounce homogenized ice cold PBS protease inhibitors immediately spun 5 min 20000 x g
0.36174858.15888448.html.plaintext.txt	64	For carbonate soluble A analysis PBS insoluble pellet homogenized ice cold 100 mM carbonate 50 mM NaCl pH 11
0.36174858.15888448.html.plaintext.txt	65	5 protease inhibitors immediately spun 10 min 20000 x g
0.36174858.15888448.html.plaintext.txt	66	For carbonate insoluble A analysis carbonate insoluble pellet lysed 3 h rotation 5 M guanidine 50 mM Tris protease inhibitors
0.36174858.15888448.html.plaintext.txt	67	All experimental protocols approved animal studies committee Washington University
0.36174858.15888448.html.plaintext.txt	68	Biochemical Histological Analysis A40 A42 quantified enzyme linked immunosorbent assay described previously 26
0.36174858.15888448.html.plaintext.txt	69	A deposition assessed immunostaining 3D6 antibody recognizing amino acids 1 5 stereological analysis previously described 7
0.36174858.15888448.html.plaintext.txt	70	ApoE measured cortical tissue Dounce homogenized briefly PBS protease inhibitors spun immediately 20000 x g 5 min
0.36174858.15888448.html.plaintext.txt	71	Murine apoE quantified using sandwich enzyme linked immunosorbent assay pooled C57BL6J plasma serving standard apoE set 68 microgml 27 sensitivity 5 ngml
0.36174858.15888448.html.plaintext.txt	72	Human apoE quantified using enzyme linked immunosorbent assay protocol except standard used purified apoE isolated human VLDL BioDesign Sako ME
0.36174858.15888448.html.plaintext.txt	73	The 96 well microtiter plates coated overnight 4 degrees C 20 microgml monoclonal anti apoE antibody WUE4 28
0.36174858.15888448.html.plaintext.txt	74	All washes performed 8 timeswell PBS standard microplate washer
0.36174858.15888448.html.plaintext.txt	75	Plates washed blocked 1 dry milk PBS 60 min 37 degrees C
0.36174858.15888448.html.plaintext.txt	76	Plates washed samples standards loaded 0
0.36174858.15888448.html.plaintext.txt	77	5 bovine serum albumin PBS 0
0.36174858.15888448.html.plaintext.txt	78	025 Tween 20 containing protease inhibitors incubated 90 min 37 degrees C
0.36174858.15888448.html.plaintext.txt	79	Plates washed incubated goat anti apoE antiserum Calbiochem 1500 dilution 0
0.36174858.15888448.html.plaintext.txt	80	5 bovine serum albumin PBS 0
0.36174858.15888448.html.plaintext.txt	81	025 Tween 20 90 min 37 degrees C
0.36174858.15888448.html.plaintext.txt	82	Plates washed horseradish peroxidase conjugated horse anti goat antibody 15000 dilution Vector Laboratories Burlingame CA incubated 90 min room temperature
0.36174858.15888448.html.plaintext.txt	83	Plates washed tetramethylbenzidine substrate Sigma added absorbance monitored 650 nm
0.36174858.15888448.html.plaintext.txt	84	The Amplex Red kit Molecular Probes Eugene OR used measure total cholesterol content
0.36174858.15888448.html.plaintext.txt	85	Western Blotting Tissue samples homogenized radioimmune precipitation assay buffer 150 mM NaCl 50 mM Tris 2
0.36174858.15888448.html.plaintext.txt	86	1 SDS pH 8 protease inhibitors passed 10 times 33 gauge needle incubated 1 h room temperature rotation
0.36174858.15888448.html.plaintext.txt	87	Insoluble material pelleted centrifugation 20000 x g
0.36174858.15888448.html.plaintext.txt	88	Protein content supernatant quantified using BCA kit Pierce protein 30 microglane run SDS PAGE gels transferred nitrocellulose Western blotting using standard techniques
0.36174858.15888448.html.plaintext.txt	89	To detect full length APP C terminal fragments APP blot probed CT15 generous gift Dr
0.36174858.15888448.html.plaintext.txt	90	Ed Koo University California San Diego CA rabbit polyclonal antibody raised C terminal 15 amino acids APP 29
0.36174858.15888448.html.plaintext.txt	91	To detect LRP blots probed rabbit anti LRP antibody 17
0.36174858.15888448.html.plaintext.txt	92	Images captured using Kodak ImageStation 440CF densitometric analysis bands performed using Kodak 1D Image Analysis software Eastman Kodak Co
0.36174858.15888448.html.plaintext.txt	93	Statistical Analysis Data reported mean plus minus S
0.36174858.15888448.html.plaintext.txt	94	analyzed using PRISM version 4
0.36174858.15888448.html.plaintext.txt	95	00 software GraphPad San Diego CA
0.36174858.15888448.html.plaintext.txt	96	RESULTS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES To begin determine whether one two major apoE receptors brain LDLR LRP could regulate apoE levels brain purified astrocyte secreted apoE containing lipoprotein particles described previously 18 determined ability endocytosed mouse embryonic fibroblasts derived wild type Ldlr Lrp double knock Ldlr Lrp mouse embryos 21
0.36174858.15888448.html.plaintext.txt	97	DiI labeled apoE lipoprotein particles readily taken endocytic vesicles wild type Lrp cells Fig
0.36174858.15888448.html.plaintext.txt	98	This punctate pattern staining typical receptor mediated endocytosis represents endosomallysosomal distribution endocytosed ligands
0.36174858.15888448.html.plaintext.txt	99	However cells Ldlr double knock Ldlr Lrp cells showed appreciable endocytosis astrocyte secreted apoE containing lipoprotein particles Fig
0.36174858.15888448.html.plaintext.txt	100	To clarify role LDLR family members mediating receptor mediated endocytosis astrocyte derived apoE used Chinese hamster ovary cells lack endogenous LRP stably transfected LDLR LRP mini receptors apoER2 VLDL receptor analyze potential uptake degradation apoE containing lipoprotein particles 19
0.36174858.15888448.html.plaintext.txt	101	These cells expressing different LDLR family members shown previously bind endocytose control ligands 19
0.36174858.15888448.html.plaintext.txt	102	These receptors main candidate apoE receptors expressed brain 15
0.36174858.15888448.html.plaintext.txt	103	Application 125I labeled astrocyte secreted apoE containing lipoprotein particles cells overexpressing LDLR resulted large increase RAP inhibitable endocytosis degradation apoE Fig
0.36174858.15888448.html.plaintext.txt	104	However cells overexpressing LDLR family members vector alone result appreciable uptake degradation astrocyte derived apoE Fig
0.36174858.15888448.html.plaintext.txt	105	View larger version 26K FIG
0.36174858.15888448.html.plaintext.txt	106	LDLR regulates cellular uptake astrocyte secreted apoE
0.36174858.15888448.html.plaintext.txt	107	A DiI labeled astrocyte secreted apoE3 containing lipoprotein particles readily endocytosed wild type Lrp mouse embryonic fibroblast cells Ldlr double null Ldlr Lrp mouse embryonic fibroblast cells
0.36174858.15888448.html.plaintext.txt	108	B astrocyte secreted apoE lipoprotein particles labeled 125I applied Chinese hamster ovary LRP null cells overexpressing LDLR family members
0.36174858.15888448.html.plaintext.txt	109	RAP inhibitable binding 125I labeled apoE3 calculated presented percentage pcDNA3
0.36174858.15888448.html.plaintext.txt	110	Only cells overexpressing LDLR able endocytose degrade apoE evidenced trichloroacetic acid soluble counts cell culture supernatant percentage control p 0
0.36174858.15888448.html.plaintext.txt	111	001 analysis variance post hoc Tukey test
0.36174858.15888448.html.plaintext.txt	112	To determine potential role LDLR brain apoE metabolism vivo used sandwich enzyme linked immunosorbent assay measure level murine apoE extracellular space brain CSF wild type Ldlr LDLR knock Ldlr mice
0.36174858.15888448.html.plaintext.txt	113	Because apoE secreted brain extracellular space expected receptor LDLR involved endocytosis absent extracellular levels would elevated
0.36174858.15888448.html.plaintext.txt	114	For example apoE elevated severalfold plasma Ldlr mice 23 well humans familial hypercholesterolemia resulting reduced LDLR expression andor function 30 31
0.36174858.15888448.html.plaintext.txt	115	We found Ldlr mice 53 increase CSF levels apoE relative Ldlr mice Fig
0.36174858.15888448.html.plaintext.txt	116	Furthermore found apoE levels cortical tissue homogenized PBS reflection extracellular pools apoE significantly increased 57 Ldlr mice compared Ldlr mice Fig
0.36174858.15888448.html.plaintext.txt	117	Together vitro vivo data suggest LDLR plays important role apoE receptor mediates uptake degradation level apoE brain
0.36174858.15888448.html.plaintext.txt	118	View larger version 16K FIG
0.36174858.15888448.html.plaintext.txt	119	LDLR regulates level apoE CNS
0.36174858.15888448.html.plaintext.txt	120	A level endogenous apoE CSF 3 month old mice 1
0.36174858.15888448.html.plaintext.txt	121	08 microgml Ldlr mice n 8 versus 1
0.36174858.15888448.html.plaintext.txt	122	17 microgml Ldlr mice n 7 p 0
0.36174858.15888448.html.plaintext.txt	123	01 unpaired two tailed test
0.36174858.15888448.html.plaintext.txt	124	B level endogenous apoE cortical PBS homogenates 0
0.36174858.15888448.html.plaintext.txt	125	05 microgmg Ldlr mice n 8 versus 0
0.36174858.15888448.html.plaintext.txt	126	08 microgmg Ldlr mice n 7 p 0
0.36174858.15888448.html.plaintext.txt	127	01 unpaired two tailed test
0.36174858.15888448.html.plaintext.txt	128	Because Ldlr mice elevated extracellular levels apoE brain apoE acts A chaperone soluble insoluble A wanted determine effect LDLR deposition A vivo
0.36174858.15888448.html.plaintext.txt	129	To determine whether LDLR direct effect A aggregation deposition vivo used PDAPP mouse model AD generate PDAPP Ldlr PDAPP Ldlr mice littermates
0.36174858.15888448.html.plaintext.txt	130	PDAPP mice express human APP transgene containing familial AD mutation amino acid 717 overproduce A particularly A42
0.36174858.15888448.html.plaintext.txt	131	In hippocampus mice amount soluble insoluble A increases age dependent manner beginning 6 9 months age plaques begin deposit 25 32
0.36174858.15888448.html.plaintext.txt	132	We first examined levels A40 A42 young PDAPP Ldlr PDAPP Ldlr mice 3 months age well deposition A begins
0.36174858.15888448.html.plaintext.txt	133	PBS soluble levels A40 A42 hippocampus significantly different two genotypes Fig
0.36174858.15888448.html.plaintext.txt	134	Carbonate soluble levels A40 A42 hippocampus also significantly different two genotypes Fig
0.36174858.15888448.html.plaintext.txt	135	We next examined PDAPP Ldlr PDAPP Ldlr mice 10 months age determine effect LDLR A deposition
0.36174858.15888448.html.plaintext.txt	136	The area hippocampus covered A immunoreactive deposits tissue sections 31 higher 10 month old PDAPP Ldlr mice compared PDAPP Ldlr mice Fig
0.36174858.15888448.html.plaintext.txt	137	4A increase statistically significant
0.36174858.15888448.html.plaintext.txt	138	Similar results found thioflavine S positive fibrillar deposits comparable results found cortex data shown
0.36174858.15888448.html.plaintext.txt	139	A biochemical analysis carbonate soluble A levels hippocampus revealed slight nonsignificant increases A40 17 A42 53 10 month old PDAPP Ldlr mice compared PDAPP Ldlr mice Fig
0.36174858.15888448.html.plaintext.txt	140	Carbonate insoluble A levels hippocampus also revealed slight nonsignificant increases A40 51 A42 10 10 month old PDAPP Ldlr mice compared PDAPP Ldlr mice Fig
0.36174858.15888448.html.plaintext.txt	141	Whereas Ldlr mice increase plasma cholesterol 79 compared wild type Ldlr mice Fig
0.36174858.15888448.html.plaintext.txt	142	5A differences either brain CSF cholesterol Fig
0.36174858.15888448.html.plaintext.txt	143	There also evidence processing APP Fig
0.36174858.15888448.html.plaintext.txt	144	5D levels total APP protein data shown different genotypes
0.36174858.15888448.html.plaintext.txt	145	Additionally hippocampal LRP levels altered absence LDLR data shown
0.36174858.15888448.html.plaintext.txt	146	Thus although level murine apoE elevated 50 extracellular CNS pools Ldlr mice data suggest degree change level apoE sufficiently increased significantly affect A levels young ages early stages A deposition PDAPP transgenic mice
0.36174858.15888448.html.plaintext.txt	147	View larger version 22K FIG
0.36174858.15888448.html.plaintext.txt	148	LDLR affect A levels hippocampus young PDAPP mice
0.36174858.15888448.html.plaintext.txt	149	A level PBS soluble A40 significantly different PDAPP Ldlr mice 0
0.36174858.15888448.html.plaintext.txt	150	024 ngmg compared PDAPP Ldlr mice 0
0.36174858.15888448.html.plaintext.txt	151	The level PBS soluble A42 also significantly different PDAPP Ldlr mice 0
0.36174858.15888448.html.plaintext.txt	152	015 ngmg compared PDAPP Ldlr mice 0
0.36174858.15888448.html.plaintext.txt	153	B level carbonate soluble A40 significantly different PDAPP Ldlr mice 0
0.36174858.15888448.html.plaintext.txt	154	041 ngmg compared PDAPP Ldlr mice 0
0.36174858.15888448.html.plaintext.txt	155	The level carbonate soluble A42 also significantly different PDAPP Ldlr mice 0
0.36174858.15888448.html.plaintext.txt	156	018 ngmg compared PDAPP Ldlr mice 0
0.36174858.15888448.html.plaintext.txt	157	To explore possibility LDLR may differentially regulate level human apoE isoforms CNS compared murine apoE bred human APOE2 APOE3 APOE4 targeted replacement mice knock onto Ldlr mouse background
0.36174858.15888448.html.plaintext.txt	158	To confirm previous findings noted mice 33 assessed plasma cholesterol apoE found significantly elevated absence LDLR genotypes data shown
0.36174858.15888448.html.plaintext.txt	159	To determine extent LDLR regulates human apoE levels extracellular space CNS measured apoE levels CSF
0.36174858.15888448.html.plaintext.txt	160	We found levels human apoE3 human apoE4 CSF significantly higher 210 380 respectively absence LDLR Fig
0.36174858.15888448.html.plaintext.txt	161	The level human apoE2 CSF significantly altered presence absence LDLR Fig
0.36174858.15888448.html.plaintext.txt	162	6A expected human apoE2 isoform exhibits 2 binding LDLR 34
0.36174858.15888448.html.plaintext.txt	163	However interesting note level human apoE2 substantially higher apoE3 apoE4 CSF Fig
0.36174858.15888448.html.plaintext.txt	164	Despite increase human apoE levels absence LDLR significant increase level brain cholesterol mice Fig
0.36174858.15888448.html.plaintext.txt	165	View larger version 16K FIG
0.36174858.15888448.html.plaintext.txt	166	LDLR affect A deposition PDAPP mice 10 months age
0.36174858.15888448.html.plaintext.txt	167	A percentage cross sectional area hippocampus covered A immunoreactive deposits significantly different PDAPP Ldlr mice 1
0.36174858.15888448.html.plaintext.txt	168	66 compared PDAPP Ldlr mice 2
0.36174858.15888448.html.plaintext.txt	169	B level carbonate soluble A40 significantly different PDAPP Ldlr mice 0
0.36174858.15888448.html.plaintext.txt	170	085 ngmg compared PDAPP Ldlr mice 0
0.36174858.15888448.html.plaintext.txt	171	The level carbonate soluble A42 also significantly different PDAPP Ldlr mice 4
0.36174858.15888448.html.plaintext.txt	172	66 ngmg compared PDAPP Ldlr mice 6
0.36174858.15888448.html.plaintext.txt	173	C level carbonate insoluble A40 significantly different PDAPP Ldlr mice 6
0.36174858.15888448.html.plaintext.txt	174	80 ngmg compared PDAPP Ldlr mice 9
0.36174858.15888448.html.plaintext.txt	175	The level carbonate soluble A42 also significantly different PDAPP Ldlr mice 262 plus minus 58 ngmg compared PDAPP Ldlr mice 288 plus minus 47 ngmg
0.36174858.15888448.html.plaintext.txt	176	View larger version 19K FIG
0.36174858.15888448.html.plaintext.txt	177	LDLR influences levels plasma cholesterol effect hippocampal CSF cholesterol APP processing
0.36174858.15888448.html.plaintext.txt	178	A level total plasma cholesterol 69
0.36174858.15888448.html.plaintext.txt	179	63 mgdl Ldlr mice n 6 compared 124 plus minus 8
0.36174858.15888448.html.plaintext.txt	180	82 mgdl Ldlr mice n 6 p 0
0.36174858.15888448.html.plaintext.txt	181	001 unpaired two tailed test
0.36174858.15888448.html.plaintext.txt	182	Level total cholesterol hippocampus B CSF C APP processing assessed semiquantitative Western blotting C terminal fragment CTF D significantly different genotypes n 5 7group
0.36174858.15888448.html.plaintext.txt	183	View larger version 27K FIG
0.36174858.15888448.html.plaintext.txt	184	LDLR influences levels human apoE3 apoE4 apoE2 cerebrospinal fluid
0.36174858.15888448.html.plaintext.txt	185	A level apoE cerebrospinal fluid measured human APOE2 APOE3 itsup APOE4 targeted replacement mice knock presence Ldlr absence Ldlr endogenous LDLR
0.36174858.15888448.html.plaintext.txt	186	The level human apoE significantly higher APOE2 mice 5
0.36174858.15888448.html.plaintext.txt	187	78 microgml compared APOE3 1
0.36174858.15888448.html.plaintext.txt	188	26 microgml mice p 0
0.36174858.15888448.html.plaintext.txt	189	001 analysis variance post hoc Tukey test
0.36174858.15888448.html.plaintext.txt	190	As expected previous studies level human apoE significantly different APOE2 Ldlr APOE2 Ldlr mice
0.36174858.15888448.html.plaintext.txt	191	The level human apoE significantly higher APOE3 Ldlr mice 4
0.36174858.15888448.html.plaintext.txt	192	51 microgml compared APOE3 Ldlr mice 1
0.36174858.15888448.html.plaintext.txt	193	05 analysis variance post hoc Tukey test
0.36174858.15888448.html.plaintext.txt	194	The level human apoE also significantly higher APOE4 Ldlr mice 4
0.36174858.15888448.html.plaintext.txt	195	47 microgml compared APOE3 Ldlr mice 1
0.36174858.15888448.html.plaintext.txt	196	001 analysis variance post hoc Tukey test
0.36174858.15888448.html.plaintext.txt	197	B level total cholesterol cortex increased human APOE2 APOE3 APOE4 knock mice absence LDLR
0.36174858.15888448.html.plaintext.txt	198	Interestingly human APOE3 slight significant decrease level cholesterol cortex absence LDLR p 0
0.36174858.15888448.html.plaintext.txt	199	DISCUSSION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES In present study found LDLR LDLR family members able efficiently bind endocytose degrade astrocyte secreted apoE containing lipoprotein particles Ldlr mice 50 higher levels apoE CSF extracellular pools brain tissue
0.36174858.15888448.html.plaintext.txt	200	However PDAPP mouse model AD bred onto Ldlr background significant increase levels A40 A42 young ages deposition A begins
0.36174858.15888448.html.plaintext.txt	201	Additionally significant increase A deposition defined immunohistochemical biochemical measures 10 month old PDAPP Ldlr PDAPP Ldlr mice
0.36174858.15888448.html.plaintext.txt	202	Interestingly using human APOE knock mice found increase level apoE3 apoE4 apoE2 Ldlr background much greater murine apoE Ldlr background
0.36174858.15888448.html.plaintext.txt	203	Our vitro data indicate LDLR family members including LRP VLDL receptor apoER2 able appreciably internalize degrade astrocyte secreted apoE containing lipoproteins
0.36174858.15888448.html.plaintext.txt	204	Previous work clearly demonstrated LDLR family members able efficiently bind endocytose apoE reconstituted large cholesterol rich lipoprotein particles termed VLDL 35
0.36174858.15888448.html.plaintext.txt	205	However VLDL particles differ astrocyte secreted apoE lipid composition presence apoproteins amount sialation 12
0.36174858.15888448.html.plaintext.txt	206	The apolipoprotein lipidation state alter receptor binding characteristics
0.36174858.15888448.html.plaintext.txt	207	For example previous studies shown recombinant apoE absence lipid prefers binding LRP LDLR 22
0.36174858.15888448.html.plaintext.txt	208	This form apoE shown present physiological conditions
0.36174858.15888448.html.plaintext.txt	209	Together results indicate lipid content form apoE lipoprotein particles alter receptor binding specificity
0.36174858.15888448.html.plaintext.txt	210	They also demonstrate LDLR important apoE receptor regulates human murine apoE endocytosis levels brain
0.36174858.15888448.html.plaintext.txt	211	Although results study rule LDLR family members contribute way level apoE brain clearly show LDLR plays important role brain apoE metabolism
0.36174858.15888448.html.plaintext.txt	212	Recent studies shown increasing decreasing cellular cholesterol influence cellular A secretion 36
0.36174858.15888448.html.plaintext.txt	213	Although Ldlr mice elevated plasma cholesterol levels found level brain cholesterol unaffected mice previously reported 37
0.36174858.15888448.html.plaintext.txt	214	The exact mechanism apoE affects AD pathogenesis unclear
0.36174858.15888448.html.plaintext.txt	215	However large body evidence suggests one mechanism influences age onset AD acting chaperone soluble insoluble A thereby influencing A clearance fibrillogenesis 3 5 7 32
0.36174858.15888448.html.plaintext.txt	216	Our current results suggest although LDLR regulates extracellular levels apoE brain 50 increase level murine apoE endogenous levels sufficient alter A levels young ages early stages A deposition PDAPP mice 10 months age
0.36174858.15888448.html.plaintext.txt	217	This may represent ceiling effect level murine apoE indicate larger increase level murine apoE may necessary effect change A levels model
0.36174858.15888448.html.plaintext.txt	218	Alternatively pathways apoE mediated clearance A play much larger role metabolism A LRP bulk flow along interstitial fluid drainage pathways
0.36174858.15888448.html.plaintext.txt	219	Unfortunately Lrp mice die early embryonic stages thus effect endogenous LRP brain apoE levels difficult assess shown study
0.36174858.15888448.html.plaintext.txt	220	Additionally LDLR may play role A deposition later stages deposition found LRP PDAPP mice 17
0.36174858.15888448.html.plaintext.txt	221	It also possible LDLR may differentially regulate human apoE isoforms CNS greater extent murine apoE therefore influence A levels deposition
0.36174858.15888448.html.plaintext.txt	222	It interesting independent effect LDLR level apoE CSF human APOE2 mice significantly higher APOE3 APOE4 mice
0.36174858.15888448.html.plaintext.txt	223	This suggests humans LDLR may play important role regulating CNS apoE levels AD pathogenesis
0.36174858.15888448.html.plaintext.txt	224	Studies human CSF reported significant differences level human apoE individuals expressing APOE3 APOE4 alleles level CSF apoE APOE22 homozygous individuals assessed knowledge
0.36174858.15888448.html.plaintext.txt	225	Given APOE2 associated decreased risk developing AD intriguing possibility absolute level apoE present brain individuals could account decrease risk
0.36174858.15888448.html.plaintext.txt	226	Human murine apoE differ 25 amino acid level human apoE isoforms murine apoE isolated VLDL shown differentially bind LDLR 33
0.36174858.15888448.html.plaintext.txt	227	Using PDAPP mouse model previous studies group shown expression human apoE isoforms control glial fibrillary acidic protein promoter results significant delay deposition compared mice expressing endogenous murine apoE 7 32
0.36174858.15888448.html.plaintext.txt	228	More recently human apoE knock mice used study crossed PDAPP mice delay A deposition isoform dependent effect A deposition E4 E3 E2 found 38
0.36174858.15888448.html.plaintext.txt	229	Additionally recently replicated result APPsw mouse model AD utilizing APOE3 APOE4 knock mice used study 39
0.36174858.15888448.html.plaintext.txt	230	Clearly human apoE isoforms affect A metabolism deposition differently murine apoE whether due altered clearance andor structure A vivo remains determined
0.36174858.15888448.html.plaintext.txt	231	Determining role LDLR receptors clearance pathways brain also involved regulating apoE levels central understanding apoE influences A metabolism AD pathogenesis
0.36174858.15888448.html.plaintext.txt	232	FOOTNOTES This work supported National Institutes Health Grants AG13956 P50 AG05681 AG11355 MetLife Foundation Eli Lilly Co
0.36174858.15888448.html.plaintext.txt	233	The costs publication article defrayed part payment page charges
0.36174858.15888448.html.plaintext.txt	234	This article must therefore hereby marked advertisement accordance 18 U
0.36174858.15888448.html.plaintext.txt	235	Section 1734 solely indicate fact
0.36174858.15888448.html.plaintext.txt	236	j To correspondence addressed Dept
0.36174858.15888448.html.plaintext.txt	237	Neurology Campus Box 8111 660 S
0.36174858.15888448.html.plaintext.txt	238	314 362 9872 Fax 314 362 2826 E mail holtzmanatwustl
0.36174858.15888448.html.plaintext.txt	239	1 The abbreviations used AD Alzheimer disease LDLR low density lipoprotein receptor apoE apolipoprotein E APP amyloid precursor protein A amyloid LRP low density lipoprotein receptor related protein CSF cerebrospinal fluid CNS central nervous system VLDL low density lipoprotein RAP receptor associated protein PBS phosphate buffered saline
0.36174858.15888448.html.plaintext.txt	240	REFERENCES TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Selkoe D
0.36174858.15888448.html.plaintext.txt	241	1101375 1381Free Full Text Hock B
0.36174858.15888448.html.plaintext.txt	242	17S7 S12CrossRefMedline Order article via Infotrieve Corder E
0.36174858.15888448.html.plaintext.txt	243	1993 Science 261921 923Medline Order article via Infotrieve Wisniewski T
0.36174858.15888448.html.plaintext.txt	244	4313 328CrossRefMedline Order article via Infotrieve Bales K
0.36174858.15888448.html.plaintext.txt	245	17263 264Medline Order article via Infotrieve Holtzman D
0.36174858.15888448.html.plaintext.txt	246	103R15 R21Medline Order article via Infotrieve Holtzman D
0.36174858.15888448.html.plaintext.txt	247	972892 2897AbstractFree Full Text DeMattos R
0.36174858.15888448.html.plaintext.txt	248	2004 Neuron 41193 202CrossRefMedline Order article via Infotrieve Bales K
0.36174858.15888448.html.plaintext.txt	249	9615233 15238AbstractFree Full Text Holtzman D
0.36174858.15888448.html.plaintext.txt	250	CO2 8linktypeDOI CrossRefMedline Order article via Infotrieve Linton M
0.36174858.15888448.html.plaintext.txt	251	88 270 281Medline Order article via Infotrieve Pitas R
0.36174858.15888448.html.plaintext.txt	252	Acta 917148 161Medline Order article via Infotrieve Pitas R
0.36174858.15888448.html.plaintext.txt	253	26214352 14360AbstractFree Full Text Brown M
0.36174858.15888448.html.plaintext.txt	254	1986 Science 23234 47Medline Order article via Infotrieve Beffert U
0.36174858.15888448.html.plaintext.txt	255	45403 409AbstractFree Full Text Van Uden E
0.36174858.15888448.html.plaintext.txt	256	229298 9304AbstractFree Full Text Zerbinatti C
0.36174858.15888448.html.plaintext.txt	257	1011075 1080AbstractFree Full Text DeMattos R
0.36174858.15888448.html.plaintext.txt	258	39 415 425CrossRefMedline Order article via Infotrieve Li Y
0.36174858.15888448.html.plaintext.txt	259	27618000 18006AbstractFree Full Text Pitas R
0.36174858.15888448.html.plaintext.txt	260	1981 Arteriosclerosis 1 177 185Abstract Reblin T
0.36174858.15888448.html.plaintext.txt	261	382103 2110Abstract Narita M
0.36174858.15888448.html.plaintext.txt	262	Tokyo 132743 749Abstract Ishibashi S
0.36174858.15888448.html.plaintext.txt	263	92883 893Medline Order article via Infotrieve Sullivan P
0.36174858.15888448.html.plaintext.txt	264	27217972 17980AbstractFree Full Text Games D
0.36174858.15888448.html.plaintext.txt	265	1995 Nature 373523 527CrossRefMedline Order article via Infotrieve DeMattos R
0.36174858.15888448.html.plaintext.txt	266	988850 8855AbstractFree Full Text Lusis A
0.36174858.15888448.html.plaintext.txt	267	2627594 7604AbstractFree Full Text Krul E
0.36174858.15888448.html.plaintext.txt	268	291309 1325Abstract Sisodia S
0.36174858.15888448.html.plaintext.txt	269	133136 3142Abstract Gibson J
0.36174858.15888448.html.plaintext.txt	270	1987 Arteriosclerosis 7401 407Abstract Kajinami K
0.36174858.15888448.html.plaintext.txt	271	Acta 211 93 99CrossRefMedline Order article via Infotrieve Fagan A
0.36174858.15888448.html.plaintext.txt	272	9305 318CrossRefMedline Order article via Infotrieve Knouff C
0.36174858.15888448.html.plaintext.txt	273	Acta 16848 17Medline Order article via Infotrieve Schneider W
0.36174858.15888448.html.plaintext.txt	274	681075 1085Medline Order article via Infotrieve Mahley R
0.36174858.15888448.html.plaintext.txt	275	1988 Science 240622 630Medline Order article via Infotrieve Wolozin B
0.36174858.15888448.html.plaintext.txt	276	2004 Neuron 41 7 10CrossRefMedline Order article via Infotrieve Quan G
0.36174858.15888448.html.plaintext.txt	277	146 87 98Medline Order article via Infotrieve Bales K
0.36174858.15888448.html.plaintext.txt	278	252803 2810AbstractFree Full Text
0.31515914.11823322.html.plaintext.txt	0	Genotype phenotype Alzheimers disease CLIVE HOLMES MRCPsych
0.31515914.11823322.html.plaintext.txt	1	Thornhill Research Unit University Southampton Moorgreen Hospital Botley Road West End Southampton SO30 3JB UK
0.31515914.11823322.html.plaintext.txt	2	Background Patients Alzheimers disease show wide variation clinical phenotype
0.31515914.11823322.html.plaintext.txt	3	Genetic research largely concerned role mutations common variants risk factors disease
0.31515914.11823322.html.plaintext.txt	4	Do genetic factors also influence clinical phenotype
0.31515914.11823322.html.plaintext.txt	5	Aims To examine evidence genetic factors influence clinical expression disease addition influencing risk
0.31515914.11823322.html.plaintext.txt	6	Method A selective review made key literature
0.31515914.11823322.html.plaintext.txt	7	Results Mutations three genes coding amyloid precursor protein presenilin 1 presenilin 2 common variation 4 another gene APOE shown lead earlier development disease
0.31515914.11823322.html.plaintext.txt	8	More recently genetic association twin studies suggested role genetic factors development aspects clinical phenotype notably appearance non cognitive symptoms
0.31515914.11823322.html.plaintext.txt	9	Conclusions In Alzheimers disease genetic variation influences number aspects clinical phenotype
0.31515914.11823322.html.plaintext.txt	10	Early family twin studies indicated number genes important part play development Alzheimers disease
0.31515914.11823322.html.plaintext.txt	11	Variation genes including rare mutations common polymorphisms appears confer increased risk development disease
0.31515914.11823322.html.plaintext.txt	12	However apparent increased risk may largely explained effects genetic variation clinical phenotype Alzheimers disease particularly age disease presents
0.31515914.11823322.html.plaintext.txt	13	More recently proposed genetic variation may also explain features clinical phenotype including development non cognitive symptoms
0.31515914.11823322.html.plaintext.txt	14	The clearest evidence genetic contribution aetiology Alzheimers disease existence families disease transmitted clear autosomal dominant pattern
0.31515914.11823322.html.plaintext.txt	15	Study one large pedigrees revealed transmission generation generation single point mutation gene amyloid precursor protein APP found chromosome 21 family members developing early onset Alzheimers disease
0.31515914.11823322.html.plaintext.txt	16	Further studies families led discovery point mutations gene later presence mutations two genes encoding presenilin 1 PS 1 presenilin 2 PS 2 found chromosomes 14 1 respectively
0.31515914.11823322.html.plaintext.txt	17	To date 12 Alzheimers disease related mutations discovered APP gene 69 mutations PS 1 gene 5 mutations PS 2 gene
0.31515914.11823322.html.plaintext.txt	18	Significantly research suggests different mutations three genes lead common result increase ss A4 peptide fragment APP forms core neuritic plaques found brains people Alzheimers disease
0.31515914.11823322.html.plaintext.txt	19	While findings immense importance terms elucidating biological pathogenesis Alzheimers diease important recognise three causal genes may account 30 50 autosomal dominant early onset cases around 10 familial early onset cases Cruts et al 1998
0.31515914.11823322.html.plaintext.txt	20	Thus given majority cases 95 Alzheimers disease occurs age 60 years clear genetic mutations make small contribution risk developing disease general
0.31515914.11823322.html.plaintext.txt	21	The inheritance late onset Alzheimers disease complex early onset form
0.31515914.11823322.html.plaintext.txt	22	In cross sectional studies presence positive family history late onset Alzheimers disease consistent risk factor subjects late onset form clear autosomal dominant pattern inheritance rare
0.31515914.11823322.html.plaintext.txt	23	Both twin family studies suggest polygenic multifactorial mode inheritance consequence elucidation genetic risk factors late onset Alzheimers disease requires different methods used early onset disease simple Mendelian patterns inheritance
0.31515914.11823322.html.plaintext.txt	24	Association studies far dominated genetics late onset Alzheimers disease
0.31515914.11823322.html.plaintext.txt	25	Such studies look variation frequency allele samples unrelated patients late onset Alzheimers disease compared unrelated control subjects
0.31515914.11823322.html.plaintext.txt	26	These studies resulted number candidate genes proposed importance risk factors late onset Alzheimers disease include associations variation genes encoding low density lipoprotein VLDL receptor PS 1 intronic mutation associated early onset Alzheimers disease butyrylcholinesterase angiotensin 1 converting enzyme 1 antichymotrypsin human leucocyte antigen HLA complex 2 macroglobulin low density lipoprotein like receptor serotonin transporter interleukin 1
0.31515914.11823322.html.plaintext.txt	27	Typically interest candidates diminished independent replication forthcoming little evidence remains important role genetic variation VLDL receptor PS 1 1 antichymotrypsin genes development late onset Alzheimers disease
0.31515914.11823322.html.plaintext.txt	28	The candidate genes still advocates remain hotly disputed
0.31515914.11823322.html.plaintext.txt	29	More recently results number linkage studies become available
0.31515914.11823322.html.plaintext.txt	30	The methods used linkage studies complex non Mendelian diseases late onset Alzheimers disease less powerful used early onset form
0.31515914.11823322.html.plaintext.txt	31	However studies reveal areas interest genome might later explored association studies
0.31515914.11823322.html.plaintext.txt	32	A complete genomic screen series multiplex families affected late onset Alzheimers disease revealed five regions interest chromosomes 4 6 12 19 20
0.31515914.11823322.html.plaintext.txt	33	Excluding effects APOE4 locus maximum log likelihood ratio lod score study occurred region located short arm chromosome 12 Pericak Vance et al 1997
0.31515914.11823322.html.plaintext.txt	34	However two subsequent studies following similar methods Blacker et al 1998 Wu et al 1998 unable confirm linkage area
0.31515914.11823322.html.plaintext.txt	35	A large sibpair study Kehoe et al 1999 revealed many possible loci showing linkage late onset Alzheimers disease
0.31515914.11823322.html.plaintext.txt	36	These include loci chromosomes 1 5 9 10 12 14 19 close APOE 21 close APP gene
0.31515914.11823322.html.plaintext.txt	37	Currently main focus attention chromosome 10 two independent studies showing evidence susceptibility locus region Ertekin Taner et al 2000 Myers et al 2000
0.31515914.11823322.html.plaintext.txt	38	However clear large number loci implicated disagreement studies predicted areas interest
0.31515914.11823322.html.plaintext.txt	39	These findings demonstrate limitations approach also serve emphasise polygenic nature late onset Alzheimers disease
0.31515914.11823322.html.plaintext.txt	40	Further exploration areas association studies positional candidate approach likely dominate genetics Alzheimers disease future
0.31515914.11823322.html.plaintext.txt	41	Of genetic risk factors advocated role development late onset Alzheimers disease least controversial remains increased risk associated possession one copies APOE4 allele coding apolipoprotein E ApoE variant 4
0.31515914.11823322.html.plaintext.txt	42	Significantly importance APOE4 determined using positional candidate gene approach
0.31515914.11823322.html.plaintext.txt	43	Since finding studies Artiga et al 1998 Bullido et al 1998 Lambert et al 1998 also suggested association number polymorphisms within transcriptional regulatory region APOE gene late onset Alzheimers disease independent ApoE 4 status
0.31515914.11823322.html.plaintext.txt	44	Based data suggested two independent mechanisms risk late onset Alzheimers disease modified APOE gene first variations coding regions alter functional properties APOE second presence promoter variants result quantitative differences APOE expression Artiga et al 1998
0.31515914.11823322.html.plaintext.txt	45	However hypothesis controversial recent studies Helisalmi et al 1999 Zurutuza et al 2000 failed support independence APOE promoter variants development Alzheimers disease
0.31515914.11823322.html.plaintext.txt	46	GENETIC INFLUENCES ON CLINICAL PHENOTYPE
0.31515914.11823322.html.plaintext.txt	47	Age onset Families carrying mutations APP gene ages onset largely within range 40 65 years
0.31515914.11823322.html.plaintext.txt	48	To date APP mutation carrier reported unaffected beyond age 67 years
0.31515914.11823322.html.plaintext.txt	49	Families carrying mutations PS 1 gene earliest ages onset fall largely within range 35 55 years although one family member recently recorded onset 24 years Wisniewski et al 1998
0.31515914.11823322.html.plaintext.txt	50	These mutations largely associated early onset familial Alzheimers disease least two mutations Ala79Val His163Tyr observed late onset Alzheimers disease may non penetrant Cruts et al 1998
0.31515914.11823322.html.plaintext.txt	51	Families carrying mutations PS 2 gene ages onset largely within range 40 70 years thus show overlap late onset Alzheimers disease
0.31515914.11823322.html.plaintext.txt	52	Penetrance high may 100 least two reported cases non penetrance age 80 years Bird et al 1996
0.31515914.11823322.html.plaintext.txt	53	The familial influence age onset late onset Alzheimers disease may substantial
0.31515914.11823322.html.plaintext.txt	54	Thus one study affected sib pairs suggests shared familial effects may account 40 variance Tunstall et al 2000
0.31515914.11823322.html.plaintext.txt	55	Indeed studies shown late onset disease age onset approximately 6 years earlier individuals carry two copies APOE4 allele compared non carriers
0.31515914.11823322.html.plaintext.txt	56	This led suggestion APOE4 allele risk factor Alzheimers disease mainly old age Alzheimers disease death competing risks
0.31515914.11823322.html.plaintext.txt	57	Any factor leading earlier age onset Alzheimers disease elderly hence development disease prior death associated Alzheimers disease
0.31515914.11823322.html.plaintext.txt	58	Evidence confirming hypothesis come large study approximately 5000 individuals Meyer et al 1998
0.31515914.11823322.html.plaintext.txt	59	This study showed clear decline relative risk developing late onset Alzheimers disease subjects increasing age clear plateau beyond new cases disease reported
0.31515914.11823322.html.plaintext.txt	60	The age plateau reached earlier carriers APOE4 allele
0.31515914.11823322.html.plaintext.txt	61	Thus appears clear APOE4 allele predominant effect determining individual develops late onset Alzheimers disease Meyer et al 1998
0.31515914.11823322.html.plaintext.txt	62	Non cognitive features If genetic risk factors Alzheimers disease associated non cognitive symptoms one might anticipate subjects family history disease increased frequency symptoms
0.31515914.11823322.html.plaintext.txt	63	Likewise one would expect association known genetic risk factors Alzheimers disease including genes APP PS 1 PS 2 ApoE 4 allele symptoms Alzheimers disease
0.31515914.11823322.html.plaintext.txt	64	In fact appears little consistent evidence association either positive family history Alzheimers disease variation known candidate genes increase frequency non cognitive symptoms occurring first time within disease
0.31515914.11823322.html.plaintext.txt	65	It thus seems unlikely major genetic risk factors development late onset Alzheimers disease substantial role play development non cognitive symptoms within late onset disease
0.31515914.11823322.html.plaintext.txt	66	However mean symptoms genetic basis since genes may influence phenotypic expression disease without involved directly aetiology
0.31515914.11823322.html.plaintext.txt	67	Indeed early studies shown evidence association positive family history depressive illness increase frequency depressive symptoms occurring first time within Alzheimers disease Pearlson et al 1990
0.31515914.11823322.html.plaintext.txt	68	These early findings supported sib pair study Tunstall et al 2000 showing familial factors role development depressive illness late onset Alzheimers disease
0.31515914.11823322.html.plaintext.txt	69	In addition small study also suggests role familial factors wide variety non cognitive symptoms including agitation aggression psychosis
0.31515914.11823322.html.plaintext.txt	70	A direct approach also adopted whereby common genetic polymorphisms previously showing associations neuropsychiatric conditions found associated non cognitive symptoms late onset Alzheimers disease
0.31515914.11823322.html.plaintext.txt	71	For example one study Holmes et al 1998 people late onset Alzheimers disease found association common polymorphic variations 5 HT2A 5 HT2C serotonin receptor genes 102 TC Cys23Ser polymorphisms respectively previously implicated schizophrenia bipolar affective disorder psychotic symptoms Alzheimers disease
0.31515914.11823322.html.plaintext.txt	72	Associations found presence C102 allele presence visual auditory hallucinations presence Ser23 allele visual hallucinations
0.31515914.11823322.html.plaintext.txt	73	Another study Sweet et al 1998 found evidence suggest association psychosis aggression patients Alzheimers disease carry common polymorphisms dopamine receptor genes DRD1 DRD3
0.31515914.11823322.html.plaintext.txt	74	These studies need replicated suggest common receptor polymorphisms may role genesis psychotic non cognitive symptoms implicated genetic risk factors late onset Alzheimers disease
0.31515914.11823322.html.plaintext.txt	75	Cognitive decline No study date looked rates decline carriers APP PS 1 PS 2 mutations patients late onset Alzheimers disease positive family history Alzheimers disease show evidence increased rates decline
0.31515914.11823322.html.plaintext.txt	76	The majority studies also failed show relationships possession APOE4 allele increased rates decline
0.31515914.11823322.html.plaintext.txt	77	This lack association interesting since implies genetic factors may determine disease starts rate degeneration
0.31515914.11823322.html.plaintext.txt	78	Clearly caution required interpreting negative finding may associations always difficult establish large number confounding factors may influence cognitive deterioration well difficulties use psychometric scales short periods
0.31515914.11823322.html.plaintext.txt	79	Indeed study Craft et al 1998 suggested increased rate cognitive decline APOE4 carriers may detectable using long follow period
0.31515914.11823322.html.plaintext.txt	80	Duration The mean duration illness families PS 1 mutations significantly shorter range 5
0.31515914.11823322.html.plaintext.txt	81	8 years families PS 2 range 4
0.31515914.11823322.html.plaintext.txt	82	8 years APP mutations range 9
0.31515914.11823322.html.plaintext.txt	83	0 16 years reflecting severity PS 1 associated Alzheimers disease
0.31515914.11823322.html.plaintext.txt	84	Studies late onset Alzheimers disease suggest duration illness tends longer people positive family history carriers APOE4 allele
0.31515914.11823322.html.plaintext.txt	85	However since shown relationship longer holds true confounding effects age onset taken account
0.31515914.11823322.html.plaintext.txt	86	Thus late onset Alzheimers disease increased survival directly related earlier age onset influenced number factors exclusively genetic
0.31515914.11823322.html.plaintext.txt	87	Clinical Implications Limitations
0.31515914.11823322.html.plaintext.txt	88	CLINICAL IMPLICATIONS A number genes implicated risk factors development Alzheimers disease
0.31515914.11823322.html.plaintext.txt	89	Variation genes appears major effect determining disease develop
0.31515914.11823322.html.plaintext.txt	90	Other aspects clinical phenotype notably non cognitive symptoms also influenced genetic variation
0.31515914.11823322.html.plaintext.txt	91	LIMITATIONS A number risk genes yet identified
0.31515914.11823322.html.plaintext.txt	92	The influence unknown genes clinical phenotype yet undetermined
0.31515914.11823322.html.plaintext.txt	93	The influence genetic variation non cognitive symptoms relatively unexplored
0.31515914.11823322.html.plaintext.txt	94	et al 1998 Risk Alzheimers disease correlates transcriptional activity APOE gene
0.31515914.11823322.html.plaintext.txt	95	Human Molecular Genetics 7 1887 1892
0.31515914.11823322.html.plaintext.txt	96	et al 1996 Wide range age onset chromosome I related familial Alzheimers disease
0.31515914.11823322.html.plaintext.txt	97	Annals Neurology 40 932 936
0.31515914.11823322.html.plaintext.txt	98	et al 1998 Alpha 2 macroglobulin genetically associated Alzheimers disease
0.31515914.11823322.html.plaintext.txt	99	et al 1998 A polymorphism regulatory region APOE associated risk Alzheimers dementia
0.31515914.11823322.html.plaintext.txt	100	et al 1998 Accelerated decline apolipoprotein E epsilon4 homozygotes Alzheimers disease
0.31515914.11823322.html.plaintext.txt	101	et al 1998 Estimation genetic contribution presenilin 1 2 mutations population based study presenile Alzheimer disease
0.31515914.11823322.html.plaintext.txt	102	Human Molecular Genetics 7 43 51
0.31515914.11823322.html.plaintext.txt	103	et al 2000 Linkage plasma A ss 42 quantitative locus chromosome 10 late onset Alzheimers disease pedigrees
0.31515914.11823322.html.plaintext.txt	104	et al 1999 Promoter polymorphism 491AT APOE gene Finnish Alzheimers disease patients control individuals
0.31515914.11823322.html.plaintext.txt	105	Journal Neurology 246 821 824
0.31515914.11823322.html.plaintext.txt	106	et al 1998 5 HT2A 5 HT2C receptor polymorphisms psychopathology late onset Alzheimers disease
0.31515914.11823322.html.plaintext.txt	107	Human Molecular Genetics 7 1507 1509
0.31515914.11823322.html.plaintext.txt	108	et al 1999 A full genome scan late onset Alzheimers disease
0.31515914.11823322.html.plaintext.txt	109	Human Molecular Genetics 8 237 245
0.31515914.11823322.html.plaintext.txt	110	et al 1998 Pronounced impact Th1E47 cs mutation compared 491 AT mutation neural APOE gene expression risk developing Alzheimers disease
0.31515914.11823322.html.plaintext.txt	111	Human Molecular Genetics 7 1511 1516
0.31515914.11823322.html.plaintext.txt	112	et al 1998 APOE genotype predicts whether one predisposed develop Alzheimer disease
0.31515914.11823322.html.plaintext.txt	113	et al 2000 Susceptibility locus Alzheimers disease chromosome 10
0.31515914.11823322.html.plaintext.txt	114	et al 1990 Association family history affective disorder depressive syndrome Alzheimers disease
0.31515914.11823322.html.plaintext.txt	115	American Journal Psychiatry 147 452 456
0.31515914.11823322.html.plaintext.txt	116	et al 1997 Complete genomic screen late onset familial Alzheimer disease
0.31515914.11823322.html.plaintext.txt	117	Evidence new locus chromosome 12
0.31515914.11823322.html.plaintext.txt	118	et al 1998 Dopamine receptor genetic variation psychosis aggression Alzheimers disease
0.31515914.11823322.html.plaintext.txt	119	Archives Neurology 55 1335 1340
0.31515914.11823322.html.plaintext.txt	120	et al 2000 Familial influence variation age onset behavioural phenotype Alzheimers disease
0.31515914.11823322.html.plaintext.txt	121	British Journal Psychiatry 176 156 159
0.31515914.11823322.html.plaintext.txt	122	et al 1998 A novel Polish presenilin 2 mutation P117L associated familial Alzheimers disease leads death early age 28 years
0.31515914.11823322.html.plaintext.txt	123	et al 1998 Genetic studies chromosome 12 late onset Alzheimer disease
0.31515914.11823322.html.plaintext.txt	124	et al 2000 APOE promoter polymorphisms confer independent risk Alzheimers Disease French population
0.31515914.11823322.html.plaintext.txt	125	European Journal Human Genetics 8 713 716
0.31515914.11823322.html.plaintext.txt	126	Received publication May 16 2000
0.31515914.11823322.html.plaintext.txt	127	Revision received May 14 2001
0.31515914.11823322.html.plaintext.txt	128	Accepted publication May 23 2001
0.31515914.11823322.html.plaintext.txt	129	Highlights issue ELIZABETH WALSH BJP 2002 180 0
0.31515914.11823322.html.plaintext.txt	130	Old age psychiatry ALISTAIR BURNS IAN G
0.33803913.15066991.html.plaintext.txt	0	Apolipoprotein A I stimulated Apolipoprotein E Secretion Human Macrophages Is Independent Cholesterol Efflux Maaike Kockxa Kerry Anne Ryeb Katharina Gausa Carmel M
0.33803913.15066991.html.plaintext.txt	1	Quinna Janelle Wrighta Timothy Sloanea Dimitri Sviridovc Ying Fuc David Sullivand John R
0.33803913.15066991.html.plaintext.txt	2	Burnette Stephan Rustf Gerd Assmannf G
0.33803913.15066991.html.plaintext.txt	3	Palgunacharig Sissel Lund Katzh Michael C
0.33803913.15066991.html.plaintext.txt	4	Deani Wendy Jessupa Leonard Kritharidesabjk
0.33803913.15066991.html.plaintext.txt	5	From Macrophage Biology Group Centre Vascular Research University New South Wales Sydney 2052 Australia b The Heart Research Institute Sydney 2050 Australia c Baker Heart Research Institute Melbourne 8008 Australia d Department Clinical Biochemistry Royal Prince Alfred Hospital University Sydney Sydney 2050 Australia e Department Core Clinical Pathology Biochemistry Royal Perth Hospital School Medicine Pharmacology University Western Australia Perth 6847 Australia f Institut fur Arterioskleroseforschung der Westfalischen Wilhelms Universitat Munster Munster 48149 Germany g University Alabama Birmingham Medical Center Birmingham Alabama 35294 hChildrens Hospital Philadelphia Stokes Research Institute Philadelphia Pennsylvania 19104 4318 University Canberra Australian Capital Territory 2601 Australia j Department Cardiology Concord Hospital University Sydney Sydney 2139 Australia
0.33803913.15066991.html.plaintext.txt	6	Received publication February 3 2004 revised form March 29 2004
0.33803913.15066991.html.plaintext.txt	7	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Apolipoprotein A I apoA I mediated cholesterol efflux involves binding apoA I plasma membrane via C terminus requires cellular ATP binding cassette transporter ABCA1 activity
0.33803913.15066991.html.plaintext.txt	8	ApoA I also stimulates secretion apolipoprotein E apoE macrophage foam cells although mechanism process understood
0.33803913.15066991.html.plaintext.txt	9	In study demonstrate apoA I stimulates secretion apoE independently ABCA1 mediated cholesterol efflux lipid binding C terminus
0.33803913.15066991.html.plaintext.txt	10	Pulse chase experiments using 35S labeled cellular apoE demonstrate macrophage apoE exists relatively mobile Em stable Es pools apoA I diverts apoE degradation secretion small proportion apoA I mobilized apoE derived cell surface
0.33803913.15066991.html.plaintext.txt	11	The structural requirements induction apoE secretion cholesterol efflux clearly dissociated C terminal deletions recombinant apoA I reduce cholesterol efflux increase apoE secretion deletion central helices 5 6 decreases apoE secretion without perturbing cholesterol efflux
0.33803913.15066991.html.plaintext.txt	12	Moreover range 11 22 mer helical peptides representing amphipathic helical segments apoA I stimulate apoE secretion whereas C terminal helix domains 220 241 stimulates cholesterol efflux
0.33803913.15066991.html.plaintext.txt	13	Other helix containing apolipoproteins apoA II apoA IV apoE2 apoE3 apoE4 also stimulate apoE secretion implying positive feedback autocrine loop apoE secretion although apoE4 less effective
0.33803913.15066991.html.plaintext.txt	14	Finally apoA I stimulates apoE secretion normally macrophages two unrelated subjects genetically confirmed Tangier Disease mutations C733R c
0.33803913.15066991.html.plaintext.txt	15	5220 5222delTCT mutations A1046D c
0.33803913.15066991.html.plaintext.txt	16	4629 4630insA despite severely inhibited cholesterol efflux
0.33803913.15066991.html.plaintext.txt	17	We conclude apoA I stimulates secretion apoE independently cholesterol efflux represents novel ABCA 1 independent positive feedback pathway stimulation potentially anti atherogenic apoE secretion helix containing molecules including apoA I apoE
0.33803913.15066991.html.plaintext.txt	18	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES The anti atherogenic effects high density lipoprotein HDL1 1 least part attributed ability HDL stimulate cholesterol phospholipid efflux lipid loaded macrophages providing initial step reverse cholesterol transport RCT
0.33803913.15066991.html.plaintext.txt	19	Apolipoprotein A I apoA I major protein component HDL understood play important role process 1
0.33803913.15066991.html.plaintext.txt	20	Lipid removal apoA I involves cAMP inducible active transport pathway 2 known mediated ATP binding cassette transporter 1 ABCA1ABC 1 3
0.33803913.15066991.html.plaintext.txt	21	These transporters membrane proteins utilize ATP hydrolysis transport substrates across membranes 4
0.33803913.15066991.html.plaintext.txt	22	Mutations ABCA1ABC 1 cause Tangier disease TD severe HDL deficiency syndrome characterized low plasma levels HDL apoA I accumulation cholesterol tissue macrophages predisposition atherosclerosis 5 7
0.33803913.15066991.html.plaintext.txt	23	Fibroblasts subjects Tangier disease show impaired cholesterol phospholipid release lipid free apolipoproteins 8
0.33803913.15066991.html.plaintext.txt	24	In addition inhibition ABCA1 expression activity inhibits lipid efflux apoA I normal fibroblasts 3 6
0.33803913.15066991.html.plaintext.txt	25	Properties additional induction cholesterol efflux may contribute anti atherogenic effect apoA 1
0.33803913.15066991.html.plaintext.txt	26	Human atherosclerotic lesions contain apoE protein mRNA especially association macrophage foam cells 9
0.33803913.15066991.html.plaintext.txt	27	Secretion apoE macrophages may protect atherosclerosis indicated effects transplantation apoE expressing bone marrow apoE null mice 10 11
0.33803913.15066991.html.plaintext.txt	28	This may depend upon enhanced local clearance cellular lipids andor inhibition local inflammatory responses addition lowering plasma concentrations atherogenic plasma lipoproteins
0.33803913.15066991.html.plaintext.txt	29	Recent studies demonstrated apoA I stimulates apoE secretion cholesterol efflux human mouse foam cell macrophages 12 13
0.33803913.15066991.html.plaintext.txt	30	Stimulation apoE secretion apoA I HDL likely post transcriptionally regulated observed endogenous apoE macrophages recycled apoE hepatocytes 12 15
0.33803913.15066991.html.plaintext.txt	31	Recent studies indicate ABCA1 may involved basal apoE secretion 16
0.33803913.15066991.html.plaintext.txt	32	However requirement ABCA1 activity apoA I induced apoE secretion never reported
0.33803913.15066991.html.plaintext.txt	33	In study provide evidence apoA I stimulated apoE secretion mechanistically distinct stimulation ABCA1 mediated cholesterol efflux
0.33803913.15066991.html.plaintext.txt	34	We demonstrate apoA I promotes secretion mobile pool apoE otherwise destined intracellular degradation process require interactions C terminus apoA I plasma membrane occurs normally macrophages patients Tangier disease implying independence ABCA1 activity
0.33803913.15066991.html.plaintext.txt	35	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Reagents All solvents high performance liquid chromatography HPLC grade Mallinckrodt
0.33803913.15066991.html.plaintext.txt	36	Polyclonal goat anti human antibodies human apoE obtained Chemicon International Inc
0.33803913.15066991.html.plaintext.txt	37	For immunoblotting nitrocellulose membranes non denaturing gel electrophoresis polyclonal goat antibodies human apoA I polyclonal sheep antibodies human apoA II Roche Applied Science used
0.33803913.15066991.html.plaintext.txt	38	Secondary rabbit polyclonal anti goat anti sheep horseradish peroxidase linked antibodies nitrocellulose membranes 0
0.33803913.15066991.html.plaintext.txt	39	45 microm enhanced chemiluminescence ECL reagents Hyperfilm obtained Amersham Biosciences
0.33803913.15066991.html.plaintext.txt	40	Human apoE standard Biodesign
0.33803913.15066991.html.plaintext.txt	41	12n 3Hcholesterol methyl 3Hcholine chloride supplied Amersham Biosciences specific activity 44 Cimmol 79 Cimmol respectively
0.33803913.15066991.html.plaintext.txt	42	LDL acetylated LDL AcLDL 3Hcholesterol labeled AcLDL prepared described 17 18
0.33803913.15066991.html.plaintext.txt	43	1 Palmitoyl 2 oleoyl phosphatidylcholine POPC egg yolk sphingomyelin SPM sodium cholate purchased Sigma
0.33803913.15066991.html.plaintext.txt	44	Bicinchoninic acid BCA reagent protein determination also supplied Sigma Aldrich
0.33803913.15066991.html.plaintext.txt	45	For pulse chase studies methionine free medium supplied Invitrogen 35STRAN label 1175 Cimmol ICN
0.33803913.15066991.html.plaintext.txt	46	Apolipoproteins Human apoA I apoA II isolated HDL ultracentrifugation anion exchange chromatography 17 19
0.33803913.15066991.html.plaintext.txt	47	Human apoA IV isolated density 1
0.33803913.15066991.html.plaintext.txt	48	25 gml fraction plasma adsorption onto synthetic triglyceride rich microemulsions
0.33803913.15066991.html.plaintext.txt	49	The microemulsions delipidated apoA IV purified anion exchange chromatography Q Sepharose fast flow column 20 21
0.33803913.15066991.html.plaintext.txt	50	Human apoE2 apoE3 apoE4 expressed BL21 Escherichia coli provided Dr
0.33803913.15066991.html.plaintext.txt	51	Karl Weisgraber Gladstone Institute purified gel filtration chromatography
0.33803913.15066991.html.plaintext.txt	52	ApoA I Peptides Recombinant Proteins Pure peptides representing peptides apoA I synthesized using automated solid phase peptide synthesizer described previously 22 24
0.33803913.15066991.html.plaintext.txt	53	To promote helical stability peptide molecules N C termini acetylated amidated except peptide 1 33 respectively 25
0.33803913.15066991.html.plaintext.txt	54	Truncated apoA I propeptide mutants expressed E
0.33803913.15066991.html.plaintext.txt	55	coliPGEX expression system 26
0.33803913.15066991.html.plaintext.txt	56	Cholesterol efflux proteins previously published 27
0.33803913.15066991.html.plaintext.txt	57	ApoA I deletion mutants constructed described previously 28 29
0.33803913.15066991.html.plaintext.txt	58	Wild type apoA I engineered variants apoA I expressed expression host E
0.33803913.15066991.html.plaintext.txt	59	coli strain Bl21 DE3 isolated gel filtration anion exchange chromatography 29
0.33803913.15066991.html.plaintext.txt	60	Identical stimulation apoE secretion human macrophage foam cells observed control experiments using recombinant wild type apoA I human apoA I prepared human plasma
0.33803913.15066991.html.plaintext.txt	61	In previous studies established 5 10 microgml apoA I saturating cholesterol efflux apoE secretion human murine macrophages 13
0.33803913.15066991.html.plaintext.txt	62	In present studies peptides proteins added cells final concentration 25 microgml culture medium first establishing excess saturating concentrations induction apoE secretion molecules
0.33803913.15066991.html.plaintext.txt	63	Preparation Phospholipid ApoA I Phospholipid ApoA II Discs Discs prepared described previously 19 using cholate dialysis method 30
0.33803913.15066991.html.plaintext.txt	64	After preparation discs dialyzed extensively 0
0.33803913.15066991.html.plaintext.txt	65	01 M Tris buffered saline containing 0
0.33803913.15066991.html.plaintext.txt	66	005 wv EDTA Na2 0006 wv NaN3 stored argon
0.33803913.15066991.html.plaintext.txt	67	Lipid free apoA I apoA II present preparations judged electrophoresis non denaturing 3 40 gradient gels
0.33803913.15066991.html.plaintext.txt	68	Phospholipid composition varied altering proportions phospholipids added time preparation
0.33803913.15066991.html.plaintext.txt	69	All chemical analyses reconstituted particles carried RocheHitachi 902 analyzer Roche Diagnostics Zurich Switzerland
0.33803913.15066991.html.plaintext.txt	70	Phospholipid concentrations determined enzymatically 31 32
0.33803913.15066991.html.plaintext.txt	71	The Stokes diameter surface charge particles measured non denaturing PAGE agarose gel electrophoresis 19 33
0.33803913.15066991.html.plaintext.txt	72	In experiments cell efflux incubations media containing apoA I phospholipid apoA II phospholipid discs underwent non denaturing polyacrylamide gel electrophoresis followed electrophoretic transfer nitrocellulose membranes immunoblotting apoE apoA I apoA II investigate possible association apoE phospholipid containing particles
0.33803913.15066991.html.plaintext.txt	73	Isolation Culture Human Monocyte derived Macrophages HMDM Human monocytes apoE3E3 phenotype isolated white cell concentrates healthy donors using centrifugal elutriation described 13
0.33803913.15066991.html.plaintext.txt	74	Genotyping completed Taq polymerase chain reaction amplification 232 base pair fragment apoE gene followed cutting restriction endonuclease Cfo1 Department Biochemistry Royal Prince Alfred Hospital
0.33803913.15066991.html.plaintext.txt	75	White cell buffy coat concentrates 24 h ex vivo human serum provided New South Wales Red Cross blood transfusion service Sydney Australia
0.33803913.15066991.html.plaintext.txt	76	Purified monocytes 95 purity nonspecific esterase staining differentiated plating 1
0.33803913.15066991.html.plaintext.txt	77	5 x 106 cells per 22 mm diameter culture dish Costar RPMI 1640 containing penicillin G streptomycin 50 unitsml 50 microgml respectively L glutamine 2 mM 10 vv heat inactivated whole human serum 6 days
0.33803913.15066991.html.plaintext.txt	78	Following differentiation cells washed enriched unesterified cholesterol FC cholesteryl ester CE incubation RPMI 1640 containing 10 LPDS vv AcLDL 50 microg proteinml 4 days 13
0.33803913.15066991.html.plaintext.txt	79	Mononuclear cells individual donors Tangier disease subjects controls isolated minor modification previously described density separation method 34 35 using OptiPrepTM solution density 1
0.33803913.15066991.html.plaintext.txt	80	068 gml solution density 1
0.33803913.15066991.html.plaintext.txt	81	063 gml remove platelets lymphocytes respectively
0.33803913.15066991.html.plaintext.txt	82	Total cells plated density 2 x 106 cells22 mm diameter culture well Falcon
0.33803913.15066991.html.plaintext.txt	83	Cells differentiated macrophages RPMI 1640 containing antibiotics glutamine 50 ngml M CSF 36 heat inactivated whole human serum 13 37 6 days
0.33803913.15066991.html.plaintext.txt	84	At time cells washed prior cholesterol enrichment see
0.33803913.15066991.html.plaintext.txt	85	Direct comparisons HMDM isolated normal donors density centrifugation centrifugal elutriation confirmed identical cholesterol efflux apoE secretion either method
0.33803913.15066991.html.plaintext.txt	86	Lipid Efflux ApoE Secretion To achieve cholesterol loading macrophages 2 microCiml 3Hcholesterol ethanol incorporated AcLDL incubating cells 4 days described 18
0.33803913.15066991.html.plaintext.txt	87	Triplicate cultures harvested loading confirm efficient enrichment FC CE HPLC
0.33803913.15066991.html.plaintext.txt	88	Cells subsequently washed equilibrated overnight RPMI 1640 containing 0
0.33803913.15066991.html.plaintext.txt	89	1 wv bovine serum albumin allow equilibration 3Hcholesterol FC CE pools
0.33803913.15066991.html.plaintext.txt	90	In experiments cells loaded AcLDL without 3Hcholesterol phospholipids labeled end 4 day cholesterol loading period incubating cells RPMI 1640 containing 3 microCiml 3Hcholine chloride ethanol final 2 vv 0
0.33803913.15066991.html.plaintext.txt	91	1 bovine serum albumin wv 22 h followed equilibration 1 h RPMI 1640 containing 0
0.33803913.15066991.html.plaintext.txt	92	Equilibrated cholesterol enriched cells washed warm PBS incubated 1
0.33803913.15066991.html.plaintext.txt	93	0 ml efflux medium comprising RPMI 1640 without 25 microgml apoA I appropriate additions
0.33803913.15066991.html.plaintext.txt	94	After 1 8 h media removed mixed Complete protease inhibitor Roche Applied Science 0
0.33803913.15066991.html.plaintext.txt	95	02 TIU aprotinin Sigma spun 2 min 16000 x g remove detached cells
0.33803913.15066991.html.plaintext.txt	96	The cultures washed twice ice cold PBS scraped 0
0.33803913.15066991.html.plaintext.txt	97	8 ml cold PBS containing Complete protease inhibitor aprotinin
0.33803913.15066991.html.plaintext.txt	98	Quantitation Cholesterol Cholesteryl Ester Cells Media 40 microl media aliquots 5 microl cell aliquots analyzed scintillation counting quantify efflux 3Hcholesterol
0.33803913.15066991.html.plaintext.txt	99	The proportions label cell 3HFC 3HCE determined separation TLC heptaneethyl acetate 11 vv
0.33803913.15066991.html.plaintext.txt	100	Standards FC CE identified charring 100 degrees C 10 CuSO4 8
0.33803913.15066991.html.plaintext.txt	101	The masses FC CE cells media determined reverse phase HPLC extraction methanolhexane 17 38
0.33803913.15066991.html.plaintext.txt	102	Radiochemical equilibrium determined calculating specific activity free esterified cholesterol dpm per nmol 18 reproducibly achieved 4 days cholesterol enrichment overnight equilibration
0.33803913.15066991.html.plaintext.txt	103	Quantitation Phospholipids Cells Media Phospholipids extracted 150 microl aliquots cell lysates media samples using method Bligh Dyer including two backwashes methanolwater 109 vv described previously 39
0.33803913.15066991.html.plaintext.txt	104	After evaporation chloroform phase lipids dissolved 200 microl chloroformmethanol 21 vv 50 microl aliquots counted scintillation counting determine phospholipid efflux
0.33803913.15066991.html.plaintext.txt	105	Total phospholipid mass determined using modification Bartlett assay described 40 used determine specific activity dpm per nmol phospholipid
0.33803913.15066991.html.plaintext.txt	106	Quantitation ApoE Cell Lysates Efflux Media Western Blot ELISA Aliquots 55 microl cell culture medium mixed sample buffer 27
0.33803913.15066991.html.plaintext.txt	107	5 microl containing 10 mM dithiothreitol heated 100 degrees C 5 min separated SDS PAGE using 4 stacking gel 12
0.33803913.15066991.html.plaintext.txt	108	5 polyacrylamide resolving gel reducing conditions Tris glycine buffer described 13
0.33803913.15066991.html.plaintext.txt	109	Electrophoretic Western blot transfer onto 0
0.33803913.15066991.html.plaintext.txt	110	45 microM nitrocellulose membranes performed Trisglycine buffer 1 h 25 30 V blocked incubating primary antibody apoE goat anti human polyclonal 15000 dilution washing incubating 15000 dilution secondary antibody rabbit anti goat IgG conjugated horseradish peroxidase 13
0.33803913.15066991.html.plaintext.txt	111	Membrane chemiluminescence signal quantified using Kodak Digital Science 1D expressed arbitrary units AU per mg cell protein
0.33803913.15066991.html.plaintext.txt	112	In experiments serial dilution authentic human apoE standard sample buffer separated blotted parallel allow calculation secreted apoE mass microgram per culture microg per mg cell protein
0.33803913.15066991.html.plaintext.txt	113	The linear response range chemiluminescence signal mass authentic human apoE standard defined Western blot experiment
0.33803913.15066991.html.plaintext.txt	114	In addition apoE secretion measured experiments using ELISA
0.33803913.15066991.html.plaintext.txt	115	NUNC 96 well immunoplates coated 1
0.33803913.15066991.html.plaintext.txt	116	5 microgml mouse monoclonal anti human apoE antibody Biodesign 0
0.33803913.15066991.html.plaintext.txt	117	Standards prepared purified human apoE Biodesign whereas antibodies used Western analysis used tagging antibodies goat anti human polyclonal 13750 rabbit antigoat horseradish peroxidase 12500
0.33803913.15066991.html.plaintext.txt	118	Metabolic Labeling Cell Proteins 35SMethionineCysteine To study fate newly synthesized apoE cholesterol enriched HMDM labeled methionine free medium Invitrogen containing 250 microCiml 35STRAN label 1175 Cimmol ICN 3 h washed chased RPMI 1640 media containing 2 mM methionine Sigma cysteine Sigma
0.33803913.15066991.html.plaintext.txt	119	35S labeled apoE cell lysates culture medium determined immunoprecipitation using 110000 dilution polyclonal goat antibody human apoE protein A Sepharose Amersham Biosciences separation SDS PAGE quantified phosphorimaging Photostimulated Luminescence Fujix BAS 1000 expressed AU apoEmg cell protein 13
0.33803913.15066991.html.plaintext.txt	120	Where indicated experiments detecting small amounts secreted apoE requiring increased sensitivity immunoprecipitated 35S labeled apoE directly quantified radiometric detection confirming single band SDS PAGE phosphorimaging
0.33803913.15066991.html.plaintext.txt	121	35SMethioninecysteine labeling also used discriminate cell derived secreted exogenous apoE experiments investigating secretion apoE recombinant apoE2 E3 E4
0.33803913.15066991.html.plaintext.txt	122	Biotinylation Isolation Biotinylated ApoE Cholesterol enriched HMDM incubated 200 microCiml 35STRAN label methionine free Dulbeccos modified Eagles medium DMEM containing 10 DMEM 16 h
0.33803913.15066991.html.plaintext.txt	123	Surface proteins biotinylated placing cells ice 5 min followed incubation 1 mgml sulfo NHS SS Biotin Pierce PBS 4 degrees C 45 min
0.33803913.15066991.html.plaintext.txt	124	Cells washed twice ice cold PBS subsequently incubated without 25 microgml apoA I 30 min 37 degrees C
0.33803913.15066991.html.plaintext.txt	125	ApoE immunoprecipitated described biotinylated apoE separated total immunoprecipitated apoE described 41
0.33803913.15066991.html.plaintext.txt	126	In short total apoE released protein A Sepharose beads boiling 100 microl HEPES buffered saline containing 1 SDS 90 degrees C 3 min
0.33803913.15066991.html.plaintext.txt	127	Biotinylated apoE separated unbiotinylated apoE using ImmunoPure Immobilized Streptavidin Pierce quantified using scintillation counting SDS PAGEphosphorimaging
0.33803913.15066991.html.plaintext.txt	128	Biotinylated apoE quantified AU apoEmg cell protein percent total immunoprecipitated secreted apoE
0.33803913.15066991.html.plaintext.txt	129	5 total cellular apoE biotinylated 34
0.33803913.15066991.html.plaintext.txt	130	7 cellular apoE protein plasma membrane fractions isolated sucrose density gradient 42
0.33803913.15066991.html.plaintext.txt	131	As cell surface proteins biotinylated 4 degrees C 41 estimated 11
0.33803913.15066991.html.plaintext.txt	132	2 plasma membrane pool apoE biotinylated experiments
0.33803913.15066991.html.plaintext.txt	133	Analysis apoE mRNA Real Time PCR Cells harvested total RNA using Tri Reagent Sigma according manufacturers instructions exception 1 bromo 3 chloropropane Sigma substituted chloroform
0.33803913.15066991.html.plaintext.txt	134	For reverse transcription reaction 1 microg total RNA reverse transcribed using oligodT primers Invitrogen Superscript II reverse transcriptase Invitrogen
0.33803913.15066991.html.plaintext.txt	135	Relative real time RT PCR performed using IQ SYBR Green Supermix Bio Rad ABI 7700 Sequence Detector PE Biosystems analyzed using ABI Prism sequence detector software v1
0.33803913.15066991.html.plaintext.txt	136	Gene specific primers used follows ApoE 5 CTGCTCAGCTCCCAGGTCACCCAGG 3forward 5 CTTCTGCAGGTCATCGGCATCGCGG 3reverse annealing 60 degrees C 30 cycles product size 321 base pairs
0.33803913.15066991.html.plaintext.txt	137	ABCA1 5 GCACTGAGGAAGATGCTGAAA 3forward 5 AGTTCCTGGAAGGTCTTGTTCAC 3 reverse annealing 60 degrees C 28 cycles product size 205 base pairs
0.33803913.15066991.html.plaintext.txt	138	Results normalized housekeeping gene PBGD 5 GAGTGATTCGCGTGGGTACC 3 forward 5 GGCTCCGATGGTGAAGCC 3 reverse annealing 55 60 degrees C
0.33803913.15066991.html.plaintext.txt	139	Melting curve analysis performed confirm production single product reactions
0.33803913.15066991.html.plaintext.txt	140	Results exposure apoA I related without apoA I RPMI 1640 medium control experiment results three experiments averaged
0.33803913.15066991.html.plaintext.txt	141	Sucrose Density Ultracentrifugation To determine buoyant density secreted apoE media samples subjected sucrose density ultracentrifugation using minor modification published protocol 43
0.33803913.15066991.html.plaintext.txt	142	Following efflux 625 microl aliquots media centrifuged 16000 x g 2 min remove cellular debris supernatant underlayed
0.33803913.15066991.html.plaintext.txt	143	Underlay completed using 2 ml 1
0.33803913.15066991.html.plaintext.txt	144	23 ml 35 sucrose solution 1
0.33803913.15066991.html.plaintext.txt	145	23 ml 65 sucrose solution 5
0.33803913.15066991.html.plaintext.txt	146	1 ml Beckman quick seal tubes samples centrifuged 100000 rpm 543000 x g 20 h 16 degrees C using TL100
0.33803913.15066991.html.plaintext.txt	147	4 rotor Beckman TLX Ultracentrifuge
0.33803913.15066991.html.plaintext.txt	148	15 x 250 microl aliquots taken analyzed 3Hcholesterol apoE Western blot
0.33803913.15066991.html.plaintext.txt	149	Tangier Disease Patients TD1 TD2 A previously unreported 56 year old male clinical features consistent Tangier Disease TD1 identified
0.33803913.15066991.html.plaintext.txt	150	The patient premature coronary artery disease low plasma HDL cholesterol 3
0.33803913.15066991.html.plaintext.txt	151	7 mgdl normal range 30 70 mgdl apoA I concentrations 0
0.33803913.15066991.html.plaintext.txt	152	006 mgdl normal 110 140 mgdl low total cholesterol 61
0.33803913.15066991.html.plaintext.txt	153	4 mgdl normal range 116 225 mgdl LDL cholesterol 19
0.33803913.15066991.html.plaintext.txt	154	3 mgdl normal range 50 190 mgdl level
0.33803913.15066991.html.plaintext.txt	155	He also elevated plasma triglycerides 177
0.33803913.15066991.html.plaintext.txt	156	6 mgdl normal 200 mgdl bilateral cataracts hepatomegaly
0.33803913.15066991.html.plaintext.txt	157	There splenomegaly tonsils removed childhood
0.33803913.15066991.html.plaintext.txt	158	Assmann Institut fur Arterioskleroseforschung der Westfalischen Wilhelms Universitat Munster Germany
0.33803913.15066991.html.plaintext.txt	159	Two novel amino acid mutations within ABCA1 gene found C733R exon 16 c
0.33803913.15066991.html.plaintext.txt	160	2197C T deletion three nucleotides exon 38 c
0.33803913.15066991.html.plaintext.txt	161	5220 5222delTCT different alleles shown segregation analysis numbering follows recommendations international nomenclature working group
0.33803913.15066991.html.plaintext.txt	162	Both mutations affect amino acids conserved human mice
0.33803913.15066991.html.plaintext.txt	163	Neither mutations previously described
0.33803913.15066991.html.plaintext.txt	164	A healthy subject normal lipoprotein profile history vascular disease used source control macrophages HC1
0.33803913.15066991.html.plaintext.txt	165	Since completion study TD1 died
0.33803913.15066991.html.plaintext.txt	166	A second TD patient TD2 healthy normal brother HC2 heterozygous parents HZ2A mother HZ2B father previously described 44 45
0.33803913.15066991.html.plaintext.txt	167	The ABCA1 mutations TD patient published missense mutation exon 21 A986D frameshift mutation exon 33 4570insA A1484 X1492 45
0.33803913.15066991.html.plaintext.txt	168	Using current nomenclature respectively equivalent missense mutation exon 22 c
0.33803913.15066991.html.plaintext.txt	169	3137C A A1046D frameshift mutation exon 34 c
0.33803913.15066991.html.plaintext.txt	170	4629 4630insA A1544 fs X1552
0.33803913.15066991.html.plaintext.txt	171	HC2 neither ABCA1 mutation HZ2A HZ2B contain 4629insA A1046D mutations respectively
0.33803913.15066991.html.plaintext.txt	172	Plasma HDL cholesterol concentrations HC2 TD2 HZ2A HZ2B respectively 43
0.33803913.15066991.html.plaintext.txt	173	6 mgdl apoA I levels respectively 129 4
0.33803913.15066991.html.plaintext.txt	174	Plasma triglyceride concentrations elevated subjects 507
0.33803913.15066991.html.plaintext.txt	175	Protein Estimation Protein contents LDL samples cell lysates determined duplicate triplicate sample measured using BCA method bovine serum albumin standard 17
0.33803913.15066991.html.plaintext.txt	176	Cell Viability Cell viability following various treatments routinely assessed light microscopic morphology estimation cell protein measuring leakage lactate dehydrogenase medium 46
0.33803913.15066991.html.plaintext.txt	177	Cell viability routinely 85 100 incubation efflux media
0.33803913.15066991.html.plaintext.txt	178	Data Analysis The degradation secretion cellular apoE pulse chase experiments simultaneously fitted first order rate equation k1 k2 describing rate constants secretion degradation respectively
0.33803913.15066991.html.plaintext.txt	179	The first order rate equation shown Equation 1
0.33803913.15066991.html.plaintext.txt	180	1 fitted experimental secretion degradation data using non linear least squares fitting program Solver Microsoft Excel
0.33803913.15066991.html.plaintext.txt	181	The quality fit evaluated error function previously described 42
0.33803913.15066991.html.plaintext.txt	182	Efflux calculated 3Hlipids e
0.33803913.15066991.html.plaintext.txt	183	cholesterol phospholipid released medium expressed percentage total 3H cellular lipids T0 17 18
0.33803913.15066991.html.plaintext.txt	184	Unless otherwise stated data presented mean plus minus S
0.33803913.15066991.html.plaintext.txt	185	triplicate cultures single experiments representative least 2 3 independent experiments
0.33803913.15066991.html.plaintext.txt	186	The significance results assessed unpaired Students test simple comparisons two groups one way analysis variance using Tukeys test post hoc correction multiple comparisons
0.33803913.15066991.html.plaintext.txt	187	Differences considered significant p 0
0.33803913.15066991.html.plaintext.txt	188	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES ApoA I Stimulates Secretion ApoE We previously shown apoA I stimulates secretion murine macrophage apoE time concentration dependent manner inhibited transcription inhibitor actinomycin D 13
0.33803913.15066991.html.plaintext.txt	189	Here confirm apoA I stimulates apoE secretion primary human macrophages time dependent manner without affecting net cell associated apoE protein cellular apoE mRNA levels Fig
0.33803913.15066991.html.plaintext.txt	190	Secreted apoE always 34 kDa consistent known extensive glycosylation secreted apoE whereas cell associated apoE multiple masses consistent variable degrees glycosylation apoE processing within cells
0.33803913.15066991.html.plaintext.txt	191	View larger version 21K FIG
0.33803913.15066991.html.plaintext.txt	192	Post transcriptional stimulation apoE secretion apoA I
0.33803913.15066991.html.plaintext.txt	193	HMDM incubated 4 days 50 microgml AcLDL washed incubated times indicated RPMI 1640 apoA I without Control 25 microgml apoA I
0.33803913.15066991.html.plaintext.txt	194	ApoE protein determined Western blotting 8 h A three independent cell cultures media cell lysates ELISA variable times B
0.33803913.15066991.html.plaintext.txt	195	ApoE mRNA levels C determined 8 h real time RT PCR relative housekeeping gene PBGD described Experimental Procedures
0.33803913.15066991.html.plaintext.txt	196	To determine effect apoA I secretion degradation preformed apoE absence ongoing de novo synthesis pulse chase experiments performed
0.33803913.15066991.html.plaintext.txt	197	Pulse incubations first incorporated 35Smethionine cellular apoE chased without apoA I absence label Fig
0.33803913.15066991.html.plaintext.txt	198	ApoA I rapidly stimulated secretion 35SapoE differences apoA I containing control media apparent within 30 min incubation
0.33803913.15066991.html.plaintext.txt	199	Analysis residual cell 35S labeled apoE chase incubations demonstrated rapid nearly identical decline cell associated apoE without apoA I
0.33803913.15066991.html.plaintext.txt	200	Net degradation apoE cells plus media lower apoA I containing cultures relative control conditions matched increased secretion apoE apoA I containing media
0.33803913.15066991.html.plaintext.txt	201	The identical rate decline cell associated apoE control apoA I exposed conditions suggests apoA I diverts apoE secretion cellular pool apoE otherwise degraded
0.33803913.15066991.html.plaintext.txt	202	View larger version 15K FIG
0.33803913.15066991.html.plaintext.txt	203	ApoA I stimulates secretion preformed apoE decreases net apoE degradation
0.33803913.15066991.html.plaintext.txt	204	HMDM incubated 4 days 50 microgml AcLDL washed incubated methionine free Dulbeccos modified Eagles medium 200 microCiml 35Smethioninecysteine 3 h
0.33803913.15066991.html.plaintext.txt	205	Cells washed chased without 25 microgml apoA I
0.33803913.15066991.html.plaintext.txt	206	At indicated times 35S labeled apoE immunoprecipitated media cell lysates separated detected SDS PAGE phosphorimaging single 34 kDa band measured scintillation counting excised band described Experimental Procedures
0.33803913.15066991.html.plaintext.txt	207	At start chase T0 total apoE 2
0.33803913.15066991.html.plaintext.txt	208	A secreted apoE B cell associated apoE C net degradation apoE calculated subtracting residual apoE cells media apoE cells T0
0.33803913.15066991.html.plaintext.txt	209	All data expressed percent total apoE T0
0.33803913.15066991.html.plaintext.txt	210	To investigate pool apoE mobilized apoA I degradation secretion cellular apoE simultaneously fitted first order rate equation k1 describing rate constant secretion k2 degradation
0.33803913.15066991.html.plaintext.txt	211	As previously described boundary conditions accepting modeling experimental data error function ERF 0
0.33803913.15066991.html.plaintext.txt	212	An initial model assumed de novo synthesized apoE equally susceptible degradation secretion net degradation secretion proceeded constant rates independent
0.33803913.15066991.html.plaintext.txt	213	However comparison experimental calculated data using model identified ERF excessive fulfill boundary conditions ERF control 0
0.33803913.15066991.html.plaintext.txt	214	A second model simultaneously fitted degradation secretion 35S labeled cellular apoE first order rate equation described Experimental Procedures
0.33803913.15066991.html.plaintext.txt	215	The cellular labeled apoE start chase divided two pools larger mobile pool apoE EM 75 smaller stable pool Es 25 neither degraded secreted duration experiment
0.33803913.15066991.html.plaintext.txt	216	The presence Es apparent residual pool undegraded cell associated apoE presence stable pool previously identified surface HepG2 cells 47
0.33803913.15066991.html.plaintext.txt	217	Using model secretion degradation apoE mutually dependent boundary conditions goodness fit fulfilled Fig
0.33803913.15066991.html.plaintext.txt	218	ApoA I increased rate constant secretion k1 decreased rate constant degradation k2 relative control conditions substantially alter size Es Em
0.33803913.15066991.html.plaintext.txt	219	Thus apoA I stimulated secretion mobile pool apoE otherwise fated intracellular degradation
0.33803913.15066991.html.plaintext.txt	220	View larger version 16K FIG
0.33803913.15066991.html.plaintext.txt	221	ApoA I diverts apoE degradation secretion
0.33803913.15066991.html.plaintext.txt	222	The degradation secretion 35S labeled cellular apoE pulse chase experiments simultaneously fitted first order rate equation described Experimental Procedures
0.33803913.15066991.html.plaintext.txt	223	A model apoE turnover Es Em representing stable mobile cellular apoE pools respectively k1 k2 respectively describing rate constants secretion degradation
0.33803913.15066991.html.plaintext.txt	224	B experimental open symbols dashed line calculated closed symbols solid line kinetic data secreted cellular degraded apoE presence apoA I
0.33803913.15066991.html.plaintext.txt	225	C summary modeling parameters Es representing percent cellular apoE stable pool ERF representing error function modeling parameters
0.33803913.15066991.html.plaintext.txt	226	We considered cell surface apoE might contribute mobile pool apoE secreted apoA I apoE mobilized surface cells 48
0.33803913.15066991.html.plaintext.txt	227	To investigate 35Smethionine labeled HMDM incubated 4 degrees C biotin label cell surface proteins cells exposed control media apoA I 30 min 37 degrees C allow apoE secretion Fig
0.33803913.15066991.html.plaintext.txt	228	Cell medium samples sequentially immunoprecipitated first using antibodies apoE biotin
0.33803913.15066991.html.plaintext.txt	229	ApoA I stimulated secretion biotin labeled apoE 2 fold relative control medium indicating cell surface apoE contribute secreted apoE
0.33803913.15066991.html.plaintext.txt	230	However biotin labeled apoE represented 2 secreted apoE control 0
0.33803913.15066991.html.plaintext.txt	231	3 conditions 30 min much less estimated proportion plasma membrane apoE biotinylated 11
0.33803913.15066991.html.plaintext.txt	232	2 see Experimental Procedures
0.33803913.15066991.html.plaintext.txt	233	These data indicated net contribution cell surface pool overall apoE secretion minor
0.33803913.15066991.html.plaintext.txt	234	View larger version 11K FIG
0.33803913.15066991.html.plaintext.txt	235	ApoA I stimulates release cell surface pools apoE
0.33803913.15066991.html.plaintext.txt	236	HMDM cholesterol enriched AcLDL radiolabeled 35S methioninecysteine 16 h
0.33803913.15066991.html.plaintext.txt	237	A 35Smethionine labeled HMDM placed ice 4 degrees C cell surface proteins biotinylated described Experimental Procedures
0.33803913.15066991.html.plaintext.txt	238	Cells incubated medium without Control 25 microgml apoA I apoA I 30 min 37 degrees C
0.33803913.15066991.html.plaintext.txt	239	Total 35S labeled apoE immunoprecipitated biotinylated pool immunoprecipitated pool quantified
0.33803913.15066991.html.plaintext.txt	240	Total 35S labeled apoE immunoprecipitated cell cultures T0 838768 plus minus 33266 dpmmg cell protein
0.33803913.15066991.html.plaintext.txt	241	B 35Smethionine labeled HMDM placed ice incubated without apoA I 30 min 4 degrees C
0.33803913.15066991.html.plaintext.txt	242	35S labeled apoE released medium immunoprecipitated quantified represented 3
0.33803913.15066991.html.plaintext.txt	243	5 total cellular apoE T0 Control apoA I respectively
0.33803913.15066991.html.plaintext.txt	244	significantly different versus Control p 0
0.33803913.15066991.html.plaintext.txt	245	As cell surface apoE re endocytosed 41 pool biotin labeled apoE secreted apoA I could represent apoE directly mobilized cell surface apoE re internalized re secreted although little recycling would expected 30 min
0.33803913.15066991.html.plaintext.txt	246	To confirm apoA I directly mobilizes cell surface apoE 35Smethionine labeled HMDM precooled 4 degrees C incubated control medium apoA I 4 degrees C 30 min Fig
0.33803913.15066991.html.plaintext.txt	247	ApoA I approximately doubled release cell surface apoE 4 degrees C 3
0.33803913.15066991.html.plaintext.txt	248	5 total cell apoE present T0 indicating cell surface apoE contribute directly mobile pool apoE released apoA I although overall remains minor proportion total apoE released
0.33803913.15066991.html.plaintext.txt	249	C terminal Truncations pro ApoA I Differentially Affect Cholesterol Efflux ApoE Secretion Previous studies indicated C terminus apoA I particularly important stimulation cholesterol efflux binding apoA I cell surface 49 related lipid binding ability C terminus 27 50
0.33803913.15066991.html.plaintext.txt	250	We investigated role C terminus inducing apoE secretion primary human foam cell macrophages using recombinant pro apoA I 6 243 truncations C terminus 6 150 6 222 Fig
0.33803913.15066991.html.plaintext.txt	251	Initial studies confirmed pro apoA I native human apoA I induced similar cholesterol efflux apoE secretion data shown
0.33803913.15066991.html.plaintext.txt	252	Consistent previous studies HepG2 cells 27 deletion C terminal 21 amino acids 6 222 decreased cholesterol efflux relative whole apoA I 6 243 whereas deletion C terminal 93 amino acids 6 150 effect
0.33803913.15066991.html.plaintext.txt	253	This correlated relative abilities proteins stimulate phospholipid efflux Fig
0.33803913.15066991.html.plaintext.txt	254	In contrast C terminal deletions increased apoE secretion relative full length pro apoA I
0.33803913.15066991.html.plaintext.txt	255	The discrepant effects C terminal deletion lipid efflux apoE secretion suggest induction apoE secretion linked apoA I lipid affinity stimulation cholesterol efflux via ABCA1
0.33803913.15066991.html.plaintext.txt	256	View larger version 18K FIG
0.33803913.15066991.html.plaintext.txt	257	Truncation C terminal domain recombinant pro apoA I increases apoE secretion human macrophages
0.33803913.15066991.html.plaintext.txt	258	Monocytes differentiated incubated 4 days 50 microgml AcLDL 3Hcholesterol A AcLDL 3Hcholine B described Experimental Procedures
0.33803913.15066991.html.plaintext.txt	259	Cells washed equilibrated incubated RPMI 1640 Control 25 microgml indicated recombinant whole pro apoA I 6 243 pro apoA I varying C terminal truncations 6 222 6 150
0.33803913.15066991.html.plaintext.txt	260	Aliquots media removed 8 h cholesterol efflux A phospholipid efflux B apoE secretion C Western blot inset measured described Experimental Procedures
0.33803913.15066991.html.plaintext.txt	261	Lipid composition loading T0 FC 38
0.33803913.15066991.html.plaintext.txt	262	5 nmolmg cell protein specific activity FC 17856 plus minus 3188 dpmnmol specific activity CE 22771 plus minus 6928 dpmnmol
0.33803913.15066991.html.plaintext.txt	263	B specific activity PL 45817 plus minus 6110 dpmnmol
0.33803913.15066991.html.plaintext.txt	264	significantly different versus control values p 0
0.33803913.15066991.html.plaintext.txt	265	05 significantly different versus 6 243 pro apoA I p 0
0.33803913.15066991.html.plaintext.txt	266	Selected Deletions Point Mutations Recombinant A I Modulate Stimulation ApoE Secretion The 6 amino acid residue N terminal prosegment pro apoA I interfere cholesterol efflux apoA I 27
0.33803913.15066991.html.plaintext.txt	267	However structural requirements apoE secretion cholesterol efflux appeared dissociated studied second series recombinant apoA I molecules lacking propeptide
0.33803913.15066991.html.plaintext.txt	268	The roles C terminus N terminus central protein LCAT activation domains d123 166 mediating apoA I stimulated apoE secretion cholesterol efflux determined Fig
0.33803913.15066991.html.plaintext.txt	269	View larger version 22K FIG
0.33803913.15066991.html.plaintext.txt	270	Recombinant ApoA I selected deletions differentially promote apoE secretion human macrophages
0.33803913.15066991.html.plaintext.txt	271	Monocytes differentiated cholesterol enriched incubated RPMI 1640 Control 25 microgml whole apoA I 25 microgml recombinant apoA I proteins deletions C terminal d190 243 N terminal d44 126 central d123 166 domains
0.33803913.15066991.html.plaintext.txt	272	Aliquots media removed 8 h cholesterol efflux A apoE secretion B measured described Experimental Procedures
0.33803913.15066991.html.plaintext.txt	273	Lipid composition loading 0 FC 79
0.33803913.15066991.html.plaintext.txt	274	1 nmolmg cell protein CE 26
0.33803913.15066991.html.plaintext.txt	275	3 nmolmg cell protein specific activity FC 63622 plus minus 3234 dpmnmol specific activity CE 74321 plus minus 15523 dpmnmol
0.33803913.15066991.html.plaintext.txt	276	Recombinant whole apoA I isolated human apoA I induced identical apoE secretion cholesterol efflux data shown
0.33803913.15066991.html.plaintext.txt	277	significantly different versus apoA I p 0
0.33803913.15066991.html.plaintext.txt	278	Deletion major domains within N terminal segment d44 126 central protein segment d123 166 stimulated equivalent cholesterol efflux whole apoA I whereas recombinant apoA I C terminal deletion d190 243 significantly less effective intact apoA I Fig
0.33803913.15066991.html.plaintext.txt	279	6A consistent previous reports 29
0.33803913.15066991.html.plaintext.txt	280	Although d190 243 caused much less cholesterol efflux induced significantly apoE secretion native intact apoA I
0.33803913.15066991.html.plaintext.txt	281	Significantly deletion central region apoA I domain d123 166 important stimulation apoE secretion absence domain halved apoE secretion relative whole apoA I effect cholesterol efflux
0.33803913.15066991.html.plaintext.txt	282	This consistent important role apoA I flexibility recently described 29 contributing apoE secretion
0.33803913.15066991.html.plaintext.txt	283	These data also support findings experiments using pro apoA I indicating C terminal membrane binding lipid efflux rate limiting apoA I mediated apoE secretion
0.33803913.15066991.html.plaintext.txt	284	Synthetic Peptides Representing Helical Segments ApoA I Induce ApoE Secretion ApoA I contains 10 helical segments 11 22 amino acids length 24
0.33803913.15066991.html.plaintext.txt	285	Peptides representing segments induce cholesterol efflux approximately proportion lipid bilayer binding lipid affinity segment 50
0.33803913.15066991.html.plaintext.txt	286	To investigate whether apparent differences recombinant apoA I molecules stimulation apoE secretion attributable specific helical domains within apoA I particularly N terminal central domains compared apoE secretion 11 22 mer helical peptides representing specific amphipathic helical segments apoA I Table I
0.33803913.15066991.html.plaintext.txt	287	Only C terminal peptide 220 241 stimulated cholesterol efflux significantly basal control medium level
0.33803913.15066991.html.plaintext.txt	288	Although significant cholesterol efflux peptide 220 241 less intact apoA I 6
0.33803913.15066991.html.plaintext.txt	289	05 consistent previous literature 50
0.33803913.15066991.html.plaintext.txt	290	In contrast cholesterol efflux helical peptides stimulated apoE secretion
0.33803913.15066991.html.plaintext.txt	291	0 fold control medium many peptides achieved stimulation apoE secretion equivalent achieved apoA I e
0.33803913.15066991.html.plaintext.txt	292	peptides 1 33 44 87 88 120 143 186 220 241
0.33803913.15066991.html.plaintext.txt	293	There correlation known helical content peptides 24 stimulation apoE secretion R2 0
0.33803913.15066991.html.plaintext.txt	294	The peptides studied represent segments N terminus central region C terminus apoA I many display low lipid affinity 50
0.33803913.15066991.html.plaintext.txt	295	This indicates stimulation apoE secretion whole apoA I recombinant apoA I molecules attributable individual helical segments isolated domains within apoA I
0.33803913.15066991.html.plaintext.txt	296	View table TABLE I Cholesterol efflux apoE secretion helical segments apoA I
0.33803913.15066991.html.plaintext.txt	297	HMDM incubated 8 h RPMI 1640 medium alone control control medium containing 25 microgml apoA I control medium containing 25 microgml helical peptides representing segments apoA I
0.33803913.15066991.html.plaintext.txt	298	Values mean plus minus S
0.33803913.15066991.html.plaintext.txt	299	triplicate cultures one experiment representative three experiments
0.33803913.15066991.html.plaintext.txt	300	Percent cholesterol efflux calculated dividing 3Hcholesterol released medium total 3Hcholesterol cells equilibration T0 apoE determined Western blotting
0.33803913.15066991.html.plaintext.txt	301	Buoyant Density ApoE Secreted Response ApoA I Previous studies shown secreted apoE predominantly lipidated density 1
0.33803913.15066991.html.plaintext.txt	302	21 gml 12 51 proportion secreted apoE cell surface apoE lipid poor 48 52
0.33803913.15066991.html.plaintext.txt	303	As apoA I mediated apoE secretion appeared independent apoA I lipid affinity apoA I mediated lipid efflux investigated whether apoA I induced secretion non lipidated non buoyant apoE Fig
0.33803913.15066991.html.plaintext.txt	304	Under basal conditions without apoA I secreted apoE found buoyant density range 1
0.33803913.15066991.html.plaintext.txt	305	22 gml predominant density 1
0.33803913.15066991.html.plaintext.txt	306	Addition apoA I stimulated increase apoE across density range 1
0.33803913.15066991.html.plaintext.txt	307	22 gml although proportion present less buoyant fractions density 1
0.33803913.15066991.html.plaintext.txt	308	20 gml much greater controls
0.33803913.15066991.html.plaintext.txt	309	The density distribution cell derived cholesterol media basal stimulated conditions 1
0.33803913.15066991.html.plaintext.txt	310	17 gml corresponding buoyant apoE fractions
0.33803913.15066991.html.plaintext.txt	311	Thus apoE secreted control stimulated conditions buoyant however presence apoA I significant proportion dense cholesterol containing particles medium
0.33803913.15066991.html.plaintext.txt	312	These observations consistent independent regulation apoE secretion cholesterol efflux apoA I exposure suggest apoA I induces pathway apoE secretion distinct involved basal apoE secretion
0.33803913.15066991.html.plaintext.txt	313	View larger version 32K FIG
0.33803913.15066991.html.plaintext.txt	314	Density secreted apoE without stimulation apoA I
0.33803913.15066991.html.plaintext.txt	315	Monocytes differentiated loaded 4 days 50 microgml AcLDL 3Hcholesterol washed equilibrated incubated control medium plus minus 25 microgml apoA I
0.33803913.15066991.html.plaintext.txt	316	Aliquots media subjected ultracentrifugation 1
0.33803913.15066991.html.plaintext.txt	317	33 65 sucrose gradients analyzed 3Hcholesterol apoE described Experimental Procedures
0.33803913.15066991.html.plaintext.txt	318	A cholesterol efflux without open circles apoA I closed circles B apoE secretion without open circles apoA I closed circles
0.33803913.15066991.html.plaintext.txt	319	Density fractions indicated open diamonds
0.33803913.15066991.html.plaintext.txt	320	Total cholesterol efflux control apoA I 3
0.33803913.15066991.html.plaintext.txt	321	0 respectively total apoE secretion control apoA I 0
0.33803913.15066991.html.plaintext.txt	322	In C fractions analyzed Western blot diluting media cultures exposed apoA I 4
0.33803913.15066991.html.plaintext.txt	323	0 fold facilitate comparison relative distribution apoE among fractions
0.33803913.15066991.html.plaintext.txt	324	Data representative three independent experiments
0.33803913.15066991.html.plaintext.txt	325	Stimulation ApoE Secretion Is Induced Other Helix containing Apolipoproteins The broad specificity stimulation apoE secretion helical peptides apoA I suggested amphiphathic containing apolipoproteins might induce apoE secretion
0.33803913.15066991.html.plaintext.txt	326	Such apolipoproteins specifically apoA II apoA IV 53 also stimulate cholesterol phospholipid efflux cells 50 vary markedly total helical content hydrophobicity 54
0.33803913.15066991.html.plaintext.txt	327	We incubated apolipoproteins HMDM saturating conditions 25 microgml found human apoA I apoA II apoA IV stimulated apoE secretion equally effectively Fig
0.33803913.15066991.html.plaintext.txt	328	They also induced similar modest cholesterol efflux primary human macrophages ranging 8 15 8 h 2 3 fold control medium significant difference apolipoproteins induction cholesterol efflux multiple independent experiments
0.33803913.15066991.html.plaintext.txt	329	View larger version 19K FIG
0.33803913.15066991.html.plaintext.txt	330	ApoE secretion stimulated apolipoproteins apoA I
0.33803913.15066991.html.plaintext.txt	331	Monocytes differentiated cholesterol enriched AcLDL radiolabeled 35Smethionine incubation 25 microgml indicated apolipoprotein
0.33803913.15066991.html.plaintext.txt	332	A aliquots media removed 8 h apoE immunoprecipitated secretion media containing apoA I apoA II apoA IV apoE3 determined AU 35SapoE per mg cell protein phosphorimaging 34 kDa band described Experimental Procedures
0.33803913.15066991.html.plaintext.txt	333	ApoE secretion apoA I A II A IV confirmed Western blot well phosphorimaging
0.33803913.15066991.html.plaintext.txt	334	In B data expressed AU 35Smethionine labeled apoE secretedmg cell protein
0.33803913.15066991.html.plaintext.txt	335	Cholesterol efflux apolipoproteins 2 3 fold control differ apolipoproteins data shown
0.33803913.15066991.html.plaintext.txt	336	significantly different versus apoE3 p 0
0.33803913.15066991.html.plaintext.txt	337	ApoE also HDL associated contains helixes extracellular apoE stimulate secretion apoE macrophages may mediate potentially anti atherogenic autocrine loop artery wall
0.33803913.15066991.html.plaintext.txt	338	ApoE stimulate secretion de novo synthesized 35S labeled apoE comparable efficiency apoA I apoA II apoA IV
0.33803913.15066991.html.plaintext.txt	339	E2 E3 E4 differ effects risk atherosclerosis differ substantially helix organization N C terminal domain organization 55 respective lipid binding properties C terminus 56
0.33803913.15066991.html.plaintext.txt	340	We therefore investigated whether structural differences affected stimulation apoE secretion
0.33803913.15066991.html.plaintext.txt	341	All three isoforms stimulated macrophage apoE secretion basal levels
0.33803913.15066991.html.plaintext.txt	342	However apoE3 stimulated apoE secretion apoE4 p 0
0.33803913.15066991.html.plaintext.txt	343	In contrast cholesterol efflux three apoE isoforms differ data shown consistent previous study 2
0.33803913.15066991.html.plaintext.txt	344	On non reducing SDS PAGE apoE3 E2 contain one two cysteine molecules respectively self associated trimers tetramers reducible dithiothreitol whereas apoE4 data shown
0.33803913.15066991.html.plaintext.txt	345	Thus possible either N C terminal organization exogenous apoE4 lesser self association may contribute lesser apoE secretion isoform
0.33803913.15066991.html.plaintext.txt	346	ApoA I Maintains Ability Stimulate ApoE Secretion Its Lipid bound Conformation When complexed phospholipids e
0.33803913.15066991.html.plaintext.txt	347	nascent HDL discs apoA I undergoes conformational change increases helicity molecule 54 57 potentially increases exposure polar residues cell surface
0.33803913.15066991.html.plaintext.txt	348	Such changes may affect efficacy apoA I mediated apoE secretion lipidated particles
0.33803913.15066991.html.plaintext.txt	349	ApoE secretion may thus diminished critical domains apoA I obscured lipidation may enhanced greater exposure polar domains enhances apoE secretion
0.33803913.15066991.html.plaintext.txt	350	There also potential synergy phospholipid apoA I previous studies identified lipid soluble pool apoE associated extracellular matrix HepG2 cells macrophages 13 41 48 58
0.33803913.15066991.html.plaintext.txt	351	ApoA I phospholipid discs containing POPC A I POPC POPCSPM A I POPCSPM compared POPC liposomes lipid free apoA I ability induce cholesterol efflux apoE secretion Table II
0.33803913.15066991.html.plaintext.txt	352	Acceptors added concentrations matched apoA I content allow accurate comparisons efficiency stimulating apoE secretion
0.33803913.15066991.html.plaintext.txt	353	Lipidation apoA I POPC significantly increased apoE secretion 2 3 fold relative apoA I alone whereas POPC alone significantly stimulate apoE secretion
0.33803913.15066991.html.plaintext.txt	354	These data suggest lipidation apoA I promotes apoE secretion might caused secondary conformational changes increased exposure polar residues apoA I cell surface
0.33803913.15066991.html.plaintext.txt	355	View table TABLE II Lipidation enhances apoE secretion apoA I apoA II
0.33803913.15066991.html.plaintext.txt	356	Pre HDL important initial acceptors cell cholesterol 59 represent dynamic pool apoA I may play role stimulating apoE secretion artery wall
0.33803913.15066991.html.plaintext.txt	357	As pre HDL contain increased concentrations SPM relative mature HDL 59 investigated whether SPM modulated ability apoA I stimulate apoE secretion whether cholesterol efflux modulated parallel Table II
0.33803913.15066991.html.plaintext.txt	358	A I POPCSPM particles containing 25 SPM 75 POPC achieved 1
0.33803913.15066991.html.plaintext.txt	359	05 cholesterol efflux achieved A I POPC increase apoE secretion relative A I POPC
0.33803913.15066991.html.plaintext.txt	360	This indicates synergistic interaction apoA I phospholipids inducing apoE secretion independent variations phospholipid subtype
0.33803913.15066991.html.plaintext.txt	361	ApoA II higher average residue hydrophobicity apoA I 54
0.33803913.15066991.html.plaintext.txt	362	Consequently conformation POPC disc may differ apoA I
0.33803913.15066991.html.plaintext.txt	363	Unlike secretion apoA I apoA II stimulated apoE secretion increased significantly lipidation POPC even though cholesterol efflux enhanced Table II Part B
0.33803913.15066991.html.plaintext.txt	364	This suggests relatively specific conformation change apoA I seen apoA II important enhanced stimulation apoE secretion apoA I following lipidation
0.33803913.15066991.html.plaintext.txt	365	To investigate whether secreted apoE associated apoA I POPC particles density gradient analysis non denaturing gel electrophoresis performed efflux media
0.33803913.15066991.html.plaintext.txt	366	ApoE shared buoyant density effluxed cholesterol apoA I media containing apoA I POPC discs density range 1
0.33803913.15066991.html.plaintext.txt	367	This differed media containing lipid free apoA I effluxed cholesterol buoyant density secreted apoE consistent possibility apoE associated apoA I POPC discs
0.33803913.15066991.html.plaintext.txt	368	This directly investigated non denaturing gel electrophoresis media containing apoA I POPC apoA II POPC discs followed electrophoretic transfer nitrocellulose membranes immunoblotting apoA I apoA II apoE 33
0.33803913.15066991.html.plaintext.txt	369	After efflux apoA I apoA II migrated POPC discs 9
0.33803913.15066991.html.plaintext.txt	370	6 nm diameter respectively without evidence displacement lipid free apoA I apoA II discs data shown
0.33803913.15066991.html.plaintext.txt	371	Most secreted apoE migrated large diameter 17
0.33803913.15066991.html.plaintext.txt	372	1 nm particles small proportion migrated particles diameter apoA I apoA II POPC containing discs 9
0.33803913.15066991.html.plaintext.txt	373	The association apoE apoA I POPC apoA II POPC discs would expected increase size particles
0.33803913.15066991.html.plaintext.txt	374	As size apoA I POPC apoA II POPC particles unaltered secretion apoE data suggest secreted apoE significantly associate apoA I apoA II POPC discs displace apoA I apoA II particles
0.33803913.15066991.html.plaintext.txt	375	These results also imply amount apoE secreted apoA I POPC apoA II POPC particles explained differential displacement apoA I apoA II POPC particles
0.33803913.15066991.html.plaintext.txt	376	ApoA I mediated ApoE Secretion Is Independent ABCA1 Activity ApoA I mediated cholesterol efflux known critically dependent upon ABCA1 activity
0.33803913.15066991.html.plaintext.txt	377	Our data dissociating structural requirements apoA I stimulated apoE secretion cholesterol efflux imply apoA I mediated apoE secretion may independent ABCA1
0.33803913.15066991.html.plaintext.txt	378	Patients Tangier disease impaired ABCA1 activity although previous study indicated basal apoE secretion impaired TD macrophages 16 apoA I stimulated apoE secretion investigated
0.33803913.15066991.html.plaintext.txt	379	To directly investigate role ABCA1 apoE secretion human macrophages studied macrophages two unrelated patients molecular clinical cellular phenotypes TD
0.33803913.15066991.html.plaintext.txt	380	The first subject TD TD1 see Experimental Procedures compound heterozygote novel ABCA1 mutations C733R exon 16 deletion three nucleotides c
0.33803913.15066991.html.plaintext.txt	381	5220 5222 delTCT exon 38 TD1 HMDM
0.33803913.15066991.html.plaintext.txt	382	ApoA I mediated cholesterol efflux TD1 HMDM severely impaired relative unrelated healthy control HC1 HMDM confirming cellular TD phenotype Table III A
0.33803913.15066991.html.plaintext.txt	383	Basal apoE secretion lower TD1 HMDM HC1 macrophages consistent earlier study 16
0.33803913.15066991.html.plaintext.txt	384	However apoA I strongly stimulated apoE secretion TD1 HMDM 11 fold increase p 0
0.33803913.15066991.html.plaintext.txt	385	01 relative control media control HMDM 3
0.33803913.15066991.html.plaintext.txt	386	01 relative control media achieving total apoE secretion TD1 HMDM HC1 HMDM
0.33803913.15066991.html.plaintext.txt	387	Thus despite severely impaired ABCA 1 mediated cholesterol efflux apoA I stimulated apoE secretion normally TD macrophages
0.33803913.15066991.html.plaintext.txt	388	View table TABLE III ApoA I induced apoE secretion normal HMDM subjects Tangier Disease
0.33803913.15066991.html.plaintext.txt	389	Note apoA I stimulated apoE secretion significantly differ subjects panels A B
0.33803913.15066991.html.plaintext.txt	390	All cellular data mean plus minus S
0.33803913.15066991.html.plaintext.txt	391	three cell cultures subject
0.33803913.15066991.html.plaintext.txt	392	To exclude mutation specific effect macrophages second unrelated Tangier Patient TD2 HMDM see Experimental Procedures studied
0.33803913.15066991.html.plaintext.txt	393	Cells TD2 compound heterozygote mutations A1046D c
0.33803913.15066991.html.plaintext.txt	394	4629 4630insA compared healthy brother known free ABCA1 mutations HC2 HMDM heterozygous parents mutations 4629insA HZ2A HMDM A1046D HZ2B HMDM 44 45 Table III B
0.33803913.15066991.html.plaintext.txt	395	Basal cholesterol efflux similar four subjects 0
0.33803913.15066991.html.plaintext.txt	396	ApoA I mediated cholesterol efflux TD2 cells severely impaired relative family members confirming dysfunctional ABCA1
0.33803913.15066991.html.plaintext.txt	397	Despite apoA I strongly equally increased apoE secretion macrophages including TD2 HMDM
0.33803913.15066991.html.plaintext.txt	398	These findings support structural studies clearly dissociate apoA I induced cholesterol efflux via ABCA1 apoA I induced apoE secretion
0.33803913.15066991.html.plaintext.txt	399	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES The secretion apoE macrophages shown anti atherogenic 11 factors enhance secretion may important targets treatment prevention atherosclerosis
0.33803913.15066991.html.plaintext.txt	400	We demonstrated apoA I stimulates secretion mobile pool apoE part derived cell surface otherwise destined intracellular degradation
0.33803913.15066991.html.plaintext.txt	401	We also identified first time biological activity apoA I independent lipid binding properties demonstrating apoA I stimulated apoE secretion enhanced C terminal deletions independent ABCA 1 mediated cholesterol efflux
0.33803913.15066991.html.plaintext.txt	402	These data establish non ABCA1 mediated processes contribute prosecretory roles potentially anti atherogenic effects apoA I
0.33803913.15066991.html.plaintext.txt	403	In previous studies including secretion apoE exposure cells HDL apoA I concurrent efflux cholesterol 12 1560
0.33803913.15066991.html.plaintext.txt	404	However cyclodextrin stimulated cholesterol efflux induce apoE secretion acute inhibition apoE synthesis secretion cycloheximide inhibit cholesterol efflux apoA I 13
0.33803913.15066991.html.plaintext.txt	405	The latter observations dissociate stimulation apoA I mediated cholesterol efflux apoE secretion
0.33803913.15066991.html.plaintext.txt	406	A similar dissociation earlier reported HDL mediated cholesterol efflux apoE secretion 61
0.33803913.15066991.html.plaintext.txt	407	We investigated detail structural functional requirements apoA I induced apoE secretion identify quite distinct required apoA I induced cholesterol efflux
0.33803913.15066991.html.plaintext.txt	408	ApoA I increase macrophage apoE mRNA levels pulse chase experiments demonstrate apoA I stimulates secretion newly synthesized apoE confirming apoA I stimulates apoE secretion post transcriptionally
0.33803913.15066991.html.plaintext.txt	409	Modeling pulse chase data indicated human macrophages contain larger mobile pool apoE Em lesser stable pool apoE Es
0.33803913.15066991.html.plaintext.txt	410	Previous studies indicate heterogeneous pools apoE may include apoE cell surface 47
0.33803913.15066991.html.plaintext.txt	411	Pronase treatment human macrophages experimental conditions indicates small proportion Es cell surface
0.33803913.15066991.html.plaintext.txt	412	2 Em basis biotin labeling 4 degrees C displacement studies part derived cell surface pool apoE apoA I increases secretion concurrently diminishes degradation apoE pool
0.33803913.15066991.html.plaintext.txt	413	However biotin labeled pool represents minor proportion total apoE secreted 2 quantitative significance unclear
0.33803913.15066991.html.plaintext.txt	414	These data consistent either continual displacement apoE cell surface recycling ongoing replenishment intracellular pools 41 consistent two sources secreted apoE smaller cell surface pool larger intracellular pool mobilized apoA I
0.33803913.15066991.html.plaintext.txt	415	It clear structural requirements apoA I mediated apoE secretion distinct required cholesterol efflux
0.33803913.15066991.html.plaintext.txt	416	Our studies recombinant pro apoA I molecules demonstrate deletion C terminus apoA I enhances apoE secretion whereas impairs cholesterol efflux phospholipid efflux
0.33803913.15066991.html.plaintext.txt	417	This remarkable previous studies apoA I function emphasized importance lipid binding C terminal domain functional integrity binding extracellular matrix cell surface 62
0.33803913.15066991.html.plaintext.txt	418	That C terminal deletion enhances apoE secretion suggests apoA I bind extracellular matrix achieve 62
0.33803913.15066991.html.plaintext.txt	419	This consistent previous studies indicating heparinase pretreatment inhibit apoA I mediated apoE secretion primary macrophages 13
0.33803913.15066991.html.plaintext.txt	420	The central domain apoA I regulates LCAT activity 63 HDL mediated inhibition macrophage homing atherosclerotic plaque 64
0.33803913.15066991.html.plaintext.txt	421	Deletion central region apoA I d123 166 modification decreased stimulation apoE secretion apoA I
0.33803913.15066991.html.plaintext.txt	422	As domain affects apoA I flexibility 29 suggests whole apoA I flexibility important lipid affinity inducing apoE secretion
0.33803913.15066991.html.plaintext.txt	423	It unlikely contain epitope specific apoA I induced apoE secretion given helical peptides away domain apolipoproteins also induced apoE secretion
0.33803913.15066991.html.plaintext.txt	424	Whether apolipoprotein flexibility also important apolipoproteins e
0.33803913.15066991.html.plaintext.txt	425	apoA II apoA IV apoEs unknown
0.33803913.15066991.html.plaintext.txt	426	Systematic comparison individual helical peptides apoA I identified C terminal helical peptide capable independently inducing cholesterol efflux primary human macrophages consistent earlier studies 50
0.33803913.15066991.html.plaintext.txt	427	In contrast helical peptides stimulated apoE secretion
0.33803913.15066991.html.plaintext.txt	428	As cholesterol efflux peptides related lipid affinity 50 property appear determine induction apoE secretion
0.33803913.15066991.html.plaintext.txt	429	Stimulation apoE secretion appears general structural property helical proteins peptides case whole apoA I enhanced overall protein flexibility inhibited lipid binding plasma membrane
0.33803913.15066991.html.plaintext.txt	430	One striking observations enhanced secretion apoE apoA I POPC discs relative apoA I
0.33803913.15066991.html.plaintext.txt	431	This observed apoA II stimulated apoE secretion extent free lipid bound state
0.33803913.15066991.html.plaintext.txt	432	The difference response lipidation apoA I apoA II interesting given cholesterol efflux apolipoproteins increased lipidation
0.33803913.15066991.html.plaintext.txt	433	Apolipoprotein mediated apoE secretion may allow subsequent binding secreted apoE exogenous phospholipids could explain apparent synergy apoA I POPC
0.33803913.15066991.html.plaintext.txt	434	However association apoE apoA I apoA II POPC discs would expected require displacement apoA I apoA II andor increase apparent size POPC containing particles neither found non denaturing gel electrophoresis
0.33803913.15066991.html.plaintext.txt	435	The absence synergy apoA II POPC therefore suggests conformational changes unique apoA I occur lipidation
0.33803913.15066991.html.plaintext.txt	436	We suggest apoA I exposes polar non lipid bound residues POPC disc apoA II enhances interaction exposed residues apoE cell surface undefined plasma membrane sites critical stimulating vesicular trafficking apoE cell surface
0.33803913.15066991.html.plaintext.txt	437	ApoA I A II A IV E3 apolipoprotein phospholipid discs stimulated apoE secretion efficiently indicating stimulation apoE secretion broad relevance vivo
0.33803913.15066991.html.plaintext.txt	438	The ability apoE stimulate apoE secretion highly significant local autocrine secretion apoE artery wall could mediate apoE secretion neighboring cells independently requirement plasma derived HDL species
0.33803913.15066991.html.plaintext.txt	439	ApoE4 increases risk atherosclerosis Alzheimers disease relative apoE3 65
0.33803913.15066991.html.plaintext.txt	440	Reduced local stimulation apoE secretion apoE4 artery CNS might contribute disease states associated apoE4 phenotype
0.33803913.15066991.html.plaintext.txt	441	ApoE4 differs apoE3 single amino acid substitution arginine instead cysteine position 112
0.33803913.15066991.html.plaintext.txt	442	This confers positive apoE charge causes conformational change N terminal helix apoE4 salt bridge forms Arg112 Glu109 alters conformation Arg61 interacts Glu255 55
0.33803913.15066991.html.plaintext.txt	443	E4 also differs E3 E2 lacking potential disulfide formation self association
0.33803913.15066991.html.plaintext.txt	444	In previous study Smith et al
0.33803913.15066991.html.plaintext.txt	445	2 identified binding E2 E3 E4 RAW macrophages cholesterol efflux induced isoforms
0.33803913.15066991.html.plaintext.txt	446	Our studies confirmed similar efflux various apoE isoforms supporting differences inducible apoE secretion cannot explained altered efflux binding
0.33803913.15066991.html.plaintext.txt	447	A recent study indicates apoE4 higher lipid affinity apoE isoforms 56 respect data support observations C terminal deletions apoA I diminish lipid affinity enhance ability induce apoE secretion
0.33803913.15066991.html.plaintext.txt	448	That apoA I mediated cholesterol efflux apoE secretion independently regulated directly confirmed apoA I stimulated apoE secretion two unrelated subjects clinical molecular cellular phenotype Tangier disease
0.33803913.15066991.html.plaintext.txt	449	Despite impaired ABCA1 mediated cholesterol efflux severely reduced basal apoE secretion apoA I stimulated apoE secretion normally
0.33803913.15066991.html.plaintext.txt	450	Recent studies shown apoA I mediated cholesterol efflux via ABCA1 linked accelerated secretory vesicular transport Golgi plasma membrane absent Tangier disease fibroblasts 66
0.33803913.15066991.html.plaintext.txt	451	As apoA I stimulated apoE secretion normally Tangier disease macrophages conclude apoA I must stimulate distinct pathway apoE secretion unrelated interactions ABCA1 stimulation cholesterol efflux
0.33803913.15066991.html.plaintext.txt	452	As apoE secretion induced apoA I severalfold greater basal apoE secretion ABCA1 independent secretion likely quantitatively important related ABCA1 activity
0.33803913.15066991.html.plaintext.txt	453	To knowledge findings represent first reported non ABCA1 mediated cellular process mediated apoA I
0.33803913.15066991.html.plaintext.txt	454	It unlikely apoA I stimulates apoE secretion directly inhibiting lysosomal proteasomal degradation apoE
0.33803913.15066991.html.plaintext.txt	455	ApoE degraded lysosomal proteasomal compartments 67 68 although direct inhibition lysosomal cysteine proteases inhibit apoE degradation increase apoE secretion 58
0.33803913.15066991.html.plaintext.txt	456	The possibility apoA I exchanges cellular apoE apoA I degraded place apoE also seems unlikely mass apoA I degraded corresponds 30 mass apoE secreted human macrophages time course experiments
0.33803913.15066991.html.plaintext.txt	457	3 It likely apoA I promotes apoE secretion inhibiting trafficking degradatory compartments lysosome proteasome stimulating vesicular traffic plasma membrane analogous effects described fibroblasts 66
0.33803913.15066991.html.plaintext.txt	458	Although HDL stimulates range protein kinase C dependent independent signaling pathways necessarily activated apoA I 69 mechanisms apoA I regulates vesicle traffic general protein secretion particular require investigation
0.33803913.15066991.html.plaintext.txt	459	We conclude apoA I mediated apoE secretion structural requirements distinct regulating stimulation cholesterol efflux facilitated central hinge region apoA I inhibited C terminal domain independent macrophage ABCA1 activity
0.33803913.15066991.html.plaintext.txt	460	This represents novel ABCA 1 independent positive feedback process secretion anti atherogenic cholesterol efflux inducing apoE helix containing molecules
0.33803913.15066991.html.plaintext.txt	461	FOOTNOTES This work supported grants aid W
0.33803913.15066991.html.plaintext.txt	462	National Health Medical Research Council Australia National Institutes Health Grants HL22633 HL34343 National Heart Foundation Australia Australian Research Council K
0.33803913.15066991.html.plaintext.txt	463	The costs publication article defrayed part payment page charges
0.33803913.15066991.html.plaintext.txt	464	This article must therefore hereby marked advertisement accordance 18 U
0.33803913.15066991.html.plaintext.txt	465	Section 1734 solely indicate fact
0.33803913.15066991.html.plaintext.txt	466	k To correspondence addressed Macrophage Biology Group Centre Vascular Research 4th Floor Wallace Wurth Bldg
0.33803913.15066991.html.plaintext.txt	467	University New South Wales UNSW Sydney NSW 2052 Australia
0.33803913.15066991.html.plaintext.txt	468	61 2 93851179 Fax 61 2 93851389 E mail l
0.33803913.15066991.html.plaintext.txt	469	1 The abbreviations used HDL high density lipoprotein PLV phospholipid vesicles apoA apolipoprotein ABCA1 ATP binding cassette transporter SPM sphingomyelin PC phosphatidylcholine TD Tangier disease LDL low density lipoprotein apo apolipoprotein ABCA1 ATP binding cassette transporter A1 RCT reverse cholesterol transport AcLDL acetylated LDL HMDM human primary monocyte derived macrophages POPC 1 palmitoyl 2 oleoyl phosphatidylcholine SPM egg yolk sphingomyelin BCA bicinchoninic acid PBS phosphate buffered saline AU arbitrary units RT PCR reverse transcriptase PCR
0.33803913.15066991.html.plaintext.txt	470	Kritharides unpublished observations
0.33803913.15066991.html.plaintext.txt	471	Kritharides unpublished observations
0.33803913.15066991.html.plaintext.txt	472	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Asztalos B
0.33803913.15066991.html.plaintext.txt	473	15 1419 1423AbstractFree Full Text Smith J
0.33803913.15066991.html.plaintext.txt	474	271 30647 30655AbstractFree Full Text Lawn R
0.33803913.15066991.html.plaintext.txt	475	104 R25 31Medline Order article via Infotrieve Higgins C
0.33803913.15066991.html.plaintext.txt	476	8 67 113CrossRefMedline Order article via Infotrieve Bodzioch M
0.33803913.15066991.html.plaintext.txt	477	22 347 351CrossRefMedline Order article via Infotrieve Brooks Wilson A
0.33803913.15066991.html.plaintext.txt	478	22 336 345CrossRefMedline Order article via Infotrieve Rust S
0.33803913.15066991.html.plaintext.txt	479	22 352 355CrossRefMedline Order article via Infotrieve Remaley A
0.33803913.15066991.html.plaintext.txt	480	17 1813 1821AbstractFree Full Text OBrien K
0.33803913.15066991.html.plaintext.txt	481	144 538 548Abstract Linton M
0.33803913.15066991.html.plaintext.txt	482	1995 Science 267 1034 1037Medline Order article via Infotrieve Bellosta S
0.33803913.15066991.html.plaintext.txt	483	96 2170 2179Medline Order article via Infotrieve Bielicki J
0.33803913.15066991.html.plaintext.txt	484	40 85 92AbstractFree Full Text Rees D
0.33803913.15066991.html.plaintext.txt	485	274 27925 27933AbstractFree Full Text Dory L
0.33803913.15066991.html.plaintext.txt	486	30 809 816Abstract Heeren J
0.33803913.15066991.html.plaintext.txt	487	278 14370 14378AbstractFree Full Text Von Eckardstein A
0.33803913.15066991.html.plaintext.txt	488	15 1555 1561AbstractFree Full Text Kritharides L
0.33803913.15066991.html.plaintext.txt	489	15 276 289AbstractFree Full Text Kritharides L
0.33803913.15066991.html.plaintext.txt	490	18 1589 1599AbstractFree Full Text Rye K
0.33803913.15066991.html.plaintext.txt	491	269 10298 10303AbstractFree Full Text Steinmetz A
0.33803913.15066991.html.plaintext.txt	492	487 154 160Medline Order article via Infotrieve Weinberg R
0.33803913.15066991.html.plaintext.txt	493	263 282 296Medline Order article via Infotrieve Anantharamaiah G
0.33803913.15066991.html.plaintext.txt	494	128 627 647Medline Order article via Infotrieve Palgunachari M
0.33803913.15066991.html.plaintext.txt	495	16 328 338AbstractFree Full Text Mishra V
0.33803913.15066991.html.plaintext.txt	496	1998 Biochemistry 37 10313 10324CrossRefMedline Order article via Infotrieve Venkatachalapathi Y
0.33803913.15066991.html.plaintext.txt	497	1993 Proteins 15 349 359Medline Order article via Infotrieve Pyle L
0.33803913.15066991.html.plaintext.txt	498	36 2355 2361Abstract Sviridov D
0.33803913.15066991.html.plaintext.txt	499	271 33277 33283AbstractFree Full Text Holvoet P
0.33803913.15066991.html.plaintext.txt	500	1995 Biochemistry 34 13334 13342Medline Order article via Infotrieve Saito H
0.33803913.15066991.html.plaintext.txt	501	278 23227 23232AbstractFree Full Text Matz C
0.33803913.15066991.html.plaintext.txt	502	257 4535 4540AbstractFree Full Text Trinder P
0.33803913.15066991.html.plaintext.txt	503	Acta 79 93 98CrossRefMedline Order article via Infotrieve Liang H
0.33803913.15066991.html.plaintext.txt	504	35 1187 1199Abstract Boyum A
0.33803913.15066991.html.plaintext.txt	505	108 88 102Medline Order article via Infotrieve Becq F
0.33803913.15066991.html.plaintext.txt	506	272 2695 2699AbstractFree Full Text Langmann T
0.33803913.15066991.html.plaintext.txt	507	257 29 33CrossRefMedline Order article via Infotrieve Garner B
0.33803913.15066991.html.plaintext.txt	508	1997 Atherosclerosis 128 47 58CrossRefMedline Order article via Infotrieve Kritharides L
0.33803913.15066991.html.plaintext.txt	509	213 79 89CrossRefMedline Order article via Infotrieve Gelissen I
0.33803913.15066991.html.plaintext.txt	510	40 1636 1646AbstractFree Full Text Sokoloff L
0.33803913.15066991.html.plaintext.txt	511	275 4759 4765AbstractFree Full Text Gaus K
0.33803913.15066991.html.plaintext.txt	512	2001 Biochemistry 40 9363 9373CrossRefMedline Order article via Infotrieve Arakawa R
0.33803913.15066991.html.plaintext.txt	513	41 1952 1962AbstractFree Full Text Burnett J
0.33803913.15066991.html.plaintext.txt	514	73 923 925Medline Order article via Infotrieve Wang J
0.33803913.15066991.html.plaintext.txt	515	20 1983 1989AbstractFree Full Text Dean R
0.33803913.15066991.html.plaintext.txt	516	47 454 462Medline Order article via Infotrieve Burgess J
0.33803913.15066991.html.plaintext.txt	517	42 1413 1420AbstractFree Full Text Burgess J
0.33803913.15066991.html.plaintext.txt	518	273 5645 5654AbstractFree Full Text Burgess J
0.33803913.15066991.html.plaintext.txt	519	1999 Biochemistry 38 14524 14533CrossRefMedline Order article via Infotrieve Gillotte K
0.33803913.15066991.html.plaintext.txt	520	274 2021 2028AbstractFree Full Text Basu S
0.33803913.15066991.html.plaintext.txt	521	1983 Science 219 871 873Medline Order article via Infotrieve Herscovitz H
0.33803913.15066991.html.plaintext.txt	522	33 791 803Abstract Segrest J
0.33803913.15066991.html.plaintext.txt	523	33 141 166Abstract Jonas A
0.33803913.15066991.html.plaintext.txt	524	1992 Structure Function Apolipoproteins Von Rosseneu M
0.33803913.15066991.html.plaintext.txt	525	269 22358 22365AbstractFree Full Text Saito H
0.33803913.15066991.html.plaintext.txt	526	278 40723 40729AbstractFree Full Text Jonas A
0.33803913.15066991.html.plaintext.txt	527	264 4818 4824AbstractFree Full Text Lucas M
0.33803913.15066991.html.plaintext.txt	528	271 13454 13460AbstractFree Full Text Fielding C
0.33803913.15066991.html.plaintext.txt	529	36 211 228Abstract Mazzone T
0.33803913.15066991.html.plaintext.txt	530	262 11657 11662AbstractFree Full Text Dory L
0.33803913.15066991.html.plaintext.txt	531	32 783 792Abstract Burgess J
0.33803913.15066991.html.plaintext.txt	532	277 31318 31326AbstractFree Full Text Sorci Thomas M
0.33803913.15066991.html.plaintext.txt	533	268 21403 21409AbstractFree Full Text Holvoet P
0.33803913.15066991.html.plaintext.txt	534	21 1977 1983AbstractFree Full Text Nathan B
0.33803913.15066991.html.plaintext.txt	535	1994 Science 264 850 852Medline Order article via Infotrieve Zha X
0.33803913.15066991.html.plaintext.txt	536	278 10002 10005AbstractFree Full Text Deng J
0.33803913.15066991.html.plaintext.txt	537	36 2129 2140Abstract Duan H
0.33803913.15066991.html.plaintext.txt	538	272 31156 31162AbstractFree Full Text Grewal T
0.33803913.15066991.html.plaintext.txt	539	278 16478 16481AbstractFree Full Text
0.3392243.12502505.html.plaintext.txt	0	Apolipoprotein E Influences Aspects Intellectual Ability Type 1 Diabetes Stewart C
0.3392243.12502505.html.plaintext.txt	1	Evans3 Sian Ellard3 Andrew T
0.3392243.12502505.html.plaintext.txt	2	1 Department Diabetes Royal Infirmary Edinburgh Edinburgh Scotland U
0.3392243.12502505.html.plaintext.txt	3	2 Department Psychology University Edinburgh Edinburgh Scotland U
0.3392243.12502505.html.plaintext.txt	4	3 Centre Molecular Genetics Exeter University Exeter England U
0.3392243.12502505.html.plaintext.txt	5	ABSTRACT TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES The 4 allele apolipoprotein E APOE gene associated poor outcome following various cerebral insults
0.3392243.12502505.html.plaintext.txt	6	The relationship APOE genotype cognitive function patients type 1 diabetes unknown
0.3392243.12502505.html.plaintext.txt	7	In cross sectional study 96 people type 1 diabetes subjects APOE genotyped previous exposure severe hypoglycemia estimated questionnaire cognition assessed neuropsychological testing
0.3392243.12502505.html.plaintext.txt	8	Cognitive abilities compared using multivariate general linear modeling multiple analysis covariance MANCOVA n 21 without n 75 APOE 4 allele
0.3392243.12502505.html.plaintext.txt	9	APOE 4 selectively influenced cognitive ability sex specific manner F 2
0.3392243.12502505.html.plaintext.txt	10	15 women APOE 4 performed less well tests current nonverbal intellectual ability Wechsler Adult Intelligence Scale Revised performance test score P 0
0.3392243.12502505.html.plaintext.txt	11	26 frontal lobe executive function Borkowski verbal fluency P 0
0.3392243.12502505.html.plaintext.txt	12	Previous exposure severe hypoglycemia interact APOE 4 produce cognitive disadvantage
0.3392243.12502505.html.plaintext.txt	13	The APOE 4 genotype associated specific cognitive disadvantage young women type 1 diabetes
0.3392243.12502505.html.plaintext.txt	14	APOE 4 unlikely mediate susceptibility hypoglycemia induced cognitive disadvantage
0.3392243.12502505.html.plaintext.txt	15	Permanent cognitive impairment rare consequence insulin induced hypoglycemia
0.3392243.12502505.html.plaintext.txt	16	In insulin treated diabetes severe hypoglycemia common annual prevalence 30 type 1 diabetes higher incidence people impaired awareness hypoglycemia strict glycemic control 1
0.3392243.12502505.html.plaintext.txt	17	Whether recurrent exposure severe hypoglycemia promotes long term cognitive sequelae unresolved
0.3392243.12502505.html.plaintext.txt	18	Retrospective cross sectional studies indicated people type 1 diabetes suffer modest cognitive decrement 2 finding replicated prospective observations 10 years 34
0.3392243.12502505.html.plaintext.txt	19	The cross sectional studies reported individual differences cognitive decrements exposed severe hypoglycemia 2 suggesting factors neuroglycopenia may influence risk developing subsequent cognitive impairment
0.3392243.12502505.html.plaintext.txt	20	Chronological age diabetes duration coexistent microvascular macrovascular complications proposed potential mediators susceptibility hypoglycemia induced cognitive impairment 2 whereas genetic susceptibility examined
0.3392243.12502505.html.plaintext.txt	21	Genetic factors influence cognitive aging polymorphism gene apolipoprotein E APOE important genetic determinant late onset Alzheimer disease 5
0.3392243.12502505.html.plaintext.txt	22	The APOE gene three common alleles 2 3 4 coding three protein isoforms designated E2 E3 E4
0.3392243.12502505.html.plaintext.txt	23	Apolipoprotein E APOE mediates central nervous system cholesterol transport isoform specific manner 6
0.3392243.12502505.html.plaintext.txt	24	APOE activity important neuronal repair maintenance least active E4 isoform confers survival disadvantage injured neurons 6
0.3392243.12502505.html.plaintext.txt	25	APOE polymorphism influences cognitive ability health disease apparently healthy middle aged adults possessing 4 allele average relatively low learning memory ability 7 4 allele associated poorer cognitive neurological outcome head injury demyelinating disease intracerebral hemorrhage cardiopulmonary bypass surgery 8
0.3392243.12502505.html.plaintext.txt	26	The aim present study examine whether possession APOE 4 allele associated cognitive disadvantage people type 1 diabetes secondly determine whether magnitude difference cognitive ability modified preceding exposure recurrent severe hypoglycemia
0.3392243.12502505.html.plaintext.txt	27	RESEARCH DESIGN AND METHODS TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES A total 96 people type 1 diabetes recruited completed cross sectional study protocol
0.3392243.12502505.html.plaintext.txt	28	Participants selected two preexisting cohorts 63 patients 9 33 patients 10 completed identical neuropsychological assessments
0.3392243.12502505.html.plaintext.txt	29	To minimize influences confounding neuropsychological performance following exclusion criteria applied hypertension defined blood pressure 14090 mmHg previous central nervous system pathology psychiatric disease alcoholism drug misuse multisystem disease known affect central nervous system
0.3392243.12502505.html.plaintext.txt	30	Assessment neuropsychological function
0.3392243.12502505.html.plaintext.txt	31	The neuropsychological test battery chosen sensitive cognitive decrements across diverse cognitive abilities
0.3392243.12502505.html.plaintext.txt	32	Assessors blinded diabetes characteristics APOE genotype participants administered neuropsychological tests fixed order
0.3392243.12502505.html.plaintext.txt	33	Incipient hypoglycemia hypoglycemia within preceding 24 h excluded neuropsychological assessment
0.3392243.12502505.html.plaintext.txt	34	Evidence biochemical blood glucose 3
0.3392243.12502505.html.plaintext.txt	35	5 mmoll symptomatic hypoglycemia resulted rescheduling neuropsychological session
0.3392243.12502505.html.plaintext.txt	36	The psychometric instruments used follows
0.3392243.12502505.html.plaintext.txt	37	The Hospital Anxiety Depression Scale 11 evaluated potential confounding effects low mood anxiety
0.3392243.12502505.html.plaintext.txt	38	The Wechsler Adult Intelligence Scale Revised WAIS R 12 uses performance subtests measure current intellectual performance fluid nonverbal intelligence sensitive disruption organic brain disease
0.3392243.12502505.html.plaintext.txt	39	Four performance subtests utilized picture completion object assembly block design digit symbol tests
0.3392243.12502505.html.plaintext.txt	40	The National Adult Reading Test NART 13 relatively resistant effect age types organic brain disease
0.3392243.12502505.html.plaintext.txt	41	NART performance correlates closely premorbid IQ demographic variables used control confounding effects prior intellectual ability premorbid IQ crystallized intelligence present study
0.3392243.12502505.html.plaintext.txt	42	Inspection time 14 used assess visual perceptual speed component information processing ability
0.3392243.12502505.html.plaintext.txt	43	Participants discriminated spatial position left right longer two briefly presented vertical lines
0.3392243.12502505.html.plaintext.txt	44	The stimuli backward masked presentation duration varied duration time required reliably distinguish stimulus 85 correct termed inspection time
0.3392243.12502505.html.plaintext.txt	45	Choice reaction time 15 used assess psychomotor speed completed tests information processing ability 1248 8421 choice reaction times examined
0.3392243.12502505.html.plaintext.txt	46	The Borkowski Verbal Fluency Test controlled association 16 thought assess frontal lobe executive function
0.3392243.12502505.html.plaintext.txt	47	Participants 60 state many words possible beginning letters alphabet specified assessor
0.3392243.12502505.html.plaintext.txt	48	The Paced Auditory Serial Addition Task 17 used assess ability sustain attention concentration
0.3392243.12502505.html.plaintext.txt	49	Participants listened number list required add together according given rule
0.3392243.12502505.html.plaintext.txt	50	After practice two consecutive 61 number trials performed 4 2 successive digits respectively
0.3392243.12502505.html.plaintext.txt	51	Assessment severe hypoglycemia exposure
0.3392243.12502505.html.plaintext.txt	52	Severe hypoglycemia defined episode requiring external assistance facilitate recovery 18 exposure assessed retrospectively using validated formatted hypoglycemia questionnaire 9
0.3392243.12502505.html.plaintext.txt	53	Participants asked discuss history severe hypoglycemia family partners friends completing questionnaires improve accuracy estimates
0.3392243.12502505.html.plaintext.txt	54	The total number lifetime episodes frequency episodes total numbers hypoglycemic seizures coma episodes requiring medical intervention recorded
0.3392243.12502505.html.plaintext.txt	55	DNA extracted venous blood subjects using standard methods
0.3392243.12502505.html.plaintext.txt	56	APOE genotyping performed using PCR restriction fragment length polymorphism assay described Wenham et al
0.3392243.12502505.html.plaintext.txt	57	0 SPSS Chicago IL used statistical analysis
0.3392243.12502505.html.plaintext.txt	58	Demographic factors influencing neuropsychological performance age sex duration diabetes premorbid intellectual ability NART groupings interest severe hypoglycemia category APOE genotype evaluated multivariate general linear modeling multiple analysis covariance MANCOVA
0.3392243.12502505.html.plaintext.txt	59	Severe hypoglycemia dichotomized two groups group 1 naive severe hypoglycemia group 2 previously exposed severe hypoglycemia based upon total number previous episodes
0.3392243.12502505.html.plaintext.txt	60	APOE genotype categorized two groups 4 4
0.3392243.12502505.html.plaintext.txt	61	MANCOVA used determine significance P magnitude Eta2 variables effects cognitive performance
0.3392243.12502505.html.plaintext.txt	62	The clinical characteristics participants shown Table 1
0.3392243.12502505.html.plaintext.txt	63	Data glycemic control included laboratory reference ranges methodology estimating glycated hemoglobin changed across two time frames data participants collated
0.3392243.12502505.html.plaintext.txt	64	View table TABLE 1 Characteristics participants subdivided presence APOE 4 allele
0.3392243.12502505.html.plaintext.txt	65	Subdivision participants APOE 4 produced two groups 4 n 21 4 n 75
0.3392243.12502505.html.plaintext.txt	66	The clinical characteristics shown Table 1
0.3392243.12502505.html.plaintext.txt	67	The subgroups similar premorbid intellectual ability NART similar exposure severe hypoglycemia
0.3392243.12502505.html.plaintext.txt	68	Those possessing 4 slightly older P 0
0.3392243.12502505.html.plaintext.txt	69	033 test tended diabetes longer duration P 0
0.3392243.12502505.html.plaintext.txt	70	RESULTS TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES Severe hypoglycemia neuropsychological performance
0.3392243.12502505.html.plaintext.txt	71	The range exposure severe hypoglycemia wide naive severe hypoglycemia 30 experienced 10 episodes 29 Table 1
0.3392243.12502505.html.plaintext.txt	72	No significant difference cognitive ability observed previously exposed severe hypoglycemia naive severe hypoglycemia estimated marginal mean differences without history severe hypoglycemia shown Table 2
0.3392243.12502505.html.plaintext.txt	73	View table TABLE 2 Effect severe hypoglycemia cognitive ability interaction APOE
0.3392243.12502505.html.plaintext.txt	74	APOE 4 neuropsychological performance
0.3392243.12502505.html.plaintext.txt	75	The APOE 4 allele associated disadvantage current intellectual performance WAIS R performance test score P 0
0.3392243.12502505.html.plaintext.txt	76	072 trend toward poorer frontal lobe executive functions Borkowski Verbal Fluency P 0
0.3392243.12502505.html.plaintext.txt	77	057 consideration age sex duration diabetes preceding severe hypoglycemia premorbid intellectual ability Table 3
0.3392243.12502505.html.plaintext.txt	78	The relative disadvantage associated APOE 4 appeared sex specific APOE x sex interaction F 2
0.3392243.12502505.html.plaintext.txt	79	Because sex specificity MANCOVA thereafter performed separately men women using similar model excluding sex subjects factor
0.3392243.12502505.html.plaintext.txt	80	APOE genotype significantly influenced cognitive ability women men Table 4
0.3392243.12502505.html.plaintext.txt	81	Women APOE 4 exhibited significant cognitive disadvantage affecting current intellectual performance WAIS R performance test score P 0
0.3392243.12502505.html.plaintext.txt	82	26 frontal lobe executive function Borkowski Verbal Fluency P 0
0.3392243.12502505.html.plaintext.txt	83	The difference ability associated possession APOE 4 women moderate large Eta2
0.3392243.12502505.html.plaintext.txt	84	View table TABLE 3 Effect APOE 4 4 age premorbid intellectual ability NART cognitive performance
0.3392243.12502505.html.plaintext.txt	85	View table TABLE 4 APOE alleles cognition sex
0.3392243.12502505.html.plaintext.txt	86	Apolipoprotein E genotype severe hypoglycemia
0.3392243.12502505.html.plaintext.txt	87	There statistical evidence detrimental interaction APOE genotype previous exposure severe hypoglycemia cognitive ability APOE x severe hypoglycemia interaction F 0
0.3392243.12502505.html.plaintext.txt	88	The cognitive ability subjects APOE 4 allele subdivided exposed previously severe hypoglycemia n 15 naive severe hypoglycemia n 6 shown Table 2
0.3392243.12502505.html.plaintext.txt	89	No significant difference cognitive ability demonstrated subgroups although numbers subjects analysis small confident nonsignificant difference Table 4
0.3392243.12502505.html.plaintext.txt	90	DISCUSSION TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES The presence APOE 4 allele associated significant disadvantage current intellectual performance WAIS R performance test score frontal lobe executive functions Borkowski Verbal Fluency women type 1 diabetes
0.3392243.12502505.html.plaintext.txt	91	The deficits encompass aspects cognitive ability present women evident younger age 39 years reported people diabetes 7
0.3392243.12502505.html.plaintext.txt	92	Female susceptibility APOE 4 associated cognitive disadvantage described WAIS R performance test ability healthy elderly women 20 although pathogenesis possible sex difference remains unclear
0.3392243.12502505.html.plaintext.txt	93	Age influences effect APOE 4 cognitive ability neuropsychological performance healthy children 21 healthy young adults 22 affected 4 allele middle aged otherwise healthy adults mean age 46 years observed impaired learning memory ability 7
0.3392243.12502505.html.plaintext.txt	94	The younger age median age 39 years 4 associated cognitive disadvantage observed adults type 1 diabetes present study implies premature susceptibility compared nondiabetic individuals
0.3392243.12502505.html.plaintext.txt	95	Laboratory clinical evidence supports concept 4 associated premature cognitive aging diabetes
0.3392243.12502505.html.plaintext.txt	96	Elderly people type 2 diabetes 4 allele exhibit greater cognitive decrement 23 accelerated cognitive decline 24 compared age matched 4 healthy control subjects APOE people diabetes irreversibly glycated exhibits less vitro bioactivity 25 compared nondiabetic control subjects
0.3392243.12502505.html.plaintext.txt	97	APOE bioactivity appears clinical relevance outcomes variety cerebral pathologies poorer individuals possessing least biologically active E4 isoform 8
0.3392243.12502505.html.plaintext.txt	98	As present study include healthy comparator group notion APOE 4 associated premature cognitive aging type 1 diabetes speculative present whereas demonstrated type 2 diabetes 2324
0.3392243.12502505.html.plaintext.txt	99	The present study support hypothesis polymorphism APOE gene may contribute susceptibility hypoglycemia induced cognitive decrement people type 1 diabetes
0.3392243.12502505.html.plaintext.txt	100	The number subjects 4 subgroup n 15 previous severe hypoglycemia vs
0.3392243.12502505.html.plaintext.txt	101	n 6 hypoglycemia naive give sufficient power allow definitive conclusions appropriately powered investigation required evaluate hypothesis
0.3392243.12502505.html.plaintext.txt	102	Irrespective influence APOE alleles cognitive performance unaffected severe hypoglycemia per se consistent conclusions Diabetes Control Complications Trial 3 Stockholm Diabetes Intervention Study 4 many participants type 1 diabetes relatively short duration conflicting retrospective cross sectional studies 2 examined older subjects diabetes long duration
0.3392243.12502505.html.plaintext.txt	103	In conclusion data modestly powered study suggest APOE 4 confers cognitive disadvantage young women type 1 diabetes
0.3392243.12502505.html.plaintext.txt	104	Further investigation required verify findings determine whether APOE 4 allele associated premature accelerated cognitive aging people type 1 diabetes diabetes specific factors may mediating disadvantage possible interaction sex
0.3392243.12502505.html.plaintext.txt	105	supported funding Eli Lilly Company Ltd
0.3392243.12502505.html.plaintext.txt	106	study supported Royal Infirmary Edinburgh NHS Trust
0.3392243.12502505.html.plaintext.txt	107	received Millhayes Scholarship Exeter University
0.3392243.12502505.html.plaintext.txt	108	recipient Royal Society Wolfson Research Merit Award
0.3392243.12502505.html.plaintext.txt	109	FOOTNOTES Address correspondence reprint requests Prof
0.3392243.12502505.html.plaintext.txt	110	Deary Department Psychology University Edinburgh 7 George Square Edinburgh EH8 9JZ Scotland
0.3392243.12502505.html.plaintext.txt	111	Received publication 13 May 2002 accepted revised form 7 October 2002
0.3392243.12502505.html.plaintext.txt	112	APOE apolipoprotein E MANCOVA multiple analysis covariance NART National Adult Reading Test WAIS R Wechsler Adult Intelligence Scale Revised
0.3392243.12502505.html.plaintext.txt	113	REFERENCES TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES Tattersall RB Frequency causes treatment hypoglycaemia
0.3392243.12502505.html.plaintext.txt	114	In Hypoglycaemia Clinical Diabetes
0.3392243.12502505.html.plaintext.txt	115	Chichester John Wiley Sons Ltd
0.3392243.12502505.html.plaintext.txt	116	55 88 Perros P Deary IJ Long term effect hypoglycaemia cognitive function brain diabetes
0.3392243.12502505.html.plaintext.txt	117	In Hypoglycaemia Clinical Diabetes
0.3392243.12502505.html.plaintext.txt	118	Chichester John Wiley Sons Ltd
0.3392243.12502505.html.plaintext.txt	119	187 210 Diabetes Control Complications Trial Research Group Effects intensive diabetes therapy neuropsychological function adults Diabetes Control Complications Trial
0.3392243.12502505.html.plaintext.txt	120	Ann Intern Med124 379 3881996AbstractFree Full Text Reichard P Pihl M Rosenqvist U Sule J Complications IDDM caused elevated blood glucose level Stockholm Diabetes Intervention Study SDIS 10 year follow
0.3392243.12502505.html.plaintext.txt	121	Diabetologia39 1483 14881996Medline Corder EH Saunders AM Strittmatter WJ Schmechel DE Gaskell PC Small GW Roses AD Haines JL Pericak Vance MA Gene dose apolipoprotein E type 4 allele risk Alzheimer disease late onset families
0.3392243.12502505.html.plaintext.txt	122	Science261 921 9231993Medline Maclullich AMJ Seckl JR Starr JM Deary IJ The biology intelligence association mechanism
0.3392243.12502505.html.plaintext.txt	123	Intelligence26 63 731998 Flory JD Manuck SB Ferrell RE Ryan CM Muldoon MF Memory performance apolipoprotein E polymorphism community sample middle aged adults
0.3392243.12502505.html.plaintext.txt	124	Am J Med Genet96 707 7112000Medline Smith JD Apolipoprotein E4 allele associated many diseases
0.3392243.12502505.html.plaintext.txt	125	Ann Med32 118 1272000Medline Deary IJ Crawford JR Hepburn DA Langan SJ Blackmore LM Frier BM Severe hypoglycemia intelligence adult patients insulin treated diabetes
0.3392243.12502505.html.plaintext.txt	126	Diabetes42 341 3441993Abstract Ferguson SC Blane A Perros P McCrimmon RJ Best JJK Wardlaw J Dreary IJ Frier BM Cognitive ability brain structure type 1 diabetes relation microangiopathy preceding severe hypoglycemia
0.3392243.12502505.html.plaintext.txt	127	Diabetes52 149 1562003AbstractFree Full Text Zigmond AS Snaith RP The Hospital Anxiety Depression Scale
0.3392243.12502505.html.plaintext.txt	128	Acta Psychiatr Scand67 361 3701983Medline Wechsler D Manual Wechsler Adult Intelligence Scale Revised
0.3392243.12502505.html.plaintext.txt	129	New York Psychological Corporation1981 Nelson HE Willison JR National Adult Reading Test NART Test Manual
0.3392243.12502505.html.plaintext.txt	130	Windsor NFER Nelson1991 McCrimmon RJ Deary IJ Huntly BJH MacLeod KJM Frier BM Visual information processing controlled hypoglycaemia humans
0.3392243.12502505.html.plaintext.txt	131	Brain119 1277 12871996Abstract Jensen AR Individual differences Hick paradigm
0.3392243.12502505.html.plaintext.txt	132	In Speed Information Processing Intelligence
0.3392243.12502505.html.plaintext.txt	133	101 175 Borkowski JG Benton AL Word fluency brain damage
0.3392243.12502505.html.plaintext.txt	134	Neuropsychologia5 135 140
0.3392243.12502505.html.plaintext.txt	135	1967 Deary IJ Langan SJ Hepburn DA Frier BM Which abilities PASAT test Pers Indiv Diff12 983 9871991 The Diabetes Control Complications Trial Research Group Hypoglycemia Diabetes Control Complications Trial
0.3392243.12502505.html.plaintext.txt	136	Diabetes46 271 2861997Abstract Wenham PR Price WH Blandell G Apolipoprotein E genotyping one stage PCR
0.3392243.12502505.html.plaintext.txt	137	Lancet337 1158 11591991Medline Mortensen EL Hogh P A gender difference association APOE genotype age related cognitive decline
0.3392243.12502505.html.plaintext.txt	138	Neurology57 89 952001AbstractFree Full Text Turic D Fisher PJ Plomin R Owen MJ No association apolipoprotein E polymorphisms general cognitive ability children
0.3392243.12502505.html.plaintext.txt	139	Neurosci Lett299 97 1002001Medline Yu YW Lin CH Chen SP Hong CJ Tsai SJ Intelligence event related potentials young female human volunteer apolipoprotein E epsilon4 non epsilon4 carriers
0.3392243.12502505.html.plaintext.txt	140	Neurosci Lett294 179 1812000Medline Kalmijn S Feskens EJ Launer LJ Kromhout D Cerebrovascular disease apolipoprotein e4 allele cognitive decline community based study elderly men
0.3392243.12502505.html.plaintext.txt	141	Stroke27 2230 22351996AbstractFree Full Text Haan MN Shemanski L Jagust WJ Manolio TA Kuller L The role APOE epsilon4 modulating effects risk factors cognitive decline elderly persons
0.3392243.12502505.html.plaintext.txt	142	JAMA282 40 461999AbstractFree Full Text Shuvaev VV Fujii J Kawasaki Y Itoh H Hamaoka R Barbier A Ziegler O Siest G Taniguchi N Glycation apolipoprotein E impairs binding heparin identification major glycation site
0.3392243.12502505.html.plaintext.txt	143	Biochim Biophys Acta1454 296 3081999Medline
0.3418416.10912224.html.plaintext.txt	0	APOE 4 influences manifestation Alzheimers disease adults Downs syndrome SHOUMITRO DEB FRCPsych JOHN BRAGANZA MRCPsych NADINE NORTON BSc HYWEL WILLIAMS BSc PATRICK G
0.3418416.10912224.html.plaintext.txt	1	KEHOE PhD JULIE WILLIAMS PhD MICHAEL OWEN FRCPsych
0.3418416.10912224.html.plaintext.txt	2	Division Psychological Medicine University Wales College Medicine Cardiff
0.3418416.10912224.html.plaintext.txt	3	Declaration interest This study partly funded Medical Research Council grant
0.3418416.10912224.html.plaintext.txt	4	Deb Division Psychological Medicine University Wales College Medicine Heath Park Cardiff CF4 4xN
0.3418416.10912224.html.plaintext.txt	5	ABSTRACT TOP ABSTRACT INTRODUCTION METHOD RESULTS DISCUSSION Clinical Implications
0.3418416.10912224.html.plaintext.txt	6	ACKNOWLEDGMENTS REFERENCES Background Recent studies relationship apolipoprotein E APOE gene Alzheimers disease adults Downs syndrome revealed inconsistent results
0.3418416.10912224.html.plaintext.txt	7	Aims To assess role APOE gene manifestation Alzheimers disease adults Downs syndrome
0.3418416.10912224.html.plaintext.txt	8	Method We studied APOE genotypes 24 adults dementia 33 non demented adults Downs syndrome 35 years age additional group 164 non learning disabled adults
0.3418416.10912224.html.plaintext.txt	9	We also carried meta analysis previously published studies association APOE Downs syndrome incorporating current data
0.3418416.10912224.html.plaintext.txt	10	Results We observed non significant excess APOE 4 reduction 2 adults dementia compared non demented adults Downs syndrome sample
0.3418416.10912224.html.plaintext.txt	11	However meta analysis showed significantly higher frequency 4 adults dementia compared non demented adults Downs syndrome odds ratio2
0.3418416.10912224.html.plaintext.txt	12	001 significant reduction frequency 2
0.3418416.10912224.html.plaintext.txt	13	Conclusions The APOE 4 allele acts risk factor age specific manifestation Alzheimers disease people Downs syndrome
0.3418416.10912224.html.plaintext.txt	14	INTRODUCTION TOP ABSTRACT INTRODUCTION METHOD RESULTS DISCUSSION Clinical Implications
0.3418416.10912224.html.plaintext.txt	15	ACKNOWLEDGMENTS REFERENCES Autopsy studies shown adults Downs syndrome aged 40 years almost universally exhibit Alzheimers disease neuropathology Mann 1988 fact supported neuro imaging studies Deb et al 1992
0.3418416.10912224.html.plaintext.txt	16	Saunders et al 1993 reported association APOE 4 late onset Alzheimers disease
0.3418416.10912224.html.plaintext.txt	17	A number studies produced inconsistent support APOE 4 risk factor APOE 2 protective factor Alzheimers disease people Downs syndrome Prasher et al 1997 Tyrell et al 1998
0.3418416.10912224.html.plaintext.txt	18	Our study examined whether age specific manifestation Alzheimers disease adults Downs syndrome influenced risk factors age APOE status genotype intronic polymorphism PS 1 gene also reputedly associated late onset Alzheimers disease Kehoe et al 1996
0.3418416.10912224.html.plaintext.txt	19	We examined APOE polymorphism three groups population based sample adults dementia Downs syndrome aged 35 years b elderly group non demented adults Downs syndrome drawn population based sample c group normal non demented adults selected intelligence collected geographical area first two groups
0.3418416.10912224.html.plaintext.txt	20	We also carried meta analysis comprising published studies association APOE gene Alzheimers disease adults Downs syndrome incorporating data current study
0.3418416.10912224.html.plaintext.txt	21	METHOD TOP ABSTRACT INTRODUCTION METHOD RESULTS DISCUSSION Clinical Implications
0.3418416.10912224.html.plaintext.txt	22	ACKNOWLEDGMENTS REFERENCES Subjects The names known adults Downs syndrome age 35 years collected clinicians staff Community Learning Disability Teams five Health Districts South Wales
0.3418416.10912224.html.plaintext.txt	23	Subjects assessed Alzheimers disease using ICD 10 World Health Organization 1992 criteria accordance guidelines produced international consensus panel established auspices Ageing Special Interest Group International Association Scientific Study Intellectual Disabilities IASSID Aylward et al 1997
0.3418416.10912224.html.plaintext.txt	24	The diagnosis dementia supported using two observer rated questionnaires namely Dementia Questionnaire Mentally Retarded Persons DMR Evenhuis 1992 Dementia Scale Downs syndrome DSDS Gedye 1995
0.3418416.10912224.html.plaintext.txt	25	Both questionnaires reported good inter rater reliability internal validity Evenhuis 1992 Gedye 1995
0.3418416.10912224.html.plaintext.txt	26	Deb Braganza 1999 recently reported positive correlation diagnosis dementia clinician adults Downs syndrome diagnosis carried according DSDS criteria specificity0
0.3418416.10912224.html.plaintext.txt	27	85 DMR criteria specificity0
0.3418416.10912224.html.plaintext.txt	28	The age onset dementia determined asking carers adults Downs syndrome clinical symptoms dementia first noticed
0.3418416.10912224.html.plaintext.txt	29	Diagnosis Downs syndrome based characteristic clinical features karyotyping carried
0.3418416.10912224.html.plaintext.txt	30	The level intellectual disability determined either basis IQ scores assessment adaptive behaviours
0.3418416.10912224.html.plaintext.txt	31	We excluded adults Downs syndrome showed medical psychiatric neurological laboratory characteristics related Alzheimers disease might explain mental deterioration particular severe hearing loss untreated hypothyroidism depression n2
0.3418416.10912224.html.plaintext.txt	32	In 24 adults Downs syndrome diagnosis Alzheimers disease included study
0.3418416.10912224.html.plaintext.txt	33	We ascertained second group 33 individuals identified oldest adults list non demented adults Downs syndrome
0.3418416.10912224.html.plaintext.txt	34	As prevalence dementia adults Downs syndrome tends increase age Lai Williams 1989 anticipated lived longer without manifesting clinical dementia least risk factors developing dementia therefore provides appropriate group comparison
0.3418416.10912224.html.plaintext.txt	35	Finally control group 164 non demented adults representative local population unselected intelligence used 54 male mean age 38
0.3418416.10912224.html.plaintext.txt	36	Genotyping Both adults dementia non demented adults Downs syndrome non demented non learning disabled control group genotyped APOE PS 1 polymorphisms using standard techniques Wenham et al 1991 Wragg et al 1996
0.3418416.10912224.html.plaintext.txt	37	For detailed description PS 1 data see Deb et al 1998 data relation multivariate analysis risk factors relation Alzheimers disease Downs syndrome presented paper
0.3418416.10912224.html.plaintext.txt	38	The study performed approval local research ethics committee written informed consent obtained participants carers appropriate
0.3418416.10912224.html.plaintext.txt	39	Statistical analysis The 2 Fishers exact tests used test association APOE Alzheimers disease Downs syndrome
0.3418416.10912224.html.plaintext.txt	40	Multiple logistic regression analysis also carried estimate relative influence risk factors age gender APOE PS 1 genotype development Alzheimers disease adults Downs syndrome
0.3418416.10912224.html.plaintext.txt	41	The Woolf method Woolf 1955 used perform meta analysis association APOE genotype Alzheimers disease Downs syndrome
0.3418416.10912224.html.plaintext.txt	42	A Mann Whitney U test used test relationship APOE age onset Alzheimers disease Downs syndrome
0.3418416.10912224.html.plaintext.txt	43	A probability less one 20 P 0
0.3418416.10912224.html.plaintext.txt	44	05 regarded significant statistical analyses
0.3418416.10912224.html.plaintext.txt	45	RESULTS TOP ABSTRACT INTRODUCTION METHOD RESULTS DISCUSSION Clinical Implications
0.3418416.10912224.html.plaintext.txt	46	ACKNOWLEDGMENTS REFERENCES Current study The age range total cohort adults Downs syndrome 35 72 years mean 51
0.3418416.10912224.html.plaintext.txt	47	4 aged 35 49 years 34 59
0.3418416.10912224.html.plaintext.txt	48	The age range Downs syndrome adults dementia 35 71 mean 54
0.3418416.10912224.html.plaintext.txt	49	24 without dementia 35 72 years mean 49
0.3418416.10912224.html.plaintext.txt	50	8 mild IQ 70 50 37 65 moderate IQ 50 35 seven severe 12
0.3418416.10912224.html.plaintext.txt	51	2 intellectual disability IQ 35
0.3418416.10912224.html.plaintext.txt	52	There statistically significant difference proportion subjects different degrees severity learning disability adults dementia non demented adults Downs syndrome
0.3418416.10912224.html.plaintext.txt	53	The distribution APOE alleles among three study groups shown Table 1 distribution APOE genotypes presented Table 2
0.3418416.10912224.html.plaintext.txt	54	No statistically significant differences observed inter group comparisons shown Table 1 Table 2
0.3418416.10912224.html.plaintext.txt	55	However higher frequency 4 allele 17 v
0.3418416.10912224.html.plaintext.txt	56	2 lower frequency 2 allele 0 v
0.3418416.10912224.html.plaintext.txt	57	26 Fishers exact test observed among adults Downs syndrome dementia compared without see Table 1
0.3418416.10912224.html.plaintext.txt	58	View table Table 2 APOE genotypes different groups
0.3418416.10912224.html.plaintext.txt	59	Adults Downs syndrome divided two age groups 50 years 50 years older two gender groups male female
0.3418416.10912224.html.plaintext.txt	60	This done Sekijama et als 1998 finding frequency 4 allele Downs syndrome adults Alzheimers disease 50 years significantly higher 28
0.3418416.10912224.html.plaintext.txt	61	6 Schupf et als 1998 finding earlier onset Alzheimers disease men Downs syndrome
0.3418416.10912224.html.plaintext.txt	62	The APOE 4 allele frequency adults dementia non demented adults Downs syndrome according age gender groups presented Table 3
0.3418416.10912224.html.plaintext.txt	63	None inter group comparisons Table 3 statistically significant
0.3418416.10912224.html.plaintext.txt	64	View table Table 3 Frequency APOE 4 2 alleles adults Downs syndrome according age gender group
0.3418416.10912224.html.plaintext.txt	65	A multiple logistic regression analysis carried whole cohort adults Downs syndrome using presence dementia dependent variable age gender APOE status PS 1 polymorphism convariates
0.3418416.10912224.html.plaintext.txt	66	The presence dementia significantly related age adults Downs syndrome
0.3418416.10912224.html.plaintext.txt	67	To assess influence APOE 4 age onset dementia adults Downs syndrome compared mean age onset 4 allele
0.3418416.10912224.html.plaintext.txt	68	The mean age onset dementia among 4 positive cases least one 4 allele 51 years 53 years 4 allele
0.3418416.10912224.html.plaintext.txt	69	A comparison ages onset without 4 allele statistically significant
0.3418416.10912224.html.plaintext.txt	70	Meta analysis Prasher et al 1997 presented meta analysis data collected known published papers addition data relation APOE status adults Downs syndrome without Alzheimers disease
0.3418416.10912224.html.plaintext.txt	71	We added data two recent studies Sekijama et al 1998 Tyrell et al 1998 current study analysed Prasher et al 1997 presented Table 4
0.3418416.10912224.html.plaintext.txt	72	However excluded Wisniewski et als 1995 data included Prasher et als 1997 meta analysis unlike studies diagnosed Alzheimers disease basis neuropathological findings alone absence clinical data
0.3418416.10912224.html.plaintext.txt	73	The previous meta analysis Prasher et al 1997 show statistically significant difference distribution APOE alleles adults dementia Downs syndrome non demented adults Downs syndrome
0.3418416.10912224.html.plaintext.txt	74	However meta analysis current study showed statistically significant excess APOE 4 Downs syndrome cases Alzheimers disease compared without odds ratio2
0.3418416.10912224.html.plaintext.txt	75	001 evidence heterogeneity P0
0.3418416.10912224.html.plaintext.txt	76	We observe significantly lower rate APOE 2 allele frequency Downs syndrome adults Alzheimers disease odds ratio0
0.3418416.10912224.html.plaintext.txt	77	The odds ratios along 95 CIs individual studies statistically significant excess APOE 4 reduction 2 allele frequency observed among adults Downs syndrome Alzheimers disease presented bottom Table 4
0.3418416.10912224.html.plaintext.txt	78	View table Table 4 Meta analysis pooled data reports APOE allele frequency adults without dementia updated Prasher et als 1997 data
0.3418416.10912224.html.plaintext.txt	79	DISCUSSION TOP ABSTRACT INTRODUCTION METHOD RESULTS DISCUSSION Clinical Implications
0.3418416.10912224.html.plaintext.txt	80	ACKNOWLEDGMENTS REFERENCES The current study We observed higher frequency APOE 4 allele among subjects dementia Downs syndrome compared without dementia although trend statistically significant
0.3418416.10912224.html.plaintext.txt	81	Similarly slightly lower frequency protective 2 alleles observed among adults dementia Downs syndrome
0.3418416.10912224.html.plaintext.txt	82	The small cohort size current study reduced statistical power study 24 power 5 level detect effect size reported previously
0.3418416.10912224.html.plaintext.txt	83	However study age matching two groups patients Downs syndrome one dementia done way increase sensitivity thus lessen influence statistical weakness
0.3418416.10912224.html.plaintext.txt	84	Meta analysis To increase possibility detecting small effect sizes collated data known published studies association APOE status Downs syndrome Alzheimers disease
0.3418416.10912224.html.plaintext.txt	85	This method employed recently Prasher et al 1997 showed evidence support involvement APOE
0.3418416.10912224.html.plaintext.txt	86	However meta analysis reported showed statistically significant excess APOE 4 allele among subjects dementia compared non demented group adults Downs syndrome
0.3418416.10912224.html.plaintext.txt	87	However observe significant reduction APOE 2 alleles among adults dementia Downs syndrome
0.3418416.10912224.html.plaintext.txt	88	Certain factors may influenced outcome meta analysis current study well Prasher et als 1997 study
0.3418416.10912224.html.plaintext.txt	89	It likely age difference cohorts used previous studies Table 4 factor may introduced errors results meta analysis
0.3418416.10912224.html.plaintext.txt	90	The age range subjects included studies varied used age 18 whereas others used age 35 40 50 respectively minimum age inclusion study
0.3418416.10912224.html.plaintext.txt	91	If APOE responsible earlier age onset Alzheimers disease differential rate age range among different cohorts make interpretation meta analysis difficult
0.3418416.10912224.html.plaintext.txt	92	The lack appropriately matched control group another likely source bias
0.3418416.10912224.html.plaintext.txt	93	Only current study Tyrell et als 1998 study van Gool et als 1995 study matched dementia group non dementia group
0.3418416.10912224.html.plaintext.txt	94	Prasher et als 1997 study originally matched demonstrated statistically significant difference two groups age gender distribution
0.3418416.10912224.html.plaintext.txt	95	The cohort size also likely source error
0.3418416.10912224.html.plaintext.txt	96	Apart current study two studies see Table 4 included 20 adults dementia cohort
0.3418416.10912224.html.plaintext.txt	97	Another source error use different diagnostic criteria defining dementia different studies
0.3418416.10912224.html.plaintext.txt	98	Some used formal tools like DMR scale Evenhuis 1992 Adaptive Behaviour Scale Nihira et al 1974 whereas others made diagnosis basis clinical findings alone
0.3418416.10912224.html.plaintext.txt	99	Age onset Alzheimers disease In current study regression analysis unequivocally showed influence ageing occurrence Alzheimers disease adults Downs syndrome
0.3418416.10912224.html.plaintext.txt	100	Age well known risk factor development Alzheimers disease general population adults Downs syndrome
0.3418416.10912224.html.plaintext.txt	101	This effect seems pronounced among adults Downs syndrome
0.3418416.10912224.html.plaintext.txt	102	Some suggested age death among adults Downs syndrome influenced APOE status
0.3418416.10912224.html.plaintext.txt	103	In Hardy et als 1994 autopsy study Downs syndrome cases showing Alzheimers disease neuropathology APOE 4 n10 allele tended die younger age age death ranged 48 60 years mean 54
0.3418416.10912224.html.plaintext.txt	104	6 2 allele n2 age death 69 76 years respectively
0.3418416.10912224.html.plaintext.txt	105	A similar trend also reported Royston et al 1994 Mann et al 1995 based small cohort studies
0.3418416.10912224.html.plaintext.txt	106	Some suggested APOE status also influences age onset Alzheimers disease general population Corder et al 1993
0.3418416.10912224.html.plaintext.txt	107	However findings current study suggest trend among cases Downs syndrome
0.3418416.10912224.html.plaintext.txt	108	Considering small cohort size included analysis age onset data current study Type II error likely influence come
0.3418416.10912224.html.plaintext.txt	109	As early symptoms Alzheimers disease could difficult detect adults Downs syndrome difficult precise exact age onset Alzheimers disease cohort
0.3418416.10912224.html.plaintext.txt	110	The frequency APOE 4 allele distribution among adults dementia Downs syndrome different studies mentioned Table 4 varied 12
0.3418416.10912224.html.plaintext.txt	111	4 apart Prasher et als 1997 study showed much lower 5
0.3418416.10912224.html.plaintext.txt	112	9 frequency expected general population
0.3418416.10912224.html.plaintext.txt	113	In contrast frequency APOE 2 alleles varied widely 0 current study Schupf et als 1996 Tyrell et als 1998 11
0.3418416.10912224.html.plaintext.txt	114	8 observed Prasher et als 1997 study higher expected even general population
0.3418416.10912224.html.plaintext.txt	115	The frequency 2 allele among non demented subjects Downs syndrome average much higher expected general population wide range 2
0.3418416.10912224.html.plaintext.txt	116	3 Sekijima et als 1998 study 50 Royston et als 1994 study
0.3418416.10912224.html.plaintext.txt	117	Overall data indicative APOE 4 risk factor manifestation Alzheimers disease adults Downs syndrome
0.3418416.10912224.html.plaintext.txt	118	APOE 4 Alzheimers disease neuropathology Downs syndrome The findings autopsy studies patients Downs syndrome however show somewhat unclear relationship APOE 4 Alzheimers disease neuropathology population
0.3418416.10912224.html.plaintext.txt	119	For example Wisniewski et als 1995 autopsy study brains 40 subjects Downs syndrome 15 showed Alzheimers disease neuropathology one 21 year old subject APOE 4 allele 34 genotype brain show Alzheimers disease neuropathology
0.3418416.10912224.html.plaintext.txt	120	In Mann et als 1995 study 20 brains subjects Downs syndrome showed Alzheimers disease neuropathology 35 n7 APOE 4 allele one 24 six 34
0.3418416.10912224.html.plaintext.txt	121	Similarly Hardy et als 1994 series 22 autopsy brains subjects Downs syndrome showed Alzheimers disease neuropathology 45 n10 APOE 4 34 allele
0.3418416.10912224.html.plaintext.txt	122	Further research needed clarify apparent discrepancy perhaps using immunoneuropathological techniques
0.3418416.10912224.html.plaintext.txt	123	It also important explore exact mechanism APOE 4 may influence clinical manifestation Alzheimers disease Downs syndrome subjects
0.3418416.10912224.html.plaintext.txt	124	However well known despite increased risk associated 4 allele presence 4 neither necessary sufficient development Alzheimers disease Blacker Tanzi 1998
0.3418416.10912224.html.plaintext.txt	125	Clinical Implications Limitations TOP ABSTRACT INTRODUCTION METHOD RESULTS DISCUSSION Clinical Implications
0.3418416.10912224.html.plaintext.txt	126	ACKNOWLEDGMENTS REFERENCES CLINICAL IMPLICATIONS APOE 4 allele influences manifestation Alzheimers disease adults Downs syndrome
0.3418416.10912224.html.plaintext.txt	127	The role APOE 2 allele relation Alzheimers disease adults Downs syndrome clear
0.3418416.10912224.html.plaintext.txt	128	The influence APOE 4 allele age onset Alzheimers disease adults Downs syndrome clear
0.3418416.10912224.html.plaintext.txt	129	LIMITATIONS The studies included meta analysis used cohorts different age groups
0.3418416.10912224.html.plaintext.txt	130	The adults Downs syndrome without Alzheimers disease always matched studies
0.3418416.10912224.html.plaintext.txt	131	Criteria used diagnosing Alzheimers disease varied different studies
0.3418416.10912224.html.plaintext.txt	132	ACKNOWLEDGMENTS TOP ABSTRACT INTRODUCTION METHOD RESULTS DISCUSSION Clinical Implications
0.3418416.10912224.html.plaintext.txt	133	ACKNOWLEDGMENTS REFERENCES We thank subjects carers taking part study Dr Frank Dunstan advice statistical analysis Mrs J
0.3418416.10912224.html.plaintext.txt	134	Wheeler typing manuscript
0.3418416.10912224.html.plaintext.txt	135	REFERENCES TOP ABSTRACT INTRODUCTION METHOD RESULTS DISCUSSION Clinical Implications
0.3418416.10912224.html.plaintext.txt	136	ACKNOWLEDGMENTS REFERENCES Aylward E
0.3418416.10912224.html.plaintext.txt	137	et al 1997 Diagnosis dementia individuals intellectual disability
0.3418416.10912224.html.plaintext.txt	138	Journal Intellectual Disability Research 41 15 164
0.3418416.10912224.html.plaintext.txt	139	1998 The genetics Alzheimers disease
0.3418416.10912224.html.plaintext.txt	140	Archives Neurology 55 294 296
0.3418416.10912224.html.plaintext.txt	141	et al 1993 Gene dose apolipoprotein E type 4 allele risk Alzheimers disease late onset families
0.3418416.10912224.html.plaintext.txt	142	et al 1992 Alzheimers disease adults Downs syndrome relationship regional cerebral blood flow deficits dementia
0.3418416.10912224.html.plaintext.txt	143	Acta Psychiatrica Scandinavica 86 340 345
0.3418416.10912224.html.plaintext.txt	144	et al 1998 No significant association PS I intronic polymorphism dementia Downs syndrome
0.3418416.10912224.html.plaintext.txt	145	Alzheimers Report 1 365 368
0.3418416.10912224.html.plaintext.txt	146	1999 Comparison rating scales diagnosis dementia adults Downs syndrome
0.3418416.10912224.html.plaintext.txt	147	Journal Intellectual Disability Research 43 400 407
0.3418416.10912224.html.plaintext.txt	148	1992 Evaluation screening instrument dementia aging mentally retarded persons
0.3418416.10912224.html.plaintext.txt	149	Journal Intellectual Disability Research 36 337 347
0.3418416.10912224.html.plaintext.txt	150	1995 Dementia Scale Down Syndrome Manual
0.3418416.10912224.html.plaintext.txt	151	Vancouver Gedye Research Consulting
0.3418416.10912224.html.plaintext.txt	152	et al 1994 Apo E genotype Downs syndrome
0.3418416.10912224.html.plaintext.txt	153	et al 1996 Association PS I intronic polymorphism late onset Alzheimers disease
0.3418416.10912224.html.plaintext.txt	154	1989 A prospective study Alzheimers disease Down syndrome
0.3418416.10912224.html.plaintext.txt	155	Archives Neurology 46 849 853
0.3418416.10912224.html.plaintext.txt	156	et al 1996 Analysis APOE alleles impact Downs syndrome
0.3418416.10912224.html.plaintext.txt	157	Neuroscience Letters 200 57 60
0.3418416.10912224.html.plaintext.txt	158	1988 Alzheimers disease Downs syndrome
0.3418416.10912224.html.plaintext.txt	159	et al 1995 The extent amyloid deposition brain patients Downs syndrome depend upon apolipoprotein E genotype
0.3418416.10912224.html.plaintext.txt	160	Neuroscience Letters 196 105 108
0.3418416.10912224.html.plaintext.txt	161	et al 1995 ApoE genotypes Australia Roles early late onset Alzheimers disease Downs syndrome
0.3418416.10912224.html.plaintext.txt	162	et al 1974 Adaptive Behavior Scale
0.3418416.10912224.html.plaintext.txt	163	Washington DC American Association Mental Retardation
0.3418416.10912224.html.plaintext.txt	164	et al 1997 APOE genotype Alzheimers disease adults syndrome meta analysis
0.3418416.10912224.html.plaintext.txt	165	American Journal Mental Retardation 102 103 110
0.3418416.10912224.html.plaintext.txt	166	et al 1994 Apolipoprotein E 2 allele promotes longevity protects patients Down syndrome dementia
0.3418416.10912224.html.plaintext.txt	167	et al 1993 Association apolipoprotein E allele 4 late onset familial sporadic Alzheimers disease
0.3418416.10912224.html.plaintext.txt	168	et al 1998 Prevalence dementia Alzheimer type apolipoprotein E phenotypes aged patients Downs syndrome
0.3418416.10912224.html.plaintext.txt	169	European Neurology 39 234 237
0.3418416.10912224.html.plaintext.txt	170	et al 1996 Onset dementia associated apolipoprotein E 4
0.3418416.10912224.html.plaintext.txt	171	Archives Neurology 40 799 801
0.3418416.10912224.html.plaintext.txt	172	et al 1998 Earlier onset Alzheimers disease men Down syndrome
0.3418416.10912224.html.plaintext.txt	173	et al 1998 A protective effect apolipoprotein E 2 allele dementia Downs syndrome
0.3418416.10912224.html.plaintext.txt	174	Biological Psychiatry 43 397 400
0.3418416.10912224.html.plaintext.txt	175	1995 A case controlled study apolipoprotein E genotypes Alzheimers disease associated Downs syndrome
0.3418416.10912224.html.plaintext.txt	176	Annals Neurology 38 225 230
0.3418416.10912224.html.plaintext.txt	177	1991 Apolipoprotein E genotyping one stage PCR
0.3418416.10912224.html.plaintext.txt	178	et al 1995 The influence apolipoprotein E isotopes Alzheimers disease pathology 40 cases Downs syndrome
0.3418416.10912224.html.plaintext.txt	179	Annals Neurology 37 136 138
0.3418416.10912224.html.plaintext.txt	180	1955 On estimating relation blood group disease
0.3418416.10912224.html.plaintext.txt	181	Annals Human Genetics 19 251 253
0.3418416.10912224.html.plaintext.txt	182	World Health Organization 1992 The Tenth Revision International Classification Diseases Related Disorders ICD 10
0.3418416.10912224.html.plaintext.txt	183	1996 Genetic association intronic polymorphism presenilin I gene late onset Alzheimers disease
0.3418416.10912224.html.plaintext.txt	184	Received publication June 15 1999
0.3418416.10912224.html.plaintext.txt	185	Revision received September 29 1999
0.3418416.10912224.html.plaintext.txt	186	Accepted publication October 1 1999
0.3207539.15509658.html.plaintext.txt	0	ApoE mediated cholesterol efflux macrophages separation autocrine paracrine effects Dwayne E
0.3207539.15509658.html.plaintext.txt	1	Linton23 Sergio Fazio12
0.3207539.15509658.html.plaintext.txt	2	1Department Pathology 2Division Cardiovascular Medicine Department Medicine 3Department Pharmacology Vanderbilt University Medical Center Nashville Tennessee
0.3207539.15509658.html.plaintext.txt	3	Submitted 28 April 2004 accepted final form 19 October 2004
0.3207539.15509658.html.plaintext.txt	4	ABSTRACT TOP ABSTRACT Glossary MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Macrophages vessel wall secrete high levels apolipoprotein E apoE
0.3207539.15509658.html.plaintext.txt	5	Cholesterol efflux macrophages apoE shown decrease foam cell formation prevent atherosclerosis
0.3207539.15509658.html.plaintext.txt	6	An apoE molecule mediate cholesterol efflux macrophage originally secreted autocrine effect surrounding macrophages paracrine effect
0.3207539.15509658.html.plaintext.txt	7	Traditional methodologies able separate serial effects
0.3207539.15509658.html.plaintext.txt	8	The novel methodology presented developed separate autocrine paracrine effects using simple mathematical model interpret effects dilution apoE mediated cholesterol efflux
0.3207539.15509658.html.plaintext.txt	9	Our results show dilute concentrations paracrine effect apoE evident autocrine effect becomes dominant mediator efflux
0.3207539.15509658.html.plaintext.txt	10	However saturating concentrations paracrine apoE causes 80 90 apoE mediated cholesterol efflux whereas autocrine apoE responsible remaining 10 20
0.3207539.15509658.html.plaintext.txt	11	These results suggest relative importance autocrine paracrine apoE depends size local distribution volume factor considered previous vitro studies apoE function
0.3207539.15509658.html.plaintext.txt	12	Furthermore autocrine effects apoE could critical prevention foam cell formation vivo
0.3207539.15509658.html.plaintext.txt	13	This novel methodology may applicable types mixed autocrineparacrine systems signal transduction systems
0.3207539.15509658.html.plaintext.txt	14	autocrineparacrine system cholesterol acceptor extracellular space distribution volume
0.3207539.15509658.html.plaintext.txt	15	AN IMPORTANT CHALLENGE atherosclerosis research characterization effects locally synthesized apolipoprotein E apoE within vessel wall
0.3207539.15509658.html.plaintext.txt	16	Endogenous synthesis secretion apoE macrophages vessel wall shown protect atherosclerosis 22
0.3207539.15509658.html.plaintext.txt	17	Arterial macrophages participate inflammation tissue remodeling lipid metabolism
0.3207539.15509658.html.plaintext.txt	18	ApoE synthesized hepatocytes adipocytes macrophages mediates lipoprotein metabolism affects cellular cholesterol homeostasis
0.3207539.15509658.html.plaintext.txt	19	apoE macrophages accepts cholesterol cells vessel wall transports back liver cholesterol excreted bile 3 9
0.3207539.15509658.html.plaintext.txt	20	This pathway called reverse cholesterol transport RCT system
0.3207539.15509658.html.plaintext.txt	21	The effect apoE due cellular extracellular positioning therefore apoE molecule mediate cholesterol efflux macrophage originally secreted autocrine effect surrounding macrophages paracrine effect
0.3207539.15509658.html.plaintext.txt	22	The terms autocrine paracrine traditionally applied signaling peptides hormones also used describe actions mediators broad range functions besides signal transduction 1 7 25
0.3207539.15509658.html.plaintext.txt	23	It assumed sake cholesterol efflux individual macrophage cannot distinguish apoE secretes apoE derived neighboring cells
0.3207539.15509658.html.plaintext.txt	24	However endogenous synthesis apoE causes high spatial proximity autocrine apoE advantage compared paracrine apoE
0.3207539.15509658.html.plaintext.txt	25	The spatial proximity advantage endogenous apoE results temporal sequence autocrine effects occurring paracrine effects concentration gradient autocrine compartment high concentration paracrine compartment low concentration
0.3207539.15509658.html.plaintext.txt	26	Making comparisons autocrine paracrine effects apoE synthesized macrophages proven difficult
0.3207539.15509658.html.plaintext.txt	27	For vitro experiments cultured macrophages exogenously applied apoE used approximate paracrine endocrine apoE 14 19
0.3207539.15509658.html.plaintext.txt	28	Endogenously synthesized apoE used approximate autocrine apoE 16 19 21
0.3207539.15509658.html.plaintext.txt	29	These approximations consider single molecule endogenously synthesized mediator series interactions employ combination autocrine paracrine mechanisms 4
0.3207539.15509658.html.plaintext.txt	30	The novel methodology discussed developed separate autocrine paracrine mechanisms using simple mathematical model interpret mediator induced biological effects
0.3207539.15509658.html.plaintext.txt	31	This study shows whereas macrophage apoE autocrine paracrine effects cholesterol efflux autocrine apoE smaller consistent effects paracrine apoE
0.3207539.15509658.html.plaintext.txt	32	Whereas macrophage apoE used demonstrate novel methodology concepts applications separating autocrine paracrine effects many secreted biological mediators including growth factors cytokines carrier proteins
0.3207539.15509658.html.plaintext.txt	33	Glossary TOP ABSTRACT Glossary MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES tTime h
0.3207539.15509658.html.plaintext.txt	34	EWTCholesterol efflux efflux apoE macrophages
0.3207539.15509658.html.plaintext.txt	35	EKOCholesterol efflux efflux apoE macrophages
0.3207539.15509658.html.plaintext.txt	36	EapoE mediated cholesterol efflux efflux
0.3207539.15509658.html.plaintext.txt	37	VVolume extracellular space ml
0.3207539.15509658.html.plaintext.txt	38	V 1Relative concentration ml 1 apoE extracellular space
0.3207539.15509658.html.plaintext.txt	39	mSlope effluxml 1 linear E vs
0.3207539.15509658.html.plaintext.txt	40	Intercept efflux linear E vs
0.3207539.15509658.html.plaintext.txt	41	CEffective concentration ml 1 apoE juxtacellular space
0.3207539.15509658.html.plaintext.txt	42	nSlope ml 124 h bt vs
0.3207539.15509658.html.plaintext.txt	43	fy Intercept efflux24 h bt vs
0.3207539.15509658.html.plaintext.txt	44	kECoefficient ml 1 apoE mediated cholesterol efflux
0.3207539.15509658.html.plaintext.txt	45	kICoefficient ml 1 apoE mediated cholesterol influx
0.3207539.15509658.html.plaintext.txt	46	MATERIALS AND METHODS TOP ABSTRACT Glossary MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Primary culture peritoneal macrophages
0.3207539.15509658.html.plaintext.txt	47	Murine peritoneal macrophages elicited intraperitoneal injection 3 thioglycollate
0.3207539.15509658.html.plaintext.txt	48	Macrophages harvested 3 4 days injection peritoneal lavage ice cold DMEM washed counted plated DMEM 10 FBS 37 degrees C
0.3207539.15509658.html.plaintext.txt	49	Macrophages plated 4 x 105 macrophageswell 24 well plates treated 100 microgml acetyl LDL acLDL DMEM 2 FBS 48 h load cholesterol stimulate apoE secretion 24
0.3207539.15509658.html.plaintext.txt	50	Lipoprotein preparation chemical modification
0.3207539.15509658.html.plaintext.txt	51	Lipoproteins isolated human blood plasma sequential ultracentrifugation density 1
0.3207539.15509658.html.plaintext.txt	52	LDL dialyzed 4 degrees C lipoprotein buffer 0
0.3207539.15509658.html.plaintext.txt	53	acLDL prepared repeated addition acetic anhydride LDL 2
0.3207539.15509658.html.plaintext.txt	54	After modification reaction acLDL dialyzed lipoprotein buffer
0.3207539.15509658.html.plaintext.txt	55	Lipoprotein species modifications confirmed electrophoretic mobility agarose gels
0.3207539.15509658.html.plaintext.txt	56	Protein concentrations determined modified Lowry assay 23
0.3207539.15509658.html.plaintext.txt	57	Modified lipoproteins filtered 0
0.3207539.15509658.html.plaintext.txt	58	45 microm syringe filters immediately applied cultured cells
0.3207539.15509658.html.plaintext.txt	59	Macrophages labeled 2 microCiml 12 3HNcholesterol Perkin Elmer Life Sciences Boston MA DMEM 12 h 19 26
0.3207539.15509658.html.plaintext.txt	60	ApoE apoE macrophages 64
0.3207539.15509658.html.plaintext.txt	61	3 microg total cholesterolmg cell protein respectively
0.3207539.15509658.html.plaintext.txt	62	apoE apoE macrophages 786
0.3207539.15509658.html.plaintext.txt	63	93 cpmmg cell protein respectively
0.3207539.15509658.html.plaintext.txt	64	Labeled macrophages rinsed three times DMEM 0
0.3207539.15509658.html.plaintext.txt	65	The efflux period initiated addition DMEM acceptors 0
0.3207539.15509658.html.plaintext.txt	66	Efflux medium removed efflux period 8 24 48 72 h cell debris removed centrifugation
0.3207539.15509658.html.plaintext.txt	67	Remaining cellular 3Hcholesterol harvested rinsing cells PBS lysing cells 1
0.3207539.15509658.html.plaintext.txt	68	Counts cpm medium lysate detected Beckman LS 6000IC scintillation counter Ecolite scintillation fluid ICN Costa Mesa CA
0.3207539.15509658.html.plaintext.txt	69	Cholesterol efflux calculated counts medium percentage total counts medium lysate
0.3207539.15509658.html.plaintext.txt	70	The difference cholesterol efflux E apoE KO apoE WT macrophages considered cholesterol efflux specifically mediated apoE
0.3207539.15509658.html.plaintext.txt	71	Western blot analysis secreted apoE
0.3207539.15509658.html.plaintext.txt	72	Macrophages incubated DMEM acceptors 0
0.3207539.15509658.html.plaintext.txt	73	0 ml 18 h cell debris removed centrifugation
0.3207539.15509658.html.plaintext.txt	74	ApoE extracted total volume culture medium Liposorb gel Calbiochem San Diego CA
0.3207539.15509658.html.plaintext.txt	75	For Western blot analysis secreted apoE extracted apoE separated 4 12 NuPAGE Bis Tris gels Invitrogen Carlsbad CA transferred nitrocellulose membranes
0.3207539.15509658.html.plaintext.txt	76	ApoE detected anti murine apoE rabbit antiserum visualized chemiluminescent ECL Plus Amersham Biosciences Piscataway NJ
0.3207539.15509658.html.plaintext.txt	77	14C labeled adenine release assay cellular toxicity
0.3207539.15509658.html.plaintext.txt	78	Cytotoxicity cultured macrophages assayed measuring release 14C labeled adenine 34
0.3207539.15509658.html.plaintext.txt	79	Cells labeled 3 h DMEM 0
0.3207539.15509658.html.plaintext.txt	80	4 microCiml U 14Cadenine Amersham Biosciences
0.3207539.15509658.html.plaintext.txt	81	Cells rinsed three times DMEM
0.3207539.15509658.html.plaintext.txt	82	The release period initiated addition DMEM
0.3207539.15509658.html.plaintext.txt	83	Medium removed release period 24 h cell debris removed centrifugation
0.3207539.15509658.html.plaintext.txt	84	Cellular 14Cadenine harvested rinsing cells PBS lysing cells 1
0.3207539.15509658.html.plaintext.txt	85	Sample aliquots loaded Ecolite scintillation fluid 14Cadenine counts detected Beckman LS 6000IC scintillation counter
0.3207539.15509658.html.plaintext.txt	86	Adenine release calculated medium 14Cadenine counts expressed percentage total counts lysate medium
0.3207539.15509658.html.plaintext.txt	87	To manipulate extracellular concentration endogenously synthesized biological mediator volume dependence theory takes advantage implicit relationship concentration distribution volume
0.3207539.15509658.html.plaintext.txt	88	The concentration secreted mediator apoE proportional reciprocal extracellular distribution volume
0.3207539.15509658.html.plaintext.txt	89	Increasing distribution volume V causes decrease relative concentration V 1 secreted mediator
0.3207539.15509658.html.plaintext.txt	90	Varying extracellular volume given number cells Fig
0.3207539.15509658.html.plaintext.txt	91	1A allows juxtacellular extracellular mechanisms synthesized mediator mathematically separated characterized
0.3207539.15509658.html.plaintext.txt	92	This theory illustrated graphically follows
0.3207539.15509658.html.plaintext.txt	93	For plot biological effect E vs
0.3207539.15509658.html.plaintext.txt	94	extracellular volume V extracellular volume increased effect decreases asymptotically plateau represents portion total effect independent extracellular volume Fig
0.3207539.15509658.html.plaintext.txt	95	The value plateau y intercept b plot biological effect E vs
0.3207539.15509658.html.plaintext.txt	96	reciprocal volume V 1 Fig
0.3207539.15509658.html.plaintext.txt	97	This dose response curve linear low relative concentrations V 1 fits linear equation
0.3207539.15509658.html.plaintext.txt	98	View larger version 28K Fig
0.3207539.15509658.html.plaintext.txt	99	Theoretical basis separation autocrine paracrine effects apolipoprotein E apoE cholesterol efflux
0.3207539.15509658.html.plaintext.txt	100	A experimental design changes relative concentrations apoE increasing extracellular distribution volume
0.3207539.15509658.html.plaintext.txt	101	B dependence effect apoE distribution volume
0.3207539.15509658.html.plaintext.txt	102	C dependence effect apoE reciprocal volume
0.3207539.15509658.html.plaintext.txt	103	Effects apoE depend relative concentration extracellular distribution volume paracrine
0.3207539.15509658.html.plaintext.txt	104	Effects occur solely juxtacellular space independent extracellular distribution volume autocrine
0.3207539.15509658.html.plaintext.txt	105	Data expressed means plus minus SD
0.3207539.15509658.html.plaintext.txt	106	Means compared Students test
0.3207539.15509658.html.plaintext.txt	107	Curves analyzed linear regression
0.3207539.15509658.html.plaintext.txt	108	RESULTS TOP ABSTRACT Glossary MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Volume dependence apoE mediated cholesterol efflux
0.3207539.15509658.html.plaintext.txt	109	In apoE macrophages efflux decreased distribution volume increased Fig
0.3207539.15509658.html.plaintext.txt	110	ApoE mediated efflux appeared saturated smaller distribution volumes fell plateau b volume increased
0.3207539.15509658.html.plaintext.txt	111	At 48 h dependence apoE mediated efflux reciprocal volume initially linear m 2
0.3207539.15509658.html.plaintext.txt	112	92 determined linear regression analysis Fig
0.3207539.15509658.html.plaintext.txt	113	Similar trends seen 8 24 72 h
0.3207539.15509658.html.plaintext.txt	114	At least 10 20 b expressed maximum efflux apoE mediated cholesterol efflux independent reciprocal volume Table 1
0.3207539.15509658.html.plaintext.txt	115	The remaining 80 90 apoE mediated cholesterol efflux linearly dependent reciprocal volume Table 1
0.3207539.15509658.html.plaintext.txt	116	The volume independent contributions efflux become dominant extracellular apoE became dilute
0.3207539.15509658.html.plaintext.txt	117	A descriptive equation apoE mediated cholesterol efflux generated data
0.3207539.15509658.html.plaintext.txt	118	View larger version 28K Fig
0.3207539.15509658.html.plaintext.txt	119	Volume dependence apoE mediated cholesterol efflux
0.3207539.15509658.html.plaintext.txt	120	A B volume V dependence A relative concentration V 1 dependence B cholesterol efflux apoE apoE macrophages apoE mediated efflux
0.3207539.15509658.html.plaintext.txt	121	Values expressed means plus minus SD 4 samples efflux apoE apoE macrophages
0.3207539.15509658.html.plaintext.txt	122	Statistically significant difference P 0
0.3207539.15509658.html.plaintext.txt	123	C linear fit apoE mediated efflux E vs
0.3207539.15509658.html.plaintext.txt	124	reciprocal volume 8 24 48 72 h
0.3207539.15509658.html.plaintext.txt	125	Volume independent volume dependent apoE effects contribute cholesterol efflux
0.3207539.15509658.html.plaintext.txt	126	Volume dependence apoE secretion
0.3207539.15509658.html.plaintext.txt	127	Western blot analysis performed determine whether changes apoE secretion related trends efflux
0.3207539.15509658.html.plaintext.txt	128	To determine whether macrophages secreted equal masses apoE apoE extracted culture medium
0.3207539.15509658.html.plaintext.txt	129	By densitometric analysis macrophages cultured higher medium volumes 0
0.3207539.15509658.html.plaintext.txt	130	0 ml secreted similar amounts apoE per cell culture suggesting size distribution volume effect apoE secretion Fig
0.3207539.15509658.html.plaintext.txt	131	However macrophages cultured smaller volumes 0
0.3207539.15509658.html.plaintext.txt	132	5 ml secreted apoE per cell culture
0.3207539.15509658.html.plaintext.txt	133	View larger version 13K Fig
0.3207539.15509658.html.plaintext.txt	134	Volume dependence apoE secretion macrophage viability
0.3207539.15509658.html.plaintext.txt	135	Secretion apoE per cell culture A viability apoE macrophages varying volumes B reciprocal volumes C shown
0.3207539.15509658.html.plaintext.txt	136	Values expressed means plus minus SD 4 samples adenine release apoE macrophages
0.3207539.15509658.html.plaintext.txt	137	Volume dependence cellular viability
0.3207539.15509658.html.plaintext.txt	138	14Cadenine release studies performed determine whether changes viability related trends efflux apoE secretion
0.3207539.15509658.html.plaintext.txt	139	Viability increased smaller distribution volumes indicated higher amounts 14Cadenine remaining Fig
0.3207539.15509658.html.plaintext.txt	140	Viability increased log linear fashion R2 0
0.3207539.15509658.html.plaintext.txt	141	99 increasing reciprocal volume Fig
0.3207539.15509658.html.plaintext.txt	142	This log linear trend viability different linear trend efflux
0.3207539.15509658.html.plaintext.txt	143	Model apoE mediated cholesterol efflux
0.3207539.15509658.html.plaintext.txt	144	With limited number assumptions mathematical model generated suggests physical model autocrine paracrine effects apoE cholesterol efflux
0.3207539.15509658.html.plaintext.txt	145	1 assumes difference primary effect apoE secondary effect changes cellular cholesterol homeostasis
0.3207539.15509658.html.plaintext.txt	146	changes viability changes membrane fluidity
0.3207539.15509658.html.plaintext.txt	147	3 assume evaporation extracellular distribution volume negligible
0.3207539.15509658.html.plaintext.txt	148	However evaporation determined 0
0.3207539.15509658.html.plaintext.txt	149	The evaporation rate affects calculation E calculation V 1
0.3207539.15509658.html.plaintext.txt	150	Factoring evaporation rate change trends data
0.3207539.15509658.html.plaintext.txt	151	However evaporation corrections necessary estimate parameters mathematical model data shown
0.3207539.15509658.html.plaintext.txt	152	From extrapolation concentration dependence lines common x intercept observed assigned value negative C 0
0.3207539.15509658.html.plaintext.txt	153	The common x intercept C 0 lines fit Eq
0.3207539.15509658.html.plaintext.txt	154	2 yields following equation
0.3207539.15509658.html.plaintext.txt	155	3 This reveals concentration dependence lines combined one equation function time rather contained within four unrelated equations
0.3207539.15509658.html.plaintext.txt	156	This would expected secretion apoE function time therefore apoE mediated effects would also function time
0.3207539.15509658.html.plaintext.txt	157	If y intercept represents autocrine effect results constant rate secretion apoE normalizing y intercept time would reveal constant f
0.3207539.15509658.html.plaintext.txt	158	4 Normalized y intercepts bt however constant time point 0
0.3207539.15509658.html.plaintext.txt	159	A plot normalized y intercepts bt vs
0.3207539.15509658.html.plaintext.txt	160	corresponding slope m reveals unexpected relationship linear n 0
0.3207539.15509658.html.plaintext.txt	161	00 determined linear regression analysis expressed
0.3207539.15509658.html.plaintext.txt	162	5 Equations 2 3 5 combined generate function describe effects apoE cholesterol efflux interpreted mechanistically compartmentalized manner
0.3207539.15509658.html.plaintext.txt	163	6 Equation 6 fits experimental data Fig
0.3207539.15509658.html.plaintext.txt	164	6 expresses apoE mediated cholesterol efflux product capacity ft system ratio two coefficients efflux coefficient kE V 1 C influx coefficient kI C nt
0.3207539.15509658.html.plaintext.txt	165	On basis mathematical model biological model proposed Fig
0.3207539.15509658.html.plaintext.txt	166	View larger version 23K Fig
0.3207539.15509658.html.plaintext.txt	167	Mathematical trends apoE mediated cholesterol efflux data
0.3207539.15509658.html.plaintext.txt	168	A common x intercept C 0 arrow lines apoE mediated efflux vs
0.3207539.15509658.html.plaintext.txt	169	B kinetics apoE mediated efflux distribution volumes 1
0.3207539.15509658.html.plaintext.txt	170	The experimental data fit Eq
0.3207539.15509658.html.plaintext.txt	171	6 experimentally estimated values parameters effective apoE concentration C slope n y intercept f
0.3207539.15509658.html.plaintext.txt	172	C correlation experimental theoretical values proposed model apoE mediated efflux Eq
0.3207539.15509658.html.plaintext.txt	173	View larger version 17K Fig
0.3207539.15509658.html.plaintext.txt	174	Proposed model apoE mediated cholesterol efflux autocrine paracrine effects
0.3207539.15509658.html.plaintext.txt	175	There 2 compartments secreted apoE distributed juxtacellular space extracellular space
0.3207539.15509658.html.plaintext.txt	176	All endogenously synthesized apoE initially distributed juxtacellular space accepts cholesterol autocrine fashion
0.3207539.15509658.html.plaintext.txt	177	apoE eventually distributed extracellular space accepts cholesterol paracrine fashion sensitive volume cells cultured
0.3207539.15509658.html.plaintext.txt	178	Determining volume independent effects cholesterol efflux distinguish autocrine actions apoE paracrine actions
0.3207539.15509658.html.plaintext.txt	179	kE coefficient apoE mediated efflux kI coefficient apoE mediated influx
0.3207539.15509658.html.plaintext.txt	180	DISCUSSION TOP ABSTRACT Glossary MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES To determine whether autocrine paracrine actions apoE separated quantified measured cholesterol efflux macrophages cultured varying distribution volumes
0.3207539.15509658.html.plaintext.txt	181	We found volume independent effects apoE identified using simple mathematical model Eq
0.3207539.15509658.html.plaintext.txt	182	We theorize volume independent effects correspond autocrine actions apoE
0.3207539.15509658.html.plaintext.txt	183	The basis theory range autocrine signals approximates width secretion layer separates cell bulk medium
0.3207539.15509658.html.plaintext.txt	184	30 suggest two phenomena occur mediator goes beyond autocrine range 1 mediator longer autocrine 2 mediator becomes diluted bulk medium
0.3207539.15509658.html.plaintext.txt	185	Our data suggest relative importance autocrine paracrine effects apoE depends size local distribution volume autocrine effects remaining constant even paracrine effects diminished apoE dilution
0.3207539.15509658.html.plaintext.txt	186	The descriptive equation generated data Eq
0.3207539.15509658.html.plaintext.txt	187	6 suggests autocrine paracrine apoE work parallel mediate cholesterol efflux macrophages
0.3207539.15509658.html.plaintext.txt	188	Our study suggests autocrine apoE advantages biologically relevant
0.3207539.15509658.html.plaintext.txt	189	Even extracellular space saturated apoE least 10 20 apoE mediated cholesterol efflux result volume independent interactions endogenous apoE Table 1
0.3207539.15509658.html.plaintext.txt	190	19 found apoE deficient cells exogenous application apoE 10 times concentration normal endogenous apoE secretion increase cholesterol efflux much normal endogenous apoE secretion apoE producing cells
0.3207539.15509658.html.plaintext.txt	191	The fundamental importance media transfer studies show exogenous apoE paracrine equivalent endogenous apoE autocrine paracrine
0.3207539.15509658.html.plaintext.txt	192	For macrophage endogenously synthesized apoE advantage autocrine apoE may become critical homeostasis challenged cholesterol loading conditioned space large making apoE diluted turnover conditioned space high interstitial flow macrophage isolated macrophages
0.3207539.15509658.html.plaintext.txt	193	The interstitial concentration distribution volume turnover macrophage apoE vessel wall known
0.3207539.15509658.html.plaintext.txt	194	These factors critical interpretation data vitro cell culture systems generalization data biology macrophages vivo
0.3207539.15509658.html.plaintext.txt	195	For example trend viability may related changes apoE secretion observed low volumes Fig
0.3207539.15509658.html.plaintext.txt	196	The log linear trend viability Fig
0.3207539.15509658.html.plaintext.txt	197	3C may due relative concentrations confounding mediators like growth factors culture gases e
0.3207539.15509658.html.plaintext.txt	198	CO2 varying distribution volumes
0.3207539.15509658.html.plaintext.txt	199	Because apoE mediator secreted system necessary subtract effects confounding mediators
0.3207539.15509658.html.plaintext.txt	200	This apoE macrophages compared apoE macrophages specific apoE effect calculated apoE mediated cholesterol efflux E
0.3207539.15509658.html.plaintext.txt	201	The effects confounding mediators cholesterol efflux minimal Fig
0.3207539.15509658.html.plaintext.txt	202	Although major role apoE extracellular cholesterol acceptor also possible portion effect apoE cholesterol efflux consequence actions apoE receptor proteoglycan binding 17 intracellular cholesterol routing 8 even stabilization cytoskeleton 6
0.3207539.15509658.html.plaintext.txt	203	Irrespective ultimate mechanisms combination effects may responsible modulation cholesterol efflux apoE occur either autocrine paracrine events therefore addressed whole study
0.3207539.15509658.html.plaintext.txt	204	Although volume dependence apoE secretion viability could explain volume dependent trends apoE mediated efflux Fig
0.3207539.15509658.html.plaintext.txt	205	2C data definitely underscore sensitivity biological processes vitro culture volumes
0.3207539.15509658.html.plaintext.txt	206	Some higher order characteristics macrophage tissue could overlooked vitro studies macrophages
0.3207539.15509658.html.plaintext.txt	207	For example aggregate macrophages may become tissue works autocrine efficiency instead sum autocrineparacrine cellular units
0.3207539.15509658.html.plaintext.txt	208	The spatial range autocrine effect 30 important another cell within range possibility autocrine cooperation
0.3207539.15509658.html.plaintext.txt	209	This possibility could explored vitro vivo studies effects geometry density cell aggregates apoE mediated cholesterol efflux
0.3207539.15509658.html.plaintext.txt	210	Compared exogenous lipoprotein bound apoE hepatic origin local secretion lipid free apoE macrophages results decreased atherosclerosis due small amount apoE critical location 12 22
0.3207539.15509658.html.plaintext.txt	211	12 WT mice transplanted apoE bone marrow
0.3207539.15509658.html.plaintext.txt	212	These chimeric mice normal plasma apoE macrophage apoE production vessel walls
0.3207539.15509658.html.plaintext.txt	213	Although immunocytochemical staining lesions WT macrophages reveals high apoE levels chimeric mice plasma apoE little apoE lesions
0.3207539.15509658.html.plaintext.txt	214	The lack staining plasma derived apoE within artery wall suggests penetration clusters macrophages limited
0.3207539.15509658.html.plaintext.txt	215	The macrophage plasma derived apoE primary source apoE RCT 5 12 22
0.3207539.15509658.html.plaintext.txt	216	Along lines paracrine apoE may able fulfill critical actions small amount autocrine apoE juxtacellular space possibly even intracellular space
0.3207539.15509658.html.plaintext.txt	217	apoE recycling internalization resecretion apoE 10 13 33 reported mediate cholesterol efflux hepatocytes macrophages 13
0.3207539.15509658.html.plaintext.txt	218	The methodology study unable resolve internal autocrine 31 intracrine 28 29 mechanism could mediated intracellular apoE
0.3207539.15509658.html.plaintext.txt	219	6 macrophages secrete apoE create extracellular sink cellular cholesterol
0.3207539.15509658.html.plaintext.txt	220	The capacity concentration compartmentalization sink affect cholesterol efflux Fig
0.3207539.15509658.html.plaintext.txt	221	The sink capacity ft expands apoE secreted
0.3207539.15509658.html.plaintext.txt	222	The sink separated two compartments consequence location apoE juxtacellular extracellular space also described secretion layer bulk layer respectively 18 27
0.3207539.15509658.html.plaintext.txt	223	The dilution apoE moves extracellular space diminishes efficacy
0.3207539.15509658.html.plaintext.txt	224	ApoE mediated efflux E balance efflux influx cholesterol
0.3207539.15509658.html.plaintext.txt	225	Efflux depends sink capacity ft concentration extracellular apoE V 1 functional concentration juxtacellular apoE C
0.3207539.15509658.html.plaintext.txt	226	Influx depends cholesterol apoE sink E functional concentration juxtacellular apoE kI
0.3207539.15509658.html.plaintext.txt	227	Decreases functional concentration apoE contribute influx nt may represent changes capacitance apoE due accumulation phospholipids stabilize cholesterol proteolytic alteration apoE
0.3207539.15509658.html.plaintext.txt	228	It also possible n artifact slight changes viability apoE secretion
0.3207539.15509658.html.plaintext.txt	229	In many documents found literature search term autocrine terms autocrine andor paracrine describe proposed mechanism action
0.3207539.15509658.html.plaintext.txt	230	It difficult quantitatively separate two mechanisms experimentally
0.3207539.15509658.html.plaintext.txt	231	Traditional approaches problem limitations rely simple qualitative assessments
0.3207539.15509658.html.plaintext.txt	232	Traditional methodologies used study macrophage apoE include characterizing tissue distribution apoE 11 measuring effects endogenous synthesis apoE vs
0.3207539.15509658.html.plaintext.txt	233	complete absence 11 measuring effects endogenous synthesis vs
0.3207539.15509658.html.plaintext.txt	234	exogenous application apoE 15 19
0.3207539.15509658.html.plaintext.txt	235	These methods useful comparative assessments unable simultaneously quantify serial effects mediated apoE secreted biological mediators
0.3207539.15509658.html.plaintext.txt	236	In present study performed experiments based theory portion endogenous acceptor mediates autocrine effects cannot diluted
0.3207539.15509658.html.plaintext.txt	237	Previous studies utilized experimental strategies similar one used study
0.3207539.15509658.html.plaintext.txt	238	32 performed volume dependence experiments study whether efflux exogenous acceptors proceeded aqueous diffusion cholesterol acceptor membrane collisions
0.3207539.15509658.html.plaintext.txt	239	They found certain types acceptors efflux approached volume insensitive plateau proposed types acceptors may sites efficient collisional transfer 32
0.3207539.15509658.html.plaintext.txt	240	Our studies endogenously synthesized acceptors suggest sites may combination binding sites membrane enriched aqueous layer around membrane
0.3207539.15509658.html.plaintext.txt	241	27 used theoretical model study escape autocrine signaling ligands extracellular space
0.3207539.15509658.html.plaintext.txt	242	They found model ligand receptor signaling system varying volume heights shows little effect ligand concentrations
0.3207539.15509658.html.plaintext.txt	243	It remains seen whether dilution methodology discussed change mediator concentrations large dynamic range many orders magnitude log linear dose response curve seen ligand receptor signaling pathways
0.3207539.15509658.html.plaintext.txt	244	In summary study separates quantifies autocrine paracrine effects apoE cholesterol efflux macrophages
0.3207539.15509658.html.plaintext.txt	245	These data suggest relative importance autocrine paracrine apoE depends size local distribution volume autocrine effects remaining constant even paracrine effects diminished dilution apoE
0.3207539.15509658.html.plaintext.txt	246	GRANTS TOP ABSTRACT Glossary MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES M
0.3207539.15509658.html.plaintext.txt	247	Fazio supported National Heart Lung Blood Institute NHLBI Grants HL 53989 HL 65709 HL 57986 HL 65405
0.3207539.15509658.html.plaintext.txt	248	Dove supported NHLBI Training Grant HL 07751 08
0.3207539.15509658.html.plaintext.txt	249	FOOTNOTES Address reprint requests correspondence S
0.3207539.15509658.html.plaintext.txt	250	Cardiovascular Medicine 383 Preston Research Bldg
0.3207539.15509658.html.plaintext.txt	251	Nashville TN 37232 6300 E mail sergio
0.3207539.15509658.html.plaintext.txt	252	The costs publication article defrayed part payment page charges
0.3207539.15509658.html.plaintext.txt	253	The article must therefore hereby marked advertisement accordance 18 U
0.3207539.15509658.html.plaintext.txt	254	Section 1734 solely indicate fact
0.3207539.15509658.html.plaintext.txt	255	REFERENCES TOP ABSTRACT Glossary MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES 1
0.3207539.15509658.html.plaintext.txt	256	Balboa MA Perez R Balsinde J
0.3207539.15509658.html.plaintext.txt	257	Amplification mechanisms inflammation paracrine stimulation arachidonic acid mobilization secreted phospholipase A2 regulated cytosolic phospholipase A2 derived hydroperoxyeicosatetraenoic acid
0.3207539.15509658.html.plaintext.txt	258	J Immunol 171 989 994 2003
0.3207539.15509658.html.plaintext.txt	259	Basu SK Goldstein JL Anderson GW Brown MS
0.3207539.15509658.html.plaintext.txt	260	Degradation cationized low density lipoprotein regulation cholesterol metabolism homozygous familial hypercholesterolemia fibroblasts
0.3207539.15509658.html.plaintext.txt	261	Proc Natl Acad Sci USA 73 3178 3182 1976
0.3207539.15509658.html.plaintext.txt	262	Basu SK Goldstein JL Brown MS
0.3207539.15509658.html.plaintext.txt	263	Independent pathways secretion cholesterol apolipoprotein E macrophages
0.3207539.15509658.html.plaintext.txt	264	Batsilas L Berezhkovskii AM Shvartsman SY
0.3207539.15509658.html.plaintext.txt	265	Stochastic model autocrine paracrine signals cell culture assays
0.3207539.15509658.html.plaintext.txt	266	Biophys J 85 3659 3665 2003
0.3207539.15509658.html.plaintext.txt	267	Blum CB Aron L Sciacca R
0.3207539.15509658.html.plaintext.txt	268	Radioimmunoassay studies human apolipoprotein E
0.3207539.15509658.html.plaintext.txt	269	J Clin Invest 66 1240 1250 1980
0.3207539.15509658.html.plaintext.txt	270	Brecht WJ Harris FM Chang S Tesseur I Yu GQ Xu Q Dee Fish J Wyss Coray T Buttini M Mucke L Mahley RW Huang Y
0.3207539.15509658.html.plaintext.txt	271	Neuron specific apolipoprotein e4 proteolysis associated increased tau phosphorylation brains transgenic mice
0.3207539.15509658.html.plaintext.txt	272	J Neurosci 24 2527 2534 2004
0.3207539.15509658.html.plaintext.txt	273	Coussens LM Tinkle CL Hanahan D Werb Z
0.3207539.15509658.html.plaintext.txt	274	MMP 9 supplied bone marrow derived cells contributes skin carcinogenesis
0.3207539.15509658.html.plaintext.txt	275	Lysosomal degradation sorting apolipoprotein E macrophages
0.3207539.15509658.html.plaintext.txt	276	J Lipid Res 36 2129 2140 1995
0.3207539.15509658.html.plaintext.txt	277	Synthesis secretion apoE thioglycolate elicited mouse peritoneal macrophages effect cholesterol efflux
0.3207539.15509658.html.plaintext.txt	278	J Lipid Res 30 809 816 1989
0.3207539.15509658.html.plaintext.txt	279	Farkas MH Swift LL Hasty AH Linton MF Fazio S
0.3207539.15509658.html.plaintext.txt	280	The recycling apolipoprotein E primary cultures mouse hepatocytes
0.3207539.15509658.html.plaintext.txt	281	Evidence physiologic connection high density lipoprotein metabolism
0.3207539.15509658.html.plaintext.txt	282	J Biol Chem 278 9412 9417 2003
0.3207539.15509658.html.plaintext.txt	283	Fazio S Babaev VR Burleigh ME Major AS Hasty AH Linton MF
0.3207539.15509658.html.plaintext.txt	284	Physiological expression macrophage apoE artery wall reduces atherosclerosis severely hyperlipidemic mice
0.3207539.15509658.html.plaintext.txt	285	J Lipid Res 43 1602 1609 2002
0.3207539.15509658.html.plaintext.txt	286	Fazio S Babaev VR Murray AB Hasty AH Carter KJ Gleaves LA Atkinson JB Linton MF
0.3207539.15509658.html.plaintext.txt	287	Increased atherosclerosis mice reconstituted apolipoprotein E null macrophages
0.3207539.15509658.html.plaintext.txt	288	Proc Natl Acad Sci USA 94 4647 4652 1997
0.3207539.15509658.html.plaintext.txt	289	Heeren J Grewal T Laatsch A Rottke D Rinninger F Enrich C Beisiegel U
0.3207539.15509658.html.plaintext.txt	290	Recycling apoprotein E associated cholesterol efflux high density lipoprotein internalization
0.3207539.15509658.html.plaintext.txt	291	J Biol Chem 278 14370 14378 2003
0.3207539.15509658.html.plaintext.txt	292	Ho YY Al Haideri M Mazzone T Vogel T Presley JF Sturley SL Deckelbaum RJ
0.3207539.15509658.html.plaintext.txt	293	Endogenously expressed apolipoprotein E different effects cell lipid metabolism compared exogenous apolipoprotein E carried triglyceride rich particles
0.3207539.15509658.html.plaintext.txt	294	Biochemistry 39 4746 4754 2000
0.3207539.15509658.html.plaintext.txt	295	Ho YY Deckelbaum RJ Chen Y Vogel T Talmage DA
0.3207539.15509658.html.plaintext.txt	296	Apolipoprotein E inhibits serum stimulated cell proliferation enhances serum independent cell proliferation
0.3207539.15509658.html.plaintext.txt	297	J Biol Chem 276 43455 43462 2001
0.3207539.15509658.html.plaintext.txt	298	Huang ZH Lin CY Oram JF Mazzone T
0.3207539.15509658.html.plaintext.txt	299	Sterol efflux mediated endogenous macrophage ApoE expression independent ABCA1
0.3207539.15509658.html.plaintext.txt	300	Arterioscler Thromb Vasc Biol 21 2019 2025 2001
0.3207539.15509658.html.plaintext.txt	301	Ji ZS Pitas RE Mahley RW
0.3207539.15509658.html.plaintext.txt	302	Differential cellular accumulationretention apolipoprotein E mediated cell surface heparan sulfate proteoglycans
0.3207539.15509658.html.plaintext.txt	303	Apolipoproteins E3 E2 greater e4
0.3207539.15509658.html.plaintext.txt	304	J Biol Chem 273 13452 13460 1998
0.3207539.15509658.html.plaintext.txt	305	Lauffenburger DA Oehrtman GT Walker L Wiley HS
0.3207539.15509658.html.plaintext.txt	306	Real time quantitative measurement autocrine ligand binding indicates autocrine loops spatially localized
0.3207539.15509658.html.plaintext.txt	307	Proc Natl Acad Sci USA 95 15368 15373 1998
0.3207539.15509658.html.plaintext.txt	308	Apolipoprotein E dependent cholesterol efflux macrophages kinetic study divergent mechanisms endogenous versus exogenous apolipoprotein E
0.3207539.15509658.html.plaintext.txt	309	J Lipid Res 40 1618 1627 1999
0.3207539.15509658.html.plaintext.txt	310	Lin CY Huang ZH Mazzone T
0.3207539.15509658.html.plaintext.txt	311	Interaction proteoglycans enhances sterol efflux produced endogenous expression macrophage apoE
0.3207539.15509658.html.plaintext.txt	312	J Lipid Res 42 1125 1133 2001
0.3207539.15509658.html.plaintext.txt	313	Lin CY Lucas M Mazzone T
0.3207539.15509658.html.plaintext.txt	314	Endogenous apoE expression modulates HDL3 binding macrophages
0.3207539.15509658.html.plaintext.txt	315	J Lipid Res 39 293 301 1998
0.3207539.15509658.html.plaintext.txt	316	Linton MF Atkinson JB Fazio S
0.3207539.15509658.html.plaintext.txt	317	Prevention atherosclerosis apolipoprotein E deficient mice bone marrow transplantation
0.3207539.15509658.html.plaintext.txt	318	Science 267 1034 1037 1995
0.3207539.15509658.html.plaintext.txt	319	Lowry OH Rosebrough NJ Farr AL Randall RJ
0.3207539.15509658.html.plaintext.txt	320	Protein measurement Folin phenol reagent
0.3207539.15509658.html.plaintext.txt	321	J Biol Chem 193 265 275 1951
0.3207539.15509658.html.plaintext.txt	322	Mazzone T Gump H Diller P Getz GS
0.3207539.15509658.html.plaintext.txt	323	Macrophage free cholesterol content regulates apolipoprotein E synthesis
0.3207539.15509658.html.plaintext.txt	324	J Biol Chem 262 11657 11662 1987
0.3207539.15509658.html.plaintext.txt	325	Moran EC Kamiguti AS Cawley JC Pettitt AR
0.3207539.15509658.html.plaintext.txt	326	Cytoprotective antioxidant activity serum albumin autocrine catalase chronic lymphocytic leukaemia
0.3207539.15509658.html.plaintext.txt	327	Br J Haematol 116 316 328 2002
0.3207539.15509658.html.plaintext.txt	328	Mukherjee S Zha X Tabas I Maxfield FR
0.3207539.15509658.html.plaintext.txt	329	Cholesterol distribution living cells fluorescence imaging using dehydroergosterol fluorescent cholesterol analog
0.3207539.15509658.html.plaintext.txt	330	Biophys J 75 1915 1925 1998
0.3207539.15509658.html.plaintext.txt	331	Oehrtman GT Wiley HS Lauffenburger DA
0.3207539.15509658.html.plaintext.txt	332	Escape autocrine ligands extracellular medium experimental test theoretical model predictions
0.3207539.15509658.html.plaintext.txt	333	Biotechnol Bioeng 57 571 582 1998
0.3207539.15509658.html.plaintext.txt	334	CO2 DlinktypeDOI CrossRefISIMedline
0.3207539.15509658.html.plaintext.txt	335	Emerging issues cellular biology cardiovascular system
0.3207539.15509658.html.plaintext.txt	336	Am J Cardiol 62 7G 12G 1988
0.3207539.15509658.html.plaintext.txt	337	The origins intracrine hormone action
0.3207539.15509658.html.plaintext.txt	338	Am J Med Sci 323 43 48 2002
0.3207539.15509658.html.plaintext.txt	339	Shvartsman SY Wiley HS Deen WM Lauffenburger DA
0.3207539.15509658.html.plaintext.txt	340	Spatial range autocrine signaling modeling computational analysis
0.3207539.15509658.html.plaintext.txt	341	Biophys J 81 1854 1867 2001
0.3207539.15509658.html.plaintext.txt	342	Autocrine secretion 10 years later
0.3207539.15509658.html.plaintext.txt	343	Ann Intern Med 117 408 414 1992
0.3207539.15509658.html.plaintext.txt	344	Steck TL Kezdy FJ Lange Y
0.3207539.15509658.html.plaintext.txt	345	An activation collision mechanism cholesterol transfer membranes
0.3207539.15509658.html.plaintext.txt	346	J Biol Chem 263 13023 13031 1988
0.3207539.15509658.html.plaintext.txt	347	Swift LL Farkas MH Major AS Valyi Nagy K Linton MF Fazio S
0.3207539.15509658.html.plaintext.txt	348	A recycling pathway resecretion internalized apolipoprotein E liver cells
0.3207539.15509658.html.plaintext.txt	349	J Biol Chem 276 22965 22970 2001
0.3207539.15509658.html.plaintext.txt	350	Warner GJ Stoudt G Bamberger M Johnson WJ Rothblat GH
0.3207539.15509658.html.plaintext.txt	351	Cell toxicity induced inhibition acyl coenzyme Acholesterol acyltransferase accumulation unesterified cholesterol
0.3207539.15509658.html.plaintext.txt	352	J Biol Chem 270 5772 5778 1995
0.38120866.16091415.html.plaintext.txt	0	Sense antisense transcripts apolipoprotein E gene normal ApoE knockout mice expression spinal cord injury corresponding human transcripts Alexander Seitz Dmitri Gourevitch Xiang Ming Zhang Lise Clark Pan Chen Maja Kragol Natasha Levenkova John Rux Stefan Samulewicz Ellen Heber Katz
0.38120866.16091415.html.plaintext.txt	1	The Wistar Institute Philadelphia PA 19104 USA
0.38120866.16091415.html.plaintext.txt	2	To correspondence addressed
0.38120866.16091415.html.plaintext.txt	3	Tel 1 2158983710 Fax 1 2158983868 Email heberkatzatwistar
0.38120866.16091415.html.plaintext.txt	4	Received June 17 2005 Revised July 20 2005 Accepted August 1 2005
0.38120866.16091415.html.plaintext.txt	5	ABSTRACT TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES The apolipoprotein E ApoE gene linked maladies hypercholesterolemia CNS injury disease
0.38120866.16091415.html.plaintext.txt	6	In study present evidence addition known transcript ApoE S1 translates ApoE three additional transcripts mice
0.38120866.16091415.html.plaintext.txt	7	Two transcripts ApoE S2 ApoE S3 predicted transmembrane proteins transcribed sense strand
0.38120866.16091415.html.plaintext.txt	8	ApoE AS1 transcribed antisense strand complementary exon 4 ApoE S1
0.38120866.16091415.html.plaintext.txt	9	The open reading frame ApoE AS1 conserved human mouse
0.38120866.16091415.html.plaintext.txt	10	The antisense transcript falls within region human epsilon 4 allele linked familial onset form Alzheimers disease
0.38120866.16091415.html.plaintext.txt	11	We also demonstrate expression ApoE S3 ApoE AS1 ApoE knockout mice ApoE S1 ApoE S2 get transcribed
0.38120866.16091415.html.plaintext.txt	12	We previously identified ApoE S1 upregulated mice spinal cord injury
0.38120866.16091415.html.plaintext.txt	13	In study show spinal cord injured C57BL6 mice ApoE S1 ApoE S3 transcripts 10 fold upregulated antisense ApoE AS1 100 fold upregulated compared normal levels
0.38120866.16091415.html.plaintext.txt	14	Such data suggest alternate transcripts involved molecular pathogenesis CNS disease perhaps ApoE expression general show ApoE S2 AS1 also transcribed human
0.38120866.16091415.html.plaintext.txt	15	INTRODUCTION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES The molecule apolipoprotein E ApoE originally found liver associates plasma lipoproteins 34 kDa glycosylated protein first shown plasma protein involved systemic lipid metabolism cholesterol transport 1
0.38120866.16091415.html.plaintext.txt	16	This molecule two structural domains N terminus residues 1 191 bind low density lipoprotein LDL receptor interact heparin sulfate proteoglycans cell surface C terminus residues 222 299 high affinity lipids responsible lipoprotein binding 2 4
0.38120866.16091415.html.plaintext.txt	17	These subunits connected flexible unstructured region encompassing amino acids 191 216 3
0.38120866.16091415.html.plaintext.txt	18	ApoE also synthesized secreted tissues including CNS spleen kidney adrenal glands large intestine lung 56 associated cardiovascular CNS disease use different alleles gene 7 10
0.38120866.16091415.html.plaintext.txt	19	In CNS 4 ApoE allelic form identified shown associated Alzheimers disease 9
0.38120866.16091415.html.plaintext.txt	20	ApoE thought important normal functioning neural tissue response injury although exact mechanisms clear
0.38120866.16091415.html.plaintext.txt	21	It shown synthesized secreted astrocytes 611 monocytes 1213
0.38120866.16091415.html.plaintext.txt	22	The finding ApoE neurons brain 14 explained presence ApoE receptors reflect uptake molecule 15
0.38120866.16091415.html.plaintext.txt	23	Using spinal cord injury model 16 previously showed ApoE mRNA protein levels upregulated spinal cord injury mouse 17
0.38120866.16091415.html.plaintext.txt	24	The effects knocking ApoE gene studied mice 18
0.38120866.16091415.html.plaintext.txt	25	Creation knockout involved insertion neomycin resistance gene homologous recombination place exon 3 part intron 3 ApoE gene
0.38120866.16091415.html.plaintext.txt	26	Mice heterozygous knockout gene reported healthy 3 months age produce homozygous knockouts expected frequency
0.38120866.16091415.html.plaintext.txt	27	These homozygous knockout progeny appear healthy despite absence ApoE plasma
0.38120866.16091415.html.plaintext.txt	28	In present study show evidence two additional mouse sense transcripts generated ApoE gene could transmembrane proteins antisense transcript open reading frame exon 4 conserved mouse human
0.38120866.16091415.html.plaintext.txt	29	The antisense protein falls within region epsilon 4 allele linked familial onset form Alzheimers disease 919
0.38120866.16091415.html.plaintext.txt	30	We also demonstrate expression one sense antisense ApoE transcripts ApoE knockout mice
0.38120866.16091415.html.plaintext.txt	31	Furthermore show transcripts upregulated B6 mice spinal cord injury follow upregulation ApoE
0.38120866.16091415.html.plaintext.txt	32	Finally find one additional sense transcripts antisense transcript corresponding RNAs exist human
0.38120866.16091415.html.plaintext.txt	33	RESULTS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Database support new ApoE gene products mouse We previously showed ApoE mRNA protein levels upregulated spinal cord injury mouse 17
0.38120866.16091415.html.plaintext.txt	34	In examining cell types involved situ hybridization carried using ApoE antisense sense probes exon 4 tissue sections
0.38120866.16091415.html.plaintext.txt	35	Both probes produced signal suggesting presence antisense transcript exon 4
0.38120866.16091415.html.plaintext.txt	36	For complete picture looked additional transcripts using silico approach
0.38120866.16091415.html.plaintext.txt	37	The Gene2EST BLAST Server 39 used align ESTs mouse human rat genomic sequences corresponding ApoE gene
0.38120866.16091415.html.plaintext.txt	38	1 mappings visualized Artemis 40
0.38120866.16091415.html.plaintext.txt	39	This search well RT PCR sequencing efforts uncovered several new transcripts relative original known transcript
0.38120866.16091415.html.plaintext.txt	40	Our current model mouse ApoE gene including sense antisense transcripts well primer RNA probe locations used subsequent experiments represented Figure 1
0.38120866.16091415.html.plaintext.txt	41	All positional information made reference genomic sequence ApoE D00466 corrected two deletions discussed subsequently
0.38120866.16091415.html.plaintext.txt	42	View larger version 23K Figure 1
0.38120866.16091415.html.plaintext.txt	43	A Representation ApoE gene mouse accession
0.38120866.16091415.html.plaintext.txt	44	1 two corrections made deletion C position 2882 TG C CTC C 2898 TGG C CCC
0.38120866.16091415.html.plaintext.txt	45	The known transcript named ApoE S1
0.38120866.16091415.html.plaintext.txt	46	Start stop sites translation indicated black lines bars predicted transmembrane regions shown solid black rectangle
0.38120866.16091415.html.plaintext.txt	47	ApoE S1 S2 use frame ApoE S3 uses different frame
0.38120866.16091415.html.plaintext.txt	48	ApoE AS1 translates protein antisense direction gene
0.38120866.16091415.html.plaintext.txt	49	Primers shown 5 location
0.38120866.16091415.html.plaintext.txt	50	Also shown location neo insert ApoE knockout mouse C57BL6J Apoetm1Unc Jackson 18
0.38120866.16091415.html.plaintext.txt	51	B Representation human APOE gene accession
0.38120866.16091415.html.plaintext.txt	52	ApoE S2 corresponds mouse transcript however protein translated identical ApoE S1
0.38120866.16091415.html.plaintext.txt	53	The antisense trancript highly conserved human mouse
0.38120866.16091415.html.plaintext.txt	54	There two alternative stop codons shown AS1 molecule one 3819 open one allelic variations Table 1
0.38120866.16091415.html.plaintext.txt	55	ApoE S2 EST accession nos AI049252 BF236692 AI313990 AA537923 lacks exon 1 translation start site ATG 99 bases upstream ApoE S1 exon 2
0.38120866.16091415.html.plaintext.txt	56	Thereafter amino acid sequence identical ApoE S1
0.38120866.16091415.html.plaintext.txt	57	Starting transcription manner upstream exon 2 transforms secretory signal peptide transmembrane helix
0.38120866.16091415.html.plaintext.txt	58	Thus ApoE S2 could encode 352 amino acid protein molecular weight 40
0.38120866.16091415.html.plaintext.txt	59	3 kDa transmembrane helix amino acids 43 65 SOSUI 23
0.38120866.16091415.html.plaintext.txt	60	A BlastP similarity search ApoE S2 NCBIs non redundant protein sequence database nr return hits
0.38120866.16091415.html.plaintext.txt	61	A third transcript ApoE S3 EST accession nos AA067884 AI614580 codes transmembrane protein well
0.38120866.16091415.html.plaintext.txt	62	Using published sequence mouse gene D00466
0.38120866.16091415.html.plaintext.txt	63	1 predicted translational start ATG 117 bases ApoE S1 exon 4 using reading frame ApoE S1 within exon 4
0.38120866.16091415.html.plaintext.txt	64	However sequencing could account two bases published sequence D00466
0.38120866.16091415.html.plaintext.txt	65	1 C position 2882 TTG C CTC C 2898 TGG C CCC
0.38120866.16091415.html.plaintext.txt	66	This confirmed genomic mRNA level
0.38120866.16091415.html.plaintext.txt	67	The corrected sequence ApoE S3 still predicts open reading frame however resulting amino acid sequence entirely different ApoE S1 even shared part exon 4 ApoE S3 using different reading frame
0.38120866.16091415.html.plaintext.txt	68	ApoE S3 translated 156 amino acids long molecular weight 15
0.38120866.16091415.html.plaintext.txt	69	9 kDa predicted transmembrane helix SOSUI 23 amino acids 16 38
0.38120866.16091415.html.plaintext.txt	70	The antisense transcript ApoE AS1 complimentary ApoE S3 Fig
0.38120866.16091415.html.plaintext.txt	71	Its translational start site near stop codon ApoE S1 frame open throughout exon 4 polyA signal 2744
0.38120866.16091415.html.plaintext.txt	72	It encodes 219 amino acid long soluble protein molecular weight 26
0.38120866.16091415.html.plaintext.txt	73	A conserved domain database search return hits 24
0.38120866.16091415.html.plaintext.txt	74	An NCBI blastp protein search uncovered low level similarity proteins last 100 amino acids class I helical cytokine receptor member 2 Tetraodon nigroviridis accession
0.38120866.16091415.html.plaintext.txt	75	1 highest score 40
0.38120866.16091415.html.plaintext.txt	76	We used Neural Network Promoter Prediction software 25 predict promoters transcriptional start sites ApoE S2 ApoE S3 ApoE AS1
0.38120866.16091415.html.plaintext.txt	77	No appropriate targets found
0.38120866.16091415.html.plaintext.txt	78	The program however predict correct promoter transcriptional start ApoE S1
0.38120866.16091415.html.plaintext.txt	79	Expression new ApoE derived transcripts mouse Expression predicted forms ApoE initially tested RT PCR
0.38120866.16091415.html.plaintext.txt	80	Reverse transcription reactions RNA variety tissues primed oligo dT amplified transcript specific pairs PCR primers Fig
0.38120866.16091415.html.plaintext.txt	81	Although approach could differentiate sense antisense transcripts illustrate tissue specific expression pattern different ApoE transcripts
0.38120866.16091415.html.plaintext.txt	82	ApoE S1 present tissues tested
0.38120866.16091415.html.plaintext.txt	83	ApoE S2 expressed almost exclusively liver marginal levels expression cerebellum parotis kidney lung thymus
0.38120866.16091415.html.plaintext.txt	84	ApoE S3 antisense ApoE AS1 found liver thymus lower levels lung parotis heart small intestine
0.38120866.16091415.html.plaintext.txt	85	Marginal levels appear skeletal muscle cerebellum brainstem
0.38120866.16091415.html.plaintext.txt	86	The rest organs brain ear spleen adrenal gland bone marrow fat negative
0.38120866.16091415.html.plaintext.txt	87	View larger version 50K Figure 2
0.38120866.16091415.html.plaintext.txt	88	A RT PCR showing expression levels different transcripts variety tissues
0.38120866.16091415.html.plaintext.txt	89	Primers used ApoE S1 52F 40R ApoE S2 40F 40R ApoE S3AS1 44F 40R GAPDH 47F 47R
0.38120866.16091415.html.plaintext.txt	90	Controls samples omitted enzyme RT reaction included primer pair negative data shown
0.38120866.16091415.html.plaintext.txt	91	B C Directional specific RT PCR demonstrating presence sense ApoE S3 antisense transcripts ApoE AS1 liver
0.38120866.16091415.html.plaintext.txt	92	B ApoE S3 RT primer used 45R PCR 69F 70R
0.38120866.16091415.html.plaintext.txt	93	C ApoE AS1 RT primer used 44F PCR 69F 45R lanes 1 4 49F 46R lanes 2 5 49F 40R lanes 3 6
0.38120866.16091415.html.plaintext.txt	94	Lanes 1 3 RT lanes 4 6 RT
0.38120866.16091415.html.plaintext.txt	95	All products gel purified sequence verified
0.38120866.16091415.html.plaintext.txt	96	To distinguish ApoE S3AS1 RT PCR performed liver RNA using RT subsequent PCR primers specifically amplify ApoE S3 ApoE AS1 Fig
0.38120866.16091415.html.plaintext.txt	97	The presence ApoE S1 ApoE S2 ApoE S3 ApoE AS1 also confirmed northern analysis Fig
0.38120866.16091415.html.plaintext.txt	98	Probes designed hybridize specific target
0.38120866.16091415.html.plaintext.txt	99	In addition binding sense probe
0.38120866.16091415.html.plaintext.txt	100	1 ApoE AS1 also hybridized sense probe
0.38120866.16091415.html.plaintext.txt	101	4 C57BL6 liver data shown confirming antisense transcript least extends start stop codon
0.38120866.16091415.html.plaintext.txt	102	View larger version 55K Figure 4
0.38120866.16091415.html.plaintext.txt	103	Northern blot analysis demonstrating expression ApoE transcripts normal knockout mice using 32P labeled RNA probes specific message
0.38120866.16091415.html.plaintext.txt	104	For probe locations see Figure 1
0.38120866.16091415.html.plaintext.txt	105	A ApoE S1 antisense probe
0.38120866.16091415.html.plaintext.txt	106	1 B ApoE S2 antisense probe
0.38120866.16091415.html.plaintext.txt	107	2 show signal arrow normal signal knockout
0.38120866.16091415.html.plaintext.txt	108	C ApoE S3 antisense probe
0.38120866.16091415.html.plaintext.txt	109	3 D ApoE AS1 sense probe
0.38120866.16091415.html.plaintext.txt	110	3 found liver mouse strains however much lower levels knockout
0.38120866.16091415.html.plaintext.txt	111	Expression new ApoE derived transcripts APOE knockout mice The ApoE knockout mouse important tool determining role ApoE variety systems
0.38120866.16091415.html.plaintext.txt	112	Therefore wanted investigate effect knocking gene expression ApoE transcripts
0.38120866.16091415.html.plaintext.txt	113	In knockout mouse used study ApoE gene disrupted upstream exon 4 Fig
0.38120866.16091415.html.plaintext.txt	114	Again employed oligo dT primed RT PCR transcript specific PCR primers investigate whether ApoE transcripts could detected ApoE knockout mouse
0.38120866.16091415.html.plaintext.txt	115	Only ApoE S3AS1 could amplified method Fig
0.38120866.16091415.html.plaintext.txt	116	Furthermore expression profile differed wild type ApoE S3AS1 could amplified normal brain spleen Fig
0.38120866.16091415.html.plaintext.txt	117	View larger version 60K Figure 3
0.38120866.16091415.html.plaintext.txt	118	RT PCR ApoE knockout tissue
0.38120866.16091415.html.plaintext.txt	119	A The RT primed oligo dT primers used Figure 2
0.38120866.16091415.html.plaintext.txt	120	Again product seen row 3 demonstrates existence sense ApoE S3 andor antisense ApoE AS1 transcript ApoE knockout mice C57BL6J Apoetm1Unc Jackson
0.38120866.16091415.html.plaintext.txt	121	Controls used samples omitted enzyme RT reaction included primer pair negative data shown
0.38120866.16091415.html.plaintext.txt	122	B Demonstration specific sense antisense transcripts liver
0.38120866.16091415.html.plaintext.txt	123	For S3 lanes 3 4 RT carried using primer 45R
0.38120866.16091415.html.plaintext.txt	124	For AS1 lanes 1 2 RT carried using primer 44F
0.38120866.16091415.html.plaintext.txt	125	Both RT reactions PCR amplified using primers 69F 40R
0.38120866.16091415.html.plaintext.txt	126	Control reactions performed absence RT
0.38120866.16091415.html.plaintext.txt	127	The use specific RT PCR primers revealed ApoE S3 ApoE AS1 expressed liver knockout Fig
0.38120866.16091415.html.plaintext.txt	128	Northern blot analysis also demonstrates presence ApoE AS1 knockout mouse
0.38120866.16091415.html.plaintext.txt	129	Although knockout seems affect transcription level ApoE S3 almost detection limit technique Fig
0.38120866.16091415.html.plaintext.txt	130	4D present knockout wild type mice
0.38120866.16091415.html.plaintext.txt	131	Functional expression new ApoE transcripts As follow previous studies showing ApoE expression following spinal cord injury C57BL6 mice 17 examined expression various transcripts ApoE gene spinal cord injury
0.38120866.16091415.html.plaintext.txt	132	ApoE S2 could demonstrated brain marginal levels cerebellum Fig
0.38120866.16091415.html.plaintext.txt	133	Using RT PCR ApoE S2 also could detected uninjured injured spinal cord data shown
0.38120866.16091415.html.plaintext.txt	134	However northern blot analysis shows expression two newly identified products gene ApoE S3 ApoE AS1 within week injury Fig
0.38120866.16091415.html.plaintext.txt	135	View larger version 60K Figure 5
0.38120866.16091415.html.plaintext.txt	136	Expression profiles ApoE transcripts spinal cord injury
0.38120866.16091415.html.plaintext.txt	137	Upper panel showing northern blot analyses
0.38120866.16091415.html.plaintext.txt	138	A ApoE S3 antisense probe
0.38120866.16091415.html.plaintext.txt	139	1 B ApoE AS1 sense probe
0.38120866.16091415.html.plaintext.txt	140	1 upregulation spinal cord injury
0.38120866.16091415.html.plaintext.txt	141	Animals injured transection TH8 9 followed 7 14 21 days
0.38120866.16091415.html.plaintext.txt	142	Lower box showing levels GAPDH
0.38120866.16091415.html.plaintext.txt	143	C F Real time RT PCR showing expression levels different transcripts spinal cord injury
0.38120866.16091415.html.plaintext.txt	144	The RT designed exclusively amplify transcripts shown
0.38120866.16091415.html.plaintext.txt	145	In C D RT primed 45R
0.38120866.16091415.html.plaintext.txt	146	PCR shown C carried primer pair 52F 41R show levels ApoE S1 D 44F 40R ApoE S3
0.38120866.16091415.html.plaintext.txt	147	In E RT primed 45F amplified 46F 46R demonstrating levels expression ApoE AS1
0.38120866.16091415.html.plaintext.txt	148	To normalize included gene specific primer GAPDH 48R RT reactions background correction levels obtained amplifying GAPDH 47F 47R
0.38120866.16091415.html.plaintext.txt	149	F To exclude levels seen due different levels genomic background included experiment samples lacked enzyme RT reaction amplifying genomic ApoE GAPDH
0.38120866.16091415.html.plaintext.txt	150	Real time RT PCR RNA extracted injured C57BL6 mice actually reveals increase expression species early 4 days post injury maximal expression around 2 weeks Fig
0.38120866.16091415.html.plaintext.txt	151	At highest level ApoE S1 ApoE S3 10 fold upregulated compared normal levels
0.38120866.16091415.html.plaintext.txt	152	In contrast ApoE AS1 100 fold upregulated
0.38120866.16091415.html.plaintext.txt	153	Detection ApoE S2 protein western blot analysis As ApoE S2 protein includes ApoE S1 protein sequence antibodies ApoE S1 also bind ApoE S2
0.38120866.16091415.html.plaintext.txt	154	Therefore western blot exposed ApoE antiserum
0.38120866.16091415.html.plaintext.txt	155	In addition 34 kDa band depicting ApoE S1 mouse liver serum Fig
0.38120866.16091415.html.plaintext.txt	156	6A B mouse serum antibody bound protein 40 kDa arrow Fig
0.38120866.16091415.html.plaintext.txt	157	6B size predicted ApoE S2
0.38120866.16091415.html.plaintext.txt	158	As ApoE S2 protein present ApoE knockout specificity demonstrated including knockout samples negative controls blot
0.38120866.16091415.html.plaintext.txt	159	Binding 34 40 kDa proteins absent ApoE knockout mice demonstrating specificity
0.38120866.16091415.html.plaintext.txt	160	Even though ApoE S2 protein could detected liver western blot analysis likely secreted liver ApoE S2 message almost exclusively expressed liver organs investigated
0.38120866.16091415.html.plaintext.txt	161	One cannot however rule another organ represented Figure 2 source protein
0.38120866.16091415.html.plaintext.txt	162	It possible protein levels liver detection limits western blot analysis though protein secreted blood accumulates detected
0.38120866.16091415.html.plaintext.txt	163	View larger version 21K Figure 6
0.38120866.16091415.html.plaintext.txt	164	Western blot demonstrating ApoE S1 protein A liver B serum lower band ApoE S2 protein upper bandarrow B serum
0.38120866.16091415.html.plaintext.txt	165	Knockout samples included negative controls
0.38120866.16091415.html.plaintext.txt	166	Transcripts human gene Finally investigate whether corresponding transcripts mouse ApoE S2 S3 AS1 transcripts also present human RT PCR analysis carried human liver RNA
0.38120866.16091415.html.plaintext.txt	167	The resulting model human gene transcription products shown Figure 1B
0.38120866.16091415.html.plaintext.txt	168	Human ApoE S2 could amplified RT primed oligo 1R subsequent PCR primed either 6F 5R lane 1 Fig
0.38120866.16091415.html.plaintext.txt	169	The human ApoE S2 sequence also backed EST accession
0.38120866.16091415.html.plaintext.txt	170	In contrast mouse human protein translated Apoe S2 Apoe S1
0.38120866.16091415.html.plaintext.txt	171	View larger version 60K Figure 7
0.38120866.16091415.html.plaintext.txt	172	RT PCR human liver samples
0.38120866.16091415.html.plaintext.txt	173	A ApoE S2 expression RT primed 1R PCR 6F 5R lanes 1 3 7F 5R lanes 2 4
0.38120866.16091415.html.plaintext.txt	174	B ApoE AS1 expression RT primed 3F PCR 8F 1R
0.38120866.16091415.html.plaintext.txt	175	Lower band lane 1 AS1 upper band APOE gene transcript
0.38120866.16091415.html.plaintext.txt	176	All products gel purified sequence verified
0.38120866.16091415.html.plaintext.txt	177	A human sequence corresponding ApoE S3 could amplified
0.38120866.16091415.html.plaintext.txt	178	RT using 1R subsequent PCR primer combinations 3F 2R 8F 2R 4F 2R yield products transcribed ApoE gene
0.38120866.16091415.html.plaintext.txt	179	The presence human ApoE AS1 demonstrated RT primed 3F followed PCR primer 8F 1R lane 1 Fig
0.38120866.16091415.html.plaintext.txt	180	Two products amplified reaction sequencing lower band confirmed originating ApoE AS1 message
0.38120866.16091415.html.plaintext.txt	181	The upper band product ApoE gene
0.38120866.16091415.html.plaintext.txt	182	If translated human mouse proteins highly conserved
0.38120866.16091415.html.plaintext.txt	183	DISCUSSION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES In study shown multiple RNAs sense antisense orientation produced mouse human ApoE gene thereby adding gene growing list genes known transcribed strands
0.38120866.16091415.html.plaintext.txt	184	This list conservatively estimated number 1600 8 genes contained human genome 26
0.38120866.16091415.html.plaintext.txt	185	27 show 22 clusters transcribe sense antisense pairs highest number far supported EST evidence
0.38120866.16091415.html.plaintext.txt	186	Matching accession numbers data found ApoE one genes
0.38120866.16091415.html.plaintext.txt	187	However number genes transcribe strands identified far show antisense transcription greatly underestimated contribution genomic complexity
0.38120866.16091415.html.plaintext.txt	188	One set ApoE transcripts identified code putative transmembrane proteins one frame shifted antisense RNA
0.38120866.16091415.html.plaintext.txt	189	Both sense antisense messages sequences recognized translation start sites therefore could exist protein
0.38120866.16091415.html.plaintext.txt	190	Examples demonstrating expression antisense message shown variety genes reviewed 28 29 including urocortin 30 cardiac troponin 31 basic fibroblast growth factor bFGF 32
0.38120866.16091415.html.plaintext.txt	191	The scenario describe ApoE closely resembles bFGF expression
0.38120866.16091415.html.plaintext.txt	192	The bFGF gene locus known transcribed multiple mRNA products including least one antisense transcript
0.38120866.16091415.html.plaintext.txt	193	This antisense transcript may involved regulating gene expression hybridizing sense transcript still nucleus perhaps affecting developmental patterns tissue differentiation 32
0.38120866.16091415.html.plaintext.txt	194	The bFGF transcript isolated Xenopus could also however translated 25 kDa protein yet unknown function 33
0.38120866.16091415.html.plaintext.txt	195	At point unclear whether newly identified ApoE transcripts including antisense transcript fact translated except ApoE S2 protein found serum
0.38120866.16091415.html.plaintext.txt	196	Beyond translated protein transcripts could participate regulating others levels process like RNAi
0.38120866.16091415.html.plaintext.txt	197	Marking yet another similarity bFGF antisense transcript present human mouse 33
0.38120866.16091415.html.plaintext.txt	198	For ApoE antisense transcript say reading frame also open humans consequently possibility antisense message actually translated protein
0.38120866.16091415.html.plaintext.txt	199	The protein predicted sequence M10065 198 amino acids signal peptide predicted SignalP 3
0.38120866.16091415.html.plaintext.txt	200	0 HMM program 34 probability 0
0.38120866.16091415.html.plaintext.txt	201	In contrast mouse AS1 protein program predicts signal peptide probability 0
0.38120866.16091415.html.plaintext.txt	202	Even deleting first 21 amino acids mouse protein human protein lacks increases probability 0
0.38120866.16091415.html.plaintext.txt	203	Therefore even though human sequence probably enters secretory pathway mouse sequence seems lack signal peptide
0.38120866.16091415.html.plaintext.txt	204	0 HMM focusing prediction classical signal peptides one cannot exclude presence signal motifs mouse protein
0.38120866.16091415.html.plaintext.txt	205	The ApoE antisense protein encoded exon 4 exon accounts three major allelic variants humans
0.38120866.16091415.html.plaintext.txt	206	These allelic variations sense protein defined substitution arginine positively charged polar amino acid cysteine non polar amino acid positions 112 158 protein 3536
0.38120866.16091415.html.plaintext.txt	207	In putative antisense protein arginine substituted histidine positively charged polar amino acids
0.38120866.16091415.html.plaintext.txt	208	Therefore two variants probably affecting function antisense protein less sense protein therefore conservative antisense direction
0.38120866.16091415.html.plaintext.txt	209	However studies allelic variations implications disease always conducted reference sense protein prominent variations Table 1 might lead functional relevant changes
0.38120866.16091415.html.plaintext.txt	210	One dramatic change variation positions 3817 3819 sequence position reference M10065
0.38120866.16091415.html.plaintext.txt	211	The substitution TAG GCT antisense strand opens reading frame translation continue another 113 amino acids
0.38120866.16091415.html.plaintext.txt	212	The E4 allele published Paik et al
0.38120866.16091415.html.plaintext.txt	213	36 contains stop codon positions 3817 3819
0.38120866.16091415.html.plaintext.txt	214	However point clear allelic variation opens reading frame linked major allelic forms like E4 E3 E2 genotype observed haplotypes see Table 1 37 relative frequencies ApoE sequence variants within E4 E3 E2 genotypes see Table 3 38
0.38120866.16091415.html.plaintext.txt	215	Therefore involvement putative antisense protein diseases correlated allelic variants cannot excluded
0.38120866.16091415.html.plaintext.txt	216	For example Alzheimers disease specific molecular pathway ApoE modifies expression disease remains elusive 19
0.38120866.16091415.html.plaintext.txt	217	Furthermore sequence variations different alleles 34 conservative sense direction might lead amino acid substitutions even stop signals antisense direction
0.38120866.16091415.html.plaintext.txt	218	Sequence variations human ApoE gene accession
0.38120866.16091415.html.plaintext.txt	219	M10065 relation ApoE S1 AS1 protein intron 3 exon 4 Even though sequence work thus far suggests human ApoE S2 translated protein ApoE S1 allelic variation might cause open reading frame similar one seen C57BL6 mice leading presence transmembrane version ApoE
0.38120866.16091415.html.plaintext.txt	220	Knockout organisms created investigate phenotypic changes may take place organism absence gene
0.38120866.16091415.html.plaintext.txt	221	Our data suggest genetic manipulation used generate ApoE knockout eliminated expression ApoE S1 ApoE S2 transcripts
0.38120866.16091415.html.plaintext.txt	222	We found ApoE S3 putative transmembrane protein sequence completely different known ApoE protein ApoE AS1 protein potentially produced antisense transcript still expressed knockout
0.38120866.16091415.html.plaintext.txt	223	This possible region gene responsible transcripts particular exon 4 disrupted insertion neo gene knockout
0.38120866.16091415.html.plaintext.txt	224	The roles transcripts currently unknown
0.38120866.16091415.html.plaintext.txt	225	In addition work must done determine whether translated vivo
0.38120866.16091415.html.plaintext.txt	226	An indication potentially important role ApoE S3 ApoE AS1 antisense messages CNS disease comes data mouse spinal cord injury model 1617
0.38120866.16091415.html.plaintext.txt	227	In response spinal injury transcripts upregulated follow expression pattern ApoE S1
0.38120866.16091415.html.plaintext.txt	228	However ApoE AS1 10 fold upregulated either ApoE S1 S3 might also involved influencing translation
0.38120866.16091415.html.plaintext.txt	229	Again would useful know either alternate mRNAs translated response spinal injury
0.38120866.16091415.html.plaintext.txt	230	ApoE lipoprotein class proteins responsible carrying cholesterol fats bloodstream little packages essential normal breakdown molecules
0.38120866.16091415.html.plaintext.txt	231	In particular ApoE major component specific lipoproteins called low density lipoproteins VLDLs
0.38120866.16091415.html.plaintext.txt	232	A major function VLDLs remove excess cholesterol blood carry liver processing
0.38120866.16091415.html.plaintext.txt	233	Maintaining normal levels cholesterol essential prevention cardiovascular diseases including heart attacks stroke
0.38120866.16091415.html.plaintext.txt	234	There least three slightly different versions ApoE gene
0.38120866.16091415.html.plaintext.txt	235	The major versions alleles called 2 3 4
0.38120866.16091415.html.plaintext.txt	236	The common allele 3 found half population
0.38120866.16091415.html.plaintext.txt	237	Researchers found people familial hypercholesterolemia condition causes high levels cholesterol increased risk heart attacks strokes two copies 2 allele
0.38120866.16091415.html.plaintext.txt	238	This allele seems one several genetic factors play part disorder
0.38120866.16091415.html.plaintext.txt	239	In addition ApoE allelic version 4 risk factor coronary artery disease
0.38120866.16091415.html.plaintext.txt	240	People inherit least one copy ApoE 4 allele increased risk developing type 2 Alzheimers disease first appears later life
0.38120866.16091415.html.plaintext.txt	241	Studies shown people inherit two copies ApoE 4 highest chance developing disease
0.38120866.16091415.html.plaintext.txt	242	It yet known allele affects persons risk Alzheimers disease however found increases number amyloid plaques characteristic disease 919
0.38120866.16091415.html.plaintext.txt	243	Finally EST evidence ApoE alternative splice variant human exist 41
0.38120866.16091415.html.plaintext.txt	244	One EST corresponds last exon different ApoE S2 S3
0.38120866.16091415.html.plaintext.txt	245	This validated RT PCR showed expressed lung cancer strongly normal tissue
0.38120866.16091415.html.plaintext.txt	246	In conclusion ApoE protein may play vital role occurrence diverse group maladies
0.38120866.16091415.html.plaintext.txt	247	It appears ApoE gene characterized complex expression pattern multiple start sites sense antisense direction
0.38120866.16091415.html.plaintext.txt	248	As open reading frame transcripts may translated proteins
0.38120866.16091415.html.plaintext.txt	249	Work must done determine whether antisense transcript involved regulating expression post transcriptionally translated novel protein
0.38120866.16091415.html.plaintext.txt	250	In addition given significance exon 4 various allelic versions ApoE knockout exon may give insight role
0.38120866.16091415.html.plaintext.txt	251	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES RT PCR mouse Tissue dissected CO2 euthanized 8 week old female C57BL6 mice ApoE knockout mice C57BL6J Apoetm1Unc Jackson Laboratory Bar Harbor ME USA stored 80 degrees C use
0.38120866.16091415.html.plaintext.txt	252	RNA isolated homogenizing pooled tissue two animals Trizol Gibco BRL following manufacturers instructions
0.38120866.16091415.html.plaintext.txt	253	RNA treated 30 min DNase Promega remove DNA might copurified
0.38120866.16091415.html.plaintext.txt	254	RNA concentration determined OD260 readings
0.38120866.16091415.html.plaintext.txt	255	Three micrograms total RNA reverse transcribed 42 degrees C 20 microl cocktail included 1 U RNase IN 0
0.38120866.16091415.html.plaintext.txt	256	2 microM dNTPs 1 microM Oligo dT 200 U SuperScript reverse transcriptase Gibco BRL 1x RT buffer
0.38120866.16091415.html.plaintext.txt	257	Control reactions omitted RT enzyme
0.38120866.16091415.html.plaintext.txt	258	The samples brought 200 microl H2O
0.38120866.16091415.html.plaintext.txt	259	For PCR 20 microl reaction used including 50 mM Tris HCl pH 8
0.38120866.16091415.html.plaintext.txt	260	4 750 microgml bovine serum albumin 0
0.38120866.16091415.html.plaintext.txt	261	2 mM deoxyribonucleoside triphosphate 0
0.38120866.16091415.html.plaintext.txt	262	8 U Taq DNA polymerase Platinum Taq Life Technologies Inc
0.38120866.16091415.html.plaintext.txt	263	Primers used PCR included ApoE S1 52F 40R ApoE S2 40F 40R ApoE S3AS1 44F 40R
0.38120866.16091415.html.plaintext.txt	264	GAPDH 47F 47R included positive control Table 2
0.38120866.16091415.html.plaintext.txt	265	All PCR products sequence verified
0.38120866.16091415.html.plaintext.txt	266	Primers mouse ApoE GenBank accession
0.38120866.16091415.html.plaintext.txt	267	1 mouse GAPDH M32599 human ApoE M10065 RT PCR human Human liver RNA obtained Stratagene catalog
0.38120866.16091415.html.plaintext.txt	268	Enzymatic reactions carried described earlier
0.38120866.16091415.html.plaintext.txt	269	For APOE S2 RT carried primer 1R PCR primers 6F 5R 7F 5R
0.38120866.16091415.html.plaintext.txt	270	For APOE AS1 RT carried primer 3F PCR primers 8F 1R Fig
0.38120866.16091415.html.plaintext.txt	271	Gene sense antisense specific reverse transcription mouse RNA extracted either exsanguinated liver spinal cord Trizol treated DNase re extracted phenolchloroform precipitated alcohol
0.38120866.16091415.html.plaintext.txt	272	Samples time point pooled equally according OD260 reverse transcription carried 0
0.38120866.16091415.html.plaintext.txt	273	75 microg time point 10 microl reaction described earlier exception gene specific primers used
0.38120866.16091415.html.plaintext.txt	274	To selectively amplify ApoE exon 4 sense strand used primers 45R 48R GAPDH control ii antisense used primers 45F 48R GAPDH control
0.38120866.16091415.html.plaintext.txt	275	Control reactions omitted reverse transcriptase
0.38120866.16091415.html.plaintext.txt	276	Reverse transcription carried 42 degrees C 1 h
0.38120866.16091415.html.plaintext.txt	277	Samples brought 100 microl H2O passed though Chroma Spin 100 size exclusion column Clontech exclude unused primers re extracted phenolchloroform precipitated alcohol
0.38120866.16091415.html.plaintext.txt	278	Real time RT PCR mouse Real time RT PCR mouse 20 carried Lightcycler Roche 21 determine amount ApoE S1 RT primed 45R PCR primers 52F 41R antisense exon 4 RT primed 45F PCR primers 46F 46R well ApoE S3 RT primed 45R PCR primers 44F 40R
0.38120866.16091415.html.plaintext.txt	279	The reaction set using Faststart DNA Master Sybr Green I Kit Roche according instructions 10 microl cocktail magnesium concentration 2 mM
0.38120866.16091415.html.plaintext.txt	280	A period 10 min 95 degrees C used denature inactivate Taq start antibody
0.38120866.16091415.html.plaintext.txt	281	Cycling carried 45 times using 95 degrees C 10 61 degrees C 10 72 degrees C 20 acquisition temperature set 85 degrees C 10
0.38120866.16091415.html.plaintext.txt	282	Levels quantified basis fluorescence intercalated SYBER Green I dye dsDNA cycle
0.38120866.16091415.html.plaintext.txt	283	Quality control includes exponential curves melting product analysis ensure amplification one template well size analysis gel electrophoresis
0.38120866.16091415.html.plaintext.txt	284	Northern hybridization mouse Total RNA extracted Trizol treated DNase 10 microg run denaturing 3
0.38120866.16091415.html.plaintext.txt	285	5 polyacrylamide urea 8 M gels 1xTBE buffer
0.38120866.16091415.html.plaintext.txt	286	Electroblotting done onto Hydrobond N Amersham Pharmacia 0
0.38120866.16091415.html.plaintext.txt	287	The RNA checked UV light integrity evenness transfer
0.38120866.16091415.html.plaintext.txt	288	RNA immobilized onto membrane backing vacuum 80 degrees C 30 min
0.38120866.16091415.html.plaintext.txt	289	Sense antisense specific RNA probes synthesized T7 T3 polymerase using Epicintres RiboScribe kit
0.38120866.16091415.html.plaintext.txt	290	Gel purified PCR products generated gene specific primers Table 2 included either T7 T3 promoter served templates generating probes
0.38120866.16091415.html.plaintext.txt	291	Location probes indicated Figure 1
0.38120866.16091415.html.plaintext.txt	292	T7 T3 reactions 20 microl1 microg template ATP GTP CTP 0
0.38120866.16091415.html.plaintext.txt	293	5 mM 15 microM UTP 10 mM DTT 5 microCi microl 32PUTP polymerase 0
0.38120866.16091415.html.plaintext.txt	294	5 U microl carried 37 degrees C 3 h followed 15 min DNase treatment 37 degrees C
0.38120866.16091415.html.plaintext.txt	295	Probes purified Chroma Spin 100 size exclusion column Clontech aliquot run 2 agarose checking size labeling
0.38120866.16091415.html.plaintext.txt	296	Hybridization carried Ultrahyb Ambion hybridization buffer overnight 68 degrees C 1 h blocking rotating chambers
0.38120866.16091415.html.plaintext.txt	297	Membranes washed 2x5 min 65 degrees C 2xSSC 0
0.38120866.16091415.html.plaintext.txt	298	1 SDS followed 2x15 min 68 degrees C 0
0.38120866.16091415.html.plaintext.txt	299	Signal collected Phosphor Screens scanned Storm scanner Molecular Dynamics
0.38120866.16091415.html.plaintext.txt	300	Primers RT PCR Primers designed using software primer 3www
0.38120866.16091415.html.plaintext.txt	301	2 22 applied ApoE genomic sequence GenBank accession
0.38120866.16091415.html.plaintext.txt	302	Specificity determined size sequence verification product
0.38120866.16091415.html.plaintext.txt	303	The location primer pair seen Figure 1
0.38120866.16091415.html.plaintext.txt	304	Primer sequences shown Table 2
0.38120866.16091415.html.plaintext.txt	305	When used amplify templates vitro transcription RNA probes T7 5 TAATACGACTCACTATAGGG 3 T3 5 AATTAACCCTCACTAAAGGG 3 promoter added
0.38120866.16091415.html.plaintext.txt	306	Primers synthesized desalted Integrated DNA Technologies Coralville IA USA
0.38120866.16091415.html.plaintext.txt	307	Spinal cord injuries For experiments female C57BL6 mice Jackson Laboratory used age 8 10 weeks
0.38120866.16091415.html.plaintext.txt	308	Animals injured using previously described surgical model complete spinal cord transection including meninges cut dura model 1617
0.38120866.16091415.html.plaintext.txt	309	In short animals anesthetized ketamine xylazine 100 15 mgkg
0.38120866.16091415.html.plaintext.txt	310	The skin surgically scrubbed chlorohexadine hair surgical field removed
0.38120866.16091415.html.plaintext.txt	311	A complete transection cord carried level TH8 9 using microscalpel 5 mm blade depth 15 degrees catalog
0.38120866.16091415.html.plaintext.txt	312	37 7515 Roboz Surgical Instruments
0.38120866.16091415.html.plaintext.txt	313	Two sham two unoperated controls three animals per time point used real time RT PCR analysis injury site TH7 10
0.38120866.16091415.html.plaintext.txt	314	For northern analysis 10 microg DNase treated Trizol extracted total RNA one animal per time point used
0.38120866.16091415.html.plaintext.txt	315	Dissected spinal cord tissue stored 80 degrees C use
0.38120866.16091415.html.plaintext.txt	316	Western blot mouse Liver serum samples collected C57BL6 Apoe ko mice Jackson Laboratory age 4 5 months
0.38120866.16091415.html.plaintext.txt	317	For serum blood collected tail vein left coagulate 2 h 4 degrees C separation
0.38120866.16091415.html.plaintext.txt	318	Liver collected wet ice homogenized glass homogenizer mixed lysis buffer containing proteinase inhibitor cocktail CompleteTM Boehringer Mannheim 1xPBS 0
0.38120866.16091415.html.plaintext.txt	319	Total protein concentration sera liver samples determined using standard Lowry protein assay procedure DC Protein Assay Kit BioRad Laboratories catalog
0.38120866.16091415.html.plaintext.txt	320	500 0116 equilibrated total protein concentration 10 mgml
0.38120866.16091415.html.plaintext.txt	321	Protein samples mixed 4xSDS gel loading buffer boiled 10 min loaded onto 10 SDS PAGE liver samples 20 30 microg per well lane loaded onto 12 gel serum samples 20 30 microgwell
0.38120866.16091415.html.plaintext.txt	322	The gel electroblotted Immobilon P Millipore 25 mM Tris OH 250 mM glycine 10 methanol 8 V 30 mA overnight
0.38120866.16091415.html.plaintext.txt	323	The blot blocked PBS Tween 20 0
0.38120866.16091415.html.plaintext.txt	324	To detect ApoE S1 ApoE S2 blots incubated goat anti apoe antibody 1300 sc 6384 Santa Cruz Biotechnology overnight 4 degrees C
0.38120866.16091415.html.plaintext.txt	325	As secondary antibody HRP labeled mouse monoclonal anti goatsheep antibody used Sigma A 9452 1 h RT following concentration liver 15000 serum 17000
0.38120866.16091415.html.plaintext.txt	326	The blot developed using chemiluminescence kit Boehringer Mannheim
0.38120866.16091415.html.plaintext.txt	327	The chemiluminescent signal scanned digitalized
0.38120866.16091415.html.plaintext.txt	328	ACKNOWLEDGEMENT This work generously supported grant F
0.38120866.16091415.html.plaintext.txt	329	Kirby Foundation Commonwealth Universal Research Enhancement Program Pennsylvania Department Health
0.38120866.16091415.html.plaintext.txt	330	REFERENCES TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Mahley R
0.38120866.16091415.html.plaintext.txt	331	1988 Apolipoprotein E cholesterol transport protein expanding role cell biology
0.38120866.16091415.html.plaintext.txt	332	1991 Three dimensional structure LDL receptor binding domain human apolipoprotein E
0.38120866.16091415.html.plaintext.txt	333	1988 Human apolipoprotein E3 aqueous solution
0.38120866.16091415.html.plaintext.txt	334	Evidence two structural domains
0.38120866.16091415.html.plaintext.txt	335	1988 Human apolipoprotein E3 aqueous solution
0.38120866.16091415.html.plaintext.txt	336	Properties amino carboxyl terminal domain
0.38120866.16091415.html.plaintext.txt	337	1984 Extrahepatic synthesis apolipoprotein E
0.38120866.16091415.html.plaintext.txt	338	1985 Apolipoprotein E mRNA abundant brain adrenals well liver present peripheral tissues rats marmosets
0.38120866.16091415.html.plaintext.txt	339	2002 Cognitive change APOE epsilon 4 allele
0.38120866.16091415.html.plaintext.txt	340	1998 Apolipoprotein E CNS response injury
0.38120866.16091415.html.plaintext.txt	341	1993 Apolipoprotein E high avidity binding beta amyloid increased frequency type 4 allele late onset familial Alzheimer disease
0.38120866.16091415.html.plaintext.txt	342	1977 Polymorphism apolipoprotein E occurrence dysbetalipoproteinaemia man
0.38120866.16091415.html.plaintext.txt	343	1985 Apolipoprotein E associated astrocytic glia central nervous system nonmyelinating glia peripheral nervous system
0.38120866.16091415.html.plaintext.txt	344	1996 Expression apolipoprotein E mRNA rat microglia
0.38120866.16091415.html.plaintext.txt	345	1997 Astrocytes microglia respond estrogen increased ApoE mRNA vivo vitro
0.38120866.16091415.html.plaintext.txt	346	1996 Neurons human frontal cortex display apolipoprotein E immunoreactivity implications Alzheimers disease
0.38120866.16091415.html.plaintext.txt	347	2000 Astrocyte lipoproteins effects ApoE neuronal function role ApoE amyloid beta deposition vivo
0.38120866.16091415.html.plaintext.txt	348	CO2 ClinktypeDOI CrossRef
0.38120866.16091415.html.plaintext.txt	349	2002 Recovery spinal cord injury new transection model C57Bl6 mouse
0.38120866.16091415.html.plaintext.txt	350	2003 Apo E expression spinal cord injury mouse
0.38120866.16091415.html.plaintext.txt	351	1992 Generation mice carrying mutant apolipoprotein E gene inactivated gene targeting embryonic stem cells
0.38120866.16091415.html.plaintext.txt	352	2000 Apolipoprotein E Alzheimers disease
0.38120866.16091415.html.plaintext.txt	353	1997 Continuous fluorescence monitoring rapid cycle DNA amplification
0.38120866.16091415.html.plaintext.txt	354	1997 The LightCycler microvolume multi sample fluorimeter rapid temperature control
0.38120866.16091415.html.plaintext.txt	355	edugenomesoftwareotherprimer3
0.38120866.16091415.html.plaintext.txt	356	1998 SOSUI classification secondary structure prediction system membrane proteins
0.38120866.16091415.html.plaintext.txt	357	Bioinformatics 14 378 379
0.38120866.16091415.html.plaintext.txt	358	2003 CDD curated Entrez database conserved domain alignments
0.38120866.16091415.html.plaintext.txt	359	1996 Large scale sequencing specific neural networks promoter splice site recognition
0.38120866.16091415.html.plaintext.txt	360	eds Biocomputing Proceedings 1996 Pacific Symposium
0.38120866.16091415.html.plaintext.txt	361	World Scientific Publishing Co
0.38120866.16091415.html.plaintext.txt	362	2003 Widespread occurrence antisense transcription human genome
0.38120866.16091415.html.plaintext.txt	363	2004 Over 20 human transcripts might form sense antisense pairs
0.38120866.16091415.html.plaintext.txt	364	1998 Antisense RNA function fate duplex RNA cells higher eukaryotes
0.38120866.16091415.html.plaintext.txt	365	1998 Do natural antisense transcripts make sense eukaryotes Gene 211 1 9
0.38120866.16091415.html.plaintext.txt	366	2000 Identification urocortin mRNA antisense transcripts rat tissue
0.38120866.16091415.html.plaintext.txt	367	2002 Cardiac troponin I sense antisense RNA duplexes myocardium
0.38120866.16091415.html.plaintext.txt	368	1997 Characterization tissue specific expression rat basic fibroblast growth factor antisense mRNA protein
0.38120866.16091415.html.plaintext.txt	369	1989 An antisense transcript Xenopus laevis bFGF gene coding evolutionarily conserved 24 kDa protein
0.38120866.16091415.html.plaintext.txt	370	2004 Improved prediction signal peptides SignalP 3
0.38120866.16091415.html.plaintext.txt	371	1985 Nucleotide sequence structure human apolipoprotein E gene
0.38120866.16091415.html.plaintext.txt	372	1988 Genotyping sequence analysis apolipoprotein E isoforms
0.38120866.16091415.html.plaintext.txt	373	2000 Apolipoprotein E variation sequence haplotype level implications origin maintenance major human polymorphism
0.38120866.16091415.html.plaintext.txt	374	2000 Sequence diversity large scale typing SNPs human apolipoprotein E gene
0.38120866.16091415.html.plaintext.txt	375	2001 Gene2EST BLAST2 server searching expressed sequence tag EST databases eukaryotic gene sized queries
0.38120866.16091415.html.plaintext.txt	376	2000 Artemis sequence visualisation annotation
0.38120866.16091415.html.plaintext.txt	377	Bioinformatics 16 944 945
0.38120866.16091415.html.plaintext.txt	378	Identification alternatively spliced mRNA variants related cancers genome wide ESTs alignment
0.38120866.16091415.html.plaintext.txt	379	This Article Abstract Full Text PDF All Versions Article 14182661 recent ddi296v1 Alert article cited Alert correction posted Services Email article friend Similar articles journal Similar articles PubMed Alert new issues journal Add My Personal Archive Download citation manager Request Permissions Google Scholar Articles Seitz A
0.38120866.16091415.html.plaintext.txt	380	PubMed PubMed Citation Articles Seitz A
0.38120866.16091415.html.plaintext.txt	381	Online ISSN 1460 2083 Print ISSN 0964 6906 Copyright 2006 Oxford University Press Oxford Journals Oxford University Press Site Map Terms Conditions Privacy Policy Frequently Asked Questions Other Oxford University Press sites Oxford University Press American National Biography Booksellers Information Service Childrens Fiction Poetry Childrens Reference Corporate Special Sales Dictionaries Dictionary National Biography Digital Reference English Language Teaching Higher Education Textbooks Humanities International Education Unit Law Medicine Music Online Products Oxford English Dictionary Reference Rights Permissions Science School Books Social Sciences Very Short Introductions Worlds Classics
0.976726.15003956.html.plaintext.txt	0	Meta Analysis Association Cathepsin D Ala224Val Gene Polymorphism Risk Alzheimer Disease A HuGE Gene Disease Association Review Christos Ntais1 Anastasia Polycarpou1 John P
0.976726.15003956.html.plaintext.txt	1	1 Clinical Molecular Epidemiology Unit Department Hygiene Epidemiology University Ioannina School Medicine Ioannina Greece
0.976726.15003956.html.plaintext.txt	2	2 Biomedical Research Institute Foundation Research Technology Hellas Ioannina Greece
0.976726.15003956.html.plaintext.txt	3	3 Institute Clinical Research Health Policy Studies Department Medicine Tufts New England Medical Center Tufts University School Medicine Boston MA
0.976726.15003956.html.plaintext.txt	4	Received publication August 5 2003 accepted publication October 10 2003
0.976726.15003956.html.plaintext.txt	5	ABSTRACT TOP ABSTRACT INTRODUCTION GENE GENE VARIANTS DISEASE META ANALYSIS METHODS META ANALYSIS RESULTS DISCUSSION LABORATORY TESTS POPULATION TESTING REFERENCES A C T polymorphism exon 2 cathepsin D gene encoding cathepsin D CTSD implicated risk factor Alzheimer disease
0.976726.15003956.html.plaintext.txt	6	The authors performed meta analysis 14 studies 16 comparisons CTSD genotyping 3174 Alzheimer disease cases 3298 controls
0.976726.15003956.html.plaintext.txt	7	Overall random effects odds ratio T versus C allele 1
0.976726.15003956.html.plaintext.txt	8	17 95 confidence interval CI 0
0.976726.15003956.html.plaintext.txt	9	44 study heterogeneity p 0
0.976726.15003956.html.plaintext.txt	10	There significant study heterogeneity evidence significant association first hypothesis generating study excluded calculations odds ratio OR 1
0.976726.15003956.html.plaintext.txt	11	The summary odds ratio T carriers versus T noncarriers similar subjects carrying carrying apolipoprotein E 4 allele APOE4
0.976726.15003956.html.plaintext.txt	12	The increased susceptibility Alzheimer disease conferred APOE4 carriage tended prominent presence T allele random effects OR 6
0.976726.15003956.html.plaintext.txt	13	31 T carriers noncarriers respectively
0.976726.15003956.html.plaintext.txt	14	The meta analysis shows CTSD polymorphism major risk factor Alzheimer disease although small effect enhancement APOE4 effect cannot excluded
0.976726.15003956.html.plaintext.txt	15	Alzheimer disease cathepsin D CTSD epidemiology genetics meta analysis polymorphism genetics
0.976726.15003956.html.plaintext.txt	16	Abbreviations Abbreviations CI confidence interval OR odds ratio
0.976726.15003956.html.plaintext.txt	17	INTRODUCTION TOP ABSTRACT INTRODUCTION GENE GENE VARIANTS DISEASE META ANALYSIS METHODS META ANALYSIS RESULTS DISCUSSION LABORATORY TESTS POPULATION TESTING REFERENCES Editor note This paper also available website Human Genome Epidemiology Network httpwww
0.976726.15003956.html.plaintext.txt	18	GENE TOP ABSTRACT INTRODUCTION GENE GENE VARIANTS DISEASE META ANALYSIS METHODS META ANALYSIS RESULTS DISCUSSION LABORATORY TESTS POPULATION TESTING REFERENCES Cathepsin D intracellular acid protease exhibits beta secretase activity vitro implicated processing amyloid precursor protein tau protein 1 2
0.976726.15003956.html.plaintext.txt	19	The cathepsin D gene CTSD located short arm chromosome 11 11p15
0.976726.15003956.html.plaintext.txt	20	The synthesis beta amyloid peptide putative key event pathogenesis Alzheimer disease
0.976726.15003956.html.plaintext.txt	21	Beta amyloid derives precursor protein via proteolytic cleavage secretases
0.976726.15003956.html.plaintext.txt	22	Therefore postulated variants genes coding enzymes involved proteolytic cleavage amyloid precursor protein degradation clearance beta amyloid central nervous system may potential risk factors Alzheimer disease
0.976726.15003956.html.plaintext.txt	23	GENE VARIANTS TOP ABSTRACT INTRODUCTION GENE GENE VARIANTS DISEASE META ANALYSIS METHODS META ANALYSIS RESULTS DISCUSSION LABORATORY TESTS POPULATION TESTING REFERENCES The CTSD gene contains polymorphic C T transition site position 224 exon 2
0.976726.15003956.html.plaintext.txt	24	This polymorphism results Ala38 Val substitution cathepsin D profragment 3
0.976726.15003956.html.plaintext.txt	25	The polymorphism associated increased secretion altered intracellular maturation cathep sin D profragment one study 3
0.976726.15003956.html.plaintext.txt	26	Moreover T allele associated 50 percent decrease beta amyloid peptide 1 42 levels cerebrospinal fluid patients Alzheimer disease 4
0.976726.15003956.html.plaintext.txt	27	Finally polymorphism recently reported significantly associated general intelligence healthy elderly people 5
0.976726.15003956.html.plaintext.txt	28	Molecular epidemiologic studies presented seemingly contradictory results concerning potential role CTSD polymorphism Alzheimer disease 6 19
0.976726.15003956.html.plaintext.txt	29	There also controversy whether polymorphism may interact apolipoprotein E 4 allele APOE4 best known genetic determinant sporadic Alzhei mer disease 20
0.976726.15003956.html.plaintext.txt	30	Single studies may underpowered detect interactions even overall effects
0.976726.15003956.html.plaintext.txt	31	Given amount accumulated data deemed important perform quantitative synthesis evidence using rigorous methods
0.976726.15003956.html.plaintext.txt	32	Thus conducted comprehensive meta analysis available studies relating CTSD polymorphism risk Alzheimer disease
0.976726.15003956.html.plaintext.txt	33	DISEASE TOP ABSTRACT INTRODUCTION GENE GENE VARIANTS DISEASE META ANALYSIS METHODS META ANALYSIS RESULTS DISCUSSION LABORATORY TESTS POPULATION TESTING REFERENCES Alzheimer disease common cause progressive cognitive impairment elderly annual incidence approximately 1 percent 65 69 years increasing 40 percent elderly 85 years age 21 22
0.976726.15003956.html.plaintext.txt	34	Mutations amyloid precursor protein presenilin 1 presenilin 2 genes account 5 percent cases result autosomally dominant pattern expressed complete penetrance early manifestations 23
0.976726.15003956.html.plaintext.txt	35	Alzheimer disease probably slightly common females 24
0.976726.15003956.html.plaintext.txt	36	Other proven postulated risk factors include head injury particular among males 25 well family history low income low education low occupational status depression exposure aluminum drinking water hypertension Down syndrome 26 27
0.976726.15003956.html.plaintext.txt	37	Conversely use nonsteroidal antiinflammatory drugs treat arthritis associated reduced risk Alzhei mer disease estrogen use postmenopausal women 27
0.976726.15003956.html.plaintext.txt	38	Physical activity diets high levels vitamins B6 B12 folate red wine moderate quantities may protective 27
0.976726.15003956.html.plaintext.txt	39	The prevalence Alzheimer disease varies considerably among different population groups 28
0.976726.15003956.html.plaintext.txt	40	At least dozens polymorphisms examined relation sporadic Alzheimer disease published reviews available 23 29
0.976726.15003956.html.plaintext.txt	41	Among conclusive evidence several studies meta analysis thereof APOE4 strong risk factor developing Alzheimer disease male female subjects early onset 65 years late onset disease 20 approximately fivefold increase odds developing Alzheimer disease
0.976726.15003956.html.plaintext.txt	42	Single studies also implicated polymorphisms important although reported odds ratios much smaller seen APOE4 attempts replication subsequent research conclusive
0.976726.15003956.html.plaintext.txt	43	Meta analyses polymorphisms already appeared literature 30 35
0.976726.15003956.html.plaintext.txt	44	They suggest significant overall associations several polymorphisms including myeloperoxidase gene promoter polymorphism 30 intronic promoter region polymorphisms presenilin 1 late onset disease 31 insertion deletion polymorphism missense mutation alpha 2 macroglobulin gene 32 several polymorphisms protein tau gene 33
0.976726.15003956.html.plaintext.txt	45	Associations modest effect size odds ratios ORs 1
0.976726.15003956.html.plaintext.txt	46	35 claimed meta analyses low density lipoprotein receptor related protein gene exon 3 polymorphism 34 insertion deletion polymorphism angiotensin converting enzyme I gene 35
0.976726.15003956.html.plaintext.txt	47	META ANALYSIS METHODS TOP ABSTRACT INTRODUCTION GENE GENE VARIANTS DISEASE META ANALYSIS METHODS META ANALYSIS RESULTS DISCUSSION LABORATORY TESTS POPULATION TESTING REFERENCES Identification eligibility relevant studies We considered studies examined association CTSD polymorphism Alzheimer disease
0.976726.15003956.html.plaintext.txt	48	Sources included MEDLINE EMBASE January 1994 September 2003
0.976726.15003956.html.plaintext.txt	49	The search strategy based combinations Alzheimer disease CTSD cathepsin D polymorphism allele genetics
0.976726.15003956.html.plaintext.txt	50	References retrieved articles also screened
0.976726.15003956.html.plaintext.txt	51	Case control studies eligible determined distribution CTSD genotypes Alzheimer disease cases regardless age onset concurrent control group dementia free subjects using molecular method genotyping
0.976726.15003956.html.plaintext.txt	52	Cases Alzheimer disease eligible regardless whether family history Alzhei mer disease
0.976726.15003956.html.plaintext.txt	53	However excluded family based studies pedigrees several affected cases per family analysis based linkage considerations
0.976726.15003956.html.plaintext.txt	54	Data extraction Two investigators independently extracted data reached consensus items
0.976726.15003956.html.plaintext.txt	55	The following information sought report authors journal year publication country origin selection characteristics Alzheimer disease cases controls demographics ethnic group study population eligible genotyped cases controls number cases controls CTSD genotype
0.976726.15003956.html.plaintext.txt	56	For studies including subjects different ethnic groups data extracted separately ethnicity whenever possible
0.976726.15003956.html.plaintext.txt	57	Furthermore examined whether matching used whether specific mention blinding personnel performed genotyping clinical status subjects whether genotyping method validated
0.976726.15003956.html.plaintext.txt	58	Meta analysis The primary analysis compared Alzheimer disease cases controls contrast T versus C alleles
0.976726.15003956.html.plaintext.txt	59	This analysis aims detect overall differences
0.976726.15003956.html.plaintext.txt	60	We also examined contrast extremes homozygotes TT versus CC
0.976726.15003956.html.plaintext.txt	61	Finally examined contrast TT versus CT CC contrast CT TT versus CC
0.976726.15003956.html.plaintext.txt	62	These contrasts correspond recessive dominant effects respectively T allele
0.976726.15003956.html.plaintext.txt	63	The odds ratio used metric choice
0.976726.15003956.html.plaintext.txt	64	For genetic contrast estimated study heterogeneity across eligible comparisons using chi square based Q statistic 36
0.976726.15003956.html.plaintext.txt	65	Heterogeneity considered significant p 0
0.976726.15003956.html.plaintext.txt	66	Data combined using fixed effects Mantel Haenszel random effects DerSimonian Laird models 37
0.976726.15003956.html.plaintext.txt	67	Random effects incorporate estimate study variance tend provide wider confidence intervals results constituent studies differ among
0.976726.15003956.html.plaintext.txt	68	In absence study heterogeneity two methods provide identical results
0.976726.15003956.html.plaintext.txt	69	Random effects appropriate heterogeneity present 37
0.976726.15003956.html.plaintext.txt	70	We also performed cumulative meta analysis 38 recursive cumulative meta analysis 39 40 evaluate whether summary odds ratio T versus C contrast changed time data accumulated whether strength association changed first hypothesis generating study excluded calculations 41
0.976726.15003956.html.plaintext.txt	71	Inverted funnel plots Begg Mazumdar publication bias diagnostic nonparametric correlation coefficient 42 evaluated whether magnitude observed association related variance study whether large studies gave different results compared smaller ones 43
0.976726.15003956.html.plaintext.txt	72	Finally evaluated whether summary results different analysis limited studies intensive efforts exclude Alzheimer disease controls clearly performed neuropsychological testing controls
0.976726.15003956.html.plaintext.txt	73	Previous investigations alluded possibility T allele may interact APOE4 allele conferring susceptibility Alzheimer disease 7 9
0.976726.15003956.html.plaintext.txt	74	Thus also evaluated effect T allele carriage risk Alzheimer disease separately APOE4 positive APOE4 negative subjects
0.976726.15003956.html.plaintext.txt	75	Moreover evaluated genetic effect conferred presence APOE4 separately subjects carrying T allele carrying T allele
0.976726.15003956.html.plaintext.txt	76	Odds ratios combined fixed random effects models described
0.976726.15003956.html.plaintext.txt	77	When data reported communicated primary investigators obtain information whenever possible
0.976726.15003956.html.plaintext.txt	78	Analyses performed SPSS 11
0.976726.15003956.html.plaintext.txt	79	Chicago Illinois Meta Analyst Joseph Lau Boston Massachusetts software
0.976726.15003956.html.plaintext.txt	80	Whenever 0 values 2 x 2 table added 0
0.976726.15003956.html.plaintext.txt	81	5 four cells odds ratio could calculated
0.976726.15003956.html.plaintext.txt	82	META ANALYSIS RESULTS TOP ABSTRACT INTRODUCTION GENE GENE VARIANTS DISEASE META ANALYSIS METHODS META ANALYSIS RESULTS DISCUSSION LABORATORY TESTS POPULATION TESTING REFERENCES Eligible studies Fourteen studies probing relation CTSD polymorphism Alzheimer disease susceptibility identified 6 19 profiled table 1
0.976726.15003956.html.plaintext.txt	83	Two eligible studies 6 15 contained subjects two different ethnic groups total 16 separate comparisons considered
0.976726.15003956.html.plaintext.txt	84	There considerable diversity ethnic groups
0.976726.15003956.html.plaintext.txt	85	Eleven studies 6 15 19 selected Alzheimer disease cases according criteria National Institute Neurological Communicative Disorders Stroke Alzheimer Disease Related Disorders Association NINCDS ADRDA two studies 16 18 selected Alzhei mer disease cases according Diagnostic Statistical Manual Mental Disorders DSM IIIR DSM IV criteria one study 17 clarify exact criteria used diagnosis Alzheimer disease
0.976726.15003956.html.plaintext.txt	86	Five studies 13 17 also included autopsy confirmed Alzheimer disease cases
0.976726.15003956.html.plaintext.txt	87	Two studies 7 16 mentioned included cases family history Alzheimer disease eight studies 9 14 18 19 specifically excluded patients remaining clarify background family history
0.976726.15003956.html.plaintext.txt	88	One study 6 mentioned 61 percent Alzheimer disease cases late onset disease age onset 65 years five studies 8 12 14 19 specifically included late onset Alzheimer disease cases one study 18 specifically excluded patients remaining clarify age onset
0.976726.15003956.html.plaintext.txt	89	Controls diagnosis Alzheimer disease amount additional screening general physical neurologic examination psychiatric interview neuropsychological testing blood cerebrospinal fluid studies computed tomography scan Mini Mental State Examination score exclude Alzheimer disease differed substantially across studies
0.976726.15003956.html.plaintext.txt	90	Characteristics studies included meta analysis Specific matching age described five studies 10 12 15
0.976726.15003956.html.plaintext.txt	91	One study also matched sex 10
0.976726.15003956.html.plaintext.txt	92	Only one study 7 specifically mentioned blinding personnel performed genotyping
0.976726.15003956.html.plaintext.txt	93	Appropriate molecular methods genotyping used
0.976726.15003956.html.plaintext.txt	94	All studies used polymerase chain reaction two studies 14 18 also used dynamic allele specific hybridization
0.976726.15003956.html.plaintext.txt	95	Meta analysis database The eligible studies summarized table 2 included total 3175 cases Alzheimer disease 3334 controls 3174 3298 respectively genotype data
0.976726.15003956.html.plaintext.txt	96	The T allele highly represented among controls American descent overall prevalence 8
0.976726.15003956.html.plaintext.txt	97	6 percent 95 percent confidence interval CI 7
0.976726.15003956.html.plaintext.txt	98	1 controls European 7
0.976726.15003956.html.plaintext.txt	99	There significant heterogeneity prevalence rates T allele even across control subjects European descent rate 14
0.976726.15003956.html.plaintext.txt	100	3 percent among Hispanic Americans 10
0.976726.15003956.html.plaintext.txt	101	1 percent Spain lower rates northern European countries 7
0.976726.15003956.html.plaintext.txt	102	6 percent United Kingdom 6
0.976726.15003956.html.plaintext.txt	103	1 percent Germany lowest prevalence rate 4
0.976726.15003956.html.plaintext.txt	104	5 percent Polish population
0.976726.15003956.html.plaintext.txt	105	Overall prevalence TT homozygosity 0
0.976726.15003956.html.plaintext.txt	106	2 percent control subjects American European Asian descent respectively
0.976726.15003956.html.plaintext.txt	107	The respective prevalence rates CT heterozygosity 16
0.976726.15003956.html.plaintext.txt	108	5 percent respective rates CC homozygosity 83
0.976726.15003956.html.plaintext.txt	109	The distribution genotypes control groups consistent Hardy Weinberg equilibrium studies
0.976726.15003956.html.plaintext.txt	110	Distribution CTSD alleles among Alzheimer disease cases controls included studies Overall effects There trend suggesting T allele may confer increased susceptibility Alzheimer disease figure 1
0.976726.15003956.html.plaintext.txt	111	As shown table 3 summary odds ratio 1
0.976726.15003956.html.plaintext.txt	112	14 significant heterogeneity among 16 study comparisons p 0
0.976726.15003956.html.plaintext.txt	113	We found evidence association TT genotype risk Alzheimer disease relative CC genotype
0.976726.15003956.html.plaintext.txt	114	There significant study heterogeneity
0.976726.15003956.html.plaintext.txt	115	No evidence association Alzhei mer disease discerned also recessive model examined effect T trend association seen dominant model random effects OR 1
0.976726.15003956.html.plaintext.txt	116	There study heterogeneity recessive model contrast significant heterogeneity p 0
0.976726.15003956.html.plaintext.txt	117	05 still seen dominant model contrast
0.976726.15003956.html.plaintext.txt	118	Subgroup analysis studies cases controls European descent yielded similar results 15 comparisons 11436 alleles OR 1
0.976726.15003956.html.plaintext.txt	119	View larger version 26K FIGURE 1
0.976726.15003956.html.plaintext.txt	120	Meta analysis effect T allele versus C allele risk Alzheimer disease
0.976726.15003956.html.plaintext.txt	121	Each comparison presented name first author year publication
0.976726.15003956.html.plaintext.txt	122	H signifies Hispanic subjects J signifies Japanese subjects
0.976726.15003956.html.plaintext.txt	123	For comparison point estimate odds ratio accompanying 95 confidence interval CI shown
0.976726.15003956.html.plaintext.txt	124	ALL represents summary random effects estimate comparison along respective 95 confidence interval
0.976726.15003956.html.plaintext.txt	125	Values 1 denote increased risk Alzheimer disease T allele
0.976726.15003956.html.plaintext.txt	126	Summary odds ratios various contrasts Bias diagnostics In cumulative meta analysis recursive cumulative meta analysis magnitude summary odds ratio stable time changed considerably per year apparent dissipation postulated effect random effects summary OR T vs
0.976726.15003956.html.plaintext.txt	127	Excluding first hypothesis generating study 9 found summary odds ratio became 1
0.976726.15003956.html.plaintext.txt	128	29 significant study heterogeneity p 0
0.976726.15003956.html.plaintext.txt	129	05 evidence association even comparison homozygotes TT vs
0.976726.15003956.html.plaintext.txt	130	91 study heterogeneity
0.976726.15003956.html.plaintext.txt	131	There relation effect size variance study suggesting larger studies agreed results smaller studies
0.976726.15003956.html.plaintext.txt	132	Analyses limited studies intensive efforts exclude Alzheimer disease controls yielded similar results 11 comparisons 10382 alleles OR 1
0.976726.15003956.html.plaintext.txt	133	Interaction APOE genotype Nine studies 7 9 11 14 16 18 obtained data CTSD APOE genotypes
0.976726.15003956.html.plaintext.txt	134	With one study 8 separating male female subjects 10 comparisons became available
0.976726.15003956.html.plaintext.txt	135	These nine comparative studies tended gave slightly inflated effect T allele compared full meta analysis 14 comparisons summary OR random effects 1
0.976726.15003956.html.plaintext.txt	136	17 complete meta analysis thus inferences cautious
0.976726.15003956.html.plaintext.txt	137	Among carriers high risk APOE4 allele T allele carriers random effects odds ratio 1
0.976726.15003956.html.plaintext.txt	138	15 Alzheimer disease compared subjects carrying T allele
0.976726.15003956.html.plaintext.txt	139	Among subjects carrying APOE4 allele respective odds ratio 1
0.976726.15003956.html.plaintext.txt	140	There significant study heterogeneity APOE4 positive group p 0
0.976726.15003956.html.plaintext.txt	141	The two effect sizes overlapped widely
0.976726.15003956.html.plaintext.txt	142	Among carriers T allele presence APOE4 increased risk Alzheimer disease 6
0.976726.15003956.html.plaintext.txt	143	79 study heterogeneity
0.976726.15003956.html.plaintext.txt	144	Among subjects without T allele presence APOE4 increased risk Alzheimer disease 4
0.976726.15003956.html.plaintext.txt	145	31 significant study heterogeneity p 0
0.976726.15003956.html.plaintext.txt	146	The two estimates overlapped widely individual studies overall typically odds ratios larger group T allele carriers figure 2
0.976726.15003956.html.plaintext.txt	147	View larger version 22K FIGURE 2
0.976726.15003956.html.plaintext.txt	148	Meta analysis effect APOE4 allele T carriers T noncarriers risk Alzheimer disease AD
0.976726.15003956.html.plaintext.txt	149	Each comparison presented name first author
0.976726.15003956.html.plaintext.txt	150	M signifies male subjects F signifies female subjects
0.976726.15003956.html.plaintext.txt	151	For comparison point estimate odds ratio accompanying 95 confidence interval CI shown
0.976726.15003956.html.plaintext.txt	152	Filled squares represent T carriers open circles represent T noncarriers
0.976726.15003956.html.plaintext.txt	153	ALL represents summary random effects estimate comparison along respective 95 confidence interval
0.976726.15003956.html.plaintext.txt	154	Papassotiropoulos 2 1 pertain following respective references 7 9
0.976726.15003956.html.plaintext.txt	155	DISCUSSION TOP ABSTRACT INTRODUCTION GENE GENE VARIANTS DISEASE META ANALYSIS METHODS META ANALYSIS RESULTS DISCUSSION LABORATORY TESTS POPULATION TESTING REFERENCES This meta analysis includes data 14 case control studies 6000 genotyped Alzheimer disease cases controls proves CTSD polymorphism strong risk factor Alzheimer disease
0.976726.15003956.html.plaintext.txt	156	The current evidence cannot exclude T allele CTSD polymorphism may increase modestly risk Alzheimer disease significant heterogeneity results various studies
0.976726.15003956.html.plaintext.txt	157	However found bias might exist decreasing effect size data accumulated time
0.976726.15003956.html.plaintext.txt	158	Moreover meta analysis also cannot exclude possibility presence CTSD T allele may enhance increased susceptibility toward Alzheimer disease conferred APOE4
0.976726.15003956.html.plaintext.txt	159	However even true would pertain relatively small group subjects carry APOE4 CTSD T alleles
0.976726.15003956.html.plaintext.txt	160	In impact T allele population level would small present
0.976726.15003956.html.plaintext.txt	161	The meta analysis findings may interpreted postulated biologic context CTSD polymorphism
0.976726.15003956.html.plaintext.txt	162	Cathepsin D intracellular acid protease beta secretase activity vitro 1 2 cleave amyloid precursor protein tau protein generate fragments intact microtubule binding domains 44 might play role pathogenesis paired helical filaments
0.976726.15003956.html.plaintext.txt	163	One study shown CTSD polymorphism associated increased secretion altered intracellular maturation procathepsin D 3
0.976726.15003956.html.plaintext.txt	164	It noted clear whether CTSD polymorphism functional consequences mature form enzyme
0.976726.15003956.html.plaintext.txt	165	Although cannot exclude biologic effect CTSD polymorphism findings accordance results recent full genome scan showing significant linkage Alzheimer disease short arm chromosome 11 region CTSD gene located 45 47
0.976726.15003956.html.plaintext.txt	166	Attention given design individual studies
0.976726.15003956.html.plaintext.txt	167	The results meta analyses may affected methodological problems potential biases designs constituent studies
0.976726.15003956.html.plaintext.txt	168	Nondifferential misclassification errors may dilute strength observed association
0.976726.15003956.html.plaintext.txt	169	Alzheimer disease cases generally selected according appropriate criteria
0.976726.15003956.html.plaintext.txt	170	However young control subjects may developed Alzheimer disease older ages
0.976726.15003956.html.plaintext.txt	171	The choice appropriate age window assessing postulated genetic risk factor Alzheimer disease difficult
0.976726.15003956.html.plaintext.txt	172	Studies younger subjects may suitable identifying risk factors result early onset Alzhei mer disease
0.976726.15003956.html.plaintext.txt	173	Conversely selection younger subjects may less appropriate influence postulated genetic risk factor important late onset Alzhei mer disease
0.976726.15003956.html.plaintext.txt	174	Subgroup effects effect modification e
0.976726.15003956.html.plaintext.txt	175	differential effects genetic polymorphism early vs
0.976726.15003956.html.plaintext.txt	176	late onset Alzheimer disease cases familial vs
0.976726.15003956.html.plaintext.txt	177	sporadic disease complex interactions genes may also need considered 48
0.976726.15003956.html.plaintext.txt	178	Our analyses addressed interactions APOE4 major known genetic determinant Alzhei mer disease
0.976726.15003956.html.plaintext.txt	179	Interactions genetic environmental factors studied
0.976726.15003956.html.plaintext.txt	180	The trend stronger effect APOE4 presence T allele carriage interesting light data suggesting T carriage may affect general intelligence 5
0.976726.15003956.html.plaintext.txt	181	However subgroup interaction analyses interpreted cautiously since differences subgroups may occur chance 49 validation would require studies even larger sample sizes several thousand included meta analysis
0.976726.15003956.html.plaintext.txt	182	Finally population stratification may theoretically affected results constituent studies meta analysis 50 since documented frequency T allele varied considerably among different ethnic groups even among different ethnic groups European descent
0.976726.15003956.html.plaintext.txt	183	However studies strictly ethnically defined population stratification effect unlikely considerable magnitude
0.976726.15003956.html.plaintext.txt	184	Because increasing prevalence Alzheimer disease worldwide crucial identify genetic risk factors neurodegenerative disease
0.976726.15003956.html.plaintext.txt	185	Thus list identified polymorphisms may influence risk Alzheimer disease continuously expanding 23 29 reported associations candidate genes date remain nonreplicated least controversial subsequent investigation
0.976726.15003956.html.plaintext.txt	186	Early small genetic association studies may come spurious findings 41 51 52
0.976726.15003956.html.plaintext.txt	187	Even genetic associations replicated usually major public health impact would lead screening recommendations 53
0.976726.15003956.html.plaintext.txt	188	Nevertheless knowledge could improve understanding pathogenesis complex diseases Alzheimer disease
0.976726.15003956.html.plaintext.txt	189	LABORATORY TESTS TOP ABSTRACT INTRODUCTION GENE GENE VARIANTS DISEASE META ANALYSIS METHODS META ANALYSIS RESULTS DISCUSSION LABORATORY TESTS POPULATION TESTING REFERENCES The methods used CTSD genotyping analyzed studies straightforward include polymerase chain reaction 9 dynamic allele specific hybridization 14
0.976726.15003956.html.plaintext.txt	190	The error rate due misclassification likely small
0.976726.15003956.html.plaintext.txt	191	Future studies nevertheless ensure clearly report assessment genotyping performed blinded clinical status patient
0.976726.15003956.html.plaintext.txt	192	POPULATION TESTING TOP ABSTRACT INTRODUCTION GENE GENE VARIANTS DISEASE META ANALYSIS METHODS META ANALYSIS RESULTS DISCUSSION LABORATORY TESTS POPULATION TESTING REFERENCES To date population testing CTSD polymorphism
0.976726.15003956.html.plaintext.txt	193	Based results meta analysis testing would indicated given currently available data
0.976726.15003956.html.plaintext.txt	194	ACKNOWLEDGMENTS The authors thank Jonathan A
0.976726.15003956.html.plaintext.txt	195	Prince Patrizia Mecocci Anthony J
0.976726.15003956.html.plaintext.txt	196	Brookes providing additional data studies
0.976726.15003956.html.plaintext.txt	197	NOTES Correspondence Dr
0.976726.15003956.html.plaintext.txt	198	Ioannidis Department Hygiene Epidemiology University Ioannina School Medicine Ioannina 45110 Greece e mail jioannidatcc
0.976726.15003956.html.plaintext.txt	199	REFERENCES TOP ABSTRACT INTRODUCTION GENE GENE VARIANTS DISEASE META ANALYSIS METHODS META ANALYSIS RESULTS DISCUSSION LABORATORY TESTS POPULATION TESTING REFERENCES McDermott JR Gibson AM
0.976726.15003956.html.plaintext.txt	200	Degradation Alzheimer beta amyloid protein human cathepsin D
0.976726.15003956.html.plaintext.txt	201	ISIMedline Chevalier N Vizzavona J Marambaud P et al
0.976726.15003956.html.plaintext.txt	202	Cathepsin D displays vitro beta secretase like specificity
0.976726.15003956.html.plaintext.txt	203	CrossRefISIMedline Touitou I Capony F Brouillet JP et al
0.976726.15003956.html.plaintext.txt	204	Missense polymorphism CT224 human cathepsin D pro fragment determined polymerase chain reaction single strand conformational polymorphism analysis possible consequences cancer cells
0.976726.15003956.html.plaintext.txt	205	Eur J Cancer 199430A390 4
0.976726.15003956.html.plaintext.txt	206	ISIMedline Papassotiropoulos A Lewis HD Bagli M et al
0.976726.15003956.html.plaintext.txt	207	Cerebrospinal fluid levels ss amyloid42 patients Alzheimer disease related exon 2 polymorphism cathepsin D gene
0.976726.15003956.html.plaintext.txt	208	CrossRefISIMedline Payton A Holland F Diggle P et al
0.976726.15003956.html.plaintext.txt	209	Cathepsin D exon 2 polymorphism associated general intelligence healthy older population
0.976726.15003956.html.plaintext.txt	210	Mol Psychiatry 2003814 18
0.976726.15003956.html.plaintext.txt	211	CrossRefISIMedline Crawford FC Freeman MJ Schinka J et al
0.976726.15003956.html.plaintext.txt	212	The genetic association cathepsin D Alzheimer disease
0.976726.15003956.html.plaintext.txt	213	Neurosci Lett 200028961 5
0.976726.15003956.html.plaintext.txt	214	CrossRefISIMedline Papassotiropoulos A Bagli M Kurz A et al
0.976726.15003956.html.plaintext.txt	215	A genetic variation cathepsin D major risk factor Alzheimer disease
0.976726.15003956.html.plaintext.txt	216	CrossRefISIMedline Papassotiropoulos A Bagli M Feder O et al
0.976726.15003956.html.plaintext.txt	217	Genetic polymorphism cathepsin D strongly associated risk developing sporadic Alzheimer disease
0.976726.15003956.html.plaintext.txt	218	Neurosci Lett 1999262171 4
0.976726.15003956.html.plaintext.txt	219	CrossRefISIMedline McIlroy SP Dynan KB McGleenon BM et al
0.976726.15003956.html.plaintext.txt	220	Cathepsin D gene exon 2 polymorphism sporadic Alzheimer disease
0.976726.15003956.html.plaintext.txt	221	Neurosci Lett 1999273140 1
0.976726.15003956.html.plaintext.txt	222	CrossRefISIMedline Mateo I Sanchez Guerra M Combarros O et al
0.976726.15003956.html.plaintext.txt	223	Lack association cathepsin D genetic polymorphism Alzheimer disease Spanish sample
0.976726.15003956.html.plaintext.txt	224	Am J Med Genet 200211431 3
0.976726.15003956.html.plaintext.txt	225	CrossRefISIMedline Ingegni T Nocentini G Mariani E et al
0.976726.15003956.html.plaintext.txt	226	Cathepsin D polymorphism Italian elderly subjects sporadic late onset Alzheimer disease
0.976726.15003956.html.plaintext.txt	227	Dement Geriatr Cogn Disord 200316151 5
0.976726.15003956.html.plaintext.txt	228	CrossRefISIMedline Bhojak TJ DeKosky ST Ganguli M et al
0.976726.15003956.html.plaintext.txt	229	Genetic polymorphisms cathespin D interleukin 6 genes risk Alzheimer disease
0.976726.15003956.html.plaintext.txt	230	Neurosci Lett 200028821 4
0.976726.15003956.html.plaintext.txt	231	CrossRefISIMedline Prince JA Feuk L Sawyer SL et al
0.976726.15003956.html.plaintext.txt	232	Lack replication association findings complex disease analysis 15 polymorphisms prior candidate genes sporadic Alzheimer disease
0.976726.15003956.html.plaintext.txt	233	Eur J Hum Genet 20019437 44
0.976726.15003956.html.plaintext.txt	234	CrossRefISIMedline Matsui T Morikawa Y Tojo M et al
0.976726.15003956.html.plaintext.txt	235	Cathepsin D polymorphism associated Alzheimer disease Japanese
0.976726.15003956.html.plaintext.txt	236	Bagnoli S Nacmias B Tedde A et al
0.976726.15003956.html.plaintext.txt	237	Cathepsin D polymorphism Italian sporadic familial Alzheimer disease
0.976726.15003956.html.plaintext.txt	238	Neurosci Lett 2002328273 6
0.976726.15003956.html.plaintext.txt	239	CrossRefISIMedline Bertram L Guenette S Jones J et al
0.976726.15003956.html.plaintext.txt	240	No evidence genetic association linkage cathepsin D CTSD exon 2 polymorphism Alzheimer disease
0.976726.15003956.html.plaintext.txt	241	CO2 M disease highlight problems complex disease analysis
0.976726.15003956.html.plaintext.txt	242	Trends Genet 200117407 13
0.976726.15003956.html.plaintext.txt	243	CrossRefISIMedline Styczynska M Religa D Pfeffer A et al
0.976726.15003956.html.plaintext.txt	244	Simultaneous analysis five genetic risk factors Polish patients Alzheimer disease
0.976726.15003956.html.plaintext.txt	245	Neurosci Lett 200334499 102
0.976726.15003956.html.plaintext.txt	246	CrossRefISIMedline Farrer LA Cupples LA Haines JL et al
0.976726.15003956.html.plaintext.txt	247	Effects age sex ethnicity association apolipoprotein E genotype Alzheimer disease
0.976726.15003956.html.plaintext.txt	248	APOE Alzheimer Disease Meta Analysis Consortium
0.976726.15003956.html.plaintext.txt	249	Abstract Hebert LE Scherr PA Beckett LA et al
0.976726.15003956.html.plaintext.txt	250	Age specific incidence Alzheimer disease community population
0.976726.15003956.html.plaintext.txt	251	Free Full Text St George Hyslop PH
0.976726.15003956.html.plaintext.txt	252	Molecular genetics Alzheimer disease
0.976726.15003956.html.plaintext.txt	253	Biol Psychiatry 200047183 99
0.976726.15003956.html.plaintext.txt	254	CrossRefISIMedline Gao S Hendrie HC Hall KS et al
0.976726.15003956.html.plaintext.txt	255	The relationships age sex incidence dementia Alzheimer disease meta analysis
0.976726.15003956.html.plaintext.txt	256	Arch Gen Psychiatry 199855809 15
0.976726.15003956.html.plaintext.txt	257	AbstractFree Full Text Fleminger S Oliver DL Lovestone S et al
0.976726.15003956.html.plaintext.txt	258	Head injury risk factor Alzheimer disease evidence 10 years partial replication
0.976726.15003956.html.plaintext.txt	259	J Neurol Neurosurg Psychiatry 200374857 62
0.976726.15003956.html.plaintext.txt	260	AbstractFree Full Text Launer LJ Andersen K Dewey ME et al
0.976726.15003956.html.plaintext.txt	261	Rates risk factors dementia Alzheimer disease
0.976726.15003956.html.plaintext.txt	262	AbstractFree Full Text McDowell I
0.976726.15003956.html.plaintext.txt	263	Alzheimer disease insights epidemiology
0.976726.15003956.html.plaintext.txt	264	Aging Milano 200113143 62
0.976726.15003956.html.plaintext.txt	265	ISIMedline Hendrie HC Ogunniyi A Hall KS et al
0.976726.15003956.html.plaintext.txt	266	Incidence dementia Alzheimer disease 2 communities
0.976726.15003956.html.plaintext.txt	267	AbstractFree Full Text Combarros O Alvarez Arcaya A Sanchez Guerra M et al
0.976726.15003956.html.plaintext.txt	268	Candidate gene association studies sporadic Alzheimer disease
0.976726.15003956.html.plaintext.txt	269	Dement Geriatr Cogn Disord 20021441 54
0.976726.15003956.html.plaintext.txt	270	CrossRefISIMedline Combarros O Infante J Llorca J et al
0.976726.15003956.html.plaintext.txt	271	The myeloperoxidase gene Alzheimer disease case control study meta analysis
0.976726.15003956.html.plaintext.txt	272	Neurosci Lett 200232633 6
0.976726.15003956.html.plaintext.txt	273	CrossRefISIMedline Dermaut B Roks G Theuns J et al
0.976726.15003956.html.plaintext.txt	274	Variable expression presenilin 1 major determinant risk late onset Alzheimer disease
0.976726.15003956.html.plaintext.txt	275	CrossRefISIMedline Koster MN Dermaut B Cruts M et al
0.976726.15003956.html.plaintext.txt	276	The 2 macroglobulin gene AD population based study meta analysis
0.976726.15003956.html.plaintext.txt	277	AbstractFree Full Text Russ C Powell JF Zhao J et al
0.976726.15003956.html.plaintext.txt	278	The microtubule associated protein tau gene Alzheimer disease association study meta analysis
0.976726.15003956.html.plaintext.txt	279	Neurosci Lett 200131492 6
0.976726.15003956.html.plaintext.txt	280	CrossRefISIMedline Sanchez Guerra M Combarros O Infante J et al
0.976726.15003956.html.plaintext.txt	281	Case control study meta analysis low density lipoprotein receptor related protein gene exon 3 polymorphism Alzheimer disease
0.976726.15003956.html.plaintext.txt	282	Neurosci Lett 200131617 20
0.976726.15003956.html.plaintext.txt	283	CrossRefISIMedline Kehoe PG Katzov H Feuk L et al
0.976726.15003956.html.plaintext.txt	284	Haplotypes extending across ACE associated Alzheimer disease
0.976726.15003956.html.plaintext.txt	285	Hum Mol Genet 200312859 67
0.976726.15003956.html.plaintext.txt	286	AbstractFree Full Text Lau J Ioannidis JP Schmid CH
0.976726.15003956.html.plaintext.txt	287	Quantitative synthesis systematic reviews
0.976726.15003956.html.plaintext.txt	288	Ann Intern Med 1997127820 6
0.976726.15003956.html.plaintext.txt	289	AbstractFree Full Text Petitti DB
0.976726.15003956.html.plaintext.txt	290	Meta analysis decision analysis cost effectiveness analysis
0.976726.15003956.html.plaintext.txt	291	New York NY Oxford University Press 1994
0.976726.15003956.html.plaintext.txt	292	Lau J Antman EM Jimenez Silva J et al
0.976726.15003956.html.plaintext.txt	293	Cumulative meta analysis therapeutic trials myocardial infarction
0.976726.15003956.html.plaintext.txt	294	N Engl J Med 1992327248 54
0.976726.15003956.html.plaintext.txt	295	Abstract Ioannidis JP Contopoulos Ioannidis DG Lau J
0.976726.15003956.html.plaintext.txt	296	Recursive cumulative meta analysis diagnostic evolution total randomized evidence group individual patient data
0.976726.15003956.html.plaintext.txt	297	J Clin Epidemiol 199952281 91
0.976726.15003956.html.plaintext.txt	298	CrossRefISIMedline Ioannidis J Lau J
0.976726.15003956.html.plaintext.txt	299	Evolution treatment effects time empirical insight recursive cumulative metaanalyses
0.976726.15003956.html.plaintext.txt	300	Proc Natl Acad Sci U S A 200198831 6
0.976726.15003956.html.plaintext.txt	301	AbstractFree Full Text Ioannidis JP Ntzani EE Trikalinos TA et al
0.976726.15003956.html.plaintext.txt	302	Replication validity genetic association studies
0.976726.15003956.html.plaintext.txt	303	CrossRefISIMedline Begg CB Mazumdar M
0.976726.15003956.html.plaintext.txt	304	Operating characteristics rank correlation test publication bias
0.976726.15003956.html.plaintext.txt	305	Biometrics 1994501088 101
0.976726.15003956.html.plaintext.txt	306	ISIMedline Ioannidis JP Trikalinos TA Ntzani EE et al
0.976726.15003956.html.plaintext.txt	307	Genetic associations large versus small studies empirical assessment
0.976726.15003956.html.plaintext.txt	308	CrossRefISIMedline Kenessey A Nacharaju P Ko LW et al
0.976726.15003956.html.plaintext.txt	309	Degradation tau lysosomal enzyme cathepsin D implication Alzheimer neurofibrillary degeneration
0.976726.15003956.html.plaintext.txt	310	J Neurochem 1997692026 38
0.976726.15003956.html.plaintext.txt	311	ISIMedline Kehoe P Wavrant De Vrieze F Crook R et al
0.976726.15003956.html.plaintext.txt	312	A full genome scan late onset Alzheimer disease
0.976726.15003956.html.plaintext.txt	313	Hum Mol Genet 19998237 45
0.976726.15003956.html.plaintext.txt	314	AbstractFree Full Text Collins JS Perry RT Watson B Jr et al
0.976726.15003956.html.plaintext.txt	315	Association haplotype tumor necrosis factor siblings late onset Alzheimer disease NIMH Alzheimer Disease Genetics Initiative
0.976726.15003956.html.plaintext.txt	316	Am J Med Genet 200096823 30
0.976726.15003956.html.plaintext.txt	317	AbstractFree Full Text Lehmann DJ Williams J McBroom J et al
0.976726.15003956.html.plaintext.txt	318	Using meta analysis explain diversity results genetic studies late onset Alzheimer disease identify high risk subgroups
0.976726.15003956.html.plaintext.txt	319	Neuroscience 2001108541 54
0.976726.15003956.html.plaintext.txt	320	CrossRefISIMedline Oxman AD Guyatt GH
0.976726.15003956.html.plaintext.txt	321	A consumer guide subgroup analyses
0.976726.15003956.html.plaintext.txt	322	Ann Intern Med 199211678 84
0.976726.15003956.html.plaintext.txt	323	ISIMedline Cardon LR Palmer LJ
0.976726.15003956.html.plaintext.txt	324	Population stratification spurious allelic association
0.976726.15003956.html.plaintext.txt	325	CrossRefISIMedline Lohmueller KE Pearce CL Pike M et al
0.976726.15003956.html.plaintext.txt	326	Meta analysis genetic association studies supports contribution common variants susceptibility common disease
0.976726.15003956.html.plaintext.txt	327	CrossRefISIMedline Ioannidis JPA
0.976726.15003956.html.plaintext.txt	328	Genetic associations false true Trends Mol Med 20039135 8
0.976726.15003956.html.plaintext.txt	329	CrossRefISIMedline Little J Khoury MJ Bradley L et al
0.976726.15003956.html.plaintext.txt	330	The Human Genome Project complete
0.976726.15003956.html.plaintext.txt	331	How develop handle pump Am J Epidemiol 2003157667 73
0.29964596.11030760.html.plaintext.txt	0	Intramuscular injection plasmid vector expressing human apolipoprotein E limits progression xanthoma aortic atheroma apoE deficient mice Takis Athanasopoulos1 James S
0.29964596.11030760.html.plaintext.txt	1	Owen2 David Hassall3 Matthew G
0.29964596.11030760.html.plaintext.txt	2	Dunckley1 Jeffrey Drew1 Joanne Goodman3 Aristedes D
0.29964596.11030760.html.plaintext.txt	3	Riddell2 George Dickson 1
0.29964596.11030760.html.plaintext.txt	4	1Division Biochemistry School Biological Sciences Royal Holloway University London Egham Surrey TW20 OEX UK 2Department Medicine Royal Free University College Medical School University College London Royal Free Campus London NW3 2PF UK 3GlaxoWellcome Research Development Medicines Research Centre Stevenage Hertfordshire SG1 2NY UK
0.29964596.11030760.html.plaintext.txt	5	Received 26 June 2000 Revised Accepted 17 August 2000
0.29964596.11030760.html.plaintext.txt	6	ABSTRACT TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Apolipoprotein E apoE protects coronary artery disease via hepatic removal atherogenic remnant lipoproteins sequestration cholesterol vessel walls local anti oxidant anti platelet anti inflammatory actions
0.29964596.11030760.html.plaintext.txt	7	ApoE gene transfer may thus ameliorate hyperlipidaemic profile beneficial effects lesion sites prevent regress atherosclerosis concept endorsed adenoviral mediated hepatic expression studies
0.29964596.11030760.html.plaintext.txt	8	Here using plasmid vectors expressing allelic human apoE2 apoE3 isoforms skeletal muscle evaluated effective secretory platform apoE gene augmentation
0.29964596.11030760.html.plaintext.txt	9	Transfected myoblasts myotubes found efficiently secrete recombinant apoE vitro spherical 10 16 nm lipoprotein particles pre ss mobility
0.29964596.11030760.html.plaintext.txt	10	Intramuscular plasmid injection apoE mice develop spontaneous atherosclerotic plaque xanthoma resulted expression secretion apoE
0.29964596.11030760.html.plaintext.txt	11	Human apoE mRNA detected RT PCR injected muscles although concentrations apoE3 rapidly cleared plasma near ELISA detection limits levels plasma apoE2 measurable 17
0.29964596.11030760.html.plaintext.txt	12	To assess whether muscle based expression apoE2 could inhibit atherogenesis long term follow studies conducted
0.29964596.11030760.html.plaintext.txt	13	Although hyperlipidaemia reduced treated animals end point pathology showed clear retardation atherosclerotic xanthomatous lesions
0.29964596.11030760.html.plaintext.txt	14	Up 9 months following single apoE2 plasmid administration atherosclerotic lesion coverage proximal aorta significantly reduced 20 30 P 0
0.29964596.11030760.html.plaintext.txt	15	01 whereas development gross dorsal xanthoma 5 mm diameter effectively reduced zero
0.29964596.11030760.html.plaintext.txt	16	We conclude expression apoE ectopic muscle sites therapeutic potential limit progression atherosclerosis
0.29964596.11030760.html.plaintext.txt	17	INTRODUCTION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Human apoE 34 kDa polymorphic protein associated surface triglyceride rich lipoproteins chylomicrons low density lipoprotein VLDLs remnants certain high density lipoprotein HDL particles 1 3
0.29964596.11030760.html.plaintext.txt	18	Of three major isoforms rarest variant apoE2 associated type III hyperlipoproteinaemia 45 differs wild type apoE3 R158C substitution apoE4 C112R produces dominant hyperlipidaemia 6 implicated re stenosis 7
0.29964596.11030760.html.plaintext.txt	19	ApoE protects coronary heart disease part mediating hepatic clearance atherogenic remnant lipoproteins two receptors LDL receptor LDL receptor related protein LRP differential binding activity E4 E3 E2 8
0.29964596.11030760.html.plaintext.txt	20	Low apoE important risk factor coronary heart disease 910 whereas severe hyperlipidaemia atherosclerosis ensues humans animal models apoE dysfunctional absent 1112
0.29964596.11030760.html.plaintext.txt	21	Expression apoE3Leiden apoE4Arg142Cys mice natural variants produces type III hyperlipidaemia phenotype 1314 whereas apoE deficient apoE mice markedly hypercholesterolaemic develop spontaneous atherosclerosis 15 17
0.29964596.11030760.html.plaintext.txt	22	In contrast apoE infusion hyperlipidaemic rabbits reduces plasma cholesterol regresses atheromatic lesions 18 whereas apoE transgenic mice expressing apoE rapidly clear VLDLLDL cholesterol resist diet induced diabetic hyperlipidaemia 1920
0.29964596.11030760.html.plaintext.txt	23	These findings suggest gene based strategies correct dysfunctional apoE atheroprotective
0.29964596.11030760.html.plaintext.txt	24	Indeed adenovirus mediated gene transfer human apoE3 liver apoE mice reverses hyperlipidaemia restricts lesion progression 2122
0.29964596.11030760.html.plaintext.txt	25	Increasing evidence suggests skeletal muscle serve efficient secretory platform circulating proteins 23 28
0.29964596.11030760.html.plaintext.txt	26	Moreover direct injection plasmid vector muscle permanent systemic delivery apoE may offer significant advantages viral transduction hepatocytes
0.29964596.11030760.html.plaintext.txt	27	Here show cultured mouse C2C12 myoblast myotube cells transfected plasmids encoding human apoE2 apoE3 cDNAs secrete apoE protein short term experiment demonstrate injecting plasmids regenerating muscle apoE mice results detectable expression apoE secretion plasma
0.29964596.11030760.html.plaintext.txt	28	Finally long term studies 6 9 months show injection pCMVapoE2 vector restricts lesion xanthomata formation even though improvement hyperlipidaemia
0.29964596.11030760.html.plaintext.txt	29	RESULTS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Secretion recombinant human apoE transfected cultures C2C12 muscle cells The ability proliferating mononucleate myoblasts multinucleate post mitotic myotubes synthesize secrete apoE evaluated
0.29964596.11030760.html.plaintext.txt	30	Mouse C2C12 cells transfected pCMVapoE2 pCMVapoE3 control pCMV plasmids culture media harvested 24 h cases following differentiation fusion myoblasts myotubes
0.29964596.11030760.html.plaintext.txt	31	Analysis media samples ELISA yielded values 0
0.29964596.11030760.html.plaintext.txt	32	5 microg apoE secreted per 106 transfected cells myoblast myotube cultures respectively
0.29964596.11030760.html.plaintext.txt	33	SDS PAGE western blotting revealed recombinant apoE migrated 34 kDa doublet Fig
0.29964596.11030760.html.plaintext.txt	34	1A presumably reflecting differential O glycosylation Thr194 previously reported human plasma apoE Weisgraber 3
0.29964596.11030760.html.plaintext.txt	35	View larger version 74K Figure 1
0.29964596.11030760.html.plaintext.txt	36	Secretion human apoE transfected C2C12 myotube cultures
0.29964596.11030760.html.plaintext.txt	37	C2C12 myoblasts transfected pCMVapoE control plasmids switched differentiation medium
0.29964596.11030760.html.plaintext.txt	38	After 2 days derived myotube containing cultures changed serum free medium collected analyses 24 h later
0.29964596.11030760.html.plaintext.txt	39	A SDS PAGE western blot analysis media pCMVapoE2 lane 1 control pCMV lane 2 pCMVapoE3 lane 3 cultures
0.29964596.11030760.html.plaintext.txt	40	B Transmission electron micrograph negatively stained lipoprotein particles released pCMVapoE2 transfected cultures
0.29964596.11030760.html.plaintext.txt	41	Spherical particles 10 16 nm diameter present scale bar 50 nm
0.29964596.11030760.html.plaintext.txt	42	A similar result obtained media samples pCVMapoE3 transfected cultures
0.29964596.11030760.html.plaintext.txt	43	C Non denaturing agarose gel electrophoresis apoE western blotting normal human plasma lane1 media samples control pCMV lane 2 pCMVapoE2 lane 3 pCMVapoE3 lane 4 transfected myotubes
0.29964596.11030760.html.plaintext.txt	44	The mobility apoE containing lipoproteins pre ss ss mobility indicated
0.29964596.11030760.html.plaintext.txt	45	To characterize physical nature lipoprotein particles released apoE transfected muscle cells culture media apoE2 apoE3 expressing myotubes collected examined firstly transmission electron microscopy TEM following negative staining secondly non denaturing agarose gel electrophoresis immunoblotting apoE antibodies
0.29964596.11030760.html.plaintext.txt	46	Using TEM lipoproteins detected media control untransfected C2C12 myotubes data shown
0.29964596.11030760.html.plaintext.txt	47	In contrast media myotubes expressing human apoE2 apoE3 contained abundant small spherical particles 10 16 nm diameter Fig
0.29964596.11030760.html.plaintext.txt	48	1B similar secreted apoE recombinant cell lines 29 released naturally human monocyte macrophage cells 30
0.29964596.11030760.html.plaintext.txt	49	There difference diameter released lipoprotein particles pCMVapoE2 pCMVapoE3 transfected cells 12
0.29964596.11030760.html.plaintext.txt	50	Immunoblotting normal human plasma showed major apoE containing lipoproteins expected pre ss mobilities HDL VLDL respectively Fig
0.29964596.11030760.html.plaintext.txt	51	Some heterogeneity seen particles released pCMVapoE2 pCMVapoE3 transfected myotubes pre ss mobility Fig
0.29964596.11030760.html.plaintext.txt	52	Acute expression human apoE following intramuscular plasmid injection apoE mice To initially evaluate expression recombinant apoE ectopic site skeletal musculature groups apoE mice subjected intramuscular injection pCMVapoE2 pCMVapoE3 control pCMV plasmids
0.29964596.11030760.html.plaintext.txt	53	Injections performed single tibialis anterior muscles 3 days BaCl2 induced regeneration enhance transfection myofibres 32
0.29964596.11030760.html.plaintext.txt	54	At 6 days following plasmid injection blood plasma samples collected assayed apoE ELISA total cholesterol triglyceride levels Table 1
0.29964596.11030760.html.plaintext.txt	55	As ELISA used human apoE specific monoclonal antibody capture apoE detected wild type C57BL6 mice
0.29964596.11030760.html.plaintext.txt	56	However human apoE clearly detectable plasma pCMVapoE2 injected mice 17
0.29964596.11030760.html.plaintext.txt	57	3 microgml reliable detection limit pCMVapoE3 treated animals 5 microgml
0.29964596.11030760.html.plaintext.txt	58	In mice total RNA extracted excised muscle examined apoE mRNA using RT PCR published protocol 33
0.29964596.11030760.html.plaintext.txt	59	The expected product 244 bp seen pCMVapoE2 pCMVapoE3 treated muscle absent animal receiving pCMV data shown
0.29964596.11030760.html.plaintext.txt	60	ApoE cholesterol triglyceride levels plasma apoE mice following intramuscular injection pCMVapoE plasmids Although apoE mice exhibited 6 fold increase plasma cholesterol compared controls injection pCMVapoE2 pCMVapoE3 result significant reductions Table 1
0.29964596.11030760.html.plaintext.txt	61	Total plasma triglyceride levels similar four groups Table 1
0.29964596.11030760.html.plaintext.txt	62	To examine lipoprotein metabolism control pCMVapoE2 pCMVapoE3 injected mice plasma lipoproteins separated isopycnic centrifugation yield standard VLDL IDL LDL HDL fractions assayed cholesterol content
0.29964596.11030760.html.plaintext.txt	63	The two treatment groups show obvious differences lipoprotein cholesterol profiles control pCMV injected apoE mice although VLDL elevated pCMVapoE2 injected group P 0
0.29964596.11030760.html.plaintext.txt	64	View larger version 32K Figure 2
0.29964596.11030760.html.plaintext.txt	65	Distribution lipoprotein subclasses plasma samples control C57BL6 mice apoE mice injected intramuscularly 50 microg pCMV pCMVapoE2 pCMVapoE3
0.29964596.11030760.html.plaintext.txt	66	BaCl2 treated tibialis anterior muscles injected plasmids blood plasma collected 6 days
0.29964596.11030760.html.plaintext.txt	67	Plasma samples subjected sequential isopycnic centrifugation isolate VLDL IDL LDL HDL compartments lipoprotein fractions assayed cholesterol content normalized original plasma volume
0.29964596.11030760.html.plaintext.txt	68	Inhibition atherosclerotic plaque xanthoma formation apoE mice following intramuscular pCMVapoE2 injection Due apoE deficiency gross hyperlipidaemia apoE mice develop aortic atherosclerosis exhibit gross bilateral xanthoma formation 3 months age 1516
0.29964596.11030760.html.plaintext.txt	69	To evaluate long term effects ectopic muscle based expression apoE following intramuscular plasmid injection atherosclerotic plaque xanthoma formation examined 9 months following intramuscular plasmid injection
0.29964596.11030760.html.plaintext.txt	70	As pCMVapoE2 produced measurable levels apoE plasma Table 1 vector used injection
0.29964596.11030760.html.plaintext.txt	71	Mice 6 8 weeks old subjected single regime intramuscular pCMVapoE2 plasmid injection sacrificed 6 9 months later control animals received pCMV
0.29964596.11030760.html.plaintext.txt	72	Animals dissected evaluated presence gross bilateral xanthoma physical examination aortic atheroma quantitative morphometry described Materials Methods
0.29964596.11030760.html.plaintext.txt	73	In 6 month group untreated mice visible macroscopic dorsal xanthoma 3 5 scored diameter 5 mm Table 2 Fig
0.29964596.11030760.html.plaintext.txt	74	In contrast plasmid injected group animals animals dorsal xanthoma 5 mm Table 2 group four five animals exhibited macroscopically visible xanthoma one clear xanthoma formation 5 mm
0.29964596.11030760.html.plaintext.txt	75	Similarly significant reduction atherosclerotic plaque Table 2 Fig
0.29964596.11030760.html.plaintext.txt	76	3B seen treated mice 30 less untreated animals
0.29964596.11030760.html.plaintext.txt	77	The mean percentage surface area aorta staining Oil Red O reduced 29
0.29964596.11030760.html.plaintext.txt	78	1 pCMVapoE2 injected animals P 0
0.29964596.11030760.html.plaintext.txt	79	Comparable findings seen 9 months Table 2 even though atherosclerotic lesions advanced
0.29964596.11030760.html.plaintext.txt	80	Thus Oil Red O staining plaque area aorta reduced 20 47
0.29964596.11030760.html.plaintext.txt	81	At 9 months animals control group macroscopically visible dorsal xanthoma four six mice exhibiting lesions 5 mm diameter
0.29964596.11030760.html.plaintext.txt	82	In treated group 9 months two six animals grossly observable xanthoma none xanthoma 5 mm
0.29964596.11030760.html.plaintext.txt	83	There significant differences mean plasma concentrations cholesterol triglyceride treated untreated mice 6 9 month time points data shown
0.29964596.11030760.html.plaintext.txt	84	Examples xanthomatous atherosclerotic plaque lesions arising apoE mice 8 months old
0.29964596.11030760.html.plaintext.txt	85	A Subcutaneous bilateral xanthoma formation white arrows
0.29964596.11030760.html.plaintext.txt	86	B Atherosclerotic lesions black arrows viewed en face internal vessel surface following dissection longitudinal opening Oil Red O staining proximal aorta
0.29964596.11030760.html.plaintext.txt	87	DISCUSSION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Cultured mouse C2C12 muscle cells transfected pCMVapoE23 expression vectors efficiently synthesized secreted recombinant human apoE whether grown mononucleated myoblasts differentiated post mitotic multinucleate myotubes
0.29964596.11030760.html.plaintext.txt	88	This implies injection plasmid vector skeletal muscle would result apoE expression confirmed direct measurements apoE2 clearly detected plasma 6 days following intramuscular injection plasmid apoE mice
0.29964596.11030760.html.plaintext.txt	89	Release corresponding protein plasma following intramuscular injection expression vector plasmids reported several different proteins including decorin endostatin galactosidase factor IX growth hormone erythropoietin 25 28
0.29964596.11030760.html.plaintext.txt	90	ApoE mice recognized valuable model human atherosclerosis 34
0.29964596.11030760.html.plaintext.txt	91	The animals grossly hypercholesterolaemic normal chow exhibit spontaneous xanthoma formation develop atheroma coronary arteries 2 months
0.29964596.11030760.html.plaintext.txt	92	Widespread fibroproliferative atherosclerotic lesions evolve form fibrous plaques smooth muscle cell caps necrotic cores 5 months whereas near total occlusion coronary artery ostium profound atheroma observed 8 months
0.29964596.11030760.html.plaintext.txt	93	In 6 day study intramuscular injection pCMVapoE2 pCMVapoE3 reduce plasma lipid levels reductions seen long term studies single double injections pCMVapoE2 used
0.29964596.11030760.html.plaintext.txt	94	This may largely reflect low efficiency gene expression apoE synthesis secretion
0.29964596.11030760.html.plaintext.txt	95	Thus although plasma apoE low 0
0.29964596.11030760.html.plaintext.txt	96	4 microgml compared normal level 30 60 microgml effectively reduce plasma cholesterol 35 concentration reached study
0.29964596.11030760.html.plaintext.txt	97	The lower level plasma apoE3 compared apoE2 likely explained increased binding affinity hepatic LRP receptor responsible clearing remnant lipoproteins lipolysis 11
0.29964596.11030760.html.plaintext.txt	98	Similar results described Yoshida Wistar rats receiving intramuscular injection naked plasmid DNA local expression human apoE3 demonstrated muscle recombinant protein could detected plasma 36
0.29964596.11030760.html.plaintext.txt	99	In line study observed local expression apoE2 apoE3 cDNA treated muscles apoE knockouts plasma accumulation recombinant apoE2 protein
0.29964596.11030760.html.plaintext.txt	100	This effect presumably due reduced plasma clearance liver uptake exogenous apoE2 compared apoE3 accordingly expression low levels apoE2 significantly alter plasma cholesterol triglyceride levels
0.29964596.11030760.html.plaintext.txt	101	Despite unchanged hyperlipidaemia end point pathologies 6 9 months following gene transfer showed clear evidence atherosclerotic plaque xanthoma retardation animals treated pCMVapoE2
0.29964596.11030760.html.plaintext.txt	102	We believe inhibition reflects anti atherogenic actions apoE lesion sites
0.29964596.11030760.html.plaintext.txt	103	Although plasma apoE secreted liver significant proportion 10 macrophage derived transplantation bone marrow normal mice apoE animals prevents development atherosclerosis 3738
0.29964596.11030760.html.plaintext.txt	104	In part represents ability macrophage derived apoE promote clearance atherogenic lipoproteins reduce serum cholesterol concentration 39
0.29964596.11030760.html.plaintext.txt	105	However low dose expression human mouse apoE transgenes macrophages apoE mice giving plasma apoE 5 wild type levels inhibits atherogenesis without correcting hyperlipidaemia 40
0.29964596.11030760.html.plaintext.txt	106	This implies direct atheroprotective effects apoE artery wall view endorsed abundance apoE atherosclerotic lesions 41 finding transfecting endothelium secrete apoE prevents lesion progression 42
0.29964596.11030760.html.plaintext.txt	107	However although clear endogenous apoE within lesions supplied infiltrating macrophages effectively retards foam cell formation progression atherosclerosis atheroprotective actions also carried exogenously derived apoE
0.29964596.11030760.html.plaintext.txt	108	Thus liver derived apoE also infiltrates accumulates within arterial intima regress atherosclerosis apoE mice 43
0.29964596.11030760.html.plaintext.txt	109	Importantly studies transgenic mice expressing adrenal apoE shown even low plasma levels 1 2 normal extrahepatic non macrophage apoE limit atherosclerosis without reversing hyperlipidaemia 44 presumably muscle derived apoE similar effect
0.29964596.11030760.html.plaintext.txt	110	One mechanism locally produced apoE atheroprotective enhancing cellular cholesterol efflux function largely restored plasma apoE mice low dose expression human apoE3 gene macrophages 41
0.29964596.11030760.html.plaintext.txt	111	Whether action could contribute apoE2 mediated inhibition atherogenesis seen study uncertain although evidence efficient cholesterol efflux restricted apoE3 isoform 45
0.29964596.11030760.html.plaintext.txt	112	Other atheroprotective actions apoE include inhibiting smooth muscle cell proliferation 46 reducing oxidative insults 47 restricting platelet aggregation 48 downregulating VCAM 1 expression endothelial cells A
0.29964596.11030760.html.plaintext.txt	113	Here less isoform dependency apoE2 greater antioxidant activity apoE3 whereas studies anti platelet anti inflammatory properties apoE find obvious difference isoforms 48
0.29964596.11030760.html.plaintext.txt	114	Increasingly skeletal muscle proposed important target cell mediated gene therapy
0.29964596.11030760.html.plaintext.txt	115	Muscle tissues stable little nuclear turnover well vascularized actively secretory readily accessible gene delivery
0.29964596.11030760.html.plaintext.txt	116	The present study shows first time expression even low levels apoE ectopic muscle sites therapeutic potential limit progression atherosclerosis
0.29964596.11030760.html.plaintext.txt	117	However studies needed critically evaluate strategy including use efficient vectors adeno associated virus AAV based vectors 4950
0.29964596.11030760.html.plaintext.txt	118	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Materials ApoE expression plasmids constructed ligating full length human apoE2 apoE3 cDNAs pCMVss Clontech Laboratories Basingstoke UK removal LacZ gene NotI digestion
0.29964596.11030760.html.plaintext.txt	119	A control vector pCMV also produced lacking LacZ
0.29964596.11030760.html.plaintext.txt	120	Plasmids bulked purified using Endofree Plasmid kit Qiagen Crawley UK
0.29964596.11030760.html.plaintext.txt	121	Dulbecco modified Eagle medium DMEM additional tissue culture materials lipofectAMINE purchased Life Technologies Paisley UK
0.29964596.11030760.html.plaintext.txt	122	Other chemicals reagents Sigma Aldrich unless stated otherwise Poole UK
0.29964596.11030760.html.plaintext.txt	123	Expression secretion apoE cultured mouse muscle cells Murine myoblast cells C2C12 grown adherent monolayers subconfluence DMEM supplemented 10 fetal bovine serum FBS 2 mM glutamine
0.29964596.11030760.html.plaintext.txt	124	Cultures transfected plasmid DNAs using lipofectAMINE previously described Dodds et al
0.29964596.11030760.html.plaintext.txt	125	Following transfection cultures grown normal conditions 24 h either processed apoE analyses see transferred 2 days DMEM containing 5 heat inactivated horse serum induce cell differentiation fusion large multinucleate myotubes
0.29964596.11030760.html.plaintext.txt	126	For evaluation apoE expression cultures grown 24 h serum free media collected analysis
0.29964596.11030760.html.plaintext.txt	127	Secreted human apoE measured directly commercial ELISA kit according manufacturer instructions Apo Tek ApoE kit Per Immune Rockville MD
0.29964596.11030760.html.plaintext.txt	128	For analyses medium concentrated 10 fold ultrafiltration VIVASPIN 10 000 mwco Vivascience Westford MA
0.29964596.11030760.html.plaintext.txt	129	Western blot analyses performed following 15 SDS PAGE transfer Hybond membranes Nycomed Amersham Little Chalfont UK probed polyclonal goat anti apoE antibody 13000 Calbiochem Nottingham UK followed horseradish peroxidase conjugated anti goat secondary 110 000 Sigma chemiluminescence detection ECL western blotting kit Amersham Pharmacia
0.29964596.11030760.html.plaintext.txt	130	The electrophoretic mobility natively secreted apoE containing particles determined agarose gel electrophoresis immunoblotting 29 whereas particle diameters quantified negative staining TEM
0.29964596.11030760.html.plaintext.txt	131	Expression human apoE skeletal muscle apoE mice The apoE deficient mice used study provided animal husbandry Glaxo Wellcome described Piedrahita et al
0.29964596.11030760.html.plaintext.txt	132	For plasmid injections female apoE mice 6 8 weeks old anaesthetized 50 microl 1
0.29964596.11030760.html.plaintext.txt	133	2 wv BaCl2 solution phosphate buffered saline PBS injected tibialis anterior muscle induce regeneration
0.29964596.11030760.html.plaintext.txt	134	Three days later mice injected plasmids receiving 50 microg DNA 50 microl PBS
0.29964596.11030760.html.plaintext.txt	135	Plasma analyses Citrated plasma samples collected mice intermediate times tail bleeds 50 microl end point cardiac puncture terminal anaesthesia
0.29964596.11030760.html.plaintext.txt	136	Plasma apoE quantified Apo Tek ApoE kit
0.29964596.11030760.html.plaintext.txt	137	Total serum cholesterol triglycerides measured microtitre plates using commercial reagents standards CHOD PAP Roche Products Lewes UK
0.29964596.11030760.html.plaintext.txt	138	Plasma lipoproteins fractionated sequential isopycnic ultracentrifugation VLDL 1
0.29964596.11030760.html.plaintext.txt	139	21 gml described previously Owen et al
0.29964596.11030760.html.plaintext.txt	140	Tissue analyses Following exsanguination animal heart thoracic aorta removed en bloc vessel dissected clean adventitial fat
0.29964596.11030760.html.plaintext.txt	141	The bottom half heart removed remaining portion cut open expose aortic cusps
0.29964596.11030760.html.plaintext.txt	142	The aorta opened along length pinned en face onto piece cork
0.29964596.11030760.html.plaintext.txt	143	Fixation tissue achieved placing phosphate buffered formalin least 3 days
0.29964596.11030760.html.plaintext.txt	144	Tissues stained Oil Red O mean lesion surface area per section quantified blind using computer assisted image analysis Sigmascan according Plump et al
0.29964596.11030760.html.plaintext.txt	145	In animals injected muscles excised examined apoE mRNA using RT PCR published primer set 33 negative controls included RNA template omission reverse transcriptase
0.29964596.11030760.html.plaintext.txt	146	The presence bilateral dorsal xanthoma evaluated blind manner visual inspection animal per animal basis scored positively gross xanthoma 5 mm diameter present
0.29964596.11030760.html.plaintext.txt	147	Statistics Results shown means plus minus SD statistical analysis performed Student test SigmaStat P 0
0.29964596.11030760.html.plaintext.txt	148	05 considered significant
0.29964596.11030760.html.plaintext.txt	149	thanks State Scholarship Foundation Greece fellowship
0.29964596.11030760.html.plaintext.txt	150	Parts work supported British Heart Foundation Sir Jules Thorn Charitable Trust European Union
0.29964596.11030760.html.plaintext.txt	151	FOOTNOTES Present address Imperial College School Medicine Hammersmith Campus Du Cane Road London W12 ONN UK
0.29964596.11030760.html.plaintext.txt	152	Present address Marie Curie Research Institute The Chart Oxted Surrey RH8 OTL UK To correspondence addressed
0.29964596.11030760.html.plaintext.txt	153	Tel 44 1784 443545 Fax 44 1784 434326 Email g
0.29964596.11030760.html.plaintext.txt	154	REFERENCES TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES 1 Mahley R
0.29964596.11030760.html.plaintext.txt	155	1999 Apolipoprotein E atherosclerosis Alzheimer disease beyond
0.29964596.11030760.html.plaintext.txt	156	1988 Apolipoprotein E cholesterol transport protein expanding role cell biology
0.29964596.11030760.html.plaintext.txt	157	1994 Apolipopoprotein E structure function relationships
0.29964596.11030760.html.plaintext.txt	158	1997 Genetic factors precipitating type III hyperlipoproteinemia hypolipidemic transgenic mice expressing human apolipoprotein E2
0.29964596.11030760.html.plaintext.txt	159	1998 Type III hyperlipoproteinemia spontaneous atherosclerosis mice resulting gene replacement mouse ApoE human APOE2
0.29964596.11030760.html.plaintext.txt	160	1984 Apolipoprotein E phenotypes hyperlipidemia
0.29964596.11030760.html.plaintext.txt	161	1997 Polymorphism apolipoprotein E gene early carotid atherosclerosis defined ultrasonography asymptomatic adults
0.29964596.11030760.html.plaintext.txt	162	1991 3 dimensional structure LDL receptor binding domain human apolipoprotein E
0.29964596.11030760.html.plaintext.txt	163	1993 Alterations concentration apolipoprotein E containing subfraction plasma high density lipoprotein coronary heart disease
0.29964596.11030760.html.plaintext.txt	164	1996 Apolipoprotein E risk factor coronary heart disease genetic molecular biology approach
0.29964596.11030760.html.plaintext.txt	165	1999 Pathogenesis type III hyperlipoproteinemia dysbetalipoproteinemia questions quandaries paradoxes
0.29964596.11030760.html.plaintext.txt	166	1994 Susceptibility diet induced atheroscelerosis transgenic mice expressing dysfunctional human apolipoprotein E Arg122 Cys142
0.29964596.11030760.html.plaintext.txt	167	1996 Modulation low density lipoprotein production clearance contributes age gender dependent hyperlipoproteinemia apolipoprotein E3 Leiden transgenic mice
0.29964596.11030760.html.plaintext.txt	168	1993 Type III hyperlipoproteinemic phenotype transgenic mice expressing dysfunctional apolipoprotein E
0.29964596.11030760.html.plaintext.txt	169	1992 Generation mice carrying mutant apolipoprotein E gene inactivated gene targeting embryonic stem cells Proc
0.29964596.11030760.html.plaintext.txt	170	1992 Severe hypercholesterolemia atherosclerosis apolipoprotein E deficient mice created homologous recombination ES cells
0.29964596.11030760.html.plaintext.txt	171	1992 Spontaneous hypercholesterolemia arterial lesions mice lacking apolipoprotein E
0.29964596.11030760.html.plaintext.txt	172	1989 Intravenous infusion apolipoprotein E accelerates clearance plasma lipoproteins rabbits
0.29964596.11030760.html.plaintext.txt	173	1998 Transgenic mouse models study role ApoE hyperlipidemia atherosclerosis
0.29964596.11030760.html.plaintext.txt	174	1992 Plasma lipoprotein metabolism transgenic mice overexpressing apolipoprotein E accelerated clearance lipoproteins containing apolipoprotein B
0.29964596.11030760.html.plaintext.txt	175	1995 Phenotypic correction hypercholesterolemia apoE deficient mice adenovirus mediated vivo gene transfer
0.29964596.11030760.html.plaintext.txt	176	1995 Apolipoprotein E deficiency mice gene replacement prevention atherosclerosis using adenovirus vectors J
0.29964596.11030760.html.plaintext.txt	177	1996 Muscle based gene therapy realistic possibilities future
0.29964596.11030760.html.plaintext.txt	178	1995 Myoblast based gene therapies
0.29964596.11030760.html.plaintext.txt	179	1999 Systemic inhibition tumor growth tumor metastases intramuscular administration endostatin gene
0.29964596.11030760.html.plaintext.txt	180	1997 Gene transfer expression human galactosidase mouse muscle vitro vivo
0.29964596.11030760.html.plaintext.txt	181	1998 Systemic effect human growth hormone intramuscular injection single dose muscle specific gene medicine
0.29964596.11030760.html.plaintext.txt	182	1996 Gene therapy skeletal muscle expression decorin prevents fibrotic disease rat kidney
0.29964596.11030760.html.plaintext.txt	183	1998 A low dose expression human apolipoprotein E transgene macrophages restores cholesterol efflux capacity apolipoprotein E deficient mouse plasma
0.29964596.11030760.html.plaintext.txt	184	1995 A lipoprotein containing apoE present normal HDL deficient plasmas releases cholesterol cells
0.29964596.11030760.html.plaintext.txt	185	Atherosclerosis 10 662 665
0.29964596.11030760.html.plaintext.txt	186	1997 Characterization human plasma apolipoprotein E containing lipoproteins high density lipoprotein size range focus pre beta1 LpE pre beta2 LpE alpha LpE
0.29964596.11030760.html.plaintext.txt	187	1993 Improved gene transfer direct plasmid injection associated regeneration mouse skeletal muscle
0.29964596.11030760.html.plaintext.txt	188	1990 Restriction isotyping human apolipoprotein E gene amplification cleavage HhaI
0.29964596.11030760.html.plaintext.txt	189	1996 Mouse models atherosclerosis
0.29964596.11030760.html.plaintext.txt	190	1999 Determination lower threshold apolipoprotein E resulting remnant lipoprotein clearance
0.29964596.11030760.html.plaintext.txt	191	1994 Accumulation human apolipoprotein E rat plasma vivo intramuscular injection naked DNA
0.29964596.11030760.html.plaintext.txt	192	1995 Treatment severe hypercholesterolemia apolipoprotein E deficient mice bone marrow transplantation
0.29964596.11030760.html.plaintext.txt	193	1995 Prevention atherosclerosis apolipoprotein E deficient mice bone marrow transplantation
0.29964596.11030760.html.plaintext.txt	194	1996 Murine bone marrow transplantation novel approach studying role macrophages lipoprotein metabolism atherogenesis
0.29964596.11030760.html.plaintext.txt	195	1999 Retroviral gene therapy ApoE deficient mice ApoE expression artery wall reduces early foam cell lesion formation
0.29964596.11030760.html.plaintext.txt	196	1993 Abundant expression apoprotein E macrophages human rabbit atherosclerotic lesions
0.29964596.11030760.html.plaintext.txt	197	1995 Inhibition diet induced atheroma formation transgenic mice expressing apolipoprotein E arterial wall
0.29964596.11030760.html.plaintext.txt	198	1997 Liver directed gene transfer prolonged expression three major human ApoE isoforms ApoE deficient mice
0.29964596.11030760.html.plaintext.txt	199	2000 Low levels extrahepatic non macrophage apoE inhibits atherosclerosis without correcting hypercholesterolaemia apoE deficient mice
0.29964596.11030760.html.plaintext.txt	200	1996 Cyclic AMP induces apolipoprotein E binding activity promotes cholesterol efflux macrophage cell line apolipoprotein acceptors
0.29964596.11030760.html.plaintext.txt	201	1998 Apolipoprotein E inhibits platelet derived growth factor induced vascular smooth muscle cell migration proliferation suppressing signal transduction preventing cell entry G1 phase
0.29964596.11030760.html.plaintext.txt	202	1996 Apolipoprotein E allele specific antioxidant activity effects cytotoxicity oxidative insults beta amyloid peptides
0.29964596.11030760.html.plaintext.txt	203	1997 Apolipoprotein E inhibits platelet aggregation L argininenitric oxide pathway implications vascular disease
0.29964596.11030760.html.plaintext.txt	204	1998 Efficient coexpression secretion antiatherogenic human apolipoprotein Al lecithin cholesterol acyltransferase cultured muscle cells using adeno associated virus plasmid vectors
0.29964596.11030760.html.plaintext.txt	205	2000 Evidence gene transfer expression factor IX haemophilia B patients treated AAV vector
0.29964596.11030760.html.plaintext.txt	206	1998 Lipofection cultured mouse muscle cells direct comparison Lipofectamine DOSPER
0.29964596.11030760.html.plaintext.txt	207	1984 Abnormal high density lipoproteins patients liver disease regulate cholesterol metabolism cultured human skin fibroblasts
0.3103701.9811940.html.plaintext.txt	0	Genetic association alpha2 macroglobulin Val1000Ile polymorphism Alzheimers disease
0.3103701.9811940.html.plaintext.txt	1	Alzheimer Research Unit Neurology Service Massachusetts General Hospital 149 13th Street CNY 6405 Charlestown MA 02129 USA 1University Hamburg Hamburg Germany 2IRCCS S
0.3103701.9811940.html.plaintext.txt	2	Giovanni de Dio FBF Brescia Italy 3University Basel Basel Switzerland
0.3103701.9811940.html.plaintext.txt	3	Received July 2 1998 Revised Accepted August 20 1998
0.3103701.9811940.html.plaintext.txt	4	alpha2 Macroglobulin A2M proteinase inhibitor found association senile plaques SP Alzheimers disease AD
0.3103701.9811940.html.plaintext.txt	5	A2M implicated biochemically binding degradation amyloid beta Abeta protein accumulates SP
0.3103701.9811940.html.plaintext.txt	6	We studied relationship Alzheimers disease common A2M polymorphism Val1000 GTCIle1000 ATC occurs near thiolester active site molecule
0.3103701.9811940.html.plaintext.txt	7	In initial exploratory data set 90 controls 171 Alzheimers disease noted increased frequency GG genotype 0
0.3103701.9811940.html.plaintext.txt	8	We therefore tested hypothesis GG genotype represented Alzheimers disease additional independent data set group 359 controls 566 Alzheimers disease patients
0.3103701.9811940.html.plaintext.txt	9	In hypothesis testing cohort GG genotype increased 0
0.3103701.9811940.html.plaintext.txt	10	12 Alzheimers disease P 0
0.3103701.9811940.html.plaintext.txt	11	The odds ratio Alzheimers disease associated GG genotype 1
0.3103701.9811940.html.plaintext.txt	12	01 combination APOE4 9
0.3103701.9811940.html.plaintext.txt	13	The presence G allele associated increase Abeta burden small series
0.3103701.9811940.html.plaintext.txt	14	The A2M receptor A2M rLRP multifunctional receptor whose ligands include apolipoprotein E amyloid precursor protein
0.3103701.9811940.html.plaintext.txt	15	These four proteins genetically linked Alzheimers disease suggesting may participate common disease pathway
0.3103701.9811940.html.plaintext.txt	16	alpha2 Macroglobulin A2M proteinase inhibitor inhibits proteinases classes steric trapping mechanism
0.3103701.9811940.html.plaintext.txt	17	The tetrameric A2M structure undergoes conformational change upon cleavage peptide bond bait region proteinase conformational change traps proteinase
0.3103701.9811940.html.plaintext.txt	18	A2M implicated several pathophysiological processes Alzheimers disease
0.3103701.9811940.html.plaintext.txt	19	A2M immunostains senile plaques SP 1 3 binds amyloid beta protein Abeta 1 42 high affinity apparent Kd 1
0.3103701.9811940.html.plaintext.txt	20	Moreover recent data suggest serine proteinase A2M complex degrade Abeta 5 trypsin activated A2M efficiently degrades Abeta vitro prevents vitro formation thioflavin S positive Abeta fibrils well Abeta induced toxicity cultured human cortical neuronal cells 6
0.3103701.9811940.html.plaintext.txt	21	After activated A2M cleared A2M rlow density lipoprotein receptor related protein A2M rLRP
0.3103701.9811940.html.plaintext.txt	22	A2M rLRP multifunctional receptor interestingly also primary neuronal apolipoprotein E apoE receptor 78
0.3103701.9811940.html.plaintext.txt	23	LRP also binds clears Kunitz proteinase inhibitor containing isoforms amyloid precursor protein APP 9
0.3103701.9811940.html.plaintext.txt	24	Thus A2M potentially impacts apoE APP metabolism brain
0.3103701.9811940.html.plaintext.txt	25	Because biological links Alzheimers disease studied possible association previously reported polymorphism A2M gene Alzheimers disease
0.3103701.9811940.html.plaintext.txt	26	10 screened 30 normal 30 pulmonary disease patients A2M polymorphisms near active site reported three A2M polymorphisms
0.3103701.9811940.html.plaintext.txt	27	The common occurred 25 amino acids downstream thiolester site interchanging Val1000 GTC Ile1000 ATC 10
0.3103701.9811940.html.plaintext.txt	28	Numbering based cDNA sequence includes 24 amino acid signal peptide corresponds ValIle976 mature protein
0.3103701.9811940.html.plaintext.txt	29	Allele frequencies 60 probands 0
0.3103701.9811940.html.plaintext.txt	30	No difference A2M serum levels associated two alleles
0.3103701.9811940.html.plaintext.txt	31	This polymorphism especially interesting potential biologically relevant function A2M proteinase inhibitor occurs near thiolester active site molecule
0.3103701.9811940.html.plaintext.txt	32	Our initial exploratory experiment tested possibility less common form A2M G allele would associated Alzheimers disease
0.3103701.9811940.html.plaintext.txt	33	Because potential error due multiple hypothesis testing planned use initial data set exploratory data set intent formulate specific hypotheses would tested formally second independent data set
0.3103701.9811940.html.plaintext.txt	34	We genotyped 90 non Alzheimers individuals either undergone screening tests Blessed dementia scale 11 whose DNA isolated autopsy material demonstrated Alzheimers disease 171 individuals either clinical diagnosis Alzheimers disease neuropathologically proven Alzheimers disease Table 1
0.3103701.9811940.html.plaintext.txt	35	Genotypes determined PCR amplification DNA restriction enzyme digestion Fig
0.3103701.9811940.html.plaintext.txt	36	In control series G allele frequency 0
0.3103701.9811940.html.plaintext.txt	37	28 six 90 individuals contained GG genotype 0
0.3103701.9811940.html.plaintext.txt	38	In Alzheimers disease set G allele frequency 0
0.3103701.9811940.html.plaintext.txt	39	We noticed GG genotype frequency increased Alzheimers group 0
0.3103701.9811940.html.plaintext.txt	40	These results suggest possible influence A2M polymorphism genetic risk factor Alzheimers disease
0.3103701.9811940.html.plaintext.txt	41	Electrophoresis pattern restriction digest demonstrating bands representing G 532 bp A alleles 429 bp
0.3103701.9811940.html.plaintext.txt	42	Over representation A2M GG genotype Alzheimers disease n G allele GG genotype Exploratory data set Control 90 0
0.3103701.9811940.html.plaintext.txt	43	12 Hypothesis testing data set Control 359 0
0.3103701.9811940.html.plaintext.txt	44	12a Combined data set total Control 449 0
0.3103701.9811940.html.plaintext.txt	45	To formally test hypothesis GG genotype A2M represented Alzheimers disease collected genotyped additional independent groups patients controls
0.3103701.9811940.html.plaintext.txt	46	Power analysis showed 500 Alzheimers disease control individuals would necessary 80 chance showing difference genotype frequencies 0
0.3103701.9811940.html.plaintext.txt	47	We therefore collected cases controls several sites order approximate number samples
0.3103701.9811940.html.plaintext.txt	48	The second data set consisted individuals met criteria Alzheimers disease control hypothesis generating set derived sporadic Alzheimers disease patients Massachusetts three European centers probands multicenter US study sib pairs small families
0.3103701.9811940.html.plaintext.txt	49	The results second data set supported hypothesis GG genotype frequencies 0
0.3103701.9811940.html.plaintext.txt	50	12 Alzheimers disease P 0
0.3103701.9811940.html.plaintext.txt	51	05 Fishers exact test Table 1
0.3103701.9811940.html.plaintext.txt	52	The G allele represented data set control 0
0.3103701.9811940.html.plaintext.txt	53	No difference age onset GG non GG found second data set
0.3103701.9811940.html.plaintext.txt	54	Multivariate analysis showed site collection influence genotype frequencies
0.3103701.9811940.html.plaintext.txt	55	We also compared rate controls subset 387 clinic based Alzheimers disease cases GG frequency 11
0.3103701.9811940.html.plaintext.txt	56	06 subset 179 familial Alzheimers disease samples GG frequency 12
0.3103701.9811940.html.plaintext.txt	57	056 found essentially equal representation GG
0.3103701.9811940.html.plaintext.txt	58	These data support association GG genotype Alzheimers disease
0.3103701.9811940.html.plaintext.txt	59	We carried series exploratory analyses using pooled data individuals 737 Alzheimers disease patients 449 controls
0.3103701.9811940.html.plaintext.txt	60	The GG genotype present 11
0.3103701.9811940.html.plaintext.txt	61	9 Alzheimer patients 7
0.3103701.9811940.html.plaintext.txt	62	The genotype frequency controls consistent Hardy Weinberg equilibrium
0.3103701.9811940.html.plaintext.txt	63	Age onset different Alzheimers disease patients GG 70
0.3103701.9811940.html.plaintext.txt	64	2 mean plus minus SD non GG carriers 70
0.3103701.9811940.html.plaintext.txt	65	A multivariate logistic model controlled presence APOE4 allele gender showed odds ratio 1
0.3103701.9811940.html.plaintext.txt	66	01 presence A2M GG genotype
0.3103701.9811940.html.plaintext.txt	67	The presence APOE4 model associated odds ratio 4
0.3103701.9811940.html.plaintext.txt	68	The odds ratio combination GG APOE4 9
0.3103701.9811940.html.plaintext.txt	69	001 relative neither risk factor
0.3103701.9811940.html.plaintext.txt	70	To explore whether GG mediated risk influenced presence absence APOE4 stratified sample presence absence APOE4
0.3103701.9811940.html.plaintext.txt	71	Similar representations GG genotype seen strata without APOE4 suggesting effects two risk factors independent
0.3103701.9811940.html.plaintext.txt	72	Multivariate analysis interaction GG genotype either APOE4 gender demonstrated interactions P 0
0.3103701.9811940.html.plaintext.txt	73	Analysis based Mantel Haenszel estimator suggested heterogeneity odds ratios strata without APOE4 P 0
0.3103701.9811940.html.plaintext.txt	74	5 consistent absence interaction A2M APOE4 logistic regression model
0.3103701.9811940.html.plaintext.txt	75	We next turned attention possible biological effects inheritance A2M GG genotype
0.3103701.9811940.html.plaintext.txt	76	Our previous studies A2M immunohistochemistry Alzheimer brain suggested SP different cases stained varying intensity 3
0.3103701.9811940.html.plaintext.txt	77	We explored possibility variability due different genotypes immunostaining eight Alzheimers disease cases known GG AA genotype
0.3103701.9811940.html.plaintext.txt	78	In instances A2M immunoreactivity present robustly SP astrocytes neurons qualitative differences observed genotype groups
0.3103701.9811940.html.plaintext.txt	79	We also explored effect inheritance A2M GG genotype neuropathological phenotype Alzheimers disease Table 2
0.3103701.9811940.html.plaintext.txt	80	We previously used stereological techniques quantitative image analysis measure amount Abeta present amyloid burden neocortical association area surrounding superior temporal sulcus number neurofibrillary tangles present region 12
0.3103701.9811940.html.plaintext.txt	81	Thirty one previously analyzed Alzheimers disease cases A2M genotyped selected analysis
0.3103701.9811940.html.plaintext.txt	82	Initial inspection data suggested increase Abeta individuals AG GG difference two groups
0.3103701.9811940.html.plaintext.txt	83	A statistically significant increase Abeta deposition seen comparing G containing cases non G containing cases 8
0.3103701.9811940.html.plaintext.txt	84	The effect appears primarily due presence least one G allele difference AG GG genotypes observed although sample size limits power comparison
0.3103701.9811940.html.plaintext.txt	85	There statistically significant differences neurofibrillary tangle number G alleles suggesting specific effect Abeta deposition
0.3103701.9811940.html.plaintext.txt	86	Neuropathological correlates A2M genotype Genotype n Amyloid burden Neurofibrillary tangles x 103 AA 10 6
0.3103701.9811940.html.plaintext.txt	87	Exploratory studies genetic risk factors run risk type I errors large number hypotheses either explicitly implicitly tested
0.3103701.9811940.html.plaintext.txt	88	Alternatively type II errors occur sample size insufficient
0.3103701.9811940.html.plaintext.txt	89	In order overcome difficulties inherent exploratory studies genetic risk factors used independent data sets first generate test hypothesis GG genotype associated Alzheimers disease
0.3103701.9811940.html.plaintext.txt	90	Two separate control populations gave identical genotype frequencies hypothesis testing data set made two groups sporadic AD probands multicenter study Alzheimers disease sib pairs small families gave essentially identical genotype frequencies representation GG genotype
0.3103701.9811940.html.plaintext.txt	91	The A2M GG effect dependent APOE genotype effect additive substantial odds ratio GG presence APOE4 allele showed almost 10 fold increased risk
0.3103701.9811940.html.plaintext.txt	92	Power analysis using size effect observed combined data set using 500 samples suggests group size 578 controls 578 Alzheimers disease patients would necessary alpha 0
0.3103701.9811940.html.plaintext.txt	93	05 beta 80 hypothesis GG genotype increased 0
0.3103701.9811940.html.plaintext.txt	94	The association GG A2M genotype risk factor Alzheimers disease leads several interesting mechanistic interpretations
0.3103701.9811940.html.plaintext.txt	95	Previous data shown A2M immunostains SP implicated A2M amyloid precursor protein metabolism 13 well possible interactions binding Abeta 4 mediation degradation Abeta 56
0.3103701.9811940.html.plaintext.txt	96	A2M Abeta complexes undergo endocytosis via A2M rLRP receptor 14
0.3103701.9811940.html.plaintext.txt	97	A2M associates Abeta prevents fibril formation 15
0.3103701.9811940.html.plaintext.txt	98	In addition A2M viewed subacute phase reactive molecule potent proteinase inhibitor might participate inflammatory response Alzheimer brain
0.3103701.9811940.html.plaintext.txt	99	Interestingly A2M also implicated trophic factor possibly result binding transporting number polypeptide growth factors cytokines 16
0.3103701.9811940.html.plaintext.txt	100	Like apoE A2M may serve binding protein targeting various bioactive molecules site action clearing 3
0.3103701.9811940.html.plaintext.txt	101	Finally fact apoE APP two ligands A2M rLRP receptor clearly involved pathophysiology Alzheimers disease support plausibility idea A2M polymorphism might contribute risk Alzheimers disease
0.3103701.9811940.html.plaintext.txt	102	In fact polymorphism A2M rLRP recently reported two studies show genetic association Alzheimers disease 1718
0.3103701.9811940.html.plaintext.txt	103	Although strong biological rationale involvement A2M polymorphism Alzheimers disease possibility remains genetic association observe reflects linkage another mutation polymorphism either A2M gene nearby gene chromosome 12
0.3103701.9811940.html.plaintext.txt	104	The A2M gene resides 25 cM distal marker D12S1042 yielded maximal LOD score recent linkage study suggesting chromosome 12 contains Alzheimer risk factor 19
0.3103701.9811940.html.plaintext.txt	105	However likelihood A2M risk factor supported results recent separate study observed association intronic 5prime splice site exon 18 pentanucleotide deletion allele 2 within A2M gene Alzheimers disease sibship analysis Alzheimers disease sib pairs small Alzheimers disease families 20
0.3103701.9811940.html.plaintext.txt	106	Our current results extend observation showing linkage missense mutation case control sample rather family based association
0.3103701.9811940.html.plaintext.txt	107	We currently studying two A2M polymorphisms relate one another preliminary results consistent hypothesis act independent risk factors
0.3103701.9811940.html.plaintext.txt	108	Initial study group evaluated polymorphisms suggests G allele inherited 1 allele 70 G chromosomes examined 35 GG individuals 97 allele 1 3 allele 2 compared allele 2 frequency 15 P 0
0.3103701.9811940.html.plaintext.txt	109	005 chi2 analysis Yates correction
0.3103701.9811940.html.plaintext.txt	110	Taken together believe polymorphisms A2M gene may contribute risk Alzheimers disease
0.3103701.9811940.html.plaintext.txt	111	Moreover data focus attention mechanisms pathophysiology impact A2M rLRP ligands including clearance mechanisms mediated A2M rLRP 714 suggest A2M rLRP ligands may candidate Alzheimers disease genes well
0.3103701.9811940.html.plaintext.txt	112	An initial hypothesis generating data set established 171 Alzheimers disease patients clinical history probable Alzheimers disease 90 age compatible control individuals primarily spouses patients
0.3103701.9811940.html.plaintext.txt	113	A second hypothesis testing data set collected several sources attempt approximate 500 patients controls estimated power analysis adequately test hypothesis GG genotype represented Alzheimers disease
0.3103701.9811940.html.plaintext.txt	114	These individuals included additional cases 380 sporadic Alzheimer disease 337 controls matched site primarily cognitively tested spouses collected Massachusetts General Hospital Memory Disorder Unit consortium European Centers University Hamburg Germany University Basel Switzerland S
0.3103701.9811940.html.plaintext.txt	115	Cuore Fatebenefratelli Hospital Brescia Italy 179 probands multicenter study Alzheimer disease sib pairs small Alzheimers disease families 21
0.3103701.9811940.html.plaintext.txt	116	Genomic DNA isolated brain tissue blood amplified PCR presence oligonucleotide sense primer C23 5prime ATC CCT GAA ACT GCC ACC AA 3prime antisense primer AS24 5prime GTA ACT GAA ACC TAC TGG AA 3prime 10 mM Tris HC1 50 mM KC1 pH 8
0.3103701.9811940.html.plaintext.txt	117	5 mM MgC12 5 mM dNTPs 5 pmol primer 1
0.3103701.9811940.html.plaintext.txt	118	The PCR carried touchdown procedure stepped annealing temperature increase primer specificity follows one cycle 94 degrees C 5 min four cycles 94 degrees C 30 65 degrees C 30 72 degrees C 1 min four cycles 94 degrees C 30 62 degrees C 30 72 degrees C 1 min four cycles 94 degrees C 30 59 degrees C 30 72 degrees C 1 min 20 cycles 94 degrees C 30 56 degrees C 30 72 degrees C 1 min one cycle 72 degrees C 5 min
0.3103701.9811940.html.plaintext.txt	119	In reaction mixture MboI added amplified product 615 bp digestion carried 37 degrees C 3 h producing fragments 532 G allele 429 bp A allele
0.3103701.9811940.html.plaintext.txt	120	The digested product loaded onto 2 agarose gel treated ethidium bromide 0
0.3103701.9811940.html.plaintext.txt	121	005 electrophoresed 2 h constant voltage 150 V sufficient separate digested product 532 429 bp bands distinguished
0.3103701.9811940.html.plaintext.txt	122	After electrophoresis DNA fragments visualized UV illumination using Bio Rad Gel Doc system
0.3103701.9811940.html.plaintext.txt	123	Incomplete digestion monitored continued presence 615 bp product
0.3103701.9811940.html.plaintext.txt	124	Immunohistochemical analysis used anti A2M antibody 1500 Zymed
0.3103701.9811940.html.plaintext.txt	125	A goat Cy3 linked secondary antibody Jackson Immunoresearch used visualize immunostaining
0.3103701.9811940.html.plaintext.txt	126	In instances double immunofluorescence carried Abeta counterstain antibody 10D5 courtesy Dr D
0.3103701.9811940.html.plaintext.txt	127	Schenk Athena Neurosciences using bodipy fluorescein linked secondary antibody Molecular Probes second fluorochrome
0.3103701.9811940.html.plaintext.txt	128	Quantitative neuropathological techniques measuring Abeta burden neurofibrillary tangles number superior temporal sulcus area previously published 12
0.3103701.9811940.html.plaintext.txt	129	Comparisons A2M allele frequency proportion chromosomes allele present genotype frequency proportion individuals genotype performed 2 x 2 tables using Fishers exact test significance
0.3103701.9811940.html.plaintext.txt	130	Age onset Alzheimers disease normally distributed compared test
0.3103701.9811940.html.plaintext.txt	131	Multivariate analysis odds Alzheimers disease performed logistic regression APOE genotype coded according presence absence APOE4
0.3103701.9811940.html.plaintext.txt	132	Similar results obtained group APOE4 coded separately heterozygotes homozygotes allele
0.3103701.9811940.html.plaintext.txt	133	Odds ratios presented 95 confidence intervals CIs
0.3103701.9811940.html.plaintext.txt	134	All analyses performed Stata software College Park TX
0.3103701.9811940.html.plaintext.txt	135	All significance tests two tailed
0.3103701.9811940.html.plaintext.txt	136	Maschke technical assistance
0.3103701.9811940.html.plaintext.txt	137	We thank Massachusetts Alzheimers Research Center AG05134 Brain Bank Dr E
0.3103701.9811940.html.plaintext.txt	138	Hedley Whyte neuropathological specimens
0.3103701.9811940.html.plaintext.txt	139	Additional neurological pathological specimens obtained Brain Tissue Research Center MHNS 31862
0.3103701.9811940.html.plaintext.txt	140	This work supported NIH grants AG12406 AG08487
0.3103701.9811940.html.plaintext.txt	141	1991 Interleukin 6 alpha 2 macroglobulin indicate acute phase state Alzheimers disease cortices
0.3103701.9811940.html.plaintext.txt	142	1993 alpha2 Macroglobulin expression neuritic type plaques patients Alzheimers disease
0.3103701.9811940.html.plaintext.txt	143	1995 Multiple diverse senile plaque associated proteins ligands apolipoprotein E receptor alpha 2 macroglobulin receptorlow density lipoprotein receptor related protein
0.3103701.9811940.html.plaintext.txt	144	1997 Alpha 2 macroglobulin beta amyloid peptide binding plasma protein
0.3103701.9811940.html.plaintext.txt	145	1996 Degradation amyloid beta protein serine protease alpha 2 macroglobulin complex
0.3103701.9811940.html.plaintext.txt	146	1996 Inhibition alpha 2 macroglobulinproteinase mediated degradation amyloid beta peptide apolipoprotein E alpha 1 antichymotrypsin
0.3103701.9811940.html.plaintext.txt	147	1993 Apolipoprotein E sporadic Alzheimers disease allelic variation receptor interactions
0.3103701.9811940.html.plaintext.txt	148	1990 Sequence identity alpha2 macroglobulin receptor low density lipoprotein receptor related protein suggests molecule multifunctional receptor
0.3103701.9811940.html.plaintext.txt	149	1995 LDL receptor related protein multifunctional ApoE receptor binds secreted beta amyloid precursor protein mediates degradation
0.3103701.9811940.html.plaintext.txt	150	1992 Cloning human alpha 2 macroglobulin gene detection mutations two functional domains bait region thiolester site
0.3103701.9811940.html.plaintext.txt	151	1968 The association quantitative measures dementia senile change cerebral grey matter elderly subjects
0.3103701.9811940.html.plaintext.txt	152	1997 Neuronal loss parallels exceeds tangle formation Alzheimers disease
0.3103701.9811940.html.plaintext.txt	153	1991 Alpha 2 macroglobulin synthesis interleukin 6 stimulated human neuronal SH SY5Y neuroblastoma cells
0.3103701.9811940.html.plaintext.txt	154	1997 Alpha 2 macroglobulin complexes mediates endocytosis beta amyloid peptide via cell surface low density lipoprotein receptor related protein
0.3103701.9811940.html.plaintext.txt	155	1998 Alpha 2 macroglobulin associates beta amyloid peptide prevents fibril formation
0.3103701.9811940.html.plaintext.txt	156	1992 alpha2 Macroglobulin multifunctional binding protein targeting characteristics
0.3103701.9811940.html.plaintext.txt	157	1997 Genetic association low density lipoprotein receptor related protein gene LRP apolipoprotein E receptor late onset Alzheimers disease
0.3103701.9811940.html.plaintext.txt	158	1998 Confirmation association polymorphism exon 3 low density lipoprotein receptor related protein gene Alzheimers disease
0.3103701.9811940.html.plaintext.txt	159	1997 Complete genomic screen late onset familial Alzheimer disease
0.3103701.9811940.html.plaintext.txt	160	Evidence new locus chromosome 12
0.3103701.9811940.html.plaintext.txt	161	1998 Alpha 2 macroglobulin genetically associated Alzheimers disease
0.3103701.9811940.html.plaintext.txt	162	1997 ApoE 4 age onset Alzheimers disease NIMH genetics initiative
0.3103701.9811940.html.plaintext.txt	163	To correspondence addressed
0.3103701.9811940.html.plaintext.txt	164	Tel 1 617 726 2299 Fax 1 617 726 5677 Email bhymanhelix
0.3103701.9811940.html.plaintext.txt	165	edu This page run Oxford University Press Great Clarendon Street Oxford OX2 6DP part OUP Journals Comments feedback www adminatoup
0.3103701.9811940.html.plaintext.txt	166	uk u d Last modification 12 Nov 1998 Copyright Oxford University Press 1998
0.3230321.11350966.html.plaintext.txt	0	Apolipoprotein E Receptor Binding Versus Heparan Sulfate Proteoglycan Binding Its Regulation Smooth Muscle Cell Migration Proliferation Debi K
0.3230321.11350966.html.plaintext.txt	1	From Department Pathology Laboratory Medicine University Cincinnati College Medicine Cincinnati Ohio 45267 0529
0.3230321.11350966.html.plaintext.txt	2	Received publication March 15 2001 revised form May 2 2001
0.3230321.11350966.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.3230321.11350966.html.plaintext.txt	4	This study showed synthetic peptides containing either single copy tandem repeat receptor binding domain sequence apolipoprotein apo E peptide containing C terminal heparin binding domain apoE 211 243 effective inhibitors platelet derived growth factor PDGF stimulated smooth muscle cell proliferation
0.3230321.11350966.html.plaintext.txt	5	In contrast peptide containing tandem repeating unit receptor binding domain sequence apoE apoE 141 1552 capable inhibiting PDGF directed smooth muscle cell migration
0.3230321.11350966.html.plaintext.txt	6	Peptide containing single unit sequence apoE 141 155 apoE 211 243 peptide ineffective inhibiting PDGF directed smooth muscle cell migration
0.3230321.11350966.html.plaintext.txt	7	Additional experiments showed reductively methylated apoE incapable receptor binding yet retains heparin binding capability equally effective apoE inhibiting PDGF stimulated smooth muscle cell proliferation
0.3230321.11350966.html.plaintext.txt	8	However reductively methylated apoE unable inhibit smooth muscle cell migration toward PDGF
0.3230321.11350966.html.plaintext.txt	9	Additionally receptor binding domain specific apoE antibody 1D7 also mitigated anti migratory properties apoE smooth muscle cells
0.3230321.11350966.html.plaintext.txt	10	Finally pretreatment cells heparinase failed abolish apoE inhibition smooth muscle cell migration
0.3230321.11350966.html.plaintext.txt	11	Taken together data documented apoE inhibition PDGF stimulated smooth muscle cell proliferation mediated binding heparan sulfate proteoglycans inhibition cell migration mediated apoE binding cell surface receptors
0.3230321.11350966.html.plaintext.txt	12	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.3230321.11350966.html.plaintext.txt	13	Research past two decades clearly demonstrated apolipoprotein apo1 E protects vascular disease 1
0.3230321.11350966.html.plaintext.txt	14	Mice deficient apoE emphasize importance apoE protection atherosclerosis
0.3230321.11350966.html.plaintext.txt	15	The apoE deficient mice generated gene targeting approach plasma cholesterol levels 400 500 mgdl develop severe atherosclerosis fed chow diet 2 5
0.3230321.11350966.html.plaintext.txt	16	In contrast wild type mice plasma cholesterol levels 60 85 mgdl develop atherosclerosis normal conditions
0.3230321.11350966.html.plaintext.txt	17	Atherosclerotic lesions mice one copy apoE gene apoE 10 times severe lesions wild type mice fed high fathigh cholesterol diet despite relative similar cholesterol levels two groups animals 326 versus 238 mgdl
0.3230321.11350966.html.plaintext.txt	18	In studies direct correlation serum cholesterol levels atherosclerotic lesion size observed
0.3230321.11350966.html.plaintext.txt	19	Additionally transgenic expression apoE arterial wall inhibited atheroma formation severity without affecting plasma cholesterol level lipoprotein profile cholesterol fed C57BL6 mice 6
0.3230321.11350966.html.plaintext.txt	20	Taken together data showing inverse relationship apoE level atherosclerotic lesion size lack correlation total cholesterol atherosclerosis lesion size led hypothesis apoE may direct impact vascular occlusive diseases manner addition independent property cholesterol transporting apolipoprotein 7
0.3230321.11350966.html.plaintext.txt	21	Recent data laboratory indicated apoE protection vascular occlusive disease may directly related modulation vascular smooth muscle cell response stimulation
0.3230321.11350966.html.plaintext.txt	22	We shown apoE inhibits platelet derived growth factor PDGF oxidized LDL induced smooth muscle cell migration proliferation 8
0.3230321.11350966.html.plaintext.txt	23	ApoE inhibition smooth muscle cell proliferation shown due cell cycle arrest resulting inhibition growth factor induced cyclin D1 activation 8
0.3230321.11350966.html.plaintext.txt	24	The mechanism inhibition appeared mediated inducible nitric oxide synthase signaling pathways 9
0.3230321.11350966.html.plaintext.txt	25	In contrast apoE inhibition growth factor induced smooth muscle cell migration independent inducible nitric oxide synthase activation 9
0.3230321.11350966.html.plaintext.txt	26	Thus likely apoE inhibition smooth muscle cell migration mediated mechanisms distinct pathways involved anti proliferative effects
0.3230321.11350966.html.plaintext.txt	27	The hypothesis apoE inhibits growth factor induced smooth muscle cell migration proliferation via distinct mechanisms supported data showing low doses 0
0.3230321.11350966.html.plaintext.txt	28	1 5 microgml apoE capable inhibiting smooth muscle cell migration higher doses 25 50 microgml necessary apoE inhibition smooth muscle cell proliferation 9
0.3230321.11350966.html.plaintext.txt	29	Apolipoprotein E binds members LDL receptor gene family well heparan sulfate proteoglycans HSPG surface mammalian cells 10 12
0.3230321.11350966.html.plaintext.txt	30	Recent studies several laboratories showed ligand binding LDL receptor gene family members mediate signal transduction events 13 19
0.3230321.11350966.html.plaintext.txt	31	Likewise ligand binding heparan sulfate proteoglycans may also induce signal transduction events 20 22
0.3230321.11350966.html.plaintext.txt	32	Smooth muscle cells known express HSPG well many receptors LDL receptor gene family including LDL receptor LRP VLDL receptor apoE receptor 2 LR8 10 11 23
0.3230321.11350966.html.plaintext.txt	33	The goal current study determine whether apoE inhibition smooth muscle cell migration proliferation mediated interaction cell surface receptors HSPG
0.3230321.11350966.html.plaintext.txt	34	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.3230321.11350966.html.plaintext.txt	35	Materials Type I collagenase elastase heparinase III obtained Sigma
0.3230321.11350966.html.plaintext.txt	36	Dulbeccos modified Eagles medium DMEM fetal bovine serum PDGF BB purchased Life Technologies Inc
0.3230321.11350966.html.plaintext.txt	37	3HThymidine obtained PerkinElmer Life Sciences Transwell polycarbonate membrane filters purchased Corning Costar Corp
0.3230321.11350966.html.plaintext.txt	38	Antibodies smooth muscle specific actin obtained Sigma
0.3230321.11350966.html.plaintext.txt	39	Human ApoE ApoE Peptides Human apoE isolated fresh plasma healthy volunteers method Cardin et al
0.3230321.11350966.html.plaintext.txt	40	The purity apoE assessed SDS polyacrylamide gel electrophoresis samples containing single band Mr 34000 used
0.3230321.11350966.html.plaintext.txt	41	Purified apoE resuspended phosphate buffered saline added directly culture medium without reconstitution lipids
0.3230321.11350966.html.plaintext.txt	42	In selected experiments lysine residues apoE modified reductive methylation according procedure Weisgraber et al
0.3230321.11350966.html.plaintext.txt	43	The reductive methylated apoE extensively dialyzed phosphate buffered saline stored 4 degrees C 1 week prior use
0.3230321.11350966.html.plaintext.txt	44	Peptides containing residues 141 155 heretofore designated apoE 141 155 tandem repeat sequence apoE 141 1552 residues 211 243 designated apoE 211 243 synthesized chemically Synpep Co
0.3230321.11350966.html.plaintext.txt	45	The sequence peptide verified mass spectrometry
0.3230321.11350966.html.plaintext.txt	46	The lyophilized peptides reconstituted phosphate buffered saline dialyzed extensively buffer aliquoted small quantities stored 20 degrees C use
0.3230321.11350966.html.plaintext.txt	47	Isolation Primary Mouse Smooth Muscle Cells Mouse aortic smooth muscle cells isolated using modification Mimuras procedure 26
0.3230321.11350966.html.plaintext.txt	48	Briefly thoracic aortas dissected eight mice adventitial tissue trimmed away
0.3230321.11350966.html.plaintext.txt	49	The aortas incubated Hanks solution containing 1 mgml collagenase 3
0.3230321.11350966.html.plaintext.txt	50	3 unitsml elastase 30 min 37 degrees C
0.3230321.11350966.html.plaintext.txt	51	Remaining adventitial tissue dissected away remaining tissue incubated Hanks solution containing collagenase 1 mgml elastase 3
0.3230321.11350966.html.plaintext.txt	52	3 unitsml 1 h 37 degrees C
0.3230321.11350966.html.plaintext.txt	53	Cell clumps dissociated aspiration 10 ml pipette
0.3230321.11350966.html.plaintext.txt	54	The cell suspension centrifuged 150 x g 5 min room temperature resuspended 10 ml DMEM containing 10 fetal bovine serum
0.3230321.11350966.html.plaintext.txt	55	The isolated cells characterized smooth muscle cells based positive immunohistochemistry staining anti actin antibodies morphological characteristics similar observed human smooth muscle cells
0.3230321.11350966.html.plaintext.txt	56	The primary smooth muscle cells cultured DMEM containing 10 fetal bovine serum 100 unitsml penicillin 0
0.3230321.11350966.html.plaintext.txt	57	Cells passage 1 5 used experiments
0.3230321.11350966.html.plaintext.txt	58	Smooth Muscle Cell Migration Assay The migration mouse vascular smooth muscle cells toward PDGF BB gradient examined according procedure Law et al
0.3230321.11350966.html.plaintext.txt	59	27 described previously 8 9
0.3230321.11350966.html.plaintext.txt	60	Briefly smooth muscle cells made quiescent incubation DMEM 0
0.3230321.11350966.html.plaintext.txt	61	Cells 2 x 105ml incubated solution without apoE 30 min 37 degrees C 0
0.3230321.11350966.html.plaintext.txt	62	1 ml aliquots added top chamber tissue culture treated Transwell polycarbonate membrane 8 microm pores 24 well plates
0.3230321.11350966.html.plaintext.txt	63	The lower Transwell compartment contained 0
0.3230321.11350966.html.plaintext.txt	64	2 bovine serum albumin without 10 ngml PDGF BB
0.3230321.11350966.html.plaintext.txt	65	After incubating 4 h 37 degrees C upper surface filters washed phosphate buffered saline
0.3230321.11350966.html.plaintext.txt	66	The cells fixed methanol 10 min 4 degrees C followed hematoxylin staining
0.3230321.11350966.html.plaintext.txt	67	The number cells migrated lower surface filter determined counting cells six high power fields x 320
0.3230321.11350966.html.plaintext.txt	68	Data presented percentage cells migrated lower surface compared PDGF treatment alone without apoE
0.3230321.11350966.html.plaintext.txt	69	All experiments performed triplicate repeated least three times
0.3230321.11350966.html.plaintext.txt	70	Determination Smooth Muscle Cell Proliferation Smooth muscle cell proliferation measured based incorporation 3Hthymidine cellular DNA described previously 8 9
0.3230321.11350966.html.plaintext.txt	71	Briefly cells plated 96 well plates density 2
0.3230321.11350966.html.plaintext.txt	72	5 x 103 cellswell allowed attach 24 h 37 degrees C
0.3230321.11350966.html.plaintext.txt	73	Quiescence induced incubating cells DMEM containing 0
0.3230321.11350966.html.plaintext.txt	74	4 fetal bovine serum 48 h 37 degrees C time experiment initiated
0.3230321.11350966.html.plaintext.txt	75	Test reagents apoE apoE peptides diluted DMEM containing 0
0.3230321.11350966.html.plaintext.txt	76	2 bovine serum albumin 10 ngml PDGF BB adding cell culture
0.3230321.11350966.html.plaintext.txt	77	Cells incubated medium without PDGF BB served control determine basal 3Hthymidine incorporation cellular DNA quiescence phase
0.3230321.11350966.html.plaintext.txt	78	Five hours prior end experiment 1 microCi 3Hthymidine added culture medium
0.3230321.11350966.html.plaintext.txt	79	Cells harvested onto filters using cell harvester determine 3Hthymidine incorporation 24 h addition test reagents
0.3230321.11350966.html.plaintext.txt	80	Radioactivity quantified liquid scintillation counting
0.3230321.11350966.html.plaintext.txt	81	Data shown individual representative experiment
0.3230321.11350966.html.plaintext.txt	82	All experiments performed five replicates per experiment experiment repeated least three times
0.3230321.11350966.html.plaintext.txt	83	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.3230321.11350966.html.plaintext.txt	84	Initial experiments compared peptides containing either single receptor binding domain sequence apoE tandem repeat sequence peptide containing C terminal heparin binding domain sequence apoE inhibition PDGF induced smooth muscle cell migration proliferation
0.3230321.11350966.html.plaintext.txt	85	While none peptides cytotoxic determined lactate dehydrogenase release incubation smooth muscle cells 3 12 microM concentration apoE peptides resulted suppression PDGF stimulated cell proliferation Fig
0.3230321.11350966.html.plaintext.txt	86	The apoE 211 243 peptide found effective inhibiting smooth muscle cell proliferation complete abolishment 3Hthymidine incorporation cellular DNA observed 12 microM
0.3230321.11350966.html.plaintext.txt	87	The apoE 141 155 apoE 141 1552 peptides less active apoE 211 243 peptide 50 inhibition observed 12 microM Fig
0.3230321.11350966.html.plaintext.txt	88	View larger version 17K Fig
0.3230321.11350966.html.plaintext.txt	89	Effect apoE peptides PDGF stimulated proliferation aortic smooth muscle cells
0.3230321.11350966.html.plaintext.txt	90	Serum starved mouse smooth muscle cells incubated 24 h 96 well plates 2
0.3230321.11350966.html.plaintext.txt	91	5 x 103 cellswell presence PDGF BB apoE synthetic peptides apoE 141 1552 filled circles apoE 141 155 open circles apoE 211 243 filled triangles
0.3230321.11350966.html.plaintext.txt	92	Cell proliferation determined liquid scintillation counting 3Hthymidine incorporated cellular DNA last 5 h incubation
0.3230321.11350966.html.plaintext.txt	93	Data represented percent maximum proliferation induced PDGF BB absence apoE
0.3230321.11350966.html.plaintext.txt	94	indicates significant difference results peptides p 0
0.3230321.11350966.html.plaintext.txt	95	The data mean plus minus S
0.3230321.11350966.html.plaintext.txt	96	five different determinations single representative experiment
0.3230321.11350966.html.plaintext.txt	97	Similar trends observed least three different experiments
0.3230321.11350966.html.plaintext.txt	98	The effect apoE peptides smooth muscle cell migration toward PDGF dramatically different observed inhibition cell proliferation
0.3230321.11350966.html.plaintext.txt	99	The peptide tandem repeating sequence receptor binding domain apoE 141 1552 inhibited PDGF directed smooth muscle cell migration used concentration greater 0
0.3230321.11350966.html.plaintext.txt	100	Thus effectiveness apoE 141 1552 peptide inhibiting smooth muscle cell migration similar observed intact apoE Fig
0.3230321.11350966.html.plaintext.txt	101	In contrast peptide containing single copy receptor binding domain apoE apoE 141 155 peptide containing C terminal heparin binding domain sequence apoE 211 243 ineffective inhibiting PDGF directed smooth muscle cell migration even higher concentrations used Fig
0.3230321.11350966.html.plaintext.txt	102	View larger version 16K Fig
0.3230321.11350966.html.plaintext.txt	103	Effect tandem repeat peptide apoE receptor binding domain PDGF directed migration smooth muscle cells
0.3230321.11350966.html.plaintext.txt	104	Quiescent mouse smooth muscle cells incubated either native apoE open circles apoE tandem peptide apoE 141 1552 filled circles 30 min 37 degrees C prior adding cells top chamber Transwell membranes density 2 x 104 cellswell 24 well plate
0.3230321.11350966.html.plaintext.txt	105	The lower chamber plate contained basal medium DMEM 0
0.3230321.11350966.html.plaintext.txt	106	2 bovine serum albumin PDGF BB 10 ngml
0.3230321.11350966.html.plaintext.txt	107	Cells incubated Transwells 4 h 37 degrees C
0.3230321.11350966.html.plaintext.txt	108	The number cells migrated lower surface counted
0.3230321.11350966.html.plaintext.txt	109	Basal migration determined absence PDGF BB
0.3230321.11350966.html.plaintext.txt	110	Data presented percent cells migrated lower surface relative cells incubated PDGF BB
0.3230321.11350966.html.plaintext.txt	111	Data expressed mean plus minus S
0.3230321.11350966.html.plaintext.txt	112	three samples single representative experiment
0.3230321.11350966.html.plaintext.txt	113	Each experiment repeated least three times similar results
0.3230321.11350966.html.plaintext.txt	114	View larger version 17K Fig
0.3230321.11350966.html.plaintext.txt	115	The effect apoE peptides PDGF directed smooth muscle cell migration
0.3230321.11350966.html.plaintext.txt	116	Quiescent smooth muscle cells incubated apoE 141 1552 filled circles apoE 141 155 open circles apoE 211 243 filled triangles 30 min prior plating cells 2 x 104 cellswell Transwell membrane
0.3230321.11350966.html.plaintext.txt	117	The lower chamber Transwell contained basal medium DMEM 0
0.3230321.11350966.html.plaintext.txt	118	2 bovine serum albumin PDGF BB 10 ngml
0.3230321.11350966.html.plaintext.txt	119	After 4 h incubation 37 degrees C Transwells cells migrated lower surface counted
0.3230321.11350966.html.plaintext.txt	120	Basal migration determined absence PDGF BB
0.3230321.11350966.html.plaintext.txt	121	Data presented percent cells migrated bottom chamber presence apoE peptides relative number cells migrated toward PDGF BB absence apoE peptides
0.3230321.11350966.html.plaintext.txt	122	Data represent mean plus minus S
0.3230321.11350966.html.plaintext.txt	123	three replicates single experiment
0.3230321.11350966.html.plaintext.txt	124	The experiment repeated least three times similar results
0.3230321.11350966.html.plaintext.txt	125	Previous studies shown receptor binding domain domain residues 211 243 capable heparin binding 28 29
0.3230321.11350966.html.plaintext.txt	126	Moreover receptor binding properties apoE require multiple copies receptor binding domain 30 31
0.3230321.11350966.html.plaintext.txt	127	Thus differential effects apoE peptides PDGF stimulated smooth muscle cell proliferation migration suggest apoE inhibition smooth muscle cell migration may mediated interaction cell surface receptors inhibition cell proliferation requires interaction HSPG
0.3230321.11350966.html.plaintext.txt	128	This hypothesis examined taking advantage previous observations reductive methylation lysine residues apoE abolished ability bind receptors 25 32 without interfering heparin binding properties 25 33
0.3230321.11350966.html.plaintext.txt	129	In current experiments reductively methylated apoE found equally effective native apoE inhibiting PDGF stimulated smooth muscle cell proliferation complete inhibition observed 1
0.3230321.11350966.html.plaintext.txt	130	In contrast results observed apoE inhibition cell proliferation reductive methylation apoE abolished ability inhibit smooth muscle cell migration toward PDGF Fig
0.3230321.11350966.html.plaintext.txt	131	View table Table I Effect reductive methylation apoE inhibition smooth muscle cell proliferation Serum starved mouse smooth muscle cells incubated 24 h 96 well plates 2
0.3230321.11350966.html.plaintext.txt	132	5 x 103 cellswell presence absence 10 ngml PDGF BB 1
0.3230321.11350966.html.plaintext.txt	133	5 microM native apoE reductively methylated apoE CH3 apoE
0.3230321.11350966.html.plaintext.txt	134	3HThymidine 1 microCi added well 5 h prior end incubation period
0.3230321.11350966.html.plaintext.txt	135	Cell proliferation determined amount 3Hthymidine incorporated cellular DNA
0.3230321.11350966.html.plaintext.txt	136	Maximum stimulation determined subtracting basal amount 3Hthymidine incorporated cellular DNA absence growth factor stimulation observed PDGF stimulation absence apoE
0.3230321.11350966.html.plaintext.txt	137	The data represent mean plus minus S
0.3230321.11350966.html.plaintext.txt	138	triplicate determinations two separate experiments
0.3230321.11350966.html.plaintext.txt	139	View larger version 16K Fig
0.3230321.11350966.html.plaintext.txt	140	Effects reductive methylation ability apoE inhibit PDGF BB directed smooth muscle cell migration
0.3230321.11350966.html.plaintext.txt	141	Quiescent smooth muscle cells incubated apoE closed bars reductively methylated apoE open bars 30 min 37 degrees C adding top chamber Transwell membranes 24 well dishes density 2 x 104 cellswell
0.3230321.11350966.html.plaintext.txt	142	Cells migrated toward lower chamber Transwells contained basal medium PDGF BB 10 ngml determined 4 h incubation period
0.3230321.11350966.html.plaintext.txt	143	Basal migration determined absence PDGF BB
0.3230321.11350966.html.plaintext.txt	144	Maximum stimulation determined incubating cells absence apoE hatched bar
0.3230321.11350966.html.plaintext.txt	145	Data represent mean plus minus S
0.3230321.11350966.html.plaintext.txt	146	triplicate samples representative experiment
0.3230321.11350966.html.plaintext.txt	147	The experiment repeated least three times similar results
0.3230321.11350966.html.plaintext.txt	148	The importance receptor binding domain mediating anti migratory properties apoE tested determining effect receptor binding domain specific apoE antibody 1D7 34 35 PDGF induced smooth muscle cell migration
0.3230321.11350966.html.plaintext.txt	149	Results showed 1D7 antibody alleviated apoE inhibition smooth muscle cell migration toward PDGF Fig
0.3230321.11350966.html.plaintext.txt	150	Importantly 1D7 similar concentrations alleviate apoE inhibition smooth muscle cell proliferation data shown
0.3230321.11350966.html.plaintext.txt	151	View larger version 16K Fig
0.3230321.11350966.html.plaintext.txt	152	Antibody inhibition apoE effects PDGF directed smooth muscle cell migration
0.3230321.11350966.html.plaintext.txt	153	Serum starved mouse smooth muscle cells preincubated presence absence apoE receptor binding domain specific antibody 1D7 30 min 37 degrees C prior addition top chamber Transwell membranes 24 well plates density 2 x 104 cellswell
0.3230321.11350966.html.plaintext.txt	154	Cells allowed migrate toward PDGF BB 10 ngml lower chamber 4 h 37 degrees C
0.3230321.11350966.html.plaintext.txt	155	Cells migrated lower surface membrane counted expressed percent cells migrated toward PDGF lower chamber absence apoE pretreatment
0.3230321.11350966.html.plaintext.txt	156	Data represent mean plus minus S
0.3230321.11350966.html.plaintext.txt	157	triplicate determinations two separate experiments
0.3230321.11350966.html.plaintext.txt	158	Additional experiments performed test hypothesis apoE inhibition smooth muscle cell migration independent HSPG binding
0.3230321.11350966.html.plaintext.txt	159	In experiments smooth muscle cells preincubated 1 unitml heparinase presence absence apoE prior determination PDGF directed smooth muscle cell migration
0.3230321.11350966.html.plaintext.txt	160	Heparinase pretreatment inhibited PDGF stimulated smooth muscle cell proliferation data shown
0.3230321.11350966.html.plaintext.txt	161	Thus approach cannot used assess HSPG binding cell proliferation
0.3230321.11350966.html.plaintext.txt	162	However treating cells 1 unitml heparinase effect PDGF directed smooth muscle cell migration Fig
0.3230321.11350966.html.plaintext.txt	163	Importantly preincubation cells heparinase also effect apoE inhibition PDGF directed smooth muscle cell migration Fig
0.3230321.11350966.html.plaintext.txt	164	These results document apoE inhibition smooth muscle cell migration independent apoE binding HSPG
0.3230321.11350966.html.plaintext.txt	165	View larger version 14K Fig
0.3230321.11350966.html.plaintext.txt	166	Heparinase treatment smooth muscle cells apoE inhibition PDGF BB directed migration
0.3230321.11350966.html.plaintext.txt	167	Serum starved mouse smooth muscle cells preincubated presence absence heparinase III 1 unitml apoE 1
0.3230321.11350966.html.plaintext.txt	168	5 microM 30 min 37 degrees C prior addition top chamber Transwell membranes 24 well plates density 2 x 104 cellswell
0.3230321.11350966.html.plaintext.txt	169	Cells allowed migrate toward PDGF BB 10 ngml lower chamber 4 h 37 degrees C
0.3230321.11350966.html.plaintext.txt	170	Cells migrated lower surface membrane counted expressed percent cells migrated toward PDGF lower chamber absence apoE heparinase pretreatment
0.3230321.11350966.html.plaintext.txt	171	Heparinase treatment cells alter ability cells migrate toward PDGF BB
0.3230321.11350966.html.plaintext.txt	172	Data represent mean plus minus S
0.3230321.11350966.html.plaintext.txt	173	triplicate determinations single representative experiment
0.3230321.11350966.html.plaintext.txt	174	The experiment repeated least three times similar results
0.3230321.11350966.html.plaintext.txt	175	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.3230321.11350966.html.plaintext.txt	176	Previous studies documented residues 141 155 encompass receptor binding domain apoE 34
0.3230321.11350966.html.plaintext.txt	177	This domain one encompassing residues 211 243 also identified heparin interaction sites apoE 28 29
0.3230321.11350966.html.plaintext.txt	178	The difference receptor heparin binding properties apoE multiple copies receptor binding domain necessary receptor interaction 30 31 36 single copy either domain sufficient confer heparin interaction 28 29
0.3230321.11350966.html.plaintext.txt	179	Results current study showed peptides containing least one copy either receptor binding domain distal heparin binding site apoE capable inhibiting PDGF stimulated smooth muscle cell proliferation
0.3230321.11350966.html.plaintext.txt	180	These results indicated apoE inhibition smooth muscle cell proliferation mediated via interaction HSPG cell surface
0.3230321.11350966.html.plaintext.txt	181	Interestingly none peptides effective native apoE inhibiting smooth muscle cell proliferation
0.3230321.11350966.html.plaintext.txt	182	This observation suggested optimal inhibition smooth muscle cell proliferation may involve multiple domain interactions apoE HSPG
0.3230321.11350966.html.plaintext.txt	183	The interactive role apoE HSPG modulation cell functions proposed previously
0.3230321.11350966.html.plaintext.txt	184	37 showed endogenously expressed apoE enhances cellular proteoglycan synthesis
0.3230321.11350966.html.plaintext.txt	185	Exogenously added apoE also yielded 2 fold induction proteoglycan synthesis secretion smooth muscle cells 38 39
0.3230321.11350966.html.plaintext.txt	186	The latter study demonstrated correlation apoE inhibition cell proliferation induction HSPG synthesis
0.3230321.11350966.html.plaintext.txt	187	Anti perlecan antibody also shown completely abrogate anti proliferative effect apoE 38
0.3230321.11350966.html.plaintext.txt	188	Based observations investigators proposed apoE like anti proliferative agents transforming growth factor 40 heparin 41 inhibits smooth muscle cell proliferation promoting synthesis secretion perlecan 38
0.3230321.11350966.html.plaintext.txt	189	However mechanism apoE stimulates perlecan synthesis cell surface molecules responsible apoE effects determined
0.3230321.11350966.html.plaintext.txt	190	The current study showed apoE inhibits smooth muscle cell proliferation via binding cell surface HSPG
0.3230321.11350966.html.plaintext.txt	191	Thus likely apoE HSPG interaction induces intracellular signals required activation perlecan synthesis subsequent inhibition cell proliferation
0.3230321.11350966.html.plaintext.txt	192	The observation reductively methylated apoE bind receptors remains active HSPG binding capable inhibiting smooth muscle cell proliferation supportive conclusion
0.3230321.11350966.html.plaintext.txt	193	In contrast effects cell proliferation peptides containing either single copy receptor binding domain distal heparin binding domain apoE inhibit PDGF directed smooth muscle cell migration
0.3230321.11350966.html.plaintext.txt	194	Only peptide containing tandem repeating sequence receptor binding domain apoE displayed anti migratory effects
0.3230321.11350966.html.plaintext.txt	195	In fact apoE 141 1552 peptide equally active native apoE inhibiting PDGF directed smooth muscle cell migration
0.3230321.11350966.html.plaintext.txt	196	Moreover results also showed reductive methylation apoE abolished receptor heparin binding activities 25 33 also abolished anti migratory anti proliferative effects apoE
0.3230321.11350966.html.plaintext.txt	197	These results taken together observations showing receptor domain specific apoE antibody abolished anti migratory properties apoE indicated apoE inhibition smooth muscle migration mediated via binding cell surface receptors independent HSPG interaction
0.3230321.11350966.html.plaintext.txt	198	The mechanism apoE interaction receptors results inhibition cell migration remains unknown time
0.3230321.11350966.html.plaintext.txt	199	However increasing evidence suggest apoE interaction LDL receptor gene family member proteins may lead signal transduction events modulate cell functions
0.3230321.11350966.html.plaintext.txt	200	For example apoE binding apoE receptor 2 LR8 platelets shown induce nitric oxide synthesis inhibit agonist induced platelet aggregation 42 43
0.3230321.11350966.html.plaintext.txt	201	Interestingly LR8 contains Src homology 3 SH3 consensus sequence well domains serve targets cGMP cAMP dependent protein kinases
0.3230321.11350966.html.plaintext.txt	202	Thus possible apoE inhibits platelet aggregation induction nitric oxide synthesis LR8 mediated signal transduction events
0.3230321.11350966.html.plaintext.txt	203	This receptor also present brain shown important reelin signaling activation c Jun N terminal kinase signaling pathway 14 15 44
0.3230321.11350966.html.plaintext.txt	204	Likewise VLDL receptor LRP shown interact cytosolic adaptor scaffold proteins modulate transmission extracellular signals activate intracellular tyrosine kinases 16
0.3230321.11350966.html.plaintext.txt	205	Since LRP VLDL receptor LR8 present surface smooth muscle cells possible apoE inhibition smooth muscle cell migration mediated signaling events subsequent apoE binding one receptors
0.3230321.11350966.html.plaintext.txt	206	The identification receptor responsible mediating apoE inhibition smooth muscle cell migration contribute understanding regard
0.3230321.11350966.html.plaintext.txt	207	Regardless exact mechanisms involved data documented anti proliferative anti migratory effects apoE distinct requiring different concentrations apoE 9 mediated interaction HSPG cell surface receptors respectively
0.3230321.11350966.html.plaintext.txt	208	A concentration dependent effect apoE cell functions reported previously studies examining role regulation androgen synthesis ovary
0.3230321.11350966.html.plaintext.txt	209	Dyer Curtiss 45 showed low concentrations apoE promoted androgen synthesis high concentrations apoE inhibitory
0.3230321.11350966.html.plaintext.txt	210	Subsequent studies revealed tandem repeat peptide apoE 141 1552 mimicked effect intact apoE single copy peptide encompassing apoE residues 129 162 stimulate androgen production rather inhibited androgen synthesis high concentrations 46
0.3230321.11350966.html.plaintext.txt	211	These authors suggested apoE stimulation androgen production may mediated apoE binding members LDL receptor gene family 46 inhibition androgen synthesis high apoE concentrations mediated mechanism independent LDL receptor related proteins
0.3230321.11350966.html.plaintext.txt	212	Although exact mechanism apoE modulates androgen production ovaries identified possible cell regulatory function apoE similar observed
0.3230321.11350966.html.plaintext.txt	213	processes mediated distinct cell signaling mechanisms consequence apoE interaction receptors HSPG 8 9
0.3230321.11350966.html.plaintext.txt	214	In summary study adds expanding literature documenting direct role apoE interaction receptors HSPG signal transduction modulation cell functions
0.3230321.11350966.html.plaintext.txt	215	The current study also documented apoE interaction receptors HSPG modulates distinct cell functions
0.3230321.11350966.html.plaintext.txt	216	inhibition cell migration proliferation possibly triggering different signal transduction pathways
0.3230321.11350966.html.plaintext.txt	217	Thus apoE may protect vascular occlusive diseases multiple mechanisms including reverse cholesterol transport inhibition smooth muscle cell migration proliferation
0.3230321.11350966.html.plaintext.txt	218	We previously shown apoE level circulation directly influence neointimal hyperplasia response vascular injury process independent lipid transport 47
0.3230321.11350966.html.plaintext.txt	219	Accordingly designing therapeutic agents increase apoE level circulation may beneficial combating vascular disease via multiple mechanisms
0.3230321.11350966.html.plaintext.txt	220	This work supported National Institutes Health Grant HL61332
0.3230321.11350966.html.plaintext.txt	221	The costs publication article defrayed part payment page charges
0.3230321.11350966.html.plaintext.txt	222	The article must therefore hereby marked advertisement accordance 18 U
0.3230321.11350966.html.plaintext.txt	223	Section 1734 solely indicate fact
0.3230321.11350966.html.plaintext.txt	224	Received Postdoctoral Fellowship 9920615V Southern Ohio Valley Consortium American Heart Association
0.3230321.11350966.html.plaintext.txt	225	To correspondence addressed Dept
0.3230321.11350966.html.plaintext.txt	226	Pathology Laboratory Medicine University Cincinnati College Medicine 231 Albert Sabin Way Cincinnati OH 45267 0529
0.3230321.11350966.html.plaintext.txt	227	513 558 9152 Fax 513 558 2141 E mail Huidyemail
0.3230321.11350966.html.plaintext.txt	228	Published JBC Papers Press May 11 2001 DOI 10
0.3230321.11350966.html.plaintext.txt	229	The abbreviations used apo apolipoprotein PDGF platelet derived growth factor HSPG heparan sulfate proteoglycans DMEM Dulbeccos modified Eagles medium LDL low density lipoprotein VLDL low density lipoprotein LRP LDL receptor related protein
0.3230321.11350966.html.plaintext.txt	230	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES 1
0.3230321.11350966.html.plaintext.txt	231	1988 Science 240 622 630Medline Order article via Infotrieve 2
0.3230321.11350966.html.plaintext.txt	232	1992 Cell 71 343 353Medline Order article via Infotrieve 3
0.3230321.11350966.html.plaintext.txt	233	1992 Science 258 468 471Medline Order article via Infotrieve 5
0.3230321.11350966.html.plaintext.txt	234	94 937 945Medline Order article via Infotrieve 6
0.3230321.11350966.html.plaintext.txt	235	95 469 476Medline Order article via Infotrieve 7
0.3230321.11350966.html.plaintext.txt	236	6 d526 d535Medline Order article via Infotrieve 8
0.3230321.11350966.html.plaintext.txt	237	273 20156 20161AbstractFree Full Text 9
0.3230321.11350966.html.plaintext.txt	238	20 1020 1026AbstractFree Full Text 10
0.3230321.11350966.html.plaintext.txt	239	7 298 302Medline Order article via Infotrieve 11
0.3230321.11350966.html.plaintext.txt	240	8 315 319Medline Order article via Infotrieve 12
0.3230321.11350966.html.plaintext.txt	241	268 10160 10167AbstractFree Full Text 13
0.3230321.11350966.html.plaintext.txt	242	273 33556 33560AbstractFree Full Text 15
0.3230321.11350966.html.plaintext.txt	243	275 25625 25632AbstractFree Full Text 16
0.3230321.11350966.html.plaintext.txt	244	275 25616 25624AbstractFree Full Text 17
0.3230321.11350966.html.plaintext.txt	245	2000 Nature 407 527 530CrossRefMedline Order article via Infotrieve 18
0.3230321.11350966.html.plaintext.txt	246	2000 Nature 407 530 535CrossRefMedline Order article via Infotrieve 19
0.3230321.11350966.html.plaintext.txt	247	2000 Nature 407 535 538CrossRefMedline Order article via Infotrieve 20
0.3230321.11350966.html.plaintext.txt	248	CO2 ClinktypeDOI CrossRefMedline Order article via Infotrieve 21
0.3230321.11350966.html.plaintext.txt	249	83 305 313AbstractFree Full Text 22
0.3230321.11350966.html.plaintext.txt	250	276 5228 5234AbstractFree Full Text 23
0.3230321.11350966.html.plaintext.txt	251	7 292 297Medline Order article via Infotrieve 24
0.3230321.11350966.html.plaintext.txt	252	1984 Methods Pharmacology Schwartz A
0.3230321.11350966.html.plaintext.txt	253	18 1203 1206Medline Order article via Infotrieve 27
0.3230321.11350966.html.plaintext.txt	254	98 1897 1905AbstractFree Full Text 28
0.3230321.11350966.html.plaintext.txt	255	134 783 789Medline Order article via Infotrieve 29
0.3230321.11350966.html.plaintext.txt	256	261 2068 2076AbstractFree Full Text 30
0.3230321.11350966.html.plaintext.txt	257	255 5454 5460Free Full Text 31
0.3230321.11350966.html.plaintext.txt	258	266 15009 15015AbstractFree Full Text 32
0.3230321.11350966.html.plaintext.txt	259	256 5646 5665AbstractFree Full Text 33
0.3230321.11350966.html.plaintext.txt	260	Acta 575 81 91Medline Order article via Infotrieve 34
0.3230321.11350966.html.plaintext.txt	261	258 12348 12354AbstractFree Full Text 35
0.3230321.11350966.html.plaintext.txt	262	259 860 869AbstractFree Full Text 36
0.3230321.11350966.html.plaintext.txt	263	266 22803 22806AbstractFree Full Text 37
0.3230321.11350966.html.plaintext.txt	264	20 111 118AbstractFree Full Text 38
0.3230321.11350966.html.plaintext.txt	265	274 36403 36408AbstractFree Full Text 39
0.3230321.11350966.html.plaintext.txt	266	274 4816 4823AbstractFree Full Text 40
0.3230321.11350966.html.plaintext.txt	267	272 5219 5228AbstractFree Full Text 41
0.3230321.11350966.html.plaintext.txt	268	15 331 340CrossRefMedline Order article via Infotrieve 42
0.3230321.11350966.html.plaintext.txt	269	272 89 95AbstractFree Full Text 43
0.3230321.11350966.html.plaintext.txt	270	40 1925 1930AbstractFree Full Text 44
0.3230321.11350966.html.plaintext.txt	271	1999 Cell 97 689 701Medline Order article via Infotrieve 45
0.3230321.11350966.html.plaintext.txt	272	263 10965 10973AbstractFree Full Text 46
0.3230321.11350966.html.plaintext.txt	273	61 665 672AbstractFree Full Text 47
0.3230321.11350966.html.plaintext.txt	274	157 1839 1848AbstractFree Full Text
0.3230321.11350966.html.plaintext.txt	275	Copyright 2001 The American Society Biochemistry Molecular Biology Inc
0.3285698.11042199.html.plaintext.txt	0	Apolipoprotein E4 Stimulates cAMP Response Element binding Protein Transcriptional Activity Extracellular Signal regulated Kinase Pathway Nobutaka Ohkubo Noriaki Mitsuda Michio Tamatani Atsushi Yamaguchi Young Don Lee Toshio Ogihara Michael P
0.3285698.11042199.html.plaintext.txt	1	From Department Anatomy Neuroscience Department Geriatric Medicine Graduate School Medicine Osaka University Suita Osaka 565 0871 Japan CREST Japan Science Technology Japan Department Anatomy Ajou University School Medicine Suwon 442 749 Korea Division Neurology Duke University Medical Center Durham North Carolina 27710
0.3285698.11042199.html.plaintext.txt	2	Received publication June 12 2000 revised form September 26 2000
0.3285698.11042199.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.3285698.11042199.html.plaintext.txt	4	Inheritance 4 allele apolipoprotein E gene APOE4 major risk factor development Alzheimers disease AD
0.3285698.11042199.html.plaintext.txt	5	Although association APOE4 AD well documented mechanism apolipoprotein E exerts isoform specific effect neurons disease unknown
0.3285698.11042199.html.plaintext.txt	6	In report demonstrate apoE4 stimulates transcriptional activity cAMP response element binding protein CREB activating extracellular signal regulated kinase ERK cascade rat primary hippocampal neurons
0.3285698.11042199.html.plaintext.txt	7	In contrast apoE3 unable stimulate CREB transcriptional activity unable activate ERK pathway
0.3285698.11042199.html.plaintext.txt	8	Elevation intracellular Ca2 levels also involved treatment receptor associated protein nifedipine MK801 removal Ca2 medium dantrolene served inhibit calcium elevation attenuate activation CREB
0.3285698.11042199.html.plaintext.txt	9	Treatment apoE peptide also found facilitate transcription CREB dependent genes c fos Bcl 2
0.3285698.11042199.html.plaintext.txt	10	In contrast treatment apoE3 findings suggest apoE4 apoE peptide induce novel signaling pathway
0.3285698.11042199.html.plaintext.txt	11	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.3285698.11042199.html.plaintext.txt	12	Alzheimers disease devastating neurological disorder characterized progressive memory loss cognitive deficits
0.3285698.11042199.html.plaintext.txt	13	To date four genes reported associated Alzheimers disease phenotypes including amyloid precursor protein gene chromosome 21 1 4 presenilin 1 gene chromosome 14 5 presenilin 2 gene chromosome 1 6 7 apolipoprotein E APOE 1 gene chromosome 19 8 10
0.3285698.11042199.html.plaintext.txt	14	There three common alleles APOE gene 3 common representing 78 APOE alleles 4 representing 15 2 representing 7 11
0.3285698.11042199.html.plaintext.txt	15	Although alleles give six possible genotypes risk Alzheimers disease increased age onset distribution earlier dose 4 8
0.3285698.11042199.html.plaintext.txt	16	While influence APOE 4 genotype clearly demonstrated biological mechanism mediated apoE4 translated protein isoform derived 4 allele APOE gene remains speculative
0.3285698.11042199.html.plaintext.txt	17	Several hypotheses proposed regarding potential mechanisms apoE4 enhances risk Alzheimers disease
0.3285698.11042199.html.plaintext.txt	18	One interesting hypothesis apoE4 causes toxicity hippocampal neurons apoE3 12 13
0.3285698.11042199.html.plaintext.txt	19	A 22 kDa thrombin cleavage fragment apoE4 known truncated apoE4 apoE peptide consisting tandem repeat amino acid residues 141 149 apoE showed higher toxicity neurons apoE4 14 15
0.3285698.11042199.html.plaintext.txt	20	Their toxicity apoE receptor mediated 14 involved calcium influx 16
0.3285698.11042199.html.plaintext.txt	21	Based reports started study mechanism apoE toxicity using synthetic apoE peptide
0.3285698.11042199.html.plaintext.txt	22	We employed Mercury Pathway Profiling System CLONTECH elucidate mechanistic pathways activated presence apoE peptide
0.3285698.11042199.html.plaintext.txt	23	This system evaluates several cis acting enhancer elements AP1 CRE HSE Myc NFB serum response element among transcription CRE element found activated
0.3285698.11042199.html.plaintext.txt	24	In addition apoE peptide specific isoform apoE protein found stimulate phosphorylation activates CREB
0.3285698.11042199.html.plaintext.txt	25	We examined pathway upstream CREB activation found ERK apoE receptor involved pathway
0.3285698.11042199.html.plaintext.txt	26	Downstream CREB expression c fos Bcl 2 genes modulated activated CREB also increased
0.3285698.11042199.html.plaintext.txt	27	Our finding apoE4 stimulates phosphorylation CREB ERK pathway increase transcription specific genes apoE3 suggests mechanism apoE isoform specific function neurons
0.3285698.11042199.html.plaintext.txt	28	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.3285698.11042199.html.plaintext.txt	29	Reagents Recombinant apolipoprotein E3 apolipoprotein E4 purchased Calbiochem San Diego CA U0126 cAMP dependent protein kinase specific inhibitor Promega Madison WI nifedipine dantrolene Sigma MK801 hydrogen malate KN62 Research Biochemicals International Natick MA RAP anti apolipoprotein E antibody IB5 E1 Progen Biotechnik Heidelberg Germany anti CREB antibody anti phospho CREB antibody anti ERK antibody anti phospho ERK antibody New England Biolabs Beverly MA anti c Fos antibody Santa Cruz Biotechnology Santa Cruz CA mouse anti actin monoclonal antibody C4 Chemicon International Temecula CA anti Bcl 2 antibody MBL Nagoya Japan
0.3285698.11042199.html.plaintext.txt	30	ApoE Peptide Synthesis A 30 amino acid apoE peptide tandem repeat apoE amino acid residues 141 155 LRKLRKRLLRDADDL synthesized solid phase method described previously 17 greater 95 purity determined high performance liquid chromatography mass spectrometry
0.3285698.11042199.html.plaintext.txt	31	Cell Culture Primary cultures rat hippocampal neurons prepared Wistar rats embryonic day 18 described previously 18
0.3285698.11042199.html.plaintext.txt	32	Cells routinely propagated Dulbeccos modified Eagles medium Sigma 10 fetal calf serum Life Technologies Inc
0.3285698.11042199.html.plaintext.txt	33	All experiments performed cells cultured 5 8 days
0.3285698.11042199.html.plaintext.txt	34	Primary astrocyte cultures prepared neonatal apoE deficient mice described previously 19 minor modifications
0.3285698.11042199.html.plaintext.txt	35	In brief apoE deficient mice purchased Taconic Farms Germantown NY backbred C57BL6 least six generations brains removed neonatal apoE deficient mice within 24 h birth meninges removed brain tissues digested 37 degrees C Dispase II Rochem Molecular Biochemicals Germany PBS
0.3285698.11042199.html.plaintext.txt	36	The mixture centrifuged 3000 x g 10 min plated 175 cm2 culture flasks two brainsflask cells grown Dulbeccos modified Eagles medium supplemented 10 fetal calf serum
0.3285698.11042199.html.plaintext.txt	37	After 10 days cells incubated 48 h cytosine arabinofuranoside 10 microgml Wako Osaka Japan prevent fibroblast overgrowth
0.3285698.11042199.html.plaintext.txt	38	Astrocytes separated microglia oligodendroglia agitation shaking platform Bioshaker BR 30L Tautek Tokyo Japan identified immunoreactivity anti GFAP antibody
0.3285698.11042199.html.plaintext.txt	39	Cultures used experiments 98 astrocytes based techniques
0.3285698.11042199.html.plaintext.txt	40	Stimulation Primary Astrocytes Quantification TNF Inhibition secretion TNF primary astrocytes apoE quantified described previously 20
0.3285698.11042199.html.plaintext.txt	41	Briefly primary astrocytes apoE deficient mice plated 96 well tissue culture dishes density 20000 cellswell incubated serum free media Opti MEM I Life Technologies Inc
0.3285698.11042199.html.plaintext.txt	42	containing 1 N2 supplement Life Technologies Inc
0.3285698.11042199.html.plaintext.txt	43	The following day recombinant apoE3 apoE4 control protein denatured apoE3 boiling 30 min added
0.3285698.11042199.html.plaintext.txt	44	24 h later 100 ngml lipopolysaccharide Sigma added
0.3285698.11042199.html.plaintext.txt	45	60 h later 50 microl medium removed TNF secretion measured Quantikine M Mouse TNF ELISA kit R D systems described manufacturers protocol
0.3285698.11042199.html.plaintext.txt	46	Promoter reporter Assay To detect pathway activated presence apoE peptide utilized Mercury Pathway Profiling Systems CLONTECH
0.3285698.11042199.html.plaintext.txt	47	Briefly rat hippocampal neurons cultured 6 well dishes transiently transfected promoter reporter plasmids using LipofectAMINE 2000 Life Technologies Inc
0.3285698.11042199.html.plaintext.txt	48	described manufacturers protocol
0.3285698.11042199.html.plaintext.txt	49	These plasmids contained secreted alkaline phosphatase SEAP reporter gene downstream several copies specific transcription factors binding sequences AP1 CRE HSE Myc NFB serum response element
0.3285698.11042199.html.plaintext.txt	50	Transfected neurons allowed recover 24 h 2 microM apoE peptide added media
0.3285698.11042199.html.plaintext.txt	51	Alkaline phosphatase activities media indicated times addition apoE peptide measured using Great EscApe SEAP Chemiluminescence Detection Kit CLONTECH following manufacturers protocol
0.3285698.11042199.html.plaintext.txt	52	Western Blot Analysis Cells cultured 6 well dishes washed three times PBS lysed 200 microl lysis buffer 50 mM Tris HCl pH 8
0.3285698.11042199.html.plaintext.txt	53	0 20 mM EDTA 1 SDS 100 mM NaCl
0.3285698.11042199.html.plaintext.txt	54	20 microg samples boiled 5 min electrophoresed 12
0.3285698.11042199.html.plaintext.txt	55	5 SDS polyacrylamide electrophoresis gels transferred onto Immobilon membrane Millipore Corp
0.3285698.11042199.html.plaintext.txt	56	The membrane incubated blocking buffer 1 x PBS 5 nonfat dried milk 1 h room temperature probed primary antibody blocking buffer overnight 4 degrees C
0.3285698.11042199.html.plaintext.txt	57	After four washes PBS containing 0
0.3285698.11042199.html.plaintext.txt	58	3 Tween 20 blots probed secondary antibody blocking buffer 1 h room temperature washed PBS containing 0
0.3285698.11042199.html.plaintext.txt	59	Detection signal performed enhanced chemiluminescence detection kit Amersham International Little Chalfont United Kingdom
0.3285698.11042199.html.plaintext.txt	60	Protein Quantification The amount protein CREB ERK phosphorylated CREB phosphorylated ERK c fos Bcl 2 actin quantified scanning density immunodetected bands Immobilon membrane using ImageQuant software Molecular Dynamics Sunnyvale CA
0.3285698.11042199.html.plaintext.txt	61	Measurement Intracellular Calcium Levels Fura 2 AM Molecular probes Eugene OR Argus 50CA system Hamamatsu Photonics Japan used quantify cytoplasmic free calcium described manufacturers protocol
0.3285698.11042199.html.plaintext.txt	62	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.3285698.11042199.html.plaintext.txt	63	Recombinant ApoE4 Recombinant ApoE3 Were Equally Active Suppressing Secretion TNF Astrocytes The recombinant apoE4 apoE3 proteins used study degraded determined Western blot analysis denatured reduced apoE proteins Fig
0.3285698.11042199.html.plaintext.txt	64	To show recombinant proteins also retained biological activity examined whether equally inhibited secretion TNF astrocytes described Laskowitz et al
0.3285698.11042199.html.plaintext.txt	65	Preincubation primary astrocytes cultures prepared neonatal apoE deficient mice recombinant apoE3 recombinant apoE4 prior stimulation 100 ngml lipopolysaccharide decreased concentration TNF released conditioned medium dose dependent fashion compared untreated cells Fig
0.3285698.11042199.html.plaintext.txt	66	There significant difference TNF levels cells treated concentration apoE3 apoE4
0.3285698.11042199.html.plaintext.txt	67	Boiled denatured apoE3 used control protein suppress secretion TNF
0.3285698.11042199.html.plaintext.txt	68	View larger version 9K Fig
0.3285698.11042199.html.plaintext.txt	69	Characterization recombinant apoE3 apoE4
0.3285698.11042199.html.plaintext.txt	70	5 ng recombinant apoE3 apoE4 electrophoresed denaturing reducing polyacrylamide gels Western blotted probed anti apolipoprotein E antibody demonstrating degraded A
0.3285698.11042199.html.plaintext.txt	71	Preincubation recombinant apoE3 apoE4 inhibited secretion TNF astrocytes prepared apoE deficient mice dose dependent fashion compared heat denatured apoE3
0.3285698.11042199.html.plaintext.txt	72	The difference apoE3 apoE4 significant concentration Students test
0.3285698.11042199.html.plaintext.txt	73	All results plotted mean plus minus S
0.3285698.11042199.html.plaintext.txt	74	ApoE Peptide Facilitates CRE driven Transcription To detect signaling pathway activated presence apoE peptide utilized Mercury Pathway Profiling Systems CLONTECH
0.3285698.11042199.html.plaintext.txt	75	Several cis acting enhancer elements AP1 activator protein 1 CRE cAMP responsive element HSE heat shock element Myc NFB nuclear factor B serum response element included system assessed rat primary hippocampal neurons exposed 1 microM apoE peptide
0.3285698.11042199.html.plaintext.txt	76	Among elements transcription CRE element found activated Fig
0.3285698.11042199.html.plaintext.txt	77	View larger version 18K Fig
0.3285698.11042199.html.plaintext.txt	78	ApoE peptide treatment increases CREB responsive reporter activity transcriptional activity CREB
0.3285698.11042199.html.plaintext.txt	79	A CRE SEAP reporter plasmid containing three copies CRE elements linked TATA like promoter HSV TK gene fused SEAP gene CLONTECH transfected rat primary hippocampal neurons day 7 vitro culture using LipofectAMINE 2000 procedure Life Technologies Inc
0.3285698.11042199.html.plaintext.txt	80	The activity SEAP measured chemiluminescence Great EscApe CLONTECH medium increased time dependent fashion treatment 2 microM apoE peptide indicating apoE peptide facilitates activation transcriptional activity CREB
0.3285698.11042199.html.plaintext.txt	81	05 compared time 0 control using Students test
0.3285698.11042199.html.plaintext.txt	82	ApoE Peptide ApoE4 Not ApoE3 Facilitated Phosphorylation CREB Ser 133 Since apoE peptide stimulated transcription CRE element CREB transcription factor could activated apoE treatments
0.3285698.11042199.html.plaintext.txt	83	Phosphorylation CREB Ser 133 leads activation transcription factor 21 22
0.3285698.11042199.html.plaintext.txt	84	To monitor activation CREB directly Western blots cell lysates rat hippocampal neurons stimulated 1 microM apoE peptide indicated times probed anti CREB anti phospho CREB p CREB antibodies
0.3285698.11042199.html.plaintext.txt	85	15 min addition apoE peptide phospho CREB levels substantially increased followed gradual decrease next 12 h total amount CREB appear change Fig
0.3285698.11042199.html.plaintext.txt	86	In addition apoE peptide treatment 1 microM apoE4 protein also appeared significantly increase phospho CREB levels 1 h treatment 1 microM apoE3 protein appear change phospho CREB levels significantly time Fig
0.3285698.11042199.html.plaintext.txt	87	Although molar concentration apoE4 apoE peptide added media equivalent kinetics time course CREB phosphorylation following treatment apoE4 protein appeared slower stimulated apoE peptide treatment
0.3285698.11042199.html.plaintext.txt	88	View larger version 27K Fig
0.3285698.11042199.html.plaintext.txt	89	Treatment apoE4 apoE peptide increases phospho CREB levels
0.3285698.11042199.html.plaintext.txt	90	Rat hippocampal neurons day 7 culture treated 2 microM apoE peptide A 2 microM apoE3 B 2 microM apoE4 C indicated times
0.3285698.11042199.html.plaintext.txt	91	Cell lysates 20 microglane electrophoresed SDS PAGE Western blotted probed anti phospho CREB antibody anti CREB antibody
0.3285698.11042199.html.plaintext.txt	92	The amount phosphorylated CREB total CREB quantified scanning densitometry immunoreactive bands
0.3285698.11042199.html.plaintext.txt	93	The ratios phosphorylated CREB total CREB plotted mean plus minus S
0.3285698.11042199.html.plaintext.txt	94	least four separate experiments
0.3285698.11042199.html.plaintext.txt	95	05 compared unstimulated control using Students test A D
0.3285698.11042199.html.plaintext.txt	96	ApoE Peptide ApoE4 Not ApoE3 Facilitated ERK Activity Rat Hippocampal Neurons Since activated CREB phosphorylated Ser 133 apoE treatment increases levels phosphorylated CREB apoE may stimulate pathway resulting kinase mediated phosphorylation CREB
0.3285698.11042199.html.plaintext.txt	97	One candidate CREB phosphorylation Ser 133 ERK pathway activated double phosphorylation ERK Thr 202 Tyr 204
0.3285698.11042199.html.plaintext.txt	98	We examined ERK activation measuring phosphorylated ERK levels following treatment apoE peptide apoE3 apoE4 proteins
0.3285698.11042199.html.plaintext.txt	99	Treatment apoE peptide apoE4 protein resulted significantly increased levels phosphorylated ERK apoE3 treatment failed increase levels Fig
0.3285698.11042199.html.plaintext.txt	100	ApoE peptide increased phospho ERK levels 15 min treatment apoE4 protein increased 1 h treatment
0.3285698.11042199.html.plaintext.txt	101	Like phosphorylation CREB phosphorylation ERK following apoE4 protein treatment appeared slower following apoE peptide treatment
0.3285698.11042199.html.plaintext.txt	102	View larger version 24K Fig
0.3285698.11042199.html.plaintext.txt	103	Treatment apoE4 apoE peptide increases phosphorylated ERK levels
0.3285698.11042199.html.plaintext.txt	104	Rat hippocampal neurons day 7 culture treated 2 microM apoE peptide A 2 microM apoE3 B 2 microM apoE4 C indicated times
0.3285698.11042199.html.plaintext.txt	105	Cell lysates 20 microglane electrophoresed SDS PAGE Western blotted probed anti phospho ERK antibody anti ERK antibody
0.3285698.11042199.html.plaintext.txt	106	The amount phosphorylated ERK total ERK quantified scanning densitometry immunoreactive bands
0.3285698.11042199.html.plaintext.txt	107	The ratios phosphorylated ERK total ERK plotted mean plus minus S
0.3285698.11042199.html.plaintext.txt	108	05 compared unstimulated control using Students test A D apoE4 apoE3 p 0
0.3285698.11042199.html.plaintext.txt	109	05 using Students test apoE4 apoE3 D
0.3285698.11042199.html.plaintext.txt	110	ApoE Peptide Facilitated Expression c fos Bcl 2 Rat Hippocampal Neurons To confirm apoE peptide stimulated phosphorylation resulted increased functional activity CREB examined whether apoE peptide treatment led transactivation CRE dependent genes c fos Bcl 2
0.3285698.11042199.html.plaintext.txt	111	5 increased levels c fos Bcl 2 result treatment apoE peptide whereas level control protein actin appear increase
0.3285698.11042199.html.plaintext.txt	112	View larger version 31K Fig
0.3285698.11042199.html.plaintext.txt	113	Treatment apoE peptide increases c fos Bcl 2 levels
0.3285698.11042199.html.plaintext.txt	114	Rat hippocampal neurons day 7 culture treated 2 microM apoE peptide indicated times
0.3285698.11042199.html.plaintext.txt	115	Cell lysates electrophoresed Western blotted probed anti c fos antibody A anti Bcl 2 antibody B anti actin antibody control
0.3285698.11042199.html.plaintext.txt	116	05 compared unstimulated control using Students test
0.3285698.11042199.html.plaintext.txt	117	ApoE Receptor NMDA Receptor L type Voltage dependent Ca2 Channel Are Involved Pathway To elucidate pathway CREB phosphorylated apoE treatment examined effects RAP competitive blocker apoE receptor MK801 selective antagonist NMDA receptor nifedipine selective antagonist L type voltage dependent calcium channel LVDCC
0.3285698.11042199.html.plaintext.txt	118	Pretreatment RAP followed apoE appeared attenuate increase phospho CREB levels seen apoE treatment alone suggesting apoE receptor involved pathway Fig
0.3285698.11042199.html.plaintext.txt	119	Similarly pretreatment MK801 nifedipine appeared attenuate increase phospho CREB levels suggesting NMDA receptor andor LVDCC also involved pathway Fig
0.3285698.11042199.html.plaintext.txt	120	View larger version 29K Fig
0.3285698.11042199.html.plaintext.txt	121	Various agents inhibit apoE peptide induced increases phospho CREB levels
0.3285698.11042199.html.plaintext.txt	122	Rat hippocampal neurons day 7 culture treated 2 microM apoE peptide 30 min presence absence 1 microM RAPA presence absence 100 microM MK801 20 microM nifedipine B presence absence 10 microM U0126 10 microM cAMP dependent protein kinase inhibitor C presence absence 10 microM SB203580 10 microM KN62 10 microM U0126 D
0.3285698.11042199.html.plaintext.txt	123	Cell lysates 20 microglane electrophoresed SDS PAGE Western blotted probed anti phospho CREB antibody anti CREB antibody
0.3285698.11042199.html.plaintext.txt	124	The ratios phosphorylated CREB total CREB plotted mean plus minus S
0.3285698.11042199.html.plaintext.txt	125	least four separate experiments
0.3285698.11042199.html.plaintext.txt	126	Significance difference apoE peptide alone bar labeled treatment conditions calculated Students test double asterisks represent p 0
0.3285698.11042199.html.plaintext.txt	127	Activation MEK Protein Kinase A Is Involved Pathway To find possible pathways involving apoE receptors LVDCC andor NMDA receptors contribute phosphorylation CREB examined effect inhibiting kinases associated receptors treatment U0126 inhibitor MAPKERK kinase MEK c AMP dependent protein kinase inhibitor protein kinase A PKA
0.3285698.11042199.html.plaintext.txt	128	Pretreatment one selective inhibitors well pretreatment mostly inhibited CREB phosphorylation suggesting activation MEK PKA involved pathway Fig
0.3285698.11042199.html.plaintext.txt	129	ERK Cascade Is Major Pathway Leading ApoE Peptide stimulated Phosphorylation CREB To investigate apoE stimulation pathway examined effect inhibiting kinases associated receptor signaling treatment SB203580 inhibitor p38 MAP kinase KN62 inhibitor calmodulin dependent protein kinases CaMK IIIV U0126 inhibitor MEK
0.3285698.11042199.html.plaintext.txt	130	Of selective inhibitors CREB phosphorylation mostly inhibited pretreatment U0126 pretreatment KN62 SB203580 appear significant effect phosphorylation status CREB
0.3285698.11042199.html.plaintext.txt	131	This result suggests ERK cascade major pathway leading apoE stimulated phosphorylation CREB Fig
0.3285698.11042199.html.plaintext.txt	132	Elevation Intracellular Ca2 following ApoE Peptide Treatment Involves ApoE Receptor NMDA Receptor L type Voltage dependent Ca2 Channel To demonstrate elevation intracellular Ca2 parallels phosphorylation CREB measured concentration intracellular Ca2 unstimulated apoE peptide stimulated conditions
0.3285698.11042199.html.plaintext.txt	133	Treatment apoE peptide significantly raised concentration intracellular calcium rat hippocampal neurons
0.3285698.11042199.html.plaintext.txt	134	Preincubation RAP MK801 nifedipine significantly attenuated elevation suggesting apoE receptor NMDA receptor LVDCC involved pathway calcium elevation observed activation CREB Fig
0.3285698.11042199.html.plaintext.txt	135	View larger version 23K Fig
0.3285698.11042199.html.plaintext.txt	136	Intracellular calcium levels increase apoE peptide treatment
0.3285698.11042199.html.plaintext.txt	137	As measure intracellular calcium levels Fura 2 fluorescence 7 day old rat hippocampal neuronal cultures increases rapidly treatment apoE peptide bar labeled
0.3285698.11042199.html.plaintext.txt	138	This apoE peptide stimulated fluorescence inhibited pretreatment RAP MK801 10 100 microM nifedipine 10 100 microM
0.3285698.11042199.html.plaintext.txt	139	Peak values intracellular calcium observed 40 exposure apoE peptide least 10 neurons per experiment four separate experiments
0.3285698.11042199.html.plaintext.txt	140	Compared apoE peptide alone significant inhibition calcium fluorescence p 0
0.3285698.11042199.html.plaintext.txt	141	01 calculated Students test marked double asterisk A
0.3285698.11042199.html.plaintext.txt	142	ApoE peptide induces rapid elevation intracellular calcium fluorescence rat hippocampal neurons bar inhibited culturing Ca2 free growth medium presence growth medium containing calcium 10 microM dantrolene
0.3285698.11042199.html.plaintext.txt	143	Peak concentrations intracellular calcium least 10 neurons four experiments plotted
0.3285698.11042199.html.plaintext.txt	144	Significance difference apoE peptide alone treatment conditions calculated Students test double asterisks represent p 0
0.3285698.11042199.html.plaintext.txt	145	A Major Part Intracellular Ca2 Elevation May Be Intracellular Source To determine whether calcium influx extracellular space endoplasmic reticulum ER contributes apoE mediated Ca2 increases measured intracellular Ca2 elevation rat primary hippocampal neurons cultured medium lacking Ca2 containing 1 mM EGTA Fig
0.3285698.11042199.html.plaintext.txt	146	Under conditions apoE stimulated calcium elevation significantly attenuated suggesting calcium influx extracellular sources significantly contributes elevation intracellular Ca2
0.3285698.11042199.html.plaintext.txt	147	To confirm finding also measured contribution calcium release endoplasmic reticulum increase intracellular Ca2
0.3285698.11042199.html.plaintext.txt	148	Rat primary hippocampal neurons preincubated 10 microM dantrolene inhibitor ryanodine sensitive Ca2 channel found ER membrane followed apoE peptide treatment
0.3285698.11042199.html.plaintext.txt	149	Interestingly preincubation dantrolene also significantly attenuated elevation intracellular Ca2
0.3285698.11042199.html.plaintext.txt	150	Combining extracellular Ca2 free conditions preincubation dantrolene also attenuated calcium elevation even though significant difference calcium levels measured extracellular Ca2 free conditions without dantrolene preincubation extracellular calcium free condition dantrolene preincubation
0.3285698.11042199.html.plaintext.txt	151	Taken together hypothesize calcium influx extracellular sources triggers release Ca2 intracellular endoplasmic reticulum sources ryanodine sensitive Ca2 channels
0.3285698.11042199.html.plaintext.txt	152	Calcium influx extracellular space seems essential signaling apoE stimulated elevation intracellular Ca2 levels contributes small amount rise intracellular calcium levels compared calcium released ER
0.3285698.11042199.html.plaintext.txt	153	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.3285698.11042199.html.plaintext.txt	154	Although evidence association 4 allele APOE gene Alzheimers disease overwhelming mechanism apoE4 protein isoform influences onset progression disease pathology unknown
0.3285698.11042199.html.plaintext.txt	155	Of many suggested mechanisms focused reports apoE3 apoE4 protein isoforms differential effects neuronal plasticity survival 13 23 24
0.3285698.11042199.html.plaintext.txt	156	Compared apoE3 protein isoform apoE4 protein proteolytic fragments apoE4 protein peptides corresponding receptor binding domain apoE proteins appear actively injure certainly support maintenance healthy neurites neuronal cells 13 16
0.3285698.11042199.html.plaintext.txt	157	On larger scale failure apoE4 protein isoforms related fragments support neuronal plasticity maintenance may infer mechanism underlies association APOE gene alleles disease
0.3285698.11042199.html.plaintext.txt	158	Under many conditions eventually result neuronal death cell struggles induce protective mechanisms even though destructive forces inevitably march forward
0.3285698.11042199.html.plaintext.txt	159	In report demonstrated one scenario apoE4 apoE3 activates ERK cascade results activation CREB induction many different genes including cell protective gene Bcl 2
0.3285698.11042199.html.plaintext.txt	160	In prior reports showed overexpression Bcl 2 protein could inhibit neuronal death following toxic insult 25
0.3285698.11042199.html.plaintext.txt	161	In case treatment neurons recombinant apoE4 protein synthetic apoE peptide resulted CREB phosphorylation induced Bcl 2 expression events observed following recombinant apoE3 protein treatments
0.3285698.11042199.html.plaintext.txt	162	Time course experiments showed increase phospho CREB levels following apoE4 protein treatments appeared slower apoE peptide although molar concentrations
0.3285698.11042199.html.plaintext.txt	163	This time lag consistent previous results protease inhibitors reduced neurotoxicity apoE4 16 presumed mechanism full length apoE4 protein must digested time produce toxic fragment apoE4
0.3285698.11042199.html.plaintext.txt	164	Despite increases phospho CREB Bcl 2 also observed apoE4apoE peptide mediated increases calcium levels also observed others context association neuronal death 16 26
0.3285698.11042199.html.plaintext.txt	165	The apoE4apoE peptide mediated increase intracellular Ca2 generated calcium influx extracellular space release calcium intracellular stores
0.3285698.11042199.html.plaintext.txt	166	Significant attenuation increased intracellular calcium levels observed cultured rat primary hippocampal neurons medium lacking Ca2 containing EGTA Ca2 chelator suggesting calcium influx extracellular sources follows apoE4apoE peptide treatments
0.3285698.11042199.html.plaintext.txt	167	When measured intracellular Ca2 elevation following preincubation 10 microM dantrolene inhibitor ryanodine sensitive Ca2 channel ER membranes Ca2 elevation also significantly attenuated suggesting participation calcium influx ER elevation intracellular Ca2
0.3285698.11042199.html.plaintext.txt	168	Interestingly extracellular Ca2 free conditions seem additional effect attenuating Ca2 elevation following preincubation dantrolene suggesting calcium influx extracellular space may serve trigger larger amount Ca2 release ER ryanodine sensitive Ca2 channel Ca2 induced Ca2 release fashion
0.3285698.11042199.html.plaintext.txt	169	Thus calcium influx extracellular space may less calcium release intracellular sources endoplasmic reticulum
0.3285698.11042199.html.plaintext.txt	170	The apoE peptide mediated increase phospho CREB levels intracellular Ca2 levels inhibited pretreatment RAP MK801 nifedipine suggesting apoE receptors NMDA receptor LVDCC involved rat hippocampal neuron responses apoE
0.3285698.11042199.html.plaintext.txt	171	16 reported RAP MK801 attenuated elevation intracellular Ca2 caused truncated apoE
0.3285698.11042199.html.plaintext.txt	172	They also reported nifedipine provide protection apoE mediated rise intracellular Ca2 rat hippocampal neurons data shown
0.3285698.11042199.html.plaintext.txt	173	26 reported RAP MK801 diltiazem another inhibitor LVDCCs failed block apoE peptide induced calcium influx rat primary cultured neurons
0.3285698.11042199.html.plaintext.txt	174	Assuming neurotoxicity caused calcium influx following apoE treatment data consistent data provided Tolar et al
0.3285698.11042199.html.plaintext.txt	175	16 RAP MK801 attenuated calcium influx 16
0.3285698.11042199.html.plaintext.txt	176	This result suggests LRP apoE receptors found neurons may linked NMDA receptor
0.3285698.11042199.html.plaintext.txt	177	Our finding preincubation nifedipine almost completely inhibited apoE peptide induced calcium influx reasonable calcium entry NMDA receptors may depolarize plasma membrane open LVDCCs results larger amount calcium influx
0.3285698.11042199.html.plaintext.txt	178	Compared calcium entry LVDCCs calcium entry NMDA receptors may negligible 27
0.3285698.11042199.html.plaintext.txt	179	Nevertheless calcium elevation activate kinases ERK calmodulin kinase II function phosphorylate CREB 27
0.3285698.11042199.html.plaintext.txt	180	Further inhibition experiments showed pretreatment MEK inhibitor andor PKA inhibitor mostly prevented apoE peptide stimulated phosphorylation CREB suggesting activation MEK PKA kinases involved pathway
0.3285698.11042199.html.plaintext.txt	181	Ca2 elevation stimulates CREB phosphorylation activation PKA dependent Rap1 MEK ERK pathway 28
0.3285698.11042199.html.plaintext.txt	182	Pretreatment KN62 SB203580 appear effect phosphorylation status CREB suggesting ERK cascade major pathway leading phosphorylation CREB following apoE treatment
0.3285698.11042199.html.plaintext.txt	183	Upon binding CRE element genes promoter transcription factor known CREB facilitates transcription many different genes c fos Bcl 2 BDNF 27 29 31
0.3285698.11042199.html.plaintext.txt	184	CREB actively binds DNA element CRE typically phosphorylated serine position 133
0.3285698.11042199.html.plaintext.txt	185	Activation CREB phosphorylation serine residue 133 modulated variety effectors
0.3285698.11042199.html.plaintext.txt	186	amino 3 hydroxy 5 methyl 4 isoxazole propionic acid AMPA kainate receptors NMDA receptors associated synapses LVDCCs involved neuronal functions like long term potentiation 32 34
0.3285698.11042199.html.plaintext.txt	187	Stimulation receptors also associated increased intracellular Ca2 levels potentiation kinase activities CREB activation
0.3285698.11042199.html.plaintext.txt	188	To clarify calcium influx caused apoE treatment causes neurotoxicity parallels phosphorylation CREB measured elevation intracellular Ca2 caused apoE peptide rat hippocampal neurons upon exposure receptor antagonists
0.3285698.11042199.html.plaintext.txt	189	As others reported 16 treatment apoE peptide rat primary hippocampal neurons caused calcium influx intracellular Ca2 levels rise
0.3285698.11042199.html.plaintext.txt	190	Preincubation RAP MK801 nifedipine clearly attenuated Ca2 elevation Fig
0.3285698.11042199.html.plaintext.txt	191	7A parallels data CREB phosphorylation mediated apoE peptide suggesting involvement apoE receptor
0.3285698.11042199.html.plaintext.txt	192	We shown possible mechanism whereby apoE4 facilitates expression CRE driven genes apoE3 Fig
0.3285698.11042199.html.plaintext.txt	193	We hypothesize apoE4 stimulates CREB phosphorylation may associated synaptic plasticity
0.3285698.11042199.html.plaintext.txt	194	This apparent isoform specificity effects might relevant isoform specific association apoE4 significant risk factor late onset Alzheimers disease
0.3285698.11042199.html.plaintext.txt	195	View larger version 34K Fig
0.3285698.11042199.html.plaintext.txt	196	A model apoE mediated CREB activation hippocampal neurons
0.3285698.11042199.html.plaintext.txt	197	When apoE4 apoE3 binds apoE receptor surface hippocampal neuron NMDA receptors open
0.3285698.11042199.html.plaintext.txt	198	Activation NMDA receptor causes small amounts Ca2 entry postsynaptic spines
0.3285698.11042199.html.plaintext.txt	199	The resulting depolarization triggers opening L type voltage dependent calcium channels exist cytoplasmic membranes neurons
0.3285698.11042199.html.plaintext.txt	200	The activation L type voltage dependent calcium channels open strong depolarization permit entry larger amount Ca2 along dendrites cell bodies causing opening ryanodine sensitive Ca2 channel ER membrane influx larger amount Ca2 ER Ca2 induced Ca2 release fashion
0.3285698.11042199.html.plaintext.txt	201	The Ca2 entry extracellular space may negligible comparing ER calcium elevation allows activation PKA dependent Rap1 ERK pathway phosphorylation CREB
0.3285698.11042199.html.plaintext.txt	202	Kazunori Imaizumi Yongho Che Shin ichi Miyake Hideo Matsuzaki helpful informative discussions Yumiko Hara technical assistance
0.3285698.11042199.html.plaintext.txt	203	This work supported grants CREST JST Japan Science Technology Ministry Education Science Sports Culture Japan Novartis Foundation Gerontological Research United States National Institute Aging
0.3285698.11042199.html.plaintext.txt	204	The costs publication article defrayed part payment page charges
0.3285698.11042199.html.plaintext.txt	205	The article must therefore hereby marked advertisement accordance 18 U
0.3285698.11042199.html.plaintext.txt	206	Section 1734 solely indicate fact
0.3285698.11042199.html.plaintext.txt	207	To correspondence addressed
0.3285698.11042199.html.plaintext.txt	208	Anatomy Neuroscience Graduate School Medicine Osaka University 2 2 Yamadaoka Suita Osaka 565 0871 Japan
0.3285698.11042199.html.plaintext.txt	209	81 6 6879 3221 Fax 81 6 6879 3229 E mail mitsudaanat2
0.3285698.11042199.html.plaintext.txt	210	Published JBC Papers Press October 20 2000 DOI 10
0.3285698.11042199.html.plaintext.txt	211	The abbreviations used APOE apolipoprotein E AP1 activator protein 1 CRE cAMP response element PBS phosphate buffered saline TNF tumor necrosis factor SEAP secreted alkaline phosphatase NMDA N methyl D asparatate LVDCC L type voltage dependent calcium channel ERK extracellular signal regulated kinase MEK mitogen activated protein kinaseextracellular signal regulated kinase PAGE polyacrylamide gel electrophoresis PKA protein kinase A ER endoplasmic reticulum HSE heat shock element CREB CRE binding protein
0.3285698.11042199.html.plaintext.txt	212	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES 1
0.3285698.11042199.html.plaintext.txt	213	1990 Science 248 492 495Medline Order article via Infotrieve 2
0.3285698.11042199.html.plaintext.txt	214	1992 Nature 360 672 674CrossRefMedline Order article via Infotrieve 3
0.3285698.11042199.html.plaintext.txt	215	1994 Science 264 1336 1340Medline Order article via Infotrieve 4
0.3285698.11042199.html.plaintext.txt	216	1995 Nature 375 754 760CrossRefMedline Order article via Infotrieve 6
0.3285698.11042199.html.plaintext.txt	217	1995 Science 269 973 977Medline Order article via Infotrieve 7
0.3285698.11042199.html.plaintext.txt	218	1995 Science 269 970 973Medline Order article via Infotrieve 8
0.3285698.11042199.html.plaintext.txt	219	1993 Science 261 921 923Medline Order article via Infotrieve 9
0.3285698.11042199.html.plaintext.txt	220	7 180 184Medline Order article via Infotrieve 10
0.3285698.11042199.html.plaintext.txt	221	1988 Science 240 622 630Medline Order article via Infotrieve 12
0.3285698.11042199.html.plaintext.txt	222	1996 Neuroreport 7 2529 2532Medline Order article via Infotrieve 13
0.3285698.11042199.html.plaintext.txt	223	18 195 204AbstractFree Full Text 14
0.3285698.11042199.html.plaintext.txt	224	17 5678 5686AbstractFree Full Text 15
0.3285698.11042199.html.plaintext.txt	225	19 7100 7110AbstractFree Full Text 17
0.3285698.11042199.html.plaintext.txt	226	1995 Biochemistry 34 11142 11151Medline Order article via Infotrieve 18
0.3285698.11042199.html.plaintext.txt	227	274 8531 8538AbstractFree Full Text 19
0.3285698.11042199.html.plaintext.txt	228	76 70 74CrossRefMedline Order article via Infotrieve 21
0.3285698.11042199.html.plaintext.txt	229	1989 Cell 59 675 680Medline Order article via Infotrieve 22
0.3285698.11042199.html.plaintext.txt	230	1994 Cell 77 713 725Medline Order article via Infotrieve 23
0.3285698.11042199.html.plaintext.txt	231	18 3261 3272AbstractFree Full Text 24
0.3285698.11042199.html.plaintext.txt	232	27 663 70Medline Order article via Infotrieve 25
0.3285698.11042199.html.plaintext.txt	233	73 2037 2046Medline Order article via Infotrieve 26
0.3285698.11042199.html.plaintext.txt	234	CO2 GlinktypeDOI CrossRef 27
0.3285698.11042199.html.plaintext.txt	235	19 6348 6359AbstractFree Full Text 28
0.3285698.11042199.html.plaintext.txt	236	275 34433 34441AbstractFree Full Text 29
0.3285698.11042199.html.plaintext.txt	237	1999 Science 286 2358 2361AbstractFree Full Text 30
0.3285698.11042199.html.plaintext.txt	238	1998 Neuron 20 727 740Medline Order article via Infotrieve 31
0.3285698.11042199.html.plaintext.txt	239	1998 Neuron 20 709 726Medline Order article via Infotrieve 32
0.3285698.11042199.html.plaintext.txt	240	1999 Nature 402 297 301CrossRefMedline Order article via Infotrieve 33
0.3285698.11042199.html.plaintext.txt	241	1996 Cell 87 1327 1338Medline Order article via Infotrieve 34
0.3285698.11042199.html.plaintext.txt	242	19 10512 10519AbstractFree Full Text
0.3285698.11042199.html.plaintext.txt	243	Copyright 2001 The American Society Biochemistry Molecular Biology Inc
0.3144371.11983636.html.plaintext.txt	0	Genetic host factors dementia Downs syndrome NICOLE SCHUPF PhD
0.3144371.11983636.html.plaintext.txt	1	Laboratory Epidemiology New York State Institute Basic Research Developmental Disabilities Staten Island
0.3144371.11983636.html.plaintext.txt	2	Center Columbia University College Physicians Surgeons New York USA
0.3144371.11983636.html.plaintext.txt	3	Correspondence Nicole Schupf PhD New York State Institute Basic Research 1050 Forest Hill Road Staten Island NY 10314
0.3144371.11983636.html.plaintext.txt	4	Tel 001 718 494 5301 Fax 001 718 494 5395 e mail ns24atcolumbia
0.3144371.11983636.html.plaintext.txt	5	Declaration interest Grants IIRG 90 067 RG3 96 077 Alzheimers Association Federal grants AG14673 HD35897 P50AG08702 funds New York State Office Mental Retardation Developmental Disabilities
0.3144371.11983636.html.plaintext.txt	6	Presented part Blake Marsh Lecture Annual Meeting Royal College Psychiatrists 6 July 2000 Edinburgh
0.3144371.11983636.html.plaintext.txt	7	ABSTRACT TOP ABSTRACT INTRODUCTION AMYLOID CASCADE HYPOTHESIS ATYPICAL KARYOTYPES GENETIC SUSCEPTIBILITY FACTORS GENDER AND OESTROGEN DEFICIENCY INDIVIDUAL DIFFERENCES IN
0.3144371.11983636.html.plaintext.txt	8	DISCUSSION Clinical Implications
0.3144371.11983636.html.plaintext.txt	9	ACKNOWLEDGMENTS REFERENCES Background The high risk dementia adults Downs syndrome attributed triplication overexpression gene amyloid precursor protein APP
0.3144371.11983636.html.plaintext.txt	10	But wide variation age onset must due risk factors
0.3144371.11983636.html.plaintext.txt	11	Aims To identify factors influence age onset dementia Downs syndrome
0.3144371.11983636.html.plaintext.txt	12	Method Studies factors influence formation beta amyloid Ass reviewed including atypical karyotypes susceptibility genotypes gender oestrogen deficiency individual differences Ass peptide levels
0.3144371.11983636.html.plaintext.txt	13	Results The apolipoprotein E 4 allele oestrogen deficiency high levels Ass1 42 peptide associated earlier onset dementia atypical karyotypes apolipoprotein E 2 allele associated reduced mortality reduced risk dementia
0.3144371.11983636.html.plaintext.txt	14	Conclusions Factors influence Ass levels rather overexpression APP may account differences age onset dementia Downs syndrome
0.3144371.11983636.html.plaintext.txt	15	INTRODUCTION TOP ABSTRACT INTRODUCTION AMYLOID CASCADE HYPOTHESIS ATYPICAL KARYOTYPES GENETIC SUSCEPTIBILITY FACTORS GENDER AND OESTROGEN DEFICIENCY INDIVIDUAL DIFFERENCES IN
0.3144371.11983636.html.plaintext.txt	16	DISCUSSION Clinical Implications
0.3144371.11983636.html.plaintext.txt	17	ACKNOWLEDGMENTS REFERENCES Alzheimers disease associated characteristic neuropathology includes deposition extracellular beta amyloid Ass neuritic plaques intracellular accumulation neurofibrillary tangles
0.3144371.11983636.html.plaintext.txt	18	Adults Downs syndrome high levels Ass deposition age 40 years early onset dementia
0.3144371.11983636.html.plaintext.txt	19	However average age onset clinical dementia 55 years varies widely
0.3144371.11983636.html.plaintext.txt	20	The neuropathological manifestations Alzheimers disease Downs syndrome attributed triplication expression gene beta amyloid precursor protein APP located chromosome 21 factors influencing age onset dementia unresolved
0.3144371.11983636.html.plaintext.txt	21	Factors influence formation deposition Ass reviewed including atypical karyotypes susceptibility genotypes gender oestrogen deficiency individual differences Ass peptide levels
0.3144371.11983636.html.plaintext.txt	22	Factors modify rate degree Ass deposition rather expression APP may important determinants risk dementia Downs syndrome
0.3144371.11983636.html.plaintext.txt	23	AMYLOID CASCADE HYPOTHESIS TOP ABSTRACT INTRODUCTION AMYLOID CASCADE HYPOTHESIS ATYPICAL KARYOTYPES GENETIC SUSCEPTIBILITY FACTORS GENDER AND OESTROGEN DEFICIENCY INDIVIDUAL DIFFERENCES IN
0.3144371.11983636.html.plaintext.txt	24	DISCUSSION Clinical Implications
0.3144371.11983636.html.plaintext.txt	25	ACKNOWLEDGMENTS REFERENCES Although controversy relative importance plaques versus tangles development Alzheimers disease increasing evidence altered metabolism Ass peptides amyloid deposition neuritic plaques causes Alzheimers disease triggering complex pathological cascade produces dementia
0.3144371.11983636.html.plaintext.txt	26	The Ass peptides Ass1 40 Ass1 42 two major species Ass generated APP sequential proteolytic cleavage ss secretases
0.3144371.11983636.html.plaintext.txt	27	These enzymes ones involved breakdown APP secretase cleaves full length APP producing soluble sAPP subsequently p3
0.3144371.11983636.html.plaintext.txt	28	Because processing secretase precludes production full length Ass peptides anti amyloidogenic Younkin 1998
0.3144371.11983636.html.plaintext.txt	29	Several lines evidence suggest deposition Ass 42 important initial step pathogenesis Alzheimers disease
0.3144371.11983636.html.plaintext.txt	30	Ass1 42 aggregates rapidly deposited earlier Alzheimers disease plaques Ass1 40 Iwatsubo et al 1994
0.3144371.11983636.html.plaintext.txt	31	Mutations gene APP presenilin PS12 genes associated early onset familial Alzheimers disease selective increase Ass1 42 Borchelt et al 1996 Mann et al 1996 Scheuner et al 1996 Kosaka et al 1997 Younkin 1998
0.3144371.11983636.html.plaintext.txt	32	Brain levels Ass1 42 increase early development Alzheimers disease strongly correlated cognitive decline Cummings Cotman 1995 Naslund et al 2000 plasma levels Ass1 42 higher elderly people subsequently develop Alzheimers disease remain free dementia Mayeux et al 1999
0.3144371.11983636.html.plaintext.txt	33	Virtually individuals Downs syndrome neuropathological changes consistent diagnosis Alzheimers disease time reach 40 years age including deposition Ass diffuse neuritic plaques Wisniewski H
0.3144371.11983636.html.plaintext.txt	34	et al 1995 Mann 1988 develop dementia end seventh decade life Lai Williams 1989
0.3144371.11983636.html.plaintext.txt	35	Despite nearly universal occurrence Alzheimers disease pathology middle age wide variation age onset dementia
0.3144371.11983636.html.plaintext.txt	36	The prevalence Alzheimers disease age 65 ranged 30 75 Zigman et al 1997
0.3144371.11983636.html.plaintext.txt	37	Most studies shown average age onset dementia 50 55 years range 38 70 years Lai Williams 1989 Prasher Krishnan 1993
0.3144371.11983636.html.plaintext.txt	38	Methodological problems may account variation estimated prevalence Alzheimers disease Downs syndrome
0.3144371.11983636.html.plaintext.txt	39	Diagnosis Alzheimers disease population requires documentation clinically significant decline cognitive adaptive competence previously attained levels performance documentation absence condition might cause declines performance Aylward et al 1997
0.3144371.11983636.html.plaintext.txt	40	Both requirements particularly difficult address adults Downs syndrome given lifelong intellectual disability
0.3144371.11983636.html.plaintext.txt	41	The wide range premorbid levels performance associated differences level intellectual disability requires specific criteria clinically significant decline indicative dementia level function beginning developed
0.3144371.11983636.html.plaintext.txt	42	There yet consensus set cognitive assessment tasks diagnostic criteria existing cognitive assessment batteries differentiate adults Downs syndrome dementia early stages
0.3144371.11983636.html.plaintext.txt	43	Presently diagnoses Alzheimers disease adults Downs syndrome made clinically relatively late stages disease without systematic cognitive functional testing time
0.3144371.11983636.html.plaintext.txt	44	The neuropathological manifestations Alzheimers disease Downs syndrome attributed triplication overexpression gene APP located chromosome 21 Rumble et al 1989 increased risk dementia Downs syndrome may mediated increased substrate cellular production Ass peptides
0.3144371.11983636.html.plaintext.txt	45	Recent neuropathological studies shown diffuse plaques prevalent Alzheimer type lesion seen individuals Downs syndrome age 50 associated dementia
0.3144371.11983636.html.plaintext.txt	46	Diffuse plaques contain non fibrillar amyloid appear younger ages neuritic plaques associated neuronal degeneration appear affect structure function neurons
0.3144371.11983636.html.plaintext.txt	47	In contrast increases numbers neuritic plaques containing substantial amounts fibrillised Ass peptides observed adults Downs syndrome predominantly 50 years age associated neuronal degeneration loss function Wisniewski T
0.3144371.11983636.html.plaintext.txt	48	Examination age specific prevalence dementia Downs syndrome supports hypothesis clinical manifestations Alzheimers disease Downs syndrome closely associated development fibrillised plaques Lai Williams 1989 Visser et al 1997 Holland et al 1998 Lai et al 1999 see Fig
0.3144371.11983636.html.plaintext.txt	49	Although prevalence studies employed varying sampling diagnostic methods remarkable agreement across studies risk Alzheimers disease increases primarily 50 years age
0.3144371.11983636.html.plaintext.txt	50	In addition adults Downs syndrome develop dementia even reach ages presence high densities neuritic plaques presumed
0.3144371.11983636.html.plaintext.txt	51	Thus triplication gene APP may serve increase diffuse plaques adults Downs syndrome factors distinct APP triplication must account individual differences susceptibility formation fibrillised plaques wide range age onset dementia
0.3144371.11983636.html.plaintext.txt	52	A central task epidemiology dementia Downs syndrome identify factors may influence risk Alzheimers disease accelerating formation Ass
0.3144371.11983636.html.plaintext.txt	53	Several avenues investigation suggested existing findings I review role atypical karyotypes b genetic susceptibility factors c gender oestrogen deficiency d individual differences Ass peptide levels
0.3144371.11983636.html.plaintext.txt	54	View larger version 14K Fig
0.3144371.11983636.html.plaintext.txt	55	1 Age specific prevalence dementia adults Downs syndrome
0.3144371.11983636.html.plaintext.txt	56	data Lai Williams 1989 data Visser et al 1997 data Lai et al 1999
0.3144371.11983636.html.plaintext.txt	57	data Holland et al 1998
0.3144371.11983636.html.plaintext.txt	58	ATYPICAL KARYOTYPES TOP ABSTRACT INTRODUCTION AMYLOID CASCADE HYPOTHESIS ATYPICAL KARYOTYPES GENETIC SUSCEPTIBILITY FACTORS GENDER AND OESTROGEN DEFICIENCY INDIVIDUAL DIFFERENCES IN
0.3144371.11983636.html.plaintext.txt	59	DISCUSSION Clinical Implications
0.3144371.11983636.html.plaintext.txt	60	ACKNOWLEDGMENTS REFERENCES There evidence case studies adults Downs syndrome atypical karyotypes including translocations partial trisomies varying degrees mosaicism associated improved survival decreased risk Alzheimers disease
0.3144371.11983636.html.plaintext.txt	61	Prasher et al 1998 presented interesting case 78 year old woman partial trisomy 21 46XXrec21dup q inv21p12q22
0.3144371.11983636.html.plaintext.txt	62	1 conducted comprehensive analysis clinical molecular genetic correlates partial trisomy
0.3144371.11983636.html.plaintext.txt	63	While general appearance suggestive typical Downs syndrome phenotype experienced several common age related medical conditions characteristic Downs syndrome including hypothyroidism cataracts hypotonia hearing impairment
0.3144371.11983636.html.plaintext.txt	64	Analysis gene sequences chromosome 21 using fluorescent situ hybridisation showed partial trisomy excluded region containing gene APP present two copies
0.3144371.11983636.html.plaintext.txt	65	There evidence decline cognitive adaptive competence 5 years preceding death pneumonia evidence Alzheimers disease found magnetic resonance imaging neuropathological assessment
0.3144371.11983636.html.plaintext.txt	66	Similarly two reports women Downs syndrome 25 86 disomy chromosome 21 respectively Chicoine McGuire 1997 W
0.3144371.11983636.html.plaintext.txt	67	Zigman personal communication 2000
0.3144371.11983636.html.plaintext.txt	68	Both women characteristic Downs syndrome phenotype typical age related medical conditions including hypothyroidism cataracts
0.3144371.11983636.html.plaintext.txt	69	The woman 25 disomy chromosome 21 died age 83 following hospitalisation hip fracture free dementia death woman 86 disomy still living age 74 shows evidence dementia based evaluations cognitive adaptive behaviour
0.3144371.11983636.html.plaintext.txt	70	GENETIC SUSCEPTIBILITY FACTORS TOP ABSTRACT INTRODUCTION AMYLOID CASCADE HYPOTHESIS ATYPICAL KARYOTYPES GENETIC SUSCEPTIBILITY FACTORS GENDER AND OESTROGEN DEFICIENCY INDIVIDUAL DIFFERENCES IN
0.3144371.11983636.html.plaintext.txt	71	DISCUSSION Clinical Implications
0.3144371.11983636.html.plaintext.txt	72	ACKNOWLEDGMENTS REFERENCES Four genes increase risk Alzheimers disease identified
0.3144371.11983636.html.plaintext.txt	73	Mutations three genes APP presenilin 1 PS1 presenilin 2 PS2 associated early onset familial forms Alzheimers disease transmitted autosomal dominant Goate et al 1991 Levy Lehad et al 1995 Sherrington et al 1995
0.3144371.11983636.html.plaintext.txt	74	Homozygosity common variant PS1 1 allele associated increased risk Alzheimers disease studies Higuchi et al 1996 Kehoe et al 1996 Scott et al 1996 Wragg et al 1996
0.3144371.11983636.html.plaintext.txt	75	Only one study examined influence PS1 alleles risk dementia Downs syndrome
0.3144371.11983636.html.plaintext.txt	76	In study adults Downs syndrome significant differences allele frequencies individuals dementia age matched individuals without dementia Tyrrell et al 1999
0.3144371.11983636.html.plaintext.txt	77	Polymorphisms gene apolipoprotein E APOE associated risk common late onset Alzheimers disease onset 65 years age
0.3144371.11983636.html.plaintext.txt	78	There three common variants gene APOE encoded three alleles 2 3 4
0.3144371.11983636.html.plaintext.txt	79	In numerous cross sectional case control studies patients Alzheimers disease found significantly likely peers one copies APOE 4 allele Corder et al 1993 Mayeux et al 1993 Saunders et al 1993
0.3144371.11983636.html.plaintext.txt	80	The APOE 4 protein may act increasing rate process leads Alzheimers disease predisposing greater accumulation Ass without Alzheimers disease Roses et al 1994 Hyman et al 1995 Polvikoski et al 1995
0.3144371.11983636.html.plaintext.txt	81	The presence least common allele APOE 2 associated delay disease onset even protection investigators Corder et al 1994 Roses et al 1994
0.3144371.11983636.html.plaintext.txt	82	Apolipoprotein E Downs syndrome The relation APOE genotype risk Alzheimers disease Downs syndrome difficult establish
0.3144371.11983636.html.plaintext.txt	83	All studies consistently found presence APOE 2 allele increases longevity reduces risk dementia role 4 allele controversial Hardy et al 1994 Royston et al 1994 Martins et al 1995 van Gool et al 1995 Cosgrave et al 1996 Lambert et al 1996 Schupf et al 1996 Prasher et al 1997 Schupf et al 1998 Sekijima et al 1998 Tyrrell et al 1998 Lai et al 1999 Rubinszstein et al 1999 Deb et al 2000
0.3144371.11983636.html.plaintext.txt	84	Small sample sizes importantly failure consider differences age onset dementia among without 4 allele may account negative findings
0.3144371.11983636.html.plaintext.txt	85	Since effect 4 allele expressed midlife inclusion sufficient numbers adults 50 years age analysis using survival methods adjust age years follow important methodological considerations
0.3144371.11983636.html.plaintext.txt	86	Our group used survival methods analysis found presence 4 allele associated earlier onset dementia greater decline adaptive behaviour Schupf et al 1996
0.3144371.11983636.html.plaintext.txt	87	Compared APOE 33 genotype adults Downs syndrome 4 allele five times likely develop dementia age 65 one 2 allele developed dementia see Fig
0.3144371.11983636.html.plaintext.txt	88	Among affected individuals mean age onset dementia 53
0.3144371.11983636.html.plaintext.txt	89	3 years 4 allele 58
0.3144371.11983636.html.plaintext.txt	90	0 years 33 genotype
0.3144371.11983636.html.plaintext.txt	91	Four studies found increased frequency 4 allele adults Downs syndrome dementia compared Downs syndrome without dementia Martins et al 1995 Sekijima et al 1998 Rubinsztein et al 1999 Deb et al 2000
0.3144371.11983636.html.plaintext.txt	92	View larger version 13K Fig
0.3144371.11983636.html.plaintext.txt	93	2 Cumulative incidence dementia adults Downs syndrome apolipoprotein E APOE genotype UNK UNK APOE 34 44 genotypes APOE 33 genotype APOE 22 23 24 genotypes
0.3144371.11983636.html.plaintext.txt	94	Based Schupf et al 1996 kind permission Lippincott Williams Wilkins
0.3144371.11983636.html.plaintext.txt	95	The results studies APOE genotype adults Downs syndrome mixed
0.3144371.11983636.html.plaintext.txt	96	Several studies found APOE 2 allele decreased risk dementia sample sizes small demonstrate significant effect 4 allele Hardy et al 1994 Royston et al 1994 Wisniewski T
0.3144371.11983636.html.plaintext.txt	97	Two case control studies adults Downs syndrome compared allele frequencies individuals without dementia found significant association APOE genotype Alzheimers disease adjust age van Gool et al 1995 Prasher et al 1997
0.3144371.11983636.html.plaintext.txt	98	One large study examined 100 adults Downs syndrome 40 70 years age used survival analyses examine age onset dementia APOE genotype Lai et al 1999
0.3144371.11983636.html.plaintext.txt	99	The cumulative incidence dementia age 65 55 APOE 23 genotype 88 APOE 33 genotype 100 4 allele
0.3144371.11983636.html.plaintext.txt	100	The effect 4 allele stronger younger ages consistent findings studies general population effect 4 allele accelerate onset Alzheimers disease Corder et al 1993 Saunders et al 1993 Meyer et al 1998
0.3144371.11983636.html.plaintext.txt	101	Cumulative incidence age 55 0
0.3144371.11983636.html.plaintext.txt	102	71 among 4 allele 0
0.3144371.11983636.html.plaintext.txt	103	40 among APOE 33 genotype
0.3144371.11983636.html.plaintext.txt	104	The authors suggested 4 effect study may attenuated high rates dementia advanced ages
0.3144371.11983636.html.plaintext.txt	105	They concluded effect 4 allele may dependent age study sample
0.3144371.11983636.html.plaintext.txt	106	These findings consistent reduced Ass deposition Polvikoski et al 1995 less plaque formation Benjamin et al 1994 Lippa et al 1994 2 allele acceleration Ass pathology 4 allele Hymen et al 1995 Polvikoski et al 1995
0.3144371.11983636.html.plaintext.txt	107	The size 4 effect relation presence 4 allele early mortality interaction APOE genotype risk factors dementia Downs syndrome gender level learning disability remain resolved
0.3144371.11983636.html.plaintext.txt	108	This require larger older samples analytic procedures provide better adjustment age potential confounders
0.3144371.11983636.html.plaintext.txt	109	GENDER AND OESTROGEN DEFICIENCY TOP ABSTRACT INTRODUCTION AMYLOID CASCADE HYPOTHESIS ATYPICAL KARYOTYPES GENETIC SUSCEPTIBILITY FACTORS GENDER AND OESTROGEN DEFICIENCY INDIVIDUAL DIFFERENCES IN
0.3144371.11983636.html.plaintext.txt	110	DISCUSSION Clinical Implications
0.3144371.11983636.html.plaintext.txt	111	ACKNOWLEDGMENTS REFERENCES Loss gonadal hormones following menopause may important determinant cognitive decline risk Alzheimers disease ageing women
0.3144371.11983636.html.plaintext.txt	112	Before menopause oestrogen promotes growth prolongs survival cholinergic neurons brain regions serving cognitive function Toran Allerand et al 1992 increases cholinergic activity antioxidant properties regulates metabolism APP protect formation Ass Jaffe et al 1994 Goodman et al 1996 Petanceska et al 2000
0.3144371.11983636.html.plaintext.txt	113	In human studies data show higher age specific rates Alzheimers disease women compared men Bachman et al 1993 approximately half risk Alzheimers disease women received oestrogen replacement therapy Barrett Conner Kritz Silverstein 1993 Brenner et al 1994 Henderson et al 1994 Paganini Hill Henderson 1994 Mortel Meyer 1995 Tang et al 1996
0.3144371.11983636.html.plaintext.txt	114	Such findings support hypothesis oestrogen deficiency contributes aetiology Alzheimers disease
0.3144371.11983636.html.plaintext.txt	115	In contrast randomised controlled clinical trials oestrogen replacement therapy women moderate severe Alzheimers disease failed show cognitive improvement suggesting major effect oestrogen delay onset rather reverse cognitive functional decline Henderson et al 2000 Mulnard et al 2000
0.3144371.11983636.html.plaintext.txt	116	Gender differences effects oestrogen Downs syndrome systematically investigated work needed clarify hormonal risk factors may influence onset dementia
0.3144371.11983636.html.plaintext.txt	117	Few studies presented results separately men women
0.3144371.11983636.html.plaintext.txt	118	Studies compared women men found conflicting results different studies showing earlier onset Raghaven et al 1994 Lai et al 1999 later onset Farrer et al 1997 Schupf et al 1998 difference age onset Visser et al 1997 Lai Williams 1989 gender
0.3144371.11983636.html.plaintext.txt	119	Two studies employed survival methods examine age onset distributions gender adjusting age level learning disability found conflicting results
0.3144371.11983636.html.plaintext.txt	120	My colleagues I found men Downs syndrome three times likely women develop Alzheimers disease age 65 see Fig
0.3144371.11983636.html.plaintext.txt	121	3a effect gender observed age groups 50 years Schupf et al 1998
0.3144371.11983636.html.plaintext.txt	122	Both men women Downs syndrome show elevations follicle stimulating hormone FSH luteinising hormone puberty indicative primary gonadal dysfunction appear progress age frequent men women Hasen et al 1980 Campbell et al 1982 Hsiang et al 1987 Hestnes et al 1991
0.3144371.11983636.html.plaintext.txt	123	Thus older men may benefit relative preservation oestrogen proposed account lower risk Alzheimers disease men general population
0.3144371.11983636.html.plaintext.txt	124	In contrast another study found women Downs syndrome approximately twice likely develop dementia men Lai et al 1999 see Fig
0.3144371.11983636.html.plaintext.txt	125	In study effect gender seen primarily younger ages
0.3144371.11983636.html.plaintext.txt	126	In studies gender differences largest APOE 33 genotype suggesting high risk associated presence APOE 4 allele mask gender effects
0.3144371.11983636.html.plaintext.txt	127	The basis different results studies gender differences clear
0.3144371.11983636.html.plaintext.txt	128	View larger version 12K Fig
0.3144371.11983636.html.plaintext.txt	129	3 Cumulative incidence dementia adults Downs syndrome gender based Schupf et al 1998 b based Lai et al 1999 kind permission Lippincott Williams Wilkins
0.3144371.11983636.html.plaintext.txt	130	Only one published study examined influence oestrogen deficiency age onset dementia women Downs syndrome Cosgrave et al 1999
0.3144371.11983636.html.plaintext.txt	131	Menstrual profiles risk dementia 143 women Downs syndrome studied
0.3144371.11983636.html.plaintext.txt	132	Twelve women postmenopausal diagnosed dementia
0.3144371.11983636.html.plaintext.txt	133	There significant relationship age menopause age onset dementia subsample r0
0.3144371.11983636.html.plaintext.txt	134	Although sample size small results consistent hypothesis higher endogenous oestrogen levels lower risk dementia decreasing Ass peptide levels maintaining cholinergic function critical neuronal populations
0.3144371.11983636.html.plaintext.txt	135	If association age menopause onset dementia confirmed supporting hormonal data provided oestrogen replacement therapy might prove important intervention delay onset dementia
0.3144371.11983636.html.plaintext.txt	136	INDIVIDUAL DIFFERENCES IN Ass PEPTIDE LEVELS TOP ABSTRACT INTRODUCTION AMYLOID CASCADE HYPOTHESIS ATYPICAL KARYOTYPES GENETIC SUSCEPTIBILITY FACTORS GENDER AND OESTROGEN DEFICIENCY INDIVIDUAL DIFFERENCES IN
0.3144371.11983636.html.plaintext.txt	137	DISCUSSION Clinical Implications
0.3144371.11983636.html.plaintext.txt	138	ACKNOWLEDGMENTS REFERENCES In Downs syndrome Alzheimers disease deposition Ass1 42 precedes appearance Ass1 40 Iwatsubo et al 1995
0.3144371.11983636.html.plaintext.txt	139	Ass1 42 predominant species brains young age 50 years individuals Downs syndrome Ass1 40 deposits observed decade later
0.3144371.11983636.html.plaintext.txt	140	Compared age matched controls general population plasma levels Ass1 42 Ass1 40 increased adults Downs syndrome Tokuda et al 1997 Mehta et al 1998 one study found increase related dementia status Tokuda et al 1997
0.3144371.11983636.html.plaintext.txt	141	Our group studied plasma Ass1 42 Ass1 40 levels 108 adults Downs syndrome without dementia compared plasma levels 64 adults without dementia general population Schupf et al 2001
0.3144371.11983636.html.plaintext.txt	142	Ass1 42 Ass1 40 levels significantly higher adults Downs syndrome controls general population P0
0.3144371.11983636.html.plaintext.txt	143	0001 highest adults dementia Downs syndrome mean plasma levels Ass1 42 Ass1 40 higher individuals APOE 4 allele without 4 allele regardless dementia status see Fig
0.3144371.11983636.html.plaintext.txt	144	The effect APOE 4 allele Ass1 42 levels may related acceleration rate amyloid fibril formation Ma et al 1994 diminished clearance Ass McNamara et al 1998
0.3144371.11983636.html.plaintext.txt	145	View larger version 9K Fig
0.3144371.11983636.html.plaintext.txt	146	4 Plasma levels Ass1 42 Ass1 40 adults Downs syndrome without dementia APOE genotype
0.3144371.11983636.html.plaintext.txt	147	From Schupf et al 2001 permission Elsevier Science
0.3144371.11983636.html.plaintext.txt	148	DISCUSSION TOP ABSTRACT INTRODUCTION AMYLOID CASCADE HYPOTHESIS ATYPICAL KARYOTYPES GENETIC SUSCEPTIBILITY FACTORS GENDER AND OESTROGEN DEFICIENCY INDIVIDUAL DIFFERENCES IN
0.3144371.11983636.html.plaintext.txt	149	DISCUSSION Clinical Implications
0.3144371.11983636.html.plaintext.txt	150	ACKNOWLEDGMENTS REFERENCES Factors influence formation Ass APOE 4 allele oestrogen deficiency high levels Ass1 42 peptides associated earlier onset dementia Downs syndrome factors decrease formation Ass APOE 2 allele atypical karyotypes reduce APP gene dose associated lower mortality reduced risk dementia
0.3144371.11983636.html.plaintext.txt	151	An important task future work identify sources individual variation premorbid Ass levels
0.3144371.11983636.html.plaintext.txt	152	Since 95 people Downs syndrome triplication APP associated free trisomy overexpression APP cannot account differences age onset dementia within population
0.3144371.11983636.html.plaintext.txt	153	Rather joint effects variety factors including reviewed others yet identified must influence development Alzheimers disease
0.3144371.11983636.html.plaintext.txt	154	This suggests need focus younger adults Downs syndrome identify causes individual differences lifespan development determine begin exert effects
0.3144371.11983636.html.plaintext.txt	155	Clinical Implications Limitations TOP ABSTRACT INTRODUCTION AMYLOID CASCADE HYPOTHESIS ATYPICAL KARYOTYPES GENETIC SUSCEPTIBILITY FACTORS GENDER AND OESTROGEN DEFICIENCY INDIVIDUAL DIFFERENCES IN
0.3144371.11983636.html.plaintext.txt	156	DISCUSSION Clinical Implications
0.3144371.11983636.html.plaintext.txt	157	ACKNOWLEDGMENTS REFERENCES CLINICAL IMPLICATIONS Onset dementia Downs syndrome modified risk factors influence formation deposition beta amyloid well triplication gene amyloid precursor protein
0.3144371.11983636.html.plaintext.txt	158	Investigation risk factor profiles considered part differential diagnosis dementia Downs syndrome
0.3144371.11983636.html.plaintext.txt	159	Studies younger adults Downs syndrome may help identify causes individual differences development Alzheimers disease
0.3144371.11983636.html.plaintext.txt	160	LIMITATIONS Reliable valid cognitive assessment batteries diagnostic criteria required detect dementia early stages improve studies risk factors
0.3144371.11983636.html.plaintext.txt	161	Most studies small sample sizes controlled potential confounders modifiers age gender level intellectual disability
0.3144371.11983636.html.plaintext.txt	162	Most studies used prevalent rather incident cases may mask effect risk factors disease onset confounding differential survival
0.3144371.11983636.html.plaintext.txt	163	ACKNOWLEDGMENTS TOP ABSTRACT INTRODUCTION AMYLOID CASCADE HYPOTHESIS ATYPICAL KARYOTYPES GENETIC SUSCEPTIBILITY FACTORS GENDER AND OESTROGEN DEFICIENCY INDIVIDUAL DIFFERENCES IN
0.3144371.11983636.html.plaintext.txt	164	DISCUSSION Clinical Implications
0.3144371.11983636.html.plaintext.txt	165	ACKNOWLEDGMENTS REFERENCES I thank collaborators work Richard Mayeux MD Warren Zigman PhD Wayne Silverman PhD Benjamin Tycko MD Pankaj Mehta PhD Edmund Jenkins PhD Deborah Pang MPH Bindu Patel MPH
0.3144371.11983636.html.plaintext.txt	166	REFERENCES TOP ABSTRACT INTRODUCTION AMYLOID CASCADE HYPOTHESIS ATYPICAL KARYOTYPES GENETIC SUSCEPTIBILITY FACTORS GENDER AND OESTROGEN DEFICIENCY INDIVIDUAL DIFFERENCES IN
0.3144371.11983636.html.plaintext.txt	167	DISCUSSION Clinical Implications
0.3144371.11983636.html.plaintext.txt	168	ACKNOWLEDGMENTS REFERENCES Aylward E
0.3144371.11983636.html.plaintext.txt	169	et al 1997 Diagnosis dementia individuals intellectual disability
0.3144371.11983636.html.plaintext.txt	170	Journal Intellectual Disability Research 41 152 164
0.3144371.11983636.html.plaintext.txt	171	et al 1993 Incidence dementia probable Alzheimers disease general population Framingham Study
0.3144371.11983636.html.plaintext.txt	172	1993 Estrogen replacement therapy cognitive function older women
0.3144371.11983636.html.plaintext.txt	173	Journal American Medical Association 269 2637 2641
0.3144371.11983636.html.plaintext.txt	174	et al 1994 Protective effect apoE 2 Alzheimers disease
0.3144371.11983636.html.plaintext.txt	175	et al 1996 Familial Alzheimers disease linked presenilin I variants elevate Abetal 421 40 ratio vitro vivo
0.3144371.11983636.html.plaintext.txt	176	et al 1994 Postmenopausal estrogen replacement therapy risk Alzheimers disease population based case control study
0.3144371.11983636.html.plaintext.txt	177	American Journal Epidemiology 140 262 267
0.3144371.11983636.html.plaintext.txt	178	et al 1982 Serum gonadotrophins Down syndrome
0.3144371.11983636.html.plaintext.txt	179	Journal Medical Genetics 19 98 99
0.3144371.11983636.html.plaintext.txt	180	1997 Longevity woman Down syndrome A case study
0.3144371.11983636.html.plaintext.txt	181	Mental Retardation 35 477 479
0.3144371.11983636.html.plaintext.txt	182	et al 1993 Gene dose apolipoprotein E type 4 allele risk Alzheimers disease late onset families
0.3144371.11983636.html.plaintext.txt	183	et al 1994 Protective effect apolipoprotein E type 2 allele late onset Alzheimers disease
0.3144371.11983636.html.plaintext.txt	184	et al 1996 Lower frequency apolipoprotein E4 allele elderly Downs syndrome population
0.3144371.11983636.html.plaintext.txt	185	Biological Psychiatry 40 811 813
0.3144371.11983636.html.plaintext.txt	186	et al 1999 Age onset dementia age menopause women Downs syndrome
0.3144371.11983636.html.plaintext.txt	187	Journal Intellectual Disability Research 43 461 465
0.3144371.11983636.html.plaintext.txt	188	1995 Image analysis beta amyloid load Alzheimers disease relation dementia severity
0.3144371.11983636.html.plaintext.txt	189	2000 APOE 4 influences manifestation Alzheimers disease adults Downs syndrome
0.3144371.11983636.html.plaintext.txt	190	British Journal Psychiatry 176 468 472
0.3144371.11983636.html.plaintext.txt	191	et al 1997 Allelic variability D21S11 APP APOE associated cognitive decline Down syndrome
0.3144371.11983636.html.plaintext.txt	192	et al 1991 Segregation missense mutation amyloid precursor protein gene familial Alzheimers disease
0.3144371.11983636.html.plaintext.txt	193	et al 1996 Estrogens attenuate corticosterone exacerbates excitotoxicity oxidative injury amyloid beta peptide toxicity hippocampal neurons
0.3144371.11983636.html.plaintext.txt	194	Journal Neurochemistry 66 1836 1844
0.3144371.11983636.html.plaintext.txt	195	et al 1994 ApoE genotype Downs syndrome
0.3144371.11983636.html.plaintext.txt	196	1980 Gonadal function trisomy 21
0.3144371.11983636.html.plaintext.txt	197	et al 1994 Estrogen replacement therapy older women
0.3144371.11983636.html.plaintext.txt	198	Archives Neurology 51 896 900
0.3144371.11983636.html.plaintext.txt	199	et al 2000 Estrogen Alzheimers disease women randomized double blind placebo controlled trial
0.3144371.11983636.html.plaintext.txt	200	et al 1991 Hormonal biochemical disturbances Downs syndrome
0.3144371.11983636.html.plaintext.txt	201	Journal Mental Deficiency Research 35 179 193
0.3144371.11983636.html.plaintext.txt	202	et al 1996 Presenilin 1 polymorphism Alzheimers disease
0.3144371.11983636.html.plaintext.txt	203	et al 1998 Population based study prevalence presentation dementia adults Downs syndrome
0.3144371.11983636.html.plaintext.txt	204	British Journal Psychiatry 172 493 498
0.3144371.11983636.html.plaintext.txt	205	et al 1987 Gonadal function patients Down syndrome
0.3144371.11983636.html.plaintext.txt	206	American Journal Medical Genetics 27 449 458
0.3144371.11983636.html.plaintext.txt	207	et al 1995 Quantitative analysis senile plaques Alzheimer disease observation log normal size distribution molecular epidemiology differences associated apolipoprotein E genotype trisomy 21 Down syndrome
0.3144371.11983636.html.plaintext.txt	208	Proceedings National Academy Science USA 92 3586 3590
0.3144371.11983636.html.plaintext.txt	209	et al 1994 Visualization AB4243 AB40 senile plaques end specific AB monoclonals evidence initially deposited species AB4243
0.3144371.11983636.html.plaintext.txt	210	et al 1995 Amyloid beta protein A beta deposition A beta 4243 precedes A beta 40 Down syndrome
0.3144371.11983636.html.plaintext.txt	211	Annals Neurology 37 294 299
0.3144371.11983636.html.plaintext.txt	212	et al 1994 Estrogen regulates metabolism Alzheimer amyloid beta precursor protein
0.3144371.11983636.html.plaintext.txt	213	Journal Biological Chemistry 269 13065 13068
0.3144371.11983636.html.plaintext.txt	214	et al 1996 Presenilin 1 polymorphism Alzheimers disease
0.3144371.11983636.html.plaintext.txt	215	The UK Alzheimers Disease Collaborative Group
0.3144371.11983636.html.plaintext.txt	216	et al 1997 The beta APP717 Alzheimer mutation increases percentage plasma amyloid beta protein ending A beta 4243
0.3144371.11983636.html.plaintext.txt	217	1989 A prospective study Alzheimer disease Down syndrome
0.3144371.11983636.html.plaintext.txt	218	Archives Neurology 46 849 853
0.3144371.11983636.html.plaintext.txt	219	et al 1999 APOE genotype gender effects Alzheimer disease 100 adults Down syndrome
0.3144371.11983636.html.plaintext.txt	220	et al 1996 Analysis APOE alleles impact Downs syndrome
0.3144371.11983636.html.plaintext.txt	221	Neuroscience Letters 220 57 60
0.3144371.11983636.html.plaintext.txt	222	et al 1995 Candidate gene chromosome 1 familial Alzheimers disease locus
0.3144371.11983636.html.plaintext.txt	223	et al 1997 Apolipoprotein E 2 Alzheimers disease genotype influences pathologic phenotype
0.3144371.11983636.html.plaintext.txt	224	Jr et al 1994 Amyloid associated proteins alpha 1 antichymotrypsin apolipoprotein E promote assembly Alzheimer beta protein filaments
0.3144371.11983636.html.plaintext.txt	225	1988 Association Alzheimer disease Down syndrome
0.3144371.11983636.html.plaintext.txt	226	In Alzheimer Disease Down Syndrome Relationship eds J
0.3144371.11983636.html.plaintext.txt	227	Oxford Oxford University Press
0.3144371.11983636.html.plaintext.txt	228	et al 1996 Predominant deposition amyloid beta 4243 plaques cases Alzheimers disease hereditary cerebral hemorrhage associated mutations amyloid precursor protein gene
0.3144371.11983636.html.plaintext.txt	229	American Journal Pathology 148 1257 1266
0.3144371.11983636.html.plaintext.txt	230	et al 1995 ApoE genotypes Australia roles early late onset Alzheimers disease Downs syndrome
0.3144371.11983636.html.plaintext.txt	231	et al 1993 The apolipoprotein epsilon 4 allele patients Alzheimers disease
0.3144371.11983636.html.plaintext.txt	232	Annals Neurology 34 752 754
0.3144371.11983636.html.plaintext.txt	233	et al 1999 Plasma amyloid beta peptide 1 42 incipient Alzheimers disease
0.3144371.11983636.html.plaintext.txt	234	Annals Neurology 46 412 416
0.3144371.11983636.html.plaintext.txt	235	CO2 AlinktypeDOI CrossRefMedline
0.3144371.11983636.html.plaintext.txt	236	1998 Apolipoprotein E genotype deposits Abeta40 Abeta42 Alzheimer disease
0.3144371.11983636.html.plaintext.txt	237	Archives Neurology 55 1001 1004
0.3144371.11983636.html.plaintext.txt	238	et al 1998 Increased plasma amyloid beta protein 1 42 levels Down syndrome
0.3144371.11983636.html.plaintext.txt	239	Neuroscience Letters 241 13 16
0.3144371.11983636.html.plaintext.txt	240	et al 1998 APOE genotype predicts whetherone predisposed Alzheimers disease
0.3144371.11983636.html.plaintext.txt	241	1995 Lack postmenopausal estrogen therapy risk dementia
0.3144371.11983636.html.plaintext.txt	242	Journal Neuropsychiatry Clinical Neuroscience 14 332 337
0.3144371.11983636.html.plaintext.txt	243	2000 Estrogen replacement therapy treatment mild moderate Alzheimer disease randomized controlled trial
0.3144371.11983636.html.plaintext.txt	244	Alzheimers Disease Cooperative Study
0.3144371.11983636.html.plaintext.txt	245	Journal American Medical Association 283 1007 1015
0.3144371.11983636.html.plaintext.txt	246	et al 2000 Correlation elevated levels amyloid B peptide brain cognitive decline
0.3144371.11983636.html.plaintext.txt	247	Journal American Medical Association 283 1571 1577
0.3144371.11983636.html.plaintext.txt	248	1994 Estrogen deficiency risk Alzheimers disease women
0.3144371.11983636.html.plaintext.txt	249	American Journal Epidemiology 140 256 261
0.3144371.11983636.html.plaintext.txt	250	et al 2000 Ovariectomy 17 beta estradiol modulate levels Alzheimers amyloid beta peptides brain
0.3144371.11983636.html.plaintext.txt	251	et al 1995 Apolipoprotein E dementia cortical deposition beta amyloid protein
0.3144371.11983636.html.plaintext.txt	252	New England Journal Medicine 333 1242 1247
0.3144371.11983636.html.plaintext.txt	253	1993 Age onset duration dementia people Down syndrome Integration 98 reported cases literature
0.3144371.11983636.html.plaintext.txt	254	International Journal Geriatric Psychiatry 10 25 31
0.3144371.11983636.html.plaintext.txt	255	et al 1997 ApoE genotype Alzheimers disease adults Down syndrome meta analysis
0.3144371.11983636.html.plaintext.txt	256	American Journal Mental Retardation 102 103 110
0.3144371.11983636.html.plaintext.txt	257	et al 1998 Molecular mapping Alzheimer type dementia Downs syndrome
0.3144371.11983636.html.plaintext.txt	258	Annals Neurology 43 380 383
0.3144371.11983636.html.plaintext.txt	259	et al 1994 Gender differences phenotypic expression Alzheimers disease Downs syndrome trisomy 21
0.3144371.11983636.html.plaintext.txt	260	et al 1994 Clinical application apolipoprotein E genotyping Alzheimers disease
0.3144371.11983636.html.plaintext.txt	261	et al 1994 Apolipoprotein E epsilon 2 allele promotes longevity protects patients Downs syndrome dementia
0.3144371.11983636.html.plaintext.txt	262	et al 1999 ApoE genotypes risk dementia Down syndrome
0.3144371.11983636.html.plaintext.txt	263	American Journal Medical Genetics 88 344 347
0.3144371.11983636.html.plaintext.txt	264	CO2 TlinktypeDOI CrossRefMedline
0.3144371.11983636.html.plaintext.txt	265	et al 1989 Amyloid A4 protein precursor Downs syndrome Alzheimers disease
0.3144371.11983636.html.plaintext.txt	266	New England Journal Medicine 320 1446 1452
0.3144371.11983636.html.plaintext.txt	267	et al 1993 Apolipoprotein E epsilon 4 allele distributions late onset Alzheimers disease amyloid forming diseases
0.3144371.11983636.html.plaintext.txt	268	et al 1996 Secreted amyloid beta protein similar senile plaques Alzheimers disease increased vivo presenilin 1 2 APP mutations linked familial Alzheimers disease
0.3144371.11983636.html.plaintext.txt	269	et al 1996 Onset dementia associated apolipoprotein E 4 Down syndrome
0.3144371.11983636.html.plaintext.txt	270	Annals Neurology 40 799 801
0.3144371.11983636.html.plaintext.txt	271	et al 1998 Earlier onset Alzheimers disease men Down syndrome
0.3144371.11983636.html.plaintext.txt	272	et al 2001 Elevated plasma amyloid ss peptide 42 onset dementia Down syndrome
0.3144371.11983636.html.plaintext.txt	273	Neuroscience Letters 301 199 203
0.3144371.11983636.html.plaintext.txt	274	et al 1996 Presenilin 1 polymorphism Alzheimers disease
0.3144371.11983636.html.plaintext.txt	275	et al 1998 Prevalence dementia Alzheimer type apolipoprotein E phenotypes aged patients Down syndrome
0.3144371.11983636.html.plaintext.txt	276	European Neurology 39 234 237
0.3144371.11983636.html.plaintext.txt	277	et al 1995 Cloning novel gene bearing missense mutations early familial Alzheimers disease
0.3144371.11983636.html.plaintext.txt	278	et al 1996 Effect oestrogen menopause risk age onset Alzheimers disease
0.3144371.11983636.html.plaintext.txt	279	et al 1997 Plasma levels amyloid ss proteins AB1 40 AB1 4243 elevated Downs syndrome
0.3144371.11983636.html.plaintext.txt	280	Annals Neurology 41 271 273
0.3144371.11983636.html.plaintext.txt	281	et al 1992 Estrogen receptors colocalize low affinity nerve growth factor receptors cholinergic neurons basal forebrain
0.3144371.11983636.html.plaintext.txt	282	Proceedings National Academy Science USA 89 4668 4672
0.3144371.11983636.html.plaintext.txt	283	et al 1998 A protective effect apolipoprotein E e2 allele dementia Downs syndrome
0.3144371.11983636.html.plaintext.txt	284	Biological Psychiatry 43 397 400
0.3144371.11983636.html.plaintext.txt	285	et al 1999 Presenilin 1 alpha 1 antichymotrypsin polymorphisms Down syndrome effect presence dementia
0.3144371.11983636.html.plaintext.txt	286	American Journal Medical Genetics 88 616 620
0.3144371.11983636.html.plaintext.txt	287	CO2 IlinktypeDOI CrossRefMedline
0.3144371.11983636.html.plaintext.txt	288	1995 A case control study apolipoprotein E genotypes Alzheimers disease associated Downs syndrome
0.3144371.11983636.html.plaintext.txt	289	Dutch Study Group Downs Syndrome Ageing
0.3144371.11983636.html.plaintext.txt	290	Annals Neurology 38 225 230
0.3144371.11983636.html.plaintext.txt	291	et al 1997 Prospective study prevalence Alzheimer type dementia institutionalized individuals Down syndrome
0.3144371.11983636.html.plaintext.txt	292	American Journal Mental Retardation 101 400 412
0.3144371.11983636.html.plaintext.txt	293	1995 Age associated development diffuse thioflavin S positive plaques Down syndrome
0.3144371.11983636.html.plaintext.txt	294	Developmental Brain Dysfunction 7 330 339
0.3144371.11983636.html.plaintext.txt	295	et al 1995 The influence apolipoprotein E isotypes Alzheimers disease pathology 40 cases Downs syndrome
0.3144371.11983636.html.plaintext.txt	296	Annals Neurology 37 136 138
0.3144371.11983636.html.plaintext.txt	297	1996 Genetic association intronic polymorphism presenilin 1 gene late onset Alzheimers disease
0.3144371.11983636.html.plaintext.txt	298	1998 The role A beta 42 Alzheimers disease
0.3144371.11983636.html.plaintext.txt	299	Journal Physiology Paris 92 289 292
0.3144371.11983636.html.plaintext.txt	300	et al 1997 The epidemiology Alzheimer disease intellectual disability results recommendations international conference
0.3144371.11983636.html.plaintext.txt	301	Journal Intellectual Disability Research 41 76 80
0.3144371.11983636.html.plaintext.txt	302	Received publication January 5 2001
0.3144371.11983636.html.plaintext.txt	303	Revision received June 8 2001
0.3144371.11983636.html.plaintext.txt	304	Accepted publication June 13 2001
0.29722524.9461617.html.plaintext.txt	0	A Minimally Lipidated Form Cell derived Apolipoprotein E Exhibits Isoform specific Stimulation Neurite Outgrowth Absence Exogenous Lipids Lipoproteins Ronald B
0.29722524.9461617.html.plaintext.txt	1	From Department Pharmacological Sciences University Medical Center State University New York Stony Brook New York 11794 Departments Immunology Vascular Biology The Scripps Research Institute La Jolla California 92037
0.29722524.9461617.html.plaintext.txt	2	ABSTRACT Top Abstract Introduction Procedures Results Discussion References
0.29722524.9461617.html.plaintext.txt	3	Within central nervous system apolipoprotein E apoE synthesis increased response nerve injury finding may reflect role apoE neuronal remodeling
0.29722524.9461617.html.plaintext.txt	4	Recent studies show apoE3 promotes apoE4 inhibits neurite outgrowth cultured neuronal cells
0.29722524.9461617.html.plaintext.txt	5	Interestingly isoform specific effects observed apoE presented cells presence exogenous lipid source rabbit low density lipoprotein VLDL making difficult discern biologically active form apoE understand role lipid source
0.29722524.9461617.html.plaintext.txt	6	In present study tested whether cell derived lipidated form apoE alter neurite outgrowth absence VLDL constructing Neuro 2a cell lines expressing high levels apoE
0.29722524.9461617.html.plaintext.txt	7	Our results showed endogenous apoE3 stimulated neurite outgrowth whereas endogenous apoE4 isoform neutral
0.29722524.9461617.html.plaintext.txt	8	Furthermore VLDL antagonized stimulatory effects endogenous apoE3
0.29722524.9461617.html.plaintext.txt	9	Characterization secreted apoE3 indicated neurite outgrowth stimulating activity could recovered culture medium anti apoE immunoaffinity column present poorly lipidated particle density 1
0.29722524.9461617.html.plaintext.txt	10	These results indicated biological activity apoE3 stimulating neurite outgrowth inherent cell derived apoE particle dependent either interaction apoE3 artificial lipid source b independent actions apoE3 VLDL
0.29722524.9461617.html.plaintext.txt	11	INTRODUCTION Top Abstract Introduction Procedures Results Discussion References
0.29722524.9461617.html.plaintext.txt	12	Apolipoprotein E apoE1 299 amino acid glycoprotein 1 first identified 1973 constituent human low density lipoprotein VLDL subsequently found lipoprotein classes
0.29722524.9461617.html.plaintext.txt	13	ApoE plays key role cholesterol homeostasis mediating hepatic clearance plasma cholesteryl ester rich VLDL chylomicron remnants
0.29722524.9461617.html.plaintext.txt	14	In contrast apolipoproteins synthesized liver gut apoE expressed variety tissues cell types including abundant expression steroidogenic cells astrocytes brain 1 4
0.29722524.9461617.html.plaintext.txt	15	ApoE present cerebrospinal fluid CSF 5 10 microgml approximately 5 10 plasma concentration 5 6
0.29722524.9461617.html.plaintext.txt	16	The endogenous lipoproteins CSF predominantly HDL like particles arise astrocyte derived apoE addition apoAI presumably crosses blood brain barrier 7 8
0.29722524.9461617.html.plaintext.txt	17	The role brain apoE known although expression appears correlated nerve injury neuronal remodeling 8 13
0.29722524.9461617.html.plaintext.txt	18	The three common isoforms human apoE result cysteine arginine interchanges residues 112 158 14
0.29722524.9461617.html.plaintext.txt	19	ApoE3 contains cysteine residue 112 arginine residue 158
0.29722524.9461617.html.plaintext.txt	20	ApoE2 contains 2 cysteines whereas apoE4 contains arginines residues
0.29722524.9461617.html.plaintext.txt	21	A correlation apoE 4 allele late onset familial Alzheimers disease identified 15 17
0.29722524.9461617.html.plaintext.txt	22	However role apoE pathology Alzheimers disease still unknown
0.29722524.9461617.html.plaintext.txt	23	There evidence apoE interacts protein components pathologic features Alzheimers disease amyloid plaques neurofibrillary tangles isoform specific manner 18 19
0.29722524.9461617.html.plaintext.txt	24	In addition purified delipidated apoE stimulate isoform specific differences neurite outgrowth added neuronal cells culture 14 20 21
0.29722524.9461617.html.plaintext.txt	25	A murine neuroblastoma cell line Neuro 2a exposed delipidated apoE3 significantly longer neurite extensions compared either control cells cells treated apoE4 14
0.29722524.9461617.html.plaintext.txt	26	The delipidated apoE4 isoform inhibitory effect neurite outgrowth correlates destabilization microtubular arrays 14
0.29722524.9461617.html.plaintext.txt	27	Interestingly isoform specific differences observed exogenous lipid source rabbit VLDL added along delipidated apoE isoforms
0.29722524.9461617.html.plaintext.txt	28	Neither rabbit VLDL contains abundant rabbit apoE human apoE alone alters neurite outgrowth
0.29722524.9461617.html.plaintext.txt	29	Neuro 2a cell lines expressing low quantities apoE isoforms display similar isoform specific differences presence rabbit VLDL yet indistinguishable control cells lack apoE expression absence exogenous lipid source 22
0.29722524.9461617.html.plaintext.txt	30	Multiple lipid sources VLDL triglyceride rich emulsions HDL HDL like CSF lipoproteins substitute VLDL propagate similar isoform specific differences 21 23
0.29722524.9461617.html.plaintext.txt	31	However puzzling aspect studies CSF lipoproteins fail induce difference neuritogenesis unless enriched exogenous human apoE 23 even though CSF HDL like particles already contain apoE 7 23
0.29722524.9461617.html.plaintext.txt	32	Importantly studies identify physiologically significant biologically active form apoE require artificial lipid sources observe apoE induced stimulated neurite outgrowth
0.29722524.9461617.html.plaintext.txt	33	If apoE mediated alterations neurite outgrowth relevant neuronal remodeling events vivo likely biologically active form apoE cell derived lipidated complex act absence VLDL artificial lipid sources
0.29722524.9461617.html.plaintext.txt	34	To test possibility constructed Neuro 2a cell lines secrete higher levels apoE isoforms
0.29722524.9461617.html.plaintext.txt	35	These cells produced minimally lipidated apoE3 stimulated neurite outgrowth absence exogenous lipid
0.29722524.9461617.html.plaintext.txt	36	Under identical conditions apoE4 effect neurite outgrowth indicating E4 isoform neutral inhibitory
0.29722524.9461617.html.plaintext.txt	37	Furthermore exogenous VLDL antagonized stimulatory effects cell derived apoE3
0.29722524.9461617.html.plaintext.txt	38	Thus studies identified minimally lipidated form apoE biologically active promoting neurite outgrowth
0.29722524.9461617.html.plaintext.txt	39	EXPERIMENTAL PROCEDURES Top Abstract Introduction Procedures Results Discussion References Apolipoprotein E Expression Vectors
0.29722524.9461617.html.plaintext.txt	40	A high expression apoE3 vector constructed inserting PCR generated apoE3 cDNA pcDNA3 Invitrogen
0.29722524.9461617.html.plaintext.txt	41	The apoE3 insert produced following PCR conditions 17 ng template pHE54 generous gift John Taylor David Walker Gladstone Institute Cardiovascular Disease 5 units Taq polymerase 50 microM dNTPs 1
0.29722524.9461617.html.plaintext.txt	42	01 gelatin 10 Me2SO 50 mM KCl 10 mM Tris HCl pH 8
0.29722524.9461617.html.plaintext.txt	43	3 5 microM high annealing temperature primers incorporating unique 5 restriction enzyme site
0.29722524.9461617.html.plaintext.txt	44	The translational enhancer alpha mosaic virus expression plasmid pCMV4 24 inserted 4 bases upstream apoE3 cDNA yield pC1E3
0.29722524.9461617.html.plaintext.txt	45	The apoE4 expression vector pC1E4 made substituting SacII FseI fragment pC1E3 corresponding fragment apoE4 sequence plasmid pFE 25
0.29722524.9461617.html.plaintext.txt	46	All PCR inserts junctions verified standard sequencing techniques
0.29722524.9461617.html.plaintext.txt	47	Production Stable ApoE3 ApoE4 transfected Neuro 2a Cell Lines
0.29722524.9461617.html.plaintext.txt	48	Neuro 2a cells maintained 37 degrees C humidified 95 air 5 CO2 incubator medium A Dulbeccos modified Eagles mediumHams F12 11 supplemented 10 heat inactivated fetal bovine serum FBS Atlanta Biologicals 4 mM glutamine 100 unitsml penicillin 100 unitsml streptomycin sulfate 0
0.29722524.9461617.html.plaintext.txt	49	Neuro 2a cells plated 1
0.29722524.9461617.html.plaintext.txt	50	0 x 106 cells 10 ml medium A per 10 cm dish transfected 20 microg plasmid using standard calcium phosphate precipitation protocol 26
0.29722524.9461617.html.plaintext.txt	51	Stable integrants selected maintained medium B medium A plus 350 microgml G418 Life Technologies Inc
0.29722524.9461617.html.plaintext.txt	52	Characterization Parental ApoE3 ApoE4 Neuro 2a Cell Lines
0.29722524.9461617.html.plaintext.txt	53	Northern Blotting Analysis Total RNA isolated confluent 10 cm plates parental apoE3 apoE4 cell lines using Stat 60 Tel Test reagent protocol
0.29722524.9461617.html.plaintext.txt	54	Total RNA 25 microg denatured subjected electrophoresis 1
0.29722524.9461617.html.plaintext.txt	55	2 M formaldehyde transferred nylon membrane overnight capillary transfer
0.29722524.9461617.html.plaintext.txt	56	The membrane probed 32P random primed apoE fragment nucleotides 209 653 hybridization visualized Molecular Dynamics PhosphorImager
0.29722524.9461617.html.plaintext.txt	57	Western Blotting Analysis Cells plated 1
0.29722524.9461617.html.plaintext.txt	58	0 x 107 cells 10 ml medium A per 10 cm dish incubated overnight 37 degrees C washed twice medium A incubated additional 24 h 10 ml fresh medium A
0.29722524.9461617.html.plaintext.txt	59	Conditioned medium removed cells washed 2 times PBS solubilized 0
0.29722524.9461617.html.plaintext.txt	60	5 ml 2 SDS PBS total protein determination
0.29722524.9461617.html.plaintext.txt	61	Conditioned medium run 10 SDS polyacrylamide gel electrophoretically transferred nitrocellulose blocked 1 h room temperature 20 mM Tris HCl pH 7
0.29722524.9461617.html.plaintext.txt	62	4 150 mM NaCl TBS containing 7 nonfat milk 0
0.29722524.9461617.html.plaintext.txt	63	The blocked membrane incubated affinity purified polyclonal goat anti human apoE antibody Biodesign International 2 microgml overnight room temperature TBS containing 1 nonfat milk 0
0.29722524.9461617.html.plaintext.txt	64	The membrane washed three times TBS containing 0
0.29722524.9461617.html.plaintext.txt	65	05 Tween 20 incubated horseradish peroxidase conjugated anti goat IgG Sigma 1 h room temperature TBS containing 1 nonfat milk 0
0.29722524.9461617.html.plaintext.txt	66	Bands visualized enhanced chemiluminescence Amersham Corp
0.29722524.9461617.html.plaintext.txt	67	Neuro 2a cells plated onto 18 mm glass circle coverslips 12 well tissue culture plates 5
0.29722524.9461617.html.plaintext.txt	68	0 x 103 cells 4 ml medium A per well allowed adhere overnight 37 degrees C
0.29722524.9461617.html.plaintext.txt	69	Cells washed twice PBS fixed ice cold PBS containing 3 paraformaldehyde 30 min
0.29722524.9461617.html.plaintext.txt	70	Cells washed twice PBS permeabilized ice cold PBS containing 0
0.29722524.9461617.html.plaintext.txt	71	5 Triton X 100 15 min blocked PBS containing 10 FBS 0
0.29722524.9461617.html.plaintext.txt	72	5 Triton X 100 additional 15 min 37 degrees C
0.29722524.9461617.html.plaintext.txt	73	Cells incubated affinity purified polyclonal goat anti human apoE antibody 2 microgml PBS containing 1 FBS 0
0.29722524.9461617.html.plaintext.txt	74	5 Triton X 100 1 h 37 degrees C
0.29722524.9461617.html.plaintext.txt	75	The cells washed three times PBS containing 0
0.29722524.9461617.html.plaintext.txt	76	5 Triton X 100 incubated rhodamine conjugated donkey anti goat IgG antibody Jackson Immuno Research 12000 PBS containing 1 FBS 0
0.29722524.9461617.html.plaintext.txt	77	5 Triton X 100 1 h 37 degrees C
0.29722524.9461617.html.plaintext.txt	78	Glass slips washed three times PBS containing 0
0.29722524.9461617.html.plaintext.txt	79	5 Triton X 100 mounted SlowFade Molecular Probes analyzed Bio Rad MRC 600 scanning confocal system mounted Nikon Diaphot inverted microscope
0.29722524.9461617.html.plaintext.txt	80	Images saved Bio Rad Pic files subsequently converted Tif files
0.29722524.9461617.html.plaintext.txt	81	ApoE concentration conditioned medium determined ELISA follows 96 well plates coated 100 microl affinity purified goat anti human apoE antibody 5 microgml PBS overnight 4 degrees C
0.29722524.9461617.html.plaintext.txt	82	The plate washed twice PBS blocked 400 microl PBS containing 7 non fat milk 1 h 37 degrees C washed twice
0.29722524.9461617.html.plaintext.txt	83	The coated plate incubated 37 degrees C 1 h 100 microl conditioned medium washed twice 100 microl biotin labeled affinity purified goat anti human apoE polyclonal diluted 11000 PBS containing 0
0.29722524.9461617.html.plaintext.txt	84	5 non fat milk added incubated 37 degrees C 30 min
0.29722524.9461617.html.plaintext.txt	85	After washing four times 100 microl streptavidinhorseradish peroxidase Life Technologies Inc
0.29722524.9461617.html.plaintext.txt	86	diluted 11000 PBS containing 0
0.29722524.9461617.html.plaintext.txt	87	5 non fat milk added plate incubated 37 degrees C 30 min
0.29722524.9461617.html.plaintext.txt	88	The plate washed six times 150 microl 3355 tetramethylbenzidine liquid substrate Sigma added color development monitored 650 nm
0.29722524.9461617.html.plaintext.txt	89	A standard curve generated purified human apoE Panvera concentrations ranging 1 50 ng
0.29722524.9461617.html.plaintext.txt	90	Samples assayed triplicate
0.29722524.9461617.html.plaintext.txt	91	Parental apoE3 apoE4 Neuro 2a cell lines trypsinized plated low cell densities days 4 2
0.29722524.9461617.html.plaintext.txt	92	At time 0 cells trypsinized exactly 2 min subsequently plated medium A density 2
0.29722524.9461617.html.plaintext.txt	93	After 2 h 37 degrees C medium removed dish washed twice basal medium medium A lacking FBS freshly made basal medium plus N2 growth supplement Life Technologies Inc
0.29722524.9461617.html.plaintext.txt	94	either without rabbit VLDL 40 microg cholesterolml added
0.29722524.9461617.html.plaintext.txt	95	Cells incubated 96 h 37 degrees C 1 medium change 48 h
0.29722524.9461617.html.plaintext.txt	96	At 96 h cells fixed PBS containing 2
0.29722524.9461617.html.plaintext.txt	97	5 glutaraldehyde 30 min room temperature nonspecifically stained 0
0.29722524.9461617.html.plaintext.txt	98	002 acridine orange PBS 30 min
0.29722524.9461617.html.plaintext.txt	99	Cells washed three times PBS coverslipped
0.29722524.9461617.html.plaintext.txt	100	Images captured 20 x objective filter group specific rhodamine fluorescence system stated
0.29722524.9461617.html.plaintext.txt	101	Images converted TIF format analyzed UTHSCSA Image Tool program developed University Texas Health Science Center San Antonio TX
0.29722524.9461617.html.plaintext.txt	102	2 Every cell contained process longer cell diameter measured longest neurite
0.29722524.9461617.html.plaintext.txt	103	Initial samples contained microsphere calibration standards Duke Scientific Corp
0.29722524.9461617.html.plaintext.txt	104	Affinity Purification Apolipoprotein E Lipid Particles
0.29722524.9461617.html.plaintext.txt	105	An affinity chromatography isolation procedure utilizing human apoE specific monoclonal antibody 1E employed
0.29722524.9461617.html.plaintext.txt	106	Purified 1E antibody coupled CNBr activated Sepharose 4B Sigma incubating 10 mg antibody 0
0.29722524.9461617.html.plaintext.txt	107	5 M NaCl 2 ml pre swelled CNBr activated Sepharose 4B rotary shaker overnight 4 degrees C
0.29722524.9461617.html.plaintext.txt	108	The gel washed 10 ml 0
0.29722524.9461617.html.plaintext.txt	109	5 M NaCl remaining active groups blocked 2 h 1 M ethanolamine pH 8
0.29722524.9461617.html.plaintext.txt	110	The gel washed three cycles alternating pH using 10 ml 0
0.29722524.9461617.html.plaintext.txt	111	The coupled gel packed glass column conditioned media cells secreting apoE3 recycled 1 mlmin overnight 4 degrees C
0.29722524.9461617.html.plaintext.txt	112	The column washed 100 ml PBS apoE3 containing particles eluted 60 ml 100 mM triethylamine pH 11
0.29722524.9461617.html.plaintext.txt	113	5 immediately neutralized 20 ml 1 M sodium phosphate pH 6
0.29722524.9461617.html.plaintext.txt	114	The apoE3 particles dialyzed concentrated PBS subsequently basal medium using Centriprep 50 concentrators Amicon
0.29722524.9461617.html.plaintext.txt	115	The final apoE3 preparation sterilized filtration pre blocked 1 bovine serum albumin PBS 0
0.29722524.9461617.html.plaintext.txt	116	2 microm filter Schleicher Schuell
0.29722524.9461617.html.plaintext.txt	117	Each apoE3 preparation analyzed Western blotting quantified ELISA described
0.29722524.9461617.html.plaintext.txt	118	Trans addition Analysis Affinity Purified ApoE Particles
0.29722524.9461617.html.plaintext.txt	119	Parental Neuro 2a cells plated density 2
0.29722524.9461617.html.plaintext.txt	120	0 x 103 cells per well 24 well tissue culture plate Costar medium A
0.29722524.9461617.html.plaintext.txt	121	After 2 h 37 degrees C medium removed dish washed twice basal medium medium A lacking FBS incubation continued 48 h 37 degrees C either basal medium plus N2 supplement alone immunopurified apoE3 30 microgml basal medium plus N2 supplements
0.29722524.9461617.html.plaintext.txt	122	The cells fixed stained analyzed stated
0.29722524.9461617.html.plaintext.txt	123	All microscopy experiments coded confocal image analysis neurite measurements using double blind coding procedures
0.29722524.9461617.html.plaintext.txt	124	Preparation rabbit VLDL described 27 except protease inhibitors omitted
0.29722524.9461617.html.plaintext.txt	125	Rabbit VLDL stored 4 degrees C nitrogen used within 2 weeks isolation
0.29722524.9461617.html.plaintext.txt	126	225 gml isolated standard ultracentrifugation techniques 28
0.29722524.9461617.html.plaintext.txt	127	The lipidation state apoE secreted Neuro 2a cells determined ultracentrifugation using KBr density adjustment
0.29722524.9461617.html.plaintext.txt	128	Conditioned medium 4 ml adjusted 1
0.29722524.9461617.html.plaintext.txt	129	20 gml underlaid 4 ml 1
0.29722524.9461617.html.plaintext.txt	130	34 gml overlaid 4 ml 1
0.29722524.9461617.html.plaintext.txt	131	Gradients centrifuged 38000 rpm SW41 rotor 48 h 18 degrees C
0.29722524.9461617.html.plaintext.txt	132	Fractions collected top tube density measured weight apoE content determined ELISA
0.29722524.9461617.html.plaintext.txt	133	Secreted apoE delipidated diethyl etherethanol described 29
0.29722524.9461617.html.plaintext.txt	134	Protein measured IgG standard 30
0.29722524.9461617.html.plaintext.txt	135	Statistical significance determined Students test
0.29722524.9461617.html.plaintext.txt	136	RESULTS Top Abstract Introduction Procedures Results Discussion References
0.29722524.9461617.html.plaintext.txt	137	High capacity expression vectors stable expression human apoE constructed incorporating alpha mosaic virus translational enhancer apoE 5 untranslated region within pcDNA3 vector expression driven strong cytomegalovirus promoterenhancer Invitrogen
0.29722524.9461617.html.plaintext.txt	138	Multiple cell lines apoE isoform isolated characterized apoE production
0.29722524.9461617.html.plaintext.txt	139	1 shows similar levels apoE3 apoE4 mRNAs representative cell lines expressing transfected apoE cDNA whereas apoE mRNA detected parental cell line
0.29722524.9461617.html.plaintext.txt	140	Conditioned media cell lines analyzed Western blotting using affinity purified apoE polyclonal antibody shown Fig
0.29722524.9461617.html.plaintext.txt	141	The parent Neuro 2a cell line completely devoid apoE immunoreactivity whereas apoE3 apoE4 cell lines showed expected 36 kDa apoE band
0.29722524.9461617.html.plaintext.txt	142	Quantification apoE accumulation conditioned medium showed high levels expression apoE3 apoE4 cell lines Table I
0.29722524.9461617.html.plaintext.txt	143	These values approximately 100 fold greater previously reported apoE expressing Neuro 2a cell lines 22
0.29722524.9461617.html.plaintext.txt	144	View larger version 40K Fig
0.29722524.9461617.html.plaintext.txt	145	Northern blotting apoE mRNA stably transfected cell lines
0.29722524.9461617.html.plaintext.txt	146	Total RNA 25 microglane prepared parental Neuro 2a line apoE3 expressing apoE4 expressing Neuro 2a cell lines denatured separated electrophoresis 1
0.29722524.9461617.html.plaintext.txt	147	After transfer nylon membrane RNA visualized ethidium bromide staining verify equal amounts intact RNA present A
0.29722524.9461617.html.plaintext.txt	148	The membrane probed 32P random primed apoE fragment nucleotides 209 653 hybridization visualized Molecular Dynamics PhosphorImager B
0.29722524.9461617.html.plaintext.txt	149	View larger version 55K Fig
0.29722524.9461617.html.plaintext.txt	150	Western blotting apoE secreted stably transfected cell lines
0.29722524.9461617.html.plaintext.txt	151	Conditioned media 100 microg protein separated SDS 10 polyacrylamide gel electrophoresis electroblotted nitrocellulose membrane
0.29722524.9461617.html.plaintext.txt	152	The membrane probed affinity purified polyclonal goat anti human apoE antibody
0.29722524.9461617.html.plaintext.txt	153	After incubation horseradish peroxidase conjugated anti goat IgG bands visualized enhanced chemiluminescence
0.29722524.9461617.html.plaintext.txt	154	The slight difference mobility apoE3 apoE4 bands due curvature running front seen experiments
0.29722524.9461617.html.plaintext.txt	155	View table Table I Apolipoprotein E secretion ApoE concentration measured two clones expressing apoE isoform parental Neuro 2a cells
0.29722524.9461617.html.plaintext.txt	156	Each cell line plated 2
0.29722524.9461617.html.plaintext.txt	157	0 x 104 cells per 60 mm dish medium A incubated 37 degrees C 2 h
0.29722524.9461617.html.plaintext.txt	158	The plates washed basal medium 4 ml medium B basal N2 supplements added plates incubated 37 degrees C 48 h
0.29722524.9461617.html.plaintext.txt	159	Triplicate plates cell line analyzed apoE accumulation medium ELISA total cell protein determined 48 h
0.29722524.9461617.html.plaintext.txt	160	Triplicate plates cell line also allowed continue another 48 h fresh medium B prior measurements apoE total cell protein
0.29722524.9461617.html.plaintext.txt	161	The apoE values means plus minus standard deviation
0.29722524.9461617.html.plaintext.txt	162	Neurite extensions measured cell line described legend Fig
0.29722524.9461617.html.plaintext.txt	163	Immunocytochemical localization Neuro 2a associated apoE showed punctate staining pattern throughout entire cell exception nucleus devoid staining Fig
0.29722524.9461617.html.plaintext.txt	164	ApoE staining particularly concentrated within growth cones extending neurites apoE3 apoE4 expressing cells
0.29722524.9461617.html.plaintext.txt	165	Each analyses indicated detectable apoE expression parental cell line importantly similar levels apoE expression apoE3 apoE4 cell lines
0.29722524.9461617.html.plaintext.txt	166	View larger version 64K Fig
0.29722524.9461617.html.plaintext.txt	167	Immunocytochemical detection apoE stably transfected cell lines
0.29722524.9461617.html.plaintext.txt	168	Neuro 2a parental cells A B Neuro 2a apoE3 secreting cells C Neuro 2a apoE4 secreting cells D grown glass coverslips
0.29722524.9461617.html.plaintext.txt	169	ApoE localization detected affinity purified polyclonal goat anti human apoE antibody rhodamine conjugated secondary antibody A C D
0.29722524.9461617.html.plaintext.txt	170	The white arrows highlight concentrated localization apoE growth cone domains apoE isoform expressing Neuro 2a cells
0.29722524.9461617.html.plaintext.txt	171	B transmitted light image parental Neuro 2a cells found A black arrows highlight 2 Neuro 2a cells
0.29722524.9461617.html.plaintext.txt	172	All images collected confocal microscopy 40 x oil immersion lens
0.29722524.9461617.html.plaintext.txt	173	The cell lines analyzed neurite extension assay
0.29722524.9461617.html.plaintext.txt	174	4A shows representative confocal images three cell lines conclusion 96 h assay absence VLDL
0.29722524.9461617.html.plaintext.txt	175	Strikingly cells secreting apoE3 substantially longer neurite extensions either apoE4 control cells
0.29722524.9461617.html.plaintext.txt	176	To quantify differences multiple images saved three independent experiments analyzed neurite length
0.29722524.9461617.html.plaintext.txt	177	5A demonstrates apoE3 secreting cell line significantly longer neurites 214 p 0
0.29722524.9461617.html.plaintext.txt	178	0001 versus control either control set 100 apoE4 secreting cells 114 absence VLDL
0.29722524.9461617.html.plaintext.txt	179	The data analyzed ascertain whether observed mean differences indicative uniform behavior within cell population due minor subpopulation cells dramatically longer neurites
0.29722524.9461617.html.plaintext.txt	180	5B illustrates distribution neurite lengths shifted throughout cell population apoE3 secreting cells whereas apoE4 secreting cells nearly indistinguishable control cells
0.29722524.9461617.html.plaintext.txt	181	View larger version 91K Fig
0.29722524.9461617.html.plaintext.txt	182	Cell derived apoE isoform effects neurite outgrowth absence presence VLDL
0.29722524.9461617.html.plaintext.txt	183	Cells grown 96 h N2 supplemented basal medium alone A presence VLDL 40 microg cholesterolml B
0.29722524.9461617.html.plaintext.txt	184	Cells fixed permeabilized nonspecifically stained acridine orange conclusion 96 h assay
0.29722524.9461617.html.plaintext.txt	185	Confocal images captured using 20 x objective filter group specific rhodamine fluorescence
0.29722524.9461617.html.plaintext.txt	186	The figure shows negative images transformed Image Tool program
0.29722524.9461617.html.plaintext.txt	187	View larger version 17K Fig
0.29722524.9461617.html.plaintext.txt	188	Quantification cell derived apoE isoform effects neurite outgrowth absence presence VLDL
0.29722524.9461617.html.plaintext.txt	189	Cells grown 96 h N2 supplemented basal medium alone presence VLDL 40 microg cholesterolml
0.29722524.9461617.html.plaintext.txt	190	Cells fixed permeabilized nonspecifically stained acridine orange
0.29722524.9461617.html.plaintext.txt	191	Multiple confocal images treatment three cell lines captured using 20 x objective analyzed Image Tool program
0.29722524.9461617.html.plaintext.txt	192	Neurite extensions determined measuring longest neurite outgrowth 60 90 responsive cells cells containing neurite least 1 cell diameter length
0.29722524.9461617.html.plaintext.txt	193	A shows average neurite extensions three independent experiments absence presence VLDL error bars indicate standard error
0.29722524.9461617.html.plaintext.txt	194	The level significance differences calculated apoE3 secreting cells compared control Neuro 2a cells absence VLDL p 0
0.29722524.9461617.html.plaintext.txt	195	0001 apoE3 secreting cells absence VLDL compared apoE3 secreting cells presence VLDL p 0
0.29722524.9461617.html.plaintext.txt	196	These data analyzed determine percentage total cells N expressing neurites defined lengths absence VLDL B presence VLDL C
0.29722524.9461617.html.plaintext.txt	197	Error bars B C indicate standard deviation
0.29722524.9461617.html.plaintext.txt	198	Error bars shown within area symbol
0.29722524.9461617.html.plaintext.txt	199	The apoE concentration medium 48 96 h extension assay measured two clonal lines expressing apoE isoform
0.29722524.9461617.html.plaintext.txt	200	Table I shows variation secreted apoE yet neurite extension results clones consistent isoform specific modulation relatively unaffected small differences secreted apoE
0.29722524.9461617.html.plaintext.txt	201	For example 1C 1E4C clones showed identical apoE concentrations 48 h 1E4C apoE concentration differed 1C concentration 20 96 h
0.29722524.9461617.html.plaintext.txt	202	Nevertheless apoE3 expressing 1C clone showed stimulation neurite outgrowth p 0
0.29722524.9461617.html.plaintext.txt	203	0001 whereas apoE4 expressing 1E4C clone
0.29722524.9461617.html.plaintext.txt	204	These data indicate cell derived apoE3 stimulated neurite outgrowth absence VLDL whereas identical conditions apoE4 neutral
0.29722524.9461617.html.plaintext.txt	205	4B shows images cell lines 96 h exposure VLDL
0.29722524.9461617.html.plaintext.txt	206	Surprisingly addition VLDL extension assays reduced apoE3 neurite extensions compared apoE3 extensions absence VLDL
0.29722524.9461617.html.plaintext.txt	207	5A VLDL reduced neurite outgrowth apoE3 expressing cells 214 control 128 control p 0
0.29722524.9461617.html.plaintext.txt	208	0005 whereas VLDL significant effect p 0
0.29722524.9461617.html.plaintext.txt	209	05 neurite outgrowth control Neruo 2a apoE4 expressing cell lines
0.29722524.9461617.html.plaintext.txt	210	5C VLDL appeared normalize neurite length distribution three cell lines
0.29722524.9461617.html.plaintext.txt	211	Thus VLDL inhibited neurite outgrowth apoE3 expressing cells p 0
0.29722524.9461617.html.plaintext.txt	212	0005 effect control apoE4 expressing cells p 0
0.29722524.9461617.html.plaintext.txt	213	An important question results whether effect apoE3 neurite outgrowth reflected extracellular action secreted protein
0.29722524.9461617.html.plaintext.txt	214	Alternative possibilities effect due intracellular apoE indirect result high level apolipoprotein secretion might perturb lipid homeostasis within cell
0.29722524.9461617.html.plaintext.txt	215	To test possibilities isolated secreted apoE3 conditioned medium affinity chromatography monoclonal antibody 1E
0.29722524.9461617.html.plaintext.txt	216	A series five trans addition experiments performed isolated apoE3 30 microgml incubated parental Neuro 2a cells 48 h extension assay
0.29722524.9461617.html.plaintext.txt	217	6A illustrates immunopurified apoE3 maintained ability stimulate significant increase average neurite length 154 control p 0
0.29722524.9461617.html.plaintext.txt	218	Furthermore population distribution neurite lengths cells treated purified apoE3 closely resembled distribution seen transfected apoE3 cell line absence VLDL Fig
0.29722524.9461617.html.plaintext.txt	219	View larger version 16K Fig
0.29722524.9461617.html.plaintext.txt	220	Effect immunopurified apoE3 neurite outgrowth Neuro 2a cells
0.29722524.9461617.html.plaintext.txt	221	Neuro 2a cells incubated N2 supplemented basal medium alone presence 30 microgml cell derived apoE3 48 h
0.29722524.9461617.html.plaintext.txt	222	Cells fixed permeabilized nonspecifically stained acridine orange
0.29722524.9461617.html.plaintext.txt	223	Multiple confocal images either treatment captured using 20 x objective analyzed Image Tool program
0.29722524.9461617.html.plaintext.txt	224	Average neurite extensions determined measuring longest neurite 30 80 responsive cells five independent experiments A
0.29722524.9461617.html.plaintext.txt	225	The error bars indicate standard error
0.29722524.9461617.html.plaintext.txt	226	The level significance difference p 0
0.29722524.9461617.html.plaintext.txt	227	These data analyzed determine percentage Neuro 2a cells N expressing neurites defined lengths B
0.29722524.9461617.html.plaintext.txt	228	Error bars indicate standard deviation
0.29722524.9461617.html.plaintext.txt	229	Previous studies shown apoE secreted non hepatic cells poorly lipidated 31 32
0.29722524.9461617.html.plaintext.txt	230	Therefore lipidation state apoE secreted Neuro 2a cells determined density gradient ultracentrifugation
0.29722524.9461617.html.plaintext.txt	231	Both secreted apoE isoforms floated density 1
0.29722524.9461617.html.plaintext.txt	232	26 gml indicating poorly lipidated particle Fig
0.29722524.9461617.html.plaintext.txt	233	None secreted apoE density typical apoE containing plasma HDL Fig
0.29722524.9461617.html.plaintext.txt	234	7C secreted apoE shifted higher density upon delipidation Fig
0.29722524.9461617.html.plaintext.txt	235	These results indicate physiologically relevant lipid poor form secreted apoE3 enhanced neurite outgrowth
0.29722524.9461617.html.plaintext.txt	236	View larger version 25K Fig
0.29722524.9461617.html.plaintext.txt	237	Density distribution Neuro 2a derived apoE
0.29722524.9461617.html.plaintext.txt	238	Cell derived apoE isoforms analyzed density distribution density gradient ultracentrifugation
0.29722524.9461617.html.plaintext.txt	239	Conditioned media apoE3 apoE4 expressing Neuro 2a cells centrifuged KBr density gradients 48 h fractions taken top tube
0.29722524.9461617.html.plaintext.txt	240	Fractions assayed ELISA apoE content densities determined weight
0.29722524.9461617.html.plaintext.txt	241	The graphs show percent total apoE3 A apoE4 B apoE HDL3 C delipidated apoE3 comparison apoE3 conditioned medium D per fraction
0.29722524.9461617.html.plaintext.txt	242	DISCUSSION Top Abstract Introduction Procedures Results Discussion References
0.29722524.9461617.html.plaintext.txt	243	We produced high expressing apoE3 apoE4 Neuro 2a cell lines test whether cell derived apoE could exhibit isoform specific stimulation neurite outgrowth absence exogenous lipid source
0.29722524.9461617.html.plaintext.txt	244	ApoE3 stimulated neurite outgrowth absence VLDL exogenous lipid sources
0.29722524.9461617.html.plaintext.txt	245	Furthermore cell derived lipidated apoE3 isolated immunoaffinity chromatography active promoting neurite outgrowth parental Neuro 2a cells
0.29722524.9461617.html.plaintext.txt	246	14 discovered co addition purified delipidated apoE VLDL Neuro 2a cells elicits isoform specific differences neurite outgrowth effects also seen cell lines primary neuronal cultures 20 23 33
0.29722524.9461617.html.plaintext.txt	247	Interestingly isoform specific effects could duplicated apoE addition alone
0.29722524.9461617.html.plaintext.txt	248	Similarly Neuro 2a cell lines express low amounts apoE isoforms also required VLDL elicit effects neurite outgrowth 22
0.29722524.9461617.html.plaintext.txt	249	It unclear studies whether apoE3 stimulates neurite outgrowth independently concert exogenous lipid whether active form apoE formed combined exogenous lipid source
0.29722524.9461617.html.plaintext.txt	250	Our results indicated biological activity apoE3 stimulating neurite outgrowths inherent cell derived lipidated particle dependent either interaction apoE3 artificial lipid source b independent actions apoE3 VLDL Neuro 2a cells
0.29722524.9461617.html.plaintext.txt	251	We demonstrated cell derived apoE4 neutral challenged neurite extension assay absence VLDL
0.29722524.9461617.html.plaintext.txt	252	Although studies implicated apoE4 inhibitory neurite outgrowth presence artificial lipid source 14 22 studies support conclusion apoE4 neutral
0.29722524.9461617.html.plaintext.txt	253	21 showed apoE3 enhancement neurite outgrowth neuronal cell line GT1 1 trk9 presence VLDL nerve growth factor significant difference apoE4 treated cells controls conditions
0.29722524.9461617.html.plaintext.txt	254	Experiments GT1 1 trk9 cells give similar results HDL sized particles human CSF substituted VLDL 23
0.29722524.9461617.html.plaintext.txt	255	In studies Puttfarcken et al
0.29722524.9461617.html.plaintext.txt	256	34 showed bulk conditioned medium HEK 293 cells stably expressing either apoE3 apoE4 isoforms moderately stimulatory primary hippocampal cultures
0.29722524.9461617.html.plaintext.txt	257	These experiments 21 34 well present results argue apoE4 isoform devoid neurite stimulating activity inhibitory presented cells alone combination exogenous lipids cell derived lipidated particle
0.29722524.9461617.html.plaintext.txt	258	When present neurite extension assay VLDL antagonized stimulatory effect apoE3 effect detected previous studies VLDL required effect delipidated apoE 14 20 23 33
0.29722524.9461617.html.plaintext.txt	259	It may experiments delipidated apoE VLDL acts lipid source facilitate formation active apoE particle time antagonizes action lipidated apoE
0.29722524.9461617.html.plaintext.txt	260	In case level apoE3 stimulated neurite outgrowth would depend balance two factors
0.29722524.9461617.html.plaintext.txt	261	Furthermore unlikely antagonism observed present study nonspecific cytotoxic effect VLDL alone modestly stimulated neurite outgrowth 111 effect also observed others 14 20 22
0.29722524.9461617.html.plaintext.txt	262	The antagonism VLDL may reflect sequestration secreted apoE competition cellular receptor site
0.29722524.9461617.html.plaintext.txt	263	Cell derived apoE occurred poorly lipidated particle density 1
0.29722524.9461617.html.plaintext.txt	264	Because minimally lipidated form apoE biologically active absence exogenous lipid source unlikely neurite outgrowth stimulation reflects action apoE simply deliver lipid cell membrane formation
0.29722524.9461617.html.plaintext.txt	265	We speculate apoE acted extracellularly direct neurite extension paracrine factor stimulate neurite growth
0.29722524.9461617.html.plaintext.txt	266	How lipidated apoE3 particle stimulate neurite outgrowth although apoE4 remains neutral The LDL receptor LDL receptor related protein LRP bind apoE containing lipoproteins expressed neuronal cells 35 37
0.29722524.9461617.html.plaintext.txt	267	Evidence several studies implicate LRP apoE isoform specific stimulation neurite outgrowth 21 22 38
0.29722524.9461617.html.plaintext.txt	268	In particular inhibition apoE3 effect neurite outgrowth anti LRP antibodies provides strong evidence involvement LRP
0.29722524.9461617.html.plaintext.txt	269	However binding studies LRP show isoform specific differences apoE3 apoE4 27
0.29722524.9461617.html.plaintext.txt	270	This discrepancy may resolved recent reports apoE receptors
0.29722524.9461617.html.plaintext.txt	271	A new apoE receptor described localizes neurons high homology LDL receptor 39
0.29722524.9461617.html.plaintext.txt	272	Additional brain specific receptors high homology LRP 40 LDL receptor 41 also identified
0.29722524.9461617.html.plaintext.txt	273	The present findings cell derived form apoE3 active stimulating neurite outgrowth permit physical characterization particles analysis isoform specific interactions recently described neuronal receptors
0.29722524.9461617.html.plaintext.txt	274	We thank Miguel Berrios William Theurkauf advice confocal microscopy David Colflesh Katherine Richards Anna Demian technical assistance
0.29722524.9461617.html.plaintext.txt	275	This work supported Grants HL 32868 HL 35297 NHLBI National Institutes Health
0.29722524.9461617.html.plaintext.txt	276	The costs publication article defrayed part payment page charges
0.29722524.9461617.html.plaintext.txt	277	The article must therefore hereby marked advertisement accordance 18 U
0.29722524.9461617.html.plaintext.txt	278	Section 1734 solely indicate fact
0.29722524.9461617.html.plaintext.txt	279	To correspondence addressed Dept
0.29722524.9461617.html.plaintext.txt	280	Pharmacological Sciences University Medical Center State University New York Stony Brook NY 11794
0.29722524.9461617.html.plaintext.txt	281	516 444 3083 Fax 516 444 3218 E mail DaveatPharm
0.29722524.9461617.html.plaintext.txt	282	1 The abbreviations used apoE apolipoprotein E VLDL low density lipoprotein LDL low density lipoprotein HDL high density lipoprotein CSF cerebrospinal fluid PBS phosphate buffered saline TBS Tris buffered saline ELISA enzyme linked immunosorbent assay LRP LDL receptor related protein FBS fetal bovine serum PCR polymerase chain reaction
0.29722524.9461617.html.plaintext.txt	283	2 Available internet anonymous FTP ftpmaxrad6
0.29722524.9461617.html.plaintext.txt	284	REFERENCES Top Abstract Introduction Procedures Results Discussion References Weisgraber K
0.29722524.9461617.html.plaintext.txt	285	45 249 302Medline Order article via Infotrieve Blue M
0.29722524.9461617.html.plaintext.txt	286	80 283 287Abstract Williams D
0.29722524.9461617.html.plaintext.txt	287	260 2444 2451Abstract Newman T
0.29722524.9461617.html.plaintext.txt	288	260 2452 2457Abstract Roheim P
0.29722524.9461617.html.plaintext.txt	289	76 4646 4649Abstract Carlsson J
0.29722524.9461617.html.plaintext.txt	290	Acta 196 167 176Medline Order article via Infotrieve Pitas R
0.29722524.9461617.html.plaintext.txt	291	262 14352 14360AbstractFree Full Text Boyles J
0.29722524.9461617.html.plaintext.txt	292	265 17805 17815AbstractFree Full Text Snipes G
0.29722524.9461617.html.plaintext.txt	293	83 1130 1134Abstract Boyles J
0.29722524.9461617.html.plaintext.txt	294	76 1501 1513Medline Order article via Infotrieve Pitas R
0.29722524.9461617.html.plaintext.txt	295	Acta 917 148 161Medline Order article via Infotrieve Ignatius M
0.29722524.9461617.html.plaintext.txt	296	83 1125 1129Abstract Dawson P
0.29722524.9461617.html.plaintext.txt	297	261 5681 5684AbstractFree Full Text Nathan B
0.29722524.9461617.html.plaintext.txt	298	270 19791 19799AbstractFree Full Text Strittmatter W
0.29722524.9461617.html.plaintext.txt	299	90 1977 1981Abstract Goedert M
0.29722524.9461617.html.plaintext.txt	300	1994 Nature 372 45 46Medline Order article via Infotrieve Strittmatter W
0.29722524.9461617.html.plaintext.txt	301	125 163 171CrossRefMedline Order article via Infotrieve Schmechel D
0.29722524.9461617.html.plaintext.txt	302	90 9649 9653Abstract Strittmatter W
0.29722524.9461617.html.plaintext.txt	303	91 11183 11186AbstractFree Full Text Nathan B
0.29722524.9461617.html.plaintext.txt	304	1994 Science 264 850 852Medline Order article via Infotrieve Holtzman D
0.29722524.9461617.html.plaintext.txt	305	92 9480 9484Abstract Bellosta S
0.29722524.9461617.html.plaintext.txt	306	270 27063 27071AbstractFree Full Text Fagan A
0.29722524.9461617.html.plaintext.txt	307	271 30121 30125AbstractFree Full Text Andersson S
0.29722524.9461617.html.plaintext.txt	308	264 8222 8229AbstractFree Full Text Reyland M
0.29722524.9461617.html.plaintext.txt	309	88 2375 2379Abstract Chen C
0.29722524.9461617.html.plaintext.txt	310	7 2745 2752Medline Order article via Infotrieve Kowal R
0.29722524.9461617.html.plaintext.txt	311	265 10771 10779AbstractFree Full Text Havel R
0.29722524.9461617.html.plaintext.txt	312	34 1345 1353Medline Order article via Infotrieve Shore V
0.29722524.9461617.html.plaintext.txt	313	1967 Biochemistry 6 1962 1969Medline Order article via Infotrieve Lowry O
0.29722524.9461617.html.plaintext.txt	314	193 265 275Free Full Text Basu S
0.29722524.9461617.html.plaintext.txt	315	78 7545 7549Abstract Herscivutzm H
0.29722524.9461617.html.plaintext.txt	316	33 791 803Abstract Huang D
0.29722524.9461617.html.plaintext.txt	317	136 251 257CrossRefMedline Order article via Infotrieve Puttfarcken P
0.29722524.9461617.html.plaintext.txt	318	68 760 769Medline Order article via Infotrieve Handelmann G
0.29722524.9461617.html.plaintext.txt	319	33 1677 1688Abstract Zheng G
0.29722524.9461617.html.plaintext.txt	320	42 531 542AbstractFree Full Text Moestrup S
0.29722524.9461617.html.plaintext.txt	321	269 375 382Medline Order article via Infotrieve Narita M
0.29722524.9461617.html.plaintext.txt	322	68 587 595Medline Order article via Infotrieve Kim D
0.29722524.9461617.html.plaintext.txt	323	271 8373 8380AbstractFree Full Text Jacobsen L
0.29722524.9461617.html.plaintext.txt	324	271 31379 31383AbstractFree Full Text Novak S
0.29722524.9461617.html.plaintext.txt	325	271 11732 11736AbstractFree Full Text
0.29722524.9461617.html.plaintext.txt	326	Copyright 1998 The American Society Biochemistry Molecular Biology Inc
0.407656.9328480.html.plaintext.txt	0	Distortion allelic expression apolipoprotein E Alzheimers disease
0.407656.9328480.html.plaintext.txt	1	Jean Charles Lambert12 Jordi Perez Tur13 Marie Joelle Dupire1 Douglas Galasko4 David Mann5 Philippe Amouyel2 John Hardy3 Andre Delacourte1 Marie Christine Chartier Harlin12
0.407656.9328480.html.plaintext.txt	2	1INSERM Unite 422 Place de Verdun 59045 Lille Cedex France 2INSERM CJF95 05 Institut Pasteur de Lille 1 rue de Calmette 59019 Lille Cedex France 3Birdsall Building Mayo Clinic Jacksonville 4500 San Pablo Road Jacksonville FL 32224 USA 4UCSD Medical Centre Pulman Ambulatory Care Centre 9350 Campus Point Drive La Jolla CA 92037 USA 5Department Pathological Sciences Stopford Building University Manchester Oxford Road Manchester M13 9PT UK
0.407656.9328480.html.plaintext.txt	3	Received July 25 1997 Revised Accepted August 2 1997
0.407656.9328480.html.plaintext.txt	4	The APOE epsis4 allele strong genetic susceptibility factor Alzheimers disease
0.407656.9328480.html.plaintext.txt	5	Interaction biological factors may modulate effect apoE isoforms
0.407656.9328480.html.plaintext.txt	6	However previous work suggested genetic variability within APOE locus influencing effect epsis4 allele may exist
0.407656.9328480.html.plaintext.txt	7	Such variability could modify expression APOE gene particular level expression APOE alleles could important determinant disease pathogenesis
0.407656.9328480.html.plaintext.txt	8	To test hypothesis examined levels expression APOE heterozygotes AD controls using new method semi quantitation
0.407656.9328480.html.plaintext.txt	9	We report relative epsis4 mRNA expression increased AD compared controls suggest genetic variability neural expression APOE contributes disease risk
0.407656.9328480.html.plaintext.txt	10	The epsis4 allele APOE gene major risk factor late onset Alzheimers disease LOAD 1 also implicated risk factor early onset disease populations 23
0.407656.9328480.html.plaintext.txt	11	Previous studies described epsis4 homozygotes higher risk developing disease epsis3epsis4 heterozygotes
0.407656.9328480.html.plaintext.txt	12	However individuals bearing one two epsis4 alleles inevitably develop disease
0.407656.9328480.html.plaintext.txt	13	Detailed genetic analysis around APOE locus suggested existence genetic variability region could contribute disease risk 4
0.407656.9328480.html.plaintext.txt	14	There two possible explanations observations another genetically variable locus vicinity APOE gene involved pathogenesis disease ii genetic variability control expression APOE gene 4
0.407656.9328480.html.plaintext.txt	15	There little examination mRNA expression APOE AD 56
0.407656.9328480.html.plaintext.txt	16	The available evidence suggests APOE expression increased neuronal damage 78 bulk expression occurs astrocytes 5
0.407656.9328480.html.plaintext.txt	17	This expression believed part compensatory mechanism aimed aiding reafferentation reactive synaptogenesis 9
0.407656.9328480.html.plaintext.txt	18	Only studies examined expression apoE protein AD cases controls relative APOE genotype 910
0.407656.9328480.html.plaintext.txt	19	suggested amount apoE protein could inversely correlated number epsis4 alleles carried subjects higher levels observed epsis3 homozygotes lower epsis4 homozygotes intermediate levels epsis3epsis4 heterozygotes 10
0.407656.9328480.html.plaintext.txt	20	We hypothesised since epsis4 homozygotes higher risk developing disease epsis3epsis4 heterozygotes high proportion individuals latter genotype reach greater age without developing AD likely explanation genetic variability neural expression APOE locus epsis3epsis4 heterozygote individuals high epsis4 expressors andor low epsis3 expressors likely develop AD individuals high epsis3 expressors andor low epsis4 expressors
0.407656.9328480.html.plaintext.txt	21	The identification APOE allele transcription products easily achieved RT PCR using restriction fragment length polymorphism
0.407656.9328480.html.plaintext.txt	22	We developed semi quantitative assay measure allelic expression APOE mRNA RT PCR using silver staining 11
0.407656.9328480.html.plaintext.txt	23	This method quantitation applied brains heterozygote subjects collected various centres used assess percentage epsis4 mRNA expression epsis3epsis4 epsis2epsis4 subjects epsis2 mRNA expression epsis2epsis3 individuals
0.407656.9328480.html.plaintext.txt	24	This carried AD cases controls
0.407656.9328480.html.plaintext.txt	25	We selected series epsis3epsis4 epsis2epsis4 epsis2epsis3 AD cases n 14 controls n 12 order measure relative level expression APOE allele frontal cortex Fig
0.407656.9328480.html.plaintext.txt	26	We observed epsis3 mRNA expression consistently greater epsis4 mRNA expression cases Fig
0.407656.9328480.html.plaintext.txt	27	In addition clear consistent difference epsis4 allelic expression ratio AD cases controls Fig
0.407656.9328480.html.plaintext.txt	28	2 AD cases showing higher relative expression epsis4 mRNA controls 34
0.407656.9328480.html.plaintext.txt	29	Regarding heterozygous genotypes small size group prevented us reaching definite conclusion
0.407656.9328480.html.plaintext.txt	30	Nevertheless trend towards situation observed epsis3epsis4 group could noted increase expression epsis4 allele epsis2epsis4 group 42
0.407656.9328480.html.plaintext.txt	31	2 control whereas nothing apparent epsis2epsis3 group 39
0.407656.9328480.html.plaintext.txt	32	4 AD case versus 45
0.407656.9328480.html.plaintext.txt	33	Furthermore difference allelic expression ratio epsis2epsis4 epsis3epsis4 AD cases observed since epsis2epsis4 patients showed 1
0.407656.9328480.html.plaintext.txt	34	25 fold increase epsis4 allele ratio P 0
0.407656.9328480.html.plaintext.txt	35	Figure 1 Semi quantitation epsis4 allele ratio control case
0.407656.9328480.html.plaintext.txt	36	The final epsis4 allele ratio calculated data 21
0.407656.9328480.html.plaintext.txt	37	Figure 2 Differential expression APOE mRNA three heterozygote genotypes Alzheimers disease cases controls
0.407656.9328480.html.plaintext.txt	38	The epsis2 mRNA percentage measured epsis2epsis3 population epsis4 mRNA percentage epsis3epsis4 epsis2epsis4 population
0.407656.9328480.html.plaintext.txt	39	The average level expression indicated bold line category
0.407656.9328480.html.plaintext.txt	40	For brain sample RT PCR semi quantitation repeated three times
0.407656.9328480.html.plaintext.txt	41	It important note measurement ratio expression two alleles heterozygotes likely much robust measurement determination absolute levels mRNA expression tissue since latter profoundly affected post mortem delay agonal state cell population density
0.407656.9328480.html.plaintext.txt	42	As seen Figure 2 level expression epsis3 allele consistently higher epsis4 allele AD group well control group
0.407656.9328480.html.plaintext.txt	43	These data suggest either differential stability different mRNA species genetic variability expression two alleles disequilibrium coding polymorphism
0.407656.9328480.html.plaintext.txt	44	However addition clear consistent difference epsis4 allelic expression ratio AD cases controls
0.407656.9328480.html.plaintext.txt	45	These results consistent notion part least genetic risk developing AD encoded APOE locus relates expression protein brain
0.407656.9328480.html.plaintext.txt	46	It would seem heterozygote individuals express relatively high proportion epsis4 allele greater risk developing disease expressing relatively low proportion
0.407656.9328480.html.plaintext.txt	47	The observation different alleles APOE equally expressed may importance formulation hypotheses relating role APOE pathogenesis AD general
0.407656.9328480.html.plaintext.txt	48	At present much speculation experimentation designed determine nature role different alleles APOE pathogenesis AD
0.407656.9328480.html.plaintext.txt	49	As previously suggested E4 isoform may facilitate 12 limit 13 amyloid substance deposition
0.407656.9328480.html.plaintext.txt	50	This isoform would protect oxidative stress conversely E2 isoform 14
0.407656.9328480.html.plaintext.txt	51	Finally suggested E2 E3 isoforms may prevent aggregation Tau protein E4 isoform may prevent paired helical filament formation 15
0.407656.9328480.html.plaintext.txt	52	However hypotheses based premise APOE allele isoforms equally expressed present similar concentrations brain
0.407656.9328480.html.plaintext.txt	53	These isoform specific differences could enhanced different representation isoform individual
0.407656.9328480.html.plaintext.txt	54	To date seems difficult link APOE mRNA apoE protein levels
0.407656.9328480.html.plaintext.txt	55	Several studies explored issue reporting contradictory findings brain 1016 cerebrospinal fluid 1718 plasma 19
0.407656.9328480.html.plaintext.txt	56	But even apoE level tested according APOE genotype none previous studies able determine relative ratio different isoforms thus results comparable
0.407656.9328480.html.plaintext.txt	57	The development isoform specific monoclonal antibodies would help determine whether variation observed population also present protein level 20
0.407656.9328480.html.plaintext.txt	58	There two major findings work
0.407656.9328480.html.plaintext.txt	59	First expression epsis3 allele consistently higher expression epsis4 allele
0.407656.9328480.html.plaintext.txt	60	Second expression epsis4 allele beyond certain level seems greatly influence vulnerability individual Alzheimers disease
0.407656.9328480.html.plaintext.txt	61	It interesting note APOE regulated consequence insult
0.407656.9328480.html.plaintext.txt	62	showed increase level expression APOE mRNA rat lesioning cerebral cortex 6
0.407656.9328480.html.plaintext.txt	63	showed APOE mRNA increased AD brains 5
0.407656.9328480.html.plaintext.txt	64	Together results support event may lead increase APOE mRNA parallel distortion allelic expression
0.407656.9328480.html.plaintext.txt	65	The distortion allelic expression may specific brain possibly restricted certain areas 21
0.407656.9328480.html.plaintext.txt	66	This suggests neural genetic susceptibility AD associated APOE gene
0.407656.9328480.html.plaintext.txt	67	Interestingly Templeton reached similar conclusion using cladistic analysis previously reported genetic data 4
0.407656.9328480.html.plaintext.txt	68	Using haplotype data markers surrounding APOE locus including APOE polymorphism Templeton showed coding polymorphism APOE gene sufficient explain increased risk AD 22
0.407656.9328480.html.plaintext.txt	69	Our data suggest influence non coding polymorphism ApoE expression may supply rest answer
0.407656.9328480.html.plaintext.txt	70	MATERIALS AND METHODS RNA extraction
0.407656.9328480.html.plaintext.txt	71	Fourteen late onset AD cases Caucasian origin mean age 74
0.407656.9328480.html.plaintext.txt	72	8 years five male nine female 12 controls mean age 83
0.407656.9328480.html.plaintext.txt	73	6 years five male seven female selected function APOE genotype 23
0.407656.9328480.html.plaintext.txt	74	The mean age sampling 75
0.407656.9328480.html.plaintext.txt	75	8 years AD cases genotyped epsis3epsis4 77
0.407656.9328480.html.plaintext.txt	76	0 years controls genotyped epsis3epsis4
0.407656.9328480.html.plaintext.txt	77	Diagnoses confirmed neuropathological examination
0.407656.9328480.html.plaintext.txt	78	Total RNA extraction performed frontal lobe samples described Gilmour et al
0.407656.9328480.html.plaintext.txt	79	24 digested DNase Eurogentec
0.407656.9328480.html.plaintext.txt	80	No DNA contamination observed DNase digestion detected PCR digested product
0.407656.9328480.html.plaintext.txt	81	RT PCR amplification APOE mRNAs
0.407656.9328480.html.plaintext.txt	82	The RT reaction performed 1 h 30 min 37 degrees C using F4 primer 5prime ACAGAATTCGCCCCGGCCTGGTA 3prime 50 pmol 1 mug total RNA template M MLV reverse transcriptase following conditions described supplier GibcoBRL
0.407656.9328480.html.plaintext.txt	83	The PCR step carried F6 primer 5prime TAAGCTTGGCACGGCTGTCCAAGGA 3prime 50 pmol final volume 10 mul 30 cycles 1 min 94 degrees C 1 min 58 degrees C 1 min 72 degrees C cycle remain linear range reaction
0.407656.9328480.html.plaintext.txt	84	Briefly PCR performed total volume 25 mul containing 1
0.407656.9328480.html.plaintext.txt	85	2 mM dNTP 4 mM DTT 0
0.407656.9328480.html.plaintext.txt	86	04 Triton X 100 10 vv glycerol using whole RT reaction template
0.407656.9328480.html.plaintext.txt	87	RT PCR DNA digested 12 U CfoI endonuclease Promega DNA fragments resolved 8 polyacrylamide gel acrylamidebisacrylamide 191 4 h 12 Vcm
0.407656.9328480.html.plaintext.txt	88	2 mul RT PCR product loaded
0.407656.9328480.html.plaintext.txt	89	The gel fixed 90 min 10 vv ethanol 0
0.407656.9328480.html.plaintext.txt	90	After two washings deionised water gel placed silver nitrate solution 1 mgml 25 min
0.407656.9328480.html.plaintext.txt	91	The gel washed twice deionised water
0.407656.9328480.html.plaintext.txt	92	The DNA polymorphism fragments stained 30 min 0
0.407656.9328480.html.plaintext.txt	93	037 formaldehyde vv hydroxyde nitrate 15 mgml
0.407656.9328480.html.plaintext.txt	94	Finally reaction stopped sodium carbonate solution 15 mgml
0.407656.9328480.html.plaintext.txt	95	The developer silver nitrate solutions prepared extemporaneously
0.407656.9328480.html.plaintext.txt	96	The gel digitalised Sharp JX 325 high resolution colour scanner fragment intensity measured using Image Master Software Pharmacia appropriate background subtract
0.407656.9328480.html.plaintext.txt	97	The percentage epsis4 allele calculated equation described ref
0.407656.9328480.html.plaintext.txt	98	roman N o sup epsilon roman 4 m R N A roman N o sup epsilon roman 4 m R N A roman N o sup epsilon roman 2 o r epsilon roman 3 m R N A roman A alpha sup prime epsilon roman 4 m R N A roman A alpha sup prime epsilon roman 4 m R N A alpha sup prime epsilon roman 2 o r epsilon roman 3 m R N A
0.407656.9328480.html.plaintext.txt	99	Noepsis4 mRNA Noepsis3 mRNA initial number epsis3 epsis4 mRNAs
0.407656.9328480.html.plaintext.txt	100	alphaprimeepsis4 mRNA alphaprimeepsis2 epsis3 mRNA coefficients allowing silver staining phenomenon saturation due staining integrated normalised
0.407656.9328480.html.plaintext.txt	101	A coefficient proportionality correcting length difference restriction fragments
0.407656.9328480.html.plaintext.txt	102	After digestion CfoI epsis3 epsis2 epsis4 alleles characterised 91 83 72 bp fragments respectively
0.407656.9328480.html.plaintext.txt	103	The A coefficient therefore calculated A 9172 epsis3epsis4 individuals A 8372 epsis2epsis4 individuals A 9183 epsis2epsis3 population
0.407656.9328480.html.plaintext.txt	104	Because epsis2 epsis3 alleles give restriction length fragment 91 bp AODepsis2 mRNA ODepsis3 mRNA OD91 bp
0.407656.9328480.html.plaintext.txt	105	The initial epsis2 allele percentage epsis2epsis3 population calculated
0.407656.9328480.html.plaintext.txt	106	roman N o sup epsilon roman 2 m R N A roman N o sup epsilon roman 2 m R N A roman N o sup epsilon roman 3 m R N A roman A alpha sup roman prime epsilon roman 2 m R N A alpha prime sup 9 1 roman b p
0.407656.9328480.html.plaintext.txt	107	Details calculations modelling method described ref
0.407656.9328480.html.plaintext.txt	108	We tested viability approach APOE alleles using genomic DNA template different parameters initial concentrations DNA template initial percentage allele compared another 11
0.407656.9328480.html.plaintext.txt	109	Linear regressions necessary perform ratio percentage Mann Whitney U test performed using SAS software release 6
0.407656.9328480.html.plaintext.txt	110	1993 Association apolipoprotein E allele epsis4 late onset familial sporadic Alzheimers disease
0.407656.9328480.html.plaintext.txt	111	1995 Reduced survival patients early onset Alzheimers disease carry Apolipoprotein Egr2 allele
0.407656.9328480.html.plaintext.txt	112	French Alzheimers disease collaborative group 1995 Evidence apolipoprotein E epsis4 association early onset Alzheimers patients late onset relatives
0.407656.9328480.html.plaintext.txt	113	1994 Apolipoprotein E epsis4 allele major risk factor sporadic early late onset forms Alzheimers disease analysis 19q13
0.407656.9328480.html.plaintext.txt	114	1991 Neuropathological changes Scrapie Alzheimers disease associated increased expression Apolipoprotein E Cathepsin D astrocytes
0.407656.9328480.html.plaintext.txt	115	1991 Astrocytic apolipoprotein E mRNA GFAP mRNA hippocampus entorhinal cortex lesioning
0.407656.9328480.html.plaintext.txt	116	1988 Apolipoprotrein E cholesterol transport protein expanding role cell biology
0.407656.9328480.html.plaintext.txt	117	1990 Regulation Apolipoprotein E gene expression injury rat sciatic nerve
0.407656.9328480.html.plaintext.txt	118	1995 Low density lipoprotein pathways central nervous system Apolipoprotein E isoform specific differences
0.407656.9328480.html.plaintext.txt	119	In Iqbal Mortimer Winblad Wisniewski eds Research Advances Alzheimers Disease Related Disorders
0.407656.9328480.html.plaintext.txt	120	1995 Association apolipoprotein E genotype brain levels apolipoprotein E apolipoprotein J clusterin Alzheimer disease
0.407656.9328480.html.plaintext.txt	121	1997 Overcoming normalisation signal saturation due silver staining way quantify allele specific RT PCR products
0.407656.9328480.html.plaintext.txt	122	1993 Binding human apolipoprotein E synthetic amyloid beta peptide isoform specific effects implications late onset Alzheimer disease
0.407656.9328480.html.plaintext.txt	123	1995 Apolipoprotein E kinetic thermodynamic inhibitor amyloid formation implication pathogenesis treatment Alzheimers disease
0.407656.9328480.html.plaintext.txt	124	1996 Apolipoprotein E allele specific antioxidant activity effects cytotoxicity oxidative insults beta amyloid peptides
0.407656.9328480.html.plaintext.txt	125	1994 Hypothesis microtubule instability paired helical filament formation Alzheimer disease related Apolipoprotein E genotype
0.407656.9328480.html.plaintext.txt	126	1996 Brain expression Apolipoprotein E J A I Alzheimers disease
0.407656.9328480.html.plaintext.txt	127	1995 Apolipoprotein E apoE polymorphism influence ApoE concentrations cerebrospinal fluid Finnish patients Alzheimers disease
0.407656.9328480.html.plaintext.txt	128	1996 Relevance quantification apolipoprotein E cerebrospinal fluid Alzheimers disease
0.407656.9328480.html.plaintext.txt	129	1997 Increased plasma apolipoprotein E apoE levels Alzheimers disease
0.407656.9328480.html.plaintext.txt	130	1995 Monoclonal antibody polymorphic site distinguishes apolipoprotein Egr4 isoforms
0.407656.9328480.html.plaintext.txt	131	1996 Accumulation apolipoprotein E b amyloid like protein trace hippocampal CA1 pyramidal cell layer ischaemic delayed neuronal death Neuroreport 7 3063 3067
0.407656.9328480.html.plaintext.txt	132	1995 A cladistic analysis phenotypic associations haplotypes inferred restriction endonuclease mapping DNA sequencing
0.407656.9328480.html.plaintext.txt	133	Analysis casecontrol sampling designs Alzheimers disease Apolipoprotein E locus
0.407656.9328480.html.plaintext.txt	134	1991 Restriction isotyping human apolipoprotein E gene amplification cleavage HhaI
0.407656.9328480.html.plaintext.txt	135	1972 Biosynthesis protamine trout testis
0.407656.9328480.html.plaintext.txt	136	To correspondence addressed INSERM CJF95 05 Institut Pasteur de Lille 1 rue de Calmette 59019 Lille Cedex France
0.407656.9328480.html.plaintext.txt	137	Tel 33 3 20 87 72 28 Fax 33 3 20 87 78 94 Email marie christine
0.407656.9328480.html.plaintext.txt	138	fr This page maintained OUP admin
0.407656.9328480.html.plaintext.txt	139	Last updated Sat Oct 18 134119 BST 1997
0.407656.9328480.html.plaintext.txt	140	Part OUP Journals World Wide Web service
0.407656.9328480.html.plaintext.txt	141	Copyright Oxford University Press 1997
0.3375625.15328426.html.plaintext.txt	0	Presence apolipoprotein E 4 allele predisposes early onset primary Sjogrens syndrome M
0.3375625.15328426.html.plaintext.txt	1	Tampere University Hospital 1 University Tampere Medical School Tampere University Hospital Tampere Finland
0.3375625.15328426.html.plaintext.txt	2	Pertovaara Department Internal Medicine Section Rheumatology Tampere University Hospital P
0.3375625.15328426.html.plaintext.txt	3	Box 2000 FIN 33521 Tampere Finland
0.3375625.15328426.html.plaintext.txt	4	Abstract Top Abstract Introduction Subjects methods Results References Background
0.3375625.15328426.html.plaintext.txt	5	Apolipoprotein E apoE polymorphism plays central role lipid metabolism recently also suggested regulate inflammation judged levels serum C reactive protein CRP
0.3375625.15328426.html.plaintext.txt	6	To establish whether polymorphism apoE genes affects susceptibility primary Sjogrens syndrome pSS degree inflammation age onset pSS
0.3375625.15328426.html.plaintext.txt	7	ApoE genotype distribution allelic frequencies analysed using PCR TaqMan system 63 Finnish Caucasian patients pSS 64 healthy controls matched sex ethnic origin area residence
0.3375625.15328426.html.plaintext.txt	8	The clinical immunological data pSS patients analysed relation apoE genotypes
0.3375625.15328426.html.plaintext.txt	9	There difference pSS patients controls apoE genotype allelic frequencies
0.3375625.15328426.html.plaintext.txt	10	The apoE 4 allele significantly associated early onset pSS entire population female patients Kaplan Meier log rank test P 0
0.3375625.15328426.html.plaintext.txt	11	The average age plus minus S
0.3375625.15328426.html.plaintext.txt	12	onset pSS apoE 4 allele carriers 46 plus minus 12 genotypes 53 plus minus 10 yr P 0
0.3375625.15328426.html.plaintext.txt	13	ApoE polymorphism associated signs inflammation evaluated markers concentration plasma CRP plasma interleukin 6 plasma TNF immunoglobulin G haemoglobin leucocyte count ESR
0.3375625.15328426.html.plaintext.txt	14	ApoE polymorphism affect susceptibility pSS levels plasma inflammatory indices patients pSS
0.3375625.15328426.html.plaintext.txt	15	However clear association prevails apoE 4 early onset pSS
0.3375625.15328426.html.plaintext.txt	16	KEY WORDS Apolipoprotein E Gene polymorphism Primary Sjogrens syndrome Age disease onset
0.3375625.15328426.html.plaintext.txt	17	Introduction Top Abstract Introduction Subjects methods Results References Primary Sjogrens syndrome pSS chronic inflammatory autoimmune disease characterized symptoms dry eyes mouth various extraglandular symptoms hypergammaglobulinaemia abundant autoantibody production
0.3375625.15328426.html.plaintext.txt	18	Plasma levels interleukin 6 IL 6 proinflammatory cytokine increased patients pSS 1
0.3375625.15328426.html.plaintext.txt	19	Apolipoprotein E apoE gene polymorphism plays significant role lipid metabolism addition recently also suggested regulate inflammation measured levels C reactive protein 2
0.3375625.15328426.html.plaintext.txt	20	The gene apoE polymorphic presenting three common alleles 2 3 4 single gene locus chromosome 19
0.3375625.15328426.html.plaintext.txt	21	These alleles form six genotypes E22 E32 E42 E33 E43 E44 E33 commonest E43 second commonest populations
0.3375625.15328426.html.plaintext.txt	22	The presence apoE 4 allele associated increased risk coronary heart disease Alzheimers disease reviewed 3
0.3375625.15328426.html.plaintext.txt	23	Circulating testosterone dehydroepiandrosterone DHEA levels recently found associated apoE genotype women carrying apoE 4 allele thus susceptible development diseases associated menopause 4
0.3375625.15328426.html.plaintext.txt	24	Sjogrens syndrome presents characteristically middle aged women
0.3375625.15328426.html.plaintext.txt	25	We hypothesized apoE could candidate gene susceptibility pSS genetic polymorphism apoE could exert effect markers inflammation patients pSS
0.3375625.15328426.html.plaintext.txt	26	Hence aims present study investigate well characterized group Finnish Caucasian patients pSS effect polymorphism apoE gene susceptibility severity pSS particularly markers inflammation age onset pSS
0.3375625.15328426.html.plaintext.txt	27	Subjects methods Top Abstract Introduction Subjects methods Results References Subjects All patients fulfilling three modified Californian criteria pSS 5 salivary flow determinations performed histological findings graded Chisholm Mason 6 scale grades 3 4 regarded diagnostic selected records patients sicca symptoms examined Department Internal Medicine Section Rheumatology Tampere University Hospital Finland years 1977 1992 n 111
0.3375625.15328426.html.plaintext.txt	28	Those alive invited letter attend gene polymorphism determinations samples genotyping obtained informed consent 63 pSS patients 61 female two male mean age 60 plus minus 12 yr mean disease duration 9 plus minus 4 yr
0.3375625.15328426.html.plaintext.txt	29	Sixty one also fulfilled revised American European consensus group criteria pSS 7
0.3375625.15328426.html.plaintext.txt	30	Clinical methods A careful clinical examination together depth interview patients covering previous diseases duration sicca symptoms existence recurrent salivary gland swellings recently conducted patients 8
0.3375625.15328426.html.plaintext.txt	31	Special emphasis laid possible extraglandular symptoms pSS dermatological endocrine gastrointestinal lymphoproliferative musculoskeletal neurological renal respiratory vascular symptoms
0.3375625.15328426.html.plaintext.txt	32	Standard laboratory tests The standard laboratory tests included blood cell count erythrocyte sedimentation rate ESR plasma C reactive protein CRP
0.3375625.15328426.html.plaintext.txt	33	Anti SS A anti SS B antibodies determined enzyme immunoassay
0.3375625.15328426.html.plaintext.txt	34	Serum concentrations immunoglobulin G IgG measured laser nephelometry serum ss2 microglobulin radioimmunoassay Pharmacia beta 2 micro RIA kit Pharmacia Diagnostics Uppsala Sweden
0.3375625.15328426.html.plaintext.txt	35	Plasma IL 6 TNF concentrations determined using commercially available ELISAs Pelikine human IL 6 ELISA kit Pelikine Compact human TNF ELISA kit CLB Amsterdam The Netherlands
0.3375625.15328426.html.plaintext.txt	36	The optical density individual wells determined Multiscan Biochromatic 348 spectrophotometer Thermo Labsystems Helsinki Finland
0.3375625.15328426.html.plaintext.txt	37	The detection limit IL 6 assay 0
0.3375625.15328426.html.plaintext.txt	38	6 pgml TNF assay 1
0.3375625.15328426.html.plaintext.txt	39	Normal controls Sixty four healthy Finnish Red Cross Transfusion Service blood donors matched sex 62 female two male ethnic origin Finnish Caucasian area residence Tampere Finland served control group DNA studies pSS patients
0.3375625.15328426.html.plaintext.txt	40	Mean age control subjects 53 plus minus 7 yr
0.3375625.15328426.html.plaintext.txt	41	Apolipoprotein E genotyping Genomic DNA extracted peripheral blood leucocytes using commercially available kit Qiagen Hilden Germany
0.3375625.15328426.html.plaintext.txt	42	For APOE 112 genotyping fluorogenic allele specific TaqMan probes primers used previously described 9
0.3375625.15328426.html.plaintext.txt	43	APOE 158 genotypes determined using allele specific fluorogenic probes conjugated minor groove binder MGB group
0.3375625.15328426.html.plaintext.txt	44	The nucleotide sequences APOE 158 primers probes used PCR deduced published sequences deposited GenBank database chosen synthesized conjunction Applied Biosystems Foster City CA USA using Assay Design tool
0.3375625.15328426.html.plaintext.txt	45	DNA samples genotyped means 5 nuclease assay allelic discrimination using ABI Prism 7000 Sequence Detection System Applied Biosystems
0.3375625.15328426.html.plaintext.txt	46	A polymerase chain reaction PCR reaction containing genomic DNA 1 x Universal PCR Master Mix 900 nM primer 200 nM probe performed 96 well plates using standard protocol total volume 25 microl
0.3375625.15328426.html.plaintext.txt	47	Water controls known control samples previously typed restriction fragment length polymorphism PCR analysis run parallel unknown DNA samples
0.3375625.15328426.html.plaintext.txt	48	After cycling end point fluorescence measured genotype calling carried using allelic discrimination analysis module
0.3375625.15328426.html.plaintext.txt	49	Statistical analysis Unpaired Students test 2 test used comparisons continuous dichotomous variables respectively
0.3375625.15328426.html.plaintext.txt	50	The association 4 allele age onset pSS analysed Kaplan Meier log rank tests
0.3375625.15328426.html.plaintext.txt	51	Findings considered statistically significant P 0
0.3375625.15328426.html.plaintext.txt	52	Statistical analyses performed SPSS 10
0.3375625.15328426.html.plaintext.txt	53	1 Windows SPSS Chicago IL USA
0.3375625.15328426.html.plaintext.txt	54	Ethical approval The study protocol approved Ethical Committee Tampere University Hospital
0.3375625.15328426.html.plaintext.txt	55	Results Top Abstract Introduction Subjects methods Results References ApoE genotypes allelic frequencies age onset pSS The apoE genotype allele frequencies pSS patients control subjects differ Table 1
0.3375625.15328426.html.plaintext.txt	56	However pSS patients carrying apoE 4 allele significantly younger mean plus minus S
0.3375625.15328426.html.plaintext.txt	57	55 plus minus 11 vs 62 plus minus 11 yr P 0
0.3375625.15328426.html.plaintext.txt	58	Moreover apoE 4 allele associated earlier onset pSS entire population female patients Kaplan Meier log rank test P 0
0.3375625.15328426.html.plaintext.txt	59	The average age disease onset apoE 4 allele carriers 46 plus minus 12 yr genotypes 53 plus minus 10 yr P 0
0.3375625.15328426.html.plaintext.txt	60	039 patients fulfilling American European consensus group criteria test
0.3375625.15328426.html.plaintext.txt	61	The mean age female patients pSS carrying apoE 4 allele 54 plus minus 11 yr compared 62 plus minus 11 yr non carriers P 0
0.3375625.15328426.html.plaintext.txt	62	023 age disease onset 45 plus minus 12 vs 53 plus minus 10 yr P 0
0.3375625.15328426.html.plaintext.txt	63	Apolipoprotein E apoE genotype allelic frequencies patients primary Sjogrens syndrome pSS healthy subjects
0.3375625.15328426.html.plaintext.txt	64	View larger version 12K FIG
0.3375625.15328426.html.plaintext.txt	65	Kaplan Meier plots showing earlier age onset female male patients primary Sjogrens syndrome pSS carrying 4 allele apolipoprotein E gene P 0
0.3375625.15328426.html.plaintext.txt	66	0407 log rank test b female patients pSS carrying 4 allele apolipoprotein E gene P 0
0.3375625.15328426.html.plaintext.txt	67	ApoE polymorphism markers inflammation The mean concentration plasma CRP pSS patients 5
0.3375625.15328426.html.plaintext.txt	68	6 pgml plasma TNF 7
0.3375625.15328426.html.plaintext.txt	69	There statistically significant differences markers inflammation plasma CRP levels 6
0.3375625.15328426.html.plaintext.txt	70	6 pgml plasma TNF concentrations 7
0.3375625.15328426.html.plaintext.txt	71	0 pgml pSS patients carrying apoE 4 allele carrying allele
0.3375625.15328426.html.plaintext.txt	72	Haemoglobin concentration 128 plus minus 7 vs 128 plus minus 13 gl leukocyte count 5
0.3375625.15328426.html.plaintext.txt	73	56 x 109l ESR 35 plus minus 20 vs 30 plus minus 20 mmh serum IgG 20
0.3375625.15328426.html.plaintext.txt	74	8 gl serum ss2 microglobulin concentrations 2
0.3375625.15328426.html.plaintext.txt	75	06 mgl differ patient groups
0.3375625.15328426.html.plaintext.txt	76	Neither anti SSA 78 plus minus 45 vs 64 plus minus 55 IUl anti SSB antibody titres 56 plus minus 70 vs 67 plus minus 76 IUl differ apoE 4 carriers non carriers
0.3375625.15328426.html.plaintext.txt	77	ApoE polymorphism clinical features pSS No differences observed frequencies extraglandular manifestations pSS history arthralgia arthritis salivary gland swelling Raynauds symptom purpura lymphadenopathy pleuritis alveolitis pulmonary fibrosis peripheral central nervous system symptoms patients without apoE 4 allele
0.3375625.15328426.html.plaintext.txt	78	The number diagnostic criteria pSS differ patient groups data shown
0.3375625.15328426.html.plaintext.txt	79	The histological grade labial salivary gland biopsies lower apoE 4 carriers non carriers grade 3 4 56 vs 80 P 0
0.3375625.15328426.html.plaintext.txt	80	Discussion Genetic variation apoE gene influences susceptibility coronary heart disease sporadic Alzheimers disease apoE 4 allele strong association
0.3375625.15328426.html.plaintext.txt	81	Recently genetic variation apoE gene also found affect degree inflammation influencing serum CRP levels dyslipidaemic middle aged men 2
0.3375625.15328426.html.plaintext.txt	82	Surprisingly however patients carrying apoE 4 allele known associated inflammation found lower CRP levels others 2
0.3375625.15328426.html.plaintext.txt	83	In patients pSS chronic inflammation present shown markedly elevated ESR levels pronounced hypergammaglobulinaemia elevated IL 6 levels
0.3375625.15328426.html.plaintext.txt	84	We therefore hypothesized genetic polymorphism apoE could effect markers inflammation patients pSS
0.3375625.15328426.html.plaintext.txt	85	However proved case first differences found apoE genotype allele frequencies pSS patients healthy controls
0.3375625.15328426.html.plaintext.txt	86	Moreover apoE 4 allele influence levels CRP patients pSS
0.3375625.15328426.html.plaintext.txt	87	This finding might explained fact pSS known belong group autoimmune diseases modest even absent CRP reaction 10
0.3375625.15328426.html.plaintext.txt	88	However addition lack differences CRP levels differences emerged well established markers inflammatory activity including plasma IL 6 TNF IgG apoE 4 carriers non carriers
0.3375625.15328426.html.plaintext.txt	89	The apoE 4 carrier state also associated clinical features disease
0.3375625.15328426.html.plaintext.txt	90	Labial salivary gland histology marker severity inflammation pSS even milder apoE 4 allele carriers compared non carriers
0.3375625.15328426.html.plaintext.txt	91	We found age disease onset significantly lower pSS patients apoE 4 allele without allele
0.3375625.15328426.html.plaintext.txt	92	Similarly noted effect apoE 4 allele coronary atherosclerosis 11 Alzheimers disease 12 age dependent
0.3375625.15328426.html.plaintext.txt	93	Moreover recent studies apoE polymorphism also found affect age onset infectious diseases 13 14
0.3375625.15328426.html.plaintext.txt	94	ApoE polymorphism found affect age becoming infected Plasmodium falciparum children Ghana 13 possible role protection early stages malaria 14
0.3375625.15328426.html.plaintext.txt	95	Epstein Barr cytomegalovirus retrovirus infections proposed act triggering agents development pSS genetically susceptible subjects 15
0.3375625.15328426.html.plaintext.txt	96	There data apoE polymorphism susceptibility age disease onset related infections
0.3375625.15328426.html.plaintext.txt	97	We know background significant association apoE 4 earlier disease onset pSS
0.3375625.15328426.html.plaintext.txt	98	One might speculate however association could mediated example possible effect time point triggering viral infection
0.3375625.15328426.html.plaintext.txt	99	A speculative explanation earlier age onset pSS particularly female subjects carrying apoE 4 allele might relation hormonal factors view strong female predominance among patients pSS also believed involved pathogenesis pSS 15
0.3375625.15328426.html.plaintext.txt	100	The gender bias concomitant characteristic late age disease onset pSS difficult interpret oestrogens considered favour autoimmunity androgens protect
0.3375625.15328426.html.plaintext.txt	101	Carriers apoE 4 held susceptible development diseases associated menopause found higher serum DHEA testosterone levels women carrying allele 4
0.3375625.15328426.html.plaintext.txt	102	Furthermore interaction oestrogen apoE Alzheimers disease process observed recent study apoE polymorphism influenced binding oestrogen receptor altered transcriptional activity response oestrogen 16
0.3375625.15328426.html.plaintext.txt	103	We demonstrated apoE polymorphism affect susceptibility pSS plasma inflammatory indices patients pSS clear association apoE 4 allele early onset pSS
0.3375625.15328426.html.plaintext.txt	104	Acknowledgments This study supported Medical Research Fund Tampere University Hospital Tampere Finland Maud Kuistilas Foundation
0.3375625.15328426.html.plaintext.txt	105	The authors declared conflicts interest
0.3375625.15328426.html.plaintext.txt	106	References Top Abstract Introduction Subjects methods Results References Hulkkonen J Pertovaara M Antonen J Pasternack A Hurme M
0.3375625.15328426.html.plaintext.txt	107	Elevated interleukin 6 plasma levels regulated promoter region polymorphism IL 6 gene primary Sjogrens syndrome pSS correlate clinical manifestations disease
0.3375625.15328426.html.plaintext.txt	108	Rheumatology 200140656 61
0.3375625.15328426.html.plaintext.txt	109	AbstractFree Full Text Manttari M Manninen V Palosuo T Ehnholm C
0.3375625.15328426.html.plaintext.txt	110	Apolipoprotein E polymorphism C reactive protein dyslipidemic middle aged men
0.3375625.15328426.html.plaintext.txt	111	Atherosclerosis 2001156237 8
0.3375625.15328426.html.plaintext.txt	112	CrossRefISIMedline Mahley RW Rall SC Jr
0.3375625.15328426.html.plaintext.txt	113	Apolipoprotein E far lipid transport protein
0.3375625.15328426.html.plaintext.txt	114	Annu Rev Genomics Hum Genet 20001507 37
0.3375625.15328426.html.plaintext.txt	115	CrossRefISIMedline Zofkova I Zajickova K Hill M Horinek A
0.3375625.15328426.html.plaintext.txt	116	Apolipoprotein E gene determines serum testosterone dehydroepiandrosterone levels postmenopausal women
0.3375625.15328426.html.plaintext.txt	117	Eur J Endocrinol 2002147503 6
0.3375625.15328426.html.plaintext.txt	118	Erratum Eur J Endocrinol 2003148587
0.3375625.15328426.html.plaintext.txt	119	ISI Fox RI Robinson CA Curd JG Kozin F Howell F
0.3375625.15328426.html.plaintext.txt	120	Proposed criteria classification
0.3375625.15328426.html.plaintext.txt	121	Arthritis Rheum 198629577 85
0.3375625.15328426.html.plaintext.txt	122	ISIMedline Chishom DM Mason DK
0.3375625.15328426.html.plaintext.txt	123	Labial salivary gland biopsy Sjogrens disease
0.3375625.15328426.html.plaintext.txt	124	J Clin Pathol 196821656 60
0.3375625.15328426.html.plaintext.txt	125	ISIMedline Vitali C Bombardieri S Jonsson R et al
0.3375625.15328426.html.plaintext.txt	126	Classification criteria Sjogrens syndrome revised version European criteria proposed American European consensus group
0.3375625.15328426.html.plaintext.txt	127	Ann Rheum Dis 200261554 9
0.3375625.15328426.html.plaintext.txt	128	AbstractFree Full Text Pertovaara M Korpela M Kouri T Pasternack A
0.3375625.15328426.html.plaintext.txt	129	The occurrence renal involvement primary Sjogrens syndrome study 78 patients
0.3375625.15328426.html.plaintext.txt	130	Rheumatology 1999381113 20
0.3375625.15328426.html.plaintext.txt	131	AbstractFree Full Text Koch W Ehrenhaft A Griesser K et al
0.3375625.15328426.html.plaintext.txt	132	TaqMan systems genotyping disease related polymorphisms present gene encoding apolipoprotein E
0.3375625.15328426.html.plaintext.txt	133	Clin Chem Lab Med 2002401123 31
0.3375625.15328426.html.plaintext.txt	134	Medline Moutsopoulos HM Elkon KB Mavridis AK Acritidis NC Hughes GRV Pepys MB
0.3375625.15328426.html.plaintext.txt	135	Serum c reactive protein primary Sjogrens syndrome
0.3375625.15328426.html.plaintext.txt	136	Clin Exp Rheumatol 1983157 8
0.3375625.15328426.html.plaintext.txt	137	ISIMedline Ilveskoski E Perola M Lehtimaki T et al
0.3375625.15328426.html.plaintext.txt	138	Age dependent association apolipoprotein E genotype coronary aortic atherosclerosis middle aged men
0.3375625.15328426.html.plaintext.txt	139	Circulation 1999100608 13
0.3375625.15328426.html.plaintext.txt	140	AbstractFree Full Text Poirier J Davignon J Bouthillier D Kogan S Bertrand B Gauthier S
0.3375625.15328426.html.plaintext.txt	141	Apolipoprotein E polymorphism Alzheimers disease
0.3375625.15328426.html.plaintext.txt	142	Wozniak MA Faragher EB Todd JA Koram KA Riley EM Itzhaki RF
0.3375625.15328426.html.plaintext.txt	143	Does apolipoprotein E polymorphism influence susceptibility malaria J Med Genet 200340348 51
0.3375625.15328426.html.plaintext.txt	144	AbstractFree Full Text Aucan C Walley AJ Hill AVS
0.3375625.15328426.html.plaintext.txt	145	Common apolipoprotein E polymorphisms risk clinical malaria Gambia
0.3375625.15328426.html.plaintext.txt	146	Free Full Text Jonsson R Gordon TP Konttinen YT
0.3375625.15328426.html.plaintext.txt	147	Recent advances understanding molecular mechanisms pathogenesis antibody profile Sjogrens syndrome
0.3375625.15328426.html.plaintext.txt	148	Curr Rheumatol Rep 20035311 6
0.3375625.15328426.html.plaintext.txt	149	Medline Lambert JC Coyle N Lendon C
0.3375625.15328426.html.plaintext.txt	150	The allelic modulation apolipoprotein E expression estrogen potential relevance Alzheimers disease
0.3375625.15328426.html.plaintext.txt	151	AbstractFree Full Text Submitted 2 June 2004 revised version accepted 23 July 2004
0.3375625.15328426.html.plaintext.txt	152	This Article Abstract Full Text PDF All Versions Article 43121484 recent keh383v1 Alert article cited Alert correction posted Services Email article friend Similar articles journal Similar articles PubMed Alert new issues journal Add My Personal Archive Download citation manager Disclaimer Request Permissions Google Scholar Articles Pertovaara M
0.3375625.15328426.html.plaintext.txt	153	PubMed PubMed Citation Articles Pertovaara M
0.3375625.15328426.html.plaintext.txt	154	Related Collections Other Rheumatology Online ISSN 1462 0332 Print ISSN 1462 0324 Copyright 2006 British Society Rheumatology Oxford Journals Oxford University Press Site Map Terms Conditions Privacy Policy Frequently Asked Questions Other Oxford University Press sites Oxford University Press American National Biography Booksellers Information Service Childrens Fiction Poetry Childrens Reference Corporate Special Sales Dictionaries Dictionary National Biography Digital Reference English Language Teaching Higher Education Textbooks Humanities International Education Unit Law Medicine Music Online Products Oxford English Dictionary Reference Rights Permissions Science School Books Social Sciences Very Short Introductions Worlds Classics
0.38527274.10655544.html.plaintext.txt	0	Altered cholesterol metabolism human apolipoprotein E4 knock mice Hiroki Hamanaka Yuko Katoh Fukui1 Kazuo Suzuki2 Mariko Kobayashi Rika Suzuki1 Yoshiko Motegi1 Yoko Nakahara1 Aya Takeshita1 Mizue Kawai2 Koichi Ishiguro Minesuke Yokoyama1 Shinobu C
0.38527274.10655544.html.plaintext.txt	1	Project 8 1Reproductive Engineering Section Mitsubishi Kasei Institute Life Sciences 11 Minamiooya Machida Tokyo 194 8511 Japan 2Pharmaceuticals Research Laboratory 1 Mitsubishi Tokyo Pharmaceuticals Inc
0.38527274.10655544.html.plaintext.txt	2	Yokohama Research Center 1000 Kamoshida cho Aoba ku Yokohama 227 8502 Japan
0.38527274.10655544.html.plaintext.txt	3	Received 15 September 1999 Revised Accepted 1 December 1999
0.38527274.10655544.html.plaintext.txt	4	ABSTRACT TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES The 4 allele apolipoprotein E apoE associated increased risk developing Alzheimer disease AD
0.38527274.10655544.html.plaintext.txt	5	To accurately determine isoform specific effects human apoE brain functions physiological pathological situations created mice expressing human apoE4 isoform place mouse apoE utilizing gene targeting technique embryonic stem cells knock
0.38527274.10655544.html.plaintext.txt	6	The homozygous 4 44 mice correctly expressed human apoE4 serum brain
0.38527274.10655544.html.plaintext.txt	7	The human apoE brain found primarily astrocytes mouse apoE wild type mice
0.38527274.10655544.html.plaintext.txt	8	In 44 mice serum cholesterol level 2
0.38527274.10655544.html.plaintext.txt	9	5 fold littermate controls regular diet
0.38527274.10655544.html.plaintext.txt	10	This marked elevation accounted accumulation low low density lipo proteins
0.38527274.10655544.html.plaintext.txt	11	In brains 44 mice however amounts total cholesterol phospholipids significantly decreased compared littermates
0.38527274.10655544.html.plaintext.txt	12	These findings indicate cholesterol lipid metabolism markedly altered 44 mice
0.38527274.10655544.html.plaintext.txt	13	Our human apoE4 knock mice useful clarifying role apoE etiologies AD cardiovascular diseases relation cholesterol lipid metabolism
0.38527274.10655544.html.plaintext.txt	14	INTRODUCTION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Apolipoprotein E apoE constituent several classes plasma lipoproteins plays important role transport cholesterol phospholipids among various cells body 1
0.38527274.10655544.html.plaintext.txt	15	It serves ligand mediates uptake lipoprotein particles cells via low density lipoprotein receptor LDLR LDLR related protein LRP
0.38527274.10655544.html.plaintext.txt	16	The brain second next liver content apoE mRNA 2 predominantly synthesized astrocytes 34
0.38527274.10655544.html.plaintext.txt	17	Although much remains clarified lipid lipoprotein metabolism brain recent studies revealed apoE present high density lipoprotein HDL like lipoprotein particles cerebrospinal fluid CSF 5 7
0.38527274.10655544.html.plaintext.txt	18	Human apoE 299 amino acid protein occurs three major isoforms apoE2 apoE3 apoE4 encoded three APOE alleles 2 3 4 differing respect presence cysteine arginine two polymorphic sites
0.38527274.10655544.html.plaintext.txt	19	ApoE3 common isoform cysteine amino acid position 112 arginine 158 apoE2 cysteine 112 158 apoE4 arginine sites 1
0.38527274.10655544.html.plaintext.txt	20	Numerous epi demiologic studies established 4 allele associated increased risk developing familial late onset sporadic Alzheimer disease AD 8 10
0.38527274.10655544.html.plaintext.txt	21	ApoE immunoreactivity detected senile plaques 11 neurofibrillary tangles NFTs 12 two hallmarks AD
0.38527274.10655544.html.plaintext.txt	22	Increased plaques found brains 4 homo zygotes 1314
0.38527274.10655544.html.plaintext.txt	23	Studies reported binding apoE amyloid ss peptide Ass 81516 tau protein 17 principal constituent NFTs
0.38527274.10655544.html.plaintext.txt	24	ApoE originally identified 37 kDa protein associated regenerating nerves 18 better defined later studies crushed sciatic nerves 19 21 lesioned brain 2223
0.38527274.10655544.html.plaintext.txt	25	Following brain injury synthesis apoE astrocytes upregulated considered play important roles mobilization redistribution cholesterol phospholipids membrane remodeling 24
0.38527274.10655544.html.plaintext.txt	26	Under conditions increased cholesterol availability cholesterol synthesis repressed peripheral nerve 25 brain 23
0.38527274.10655544.html.plaintext.txt	27	The cholesterol content brain decreases age 26 even AD 27
0.38527274.10655544.html.plaintext.txt	28	Recent studies cultured cells implicate cholesterol rich membrane microdomains processing amyloid precursor protein APP see
0.38527274.10655544.html.plaintext.txt	29	Interestingly recent work showed apoE4 induces neuronal cell death conditions suppressed cholesterol synthesis 28 suggesting apoE4 may possibly less efficient apoE3 reparative function brain compromised cholesterol supply
0.38527274.10655544.html.plaintext.txt	30	Thus cholesterol intriguing possible link apoE AD etiology
0.38527274.10655544.html.plaintext.txt	31	When allele specific differences apoE function need identified vivo desirable mouse lines murine apoE replaced human apoE isoforms expressed natural regulation protein
0.38527274.10655544.html.plaintext.txt	32	2930 produced human apoE3 apoE2 knock mouse lines recently succeeded apoE4 mice 31
0.38527274.10655544.html.plaintext.txt	33	The E4 homozygotes found plasma cholesterol levels similar E3 mice whereas E2 mice exhibited hypercholesterolemia
0.38527274.10655544.html.plaintext.txt	34	We independently undertook generation human apoE knock mice using different construct design targeting vector
0.38527274.10655544.html.plaintext.txt	35	Our E4 homozygous mice exhibit elevated serum cholesterol level compared wild type mice whereas brain cholesterol content significantly decreased
0.38527274.10655544.html.plaintext.txt	36	This suggests human apoE4 knock mice provide useful animal models AD research relation cholesterol lipid metabolism
0.38527274.10655544.html.plaintext.txt	37	RESULTS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Generation human apoE4 knock mice The knock gene targeting vector designed replace mouse Apoe coding sequences including part exon 2 entire exon 3 exon 4 human apoE4 cDNA Fig
0.38527274.10655544.html.plaintext.txt	38	To retain normal mouse Apoe regulatory sequences much possible translation initiation codon human apoE4 cDNA knock allele placed position mouse Apoe wild type locus
0.38527274.10655544.html.plaintext.txt	39	Thus non coding mouse sequences including exon 1 intron 1 first 18 bp exon 2 retained knock allele see Materials Methods
0.38527274.10655544.html.plaintext.txt	40	View larger version 18K Figure 1
0.38527274.10655544.html.plaintext.txt	41	Targeting strategy apoE4 knock mice homologous intergration transgene
0.38527274.10655544.html.plaintext.txt	42	A Schematic diagram knock targeting strategy
0.38527274.10655544.html.plaintext.txt	43	Top The structure endogenous Apoe locus including exons 1 4 black boxes
0.38527274.10655544.html.plaintext.txt	44	Middle The targeting vector containing human apoE4 cDNA hu cDNA
0.38527274.10655544.html.plaintext.txt	45	Bottom The predicted structure knock allele homologous recombination
0.38527274.10655544.html.plaintext.txt	46	The neomycin resistance neo thymidine kinase TK genes selection targeted ES cells
0.38527274.10655544.html.plaintext.txt	47	The neo cassette flanked 34 bp loxP sequences triangles
0.38527274.10655544.html.plaintext.txt	48	pA represents endogenous polyadenylation signals
0.38527274.10655544.html.plaintext.txt	49	Restriction sites B BglII E EcoRI H HindIII N NcoI S SalI X XmnI
0.38527274.10655544.html.plaintext.txt	50	B Southern blot analysis tail tip DNA wild type heterozygous 4 homozygous 44 knock mice digested HindIII hybridized 3 probe shown A
0.38527274.10655544.html.plaintext.txt	51	The wild type Apoe allele generates 8
0.38527274.10655544.html.plaintext.txt	52	0 kb HindIII fragment whereas targeted allele yields diagnostic 6
0.38527274.10655544.html.plaintext.txt	53	The knock construct introduced E14TG2aIV embryonic stem ES cells 32 electroporation cell clones selected growth media containing G418gancyclovir
0.38527274.10655544.html.plaintext.txt	54	Drug resistant ES clones screened homologous recombination Southern blot hybridization using 3 flanking sequences outside gene targeting vector exon 4 neo probes data shown
0.38527274.10655544.html.plaintext.txt	55	We identified 7 125 G418gancyclovir resistant ES clones correct insertion two clones 129 145 used studies
0.38527274.10655544.html.plaintext.txt	56	In knock ES cells human apoE immuno reactivity could demonstrated western blotting cell lysates monoclonal antibody mAb 868E5 see whereas mouse apoE detected wild type knock ES cells mAb 874B7 data shown
0.38527274.10655544.html.plaintext.txt	57	The two independently targeted ES cell clones injected C57BL6N blastocysts chimeric mice generated
0.38527274.10655544.html.plaintext.txt	58	Male chimeric mice mated C57BL6N females produce heterozygous 4 mice
0.38527274.10655544.html.plaintext.txt	59	The knock allele transmitted four seven agouti coat color offspring derived 129 ES cell clone data shown
0.38527274.10655544.html.plaintext.txt	60	The heterozygous 4 mice F2 generation crossed produced litters normal size normal Mendelian segregation pattern knock allele
0.38527274.10655544.html.plaintext.txt	61	Genotypes F3 generation mice determined using Southern blot analysis tail tip DNA digested HindIII Fig
0.38527274.10655544.html.plaintext.txt	62	The results reported obtained F3 generation animals mouse line TgHHAPE4129
0.38527274.10655544.html.plaintext.txt	63	The amino acid sequence entire transgene product confirmed correct human apoE4 3334 cDNA cloning sequencing human apoE mRNA liver transgenic mouse line
0.38527274.10655544.html.plaintext.txt	64	Expression human apoE4 knock allele To examine expression human apoE4 knock allele sera 44 4 mice analyzed western blot analysis Fig
0.38527274.10655544.html.plaintext.txt	65	Human apoE4 protein detected human apoE specific rat mAb 868E5 35 sera 44 4 mice 37 kDa position control human serum Fig
0.38527274.10655544.html.plaintext.txt	66	Western blot analysis mouse apoE specific hamster mAb 874B7 35 showed mouse apoE present 4 44 mice Fig
0.38527274.10655544.html.plaintext.txt	67	2A lower panel indicating mouse Apoe coding sequence completely replaced 44 mice
0.38527274.10655544.html.plaintext.txt	68	Although cannot precisely compare amount human mouse apoE proteins western blots due likely difference affinity antibodies seemed level human apoE4 serum 44 mice comparable mouse apoE wild type mice
0.38527274.10655544.html.plaintext.txt	69	We showed apoE knock mice recognized anti apoE4 specific antibody Ab 412 1 12 2 binds apoE4 specific epitope 36 Fig
0.38527274.10655544.html.plaintext.txt	70	View larger version 30K Figure 2
0.38527274.10655544.html.plaintext.txt	71	Correct expression apoE4 transgene production serum brain knock mice
0.38527274.10655544.html.plaintext.txt	72	A Western blot sera species specific anti apoE antibodies
0.38527274.10655544.html.plaintext.txt	73	B Sera 4 44 mice analyzed anti apoE4 isoform specific antibody 36
0.38527274.10655544.html.plaintext.txt	74	The heavy bands apoE bands due serum Ig heavy light chains respectively directly binding secondary antibody
0.38527274.10655544.html.plaintext.txt	75	C Western blot brain homogenates human apoE specific antibody shows gene dosage dependent expression transgene product
0.38527274.10655544.html.plaintext.txt	76	Bands top asterisks non specific signals due ABC binding
0.38527274.10655544.html.plaintext.txt	77	Molecular weights kDa indicated left
0.38527274.10655544.html.plaintext.txt	78	In experiments extent sialylation apoE estimated characteristic upper bands 5 seems less mouse human Fig
0.38527274.10655544.html.plaintext.txt	79	The possibility sialylation apoE differently regulated two species remains studied
0.38527274.10655544.html.plaintext.txt	80	We next examined expression human apoE4 brains knock mouse
0.38527274.10655544.html.plaintext.txt	81	Western blotting experiments showed human apoE 37 kDa expressed 44 4 mouse brains Fig
0.38527274.10655544.html.plaintext.txt	82	Histological pattern apoE expression studied immunohistochemistry frozen sections paraformaldehyde fixed brains three genotypes Fig
0.38527274.10655544.html.plaintext.txt	83	Human apoE detected astrocytes neuropil hippocampus Fig
0.38527274.10655544.html.plaintext.txt	84	3A neocortex 44 mice immunoreactivity mouse apoE detectable Fig
0.38527274.10655544.html.plaintext.txt	85	No clear apoE immunoreactivity seen neuronal somata although fluorescence microscopy could rule weak staining neuronal processes addition astrocytic processes neuropil
0.38527274.10655544.html.plaintext.txt	86	This pattern apoE staining similar distribution mouse apoE mouse brain Fig
0.38527274.10655544.html.plaintext.txt	87	Heterozygous brains showed staining human mouse apoEs intermediate intensity Fig
0.38527274.10655544.html.plaintext.txt	88	Thus expression human apoE protein knock mice apparently endogenous regulatory control
0.38527274.10655544.html.plaintext.txt	89	View larger version 144K Figure 3
0.38527274.10655544.html.plaintext.txt	90	Correct histological expression apoE brain shown anti human A C E anti mouse B D F apoE antibodies
0.38527274.10655544.html.plaintext.txt	91	Hippocampal CA1 region fixed cryostat sections 44 A B 4 C D E F mice shown
0.38527274.10655544.html.plaintext.txt	92	Note similar patterns apoE distribution astrocytes neuropil human apoE knock A mouse apoE wild type F mice also intermediate expression apoEs heterozygote C D
0.38527274.10655544.html.plaintext.txt	93	Lipid lipoprotein phenotypes As initial step studying functional impact expression human apoE protein levels total cholesterol TC triglycerides TG 44 4 apoE deficient 37 mice analyzed sera obtained 6 h fast Table 1
0.38527274.10655544.html.plaintext.txt	94	Serum TC level 44 mice 251 plus minus 23 mgdl 2
0.38527274.10655544.html.plaintext.txt	95	5 fold greater mice 101 plus minus 8 mgdl still much lower mice 697 plus minus 60 mgdl
0.38527274.10655544.html.plaintext.txt	96	Males showed higher TC levels females 289 mgdl versus 212 44 mice 115 versus 87 mice n 3
0.38527274.10655544.html.plaintext.txt	97	In 4 mice serum TC levels slightly lower mice
0.38527274.10655544.html.plaintext.txt	98	There significant difference TG levels among 44 4 mice
0.38527274.10655544.html.plaintext.txt	99	Similar results obtained another independent knock line TgHHAPE4145
0.38527274.10655544.html.plaintext.txt	100	For line TC 234 mgdl 44 compared 131 n 5
0.38527274.10655544.html.plaintext.txt	101	The nature elevated serum TC levels studied analyzing lipoprotein profiles fast protein liquid chromatography FPLC fractionation
0.38527274.10655544.html.plaintext.txt	102	As shown Figure 4A B main cholesterol carrier serum HDL fractions 17 25 4 mice
0.38527274.10655544.html.plaintext.txt	103	In 44 mice however 60 TC found regions corresponding VLDL LDL fractions 1 16 Fig
0.38527274.10655544.html.plaintext.txt	104	Distribution cholesterol apoE among lipoprotein fractions knock control mice
0.38527274.10655544.html.plaintext.txt	105	Sera A 4 B 44 C mice size fractionated FPLC
0.38527274.10655544.html.plaintext.txt	106	Cholesterol values fractions measured enzymatically shown upper panels
0.38527274.10655544.html.plaintext.txt	107	ApoE distribution profiles shown lower panels western blots corresponding fractions mouse human specific anti apoE antibodies indicated
0.38527274.10655544.html.plaintext.txt	108	The distribution apoE analyzed western blot analysis FPLC fractions Fig
0.38527274.10655544.html.plaintext.txt	109	In 4 mice mouse apoE mostly found HDL fractions 17 25 also LDL fractions 10 16 regions minor portion showing VLDL region fractions 6 7
0.38527274.10655544.html.plaintext.txt	110	The distribution pattern human apoE4 4 mice similar mouse apoE 4 mice
0.38527274.10655544.html.plaintext.txt	111	In contrast majority apoE present VLDL LDL regions two peaks fractions 6 7 12 13 44 mice addition presence HDL region
0.38527274.10655544.html.plaintext.txt	112	On western blot analysis anti mouse apoE three discrete bands 34 36 39 kDa detected
0.38527274.10655544.html.plaintext.txt	113	The relative abundance three molecular species appeared vary fractions 39 kDa species relatively abundant VLDL 36 kDa species LDL 34 kDa species HDL regions
0.38527274.10655544.html.plaintext.txt	114	With anti human apoE antibody fractions displayed 37 kDa band accompanied weak low molecular weight band likely partial degradation fragment 38 Fig
0.38527274.10655544.html.plaintext.txt	115	As serum cholesterol level markedly elevated 44 knock mice particular interest examine brain lipids
0.38527274.10655544.html.plaintext.txt	116	The brain size significantly different among mice 44 4 genotypes
0.38527274.10655544.html.plaintext.txt	117	Total cholesterol level whole brain however reduced 30 44 brain compared brain Table 2
0.38527274.10655544.html.plaintext.txt	118	A less pronounced reduction TC also observed brains heterozygotes
0.38527274.10655544.html.plaintext.txt	119	A significant reduction brain phospholipid content also found 44 mice heterozygotes
0.38527274.10655544.html.plaintext.txt	120	Brain cholesterol phospholipid levels knock control mice No difference gross morphology brain apparent among 44 4 mice
0.38527274.10655544.html.plaintext.txt	121	No significant difference noted among three genotypes preliminary histological survey brain sections 3 month old mice stained thionin antibodies specific GFAP astrocyte marker VAMP 2 synapse marker mouse apoJ
0.38527274.10655544.html.plaintext.txt	122	A thorough study needed establish absence altered anatomical phenotype knock brains
0.38527274.10655544.html.plaintext.txt	123	DISCUSSION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES We produced line human apoE4 knock mice expression human apoE4 control enhancerpromoter endogenous mouse Apoe gene mouse apoE expression completely eliminated
0.38527274.10655544.html.plaintext.txt	124	In mice serum cholesterol level 2
0.38527274.10655544.html.plaintext.txt	125	5 times littermate controls
0.38527274.10655544.html.plaintext.txt	126	This marked elevation serum cholesterol shown primarily due accumulation low low density lipoproteins
0.38527274.10655544.html.plaintext.txt	127	The brains 44 mice significantly reduced total cholesterol phospholipids compared littermate controls
0.38527274.10655544.html.plaintext.txt	128	Transgenic mouse models A number research groups past produced mice expressing human apoE isoforms instead mouse protein pronuclear injection human apoE cDNAs placed various heterologous promoters breeding apoE deficient knock lines generated earlier eliminate mouse protein 39 41
0.38527274.10655544.html.plaintext.txt	129	In type transgenic mouse generally levels patterns transgene expression vary line line due differences chromosomal integration sites unavoidable position effects well uncontrollable copy numbers inserted transgenes
0.38527274.10655544.html.plaintext.txt	130	Thus two lines precisely matched studying subtle isoform differences
0.38527274.10655544.html.plaintext.txt	131	Moreover expression apoE cell types natural expressers use heterologous promoters may provide valid model animal AD research
0.38527274.10655544.html.plaintext.txt	132	GFAP promoter used direct expression human apoE astrocytes 3940
0.38527274.10655544.html.plaintext.txt	133	However expression pattern apoE normal mouse brain exactly coincide GFAP 35
0.38527274.10655544.html.plaintext.txt	134	Expected absence apoE periphery mice cause disturbances systemic lipid metabolism 4243 may indirect consequences central nervous system CNS
0.38527274.10655544.html.plaintext.txt	135	A desirable approach therefore place transgene expression control endogenous regulatory elements
0.38527274.10655544.html.plaintext.txt	136	44 introduced large segments human genomic DNA encompassing APOE locus attendant human regulatory regions fact transgene constructs match precisely among three apoE alleles combined uncontrolled integration loci copy numbers renders interpretation results subject ambiguity
0.38527274.10655544.html.plaintext.txt	137	2930 pioneered generation human apoE3 apoE2 mice Knouff et al
0.38527274.10655544.html.plaintext.txt	138	31 recently reported apoE4 mice
0.38527274.10655544.html.plaintext.txt	139	They took advantage homo logous recombination replace segment DNA Apoe locus homologous segments human genomic DNA
0.38527274.10655544.html.plaintext.txt	140	The plasma TC level E4 homozygotes significantly different E3 homozygotes
0.38527274.10655544.html.plaintext.txt	141	We used targeting vector different design employing human apoE cDNA coding region flanked appropriate murine genomic DNAs Fig
0.38527274.10655544.html.plaintext.txt	142	Hypercholesterolemia apoE4 knock mice Our homozygous apoE4 mice displayed marked hypercholesterolemia 249 compared wild type littermates Table 1
0.38527274.10655544.html.plaintext.txt	143	Preliminary results E3 homozygotes F3 generation indicated average TC value 125 mgdl n 6 compared 93 mgdl n 5 wild type littermates indicating hypercholesterolemia E4 mice allele specific phenotype
0.38527274.10655544.html.plaintext.txt	144	The apparent discrepancy cholesterol phenotype Knouff et al
0.38527274.10655544.html.plaintext.txt	145	E4 mice likely due difference fat cholesterol content mouse diet high fat chow differentiate cholesterol phenotypes Knouff et al
0.38527274.10655544.html.plaintext.txt	146	Nevertheless possibility cannot excluded component diet may contributed discrepancy
0.38527274.10655544.html.plaintext.txt	147	This tested exchanging mice diets
0.38527274.10655544.html.plaintext.txt	148	The difference construction transgenes may also responsible
0.38527274.10655544.html.plaintext.txt	149	The ApoeAPOE gene knock mice lacks introns 2 3 whereas Knouff et al
0.38527274.10655544.html.plaintext.txt	150	mice 31 carry chimeric intron 1 human introns 2 3 possibly leading subtle difference regulation apoE expression
0.38527274.10655544.html.plaintext.txt	151	This could tested careful comparative analyses apoE protein expression
0.38527274.10655544.html.plaintext.txt	152	Our analysis lipoprotein profile Fig
0.38527274.10655544.html.plaintext.txt	153	4 showed large increase VLDL LDL cholesterol without significant changes HDL cholesterol
0.38527274.10655544.html.plaintext.txt	154	Interestingly humans also 4 carriers increased plasma cholesterol LDL 4546
0.38527274.10655544.html.plaintext.txt	155	ApoE4 shown distribute relatively preferentially VLDL rather HDL compared apoE3 4748
0.38527274.10655544.html.plaintext.txt	156	A higher catabolic rate apoE4 bearing VLDL 49 offered explanation higher plasma cholesterol levels observed among human 4 carriers 45
0.38527274.10655544.html.plaintext.txt	157	In explanation apoE4 bearing VLDL delivers cholesterol efficiently liver also accelerates conversion VLDL remnants LDL driving accumulation
0.38527274.10655544.html.plaintext.txt	158	Both lead regulation LDL receptor accumulation LDL
0.38527274.10655544.html.plaintext.txt	159	It tempting speculate similar mechanism may operate 44 mice
0.38527274.10655544.html.plaintext.txt	160	Brain cholesterol As first step toward understanding physiological pathological roles apoE brain lipids measured apoE4 mice
0.38527274.10655544.html.plaintext.txt	161	In contrast serum homozygote brain showed 32 reduction total cholesterol 17 reduction phospholipids compared wild type littermates
0.38527274.10655544.html.plaintext.txt	162	These measurements mostly reflect cell associated lipids rather lipoproteins interstitial fluid thus necessarily contradict elevated cholesterol level found serum
0.38527274.10655544.html.plaintext.txt	163	Nonetheless raises possibility mechanisms brain parenchymal cholesterol metabolism traffic may substantially different side blood brain barrier
0.38527274.10655544.html.plaintext.txt	164	In fact apoE apoAI major apolipoproteins apoB found CNS 5 LRP considered important apoE receptor brain addition LDL receptor 13
0.38527274.10655544.html.plaintext.txt	165	The decreased brain cholesterol content E4 knock mice likely consequence interspecies inconsistency human apoE murine apoE receptors brain since preliminary results indicate brain cholesterol content apoE3 knock mice significantly different wild type littermates
0.38527274.10655544.html.plaintext.txt	166	An interesting possibility would property peculiar apoE4 protein hypothetical ability extract cholesterol myelin efficiently manifests primarily CNS tissues
0.38527274.10655544.html.plaintext.txt	167	Published studies human apoE knock mice Sullivan et al
0.38527274.10655544.html.plaintext.txt	168	29 31 devoted hematologic vascular studies knowledge data available comparison regarding brain cholesterol levels
0.38527274.10655544.html.plaintext.txt	169	The reduced cholesterol content brains apoE4 knock mice particularly intriguing recent recognition Ass detected association cholesterol rich membrane microdomains 5051 cholesterol availability affects APP processing cultured cells 52 57 brain 58
0.38527274.10655544.html.plaintext.txt	170	Contents cholesterol lipids found decreased AD brains 27
0.38527274.10655544.html.plaintext.txt	171	Whether result degenerative loss synapses cells etiological significance remains studied
0.38527274.10655544.html.plaintext.txt	172	Much needs learned cholesterol metabolism aging AD brains
0.38527274.10655544.html.plaintext.txt	173	A detailed analysis cholesterol lipids brains apoE4 mice also urgent well analyses APP metabolism
0.38527274.10655544.html.plaintext.txt	174	Equally awaited study doubly transgenic mice produced breeding apoE humanized lines mice APP overexpressing transgenic lines develop pathological changes 5960 determine human apoE isoforms differentially affect Ass production deposition brain
0.38527274.10655544.html.plaintext.txt	175	Dynamic regulation apoE expression physical injury long known peripheral nervous system CNS 192122
0.38527274.10655544.html.plaintext.txt	176	More recent studies experimental ischemia 61 head injury humans 62 brain lesions apoE deficient mice 63 support idea apoE plays part neural repair processes
0.38527274.10655544.html.plaintext.txt	177	Perhaps reflection increased importance cholesterol recycling brain parenchyma ready access cholesterol general circulation 64
0.38527274.10655544.html.plaintext.txt	178	Since AD entails sporadic neuronal deaths characteristically protracted course disease small differences among apoE isoforms efficiency cholesterol transport could substantial cumulative effects timing clinical onset AD
0.38527274.10655544.html.plaintext.txt	179	Such possibility could tested comparing apoE3 apoE4 mice respect reactions one time synchronous neuronal insults caused neurotoxin administration 65 appropriate surgical lesion experiments 66
0.38527274.10655544.html.plaintext.txt	180	Our mice may useful also testing involvement apoE neuronal plasticity 2467
0.38527274.10655544.html.plaintext.txt	181	It hoped apoE4 mice reported useful producing relevant animal models athero sclerosis research also clarifying precise role apoE etiology AD developing effective measures halt progression disease
0.38527274.10655544.html.plaintext.txt	182	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Mice Mice C57BL6N strain obtained Japan Clea Tokyo Japan
0.38527274.10655544.html.plaintext.txt	183	ApoE deficient mice C57BL6J Apoe tm1Unc 37 obtained Jackson Laboratory Bar Harbor ME
0.38527274.10655544.html.plaintext.txt	184	All mice reared normal diet MF Oriental Yeast Chiba Japan containing 4
0.38527274.10655544.html.plaintext.txt	185	Construction targeting vector The targeting construct made two step ligations DNA fragments
0.38527274.10655544.html.plaintext.txt	186	0 kb fragment including mouse Apoe gene 5 flanking region exon 1 intron 1 first 18 bp exon 2 strain 129SvJ human apoE4 cDNA fragment corresponding nucleotides 59 1027 68 loxP PGK neo loxP 69 fragment ligated subcloned pBluescript II SK pTG1
0.38527274.10655544.html.plaintext.txt	187	The human apoE4 cDNA originated pKCRHAPE Japan patent 60 126989 1985 vector expression human apoE3
0.38527274.10655544.html.plaintext.txt	188	A 280bp Eco47III SacII fragment excised pKCRHAPE subcloned pBluescript
0.38527274.10655544.html.plaintext.txt	189	A point mutation resulting Cys112Arg substitution introduced Pfu DNA polymerase based mutagenesis using QuikChange site directed mutagenesis kit Stratagene La Jolla CA pair mutagenic primers E34F 5 ACATGGAGGACGTGCGCGGCCGCCTGGTG 3 E34R 5 CACCAGGCGGCCGCGCACGTCCTCCATG 3
0.38527274.10655544.html.plaintext.txt	190	The desired point mutation entire coding sequences confirmed DNA sequence analysis
0.38527274.10655544.html.plaintext.txt	191	0 kb fragment excised pTG1 2
0.38527274.10655544.html.plaintext.txt	192	6 kb fragment mouse Apoe gene 3 flanking region inserted F3 vector includes thymidine kinase gene driven promoter pMC1neo 70 giving rise targeting vector pTG2
0.38527274.10655544.html.plaintext.txt	193	Generation homozygous human apoE4 knock mice The targeting vector pTG2 linearlized SalI electroporated ES cells E14TG2aIV 32 1000 V capacitance 3 microF using Bio Rad Hercules CA Gene Pulsar
0.38527274.10655544.html.plaintext.txt	194	After double selection G418 175 microgml gancyclovir 2 microM 125 resistant clones picked among seven targeted ES cell clones identified Southern blot analysis
0.38527274.10655544.html.plaintext.txt	195	The targeted ES cells injected C57BL6N blastocysts implanted pseudopregnant recipients produce chimeric mice
0.38527274.10655544.html.plaintext.txt	196	Chimeric male mice mated C57BL6N females examime germ line transmission transgene
0.38527274.10655544.html.plaintext.txt	197	The agouti coat color male offspring heterozygous human apoE4 mated C57BL6N females produce F2 generation
0.38527274.10655544.html.plaintext.txt	198	Mice heterozygous human apoE4 F2 generation intercrossed generate homozygous human apoE4 knock mice
0.38527274.10655544.html.plaintext.txt	199	Wild type littermates crosses used controls
0.38527274.10655544.html.plaintext.txt	200	The floxed neo transgene eliminated knock mice described work
0.38527274.10655544.html.plaintext.txt	201	Genomic Southern blot analysis ES cell DNA isolated digesting cells lysis buffer A 0
0.38527274.10655544.html.plaintext.txt	202	2 SDS 100 microgml proteinase K 200 mM NaCl 100 mM Tris pH7
0.38527274.10655544.html.plaintext.txt	203	5 5 mM EDTA 55 degrees C overnight dissolved TE buffer ethanol precipitation
0.38527274.10655544.html.plaintext.txt	204	Tail tip DNA isolated digesting tail tip clippings lysis buffer B 1 SDS 2 mgml proteinase K 100 mM NaCl 50 mM Tris pH 8
0.38527274.10655544.html.plaintext.txt	205	0 100 mM EDTA 55 degrees C overnight dissolved TE phenol extraction chloroform extraction ethanol precipitation
0.38527274.10655544.html.plaintext.txt	206	Genomic DNAs digested HindIII analyzed electrophoresis transferred nylon membrane
0.38527274.10655544.html.plaintext.txt	207	Transferred DNA hybridized hybridization buffer 7 SDS 50 formamide 5x SSC 2 blocking reagent 50 mM sodium phosphate pH 7
0.38527274.10655544.html.plaintext.txt	208	1 N lauroyl sarcosine overnight 42 degrees C DIG labelled 1
0.38527274.10655544.html.plaintext.txt	209	1 kb probe corresponding XmnI NcoI fragment 3 flanking region shown Figure 1
0.38527274.10655544.html.plaintext.txt	210	The hybridized membrane washed twice 15 min 68 degrees C 0
0.38527274.10655544.html.plaintext.txt	211	1 SDS subsequently incubated Fab fragments anti DIG antibody conjugated alkaline phosphatase
0.38527274.10655544.html.plaintext.txt	212	The chemi luminescence signal detected using CSPD Roche Molecular Biochemicals Mannheim Germany
0.38527274.10655544.html.plaintext.txt	213	To clone human apoE4 cDNA knock mice polyA RNA isolated liver first strand cDNA synthesized using SuperScript Preamplification System Gibco BRL Rockville MD
0.38527274.10655544.html.plaintext.txt	214	The human apoE4 cDNA amplified PCR using oligonucleotides MF CAATTGGGAAGATGAAGGTTCTGTGGGCTG TR CGGCGTTCAGTGATTGTCGCTGGGCACAGG
0.38527274.10655544.html.plaintext.txt	215	The PCR fragment expected size cloned pGEM T Easy Vector Promega Madison WI sequenced confirm absence inadvertent mutations expressed transgene
0.38527274.10655544.html.plaintext.txt	216	Western blot analysis Human serum 0
0.38527274.10655544.html.plaintext.txt	217	5 microl mouse fasted sera 1 microl combined 10 microl SDS PAGE sample buffer 2
0.38527274.10655544.html.plaintext.txt	218	3 SDS 5 2 mercaptoethanol 10 glycerol 62
0.38527274.10655544.html.plaintext.txt	219	Whole brains homogenized 2 ml homogenization buffer 5 mM EDTA 1 mM PMSF 10 microM leupeptin 10 microM pepstatin A 150 mM NaCl 10 mM sodium phosphate pH 7
0.38527274.10655544.html.plaintext.txt	220	2 glass Teflon Potter homogenizer
0.38527274.10655544.html.plaintext.txt	221	Aliquots homogenate containing 50 microg protein dissolved 10 microl SDS PAGE sample buffer boiled 3 min
0.38527274.10655544.html.plaintext.txt	222	The samples separated 10 acrylamide SDS PAGE transferred PVDF membrane
0.38527274.10655544.html.plaintext.txt	223	The blots blocked 3 non fat dried milkphosphate buffered saline incubated 1 h room temperature primary antibodies rat monoclonal 868E5 35 hamster monoclonal 874B7 35 mouse monoclonal Ab 412 1 7 36 followed washing appropriate biotinylated secondary antibodies
0.38527274.10655544.html.plaintext.txt	224	The signal detected using Vectastain ABC kit Vector Burlingame CA combined either chloronaphthol chromogen enhanced chemiluminescence Pierce Rockford IL
0.38527274.10655544.html.plaintext.txt	225	Lipid lipoprotein analysis Three four mice sex genotype 10 weeks fasted 6 h blood collected abdominal vena cava Nembutal anesthesia
0.38527274.10655544.html.plaintext.txt	226	Brains removed immediately exsanguination frozen dry ice
0.38527274.10655544.html.plaintext.txt	227	Chloroform methanol 11 extracts brains dried nitrogen gas re extracted choloform methanol 21
0.38527274.10655544.html.plaintext.txt	228	The lower phase evaporated extracted isopropanol analyses
0.38527274.10655544.html.plaintext.txt	229	Levels total serum cholesterol triglyceride determined using enzymatic assay kits Determiner TC555 Determiner TGS555 Kyowa Medex Tokyo Japan respectively
0.38527274.10655544.html.plaintext.txt	230	For FPLC size fractionation 50 microl mouse serum injected onto Superose 6 column FPLC system Amersham Pharmacia Biotech Uppsala Sweden eluted constant flow rate 0
0.38527274.10655544.html.plaintext.txt	231	5 mlmin 1 mM EDTA 50 mM phosphate buffer
0.38527274.10655544.html.plaintext.txt	232	5 ml collected cholesterol concentrations measured enzymatically apoE distribution studied western blotting
0.38527274.10655544.html.plaintext.txt	233	Immunohistochemistry Mice fixed deep Nembutal anesthesia cardiac perfusion chilled 4 paraformaldehyde 0
0.38527274.10655544.html.plaintext.txt	234	Brains removed post fixed overnight fixative 4 degrees C cryoprotected 20 sucrosephosphate buffered saline
0.38527274.10655544.html.plaintext.txt	235	Cryostat sections 13 microm cut picked glass
0.38527274.10655544.html.plaintext.txt	236	The sections exposed overnight either hamster mAb 884F11 35 hybridoma supernatant rabbit anti human ApoEIBL18171 1200 dilution Tris buffered saline 0
0.38527274.10655544.html.plaintext.txt	237	The bound antibodies visualized either biotinylated anti hamster Ig 127 065 160 1200 Jackson ImmunoResearch West Grove PA biotinylated anti rabbit Ig RPN1004 1200 Amersham Pharmacia Biotech followed Oregon Green labeled streptavidin S 6369 1200 Molecular Probes Eugene OR
0.38527274.10655544.html.plaintext.txt	238	Fluorescence images examined Olympus BX50 fluorescence microscope captured Hamamatsu C5810 Color Chilled 3CCD Camera MacSCOPE software printed Fujix Pictrography 3000
0.38527274.10655544.html.plaintext.txt	239	ACKNOWLEDGEMENTS This work possible use E14TG2aIV ES cells generously made available Dr A
0.38527274.10655544.html.plaintext.txt	240	Kitamoto kindly provided us neo cassette
0.38527274.10655544.html.plaintext.txt	241	We acknowledge helpful gift cDNA human apoE3 Dr M
0.38527274.10655544.html.plaintext.txt	242	Seki colleagues Mitsubishi Chemical Cor poration Yokohama Research Center
0.38527274.10655544.html.plaintext.txt	243	Nukina generous gift Ab 412 1 12 2 specific human apoE4 Dr K
0.38527274.10655544.html.plaintext.txt	244	Ikeda gift anti apoE antiserum Mr S
0.38527274.10655544.html.plaintext.txt	245	Kamijo expert support concerning mouse stocks
0.38527274.10655544.html.plaintext.txt	246	Yanagisawa helpful discussions Dr K
0.38527274.10655544.html.plaintext.txt	247	FOOTNOTES Present address Laboratory Neurodegeneration Signaling Brain Science Institute RIKEN Institute Physical Chemical Research 2 1 Hirosawa Wako Saitama 351 0198 Japan
0.38527274.10655544.html.plaintext.txt	248	To correspondence addressed
0.38527274.10655544.html.plaintext.txt	249	Tel 81 42 724 6276 Fax 81 42 724 6314 Email fujitals
0.38527274.10655544.html.plaintext.txt	250	REFERENCES TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES 1 Mahley R
0.38527274.10655544.html.plaintext.txt	251	1988 Apolipoprotein E cholesterol transport protein expanding role cell biology
0.38527274.10655544.html.plaintext.txt	252	1985 Apolipoprotein E mRNA abundant brain adrenals well liver present peripheral tissues rats marmosets
0.38527274.10655544.html.plaintext.txt	253	1985 Apolipoprotein E associated astrocytic glia central nervous system nonmyelinating glia peripheral nervous system
0.38527274.10655544.html.plaintext.txt	254	1987 Astrocytes synthesize apolipoprotein E metabolize apolipoprotein E containing lipoproteins
0.38527274.10655544.html.plaintext.txt	255	1987 Lipoproteins receptors central nervous system
0.38527274.10655544.html.plaintext.txt	256	Characterization lipoproteins cerebrospinal fluid identification apolipoprotein B E LDL receptors brain
0.38527274.10655544.html.plaintext.txt	257	1991 Apolipoproteins rat cerebrospinal fluid comparison plasma lipoprotein metabolism effect aging
0.38527274.10655544.html.plaintext.txt	258	1998 Nascent astrocyte particles differ lipoproteins CSF
0.38527274.10655544.html.plaintext.txt	259	1993 Apolipoprotein E high avidity binding ss amyloid increased frequency type 4 allele late onset familial Alzheimer disease
0.38527274.10655544.html.plaintext.txt	260	1993 Apolipoprotein E polymorphism Alzheimer disease
0.38527274.10655544.html.plaintext.txt	261	1996 Apolipoprotein E alleles risk factors Alzheimer disease
0.38527274.10655544.html.plaintext.txt	262	1991 Apolipoprotein E immunoreactivity cerebral amyloid deposits neurofibrillary tangles Alzheimer disease kuru plaque amyloid Creutzfeldt Jakob disease
0.38527274.10655544.html.plaintext.txt	263	1994 Presence apolipoprotein E extracellular neurofibrillary tangles meningeal blood vessels precedes Alzheimer ss amyloid deposition
0.38527274.10655544.html.plaintext.txt	264	1993 Apolipoprotein E sporadic Alzheimer disease allelic variation receptor interactions
0.38527274.10655544.html.plaintext.txt	265	1993 Increased amyloid ss peptide deposition cerebral cortex consequence apolipoprotein E genotype late onset Alzheimer disease
0.38527274.10655544.html.plaintext.txt	266	1993 Apolipoprotein E binding soluble Alzheimer ss amyloid
0.38527274.10655544.html.plaintext.txt	267	1994 Isoform specific binding apolipoprotein E ss amyloid
0.38527274.10655544.html.plaintext.txt	268	1994 Isoform specific interactions apolipoprotein E microtubule associated protein tau implications Alzheimer disease
0.38527274.10655544.html.plaintext.txt	269	1985 A specific 37000 dalton protein accumulates regenerating nonregenerating mammalian nerves
0.38527274.10655544.html.plaintext.txt	270	1986 Expression apolipoprotein E nerve degeneration regeneration
0.38527274.10655544.html.plaintext.txt	271	1986 Nerve injury stimulates secretion apolipoprotein E nonneuronal cells
0.38527274.10655544.html.plaintext.txt	272	1989 A role apolipoprotein E apolipoprotein A I low density lipoprotein receptors cholesterol transport regeneration remyelination rat sciatic nerve
0.38527274.10655544.html.plaintext.txt	273	1991 Astrocytic apolipoprotein E mRNA GFAP mRNA hippocampus entorhinal cortex lesioning
0.38527274.10655544.html.plaintext.txt	274	1993 Cholesterol synthesis lipoprotein reuptake synaptic remodelling hippocampus adult rats
0.38527274.10655544.html.plaintext.txt	275	1994 Apolipoprotein E animal models CNS injury Alzheimer disease
0.38527274.10655544.html.plaintext.txt	276	1990 Cholesterol synthesis regulated regeneration peripheral nerve
0.38527274.10655544.html.plaintext.txt	277	1994 Membrane lipids adult human brain lipid composition frontal temporal lobe subjects age 20 100 years
0.38527274.10655544.html.plaintext.txt	278	1994 Membrane lipids selectively diminished Alzheimer brains suggest synapse loss primary event early onset form type I demyelination late onset form type II
0.38527274.10655544.html.plaintext.txt	279	1998 Apolipoprotein E4 induces neuronal cell death conditions suppressed de novo cholesterol synthesis
0.38527274.10655544.html.plaintext.txt	280	1997 Targeted replacement mouse apolipoprotein E gene common human APOE3 allele enhances diet induced hypercholesterolemia atherosclerosis
0.38527274.10655544.html.plaintext.txt	281	1998 Type III hyperlipoproteinemia spontaneous atherosclerosis mice resulting gene replacement mouse Apoe human APOE2
0.38527274.10655544.html.plaintext.txt	282	1999 ApoE structure determines VLDL clearance atherosclerosis risk mice
0.38527274.10655544.html.plaintext.txt	283	1987 HPRT deficient Lesch Nyhan mouse embryos derived germline colonization cultured cells
0.38527274.10655544.html.plaintext.txt	284	1985 Isolation characterization mapping chromosome 19 human apolipoprotein E gene
0.38527274.10655544.html.plaintext.txt	285	1994 Apolipoprotein E structure function relationships
0.38527274.10655544.html.plaintext.txt	286	1999 Apolipoprotein E found astrocytes microglia normal mouse brain
0.38527274.10655544.html.plaintext.txt	287	1995 Monoclonal antibody polymorphic site distinguishes apolipoprotein E4 isoforms
0.38527274.10655544.html.plaintext.txt	288	1992 Generation mice carrying mutant apolipoprotein E gene inactivated gene targeting embryonic stem cells
0.38527274.10655544.html.plaintext.txt	289	1988 Human apolipoprtoein E3 aqueous solution
0.38527274.10655544.html.plaintext.txt	290	Evidence two structural domains
0.38527274.10655544.html.plaintext.txt	291	1998 Human apolipoprotein E allele specific brain expressing transgenic mice
0.38527274.10655544.html.plaintext.txt	292	1998 Glial fibrillary acidic protein apolipoprotein E apoE transgenic mice astrocyte specific expression differing biological effects astrocyte secreted apoE3 apoE4 lipoproteins
0.38527274.10655544.html.plaintext.txt	293	1998 Isoform specific effects human apolipoprotein E brain function revealed ApoE knockout mice increased susceptibility females
0.38527274.10655544.html.plaintext.txt	294	1992 Spontaneous hypercholesterolemia arterial lesions mice lacking apolipoprotein E
0.38527274.10655544.html.plaintext.txt	295	1992 Severe hypercholesterolemia atherosclerosis aplipoprotein E deficient mice created homologous recombination ES cells
0.38527274.10655544.html.plaintext.txt	296	1996 Human apolipoprotein E2 E3 E4 isoform specific transgenic mice human like pattern glial neuronal immunoreactivity central nervous system observed wild type mice
0.38527274.10655544.html.plaintext.txt	297	1988 Apolipoprotein E polymorphism atherosclerosis
0.38527274.10655544.html.plaintext.txt	298	1995 Interactions apolipoprotein E genotype total cholesterol level age sex prediction Alzheimer disease case control study
0.38527274.10655544.html.plaintext.txt	299	1989 Differential distribution apolipoprotein E isoforms human plasma lipoproteins
0.38527274.10655544.html.plaintext.txt	300	Arteriosclerosis 9 405 411
0.38527274.10655544.html.plaintext.txt	301	1994 Human apolipoprotein E role arginine 61 mediating lipoprotein preferences E3 E4 isoforms
0.38527274.10655544.html.plaintext.txt	302	1986 Abnormal vivo metabolism apolipoprotein E4 humans
0.38527274.10655544.html.plaintext.txt	303	1998 A detergent insoluble membrane compartment contains Ass vivo
0.38527274.10655544.html.plaintext.txt	304	1998 The presence amyloid ss protein detergent insoluble membrane compartment human neuroblastoma cells
0.38527274.10655544.html.plaintext.txt	305	Biochemistry 37 15247 15253
0.38527274.10655544.html.plaintext.txt	306	1996 Cholesterol modulates secretase cleavage amyloid precursor protein
0.38527274.10655544.html.plaintext.txt	307	1997 Secretory processing amyloid precursor protein inhibited increase cellular cholesterol content
0.38527274.10655544.html.plaintext.txt	308	1998 Caveolae plasma membrane microdomains secretase mediated processing amyloid precursor protein
0.38527274.10655544.html.plaintext.txt	309	1998 Cholesterol depletion inhibits generation ss amyloid hippocampal neurons
0.38527274.10655544.html.plaintext.txt	310	Yanagisawa K 1998 Cholesterol dependent generation unique amyloid ss protein apically missorted amyloid precursor protein MDCK cells
0.38527274.10655544.html.plaintext.txt	311	1999 Cholesterol dependent generation seeding amyloid ss protein cell culture
0.38527274.10655544.html.plaintext.txt	312	1998 Modulation secreted ss amyloid precursor protein amyloid ss peptide brain cholesterol
0.38527274.10655544.html.plaintext.txt	313	1998 Alzheimer disease genetic studies transgenic models
0.38527274.10655544.html.plaintext.txt	314	1999 Amyloid production deposition mutant amyloid presursor protein presenilin 1 yeast artificial chromosome transgenic mice
0.38527274.10655544.html.plaintext.txt	315	1995 Complete cerebral ischemia short term survival rat induced cardiac arrest
0.38527274.10655544.html.plaintext.txt	316	Extracellular intracellular accumulation apolipoproteins E J brain
0.38527274.10655544.html.plaintext.txt	317	1995 Apolipoprotein E 4 allele associated deposition amyloid ss protein following head injury
0.38527274.10655544.html.plaintext.txt	318	1998 Evidence normal aging septo hippocampal cholinergic system apoE mice impaired clearance axonal degeneration products following injury
0.38527274.10655544.html.plaintext.txt	319	1991 Dietary cholesterol origin cholesterol brain developing rats
0.38527274.10655544.html.plaintext.txt	320	1993 Kainic acid seizures rat
0.38527274.10655544.html.plaintext.txt	321	1984 Cell biology synaptic plasticity
0.38527274.10655544.html.plaintext.txt	322	1997 Plastic neuronal remodeling impaired patients Alzheimer disease carrying apolipoprotein 4 allele
0.38527274.10655544.html.plaintext.txt	323	1984 Human apolipoprotein E mRNA
0.38527274.10655544.html.plaintext.txt	324	cDNA cloning nucleotide sequencing new variant
0.38527274.10655544.html.plaintext.txt	325	1996 Humanized prion protein knock cre induced site specific recombination mouse
0.38527274.10655544.html.plaintext.txt	326	1987 Site directed mutagenesis gene targeting mouse embryo derived stem cells
0.42286012.9811931.html.plaintext.txt	0	Risk Alzheimers disease correlates transcriptional activity APOE gene
0.42286012.9811931.html.plaintext.txt	1	Departamento de Biologia Molecular Centro de Biologia Molecular Severo Ochoa CSIC UAM Universidad Autonoma de Madrid Cantoblanco 28049 Madrid Spain 1Servicio de Neurologia Hospital Universitario La Paz UAM 28034 Madrid Spain 2Departments Psychiatry Neurology Genetics Washington University School Medicine St Louis MO 63110 USA
0.42286012.9811931.html.plaintext.txt	2	Received May 21 1998 Revised Accepted August 18 1998
0.42286012.9811931.html.plaintext.txt	3	While epsis4 allele apolipoprotein E APOE gene ApoE protein widely accepted major genetic risk factor late onset form Alzheimers disease AD recent evidence points variations ApoE levels another important factor
0.42286012.9811931.html.plaintext.txt	4	We previously reported common variant regulatory region APOE 491A associated risk late onset AD
0.42286012.9811931.html.plaintext.txt	5	In report analyze association another APOE promoter polymorphism 427TC AD two case control clinical samples demonstrate correlation APOE promoter transcriptional activity risk AD
0.42286012.9811931.html.plaintext.txt	6	The association studies show allelic variant 427C haplotype 491A 427C APOE promoter associated increased risk AD
0.42286012.9811931.html.plaintext.txt	7	Study transcriptional activity common haplotypes defined combination 491 427 alleles indicated risk late onset AD positively correlates transcriptional activity APOE gene suggesting increases local expression ApoE could responsible association APOE promoter polymorphism AD
0.42286012.9811931.html.plaintext.txt	8	Alzheimers disease AD common cause dementia elderly exists familial sporadic forms
0.42286012.9811931.html.plaintext.txt	9	Genetic studies led identification three genes beta amyloid precursor protein APP 1 presenilin 1 2 presenilin 2 3 mutated cause autosomal dominant forms familial AD
0.42286012.9811931.html.plaintext.txt	10	However mutations three genes responsible small fraction AD cases vast majority patients AD presents late age onset shows non Mendelian inheritance
0.42286012.9811931.html.plaintext.txt	11	The absence Mendelian inheritance indicates late onset AD complex disease genetic non genetic factors likely interacting
0.42286012.9811931.html.plaintext.txt	12	The epsis4 allele apolipoprotein E APOE gene ApoE protein associated increased risk developing AD 4
0.42286012.9811931.html.plaintext.txt	13	However many AD cases APOE epsis4 alleles
0.42286012.9811931.html.plaintext.txt	14	Thus likely additional AD risk factors genetic environmental still identified
0.42286012.9811931.html.plaintext.txt	15	We screened genetic variability proximal promoter region APOE nt 1017 406 observed three new polymorphic sites 491 427 219 5 previously described one 113 6 within region
0.42286012.9811931.html.plaintext.txt	16	We recently reported one variants 491A associated risk AD 7
0.42286012.9811931.html.plaintext.txt	17	We report allelic variant 427C APOE promoter also associated AD whereas found significant association 219 113 polymorphisms risk AD
0.42286012.9811931.html.plaintext.txt	18	Results others suggested 219 polymorphism acts modifier ApoE4 associated risk 8
0.42286012.9811931.html.plaintext.txt	19	Study transcriptional activity haplotypes defined combination 491 427 alleles indicates risk late onset AD correlates transcriptional activity APOE gene
0.42286012.9811931.html.plaintext.txt	20	During screening transcriptional regulatory region APOE gene novel polymorphic site 427TC identified 5
0.42286012.9811931.html.plaintext.txt	21	The possible genetic association polymorphism risk AD studied Spanish case control sample previously observed association polymorphism position 491 APOE promoter risk AD 7
0.42286012.9811931.html.plaintext.txt	22	The genotype allele distributions 427TC polymorphism shown Table 1
0.42286012.9811931.html.plaintext.txt	23	The TC genotype C allele frequent although differences achieved statistical significance AD group controls suggesting associated increased risk AD odds ratio OR 1
0.42286012.9811931.html.plaintext.txt	24	87 95 confidence interval CI 0
0.42286012.9811931.html.plaintext.txt	25	91 TC genotype OR 1
0.42286012.9811931.html.plaintext.txt	26	APOE 427TC genotype allele frequencies f Spain age onset 60 years ApoE4 status Genotype n f Allele n f TT TC CC T C Whole sample Cases 90 0
0.42286012.9811931.html.plaintext.txt	27	05 ApoE4 non carriers Cases 28 0
0.42286012.9811931.html.plaintext.txt	28	05 Carriers Cases 62 0
0.42286012.9811931.html.plaintext.txt	29	06 2 x 2 chi2 tests compare TT TC genotype frequency AD versus controls performed whole sample P 0
0.42286012.9811931.html.plaintext.txt	30	In order determine whether variation risk AD associated 427TC polymorphism independent risk conferred ApoE4 sample stratified basis absence presence ApoE4 allele Table 1
0.42286012.9811931.html.plaintext.txt	31	No difference frequency 427C allele 427TC genotype observed AD patients controls bearing one two ApoE4 alleles 427C allele clearly associated increased risk AD individuals bearing ApoE4 alleles OR 3
0.42286012.9811931.html.plaintext.txt	32	Similarly 427TC genotype associated 3 fold increase risk AD subpopulation OR 3
0.42286012.9811931.html.plaintext.txt	33	45 indicating variation risk AD conferred 427TC polymorphism apparent individuals carrying ApoE4 allele
0.42286012.9811931.html.plaintext.txt	34	The trend observed US group individuals bearing ApoE4 alleles OR 1
0.42286012.9811931.html.plaintext.txt	35	01 TC genotype although differences allelic frequencies achieve statistical significance population
0.42286012.9811931.html.plaintext.txt	36	Since 427TC 491AT polymorphisms located close within proximal 5prime flanking region APOE gene appeared associated risk developing AD analyzed effect AD risk combined haplotypes
0.42286012.9811931.html.plaintext.txt	37	We first analyzed 491 427 haplotype distribution Spanish US samples
0.42286012.9811931.html.plaintext.txt	38	A combined digestion APOE fragment spanning nt 512 285 DraI AluI performed allowed identification four haplotypes 10 genotypes defined combination 491 427 alleles
0.42286012.9811931.html.plaintext.txt	39	Haplotype A T 491 427 common followed T T A C
0.42286012.9811931.html.plaintext.txt	40	No subjects T C haplotype found either sample
0.42286012.9811931.html.plaintext.txt	41	The distribution haplotypes genotypes close expected Hardy Weinberg equilibrium chi2 test P 0
0.42286012.9811931.html.plaintext.txt	42	Furthermore statistically significant evidence linkage disequilibrium polymorphisms detected chi2 test P 0
0.42286012.9811931.html.plaintext.txt	43	The frequent genotype A TA T followed A TT T A TA C three genotypes accounted 92 Spanish St Louis control populations
0.42286012.9811931.html.plaintext.txt	44	The frequency genotypes T TT T A CT T 5 frequencies genotypes ranged 0 2
0.42286012.9811931.html.plaintext.txt	45	The distribution major haplotypes genotypes Spanish St Louis samples shown Table 2
0.42286012.9811931.html.plaintext.txt	46	Since previous study revealed differences transcription associated 491 polymorphism 57 examined functional characteristics major 491 427 haplotypes present populations
0.42286012.9811931.html.plaintext.txt	47	The APOE proximal promoter activity three haplotypes T T A T A C measured U87 human astrocytoma cells using luciferase based transient transfection system employed previous studies 5719
0.42286012.9811931.html.plaintext.txt	48	As shown Figure 1 transcriptional activity haplotypes A T A C increased 30 100 respectively haplotype T T suggesting presence alleles conferring increased risk AD 491A 427C associated increased constitutive levels APOE promoter activity human astrocytoma cells
0.42286012.9811931.html.plaintext.txt	49	The three haplotypes T T A T A C thus named minus even x plus respectively according transcriptional activity
0.42286012.9811931.html.plaintext.txt	50	Additional information obtained using oligonucleotide probes corresponding 491 427 allelic forms electrophoretic mobility shift assays freshly prepared nuclear extracts U87 cells
0.42286012.9811931.html.plaintext.txt	51	As shown Figure 2 one three specific band shifts detected 427T probe arrows detected 427C probe suggesting T C substitution hinders binding probe nuclear protein
0.42286012.9811931.html.plaintext.txt	52	This finding agreement data obtained previous work using 491 probes 7 strongly suggests differential transcriptional activities three 491 427 haplotypes encountered astrocytoma cells consequence differential binding nuclear proteins present cells
0.42286012.9811931.html.plaintext.txt	53	APOE 491 427 major genotype haplotype frequencies f age onset 60 years Genotype n f Haplotype n f A TA T A TT T A TA C A T T T A C Spain Madrid Cases 68 0
0.42286012.9811931.html.plaintext.txt	54	05 USA St Louis Cases 104 0
0.42286012.9811931.html.plaintext.txt	55	09 2 x 2 chi2 test A TA C versus A TT T Spain P 0
0.42286012.9811931.html.plaintext.txt	56	2 x 2 chi2 test A TA T versus A TT T Spain P 0
0.42286012.9811931.html.plaintext.txt	57	Transcriptional activity 491 427 haplotypes APOE promoter
0.42286012.9811931.html.plaintext.txt	58	Luciferasebeta galactosidase activity ratios pXP2 constructs containing T T A T x A C APOE haplotypes transfected U87 astrocytoma cells expressed percentages activity T T construct
0.42286012.9811931.html.plaintext.txt	59	Data means plus minus SEM six determinations representative five experiments
0.42286012.9811931.html.plaintext.txt	60	Protein binding 427TC allelic forms APOE promoter
0.42286012.9811931.html.plaintext.txt	61	32P labeled 427T 427C probes incubated U87 nuclear extract NE subjected electrophoretic mobility shift assays
0.42286012.9811931.html.plaintext.txt	62	Competition experiments performed pre incubating nuclear extract 50 fold excess unlabeled oligonucleotide addition probe
0.42286012.9811931.html.plaintext.txt	63	Arrows specific shift bands asterisk non specific band
0.42286012.9811931.html.plaintext.txt	64	Results representative four independent experiments
0.42286012.9811931.html.plaintext.txt	65	Association APOE promoter activity risk AD analyzed Spanish population stratified according ApoE status Table 3
0.42286012.9811931.html.plaintext.txt	66	A strong association AD risk promoter activity three predominant genotypes x xx x observed Spanish non ApoE4 individuals taking reference x individuals risk AD found increase 6 18 fold xx x individuals respectively
0.42286012.9811931.html.plaintext.txt	67	Statistical significance data evaluated logistic regression model
0.42286012.9811931.html.plaintext.txt	68	Analysis subgroup non E4 carriers showed highly significant association AD risk promoter activity P 10 10 yielded predicted ORs 4
0.42286012.9811931.html.plaintext.txt	69	3 18 95 CI 8 40 genotypes xx x respectively Fig
0.42286012.9811931.html.plaintext.txt	70	Association risk AD APOE promoter genotypes Spanish b US non ApoE4 subpopulations
0.42286012.9811931.html.plaintext.txt	71	The risks represented log odds scale taking reference genotype x bears weakest expressing haplotype
0.42286012.9811931.html.plaintext.txt	72	Bars represent calculated ORs
0.42286012.9811931.html.plaintext.txt	73	The superimposed line represents ORs estimated logistic regression model error bars indicate 95 CIs
0.42286012.9811931.html.plaintext.txt	74	Finally hypothesis AD risk increases promoter transcriptional activity measured transfection assays tested St Louis population
0.42286012.9811931.html.plaintext.txt	75	Although association less impressive encountered Spanish population similar dependence OR developing AD promoter activity three predominant genotypes detected non E4 subpopulation Table 3
0.42286012.9811931.html.plaintext.txt	76	The logistic regression analysis indicated highly statistically significant association AD risk promoter activity P 10 10 ORs 1
0.42286012.9811931.html.plaintext.txt	77	2 genotypes xx x respectively Fig
0.42286012.9811931.html.plaintext.txt	78	In paper report association polymorphisms proximal region APOE promoter risk AD
0.42286012.9811931.html.plaintext.txt	79	We previously reported association homozygosity 491A allele risk AD 7
0.42286012.9811931.html.plaintext.txt	80	Here show 427C allele also associated risk AD
0.42286012.9811931.html.plaintext.txt	81	Furthermore combination two alleles 491A 427C haplotype generates high risk AD particular Spanish population individuals bearing ApoE4 alleles
0.42286012.9811931.html.plaintext.txt	82	The effect observed St Louis sample although relative risk lower Spanish sample
0.42286012.9811931.html.plaintext.txt	83	The difference relative risk probably attributable differences frequencies APOE promoter haplotypes two control populations since two AD samples show similar frequencies promoter haplotypes
0.42286012.9811931.html.plaintext.txt	84	It well documented population based differences ApoE4 allele frequency 910 give rise population differences relative risk AD associated allele
0.42286012.9811931.html.plaintext.txt	85	Consistently samples OR associated ApoE4 Spanish population 8
0.42286012.9811931.html.plaintext.txt	86	3 double St Louis sample 3
0.42286012.9811931.html.plaintext.txt	87	Based data anticipate wide variation relative risk AD associated APOE promoter polymorphism different populations already noted ApoE4 allele 11
0.42286012.9811931.html.plaintext.txt	88	Dividing sample basis presence absence ApoE4 revealed promoter polymorphisms ApoE4 independent risk factors
0.42286012.9811931.html.plaintext.txt	89	Indeed risk due promoter polymorphism prominent individuals without ApoE4 alleles
0.42286012.9811931.html.plaintext.txt	90	APOE 491 427 major genotype distribution ApoE epsis4 carriers non carriers age onset 60 years ApoE4 status Spain Madrid n f USA St Louis n f A TA T A TT T A TA C A TA T A TT T A TA C Cases 21 0
0.42286012.9811931.html.plaintext.txt	91	17 2 x 2 chi2 test A TA C versus A TT T ApoE4 non carriers Spain P 0
0.42286012.9811931.html.plaintext.txt	92	2 x 2 chi2 test A TA T versus A TT T ApoE4 non carriers Spain P 0
0.42286012.9811931.html.plaintext.txt	93	P values ApoE4 carriers 0
0.42286012.9811931.html.plaintext.txt	94	05 significant samples
0.42286012.9811931.html.plaintext.txt	95	ApoE expression regulated complex interactions developmental hormonal dietary factors 12 15
0.42286012.9811931.html.plaintext.txt	96	Regulation APOE expression investigated thoroughly hepatoma cells shown elements required efficient expression located 5prime proximal region first intron 16 18
0.42286012.9811931.html.plaintext.txt	97	More recently demonstrated region also drives efficient expression APOE astrocytoma cells 19
0.42286012.9811931.html.plaintext.txt	98	The data presented report strongly suggest allelic polymorphism transcriptional regulatory region APOE may contribute differences levels ApoE synthesis astrocytes
0.42286012.9811931.html.plaintext.txt	99	Specifically data indicate single base substitutions corresponding 491 427 APOE polymorphic sites produce differences transcriptional activity APOE promoter due differential binding nuclear proteins
0.42286012.9811931.html.plaintext.txt	100	It well documented single nucleotide changes within promoter region dramatically affect transcriptional activity mediated transcription factors 20 22
0.42286012.9811931.html.plaintext.txt	101	The data presented strongly suggest existence direct correlation risk AD APOE promoter activity astrocytic cells
0.42286012.9811931.html.plaintext.txt	102	higher expression ApoE higher risk AD
0.42286012.9811931.html.plaintext.txt	103	There increasing evidence suggesting increased levels ApoE associated AD pathogenesis
0.42286012.9811931.html.plaintext.txt	104	Several studies reported ApoE levels elevated brain plasma AD patients 23 25
0.42286012.9811931.html.plaintext.txt	105	Intracellular accumulation ApoE also correlated neuronal cell death intracellular Abeta stabilization 26
0.42286012.9811931.html.plaintext.txt	106	Recent studies also demonstrated level ApoE expression modify cytotoxic effects ApoE propensity Abeta deposit murine brain
0.42286012.9811931.html.plaintext.txt	107	ApoE concentrations found cerebrospinal fluid protects neuronal cells Abeta peptides higher ApoE concentrations could lead neuronal cell death 27
0.42286012.9811931.html.plaintext.txt	108	Crossing APOE knockout mice mice overexpressing human mutant APP gene indicates Abeta deposition correlates positively ApoE dose suggests ApoE may facilitate Abeta peptide deposition vivo 28
0.42286012.9811931.html.plaintext.txt	109	Despite evidence implicating ApoE4 single important genetic determinant susceptibility late onset AD pathogenic role well understood
0.42286012.9811931.html.plaintext.txt	110	The amino acid substitutions associated E2 E3 E4 ApoE isoforms lead differences predicted three dimensional structure ApoE likely alter functional properties molecule
0.42286012.9811931.html.plaintext.txt	111	Several potential mechanisms action ApoE4 AD risk proposed based ApoE isoform specific differences observed several assays developed brain cells 28 35
0.42286012.9811931.html.plaintext.txt	112	However date adequate explanation variation risk AD associated different ApoE isoforms
0.42286012.9811931.html.plaintext.txt	113	Based upon data presented elsewhere suggest two independent mechanisms AD risk modified APOE gene
0.42286012.9811931.html.plaintext.txt	114	The first involves variants coding region alter functional properties ApoE molecule second involves promoter region variants result quantitative differences ApoE expression
0.42286012.9811931.html.plaintext.txt	115	These two factors associated AD risk independently
0.42286012.9811931.html.plaintext.txt	116	one produce risk may interact resulting overall risk individuals bearing ApoE4 high expressing APOE promoter forms would depend relative contribution two risk factors
0.42286012.9811931.html.plaintext.txt	117	In summary data strongly suggest risk AD associated APOE promoter polymorphisms directly correlates transcriptional activity gene
0.42286012.9811931.html.plaintext.txt	118	Further speculate increases local expression ApoE due APOE promoter polymorphisms could lead enhanced deposition Abeta peptide brain thus explaining increased risk AD
0.42286012.9811931.html.plaintext.txt	119	If correct drugs either control ApoE synthesis inhibit Abeta production deposition may useful treatment AD
0.42286012.9811931.html.plaintext.txt	120	MATERIALS AND METHODS Study subjects
0.42286012.9811931.html.plaintext.txt	121	The test sample consisted 132 healthy controls age onset 72 plus minus 7 years mean plus minus SD 110 late onset sporadic AD cases 68 plus minus 5 years Madrid region Spain recruited Neurology Service Hospital La Paz Madrid
0.42286012.9811931.html.plaintext.txt	122	The replication sample composed 175 healthy controls 78 plus minus 9 years 160 AD 3637 cases 75 plus minus 8 years St Louis metropolitan region USA recruited Alzheimers Disease Research Center Washington University
0.42286012.9811931.html.plaintext.txt	123	Both samples included individuals Caucasian origin
0.42286012.9811931.html.plaintext.txt	124	Genotyping 491AT 427TC ApoE polymorphisms
0.42286012.9811931.html.plaintext.txt	125	The APOE region 512 285 amplified nested PCR using mismatched primer generate DraI site specific 491A allele
0.42286012.9811931.html.plaintext.txt	126	Briefly PCR used amplify 1423 bp fragment transcriptional regulatory region spanning 1017 406 relative transcriptional start site 16
0.42286012.9811931.html.plaintext.txt	127	Primers 5prime CAAGGTCACACAGCTGGCAAC 3prime 5prime TCCAATCGACGGCTAGCTACC 3prime used amplify whole transcriptional regulatory region
0.42286012.9811931.html.plaintext.txt	128	A nested PCR used difficulty reliably amplifying 512 285 fragment directly genomic DNA
0.42286012.9811931.html.plaintext.txt	129	The 1423 bp PCR product therefore used template following reaction
0.42286012.9811931.html.plaintext.txt	130	The forward mismatched primer 5prime TGTTGGCCAGGCTGGTTTTAA 3prime reverse primer 5prime CCTCCTTTCCTGACCCTGTCC 3prime
0.42286012.9811931.html.plaintext.txt	131	To analyze 491 427 genotypes well 491 427 haplotype product digested DraI AluI restriction enzymes together
0.42286012.9811931.html.plaintext.txt	132	ApoE isoform genotyping performed described 3839
0.42286012.9811931.html.plaintext.txt	133	The 5prime region positions 1017 406 APOE gene cloned pXP2 luciferase reporter plasmid described 19
0.42286012.9811931.html.plaintext.txt	134	PCR based site directed mutagenesis used replace A T 491 T C 427 using modification described method 40
0.42286012.9811931.html.plaintext.txt	135	The constructs transfected U87 human astrocytoma cells luciferase beta galactosidase activities extracts determined described 19
0.42286012.9811931.html.plaintext.txt	136	Electrophoretic mobility shift assays EMSA
0.42286012.9811931.html.plaintext.txt	137	EMSA oligonucleotide probes U87 nuclear extracts performed described 57
0.42286012.9811931.html.plaintext.txt	138	The oligonucleotides 5prime GCTGGTCTCAAATCTCCTGACCTTAA 3prime 5prime ACAGGCGTGAGCTCACCGCCCCCAGC 3prime used study nuclear protein binding 491 427 sites respectively
0.42286012.9811931.html.plaintext.txt	139	Genotype allelehaplotype distributions analyzed 2 x 2 chi2 test
0.42286012.9811931.html.plaintext.txt	140	Relative risks ORs 95 CIs calculated described 41
0.42286012.9811931.html.plaintext.txt	141	A logistic regression model used estimate relative risks AD major APOE promoter genotypes function transcriptional activity
0.42286012.9811931.html.plaintext.txt	142	Alonso Hospital Ramon y Cajal Madrid kind collaboration sample collection P
0.42286012.9811931.html.plaintext.txt	143	Diez Tejedor Hospital La Paz Madrid advice clinical work faculty staff Washington University Alzheimers Disease Research Center patient evaluation sample collection
0.42286012.9811931.html.plaintext.txt	144	Baty Washington University Division Biostatistics advice statistical analysis
0.42286012.9811931.html.plaintext.txt	145	Mayor continuous encouragement help
0.42286012.9811931.html.plaintext.txt	146	We thank patients healthy individuals participated research
0.42286012.9811931.html.plaintext.txt	147	This work supported Boehringer Ingelheim Espana Fondo de Investigacion Sanitaria grant
0.42286012.9811931.html.plaintext.txt	148	95 0022 NIH AG05681 AG03991 Alzheimers Association Nettie Rebecca Brown Foundation Metropolitan Life Foundation
0.42286012.9811931.html.plaintext.txt	149	The institutional grant Fundacion Ramon Areces CBMSO acknowledged
0.42286012.9811931.html.plaintext.txt	150	recipient fellowship Fondo de Investigacion Sanitaria
0.42286012.9811931.html.plaintext.txt	151	recipient fellowship Spanish Ministerio de Educacion y Ciencia
0.42286012.9811931.html.plaintext.txt	152	post doctoral fellow Washington University Alzheimers Disease Research Center
0.42286012.9811931.html.plaintext.txt	153	recipient NIH career development award AG00634
0.42286012.9811931.html.plaintext.txt	154	AD Alzheimers disease ApoE apolipoprotein E APOE apolipoprotein E gene APP beta amyloid precursor protein CI confidence interval OR odds ratio
0.42286012.9811931.html.plaintext.txt	155	1991 Segregation missense mutation amyloid precursor protein gene familial Alzheimers disease
0.42286012.9811931.html.plaintext.txt	156	1995 Cloning gene bearing missense mutations early onset familial Alzheimers disease
0.42286012.9811931.html.plaintext.txt	157	1995 Candidate gene chromosome 1 familial Alzheimers disease locus
0.42286012.9811931.html.plaintext.txt	158	1993 Gene dose apolipoprotein E type 4 allele risk AD late onset families
0.42286012.9811931.html.plaintext.txt	159	1998 Allelic polymorphisms transcriptional regulatory region apolipoprotein E gene
0.42286012.9811931.html.plaintext.txt	160	1996 A newly identified polymorphism apolipoprotein E enhancer gene region associated Alzheimers disease strongly epsis4 allele
0.42286012.9811931.html.plaintext.txt	161	1998 A polymorphism regulatory region APOE associated risk Alzheimers dementia
0.42286012.9811931.html.plaintext.txt	162	1998 A new polymorphism APOE promoter associated risk developing Alzheimers dementia
0.42286012.9811931.html.plaintext.txt	163	1992 Apolipoprotein E polymorphism Danish population compared findings 45 study populations around world
0.42286012.9811931.html.plaintext.txt	164	1997 Pattern gradient apolipoprotein E allele 4 frequencies western Europe
0.42286012.9811931.html.plaintext.txt	165	1997 Effects age sex ethnicity association apolipoprotein E genotype Alzheimer disease
0.42286012.9811931.html.plaintext.txt	166	APOE Alzheimer Disease Meta Analysis Consortium
0.42286012.9811931.html.plaintext.txt	167	1981 Effects atherogenic diet apolipoprotein E biosynthesis rat
0.42286012.9811931.html.plaintext.txt	168	1984 Cloning regulation messenger RNA mouse apolipoprotein E
0.42286012.9811931.html.plaintext.txt	169	1985 Apolipoprotein E mRNA abundant brain adrenals well liver present peripheral tissues rats marmosets
0.42286012.9811931.html.plaintext.txt	170	1985 The secretion apolipoprotein E human monocyte derived macrophages
0.42286012.9811931.html.plaintext.txt	171	1988 Identification characterization transcriptional regulatory regions associated expression human apolipoprotein E gene
0.42286012.9811931.html.plaintext.txt	172	1988 Expression human apolipoprotein E gene regulated multiple positive negative elements
0.42286012.9811931.html.plaintext.txt	173	1995 The human apolipoprotein E gene negatively regulated human liver HepG2 cells transcription factor BEF 1
0.42286012.9811931.html.plaintext.txt	174	1996 Transcriptional factor AP 2 regulates human apolipoprotein E gene expression astrocytoma cells
0.42286012.9811931.html.plaintext.txt	175	1992 Single base pair substitutions within HLA DRA gene promoter separate functions X1 X2 boxes
0.42286012.9811931.html.plaintext.txt	176	1994 A polymorphism G A transition 78 position apolipoprotein A I promoter increases transcription efficiency
0.42286012.9811931.html.plaintext.txt	177	1992 Polymorphism human apolipoprotein A 1 gene promoter region
0.42286012.9811931.html.plaintext.txt	178	Association minor allele decreased production rate vivo promoter activity vitro
0.42286012.9811931.html.plaintext.txt	179	1995 Apolipoprotein E mRNA brains patients Alzheimers disease
0.42286012.9811931.html.plaintext.txt	180	1997 Distortion allelic expression apolipoprotein E Alzheimers disease
0.42286012.9811931.html.plaintext.txt	181	1997 Increased plasma apolipoprotein E apoE levels Alzheimers disease
0.42286012.9811931.html.plaintext.txt	182	1997 Neuronal cell death Alzheimers disease correlates apoE uptake intracellular Abeta stabilization
0.42286012.9811931.html.plaintext.txt	183	1996 Apolipoprotein E allele specific antioxidant activity effects cytotoxicity oxidative insults beta amyloid peptides
0.42286012.9811931.html.plaintext.txt	184	1997 Lack apolipoprotein E dramatically reduces amyloid beta peptide deposition
0.42286012.9811931.html.plaintext.txt	185	1996 Alterations apolipoprotein E expression aging neurodegeneration
0.42286012.9811931.html.plaintext.txt	186	1989 A role apolipoprotein E apolipoprotein A I low density lipoprotein receptors cholesterol transport regeneration remyelination rat sciatic nerve
0.42286012.9811931.html.plaintext.txt	187	1995 Apolipoprotein E impact cytoskeletal stability neurons relationship Alzheimers disease
0.42286012.9811931.html.plaintext.txt	188	1995 Interaction apolipoprotein E laminin increases neuronal adhesion alters neurite morphology
0.42286012.9811931.html.plaintext.txt	189	1994 Apolipoprotein E cholesterol affect neuronal calcium signalling possible relationship beta amyloid neurotoxicity
0.42286012.9811931.html.plaintext.txt	190	1998 Glial fibrillary acidic protein apolipoprotein E apoE transgenic mice astrocyte specific expression differing biological effects astrocyte secreted apoE3 apoE4 lipoproteins
0.42286012.9811931.html.plaintext.txt	191	1998 Differential cellular accumulationretention apolipoprotein E mediated cell surface heparan sulfate proteoglicans
0.42286012.9811931.html.plaintext.txt	192	Apolipoproteins E3 E2 greater E4
0.42286012.9811931.html.plaintext.txt	193	1984 Clinical diagnosis Alzheimers disease report NINCDS ADRDA Work Group auspices Department Health Human Services Task Force Alzheimers disease
0.42286012.9811931.html.plaintext.txt	194	1990 Restriction isotyping human apolipoprotein E gene amplification cleavage HhaI
0.42286012.9811931.html.plaintext.txt	195	1994 Protection Alzheimers disease apoE epsilon 2
0.42286012.9811931.html.plaintext.txt	196	Academic Press New York NY pp
0.42286012.9811931.html.plaintext.txt	197	1988 Calculating confidence intervals relative risks odds ratios standardised ratios rates
0.42286012.9811931.html.plaintext.txt	198	To correspondence addressed
0.42286012.9811931.html.plaintext.txt	199	Tel 34 91 397 84 71 Fax 34 91 397 48 70 Email fvaldiviesoat cbm
0.42286012.9811931.html.plaintext.txt	200	es u d The first two authors contributed equally work This page run Oxford University Press Great Clarendon Street Oxford OX2 6DP part OUP Journals Comments feedback www adminatoup
0.42286012.9811931.html.plaintext.txt	201	uk u d Last modification 12 Nov 1998 Copyright Oxford University Press 1998
0.4035247.9467014.html.plaintext.txt	0	A new polymorphism APOE promoter associated risk developing Alzheimers Disease
0.4035247.9467014.html.plaintext.txt	1	Jean Charles Lambert1 Florence Pasquier2 Dominique Cottel1 Bernard Frigard3 Philippe Amouyel1 Marie Christine Chartier Harlin1
0.4035247.9467014.html.plaintext.txt	2	1INSERM CJF95 05 Institut Pasteur de Lille 1 rue du Professeur Calmette 59019 Lille Cedex France 2CHR et U de Lille Clinique Neurologique Centre de la Memoire Hopital Salengro 59037 Lille cedex France 3Centre de Geriartrie de Wasquehal Molinel rue Salvador Allende B
0.4035247.9467014.html.plaintext.txt	3	Received October 28 1997 Revised Accepted December 19 1997
0.4035247.9467014.html.plaintext.txt	4	The epsis4 allele Apolipoprotein E gene APOE one main allele APOE polymorphism major risk factor development Alzheimers disease
0.4035247.9467014.html.plaintext.txt	5	However several data suggest genetic factors within APOE locus may also modulate risk associated polymorphism
0.4035247.9467014.html.plaintext.txt	6	We look new mutations APOE promoter susceptible modify risk associated APOE epsis4 allele
0.4035247.9467014.html.plaintext.txt	7	We characterised GrarrT mutation 186 bp APOE gene TATA box named Th1E47cs
0.4035247.9467014.html.plaintext.txt	8	This new polymorphism located consensus sequence potential transcriptional Th1E47 factor binding site
0.4035247.9467014.html.plaintext.txt	9	We studied impact new polymorphism markers APOE locus large case control study observed Th1E47cs modulated influence APOE epsis4 allele risk Alzheimers disease
0.4035247.9467014.html.plaintext.txt	10	The apolipoprotein E gene APOE key player lipid transport exists three main alleles general population epsis2 epsis3 epsis4
0.4035247.9467014.html.plaintext.txt	11	These polymorphisms correspond mutations coding sequence APOE gene resulting amino acid substitutions Arg Cys positions 112 158 protein
0.4035247.9467014.html.plaintext.txt	12	This gene located chromosome 19 position q13
0.4035247.9467014.html.plaintext.txt	13	The implication chromosome 19 Alzheimers disease AD suspected least three occasions 1 3 report association late onset AD APOE epsis4 allele 4
0.4035247.9467014.html.plaintext.txt	14	Numerous studies confirmed finding extended observation early onset AD 5 7
0.4035247.9467014.html.plaintext.txt	15	It established carrying epsis4 allele increases risk AD allele dose dependent manner shifts age onset disease earlier ages 8
0.4035247.9467014.html.plaintext.txt	16	Conversely bearing epsis2 allele confers protection disease 5910
0.4035247.9467014.html.plaintext.txt	17	Thus APOE genotype appears important biological marker AD susceptibility accounting 45 60 AD genetic variability
0.4035247.9467014.html.plaintext.txt	18	Several biological mechanisms proposed underlie association
0.4035247.9467014.html.plaintext.txt	19	The E4 isoform would facilitate limit amyloid substance deposition 1112
0.4035247.9467014.html.plaintext.txt	20	This isoform may protect oxidative stress contrast E2 isoform 13
0.4035247.9467014.html.plaintext.txt	21	It also suggested E2 E3 isoforms would prevent aggregation Tau protein limiting abnormal phosphorylation leading constitution paired helical filament E4 isoform would 14
0.4035247.9467014.html.plaintext.txt	22	However none hypotheses fully explained many 50 homozygous subjects survive 80 years develop AD
0.4035247.9467014.html.plaintext.txt	23	This observation suggests factors influence APOE associated risk
0.4035247.9467014.html.plaintext.txt	24	Indeed genetic environmental factors family history gender smoking oestrogen cholesterol level polymorphisms located APOE receptor genes instance 15 20 may modify APOE associated risk
0.4035247.9467014.html.plaintext.txt	25	However recent reports suggest additional genetic factors within APOE locus may also modulate risk
0.4035247.9467014.html.plaintext.txt	26	Firstly genetic study markers vicinity APOE locus demonstrated combination three polymorphisms increases estimation APOE associated risk AD compared APOE polymorphism alone 5
0.4035247.9467014.html.plaintext.txt	27	Secondly distortion allelic expression APOE gene observed brain affected patients indeed relative expression epsis4 allele increased 1
0.4035247.9467014.html.plaintext.txt	28	5 fold epsis3epsis4 bearer AD patients compared epsis3epsis4 bearer controls 21
0.4035247.9467014.html.plaintext.txt	29	Together data suggest potential existence one additional genetic susceptibility factors APOE sequence modifying risk associated APOE epsis4 allele occurrence AD
0.4035247.9467014.html.plaintext.txt	30	Detailed sequence analyses study APOE locus needed characterise additional genetic factors
0.4035247.9467014.html.plaintext.txt	31	reported polymorphism 1E1 first intron APOE gene strong linkage disequilibrium APOE epsis4 allele 22
0.4035247.9467014.html.plaintext.txt	32	To go hunt polymorphisms sequenced 375 bp upstream APOE TATA box detected new polymorphism whose impact AD risk together APOE epsis4 allele investigated large case control study
0.4035247.9467014.html.plaintext.txt	33	Sequencing 375 bp upstream TATA box APOE found GrarrT polymorphism position 186 TATA box located potential consensus binding sequence Th1E47 heterodimer transcriptional factor Fig
0.4035247.9467014.html.plaintext.txt	34	Because location named Th1E47cs polymorphism Th1E47 consensus sequence polymorphism
0.4035247.9467014.html.plaintext.txt	35	Autoradiograph sequencing gel part APOE promoter heterozygous Th1E47cs individual showing GrarrT base pair change
0.4035247.9467014.html.plaintext.txt	36	b Comparison APOE promoter sequence including Th1E47cs polymorphism consensus sequence predicted binding site Th1E47cs heterodimer 21
0.4035247.9467014.html.plaintext.txt	37	The predicted positions Th1 E47 binding site indicated top based known half site specificity E47 predicted Th1
0.4035247.9467014.html.plaintext.txt	38	The GrarrT mutation boxed located half site specificity E47
0.4035247.9467014.html.plaintext.txt	39	Nucleotide positions numbered relative canonical E box sequence
0.4035247.9467014.html.plaintext.txt	40	We studied association Th1E47cs polymorphism AD large case control study 310 cases age 74
0.4035247.9467014.html.plaintext.txt	41	3 years 293 controls age 73
0.4035247.9467014.html.plaintext.txt	42	We analysed Th1E47cs polymorphism together APOE 1E1 D19S178 repeat polymorphisms
0.4035247.9467014.html.plaintext.txt	43	The distributions polymorphisms presented Table 1
0.4035247.9467014.html.plaintext.txt	44	No deviation Hardy Weinberg equilibrium observed polymorphisms
0.4035247.9467014.html.plaintext.txt	45	As expected epsis4 allele strongly associated AD OR 4
0.4035247.9467014.html.plaintext.txt	46	67 epsis2 allele exhibited protective effect OR 0
0.4035247.9467014.html.plaintext.txt	47	In control population Th1E47cs G allele common one 0
0.4035247.9467014.html.plaintext.txt	48	531 contrast AD population 0
0.4035247.9467014.html.plaintext.txt	49	The allelic genotypic distributions significantly different AD cases compared control cases P 0
0.4035247.9467014.html.plaintext.txt	50	The Th1E47cs T allele associated increased risk developing AD OR 1
0.4035247.9467014.html.plaintext.txt	51	002 individuals bearing least one T allele
0.4035247.9467014.html.plaintext.txt	52	For 1E1 polymorphism allelic genotypic distributions similar ones reported Mui et al
0.4035247.9467014.html.plaintext.txt	53	20 significantly different AD control populations P 0
0.4035247.9467014.html.plaintext.txt	54	The 1E1 C allele associated decreased risk developing AD OR 0
0.4035247.9467014.html.plaintext.txt	55	No difference allelic genotypic distributions D19S178 repeat alleles observed P 0
0.4035247.9467014.html.plaintext.txt	56	We calculated pairwise linkage disequilibriums D19S178 Th1E47cs 1E1 APOE polymorphisms Table 2
0.4035247.9467014.html.plaintext.txt	57	As expected significant linkage disequilibriums existed Th1E47cs 1E1 APOE polymorphisms
0.4035247.9467014.html.plaintext.txt	58	D19S178 independent polymorphisms although weak linkage disequilibrium existed APOE control population
0.4035247.9467014.html.plaintext.txt	59	We estimated haplotypes generated four polymorphisms using myriad haplotype algorithm
0.4035247.9467014.html.plaintext.txt	60	Among 16 theoretical haplotypes 15 observed Table 3a
0.4035247.9467014.html.plaintext.txt	61	All haplotypes observed AD cases three nos 2 5 7 represented controls
0.4035247.9467014.html.plaintext.txt	62	The difference distribution estimated haplotype frequencies cases controls tested likelihood ratio test 13 degrees freedom chi2 696
0.4035247.9467014.html.plaintext.txt	63	To take account strong association APOE epsis4 allele AD compared estimated haplotype distributions epsis3epsis3 epsis3epsis4 AD control subgroups Table 3b c
0.4035247.9467014.html.plaintext.txt	64	In subgroup epsis3epsis3 epsis3epsis4 genotype bearers respectively estimated haplotype distributions significantly different AD control subjects likelihood test chi2 374 df 8 chi2 160 df 6 respectively suggesting potential independent effect polymorphisms
0.4035247.9467014.html.plaintext.txt	65	Distribution combination different polymorphism alleles controls AD cases Allele frequency Genotype frequency APOEa n epsis2 epsis3 epsis4 epsis2epsis2 epsis2epsis3 epsis2epsis4 epsis3epsis3 epsis3epsis4 epsis4epsis4 Control cases 308 0
0.4035247.9467014.html.plaintext.txt	66	113 Th1E47cs n Gb T GGc GT TT Control cases 310 0
0.4035247.9467014.html.plaintext.txt	67	272 1E1 n Gd C GGe GC CC Control cases 307 0
0.4035247.9467014.html.plaintext.txt	68	085 D19S178f n L S LL LS SS Control cases 272 0
0.4035247.9467014.html.plaintext.txt	69	243 n epsis2epsis3g epsis3epsis3 epsis3epsis4 epsis4epsis4 epsis2epsis4 APOE 1E1 polymorphism combination AD cases CC 22 1 20 1 GC 100 4 50 46 GG 139 4 44 56 27 8 Total 261 9 114 102 28 8 Control cases CC 41 0 41 0 GC 112 12 76 24 GG 100 25 50 15 3 7 Total 253 37 167 39 3 7 APOE Th1E47cs polymorphism combination AD cases GG 55 4 36 13 1 1 GT 134 5 54 60 8 7 TT 78 24 29 19 Total 261 9 114 102 28 8 Control cases GG 85 25 52 5 3 GT 108 11 76 16 1 4 TT 60 1 39 18 2 Total 253 36 167 39 3 7 aP 0
0.4035247.9467014.html.plaintext.txt	70	0005 fNS gone individual epsis2epsis2 control cases
0.4035247.9467014.html.plaintext.txt	71	Pairwise linkage disequilibrium 19q13
0.4035247.9467014.html.plaintext.txt	72	2 chromosomal region D19S178 Th1E47cs 1E1 APOE AD cases D19S178 1
0.4035247.9467014.html.plaintext.txt	73	1 APOE 6 49 54 Controls D19S178 0
0.4035247.9467014.html.plaintext.txt	74	7 APOE 32 42 APOE polymorphism analysed biallelic marker
0.4035247.9467014.html.plaintext.txt	75	allele 4 versus allele 2 3
0.4035247.9467014.html.plaintext.txt	76	Above diagonal Delta standardised linkage disequilibrium coefficient
0.4035247.9467014.html.plaintext.txt	77	Below diagonal Dprime percentage linkage disequilibrium coefficient maximum possible value given allele frequencies
0.4035247.9467014.html.plaintext.txt	78	Polymorphism haplotype estimations along 19q
0.4035247.9467014.html.plaintext.txt	79	2 chromosomal region Haplotype Polymorphisms Estimated haplotype frequencies No
0.4035247.9467014.html.plaintext.txt	80	D19S178 Th1E47cs 1E1 APOE AD cases Controls Expected controls General population 1 S T G epsis4 0
0.4035247.9467014.html.plaintext.txt	81	084a Number chromosomes 522 506 b Population genotyped epsis3epsis3 1 S T G 0
0.4035247.9467014.html.plaintext.txt	82	119a Number chromosomes 228 334 c Population genotyped epsis3epsis4 1 S T G 0
0.4035247.9467014.html.plaintext.txt	83	056 Number chromosomes 204 78 aP 0
0.4035247.9467014.html.plaintext.txt	84	In whole population AD 261 Controls 253 estimated OR developing AD subjects least one allele genotype polymorphism separately Table 4
0.4035247.9467014.html.plaintext.txt	85	As expected significant effect observed except D19S178
0.4035247.9467014.html.plaintext.txt	86	To determine effect Th1E47cs 1E1 polymorphisms due linkage disequilibrium existing APOE polymorphism performed multivariate logistic regression taking account age gender four polymorphisms model
0.4035247.9467014.html.plaintext.txt	87	The effects Th1E47cs 1E1 polymorphisms persisted even increased reinforcing hypothesis several genetic susceptibility factors within APOE locus
0.4035247.9467014.html.plaintext.txt	88	Adjusted odds ratio estimated multiple logistic regression OR 95 CI D19S178SS LSLL Th1E47csTT GTGG 1E1CC GCGG APOEwith epsis4without epsis4 Non adjusted 0
0.4035247.9467014.html.plaintext.txt	89	0001 Adjusted gender age 0
0.4035247.9467014.html.plaintext.txt	90	02 polymorphisms P 0
0.4035247.9467014.html.plaintext.txt	91	If assume level expression APOE alleles increased due cis mutations promoter region hypothesis three major implications promoter mutation may modulate expression APOE alleles leading increased deleterious risk epsis4 increased protective effect epsis2 ii given determines risk importance relative level expression alleles APOE promoter mutation differential effect APOE heterozygous homozygous genotypes iii effect cis mutation heterozygous individuals depend phase polymorphism APOE epsis alleles
0.4035247.9467014.html.plaintext.txt	92	In heterozygous Th1E47cs APOE epsis4 genotype bearers epsis4 allele may combined either Th1E47cs T G allele
0.4035247.9467014.html.plaintext.txt	93	One combinations may increase relative expression level epsis4 allele decrease relative expression level epsis3 allele combination inverse influence
0.4035247.9467014.html.plaintext.txt	94	Thus epsis3epsis4 genotype bearers risk developing AD different Th1E47cs heterozygous homozygous individuals
0.4035247.9467014.html.plaintext.txt	95	To test assumptions studied gender age adjusted OR developing AD Th1E47cs heterozygous genotype bearers compared homozygous Th1E47cs individuals
0.4035247.9467014.html.plaintext.txt	96	The Th1E47cs heterozygous genotype associated increased risk developing AD heterozygous APOE individuals OR 2
0.4035247.9467014.html.plaintext.txt	97	001 homozygous APOE individuals OR 1
0.4035247.9467014.html.plaintext.txt	98	In particular epsis3epsis4 sub population Table 5 risk developing AD heterozygous Th1E47cs individuals increased compared homozygous Th1E47cs individuals OR 1
0.4035247.9467014.html.plaintext.txt	99	06 AD 107 Controls 54
0.4035247.9467014.html.plaintext.txt	100	This increased risk became significant larger epsis3epsis4 population OR 2
0.4035247.9467014.html.plaintext.txt	101	008 AD 152 Controls 91
0.4035247.9467014.html.plaintext.txt	102	However risk obtained heterozygous 1E1 individuals significant compared homozygous 1E1 individuals OR 0
0.4035247.9467014.html.plaintext.txt	103	To assess contribution polymorphism risk developing AD epsis3epsis4 population performed multiple logistic regression
0.4035247.9467014.html.plaintext.txt	104	We detected increased risk tendency developing AD heterozygous Th1E47cs OR 1
0.4035247.9467014.html.plaintext.txt	105	027 heterozygous 1E1 bearers OR 0
0.4035247.9467014.html.plaintext.txt	106	Altogether data suggest Th1E47cs polymorphism could modify relative level expression APOE alleles
0.4035247.9467014.html.plaintext.txt	107	Distribution 1E1 Th1E47cs genotypes larger epsis3epsis4 population 1E1 polymorphisma Th1E47cs polymorphismb n GG GC GG GT TT Control cases 91 50 41 16 38 37 AD cases 152 67 85 19 89 44 aP 0
0.4035247.9467014.html.plaintext.txt	108	In order approach influence phase Th1E47cs APOE polymorphisms AD risk estimated frequencies haplotypes Th1E47cs T G allele associated epsis4 allele AD controls epsis3epsis4 bearer populations described Materials Methods
0.4035247.9467014.html.plaintext.txt	109	For APOE epsis3epsis4 Th1E47cs GT bearers 57
0.4035247.9467014.html.plaintext.txt	110	6 controls estimated epsis4 T alleles chromosome proportion 69
0.4035247.9467014.html.plaintext.txt	111	7 case group leading estimated OR 1
0.4035247.9467014.html.plaintext.txt	112	Recently hypothesis others mutations nearby APOE gene fuelled new physiological data difference allelic expression APOE gene observed 19 suggesting non coding polymorphisms regulatory regions APOE gene could modify risk developing AD
0.4035247.9467014.html.plaintext.txt	113	Looking new polymorphisms found GrarrT polymorphism located position 7 degenerative E box consensus Fig
0.4035247.9467014.html.plaintext.txt	114	1 23 influenced effect APOE polymorphisms AD expected way
0.4035247.9467014.html.plaintext.txt	115	The Th1E47cs 1E1 polymorphisms associated AD studied separately
0.4035247.9467014.html.plaintext.txt	116	Although strong linkage disequilibrium existed epsis4 Th1E47cs T 1E1 G alleles effect polymorphisms persisted introduced logistic regression model
0.4035247.9467014.html.plaintext.txt	117	This observation suggested risk associated APOE epsis alleles may modulated according combination polymorphisms
0.4035247.9467014.html.plaintext.txt	118	To least one Th1E47cs T 1E1 C allele significantly modified risk developing AD whole population
0.4035247.9467014.html.plaintext.txt	119	Furthermore impact epsis4 allele seemed decreased suggesting part effect may attributed promoter polymorphisms
0.4035247.9467014.html.plaintext.txt	120	Another argument brought forward estimating risk associated phase
0.4035247.9467014.html.plaintext.txt	121	The estimated risk developing disease epsis3epsis4 genotype bearers similar according combination Th1E47cs APOE epsis alleles chromosome
0.4035247.9467014.html.plaintext.txt	122	These results accordance previous data suggest epsis3epsis4 individuals preferentially develop AD expressed epsis4 allele greater level
0.4035247.9467014.html.plaintext.txt	123	Thus cis mutation APOE promoter may favour relative expression level epsis4 allele potentially deleterious action E4 isoform
0.4035247.9467014.html.plaintext.txt	124	The Th1E47cs polymorphism characterised binding site basic helix loop helix transcription factor E47
0.4035247.9467014.html.plaintext.txt	125	This factor E47 belongs class A proteins ubiquitously expressed form combinatorial interactions class B proteins control tissue specific gene expression 24
0.4035247.9467014.html.plaintext.txt	126	In particular E47 expressed brain associated multiple class B protein implicated development maintenance mammalian nervous system 25 27
0.4035247.9467014.html.plaintext.txt	127	Little known Th1 factor
0.4035247.9467014.html.plaintext.txt	128	It identified screen mouse embryo cDNA library
0.4035247.9467014.html.plaintext.txt	129	Its homologous protein Drosophila partner Drosophila class A protein daughterless expression essential neurogenesis 28
0.4035247.9467014.html.plaintext.txt	130	Nevertheless essential determine vitro vivo functionality transcriptional factor sequence binding
0.4035247.9467014.html.plaintext.txt	131	Furthermore effect new polymorphism susceptible modulate risk associated APOE alleles must confirmed epidemiological studies profound analysis performed determine haplotypes
0.4035247.9467014.html.plaintext.txt	132	In conclusion The Th1E47cs polymorphism located within putative regulatory element APOE promoter could contribute APOE expression level polymorphisms regulatory sequences gene may exist extended screening regulatory regions needs developed
0.4035247.9467014.html.plaintext.txt	133	The regulation APOE gene could important deciphering mechanisms involvement APOE alleles particular better define subjects higher risk developing AD
0.4035247.9467014.html.plaintext.txt	134	POPULATION AND METHODS Populations
0.4035247.9467014.html.plaintext.txt	135	The AD control samples Caucasian originating France
0.4035247.9467014.html.plaintext.txt	136	Sixteen cases European countries
0.4035247.9467014.html.plaintext.txt	137	These different ethnic origins influence genotype distributions
0.4035247.9467014.html.plaintext.txt	138	Diagnoses probable AD established according DSM III R NINCS ADRDA criteria n 293 age 74
0.4035247.9467014.html.plaintext.txt	139	3 range 51 98 age onset 71
0.4035247.9467014.html.plaintext.txt	140	The Caucasian controls defined subjects without DMS III R dementia criteria integrity cognitive functions n 310 age 73
0.4035247.9467014.html.plaintext.txt	141	Each individual relatives signed informed consent
0.4035247.9467014.html.plaintext.txt	142	The number subjects tested different polymorphisms varied followed Th1E47cs study 279 AD cases 310 controls 1E1 study 293 AD cases 307 controls D19S178 study 272 AD cases 279 controls
0.4035247.9467014.html.plaintext.txt	143	In order increase statistical power study analysis heterozygous individuals increased number individuals epsis3epsis4 genotype adding new epsis3epsis4 subjects independent populations total 152 AD 91 control cases 73
0.4035247.9467014.html.plaintext.txt	144	Direct sequencing performed 70770 sequenase version 2
0.4035247.9467014.html.plaintext.txt	145	0 DNA sequencing kit Amersham Life Science using gamma 35SdATP
0.4035247.9467014.html.plaintext.txt	146	APOE PCR products obtained described ASO technique see
0.4035247.9467014.html.plaintext.txt	147	Reactions run 6 acrylamide8 M urea gel 1 2 h 60 W
0.4035247.9467014.html.plaintext.txt	148	The gels exposed X ray film
0.4035247.9467014.html.plaintext.txt	149	Genomic DNA extracted white blood cells
0.4035247.9467014.html.plaintext.txt	150	We analysed Th1E47cs polymorphism distribution together two polymorphisms located 19q13
0.4035247.9467014.html.plaintext.txt	151	2 chromosomal region flanking Th1E47cs polymorphism 1E1 polymorphism located 1
0.4035247.9467014.html.plaintext.txt	152	15 kb downstream Th1E47cs polymorphism anonymous CAn repeat DNA marker D19S178 located 2
0.4035247.9467014.html.plaintext.txt	153	The frequency D19S178 repeat alleles dichotomised long 167 short alleles 5
0.4035247.9467014.html.plaintext.txt	154	The four markers amplified polymerase chain reaction Perkin Elmer Cetus thermal cycler
0.4035247.9467014.html.plaintext.txt	155	The anonymous CAn repeat DNA marker D19S178 1E1 polymorphism APOE polymorphism tested previously described 82231
0.4035247.9467014.html.plaintext.txt	156	Because Th1E47cs polymorphism create destroy restriction enzyme sites two techniques used confirm results
0.4035247.9467014.html.plaintext.txt	157	The first one consisted designing mismatch primer contained one mismatched base pair four bases away 3prime end forward primer five bases polymorphism
0.4035247.9467014.html.plaintext.txt	158	When incorporated PCR product primer produced Bstn I cut site G present cut site T present polymorphic site
0.4035247.9467014.html.plaintext.txt	159	Briefly PCR step performed 40 cycles 1 min 94 degrees C 1 min 15 54 degrees C 1 min 72 degrees C cycle forward primer 5prime AGAATGGAGGAGGGTGCCTG 3prime reverse primer 5prime ACTCAAGGATCCCAGACTTG 3prime total volume 50 microl containing 1
0.4035247.9467014.html.plaintext.txt	160	2 mM dNTP 1 DMSO 0
0.4035247.9467014.html.plaintext.txt	161	Twenty five microl PCR product digested 1 U Bstn I 60 degrees C overnight
0.4035247.9467014.html.plaintext.txt	162	Digestion products visualised 12 polyacrylamide gel
0.4035247.9467014.html.plaintext.txt	163	The Th1E47cs T allele characterised 49 bp fragment G allele 31 bp fragment
0.4035247.9467014.html.plaintext.txt	164	The second technique consisted performing allele specific oligonucleotide ASO hybridisation
0.4035247.9467014.html.plaintext.txt	165	A 375 bp fragment containing Th1E47cs polymorphism amplified using forward primer 5prime TACTTTCTTTCTGGGATCCAGG 3prime reverse primer 5prime ACTCAAGGATCCCAGACTTG 3prime
0.4035247.9467014.html.plaintext.txt	166	PCR performed total volume 50 microl 35 cycles 1 min 94 degrees C 1 min 50 degrees C 1 min 72 degrees C cycle containing 1
0.4035247.9467014.html.plaintext.txt	167	2 mM dNTP 1 mM MgCl2
0.4035247.9467014.html.plaintext.txt	168	The two primers 5prime GCCCAGTAATCCAGACACCC 3prime 5prime GCCCAGTAATACAGACACCC 3prime G T allele detection respectively 5prime end labelled DIG Boerhinger Mannheim
0.4035247.9467014.html.plaintext.txt	169	Allele specific hybridisation obtained washing 3 min 0
0.4035247.9467014.html.plaintext.txt	170	5 x SSC solution 61 degrees C 62 degrees C G T allele hybridisation respectively
0.4035247.9467014.html.plaintext.txt	171	Detection realised described supplier Boerhinger Mannheim
0.4035247.9467014.html.plaintext.txt	172	Univariate analysis performed using Pearsons chi2 test Fisher exact test necessary
0.4035247.9467014.html.plaintext.txt	173	Since impact epsis4 allele pronounced range 60 75 years 3233 since significant difference observed distribution different markers according age cut 65 years tested analysed different polymorphisms without performing distinction early late onset
0.4035247.9467014.html.plaintext.txt	174	Deviations Hardy Weinberg equilibrium hypothesis tested
0.4035247.9467014.html.plaintext.txt	175	Pairwise linkage disequilibriums measured collapsed data estimation two marker haplotype frequencies maximum likelihood procedure D19S178 Th1E47cs 1E1 APOE coded biallelic marker
0.4035247.9467014.html.plaintext.txt	176	allele epsis4 versus allele epsis2 epsis3 34
0.4035247.9467014.html.plaintext.txt	177	The standardised disequilibrium delta percent maximum possible value disequilibrium computed outlined Thompson et al
0.4035247.9467014.html.plaintext.txt	178	Statistical significance linkage disequilibrium considered P 0
0.4035247.9467014.html.plaintext.txt	179	001 level since multiple non independent pairwise comparisons performed
0.4035247.9467014.html.plaintext.txt	180	Extended haplotype frequencies four markers estimated collapsed data using myriad haplotype algorithm described McLean Morton 36 implemented computer program Cox et al
0.4035247.9467014.html.plaintext.txt	181	The comparisons haplotype frequencies cases controls tested likelihood ratio test
0.4035247.9467014.html.plaintext.txt	182	The estimated frequencies compared expected basis equilibrium Pearsons chi2 Fisher exact test necessary 38
0.4035247.9467014.html.plaintext.txt	183	In multivariate analysis coded genotypes subject dummy variables according tested hypotheses least one D19S178 short allele SSSL versus LL least one Th1E47cs T allele TTTG versus GG least one 1E1 C allele CCGC versus GG least one epsis4 allele
0.4035247.9467014.html.plaintext.txt	184	The effects variables disease tested multiple logistic regression model adjusted age gender
0.4035247.9467014.html.plaintext.txt	185	Estimation risk developing AD according combination Th1E47cs T epsis4 alleles epsis3epsis4 subgroup
0.4035247.9467014.html.plaintext.txt	186	According three polymorphisms presented Table 3c defined epsis3epsis4 sub populations fi xi yi 1 fi frequency haplotype 1 8 defined Table 3c xi frequency epsis3 allele found haplotype yi frequency epsis4 allele found haplotype
0.4035247.9467014.html.plaintext.txt	187	Because estimation performed epsis3epsis4 sub population equal total proportion epsis3 epsis4 alleles 2
0.4035247.9467014.html.plaintext.txt	188	Given 1E1 C allele strong linkage disequilibrium APOE epsis polymorphism Tables 2 3 associated epsis3 allele y2 y4 y6 y8 0
0.4035247.9467014.html.plaintext.txt	189	Thus x2 x4 x6 x8 values directly obtained Table 3c fi xi
0.4035247.9467014.html.plaintext.txt	190	From equation 2 obtain 3
0.4035247.9467014.html.plaintext.txt	191	xi directly approached haplotype distribution estimated epsis3epsis3 subgroup
0.4035247.9467014.html.plaintext.txt	192	If xiprime frequency haplotype epsis3epsis3 AD control subgroup xi value estimated follows 4 equation 4 5
0.4035247.9467014.html.plaintext.txt	193	The yi value deduced equation 1
0.4035247.9467014.html.plaintext.txt	194	Thus estimated frequency four possible phases Th1E47cs GT APOE epsis3epsis4 heterozygous AD control sub populations follows epsis4 Th1E47cs T allele x1 x3 epsis4 Th1E47cs G allele x2 x4 epsis3 Th1E47cs T allele y1 y2 y5 y6 epsis3 Th1E47cs G allele y3 y4 y7 y8 ACKNOWLEDGEMENTS
0.4035247.9467014.html.plaintext.txt	195	recipient Ministere d lEnseignement superieur et de la Recherche
0.4035247.9467014.html.plaintext.txt	196	This work supported Institut National de la Sante et de la Recherche Medicale INSERM Institut Pasteur de Lille IPL Conseil Regional du Nord Pas de Calais axe regional de recherche sur les maladies neurodegeneratives et le vieillissement cerebral P
0.4035247.9467014.html.plaintext.txt	197	1987 Association Apolipoprotein CII allele familial dementia Alzheimer type
0.4035247.9467014.html.plaintext.txt	198	1991 Linkage studies familial Alzheimer disease evidence chromosome 19 linkage
0.4035247.9467014.html.plaintext.txt	199	1992 Genetic association linkage analysis apolipoprotein E CII locus Familial Alzheimers disease
0.4035247.9467014.html.plaintext.txt	200	1993 Apolipoprotein E high avidity binding beta amyloid increased frequency type 4 allele late onset familial Alzheimers disease
0.4035247.9467014.html.plaintext.txt	201	1994 Apolipoprotein E epsis4 allele major risk factor sporadic early late onset forms Alzheimers disease analysis 19q13
0.4035247.9467014.html.plaintext.txt	202	1995 Reduced survival patients early onset alzheimers disease carry Apolipoprotein E2 allele
0.4035247.9467014.html.plaintext.txt	203	French Alzheimers disease collaborative group 1995 Evidence apolipoprotein E epsis4 association early onset alzheimers patients late onset relatives
0.4035247.9467014.html.plaintext.txt	204	1993 Gene dose apolipoprotein E type 4 allele risk Alzheimers disease late onset families
0.4035247.9467014.html.plaintext.txt	205	1994 Protective effect apolipoprotein E type 2 late onset alzheimers disease
0.4035247.9467014.html.plaintext.txt	206	1994 Protection Alzheimers disease APOE epsis2
0.4035247.9467014.html.plaintext.txt	207	1993 Binding human apolipoprotein E synthetic amyloid beta peptide isoform specific effects implications late onset alzheimer disease
0.4035247.9467014.html.plaintext.txt	208	1995 Apolipoprotein E kinetic thermodynamic inhibitor amyloid formation implication pathogenesis treatment Alzheimers disease
0.4035247.9467014.html.plaintext.txt	209	1996 Apolipoprotein E allele specific antioxidant activity effects cytotoxicity oxidative insults beta amyloid peptides
0.4035247.9467014.html.plaintext.txt	210	1994 Hypothesis microtubule instability paired helical filament formation Alzheimer disease related Apolipoprotein E genotype
0.4035247.9467014.html.plaintext.txt	211	1994 Apolipoprotein E4 allele population based study early onset alzheimers disease
0.4035247.9467014.html.plaintext.txt	212	1994 Alzheimers disease apolipoprotein E4 gender
0.4035247.9467014.html.plaintext.txt	213	1995 Apolipoprotein E genotype association smoking early onset alzheimers disease
0.4035247.9467014.html.plaintext.txt	214	1995 Interactions apolipoprotein E genotype total cholesterol level age sex prediction Alzheimers disease case control study
0.4035247.9467014.html.plaintext.txt	215	1997 Association low density lipoprotein related receptor protein LRP Alzheimers disease
0.4035247.9467014.html.plaintext.txt	216	1998 The low density lipoprotein VLDL receptor genetic susceptibility factor Alzheimers disease European Caucasian population Alzheimers disease related disorders press
0.4035247.9467014.html.plaintext.txt	217	1997 Distortion allelic expression apolipoprotein E Alzheimers disease
0.4035247.9467014.html.plaintext.txt	218	1996 A newly identified polymorphism apolipoprotein E enhancer gene region associated AD strongly epsis4 allele
0.4035247.9467014.html.plaintext.txt	219	1995 Identification new family tissue specific basic helix loop helix proteins two hybrid system
0.4035247.9467014.html.plaintext.txt	220	1989 A new DNA binding dimerization motif immunoglobulin enhancer binding daughterless MyoD myc proteins
0.4035247.9467014.html.plaintext.txt	221	1995 MATH 2 mammalian helix loop helix factor structurally related product drosophilia proneuronal gene atonal specifically expressed nervous system
0.4035247.9467014.html.plaintext.txt	222	KageyamaR 1995 A mammalian helix loop helix factor structurally related product drosophilia proneuronal gene atonal positive transcriptional regulator expressed developing nervous system
0.4035247.9467014.html.plaintext.txt	223	1996 BETA3 novel helix loop helix protein act negative regulator BETA2 MyoD responsive genes
0.4035247.9467014.html.plaintext.txt	224	1988 Daughterless drosophilia gene essential neurogenesis sex determination sequence similarities myc achaete scute complex
0.4035247.9467014.html.plaintext.txt	225	American Psychiatric Association 1987 Diagnostic statistical manual mental disorders
0.4035247.9467014.html.plaintext.txt	226	Third edition revised DMS III R American Psychatric Association ed
0.4035247.9467014.html.plaintext.txt	227	1984 Clinical diagnosis Alzheimers disease report NINCDS ADRA work group
0.4035247.9467014.html.plaintext.txt	228	1991 Restriction isotyping human apolipoprotein E gene amplification cleavage HhaI
0.4035247.9467014.html.plaintext.txt	229	1997 Apolipoprotrein E Alzheimer disease genotype specific risks age sex
0.4035247.9467014.html.plaintext.txt	230	The APOE Alzheimer disease meta analysis consortium 1997 Effects age gender ethnicity association apolipoprotein E genotype Alzheimer disease
0.4035247.9467014.html.plaintext.txt	231	1975 Tests association gene frequencies several loci random mating diploid populations
0.4035247.9467014.html.plaintext.txt	232	1988 The detection linkage disequilibrium closely markers RFLPs AI CIII apolipoprotein genes
0.4035247.9467014.html.plaintext.txt	233	1985 Efficiency lod scores representing multiple locus linkage data
0.4035247.9467014.html.plaintext.txt	234	1988 Linkage disequilibrium human insulininsulin like growth factor II region human chromosome II
0.4035247.9467014.html.plaintext.txt	235	1991 Extended haplotypes linkage disequilibrium II markers APOAI C3 C4 A4 gene cluster chromosome II
0.4035247.9467014.html.plaintext.txt	236	To correspondence addressed
0.4035247.9467014.html.plaintext.txt	237	Tel 33 3 20 87 77 10 Fax 33 3 20 87 78 94 Email philippe
0.4035247.9467014.html.plaintext.txt	238	fr This page run Oxford University Press Great Clarendon Street Oxford OX2 6DP part OUP JournalsComments feedback www adminatoup
0.4035247.9467014.html.plaintext.txt	239	uk u d Last modification 14 Feb 1998Copyright Oxford University Press 1998
0.3345159.16033878.html.plaintext.txt	0	Large Meta Analysis Establishes ACE Insertion Deletion Polymorphism Marker Alzheimers Disease Donald J
0.3345159.16033878.html.plaintext.txt	1	Lehmann1 Mario Cortina Borja2 Donald R
0.3345159.16033878.html.plaintext.txt	2	David Smith1 Kristel Sleegers3 Jonathan A
0.3345159.16033878.html.plaintext.txt	3	1 The Oxford Project Investigate Memory Ageing OPTIMA Department Pharmacology University Oxford Oxford United Kingdom 2 Centre Paediatric Epidemiology Biostatistics Institute Child Health University College London London United Kingdom 3 Department Epidemiology Biostatistics Erasmus MC Rotterdam Netherlands 4 Center Genomics Bioinformatics Karolinska Institute Stockholm Sweden 5 Care Elderly Department Clinical Science North Bristol University Bristol Frenchay Hospital Bristol United Kingdom
0.3345159.16033878.html.plaintext.txt	4	Lehmann University Department Pharmacology Mansfield Road Oxford OX1 3QT United Kingdom e mail donald
0.3345159.16033878.html.plaintext.txt	5	Received publication January 5 2005
0.3345159.16033878.html.plaintext.txt	6	Accepted publication March 22 2005
0.3345159.16033878.html.plaintext.txt	7	ABSTRACT TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION References Apolipoprotein E 4 APOE4 fully established susceptibility allele Alzheimers disease
0.3345159.16033878.html.plaintext.txt	8	One studied candidates insertion Ideletion D polymorphism indel gene angiotensin I converting enzyme ACE
0.3345159.16033878.html.plaintext.txt	9	This study aimed clarify association Alzheimers disease
0.3345159.16033878.html.plaintext.txt	10	The meta analysis included 39 samples comprising 6037 cases Alzheimers disease 12099 controls using mainly primary data
0.3345159.16033878.html.plaintext.txt	11	Potential interactions gender age ethnic group carrier status apolipoprotein E 4 allele examined
0.3345159.16033878.html.plaintext.txt	12	D homozygotes reduced risk Alzheimers disease odds ratio 0
0.3345159.16033878.html.plaintext.txt	13	0004 I homozygotes showed association Alzheimers disease heterozygotes increased risk
0.3345159.16033878.html.plaintext.txt	14	Although clear differences among three ethnic groups examined North Europeans South Caucasians East Asians groups D homozygotes reduced risk
0.3345159.16033878.html.plaintext.txt	15	These results confirm association angiotensin I converting enzyme indel Alzheimers disease across diverse populations although probably due linkage disequilibrium true risk factor
0.3345159.16033878.html.plaintext.txt	16	Further North Europeans association Hardy Weinberg analysis suggested partial heterosis increased risk heterozygotes due hidden interaction another yet unknown risk factor
0.3345159.16033878.html.plaintext.txt	17	This interaction warrants investigation
0.3345159.16033878.html.plaintext.txt	18	Alzheimer disease heterogeneity meta analysis
0.3345159.16033878.html.plaintext.txt	19	Abbreviations ACE angiotensin I converting enzyme protein ACE angiotensin I converting enzyme gene APOE4 apolipoprotein E 4 allele
0.3345159.16033878.html.plaintext.txt	20	INTRODUCTION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION References In 1999 Kehoe et al
0.3345159.16033878.html.plaintext.txt	21	1 first proposed association Alzheimers disease insertion Ideletion D polymorphism indel intron 16 gene angiotensin I converting enzyme ACE chromosome 17q23
0.3345159.16033878.html.plaintext.txt	22	The enzyme converts angiotensin I angiotensin II potently hypertensive
0.3345159.16033878.html.plaintext.txt	23	The D allele associated raised plasma levels enzyme 2 3
0.3345159.16033878.html.plaintext.txt	24	1 found I positives DI II increased risk Alzheimers disease
0.3345159.16033878.html.plaintext.txt	25	The study comprised three samples Cardiff London Britain Belfast Northern Ireland strikingly similar results
0.3345159.16033878.html.plaintext.txt	26	Since potential association examined 40 samples 4 5 table 1 around world
0.3345159.16033878.html.plaintext.txt	27	Several studies replicated report increased risk I positives contradicted many found association Alzheimers disease
0.3345159.16033878.html.plaintext.txt	28	One study suggested effect age association 6 another proposed influence gender 7
0.3345159.16033878.html.plaintext.txt	29	An association onset age Alzheimers disease also proposed 8
0.3345159.16033878.html.plaintext.txt	30	Cohorts used meta analysis ACE insertion deletion polymorphism Alzheimers disease
0.3345159.16033878.html.plaintext.txt	31	The association recently studied longitudinal observational cohorts Oxford Project Investigate Memory Ageing OPTIMA Rotterdam Study 9
0.3345159.16033878.html.plaintext.txt	32	Both groups found suggestion gender difference results consistent previous report 7
0.3345159.16033878.html.plaintext.txt	33	We therefore undertook meta analysis studies association ACE indel Alzheimers disease stratified gender age ethnic group apolipoprotein E 4 allele APOE4 carrier status using mainly primary data supplied authors
0.3345159.16033878.html.plaintext.txt	34	Although three previous meta analyses ACE studies reported 10 12 subsequent studies made data available
0.3345159.16033878.html.plaintext.txt	35	Compared even latest meta analysis 12 10 samples eight studies available us 9 13 18 study Oxford Project Investigate Memory Ageing
0.3345159.16033878.html.plaintext.txt	36	In addition previous meta analyses based published data largely unstratified thus limited interpretations allowed
0.3345159.16033878.html.plaintext.txt	37	Using primary data able explore deeply searching sources heterogeneity
0.3345159.16033878.html.plaintext.txt	38	Two previous stratified meta analyses Alzheimers disease genes 19 20 based primary data deepened understanding
0.3345159.16033878.html.plaintext.txt	39	21 stressed need examine sources heterogeneity meta analyses case control studies
0.3345159.16033878.html.plaintext.txt	40	We therefore divided analysis two phases first broad overall analysis second detailed examination sources heterogeneity
0.3345159.16033878.html.plaintext.txt	41	We aimed discover whether ACE indel associated Alzheimers disease nature association
0.3345159.16033878.html.plaintext.txt	42	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION References Phase 1 broad analysis In April 2003 following PubMed searches study references abstracts communication experts wrote authors association studies ACE indel Alzheimers disease known us 33 studies involving 41 samples 4 5 table 1 including seven samples unpublished studies
0.3345159.16033878.html.plaintext.txt	43	The searches updated November 2004 without data arising
0.3345159.16033878.html.plaintext.txt	44	For stratified analyses used raw data stratified summaries received authors 26 samples
0.3345159.16033878.html.plaintext.txt	45	For overall analyses also used published data making 39 samples altogether table 1
0.3345159.16033878.html.plaintext.txt	46	Very early onset cases 50 years young controls 50 years excluded identifiable subjects incomplete data
0.3345159.16033878.html.plaintext.txt	47	Distinct populations treated separately possible
0.3345159.16033878.html.plaintext.txt	48	The large number controls cohort Sleegers et al
0.3345159.16033878.html.plaintext.txt	49	9 fully assessed 22
0.3345159.16033878.html.plaintext.txt	50	All samples genotyped ACE indel except two Prince et al
0.3345159.16033878.html.plaintext.txt	51	23 24 used ACE rs4343 marker 85 90 percent linkage disequilibrium indel North Europeans
0.3345159.16033878.html.plaintext.txt	52	Phase 2 examination heterogeneity We examined six possible sources heterogeneity
0.3345159.16033878.html.plaintext.txt	53	We performed analyses stratified age gender APOE4 status
0.3345159.16033878.html.plaintext.txt	54	For age stratifications 65 years 65 75 years 75 years divided samples two groups according ages cases defined example onset first group examination death second group
0.3345159.16033878.html.plaintext.txt	55	We also conducted analyses restricted controls diagnoses probable definite Alzheimers disease according criteria Consortium Establish Registry Alzheimers Disease CERAD 25 National Institute Neurological Communicative Disorders Stroke Alzheimers Disease Related Disorders Association NINCDS ADRDA 26 26 full samples two part samples
0.3345159.16033878.html.plaintext.txt	56	In separate analyses excluded eight samples Hardy Weinberg analysis genotyping methods compatible mistyping
0.3345159.16033878.html.plaintext.txt	57	Underreporting heterozygotes may occur unless either 5 percent dimethyl sulfoxide included polymerase chain reaction 27 DD genotype confirmed insertion specific second amplification 28
0.3345159.16033878.html.plaintext.txt	58	In analyses samples placed possible 34 39 samples one three ethnic groups North European 19 samples South Caucasian 11 samples defined Mediterranean Middle East East Asian four samples China Japan
0.3345159.16033878.html.plaintext.txt	59	Data analysis statistical methods Three methods commonly used produce odds ratios genetic association studies method 1 allelic
0.3345159.16033878.html.plaintext.txt	60	I case method 2 comparing genotype one turn e
0.3345159.16033878.html.plaintext.txt	61	DI method 3 comparing genotype turn two combined
0.3345159.16033878.html.plaintext.txt	62	All three methods subject bias degree bias depending imperfectly model fits reality
0.3345159.16033878.html.plaintext.txt	63	For instance method 1 best suited testing codominant model allelic dose effect e
0.3345159.16033878.html.plaintext.txt	64	Method 3 hand may used test either I dominantD recessive D dominantI recessive model
0.3345159.16033878.html.plaintext.txt	65	We chose follow hypothesis generating study 1 using method 3 partly preliminary examination subsequent studies shown evidence codominance
0.3345159.16033878.html.plaintext.txt	66	We also used methods 2 3 examine heterosis heterozygotes greater lesser risk either homozygote
0.3345159.16033878.html.plaintext.txt	67	Our main approach method 3 gives estimate risk associated genotype compared rest population
0.3345159.16033878.html.plaintext.txt	68	Pooled odds ratios calculated three times fixed effects method Mantel Haenszel 29 random effects method DerSimonian Laird 30 Bayesian random effects method Warn et al
0.3345159.16033878.html.plaintext.txt	69	However results three methods similar first two shown table 2
0.3345159.16033878.html.plaintext.txt	70	The methods meta analysis permit accumulation results across independent studies even number subjects ratio cases controls varies considerably cohort Sleegers et al
0.3345159.16033878.html.plaintext.txt	71	The heterogeneity test method Armitage 32
0.3345159.16033878.html.plaintext.txt	72	Logistic regression analysis used compare odds ratios among ethnic groups
0.3345159.16033878.html.plaintext.txt	73	Funnel plots 33 cumulative meta analysis 34 used investigate bias
0.3345159.16033878.html.plaintext.txt	74	Analyses performed using R 35 package rmeta Thomas Lumley httpwww
0.3345159.16033878.html.plaintext.txt	75	orgsrccontribDescriptionsrmeta
0.3345159.16033878.html.plaintext.txt	76	All tests significance two sided
0.3345159.16033878.html.plaintext.txt	77	A Bonferroni correction factor 3 applied p values genotype
0.3345159.16033878.html.plaintext.txt	78	Odds ratios Alzheimers disease ACE genotype versus two meta analysis
0.3345159.16033878.html.plaintext.txt	79	RESULTS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION References Phase 1 broad analysis Examination bias
0.3345159.16033878.html.plaintext.txt	80	We found evidence publication bias
0.3345159.16033878.html.plaintext.txt	81	Funnel plots comparisons commonly made D homozygotes versus I positives
0.3345159.16033878.html.plaintext.txt	82	DI II I homozygotes versus D positives shown figure 1
0.3345159.16033878.html.plaintext.txt	83	Figure 2 shows cumulative meta analysis study July 1998 November 2004 D homozygotes versus I positives comparison made hypothesis generating study Kehoe et al
0.3345159.16033878.html.plaintext.txt	84	After four 39 cohorts studied odds ratio DerSimonian Laird 30 became significantly less 1 remained thereafter
0.3345159.16033878.html.plaintext.txt	85	It changed little around 0
0.3345159.16033878.html.plaintext.txt	86	View larger version 18K FIGURE 1
0.3345159.16033878.html.plaintext.txt	87	Funnel plots angiotensin I converting enzyme gene ACE studies A D homozygotes versus DI II p 0
0.3345159.16033878.html.plaintext.txt	88	21 B I homozygotes versus DI DD p 0
0.3345159.16033878.html.plaintext.txt	89	D represents deletion allele I represents insertion allele
0.3345159.16033878.html.plaintext.txt	90	Horizontal lines 95 confidence intervals dashed vertical lines summary log odds ratios
0.3345159.16033878.html.plaintext.txt	91	View larger version 45K FIGURE 2
0.3345159.16033878.html.plaintext.txt	92	Cumulative meta analysis odds ratio Alzheimers disease ACED homozygotes versus I positives
0.3345159.16033878.html.plaintext.txt	93	D represents deletion allele I represents insertion allele
0.3345159.16033878.html.plaintext.txt	94	Horizontal lines 95 confidence intervals vertical dotted line summary odds ratio
0.3345159.16033878.html.plaintext.txt	95	OPTIMA Oxford Project Investigate Memory Ageing ACE angiotensin I converting enzyme gene
0.3345159.16033878.html.plaintext.txt	96	Additional study information given table 1
0.3345159.16033878.html.plaintext.txt	97	Risk Alzheimers disease genotype
0.3345159.16033878.html.plaintext.txt	98	The odds ratios genotype versus two shown figures 3 4 5 summarized table 2
0.3345159.16033878.html.plaintext.txt	99	D homozygotes reduced risk Alzheimers disease overall odds ratio 0
0.3345159.16033878.html.plaintext.txt	100	81 95 percent confidence interval 0
0.3345159.16033878.html.plaintext.txt	101	0004 method DerSimonian Laird 30
0.3345159.16033878.html.plaintext.txt	102	Heterozygotes increased risk Alzheimers disease overall odds ratio 1
0.3345159.16033878.html.plaintext.txt	103	12 95 percent confidence interval 1
0.3345159.16033878.html.plaintext.txt	104	The odds ratio Alzheimers disease I homozygotes versus D positives differ significantly 1
0.3345159.16033878.html.plaintext.txt	105	Two three results heterogeneous
0.3345159.16033878.html.plaintext.txt	106	View larger version 45K FIGURE 3
0.3345159.16033878.html.plaintext.txt	107	Odds ratios Alzheimers disease ACED homozygotes versus I positives
0.3345159.16033878.html.plaintext.txt	108	D represents deletion allele I represents insertion allele
0.3345159.16033878.html.plaintext.txt	109	Horizontal lines 95 confidence intervals
0.3345159.16033878.html.plaintext.txt	110	OPTIMA Oxford Project Investigate Memory Ageing ACE angiotensin I converting enzyme gene
0.3345159.16033878.html.plaintext.txt	111	Additional study information given table 1
0.3345159.16033878.html.plaintext.txt	112	View larger version 48K FIGURE 4
0.3345159.16033878.html.plaintext.txt	113	Odds ratios Alzheimers disease ACE heterozygotes versus homozygotes
0.3345159.16033878.html.plaintext.txt	114	Horizontal lines 95 confidence intervals
0.3345159.16033878.html.plaintext.txt	115	OPTIMA Oxford Project Investigate Memory Ageing ACE angiotensin I converting enzyme gene
0.3345159.16033878.html.plaintext.txt	116	Additional study information given table 1
0.3345159.16033878.html.plaintext.txt	117	View larger version 46K FIGURE 5
0.3345159.16033878.html.plaintext.txt	118	Odds ratios Alzheimers disease ACEI homozygotes versus D positives
0.3345159.16033878.html.plaintext.txt	119	D represents deletion allele I represents insertion allele
0.3345159.16033878.html.plaintext.txt	120	Horizontal lines 95 confidence intervals
0.3345159.16033878.html.plaintext.txt	121	OPTIMA Oxford Project Investigate Memory Ageing ACE angiotensin I converting enzyme gene
0.3345159.16033878.html.plaintext.txt	122	Additional study information given table 1
0.3345159.16033878.html.plaintext.txt	123	Onset age Alzheimers disease
0.3345159.16033878.html.plaintext.txt	124	Onset age data available 13 samples comprising 2309 cases Alzheimers disease
0.3345159.16033878.html.plaintext.txt	125	Both stratified analyses linear regression analysis performed data also subset 10 North European samples comprising 1822 cases Alzheimers disease
0.3345159.16033878.html.plaintext.txt	126	No effect ACEI carrier status onset age Alzheimers disease surprisingly modest effect APOE4 carrier status onset age seen data shown
0.3345159.16033878.html.plaintext.txt	127	Phase 2 examination heterogeneity We examined six potential sources heterogeneity age gender race APOE4 status misdiagnosis mistyping
0.3345159.16033878.html.plaintext.txt	128	Stratification gender APOE4 status
0.3345159.16033878.html.plaintext.txt	129	No significant effects seen gender APOE4 status associations Alzheimers disease stratification either two factors remove heterogeneity data shown
0.3345159.16033878.html.plaintext.txt	130	We calculated odds ratios Alzheimers disease ACED homozygotes versus I positives stratified age 65 years 65 75 years 75 years
0.3345159.16033878.html.plaintext.txt	131	Rather little effect age seen association D homozygotes Alzheimers disease data shown reduction heterogeneity stratification age
0.3345159.16033878.html.plaintext.txt	132	We repeated overall analyses three genotypes restricting data 28 samples could limited rigorous diagnoses probable definite Alzheimers disease according criteria Consortium Establish Registry Alzheimers Disease 25 National Institute Neurological Communicative Disorders Stroke Alzheimers Disease Related Disorders Association 26
0.3345159.16033878.html.plaintext.txt	133	The odds ratios similar shown table 2 significant odds ratios method DerSimonian Laird 30 0
0.3345159.16033878.html.plaintext.txt	134	15 heterozygotes nonsignificant odds ratio 1
0.3345159.16033878.html.plaintext.txt	135	Heterogeneity remained D homozygotes p 0
0.3345159.16033878.html.plaintext.txt	136	005 longer significant p 0
0.3345159.16033878.html.plaintext.txt	137	There 12 instances Hardy Weinberg disequilibrium individual studies four six groups pooled cases controls analyzed race table 3
0.3345159.16033878.html.plaintext.txt	138	We therefore excluded eight samples mistyping considered possible underreporting heterozygotes taking account genotyping methods Hardy Weinberg analysis
0.3345159.16033878.html.plaintext.txt	139	We repeated overall analyses remaining 31 samples
0.3345159.16033878.html.plaintext.txt	140	The odds ratios similar table 2 significant odds ratios 0
0.3345159.16033878.html.plaintext.txt	141	12 heterozygotes nonsignificant odds ratio 1
0.3345159.16033878.html.plaintext.txt	142	Heterogeneity remained I homozygotes p 0
0.3345159.16033878.html.plaintext.txt	143	02 longer significant D homozygotes p 0
0.3345159.16033878.html.plaintext.txt	144	Odds ratios Alzheimers disease ACE genotype meta analysis ethnic group
0.3345159.16033878.html.plaintext.txt	145	The samples divided three ethnic groups possible North European 19 samples South Caucasian Mediterranean Middle Eastern 11 samples East Asian Chinese Japanese four samples
0.3345159.16033878.html.plaintext.txt	146	This removed nearly heterogeneity table 3
0.3345159.16033878.html.plaintext.txt	147	Table 3 shows clear differences among three ethnic groups
0.3345159.16033878.html.plaintext.txt	148	There overlap whatsoever allelic frequencies among three groups
0.3345159.16033878.html.plaintext.txt	149	North Europeans East Asians differed odds ratios D homozygotes versus I positives p 0
0.3345159.16033878.html.plaintext.txt	150	0008 I homozygotes versus D positives p 0
0.3345159.16033878.html.plaintext.txt	151	South Caucasians also differed East Asians odds ratio D homozygotes versus I positives p 0
0.3345159.16033878.html.plaintext.txt	152	D homozygotes reduced risk groups particularly East Asians
0.3345159.16033878.html.plaintext.txt	153	Heterozygotes increased risk North Europeans
0.3345159.16033878.html.plaintext.txt	154	I homozygotes higher risk East Asians except Bayesian analysis
0.3345159.16033878.html.plaintext.txt	155	We examined heterosis heterozygotes greater risk North Europeans comparing DI DD II turn
0.3345159.16033878.html.plaintext.txt	156	We found heterozygotes higher risk D homozygotes odds ratio 1
0.3345159.16033878.html.plaintext.txt	157	25 95 percent confidence interval 1
0.3345159.16033878.html.plaintext.txt	158	45 significantly higher I homozygotes odds ratio 1
0.3345159.16033878.html.plaintext.txt	159	08 95 percent confidence interval 0
0.3345159.16033878.html.plaintext.txt	160	DISCUSSION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION References This large meta analysis standards Alzheimers disease genetics 39 samples comprising 6037 cases Alzheimers disease 12099 elderly controls table 1
0.3345159.16033878.html.plaintext.txt	161	We found evidence publication bias
0.3345159.16033878.html.plaintext.txt	162	ACED homozygotes reduced risk Alzheimers disease table 2 three main ethnic groups examined table 3
0.3345159.16033878.html.plaintext.txt	163	I homozygotes neutral regards Alzheimers disease risk table 2 except East Asians I homozygotes may higher risk table 3
0.3345159.16033878.html.plaintext.txt	164	Heterozygotes increased risk Alzheimers disease overall table 2 mainly North Europeans table 3
0.3345159.16033878.html.plaintext.txt	165	This example heterosis discussed
0.3345159.16033878.html.plaintext.txt	166	Very similar results achieved three methods fixed effects random effects Bayesian random effects refer Materials Methods table 2
0.3345159.16033878.html.plaintext.txt	167	Only genotypic comparisons made refer Materials Methods showed allelic dose effect except East Asians table 3 thus allelic comparisons would proved less informative
0.3345159.16033878.html.plaintext.txt	168	These findings odds ratios close 1 even though significantly different 1 tables 2 3 suggest either linkage disequilibrium true risk factor confounding hidden interaction
0.3345159.16033878.html.plaintext.txt	169	The second possibility discussed
0.3345159.16033878.html.plaintext.txt	170	Regarding former Kehoe et al
0.3345159.16033878.html.plaintext.txt	171	1 study ACE haplotypes gave evidence indel may actual risk factor rather linkage disequilibrium nearby functional polymorphism true risk factor
0.3345159.16033878.html.plaintext.txt	172	ACE haplotype analysis also proved value phenotypes enzyme levels 36 insulin levels myocardial infarction obesity 37
0.3345159.16033878.html.plaintext.txt	173	Future Alzheimers disease studies may better examine polymorphisms regulatory regions rather indel
0.3345159.16033878.html.plaintext.txt	174	The overall results consistent Kehoe et al
0.3345159.16033878.html.plaintext.txt	175	1 1999 also recent meta analyses Kehoe et al
0.3345159.16033878.html.plaintext.txt	176	11 2003 Elkins et al
0.3345159.16033878.html.plaintext.txt	177	The latter report 12 also suggested age difference however although actual ages available mean cohort ages take account different ways defining case ages refer Materials Methods strongly confounding factor
0.3345159.16033878.html.plaintext.txt	178	Because latter problem cannot exclude possibility association might stronger younger cases example aged less 65 years onset less 75 years death
0.3345159.16033878.html.plaintext.txt	179	Heterogeneity Our overall results showed heterogeneity table 2
0.3345159.16033878.html.plaintext.txt	180	Heterogeneity may due differences sample selection e
0.3345159.16033878.html.plaintext.txt	181	age gender diagnosis methods e
0.3345159.16033878.html.plaintext.txt	182	genotyping may due real differences populations e
0.3345159.16033878.html.plaintext.txt	183	race interactions risk factors e
0.3345159.16033878.html.plaintext.txt	184	We examined potential sources heterogeneity
0.3345159.16033878.html.plaintext.txt	185	We found little effect age gender APOE4 status thus confounding initial hypothesis
0.3345159.16033878.html.plaintext.txt	186	Both diagnostic genotyping differences contributed heterogeneity
0.3345159.16033878.html.plaintext.txt	187	The former mainly due diagnosis possible Alzheimers disease reported poor record confirmation autopsy 38
0.3345159.16033878.html.plaintext.txt	188	The latter largely due certain genotyping methods may lead underreporting heterozygotes 27 28 shown Hardy Weinberg analysis
0.3345159.16033878.html.plaintext.txt	189	However greatest source heterogeneity ethnic differences
0.3345159.16033878.html.plaintext.txt	190	Ethnic stratification removed nearly heterogeneity table 3
0.3345159.16033878.html.plaintext.txt	191	There clear contrasts among three ethnic groups examined North Europeans South Caucasians East Asians allelic frequencies odds ratios table 3
0.3345159.16033878.html.plaintext.txt	192	The latter might due differences linkage disequilibrium true risk polymorphism see
0.3345159.16033878.html.plaintext.txt	193	Some ethnic differences previously pointed Panza et al
0.3345159.16033878.html.plaintext.txt	194	These contrasts highlight dangers combining ethnic groups within single cohort even North South Europeans indicated Panza et al
0.3345159.16033878.html.plaintext.txt	195	Unfortunately one cohort African origin United States 41
0.3345159.16033878.html.plaintext.txt	196	Thus conclusions could drawn Africans
0.3345159.16033878.html.plaintext.txt	197	Heterosis Deviations Hardy Weinberg equilibrium common studies ACE indel previously pointed Buss et al
0.3345159.16033878.html.plaintext.txt	198	This may due either mistyping heterosis
0.3345159.16033878.html.plaintext.txt	199	Several cases disequilibrium indeed compatible mistyping
0.3345159.16033878.html.plaintext.txt	200	Most examples disequilibrium North Europeans however excess heterozygotes Alzheimers disease requires another explanation
0.3345159.16033878.html.plaintext.txt	201	We believe explanation heterosis
0.3345159.16033878.html.plaintext.txt	202	Heterosis occurs heterozygotes show either greater lesser association given trait either group homozygotes
0.3345159.16033878.html.plaintext.txt	203	In case North Europeans excess heterozygotes Alzheimers disease association heterozygotes Alzheimers disease found
0.3345159.16033878.html.plaintext.txt	204	Comings MacMurray 42 suggested three explanations heterosis second applied
0.3345159.16033878.html.plaintext.txt	205	This proposes heterosis may follow inadvertent combination two unlike subsets due hidden interaction another unknown risk factor
0.3345159.16033878.html.plaintext.txt	206	To test proposal constructed mathematical model two equal subsets based median split unknown factor X table 4
0.3345159.16033878.html.plaintext.txt	207	The model illustrates although heterozygotes may intermediate odds ratios subset emerge highest odds ratio subsets combined
0.3345159.16033878.html.plaintext.txt	208	The overall results illustrative model table 4 close present meta analysis table 2
0.3345159.16033878.html.plaintext.txt	209	We stress however heterosis found North Europeans
0.3345159.16033878.html.plaintext.txt	210	Moreover although heterozygotes greater risk D homozygotes odds ratio 1
0.3345159.16033878.html.plaintext.txt	211	25 95 percent confidence interval 1
0.3345159.16033878.html.plaintext.txt	212	45 significantly higher risk I homozygotes odds ratio 1
0.3345159.16033878.html.plaintext.txt	213	08 95 percent confidence interval 0
0.3345159.16033878.html.plaintext.txt	214	Thus partial heterosis better describes case
0.3345159.16033878.html.plaintext.txt	215	Model show heterosis may follow combination two unlike subsets
0.3345159.16033878.html.plaintext.txt	216	A hidden interaction Partial heterosis North Europeans suggests interaction another risk factor Alzheimers disease another potential source heterogeneity
0.3345159.16033878.html.plaintext.txt	217	Candidates include cardiovascular risk factors since many also contribute Alzheimers disease risk since ACE indel associated cardiovascular risk 43 47
0.3345159.16033878.html.plaintext.txt	218	Biologic background Full discussion biologic basis associations outside scope mainly analytical study
0.3345159.16033878.html.plaintext.txt	219	However note associations ACE indel nearby polymorphisms various phenotypes including cardiovascular risk 37 43 47
0.3345159.16033878.html.plaintext.txt	220	In addition ACE protein levels raised certain brain regions Alzheimers disease 48 50 enzyme reported modify ss amyloid aggregation 51 ACE inhibitors reported maintain memory aged rats 52 human patients 53 brain penetrating ACE inhibitors associated reduced incidence Alzheimers disease elderly hypertensive patients 54 less cognitive decline cases mild moderate Alzheimers disease 55
0.3345159.16033878.html.plaintext.txt	221	9 recently provided evidence magnetic resonance imaging increased atrophy hippocampus amygdala nondemented women homozygous ACEI allele together modest significant increase risk Alzheimers disease independent vascular factors
0.3345159.16033878.html.plaintext.txt	222	The D allele associated raised plasma levels ACE 2 association thought due linkage disequilibrium nearby polymorphisms 3 36
0.3345159.16033878.html.plaintext.txt	223	There apparent conflict benefits ACE inhibitor therapy associations indel Alzheimers disease risk pathology plasma levels ACE
0.3345159.16033878.html.plaintext.txt	224	However influence ACE polymorphisms brain levels enzyme yet known cannot assumed reflect levels plasma
0.3345159.16033878.html.plaintext.txt	225	This subject warrants fuller discussion possible
0.3345159.16033878.html.plaintext.txt	226	A detailed discussion given Kehoe 56 although need reconsidered perhaps revised light interacting factor factors may emerge future studies
0.3345159.16033878.html.plaintext.txt	227	Limitations meta analysis The lack information authors limitation obtained full data 84 percent subjects
0.3345159.16033878.html.plaintext.txt	228	The quality diagnosis genotyping varied among studies overall results changed questions taken account
0.3345159.16033878.html.plaintext.txt	229	There considerable heterogeneity initial results
0.3345159.16033878.html.plaintext.txt	230	However found main sources heterogeneity able remove
0.3345159.16033878.html.plaintext.txt	231	Since cardiovascular factors strong candidates potential interaction ACE variants lack data available us factors limitation hope overcome future studies
0.3345159.16033878.html.plaintext.txt	232	Cardiovascular factors might also influenced results selective mortality
0.3345159.16033878.html.plaintext.txt	233	However D homozygotes slightly increased risk cardiovascular complications 43 47 57 little evidence association reduced life span 57 62
0.3345159.16033878.html.plaintext.txt	234	Thus influence selective mortality likely small enough provide alternative explanation findings
0.3345159.16033878.html.plaintext.txt	235	Conclusions We suggest large study established ACE indel marker Alzheimers disease risk since found evidence bias found removed main sources heterogeneity excluded various potential interactions significant results remained three ethnic groups examined
0.3345159.16033878.html.plaintext.txt	236	The indel however probably linkage disequilibrium true risk polymorphism 11
0.3345159.16033878.html.plaintext.txt	237	There marked contrasts among three ethnic groups studied table 3
0.3345159.16033878.html.plaintext.txt	238	We also found evidence interaction another risk factor North Europeans
0.3345159.16033878.html.plaintext.txt	239	Potential interactions factors age gender APOE4 status examined particularly interactions cardiovascular risk factors
0.3345159.16033878.html.plaintext.txt	240	ACKNOWLEDGMENTS Financial support received Bristol Myers Squibb Phytopharm plc Medical Research Council Norman Collisson Foundation Takayama Foundation
0.3345159.16033878.html.plaintext.txt	241	Kehoe supported Gestetner Foundation Fellowship
0.3345159.16033878.html.plaintext.txt	242	The authors thank groups undertaken ACEAlzheimers disease association studies thereby providing data analyses
0.3345159.16033878.html.plaintext.txt	243	They especially thank authors generously responded requests primary data Dr
0.3345159.16033878.html.plaintext.txt	244	The authors particularly grateful Dr
0.3345159.16033878.html.plaintext.txt	245	Finkh colleagues highlighting issue Hardy Weinberg disequilibrium ACE studies 40 Dr
0.3345159.16033878.html.plaintext.txt	246	Capurso colleagues 17 39 pointing ethnic differences ACE indel frequencies
0.3345159.16033878.html.plaintext.txt	247	The authors also warmly thank Dr
0.3345159.16033878.html.plaintext.txt	248	Pembrey advice genetics Dr
0.3345159.16033878.html.plaintext.txt	249	Marchini advice statistics C
0.3345159.16033878.html.plaintext.txt	250	Aldridge administrative support M
0.3345159.16033878.html.plaintext.txt	251	Lehmann help mathematical calculations Dr
0.3345159.16033878.html.plaintext.txt	252	Conflict interest none declared
0.3345159.16033878.html.plaintext.txt	253	Note added proof Two association studies published since submission article Kolsch et al
0.3345159.16033878.html.plaintext.txt	254	Neurosci Lett 200537737 9 Zhang et al
0.3345159.16033878.html.plaintext.txt	255	Dement Geriatr Cogn Disord 20052052 6
0.3345159.16033878.html.plaintext.txt	256	References TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION References Kehoe PG Russ C McIlroy S et al
0.3345159.16033878.html.plaintext.txt	257	Variation DCP1 encoding ACE associated susceptibility Alzheimer disease
0.3345159.16033878.html.plaintext.txt	258	CrossRefISIMedline Rigat B Hubert C Alhenc Gelas F et al
0.3345159.16033878.html.plaintext.txt	259	An insertiondeletion polymorphism angiotensin I converting enzyme gene accounting half variance serum enzyme levels
0.3345159.16033878.html.plaintext.txt	260	J Clin Invest 1990861343 6
0.3345159.16033878.html.plaintext.txt	261	ISIMedline Tiret L Rigat B Visvikis S et al
0.3345159.16033878.html.plaintext.txt	262	Evidence combined segregation linkage analysis variant angiotensin I converting enzyme ACE gene controls plasma ACE levels
0.3345159.16033878.html.plaintext.txt	263	Am J Hum Genet 199251197 205
0.3345159.16033878.html.plaintext.txt	264	ISIMedline Nacmias B Tedde A Forleo P et al
0.3345159.16033878.html.plaintext.txt	265	Angiotensin converting enzyme polymorphism sporadic presenilin linked Alzheimers disease families
0.3345159.16033878.html.plaintext.txt	266	Neurology 199952 suppl 2A323
0.3345159.16033878.html.plaintext.txt	267	Wakutani Y Kowa H Kusumi M et al
0.3345159.16033878.html.plaintext.txt	268	Genetic analysis vascular factors Alzheimers disease
0.3345159.16033878.html.plaintext.txt	269	Ann N Y Acad Sci 2002977232 8
0.3345159.16033878.html.plaintext.txt	270	AbstractFree Full Text Farrer LA Sherbatich T Keryanov SA et al
0.3345159.16033878.html.plaintext.txt	271	Association angiotensin converting enzyme Alzheimer disease
0.3345159.16033878.html.plaintext.txt	272	AbstractFree Full Text Crawford F Abdullah L Schinka J et al
0.3345159.16033878.html.plaintext.txt	273	Gender specific association angiotensin converting enzyme gene Alzheimers disease
0.3345159.16033878.html.plaintext.txt	274	Neurosci Lett 2000280215 19
0.3345159.16033878.html.plaintext.txt	275	CrossRefISIMedline Kehoe PG Katzov H Andreasen N et al
0.3345159.16033878.html.plaintext.txt	276	Common variants ACE contribute variable age onset Alzheimers disease
0.3345159.16033878.html.plaintext.txt	277	CrossRefISIMedline Sleegers K den Heijer T van Dijk EJ et al
0.3345159.16033878.html.plaintext.txt	278	ACE gene associated Alzheimers disease atrophy hippocampus amygdala
0.3345159.16033878.html.plaintext.txt	279	Neurobiol Aging 2005261153 9
0.3345159.16033878.html.plaintext.txt	280	CrossRefISIMedline Narain Y Yip A Murphy T et al
0.3345159.16033878.html.plaintext.txt	281	The ACE gene Alzheimers disease susceptibility
0.3345159.16033878.html.plaintext.txt	282	AbstractFree Full Text Kehoe PG Katzov H Feuk L et al
0.3345159.16033878.html.plaintext.txt	283	Haplotypes extending across ACE associated Alzheimers disease
0.3345159.16033878.html.plaintext.txt	284	Hum Mol Genet 200312859 67
0.3345159.16033878.html.plaintext.txt	285	AbstractFree Full Text Elkins JS Douglas VC Johnston SC
0.3345159.16033878.html.plaintext.txt	286	Alzheimer disease risk genetic variation ACE
0.3345159.16033878.html.plaintext.txt	287	AbstractFree Full Text Camelo D Arboleda G Yunis JJ et al
0.3345159.16033878.html.plaintext.txt	288	Angiotensin converting enzyme alpha 2 macroglobulin gene polymorphisms associated Alzheimers disease Colombian patients
0.3345159.16033878.html.plaintext.txt	289	J Neurol Sci 200421847 51
0.3345159.16033878.html.plaintext.txt	290	CrossRefISIMedline Fernandez Novoa L Lombardi VRM Seoane S et al
0.3345159.16033878.html.plaintext.txt	291	The ACE gene Alzheimers disease
0.3345159.16033878.html.plaintext.txt	292	In Hanin I Fisher A Cacabelos R eds
0.3345159.16033878.html.plaintext.txt	293	New trends Alzheimer Parkinson related disorders
0.3345159.16033878.html.plaintext.txt	294	Bologna Italy Monduzzi Editore 2004123 6
0.3345159.16033878.html.plaintext.txt	295	Keikhaee MR Najmabadi H Pasalar P
0.3345159.16033878.html.plaintext.txt	296	Angiotensin converting enzyme apolipoprotein E genotype Alzheimers disease Iranian population
0.3345159.16033878.html.plaintext.txt	297	Neurobiol Aging 200223supplS404
0.3345159.16033878.html.plaintext.txt	298	Lendon CL Thaker U Harris JM et al
0.3345159.16033878.html.plaintext.txt	299	The angiotensin 1 converting enzyme insertion Ideletion D polymorphism influence extent amyloid tau pathology patients sporadic Alzheimers disease
0.3345159.16033878.html.plaintext.txt	300	Neurosci Lett 2002328314 18
0.3345159.16033878.html.plaintext.txt	301	CrossRefISIMedline Panza F Solfrizzi V DIntrono A et al
0.3345159.16033878.html.plaintext.txt	302	Lack association ACE polymorphism Alzheimers disease southern Italy
0.3345159.16033878.html.plaintext.txt	303	Arch Gerontol Geriatr Suppl 20028239 45
0.3345159.16033878.html.plaintext.txt	304	CrossRefMedline Seripa D Dal Forno G Matera MG et al
0.3345159.16033878.html.plaintext.txt	305	Methylenetetrahydrofolate reductase angiotensin converting enzyme gene polymorphisms two genetically diagnostically distinct cohorts Alzheimer patients
0.3345159.16033878.html.plaintext.txt	306	Neurobiol Aging 200324933 9
0.3345159.16033878.html.plaintext.txt	307	CrossRefISIMedline Farrer LA Cupples LA Haines JL et al
0.3345159.16033878.html.plaintext.txt	308	Effects age sex ethnicity association apolipoprotein E genotype Alzheimer disease meta analysis
0.3345159.16033878.html.plaintext.txt	309	Abstract Lehmann DJ Williams J McBroom J et al
0.3345159.16033878.html.plaintext.txt	310	Using meta analysis explain diversity results genetic studies late onset Alzheimers disease identify high risk subgroups
0.3345159.16033878.html.plaintext.txt	311	Neuroscience 2001108541 54
0.3345159.16033878.html.plaintext.txt	312	CrossRefISIMedline Egger M Davey Smith G Altman DGE
0.3345159.16033878.html.plaintext.txt	313	Systematic reviews health care meta analysis context
0.3345159.16033878.html.plaintext.txt	314	London United Kingdom BMJ Books 2001
0.3345159.16033878.html.plaintext.txt	315	Ott A Breteler MM van Harskamp F et al
0.3345159.16033878.html.plaintext.txt	316	Incidence risk dementia
0.3345159.16033878.html.plaintext.txt	317	Am J Epidemiol 1998147574 80
0.3345159.16033878.html.plaintext.txt	318	Abstract Prince JA Feuk L Sawyer SL et al
0.3345159.16033878.html.plaintext.txt	319	Lack replication association findings complex disease analysis 15 polymorphisms prior candidate genes sporadic Alzheimers disease
0.3345159.16033878.html.plaintext.txt	320	Eur J Hum Genet 20019437 44
0.3345159.16033878.html.plaintext.txt	321	CrossRefISIMedline Prince J Feuk L Brookes A et al
0.3345159.16033878.html.plaintext.txt	322	Genetic variation ACE influences severity Alzheimers disease
0.3345159.16033878.html.plaintext.txt	323	Neurobiol Aging 200223supplS319
0.3345159.16033878.html.plaintext.txt	324	CrossRef Mirra SS Heyman A McKeel D et al
0.3345159.16033878.html.plaintext.txt	325	The Consortium Establish Registry Alzheimers Disease CERAD
0.3345159.16033878.html.plaintext.txt	326	Standardization neuropathologic assessment Alzheimers disease
0.3345159.16033878.html.plaintext.txt	327	Abstract McKhann G Drachman D Folstein M et al
0.3345159.16033878.html.plaintext.txt	328	Clinical diagnosis Alzheimers disease report NINCDS ADRDA work group auspices Department Health Human Services task force Alzheimers disease
0.3345159.16033878.html.plaintext.txt	329	Abstract Fogarty DG Maxwell AP Doherty CC et al
0.3345159.16033878.html.plaintext.txt	330	ISIMedline Shanmugam V Sell KW Saha BK
0.3345159.16033878.html.plaintext.txt	331	PCR Methods Appl 19933120 1
0.3345159.16033878.html.plaintext.txt	332	ISIMedline Mantel N Haenszel W
0.3345159.16033878.html.plaintext.txt	333	Statistical aspects analysis data retrospective studies disease
0.3345159.16033878.html.plaintext.txt	334	J Natl Cancer Inst 195922719 48
0.3345159.16033878.html.plaintext.txt	335	ISIMedline DerSimonian R Laird N
0.3345159.16033878.html.plaintext.txt	336	Meta analysis clinical trials
0.3345159.16033878.html.plaintext.txt	337	Control Clin Trials 19867177 88
0.3345159.16033878.html.plaintext.txt	338	CrossRefISIMedline Warn DE Thompson SG Spiegelhalter DJ
0.3345159.16033878.html.plaintext.txt	339	Bayesian random effects meta analysis trials binary outcomes methods absolute risk difference relative risk scales
0.3345159.16033878.html.plaintext.txt	340	CrossRefISIMedline Armitage P
0.3345159.16033878.html.plaintext.txt	341	Statistical methods medical research
0.3345159.16033878.html.plaintext.txt	342	Oxford United Kingdom Blackwell Scientific Publications 1983
0.3345159.16033878.html.plaintext.txt	343	Egger M Davey Smith G Schneider M et al
0.3345159.16033878.html.plaintext.txt	344	Bias meta analysis detected simple graphical test
0.3345159.16033878.html.plaintext.txt	345	AbstractFree Full Text Lau J Antman EM Jimenez Silva J et al
0.3345159.16033878.html.plaintext.txt	346	Cumulative meta analysis therapeutic trials myocardial infarction
0.3345159.16033878.html.plaintext.txt	347	N Eng J Med 1992327248 54
0.3345159.16033878.html.plaintext.txt	348	Abstract Ihaka R Gentleman R
0.3345159.16033878.html.plaintext.txt	349	R language data analysis graphics
0.3345159.16033878.html.plaintext.txt	350	J Comput Graph Stat 19965299 314
0.3345159.16033878.html.plaintext.txt	351	Cox R Bouzekri N Martin S et al
0.3345159.16033878.html.plaintext.txt	352	Angiotensin 1 converting enzyme ACE plasma concentration influenced multiple ACE linked quantitative trait nucleotides
0.3345159.16033878.html.plaintext.txt	353	Hum Mol Genet 2002112969 77
0.3345159.16033878.html.plaintext.txt	354	AbstractFree Full Text Katzov H Bennet AM Kehoe P et al
0.3345159.16033878.html.plaintext.txt	355	A cladistic model ACE sequence variation implications myocardial infarction Alzheimer disease obesity
0.3345159.16033878.html.plaintext.txt	356	Hum Mol Genet 2004132647 57
0.3345159.16033878.html.plaintext.txt	357	AbstractFree Full Text Nagy Z Esiri MM Hindley NJ et al
0.3345159.16033878.html.plaintext.txt	358	Accuracy clinical operational diagnostic criteria Alzheimers disease relation different pathological diagnostic protocols
0.3345159.16033878.html.plaintext.txt	359	Dement Geriatr Cogn Disord 19989219 26
0.3345159.16033878.html.plaintext.txt	360	CrossRefISIMedline Panza F Solfrizzi V DIntrono A et al
0.3345159.16033878.html.plaintext.txt	361	Shifts angiotensin 1 converting enzyme insertion allele frequency across Europe implications Alzheimers disease risk
0.3345159.16033878.html.plaintext.txt	362	J Neurol Neurosurg Psychiatry 2003741159 61
0.3345159.16033878.html.plaintext.txt	363	Free Full Text Buss S Muller Thomsen T Hock C et al
0.3345159.16033878.html.plaintext.txt	364	No association DCP1 genotype late onset Alzheimer disease
0.3345159.16033878.html.plaintext.txt	365	Am J Med Genet 2002114440 5
0.3345159.16033878.html.plaintext.txt	366	CrossRefISIMedline Perry RT Collins JS Harrell LE et al
0.3345159.16033878.html.plaintext.txt	367	Investigation association 13 polymorphisms eight genes southeastern African American Alzheimer disease patients compared age matched controls
0.3345159.16033878.html.plaintext.txt	368	Am J Med Genet 2001105332 42
0.3345159.16033878.html.plaintext.txt	369	CrossRefISIMedline Comings DE MacMurray JP
0.3345159.16033878.html.plaintext.txt	370	Mol Genet Metab 20007119 31
0.3345159.16033878.html.plaintext.txt	371	CrossRefISIMedline Samani NJ Thompson JR OToole L et al
0.3345159.16033878.html.plaintext.txt	372	A meta analysis association deletion allele angiotensin converting enzyme gene myocardial infarction
0.3345159.16033878.html.plaintext.txt	373	AbstractFree Full Text Staessen JA Wang JG Ginocchio G et al
0.3345159.16033878.html.plaintext.txt	374	The deletioninsertion polymorphism angiotensin converting enzyme gene cardiovascular renal risk
0.3345159.16033878.html.plaintext.txt	375	J Hypertens 1997151579 92
0.3345159.16033878.html.plaintext.txt	376	CrossRefISIMedline Sharma P
0.3345159.16033878.html.plaintext.txt	377	Meta analysis ACE gene ischaemic stroke
0.3345159.16033878.html.plaintext.txt	378	J Neurol Neurosurg Psychiatry 199864227 30
0.3345159.16033878.html.plaintext.txt	379	AbstractFree Full Text Keavney B McKenzie C Parish S et al
0.3345159.16033878.html.plaintext.txt	380	Large scale test hypothesised associations angiotensin converting enzyme insertiondeletion polymorphism myocardial infarction 5000 cases 6000 controls
0.3345159.16033878.html.plaintext.txt	381	ISIMedline Sayed Tabatabaei FA Houwing Duistermaat JJ van Duijn CM et al
0.3345159.16033878.html.plaintext.txt	382	Angiotensin converting enzyme gene polymorphism carotid artery wall thickness
0.3345159.16033878.html.plaintext.txt	383	AbstractFree Full Text Arregui A Perry EK Rossor M et al
0.3345159.16033878.html.plaintext.txt	384	Angiotensin converting enzyme Alzheimers disease increased activity caudate nucleus cortical areas
0.3345159.16033878.html.plaintext.txt	385	ISIMedline Barnes NM Cheng CH Costall B et al
0.3345159.16033878.html.plaintext.txt	386	Angiotensin converting enzyme density increased temporal cortex patients Alzheimers disease
0.3345159.16033878.html.plaintext.txt	387	Eur J Pharmacol 1991200289 92
0.3345159.16033878.html.plaintext.txt	388	CrossRefISIMedline Savaskan E Hock C Olivieri G et al
0.3345159.16033878.html.plaintext.txt	389	Cortical alterations angiotensin converting enzyme angiotensin II AT1 receptor Alzheimers dementia
0.3345159.16033878.html.plaintext.txt	390	Neurobiol Aging 200122541 6
0.3345159.16033878.html.plaintext.txt	391	CrossRefISIMedline Hu J Igarashi A Kamata M et al
0.3345159.16033878.html.plaintext.txt	392	Angiotensin converting enzyme degrades Alzheimer amyloid beta peptide Ab retards Ab aggregation deposition fibril formation inhibits cytotoxicity
0.3345159.16033878.html.plaintext.txt	393	J Biol Chem 200127647863 8
0.3345159.16033878.html.plaintext.txt	394	AbstractFree Full Text Hirawa N Uehara Y Kawabata Y et al
0.3345159.16033878.html.plaintext.txt	395	Long term inhibition renin angiotensin system sustains memory function aged Dahl rats
0.3345159.16033878.html.plaintext.txt	396	Hypertension 199934496 502
0.3345159.16033878.html.plaintext.txt	397	AbstractFree Full Text Sudilovsky A Turnbull B Croog SH et al
0.3345159.16033878.html.plaintext.txt	398	Angiotensin converting enzyme memory preclinical clinical data
0.3345159.16033878.html.plaintext.txt	399	Int J Neurol 1987 8821 22145 62
0.3345159.16033878.html.plaintext.txt	400	Ohrui T Matsui T Yamaya M et al
0.3345159.16033878.html.plaintext.txt	401	Angiotensin converting enzyme inhibitors incidence Alzheimers disease Japan
0.3345159.16033878.html.plaintext.txt	402	J Am Geriatr Soc 200452649 50
0.3345159.16033878.html.plaintext.txt	403	CrossRefISIMedline Ohrui T Tomita N Sato Nakagawa T et al
0.3345159.16033878.html.plaintext.txt	404	Effects brain penetrating ACE inhibitors Alzheimer disease progression
0.3345159.16033878.html.plaintext.txt	405	The renin angiotensin aldosterone system Alzheimers disease J Renin Angiotensin Aldosterone Syst 2003480 93
0.3345159.16033878.html.plaintext.txt	406	ISIMedline Agerholm Larsen B Nordestgaard BG Steffensen R et al
0.3345159.16033878.html.plaintext.txt	407	ACE gene polymorphism ischemic heart disease longevity 10150 individuals
0.3345159.16033878.html.plaintext.txt	408	A case referent retrospective cohort study based Copenhagen City Heart Study
0.3345159.16033878.html.plaintext.txt	409	Circulation 1997952358 67
0.3345159.16033878.html.plaintext.txt	410	AbstractFree Full Text Galinsky D Tysoe C Brayne CE et al
0.3345159.16033878.html.plaintext.txt	411	Analysis apoe Eapo C I angiotensin converting enzyme methylenetetrahydrofolate reductase genes candidates affecting human longevity
0.3345159.16033878.html.plaintext.txt	412	Atherosclerosis 1997129177 83
0.3345159.16033878.html.plaintext.txt	413	CrossRefISIMedline Shimokata H Yamada Y Nakagawa M et al
0.3345159.16033878.html.plaintext.txt	414	Distribution geriatric disease related genotypes National Institute Longevity Sciences Longitudinal Study Aging NILS LSA
0.3345159.16033878.html.plaintext.txt	415	J Epidemiol 200010supplS46 55
0.3345159.16033878.html.plaintext.txt	416	Medline Blanche H Cabanne L Sahbatou M et al
0.3345159.16033878.html.plaintext.txt	417	A study French centenarians ACE APOE associated longevity C R Acad Sci III 2001324129 35
0.3345159.16033878.html.plaintext.txt	418	ISIMedline Panza F Solfrizzi V DIntrono A et al
0.3345159.16033878.html.plaintext.txt	419	Angiotensin I converting enzyme ACE gene polymorphism centenarians different allele frequencies North South Europe
0.3345159.16033878.html.plaintext.txt	420	Exp Gerontol 2003381015 20
0.3345159.16033878.html.plaintext.txt	421	CrossRefISIMedline Da Cruz IB Oliveira G Taufer M et al
0.3345159.16033878.html.plaintext.txt	422	Angiotensin I converting enzyme gene polymorphism two ethnic groups living Brazils southern region association age
0.3345159.16033878.html.plaintext.txt	423	J Gerontol A Biol Sci Med Sci 200358M851 6
0.3345159.16033878.html.plaintext.txt	424	AbstractFree Full Text Alvarez R Alvarez V Lahoz CH et al
0.3345159.16033878.html.plaintext.txt	425	Angiotensin converting enzyme endothelial nitric oxide synthase DNA polymorphisms late onset Alzheimers disease
0.3345159.16033878.html.plaintext.txt	426	J Neurol Neurosurg Psychiatry 199967733 6
0.3345159.16033878.html.plaintext.txt	427	AbstractFree Full Text Carbonell J Allen R Kalsi G et al
0.3345159.16033878.html.plaintext.txt	428	Variation DCP1 gene encoding angiotensin converting enzyme ACE associated increased susceptibility Alzheimers disease
0.3345159.16033878.html.plaintext.txt	429	Psychiatr Genet 20031347 50
0.3345159.16033878.html.plaintext.txt	430	CrossRefISIMedline Chapman J Wang N Treves TA et al
0.3345159.16033878.html.plaintext.txt	431	ACE MTHFR factor V Leiden APOE polymorphisms patients vascular Alzheimers dementia
0.3345159.16033878.html.plaintext.txt	432	AbstractFree Full Text Cheng CY Hong CJ Liu HC et al
0.3345159.16033878.html.plaintext.txt	433	Study association Alzheimers disease angiotensin converting enzyme gene polymorphism using DNA lymphocytes
0.3345159.16033878.html.plaintext.txt	434	CrossRefISIMedline Hu J Miyatake F Aizu Y et al
0.3345159.16033878.html.plaintext.txt	435	Angiotensin converting enzyme genotype associated Alzheimer disease Japanese population
0.3345159.16033878.html.plaintext.txt	436	Neurosci Lett 199927765 7
0.3345159.16033878.html.plaintext.txt	437	CrossRefISIMedline Isbir T Agachan B Yilmaz H et al
0.3345159.16033878.html.plaintext.txt	438	Angiotensin converting enzyme gene polymorphism Alzheimers disease
0.3345159.16033878.html.plaintext.txt	439	Cell Biochem Funct 200018141 2
0.3345159.16033878.html.plaintext.txt	440	Dipeptidyl carboxypeptidase 1 DCP1 butyrylcholinesterase BCHE gene interactions apolipoprotein E 4 allele risk factors Alzheimers disease Parkinsons disease coexisting Alzheimer pathology
0.3345159.16033878.html.plaintext.txt	441	AbstractFree Full Text Monastero R Caldarella R Mannino M et al
0.3345159.16033878.html.plaintext.txt	442	Lack association angiotensin converting enzyme polymorphism sporadic Alzheimers disease
0.3345159.16033878.html.plaintext.txt	443	Neurosci Lett 2002335147 9
0.3345159.16033878.html.plaintext.txt	444	CrossRefISIMedline Myllykangas L Polvikoski T Sulkava R et al
0.3345159.16033878.html.plaintext.txt	445	Cardiovascular risk factors Alzheimers disease genetic association study population aged 85
0.3345159.16033878.html.plaintext.txt	446	Neurosci Lett 2000292195 8
0.3345159.16033878.html.plaintext.txt	447	CrossRefISIMedline Palumbo B Cadini D Nocentini G et al
0.3345159.16033878.html.plaintext.txt	448	Angiotensin converting enzyme deletion allele different kinds dementia disorders
0.3345159.16033878.html.plaintext.txt	449	Neurosci Lett 199926797 100
0.3345159.16033878.html.plaintext.txt	450	CrossRefISIMedline Richard F Fromentin David I Ricolfi F et al
0.3345159.16033878.html.plaintext.txt	451	The angiotensin I converting enzyme gene susceptibility factor dementia
0.3345159.16033878.html.plaintext.txt	452	AbstractFree Full Text Scacchi R De Bernardini L Mantuano E et al
0.3345159.16033878.html.plaintext.txt	453	DNA polymorphisms apolipoprotein B angiotensin 1 converting enzyme genes relationships lipid levels Italian patients vascular dementia Alzheimers disease
0.3345159.16033878.html.plaintext.txt	454	Dement Geriatr Cogn Disord 19989186 90
0.3345159.16033878.html.plaintext.txt	455	CrossRefISIMedline Wu C Zhou D Guan Z et al
0.3345159.16033878.html.plaintext.txt	456	The association angiotensin I converting enzyme gene polymorphism Chinese late onset Alzheimer disease
0.3345159.16033878.html.plaintext.txt	457	Zhonghua Yi Xue Yi Chuan Xue Za Zhi 200219401 4
0.3345159.16033878.html.plaintext.txt	458	Medline Yang JD Feng G Zhang J et al
0.3345159.16033878.html.plaintext.txt	459	Association angiotensin converting enzyme gene late onset Alzheimers disease Han Chinese
0.3345159.16033878.html.plaintext.txt	460	Neurosci Lett 200029541 4
0.3345159.16033878.html.plaintext.txt	461	CrossRefISIMedline Zuliani G Ble A Zanca R et al
0.3345159.16033878.html.plaintext.txt	462	Genetic polymorphisms older subjects vascular Alzheimers dementia
0.3345159.16033878.html.plaintext.txt	463	Acta Neurol Scand 2001103304 8
0.3345159.16033878.html.plaintext.txt	464	CrossRefISIMedline American Psychiatric Association
0.3345159.16033878.html.plaintext.txt	465	Diagnostic statistical manual mental disorders DSM IV
0.3345159.16033878.html.plaintext.txt	466	Washington DC American Psychiatric Association 1994
0.3345159.16033878.html.plaintext.txt	467	Diagnosis Alzheimers disease
0.3345159.16033878.html.plaintext.txt	468	Arch Neurol 1985421097 105
0.28218916.14764623.html.plaintext.txt	0	Alzheimers disease one disorder many genes Lars Bertram Rudolph E
0.28218916.14764623.html.plaintext.txt	1	Genetics Aging Research Unit Department Neurology MassGeneral Institute Neurodegenerative Diseases Massachusetts General Hospital Harvard Medical School Charlestown MA USA
0.28218916.14764623.html.plaintext.txt	2	Received January 13 2004 Accepted January 26 2004
0.28218916.14764623.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION 2003 A GOOD VINTAGE
0.28218916.14764623.html.plaintext.txt	4	CONCLUSION REFERENCES The research Alzheimers disease AD genetics extremely prolific past decade currently 10 genes reported show either positive negative evidence disease association per month
0.28218916.14764623.html.plaintext.txt	5	Here review 90 studies 2003 reporting total 127 association findings candidate genes AD
0.28218916.14764623.html.plaintext.txt	6	While positive results largely contradictory identified three loci chromosomes 6p21 10q24 11q23 yielded positive results three independent studies addition well established AD association gene encoding apolipoprotein E APOE
0.28218916.14764623.html.plaintext.txt	7	Based data suggest may prudent investigators pay closer attention issues power replicability haplotype structure prior initial publication
0.28218916.14764623.html.plaintext.txt	8	This serve greatly decrease likelihood false positive false negative findings reported future years
0.28218916.14764623.html.plaintext.txt	9	INTRODUCTION TOP ABSTRACT INTRODUCTION 2003 A GOOD VINTAGE
0.28218916.14764623.html.plaintext.txt	10	CONCLUSION REFERENCES Several characteristics make search novel Alzheimers disease AD genes particularly promising
0.28218916.14764623.html.plaintext.txt	11	First importantly heritability AD high
0.28218916.14764623.html.plaintext.txt	12	This demonstrated various studies examining familial segregation disease past decades 1 3
0.28218916.14764623.html.plaintext.txt	13	Accordingly probability actually finding relevant disease causing predisposing genes relatively high well possibly even genetically complex neuropsychiatric disorders like Parkinsons disease schizophrenia affective disorders 4
0.28218916.14764623.html.plaintext.txt	14	Thus far AD achieved four genes APP PSEN1 PSEN2 APOE variation latter also plays significant role common late onset form disorder see
0.28218916.14764623.html.plaintext.txt	15	Fully penetrant mutations APP PSEN1 PSEN2 hand lead rare early onset familial forms AD via increased generation Ass42 ss amyloid deposition major neuropathological hallmark disease
0.28218916.14764623.html.plaintext.txt	16	Secondly direct evidence based simulation well empirical data presence additional AD risk genes besides APOE
0.28218916.14764623.html.plaintext.txt	17	For instance recent simulation study predicted existence four seven additional AD genes searching age onset modifiers simulating variety different disease inheritance models 3
0.28218916.14764623.html.plaintext.txt	18	This number corresponds well empirical data obtained full genome searches overlap 11 chromosomes six show significant results least one study Table 1
0.28218916.14764623.html.plaintext.txt	19	Finally progressive neurodegeneration gradually leading cognitive decline dementia AD patients exhibits distinct well established histopathological features upon post mortem examination allowing verification clinical AD 5
0.28218916.14764623.html.plaintext.txt	20	Currently accuracy clinical AD diagnosis near beyond 90 academic centers 6 8
0.28218916.14764623.html.plaintext.txt	21	This allows significant reduction number phenocopies study populations using published research criteria thereby increases power subsequent genetic epidemiological analyses
0.28218916.14764623.html.plaintext.txt	22	Overview concordant linkageassociation regions observed full genome screens published 2003 These disease specific characteristics together advent relatively inexpensive powerful high throughput genotyping technologies near completion human genome sequence led steep increase number laboratories studying genetics AD worldwide
0.28218916.14764623.html.plaintext.txt	23	To date less 12 full genome screens using linkage association based methodologies published AD using overlapping identical samples employing different sets genetic markers andor analytic strategies 8 19 Table 1
0.28218916.14764623.html.plaintext.txt	24	On hand number locus specific candidate gene based AD association studies become nearly intractable
0.28218916.14764623.html.plaintext.txt	25	Over course 2003 10 genes reported show either positive negative evidence association different AD phenotypes per month peer reviewed journals listed NCBIs PubMed
0.28218916.14764623.html.plaintext.txt	26	Despite vast efforts single gene yet emerged attain nearly degree replication consistency observed literally hundreds laboratories studying association APOE 4 AD
0.28218916.14764623.html.plaintext.txt	27	In review present discuss findings genetic AD association studies published 2003 excluding explicitly searching causes early onset familial AD cases
0.28218916.14764623.html.plaintext.txt	28	Using data example attempt pinpoint methodological difficulties likely underlie remarkable failure replicate genetic findings using current approaches
0.28218916.14764623.html.plaintext.txt	29	2003 A GOOD VINTAGE FOR AD GENETICS TOP ABSTRACT INTRODUCTION 2003 A GOOD VINTAGE
0.28218916.14764623.html.plaintext.txt	30	CONCLUSION REFERENCES Genome screens As outlined year 2003 almost unprecedented terms number studies attempting unravel causes AD genetics
0.28218916.14764623.html.plaintext.txt	31	Three full genome screens 81819 using association genetic linkage methods added nine studies already reported literature late onset AD
0.28218916.14764623.html.plaintext.txt	32	A study study comparison using P value 0
0.28218916.14764623.html.plaintext.txt	33	01 cut reveals total 16 regions 11 chromosomes yield positive signals across least two studies markers 25 Mb apart Table 1
0.28218916.14764623.html.plaintext.txt	34	Interestingly chromosomes strongest consistent signals
0.28218916.14764623.html.plaintext.txt	35	6 9 10 12 19 21 already implicated least 3 years earlier received support 2003
0.28218916.14764623.html.plaintext.txt	36	Based criteria new AD region emerge 2003 chromosome 2p23 24 position 19 29 Mb
0.28218916.14764623.html.plaintext.txt	37	Interestingly region implicated studies using association methods fairly isolated homogeneous populations
0.28218916.14764623.html.plaintext.txt	38	Finns Wadi Ara 1418
0.28218916.14764623.html.plaintext.txt	39	Note inclusion exclusion criteria applied arbitrary may overestimate total number positive signals
0.28218916.14764623.html.plaintext.txt	40	They however allow comparison across multitude methodologically divergent approaches facilitate interpretation analyses based actual candidate genes
0.28218916.14764623.html.plaintext.txt	41	Candidate gene studies Searching PubMed www
0.28218916.14764623.html.plaintext.txt	42	govPubMed keywords alzheimer AND association OR associated papers published January 1 December 31 2003 retrieved total 1037 studies December 28 2003 90 directly deal genetic association candidate polymorphisms AD
0.28218916.14764623.html.plaintext.txt	43	As seen Table 2 studies examined total 55 genetic loci locus set markers within 5 Mb genomic interval 20 different chromosomes
0.28218916.14764623.html.plaintext.txt	44	A total 55 analyzed genes within loci found positive judged authors 68 tested negative
0.28218916.14764623.html.plaintext.txt	45	Interestingly even 10 years discovery largest number n18 reports focusing single gene dealt association APOE AD using new polymorphisms new samplesethnic groups new phenotypes
0.28218916.14764623.html.plaintext.txt	46	When studies considered total 38 positive 67 negative papers remained
0.28218916.14764623.html.plaintext.txt	47	Overview chromosomal loci tested genetic association AD 2003 If 2003 represents one prolific vintages late onset AD genetic studies next pressing question large quantity studies also dilute quality product perhaps even making unpalatable quaff The answer opinion yes least majority cases
0.28218916.14764623.html.plaintext.txt	48	There growing consensus success rate reliability genetic association studies complex diseases depend fulfillment several criteria 2021 three discussed detail
0.28218916.14764623.html.plaintext.txt	49	These addition classic requirements least plausible biological andor positional candidacy investigated locus well direct proof pathophysiological consequences positive disease association
0.28218916.14764623.html.plaintext.txt	50	While former criterion fulfilled vast majority AD candidate genes investigated thus far latter condition elusive
0.28218916.14764623.html.plaintext.txt	51	This due several factors generally bedevil study genetic association complex diseases linkage disequilibrium actual functionally relevant disease modifying variant small effect sizes impede detection significant effects using basic molecular biochemical assays possibly involvement yet unknown pathophysiological mechanisms
0.28218916.14764623.html.plaintext.txt	52	The situation APOE 4 AD serves good example genetic association per se extremely well established past decade still consensus association translates pathophysiologically 2223
0.28218916.14764623.html.plaintext.txt	53	Thus attempting uncover functional consequences putative new disease association propose emphasis must placed criteria allow better distinction false positive well false negative findings prior initial publication
0.28218916.14764623.html.plaintext.txt	54	Power sample size structure enable investigators detect effect sizes moderate small extent While obvious concern reports negative outcome power study also governs rate false positive findings
0.28218916.14764623.html.plaintext.txt	55	probability observed significant association indeed genuine observed chance 24 26
0.28218916.14764623.html.plaintext.txt	56	Other factors influencing ability detect meaningful effects include attributable risk polymorphism overall genetic variance degree linkage disequilibrium LD associated allele actual disease predisposing variant mode inheritance lesser extent disease prevalence
0.28218916.14764623.html.plaintext.txt	57	While variables course difficult estimate true disease gene unknown power given sample size fairly easily calculated variety possible plausible scenarios
0.28218916.14764623.html.plaintext.txt	58	In practice however still remains exception
0.28218916.14764623.html.plaintext.txt	59	A recent study estimated minimal number cases controls sufficient achieve 80 power 0
0.28218916.14764623.html.plaintext.txt	60	05 usually far greater 200 actual disease allele tested directly even favorable circumstances 26
0.28218916.14764623.html.plaintext.txt	61	It interesting regardless estimates 20 studies published 2003 still used smaller sample sizes thus probably suitable use reaching reliable conclusion
0.28218916.14764623.html.plaintext.txt	62	Replicability result validatedreplicated independent sample sufficient size While reports significant associations putative candidate genes AD every chromosome human genome past 10 years 27 none findings exception APOE 4 yet replicated consistently
0.28218916.14764623.html.plaintext.txt	63	Many seemingly positive result could validated independent dataset prior first publication several authors long suggesting guidelines proper quality control genetic association findings 2021252829
0.28218916.14764623.html.plaintext.txt	64	The current inflation probable false positive reports may avoided independent replication sought earlier
0.28218916.14764623.html.plaintext.txt	65	If independent sample cannot found house establishment least temporary consortia collaborative laboratories test others positive signals prior publication would represent easy effective means restore credibility
0.28218916.14764623.html.plaintext.txt	66	Upon review 2003 AD genetics literature less 20 studies either referred findings two independent samples published tandem independent reports investigating candidate genes andor genetic variants
0.28218916.14764623.html.plaintext.txt	67	Haplotype structure authors made attempts elucidate structure underlying haplotype architecture The current systematic assessment haplotype structures various regions throughout genome past 3 4 years emphasized importance performing haplotype systematic LD analyses searching novel complex disease genes 3031 especially effect sizes expected lower conferred APOE 4
0.28218916.14764623.html.plaintext.txt	68	In addition increasing power analyses approach also reduces number statistical tests need performed lead decrease false positive findings
0.28218916.14764623.html.plaintext.txt	69	Several recently published complex disease associations would impossible observe without thorough assessment underlying haplotype architecture 32 34
0.28218916.14764623.html.plaintext.txt	70	Along lines recent studies APOE shown locus would easily identified means haplotype analysis alone even without prior knowledge 4 polymorphism 3536
0.28218916.14764623.html.plaintext.txt	71	Yet 2003 one third studies investigated one polymorphism per locus
0.28218916.14764623.html.plaintext.txt	72	Only half carried less thorough assessment haplotype structure
0.28218916.14764623.html.plaintext.txt	73	four polymorphisms per gene
0.28218916.14764623.html.plaintext.txt	74	Out 90 papers published 2003 topic genetic association candidate genes different AD phenotypes 21 23 fulfilled least two criteria
0.28218916.14764623.html.plaintext.txt	75	Most likely many observed discrepancies across studies could explained lack methodological thoroughness
0.28218916.14764623.html.plaintext.txt	76	Nonetheless three loci addition APOE tested positive across least three studies chromosomes 6p21 10q24 11q23 Table 2
0.28218916.14764623.html.plaintext.txt	77	These loci covered remainder review
0.28218916.14764623.html.plaintext.txt	78	Chromosome 6p21 This chromosomal region implicated harboring putative AD gene early 1980 based association finding variants highly polymorphic major histocompatibility complex region HLA A 30 Mb AD small case control study 37
0.28218916.14764623.html.plaintext.txt	79	Two potential AD candidates map within 5 Mb interval genes encoding hereditary haemochromatosis protein HFE 26 Mb tumor necrosis factor alpha TNFA 31 Mb
0.28218916.14764623.html.plaintext.txt	80	While 2003 two studies reported significant evidence association latter two genes 3839 two studies confirm findings 4041
0.28218916.14764623.html.plaintext.txt	81	Another candidate gene located region HAPA1B found associated certain neuropsychological variables 42 disease risk 43
0.28218916.14764623.html.plaintext.txt	82	Finally one study investigated variation onset age function HLA A2 allele small sample AD patients find significant effects 44
0.28218916.14764623.html.plaintext.txt	83	A literature search association studies genes including years 2003 yielded least 15 positive studies 10 reports found evidence genetic involvement factors
0.28218916.14764623.html.plaintext.txt	84	While evidence direct involvement TNFA Ass production toxicity 45 direct proof pathogenetic relevance genesproteins remains seen
0.28218916.14764623.html.plaintext.txt	85	Furthermore full genome screens AD genes consistently yielded signals 6p21 residing 39 42 Mb whereas associated genes map 10 Mb proximal
0.28218916.14764623.html.plaintext.txt	86	Thus increasing evidence supporting existence putative AD locus 6p21 general possibility actual disease gene yet identified cannot excluded despite overlapping positive results year past studies
0.28218916.14764623.html.plaintext.txt	87	Chromosome 10q24 Of six candidate loci analyzed region 10q21 10q25 2003 three reported associated AD phenotypes across multiple samples
0.28218916.14764623.html.plaintext.txt	88	CDC2VR22 TNFRSF6IDE GSTO12
0.28218916.14764623.html.plaintext.txt	89	The locus found associated one group investigators located 90 94 Mb encompasses genes TNFRSF6 90 Mb IDEKIFF11HHEX 46 48
0.28218916.14764623.html.plaintext.txt	90	Probably best candidate biological grounds IDE encoding insulin degrading enzyme protein IDE
0.28218916.14764623.html.plaintext.txt	91	This metalloprotease shown degrade monomeric Ass aggregate oligomeric forms ultimately ss amyloid plaques 49
0.28218916.14764623.html.plaintext.txt	92	While several issues proposed mode action still remain controversial e
0.28218916.14764623.html.plaintext.txt	93	precise cellular location Ass cleavage relevance IDE functiondysfunction development AD number animal models available showing predicted effects vivo 50 52
0.28218916.14764623.html.plaintext.txt	94	Before 2003 two papers published showing allelic association microsatellite markers region 5354 two reports find association IDE variants nearby markers AD 5556
0.28218916.14764623.html.plaintext.txt	95	Note data one negative studies 55 actually largely overlaps positive paper Edland et al
0.28218916.14764623.html.plaintext.txt	96	46 important exception authors first paper account potential interactions IDE APOE 4 status
0.28218916.14764623.html.plaintext.txt	97	This may crucial since latter study found significant effect IDE AD risk individuals lacking APOE 4 allele
0.28218916.14764623.html.plaintext.txt	98	Clearly studies independent samples sufficient size necessary elucidate potential role IDE variants development AD general population
0.28218916.14764623.html.plaintext.txt	99	In addition IDE locus total four genes long arm chromosome 10 found associated AD
0.28218916.14764623.html.plaintext.txt	100	Two CDC2 VR22 map 30 Mb proximal IDE two GSTO12 PRSS11 map 10 30 Mb distal
0.28218916.14764623.html.plaintext.txt	101	While none associations yet confirmed independent AD samples noteworthy two genes also found associated neurodegenerative illnesses frontotemporal dementia CDC2 57 Parkinsons disease GSTO12 58 potentially suggesting common pathway leading neuronal cell death across syndromes
0.28218916.14764623.html.plaintext.txt	102	CDC2 encodes cell division cycle 2 protein involved phosphorylation tau APP found neurons bearing neurofibrillary tangles
0.28218916.14764623.html.plaintext.txt	103	GSTO1 2 encode glutathione S transferase omega 1 2 involved physiological response oxidative stress may particular responsible regulating expression inflammatory cytokines like IL1 ss
0.28218916.14764623.html.plaintext.txt	104	Thus plausible AD candidate genes positional well biologicalbiochemical grounds studies still necessary elucidate proposed roles influencing risk andor age onset AD general population
0.28218916.14764623.html.plaintext.txt	105	Chromosome 11q23 The region near tip long arm chromosome 11 implicated one full genome screens published date 8 therefore appear Table 1
0.28218916.14764623.html.plaintext.txt	106	Yet total three studies showing significant association AD candidate gene 2003 BACE encoding ss site APP cleaving enzyme ss secretase 59 61
0.28218916.14764623.html.plaintext.txt	107	This protein excellent AD candidate biochemical grounds ss secretase cleavage APP Ass liberated precursor via secretase cleavage
0.28218916.14764623.html.plaintext.txt	108	Most interestingly contrast putative AD associations discussed appears high degree consistency respect site allelic nature underlying findings positive studies including initial report Nowotny colleagues published 2001 62 observe representations G allele synonymous SNP located codon 262 exon 5 AD cases compared healthy controls
0.28218916.14764623.html.plaintext.txt	109	Furthermore studies observed effect pronounced carriers APOE 4 allele yielding significantly elevated odds ratios ranging 2 7
0.28218916.14764623.html.plaintext.txt	110	In contrast four positive associations equal number studies literature showing apparent effects BACE polymorphism AD
0.28218916.14764623.html.plaintext.txt	111	However must pointed one studied early onset familial AD cases 63 remaining studies account potential interaction APOE 4 allele 64 66
0.28218916.14764623.html.plaintext.txt	112	Unless done similar situation encountered variants tested IDE see firm conclusions reached whether exon 5 polymorphism BACE genetic risk factor AD samples
0.28218916.14764623.html.plaintext.txt	113	Thus three known APP cleaving enzymes associated proteins ADAM910 17 ss BACE BACE2 secretase PSEN1 APH1A NCSTN PEN2 already tested genetic association AD phenotypes BACE currently shows promise genuine relevant risk factor late onset AD
0.28218916.14764623.html.plaintext.txt	114	As case putative AD genes studies using sufficiently sized samples appropriate analytic strategies need performed general conclusions reached
0.28218916.14764623.html.plaintext.txt	115	Note first study examining putative genetic role BACE late onset AD 2004 also reports significant effect exon 5 polymorphism case control sample Chinese origin 67
0.28218916.14764623.html.plaintext.txt	116	CONCLUSION TOP ABSTRACT INTRODUCTION 2003 A GOOD VINTAGE
0.28218916.14764623.html.plaintext.txt	117	CONCLUSION REFERENCES While year 2003 extremely productive terms studies examining potential associations candidate genes AD phenotypes vast majority results previous years remains controversial
0.28218916.14764623.html.plaintext.txt	118	While cases could due factors disease specific e
0.28218916.14764623.html.plaintext.txt	119	larger anticipated genetic heterogeneity andor small effect sizes individual risk alleles good proportion controversies probably caused methodological issues
0.28218916.14764623.html.plaintext.txt	120	Based recent empirical simulation data regarding genetic make complex diseases power association studies general propose attention paid providing power estimates based structure analyzed sample variety effect sizes allele frequencies ii replicating positive signal least one independent population sufficient size power prior initial publication iii thoroughly assessing haplotype structure investigated locus especially reaching negative conclusions
0.28218916.14764623.html.plaintext.txt	121	Together statistical techniques take account potential interactions genetic non genetic factors allow adequate correction multiple comparisons adherence criteria ensure successful distinction clinically relevant irrelevantfalse positive findings
0.28218916.14764623.html.plaintext.txt	122	Eventually good vintage wine strategy elevate quality AD genetics research par quantity
0.28218916.14764623.html.plaintext.txt	123	ACKNOWLEDGEMENTS This work sponsored grants NIMH NIA ADRC Alzheimer Association
0.28218916.14764623.html.plaintext.txt	124	fellow Harvard Center Neurodegeneration Repair HCNR fellow Deutsche Forschungsgemeinschaft DFG
0.28218916.14764623.html.plaintext.txt	125	FOOTNOTES To correspondence addressed Genetics Aging Research Unit Department Neurology Massachusetts General Hospital 114 16th Street Charlestown MA 02129 USA
0.28218916.14764623.html.plaintext.txt	126	Tel 1 6177266845 Fax 1 6177241823 Email tanziathelix
0.28218916.14764623.html.plaintext.txt	127	REFERENCES TOP ABSTRACT INTRODUCTION 2003 A GOOD VINTAGE
0.28218916.14764623.html.plaintext.txt	128	CONCLUSION REFERENCES Rao V
0.28218916.14764623.html.plaintext.txt	129	1996 Evidence major gene inheritance Alzheimer disease families patients without apolipoprotein E epsilon 4
0.28218916.14764623.html.plaintext.txt	130	1997 The role heredity late onset Alzheimer disease vascular dementia
0.28218916.14764623.html.plaintext.txt	131	2000 The number trait loci late onset Alzheimer disease
0.28218916.14764623.html.plaintext.txt	132	2003 The genetics adult onset neuropsychiatric disease complexities conundra Science 302 822 826
0.28218916.14764623.html.plaintext.txt	133	1984 Clinical diagnosis Alzheimers disease report NINCDS ADRDA Work Group auspices Department Health Human Services Task Force Alzheimers Disease
0.28218916.14764623.html.plaintext.txt	134	1996 Diagnostic accuracy Alzheimers disease neuropathological study
0.28218916.14764623.html.plaintext.txt	135	1996 Accuracy clinical diagnosis Alzheimer disease clinical features patients non Alzheimer disease neuropathology
0.28218916.14764623.html.plaintext.txt	136	2003 Results high resolution genome screen 437 Alzheimers disease families
0.28218916.14764623.html.plaintext.txt	137	1997 Complete genomic screen late onset familial Alzheimer disease
0.28218916.14764623.html.plaintext.txt	138	Evidence new locus chromosome 12
0.28218916.14764623.html.plaintext.txt	139	1998 A genome survey novel Alzheimer disease risk loci results 10 cM resolution
0.28218916.14764623.html.plaintext.txt	140	1999 A full genome scan late onset Alzheimers disease
0.28218916.14764623.html.plaintext.txt	141	2000 Identification novel genes late onset Alzheimers disease
0.28218916.14764623.html.plaintext.txt	142	2001 A novel method two locus linkage analysis applied genome scan late onset Alzheimers disease
0.28218916.14764623.html.plaintext.txt	143	2001 Genome wide linkage disequilibrium mapping late onset Alzheimers disease Finland
0.28218916.14764623.html.plaintext.txt	144	2002 Age onset two common neurodegenerative diseases genetically controlled
0.28218916.14764623.html.plaintext.txt	145	2002 Full genome screen Alzheimer disease Stage II analysis
0.28218916.14764623.html.plaintext.txt	146	2002 A second locus late onset Alzheimer disease genome scan reveals linkage 20p epistasis 20p amyloid precursor protein region
0.28218916.14764623.html.plaintext.txt	147	2003 Identification multiple loci Alzheimer disease consanguineous Israeli Arab community
0.28218916.14764623.html.plaintext.txt	148	2003 Ordered subsets linkage analysis detects novel Alzheimer disease Loci chromosomes 2q34 15q22
0.28218916.14764623.html.plaintext.txt	149	2001 Genetic association studies genes search diseases
0.28218916.14764623.html.plaintext.txt	150	2001 Association study designs complex diseases
0.28218916.14764623.html.plaintext.txt	151	2000 Apolipoprotein E Alzheimers disease
0.28218916.14764623.html.plaintext.txt	152	2001 Role apoeAbeta interactions pathogenesis Alzheimers disease cerebral amyloid angiopathy
0.28218916.14764623.html.plaintext.txt	153	1966 Predictive value single diagnostic test unselected populations
0.28218916.14764623.html.plaintext.txt	154	2001 Replication validity genetic association studies
0.28218916.14764623.html.plaintext.txt	155	2003 Sample size calculations population family based case control association studies marker genotypes
0.28218916.14764623.html.plaintext.txt	156	2001 Of replications refutations status Alzheimers disease genetic research
0.28218916.14764623.html.plaintext.txt	157	2002 Proposed guidelines papers describing DNA polymorphism disease associations
0.28218916.14764623.html.plaintext.txt	158	2002 Opinion candidate gene approaches studying complex genetic traits practical considerations
0.28218916.14764623.html.plaintext.txt	159	2002 The structure haplotype blocks human genome
0.28218916.14764623.html.plaintext.txt	160	2003 Using haplotype blocks map human complex trait loci
0.28218916.14764623.html.plaintext.txt	161	1997 Genetic evidence involvement tau progressive supranuclear palsy
0.28218916.14764623.html.plaintext.txt	162	2000 Genetic variation gene encoding calpain 10 associated type 2 diabetes mellitus
0.28218916.14764623.html.plaintext.txt	163	2001 Genetic variation 5q31 cytokine gene cluster confers susceptibility Crohn disease
0.28218916.14764623.html.plaintext.txt	164	2000 SNPing away complex diseases analysis single nucleotide polymorphisms around APOE Alzheimer disease
0.28218916.14764623.html.plaintext.txt	165	2001 Genetic analysis casecontrol data using estimated haplotype frequencies application APOE locus variation Alzheimers disease
0.28218916.14764623.html.plaintext.txt	166	1980 Histocompatibility antigens Alzheimers disease
0.28218916.14764623.html.plaintext.txt	167	2003 Tumour necrosis factor alpha gene polymorphisms Alzheimers disease
0.28218916.14764623.html.plaintext.txt	168	2003 Association HFE mutations neurodegeneration oxidative stress Alzheimers disease correlation APOE
0.28218916.14764623.html.plaintext.txt	169	2003 Association HFE mutations unsuccessful ageing study Alzheimers disease patients Northern Italy
0.28218916.14764623.html.plaintext.txt	170	2003 Tumor necrosis factor alpha polymorphism C 850T associated Alzheimers disease vascular dementia Italian population
0.28218916.14764623.html.plaintext.txt	171	2003 HSP70 2 HSPA1B associated noncognitive symptoms late onset Alzheimers disease
0.28218916.14764623.html.plaintext.txt	172	2003 Joint analysis candidate genes related Alzheimers disease Spanish population
0.28218916.14764623.html.plaintext.txt	173	2003 Association A2 allele HLA system age onset Alzheimers disease
0.28218916.14764623.html.plaintext.txt	174	2000 Inflammation Alzheimers disease
0.28218916.14764623.html.plaintext.txt	175	2003 Insulin degrading enzyme IDE genetic variants risk Alzheimers disease evidence effect modification apolipoprotein E APOE
0.28218916.14764623.html.plaintext.txt	176	2003 Further evidence role promoter variant TNFRSF6 gene Alzheimer disease
0.28218916.14764623.html.plaintext.txt	177	2003 Genetic variation haplotype block spanning IDE influences Alzheimer disease
0.28218916.14764623.html.plaintext.txt	178	1998 Insulin degrading enzyme regulates extracellular levels amyloid beta protein degradation
0.28218916.14764623.html.plaintext.txt	179	2003 Insulin degrading enzyme regulates levels insulin amyloid beta protein beta amyloid precursor protein intracellular domain vivo
0.28218916.14764623.html.plaintext.txt	180	2003 Amyloid beta peptide levels brain inversely correlated insulysin activity levels vivo
0.28218916.14764623.html.plaintext.txt	181	2003 Enhanced proteolysis beta amyloid APP transgenic mice prevents plaque formation secondary pathology premature death
0.28218916.14764623.html.plaintext.txt	182	2000 Evidence genetic linkage Alzheimers disease chromosome 10q
0.28218916.14764623.html.plaintext.txt	183	2002 Confirmation association D10S583 Alzheimers disease case control sample
0.28218916.14764623.html.plaintext.txt	184	2001 Substantial linkage disequilibrium across insulin degrading enzyme locus association late onset Alzheimers disease
0.28218916.14764623.html.plaintext.txt	185	2002 Polymorphisms insulin degrading enzyme gene associated Alzheimers disease
0.28218916.14764623.html.plaintext.txt	186	2003 Increased frequency new polymorphism cell division cycle 2 cdc2 gene patients Alzheimers disease frontotemporal dementia
0.28218916.14764623.html.plaintext.txt	187	2003 Glutathione S transferase omega 1 modifiesage onset Alzheimer disease Parkinson disease
0.28218916.14764623.html.plaintext.txt	188	2003 Specific BACE1 genotypes provide additional risk late onset Alzheimer disease APOE epsilon 4 carriers
0.28218916.14764623.html.plaintext.txt	189	2003 Polymorphism BACE gene influences risk Alzheimers disease
0.28218916.14764623.html.plaintext.txt	190	2003 Association study Alzheimers disease genes involved Abeta biosynthesis aggregation degradation suggestive results BACE1
0.28218916.14764623.html.plaintext.txt	191	2001 Association studies using novel polymorphisms BACE1 BACE2
0.28218916.14764623.html.plaintext.txt	192	2001 Amyloid beta secretase gene BACE neither mutated associated early onset Alzheimers disease
0.28218916.14764623.html.plaintext.txt	193	2001 The BACE gene genomic structure candidate gene study late onset Alzheimers disease
0.28218916.14764623.html.plaintext.txt	194	2001 Mutations open reading frame beta site APP cleaving enzyme BACE locus common cause Alzheimers disease
0.28218916.14764623.html.plaintext.txt	195	2003 The association beta site APP cleaving enzyme BACE C786G polymorphism Alzheimers disease
0.28218916.14764623.html.plaintext.txt	196	2004 The 1239GC polymorphism exon 5 BACE1 gene may associated sporadic Alzheimers disease Chinese Hans
0.31053388.15890642.html.plaintext.txt	0	Engineering Conformational Destabilization Mouse Apolipoprotein E A MODEL FOR A UNIQUE PROPERTY OF HUMAN APOLIPOPROTEIN E4 Danny M
0.31053388.15890642.html.plaintext.txt	1	From Gladstone Institute Neurological Disease San Francisco California 94158 Cardiovascular Research Institute Department Pathology University California San Francisco California 94143
0.31053388.15890642.html.plaintext.txt	2	Received publication April 11 2005 revised form May 11 2005
0.31053388.15890642.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Apolipoprotein apo E4 major risk factor Alzheimer cardiovascular diseases
0.31053388.15890642.html.plaintext.txt	4	ApoE4 differs two common isoforms apoE2 apoE3 lower resistance denaturation greater propensity form partially folded intermediates
0.31053388.15890642.html.plaintext.txt	5	As first step determine importance stability differences vivo reengineered partially humanized variant amino terminal domain mouse apoE T61R mouse apoE acquire destabilized conformation like apoE4
0.31053388.15890642.html.plaintext.txt	6	For process determined crystal structure wild type mouse apoE like apoE4 forms four helix bundle identified two structural differences turn helices 2 3 middle helix 3 potentially destabilizing sites
0.31053388.15890642.html.plaintext.txt	7	Introducing mutations G83T N113G sites destabilized mouse apoE conformation
0.31053388.15890642.html.plaintext.txt	8	The mutant mouse apoE rapidly remodeled phospholipid T61R mouse apoE supports hypothesis destabilized conformation promotes apoE4 lipid binding
0.31053388.15890642.html.plaintext.txt	9	INTRODUCTION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Apolipoprotein apo1 E plays central role transport metabolic fate lipids throughout central nervous cardiovascular systems 1 3
0.31053388.15890642.html.plaintext.txt	10	One common human isoforms apoE4 major risk factor cardiovascular Alzheimer diseases
0.31053388.15890642.html.plaintext.txt	11	The two common isoforms apoE3 apoE2 correlate lowered risk respectively Alzheimer disease 4 8
0.31053388.15890642.html.plaintext.txt	12	ApoE4 also associated poor outcome recovery neurological injury 9 11 rapid progression multiple sclerosis amyotrophic lateral sclerosis 12 13
0.31053388.15890642.html.plaintext.txt	13	The three isoforms encoded one gene differ one two amino acid sequence positions
0.31053388.15890642.html.plaintext.txt	14	ApoE3 cysteine position 112 arginine 158 apoE2 cysteines apoE4 arginines positions 14
0.31053388.15890642.html.plaintext.txt	15	These sequence differences result structural biophysical properties alter function hence likely affect disease
0.31053388.15890642.html.plaintext.txt	16	In apoE4 two modular domains interact unique manner known domain interaction 15 17
0.31053388.15890642.html.plaintext.txt	17	Arg 112 apoE4 causes Arg 61 side chain adopt different conformation apoE2 apoE3 allowing form putative salt bridge Glu 255 carboxyl terminal domain 16 18
0.31053388.15890642.html.plaintext.txt	18	The isoforms also differ conformational stability amino terminal domains unfold independently carboxy terminal domain contain isoform specific sequence differences 19 22
0.31053388.15890642.html.plaintext.txt	19	The amino terminal domain apoE4 least resistant chemical thermal denaturation apoE2 resistant 20 22
0.31053388.15890642.html.plaintext.txt	20	The amino terminal domain apoE4 also readily forms partially folded intermediates characteristics molten globule state 21
0.31053388.15890642.html.plaintext.txt	21	Increasing evidence indicates molten globules common mediate wide variety physiological processes including translocation across membranes increased affinity membranes binding liposomes phospholipids protein trafficking extracellular secretion cell cycle regulation 23
0.31053388.15890642.html.plaintext.txt	22	As one explanation functional differences among isoforms vivo others suggested partially folded intermediates provide apoE greater conformational adaptability bind phospholipids 21 24
0.31053388.15890642.html.plaintext.txt	23	Previously laboratory introduced domain interaction mouse apoE
0.31053388.15890642.html.plaintext.txt	24	Gene targeting used replace threonine mouse equivalent position 61 arginine T61R resulted apoE4 like lipoprotein binding preference 25 characteristic domain interaction
0.31053388.15890642.html.plaintext.txt	25	However unlike apoE4 T61R mouse apoE folds highly cooperatively lacks apparent folding intermediates
0.31053388.15890642.html.plaintext.txt	26	To gain sight differences isoform stability affect phenotype disease sought introduce T61R mouse apoE reduced folding stability characteristic apoE4
0.31053388.15890642.html.plaintext.txt	27	The objective humanize mouse apoE replacing residues apoE4 destabilize conformation
0.31053388.15890642.html.plaintext.txt	28	An empirical approach taken change urea denaturation curve T61R mouse apoE resemble apoE4
0.31053388.15890642.html.plaintext.txt	29	The crystal structure amino terminal domain wild type mouse apoE determined identify potential structural differences apoE4 mouse apoE might result packing differences leading differences urea denaturation curves
0.31053388.15890642.html.plaintext.txt	30	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Protein Expression Purification cDNAs corresponding amino terminal domains human mouse apoE cloned pET32a amino terminal thioredoxin tag fusion
0.31053388.15890642.html.plaintext.txt	31	Mutants generated QuikChange mutagenesis kit Stratagene DNA sequences verified DNA sequencing
0.31053388.15890642.html.plaintext.txt	32	The protein expressed Escherichia coli described 26
0.31053388.15890642.html.plaintext.txt	33	After expression 6 liter culture cells resuspended 30 ml 10 mM Tris pH 7
0.31053388.15890642.html.plaintext.txt	34	The cells frozen thawed lysed sonication debris removed centrifugation 15000 x g 20 min 4 degrees C
0.31053388.15890642.html.plaintext.txt	35	Dimyristoylphosphatidylcholine DMPC powder 1
0.31053388.15890642.html.plaintext.txt	36	8 g added cell lysate mixture incubated overnight 24 degrees C dialyzed 10 mM Tris pH 8
0.31053388.15890642.html.plaintext.txt	37	The fusion protein cleaved adding 1 mg bovine thrombin mixture incubated overnight room temperature
0.31053388.15890642.html.plaintext.txt	38	The apoE DMPC complexes isolated density gradient centrifugation 0
0.31053388.15890642.html.plaintext.txt	39	3265 gml KBr added lysate overlaid 1
0.31053388.15890642.html.plaintext.txt	40	48 M potassium bromide 10 mM Tris pH 7
0.31053388.15890642.html.plaintext.txt	41	4 BeckmanCoulter Quick Seal tube centrifugation 55000 rpm 12 h Beckman Ti60 rotor 15 degrees C
0.31053388.15890642.html.plaintext.txt	42	The floated pellet collected slicing tube
0.31053388.15890642.html.plaintext.txt	43	The DMPC apoE fraction dialyzed exhaustively 0
0.31053388.15890642.html.plaintext.txt	44	1 M ammonium bicarbonate lyophilized delipidated purified gel filtration described 26
0.31053388.15890642.html.plaintext.txt	45	For crystallization final anion exchange chromatography step involved DEAE resin linear salt gradient
0.31053388.15890642.html.plaintext.txt	46	Protein concentrations determined Lowry assay bovine serum albumin mass standard
0.31053388.15890642.html.plaintext.txt	47	View larger version 19K FIG
0.31053388.15890642.html.plaintext.txt	48	Urea denaturation curves amino terminal domains apoE isoforms
0.31053388.15890642.html.plaintext.txt	49	Curves derived fractional change CD ellipticity wavelength 222 nm 0 8 M urea
0.31053388.15890642.html.plaintext.txt	50	ApoE3 apoE4 wild type mouse apoE T61R mouse apoE shown
0.31053388.15890642.html.plaintext.txt	51	Crystallization X ray Diffraction Data Collection Crystals grown hanging drop technique 1
0.31053388.15890642.html.plaintext.txt	52	5 saturated sodium malonate pH 7
0.31053388.15890642.html.plaintext.txt	53	2 100 mM sodium acetate pH 5
0.31053388.15890642.html.plaintext.txt	54	Diffraction data collected beam line 7 1 Stanford Synchrotron Radiation Laboratory
0.31053388.15890642.html.plaintext.txt	55	The data collection statistics summarized Table I
0.31053388.15890642.html.plaintext.txt	56	The space group determined P212121 unit cell 29
0.31053388.15890642.html.plaintext.txt	57	Initial phases obtained using molecular replacement program EPMR 27 structure amino terminal domain apoE4 starting model
0.31053388.15890642.html.plaintext.txt	58	To decrease model bias RESOLVE 28 used refine initial phases build preliminary model
0.31053388.15890642.html.plaintext.txt	59	CNS 29 REFMAC 30 used subsequent refinement cycles
0.31053388.15890642.html.plaintext.txt	60	View table TABLE I Data collection refinement statistics
0.31053388.15890642.html.plaintext.txt	61	Urea Denaturation Curves A saturated urea solution freshly deionized filtered
0.31053388.15890642.html.plaintext.txt	62	The urea concentration determined measurement refractive index described 31
0.31053388.15890642.html.plaintext.txt	63	Circular dichroism spectra collected apoE 22 kDa fragment 0
0.31053388.15890642.html.plaintext.txt	64	5 mgml 0 8 M urea 5 mM dithiothreitol 20 mM sodium acetate pH 4
0.31053388.15890642.html.plaintext.txt	65	Samples preincubated overnight 4 degrees C spectroscopic analysis data collected 24 degrees C using 1 mm path length cuvette Applied Biophysics 180 Jasco J 720 CD spectrometer 1000 ms acquisition time
0.31053388.15890642.html.plaintext.txt	66	Ellipticity 222 nm served indicator secondary structure predominately helical folded state data adjusted fraction unfolded assuming protein 100 unfolded 8 M urea
0.31053388.15890642.html.plaintext.txt	67	DMPC Turbidity clearance Assays Samples apoE 22 kDa fragment 1 mgml prepared 1 mM Tris carboxyethylphosphine 20 mM sodium acetate pH 4
0.31053388.15890642.html.plaintext.txt	68	DMPC prepared 5 mgml buffer A incubated 42 degrees C 20 min extruded 100 nm pore filter Lipex pressure extruder
0.31053388.15890642.html.plaintext.txt	69	The resulting large unilamellar vesicles diluted 1 mgml buffer A
0.31053388.15890642.html.plaintext.txt	70	The vesicles protein samples spectrophotometer cuvette holding block pre equilibrated 26 degrees C overnight
0.31053388.15890642.html.plaintext.txt	71	Samples apoE buffer A 200 microl mixed rapidly vesicles 400 microl turbidity monitored absorbance 325 nm 20 min 26 degrees C
0.31053388.15890642.html.plaintext.txt	72	Cuvettes pre equilibrated 26 degrees C 10 min use
0.31053388.15890642.html.plaintext.txt	73	RESULTS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Differences Urea Denaturation Curves Amino terminal Domain Mouse Human ApoE Urea denaturation studies showed amino terminal domain apoE4 lower apparent conformational stability apoE3 apoE2 greater tendency form partially folded intermediates revealed less cooperative transition folded state unfolded state 21
0.31053388.15890642.html.plaintext.txt	74	The denaturation curve T61R mouse apoE displayed greater cooperativity apoE3 apoE4 unfolded urea concentrations similar apoE3 unfolds apoE4 Fig
0.31053388.15890642.html.plaintext.txt	75	Wild type mouse apoE denaturation curve similar T61R mouse apoE Fig
0.31053388.15890642.html.plaintext.txt	76	Structural Comparison Amino terminal Domain Mouse Human ApoE The crystal structure amino terminal domain wild type mouse apoE determined resolution 2
0.31053388.15890642.html.plaintext.txt	77	1 A used find clues packing differences apoE4 may influence folding stability
0.31053388.15890642.html.plaintext.txt	78	The x ray diffraction data collection refinement statistics summarized Table I
0.31053388.15890642.html.plaintext.txt	79	Excluding eight additional amino terminal residues human apoE amino terminal domains mouse apoE apoE4 differ 35 sequence positions corresponding 81 sequence identity Fig
0.31053388.15890642.html.plaintext.txt	80	The overall fold amino terminal domain wild type mouse apoE similar apoE4 Fig
0.31053388.15890642.html.plaintext.txt	81	Except residues 9 11 166 172 186 191 residues amino terminal domain mouse apoE clearly visible final electron density map
0.31053388.15890642.html.plaintext.txt	82	Although amino terminal domain mouse apoE like apoE4 forms four helix bundle structural differences
0.31053388.15890642.html.plaintext.txt	83	Alignment mouse human structures along helices 1 2 shows relative apoE4 helices 3 4 amino terminal domain mouse apoE shifted direction roughly parallel helical axis helix 3
0.31053388.15890642.html.plaintext.txt	84	In addition helices 1 2 4 longer mouse apoE apoE4
0.31053388.15890642.html.plaintext.txt	85	A crystal contact residue 20 mouse apoE likely stabilizes extension helix 1 apoE4 contact occurs
0.31053388.15890642.html.plaintext.txt	86	A crystal contact residue 126 mouse apoE seen apoE4 likely influences structure loop helices 3 4 residues 120 130
0.31053388.15890642.html.plaintext.txt	87	Two Structural Differences Positions 83 113 Are Mediated Sequence Differences After exclusion crystal contact sites two key structural differences result sequence differences
0.31053388.15890642.html.plaintext.txt	88	The loop helices 2 3 residues 81 86 forms tight turn mouse apoE extended relaxed crystal structures human apoE 33
0.31053388.15890642.html.plaintext.txt	89	This difference reflects cis conformation Gly 83 mouse apoE cannot sterically accommodated Thr 83 apoE4 Fig
0.31053388.15890642.html.plaintext.txt	90	In mouse apoE helix 2 one helical turn apoE4 dipoles helices 2 3 less parallel Fig
0.31053388.15890642.html.plaintext.txt	91	View larger version 64K FIG
0.31053388.15890642.html.plaintext.txt	92	Sequence alignment amino terminal domains mouse apoE apoE4
0.31053388.15890642.html.plaintext.txt	93	The numbering system mouse apoE standardized apoE4 sequence apoE4 eight additional amino terminal residues
0.31053388.15890642.html.plaintext.txt	94	Identical residues highlighted gray
0.31053388.15890642.html.plaintext.txt	95	Major structural elements noted sequence apoE4 black bars mouse apoE gray bars
0.31053388.15890642.html.plaintext.txt	96	The major difference residue 113 mouse apoE contains asparagine apoE4 contains glycine Fig
0.31053388.15890642.html.plaintext.txt	97	Asn 113 mouse apoE lies straight portion helix 3 Gly 113 apoE4 lies pronounced kink cannot form hydrogen bond Arg 112 formed Asn 113 mouse apoE Fig
0.31053388.15890642.html.plaintext.txt	98	The result reduced local hydrogen bond network Fig
0.31053388.15890642.html.plaintext.txt	99	In addition glycines high configurational entropy localized flexibility middle helix 3 caused Gly 113 may account lower stability greater propensity apoE4 form partially folded intermediates
0.31053388.15890642.html.plaintext.txt	100	The net effects sequence differences positions 83 113 greater stabilization helix 3 parallel alignment dipoles helices 2 3 mouse apoE apoE4 Fig
0.31053388.15890642.html.plaintext.txt	101	Thus data suggest two sequence differences contribute differences human mouse urea denaturation curves
0.31053388.15890642.html.plaintext.txt	102	View table TABLE II Potential hydrogen bonds mouse apoE human apoE4 near 112
0.31053388.15890642.html.plaintext.txt	103	View larger version 24K FIG
0.31053388.15890642.html.plaintext.txt	104	Stereo image overlay crystal structures amino terminal domain mouse apoE apoE4
0.31053388.15890642.html.plaintext.txt	105	The carbon traces apoE4 blue mouse apoE orange shown
0.31053388.15890642.html.plaintext.txt	106	The backbone deviation helices 2 3 crystal form 0
0.31053388.15890642.html.plaintext.txt	107	Introducing ApoE4 Residues Positions 83 113 Destabilizes T61R Mouse ApoE Thr 83 Gly 113 apoE4 introduced T61R mouse apoE prediction would destabilize global conformation
0.31053388.15890642.html.plaintext.txt	108	The urea denaturation curves showed mutants unfolded urea readily T61R mouse apoE mutations additive effects destabilizing conformation Fig
0.31053388.15890642.html.plaintext.txt	109	The triple mutant mouse apoE T61R G83T N113G apoE4 displayed similar denaturation curves range 0 4
0.31053388.15890642.html.plaintext.txt	110	5 M urea suggesting mutations position 83 113 account largest effects differences stability T61R mouse E apoE4 Fig
0.31053388.15890642.html.plaintext.txt	111	Seven mutants made probe influence structural differences
0.31053388.15890642.html.plaintext.txt	112	We introduced apoE4 residues Q52L andor H123Q occur sites crystal contacts apoE4 residues M114L M149L together correlate differences packing core T61R mouse apoE
0.31053388.15890642.html.plaintext.txt	113	These mutations marginal effects urea denaturation curves data shown
0.31053388.15890642.html.plaintext.txt	114	Three mutants made T61R G83T N113G backbone introduced nonconservative sequence differences minimal effects stability
0.31053388.15890642.html.plaintext.txt	115	Introducing apoE4 residues G94S N120G group residues N23G G94S N120G P25R G116V Q28L slightly reduced folding cooperativity stability Fig
0.31053388.15890642.html.plaintext.txt	116	Introduction apoE4 residues
0.31053388.15890642.html.plaintext.txt	117	apoE4 sequence without first eight amino acids yielded urea denaturation curve similar apoE4 Fig
0.31053388.15890642.html.plaintext.txt	118	This suggests additional eight residues apoE4 play minor role stability
0.31053388.15890642.html.plaintext.txt	119	In contrast mutations G83T N113G collection seven group mutations minor effects urea denaturation curve
0.31053388.15890642.html.plaintext.txt	120	Destabilizing Mutations G83T N113G Increase Lipid Binding T61R Mouse ApoE Because stability differences amino terminal domains human apoE isoforms correlate inversely lipid binding 21 34 examined lipid binding destabilized mouse apoE
0.31053388.15890642.html.plaintext.txt	121	Lipid binding assessed standard apolipoprotein lipid binding assay examines ability apoE remodel large unilamellar vesicles DMPC 35
0.31053388.15890642.html.plaintext.txt	122	Upon binding DMPC vesicles apoE forms smaller apoE DMPC particles thereby decreasing turbidity solution 36
0.31053388.15890642.html.plaintext.txt	123	Of human isoforms apoE4 clears turbidity fastest followed apoE3 apoE2 21
0.31053388.15890642.html.plaintext.txt	124	The amino terminal domain apoE4 cleared turbidity exponential decay like manner much faster T61R mouse apoE Fig
0.31053388.15890642.html.plaintext.txt	125	The destabilizing mutations G83T N113G cleared faster T61R mouse apoE mutations together increased clearance rate Fig
0.31053388.15890642.html.plaintext.txt	126	View larger version 35K FIG
0.31053388.15890642.html.plaintext.txt	127	Key structural differences mouse apoE apoE4 amino terminal domains
0.31053388.15890642.html.plaintext.txt	128	A differences carbon trace overlay mouse apoE yellow apoE4 cyan loop helices 2 3 influenced residue 83
0.31053388.15890642.html.plaintext.txt	129	B differences helical dipoles helix 3 mouse apoE yellow apoE4 cyan helices 2 3 shown
0.31053388.15890642.html.plaintext.txt	130	C differences hydrogen bond network mouse apoE yellow apoE4 cyan influenced residue 113
0.31053388.15890642.html.plaintext.txt	131	DISCUSSION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Our objective study introduce instability mouse apoE mutant T61R displays domain interaction making apoE4 like
0.31053388.15890642.html.plaintext.txt	132	Based comparison x ray crystal structures amino terminal domains human apoE4 wild type mouse apoE identified two potential structural differences loop connecting helices 2 3 position 83 middle helix 3 position 113 likely would affect stability
0.31053388.15890642.html.plaintext.txt	133	Although several differences human mouse apoE found introduction human residues G83T N113G loop helices 2 3 middle helix 3 required mimic unfolding behavior apoE4 Fig
0.31053388.15890642.html.plaintext.txt	134	The destabilized T61R mouse apoE increased lipid binding properties demonstrating analogous functional switch apoE3 like apoE4 like
0.31053388.15890642.html.plaintext.txt	135	It interesting stability apoE isoforms apoE4 apoE3 apoE2 parallels relative susceptibility carriers isoforms Alzheimer disease
0.31053388.15890642.html.plaintext.txt	136	This new model apoE4 useful testing exploring cooperative additive effects domain interaction lower stability
0.31053388.15890642.html.plaintext.txt	137	Furthermore T61R introduces domain interaction wild type mouse apoE mouse model specific apoE4 reduced stability without domain interaction made mutation E255A 16
0.31053388.15890642.html.plaintext.txt	138	For several proteins mutations conditions destabilize native conformation also facilitate formation aggregates properties amyloid fibrils consist ordered polymer strands 37 39
0.31053388.15890642.html.plaintext.txt	139	Thus destabilization compactly folded state apoE although advantageous lipid binding may predispose misfolding amyloid fibrils
0.31053388.15890642.html.plaintext.txt	140	This could provide basis amyloid formation amyloid plaques brains Alzheimer patients show apoE immunoreactivity 40 41
0.31053388.15890642.html.plaintext.txt	141	The apoE isoforms differ ability promote amyloid formation A
0.31053388.15890642.html.plaintext.txt	142	In vitro co incubation purified apoE A promotes A fibrillization fibrils coated apoE 42
0.31053388.15890642.html.plaintext.txt	143	ApoE4 facilitates formation extensive matrix A fibrils apoE3 assessed electron microscopy 42 43
0.31053388.15890642.html.plaintext.txt	144	In vivo gene dosage apoE4 Alzheimer patients correlates deposition amyloid 44
0.31053388.15890642.html.plaintext.txt	145	In mouse models Alzheimer disease
0.31053388.15890642.html.plaintext.txt	146	mice expressing human amyloid precursor protein human apoE isoforms apoE4 effective promoting deposition A apoE3 45 49
0.31053388.15890642.html.plaintext.txt	147	Furthermore apoE knock mice expressing human apoE isoforms apoE4 drives nucleation aggregation immunopositive A deposits greater extent apoE3 50
0.31053388.15890642.html.plaintext.txt	148	Differences co aggregation apoE isoforms A may provide mechanism acceleration A nucleation polymerization plaque formation
0.31053388.15890642.html.plaintext.txt	149	View larger version 23K FIG
0.31053388.15890642.html.plaintext.txt	150	Effect mutations urea denaturation curves T61R mouse apoE compared apoE4
0.31053388.15890642.html.plaintext.txt	151	A amino terminal domain T61R mouse apoE T61R G83T mouse apoE T61R N113G mouse apoE triple mutant T61R G83T N113G mouse apoE shown
0.31053388.15890642.html.plaintext.txt	152	B amino terminal domains completely humanized mouse apoE 1 8 apoE4 apoE4 triple mutant T61RG83TN113G mouse apoE multiple mutant T61RG83TN113GN23GG94SN120GP25RG116VQ28L mouse apoE multiple mutant T61RG83TN113GG94SN120G mouse apoE shown
0.31053388.15890642.html.plaintext.txt	153	The enhanced lipid remodeling properties destabilized apoE could also influence cellular functioning result pathologic effects
0.31053388.15890642.html.plaintext.txt	154	ApoE4 apoE3 potentiates A induced lysosomal leakage cultured neuronal cells suggesting apoE4 destabilizes lysosomal membrane integrity cooperatively A 51
0.31053388.15890642.html.plaintext.txt	155	Our results support hypothesis greater phospholipid binding ability destabilized variants apoE accounts greater permeabilization phospholipid membranes
0.31053388.15890642.html.plaintext.txt	156	View larger version 30K FIG
0.31053388.15890642.html.plaintext.txt	157	Turbidity clearance assay apoE amino terminal domains
0.31053388.15890642.html.plaintext.txt	158	Change absorbance followed addition apoE DMPC multilamellar vesicles
0.31053388.15890642.html.plaintext.txt	159	Data shown apoE4 single mutant T61R mouse apoE double mutants T61RG83T mouse apoE T61RN113G mouse apoE triple mutant T61RG83TN113G mouse apoE buffer alone dashed line
0.31053388.15890642.html.plaintext.txt	160	A mouse model apoE4 conformational stability valuable tool studying potential mechanisms
0.31053388.15890642.html.plaintext.txt	161	In addition system provide unique model exploring role conformational stability protein function pathology directly vivo
0.31053388.15890642.html.plaintext.txt	162	View larger version 16K FIG
0.31053388.15890642.html.plaintext.txt	163	Urea denaturation curves amino terminal domains human partially humanized mouse apoE mutants
0.31053388.15890642.html.plaintext.txt	164	A ApoE3 apoE4 shown
0.31053388.15890642.html.plaintext.txt	165	B T61R mouse apoE T61RG83TN113G mouse apoE shown
0.31053388.15890642.html.plaintext.txt	166	FOOTNOTES The atomic coordinates structure factors code 1YA9 deposited Protein Data Bank Research Collaboratory Structural Bioinformatics Rutgers University New Brunswick NJ httpwww
0.31053388.15890642.html.plaintext.txt	167	This work supported Grants P01 AG022074 R01 AG020235 National Institutes Health
0.31053388.15890642.html.plaintext.txt	168	The costs publication article defrayed part payment page charges
0.31053388.15890642.html.plaintext.txt	169	This article must therefore hereby marked advertisement accordance 18 U
0.31053388.15890642.html.plaintext.txt	170	Section 1734 solely indicate fact
0.31053388.15890642.html.plaintext.txt	171	Both authors contributed equally work
0.31053388.15890642.html.plaintext.txt	172	To correspondence addressed Gladstone Institute Neurological Disease 1650 Owens St
0.31053388.15890642.html.plaintext.txt	173	415 734 2000 Fax 415 355 0824 E mail kweisgraberatgladstone
0.31053388.15890642.html.plaintext.txt	174	1 The abbreviations used apo apolipoprotein DMPC dimyristoylphosphatidylcholine A amyloid
0.31053388.15890642.html.plaintext.txt	175	ACKNOWLEDGMENTS We thank Jon Menke Maryam Tabar Yvonne Newhouse Earl Rutenber technical assistance Stephen Ordway Gary Howard editorial assistance John Carroll Jack Hull Stephen Gonzales Chris Goodfellow graphics assistance Karina Fantillo manuscript preparation
0.31053388.15890642.html.plaintext.txt	176	REFERENCES TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Boyles J
0.31053388.15890642.html.plaintext.txt	177	76 1501 1513Medline Order article via Infotrieve Pitas R
0.31053388.15890642.html.plaintext.txt	178	262 14352 14360AbstractFree Full Text Mahley R
0.31053388.15890642.html.plaintext.txt	179	1988 Science 240 622 630Medline Order article via Infotrieve Saunders A
0.31053388.15890642.html.plaintext.txt	180	1993 Neurology 43 1467 1472Abstract Corder E
0.31053388.15890642.html.plaintext.txt	181	1993 Science 261 921 923Medline Order article via Infotrieve Strittmatter W
0.31053388.15890642.html.plaintext.txt	182	92 4725 4727AbstractFree Full Text Saunders A
0.31053388.15890642.html.plaintext.txt	183	1993 Lancet 342 710 711CrossRefMedline Order article via Infotrieve Nathan B
0.31053388.15890642.html.plaintext.txt	184	1994 Science 264 850 852Medline Order article via Infotrieve Mayeux R
0.31053388.15890642.html.plaintext.txt	185	1995 Neurology 45 555 557Abstract Slooter A
0.31053388.15890642.html.plaintext.txt	186	277 818 821Abstract Teasdale G
0.31053388.15890642.html.plaintext.txt	187	1997 Lancet 350 1069 1071CrossRefMedline Order article via Infotrieve Fazekas F
0.31053388.15890642.html.plaintext.txt	188	Psychiatry 69 25 28AbstractFree Full Text Drory V
0.31053388.15890642.html.plaintext.txt	189	190 17 20CrossRefMedline Order article via Infotrieve Weisgraber K
0.31053388.15890642.html.plaintext.txt	190	256 9077 9083Free Full Text Dong L
0.31053388.15890642.html.plaintext.txt	191	269 22358 22365AbstractFree Full Text Dong L
0.31053388.15890642.html.plaintext.txt	192	271 19053 19057AbstractFree Full Text Xu Q
0.31053388.15890642.html.plaintext.txt	193	279 25511 25516AbstractFree Full Text Weisgraber K
0.31053388.15890642.html.plaintext.txt	194	10 1485 1494AbstractFree Full Text Wetterau J
0.31053388.15890642.html.plaintext.txt	195	263 6240 6248AbstractFree Full Text Morrow J
0.31053388.15890642.html.plaintext.txt	196	2000 Biochemistry 39 11657 11666CrossRefMedline Order article via Infotrieve Morrow J
0.31053388.15890642.html.plaintext.txt	197	277 50380 50385AbstractFree Full Text Acharya P
0.31053388.15890642.html.plaintext.txt	198	Acta 1584 9 19Medline Order article via Infotrieve Ptitsyn O
0.31053388.15890642.html.plaintext.txt	199	47 83 229Medline Order article via Infotrieve Weers P
0.31053388.15890642.html.plaintext.txt	200	100 481 492CrossRefMedline Order article via Infotrieve Raffai R
0.31053388.15890642.html.plaintext.txt	201	98 11587 11591AbstractFree Full Text Morrow J
0.31053388.15890642.html.plaintext.txt	202	1999 Protein Expression Purif
0.31053388.15890642.html.plaintext.txt	203	16 224 230CrossRefMedline Order article via Infotrieve Kissinger C
0.31053388.15890642.html.plaintext.txt	204	D 55 484 491CrossRefMedline Order article via Infotrieve Terwilliger T
0.31053388.15890642.html.plaintext.txt	205	D 55 849 861CrossRefMedline Order article via Infotrieve Brunger A
0.31053388.15890642.html.plaintext.txt	206	D 54 905 921CrossRefMedline Order article via Infotrieve Murshudov G
0.31053388.15890642.html.plaintext.txt	207	D 53 240 255CrossRefMedline Order article via Infotrieve Pace C
0.31053388.15890642.html.plaintext.txt	208	131 266 280Medline Order article via Infotrieve Wilson C
0.31053388.15890642.html.plaintext.txt	209	1991 Science 252 1817 1822Medline Order article via Infotrieve Segelke B
0.31053388.15890642.html.plaintext.txt	210	9 886 897Abstract Segall M
0.31053388.15890642.html.plaintext.txt	211	43 1688 1700AbstractFree Full Text Pownall H
0.31053388.15890642.html.plaintext.txt	212	1978 Biochemistry 17 1183 1188CrossRefMedline Order article via Infotrieve Saito H
0.31053388.15890642.html.plaintext.txt	213	278 40723 40729AbstractFree Full Text Booth D
0.31053388.15890642.html.plaintext.txt	214	1997 Nature 385 787 793CrossRefMedline Order article via Infotrieve Nettleton E
0.31053388.15890642.html.plaintext.txt	215	281 553 564CrossRefMedline Order article via Infotrieve Fandrich M
0.31053388.15890642.html.plaintext.txt	216	2001 Nature 410 165 166CrossRefMedline Order article via Infotrieve Namba Y
0.31053388.15890642.html.plaintext.txt	217	541 163 166CrossRefMedline Order article via Infotrieve Wisniewski T
0.31053388.15890642.html.plaintext.txt	218	1995 Lancet 345 956 958CrossRefMedline Order article via Infotrieve Sanan D
0.31053388.15890642.html.plaintext.txt	219	94 860 869Medline Order article via Infotrieve Ma J
0.31053388.15890642.html.plaintext.txt	220	1994 Nature 372 92 94CrossRefMedline Order article via Infotrieve Schmechel D
0.31053388.15890642.html.plaintext.txt	221	90 9649 9653AbstractFree Full Text Bales K
0.31053388.15890642.html.plaintext.txt	222	17 263 264Medline Order article via Infotrieve Holtzman D
0.31053388.15890642.html.plaintext.txt	223	97 2892 2897AbstractFree Full Text Brendza R
0.31053388.15890642.html.plaintext.txt	224	Psychiatry 7 132 135CrossRefMedline Order article via Infotrieve Buttini M
0.31053388.15890642.html.plaintext.txt	225	22 10539 10548AbstractFree Full Text Dolev I
0.31053388.15890642.html.plaintext.txt	226	101 13909 13914AbstractFree Full Text Ji Z
0.31053388.15890642.html.plaintext.txt	227	277 21821 21828AbstractFree Full Text
0.3125666.12588864.html.plaintext.txt	0	Characterization Heparin Binding Sites Human Apolipoprotein E Hiroyuki Saito Padmaja Dhanasekaran David Nguyen Faye Baldwin Karl H
0.3125666.12588864.html.plaintext.txt	1	Weisgraber Suzanne Wehrli Michael C
0.3125666.12588864.html.plaintext.txt	2	Phillips Sissel Lund Katz
0.3125666.12588864.html.plaintext.txt	3	Research Institute The Childrens Hospital Philadelphia University Pennsylvania School Medicine Philadelphia Pennsylvania 19104 4318 Gladstone Institute Cardiovascular Disease Cardiovascular Research Institute Department Pathology University California San Francisco California 94141
0.3125666.12588864.html.plaintext.txt	4	Received publication December 26 2002 revised form February 14 2003
0.3125666.12588864.html.plaintext.txt	5	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.3125666.12588864.html.plaintext.txt	6	Apolipoprotein apo E mediates lipoprotein remnant clearance via interaction cell surface heparan sulfate proteoglycans
0.3125666.12588864.html.plaintext.txt	7	Both 22 kDa N terminal domain 10 kDa C terminal domain apoE contain heparin binding site N terminal site overlaps low density lipoprotein receptor binding region C terminal site undefined
0.3125666.12588864.html.plaintext.txt	8	To understand molecular details apoE heparin interaction defined microenvironments 12 lysine residues intact apoE3 examined relative contributions heparin binding
0.3125666.12588864.html.plaintext.txt	9	Nuclear magnetic resonance measurements showed apoE3 dimyristoyl phosphatidylcholine discs Lys 143 146 N terminal domain Lys 233 C terminal domain unusually low pKa values indicating high positive electrostatic potential around residues
0.3125666.12588864.html.plaintext.txt	10	Binding experiments using heparin Sepharose gel demonstrated lipid free 10 kDa fragment interacted strongly heparin point mutation K233Q largely abolished binding indicating Lys 233 involved heparin binding unusually basic lysine microenvironment critical interaction heparin
0.3125666.12588864.html.plaintext.txt	11	With lipidated apoE3 confirmed Lys 233 site completely masked N terminal site mediates heparin binding
0.3125666.12588864.html.plaintext.txt	12	In addition mutations two heparin binding sites intact apoE3 demonstrated dominant role N terminal site heparin binding apoE even lipid free state
0.3125666.12588864.html.plaintext.txt	13	These results suggest apoE interacts predominately cell surface heparan sulfate proteoglycans N terminal binding site
0.3125666.12588864.html.plaintext.txt	14	However Lys 233 may involved binding apoE certain cell surface sites protein core biglycan
0.3125666.12588864.html.plaintext.txt	15	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.3125666.12588864.html.plaintext.txt	16	Apolipoprotein E apoE1 critical ligand several hepatic lipoprotein receptors including low density lipoprotein LDL receptor LDL receptor related protein LRP cell surface heparan sulfate proteoglycans HSPG 1 3
0.3125666.12588864.html.plaintext.txt	17	Through interaction receptors HSPG LRP pathway apoE mediates catabolism remnant lipoproteins 4 5
0.3125666.12588864.html.plaintext.txt	18	In HSPG LRP pathway apoE postulated interact initially cell surface HSPG transfer LRP internalization 6 7
0.3125666.12588864.html.plaintext.txt	19	Therefore interaction apoE HSPG initial step clearance apoE containing lipoproteins plasma
0.3125666.12588864.html.plaintext.txt	20	The apoE HSPG interaction also involved differential effects apoE isoforms neurite outgrowth 8 9 existence pool newly secreted apoE cell surface 10 12 inhibition platelet derived growth factor stimulated smooth muscle cell proliferation 13
0.3125666.12588864.html.plaintext.txt	21	In addition several studies suggest binding apoE HSPG may involved Alzheimers disease 5 14 15
0.3125666.12588864.html.plaintext.txt	22	ApoE 299 amino acid single chain protein contains two independently folded functional domains 22 kDa N terminal domain residues 1 191 10 kDa C terminal domain residues 222 299 2 16
0.3125666.12588864.html.plaintext.txt	23	The N terminal domain exists lipid free state four helix bundle amphipathic helices contains LDL receptor binding region residues 136 150 helix 4 17
0.3125666.12588864.html.plaintext.txt	24	The amphipathic nature helix containing residues 136 150 critical normal binding LDL receptor 18
0.3125666.12588864.html.plaintext.txt	25	Our recent studies using nuclear magnetic resonance NMR demonstrated Lys 143 Lys 146 unusually low pKa values local increases positive electrostatic potential associated region surrounding residues 136 150 19 20
0.3125666.12588864.html.plaintext.txt	26	The C terminal domain also predicted highly helical structure contains major lipid binding region 21 22
0.3125666.12588864.html.plaintext.txt	27	The detailed molecular features helices C terminal domain poorly understood
0.3125666.12588864.html.plaintext.txt	28	The N C terminal domains contain heparin binding site 23 24
0.3125666.12588864.html.plaintext.txt	29	The N terminal domain site located residues 142 147 overlaps receptor binding region 24
0.3125666.12588864.html.plaintext.txt	30	In fact HSPG binding activity apoE variants significantly decreased mutations Arg 142 Arg 145 Lys 146 indicating basic amino acid residues contribute heparin binding 25
0.3125666.12588864.html.plaintext.txt	31	A recent study interaction heparin derived oligosaccharide N terminal domain apoE4 found Arg 142 145 form salt bridges sulfate groups octasaccharide fragment 26 consistent dramatically reduced binding affinity apoE4R142C apoE4R145C mutants HSPG 25
0.3125666.12588864.html.plaintext.txt	32	This study also predicted additional interactions heparin fragment Lys 143 Lys 146 Arg 147
0.3125666.12588864.html.plaintext.txt	33	Most recently site directed mutagenesis study showed Arg 142 Lys 143 Arg 145 Lys 146 Arg 147 required high affinity binding heparin Lys 146 participating ionic interaction heparin fragment Lys 143 participating hydrogen bond 27
0.3125666.12588864.html.plaintext.txt	34	The goal current study identify heparin binding site C terminal domain apoE characterize contribution apoE heparin interaction lipid free lipidated states
0.3125666.12588864.html.plaintext.txt	35	We demonstrated isolated C terminal domain binds heparin higher affinity N terminal domain lipid free state unusual basic microenvironment around Lys 233 involved heparin binding
0.3125666.12588864.html.plaintext.txt	36	Surprisingly C terminal site unavailable heparin binding lipid free lipidated states intact apoE molecule suggesting N terminal site contributes interaction apoE HSPG vivo
0.3125666.12588864.html.plaintext.txt	37	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.3125666.12588864.html.plaintext.txt	38	Materials 12 dimyristoyl phosphatidylcholine DMPC 1 palmitoyl 2 oleoyl phosphatidylcholine POPC purchased Avanti Polar Lipids Pelham AL stock solutions stored chloroformmethanol 21 nitrogen 20 degrees C
0.3125666.12588864.html.plaintext.txt	39	Its purity assayed thin layer chromatography silica gel G plates Analtech Newark DE chloroformmethanolwater 65254
0.3125666.12588864.html.plaintext.txt	40	Lipids visualized spraying developed thin layer plates 50 sulfuric acid solution charring 200 degrees C 15 min 100 microg quantities gave single spot charring
0.3125666.12588864.html.plaintext.txt	41	Heparin Sepharose CL 6B Lot No
0.3125666.12588864.html.plaintext.txt	42	203810 purchased Amersham Biosciences
0.3125666.12588864.html.plaintext.txt	43	Ligand density determined using enzymatic kit heparin DiaPharma West Chester OH 3 mg heparing dried gel
0.3125666.12588864.html.plaintext.txt	44	Sepharose CL 6B Sigma
0.3125666.12588864.html.plaintext.txt	45	D2O Cambridge Isotope Laboratories Andover MA routinely deoxygenated stored nitrogen
0.3125666.12588864.html.plaintext.txt	46	13CFormaldehyde 99 isotopic enrichment 20 solution water also obtained Cambridge Isotope Laboratories
0.3125666.12588864.html.plaintext.txt	47	14CFormaldehyde 40 60 Cimol distilled water purchased PerkinElmer Life Sciences
0.3125666.12588864.html.plaintext.txt	48	NaCNBH3 Aldrich Milwaukee WI recrystallized methylene chloride use
0.3125666.12588864.html.plaintext.txt	49	All salts reagents analytical grade
0.3125666.12588864.html.plaintext.txt	50	Bacteriological media obtained Fisher Pittsburgh PA
0.3125666.12588864.html.plaintext.txt	51	The prokaryotic expression vector pET32a Novagen Madison WI competent Escherichia coli strain BL21 star DE3 Invitrogen
0.3125666.12588864.html.plaintext.txt	52	coli strain DH5 Invitrogen
0.3125666.12588864.html.plaintext.txt	53	PCR supplies Qiagen Chatsworth CA
0.3125666.12588864.html.plaintext.txt	54	Restriction enzymes purchased Promega Madison WI
0.3125666.12588864.html.plaintext.txt	55	Isopropyl D galactopyranoside mercaptoethanol aprotinin ampicillin Sigma
0.3125666.12588864.html.plaintext.txt	56	Ultrapure guanidine HCl ICN Pharmaceuticals Costa Mesa CA
0.3125666.12588864.html.plaintext.txt	57	Oligonucleotides IDT Coraville IA DNA purification kits Qiagen
0.3125666.12588864.html.plaintext.txt	58	Expression Purification Proteins The mutations K146Q K146E K233Q K233E full length apoE3 K233Q K242Q K262Q 10 kDa fragment introduced using PCR create DNA inserts ligated thioredoxin fusion expression vector pET32a described 18 28
0.3125666.12588864.html.plaintext.txt	59	The mutation sequence cDNA orientation confirmed restriction enzyme analysis double stranded DNA sequencing
0.3125666.12588864.html.plaintext.txt	60	The resulting fusion proteins expressed E
0.3125666.12588864.html.plaintext.txt	61	coli cleaved purified described 28
0.3125666.12588864.html.plaintext.txt	62	C terminal truncated apoE3 apoE3 1 260 full length human apoE3 22 10 kDa fragments expressed purified described 29
0.3125666.12588864.html.plaintext.txt	63	The 12 kDa fragment apoE3 residues 192 299 prepared thrombin digestion full length apoE3 30
0.3125666.12588864.html.plaintext.txt	64	NMR Measurements Full length apoE3 complexed DMPC isolated gel filtration chromatography 19
0.3125666.12588864.html.plaintext.txt	65	The lysine residues apoE3 DMPC complexes labeled 13C reductive methylation 31
0.3125666.12588864.html.plaintext.txt	66	1H 13C heteronuclear single quantum coherence HSQC two dimensional NMR spectra 13C labeled full length apoE3 DMPC complexes obtained Bruker DM x 600 wide bore spectrometer equipped SGI 02 computer 5 mm inverse broadband probe 19
0.3125666.12588864.html.plaintext.txt	67	The two dimensional 1H 13C HSQC spectra recorded carbon decoupling acquisition 310 K
0.3125666.12588864.html.plaintext.txt	68	The time proportional phase increment method used obtain phase sensitive spectra
0.3125666.12588864.html.plaintext.txt	69	Chemical shifts line widths lipid protein complexes measured described 19 31 32
0.3125666.12588864.html.plaintext.txt	70	The chemical shifts 13Cdimethyl lysine 13Cdimethyl terminal amino residues complexes determined function pH
0.3125666.12588864.html.plaintext.txt	71	The pKa values 13Cdimethyl lysines obtained nonlinear regression fitting chemical shifts different pH values Henderson Hasselbalch equation GraphPad Prism program GraphPad Software San Diego CA 19 20
0.3125666.12588864.html.plaintext.txt	72	The sigmoidal equation Y U W x 10X Xc10X Xc 1 Y chemical shift U lower limit shift W upper limit X pH Xc pKa
0.3125666.12588864.html.plaintext.txt	73	Binding ApoE Heparin The binding apoE heparin assayed using centrifugation method 24 33
0.3125666.12588864.html.plaintext.txt	74	ApoE samples 14C labeled specific activity 1 microCimg protein reductive methylation lysines 14Cformaldehyde described 19 29 31
0.3125666.12588864.html.plaintext.txt	75	14C labeled lipid free apoE apoE DMPC complexes incubated heparin Sepharose Sepharose gel 0
0.3125666.12588864.html.plaintext.txt	76	3 mg gelml 2 h room temperature 300 microl Tris buffer 10 mM Tris HCl 150 mM NaCl 0
0.3125666.12588864.html.plaintext.txt	77	The mixture centrifuged 10000 rpm 15 min tabletop centrifuge
0.3125666.12588864.html.plaintext.txt	78	The radioactivity 200 microl aliquots top fraction 100 microl aliquots bottom fraction quantitated amount apoE bound gel calculated subtracting background free apoE concentration bottom fraction
0.3125666.12588864.html.plaintext.txt	79	Heparin bound apoE expressed g apoE bound per g dried weight gel dried incubation 24 h room temperature vacuum oven gel corrected binding Sepharose subtraction Sepharose gel bound radioactivity obtained parallel incubation
0.3125666.12588864.html.plaintext.txt	80	Binding data fitted nonlinear regression one binding site model using GraphPad Prizm program
0.3125666.12588864.html.plaintext.txt	81	Analytical Procedures Protein concentrations determined Lowry procedure 34
0.3125666.12588864.html.plaintext.txt	82	Phospholipid content monitored phosphorus analysis 35
0.3125666.12588864.html.plaintext.txt	83	14C radioactivity assessed standard liquid scintillation procedures
0.3125666.12588864.html.plaintext.txt	84	SDS PAGE 8 25 gradient performed Pharmacia Phast electrophoresis system monitor purity proteins
0.3125666.12588864.html.plaintext.txt	85	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.3125666.12588864.html.plaintext.txt	86	pKa Values Lysines Full length ApoE3 Previously used two dimensional NMR spectra 13Cdimethyl lysines study microenvironments eight lysine residues 22 kDa apoE DMPC complexes 19 20
0.3125666.12588864.html.plaintext.txt	87	In study application higher field 600 MHz NMR spectrometer enabled us evaluate microenvironments 12 lysine residues full length apoE3 enhanced resolution resonances NMR spectrum
0.3125666.12588864.html.plaintext.txt	88	1 shows NMR spectrum sequence specific assignment 12 13Cdimethyl lysine resonances full length apoE3 DMPC discoidal complexes
0.3125666.12588864.html.plaintext.txt	89	In addition eight lysine resonances N terminal domain four lysine resonances C terminal domain Lys 233 242 262 282 resolved assigned using selective lysine glutamine mutation technique 19
0.3125666.12588864.html.plaintext.txt	90	View larger version 22K Fig
0.3125666.12588864.html.plaintext.txt	91	Phase sensitive 600 MHz 1H 13C HSQC NMR spectrum full length apoE3 DMPC discoidal complexes 37 degrees C
0.3125666.12588864.html.plaintext.txt	92	All lysine residues converted 13CH32 lysine reductive methylation
0.3125666.12588864.html.plaintext.txt	93	51 ww DMPCfull length apoE3 discoidal complexes 3
0.3125666.12588864.html.plaintext.txt	94	2 mg proteinml dissolved borate buffer pH 10
0.3125666.12588864.html.plaintext.txt	95	Spectra obtained conditions similar used previously 19
0.3125666.12588864.html.plaintext.txt	96	The assignments 12 lysine resonances indicated
0.3125666.12588864.html.plaintext.txt	97	The pKa value lysine obtained monitoring chemical shift function pH range pH values 5
0.3125666.12588864.html.plaintext.txt	98	The titration curves fully reversible across pH range studied data shown pKa values lysines full length apoE3 listed Table I
0.3125666.12588864.html.plaintext.txt	99	As expected pKa values eight lysines N terminal domain full length apoE3 22 kDa fragment apoE3 reported previously 19
0.3125666.12588864.html.plaintext.txt	100	4 similar pKa values Lys 143 146 located LDL receptorheparin binding region N terminal domain apoE3
0.3125666.12588864.html.plaintext.txt	101	This suggests Lys 233 may behave similarly part heparin binding region C terminal domain
0.3125666.12588864.html.plaintext.txt	102	View table Table I pKa values lysine residues full length apoE3 discoidal complex DMPC
0.3125666.12588864.html.plaintext.txt	103	Heparin Binding 10 kDa Fragment To determine relative heparin binding activities apoE molecules measured binding apoE heparin Sepharose gel 24 33
0.3125666.12588864.html.plaintext.txt	104	The binding 10 kDa fragment heparin saturable depended salt concentration Fig
0.3125666.12588864.html.plaintext.txt	105	The dissociation constant Kd calculated 26 microgml 50 mM NaCl 76 microgml 150 mM NaCl consistent previous report 24
0.3125666.12588864.html.plaintext.txt	106	The maximal binding capacities concentrations similar corresponded 140 170 g proteing heparin
0.3125666.12588864.html.plaintext.txt	107	In contrast apoA I bind heparin even low salt concentration
0.3125666.12588864.html.plaintext.txt	108	These results indicate interaction 10 kDa fragment heparin electrostatic 36 37 amphipathic characteristics common helical apolipoproteins 38 responsible heparin binding
0.3125666.12588864.html.plaintext.txt	109	View larger version 14K Fig
0.3125666.12588864.html.plaintext.txt	110	Effect salt concentration apolipoprotein binding heparin
0.3125666.12588864.html.plaintext.txt	111	Varying concentrations apoE 10 kDa fragment Tris buffer pH 7
0.3125666.12588864.html.plaintext.txt	112	4 containing 50 mM NaCl 150 mM NaCl incubated heparin Sepharose gel 2 h room temperature
0.3125666.12588864.html.plaintext.txt	113	Binding data apoA I 50 mM NaCl buffer also shown
0.3125666.12588864.html.plaintext.txt	114	Each point represents mean plus minus S
0.3125666.12588864.html.plaintext.txt	115	two independent experiments done duplicate
0.3125666.12588864.html.plaintext.txt	116	The binding curves obtained nonlinear regression fitting one binding site model
0.3125666.12588864.html.plaintext.txt	117	The basic residues arginine lysine heparin binding region N terminal domain key interaction heparin 26 27 39
0.3125666.12588864.html.plaintext.txt	118	We compared heparin binding activities three lysine mutants K233Q K242Q K262Q 10 kDa fragment identify heparin binding site C terminal domain apoE
0.3125666.12588864.html.plaintext.txt	119	3 large decrease heparin binding observed 10 kDa K233Q variant maximal binding capacity 31 wild type 10 kDa fragment without change binding affinity Kd values 76 microgml
0.3125666.12588864.html.plaintext.txt	120	Of four lysines C terminal domain Lys 233 showed relatively low pKa value Table I suggesting unusually basic microenvironment around Lys 233 critical interaction C terminal domain heparin
0.3125666.12588864.html.plaintext.txt	121	View larger version 14K Fig
0.3125666.12588864.html.plaintext.txt	122	Binding isotherms apoE 10 kDa fragment variants heparin
0.3125666.12588864.html.plaintext.txt	123	wild type apoE 10 kDa fragment 10 kDaK233Q 10 kDaK242Q 10 kDaK262Q
0.3125666.12588864.html.plaintext.txt	124	Comparison Heparin Binding Full length ApoE3 Its 22 10 kDa Fragments To determine relative contributions N C terminal domains heparin binding apoE next compared heparin binding full length apoE3 22 10 kDa fragments lipid free lipidated forms
0.3125666.12588864.html.plaintext.txt	125	In lipid free form full length apoE 10 kDa fragment bound heparin similar affinities whereas 22 kDa fragment bound heparin much lower affinity Fig
0.3125666.12588864.html.plaintext.txt	126	When complexed DMPC heparin binding 10 kDa fragment completely abolished indicating C terminal binding site masked lipids Fig
0.3125666.12588864.html.plaintext.txt	127	Instead lipidated 22 kDa fragment bound heparin high affinity rather better full length apoE
0.3125666.12588864.html.plaintext.txt	128	Similar results obtained POPC physiological phospholipid data shown
0.3125666.12588864.html.plaintext.txt	129	Although binding capacity lipidated full length apoE3 much lower lipid free form binding affinity full length apoE3 states similar Kd lipid free lipidated forms 157 210 microgml respectively consistent previous observation using surface plasmon resonance analysis 37
0.3125666.12588864.html.plaintext.txt	130	View larger version 17K Fig
0.3125666.12588864.html.plaintext.txt	131	Binding isotherms full length apoE3 22 10 kDa fragments heparin lipid free form A complexed DMPC B
0.3125666.12588864.html.plaintext.txt	132	full length apoE3 apoE3 22 kDa fragment apoE 10 kDa fragment
0.3125666.12588864.html.plaintext.txt	133	Heparin Binding ApoE Mutants The observations suggest two apoE domains contribute differently heparin binding C terminal domain playing dominant role lipid free state N terminal domain lipidated state
0.3125666.12588864.html.plaintext.txt	134	To examine hypothesis introduced mutations two lysines full length apoE compared heparin binding activities variants
0.3125666.12588864.html.plaintext.txt	135	The mutated proteins apoEK146Q apoEK146E N terminal domains bind defectively heparin 27 apoE3K233Q apoE3K233E thought low heparin binding capacity C terminal site
0.3125666.12588864.html.plaintext.txt	136	Large decreases heparin binding observed apoEK146E lipid free Fig
0.3125666.12588864.html.plaintext.txt	137	5A DMPC complexed forms Fig
0.3125666.12588864.html.plaintext.txt	138	5B indicating Lys 146 contributes greatly heparin binding full length apoE
0.3125666.12588864.html.plaintext.txt	139	5 A B lipid free apoEK146Q exhibited much smaller decrease heparin binding wild type apoE3 apoEK146Q DMPC complexes bound heparin similar manner lipid free form
0.3125666.12588864.html.plaintext.txt	140	This disparity apoEK146E apoEK146Q variants probably ionization state glutamate residue pH 7
0.3125666.12588864.html.plaintext.txt	141	4 responsible difference heparin binding activities 27
0.3125666.12588864.html.plaintext.txt	142	View larger version 17K Fig
0.3125666.12588864.html.plaintext.txt	143	Binding isotherms full length apoE variants heparin lipid free form A C complexed DMPC B D
0.3125666.12588864.html.plaintext.txt	144	apoEK146Q apoEK146E apoE3K233Q apoEK233E
0.3125666.12588864.html.plaintext.txt	145	The data wild type apoE3 dotted line also shown comparison
0.3125666.12588864.html.plaintext.txt	146	In contrast K233Q mutation effect heparin binding activity either lipid free lipidated form
0.3125666.12588864.html.plaintext.txt	147	In case apoE3K233E variant small decrease heparin binding observed lipid free form complexing DMPC virtually effect heparin binding ability variant Fig
0.3125666.12588864.html.plaintext.txt	148	5 C D suggesting Lys 233 site unavailable heparin binding full length apoE
0.3125666.12588864.html.plaintext.txt	149	For wild type apoE apoEK146E apoEK233Q variants heparin binding free protein differs protein DMPC complexes
0.3125666.12588864.html.plaintext.txt	150	Binding DMPC results opening four helix bundle N terminal domain apoE 40 42
0.3125666.12588864.html.plaintext.txt	151	Therefore likely apoE variants subtle differences final conformations DMPC disc may modulate heparin binding properties 27
0.3125666.12588864.html.plaintext.txt	152	This may reason lipidated K146Q K223E variants bind somewhat heparin wild type apoE3
0.3125666.12588864.html.plaintext.txt	153	To explore role C terminal domain heparin binding apoE used apoE 1 260 C terminal truncated variant monomeric rather tetrameric aqueous solution 21
0.3125666.12588864.html.plaintext.txt	154	Although C terminal heparin binding site conserved variant heparin binding apoE 1 260 significantly lower wild type apoE3 close apoE3 22 kDa fragment Fig
0.3125666.12588864.html.plaintext.txt	155	This indicates tetramerization C terminal domain major influence heparin binding ability lipid free apoE
0.3125666.12588864.html.plaintext.txt	156	We also measured binding 12 kDa apoE fragment 2 heparin investigate whether hinge region plays role heparin interaction C terminal domain
0.3125666.12588864.html.plaintext.txt	157	Surprisingly heparin binding ability almost disappeared lipid free 12 kDa fragment Fig
0.3125666.12588864.html.plaintext.txt	158	6 suggesting hinge region may mask heparin binding site C terminal domain
0.3125666.12588864.html.plaintext.txt	159	View larger version 13K Fig
0.3125666.12588864.html.plaintext.txt	160	Binding isotherms apoE3 1 260 apoE 12 kDa fragment
0.3125666.12588864.html.plaintext.txt	161	apoE3 1 260 12 kDa fragment
0.3125666.12588864.html.plaintext.txt	162	The data wild type apoE3 dotted line apoE3 22 kDa fragment dashed line also shown comparison
0.3125666.12588864.html.plaintext.txt	163	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.3125666.12588864.html.plaintext.txt	164	The interaction apoE HSPG important several processes lipoprotein remnant clearance 5 43 neurite outgrowth 3 14
0.3125666.12588864.html.plaintext.txt	165	ApoE least two heparin binding sites located residues 142 147 N terminal receptor binding region 24 less well defined sites C terminal lipid binding region 23 24
0.3125666.12588864.html.plaintext.txt	166	The N terminal site recently characterized using apoE4 22 kDa fragments enzymatically prepared heparin oligosaccharide Arg 142 Lys 143 Arg 145 Lys 146 Arg 147 within site involved interaction heparin fragment 27
0.3125666.12588864.html.plaintext.txt	167	In study using site directed mutagenesis identified Lys 233 key lysine residue C terminal site also estimated relative contributions sites heparin binding full length apoE
0.3125666.12588864.html.plaintext.txt	168	Earlier studies using either synthetic apoE peptides blocking monoclonal antibodies suggested residues 211 218 23 243 272 24 contain heparin binding sites
0.3125666.12588864.html.plaintext.txt	169	The former site factor observed binding C terminal 10 kDa fragment heparin included domain
0.3125666.12588864.html.plaintext.txt	170	It also functional 12 kDa fragment bind heparin Fig
0.3125666.12588864.html.plaintext.txt	171	Presumably small peptide containing residues 211 218 23 bind conformation different present part apoE molecule
0.3125666.12588864.html.plaintext.txt	172	It possible Lys 233 part heparin binding site identified blocking antibody epitope located residues 243 272 24 presence antibody may interfere functionality Lys 233
0.3125666.12588864.html.plaintext.txt	173	Our NMR results imply among 12 lysines full length apoE3 Lys 143 146 N terminal domain Lys 233 C terminal domain unusually low pKa values indicative high positive electrostatic potential around residues
0.3125666.12588864.html.plaintext.txt	174	Previous studies showed greater positive electrostatic potential around Lys 143 146 involved high affinity binding N terminal domain apoE LDL receptor heparin
0.3125666.12588864.html.plaintext.txt	175	In study demonstrated residue Lys 233 critical heparin binding C terminal domain Fig
0.3125666.12588864.html.plaintext.txt	176	3 indicating unusually basic lysine microenvironment C terminal domain also involved heparin interaction
0.3125666.12588864.html.plaintext.txt	177	In amphipathic helix spanning region basic residues Arg 226 Lys 233 Lys 240 aligned two turns apart along one side helix
0.3125666.12588864.html.plaintext.txt	178	It interesting several acidic residues amino acid sequence near Lys 233 mostly located opposite side amphipathic helix
0.3125666.12588864.html.plaintext.txt	179	Consequently reduce positive electrostatic potential around side chain Lys 233
0.3125666.12588864.html.plaintext.txt	180	Comparison heparin binding abilities full length apoE3 22 10 kDa fragments yields interesting insights
0.3125666.12588864.html.plaintext.txt	181	In lipid free state 10 kDa fragment binds heparin higher affinity 22 kDa fragment Fig
0.3125666.12588864.html.plaintext.txt	182	In contrast heparin binding 10 kDa fragment completely abolished complexed lipid Fig
0.3125666.12588864.html.plaintext.txt	183	4B consistent previous observations showing C terminal site available interaction lipid free state 24 44
0.3125666.12588864.html.plaintext.txt	184	The C terminal domain apoE forms stable tetramer responsible self association apoE aqueous solution whereas N terminal domain primarily monomeric 16
0.3125666.12588864.html.plaintext.txt	185	Therefore stronger interaction C terminal domain heparin appears tetramerization
0.3125666.12588864.html.plaintext.txt	186	6 heparin binding affinity apoE3 1 260 variant monomeric solution much lower wild type apoE3 comparable 22 kDa fragment indicating tetramerization C terminal domain crucial heparin binding ability lipid free apoE
0.3125666.12588864.html.plaintext.txt	187	Multiple sequences heparin binding peptide enhance heparin binding cooperativity effects 45
0.3125666.12588864.html.plaintext.txt	188	Similarly multiple copies receptor binding domain necessary high affinity interaction apoE LDL receptor 46 47
0.3125666.12588864.html.plaintext.txt	189	In regard different binding affinities full length apoE3 22 kDa fragment DMPC discs Fig
0.3125666.12588864.html.plaintext.txt	190	4B may explained difference cooperativity arising different numbers N terminal domain per particle
0.3125666.12588864.html.plaintext.txt	191	Despite strong heparin binding ability 10 kDa fragment C terminal site full length apoE3 appear involved heparin binding lipid free apoE
0.3125666.12588864.html.plaintext.txt	192	5C small differences heparin binding among lipid free wild type apoE3 apoE3K233Q apoE3K233E variants suggesting even lipid free state N terminal site involved heparin interaction full length apoE
0.3125666.12588864.html.plaintext.txt	193	It clear C terminal site lipid free apoE unavailable interaction heparin
0.3125666.12588864.html.plaintext.txt	194	One possible explanation heparin interaction C terminal domain sterically hindered hinge region residues 192 215 acts spacer connecting two domains
0.3125666.12588864.html.plaintext.txt	195	Indeed 12 kDa fragment contains 10 kDa domain hinge region bound defectively heparin Fig
0.3125666.12588864.html.plaintext.txt	196	Thus interaction 10 kDa domain hinge region might mask C terminal heparin binding site basic residues around Lys 233 preventing interaction heparin
0.3125666.12588864.html.plaintext.txt	197	A recent fluorescence resonance energy transfer study apoE3 indicates spatial proximity N C terminal domains lipid free state hinge region tethering N terminal domain close C terminal domain 48
0.3125666.12588864.html.plaintext.txt	198	ApoE containing high density lipoproteins bind proteoglycan biglycan arterial walls apoE thought act bridging molecule traps particles atherosclerotic intima 49
0.3125666.12588864.html.plaintext.txt	199	This binding interaction apoE biglycan shown recently occur via C terminal domain charged residues especially lysine arginine residues 223 230 involved binding 50 51
0.3125666.12588864.html.plaintext.txt	200	The results present study suggest unusually basic microenvironment around Lys 233 contributes apoE biglycan interaction
0.3125666.12588864.html.plaintext.txt	201	Recent studies demonstrated C terminal fragments apoE complexed amyloid brain 52 53 C terminal truncated forms apoE occur Alzheimers disease 54
0.3125666.12588864.html.plaintext.txt	202	The presence apoE proteolytic fragments vivo raises possibility C terminal fragment may contribute Alzheimers disease interaction HSPG brain
0.3125666.12588864.html.plaintext.txt	203	In conclusion identified heparin binding site C terminal domain apoE
0.3125666.12588864.html.plaintext.txt	204	Our data show basic residues around lysine 233 critical heparin binding C terminal domain unavailable heparin binding full length apoE even lipid free state
0.3125666.12588864.html.plaintext.txt	205	Thus seems lipid poor apoE associates cell surface HSPG N terminal domain leaving C terminal domain available binding lipoprotein particles
0.3125666.12588864.html.plaintext.txt	206	This work supported National Institutes Health Grants HL56083 S
0.3125666.12588864.html.plaintext.txt	207	The costs publication article defrayed part payment page charges
0.3125666.12588864.html.plaintext.txt	208	The article must therefore hereby marked advertisement accordance 18 U
0.3125666.12588864.html.plaintext.txt	209	Section 1734 solely indicate fact
0.3125666.12588864.html.plaintext.txt	210	Present address National Institute Health Sciences 1 1 43 Hoenzaka Chuo ku Osaka 540 0006 Japan
0.3125666.12588864.html.plaintext.txt	211	To correspondence addressed Joseph Stokes Jr
0.3125666.12588864.html.plaintext.txt	212	The Childrens Hospital Philadelphia Abramson Research Bldg
0.3125666.12588864.html.plaintext.txt	213	Suite 302 3615 Civic Center Blvd
0.3125666.12588864.html.plaintext.txt	214	215 590 0588 Fax 215 590 0583 E mail katzs email
0.3125666.12588864.html.plaintext.txt	215	Published JBC Papers Press February 14 2003 DOI 10
0.3125666.12588864.html.plaintext.txt	216	The abbreviations used apo apolipoprotein HSPG heparan sulfate proteoglycan HSQC heteronuclear single quantum coherence LDL low density lipoprotein LRP LDL receptor related protein DMPC 12 dimyristoyl phosphatidylcholine POPC 1 palmitoyl 2 oleoyl phosphatidylcholine NMR nuclear magnetic resonance
0.3125666.12588864.html.plaintext.txt	217	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES 1
0.3125666.12588864.html.plaintext.txt	218	1988 Science 240 622 630Medline Order article via Infotrieve 2
0.3125666.12588864.html.plaintext.txt	219	45 249 302Medline Order article via Infotrieve 3
0.3125666.12588864.html.plaintext.txt	220	Genet 1 507 537CrossRefMedline Order article via Infotrieve 4
0.3125666.12588864.html.plaintext.txt	221	40 1 16AbstractFree Full Text 6
0.3125666.12588864.html.plaintext.txt	222	269 2764 2772AbstractFree Full Text 7
0.3125666.12588864.html.plaintext.txt	223	32 414 429Medline Order article via Infotrieve 8
0.3125666.12588864.html.plaintext.txt	224	273 13452 13460AbstractFree Full Text 10
0.3125666.12588864.html.plaintext.txt	225	271 13454 13460AbstractFree Full Text 11
0.3125666.12588864.html.plaintext.txt	226	273 5645 5654AbstractFree Full Text 12
0.3125666.12588864.html.plaintext.txt	227	42 1125 1133AbstractFree Full Text 13
0.3125666.12588864.html.plaintext.txt	228	276 25043 25048AbstractFree Full Text 14
0.3125666.12588864.html.plaintext.txt	229	10 1485 1494AbstractFree Full Text 15
0.3125666.12588864.html.plaintext.txt	230	280 131 134CrossRefMedline Order article via Infotrieve 16
0.3125666.12588864.html.plaintext.txt	231	263 6249 6258AbstractFree Full Text 17
0.3125666.12588864.html.plaintext.txt	232	1991 Science 252 1817 1822Medline Order article via Infotrieve 18
0.3125666.12588864.html.plaintext.txt	233	41 1087 1095AbstractFree Full Text 19
0.3125666.12588864.html.plaintext.txt	234	275 34459 34464AbstractFree Full Text 20
0.3125666.12588864.html.plaintext.txt	235	42 894 901AbstractFree Full Text 21
0.3125666.12588864.html.plaintext.txt	236	268 15745 15750AbstractFree Full Text 22
0.3125666.12588864.html.plaintext.txt	237	45 303 369Medline Order article via Infotrieve 23
0.3125666.12588864.html.plaintext.txt	238	134 783 789Medline Order article via Infotrieve 24
0.3125666.12588864.html.plaintext.txt	239	261 2068 2076AbstractFree Full Text 25
0.3125666.12588864.html.plaintext.txt	240	269 13421 13428AbstractFree Full Text 26
0.3125666.12588864.html.plaintext.txt	241	2001 Biochemistry 40 2826 2834CrossRefMedline Order article via Infotrieve 27
0.3125666.12588864.html.plaintext.txt	242	276 39138 39144AbstractFree Full Text 28
0.3125666.12588864.html.plaintext.txt	243	16 224 230CrossRefMedline Order article via Infotrieve 29
0.3125666.12588864.html.plaintext.txt	244	276 40949 40954AbstractFree Full Text 30
0.3125666.12588864.html.plaintext.txt	245	258 12341 12347AbstractFree Full Text 31
0.3125666.12588864.html.plaintext.txt	246	268 23008 23015AbstractFree Full Text 32
0.3125666.12588864.html.plaintext.txt	247	263 13831 13838AbstractFree Full Text 33
0.3125666.12588864.html.plaintext.txt	248	193 265 275Free Full Text 35
0.3125666.12588864.html.plaintext.txt	249	234 466 468Free Full Text 36
0.3125666.12588864.html.plaintext.txt	250	203 556 583Medline Order article via Infotrieve 37
0.3125666.12588864.html.plaintext.txt	251	459 353 357CrossRefMedline Order article via Infotrieve 38
0.3125666.12588864.html.plaintext.txt	252	243 157 163Medline Order article via Infotrieve 40
0.3125666.12588864.html.plaintext.txt	253	40 93 99AbstractFree Full Text 41
0.3125666.12588864.html.plaintext.txt	254	275 20775 20781AbstractFree Full Text 42
0.3125666.12588864.html.plaintext.txt	255	275 33601 33606AbstractFree Full Text 43
0.3125666.12588864.html.plaintext.txt	256	268 10160 10167AbstractFree Full Text 44
0.3125666.12588864.html.plaintext.txt	257	41 1783 1789AbstractFree Full Text 45
0.3125666.12588864.html.plaintext.txt	258	275 7701 7707AbstractFree Full Text 46
0.3125666.12588864.html.plaintext.txt	259	Tokyo 105 582 587Abstract 47
0.3125666.12588864.html.plaintext.txt	260	266 15009 15015AbstractFree Full Text 48
0.3125666.12588864.html.plaintext.txt	261	276 37853 37860AbstractFree Full Text 49
0.3125666.12588864.html.plaintext.txt	262	1998 Circulation 98 519 527AbstractFree Full Text 50
0.3125666.12588864.html.plaintext.txt	263	275 18913 18918AbstractFree Full Text 51
0.3125666.12588864.html.plaintext.txt	264	21 129 135AbstractFree Full Text 52
0.3125666.12588864.html.plaintext.txt	265	270 17610 17615AbstractFree Full Text 53
0.3125666.12588864.html.plaintext.txt	266	768 208 214CrossRefMedline Order article via Infotrieve 54
0.3125666.12588864.html.plaintext.txt	267	98 8838 8843AbstractFree Full Text
0.3125666.12588864.html.plaintext.txt	268	Copyright 2003 The American Society Biochemistry Molecular Biology Inc
0.36494276.15269217.html.plaintext.txt	0	ABCA1 Is Required Normal Central Nervous System ApoE Levels Lipidation Astrocyte secreted apoE Suzanne E
0.36494276.15269217.html.plaintext.txt	1	Wahrle Hong Jiang Maia Parsadanian Justin Legleiter Xianlin Han John D
0.36494276.15269217.html.plaintext.txt	2	Fryer Tomasz Kowalewski David M
0.36494276.15269217.html.plaintext.txt	3	From Program Neurosciences Department Neurology Department Medicine Department Molecular Biology Pharmacology Center Study Nervous System Injury Alzheimers Disease Research Center Washington University St
0.36494276.15269217.html.plaintext.txt	4	Louis Missouri 63110 Department Chemistry Carnegie Mellon University Pittsburgh Pennsylvania 15213
0.36494276.15269217.html.plaintext.txt	5	Received publication July 14 2004
0.36494276.15269217.html.plaintext.txt	6	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES ABCA1 ATP binding cassette protein transports cellular cholesterol phospholipids onto high density lipoproteins HDL plasma
0.36494276.15269217.html.plaintext.txt	7	Lack ABCA1 humans mice causes abnormal lipidation increased catabolism HDL resulting low plasma apoA I apoA II HDL
0.36494276.15269217.html.plaintext.txt	8	Herein used Abca1 mice ask whether ABCA1 involved lipidation HDL central nervous system CNS
0.36494276.15269217.html.plaintext.txt	9	ApoE abundant CNS apolipoprotein present HDL like lipoproteins CSF
0.36494276.15269217.html.plaintext.txt	10	We found Abca1 mice greatly decreased apoE levels cortex 80 reduction CSF 98 reduction
0.36494276.15269217.html.plaintext.txt	11	CSF Abca1 mice significantly reduced cholesterol well small apoE containing lipoproteins suggesting abnormal lipidation apoE
0.36494276.15269217.html.plaintext.txt	12	Astrocytes primary producer CNS apoE cultured Abca1 mice nascent lipoprotein particles collected
0.36494276.15269217.html.plaintext.txt	13	Abca1 astrocytes secreted lipoprotein particles markedly decreased cholesterol apoE smaller apoE containing particles particles Abca1 astrocytes
0.36494276.15269217.html.plaintext.txt	14	These findings demonstrate ABCA1 plays critical role CNS apoE metabolism
0.36494276.15269217.html.plaintext.txt	15	Since apoE isoforms levels strongly influence Alzheimers disease pathology risk data suggest ABCA1 may novel therapeutic target
0.36494276.15269217.html.plaintext.txt	16	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES ABCA1 founding member ATP binding cassette ABC1 family transporters largest group transmembrane transporters 48 known family members humans 1
0.36494276.15269217.html.plaintext.txt	17	All ABC transporters share homology ATP binding domain use ATP translocate wide variety substrates across extra intracellular membranes 2
0.36494276.15269217.html.plaintext.txt	18	Defects ABC transporters cause least 14 known genetic diseases 3
0.36494276.15269217.html.plaintext.txt	19	ABCA1 transports cellular cholesterol phospholipids cells onto high density lipoproteins HDL plasma 4 5
0.36494276.15269217.html.plaintext.txt	20	In humans loss function mutations ABCA1 cause Tangiers disease 6 9 characterized accumulation cholesterol lymphatic tissues increased catabolism abnormally lipidated HDL resulting low levels plasma HDL HDL associated apolipoproteins A I apoA I A II apoA II 10 11
0.36494276.15269217.html.plaintext.txt	21	ABCA1 knock mice Abca1 produced mice similar phenotype patients Tangiers disease 12
0.36494276.15269217.html.plaintext.txt	22	However neither Tangiers disease patients Abca1 mice examined determine whether ABCA1 plays role lipidation metabolism lipoproteins central nervous system CNS
0.36494276.15269217.html.plaintext.txt	23	The abundant apolipoprotein CNS apolipoprotein E apoE produced within CNS primarily astrocytes extent microglia 13 17
0.36494276.15269217.html.plaintext.txt	24	ApoE present brain tissue cerebrospinal fluid CSF present HDL like particles 18 20
0.36494276.15269217.html.plaintext.txt	25	By analyzing brain tissue CSF plasma primary astrocyte cultures Abca1 mice determined deletion ABCA1 markedly affects metabolism apoE cholesterol CNS nascent lipoprotein particles secreted cultured astrocytes
0.36494276.15269217.html.plaintext.txt	26	These findings implications neurological diseases involving apoE Alzheimers disease
0.36494276.15269217.html.plaintext.txt	27	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Animals Tissue Preparation Mice heterozygous Abca1 null allele DBA background obtained Jackson Laboratory Bar Harbor ME strain name DBA1 Abca1tm1Jdm
0.36494276.15269217.html.plaintext.txt	28	These mice similar abnormalities found humans Tangiers disease greatly reduced plasma HDL 12
0.36494276.15269217.html.plaintext.txt	29	The heterozygous mice bred one another generate littermates Abca1 genotypes wild type Abca1 heterozygous Abca1 knock Abca1
0.36494276.15269217.html.plaintext.txt	30	All animals used vivo experiments 10 14 weeks old
0.36494276.15269217.html.plaintext.txt	31	For fluid tissue analysis animals anesthetized pentobarbital CSF collected cisterna magna described 21 blood collected cardiac puncture animals perfused PBS heparin 3 unitsml
0.36494276.15269217.html.plaintext.txt	32	Regional brain dissection performed brain samples frozen dry ice
0.36494276.15269217.html.plaintext.txt	33	ApoE ELISA A sandwich ELISA mouse apoE developed sensitivity 1 ngml
0.36494276.15269217.html.plaintext.txt	34	96 well plates coated overnight 0
0.36494276.15269217.html.plaintext.txt	35	5 microgwell mouse monoclonal antibody WU E 4 raised apoE 22 washed PBS blocked 1 milk PBS washed
0.36494276.15269217.html.plaintext.txt	36	Brain samples sonicated 0
0.36494276.15269217.html.plaintext.txt	37	05 Tween PBS 1x Complete protease inhibitor mixture 1x protease inhibitors Roche Applied Science debris pelleted 10000 x g x 15 min spin supernatant diluted 0
0.36494276.15269217.html.plaintext.txt	38	Conditioned medium plasma CSF diluted directly 0
0.36494276.15269217.html.plaintext.txt	39	Standards based pooled plasma C57Bl6 mice containing 68 microgml apoE reported previously 23
0.36494276.15269217.html.plaintext.txt	40	Following sample incubation plate washed 3 microgwell biotinylated goat anti apoE added
0.36494276.15269217.html.plaintext.txt	41	The antibody Calbiochem catalog number 178479 biotinylated using biotin maleimide reagent Vector Laboratories Burlingame CA
0.36494276.15269217.html.plaintext.txt	42	After incubation secondary antibody plate washed poly horseradish peroxidase streptavidin Pierce added 16000 incubated
0.36494276.15269217.html.plaintext.txt	43	The plate washed developed tetramethylbenzidine Sigma read 650 nm Biotek 600 plate reader Bio Tek Instruments Winooski VT
0.36494276.15269217.html.plaintext.txt	44	Real time RT PCR Mouse ApoE Following perfusion animals samples cortex placed RNAlater Ambion Austin TX stored 4 degrees C
0.36494276.15269217.html.plaintext.txt	45	RNA extracted using RNeasy lipid tissue kit Qiagen Valencia CA column DNase digestion
0.36494276.15269217.html.plaintext.txt	46	RNA quantified Bio Rad SmartSpec 3000 Bio Rad
0.36494276.15269217.html.plaintext.txt	47	The forward primer used mouse apoE 5 CCGTGCTGTTGGTCACATTGCTGACAGGAT 3 reverse primer 5 GTTCTTGTGTGACTTGGGAGCTCTGCAGCT 3
0.36494276.15269217.html.plaintext.txt	48	The 18 S primerprobe reagent used normalization RNA levels ABI Foster City CA
0.36494276.15269217.html.plaintext.txt	49	Brilliant SYBR Green QRT PCR master mix kit 1 step Stratagene La Jolla CA used reverse transcription RT PCR reaction
0.36494276.15269217.html.plaintext.txt	50	Master mix RTRNase block mix added 1 microM forward reverse primers 1
0.36494276.15269217.html.plaintext.txt	51	For apoE 18 S RT PCR samples cycled ABI Prism 7000 sequence detection system following temperatures 1 50 degrees C 30 min 2 95 degrees C 10 min 3 96 degrees C 30
0.36494276.15269217.html.plaintext.txt	52	4 54 degrees C 1 min 5 72 degrees C 30 min 6 repeat steps 3 5 40 times
0.36494276.15269217.html.plaintext.txt	53	Standard curves critical threshold versus log concentration plotted RNA wild type mouse cortex relative transcript levels calculated using ABI software accompanied Prism 7000
0.36494276.15269217.html.plaintext.txt	54	ApoJ Western Blot Samples cortex sonicated 1x radioimmune precipitation buffer 1x protease inhibitors
0.36494276.15269217.html.plaintext.txt	55	Radioimmune precipitation buffer insoluble material removed spinning 10000 x g x 15 min
0.36494276.15269217.html.plaintext.txt	56	25 microg total proteinwell run 10 bis Tris gel Invitrogen transferred onto nitrocellulose membrane
0.36494276.15269217.html.plaintext.txt	57	The blot probed rabbit anti apoJ antibody developed laboratory 24 washed probed anti rabbit IgG linked horseradish peroxidase Amersham Biosciences
0.36494276.15269217.html.plaintext.txt	58	Bands visualized enhanced chemiluminescence Pierce imaged Kodak Image Station Eastman Kodak Co
0.36494276.15269217.html.plaintext.txt	59	Cholesterol Phospholipid Analyses Brain samples prepared cholesterol analysis sonication PBS
0.36494276.15269217.html.plaintext.txt	60	The homogenized whole brain suspension subjected enzymatic analysis total cholesterol using Amplex Red cholesterol kit Molecular Probes Eugene OR
0.36494276.15269217.html.plaintext.txt	61	Results using homogenized brain suspension identical using chloroform extracted lipids brain data shown
0.36494276.15269217.html.plaintext.txt	62	CSF astrocyte conditioned medium diluted reaction buffer assayed
0.36494276.15269217.html.plaintext.txt	63	Free cholesterol measured using kit omitting cholesterol esterase enzyme
0.36494276.15269217.html.plaintext.txt	64	Esterified cholesterol calculated total cholesterol minus free cholesterol
0.36494276.15269217.html.plaintext.txt	65	Quantification phospholipids species performed electrospray ionization mass spectrometry described previously 25
0.36494276.15269217.html.plaintext.txt	66	Histological Analysis Tissue sections cut coronal plane 50 microm freezing sliding microtome mounted Superfrost Plus slides Fisher
0.36494276.15269217.html.plaintext.txt	67	For oil red O staining neutral fat slides dipped consecutively 70 ethanol 1 immersed 5 min 1 oil red O Sigma 35 ethanol 50 acetone
0.36494276.15269217.html.plaintext.txt	68	Slides washed water counterstained 2 min Harris hematoxylin Sigma washed water
0.36494276.15269217.html.plaintext.txt	69	The slides dipped ammonia water 0
0.36494276.15269217.html.plaintext.txt	70	05 ammonium hydroxide blue washed mounted
0.36494276.15269217.html.plaintext.txt	71	Staining cresyl violet nuclei Luxol fast blue identify myelin performed described previously 26 27
0.36494276.15269217.html.plaintext.txt	72	Non denaturing Gradient Gel Electrophoresis Samples CSF astrocyte conditioned medium ACM mixed 11 native sample buffer electrophoresed 4 20 Tris glycine gel Invitrogen
0.36494276.15269217.html.plaintext.txt	73	Proteins known hydrated diameters used size standards Amersham Biosciences catalog number 17044501 proteins transferred nitrocellulose membrane
0.36494276.15269217.html.plaintext.txt	74	For apoE immunoblotting membrane probed goat anti mouse apoE antibody 1100 M 20 Santa Cruz Biotechnology Santa Cruz CA washed probed horse anti goat IgG linked horseradish peroxidase 11000 Vector Laboratories
0.36494276.15269217.html.plaintext.txt	75	For apoA I immunoblotting membrane probed rabbit anti mouse apoA I antibody 1500 Biodesign Saco ME washed probed goat anti rabbit IgG linked horseradish peroxidase 11000 Bio Rad
0.36494276.15269217.html.plaintext.txt	76	Bands visualized enhanced chemiluminescence Sigma imaged Kodak Image Station Kodak
0.36494276.15269217.html.plaintext.txt	77	Primary Astrocyte Cultures Primary cultures forebrain astrocytes 95 pure prepared individual neonatal 1 3 day old mice described previously 28
0.36494276.15269217.html.plaintext.txt	78	Astrocytes grown Dulbeccos modified Eagles mediumF 12 containing 10 fetal bovine serum 10 heat inactivated horse serum 1 mM sodium pyruvate 100 unitsml penicillin 100 microgml streptomycin 250 ngml Fungizone 10 ngml epidermal growth factor Sigma
0.36494276.15269217.html.plaintext.txt	79	To obtain ACM confluent astrocyte cultures washed twice sterile PBS
0.36494276.15269217.html.plaintext.txt	80	Serum free medium added Dulbeccos modified Eagles mediumF 12 1 N2 supplement Invitrogen 1 mM sodium pyruvate 100 unitsml penicillin 100 microgml streptomycin 250 ngml Fungizone cells incubated 3 days
0.36494276.15269217.html.plaintext.txt	81	Media collected spun 2000 x g x 10 min remove cellular debris
0.36494276.15269217.html.plaintext.txt	82	1 sodium azide 1x protease inhibitors added ACM stored 4 degrees C analysis
0.36494276.15269217.html.plaintext.txt	83	Following harvesting ACM astrocytes scraped flasks washed PBS pelleted sonicated PBS
0.36494276.15269217.html.plaintext.txt	84	Fractionation ACM ACM concentrated 40 fold 10 kDa molecular mass cut spin concentrator Millipore Billerica MA
0.36494276.15269217.html.plaintext.txt	85	1 ml concentrated ACM subjected gel filtration chromatography using BioLogic system Bio Rad tandem Superose 6 HR 1030 columns Amersham Biosciences 0
0.36494276.15269217.html.plaintext.txt	86	02 sodium azide described previously 29
0.36494276.15269217.html.plaintext.txt	87	Atomic Force Microscopy AFM Fraction 37 Abca1 ACM fraction 51 Abca1 stored 4 degrees C AFM analysis
0.36494276.15269217.html.plaintext.txt	88	Samples analyzed situ AFM described previously 30
0.36494276.15269217.html.plaintext.txt	89	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Plasma CNS Apolipoprotein Levels Abca1 Mice Previous studies shown near absence plasma HDL apoA I Abca1 mice consistent role ABCA1 cellular cholesterol phospholipid efflux onto plasma HDL 12
0.36494276.15269217.html.plaintext.txt	90	As apoE also constituent plasma HDL measured plasma apoE levels found decreased 96 54 Abca1 Abca1 mice respectively compared wild type littermates Fig
0.36494276.15269217.html.plaintext.txt	91	View larger version 21K FIG
0.36494276.15269217.html.plaintext.txt	92	Levels apoE apoJ Abca1 mice
0.36494276.15269217.html.plaintext.txt	93	A C apoE levels plasma CSF cortex measured ELISA
0.36494276.15269217.html.plaintext.txt	94	Cortical apoE levels normalized total protein TP
0.36494276.15269217.html.plaintext.txt	95	D relative mRNA levels apoE determined real time RT PCR normalized 18 S RNA
0.36494276.15269217.html.plaintext.txt	96	The relative mRNA level Apoe cortex 0
0.36494276.15269217.html.plaintext.txt	97	For A D n 5 mice per genotype
0.36494276.15269217.html.plaintext.txt	98	E levels apoJ cortex determined Western blotting 25 microg total protein mouse n 6 Abca1 n 5 Abca1
0.36494276.15269217.html.plaintext.txt	99	No bands visible cortical homogenate Apoj mouse
0.36494276.15269217.html.plaintext.txt	100	Unlike plasma contains variety lipoprotein classes apoA I major apoprotein constituent HDL CSF HDL like lipoproteins apoE abundant apoprotein
0.36494276.15269217.html.plaintext.txt	101	Further apoE CSF derived CNS plasma 13
0.36494276.15269217.html.plaintext.txt	102	To determine whether ABCA1 plays role CNS apoE metabolism measured apoE levels CSF brain ABCA1 deficient mice
0.36494276.15269217.html.plaintext.txt	103	Interestingly apoE levels CSF reduced similar extent plasma Abca1 mice 98 Abca1 mice 46 reductions apoE levels relative wild type littermates Fig
0.36494276.15269217.html.plaintext.txt	104	In brain tissue apoE levels cortex reduced 80 13 Abca1 mice respectively compared wild type littermates Fig
0.36494276.15269217.html.plaintext.txt	105	Real time RT PCR apoE mRNA performed cortex Abca1 mice determine whether differences apoE protein levels related gene expression
0.36494276.15269217.html.plaintext.txt	106	There differences apoE mRNA levels three genotypes Fig
0.36494276.15269217.html.plaintext.txt	107	1D suggesting ABCA1 affects apoE levels post transcriptionally CNS
0.36494276.15269217.html.plaintext.txt	108	The second abundant apoprotein produced CNS apolipoprotein J clusterin present HDL like particles CSF 19
0.36494276.15269217.html.plaintext.txt	109	To determine whether ABCA1 plays role metabolism apoJ similar manner apoE measured apoJ levels plasma CSF cortex found significant differences among different Abca1 genotypes Fig
0.36494276.15269217.html.plaintext.txt	110	ApoA I major component plasma HDL synthesized primarily periphery enters CNS small quantities relation high plasma concentration 14
0.36494276.15269217.html.plaintext.txt	111	Its levels greatly decreased CSF cortex Abca1 mice see Fig
0.36494276.15269217.html.plaintext.txt	112	Since apoA I levels plasma Abca1 mice near zero 14 CNS apoA I derived mostly plasma expected result
0.36494276.15269217.html.plaintext.txt	113	View larger version 45K FIG
0.36494276.15269217.html.plaintext.txt	114	For determination lipoprotein size CSF ACM run non denaturing gradient gels probed apoE A C apoA I B
0.36494276.15269217.html.plaintext.txt	115	A 1 microl CSF Abca1 mice loaded lane 20 microl Abca1 Apoe CSF loaded
0.36494276.15269217.html.plaintext.txt	116	B 20 microl CSF Abca1 Apoa I 1 microl CSF Abca1 mice loaded run lane
0.36494276.15269217.html.plaintext.txt	117	C 20 microl ACM Abca1 astrocytes loaded run lane
0.36494276.15269217.html.plaintext.txt	118	The Apoe ACM control bands data shown
0.36494276.15269217.html.plaintext.txt	119	D E apoE total cholesterol TC ACM measured ELISA enzymatic assay respectively normalized total protein TP astrocyte cell lysates
0.36494276.15269217.html.plaintext.txt	120	Lipids CSF Cortex Abca1 Mice Since major function ABCA1 outside CNS transport cholesterol phospholipids onto HDL examined whether ABCA1 deficiency altered levels cholesterol phospholipids within CNS
0.36494276.15269217.html.plaintext.txt	121	We found total cholesterol CSF reduced 24 Abca1 mice compared wild type littermates Fig
0.36494276.15269217.html.plaintext.txt	122	This likely ABCA1 deficiency results decreased levels HDL lipoprotein class normally carries proportion cholesterol CSF
0.36494276.15269217.html.plaintext.txt	123	In contrast CSF total cholesterol levels brain tissue cortex significantly different Abca1 mice Fig
0.36494276.15269217.html.plaintext.txt	124	Cholesterol esters cortex represented less 5 total cholesterol also significantly different data shown
0.36494276.15269217.html.plaintext.txt	125	Anionic phospholipids choline glycerophospholipids sphingomyelins ethanolamine glycerophospholipids measured cortex electrospray ionization mass spectrometry vary significantly Abca1 mice n 5 group data shown
0.36494276.15269217.html.plaintext.txt	126	View larger version 74K FIG
0.36494276.15269217.html.plaintext.txt	127	Lipids CNS Abca1 mice
0.36494276.15269217.html.plaintext.txt	128	A B total cholesterol TC levels measured CSF cortex enzymatic assay normalized total protein levels cortex
0.36494276.15269217.html.plaintext.txt	129	C images brain sections stained oil red O
0.36494276.15269217.html.plaintext.txt	130	To determine whether lipid buildup brain stained 3 month old Abca1 brain sections oil red O
0.36494276.15269217.html.plaintext.txt	131	There evidence abnormal lipid deposition Abca1 mice Fig
0.36494276.15269217.html.plaintext.txt	132	Standard histological staining methods including cresyl violet nuclei Luxol fast blue myelin also revealed abnormalities brains Abca1 mice data shown
0.36494276.15269217.html.plaintext.txt	133	Lipoprotein Particles CSF Astrocyte Conditioned Media Abca1 Mice In addition evaluating effects ABCA1 deficiency levels lipids apoE CNS vivo studied apoE apoA I containing lipoproteins CSF nascent apoE containing lipoproteins produced astrocytes examine ABCA1 deficiency affected properties
0.36494276.15269217.html.plaintext.txt	134	We determined size distribution apoE apoA I containing lipoproteins mouse CSF non denaturing gradient gel electrophoresis
0.36494276.15269217.html.plaintext.txt	135	As described previously 21 apoE CSF wild type mice HDL like particles 10 17 nm diameter abundant sizes 13 16 nm Fig
0.36494276.15269217.html.plaintext.txt	136	ApoE particles Abca1 CSF similar size wild type
0.36494276.15269217.html.plaintext.txt	137	However addition apoE levels CSF Abca1 markedly reduced apoE present within particles size distribution different wild type mice
0.36494276.15269217.html.plaintext.txt	138	In addition population particles 13 16 nm diameter CSF Abca1 mice also population smaller apoE containing particles 7 8 nm diameter suggesting poorly lipidated
0.36494276.15269217.html.plaintext.txt	139	ApoA I also greatly reduced CSF Abca1 mice small amount present particles 7
0.36494276.15269217.html.plaintext.txt	140	3 nm compared particles 8 11 nm CSF Abca1 mice Fig
0.36494276.15269217.html.plaintext.txt	141	Because Abca1 mice low CSF apoE levels altered particle size distribution led us investigate whether primary alteration nascently produced apoE containing HDL astrocytes cells produce majority apoE CNS
0.36494276.15269217.html.plaintext.txt	142	We compared total cholesterol apoE ACM derived primary astrocyte cultures Abca1 mice found total levels apoE ACM vary Abca1 genotype Fig
0.36494276.15269217.html.plaintext.txt	143	However levels total cholesterol significantly lower Abca1 ACM Fig
0.36494276.15269217.html.plaintext.txt	144	This suggests apoE secreted normal levels Abca1 astrocytes apoE normally lipidated absence ABCA1
0.36494276.15269217.html.plaintext.txt	145	To examine extent lipidation apoE containing particles ACM subjected size analysis non denaturing gradient gel electrophoresis followed Western blotting apoE
0.36494276.15269217.html.plaintext.txt	146	This demonstrated apoE containing lipoprotein populations 12 11 8 nm ACM Abca1 mice much smaller lipoproteins ACM Abca1 mice 7
0.36494276.15269217.html.plaintext.txt	147	These data suggested apoE containing particles Abca1 ACM likely lipid poor
0.36494276.15269217.html.plaintext.txt	148	To analyze lipid composition astrocyte secreted lipoproteins ACM fractionated size exclusion chromatography
0.36494276.15269217.html.plaintext.txt	149	ApoE ELISAs cholesterol assays different fractions demonstrated lipoproteins Abca1 ACM contain less apoE smaller markedly less cholesterol Abca1 ACM Fig
0.36494276.15269217.html.plaintext.txt	150	Lipoprotein associated apoE reduced Abca1 ACM 80 compared Abca1 ACM
0.36494276.15269217.html.plaintext.txt	151	As expected 75 apoE Abca1 ACM fractions 31 41 corresponding HDL size range
0.36494276.15269217.html.plaintext.txt	152	However 75 lipoprotein associated apoE Abca1 ACM fractions 45 55 corresponds much smaller particles
0.36494276.15269217.html.plaintext.txt	153	These smaller lipoprotein particles derived Abca1 astrocytes cholesterol poor compared Abca1 particles 0
0.36494276.15269217.html.plaintext.txt	154	69 microg total cholesterol microg apoE Abca1 versus 2
0.36494276.15269217.html.plaintext.txt	155	3 microg total cholesterol microg apoE Abca1
0.36494276.15269217.html.plaintext.txt	156	View larger version 34K FIG
0.36494276.15269217.html.plaintext.txt	157	Fractionation size analysis lipoproteins ACM
0.36494276.15269217.html.plaintext.txt	158	Following size exclusion gel filtration fractions subjected analysis
0.36494276.15269217.html.plaintext.txt	159	ApoE total cholesterol TC ACM measured ELISA enzymatic assay respectively normalized total protein TP astrocyte cell lysates A B
0.36494276.15269217.html.plaintext.txt	160	37 Abca1 ACM fraction 51 Fr
0.36494276.15269217.html.plaintext.txt	161	51 Abca1 ACM subjected atomic force microscopy determine appearance size lipoprotein particles C
0.36494276.15269217.html.plaintext.txt	162	Volumes lipoprotein particles obtained AFM corrected finite size tip
0.36494276.15269217.html.plaintext.txt	163	To confirm size shape abnormal Abca1 particles AFM performed size exclusion chromatography fractions Abca1 Abca1 ACM highest apoE levels
0.36494276.15269217.html.plaintext.txt	164	AFM tool choice allows characterization three dimensional shape nanoparticles nearly physiological conditions
0.36494276.15269217.html.plaintext.txt	165	Its use study lipoprotein particles protocols needed obtain reliable volume measurements recently described elsewhere 31
0.36494276.15269217.html.plaintext.txt	166	The AFM images obtained demonstrate abundant apoE containing particles Abca1 ACM significantly smaller Abca1 ACM Fig
0.36494276.15269217.html.plaintext.txt	167	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES In study analyzed brain tissue CSF plasma primary astrocyte cultures Abca1 mice determine whether deletion ABCA1 affects metabolism apoE cholesterol phospholipids CNS nascent lipoprotein particles secreted astrocytes
0.36494276.15269217.html.plaintext.txt	168	We found Abca1 mice greatly decreased apoE levels plasma 96 reduction CSF 98 reduction cortex 80 reduction compared Abca1 mice
0.36494276.15269217.html.plaintext.txt	169	The decreased apoE levels plasma brain observed similar seen others
0.36494276.15269217.html.plaintext.txt	170	2 The decreased apoE levels CNS related Apoe gene expression likely result increased catabolism abnormally lipidated apoE containing HDL lipoproteins produced CNS occurs abnormally lipidated apoA I apoA II secreted liver rapidly catabolized plasma Tangiers disease patients 10 11
0.36494276.15269217.html.plaintext.txt	171	Although alterations CNS apoE levels profound differences total CNS lipids subtle present CSF
0.36494276.15269217.html.plaintext.txt	172	Brain tissue Abca1 mice differences free cholesterol esterified cholesterol phospholipids showed evidence lipid deposition histological staining
0.36494276.15269217.html.plaintext.txt	173	These results suggest ABCA1 play major role regulating global cellular lipid levels brain tissue vivo regulation performed additional molecules
0.36494276.15269217.html.plaintext.txt	174	However CSF Abca1 mice significantly reduced cholesterol showing ABCA1 important regulating extracellular lipid levels CNS
0.36494276.15269217.html.plaintext.txt	175	Conditioned media collected primary cultures astrocytes derived Abca1 mice showed although total levels apoE secreted astrocytes affected Abca1 genotype secretion cholesterol media markedly reduced Abca1 cultures consistent ABCA1 role transporting astrocyte derived cellular cholesterol onto lipoproteins
0.36494276.15269217.html.plaintext.txt	176	This function may occur astrocyte secretory pathway extracellularly
0.36494276.15269217.html.plaintext.txt	177	Analysis nascent lipoprotein particles isolated conditioned media primary astrocyte cultures demonstrated Abca1 astrocytes secrete apoE containing particles markedly smaller size reduced cholesterol apoE demonstrating ABCA1 required main cellular producer apoE CNS normally lipidate apoE
0.36494276.15269217.html.plaintext.txt	178	Of apoE produced CNS cells astrocytes reach CSF Abca1 mice fraction particles present also abnormally small although normal size
0.36494276.15269217.html.plaintext.txt	179	Thus appears mechanism require ABCA1 lipidate apoE reaches CSF
0.36494276.15269217.html.plaintext.txt	180	However fact CSF apoE levels Abca1 2 normal suggests non ABCA1 mediated pathway inefficient apoE particles produced absence ABCA1 mediated lipidation rapidly metabolized CNS
0.36494276.15269217.html.plaintext.txt	181	ApoE apoJ two major apoproteins produced astrocytes secreted unique apoE apoJ containing particles 33
0.36494276.15269217.html.plaintext.txt	182	ApoE secreted astrocytes present particles contain approximately equal mass apoE cholesterol phospholipids 21
0.36494276.15269217.html.plaintext.txt	183	Furthermore virtually cholesterol phospholipids secreted astrocytes associated apoE 33
0.36494276.15269217.html.plaintext.txt	184	In contrast apoJ secreted astrocytes little associated cholesterol phospholipids 21 found present normal levels brains Abca1 mice
0.36494276.15269217.html.plaintext.txt	185	Thus apoJ particles stable absence ABCA1 possibly normally lipid poor require extensive lipidation stability
0.36494276.15269217.html.plaintext.txt	186	These data demonstrate complete loss ABCA1 profoundly affects apoE levels CNS
0.36494276.15269217.html.plaintext.txt	187	Additionally since Abca1 mice intermediate apoE levels subtle alterations ABCA1 gene dosage andor functionality may affect apoE metabolism
0.36494276.15269217.html.plaintext.txt	188	The Apoe genotype major risk factor Alzheimers disease AD cerebral amyloid angiopathy CAA 34 36
0.36494276.15269217.html.plaintext.txt	189	The Apoe genotype may also influence neurologic prognosis intracerebral hemorrhage 37 traumatic brain injury 38 multiple sclerosis 39
0.36494276.15269217.html.plaintext.txt	190	The effects apoE AD CAA likely mediated large part role apoE role amyloid A chaperone influences A clearance fibrillogenesis 40
0.36494276.15269217.html.plaintext.txt	191	In amyloid precursor protein transgenic mice develop many pathological changes seen AD CAA level apoE regardless species genotype markedly influences time onset conformation amount A peptide accumulates brain age 41 45
0.36494276.15269217.html.plaintext.txt	192	For example amyloid precursor protein transgenic mice crossed Apoe mice animals lacking apoE almost fibrillar A deposition neuritic plaques CAA Apoe mice less 50 much A related pathology Apoe mice 41 44
0.36494276.15269217.html.plaintext.txt	193	These results show alterations CNS apoE levels little 50 massive effects AD like pathology CNS
0.36494276.15269217.html.plaintext.txt	194	Since ABCA1 regulates level apoE well state lipidation modulation ABCA1 levels function likely directly influence apoEA interactions along A deposition negative consequences brain
0.36494276.15269217.html.plaintext.txt	195	In addition effects ABCA1 apoE recent studies also suggest ABCA1 influence cellular A production 46 48
0.36494276.15269217.html.plaintext.txt	196	These effects likely independent apoE since alterations ABCA1 expression levels affect A cell types express apoE
0.36494276.15269217.html.plaintext.txt	197	Several studies also suggest direct link Abca1 polymorphisms risk AD 32 49 50
0.36494276.15269217.html.plaintext.txt	198	In summary shown ABCA1 required normal CNS apoE levels vivo well production normally lipidated apoE containing lipoproteins astrocytes
0.36494276.15269217.html.plaintext.txt	199	Since apoE levels CNS profoundly influence AD CAA pathology vivo modulation ABCA1 function levels may novel therapeutic target AD CAA diseases CNS
0.36494276.15269217.html.plaintext.txt	200	FOOTNOTES This work supported National Institutes Health Grants AG13956 P50 AG05681 NS034467 D
0.36494276.15269217.html.plaintext.txt	201	The costs publication article defrayed part payment page charges
0.36494276.15269217.html.plaintext.txt	202	This article must therefore hereby marked advertisement accordance 18 U
0.36494276.15269217.html.plaintext.txt	203	Section 1734 solely indicate fact
0.36494276.15269217.html.plaintext.txt	204	To correspondence addressed Washington University School Medicine Dept
0.36494276.15269217.html.plaintext.txt	205	314 362 9872 Fax 314 362 1771 E mail holtzmanatneuro
0.36494276.15269217.html.plaintext.txt	206	1 The abbreviations used ABC ATP binding cassette A amyloid peptide ACM astrocyte conditioned medium AFM atomic force microscopy AD Alzheimers disease CAA cerebral amyloid angiopathy CNS central nervous system CSF cerebrospinal fluid HDL high density lipoprotein RT reverse transcription ELISA enzyme linked immunosorbent assay PBS phosphate buffered saline apoE apolipoprotein E bis Tris 2 bis2 hydroxyethylamino 2 hydroxy methylpropane 13 diol
0.36494276.15269217.html.plaintext.txt	207	ACKNOWLEDGMENTS We thank Ravi Rajaram Kirsten Jansen Mike Spinner Dr
0.36494276.15269217.html.plaintext.txt	208	Anne Fagan Hua Cheng technical assistance helpful advice
0.36494276.15269217.html.plaintext.txt	209	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Dean M
0.36494276.15269217.html.plaintext.txt	210	11 1156 1166AbstractFree Full Text Higgins C
0.36494276.15269217.html.plaintext.txt	211	152 205 210CrossRefMedline Order article via Infotrieve Klein I
0.36494276.15269217.html.plaintext.txt	212	Acta 1461 237 262Medline Order article via Infotrieve Schmitz G
0.36494276.15269217.html.plaintext.txt	213	12 129 140CrossRefMedline Order article via Infotrieve Wang N
0.36494276.15269217.html.plaintext.txt	214	23 1178 1184AbstractFree Full Text Brooks Wilson A
0.36494276.15269217.html.plaintext.txt	215	22 336 345CrossRefMedline Order article via Infotrieve Remaley A
0.36494276.15269217.html.plaintext.txt	216	96 12685 12690AbstractFree Full Text Bodzioch M
0.36494276.15269217.html.plaintext.txt	217	22 347 351CrossRefMedline Order article via Infotrieve Rust S
0.36494276.15269217.html.plaintext.txt	218	22 352 355CrossRefMedline Order article via Infotrieve Schaefer E
0.36494276.15269217.html.plaintext.txt	219	22 217 228Abstract Schaefer E
0.36494276.15269217.html.plaintext.txt	220	299 905 910Abstract McNeish J
0.36494276.15269217.html.plaintext.txt	221	97 4245 4250AbstractFree Full Text Linton M
0.36494276.15269217.html.plaintext.txt	222	88 270 281Medline Order article via Infotrieve Boyles J
0.36494276.15269217.html.plaintext.txt	223	76 1501 1513Medline Order article via Infotrieve Newman T
0.36494276.15269217.html.plaintext.txt	224	260 2452 2457Abstract Pitas R
0.36494276.15269217.html.plaintext.txt	225	Acta 917 148 161Medline Order article via Infotrieve Stone D
0.36494276.15269217.html.plaintext.txt	226	143 313 318CrossRefMedline Order article via Infotrieve Pitas R
0.36494276.15269217.html.plaintext.txt	227	262 14352 14360AbstractFree Full Text LaDu M
0.36494276.15269217.html.plaintext.txt	228	70 2070 2081Medline Order article via Infotrieve Borghini I
0.36494276.15269217.html.plaintext.txt	229	Acta 1255 192 200Medline Order article via Infotrieve DeMattos R
0.36494276.15269217.html.plaintext.txt	230	39 415 425CrossRefMedline Order article via Infotrieve Krul E
0.36494276.15269217.html.plaintext.txt	231	29 1309 1325Abstract Lusis A
0.36494276.15269217.html.plaintext.txt	232	262 7594 7604AbstractFree Full Text Han B
0.36494276.15269217.html.plaintext.txt	233	7 338 343CrossRefMedline Order article via Infotrieve Han X
0.36494276.15269217.html.plaintext.txt	234	330 317 331CrossRefMedline Order article via Infotrieve Holtzman D
0.36494276.15269217.html.plaintext.txt	235	89 1383 1387Abstract Duerstock B
0.36494276.15269217.html.plaintext.txt	236	Methods 134 101 107CrossRefMedline Order article via Infotrieve Rose K
0.36494276.15269217.html.plaintext.txt	237	1993 In Vitro Biological Methods Methods Toxicology Tyson C
0.36494276.15269217.html.plaintext.txt	238	46 60 Academic Press San Diego Fagan A
0.36494276.15269217.html.plaintext.txt	239	CO2 X 2 8linktypeDOI CrossRefMedline Order article via Infotrieve Fryer J
0.36494276.15269217.html.plaintext.txt	240	23 7889 7896AbstractFree Full Text Fukumoto H
0.36494276.15269217.html.plaintext.txt	241	277 48508 48513AbstractFree Full Text Koldamova R
0.36494276.15269217.html.plaintext.txt	242	278 13244 13256AbstractFree Full Text Sun Y
0.36494276.15269217.html.plaintext.txt	243	278 27688 27694AbstractFree Full Text Ho Hong S
0.36494276.15269217.html.plaintext.txt	244	Acta 1587 60 64Medline Order article via Infotrieve Wollmer M
0.36494276.15269217.html.plaintext.txt	245	Aging 24 421 426CrossRefMedline Order article via Infotrieve
0.3398514.15583000.html.plaintext.txt	0	Two step Mechanism Binding Apolipoprotein E Heparin IMPLICATIONS FOR THE KINETICS OF APOLIPOPROTEIN E HEPARAN SULFATE PROTEOGLYCAN COMPLEX FORMATION ON CELL SURFACES Miho Futamura Padmaja Dhanasekaran Tetsurou Handa Michael C
0.3398514.15583000.html.plaintext.txt	1	Phillips Sissel Lund Katz Hiroyuki Saito
0.3398514.15583000.html.plaintext.txt	2	From Lipid Research Group The Childrens Hospital Philadelphia University Pennsylvania School Medicine Philadelphia Pennsylvania 19104 4318 Graduate School Pharmaceutical Sciences Kyoto University Kyoto 606 8501 Japan
0.3398514.15583000.html.plaintext.txt	3	Received publication October 14 2004
0.3398514.15583000.html.plaintext.txt	4	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES The interaction apolipoprotein E apoE cell surface heparan sulfate proteoglycans important step uptake lipoprotein remnants liver
0.3398514.15583000.html.plaintext.txt	5	ApoE interacts predominantly heparin N terminal binding site spanning residues around 136 150
0.3398514.15583000.html.plaintext.txt	6	In work surface plasmon resonance analysis employed investigate amphipathic helix properties basic residue organization region modulate binding apoE heparin
0.3398514.15583000.html.plaintext.txt	7	The apoEheparin interaction involves two step process apoE initially binds heparin fast association dissociation rates followed step exhibiting much slower kinetics
0.3398514.15583000.html.plaintext.txt	8	Circular dichroism surface plasmon resonance experiments using disulfide linked mutant opening N terminal helix bundle prevented demonstrated major secondary tertiary structural change apoE upon heparin binding
0.3398514.15583000.html.plaintext.txt	9	Mutations Lys 146 key residue heparin interaction greatly reduced favorable free energy binding first step without affecting second step suggesting electrostatic interaction involved first binding step
0.3398514.15583000.html.plaintext.txt	10	Although lipid free apoE2 tended bind less apoE3 apoE4 significant differences rate equilibrium constants binding among apoE isoforms lipidated state
0.3398514.15583000.html.plaintext.txt	11	Discoidal apoE3 phospholipid complexes using substitution mutant K143RK146R showed similar binding affinity wild type apoE3 indicating basic residue specificity required effective binding apoE heparin unlike binding low density lipoprotein receptor
0.3398514.15583000.html.plaintext.txt	12	In addition disruption helix structure apoE heparin binding region led increased favorable free energy binding second step suggesting hydrophobic interactions contribute second binding step
0.3398514.15583000.html.plaintext.txt	13	Based results seems cell surface heparan sulfate proteoglycan localizes apoE enriched remnant lipoproteins vicinity receptors fast association dissociation
0.3398514.15583000.html.plaintext.txt	14	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Apolipoprotein E apoE1 key protein regulating lipid transport human plasma brain 1 4
0.3398514.15583000.html.plaintext.txt	15	It mediates hepatic clearance remnant lipoproteins high affinity ligand low density lipoprotein receptor LDLR family including LDLR LDLR related protein LRP cell surface heparan sulfate proteoglycans HSPGs 5
0.3398514.15583000.html.plaintext.txt	16	In liver HSPGs act concert LRP complete interaction remnant particles LRP process known HSPG LRP pathway apoE initially interacts HSPG cell surface transferred LRP internalization 6
0.3398514.15583000.html.plaintext.txt	17	The ability apoE interact members LDLR family HSPG also significant cell signaling events 7
0.3398514.15583000.html.plaintext.txt	18	Binding apoE LRP activates cAMP dependent protein kinase A inhibits platelet derived growth factor stimulated migration smooth muscle cells 8
0.3398514.15583000.html.plaintext.txt	19	Inhibition smooth muscle cell proliferation apoE hand mediated binding HSPG 9
0.3398514.15583000.html.plaintext.txt	20	In addition interaction apoE HSPG implicated neuronal growth repair consequently involved progression late onset familial Alzheimers disease 10 12
0.3398514.15583000.html.plaintext.txt	21	ApoE comprises single polypeptide chain 299 amino acid residues contains two independently folded functional domains 22 kDa N terminal domain residues 1 191 10 kDa C terminal domain residues 222 299 2 13
0.3398514.15583000.html.plaintext.txt	22	The N terminal domain folded four helix bundle amphipathic helices contains LDLR binding region around residues 136 150 helix 4 14 15
0.3398514.15583000.html.plaintext.txt	23	The C terminal domain also contains amphipathic helices involved binding lipoprotein particles 2 16 17
0.3398514.15583000.html.plaintext.txt	24	Both N C terminal domains contain heparin binding site 18 19
0.3398514.15583000.html.plaintext.txt	25	The N terminal domain site located residues 136 147 overlapping LDLR binding region 20 21 whereas C terminal site involves basic residues around lysine 233 22
0.3398514.15583000.html.plaintext.txt	26	Although sites functional separated fragments N terminal site available interaction lipid free lipidated states intact apoE molecule 22
0.3398514.15583000.html.plaintext.txt	27	In humans apoE polymorphic protein three major isoforms apoE2 apoE3 apoE4 differing cysteine arginine positions 112 158 11
0.3398514.15583000.html.plaintext.txt	28	ApoE3 common form contains cysteine arginine positions respectively whereas apoE2 contains cysteine apoE4 contains arginine sites
0.3398514.15583000.html.plaintext.txt	29	Both apoE3 apoE4 bind equally high affinity LDLR apoE2 defective binding LDLR associated type III hyperlipoproteinemia 23
0.3398514.15583000.html.plaintext.txt	30	ApoE4 associated increased risk coronary artery disease major risk factor Alzheimers disease 3 24 25
0.3398514.15583000.html.plaintext.txt	31	A cluster arginine lysine residues located polar face fourth amphipathic helix N terminal bundle represents binding site cell surface receptors 2
0.3398514.15583000.html.plaintext.txt	32	Despite apparent accessibility basic residues interaction apoE lipid necessary high affinity binding LDLR 26
0.3398514.15583000.html.plaintext.txt	33	Recent studies indicate lipid binding induces opening helix bundle N terminal domain 27 28 increases exposure lysines 143 146 aqueous phase thereby enhances interaction acidic elements LDLR 29
0.3398514.15583000.html.plaintext.txt	34	Disruption amphipathic helix spanning residues 140 150 abolishes LDLR binding indicating structural motif apoE critical function 30
0.3398514.15583000.html.plaintext.txt	35	In contrast binding LDLR stringency binding apoE LRP HSPG appears less severe
0.3398514.15583000.html.plaintext.txt	36	Lipid association apoE required binding LRP 31 HSPG 22 32 although apoE domain spanning residues 136 150 involved binding 21 33
0.3398514.15583000.html.plaintext.txt	37	ApoE2 highly defective LDLR binding activity 2 normal apoE3 activity significant binding activity LRP 40 50 apoE3 23 HSPG 50 90 apoE3 6
0.3398514.15583000.html.plaintext.txt	38	The detailed molecular features control high affinity binding apoE LRP HSPG yet defined fully
0.3398514.15583000.html.plaintext.txt	39	Previously characterized effect point mutations basic residues present heparin binding sites equilibrium parameters defining interaction apoE heparin 22
0.3398514.15583000.html.plaintext.txt	40	To predict distribution apoE different receptors LDLR LRP HSPG however also important establish kinetics apoE receptor association dissociation receptorligand interactions cell surface occur equilibrium
0.3398514.15583000.html.plaintext.txt	41	In study surface plasmon resonance SPR measurements employed determine affinity kinetics interaction engineered apoE molecules lipid free lipidated states heparin
0.3398514.15583000.html.plaintext.txt	42	Using approach provide novel insights mechanism apoEheparin interaction
0.3398514.15583000.html.plaintext.txt	43	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Materials 12 Dimyristoyl phosphatidylcholine DMPC purchased Avanti20Polar20LipidsAvanti Polar Lipids Pelham AL stock solutions stored chloroformmethanol 21 nitrogen 20 degrees C
0.3398514.15583000.html.plaintext.txt	44	Brain natriuretic peptide mercaptoethanol Sigma
0.3398514.15583000.html.plaintext.txt	45	Ultrapure guanidine HCl ICN Pharmaceuticals Costa Mesa CA
0.3398514.15583000.html.plaintext.txt	46	Porcine intestinal mucosa heparin average molecular weight 13500 15000 biotin conjugate purchased Calbiochem
0.3398514.15583000.html.plaintext.txt	47	Biotinylated heparin dissolved water extensively dialyzed remove contaminating free biotin use
0.3398514.15583000.html.plaintext.txt	48	Expression Purification Proteins The full length human apoE2 apoE3 apoE4 22 kDa 12 kDa 10 kDa fragments expressed purified described previously 34
0.3398514.15583000.html.plaintext.txt	49	All mutants apoE made using QuikChange site directed mutagenesis kit Stratagene La Jolla CA
0.3398514.15583000.html.plaintext.txt	50	The cDNA ligated thioredoxin fusion expression vector pET32a Novagen Madison WI transformed Escherichia coli strain BL21 star DE3 Invitrogen
0.3398514.15583000.html.plaintext.txt	51	The resulting thioredoxin apoE fusion proteins expressed purified described previously 28
0.3398514.15583000.html.plaintext.txt	52	For apoE3 22 kDa L141KK143LK146LL148K mutant expressed insoluble protein proteins solubilized cell pellet using 6 M urea 30
0.3398514.15583000.html.plaintext.txt	53	The apoE preparations least 95 pure assessed SDS PAGE
0.3398514.15583000.html.plaintext.txt	54	In experiments apoE sample freshly dialyzed 1 mercaptoethanol 6 M guanidine HCl solution Tris buffer 10 mM Tris HCl 150 mM NaCl 0
0.3398514.15583000.html.plaintext.txt	55	The disulfide linked apoE4 22 kDa mutant dialyzed 6 M guanidine HCl solution maintain interhelical disulfide bonding 27
0.3398514.15583000.html.plaintext.txt	56	DMPC complexes apoE3 22 kDa variants prepared described previously 29
0.3398514.15583000.html.plaintext.txt	57	SPR Measurements Experiments performed Biacore X 2000 SPR instruments Biacore Inc
0.3398514.15583000.html.plaintext.txt	58	A streptavidin SA sensor chip pretreated three consecutive 5 microl injections 50 mM NaOH 1 M NaCl remove nonspecifically bound contaminants
0.3398514.15583000.html.plaintext.txt	59	For immobilization heparin SA chip injection biotinylated heparin 10 microgml Tris buffer made flow rate 5 microlmin followed 10 microl injection 2 M NaCl
0.3398514.15583000.html.plaintext.txt	60	Typically 30 200 resonance units heparin immobilized effects mass transport significant low surface density ligand 35
0.3398514.15583000.html.plaintext.txt	61	An untreated flow cell used control
0.3398514.15583000.html.plaintext.txt	62	For kinetic measurement apoE interaction heparin 30 microl injection apoE sample passed sensor surface flow rate 10 microlmin
0.3398514.15583000.html.plaintext.txt	63	At end sample plug buffer passed sensor surface facilitate dissociation
0.3398514.15583000.html.plaintext.txt	64	After 3 min dissociation time sensor surface regenerated next sample using 10 microl pulse 2 M NaCl
0.3398514.15583000.html.plaintext.txt	65	The resultant sensorgrams analyzed using BIAevaluation software version 4
0.3398514.15583000.html.plaintext.txt	66	The response curves various analyte concentrations globally fitted either 11 Langmuir model two state binding model described following equation 3637
0.3398514.15583000.html.plaintext.txt	67	1 equilibrium constants binding step K1 ka1kd1 K2 ka2kd2 overall equilibrium binding constant calculated KA K11 K2 Kd 1KA
0.3398514.15583000.html.plaintext.txt	68	In model analyte A binds ligand B form initial complex AB undergoes subsequent binding conformational change form stable complex ABx
0.3398514.15583000.html.plaintext.txt	69	For apoE 10 12 kDa fragments binding responses steady state region sensorgrams Req also plotted analyte concentration C determine overall equilibrium binding affinity
0.3398514.15583000.html.plaintext.txt	70	The data subjected nonlinear regression fitting according following equation
0.3398514.15583000.html.plaintext.txt	71	2 Rmax maximum binding response Kd dissociation constant
0.3398514.15583000.html.plaintext.txt	72	Circular Dichroism CD Spectroscopy Far UV CD spectra recorded 195 250 nm 25 degrees C using Jasco J 820 spectropolarimeter
0.3398514.15583000.html.plaintext.txt	73	After dialyzing 1 mercaptoethanol 6 M guanidine HCl solution apoE sample diluted 25 microgml Tris buffer pH 7
0.3398514.15583000.html.plaintext.txt	74	For apoEheparin mixture sample apoE mixed heparin apoEheparin ratios 0
0.3398514.15583000.html.plaintext.txt	75	5 2 ww prior measurement
0.3398514.15583000.html.plaintext.txt	76	The results corrected subtracting buffer base line blank sample containing identical concentration heparin
0.3398514.15583000.html.plaintext.txt	77	The helix content calculated molar ellipticity 222 nm 222 according following equation 3839
0.3398514.15583000.html.plaintext.txt	78	Analytical Procedures Protein concentrations determined either Lowry procedure 40 absorbance coefficient 280 nm
0.3398514.15583000.html.plaintext.txt	79	Phospholipid concentrations determined enzymatic assay kit Wako Chemicals Richmond VA
0.3398514.15583000.html.plaintext.txt	80	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Comparison ApoE Binding Immobilized Heparin Heparin Sepharose Gel We previously characterized effects point mutations lysines N C terminal heparin binding sites equilibrium binding heparin using heparin Sepharose gel 22
0.3398514.15583000.html.plaintext.txt	81	In study made SPR measurements apoEheparin interaction examine real time binding kinetics
0.3398514.15583000.html.plaintext.txt	82	1A shows sensorgrams binding apoE C terminal fragments immobilized heparin sensor chip
0.3398514.15583000.html.plaintext.txt	83	Because binding equilibrium achieved injection 10 12 kDa fragments apoE determined binding isotherms relationship equilibrium binding response Req protein concentration Fig
0.3398514.15583000.html.plaintext.txt	84	These isotherms similar obtained using heparin Sepharose gel Fig
0.3398514.15583000.html.plaintext.txt	85	1C calculated Kd values methods comparable example Kd apoE 10 kDa fragmentheparin interaction 29 76 microgml Fig
0.3398514.15583000.html.plaintext.txt	86	1 B C respectively results validate SPR method studies apoEheparin interaction 41
0.3398514.15583000.html.plaintext.txt	87	View larger version 24K FIG
0.3398514.15583000.html.plaintext.txt	88	Comparison use SPR sensor chips heparin Sepharose gel determine apoEheparin interactions
0.3398514.15583000.html.plaintext.txt	89	A SPR sensorgrams interaction apoE 10 kDa 10 kDa K233Q mutant b 12 kDa fragment c 30 microgml heparin immobilized SA sensor chip
0.3398514.15583000.html.plaintext.txt	90	B steady state affinity analysis SPR data
0.3398514.15583000.html.plaintext.txt	91	C binding isotherms apoE 10 kDa fragment 10 kDa K233Q mutant b 12 kDa fragment c heparin Sepharose gel replotted Ref
0.3398514.15583000.html.plaintext.txt	92	Kinetic Analysis Heparin Binding Full length ApoE3 Its 22 10 kDa Fragments Fig
0.3398514.15583000.html.plaintext.txt	93	2 shows typical sensorgram binding full length apoE heparin
0.3398514.15583000.html.plaintext.txt	94	The kinetic data fitted well 11 Langmuir binding model indicated large value goodness fit 2 100 Fig
0.3398514.15583000.html.plaintext.txt	95	However significantly improved fit 2 7
0.3398514.15583000.html.plaintext.txt	96	4 obtained using two state binding model indicating binding apoE heparin involves either sequential two step process conformational change 36 37
0.3398514.15583000.html.plaintext.txt	97	The response curve heparin binding apoE3 22 kDa fragment also showed two state binding kinetics Fig
0.3398514.15583000.html.plaintext.txt	98	Changing injection time revealed dissociation rate progressively decreased longer injection contact time Fig
0.3398514.15583000.html.plaintext.txt	99	3A inset indicating stability initial apoE heparin complex increases time 36 37
0.3398514.15583000.html.plaintext.txt	100	Such effect contact time dissociation rate seen apoE 10 kDa binding heparin contribution second binding step overall process small Fig
0.3398514.15583000.html.plaintext.txt	101	Table I summarizes kinetic rate constants derived affinity constants full length apoE3 22 10 kDa fragments obtained using two state binding model
0.3398514.15583000.html.plaintext.txt	102	There good agreement Kd values full length apoE3 data previous report 32 discrepancy apoE3 22 kDa fragment 21 previous studies applied 11 Langmuir binding model kinetic data
0.3398514.15583000.html.plaintext.txt	103	In addition Kd value 10 kDa fragment Table I 15 microgml similar obtained steady state analysis 29 microgml Fig
0.3398514.15583000.html.plaintext.txt	104	1B validating two state binding model
0.3398514.15583000.html.plaintext.txt	105	View larger version 17K FIG
0.3398514.15583000.html.plaintext.txt	106	Two state binding apoE heparin detected SPR measurements kinetics association dissociation
0.3398514.15583000.html.plaintext.txt	107	Sensorgram binding full length apoE3 30 microgml immobilized heparin
0.3398514.15583000.html.plaintext.txt	108	Experimental data fitted two state binding model A B AB ABx see Experimental Procedures
0.3398514.15583000.html.plaintext.txt	109	Simulated curves displaying initial binding AB subsequent binding conformational change ABx additive components fitted curve
0.3398514.15583000.html.plaintext.txt	110	The inset shows result fitting 11 Langmuir binding model dashed line
0.3398514.15583000.html.plaintext.txt	111	View larger version 25K FIG
0.3398514.15583000.html.plaintext.txt	112	SPR sensorgrams binding apoE3 22 kDa A 10 kDa B fragments 30 microgml heparin
0.3398514.15583000.html.plaintext.txt	113	The experimental binding data fitted two state binding model
0.3398514.15583000.html.plaintext.txt	114	Each component shown initial complex AB transferred complex AB
0.3398514.15583000.html.plaintext.txt	115	The insets show effect increased injection time stability apoE heparin complex
0.3398514.15583000.html.plaintext.txt	116	a30s b60s c 120 d 180
0.3398514.15583000.html.plaintext.txt	117	View table TABLE I Kinetic parameters binding lipid free apoE3 fragments heparin
0.3398514.15583000.html.plaintext.txt	118	Effects Heparin Binding Secondary Tertiary Structure ApoE To examine possibility conformational change apoE occurs binding heparin far UV CD measurements employed evaluate secondary structure apoE
0.3398514.15583000.html.plaintext.txt	119	4 change spectra apoE 22 kDa fragment observed absence presence heparin
0.3398514.15583000.html.plaintext.txt	120	The helix contents derived molar ellipticity 222 nm range 47 49 heparin apoE weight ratio 2 Fig
0.3398514.15583000.html.plaintext.txt	121	4 inset indicating change secondary structure apoE upon heparin binding
0.3398514.15583000.html.plaintext.txt	122	The four helix bundle apoE 22 kDa fragment known open upon lipid binding 27 28
0.3398514.15583000.html.plaintext.txt	123	To confirm conformational change apoE involved two state binding heparin tested heparin binding triple interhelical disulfide linked apoE4 22 kDa mutant opening four helix bundle completely restricted 27
0.3398514.15583000.html.plaintext.txt	124	SPR sensorgrams heparin binding mutant still exhibited two state binding kinetics data shown indicating conformational change opening helix bundle involved two state binding apoEheparin interaction
0.3398514.15583000.html.plaintext.txt	125	View larger version 21K FIG
0.3398514.15583000.html.plaintext.txt	126	Far UV CD spectra apoE3 22 kDa alone incubated heparin broken line
0.3398514.15583000.html.plaintext.txt	127	Protein heparin concentrations 25 microgml
0.3398514.15583000.html.plaintext.txt	128	The inset shows change helix content apoE3 22 kDa function weight ratio heparin protein protein concentration 25 microgml
0.3398514.15583000.html.plaintext.txt	129	Effects Lysine Mutations Heparin Binding Sites ApoE Binding Kinetics To explore molecular mechanism two state heparin binding apoE used mutants substitutions lysines 146 233 residues located N C terminal heparin binding sites respectively contribute ionic interaction heparin 21 22
0.3398514.15583000.html.plaintext.txt	130	5 large decreases binding responses observed apoE3 K146E mutant whereas apoE3 K233E mutant exhibited responses similar wild type WT consistent previous observations using heparin Sepharose gel Lys 146 plays dominant role heparin binding full length apoE 22
0.3398514.15583000.html.plaintext.txt	131	6A summarizes relative changes rate constants mutant well mutants K146Q K233Q
0.3398514.15583000.html.plaintext.txt	132	Replacement lysines significantly affected first association rate effect rate constants second step
0.3398514.15583000.html.plaintext.txt	133	The relative contributions step overall free energy binding estimated affinity constants two individual steps Fig
0.3398514.15583000.html.plaintext.txt	134	Although first binding step contributes largest part free energy binding proteins significant decreases favorable free energy binding first step observed K146Q K146E mutants without changes second step
0.3398514.15583000.html.plaintext.txt	135	View larger version 23K FIG
0.3398514.15583000.html.plaintext.txt	136	SPR sensorgrams binding WT A K146E B K233E C mutants full length apoE3 heparin
0.3398514.15583000.html.plaintext.txt	137	The experimental binding data fitted two state binding model dashed line
0.3398514.15583000.html.plaintext.txt	138	View larger version 39K FIG
0.3398514.15583000.html.plaintext.txt	139	SPR rate constants free energy binding interaction apoE3 mutants heparin
0.3398514.15583000.html.plaintext.txt	140	A relative change SPR rate constants binding step apoE mutants heparin
0.3398514.15583000.html.plaintext.txt	141	B free energy binding step apoE mutants heparin
0.3398514.15583000.html.plaintext.txt	142	Free energy calculated according G RT ln K using binding constants step K1 K2
0.3398514.15583000.html.plaintext.txt	143	Effects ApoE Isoform Binding Kinetics Heparin We compared association dissociation rate constants equilibrium dissociation constants binding apoE isoforms heparin
0.3398514.15583000.html.plaintext.txt	144	A previous SPR study indicated three full length apoE isoforms similar affinities heparin 32
0.3398514.15583000.html.plaintext.txt	145	7A full length apoE2 exhibited somewhat slower first association rate higher Kd value full length apoE3
0.3398514.15583000.html.plaintext.txt	146	Regarding 22 kDa fragments although apoE2 displayed slower rate apoE4 faster rate first association phase compared apoE3 Kd values similar among three isoforms Fig
0.3398514.15583000.html.plaintext.txt	147	Overall results indicate apoE2 tends bind heparin somewhat less affinity apoE3 apoE4 slower first binding step
0.3398514.15583000.html.plaintext.txt	148	View larger version 29K FIG
0.3398514.15583000.html.plaintext.txt	149	Comparison SPR rate constants interaction apoE isoforms heparin
0.3398514.15583000.html.plaintext.txt	150	Full length apoE A apoE 22 kDa fragments B
0.3398514.15583000.html.plaintext.txt	151	Effects Substitution Basic Residues Disruption Helical Structure N terminal Heparin Binding Site Binding Kinetics Lipidated ApoE Previously determined structural requirements apoE receptor binding domain effective binding LDLR substituting basic residues disrupting helical structure region 30
0.3398514.15583000.html.plaintext.txt	152	To examine possibility similar requirements necessary heparin binding used two apoE3 22 kDa mutants SPR measurements
0.3398514.15583000.html.plaintext.txt	153	The first K143RK146R mutant conservative substitution two lysines arginines decreases affinity LDLR 30 WT value
0.3398514.15583000.html.plaintext.txt	154	The second L141KK143LK146LL148K mutant exchange lysines leucines disrupts helical structure spanning residues 140 150 without altering net charge eliminates binding LDLR 30
0.3398514.15583000.html.plaintext.txt	155	Because lipid association required high affinity binding apoE LDLR 26 used discoidal complexes apoE 22 kDa fragments SPR measurements compare LDLR binding abilities
0.3398514.15583000.html.plaintext.txt	156	The apoE3 22 kDa fragment DMPC discoidal complex displayed second order higher first association rate constant lipid free protein resulting much higher affinity binding heparin cf
0.3398514.15583000.html.plaintext.txt	157	Among apoE isoforms complexed DMPC significant difference association dissociation rate constants equilibrium affinity Table II
0.3398514.15583000.html.plaintext.txt	158	The mutation K143RK146R effect kinetics affinity binding heparin indicating charge specificity basic residues required effective binding heparin
0.3398514.15583000.html.plaintext.txt	159	In contrast L141KK143LK146LL148K mutant exhibited much lower responses heparin binding WT apoE3 22 kDa fragment lipidated state Fig
0.3398514.15583000.html.plaintext.txt	160	8 suggesting amphipathic nature helix spanning residues 140 150 critical heparin binding apoE
0.3398514.15583000.html.plaintext.txt	161	Interestingly mutation led increased favorable free energy binding second step well decrease free energy first step Fig
0.3398514.15583000.html.plaintext.txt	162	9 overall Kd value significantly different WT Table II
0.3398514.15583000.html.plaintext.txt	163	View table TABLE II Kinetic parameters binding apoE 22 kDa DMPC discs heparin
0.3398514.15583000.html.plaintext.txt	164	View larger version 24K FIG
0.3398514.15583000.html.plaintext.txt	165	SPR sensorgrams binding DMPC discoidal complexes apoE3 22 kDa fragments A L141KK143LK146LL148K mutant B heparin
0.3398514.15583000.html.plaintext.txt	166	The experimental binding data fitted two state binding model dashed line
0.3398514.15583000.html.plaintext.txt	167	View larger version 32K FIG
0.3398514.15583000.html.plaintext.txt	168	Comparison free energy heparin binding DMPC discoidal complexes apoE3 mutants
0.3398514.15583000.html.plaintext.txt	169	Free energy calculated according G RT ln K using binding constants step
0.3398514.15583000.html.plaintext.txt	170	01 compared apoE3 22 kDa fragment DMPC complexes
0.3398514.15583000.html.plaintext.txt	171	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES The ability apoE bind cell surface glycosaminoglycans including HSPG heparin important lipoprotein remnant metabolism
0.3398514.15583000.html.plaintext.txt	172	The binding apoE heparin studied extensively 18 21 recently defined dominant role N terminal site residues 136 150 heparin binding lipid free lipid associated apoE 22
0.3398514.15583000.html.plaintext.txt	173	However structural requirements region basic residue organization amphipathic nature helix high affinity interaction apoE heparin opposed LDLR defined yet
0.3398514.15583000.html.plaintext.txt	174	In present study characterized kinetics interaction heparin apoE isoforms various mutants lacking effective LDLR binding affinity
0.3398514.15583000.html.plaintext.txt	175	Knowledge association dissociation rate constants obtained relevant understanding events cell surface many receptorligand interactions occur equilibrium
0.3398514.15583000.html.plaintext.txt	176	Two step Mechanism Binding ApoE Heparin Our SPR data indicate binding apoE heparin two state process involving sequential binding andor conformational change
0.3398514.15583000.html.plaintext.txt	177	It known protein binds heparin induce change conformation within heparin andor protein 43
0.3398514.15583000.html.plaintext.txt	178	For interaction antithrombin heparin initial interaction induces conformational change antithrombin enables additional interactions antithrombin heparin resulting stronger binding 44
0.3398514.15583000.html.plaintext.txt	179	There also evidence relatively flexible 2 sulfoiduronic acid residue heparin change conformation upon protein binding resulting better fit enhanced binding 43
0.3398514.15583000.html.plaintext.txt	180	However CD measurements apoEheparin mixture demonstrated heparin binding induce change secondary structure apoE Fig
0.3398514.15583000.html.plaintext.txt	181	Taken together SPR data triple interhelical disulfide linked apoE4 22 kDa mutant showing two state binding heparin appears two state apoEheparin interaction observed SPR measurements due major conformational change apoE upon heparin binding
0.3398514.15583000.html.plaintext.txt	182	The dominant type interaction heparin proteins ionic clusters basic residues proteins form ion pairs spatially defined acidic groups heparin 45
0.3398514.15583000.html.plaintext.txt	183	In fact molecular modeling interaction heparin binding site apoE heparin fragment suggested eight polar residues including Lys 146 directly contact sulfate carboxyl groups heparin chain 21
0.3398514.15583000.html.plaintext.txt	184	Thus large reductions association rate favorable free energy first binding step Lys 146 mutants Fig
0.3398514.15583000.html.plaintext.txt	185	6 consistent first step involving fast electrostatic interaction basic residues apoE acidic groups heparin
0.3398514.15583000.html.plaintext.txt	186	In addition analysis dependence Kd values sodium chloride concentration data shown using proteinpolyelectrolyte interaction theory 46 indicated 3
0.3398514.15583000.html.plaintext.txt	187	7 charged residues respectively involved electrostatic component overall first binding process apoEheparin interaction
0.3398514.15583000.html.plaintext.txt	188	The similarity two values also supports idea electrostatic interaction involved first binding step
0.3398514.15583000.html.plaintext.txt	189	Besides ionic interaction known significant contribution binding heparin nonionic interactions hydrogen bonding hydrophobic interactions cases 45
0.3398514.15583000.html.plaintext.txt	190	In fact molecular modeling apoEheparin interaction predicts formation hydrogen bonding residues Lys 143 apoE heparin also hydrophobic interaction shallow groove helix apoE saccharide chains heparin 21
0.3398514.15583000.html.plaintext.txt	191	In regard significant increase contribution second step free energy binding observed L141KK143LK146LL148K mutant Fig
0.3398514.15583000.html.plaintext.txt	192	9 disruption amphipathic helix heparin binding region destabilizes N terminal helix bundle exposes hydrophobic surface 30 implies hydrophobic interaction apoE heparin contributes second binding step
0.3398514.15583000.html.plaintext.txt	193	In addition found SPR data interaction brain natriuretic peptide heparin major contribution free energy binding comes hydrogen bonding interaction 47 displayed two state binding first binding step contributed overall free energy binding data shown
0.3398514.15583000.html.plaintext.txt	194	This suggests hydrogen bonding may involved mostly first binding step
0.3398514.15583000.html.plaintext.txt	195	Structural Requirements Receptor Binding Region ApoE Heparin Interaction Although lipid association required high affinity binding apoE LDLR 26 lipid free apoE bind effectively heparin Table I
0.3398514.15583000.html.plaintext.txt	196	In addition apoE2 highly defective LDLR binding 23 exhibited similar heparin binding activity apoE3 lipid free lipidated states Fig
0.3398514.15583000.html.plaintext.txt	197	These results consistent previous observations requirements high affinity binding apoE HSPGheparin less stringent binding LDLR 6
0.3398514.15583000.html.plaintext.txt	198	It suggested multiple basic residues receptor binding region residues 136 150 apoE required particular orientation optimal binding LDLR 48
0.3398514.15583000.html.plaintext.txt	199	Indeed comparison structure residues 135 151 lipid free lipid associated apoE showed significantly different curvature basic residues less scattered forming better aligned elongated hydrophilic surface lipidated form 49 50
0.3398514.15583000.html.plaintext.txt	200	In addition nuclear magnetic resonance studies 29 51 demonstrated lipid interaction increases positive electrostatic potential around lysines 143 146 effects much less apoE2
0.3398514.15583000.html.plaintext.txt	201	Taken together appears enhanced electrostatic potential around residues 136 150 apoE required interaction LDLR necessary high affinity binding heparin
0.3398514.15583000.html.plaintext.txt	202	Previous studies relative strengths heparin binding arginine lysine demonstrated former binds 2
0.3398514.15583000.html.plaintext.txt	203	Indeed found SPR measurements lipid free substitution mutant K143RK146R displayed 2
0.3398514.15583000.html.plaintext.txt	204	6 times higher affinity heparin WT data shown
0.3398514.15583000.html.plaintext.txt	205	However shown Table II double substitution lysines arginines effect kinetics affinity binding lipidated apoE heparin although mutant exhibits much reduced binding affinity LDLR 30
0.3398514.15583000.html.plaintext.txt	206	It follows preference lysine arginine positions heparin binding lipid associated apoE
0.3398514.15583000.html.plaintext.txt	207	Disruption helical structure region 140 150 mutation L141KK143LK146LL148K greatly affected kinetics binding heparin Fig
0.3398514.15583000.html.plaintext.txt	208	8 Table II mutant still displayed overall heparin binding affinity similar WT Table II
0.3398514.15583000.html.plaintext.txt	209	This suggests amphipathic helical structural motif receptor binding region apoE critical effective binding heparin contrast situation LDLR binding
0.3398514.15583000.html.plaintext.txt	210	Such somewhat surprising results may arise appropriate arrangement basic residues required interaction heparin still maintained discoidal complex mutant
0.3398514.15583000.html.plaintext.txt	211	Presumably cooperative binding multiple copies heparin binding sites apoE molecules important determining heparin binding ability apoE bound lipid particles 22
0.3398514.15583000.html.plaintext.txt	212	Implications Sequestration Role HSPG Remnant Lipoprotein Metabolism Our SPR kinetic data apoEheparin interaction provide novel insights mechanism HSPG LRP pathway remnant lipoprotein uptake cells Fig
0.3398514.15583000.html.plaintext.txt	213	In pathway apoE postulated interact initially cell surface HSPG transfer LRP internalization 6
0.3398514.15583000.html.plaintext.txt	214	Because limited kinetic parameters apoELRP interaction available 33 compare kinetic parameters binding lipidated apoE heparin related LDLR 53 54
0.3398514.15583000.html.plaintext.txt	215	Because fast association lipidated apoE first binding step heparin long range nondirectional ionic interactions Table II follows apoE enriched remnant particles captured rapidly abundant HSPG cell surface
0.3398514.15583000.html.plaintext.txt	216	Fast dissociation step likely allow rapid transfer remnant particles LRP associated closely HSPG 55
0.3398514.15583000.html.plaintext.txt	217	The LRP could retain remnant particles cell surface endocytosis occurs slow dissociation rate apoE receptor complex 10 5 1 53
0.3398514.15583000.html.plaintext.txt	218	Such process would efficient direct binding remnant particles solution LRP remnant particles concentrated cell surface could diffuse two dimensions rapidly exchanging HSPG binding sites collide LRP form LRP remnant particle complex
0.3398514.15583000.html.plaintext.txt	219	This lateral diffusion cell surface reminiscent scooting mode proposed interfacial reaction phospholipases 56
0.3398514.15583000.html.plaintext.txt	220	It also possible initial complexes HSPG remnant particle would undergo second binding step forming stable complex internalization without LRP involvement
0.3398514.15583000.html.plaintext.txt	221	View larger version 9K FIG
0.3398514.15583000.html.plaintext.txt	222	Model two step kinetics remnant lipoprotein uptake HSPG LRP pathway
0.3398514.15583000.html.plaintext.txt	223	The apoE enriched remnant lipoproteins first captured fast association apoE cell surface HSPG
0.3398514.15583000.html.plaintext.txt	224	Because fast dissociation rate interaction remnant lipoproteins rapidly transferred LRP form stable complex characterized slow dissociation endocytosis
0.3398514.15583000.html.plaintext.txt	225	Some initial complexes HSPG remnant particle would undergo second binding step forming stable complex internalization
0.3398514.15583000.html.plaintext.txt	226	In summary characterized kinetics affinity interaction apoE heparin using SPR
0.3398514.15583000.html.plaintext.txt	227	Our data show binding apoE heparin two step process fast initial binding involving polar interaction followed relatively slow nonpolar interaction
0.3398514.15583000.html.plaintext.txt	228	We propose fast association dissociation process apoEHSPG interaction plays role HSPG LRP pathway remnant lipoproteins rapidly captured HSPG transferred LRP form stable complex internalization
0.3398514.15583000.html.plaintext.txt	229	FOOTNOTES This work supported National Institutes Health Grant HL56083 Grants aid 12470489 14572045 scientific research Japan Society Promotion Science
0.3398514.15583000.html.plaintext.txt	230	The costs publication article defrayed part payment page charges
0.3398514.15583000.html.plaintext.txt	231	This article must therefore hereby marked advertisement accordance 18 U
0.3398514.15583000.html.plaintext.txt	232	Section 1734 solely indicate fact
0.3398514.15583000.html.plaintext.txt	233	To correspondence addressed The Childrens Hospital Philadelphia Abramson Research Bldg
0.3398514.15583000.html.plaintext.txt	234	Suite 1102 3615 Civic Center Blvd
0.3398514.15583000.html.plaintext.txt	235	215 590 0588 Fax 215 590 0583 E mail katzatemail
0.3398514.15583000.html.plaintext.txt	236	1 The abbreviations used apoE apolipoprotein E DMPC 12 dimyristoyl phosphatidylcholine HSPG heparan sulfate proteoglycan LDLR low density lipoprotein receptor LRP LDLR related protein SPR surface plasmon resonance WT wild type CD circular dichroism
0.3398514.15583000.html.plaintext.txt	237	ACKNOWLEDGMENTS We thank Dr
0.3398514.15583000.html.plaintext.txt	238	Masashi Hyuga National Institute Health Sciences Tokyo Japan Kaori Morimoto BIACore K
0.3398514.15583000.html.plaintext.txt	239	Tokyo Japan valuable suggestions SPR measurements
0.3398514.15583000.html.plaintext.txt	240	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Mahley R
0.3398514.15583000.html.plaintext.txt	241	1988 Science 240 622 630Medline Order article via Infotrieve Weisgraber K
0.3398514.15583000.html.plaintext.txt	242	45 249 302Medline Order article via Infotrieve Weisgraber K
0.3398514.15583000.html.plaintext.txt	243	10 1485 1494AbstractFree Full Text Strittmatter W
0.3398514.15583000.html.plaintext.txt	244	13 119 123CrossRefMedline Order article via Infotrieve Cooper A
0.3398514.15583000.html.plaintext.txt	245	38 2173 2192Abstract Mahley R
0.3398514.15583000.html.plaintext.txt	246	40 1 16AbstractFree Full Text Swertfeger D
0.3398514.15583000.html.plaintext.txt	247	6 D526 D535Medline Order article via Infotrieve Zhu Y
0.3398514.15583000.html.plaintext.txt	248	278 36257 36263AbstractFree Full Text Swertfeger D
0.3398514.15583000.html.plaintext.txt	249	276 25043 25048AbstractFree Full Text Ji Z
0.3398514.15583000.html.plaintext.txt	250	273 13452 13460AbstractFree Full Text Mahley R
0.3398514.15583000.html.plaintext.txt	251	1 507 537CrossRefMedline Order article via Infotrieve Bazin H
0.3398514.15583000.html.plaintext.txt	252	2002 Biochemistry 41 8203 8211CrossRefMedline Order article via Infotrieve Saito H
0.3398514.15583000.html.plaintext.txt	253	43 350 380CrossRefMedline Order article via Infotrieve Wilson C
0.3398514.15583000.html.plaintext.txt	254	1991 Science 252 1817 1822Medline Order article via Infotrieve Narayanaswami V
0.3398514.15583000.html.plaintext.txt	255	Acta 1483 15 36Medline Order article via Infotrieve Westerlund J
0.3398514.15583000.html.plaintext.txt	256	268 15745 15750AbstractFree Full Text Segrest J
0.3398514.15583000.html.plaintext.txt	257	45 303 369Medline Order article via Infotrieve Cardin A
0.3398514.15583000.html.plaintext.txt	258	134 783 789Medline Order article via Infotrieve Weisgraber K
0.3398514.15583000.html.plaintext.txt	259	261 2068 2076AbstractFree Full Text Dong J
0.3398514.15583000.html.plaintext.txt	260	2001 Biochemistry 40 2826 2834CrossRefMedline Order article via Infotrieve Libeu C
0.3398514.15583000.html.plaintext.txt	261	276 39138 39144AbstractFree Full Text Saito H
0.3398514.15583000.html.plaintext.txt	262	278 14782 14787AbstractFree Full Text Mahley R
0.3398514.15583000.html.plaintext.txt	263	40 1933 1949AbstractFree Full Text Davignon J
0.3398514.15583000.html.plaintext.txt	264	1988 Arteriosclerosis 8 1 21Abstract Strittmatter W
0.3398514.15583000.html.plaintext.txt	265	92 4725 4727AbstractFree Full Text Innerarity T
0.3398514.15583000.html.plaintext.txt	266	254 4186 4190Medline Order article via Infotrieve Lu B
0.3398514.15583000.html.plaintext.txt	267	275 20775 20781AbstractFree Full Text Saito H
0.3398514.15583000.html.plaintext.txt	268	276 40949 40954AbstractFree Full Text Lund Katz S
0.3398514.15583000.html.plaintext.txt	269	275 34459 34464AbstractFree Full Text Zaiou M
0.3398514.15583000.html.plaintext.txt	270	41 1087 1095AbstractFree Full Text Narita M
0.3398514.15583000.html.plaintext.txt	271	Tokyo 132 743 749Abstract Shuvaev V
0.3398514.15583000.html.plaintext.txt	272	459 353 357CrossRefMedline Order article via Infotrieve Croy J
0.3398514.15583000.html.plaintext.txt	273	2004 Biochemistry 43 7328 7335CrossRefMedline Order article via Infotrieve Saito H
0.3398514.15583000.html.plaintext.txt	274	278 40723 40729AbstractFree Full Text Myszka D
0.3398514.15583000.html.plaintext.txt	275	8 50 57CrossRefMedline Order article via Infotrieve Karlsson R
0.3398514.15583000.html.plaintext.txt	276	Methods 200 121 133CrossRefMedline Order article via Infotrieve Lipschultz C
0.3398514.15583000.html.plaintext.txt	277	2000 Methods 20 310 318CrossRefMedline Order article via Infotrieve Morrisett J
0.3398514.15583000.html.plaintext.txt	278	1973 Biochemistry 12 1290 1299Medline Order article via Infotrieve Acharya P
0.3398514.15583000.html.plaintext.txt	279	Acta 1584 9 19Medline Order article via Infotrieve Lowry O
0.3398514.15583000.html.plaintext.txt	280	193 265 275Free Full Text Osmond R
0.3398514.15583000.html.plaintext.txt	281	310 199 207Medline Order article via Infotrieve Papo N
0.3398514.15583000.html.plaintext.txt	282	2004 Biochemistry 43 6393 6403CrossRefMedline Order article via Infotrieve Munoz E
0.3398514.15583000.html.plaintext.txt	283	24 1549 1557AbstractFree Full Text Schedin Weiss S
0.3398514.15583000.html.plaintext.txt	284	2004 Biochemistry 43 675 683CrossRefMedline Order article via Infotrieve Capila I
0.3398514.15583000.html.plaintext.txt	285	41 391 412Medline Order article via Infotrieve Olson S
0.3398514.15583000.html.plaintext.txt	286	266 6342 6352AbstractFree Full Text Hileman R
0.3398514.15583000.html.plaintext.txt	287	1998 Biochemistry 37 15231 15237CrossRefMedline Order article via Infotrieve Lalazar A
0.3398514.15583000.html.plaintext.txt	288	263 3542 3545AbstractFree Full Text Raussens V
0.3398514.15583000.html.plaintext.txt	289	277 29172 29180AbstractFree Full Text Prevost M
0.3398514.15583000.html.plaintext.txt	290	2004 Proteins 55 874 884CrossRefMedline Order article via Infotrieve Lund Katz S
0.3398514.15583000.html.plaintext.txt	291	42 894 901AbstractFree Full Text Fromm J
0.3398514.15583000.html.plaintext.txt	292	323 279 287CrossRefMedline Order article via Infotrieve Pitas R
0.3398514.15583000.html.plaintext.txt	293	76 2311 2315Abstract Pitas R
0.3398514.15583000.html.plaintext.txt	294	255 5454 5460Free Full Text Wilsie L
0.3398514.15583000.html.plaintext.txt	295	278 15758 15764AbstractFree Full Text Berg O
0.3398514.15583000.html.plaintext.txt	296	1991 Biochemistry 30 7283 7297Medline Order article via Infotrieve This Article Abstract Full Text PDF All Versions Article 28075414 recent M411719200v1 Purchase Article View Shopping Cart Alert article cited Alert correction posted Citation Map Services Email article friend Similar articles journal Similar articles PubMed Alert new issues journal Download citation manager Copyright Permissions Google Scholar Articles Futamura M
0.3398514.15583000.html.plaintext.txt	297	Articles citing Article PubMed PubMed Citation Articles Futamura M
0.3398514.15583000.html.plaintext.txt	298	HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS All ASBMB Journals Molecular Cellular Proteomics Journal Lipid Research Biochemistry Molecular Biology Education Copyright 2005 American Society Biochemistry Molecular Biology
0.37081465.15229191.html.plaintext.txt	0	Independent effects APOE cholesterol metabolism brain Ass levels Alzheimer disease mouse model Karen M
0.37081465.15229191.html.plaintext.txt	1	Thorngate3 Yuko Katoh Fukui4 Hiroki Hamanaka5 David L
0.37081465.15229191.html.plaintext.txt	2	Williams3 Shinobu Fujita6 Bruce T
0.37081465.15229191.html.plaintext.txt	3	1Department Genetics Case Western Reserve University Cleveland OH 44106 USA 2Center Human Genetics University Memory Aging Center Ireland Cancer Center University Hospitals Cleveland Cleveland OH 44106 USA 3Department Pharmacological Sciences University Medical Center Stony Brook University Stony Brook NY 11794 USA 4Department Developmental Biology National Institute Basic Biology Myodaiji cho Okazaki 444 8585 Japan 5Center Neural Science New York University New York NY 10003 6621 USA 6Mitsubishi Kagaku Institute Life Sciences Machida Tokyo Japan
0.37081465.15229191.html.plaintext.txt	4	Received March 30 2004 Accepted June 15 2004
0.37081465.15229191.html.plaintext.txt	5	ABSTRACT TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES The APOE 4 allele significant genetic risk factor associated Alzheimers disease date
0.37081465.15229191.html.plaintext.txt	6	Epidemiological studies demonstrated inheritance one 4 alleles affects age onset severity pathology development
0.37081465.15229191.html.plaintext.txt	7	Dosage APOE 2 3 alleles however appear protective effects 4
0.37081465.15229191.html.plaintext.txt	8	Although much biology APOE peripheral cholesterol metabolism understood role brain cholesterol metabolism impact AD development less defined
0.37081465.15229191.html.plaintext.txt	9	Several APOE transgenic models generated study effects APOE alleles APP processing Ass pathology
0.37081465.15229191.html.plaintext.txt	10	However models potential limitations confound understanding effects apolipoprotein E APOE levels cholesterol metabolism disease development
0.37081465.15229191.html.plaintext.txt	11	To circumvent limitations taken genomic based approach better understand relationship APOE alleles cholesterol Ass metabolism
0.37081465.15229191.html.plaintext.txt	12	We characterized APOE knock mice express human allele endogenous regulatory elements defined C57BL6J background
0.37081465.15229191.html.plaintext.txt	13	These mice significantly different serum cholesterol levels steady state brain APOE levels yet equivalent brain cholesterol levels
0.37081465.15229191.html.plaintext.txt	14	However presence human APOE significantly increases brain Ass levels genomic based model AD irrespective genotype
0.37081465.15229191.html.plaintext.txt	15	These data indicate independent role APOE cholesterol metabolism periphery relative CNS altered levels cholesterol APOE mice insufficient influence Ass metabolism mouse model Alzheimers disease
0.37081465.15229191.html.plaintext.txt	16	INTRODUCTION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Apolipoprotein E APOE functions lipid chaperone facilitates cellular uptake cholesterol lipoproteins receptor mediated endocytosis
0.37081465.15229191.html.plaintext.txt	17	The APOE gene located human chromosome 19q13
0.37081465.15229191.html.plaintext.txt	18	2 polymorphic locus represented three common alleles 2 3 4
0.37081465.15229191.html.plaintext.txt	19	These three alleles encode three APOE isoforms 34 kDa differ amino acid positions 112 158
0.37081465.15229191.html.plaintext.txt	20	These two amino acid substitutions confer slightly different functions respective proteins
0.37081465.15229191.html.plaintext.txt	21	The E2 isoform encoded 2 allele contains Cys position 158 comparison Arg found E3 E4 isoforms
0.37081465.15229191.html.plaintext.txt	22	The substitution Cys Arg alters positive ion potential within receptor binding domain thus decreases affinity E2 protein LDL receptor 1 normal binding capacity 12
0.37081465.15229191.html.plaintext.txt	23	Consequently level circulating E2 protein significantly higher E3
0.37081465.15229191.html.plaintext.txt	24	In contrast level E4 protein significantly lower E3 presumably consequence isoform specific differences lipid binding uptake
0.37081465.15229191.html.plaintext.txt	25	The ability APOE bind receptors include LDLr LRP VLDLr megalin members LDL receptor family dictates efficiency molecules delivered appropriate cells turned
0.37081465.15229191.html.plaintext.txt	26	APOE 4 first shown association studies genetic risk factor cardiovascular disease presumably role conferring high circulating cholesterol levels mainly form LDL individuals one copies allele 34
0.37081465.15229191.html.plaintext.txt	27	Subsequently APOE 4 found associated increased risk late onset Alzheimers disease LOAD 56
0.37081465.15229191.html.plaintext.txt	28	Furthermore presence one 4 alleles decreases age disease onset much 10 years 7
0.37081465.15229191.html.plaintext.txt	29	One hypothesis link APOE genotype cardiovascular disease AD involves contribution cholesterol homeostasis diseases role APOE process
0.37081465.15229191.html.plaintext.txt	30	Several studies implicated role cholesterol production Ass primary constituent senile plaques AD brain 8 12
0.37081465.15229191.html.plaintext.txt	31	High serum cholesterol levels mice transgenic APP precursor protein Ass peptide correlate increased brain Ass levels severe plaque load 1314
0.37081465.15229191.html.plaintext.txt	32	Retrospective epidemiological studies demonstrated decreased AD risk human populations statin therapy lower cholesterol levels reviewed 15 although effect may indirect several studies shown statins alter Ass levels serum 1617
0.37081465.15229191.html.plaintext.txt	33	Several studies reported association elevated serum cholesterol levels AD risk levels Ass 1819 independent APOE genotype
0.37081465.15229191.html.plaintext.txt	34	Other studies however failed demonstrate correlation serum cholesterol levels AD development 20
0.37081465.15229191.html.plaintext.txt	35	APOE 4 may affect AD risk conferring high cholesterol levels thereby increasing Ass production
0.37081465.15229191.html.plaintext.txt	36	AD patients 4 allele increased levels Ass1 40 brains CSF extensive plaque pathology 2122
0.37081465.15229191.html.plaintext.txt	37	Interestingly 2 allele confers low cholesterol levels also considered protective AD development 7
0.37081465.15229191.html.plaintext.txt	38	Several APOE transgenic mouse models generated efforts gain insight role APOE AD 23 26
0.37081465.15229191.html.plaintext.txt	39	These models utilize various promoters drive expression human APOE cDNAs neurons glia
0.37081465.15229191.html.plaintext.txt	40	This approach several limitations concerning regulation APOE brain periphery
0.37081465.15229191.html.plaintext.txt	41	First APOE transgenic studies attempted normalize APOE levels APOE 3 4 transgenic lines respect 23 endogenous levels 24
0.37081465.15229191.html.plaintext.txt	42	However several human studies suggest levels APOE vary genotype may impact AD pathogenesis
0.37081465.15229191.html.plaintext.txt	43	Second APOE transgenic lines bred onto Apoe null background confers high circulating cholesterol levels
0.37081465.15229191.html.plaintext.txt	44	Given role Apoe peripheral cholesterol metabolism growing evidence cholesterol levels influencing brain Ass metabolism unclear absence Apoe affects AD pathology animals
0.37081465.15229191.html.plaintext.txt	45	Importantly consensus impact APOE genotype AD pathogenesis studies perhaps owing complications different promoters altered levels APOE brain combined complications mixed genetic background models
0.37081465.15229191.html.plaintext.txt	46	APOE knock KI mice provide unique model understanding APOE allele behaves development Alzheimers disease
0.37081465.15229191.html.plaintext.txt	47	We obtained mice previously published Hamanaka et al
0.37081465.15229191.html.plaintext.txt	48	27 order characterize behavior human APOE alleles defined genetic background
0.37081465.15229191.html.plaintext.txt	49	We present APOE protein abundance cholesterol lipoprotein data young animals expressing APOE 2 3 4 defined C57BL6J background
0.37081465.15229191.html.plaintext.txt	50	We demonstrate significant differences protein abundance mirrors human data well significant differences serum cholesterol levels absence effect APP processing
0.37081465.15229191.html.plaintext.txt	51	The presence APOE significantly increases levels Ass cholesterol brain irrespective allele
0.37081465.15229191.html.plaintext.txt	52	This genomic based mouse model provides evidence neither cholesterol levels APOE abundance alone sufficient influence Ass metabolism young animals
0.37081465.15229191.html.plaintext.txt	53	RESULTS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Generation genetically defined APOE KI mice The APOE 4 allele significant genetic risk factor Alzheimers disease identified date Much work done mouse understand different alleles APOE affect onset development pathology AD mouse model however transgenic models several limitations confound study APOE gene regulation gene function mouse models AD
0.37081465.15229191.html.plaintext.txt	54	To circumvent limitations took advantage APOE KI animals generated Mitsubishi Kagaku Institute Life Science Japan 27
0.37081465.15229191.html.plaintext.txt	55	The targeted allele placed human cDNA APOE allele frame endogenous exon 1 sequence part exon 2
0.37081465.15229191.html.plaintext.txt	56	This allowed control human APOE expression endogenous regulatory elements time removing mouse Apoe coding sequence
0.37081465.15229191.html.plaintext.txt	57	APOE 4 KI mice generated strategy previously published 27
0.37081465.15229191.html.plaintext.txt	58	It demonstrated human APOE mice expressed serum astrocytes correct histological pattern
0.37081465.15229191.html.plaintext.txt	59	The APOE KI mice originally maintained mixed C57BL6129P2 background contained neo selection cassette targeted allele
0.37081465.15229191.html.plaintext.txt	60	Work lab others demonstrated genetic background greatly influence phenotypic expression particularly regards Ass generation deposition 28
0.37081465.15229191.html.plaintext.txt	61	In addition several lines evidence shown strong promoter neo influence expression targeted locus well neighboring genes 2930
0.37081465.15229191.html.plaintext.txt	62	For reasons APOE KI lines backcrossed onto defined C57BL6J B6 inbred background also mated ZP3 cre transgenic mice congenic B6 background 31 remove neo cassette cre mediated loxP excision
0.37081465.15229191.html.plaintext.txt	63	The cre transgene transferred onto APOE KI background expression cre mouse oocytes APOE KI females excised floxed neo cassette targeted allele
0.37081465.15229191.html.plaintext.txt	64	These females mated B6 males resulting offspring inherited targeted allele lacking neo tag demonstrated polymerase chain reaction PCR assay using primers neo Southern blot data shown
0.37081465.15229191.html.plaintext.txt	65	Animals lacking cre transgene identified subsequent progeny
0.37081465.15229191.html.plaintext.txt	66	Once APOE KI line backcrossed five generations N5 incipient congenic 98 homogeneous 32 animals intercrossed obtain populations APOE 22 33 44 mice hereafter referred 2 KI 3 KI 4 KI respectively
0.37081465.15229191.html.plaintext.txt	67	Animals PCR genotyped basis presence human APOE using human specific primers absence endogenous Apoe locus demonstrated PCR using mouse Apoe specific primers data shown
0.37081465.15229191.html.plaintext.txt	68	These mice characterized 6 8 weeks age variety parameters order understand APOE allele behaves mouse respect steady state protein levels cholesterol metabolism impacts APP processing Ass metabolism
0.37081465.15229191.html.plaintext.txt	69	Protein abundance APOE KI mice The levels steady state APOE brain liver serum three KI mouse lines determined western blot analysis using human specific APOE antibody
0.37081465.15229191.html.plaintext.txt	70	Parallel western blots recombinant E2 E3 E4 serial dilutions 6
0.37081465.15229191.html.plaintext.txt	71	5 25 50 microg protein run determine affinity antibody isoform
0.37081465.15229191.html.plaintext.txt	72	Standard curves fluorescent units isoform revealed little difference detection
0.37081465.15229191.html.plaintext.txt	73	E4 appeared detected slightly less well data shown
0.37081465.15229191.html.plaintext.txt	74	Levels APOE protein KI animal compared standard homogenate serum standard homozygous 3 KI animal
0.37081465.15229191.html.plaintext.txt	75	Figure 1 illustrates differences APOE levels compared across lines ratio steady state levels sample relative standard
0.37081465.15229191.html.plaintext.txt	76	APOE 2 KI animals average 2 fold higher steady state level APOE brain fasted liver compared 3 KI 4 KI animals Fig
0.37081465.15229191.html.plaintext.txt	77	All three lines significantly different levels APOE brain
0.37081465.15229191.html.plaintext.txt	78	Levels steady state APOE brain confirmed human specific APOE ELISA using standard curve recombinant E2 E3 E4 quantitate levels isoform
0.37081465.15229191.html.plaintext.txt	79	2 KI animals demonstrated 2 fold increase level brain APOE method well P 0
0.37081465.15229191.html.plaintext.txt	80	001 although E3 E4 significantly different
0.37081465.15229191.html.plaintext.txt	81	The difference shown western blotting 3 4 lines may explained slightly lower affinity antibody recombinant E4
0.37081465.15229191.html.plaintext.txt	82	The level APOE fasted serum 2 KI animals also significantly higher found 3 KI 4 KI animals western blotting Fig
0.37081465.15229191.html.plaintext.txt	83	The relationship genotype APOE levels KI mice recapitulates observed human serum 33 35
0.37081465.15229191.html.plaintext.txt	84	View larger version 25K Figure 1
0.37081465.15229191.html.plaintext.txt	85	Analysis APOE abundance APOE KI animals
0.37081465.15229191.html.plaintext.txt	86	Relative levels APOE brain fasted liver fasted serum APOE KI lines assayed males females 6 8 weeks age
0.37081465.15229191.html.plaintext.txt	87	Protein extracts brain fasted liver made 1 CHAPS protease inhibitors
0.37081465.15229191.html.plaintext.txt	88	APOE levels brain A n8 fasted liver B n8 fasted serum D n6 assayed western blot analysis using human specific APOE antibody Calbiochem
0.37081465.15229191.html.plaintext.txt	89	APOE quantitation expressed ratio APOE abundance sample relative standard total protein concentration
0.37081465.15229191.html.plaintext.txt	90	2 KI APOE levels significantly increased brain A fasted liver B P 0
0.37081465.15229191.html.plaintext.txt	91	001 one factor ANOVA post Tukey compared 3 KI 4 KI levels
0.37081465.15229191.html.plaintext.txt	92	2 KI APOE levels also significantly increased fasted serum D P 0
0.37081465.15229191.html.plaintext.txt	93	01 one factor ANOVA followed Dunns post test
0.37081465.15229191.html.plaintext.txt	94	3 KI levels brain significantly increased 4 KI levels P 0
0.37081465.15229191.html.plaintext.txt	95	01 one factor ANOVA post Tukey
0.37081465.15229191.html.plaintext.txt	96	A representative western blot APOE abundance brain fasted liver C demonstrates relative 4 fold increase APOE liver versus brain 2 fold higher levels 2 KI homogenates compared 3 KI 4 KI homogenates
0.37081465.15229191.html.plaintext.txt	97	APOE brain levels also measured human specific ELISA E 2 KI levels significantly increased 3 KI 4 KI levels P 0
0.37081465.15229191.html.plaintext.txt	98	001 one factor ANOVA post Tukey
0.37081465.15229191.html.plaintext.txt	99	Cholesterol metabolism APOE KI mice To examine allele affects cholesterol metabolism mouse serum cholesterol triglyceride levels measured 6 h fast using enzymatic assay
0.37081465.15229191.html.plaintext.txt	100	Analysis cholesterol levels 20 animals genotype mixed sex demonstrated inverse relationship genotype phenotype relative human data
0.37081465.15229191.html.plaintext.txt	101	The 2 KI animals highest cholesterol mean 234 mgdl triglycerides mean 115 mgdl
0.37081465.15229191.html.plaintext.txt	102	In contrast 4 KI animals lowest cholesterol mean 67 mgdl whereas 3 KI animals significantly differ B6 wild type animals Table 1
0.37081465.15229191.html.plaintext.txt	103	Triglyceride levels 3 KI 4 KI B6 animals statistically indistinguishable
0.37081465.15229191.html.plaintext.txt	104	Fasted serum cholesterol triglyceride levels APOE genotype To understand different APOE isoforms participate peripheral cholesterol metabolism mouse generated lipoprotein profiles FPLC KI line
0.37081465.15229191.html.plaintext.txt	105	The distribution APOE cholesterol analyzed profile
0.37081465.15229191.html.plaintext.txt	106	Fasted serum three animals sex pooled analysis genotype sex difference apparent data shown
0.37081465.15229191.html.plaintext.txt	107	The profiles genotype shown Figure 2
0.37081465.15229191.html.plaintext.txt	108	APOE 3 KI 4 KI profiles differ B6 wild type animals majority circulating cholesterol found HDL fraction whereas VLDL LDLIDL fractions minimal
0.37081465.15229191.html.plaintext.txt	109	In contrast 2 KI profiles demonstrated although levels HDL cholesterol remained equal found lines cholesterol distribution extended LDLIDL fraction highest level VLDL fraction
0.37081465.15229191.html.plaintext.txt	110	Thus increased total cholesterol levels 2 KI mice due increase VLDL LDLIDL cholesterol
0.37081465.15229191.html.plaintext.txt	111	View larger version 25K Figure 2
0.37081465.15229191.html.plaintext.txt	112	FPLC analysis lipoprotein profiles APOE KI animals
0.37081465.15229191.html.plaintext.txt	113	Fasted serum three animals sex APOE line pooled fractionated FPLC Superose 6 column
0.37081465.15229191.html.plaintext.txt	114	FPLC profiles generated males females line two separate experiments representative results shown figure
0.37081465.15229191.html.plaintext.txt	115	The VLDL peak around 20 min A B6 endogenous Apoe Apoewt B 4 KI C 3 KI profiles contains little cholesterol compared VLDL fraction D 2 KI profile
0.37081465.15229191.html.plaintext.txt	116	The large peak 40 min represents HDL fraction cholesterol levels four groups relatively equal fraction
0.37081465.15229191.html.plaintext.txt	117	E The distribution APOE lipoprotein fractions analyzed western blot analysis using human specific APOE antibody Calbiochem
0.37081465.15229191.html.plaintext.txt	118	Five fractions lipoprotein peak pooled equal volumes combined fractions loaded lane representative western blot APOE abundance shown
0.37081465.15229191.html.plaintext.txt	119	The absence APOE VLDL fractions Apoewt 3 KI 4 KI distinct compared abundance APOE 2 KI profile
0.37081465.15229191.html.plaintext.txt	120	The majority APOE 4 KI profile found HDL fraction contrast 3 KI Apoewt profiles show majority APOE Apoe LDLIDL fraction
0.37081465.15229191.html.plaintext.txt	121	The distribution APOE protein lipoprotein fraction determined western blot analysis
0.37081465.15229191.html.plaintext.txt	122	Five fractions lipoprotein class including peak fraction pooled run conditions APOE quantitation tissues
0.37081465.15229191.html.plaintext.txt	123	The resulting data shown Figure 2E
0.37081465.15229191.html.plaintext.txt	124	No APOE detected VLDL fractions 3 KI 4 KI non transgenic control profiles reflected low levels cholesterol fraction
0.37081465.15229191.html.plaintext.txt	125	Levels APOE highest LDLIDL fraction followed HDL fraction
0.37081465.15229191.html.plaintext.txt	126	4 KI profiles demonstrated highest levels APOE HDL fraction
0.37081465.15229191.html.plaintext.txt	127	This may reflect preferential binding E4 larger lipoproteins mouse plasma enriched large Apoe rich HDL absent normal human plasma 36
0.37081465.15229191.html.plaintext.txt	128	In contrast profiles high levels APOE observed fractions 2 KI profile consistent high levels cholesterol found distributed fractions
0.37081465.15229191.html.plaintext.txt	129	APP processing Ass metabolism brain cholesterol APOE KI mice To examine effects different APOE alleles APP biochemistry APOE KI mice crossed R1
0.37081465.15229191.html.plaintext.txt	130	40 APP transgenic line congenic B6 background
0.37081465.15229191.html.plaintext.txt	131	40 line YAC based transgenic model AD expresses APPSwe proper spatial temporal manner 37
0.37081465.15229191.html.plaintext.txt	132	40 transgenic animals display Ass deposition 13
0.37081465.15229191.html.plaintext.txt	133	APOE KI animals crossed R1
0.37081465.15229191.html.plaintext.txt	134	40 transgenic animals generate animals homozygous APOE allele hemizygous APP
0.37081465.15229191.html.plaintext.txt	135	Brains 28 day old APOEAPOE R1
0.37081465.15229191.html.plaintext.txt	136	40 animals subsequently denoted APOER1
0.37081465.15229191.html.plaintext.txt	137	utilized examine levels APP processing intermediates Ass
0.37081465.15229191.html.plaintext.txt	138	The levels APP holo protein C terminal fragments CTFs determined using 369 APP C terminal antibody
0.37081465.15229191.html.plaintext.txt	139	No differences holo APP observed lines Fig
0.37081465.15229191.html.plaintext.txt	140	In addition relative amount APP CTFs expressed ratio CTFsstotal CTFs determined APOER1
0.37081465.15229191.html.plaintext.txt	141	40 animals endogenous Apoe Fig
0.37081465.15229191.html.plaintext.txt	142	Despite significant differences serum cholesterol among three APOER1
0.37081465.15229191.html.plaintext.txt	143	4A difference ratios CTFsstotal CTFs
0.37081465.15229191.html.plaintext.txt	144	Likewise APP CTF ratios unchanged presence APOE Apoe animals 28 days age
0.37081465.15229191.html.plaintext.txt	145	View larger version 29K Figure 3
0.37081465.15229191.html.plaintext.txt	146	APP processing products analyzed 6 M urea homogenates half brains APOER1
0.37081465.15229191.html.plaintext.txt	147	Western blotting APP antibody 369 used assay levels holo APP CTFs APOER1
0.37081465.15229191.html.plaintext.txt	148	40 line n5 line well R1
0.37081465.15229191.html.plaintext.txt	149	40 animals endogenous Apoe n3
0.37081465.15229191.html.plaintext.txt	150	A representative western blot shown A
0.37081465.15229191.html.plaintext.txt	151	APP quantitation B expressed ratio APP abundance sample relative endogenous levels wild type extract total protein concentration
0.37081465.15229191.html.plaintext.txt	152	Analysis holo APP levels demonstrated difference lines P 0
0.37081465.15229191.html.plaintext.txt	153	Relative ratios CTFss total APP CTFs C unaffected APOE genotype P 0
0.37081465.15229191.html.plaintext.txt	154	05 one factor ANOVA four five animals per group
0.37081465.15229191.html.plaintext.txt	155	View larger version 20K Figure 4
0.37081465.15229191.html.plaintext.txt	156	Total cholesterol brain Ass1 40 levels APOER1
0.37081465.15229191.html.plaintext.txt	157	Measurements total cholesterol serum brain brain Ass levels obtained animals 28 days age
0.37081465.15229191.html.plaintext.txt	158	A Serum cholesterol assayed APOER1
0.37081465.15229191.html.plaintext.txt	159	40 animals endogenous Apoe colorimetric assay Thermotrace
0.37081465.15229191.html.plaintext.txt	160	The results confirmed APP transgene affect serum cholesterol metabolism
0.37081465.15229191.html.plaintext.txt	161	40 animals 2 fold higher levels total cholesterol 3R1
0.37081465.15229191.html.plaintext.txt	162	001 one factor ANOVA followed post Tukey
0.37081465.15229191.html.plaintext.txt	163	B Levels total brain cholesterol measured 6 M urea homogenates half brains colorimetic assay Thermotrace
0.37081465.15229191.html.plaintext.txt	164	The presence human APOE2 4 significantly increases brain cholesterol R1
0.37081465.15229191.html.plaintext.txt	165	40 brain cholesterol levels also elevated compared B6
0.37081465.15229191.html.plaintext.txt	166	40 animals although significant P 0
0.37081465.15229191.html.plaintext.txt	167	C Levels Ass1 40 brain measured 5 M guanidine extracts half brains ELISA Biosource significantly different APOER1
0.37081465.15229191.html.plaintext.txt	168	05 one factor ANOVA n8 line
0.37081465.15229191.html.plaintext.txt	169	40 lines significantly increased Ass1 40 levels compared B6
0.37081465.15229191.html.plaintext.txt	170	05 E4 versus B6 one factor ANOVA post Tukey
0.37081465.15229191.html.plaintext.txt	171	Levels serum cholesterol APOER1
0.37081465.15229191.html.plaintext.txt	172	40 line N8 backcross generation determined previously mentioned
0.37081465.15229191.html.plaintext.txt	173	Similar results absence R1
0.37081465.15229191.html.plaintext.txt	174	40 mice significantly higher cholesterol levels compared lines
0.37081465.15229191.html.plaintext.txt	175	40 animals slightly higher levels cholesterol relative 3
0.37081465.15229191.html.plaintext.txt	176	40 animals endogenous Apoe Fig
0.37081465.15229191.html.plaintext.txt	177	This difference compared data Table 1 N5 generation likely illustrates genetic background effect cholesterol metabolism 4 KI mice
0.37081465.15229191.html.plaintext.txt	178	Levels steady state Ass1 40 assessed ELISA half brain extracts
0.37081465.15229191.html.plaintext.txt	179	Given increased serum cholesterol conferred diet effectively increases Ass1 40 brain 14 expectation 2
0.37081465.15229191.html.plaintext.txt	180	40 animals serum cholesterol levels nearly twice 3
0.37081465.15229191.html.plaintext.txt	181	40 animals would greatest amount Ass1 40
0.37081465.15229191.html.plaintext.txt	182	However significant difference Ass1 40 levels three APOER1
0.37081465.15229191.html.plaintext.txt	183	These data suggest fundamental distinction genetic dietary control cholesterol levels effects Ass1 40 metabolism
0.37081465.15229191.html.plaintext.txt	184	Interestingly three APOER1
0.37081465.15229191.html.plaintext.txt	185	40 lines demonstrated significantly increased levels Ass1 40 relative B6
0.37081465.15229191.html.plaintext.txt	186	40 animals endogenous Apoe
0.37081465.15229191.html.plaintext.txt	187	Thus presence human APOE R1
0.37081465.15229191.html.plaintext.txt	188	40 line led increased Ass1 40 steady state levels 28 days age
0.37081465.15229191.html.plaintext.txt	189	Levels total brain cholesterol measured enzymatic assay normalized concentration protein extracted mg cholesterolmg protein
0.37081465.15229191.html.plaintext.txt	190	The average levels brain cholesterol 2
0.37081465.15229191.html.plaintext.txt	191	40 animals higher average brain cholesterol R1
0.37081465.15229191.html.plaintext.txt	192	40 animals endogenous Apoe Fig
0.37081465.15229191.html.plaintext.txt	193	This increase brain cholesterol APOER1
0.37081465.15229191.html.plaintext.txt	194	40 animals appeared coincide increased Ass1 40 levels suggesting link APOE brain cholesterol Ass metabolism
0.37081465.15229191.html.plaintext.txt	195	Despite high levels serum cholesterol 2
0.37081465.15229191.html.plaintext.txt	196	40 animals brain cholesterol levels indistinguishable 3
0.37081465.15229191.html.plaintext.txt	197	These cholesterol data lend evidence hypothesis peripheral brain cholesterol levels independently regulated
0.37081465.15229191.html.plaintext.txt	198	DISCUSSION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES The current study examines effects three common human APOE alleles APOE protein levels cholesterol metabolism APP processing Ass metabolism
0.37081465.15229191.html.plaintext.txt	199	We show APOE KI mice defined C57BL6J background significantly different levels APOE serum tissues well significantly different cholesterol levels
0.37081465.15229191.html.plaintext.txt	200	APOE increases Ass levels genomic based APP transgenic mouse absence changes APP processing
0.37081465.15229191.html.plaintext.txt	201	Unlike previously reported APOE transgenic models express normalized levels APOE brain genomic based approach allows us address two hypotheses surrounding role APOE 4 risk factor AD
0.37081465.15229191.html.plaintext.txt	202	APOE genotype AD risk humans correlate serum cholesterol levels steady state levels APOE protein
0.37081465.15229191.html.plaintext.txt	203	APOE 4 significant genetic risk factor AD associated high circulating cholesterol levels reduced steady state APOE levels
0.37081465.15229191.html.plaintext.txt	204	In contrast APOE 2 protective AD incidentally confers low serum cholesterol levels high levels APOE
0.37081465.15229191.html.plaintext.txt	205	Thus APOE may affect AD risk involvement cholesterol metabolism shown diet studies mouse directly affect Ass production
0.37081465.15229191.html.plaintext.txt	206	Alternatively brain APOE levels may influence clearance efficiency Ass peptide subsequent deposition
0.37081465.15229191.html.plaintext.txt	207	APOE abundance Much known APOE biology humans particularly role lipid metabolism
0.37081465.15229191.html.plaintext.txt	208	APOE primarily synthesized liver brain additional sites include adrenal gland kidney 3839
0.37081465.15229191.html.plaintext.txt	209	APOE genotype shown correlate APOE abundance periphery 3340 42 2 allele confers high APOE whereas 4 allele confers low APOE respect 3 levels
0.37081465.15229191.html.plaintext.txt	210	The effect APOE alleles APOE abundance brain CSF less clear owing conflicting reports many studies concentrating abundance APOE AD brains relative controls irrespective APOE genotype 354344
0.37081465.15229191.html.plaintext.txt	211	We demonstrate western blot analysis ELISA steady state levels APOE tissues serum three KI lines genotype dependent reflect human data serum APOE levels
0.37081465.15229191.html.plaintext.txt	212	2 KI animals significantly higher levels APOE tissues examined P 0
0.37081465.15229191.html.plaintext.txt	213	Our findings particularly data brain illustrate innate differences behavior three human APOE alleles mouse arguing relevance genomic based APOE model understanding APOE function
0.37081465.15229191.html.plaintext.txt	214	The differences brain APOE levels KI mice may important implications APOE influences pathology development AD mouse model
0.37081465.15229191.html.plaintext.txt	215	A recent report Sullivan et al
0.37081465.15229191.html.plaintext.txt	216	45 showing brain APOE levels genotype independent different set APOE KI animals contradicts data
0.37081465.15229191.html.plaintext.txt	217	However reported APOE lines contain neo cassette targeted allele may affect protein expression
0.37081465.15229191.html.plaintext.txt	218	An additional difference inclusion human APOE intron 1 targeted allele mice may contain additional endo genous regulatory elements
0.37081465.15229191.html.plaintext.txt	219	Further comparisons mice necessary determine innate differences two models
0.37081465.15229191.html.plaintext.txt	220	APOE cholesterol metabolism mice In addition protein levels show APOE genotype also impacts cholesterol levels periphery
0.37081465.15229191.html.plaintext.txt	221	The 4 KI animals fasted cholesterol levels slightly B6 wild type animals whereas 2 KI animals 2 fold higher cholesterol levels
0.37081465.15229191.html.plaintext.txt	222	The 3 KI B6 wild type cholesterol levels significantly differ
0.37081465.15229191.html.plaintext.txt	223	These data recapitulate shown APOE KI models 46 48 opposite findings humans 4 allele associated high 2 low cholesterol levels
0.37081465.15229191.html.plaintext.txt	224	These data highlight innate differences mouse human cholesterol metabolism include utilization different lipoproteins transport cholesterol
0.37081465.15229191.html.plaintext.txt	225	Our data also contrast initial report 4 KI mice Hamanaka et al
0.37081465.15229191.html.plaintext.txt	226	5 fold increase levels circulating cholesterol relative wild type controls
0.37081465.15229191.html.plaintext.txt	227	This discrepancy data may attributed several factors
0.37081465.15229191.html.plaintext.txt	228	The first perhaps notable difference genetic background two studies
0.37081465.15229191.html.plaintext.txt	229	Several lines evidence demonstrate strong genetic component cholesterol metabolism mouse 46 48
0.37081465.15229191.html.plaintext.txt	230	This complex trait involves genes work additive manner well epistatically 49
0.37081465.15229191.html.plaintext.txt	231	Our analysis cholesterol KI mice subsequent backcrosses argues background effects demonstrated comparing cholesterol levels 4
0.37081465.15229191.html.plaintext.txt	232	40 animals N8 backcross generation Table 1 versus Fig
0.37081465.15229191.html.plaintext.txt	233	Second KI mice report longer transmit neo cassette targeted allele
0.37081465.15229191.html.plaintext.txt	234	Although direct evidence suggest presence neo affects function APOE cholesterol metabolism mice cannot ruled
0.37081465.15229191.html.plaintext.txt	235	Finally differences diet methodology two studies may also impact reported cholesterol levels
0.37081465.15229191.html.plaintext.txt	236	Further characterization lipoprotein profiles reported 3 4 KI mice demonstrated majority cholesterol distributed HDL fraction similar B6 wild type animals
0.37081465.15229191.html.plaintext.txt	237	These data suggest presence human APOE 3 4 disrupt mouse cholesterol metabolism observation also made Maeda colleagues 50 52
0.37081465.15229191.html.plaintext.txt	238	Comparison profiles published Hamanaka et al
0.37081465.15229191.html.plaintext.txt	239	highlights distinction 4 KI model characterized
0.37081465.15229191.html.plaintext.txt	240	In contrast data Hamanaka et al
0.37081465.15229191.html.plaintext.txt	241	showed cholesterol distributed lipoprotein classes 4 KI mice including VLDL LDL
0.37081465.15229191.html.plaintext.txt	242	This profile actually similar 2 KI animals presented
0.37081465.15229191.html.plaintext.txt	243	These animals significantly higher cholesterol levels appear transport excess circulating cholesterol VLDL LDL fractions suggesting impaired cholesterol metabolism
0.37081465.15229191.html.plaintext.txt	244	The noted increase triglyceride levels 2 KI animals also suggests development type III hyperlipoproteinemia complex disorder characterized high cholesterol triglyceride levels affects 10 humans homozygous 2 allele 53
0.37081465.15229191.html.plaintext.txt	245	It suggested Sullivan et al
0.37081465.15229191.html.plaintext.txt	246	others 5154 condition manifests 2 KI mice owing presence additional genetic factors mouse genome interact 2 allele
0.37081465.15229191.html.plaintext.txt	247	Qualitative western blot analysis 3 4 KI FPLC profiles demonstrated behavior E3 mice maintained low cholesterol diet follows endogenous Apoe found mainly IDLLDL HDL fraction E4 appears enriched HDL fraction
0.37081465.15229191.html.plaintext.txt	248	This observation may reflect another difference mouse human cholesterol metabolism
0.37081465.15229191.html.plaintext.txt	249	The E4 isoform greater affinity large lipoproteins humans chylomicrons VLDL
0.37081465.15229191.html.plaintext.txt	250	E2 E3 hand prefer smaller lipoproteins primarily found associated HDL smallest lipoprotein class
0.37081465.15229191.html.plaintext.txt	251	Importantly mouse plasma enriched large Apoe rich HDL absent normal human plasma 36
0.37081465.15229191.html.plaintext.txt	252	It may E4 preference particles two isoforms
0.37081465.15229191.html.plaintext.txt	253	Our mice show enrichment APOE VLDL observed Maeda colleagues
0.37081465.15229191.html.plaintext.txt	254	This discrepancy data may explained differences genetic background diet
0.37081465.15229191.html.plaintext.txt	255	Further comparisons two sets APOE KI models including levels protein required thoroughly explain results
0.37081465.15229191.html.plaintext.txt	256	Cholesterol APP processing In order identify effects APOE allele APP processing Ass production particularly regard cholesterol metabolism APOE abundance crossed APOE KI animals R1
0.37081465.15229191.html.plaintext.txt	257	Several studies established link cholesterol APP processing 105556
0.37081465.15229191.html.plaintext.txt	258	13 demonstrated cholesterol influences cleavage APP beta secretase vivo hypercholesterolemia increasing CTFss levels
0.37081465.15229191.html.plaintext.txt	259	However neither levels holo APP CTFs altered APOER1
0.37081465.15229191.html.plaintext.txt	260	The lack effect APP processing 2 KI animals unexpected considering high serum cholesterol levels
0.37081465.15229191.html.plaintext.txt	261	Analysis Ass1 40 levels animals provided evidence serum cholesterol alone enough affect APP processing young age
0.37081465.15229191.html.plaintext.txt	262	Given strong evidence high cholesterol levels increasing Ass production 13 predicted 2 KI animals 2 fold increase total serum cholesterol would demonstrate much higher levels Ass 3 KI 4 KI mice
0.37081465.15229191.html.plaintext.txt	263	However similar CTF data levels Ass1 40 brain indistinguishable across lines
0.37081465.15229191.html.plaintext.txt	264	There several possible explanations results
0.37081465.15229191.html.plaintext.txt	265	First data present come 28 day old animals age post weaning prior sexual maturity
0.37081465.15229191.html.plaintext.txt	266	It possible ability cholesterol affect APP processing Ass metabolism time age dependent
0.37081465.15229191.html.plaintext.txt	267	Successful diet studies chronically fed mice high cholesterol diets several weeks 1314
0.37081465.15229191.html.plaintext.txt	268	Chronic exposure high serum cholesterol levels several weeks months may required affect Ass metabolism APOER140 animals
0.37081465.15229191.html.plaintext.txt	269	Assaying levels Ass1 40 older animals useful understand age component cholesterol effects APOE APP processing
0.37081465.15229191.html.plaintext.txt	270	Second show peripheral cholesterol metabolism affect CNS cholesterol regulation
0.37081465.15229191.html.plaintext.txt	271	Despite differences serum cholesterol three APOER1
0.37081465.15229191.html.plaintext.txt	272	40 lines described manuscript brain cholesterol levels indistinguishable animals
0.37081465.15229191.html.plaintext.txt	273	This finding supported large body evidence demonstrating cholesterol metabolism periphery fundamentally different independent central nervous system involving different lipoproteins apolipoproteins 57 59
0.37081465.15229191.html.plaintext.txt	274	This argues effect peripheral cholesterol processes brain
0.37081465.15229191.html.plaintext.txt	275	40 animals demonstrate significantly increased brain cholesterol levels R1
0.37081465.15229191.html.plaintext.txt	276	40 animals endogenous Apoe brain cholesterol levels E3
0.37081465.15229191.html.plaintext.txt	277	R140 animals also greater R1
0.37081465.15229191.html.plaintext.txt	278	40 although trend statistically significant
0.37081465.15229191.html.plaintext.txt	279	These data correspond significant increases brain Ass1 40 levels APOER1
0.37081465.15229191.html.plaintext.txt	280	40 animals suggesting brain cholesterol levels particular may significant impact Ass production
0.37081465.15229191.html.plaintext.txt	281	Notably one diet study increased brain cholesterol addition Ass levels 14
0.37081465.15229191.html.plaintext.txt	282	Our data argue independent roles APOE peripheral CNS cholesterol metabolism furthermore suggest distinction APOE endogenous Apoe effects murine brain cholesterol metabolism steady state Ass levels
0.37081465.15229191.html.plaintext.txt	283	APOE Alzheimers disease This manuscript highlights first report APOE mouse model utilizes endogenous regulation study native APOE levels cholesterol metabolism relation Alzheimers disease
0.37081465.15229191.html.plaintext.txt	284	Importantly correlation APOE genotype APOE steady state levels cholesterol metabolism observed humans uncoupled KI mice
0.37081465.15229191.html.plaintext.txt	285	This allows us dissect two aspects APOE function may impact development AD cholesterol metabolism Ass clearance
0.37081465.15229191.html.plaintext.txt	286	APOE abundance brains 4 KI animals low animals normal serum cholesterol levels
0.37081465.15229191.html.plaintext.txt	287	These animals allow us study effects low APOE levels absence high cholesterol often observed humans inherit 4 allele
0.37081465.15229191.html.plaintext.txt	288	Likewise 2 KI animals high serum cholesterol high brain APOE levels
0.37081465.15229191.html.plaintext.txt	289	These animals useful determine effects high cholesterol independent low APOE levels
0.37081465.15229191.html.plaintext.txt	290	Future experiments assess effects age diet APOER1
0.37081465.15229191.html.plaintext.txt	291	40 lines cholesterol metabolism particularly brain APOE abundance well Ass metabolism amyloid deposition
0.37081465.15229191.html.plaintext.txt	292	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Mice The original stocks APOE 2 3 4 KI animals produced Mitsubishi Kagaku Institute Life Sciences 4 KI animals previously published 27
0.37081465.15229191.html.plaintext.txt	293	APOE characterization male KI animals line backcrossed two generations onto C57BL6J background
0.37081465.15229191.html.plaintext.txt	294	Male progeny N2 generation crossed Zp3 cre transgenic animals congenic C57BL6J background 31
0.37081465.15229191.html.plaintext.txt	295	Female progeny cross N3 generation selected basis presence human APOE Zp3 cre transgene
0.37081465.15229191.html.plaintext.txt	296	An additional backcross animals yielded progeny N4 generation selected basis presence APOE absence neo cassette targeted allele
0.37081465.15229191.html.plaintext.txt	297	Males cross backcrossed N5 animals intercrossed obtain homozygous KI animals allele
0.37081465.15229191.html.plaintext.txt	298	These animals used characterization studies human APOE mouse longer carried ZP3 cre transgene
0.37081465.15229191.html.plaintext.txt	299	For analysis APP processing Ass metabolism APOE KI animals backcrossed N7 generation crossed B6
0.37081465.15229191.html.plaintext.txt	300	R140 APP transgenic mice congenic C57BL6J background subsequent progeny intercrossed obtain mice homozygous APOE hemizygous APP transgene
0.37081465.15229191.html.plaintext.txt	301	All mice maintained normal chow diet LabDiets 5021 9
0.37081465.15229191.html.plaintext.txt	302	5 fat accordance IACUC regulations
0.37081465.15229191.html.plaintext.txt	303	Cholesterol triglyceride measurements Serum cholesterol triglyceride measurements obtained animals fasted 6 h retro ortbital sinus bleed
0.37081465.15229191.html.plaintext.txt	304	Measurements obtained using Infinity Cholesterol reagent Infinity Triglyceride reagent respectively Thermotrace Arlington TX USA according manufacturers instructions
0.37081465.15229191.html.plaintext.txt	305	Brain cholesterol hemispheres extracted homogenization 6 M urea buffer 6 M urea 100 mM Tris pH 7
0.37081465.15229191.html.plaintext.txt	306	5 M AEBSF 1 SDS reported Levin Allerhand et al
0.37081465.15229191.html.plaintext.txt	307	Brain cholesterol measured using Inifinity Cholesterol reagent Thermotrace diluting homogenates 1 1 PBS
0.37081465.15229191.html.plaintext.txt	308	Brain cholesterol concentrations expressed mg cholesterol relative mg protein measured BCA assay Pierce Rockford IL USA
0.37081465.15229191.html.plaintext.txt	309	FPLC For analysis lipoprotein profiles cholesterol distribution APOE KI animals fasted serum three animals genotype sex pooled fractionation Superose 6 column Pharmacia Kalamazoo MI USA previously described 60
0.37081465.15229191.html.plaintext.txt	310	Western blot analysis For analysis APOE levels tissues brain liver homogenates prepared 1 CHAPS protease inhibitors 1 microM pepstatin 4
0.37081465.15229191.html.plaintext.txt	311	5 microgml leupeptin 30 microgml aprotinin 1 mM AEBSF
0.37081465.15229191.html.plaintext.txt	312	Brain fasted liver homogenates run 4 12 Bis Tris gradient gels Invitrogen Carlsbad CA USA reducing conditions according manufacturers instructions
0.37081465.15229191.html.plaintext.txt	313	Equal concentrations protein determined BCA assay loaded every gel
0.37081465.15229191.html.plaintext.txt	314	A linear standard curve serially diluted control 3 KI known concentration run every gel normalize across gels R20
0.37081465.15229191.html.plaintext.txt	315	Protein transferred Immobilon p membranes Millipore Bedford MA USA probed anti human polyclonal APOE antibody Calbiochem LaJolla CA USA followed HRP conjugated secondary antibody detected using ECL Pierce film
0.37081465.15229191.html.plaintext.txt	316	This APOE antibody used extensively detect human APOE mouse immunohistochemistry western blotting ELISA 26465152
0.37081465.15229191.html.plaintext.txt	317	APOE protein levels serum tissue quantitated calculating intensity sample relative standard concentration
0.37081465.15229191.html.plaintext.txt	318	ImageQuant software used analysis protein abundance
0.37081465.15229191.html.plaintext.txt	319	The levels APOE unfractionated serum determined loading equal concentrations protein fasted serum samples diluted PBS onto Bis Tris gels non reducing conditions following analytical paradigm tissues
0.37081465.15229191.html.plaintext.txt	320	APOE serum fractionated FPLC analyzed qualitatively combining equal volumes peak fraction 2 volumes lipoprotein class
0.37081465.15229191.html.plaintext.txt	321	APOE detected using human specific APOE antibody visualized ECL using film
0.37081465.15229191.html.plaintext.txt	322	The relative levels holo APP determined using brain homogenates prepared 6 M urea mentioned earlier
0.37081465.15229191.html.plaintext.txt	323	Equal concentrations protein every sample loaded onto 7 Tris acetate gels Invitrogen run according manufacturers instructions
0.37081465.15229191.html.plaintext.txt	324	A linear standard curve serially diluted homogenate B6 non transgenic animal run every gel normalize across gels R20
0.37081465.15229191.html.plaintext.txt	325	Protein transferred mentioned earlier membranes probed C terminal antibody human APP 369 gift Sam Gandy Thomas Jefferson University
0.37081465.15229191.html.plaintext.txt	326	The intensity APP protein band determined ECL detected using Fluor S Max imaging machine BioRad Hercules CA USA quantitated Quantity one software BioRad
0.37081465.15229191.html.plaintext.txt	327	APP CTFs determined extracts run 4 12 Bis Tris gradient gels mentioned earlier using 369 antibody
0.37081465.15229191.html.plaintext.txt	328	Quantitation carried film mentioned earlier
0.37081465.15229191.html.plaintext.txt	329	ELISA Levels human APOE brain measured human specific APOE ELISA MBL International according manufacturers instructions
0.37081465.15229191.html.plaintext.txt	330	Homogenates made 1 CHAPS mentioned earlier run duplicate detected using Pan APOE antibody
0.37081465.15229191.html.plaintext.txt	331	Standard curves recombinant E2 E3 E4 run duplicate plate
0.37081465.15229191.html.plaintext.txt	332	Levels APOE determined using standard curve respective isoform
0.37081465.15229191.html.plaintext.txt	333	Levels Ass1 40 measured human specific Ass1 40 ELISA Biosource International according manufacturers instructions
0.37081465.15229191.html.plaintext.txt	334	Half brains homogenized 5 M guanidine 100 mM Tris pH 8
0.37081465.15229191.html.plaintext.txt	335	0 incubated room temperature 3
0.37081465.15229191.html.plaintext.txt	336	5 4 h ensure complete protein extraction
0.37081465.15229191.html.plaintext.txt	337	Samples diluted standardsample buffer centrifuged loaded triplicate onto ELISA plate
0.37081465.15229191.html.plaintext.txt	338	Statistics Statistical analysis carried using Prism Graphpad software San Diego CA USA
0.37081465.15229191.html.plaintext.txt	339	The specific test used analysis indicated appropriate figure legend
0.37081465.15229191.html.plaintext.txt	340	ACKNOWLEDGEMENTS The authors acknowledge Minesuke Yokoyama Rika Migishima Yoshiko Motegi Yoko Nakahara Aya Takeshita Mariko Kobayashi involved initial generation APOE 2 3 4 KI animals
0.37081465.15229191.html.plaintext.txt	341	We thank Sam Gandy Thomas Jefferson University providing 369 APP antibody Barbara Knowles Jackson Labs Zp3 Cre animals
0.37081465.15229191.html.plaintext.txt	342	We also thank Ireland Cancer Center University Hospitals Cleveland Ohio use equipment
0.37081465.15229191.html.plaintext.txt	343	This work supported part NIH training grant GM08613 K
0.37081465.15229191.html.plaintext.txt	344	NIH grant R01 AG14451 Alzheimers Association grant IIRG 02 3750 American Health Assistance Founding Grant B
0.37081465.15229191.html.plaintext.txt	345	University Memory Aging Center P50 AG08012 Ireland Cancer Center CA 43703 NIH grant R01 HL32868 D
0.37081465.15229191.html.plaintext.txt	346	FOOTNOTES To correspondence addressed Department Genetics Case Western Reserve University 10900 Euclid Avenue Cleveland OH 44106 4955 USA
0.37081465.15229191.html.plaintext.txt	347	Tel 1 2163682979 Fax 1 2163683432 Email btlatcwru
0.37081465.15229191.html.plaintext.txt	348	REFERENCES TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Weisgraber K
0.37081465.15229191.html.plaintext.txt	349	1982 Abnormal lipoprotein receptor binding activity human E apoprotein due cysteine arginine interchange single site
0.37081465.15229191.html.plaintext.txt	350	1996 Novel mechanism defective receptor binding apolipoprotein E2 type III hyperlipoproteinemia
0.37081465.15229191.html.plaintext.txt	351	1983 Apolipoprotein E polymorphism coronary artery disease
0.37081465.15229191.html.plaintext.txt	352	Arteriosclerosis 3 310 315
0.37081465.15229191.html.plaintext.txt	353	1995 Apolipoprotein E polymorphism predicts death coronary heart disease longitudinal study elderly Finnish men
0.37081465.15229191.html.plaintext.txt	354	1993 Gene dose apolipoprotein E type 4 allele risk Alzheimers disease late onset families
0.37081465.15229191.html.plaintext.txt	355	1993 Apolipoprotein E high avidity binding beta amyloid increased frequency type 4 allele late onset familial Alzheimer disease
0.37081465.15229191.html.plaintext.txt	356	1994 Protective effect apolipoprotein E type 2 allele late onset Alzheimer disease
0.37081465.15229191.html.plaintext.txt	357	1996 Cholesterol modulates alpha secretase cleavage amyloid precursor protein
0.37081465.15229191.html.plaintext.txt	358	1999 The role cholesterol biosynthesis beta amyloid
0.37081465.15229191.html.plaintext.txt	359	1998 Cholesterol depletion inhibits generation beta amyloid hippocampal neurons
0.37081465.15229191.html.plaintext.txt	360	2002 Inhibition intracellular cholesterol transport alters presenilin localization amyloid precursor protein processing neuronal cells
0.37081465.15229191.html.plaintext.txt	361	2002 Cholesterol dependent gamma secretase activity buoyant cholesterol rich membrane microdomains
0.37081465.15229191.html.plaintext.txt	362	2000 Hypercholesterolemia accelerates Alzheimers amyloid pathology transgenic mouse model
0.37081465.15229191.html.plaintext.txt	363	2002 Increased amyloid levels APPSWE transgenic mice treated chronically physiological high fat high cholesterol diet
0.37081465.15229191.html.plaintext.txt	364	2002 Relation cholesterol levels statins Alzheimers disease human population
0.37081465.15229191.html.plaintext.txt	365	2003 Pravastatin 10 mgday decrease plasma levels either amyloid beta Abeta 40 Abeta 42 humans
0.37081465.15229191.html.plaintext.txt	366	2001 Plasma levels amyloid beta proteins differ subjects taking statins taking statins
0.37081465.15229191.html.plaintext.txt	367	2003 Mild hypercholesterolemia early risk factor development Alzheimer amyloid pathology
0.37081465.15229191.html.plaintext.txt	368	1998 Elevated low density lipoprotein Alzheimers disease correlates brain abeta 1 42 levels
0.37081465.15229191.html.plaintext.txt	369	2003 Plasma total cholesterol level risk factor Alzheimer disease Framingham Study
0.37081465.15229191.html.plaintext.txt	370	1997 Preferential deposition amyloid beta protein Abeta form Abeta40 Alzheimers disease associated gene dosage effect apolipoprotein E E4 allele
0.37081465.15229191.html.plaintext.txt	371	2000 Effect apolipoprotein E allele epsilon4 initial phase amyloid beta protein accumulation human brain
0.37081465.15229191.html.plaintext.txt	372	2001 Human apolipoprotein E4 accelerates beta amyloid deposition APPsw transgenic mouse brain
0.37081465.15229191.html.plaintext.txt	373	1999 Expression human apolipoprotein E reduces amyloid beta deposition mouse model Alzheimers disease
0.37081465.15229191.html.plaintext.txt	374	2001 Hyper expression human apolipoprotein E4 astroglia neurons enhance amyloid deposition transgenic mice
0.37081465.15229191.html.plaintext.txt	375	1998 Glial fibrillary acidic protein apolipoprotein E apoE transgenic mice astrocyte specific expression differing biological effects astrocyte secreted apoE3 apoE4 lipoproteins
0.37081465.15229191.html.plaintext.txt	376	2000 Altered cholesterol metabolism human apolipoprotein E4 knock mice
0.37081465.15229191.html.plaintext.txt	377	2003 Genetic background regulates beta amyloid precursor protein processing beta amyloid deposition mouse
0.37081465.15229191.html.plaintext.txt	378	2001 Direct removal mouse floxed neo gene three loxP conditional knockout allele two novel approaches
0.37081465.15229191.html.plaintext.txt	379	1998 Graded reduction Pafah1b1 Lis1 activity results neuronal migration defects early embryonic lethality
0.37081465.15229191.html.plaintext.txt	380	2000 Expression Cre recombinase mouse oocytes means study maternal effect genes
0.37081465.15229191.html.plaintext.txt	381	CO2 8linktypeDOI CrossRefISIMedline
0.37081465.15229191.html.plaintext.txt	382	In Mouse Genetics Concepts Applications
0.37081465.15229191.html.plaintext.txt	383	Oxford University Press New York pp
0.37081465.15229191.html.plaintext.txt	384	1985 Role apolipoprotein E polymorphism determining normal plasma lipid lipoprotein variation
0.37081465.15229191.html.plaintext.txt	385	1999 Apolipoprotein E beta amyloid levels hippocampus frontal cortex Alzheimers disease subjects disease related apolipoprotein E genotype dependent
0.37081465.15229191.html.plaintext.txt	386	1995 Association apolipoprotein E genotype brain levels apolipoprotein E apolipoprotein J clusterin Alzheimer disease
0.37081465.15229191.html.plaintext.txt	387	1994 Identification apolipoprotein B 100 low density lipoproteins apolipoprotein B 48 remnants apolipoprotein E rich high density lipoproteins mouse
0.37081465.15229191.html.plaintext.txt	388	1997 Altered metabolism familial Alzheimers disease linked amyloid precursor protein variants yeast artificial chromosome transgenic mice
0.37081465.15229191.html.plaintext.txt	389	1985 Apolipoprotein E mRNA abundant brain adrenals well liver present peripheral tissues rats marmosets
0.37081465.15229191.html.plaintext.txt	390	1983 Apolipoprotein E synthesis human kidney adrenal gland liver
0.37081465.15229191.html.plaintext.txt	391	Jr 1984 Apolipoprotein E metabolism normolipoproteinemic human subjects
0.37081465.15229191.html.plaintext.txt	392	Jr 1986 Abnormal vivo metabolism apolipoprotein E4 humans
0.37081465.15229191.html.plaintext.txt	393	2000 Association apolipoprotein ApoE genotype plasma apo E levels
0.37081465.15229191.html.plaintext.txt	394	Atherosclerosis 148 327 335
0.37081465.15229191.html.plaintext.txt	395	1996 Apolipoprotein E apoE levels brains Alzheimer disease patients controls
0.37081465.15229191.html.plaintext.txt	396	1998 Risk Alzheimers disease correlates transcriptional activity APOE gene
0.37081465.15229191.html.plaintext.txt	397	2004 Marked regional differences brain human apolipoprotein e expression targeted replacement mice
0.37081465.15229191.html.plaintext.txt	398	1985 Variation susceptibility atherosclerosis among inbred strains mice
0.37081465.15229191.html.plaintext.txt	399	2003 Quantitative trait loci determine lipoprotein cholesterol levels DBA2J CASTEi inbred mice
0.37081465.15229191.html.plaintext.txt	400	1999 Genes variation cholesterol fat intake serum lipids
0.37081465.15229191.html.plaintext.txt	401	2004 Quantitative trait loci analysis plasma HDL cholesterol concentrations atherosclerosis susceptibility inbred mouse strains C57BL6J 129S1SvImJ
0.37081465.15229191.html.plaintext.txt	402	1997 Targeted replacement mouse apolipoprotein E gene common human APOE3 allele enhances diet induced hypercholesterolemia atherosclerosis
0.37081465.15229191.html.plaintext.txt	403	1998 Type III hyperlipoproteinemia spontaneous atherosclerosis mice resulting gene replacement mouse Apoe human Apoe2
0.37081465.15229191.html.plaintext.txt	404	1999 Apo E structure determines VLDL clearance atherosclerosis risk mice
0.37081465.15229191.html.plaintext.txt	405	Jr 1999 Pathogenesis type III hyperlipoproteinemia dysbetalipoproteinemia
0.37081465.15229191.html.plaintext.txt	406	Questions quandaries paradoxes
0.37081465.15229191.html.plaintext.txt	407	1997 Genetic factors precipitating type III hyperlipoproteinemia hypolipidemic transgenic mice expressing human apolipoprotein E2
0.37081465.15229191.html.plaintext.txt	408	2003 Amyloidogenic processing Alzheimer beta amyloid precursor protein depends lipid rafts
0.37081465.15229191.html.plaintext.txt	409	2001 Low cholesterol stimulates nonamyloidogenic pathway effect alpha secretase ADAM 10
0.37081465.15229191.html.plaintext.txt	410	2001 Characterization four lipoprotein classes human cerebrospinal fluid
0.37081465.15229191.html.plaintext.txt	411	1987 Lipoproteins receptors central nervous system
0.37081465.15229191.html.plaintext.txt	412	Characterization lipoproteins cerebrospinal fluid identification apolipoprotein BELDL receptors brain
0.37081465.15229191.html.plaintext.txt	413	1979 Apolipoproteins human cerebrospinal fluid
0.37081465.15229191.html.plaintext.txt	414	2000 Low levels extrahepatic nonmacrophage ApoE inhibit atherosclerosis without correcting hypercholesterolemia ApoE deficient mice
0.37081465.15229191.html.plaintext.txt	415	This Article Abstract FREE Full Text PDF All Versions Article 13171959 recent ddh199v1 Alert article cited Alert correction posted Services Email article friend Similar articles journal Similar articles ISI Web Science Similar articles PubMed Alert new issues journal Add My Personal Archive Download citation manager Search citing articles ISI Web Science 2 Request Permissions Google Scholar Articles Mann K
0.37081465.15229191.html.plaintext.txt	416	PubMed PubMed Citation Articles Mann K
0.37081465.15229191.html.plaintext.txt	417	Online ISSN 1460 2083 Print ISSN 0964 6906 Copyright 2006 Oxford University Press Oxford Journals Oxford University Press Site Map Terms Conditions Privacy Policy Frequently Asked Questions Other Oxford University Press sites Oxford University Press American National Biography Booksellers Information Service Childrens Fiction Poetry Childrens Reference Corporate Special Sales Dictionaries Dictionary National Biography Digital Reference English Language Teaching Higher Education Textbooks Humanities International Education Unit Law Medicine Music Online Products Oxford English Dictionary Reference Rights Permissions Science School Books Social Sciences Very Short Introductions Worlds Classics
0.31518275.8817335.html.plaintext.txt	0	Alzheimers disease associated mutations presenilin 2 rare variably penetrant Alzheimers disease associated mutations presenilin 2 rare variably penetrant R
0.31518275.8817335.html.plaintext.txt	1	1Centre Research Neurodegenerative Diseases Department Medicine University Toronto Department Medicine Division Neurology The Toronto Hospital Toronto Ontario M5S 1A8 Canada 2Karolinska Institute Department Clinical Neurosciences Geriatric Medicine Novum KFC 141 86 Huddinge Sweden 3Department Neurology Psychiatry University Florence Viale Morgagni 65 Florence Italy 4Laboratoire de Genetique Moleculaire CHU Rouen 76031 Rouen France 5Department Medical Molecular Genetics University Toronto Research Institute The Hospital Sick Children 555 University Avenue Toronto Ontario Canada 6Department Neurology Hopital de la Salpetriere INSERM U289 75013 Paris France 7Surrey Place Centre Department Obstetrics Gynaecology Dept
0.31518275.8817335.html.plaintext.txt	2	Physiology University Toronto Toronto Ontario M5S 1A8 Canada 8INSERM U155 Chateau de Longchamp 75016 Paris France 9Department Neurology University Udine Udine Italy
0.31518275.8817335.html.plaintext.txt	3	Received February 20 1996 Revised Accepted April 17 1996
0.31518275.8817335.html.plaintext.txt	4	Missense mutations presenilin 2 PS 2 gene chromosome 1 sought direct nucleotide sequence analysis open reading frame 60 pedigrees familial Alzheimers disease FAD
0.31518275.8817335.html.plaintext.txt	5	In majority pedigrees PS 1 beta amyloid precursor protein betaAPP gene mutations excluded
0.31518275.8817335.html.plaintext.txt	6	While additional PS 2 pathogenic mutations detected four silent nucleotide substitutions alternative splicing nucleotides 1338 1340 Glu325 observed
0.31518275.8817335.html.plaintext.txt	7	Analysis additional members pedigree known segregate Met239Val mutation PS 2 revealed age onset symptoms highly variable range 45 88 years
0.31518275.8817335.html.plaintext.txt	8	This variability attributable differences ApoE genotypes
0.31518275.8817335.html.plaintext.txt	9	These results suggest contrast mutations PS 1 mutations PS 2 relatively rare cause FAD ii genetic environmental factors modify AD phenotype associated PS 2 mutations iii still FAD susceptibility genes remain identified
0.31518275.8817335.html.plaintext.txt	10	Missense mutations associated early onsetAlzheimers disease AD discovered two related genes termed presenilin I chromosome 14 1 presenilin II chromosome 1 2 3
0.31518275.8817335.html.plaintext.txt	11	Analysis number large data sets revealed missense mutations presenilin I PS 1 gene frequent cause early onset familial Alzheimers disease FAD accounting perhaps much 50 cases early onset FAD 1 2 4 6
0.31518275.8817335.html.plaintext.txt	12	In order determine frequency mutations presenilin II PS 2 gene undertook survey mutations open reading frame ORF PS 2 gene 60 pedigrees FAD
0.31518275.8817335.html.plaintext.txt	13	The disease families characterized occurrence AD consistent NINDS ADRDA criteria least three closely related subjects often one generation
0.31518275.8817335.html.plaintext.txt	14	In pedigrees age onset range 35 82 years 36 mean age onset 64 years 14 mean age onset 65 years 10 insufficient reliable data age onset overlapped observed pedigrees known PS 2 mutations onset 45 72 years
0.31518275.8817335.html.plaintext.txt	15	To determine penetrance PS 2 mutations also examined several additional members FLO10 pedigree previously described Met239Val missense mutation PS 2 gene 2
0.31518275.8817335.html.plaintext.txt	16	Our data suggest missense mutations PS 2 gene rare cause AD missense mutations may subject modifying action genes environmental influences
0.31518275.8817335.html.plaintext.txt	17	Fibroblasts transformed lymphoblasts peripheral blood samples obtained least one affected member 60 kindreds multiple 3 family members affected FAD ascertained familial Alzheimers disease registry University Toronto clinics University Florence Massachusetts Alzheimers Disease Research Centre Karolinska Institute Stockholm Sweden French University Hospitals National INSERM network France Indiana University Alzheimers Disease DNA Bank NIA sponsored repository Coriell Institute
0.31518275.8817335.html.plaintext.txt	18	Diagnosis AD affected members used NINDS ADRDA criteria similar CERAD criteria
0.31518275.8817335.html.plaintext.txt	19	Mutations PS 1 beta amyloid precursor protein betaAPP genes previously excluded majority pedigrees sequencing reverse transcriptase polymerase chain reaction RT PCR products corresponding PS 1 gene genomic PCR products corresponding exons 16 17 betaAPP
0.31518275.8817335.html.plaintext.txt	20	Analysis nucleotide sequence RT PCR products corresponding ORF PS 2 60 FAD pedigrees failed uncover additional mutations beyond two initial mutations Asn141Ile mutation three related kindreds Volga German origin Met239Val mutation FLO10 pedigree Italian origin previously reported data set 2
0.31518275.8817335.html.plaintext.txt	21	Specific screening Asn141Ile Met239Val mutations supplemental set genomic DNA samples affected probands 81 Swedish FAD pedigrees also failed identify instances either mutation
0.31518275.8817335.html.plaintext.txt	22	However although pathogenic nucleotide sequence differences observed four silent nucleotide substitutions detected T C 626 bpcodon 23 C T 806 bpcodon 147 C T 1571 bpcodon 402 G A 1670 bpcodon 435 sequence numbering Accession
0.31518275.8817335.html.plaintext.txt	23	All substitutions occurred third nucleotide position codon would therefore predicted cause change amino acid sequence
0.31518275.8817335.html.plaintext.txt	24	A fifth sequence variant variable presence nucleotides 1338 1340 encoding Glu325 residuewas found transcripts tissues
0.31518275.8817335.html.plaintext.txt	25	Transcripts without nucleotides 1338 1340 reflects use alternate splice donor sequence approximately equal abundance brain fibroblasts leukocytes
0.31518275.8817335.html.plaintext.txt	26	During investigation PS 2 gene several newly ascertained members FLO10 pedigree segregating Met239Val mutation PS 2 identified additional carrier mutation subject III 20 Table 1
0.31518275.8817335.html.plaintext.txt	27	Surprisingly subject aged 87 years evidence cognitive memory impairment serial follow several years age 84 years noted become mildly demented profoundly demented Mini Mental Status Examination score 430 clinical features sustain diagnosis probable AD NINDS ADRDA criteria
0.31518275.8817335.html.plaintext.txt	28	A review clinical data additional members extended pedigree also uncovered two subjects direct lineage family either historical evidence late onset AD subject I 2 affected grandfather III 20 died 75 years dementia currently clinical features consistent probable AD using NINDS ADRDA criteria subject III 39 onset 88 years
0.31518275.8817335.html.plaintext.txt	29	We others previously reported genotype Apolipoprotein E gene modulate age onset Alzheimers disease subjects Val717Ile mutation betaAPP 7 8
0.31518275.8817335.html.plaintext.txt	30	However FLO10 family Met239Val mutation PS 2 ApoE genotypes correlate age onset Table 1
0.31518275.8817335.html.plaintext.txt	31	Thus elderly symptomatic subject III 20 onset 84 years ApoE genotype epsilon3epsilon3 three affected carriers Met239Val mutation developed symptoms younger age onset 45 72 years
0.31518275.8817335.html.plaintext.txt	32	Moreover affected carrier IV 21 ApoE genotype epsilon3epsilon4 developed symptoms age 48 years similar affected sibling IV 18 ApoE genotype epsilon3epsilon3 onset 45 years Table 1 Fig
0.31518275.8817335.html.plaintext.txt	33	Our sample size small draw reliable conclusions presence absence interactions ApoE genotype Asn141Ile mutation Table 1
0.31518275.8817335.html.plaintext.txt	34	Abbreviated pedigree diagram FLO10
0.31518275.8817335.html.plaintext.txt	35	Small type face roman numerals pedigree locations subject
0.31518275.8817335.html.plaintext.txt	36	Solid symbols AD affected subjects hatched symbols risk subjects open symbols risk
0.31518275.8817335.html.plaintext.txt	37	Where known age onset age death denoted arabic numerals
0.31518275.8817335.html.plaintext.txt	38	With exception subject III 39 whose genotypes PS 2 ApoE unknown biological samples available affected subjects carried PS 2 Met239Val mutation
0.31518275.8817335.html.plaintext.txt	39	Although large cadre FAD pedigrees reported represent unbiased survey paucity missense mutations PS 2 gene amongst FAD pedigrees data set suggests contrast mutations ORF PS 1 mutations ORF gene rare cause FAD least Caucasian populations
0.31518275.8817335.html.plaintext.txt	40	We confidently exclude mutations intronic sequences associated RNA splice sites indeed one mutation affects splicing exon 10 PS 1 found FAD affected subjects T
0.31518275.8817335.html.plaintext.txt	41	However 5 UTR 3 UTR sequences searched pathogenic mutations cannot exclude formal possibility mutations might exist sequences pedigrees
0.31518275.8817335.html.plaintext.txt	42	Nevertheless two corollaries conclusion PS 2 ORF mutations rare
0.31518275.8817335.html.plaintext.txt	43	First unless phenotype uniquely associated least enriched subjects PS 2 mutants found screening programs mutations ORF PS 2 likely low yield
0.31518275.8817335.html.plaintext.txt	44	Second importantly yet unidentified FAD susceptibility loci must exist
0.31518275.8817335.html.plaintext.txt	45	Table 1 Age onset relative genotypes ApoE PS 2 genes Subject
0.31518275.8817335.html.plaintext.txt	46	The age symptom onset current age PS 2 mutation carriers displayed along subjects ApoE genotype
0.31518275.8817335.html.plaintext.txt	47	The conclusion drawn data age symptom onset subjects PS 2 mutations generally older 45 88 years observed PS 1 mutations 25 65 years highly variable even amongst affected members pedigree
0.31518275.8817335.html.plaintext.txt	48	This contrasts sharply experience PS 1 mutations age onset generally quite similar amongst affected members family often amongst members different families mutation 1 2 4 6
0.31518275.8817335.html.plaintext.txt	49	Because date subjects AD FLO10 pedigree inherited Met239Val mutation unlikely late onset cases represent phenocopies andor represents polymorphism linkage disequilibrium nearby pathogenic mutation
0.31518275.8817335.html.plaintext.txt	50	Consequently parsimonious explanation single cause disease Met239Val mutation phenotype modified genetic environmental factors
0.31518275.8817335.html.plaintext.txt	51	The limited number subjects Asn141Ile mutation data set prevents rigorous conclusions interactions ApoE genotype mutation
0.31518275.8817335.html.plaintext.txt	52	However analysis larger data set T
0.31518275.8817335.html.plaintext.txt	53	Schellenberg also reveals obvious interaction genotypes ApoE PS 2 Asn141Ile manuscript preparation
0.31518275.8817335.html.plaintext.txt	54	This absence close correlation ApoE genotype age symptom onset subjects PS 2 mutation two implications
0.31518275.8817335.html.plaintext.txt	55	First view parallel observations showing apparent interaction ApoE genotype mutations PS 1 7 9 10 together structural amino acid sequence similarities PS 1 PS 2 proteins 1 3 likely functional effect PS 1 PS 2 mutations similar either remote functional effect ApoE epsilon4 allele affect biochemical pathway leading AD different influenced ApoE epsilon4
0.31518275.8817335.html.plaintext.txt	56	Second variation age onset PS 2 mutation carriers argues modifying environmental genetic factors e
0.31518275.8817335.html.plaintext.txt	57	polymorphisms within presenilin genes differences genes must exist
0.31518275.8817335.html.plaintext.txt	58	The nature factors remains determined
0.31518275.8817335.html.plaintext.txt	59	However modifying factors identified might exploitable therapeutic tool
0.31518275.8817335.html.plaintext.txt	60	Subjects familially clustered Alzheimers disease defined occurrence least three first second degree relatives AD recruited patients referred investigation dementia University Toronto University Florence Massachusetts Alzheimers Disease Research Centre Huddinge Hospital Karolinska Institute French University Hospitals
0.31518275.8817335.html.plaintext.txt	61	All subjects provided informed consent using institutionally approved protocols
0.31518275.8817335.html.plaintext.txt	62	The diagnosis AD made affected pedigree members direct clinical examination standard laboratory procedures met exceeded stringency NINCDS ADRDA criteria 11 12
0.31518275.8817335.html.plaintext.txt	63	Evidence AD deceased family members ascertained investigation medical family records previously described 13
0.31518275.8817335.html.plaintext.txt	64	Additional FAD pedigree samples obtained Cornell Institute Camden NJ N 4 Indiana University Alzheimers Disease DNA Bank Indianapolis IN N 6
0.31518275.8817335.html.plaintext.txt	65	Mutations sought ORF PS 1 gene 4760 pedigrees exon 16 17 betaAPP gene 5160 pedigrees using methods previously described 1 14 15
0.31518275.8817335.html.plaintext.txt	66	The PS 2 gene ORF investigated North American Italian pedigrees isolating complimentary DNA fragments amplification using RT PCR oligonucleotide primer sequences reaction conditions previously described 2
0.31518275.8817335.html.plaintext.txt	67	In French families RT PCR performed using primers F1 5 caggaaacagctatgaccgagctgaccctcaaatacgg F2 5 tgtaaaacgacggccagtgagatcatacacagagatgg recover codons 85 257 primers F3 5 caggaaacagctatgacctcaagtacctcccagagtgg F4 5 tgtaaaacgacggccagtagcctgtggcacaccatgtc recover codons 251 448
0.31518275.8817335.html.plaintext.txt	68	The nucleotide sequence RT PCR products affected pedigree member determined using fluorescent dye terminator dye primer cycle sequencing
0.31518275.8817335.html.plaintext.txt	69	Mutations detected analysis resultant chromatograms heterozygous nucleotidesubstitutions using direct inspection Factura ver 1
0.31518275.8817335.html.plaintext.txt	70	0 Sequence Navigator ver 1
0.31518275.8817335.html.plaintext.txt	71	1b15 software packages ABI Foster City CA
0.31518275.8817335.html.plaintext.txt	72	The presence T C substitution base pair 1624 PS 2 cDNA sequence gives rise Met239Val mutation assessed genomic DNA previously described 2
0.31518275.8817335.html.plaintext.txt	73	Genotypes ApoE determined PCR amplification HhaI digestion previously described 16 17
0.31518275.8817335.html.plaintext.txt	74	This work supported Alzheimer Association Ontario Canadian Genetic Diseases Network Medical Research Council Canada American Health Assistance Foundation National Institute Health Scottish Rite Charitable Foundation Eva Gordon Memorial Trust Lifebeat Swedish Medical Research Council project 10819LL INSERM network 492002 Consiglio Nazionale delle Richerche PF Aging 952631 SS Telethon Italy E
0.31518275.8817335.html.plaintext.txt	75	304 BN Glaxo Canada RS Helen B
0.31518275.8817335.html.plaintext.txt	76	Hunter Foundation GL HC Peterborough Burgess Fellowship EAR Ontario Mental Health Foundation MEP
0.31518275.8817335.html.plaintext.txt	77	PStGH JMR Scholars Medical Research Council Canada
0.31518275.8817335.html.plaintext.txt	78	Cell lines obtained Indiana University Alzheimers Disease DNA bank P30 AG10133
0.31518275.8817335.html.plaintext.txt	79	1995 Cloning gene bearing missense mutations early onset familial Alzheimers disease
0.31518275.8817335.html.plaintext.txt	80	1995 Familial Alzheimers disease kindreds missense mutations novel gene chromosome 1 related Alzheimers Disease type 3 gene
0.31518275.8817335.html.plaintext.txt	81	1995 A familial Alzheimers Disease locus chromosome 1
0.31518275.8817335.html.plaintext.txt	82	1995 Molecular genetic analysis familial early onset Alzheimers Disease linked chromosome 14q24
0.31518275.8817335.html.plaintext.txt	83	1995 Mutations Presenilin 1 gene families early onsetAlzheimers disease
0.31518275.8817335.html.plaintext.txt	84	6 The Alzheimers Disease Collaborative Group 1995 The structure presenilin I gene identification six mutations early onset AD pedigrees
0.31518275.8817335.html.plaintext.txt	85	1994 Alzheimers Disease possible gene interaction
0.31518275.8817335.html.plaintext.txt	86	1995 ApoE genotype familial Alzheimers Disease possible influence age onset APP717Val Ile mutated families
0.31518275.8817335.html.plaintext.txt	87	1994 APOE genotype modulate age onset families chromosome 14 encoded Alzheimers Disease
0.31518275.8817335.html.plaintext.txt	88	10 The French Alzheimers Disease Collaborative Study Group 1996 Apolipoprotein E genotype affect age onset patients chromosome 14 encoded Alzheimers Disease
0.31518275.8817335.html.plaintext.txt	89	1984 Clinical diagnosis Alzheimer Disease report NINCDS ADRDA Work Group auspices Department Health Human Services Task force Alzheimer Disease
0.31518275.8817335.html.plaintext.txt	90	1985 Diagnosis Alzheimer Disease
0.31518275.8817335.html.plaintext.txt	91	1992 Genetic evidence novel Familial Alzheimer Disease gene chromosome 14
0.31518275.8817335.html.plaintext.txt	92	1992 Molecular prospective phenotypic characterization pedigree Familial Alzheimer Disease missense mutation codon 717 beta amyloid precursor protein APP gene
0.31518275.8817335.html.plaintext.txt	93	1992 A pathogenic mutation probable Alzheimers Disease APP gene N terminus beta amyloid
0.31518275.8817335.html.plaintext.txt	94	1993 Association Apoliprotein E allele epsilon4 late onset familial sporadic Alzheimer Disease
0.31518275.8817335.html.plaintext.txt	95	1994 Are associations Alzheimer Disease apolipoprotein genes chr 19 due linkage disequilibrium Ann
0.31518275.8817335.html.plaintext.txt	96	To correspondence addressed This page maintained OUP admin
0.31518275.8817335.html.plaintext.txt	97	Last updated Thu Oct 31 152515 GMT 1996
0.31518275.8817335.html.plaintext.txt	98	Part OUP Journals World Wide Web service
0.31518275.8817335.html.plaintext.txt	99	Copyright Oxford University Press 1996
0.34592706.9302273.html.plaintext.txt	0	Synergy genes butyrylcholinesterase K variant apolipoprotein E4 late onset confirmed Alzheimers disease Synergy genes butyrylcholinesterase K variant apolipoprotein E4 late onset confirmed Alzheimers disease D
0.34592706.9302273.html.plaintext.txt	1	Oxford Project Investigate Memory Ageing OPTIMA University Department Pharmacology Mansfield Rd Oxford OX1 3QT UK Radcliffe Infirmary Woodstock Rd Oxford OX2 6HE UK
0.34592706.9302273.html.plaintext.txt	2	Received July 3 1997 Revised Accepted July 31 1997
0.34592706.9302273.html.plaintext.txt	3	The allelic frequency gene K variant butyrylcholinesterase BCHE K 0
0.34592706.9302273.html.plaintext.txt	4	17 74 subjects late onset age 65 years histopathologically diagnosed Alzheimers disease AD higher frequencies 104 elderly control subjects 0
0.34592706.9302273.html.plaintext.txt	5	09 14 early onset cases confirmed AD 0
0.34592706.9302273.html.plaintext.txt	6	07 29 confirmed cases dementia 0
0.34592706.9302273.html.plaintext.txt	7	The association BCHE K late onset AD limited carriers epsilon4 allele apolipoprotein E gene APOE among presence BCHE K gave odds ratio confirmed late onset AD 6
0.34592706.9302273.html.plaintext.txt	8	65 29 subjects 65 years 12
0.34592706.9302273.html.plaintext.txt	9	In APOEepsilon4 carriers 75 years 122 controls compared 1024 confirmed late onset AD cases BCHE K
0.34592706.9302273.html.plaintext.txt	10	We suggest BCHE K nearby gene chromosome 3 acts synergy APOEepsilon4 susceptibility gene late onset AD
0.34592706.9302273.html.plaintext.txt	11	Butyrylcholinesterase BChE expressed human tissues 1 yet function unknown
0.34592706.9302273.html.plaintext.txt	12	BChE activity brain increases age 60 years elevated Alzheimers disease AD 2 3
0.34592706.9302273.html.plaintext.txt	13	Histochemically reactive BChE associated amyloid plaques neurofibrillary tangles amyloid angiopathy AD 4 8
0.34592706.9302273.html.plaintext.txt	14	We looked possible associations AD two common human variants gene BChE BCHE atypical allele K variant BCHE K
0.34592706.9302273.html.plaintext.txt	15	The latter point mutation nucleotide 1615 GCA ACA changes Ala539 threonine catalytic activity reduced third 9
0.34592706.9302273.html.plaintext.txt	16	BCHE K thought allelic frequency 0
0.34592706.9302273.html.plaintext.txt	17	After 178 subjects genotyped three control subjects 104 three AD cases 74 identified heterozygotes atypical BCHE allele
0.34592706.9302273.html.plaintext.txt	18	Thus association found histopathologically confirmed AD atypical allele BCHE
0.34592706.9302273.html.plaintext.txt	19	Two six atypical BCHE heterozygotes carriers BCHE K
0.34592706.9302273.html.plaintext.txt	20	Altogether 282 Caucasian subjects genotyped BCHE K APOE alleles
0.34592706.9302273.html.plaintext.txt	21	BCHE K common late onset AD cases early onset AD cases dementias controls Table 1
0.34592706.9302273.html.plaintext.txt	22	For subjects aged 65 allelic frequency BCHE K 0
0.34592706.9302273.html.plaintext.txt	23	17 74 confirmed AD cases giving odds ratio AD 2
0.34592706.9302273.html.plaintext.txt	24	Most association appeared due subjects 75 years old frequency BCHE K 0
0.34592706.9302273.html.plaintext.txt	25	19 36 confirmed AD cases chi2 Yates correction 4
0.34592706.9302273.html.plaintext.txt	26	03 giving odds ratio AD 2
0.34592706.9302273.html.plaintext.txt	27	There insufficient cases trend age reach significance nevertheless thought helpful show data 75 years subgroup well subjects 65 years Table 2
0.34592706.9302273.html.plaintext.txt	28	Taking account individuals carrier status APOE epsilon4 produced striking results
0.34592706.9302273.html.plaintext.txt	29	In subjects 65 years without APOE epsilon4 allelic frequency BCHE K 0
0.34592706.9302273.html.plaintext.txt	30	14 22 confirmed AD cases 0
0.34592706.9302273.html.plaintext.txt	31	There thus association BCHE K late onset AD subjects lacking APOE epsilon4 allele
0.34592706.9302273.html.plaintext.txt	32	In APOE epsilon4 carriers however BCHE K allelic frequencies subjects aged 65 years 0
0.34592706.9302273.html.plaintext.txt	33	18 52 confirmed AD cases 0
0.34592706.9302273.html.plaintext.txt	34	03 32 controls subjects aged 75 years frequencies 0
0.34592706.9302273.html.plaintext.txt	35	23 24 confirmed AD cases 0
0.34592706.9302273.html.plaintext.txt	36	These results gave odds ratios confirmed AD 6
0.34592706.9302273.html.plaintext.txt	37	8 BCHE K APOE epsilon4 carriers aged 65 years 75 years respectively Table 2
0.34592706.9302273.html.plaintext.txt	38	For comparison give Table 3 odds ratios confirmed AD APOE epsilon4 BCHE K carriers
0.34592706.9302273.html.plaintext.txt	39	It seen individuals BCHE K status markedly influences strength effect APOE epsilon4
0.34592706.9302273.html.plaintext.txt	40	Table 4 shows striking differences cases controls proportions subjects carry BCHE K APOE epsilon4 alleles
0.34592706.9302273.html.plaintext.txt	41	All findings indicated interaction BCHE K APOE epsilon4 confirmed logistic regression analysis
0.34592706.9302273.html.plaintext.txt	42	We fitted several logistic regression models data found parsimonious model APOE epsilon4 BCHE K interaction gave adequate fit residual deviance 5
0.34592706.9302273.html.plaintext.txt	43	In model APOE epsilon4 interaction BCHE K significantly associated AD BCHE K
0.34592706.9302273.html.plaintext.txt	44	Table 1 Allelic frequencies BCHE K APOE epsilon4 No
0.34592706.9302273.html.plaintext.txt	45	BCHE K allele frequency APOE epsilon4 allelefrequency Controls 65 years 104 1
0.34592706.9302273.html.plaintext.txt	46	54 Confirmed dementia 29 0
0.34592706.9302273.html.plaintext.txt	47	19 LOAD EOAD respectively late onset 65 years early onsetAlzheimers disease
0.34592706.9302273.html.plaintext.txt	48	For BCHE K groups exact Hardy Weinberg equilibrium
0.34592706.9302273.html.plaintext.txt	49	0001 chi2 Yates correction versus controls
0.34592706.9302273.html.plaintext.txt	50	aAges death status confirmed last clinical assessment living subjects
0.34592706.9302273.html.plaintext.txt	51	Table 2 Odds ratios confirmed late onset Alzheimers disease BCHE K alleles Subjects Controls Cases Odds ratioa 95 C
0.34592706.9302273.html.plaintext.txt	52	8 ApoE epsilon4 carriers 65 years 32 52 6
0.34592706.9302273.html.plaintext.txt	53	65 29 ApoE epsilon4 carriers 75 years 22 24 12
0.34592706.9302273.html.plaintext.txt	54	9 86 Ages Tables 2 5 onset late onset AD cases controls death confirmed last clinical assessment living
0.34592706.9302273.html.plaintext.txt	55	aThese odds ratios based alleles
0.34592706.9302273.html.plaintext.txt	56	The equivalent odds ratios BCHE K based carriers 2
0.34592706.9302273.html.plaintext.txt	57	Table 3 Odds ratios confirmed late onset Alzheimers disease APOE epsilon4 alleles Subjects Controls Cases Odds ratio 95 C
0.34592706.9302273.html.plaintext.txt	58	5 BCHE K carriers 65 years 17 23 12
0.34592706.9302273.html.plaintext.txt	59	6 58 BCHE K carriers 75 years 11 12 15
0.34592706.9302273.html.plaintext.txt	60	Table 4 Proportions controls confirmed late onset AD cases BCHE K APOE epsilon4 alleles Subjects Proportions alleles Controls Cases P All 65 years 2104 2 1874 24 0
0.34592706.9302273.html.plaintext.txt	61	0001 All 75 years 168 1 1036 28 0
0.34592706.9302273.html.plaintext.txt	62	0001 APOE epsilon4 carriers 65 years 232 6 1852 35 0
0.34592706.9302273.html.plaintext.txt	63	007 APOE epsilon4 carriers 75 years 122 5 1024 42 0
0.34592706.9302273.html.plaintext.txt	64	009 chi2 Yates correction
0.34592706.9302273.html.plaintext.txt	65	Table 5 Odds ratios confirmed late onset AD taking subjects neither APOE epsilon4 BCHE K reference APOE epsilon4 BCHE K Controls Cases Odds ratio 95 CI Age 65 years 57 17 Reference 15 5 1
0.34592706.9302273.html.plaintext.txt	66	4 108 Age 75 years 36 10 Reference 10 2 0
0.34592706.9302273.html.plaintext.txt	67	In order examine strength interaction BCHE K APOE epsilon4 give Table 5 odds ratios confirmed AD subjects different combinations two genes taking subjects neither gene reference
0.34592706.9302273.html.plaintext.txt	68	In subjects 65 years odds ratio carry BCHE K 1
0.34592706.9302273.html.plaintext.txt	69	1 APOE epsilon4 3
0.34592706.9302273.html.plaintext.txt	70	This gave predicted odds ratio 4
0.34592706.9302273.html.plaintext.txt	71	2 subjects genes assumption independent effects two genes compared observed value 30
0.34592706.9302273.html.plaintext.txt	72	In subjects 75 years predicted odds ratio 1
0.34592706.9302273.html.plaintext.txt	73	7 observed odds ratio 36
0.34592706.9302273.html.plaintext.txt	74	We therefore suggest strong synergy two alleles late onset AD
0.34592706.9302273.html.plaintext.txt	75	That APOE epsilon4 risk factor AD well established 12 13
0.34592706.9302273.html.plaintext.txt	76	Our results consistent hypothesis BCHE K associated increase risk late onset AD APOE epsilon4 carriers
0.34592706.9302273.html.plaintext.txt	77	The effect could due linkage disequilibrium another gene chromosome 3 conceivably transferrin whose C2 variant reported common 20 clinically diagnosed AD cases general population 14
0.34592706.9302273.html.plaintext.txt	78	2 15 gene transferrin 3q21 q25 16
0.34592706.9302273.html.plaintext.txt	79	On hand effect late onset AD might mediated BCHE K
0.34592706.9302273.html.plaintext.txt	80	There various potential interactions BChE apolipoprotein E apoE
0.34592706.9302273.html.plaintext.txt	81	Both proteins produced quantity liver secreted circulation 1 17
0.34592706.9302273.html.plaintext.txt	82	Not apoE probably also BChE interact lipoproteins 18 19
0.34592706.9302273.html.plaintext.txt	83	Both proteins found astrocytes 20 21 glia BChE oligodendrocytes 22 apoE microglia 23
0.34592706.9302273.html.plaintext.txt	84	Both proteins occur AD plaques intra extracellular neurofibrillary tangles association amyloid angiopathy 7 8 24 25
0.34592706.9302273.html.plaintext.txt	85	Furthermore BChE apoE implicated certain models neurite growth 26 31
0.34592706.9302273.html.plaintext.txt	86	In case apoE differences E3 E4 isoforms 29 31 case BChE suggested nature attached sugar residues may important 26 28
0.34592706.9302273.html.plaintext.txt	87	It noted K variant BChE additional threonine residue position 539 whether potential O glycosylation site indeed phosphorylation site remains shown
0.34592706.9302273.html.plaintext.txt	88	Furthermore threonine residue high propensity beta sheet formation 32
0.34592706.9302273.html.plaintext.txt	89	In lysozyme conversion isoleucine residue threonine causes amyloidosis 33 conversion alanine residue threonine transthyretin 34
0.34592706.9302273.html.plaintext.txt	90	The evidence cited provides pointers future work test hypothesis BChE apoE may interact interaction influenced allelic variants
0.34592706.9302273.html.plaintext.txt	91	Implications clinical genetics
0.34592706.9302273.html.plaintext.txt	92	Replication findings particularly important since 6 Caucasian population carry BCHE K APOE epsilon4 assuming respective allelic frequencies 0
0.34592706.9302273.html.plaintext.txt	93	Thus subject confirmation results several millions elderly carry genes high risk developing AD especially aged 75 years
0.34592706.9302273.html.plaintext.txt	94	As pointed Roses 36 ability identify risk individuals major social ethical implications
0.34592706.9302273.html.plaintext.txt	95	Since APOE epsilon4 established risk factor cardiovascular disease important see whether carriers also BCHE K greater risk cardiovascular disease
0.34592706.9302273.html.plaintext.txt	96	Such study would clinical relevance could also increase understanding role vascular risk factors 37 aetiology AD
0.34592706.9302273.html.plaintext.txt	97	We examined 282 Caucasians Oxford region recruited Oxford Project Investigate Memory Ageing OPTIMA 38
0.34592706.9302273.html.plaintext.txt	98	Eighty eight autopsy confirmed CERAD 39 definite probable AD cases 74 late
0.34592706.9302273.html.plaintext.txt	99	65 years 14 early onset 29 pathologically confirmed cases dementias 12 vascular five Parkinsons five non specific neurodegeneration three Picks one progressive supranuclear palsy normal pressure hydrocephalus Huntingtons glioma 61 living cases diagnosed possible AD probable AD NINCDSADRDA 40 criteria 31 late 30 early onset 104 controls without cognitive impairment CAMDEX 41 scores 80 14 died AD pathology necropsy
0.34592706.9302273.html.plaintext.txt	100	Subjects genotyped blind diagnosis using blood samples PCR methods atypical K variants BCHE 42 APOE 43
0.34592706.9302273.html.plaintext.txt	101	We especially thank patients volunteers members OPTIMA Department Neuropathology Radcliffe Infirmary Drs M Cortina Borja R
0.34592706.9302273.html.plaintext.txt	102	This work supported Bristol Myers Squibb
0.34592706.9302273.html.plaintext.txt	103	1974 The Biology Cholinesterases
0.34592706.9302273.html.plaintext.txt	104	North Holland publications Amsterdam The Netherlands
0.34592706.9302273.html.plaintext.txt	105	1978 Changes brain cholinesterases senile dementia Alzheimer type
0.34592706.9302273.html.plaintext.txt	106	1980 The cholinergic system old age Alzheimers disease
0.34592706.9302273.html.plaintext.txt	107	1991 Electron microscopic localization cholinesterase activity Alzheimer brain tissue
0.34592706.9302273.html.plaintext.txt	108	1992 Cholinesterases amyloid angiopathy Alzheimers disease
0.34592706.9302273.html.plaintext.txt	109	1994 Butyrylcholinesterase reactivity differentiates amyloid plaques aging dementia
0.34592706.9302273.html.plaintext.txt	110	1995 Cholinesterases pathology Alzheimer disease
0.34592706.9302273.html.plaintext.txt	111	1994 Ultrastructural localization butyrylcholinesterase neurofibrillary degeneration sites brains aged Alzheimers disease patients
0.34592706.9302273.html.plaintext.txt	112	1992 DNA mutation associated human butyrylcholinesterase K variant linkage atypical variant mutation polymorphic sites
0.34592706.9302273.html.plaintext.txt	113	1984 On identification frequency J K cholinesterase phenotypes Caucasian population
0.34592706.9302273.html.plaintext.txt	114	1985 Plasma cholinesterase variants
0.34592706.9302273.html.plaintext.txt	115	Family studies E1k gene
0.34592706.9302273.html.plaintext.txt	116	1993 Association apolipoprotein E allele epsilon4 late onset familial sporadic Alzheimers disease
0.34592706.9302273.html.plaintext.txt	117	1996 Apolipoprotein E alleles risk factors Alzheimers disease
0.34592706.9302273.html.plaintext.txt	118	1993 Increased frequency transferrin C2 subtype Alzheimers disease
0.34592706.9302273.html.plaintext.txt	119	1991 Refinement localization human butyrylcholinesterase chromosome 3q26
0.34592706.9302273.html.plaintext.txt	120	1984 Human transferrin cDNA characterization chromosomal localization
0.34592706.9302273.html.plaintext.txt	121	1988 Apolipoprotein E cholesterol transport protein expanding role cell biology
0.34592706.9302273.html.plaintext.txt	122	1961 Enzymatic activity related human serum beta lipoprotein histochemical immunoelectrophoretic quantitative studies
0.34592706.9302273.html.plaintext.txt	123	1973 Interrelationship serum beta lipoprotein cholinesterase
0.34592706.9302273.html.plaintext.txt	124	1993 Neuroglial cholinesterases normal brain Alzheimers disease relationship plaques tangles patterns selective vulnerability
0.34592706.9302273.html.plaintext.txt	125	1991 Neuropathological changes scrapie Alzheimers disease associated increased expression apolipoprotein E cathepsin D astrocytes
0.34592706.9302273.html.plaintext.txt	126	1966 Changes butyryl cholinesterase activity reactive glia
0.34592706.9302273.html.plaintext.txt	127	1994 Lipoproteins neurobiology Alzheimers disease structure function apolipoprotein E
0.34592706.9302273.html.plaintext.txt	128	1991 Apolipoprotein E immunoreactivity cerebral amyloid deposits neurofibrillary tangles Alzheimers disease kuru plaque amyloid Creutzfeldt Jakob disease
0.34592706.9302273.html.plaintext.txt	129	1993 Apolipoprotein E sporadic Alzheimers disease allelic variation receptor interactions
0.34592706.9302273.html.plaintext.txt	130	1991 Cranial nerve growth birds preceded cholinesterase expression neural crest cell migration formation HNK 1 scaffold
0.34592706.9302273.html.plaintext.txt	131	1993 Cholinesterases regulate neurite growth chick nerve cells vitro means non enzymatic mechanism
0.34592706.9302273.html.plaintext.txt	132	1995 Novel functions cholinesterases development physiology disease
0.34592706.9302273.html.plaintext.txt	133	1994 Differential effects apolipoproteins E3 E4 neuronal growth vitro
0.34592706.9302273.html.plaintext.txt	134	1995 Low density lipoprotein receptor related protein mediates apolipoprotein E dependent neurite outgrowth central nervous system derived neuronal cell line
0.34592706.9302273.html.plaintext.txt	135	1995 The inhibitory effect apolipoprotein E4 neurite outgrowth associated microtubule depolymerization
0.34592706.9302273.html.plaintext.txt	136	1994 Measurement beta sheet forming propensities amino acids
0.34592706.9302273.html.plaintext.txt	137	1993 Human lysozyme gene mutations cause hereditary systemic amyloidosis
0.34592706.9302273.html.plaintext.txt	138	1992 A new transthyretin mutation associated amyloid cardiomyopathy
0.34592706.9302273.html.plaintext.txt	139	1982 Genetic control human apolipoprotein E polymorphism comparison one two dimensional techniques isoprotein analysis
0.34592706.9302273.html.plaintext.txt	140	1997 A model susceptibility polymorphisms complex diseases apolipoprotein E Alzheimer disease
0.34592706.9302273.html.plaintext.txt	141	1997 Atherosclerosis apolipoprotein E prevalence dementia Alzheimers disease Rotterdam study
0.34592706.9302273.html.plaintext.txt	142	1992 Detection life confirmed Alzheimers disease using simple measurement medial temporal lobe atrophy computed tomography
0.34592706.9302273.html.plaintext.txt	143	1991 The Consortium establish registry Alzheimers Disease CERAD
0.34592706.9302273.html.plaintext.txt	144	Standardization neuropathologic assessment Alzheimers disease
0.34592706.9302273.html.plaintext.txt	145	1984 Clinical diagnosis Alzheimers disease report NINCDS ADRDA work group auspices Department Health Human Services task force Alzheimers disease
0.34592706.9302273.html.plaintext.txt	146	1988 CAMDEX The Cambridge Examination Mental Disorders Elderly
0.34592706.9302273.html.plaintext.txt	147	Cambridge University Press Cambridge
0.34592706.9302273.html.plaintext.txt	148	1996 Detection plasma cholinesterase K variant PCR using amplification created restriction site
0.34592706.9302273.html.plaintext.txt	149	1991 Apolipoprotein E genotyping one stage PCR
0.34592706.9302273.html.plaintext.txt	150	To correspondence addressed
0.34592706.9302273.html.plaintext.txt	151	Tel 44 1865 271883 Fax 44 1865 271882 Email david
0.31636134.15033916.html.plaintext.txt	0	Estrogen Facilitates Neurite Extension via Apolipoprotein E Cultured Adult Mouse Cortical Neurons Britto P
0.31636134.15033916.html.plaintext.txt	1	Barsukova Fei Shen Mary McAsey Robert G
0.31636134.15033916.html.plaintext.txt	2	Department Biological Sciences B
0.31636134.15033916.html.plaintext.txt	3	Eastern Illinois University Charleston Illinois 61920 Department Obstetrics Gynecology M
0.31636134.15033916.html.plaintext.txt	4	Center Alzheimer Disease R
0.31636134.15033916.html.plaintext.txt	5	Southern Illinois University School Medicine Springfield Illinois 62794
0.31636134.15033916.html.plaintext.txt	6	Address correspondence requests reprints Robert G
0.31636134.15033916.html.plaintext.txt	7	Box 19628 Center For Alzheimer Disease Related Disorders Southern Illinois University School Medicine Springfield Illinois 62794 9628
0.31636134.15033916.html.plaintext.txt	8	Abstract Top Abstract Introduction Materials Methods Results Discussion References Literature review suggests close relationship estrogen apolipoprotein E ApoE central nervous system
0.31636134.15033916.html.plaintext.txt	9	Epidemiology studies show estrogen replacement therapy ERT decreases morbidity several chronic neurological diseases
0.31636134.15033916.html.plaintext.txt	10	Alleles ApoE modify risk progression diseases
0.31636134.15033916.html.plaintext.txt	11	ApoE levels rodent brain vary estrous cycle increase 17ss estradiol administration
0.31636134.15033916.html.plaintext.txt	12	Both estradiol ApoE3 common isoform human ApoE increase extent neurite outgrowth culture
0.31636134.15033916.html.plaintext.txt	13	Combined observations suggest common mechanism whereby estrogen may increase ApoE levels facilitate neurite growth
0.31636134.15033916.html.plaintext.txt	14	We tested hypothesis characterizing effects estradiol ApoE isoforms neurite outgrowth cultured adult mouse cortical neurons
0.31636134.15033916.html.plaintext.txt	15	Estradiol increased ApoE levels neurite outgrowth
0.31636134.15033916.html.plaintext.txt	16	ApoE2 increased neurite length ApoE3 presence estradiol
0.31636134.15033916.html.plaintext.txt	17	Estradiol effect neurite outgrowth mice lacking ApoE gene ApoE4 isoform ApoE associated increased risk neurological disease exogenously supplied
0.31636134.15033916.html.plaintext.txt	18	Cultures mice transgenic human ApoE3 ApoE4 showed isoform specific effect
0.31636134.15033916.html.plaintext.txt	19	Neuronal internalization recombinant human ApoE3 greater ApoE4 ApoE3 effective ApoE4 facilitating neuronal uptake fatty acid
0.31636134.15033916.html.plaintext.txt	20	We conclude estradiol facilitates neurite growth ApoE dependent mechanism
0.31636134.15033916.html.plaintext.txt	21	The effects ERT chronic neurological diseases may vary ApoE genotype
0.31636134.15033916.html.plaintext.txt	22	The clinical use ERT may require ApoE genotyping optimal efficacy
0.31636134.15033916.html.plaintext.txt	23	Introduction Top Abstract Introduction Materials Methods Results Discussion References EPIDEMIOLOGICAL STUDIES SUGGEST estrogen replacement therapy ERT decreases risk rate progression several chronic neurological diseases
0.31636134.15033916.html.plaintext.txt	24	The majority epidemiological studies suggest history ERT decreases likelihood developing late life dementia 1 2 3 4 5 6
0.31636134.15033916.html.plaintext.txt	25	However Women Health Initiative trial continuous estrogen plus progestin arm discontinued early found protection dementia perhaps slight increase risk 7 8
0.31636134.15033916.html.plaintext.txt	26	A history ERT also may delay either onset progression Parkinson disease PD 9 10 11 12
0.31636134.15033916.html.plaintext.txt	27	These studies also mixed reporting change risk 9
0.31636134.15033916.html.plaintext.txt	28	Finally rate clinical progression multiple sclerosis attenuated estrogen 13 14
0.31636134.15033916.html.plaintext.txt	29	The disagreement studies emphasizes lack clear understanding mechanism whereby steroid replacement may decrease risk neurological diseases
0.31636134.15033916.html.plaintext.txt	30	Apolipoprotein E ApoE modifies risks several chronic neurological diseases
0.31636134.15033916.html.plaintext.txt	31	Humans three major isoforms ApoE ApoE2 ApoE3 ApoE4 produced three alleles 2 3 4 single gene locus chromosome 19 15 16
0.31636134.15033916.html.plaintext.txt	32	Inheritance 4 increases risk rate progression late onset Alzheimer disease 17 18 19
0.31636134.15033916.html.plaintext.txt	33	Individuals 4 alleles also appear earlier age onset PD greater risk developing dementia PD 20 21
0.31636134.15033916.html.plaintext.txt	34	Additionally 4 inheritance increases risk developing dementia head trauma 22 23 24 increases severity relapsing remitting multiple sclerosis 25 26
0.31636134.15033916.html.plaintext.txt	35	Neuronal repair may common factor diseases
0.31636134.15033916.html.plaintext.txt	36	Estradiol ApoE independently facilitate neuriteprocess outgrowth vivo vitro
0.31636134.15033916.html.plaintext.txt	37	Estradiol increases complexity neuritic growth axonal elongation vitro 27 28 29
0.31636134.15033916.html.plaintext.txt	38	Neuronal repair brain lesion rapid presence estradiol 30 31
0.31636134.15033916.html.plaintext.txt	39	ApoE similar estrogen dramatic effects neurite outgrowth variety cultured neurons
0.31636134.15033916.html.plaintext.txt	40	ApoE3 increases neurite outgrowth whereas absence ApoE treatment ApoE4 either decreases effect neurite outgrowth 32 33 34
0.31636134.15033916.html.plaintext.txt	41	Neuropathological studies documented deficits dendritic growth plasticity brains ApoE4 individuals 35
0.31636134.15033916.html.plaintext.txt	42	ApoE appears critical element neuronal growth repair
0.31636134.15033916.html.plaintext.txt	43	ApoE levels CNS vary estrous cycle 36 several studies show estradiol increase ApoE vivo 36 37 vitro 38 39
0.31636134.15033916.html.plaintext.txt	44	In sum observations suggest generalized mechanism whereby estrogen could increase ApoE levels
0.31636134.15033916.html.plaintext.txt	45	ApoE levels could facilitate process regrowth injury
0.31636134.15033916.html.plaintext.txt	46	We tested hypothesis cultured neurons adult mice
0.31636134.15033916.html.plaintext.txt	47	We found presence ApoE2 ApoE3 necessary obtain effect estrogen neurite outgrowth
0.31636134.15033916.html.plaintext.txt	48	In addition data suggest ApoE isoforms differential rates internalizaton lipid transport neurons
0.31636134.15033916.html.plaintext.txt	49	Materials Methods Top Abstract Introduction Materials Methods Results Discussion References Subjects An vitro culture paradigm adult cortical neurons 40 used examine effect 17ss estradiol estradiol ApoE levels neurite extension
0.31636134.15033916.html.plaintext.txt	50	The adult cortical culture procedure previously described 33 40
0.31636134.15033916.html.plaintext.txt	51	All procedures approved Eastern Illinois University Animal Care Committee
0.31636134.15033916.html.plaintext.txt	52	Control mice C57BL6 homozygous ApoE knockout KO mice bred 10 generations onto C57BL6 background C57BL6 Apoe tmiUnc obtained The Jackson Laboratory Bar Harbor ME
0.31636134.15033916.html.plaintext.txt	53	Transgenic tg human ApoE3 tg human ApoE4 mice gift Dr
0.31636134.15033916.html.plaintext.txt	54	David Holtzman Washington University St
0.31636134.15033916.html.plaintext.txt	55	The ApoE3 ApoE4 transgene inserted glial fibrillary acidic protein GFAP promoter region 34
0.31636134.15033916.html.plaintext.txt	56	Culture preparation For experiment 4 month old female mouse euthanized sodium pentobarbital 80 mgkg
0.31636134.15033916.html.plaintext.txt	57	The entire cerebral cortex dissected brain placed 2 ml B27Hibernate A medium B27HA Invitrogen Life Technologies Carlsbad CA 0
0.31636134.15033916.html.plaintext.txt	58	5 mm thickness transferred 50 ml tube containing 5 ml B27HA
0.31636134.15033916.html.plaintext.txt	59	After warming 8 min 30 C slices digested 6 ml 2 mgml papain Sigma solution B27HA 30 min 30 C gyrating water bath
0.31636134.15033916.html.plaintext.txt	60	The slices transferred 2 ml B27HA
0.31636134.15033916.html.plaintext.txt	61	After 2 min room temperature slices triturated 10 times siliconized 9 inch Pasteur pipette allowed settle 1 min
0.31636134.15033916.html.plaintext.txt	62	Approximately 2 ml supernatant transferred another tube sediment resuspended 2 ml B27HA
0.31636134.15033916.html.plaintext.txt	63	The step repeated twice total 6 ml collected
0.31636134.15033916.html.plaintext.txt	64	The resultant supernatant subjected density gradient centrifugation 800 x g 15 min
0.31636134.15033916.html.plaintext.txt	65	The density gradient prepared four 1 ml layers 35 25 20 15 Optiprep Invitrogen Life Technologies B27HA medium volvol
0.31636134.15033916.html.plaintext.txt	66	Debris 7 ml discarded
0.31636134.15033916.html.plaintext.txt	67	The rest fractions excluding bottom pellet collected diluted 5 ml B27HA
0.31636134.15033916.html.plaintext.txt	68	After centrifuging twice 200 x g 2 min cell pellets resuspended 3 ml B27neurobasal A medium Invitrogen Life Technologies 0
0.31636134.15033916.html.plaintext.txt	69	A total 4 x 104 cells plated 50 microl aliquots glass cover slips 12 mm diameter coated overnight poly D lysine 50 mgml Sigma
0.31636134.15033916.html.plaintext.txt	70	After 1 h incubation humidified incubator 37 C 5 CO2 cover slip rinsed twice B27HA transferred 24 well plate containing 0
0.31636134.15033916.html.plaintext.txt	71	4 ml B27neurobasal A medium 5 ngml fibroblast growth factor 2 Invitrogen Life Technologies
0.31636134.15033916.html.plaintext.txt	72	Estradiol 17ss Sigma dissolved 95 ethanol 40 microM added culture medium 1 d vitro 1 DIV incubation continued 4 DIV
0.31636134.15033916.html.plaintext.txt	73	Human recombinant ApoE3 ApoE4 Panvera Madison WI dialyzed overnight 0
0.31636134.15033916.html.plaintext.txt	74	The final concentrations estrogen ApoE test reagents culture medium varied based experiments
0.31636134.15033916.html.plaintext.txt	75	All quantification performed cells 4 DIV
0.31636134.15033916.html.plaintext.txt	76	Each experiment performed three times
0.31636134.15033916.html.plaintext.txt	77	ApoE quantification Media 4 DIV cultures collected centrifuged 5 min
0.31636134.15033916.html.plaintext.txt	78	ApoE immunoprecipitated incubating medium monoclonal anti ApoE 3H1 Heart Institute University Ottawa Ottawa Canada 11000 dilution media ice 1 h
0.31636134.15033916.html.plaintext.txt	79	After incubation 10 Protein A Sepharose CL 4B Sigma added 1100 medium incubated ice 1 h shaker
0.31636134.15033916.html.plaintext.txt	80	The medium centrifuged 11000 x g 15 min 4 C supernatant discarded
0.31636134.15033916.html.plaintext.txt	81	The pellet boiled 5 min 2x Lammeli sample buffer electrophoresed 4 20 sodium dodecyl sulfate polyacrylamide gradient gel EC120 Mini gel vertical system
0.31636134.15033916.html.plaintext.txt	82	The samples run 80 V separation began 140 V dye front neared bottom gel
0.31636134.15033916.html.plaintext.txt	83	After electrophoresis gel placed transfer buffer 3
0.31636134.15033916.html.plaintext.txt	84	4 g glycine 200 ml methanol 800 ml distilled H2O shaker 10 min
0.31636134.15033916.html.plaintext.txt	85	The transfer membrane Immobilon P Transfer Membrane Millipore Bedford MA first soaked methanol 5 sec washed distilled H2O 5 min remove excess methanol
0.31636134.15033916.html.plaintext.txt	86	The proteins gel transferred membrane using Bio Rad Hercules CA Trans blot Transfer Cell following manufacturer protocol
0.31636134.15033916.html.plaintext.txt	87	The membranes blocked TBS buffer 20 mM Tris HCl 150 mM NaCl pH 7
0.31636134.15033916.html.plaintext.txt	88	5 1 BSA 4 C overnight room temperature 1 h
0.31636134.15033916.html.plaintext.txt	89	After blocking membranes washed twice 5 min T TBS buffer TBS buffer 0
0.31636134.15033916.html.plaintext.txt	90	05 Tween 20 incubated goat antihuman ApoE Calbiochem San Diego CA 15000 dilution T TBS buffer 1 h shaker room temperature
0.31636134.15033916.html.plaintext.txt	91	The membranes washed four times 10 min T TBS buffer incubated horseradish peroxidase conjugated rabbit antigoat IgG Chemicon Temecula CA 110000 dilution T TBS buffer 1 h shaker room temperature
0.31636134.15033916.html.plaintext.txt	92	After washing five times 10 min T TBS buffer membranes incubated SuperSignal West Pico chemiluminescent substrate Pierce Rockford IL exposed Kodak BioMax Light 2 film Fisher Scientific Chicago IL
0.31636134.15033916.html.plaintext.txt	93	A 34 kDa band visualized consistent published molecular mass ApoE
0.31636134.15033916.html.plaintext.txt	94	Bands quantified densitometry Scion Image Frederick MD compared band recombinant human ApoE
0.31636134.15033916.html.plaintext.txt	95	Neurite extension Cells prepared described treated varying concentrations estradiol
0.31636134.15033916.html.plaintext.txt	96	1 nM vehicle estradiol included additional control
0.31636134.15033916.html.plaintext.txt	97	Single neurite extension length longest neurite neuron combined neurite length total length neurites neuron measured described previously 33
0.31636134.15033916.html.plaintext.txt	98	The first technique employed ocular micrometer measure longest neurite
0.31636134.15033916.html.plaintext.txt	99	The second technique measured total length neurites
0.31636134.15033916.html.plaintext.txt	100	A minimum ten cells per coverslip quantified
0.31636134.15033916.html.plaintext.txt	101	The values coverslip averaged yield mean longest length mean total length
0.31636134.15033916.html.plaintext.txt	102	Each experiment performed three times
0.31636134.15033916.html.plaintext.txt	103	The following experiments performed culture system
0.31636134.15033916.html.plaintext.txt	104	Experimental studies Time course ApoE levels estradiol treatment
0.31636134.15033916.html.plaintext.txt	105	The time course ApoE levels response exogenous estradiol examined
0.31636134.15033916.html.plaintext.txt	106	ApoE secretion adult mouse cultures evaluated incubating cells 0
0.31636134.15033916.html.plaintext.txt	107	After incubation medium collected secreted ApoE quantified immunoblotting immunoprecipitation
0.31636134.15033916.html.plaintext.txt	108	Dose response ApoE estradiol treatment
0.31636134.15033916.html.plaintext.txt	109	We obtained dose response curve ApoE levels estradiol addition wild type mice 3 d estradiol treatment dosages estradiol ranging 0
0.31636134.15033916.html.plaintext.txt	110	Cortical cells wild type mice treated varying concentrations estradiol 0
0.31636134.15033916.html.plaintext.txt	111	After 3 d amount secreted ApoE measured described
0.31636134.15033916.html.plaintext.txt	112	Dose response estradiol neurite extension
0.31636134.15033916.html.plaintext.txt	113	A second dose response study estradiol performed neurite outgrowth 4 DIV
0.31636134.15033916.html.plaintext.txt	114	Cultures prepared varying concentrations estradiol added cells 1 DIV
0.31636134.15033916.html.plaintext.txt	115	At 4 DIV cells evaluated neurite extension described
0.31636134.15033916.html.plaintext.txt	116	ApoE replacement neurite extension
0.31636134.15033916.html.plaintext.txt	117	We performed ApoE replacement studies estradiol treated cell cultures derived mice lacking ApoE gene ApoE KO The Jackson Laboratory
0.31636134.15033916.html.plaintext.txt	118	Cells incubated without 100 pM estradiol ethanol starting 1 DIV
0.31636134.15033916.html.plaintext.txt	119	Purified recombinant human ApoE isoforms added 3 microgml Panvera
0.31636134.15033916.html.plaintext.txt	120	This concentration comparable found human cerebrospinal fluid 41
0.31636134.15033916.html.plaintext.txt	121	After 4 DIV combined length neuritic trees obtained described
0.31636134.15033916.html.plaintext.txt	122	Estradiol effects neurite outgrowth tg mice
0.31636134.15033916.html.plaintext.txt	123	tg Mice expressing human ApoE3 ApoE4 control glial fibrillary acidic protein promoter 34 used evaluate effects endogenous ApoE estradiol stimulated neurite extension culture
0.31636134.15033916.html.plaintext.txt	124	In vivo mice show ApoE protein expression astrocytes Ref
0.31636134.15033916.html.plaintext.txt	125	Nathan personal observations
0.31636134.15033916.html.plaintext.txt	126	Cultures prepared evaluation 4 DIV
0.31636134.15033916.html.plaintext.txt	127	Because ApoE transfers lipids neurons endocytosis tested rate uptake exogenous ApoE lipid neurons cultures derived ApoE KO mice
0.31636134.15033916.html.plaintext.txt	128	We examined rate ApoE uptake rate fatty acid transported cultured neurons
0.31636134.15033916.html.plaintext.txt	129	Cultures 4 DIV ApoE KO mice incubated 1 h recombinant human ApoE3 human ApoE4 prepared immunocytochemical localization ApoE
0.31636134.15033916.html.plaintext.txt	130	Coverslips fixed 80 ethanol 1 h RT rinsed three times T TBS 0
0.31636134.15033916.html.plaintext.txt	131	Coverslips rinsed three times T TBS
0.31636134.15033916.html.plaintext.txt	132	Nonspecific binding blocked 1 BSA 15 ApoE KO mouse serum T TBS 1 h RT incubated 2 h room temperature goat anti ApoE antibody Chemicon 1200 dilution
0.31636134.15033916.html.plaintext.txt	133	After washing six times T TBS coverslips incubated fluorescently labeled antigoat antisera Pierce 30 min 1200 dilution washed five times T TBS 5 min
0.31636134.15033916.html.plaintext.txt	134	Control coverslips incubated 4 C
0.31636134.15033916.html.plaintext.txt	135	Coverslips mounted anti photobleach medium Vectashield Vector Laboratories Burlingame CA stored dark
0.31636134.15033916.html.plaintext.txt	136	Digital images 30 fields per coverslip x40 objective containing neurons obtained using fluorescence microscope excitation frequency 520 nm emission 492 nm digital camera Pixera Penguin 150CL maintaining identical exposure settings images
0.31636134.15033916.html.plaintext.txt	137	ApoE immunofluorescence measured quantifying mean optical fluorescence field using Scion Image software
0.31636134.15033916.html.plaintext.txt	138	The upper lower 20 bits cut eliminate nonspecific fluorescence mean density pixelsfield within range obtained
0.31636134.15033916.html.plaintext.txt	139	The data transformed scale 0 100 statistical analysis
0.31636134.15033916.html.plaintext.txt	140	Lipid uptake neurons quantified fluorescently labeled dodecanoic acid 44 difluoro 5 methyl 4 bora 3a4a diaza indacene 3 dodecanoic acid accumulation adult cortical neurons
0.31636134.15033916.html.plaintext.txt	141	Fluorescence absorption emission 500 510 nM respectively
0.31636134.15033916.html.plaintext.txt	142	Cells grown coverslips 4 d incubated 1 h 3 microgml either ApoE 3 ApoE 4 together 10 microgml fluorescently labeled lipid 44 difluoro 5 methyl 4 bora 3a4a diaza indacene 3 dodecanoic acid Molecular Probes Eugene OR
0.31636134.15033916.html.plaintext.txt	143	After incubation coverslips rinsed three times warm 37 C PBS fluorescent images digitized objective magnification x100 described
0.31636134.15033916.html.plaintext.txt	144	OD measured using Scion Image software described
0.31636134.15033916.html.plaintext.txt	145	Receptor inhibition ApoE uptake
0.31636134.15033916.html.plaintext.txt	146	To determine type lipoprotein receptors underlying effects ApoE isoforms neuronal internalization lipoproteins three different lipoprotein receptor inhibitors used 1 receptor associated protein RAP 5 microgml gift Dr
0.31636134.15033916.html.plaintext.txt	147	Dudley Strickland American Red Cross Rockville MD 2 lactoferrin LAC 10 microgml Sigma 3 heparinase I 10 Uml Sigma
0.31636134.15033916.html.plaintext.txt	148	Heparinase depletes cell surface heparan sulfate proteoglycans HSPGs bind ApoE enriched lipoproteins internalization via LRP whereas RAP LAC inhibits binding lipoproteins LRP
0.31636134.15033916.html.plaintext.txt	149	Cells 3 DIV ApoE KO mice preincubated 1 h medium alone medium containing one three inhibitors
0.31636134.15033916.html.plaintext.txt	150	Cultures subsequently treated 1 h recombinant ApoE3 ApoE4 prepared immunofluorescent localization ApoE
0.31636134.15033916.html.plaintext.txt	151	Images 10 neurons per coverslip digitized analyzed experimental condition
0.31636134.15033916.html.plaintext.txt	152	Statistical analysis Data experiment analyzed ANOVA
0.31636134.15033916.html.plaintext.txt	153	Per cell n 3 cases representing three replications experiment
0.31636134.15033916.html.plaintext.txt	154	When appropriate noted significant effect found ANOVA pair wise post hoc testing performed Bonferroni corrected tests maintain overall type I error rate P 0
0.31636134.15033916.html.plaintext.txt	155	In presence significant interaction data decomposed treated one way analysis Bonferroni corrected tests
0.31636134.15033916.html.plaintext.txt	156	Results Top Abstract Introduction Materials Methods Results Discussion References Time course ApoE levels estradiol treatment This experiment showed ApoE rapidly produced introduction estradiol
0.31636134.15033916.html.plaintext.txt	157	ANOVA time independent factor identified significant effect F716 81
0.31636134.15033916.html.plaintext.txt	158	Post hoc testing disclosed 4 h estradiol exposure resulted significant increase ApoE levels compared earlier time periods Fig
0.31636134.15033916.html.plaintext.txt	159	ApoE levels 4 48 h differ
0.31636134.15033916.html.plaintext.txt	160	Western blots ApoE showed expected band 34 kDa Fig
0.31636134.15033916.html.plaintext.txt	161	View larger version 15K FIG
0.31636134.15033916.html.plaintext.txt	162	Time course ApoE levels cultures response 100 pM 17ss estradiol added one DIV sampled 6 min 96 h
0.31636134.15033916.html.plaintext.txt	163	ApoE levels significantly increased 4 h addition estradiol remain elevated
0.31636134.15033916.html.plaintext.txt	164	Data presented mean plus minus SEM show variability point
0.31636134.15033916.html.plaintext.txt	165	Before 4 h variability among cultures ApoE levels extremely small
0.31636134.15033916.html.plaintext.txt	166	View larger version 21K FIG
0.31636134.15033916.html.plaintext.txt	167	Western blotting ApoE mixed cell cultures treatment estradiol
0.31636134.15033916.html.plaintext.txt	168	Little ApoE produced 4 h exposure estradiol
0.31636134.15033916.html.plaintext.txt	169	Dose response ApoE levels estradiol treatment We next examined effects increasing concentrations estradiol ApoE levels culture Fig
0.31636134.15033916.html.plaintext.txt	170	ANOVA found overall significance estradiol concentration ApoE levels F512 260
0.31636134.15033916.html.plaintext.txt	171	Post hoc testing Bonferroni corrected test showed higher dose estradiol significantly increased ApoE levels lower dose except 100 pM different 1 pM estradiol
0.31636134.15033916.html.plaintext.txt	172	A dose 1 nM estrogen exhibited highest response ApoE levels
0.31636134.15033916.html.plaintext.txt	173	A 10 nM concentration estrogen significantly smaller effect ApoE levels 1 pM 1 nM estradiol
0.31636134.15033916.html.plaintext.txt	174	Normal female mouse estradiol concentrations 10 80 pM throughout estrous cycle 42
0.31636134.15033916.html.plaintext.txt	175	Hence data suggest physiological concentration estradiol greatest effect supraphysiologic concentration less effective
0.31636134.15033916.html.plaintext.txt	176	View larger version 18K FIG
0.31636134.15033916.html.plaintext.txt	177	A Increasing concentrations estradiol significantly increase ApoE levels culture
0.31636134.15033916.html.plaintext.txt	178	Post hoc testing Bonferroni corrected test showed higher dose significant lower dose except 100 pM different 1 pM
0.31636134.15033916.html.plaintext.txt	179	Response 1 nM estrogen significantly higher doses
0.31636134.15033916.html.plaintext.txt	180	A 10 nM concentration estrogen significantly smaller effect ApoE levels than1 pM 1 nM estradiol
0.31636134.15033916.html.plaintext.txt	181	B Estradiol stimulates combined neuritic length
0.31636134.15033916.html.plaintext.txt	182	One way ANOVA showed significance P 0
0.31636134.15033916.html.plaintext.txt	183	Post hoc testing Bonferroni corrected tests showed 100 pM 1 nM estrogen significantly increased neuritic outgrowth compared control conditions estradiol ethanol alone
0.31636134.15033916.html.plaintext.txt	184	Note peak responses estrogen ApoE production neuritic outgrowth occurred identical estrogen concentrations
0.31636134.15033916.html.plaintext.txt	185	Dose response estradiol neurite extension This experiment examined effect increasing doses estradiol neurite outgrowth Fig
0.31636134.15033916.html.plaintext.txt	186	Neurons easily identifiable culture differential interference contrast microscopy Fig
0.31636134.15033916.html.plaintext.txt	187	4 previously confirmed immunocytochemistry 33
0.31636134.15033916.html.plaintext.txt	188	Longest neurite combined length correlated highly r 0
0.31636134.15033916.html.plaintext.txt	189	98 combined length reported
0.31636134.15033916.html.plaintext.txt	190	One way ANOVA showed significance estrogen treatment neurite extension F612 8
0.31636134.15033916.html.plaintext.txt	191	Post hoc testing indicated 100 pM 1 nM estrogen significantly increased neuritic outgrowth compared control conditions estradiol ethanol alone whereas response 10 nM estrogen differ control conditions
0.31636134.15033916.html.plaintext.txt	192	Therefore neuritic extension showed peak dosage effect estradiol ApoE levels
0.31636134.15033916.html.plaintext.txt	193	View larger version 123K FIG
0.31636134.15033916.html.plaintext.txt	194	Differential interference contrast digital image two adjacent neurons culture 4 DIV
0.31636134.15033916.html.plaintext.txt	195	This typical appearance neurons adult mouse cultures
0.31636134.15033916.html.plaintext.txt	196	A previous study 33 used antineurofilament antibody confirm conclusion
0.31636134.15033916.html.plaintext.txt	197	Note microglia lower left figure
0.31636134.15033916.html.plaintext.txt	198	ApoE replacement neurite extension Previous studies shown ApoE isoforms differential effects neurite outgrowth 32 33 34 43
0.31636134.15033916.html.plaintext.txt	199	This experiment determined combined effects 100 pM estradiol ApoE neurite growth cultures ApoE KO mice Fig
0.31636134.15033916.html.plaintext.txt	200	ANOVA showed significant main effect estradiol neuritic length F116 125
0.31636134.15033916.html.plaintext.txt	201	001 ApoE isoform F 256 F316 P 0
0.31636134.15033916.html.plaintext.txt	202	001 interaction estradiol treatment ApoE isoform F316 45
0.31636134.15033916.html.plaintext.txt	203	Decomposition interaction term post hoc one way ANOVA post hoc tests showed ApoE2 ApoE3 alone increased combined neurite length 30 compared cultures without ApoE ApoE4 F38 27
0.31636134.15033916.html.plaintext.txt	204	ApoE2 differ ApoE3 post hoc testing
0.31636134.15033916.html.plaintext.txt	205	These data replicate previous results 32 33
0.31636134.15033916.html.plaintext.txt	206	Analysis estradiol group also showed isoform specific effect F38 700
0.31636134.15033916.html.plaintext.txt	207	Bonferroni corrected post hoc testing showed combined neurite length KO group equivalent ApoE4 replacement group less ApoE2 P 0
0.31636134.15033916.html.plaintext.txt	208	Estradiol increased neuritic length combined ApoE2 95 ApoE3 79 absence ApoE treatment ApoE4
0.31636134.15033916.html.plaintext.txt	209	Post hoc testing found difference ApoE2 ApoE3 significant P 0
0.31636134.15033916.html.plaintext.txt	210	In sum estradiol increased neurite outgrowth presence ApoE2 ApoE3 estradiol greater effect neurite growth presence ApoE2 compared ApoE3
0.31636134.15033916.html.plaintext.txt	211	View larger version 22K FIG
0.31636134.15033916.html.plaintext.txt	212	Estradiol ApoE isoform specific effect neuritic outgrowth cultures derived ApoE KO mice
0.31636134.15033916.html.plaintext.txt	213	ANOVA showed overall significant interaction ApoE replacement estradiol treatment P 0
0.31636134.15033916.html.plaintext.txt	214	Post hoc testing found estradiol effect cultures lacking ApoE supplemented ApoE4
0.31636134.15033916.html.plaintext.txt	215	Inclusion ApoE2 ApoE3 absence estrogen significantly increased neuritic extent compared ApoE ApoE4
0.31636134.15033916.html.plaintext.txt	216	Estradiol increased neurite outgrowth beyond ApoE alone ApoE2 ApoE3 conditions
0.31636134.15033916.html.plaintext.txt	217	In addition neuritic extent significantly greater P 0
0.31636134.15033916.html.plaintext.txt	218	003 ApoE2 ApoE3 group line
0.31636134.15033916.html.plaintext.txt	219	Estradiol effects neurite outgrowth tg mice To determine whether endogenously produced ApoE isoforms differentially modulate estradiol induced neurite outgrowth added estradiol neuronal cultures derived tg mice expressing either ApoE3 ApoE4
0.31636134.15033916.html.plaintext.txt	220	After treatment neuronal cultures estradiol secreted ApoE levels Fig
0.31636134.15033916.html.plaintext.txt	221	6A comparable genotypes F18 0
0.31636134.15033916.html.plaintext.txt	222	Estradiol 100 pM significantly increased ApoE levels 30 cultures genotypes F18 81
0.31636134.15033916.html.plaintext.txt	223	There interaction estradiol treatment ApoE levels two genotypes F18 0
0.31636134.15033916.html.plaintext.txt	224	View larger version 19K FIG
0.31636134.15033916.html.plaintext.txt	225	A Amounts ApoE produced estradiol stimulation ApoE tg mice
0.31636134.15033916.html.plaintext.txt	226	Treatment 100 pM 17ss estradiol increased ApoE levels ApoE tg mice cultures 30 compared vehicle treated cultures
0.31636134.15033916.html.plaintext.txt	227	The effect genotype specific
0.31636134.15033916.html.plaintext.txt	228	B Neuritic extent ApoE tg mice
0.31636134.15033916.html.plaintext.txt	229	ApoE3 tg mice cultures greater combined neurite outgrowth ApoE4 tg mice
0.31636134.15033916.html.plaintext.txt	230	Estradiol increased difference
0.31636134.15033916.html.plaintext.txt	231	Estradiol effect neuritic extent ApoE4 tg cultures although increased ApoE levels equal estradiol treated ApoE3 tg cultures
0.31636134.15033916.html.plaintext.txt	232	Combined length neurites Fig
0.31636134.15033916.html.plaintext.txt	233	6B significantly greater ApoE3 tg ApoE4 tg mouse cultures F18 390
0.31636134.15033916.html.plaintext.txt	234	Estradiol treatment increased total length F18 58
0.31636134.15033916.html.plaintext.txt	235	There significant interaction genotype estradiol treatment
0.31636134.15033916.html.plaintext.txt	236	There effect combined neuritic length ApoE4 tg mouse cultures whereas neuritic extent increased ApoE3 tg mouse cultures F18 53
0.31636134.15033916.html.plaintext.txt	237	In essence neurites longer cultures ApoE3 tg mice estradiol increased differential cultures ApoE3 tg mice
0.31636134.15033916.html.plaintext.txt	238	ApoElipid uptake studies In experiment evaluated rate internalization two ApoE isoforms ApoE3 ApoE4 adult culture model replicate previous results higher concentrations ApoE neuroblastoma cells 32
0.31636134.15033916.html.plaintext.txt	239	We also evaluated rate uptake fluorescently labeled fatty acid function ApoE isoform
0.31636134.15033916.html.plaintext.txt	240	There less intracellular accumulation ApoE4 ApoE3 Fig
0.31636134.15033916.html.plaintext.txt	241	ApoE like immunoreactivity within neurons incubated ApoE3 significantly greater F120 6
0.31636134.15033916.html.plaintext.txt	242	02 ApoE4 previously reported 32
0.31636134.15033916.html.plaintext.txt	243	ANOVA showed neither significant effect time post addition ApoE F420 2
0.31636134.15033916.html.plaintext.txt	244	128 interaction time type ApoE F420 0
0.31636134.15033916.html.plaintext.txt	245	ApoE like immunoreactivity intense cell body extended processes vesicular like accumulations Fig
0.31636134.15033916.html.plaintext.txt	246	View larger version 20K FIG
0.31636134.15033916.html.plaintext.txt	247	A Accumulation ApoE isoforms neurons
0.31636134.15033916.html.plaintext.txt	248	ANOVA showed significant effect ApoE type P 0
0.31636134.15033916.html.plaintext.txt	249	More ApoE3 immunoreactivity found within neurons ApoE4
0.31636134.15033916.html.plaintext.txt	250	No factor reached statistical significance
0.31636134.15033916.html.plaintext.txt	251	B Lipid accumulation 1 h incubation ApoE isoforms absence ApoE KO
0.31636134.15033916.html.plaintext.txt	252	Recombinant ApoE3 facilitated fluorescently labeled dodecanoic acid accumulation neurons compared recombinant ApoE4
0.31636134.15033916.html.plaintext.txt	253	Post hoc testing showed ApoE3 ApoE4 ApoE KO total lipid uptake
0.31636134.15033916.html.plaintext.txt	254	View larger version 31K FIG
0.31636134.15033916.html.plaintext.txt	255	Immunofluoresence localization ApoE3 ApoE4 neurons
0.31636134.15033916.html.plaintext.txt	256	Neuronal internalization ApoE4 less efficient ApoE3
0.31636134.15033916.html.plaintext.txt	257	At time zero A B intensity intracellular immunoreactivity ApoE3 ApoE4 roughly comparable
0.31636134.15033916.html.plaintext.txt	258	Greater uptake ApoE 3 E4 seen 1 h C D
0.31636134.15033916.html.plaintext.txt	259	The ApoE also present vesicular like structures neurites
0.31636134.15033916.html.plaintext.txt	260	A comparable ApoE isoform specific effect fatty acid accumulation neurons present F26142
0.31636134.15033916.html.plaintext.txt	261	Accumulation fluorescent lipid cells cultured ApoE3 approximately twice P 0
0.31636134.15033916.html.plaintext.txt	262	001 post hoc test cells treated ApoE4 displayed vesicular appearance processes neurons ApoE Fig
0.31636134.15033916.html.plaintext.txt	263	ApoE4 roughly doubled P 0
0.31636134.15033916.html.plaintext.txt	264	001 post hoc test amount lipid internalized compared absence ApoE Fig
0.31636134.15033916.html.plaintext.txt	265	ApoE4 much less effective ApoE3 intracellular transport lipids although effective ApoE treatment
0.31636134.15033916.html.plaintext.txt	266	View larger version 24K FIG
0.31636134.15033916.html.plaintext.txt	267	Uptake fluorescently labeled dodecanoic acid
0.31636134.15033916.html.plaintext.txt	268	Uptake absence ApoE A less ApoE3 B ApoE4 C present
0.31636134.15033916.html.plaintext.txt	269	The perikaryal size equivalent condition appears greater ApoE3 fluorescent lipid cell body
0.31636134.15033916.html.plaintext.txt	270	Note fluorescence vesicular like neurites
0.31636134.15033916.html.plaintext.txt	271	Receptor inhibition ApoE uptake This experiment performed determine receptor specificity ApoE uptake adult neuronal cultures
0.31636134.15033916.html.plaintext.txt	272	Neither ApoE3 ApoE4 like immunoreactivity found neurons treated heparinase I therefore statistical analysis performed
0.31636134.15033916.html.plaintext.txt	273	A repeated measures ANOVA ApoE accumulation neurons RAP LAC compared inhibitor inhibition condition repeated measure showed significant main effect ApoE isoform F14 383
0.31636134.15033916.html.plaintext.txt	274	Overall less ApoE4 entered neurons ApoE3
0.31636134.15033916.html.plaintext.txt	275	A significant effect inhibitor compared inhibitor found F28 2381
0.31636134.15033916.html.plaintext.txt	276	In addition significant interaction isoform inhibitor F24 372
0.31636134.15033916.html.plaintext.txt	277	Calculating percent inhibition Fig
0.31636134.15033916.html.plaintext.txt	278	10B untreated condition showed LAC inhibited ApoE3 uptake 91 ApoE4 uptake 97
0.31636134.15033916.html.plaintext.txt	279	In contrast RAP inhibited ApoE3 uptake 76 ApoE4 99
0.31636134.15033916.html.plaintext.txt	280	View larger version 19K FIG
0.31636134.15033916.html.plaintext.txt	281	A Inhibition ApoE immunoreactivity cells LAC RAP
0.31636134.15033916.html.plaintext.txt	282	Note RAP greater effect ApoE4 ApoE3
0.31636134.15033916.html.plaintext.txt	283	Roughly equivalent inhibitory effects ApoE isoforms shown LAC
0.31636134.15033916.html.plaintext.txt	284	B Plotting inhibition B emphasizes differential effect RAP ApoE3 vs
0.31636134.15033916.html.plaintext.txt	285	Discussion Top Abstract Introduction Materials Methods Results Discussion References Numerous studies shown estradiol modifies neuronal growth culture see Ref
0.31636134.15033916.html.plaintext.txt	286	Generally effects increase survival process extension
0.31636134.15033916.html.plaintext.txt	287	The general assumption studies direct effect estradiol neuronal activation growth
0.31636134.15033916.html.plaintext.txt	288	This assumption may simplistic
0.31636134.15033916.html.plaintext.txt	289	Our data suggest ApoE plays important role neuronal activation growth stimulated estradiol
0.31636134.15033916.html.plaintext.txt	290	Previous data suggest glia primary source ApoE 45 46 47 studies ApoE tg mice support
0.31636134.15033916.html.plaintext.txt	291	Therefore selected mixed culture derived adult mouse brain evaluate estradiol effects ApoE levels neuronal process growth
0.31636134.15033916.html.plaintext.txt	292	Adult cortical neuronal cultures contain microglia astroglia early culture
0.31636134.15033916.html.plaintext.txt	293	Our previous study showed neurons comprise 70 total cells astroglia 15 microglia 15 4 DIV 33
0.31636134.15033916.html.plaintext.txt	294	Glial derived factors important synaptogenesis see Ref
0.31636134.15033916.html.plaintext.txt	295	48 inclusion glia culture may required see broader spectrum effects estrogen neurons vitro
0.31636134.15033916.html.plaintext.txt	296	For example previous report shown microglia astroglia must present obtain estrogen induced increase ApoE mRNA 38
0.31636134.15033916.html.plaintext.txt	297	Hence monotypic cell culture may give biased interpretation critical estradiol effects interactions exist glia neurons
0.31636134.15033916.html.plaintext.txt	298	Data previous studies suggest direct relationship ApoE neurite outgrowth 32 33 34 49 50
0.31636134.15033916.html.plaintext.txt	299	We found physiological concentration estradiol maximal effect ApoE levels neurite outgrowth
0.31636134.15033916.html.plaintext.txt	300	Our data also suggest synergistic effect estradiol ApoE estradiol effects neurite outgrowth facilitated ApoE3 ApoE4
0.31636134.15033916.html.plaintext.txt	301	ApoE3 alone increased neurite extent 30
0.31636134.15033916.html.plaintext.txt	302	But combined estradiol neuritic growth increased 70 80
0.31636134.15033916.html.plaintext.txt	303	In addition ApoE2 significantly effective ApoE3 facilitating neurite outgrowth presence estradiol
0.31636134.15033916.html.plaintext.txt	304	This effect corresponds studies suggest protective effect ApoE2 dementia see Ref
0.31636134.15033916.html.plaintext.txt	305	In addition differential effects ApoE3 vs
0.31636134.15033916.html.plaintext.txt	306	ApoE4 confirmed using tg mice expressing ApoE3 ApoE4
0.31636134.15033916.html.plaintext.txt	307	Estrogen increased levels ApoE3 ApoE4 similar extent adult cultures derived ApoE3 ApoE4 tg mice however ApoE3 isoform effective facilitating neurite outgrowth presence estradiol
0.31636134.15033916.html.plaintext.txt	308	A partial mechanism differential effects ApoE3 ApoE4 suggested uptake studies
0.31636134.15033916.html.plaintext.txt	309	The procedure used preparing adult cultures strips cell processes
0.31636134.15033916.html.plaintext.txt	310	During next 4 d extensive neurite sprouting occurs
0.31636134.15033916.html.plaintext.txt	311	Estradiol may stimulate neurons extend processes concurrently stimulate astroglia perhaps microglia produce ApoE
0.31636134.15033916.html.plaintext.txt	312	Glial derived ApoE supplies lipids neuronal membrane synthesis function
0.31636134.15033916.html.plaintext.txt	313	Our receptor inhibition studies suggest ApoE3 ApoE4 using low density lipoprotein receptor related protein HSPG neurite outgrowth 33 49
0.31636134.15033916.html.plaintext.txt	314	However neuronal growth slowed disrupted absence ApoE presence ApoE4
0.31636134.15033916.html.plaintext.txt	315	It worth noting ApoE4 reported show toxic effects culture 52 disrupt microtubule polymerization although 10 fold higher concentrations used study 32
0.31636134.15033916.html.plaintext.txt	316	Hence less complex neuritic field seen cells incubated ApoE4 may represent deficiency lipid combination toxic effects ApoE4
0.31636134.15033916.html.plaintext.txt	317	Process extension neuronal repair vivo may critical factor rate progression chronic neurological diseases
0.31636134.15033916.html.plaintext.txt	318	In dementia trauma degeneration repair may dynamic balance
0.31636134.15033916.html.plaintext.txt	319	Dementia cognitive decline may occur degenerative processes exceed regenerative responses
0.31636134.15033916.html.plaintext.txt	320	ApoE4 may tip scales slower incomplete regeneration accelerate cognitive decline rapidly ApoE2 ApoE3
0.31636134.15033916.html.plaintext.txt	321	Of interest ApoE4 shown dominant negative factor mice expressing ApoE3 ApoE4 49 53
0.31636134.15033916.html.plaintext.txt	322	ERT may less protective 4 allele previously noted 54
0.31636134.15033916.html.plaintext.txt	323	The full benefit ERT protection chronic neurological diseases may compromised presence ApoE4
0.31636134.15033916.html.plaintext.txt	324	Clinical studies evaluate protective effects ERT estradiol like compounds may need consider ApoE genotype obtain optimal efficacy
0.31636134.15033916.html.plaintext.txt	325	Acknowledgments The GFAP ApoE3 GFAP ApoE4 tg mice generously provided Dr
0.31636134.15033916.html.plaintext.txt	326	Holtzman Washington University St
0.31636134.15033916.html.plaintext.txt	327	RAP generous gift Dr
0.31636134.15033916.html.plaintext.txt	328	Dudley Strickland American Red Cross Rockville MD
0.31636134.15033916.html.plaintext.txt	329	Footnotes This research funded Illinois Department Public Health Alzheimer Fund B
0.31636134.15033916.html.plaintext.txt	330	National Institutes Health Academic Research Enhancement Award B
0.31636134.15033916.html.plaintext.txt	331	Eastern Illinois University council faculty research grants B
0.31636134.15033916.html.plaintext.txt	332	Southern Illinois University School Medicine Central Research Committee R
0.31636134.15033916.html.plaintext.txt	333	Abbreviations apoE Apolipoprotein E DIV days vitro ERT estrogen replacement therapy GFAP glial fibrillary acidic protein HA Hibernate A HSPG heparan sulfate proteoglycan KO knockout LAC lactoferrin PD Parkinson disease RAP receptor associated protein tg transgenic
0.31636134.15033916.html.plaintext.txt	334	Accepted publication March 11 2004
0.31636134.15033916.html.plaintext.txt	335	References Top Abstract Introduction Materials Methods Results Discussion References Paganini Hill A Henderson V 1994 Estrogen deficiency risk Alzheimer disease women
0.31636134.15033916.html.plaintext.txt	336	Am J Epidemiol 140256 261Abstract Brenner DE Kukull WA Stergachis A van Belle G Bowen JD McCormick WC Teri L Larson EB 1994 Postmenopausal estrogen replacement therapy risk Alzheimer disease population based case control study
0.31636134.15033916.html.plaintext.txt	337	Am J Epidemiol 140262 267Abstract Tang MX Jacobs D Stern Y Marder K Schofield P Gurland B Andrews H Mayeux R 1996 Effect oestrogen menopause risk age onset Alzheimer disease
0.31636134.15033916.html.plaintext.txt	338	Lancet 348429 432CrossRefMedline Kawas C Resnick S Morrison A Brookmeyer R Corrada M Zonderman A Bacal C Lingle DD Metter E 1997 A prospective study estrogen replacement therapy risk developing Alzheimer disease Baltimore Longitudinal Study Aging
0.31636134.15033916.html.plaintext.txt	339	Neurology 481517 1521Abstract LeBlanc ES Janowsky J Chan BK Nelson HD 2001 Hormone replacement therapy cognition systematic review meta analysis
0.31636134.15033916.html.plaintext.txt	340	JAMA 2851489 1499AbstractFree Full Text Zandi PP Carlson MC Plassman BL Welsh Bohmer KA Mayer LS Steffens DC Breitner JC 2002 Hormone replacement therapy incidence Alzheimer disease older women Cache County Study
0.31636134.15033916.html.plaintext.txt	341	JAMA 2882123 2129AbstractFree Full Text Rapp SR Espeland MA Shumaker SA Henderson VW Brunner RL Manson JE Gass ML Stefanick ML Lane DS Hays J Johnson KC Coker LH Dailey M Bowen D WHIMS Investigators 2003 Effect estrogen plus progestin global cognitive function postmenopausal women Women Health Initiative Memory Study randomized controlled trial
0.31636134.15033916.html.plaintext.txt	342	JAMA 2892663 2672AbstractFree Full Text Shumaker SA Legault C Rapp SR Thal L Wallace RB Ockene JK Hendrix SL Jones 3rd BN Assaf AR Jackson RD Kotchen JM Wassertheil Smoller S Wactawski Wende J WHIMS Investigators 2003 Estrogen plus progestin incidence dementia mild cognitive impairment postmenopausal women Women Health Initiative Memory Study randomized controlled trial
0.31636134.15033916.html.plaintext.txt	343	JAMA 2892651 2662AbstractFree Full Text Mayeux R Marder K Cote LJ Denaro J Hemenegildo N Mejia H Tang MX Lantigua R Wilder D Gurland B 1995 The frequency idiopathic Parkinson disease age ethnic group sex Northern Manhattan 1988 1993
0.31636134.15033916.html.plaintext.txt	344	Am J Epidemiol 142820 827Abstract Kuopio AM Marttila RJ Helenius H Rinne UK 1999 Changing epidemiology Parkinson disease southwestern Finland
0.31636134.15033916.html.plaintext.txt	345	Neurology 52302 308AbstractFree Full Text Saunders Pullman R Gordon Elliott J Parides M Fahn S Saunders HR Bressman S 1999 The effect estrogen replacement early Parkinson disease
0.31636134.15033916.html.plaintext.txt	346	Neurology 521417 1421AbstractFree Full Text Marder K Tang MX Alfaro B Mejia H Cote L Jacobs D Stern Y Sano M Mayeux R 1998 Postmenopausal estrogen use Parkinson disease without dementia
0.31636134.15033916.html.plaintext.txt	347	Neurology 501141 1143Abstract Smith R Studd JW 1992 A pilot study effect upon multiple sclerosis menopause hormone replacement therapy menstrual cycle
0.31636134.15033916.html.plaintext.txt	348	J R Soc Med 85612 613Abstract Sicotte NL Liva SM Klutch R Pfeiffer P Bouvier S Odesa S Wu TC Voskuhl RR 2002 Treatment multiple sclerosis pregnancy hormone estriol
0.31636134.15033916.html.plaintext.txt	349	Ann Neurol 52421 428CrossRefMedline Mahley RW 1988 Apolipoprotein E cholesterol transport protein expanding role cell biology
0.31636134.15033916.html.plaintext.txt	350	Science 240622 630Medline Weisgraber KH 1994 Apolipoprotein E structure function relationships
0.31636134.15033916.html.plaintext.txt	351	Adv Protein Chem 45249 302Medline Corder EH Saunders AM Strittmatter WJ Schmechel DE Gaskell PC Small GW Roses AD Haines JL Pericak Vance MA 1993 Gene dose apolipoprotein E type 4 allele risk Alzheimer disease late onset families
0.31636134.15033916.html.plaintext.txt	352	Science 261921 923Medline Roses AD 1997 Apolipoprotein E gene complex biological interactions aging brain
0.31636134.15033916.html.plaintext.txt	353	Neurobiol Dis 4170 185CrossRefMedline Strittmatter WJ Roses AD 1996 Apolipoprotein E Alzheimer
0.31636134.15033916.html.plaintext.txt	354	Annu Rev Neurosci 1953 77CrossRefMedline Tang G Xie H Xu L Hao Y Lin D Ren D 2002 Genetic study apolipoprotein E gene 1 antichymotrypsin gene sporadic Parkinson disease
0.31636134.15033916.html.plaintext.txt	355	Am J Med Genet 114446 449CrossRefMedline Zareparsi S Camicioli R Sexton G Bird T Swanson P Kaye J Nutt J Payami H 2002 Age onset Parkinson disease apolipoprotein E genotypes
0.31636134.15033916.html.plaintext.txt	356	Am J Med Genet 107156 161CrossRefMedline Mayeux R Ottman R Maestre G Ngai C Tang MX Ginsberg H Chun M Tycko B Shelanski M 1995 Synergistic effects traumatic head injury apolipoprotein 4 patients Alzheimer disease
0.31636134.15033916.html.plaintext.txt	357	Neurology 45555 557Abstract Teasdale GM Nicoll JA Murray G Fiddes M 1997 Association apolipoprotein E polymorphism outcome head injury
0.31636134.15033916.html.plaintext.txt	358	Lancet 3501069 1071CrossRefMedline Jordan BD Relkin NR Ravdin LD Jacobs AR Bennett A Gandy S 1997 Apolipoprotein E 4 associated chronic traumatic brain injury
0.31636134.15033916.html.plaintext.txt	359	JAMA 278136 140Abstract Fazekas F Strasser Fuchs S Kollegger H Berger T Kristoferitsch W Schmidt H Enzinger C Schiefermeier M Schwarz C Kornek B Reindl M Huber K Grass R Wimmer G Vass K Pfeiffer KH Hartung HP Schmidt R 2001 Apolipoprotein E epsilon 4 associated rapid progression multiple sclerosis
0.31636134.15033916.html.plaintext.txt	360	Neurology 57853 857AbstractFree Full Text Masterman T Zhang Z Hellgren D Salter H Anvret M Lilius L Lannfelt L Hillert J 2002 APOE genotypes disease severity multiple sclerosis
0.31636134.15033916.html.plaintext.txt	361	Mult Scler 898 103CrossRefMedline Ferreira A Caceres A 1991 Estrogen enhanced neurite growth evidence selective induction stable microtubules
0.31636134.15033916.html.plaintext.txt	362	J Neurosci 11392 401Abstract Diaz H Lorenzo A Carrer HF Caceres A 1992 Time lapse study neurite growth hypothalamic dissociated neurons culture sex differences estrogen
0.31636134.15033916.html.plaintext.txt	363	J Neurosci Res 33266 281Medline Brinton RD Tran J Proffitt P Montoya M 1997 17beta Estradiol enhances outgrowth survival neocortical neurons culture
0.31636134.15033916.html.plaintext.txt	364	Neurochem Res 221339 1351CrossRefMedline Morse JK DeKosky ST Scheff SW 1992 Neurotrophic effects steroids lesion induced growth thehippocampus
0.31636134.15033916.html.plaintext.txt	365	Exp Neurol 11847 52Medline Stone DJ Rozovsky I MorganTE Anderson CP Finch CE 1998 Increased synaptic sprouting response estrogen via apolipoprotein E dependent mechanism implications Alzheimer disease
0.31636134.15033916.html.plaintext.txt	366	J Neurosci 183180 3185AbstractFree Full Text Nathan BP Chang KC Bellosta S Brisch E Ge N Mahley RW Pitas RE 1995 The inhibitory effect apolipoprotein E4 neurite outgrowth associated microtubule depolymerization
0.31636134.15033916.html.plaintext.txt	367	J Biol Chem 27019791 19799AbstractFree Full Text Nathan BP Jiang Y Wong GK Shen F Brewer GJ Struble RG 2002 Apolipoprotein E4 inhibits apolipoprotein E3 promotes neurite outgrowth cultured adult mouse cortical neurons low density lipoprotein receptor related protein
0.31636134.15033916.html.plaintext.txt	368	Brain Res 92896 105CrossRefMedline Sun Y Wu S Bu G Onifade MK Patel SN LaDu MJ Fagan AM Holtzman DM 1998 Glial fibrillary acidic protein apolipoprotein E apoE transgenic mice astrocyte specific expression differing biological effects astrocyte secreted apoE3 apoE4 lipoproteins
0.31636134.15033916.html.plaintext.txt	369	J Neurosci 183261 3272AbstractFree Full Text Arendt T Schindler C Bruckner MK Eschrich K Bigl V Zedlick D Marcova L 1997 Plastic neuronal remodeling impaired patients Alzheimer disease carrying apolipoprotein 4 allele
0.31636134.15033916.html.plaintext.txt	370	J Neurosci 17516 529AbstractFree Full Text Struble RG Rosario ER Kircher ML Ludwig SM McAdamis PJ Watabe K McAsey ME Cady C Nathan BP 2003 Regionally specific modulation brain apolipoprotein E mouse estrous cycle exogenous 17ss estradiol
0.31636134.15033916.html.plaintext.txt	371	Exp Neurol 183638 644CrossRefMedline Levin Allerhand J McEwen BS Lominska CE Lubahn DB Korach KS Smith JD 2001 Brain region specific regulation mouse apoliporotein E pharmacological estrogen treatments
0.31636134.15033916.html.plaintext.txt	372	J Neurochem 79796 803CrossRefMedline Stone DJ Rozovsky I Morgan TE Anderson CP Hajian H Finch CE 1997 Astrocytes microglia respond estrogen increased apoE mRNA vivo vitro
0.31636134.15033916.html.plaintext.txt	373	Exp Neurol 143313 318CrossRefMedline Rozovsky I Hoving S Anderson CP O Callaghan J Finch CE 2002 Equine estrogens induce apolipoprotein E glial fibrillary acidic protein mixed cultures
0.31636134.15033916.html.plaintext.txt	374	Neurosci Lett 323191 194CrossRefMedline Brewer GJ 1997 Isolation culture adult rat hippocampal neurons
0.31636134.15033916.html.plaintext.txt	375	J Neurosci Methods 71143 155CrossRefMedline Demeester N Castro G Desrumaux C De Geitere C Fruchart JC Santens P Mulleners E Engelborghs S De Deyn PP Vandekerckhove J Rosseneu M Labeur C 2000 Characterization functional studies lipoproteins lipid transfer proteins lecithincholesterol acyltransferase CSF normal individuals patients Alzheimer disease
0.31636134.15033916.html.plaintext.txt	376	J Lipid Res 41963 974AbstractFree Full Text Walmer DK Wrona MA Hughes CL Nelson KG 1992 Lactoferrin expression mouse reproductive tract natural estrous cycle correlation circulating estradiol progesterone
0.31636134.15033916.html.plaintext.txt	377	Endocrinology 1311458 1466Abstract Teter B Xu PT Gilbert JR Roses AD Galasko D Cole GM 2002 Defective neuronal sprouting human apolipoprotein E4 gain negative function
0.31636134.15033916.html.plaintext.txt	378	J Neurosci Res 68331 336CrossRefMedline Brinton RD 2001 Cellular molecular mechanisms estrogen regulation memory function neuroprotection Alzheimer disease recent insights remaining challenges
0.31636134.15033916.html.plaintext.txt	379	Learn Mem 8121 133AbstractFree Full Text Boyles JK Pitas RE Wilson E Mahley RW Taylor JM 1985 Apolipoprotein E associated astrocytic glia central nervous system nonmyelinating glia peripheral nervous system
0.31636134.15033916.html.plaintext.txt	380	J Clin Invest 761501 1513Medline Pitas RE Boyles JK Lee SH Foss D Mahley RW 1987 Astrocytes synthesize apolipoprotein E metabolize apolipoprotein E containing lipoproteins
0.31636134.15033916.html.plaintext.txt	381	Biochim Biophys Acta 91748 61Medline Nathan BP Nisar R Randall S Short J Sherrow M Wong GK Struble RG 2001 Time course apolipoprotein E levels following olfactory nerve lesioning mice
0.31636134.15033916.html.plaintext.txt	382	Exp Neurol 172128 136CrossRefMedline Slezak M Pfrieger FW 2003 New roles astrocytes Regulation CNS synaptogenesis
0.31636134.15033916.html.plaintext.txt	383	Trends Neurosci 26531 535CrossRefMedline Holtzman DM Pitas RE Kilbridge J Nathan B Mahley RW Bu G Schwartz AL 1995 Low density lipoprotein receptor related protein mediates apolipoprotein E dependent neurite outgrowth central nervous system derived neuronal cell line
0.31636134.15033916.html.plaintext.txt	384	Proc Natl Acad Sci USA 929480 9484Abstract Bellosta S Nathan BP Orth M Dong LM Mahley RW Pitas RE 1995 Stable expression secretion apolipoproteins E3 E4 mouse neuroblastoma cells produces differential effects neurite outgrowth
0.31636134.15033916.html.plaintext.txt	385	J Biol Chem 27027063 27071AbstractFree Full Text Saunders AM 2000 Apolipoprotein E Alzheimer disease update genetic functional analyses
0.31636134.15033916.html.plaintext.txt	386	J Neuropathol Exp Neurol 59751 758Medline Qiu Z Crutcher KA Hyman BT Rebeck GW 2003 ApoE isoforms affect neuronal N methyl D aspartate calcium responses toxicity via receptor mediated processes
0.31636134.15033916.html.plaintext.txt	387	Neuroscience 122291 303CrossRefMedline Buttini M Akeefe H Lin C Mahley RW Pitas RE Wyss Coray T Mucke L 2000 Dominant negative effects apolipoprotein E4 revealed transgenic models neurodegenerative disease
0.31636134.15033916.html.plaintext.txt	388	Neuroscience 97207 210CrossRefMedline Yaffe K Haan M Byers A Tangen C Kuller L 2000 Estrogen use APOE cognitive decline evidence gene environment interaction
0.31636134.15033916.html.plaintext.txt	389	Neurology 541949 1954AbstractFree Full Text
0.43928444.10587578.html.plaintext.txt	0	Independent association APOE gene promoter polymorphism increased risk myocardial infarction decreased APOE plasma concentrations ECTIM Study Jean Charles Lambert1 Thierry Brousseau13 Veronique Defosse1 Alun Evans4 Dominique Arveiler5 Jean Bernard Ruidavets6 Bernadette Haas5 Jean Pierre Cambou6 Gerald Luc2 Pierre Ducimetiere7 Francois Cambien8 Marie Christine Chartier Harlin1 Philippe Amouyel1
0.43928444.10587578.html.plaintext.txt	1	1INSERM U508 2INSERM U325 Institut Pasteur de Lille 1 rue du Professeur Calmette 59019 Lille cedex France 3Faculte des Sciences Pharmaceutiques et Biologiques 3 rue du Professeur Laguesse 59006 Lille cedex France 4Belfast MONICA Project Department Epidemiology Public Health The Queen University Belfast Belfast BT12 6BJ UK 5Strasbourg MONICA Project Laboratoire d Epidemiologie Faculte de Medecine 67085 Strasbourg cedex France 6INSERM U518 Faculte de Medecine Toulouse Purpan 31073 Toulouse cedex France 7INSERM U258 Hopital Paul Brousse 16 avenue Paul Vaillant Couturier 94807 Villejuif cedex France 8INSERM SC7 17 rue du Fer Moulin 75005 Paris France
0.43928444.10587578.html.plaintext.txt	2	Received 17 July 1999 Revised Accepted 17 October 1999
0.43928444.10587578.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Apolipoprotein E APOE major protein lipid metabolism existing three common isoforms APOE2 3 4
0.43928444.10587578.html.plaintext.txt	4	The 4 allele APOE gene APOE coding APOE4 isoform associated increased risk myocardial infarction MI Alzheimer disease AD
0.43928444.10587578.html.plaintext.txt	5	Recently several polymorphisms APOE regulatory region reported
0.43928444.10587578.html.plaintext.txt	6	Some associated AD modified APOE allelic mRNA expression AD brains
0.43928444.10587578.html.plaintext.txt	7	Here investigated whether three promoter polymorphisms 491AT 427CT 219GT also modify cardiovascular risk
0.43928444.10587578.html.plaintext.txt	8	The hypothesis tested large multicentre case control study MI ECTIM Study 567 cases 678 controls
0.43928444.10587578.html.plaintext.txt	9	Among three APOE promoter polymorphisms tested 219T allele associated significantly increased risk MI OR 1
0.43928444.10587578.html.plaintext.txt	10	003 effect shown independent presence mutations including APOE 234 polymorphism
0.43928444.10587578.html.plaintext.txt	11	Moreover 219T allele greatly decreased APOE plasma concentrations dose dependent manner P 0
0.43928444.10587578.html.plaintext.txt	12	These data indicate 219GT polymorphism APOE regulatory region emerges new genetic susceptibility risk factor MI constitutes another common risk factor neurodegenerative cardiovascular diseases
0.43928444.10587578.html.plaintext.txt	13	INTRODUCTION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Apolipoprotein E APOE plays crucial role lipid metabolism ligand various cell surface receptors including low density lipoprotein LDL receptor LDL receptor related protein low density lipoprotein VLDL receptor
0.43928444.10587578.html.plaintext.txt	14	In addition APOE3 normal isoform encoded APOE 3 allele mutations occurring APOE gene APOE codons 158 APOE 2 allele 112 APOE 4 allele determine existence two isoforms APOE2 4 respectively
0.43928444.10587578.html.plaintext.txt	15	The APOE 234 polymorphism shown impact total cholesterol LDL cholesterol APOE plasma levels
0.43928444.10587578.html.plaintext.txt	16	Individuals carrying APOE 4 allele increased total cholesterol LDL cholesterol decreased APOE plasma levels 12
0.43928444.10587578.html.plaintext.txt	17	Hence genetic impact APOE 234 polymorphism total plasma cholesterol variance estimated 8 thought one powerful genetic components regulation cholesterol levels population level 34
0.43928444.10587578.html.plaintext.txt	18	Given strong impact high total LDL cholesterol plasma levels occurrence coronary heart diseases CHD effect APOE 234 polymorphism parameters APOE 234 polymorphism suspected modulate CHD risk
0.43928444.10587578.html.plaintext.txt	19	Indeed several matched case control studies shown modest significant increased prevalence APOE 4 allele CHD patients various populations 15
0.43928444.10587578.html.plaintext.txt	20	Nevertheless even APOE 4 appears significant genetic risk factor CHD individuals bearing APOE 4 inevitably develop disorder
0.43928444.10587578.html.plaintext.txt	21	This suggests genetic environmental risk factors may interact APOE 4 determining CHD risk
0.43928444.10587578.html.plaintext.txt	22	In Alzheimer disease AD APOE 4 allele also strongly associated increased risk developing disease CHD individuals bearing APOE 4 necessarily develop dementia 6
0.43928444.10587578.html.plaintext.txt	23	It lately proposed together qualitative modification APOE structure due APOE 4 allele quantitative variations APOE mRNA expression played major role risk determination 7
0.43928444.10587578.html.plaintext.txt	24	Reinforcing hypothesis polymorphisms APOE regulatory region recently described positions 491AT 427TC 219GT also called Th1E47cs associated risk developing AD 89
0.43928444.10587578.html.plaintext.txt	25	In particular 219GT polymorphism shown functional activity vitro 10 significantly modify APOE allelic mRNA expression levels human AD brain tissue 11
0.43928444.10587578.html.plaintext.txt	26	Since APOE locus implicated genetic predisposition myocardial infarction MI tested large multicentre case control study MI whether 491AT 427TC 219GT polymorphisms addition effect APOE 234 polymorphism may modify cardiovascular risk
0.43928444.10587578.html.plaintext.txt	27	RESULTS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Allelic genotypic distributions Hardy Weinberg equilibrium polymorphisms characterized Table 1
0.43928444.10587578.html.plaintext.txt	28	A statistically significant difference distribution cases controls detected 219GT APOE 234 polymorphisms APOE 4 219T alleles frequent cases controls Table 1
0.43928444.10587578.html.plaintext.txt	29	As previously described ECTIM Study relative risk MI approximated odds ratio OR men carrying APOE 4 allele significantly increased OR 1
0.43928444.10587578.html.plaintext.txt	30	008 compared non carriers
0.43928444.10587578.html.plaintext.txt	31	Furthermore men carrying 219T allele risk developing MI also significantly increased OR 1
0.43928444.10587578.html.plaintext.txt	32	After adjustment covariates increased relative risks associated APOE 4 allele 219T allele remained significant Table 2
0.43928444.10587578.html.plaintext.txt	33	Impact 219GT 234 polymorphisms OR 95 CI occurrence myocardial infarction The previously described strong linkage disequilibrium four polymorphisms 8911 verified present study Table 3
0.43928444.10587578.html.plaintext.txt	34	Therefore estimated effect polymorphism MI risk independently others multivariate regression analysis Table 2
0.43928444.10587578.html.plaintext.txt	35	These data indicated risk associated presence APOE 4 219T alleles borderline significant OR 1
0.43928444.10587578.html.plaintext.txt	36	In order complete multiple regression approach stratified sample without 4 allele Table 2
0.43928444.10587578.html.plaintext.txt	37	In case 219T allele associated significant increased risk MI 4 population OR 1
0.43928444.10587578.html.plaintext.txt	38	02 similar trend 4 population lack significance likely due sample size OR 1
0.43928444.10587578.html.plaintext.txt	39	Pairwise linkage disequilibrium APOE locus Assuming presence APOE 4 219T alleles would powerful risk factor early onset MI compared estimated frequencies APOE 234 219GT haplotypes cases aged 55 years less date onset cases aged 55 years median age onset
0.43928444.10587578.html.plaintext.txt	40	The frequency APOE 4 219T haplotype significantly higher younger older cases 14
0.43928444.10587578.html.plaintext.txt	41	Conversely frequencies haplotypes statistically differ young old cases
0.43928444.10587578.html.plaintext.txt	42	Moreover APOE 44 homozygous cases mean age ten 219TT bearers 49
0.43928444.10587578.html.plaintext.txt	43	6 years eight 219TT non bearers non parametric Wilcoxon test P 0
0.43928444.10587578.html.plaintext.txt	44	Given key role APOE circulating lipid metabolism major impact plasma lipids cardiovascular disease effect 219GT polymorphism MI risk tested impact 219GT polymorphism various lipid lipoprotein plasma concentrations non treated controls participating study
0.43928444.10587578.html.plaintext.txt	45	The 219GT polymorphism associated significant differences lipid lipoprotein plasma levels
0.43928444.10587578.html.plaintext.txt	46	However identified highly significant difference plasma APOE concentrations according 219GT genotype P 0
0.43928444.10587578.html.plaintext.txt	47	0001 plasma APOE concentrations appearing allele dose dependent Table 4
0.43928444.10587578.html.plaintext.txt	48	The two promoter polymorphisms effect APOE plasma concentrations data shown
0.43928444.10587578.html.plaintext.txt	49	Since APOE 234 polymorphism strongly determined APOE concentrations 1 impact 219GT polymorphism plasma APOE reanalysed adjustment APOE 234 polymorphism impact 219T allele remained significant P 0
0.43928444.10587578.html.plaintext.txt	50	Furthermore ECTIM control group stratified according APOE genotypes similar trends 219GT polymorphism effect APOE plasma concentrations observed 33 34 44 subgroups Table 4
0.43928444.10587578.html.plaintext.txt	51	In similar way 219T allele associated decreased APOE plasma concentrations case group mainly due TT genotype GG 5
0.43928444.10587578.html.plaintext.txt	52	After adjustment 234 polymorphisms statistical significance remains borderline P 0
0.43928444.10587578.html.plaintext.txt	53	Effect 219GT genotypes lipid APOE plasma concentrations controls effect 219GT polymorphism APOE plasma concentrations subgroups 234 genotypes DISCUSSION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES In ECTIM Study data demonstrate 219GT polymorphism located APOE promoting sequence significantly modulates risk MI independently APOE 234 polymorphism
0.43928444.10587578.html.plaintext.txt	54	Given role APOE plasma lipid metabolism order determine mechanism 219GT polymorphism may modify risk MI tested impact polymorphism various lipid lipoprotein plasma concentrations
0.43928444.10587578.html.plaintext.txt	55	Despite strong effect mutation APOE plasma concentrations major effect lipids could observed especially total cholesterol atherogenic LDL subfraction
0.43928444.10587578.html.plaintext.txt	56	However able associate 219T allele lower APOE plasma concentrations observation agreement previously reported lower expression APOE associated presence 219T allele HepG2 transfected cells 10
0.43928444.10587578.html.plaintext.txt	57	Other mutations affecting APOE promoter 491AT 427TC polymorphisms show effect lipid levels risk MI
0.43928444.10587578.html.plaintext.txt	58	A major question concerns mechanism 219GT polymorphism may influence cardiovascular risk
0.43928444.10587578.html.plaintext.txt	59	Indeed contribution polymorphism MI risk unlikely mediated though modulation plasma lipoprotein metabolism suggested explain functionality APOE 234 polymorphism
0.43928444.10587578.html.plaintext.txt	60	Using HepG2 hepatoma cells model Bohnet et al
0.43928444.10587578.html.plaintext.txt	61	12 demonstrated APOE concentrations VLDL addition APOE 234 polymorphism help determine VLDL affinity APOE binding receptors probably subsequent variations plasma total LDL cholesterol levels
0.43928444.10587578.html.plaintext.txt	62	In present study plasma VLDL cholesterol levels highly associated APOE 234 polymorphism confirming circulating VLDL cholesterol strongly determined affinity APOE isoforms carried VLDL lipoproteins 1
0.43928444.10587578.html.plaintext.txt	63	However VLDL cholesterol concentrations associated variations 219GT locus even stratification APOE 234 genotypes
0.43928444.10587578.html.plaintext.txt	64	Since 219GT polymorphism shown influence APOE expression data suggest APOE concentrations VLDL unaffected hepatic APOE expression
0.43928444.10587578.html.plaintext.txt	65	As consequence 219GT polymorphism unlikely modulate VLDL binding affinity receptors subsequent plasma lipid lipoprotein variations
0.43928444.10587578.html.plaintext.txt	66	Indeed study 219GT polymorphism associated significant variation lipid lipoprotein plasma levels
0.43928444.10587578.html.plaintext.txt	67	Since deleterious impact 219T allele MI cannot explained major effect circulating lipids may mediated subtle local mechanisms involved instance course atherosclerotic plaque formation
0.43928444.10587578.html.plaintext.txt	68	Interestingly abundant APOE mainly produced macrophages found atherosclerotic lesions suggesting macrophage derived APOE may anti atherogenic 1314
0.43928444.10587578.html.plaintext.txt	69	Indeed studying effect macrophage specific expression human apoE apoE null mice Bellosta et al
0.43928444.10587578.html.plaintext.txt	70	15 showed specific apoE expression reduced atherosclerotic lesion development compared control littermates matched cholesterol level lipoprotein profile
0.43928444.10587578.html.plaintext.txt	71	Several mechanisms proposed explain macrophage derived APOE may anti atherogenic instance ApoE may protect oxidative stress isoform specific antioxidant activities described APOE2 isoform effective agent APOE4 isoform lesser 16 ii macrophage APOE may also modulate cholesterol balance arterial wall isoform dependent manner 1718 APOE2APOE2 macro phages secreting cholesterol efficiently APOE3APOE3 APOE4APOE4 cells 19
0.43928444.10587578.html.plaintext.txt	72	Together data suggest genetically determined quantitative limitations APOE expression may major effects humans especially stressed atherogenic diet least regulating antioxidant activities cholesterol balance within arterial wall
0.43928444.10587578.html.plaintext.txt	73	In context increased risk MI decreased APOE plasma concentrations associated 219T allele may suggest addition deleterious effect APOE 4 allele basal ability cells synthesize secrete APOE may particular relevance irrespective extent isoform
0.43928444.10587578.html.plaintext.txt	74	With mind calculating mean age APOE 44 homozygotes cases according 219GT status suggested 219TT homozygotes may higher risk MI
0.43928444.10587578.html.plaintext.txt	75	In conclusion studying impact mutations affecting APOE promoter cardiovascular disease risk reinforced probability functionality 219GT polymorphism mutations seem exert major effects
0.43928444.10587578.html.plaintext.txt	76	The 219GT polymorphism significantly influence level synthesis APOE may addition specific properties various isoforms critical determinant physiological pathological mechanisms involved cardiovascular neuro degenerative disorders relating APOE locus
0.43928444.10587578.html.plaintext.txt	77	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Population studied This work carried large multicentre case control study ECTIM Study Etude Cas Temoins de l Infarctus du Myocarde based four centres participating WHO MONICA Project Lille suburbs Strasbourg region Bas Rhin Toulouse region Haute Garonne France Belfast surroundings Northern Ireland 20
0.43928444.10587578.html.plaintext.txt	78	A total population 587 men aged 25 64 years surviving definite MI recruited compared random sample 727 age matched male controls geographical areas
0.43928444.10587578.html.plaintext.txt	79	Blood sampling lipid lipoprotein apolipoprotein analyses Blood sampling lipid apolipoprotein lipoprotein measurements performed according methods described elsewhere 20
0.43928444.10587578.html.plaintext.txt	80	Samples cases obtained 3 9 months MI
0.43928444.10587578.html.plaintext.txt	81	DNA extraction genetic analysis Genomic DNA extraction PCR amplifications performed previously described 89
0.43928444.10587578.html.plaintext.txt	82	The 491AT 427TC 219GT APOE 234 genotypes could obtained 1245 subjects 567 cases versus 678 controls
0.43928444.10587578.html.plaintext.txt	83	APOE 234 deduced phenotyping analysis 1
0.43928444.10587578.html.plaintext.txt	84	For polymorphism mutations detected adequate enzymatic digestion followed electrophoretic step ethidium bromide stained agarose polyacrylamide gels
0.43928444.10587578.html.plaintext.txt	85	Statistical analysis The data analysed using SAS statistical software release 6
0.43928444.10587578.html.plaintext.txt	86	Genotype frequencies compared cases controls multivariate logistic regression analysis including dummy variables take populations population genotype interactions account
0.43928444.10587578.html.plaintext.txt	87	Genotypes coded according hypothesis tested dose dependent model observed Table 1
0.43928444.10587578.html.plaintext.txt	88	Extended haplotype frequencies four markers estimated collapsed data using myriad algorithm described McLean Morton 21 using computer program Cox et al
0.43928444.10587578.html.plaintext.txt	89	The percent maximum possible value linkage disequilibrium computed outlined Thompson et al
0.43928444.10587578.html.plaintext.txt	90	In controls lipid lipoprotein levels compared genotypes analysis covariance
0.43928444.10587578.html.plaintext.txt	91	The tests adjusted age centre body mass index tobacco alcohol consumption
0.43928444.10587578.html.plaintext.txt	92	Triglycerides APOE plasma concentrations analysed log transformation
0.43928444.10587578.html.plaintext.txt	93	To take account multiple adjustments level significance P 0
0.43928444.10587578.html.plaintext.txt	94	FOOTNOTES To correspondence addressed
0.43928444.10587578.html.plaintext.txt	95	Tel 33 3 20 87 77 10 Fax 33 3 20 87 78 94 Email philippe
0.43928444.10587578.html.plaintext.txt	96	REFERENCES TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES 1 Luc G
0.43928444.10587578.html.plaintext.txt	97	1994 Impact apolipoprotein E polymorphism lipoproteins risk myocardial infarction
0.43928444.10587578.html.plaintext.txt	98	1988 Simultaneous effects apolipoprotein E polymorphism apolipoprotein E apolipoprotein B cholesterol metabolism
0.43928444.10587578.html.plaintext.txt	99	1985 Role apolipoprotein E polymorphism determining normal plasma lipid lipoprotein variation
0.43928444.10587578.html.plaintext.txt	100	1987 The use measured genotype information analysis quantitative phenotypes men
0.43928444.10587578.html.plaintext.txt	101	The role apolipoprotein polymorphism determining levels variability covariability cholesterol beta lipoprotein triglycerides sample unrelated individuals
0.43928444.10587578.html.plaintext.txt	102	1998 Polymorphism apolipoprotein E angiotensin I converting enzyme genes Japanese patients myocardial infarction
0.43928444.10587578.html.plaintext.txt	103	1993 Binding human apolipoprotein E synthetic amyloid beta peptide isoform specific effects implications late onset Alzheimer disease
0.43928444.10587578.html.plaintext.txt	104	1997 Distorsion allelic expression apolipoprotein E Alzheimer disease
0.43928444.10587578.html.plaintext.txt	105	1998 A new polymorphism APOE promoter associated risk developing Alzheimer disease
0.43928444.10587578.html.plaintext.txt	106	1998 A polymorphism regulatory region APOE associated risk Alzheimer dementia
0.43928444.10587578.html.plaintext.txt	107	1998 Allelic polymorphisms transcriptional regulatory region apolipoprotein E gene
0.43928444.10587578.html.plaintext.txt	108	1998 Pronounced impact 219 GT mutation compared 491 AT mutation neural APOE gene expression risk developing Alzheimer disease
0.43928444.10587578.html.plaintext.txt	109	1996 Apolipoprotein apo E genotype apoE concentration determine binding normal low density lipoproteins HepG2 cell surface receptors
0.43928444.10587578.html.plaintext.txt	110	1993 Abundant expression apolipoprotein E macrophages human rabbit atherosclerotic lesions
0.43928444.10587578.html.plaintext.txt	111	1994 Apolipoprotein E localization human coronary atherosclerosis plaques situ hybridization immunohistochemistry comparison lipoprotein lipase
0.43928444.10587578.html.plaintext.txt	112	1995 Macrophage specific expression human apolipoprotein E reduces atherosclerosis hypercholesterolemic apolipoprotein E null mice
0.43928444.10587578.html.plaintext.txt	113	1996 Apolipoprotein E allele specific antioxidant activity effects cytotoxicity oxidative insults beta amyloid peptides
0.43928444.10587578.html.plaintext.txt	114	1994 Production cholesterol enriched nascent high density lipoproteins human monocyte derived macrophages mechanism contributes macrophage cholesterol efflux
0.43928444.10587578.html.plaintext.txt	115	1994 Expression heterologous human apolipoprotein E J774 macrophages enhances cholesterol efflux HDL3
0.43928444.10587578.html.plaintext.txt	116	1998 Phenotype dependent differences apolipoprotein E metabolism cholesterol homeostasis human monocyte derived macrophages
0.43928444.10587578.html.plaintext.txt	117	1992 A case control study lipoprotein particles two populations contrasting risk coronary heart disease
0.43928444.10587578.html.plaintext.txt	118	1985 Efficiency lod scores representing multiple locus linkage data
0.43928444.10587578.html.plaintext.txt	119	1988 Linkage disequilibrium human insulininsulin like growth factor II region human chromosome II
0.43928444.10587578.html.plaintext.txt	120	1988 The detection linkage disequilibrium closely markers RFLPs AI CIII apolipoprotein genes
0.31263503.15319409.html.plaintext.txt	0	Methodological problems genetic association studies longevity apolipoprotein E gene example Sarah J Lewis Eric J Brunner
0.31263503.15319409.html.plaintext.txt	1	International Centre Health Society Department Epidemiology Public Health University College London London UK
0.31263503.15319409.html.plaintext.txt	2	Correspondence Sarah J Lewis Department Social Medicine University Bristol Canynge Hall Whiteladies Road Bristol BS8 2PR UK
0.31263503.15319409.html.plaintext.txt	3	Abstract Top Abstract Approaches studying
0.31263503.15319409.html.plaintext.txt	4	Methods Results Discussion Conclusion References Background Cross sectional genetic association studies widely employed look genes confer longevity
0.31263503.15319409.html.plaintext.txt	5	Such studies based two assumptions initial relative allele frequencies different age cohorts similar b risk mortality conferred genotypes depend year birth
0.31263503.15319409.html.plaintext.txt	6	Methods We explored validity assumptions reviewed 15 cross sectional studies common apolipoprotein E APOE polymorphisms longevity
0.31263503.15319409.html.plaintext.txt	7	Results Higher relative 2 frequencies lower relative 4 allele frequencies observed elderly versus younger populations
0.31263503.15319409.html.plaintext.txt	8	If assumptions b correct estimates 2 4 alleles respectively versus 3 alleles would 1
0.31263503.15319409.html.plaintext.txt	9	63 elderly versus younger individuals
0.31263503.15319409.html.plaintext.txt	10	However association relative 4 allele frequency controls APOE 4 effect ss 0
0.31263503.15319409.html.plaintext.txt	11	In relation assumption substantial variation relative APOE allele frequencies 4 21 considerable heterogeneity evident within geographically proximate populations population admixture likely resulted changes allele frequency time assumption b APOE related causes death context specific changed considerably last 30 years
0.31263503.15319409.html.plaintext.txt	12	Conclusion The validity case control type studies genetic basis longevity based assumptions questionable especially considerable differences exist allele frequency population genes question interact environmental factors vary time place
0.31263503.15319409.html.plaintext.txt	13	Keywords Longevity ageing genetic association gene APOE methodology
0.31263503.15319409.html.plaintext.txt	14	Twin studies longevity suggest around 25 variation lifespan developed countries may inherited
0.31263503.15319409.html.plaintext.txt	15	1 Understanding heritability consequently biological processes involved ageing longevity one greatest scientific challenges time
0.31263503.15319409.html.plaintext.txt	16	In post genomic era large DNA resources becoming available within epidemiological studies better placed ever begin unravel complex problem
0.31263503.15319409.html.plaintext.txt	17	Epidemiological studies widely used look genes conferring risk common multifactorial diseases comparing genotype distributions cases controls
0.31263503.15319409.html.plaintext.txt	18	2 More recently case control designs used identify differences genotypes allele frequencies elderly compared younger populations
0.31263503.15319409.html.plaintext.txt	19	34 Centenarians typically studied represent survivors may lack disease susceptibility genes genes associated premature mortality
0.31263503.15319409.html.plaintext.txt	20	However specific methodological problems inherent studies comparing populations across time periods although alluded several reviews adequately addressed study designs date
0.31263503.15319409.html.plaintext.txt	21	We argue previous claims resulting studies may flawed based following assumptions initial relative allele frequencies different age groups similar b risk mortality conferred genotype depend year birth
0.31263503.15319409.html.plaintext.txt	22	Further due secular trends common disease incidence changes patterns exposure environmental risk factors smoking genetic associations found studies unlikely contribute blueprint future longevity unless improvements made methodology used
0.31263503.15319409.html.plaintext.txt	23	An indication type changes needed provided concluding section paper
0.31263503.15319409.html.plaintext.txt	24	Approaches studying genetics ageing Top Abstract Approaches studying
0.31263503.15319409.html.plaintext.txt	25	Methods Results Discussion Conclusion References Centenarians quite rare linkage studies require relatively large number long lived sib pairs together DNA sibs died early avoid acertainment bias
0.31263503.15319409.html.plaintext.txt	26	Ideally DNA would also available one generation
0.31263503.15319409.html.plaintext.txt	27	Genetic association studies therefore feasible becoming widely used look genes important longevity
0.31263503.15319409.html.plaintext.txt	28	It likely many genes contribute longevity
0.31263503.15319409.html.plaintext.txt	29	Candidate genes selected either 1 genes implicated general processes cellular maintenance repair superoxide dismutase 2 SOD2 involved scavenging reactive oxygen species apoptosis 2 genes confer increased susceptibility age related diseases apolipoprotein E APOE gene involved lipoprotein metabolism proposed risk factor coronary heart disease CHD Alzheimers disease
0.31263503.15319409.html.plaintext.txt	30	78 Since genetic studies longevity date second type paper focus studies disease risk genes
0.31263503.15319409.html.plaintext.txt	31	Initial gene frequencies age cohorts represented longevity study likely different necessarily represented frequencies youngercontrol population Population stratification Genetic association studies received large amount negative press recently mainly due lack repeatability results opportunity spurious results
0.31263503.15319409.html.plaintext.txt	32	29 12 One reason problems population stratification phenomenon pertinent studies longevity
0.31263503.15319409.html.plaintext.txt	33	Whilst genuine differences elderly cohorts younger individuals may exist due role genes longevity artefactual results genetic effects may also arise due variations initial relative allele frequency two comparison groups result population admixture
0.31263503.15319409.html.plaintext.txt	34	Although novel mutations infrequent diffuse slowly interval human generations long gene pool given population change considerably relatively short period result geographical mobility ethnic admixing selective mating
0.31263503.15319409.html.plaintext.txt	35	Migration If take Britain example last 100 years mass emigration USA South Africa Australia New Zealand coupled influx individuals India Pakistan Bangladesh China Caribbean Africa
0.31263503.15319409.html.plaintext.txt	36	More recently migration countries Europe become common result constitutional rights established within European Union
0.31263503.15319409.html.plaintext.txt	37	The scale movement substantial
0.31263503.15319409.html.plaintext.txt	38	Of respondents decennial census England 13 population England gave ethnic origin white British 2001 compared 11 1991 increase 18 10 years
0.31263503.15319409.html.plaintext.txt	39	13 Since migration among young adults tends work education net inflows often concentrated cities genetic association studies may based
0.31263503.15319409.html.plaintext.txt	40	In England highest levels flow South East
0.31263503.15319409.html.plaintext.txt	41	3 residents classified white British Irish 2001 census
0.31263503.15319409.html.plaintext.txt	42	13 Whilst genetic association studies usually collect data ethnic group rarely distinguish Caucasians hence group together individuals different countries regions origin
0.31263503.15319409.html.plaintext.txt	43	Migration within countries individuals better placed work health care may also played role population mixing last century
0.31263503.15319409.html.plaintext.txt	44	Movement regions result changes genetic structure regional populations
0.31263503.15319409.html.plaintext.txt	45	Approximately 20 individuals born England Scotland Wales 3 9 March 1958 resided different region 1981 birth resulted reduction interregional variability ABO blood groups
0.31263503.15319409.html.plaintext.txt	46	15 Migration patterns differ widely countries time periods scale problem depend study population
0.31263503.15319409.html.plaintext.txt	47	The risk mortality conferred genotypes depend birth year cohort Secular trends disease risk Migration different gene pools may change genetic risk within given population influence mortality rates time periods order decades
0.31263503.15319409.html.plaintext.txt	48	By addressing first assumption effect also addressing dynamic
0.31263503.15319409.html.plaintext.txt	49	Aside changes population genetic structure environmental risk factors disease changed considerably last 100 years two populations born decades apart likely exposed different pattern stressors
0.31263503.15319409.html.plaintext.txt	50	For reason populations different susceptibilities disease regardless genotype
0.31263503.15319409.html.plaintext.txt	51	Environmental risk factors unlikely change population distribution genetic variants unless offer strong selection particular allele childhood reproductive years
0.31263503.15319409.html.plaintext.txt	52	Therefore secular trends genetic susceptibility diseases elderly confounded environment rather environment acts effect modifier
0.31263503.15319409.html.plaintext.txt	53	Life expectancy doubled first half 20th century largely due reduction malnutrition childhood infection
0.31263503.15319409.html.plaintext.txt	54	Chronic diseases heart disease cancer occur later life became major causes death developed countries
0.31263503.15319409.html.plaintext.txt	55	16 This shift causes mortality epidemiological transition occurred relatively short period
0.31263503.15319409.html.plaintext.txt	56	It suggested rise CHD cancer incidence Western countries consequence ageing populations
0.31263503.15319409.html.plaintext.txt	57	However increase rates mortality cancer took place among men Britain 1921 1960 largely attributed lung cancer smoking main environmental cause
0.31263503.15319409.html.plaintext.txt	58	17 Levels smoking Britain reached peak 1960s followed steady decline although approximately 30 adult population continue smoke Figure 116
0.31263503.15319409.html.plaintext.txt	59	Similarly national CHD mortality rates rose fell past century
0.31263503.15319409.html.plaintext.txt	60	Deaths CHD reached peak many westernized countries 1970s declining Figure 2
0.31263503.15319409.html.plaintext.txt	61	18 Hence disease risks changed time levels exposure major environmental causes changed
0.31263503.15319409.html.plaintext.txt	62	View larger version 11K Figure 1 Number cigarettes smoked per person per day Britain16
0.31263503.15319409.html.plaintext.txt	63	View larger version 21K Figure 2 Mortality cardiovascular disease seven different countries18
0.31263503.15319409.html.plaintext.txt	64	Smoking nutrition physical activity sexual behaviour poverty occupation stress education social contacts health care pollution war infectious disease factors play part disease risk longevity individual societal level
0.31263503.15319409.html.plaintext.txt	65	Patterns availability exposure many changed enormously secular socio economic cultural trends last 100 years seen case smoking
0.31263503.15319409.html.plaintext.txt	66	Treatment disease may also impact mortality rates depend disease year contracted
0.31263503.15319409.html.plaintext.txt	67	APOE longevity Possibly extensively studied gene relation longevity APOE
0.31263503.15319409.html.plaintext.txt	68	The protein encoded gene ligand low density lipoprotein LDL receptor receptors LDL receptor gene family cell matrix associated heparin sulphate proteoglycans
0.31263503.15319409.html.plaintext.txt	69	The gene plays important role lipoprotein metabolism shown associated CHD risk
0.31263503.15319409.html.plaintext.txt	70	719 Three common polymorphic forms APOE known exist 2 3 4
0.31263503.15319409.html.plaintext.txt	71	The various APOE isoforms produced result polymorphism interact differently specific lipoprotein receptors ultimately altering circulating levels cholesterol
0.31263503.15319409.html.plaintext.txt	72	High LDL cholesterol levels associated APOE 4 low levels APOE 2 APOE 3 levels intermediate two
0.31263503.15319409.html.plaintext.txt	73	19 The APOE 4 allele also associated increase risk Alzheimers disease
0.31263503.15319409.html.plaintext.txt	74	8 Although mechanism entirely clear association could due 1 effects amyloid ss metabolism 2 effects neurons glial cells including neuronal survival neurite extension 3 effects related atherosclerosis cerebral blood flow blood brain barrier
0.31263503.15319409.html.plaintext.txt	75	19 Since CHD Alzheimers disease common disease old age APOE become candidate gene studies longevity
0.31263503.15319409.html.plaintext.txt	76	Several studies comparing APOE genotypes elderly versus younger populations carried out20 34 overview literature Gerdes et al
0.31263503.15319409.html.plaintext.txt	77	28 found APOE 4 associated premature death
0.31263503.15319409.html.plaintext.txt	78	To determine inaccurate assumptions initial APOE allele frequencies among elderly populations may influence outcome gene association studies whether increased risk mortality conferred APOE gene depends year birth determine whether published studies addressed problems carried review studies comparing APOE allele frequencies elderly versus younger populations
0.31263503.15319409.html.plaintext.txt	79	Methods Top Abstract Approaches studying
0.31263503.15319409.html.plaintext.txt	80	Methods Results Discussion Conclusion References Search strategy selection criteria Papers published prior end April 2003 identified search Medline www
0.31263503.15319409.html.plaintext.txt	81	gov using following search terms longevity centenarian aging ageing apolipoprotein E APO E APOE
0.31263503.15319409.html.plaintext.txt	82	Publications also identified review bibliographies retrieved articles
0.31263503.15319409.html.plaintext.txt	83	Studies included control group country elderly group least 80 years old
0.31263503.15319409.html.plaintext.txt	84	There restrictions publications based health participants
0.31263503.15319409.html.plaintext.txt	85	Where results study population published recent report used
0.31263503.15319409.html.plaintext.txt	86	Only studies published English abstract English included
0.31263503.15319409.html.plaintext.txt	87	Statistical methods Unadjusted odds ratios OR based published allele frequencies calculated proportion 2 alleles 4 alleles elderly versus control populations using relative 3 allele frequencies reference
0.31263503.15319409.html.plaintext.txt	88	The effect APOE allele shown dependent upon genotype
0.31263503.15319409.html.plaintext.txt	89	3536 However expected relative frequency 22 44 homozygotes low around 1 2
0.31263503.15319409.html.plaintext.txt	90	5 respectively stable estimates effect homozygotes longevity possible small studies
0.31263503.15319409.html.plaintext.txt	91	Relative frequencies 22 44 homozygotes available 3 15 studies reviewed
0.31263503.15319409.html.plaintext.txt	92	242932 Most studies compare allele frequencies combine 22 homozygotes 32 heterozygotes combine 44 homozygotes 34 heterozygotes give estimates 2 carriers versus 33 homozygotes 4 carriers versus 33 homozygotes
0.31263503.15319409.html.plaintext.txt	93	In using allele frequencies weighted effect size genotype frequency
0.31263503.15319409.html.plaintext.txt	94	However analysis genotype instead allele frequency gave similar results shown
0.31263503.15319409.html.plaintext.txt	95	Random effects models used calculate summary OR standard errors
0.31263503.15319409.html.plaintext.txt	96	Three studies provided genotypeallele frequencies one age group control population222327 data different age groups studies combined give overall estimate age less 80
0.31263503.15319409.html.plaintext.txt	97	Combined relative risks males females presented
0.31263503.15319409.html.plaintext.txt	98	Forest plots constructed logarithmic scales
0.31263503.15319409.html.plaintext.txt	99	To assess association frequency 2 4 alleles control group log OR allele frequency elderly populations versus controls used Bayesian random effects meta regression model fitted using BUGS WinBUGS 1
0.31263503.15319409.html.plaintext.txt	100	37 This avoids bias caused association allele frequency OR arises due sampling error
0.31263503.15319409.html.plaintext.txt	101	All statistical analysis carried STATA version 8 STATA corporation Texas
0.31263503.15319409.html.plaintext.txt	102	Tests funnel plot asymmetry3839 used investigate publication bias
0.31263503.15319409.html.plaintext.txt	103	Studies grouped geographical location North America included studies USA Canada Asia included studies China Japan Korea Northern Europe included Finland Denmark UK Central Europe included France Southern Europe included Italy
0.31263503.15319409.html.plaintext.txt	104	Results Top Abstract Approaches studying
0.31263503.15319409.html.plaintext.txt	105	Methods Results Discussion Conclusion References Fifteen studies met inclusion criteria characteristics studies summarized Table 1
0.31263503.15319409.html.plaintext.txt	106	The first study carried Canada one study carried USA four Asia remaining nine Europe
0.31263503.15319409.html.plaintext.txt	107	OR elderly versus control populations ranged 0
0.31263503.15319409.html.plaintext.txt	108	06 presence 2 allele 0
0.31263503.15319409.html.plaintext.txt	109	66 presence 4 allele
0.31263503.15319409.html.plaintext.txt	110	The summary effect estimate 1
0.31263503.15319409.html.plaintext.txt	111	35 presence 2 allele 0
0.31263503.15319409.html.plaintext.txt	112	63 presence 4 allele elderly versus younger individuals
0.31263503.15319409.html.plaintext.txt	113	View table Table 1 Cross sectional studies apolipoprotein E APOE polymorphisms longevity
0.31263503.15319409.html.plaintext.txt	114	Large differences relative APOE allele frequencies existed control populations 2 4 10 4 4 21
0.31263503.15319409.html.plaintext.txt	115	There regional variations APOE allele frequencies high relative APOE 4 Northern Europe 15 21 intermediate frequencies Central Europe 11 13 Asia 8 13 North America 12 15 low frequencies Southern Europe 4 6
0.31263503.15319409.html.plaintext.txt	116	In elderly people 4 allele frequencies converged homogeneous 2 12
0.31263503.15319409.html.plaintext.txt	117	Despite differences 2 15 studies reportedly matched geographic origin one study matched ethnicity
0.31263503.15319409.html.plaintext.txt	118	A meta analysis including studies gave result closer null RR 0
0.31263503.15319409.html.plaintext.txt	119	56 presence 4 elderly versus younger populations
0.31263503.15319409.html.plaintext.txt	120	A four studies stated controls nationality21232731 although necessarily exclude migrants particularly second generation migrants
0.31263503.15319409.html.plaintext.txt	121	The regression coefficient association log odds 4 control group log OR 4 allele frequency elderly versus controls 0
0.31263503.15319409.html.plaintext.txt	122	00 providing evidence association two
0.31263503.15319409.html.plaintext.txt	123	In Finnish study23 frequency 4 allele 20 OR 0
0.31263503.15319409.html.plaintext.txt	124	54 obtained whereas Italian study26 4 frequency 4 OR 2
0.31263503.15319409.html.plaintext.txt	125	There significant association 2 effect size relative 2 allele frequencies control group ss 0
0.31263503.15319409.html.plaintext.txt	126	A meta analysis considering studies centenarians gave point estimate 1
0.31263503.15319409.html.plaintext.txt	127	58 4 frequency among centenarians versus controls
0.31263503.15319409.html.plaintext.txt	128	On whole approaches validating laboratory results stated papers
0.31263503.15319409.html.plaintext.txt	129	30 reported re genotyping 1994 cohort published Schachter 199421 finding discordance rate 5
0.31263503.15319409.html.plaintext.txt	130	A Beggs funnel plot Figure 5 Eggers test standardized effect versus precision provide evidence publication bias P 0
0.31263503.15319409.html.plaintext.txt	131	View larger version 8K Figure 5 Beggs funnel plot cross sectional studies APOE 4 allele longevity
0.31263503.15319409.html.plaintext.txt	132	View larger version 11K Figure 3 Schematic illustration APOE Longevity
0.31263503.15319409.html.plaintext.txt	133	View larger version 21K Figure 4 Forest plots representing case control studies APOE longevity ordered allele frequency controls
0.31263503.15319409.html.plaintext.txt	134	APOE 2 allele longevitya
0.31263503.15319409.html.plaintext.txt	135	b APOE 4 allele longevitya
0.31263503.15319409.html.plaintext.txt	136	aStudies order allele frequency control population low top high bottom
0.31263503.15319409.html.plaintext.txt	137	Discussion Top Abstract Approaches studying
0.31263503.15319409.html.plaintext.txt	138	Methods Results Discussion Conclusion References We reviewed 15 cross sectional studies APOE polymorphisms longevity determine whether two key methodological assumptions addressed
0.31263503.15319409.html.plaintext.txt	139	The studies provide direct evidence size genetic effect interest sensitive relative allele frequency among controls relative APOE 4 allele frequency exhibits wide variation within proximate populations
0.31263503.15319409.html.plaintext.txt	140	Our inference initial allele frequencies likely differ age cohorts compared groups drawn assumption generally invalid
0.31263503.15319409.html.plaintext.txt	141	Further biology epidemiology presumed APOE related diseases particular great variation coronary death rates time place provides indirect evidence mortality risk conferred APOE genotype depends interaction environmental behavioural risk factors life course
0.31263503.15319409.html.plaintext.txt	142	The pattern exposures closely related year birth thus assumption b likely invalid gene environment interaction important case APOE
0.31263503.15319409.html.plaintext.txt	143	Since genetic studies common polygenic disease recent phenomenon impossible determine directly whether initial allele frequencies elderly individuals represented younger controls similarly whether risk mortality associated common genetic variants depends year birth
0.31263503.15319409.html.plaintext.txt	144	However case APOE 4 clear allele frequencies differ widely population even among neighbouring countries geographically separated populations within country example Lapps Finns
0.31263503.15319409.html.plaintext.txt	145	40 While migration patterns differ country substantial internal international migration many countries within last 100 years
0.31263503.15319409.html.plaintext.txt	146	41 These factors likely produced differences APOE allele frequency age group within given geographical area recent decades
0.31263503.15319409.html.plaintext.txt	147	Migration particularly prevalent among younger populations large university cities14 studies carried
0.31263503.15319409.html.plaintext.txt	148	Whilst almost studies showed deficit APOE 4 alleles elderly versus younger populations heterogeneity effect size remained even populations stratified region
0.31263503.15319409.html.plaintext.txt	149	We able make inferences based biology epidemiology APOE suggests assumption b invalid longevity effect may subject modification periods years decades corresponding age difference elderly control groups
0.31263503.15319409.html.plaintext.txt	150	APOE plays important role lipoprotein metabolism therefore APOE genotype one influence health effects dietary fat intake
0.31263503.15319409.html.plaintext.txt	151	APOE associated CHD risk one mechanism proposed explain association APOE longevity
0.31263503.15319409.html.plaintext.txt	152	In last 30 years CHD mortality decreased substantially many countries Figure 2
0.31263503.15319409.html.plaintext.txt	153	Factors underlying decrease include changes diet smoking treatments CHD
0.31263503.15319409.html.plaintext.txt	154	In studies reviewed size APOE 4 effect differed population providing evidence 4 effects context dependant
0.31263503.15319409.html.plaintext.txt	155	There appeared association 4 allele frequency controls effect 4 longevity
0.31263503.15319409.html.plaintext.txt	156	Sampling variation important potential explanation
0.31263503.15319409.html.plaintext.txt	157	If chance estimated 4 prevalence true prevalence former tend high within distribution effect size tend extreme due regression mean
0.31263503.15319409.html.plaintext.txt	158	However relative APOE 4 allele frequency known vary population studies reviewed anomalous respect
0.31263503.15319409.html.plaintext.txt	159	Among Europeans relative APOE 4 frequencies exhibit North South cline
0.31263503.15319409.html.plaintext.txt	160	42 Accordingly high relative APOE 4 allele frequencies observed studies Northern European participants 15 21 low frequencies Southern European studies 4 6
0.31263503.15319409.html.plaintext.txt	161	Furthermore Bayesian approach used calculate association control allele frequency effect size avoids bias arise due sampling error
0.31263503.15319409.html.plaintext.txt	162	It remains unclear whether sampling younger control population produces valid estimates initial allele frequencies corresponding elderly population
0.31263503.15319409.html.plaintext.txt	163	Migration population substructure may confound studies
0.31263503.15319409.html.plaintext.txt	164	If relative allele frequencies control populations overestimate initial relative allele frequencies elderly group spurious estimate longevity effect obtained
0.31263503.15319409.html.plaintext.txt	165	Migration likely change relative allele frequencies substantially source recipient populations different allele frequencies
0.31263503.15319409.html.plaintext.txt	166	Because changes allele frequency short term function difference frequency migration rate large differences seen one generation
0.31263503.15319409.html.plaintext.txt	167	43 Net immigration regions relatively high allele frequency overestimate decrease 4 elderly relative controls
0.31263503.15319409.html.plaintext.txt	168	Conversely net immigration areas relatively low allele frequency underestimate difference
0.31263503.15319409.html.plaintext.txt	169	For example Canadian study20 relative APOE 4 allele frequency control group 15
0.31263503.15319409.html.plaintext.txt	170	If represents allele frequency elderly population birth 0
0.31263503.15319409.html.plaintext.txt	171	88 good estimate link APOE 4 longevity
0.31263503.15319409.html.plaintext.txt	172	However 19 current Canadian residents born Canada
0.31263503.15319409.html.plaintext.txt	173	41 If migrants came countries relatively high allele frequencies 31 reported among Lapps44 migration would result overestimation real initial relative allele frequency 11
0.31263503.15319409.html.plaintext.txt	174	5 true 4 effect closer null 0
0.31263503.15319409.html.plaintext.txt	175	Alternatively migrants came countries areas low APOE 4 frequency frequencies 5 reported Sardinians45 real initial frequency would higher around 17
0.31263503.15319409.html.plaintext.txt	176	6 4 effect around 0
0.31263503.15319409.html.plaintext.txt	177	This simple example international migration occurring within one generation take account second generation migrants born Canada internal migration
0.31263503.15319409.html.plaintext.txt	178	While involves somewhat unrealistic assumptions migration patterns example offer insight migration may influence results genetic association studies longevity
0.31263503.15319409.html.plaintext.txt	179	Only 3 15 studies matched ethnicity andor place birth
0.31263503.15319409.html.plaintext.txt	180	The remaining studies assumed static population identical gene pool elderly younger age groups
0.31263503.15319409.html.plaintext.txt	181	A meta analysis including studies matching origin ethnicity gave result closer null consistent artefactual explanation studies failing take account genetic heterogeneity
0.31263503.15319409.html.plaintext.txt	182	The remaining studies effectively assumed static population identical gene pool elderly younger age groups
0.31263503.15319409.html.plaintext.txt	183	A explanation apparent association 4 prevalence magnitude 4 effect longevity impact greater populations higher underlying risk CHD
0.31263503.15319409.html.plaintext.txt	184	International comparisons suggest APOE 4 allele frequency may explain geographical variation CHD risk
0.31263503.15319409.html.plaintext.txt	185	46 In Japan low CHD risk population ratio relative 4 frequency elderly versus younger populations 0
0.31263503.15319409.html.plaintext.txt	186	5825 whereas Finland high CHD risk population ratio found 0
0.31263503.15319409.html.plaintext.txt	187	23 The difference CHD risk Japan Finland could due genetic susceptibility environmental factors likely combination
0.31263503.15319409.html.plaintext.txt	188	For example Northern Europe high APOE 4 relative allele frequencies historically accompanied high levels saturated fat intake
0.31263503.15319409.html.plaintext.txt	189	The influence genetic variation longevity priori important research question
0.31263503.15319409.html.plaintext.txt	190	Proponents genetic epidemiology argue predicting multifactorial disease outcomes without consideration epigenetic networks increasingly seen naive
0.31263503.15319409.html.plaintext.txt	191	47 The implication methodology genetic dimension included risk factor models chronic disease extension longevity
0.31263503.15319409.html.plaintext.txt	192	The papers reviewed focus single genetic effect main effect APOE longevity represent early attempts develop genetic perspective field dominated environmental explanations
0.31263503.15319409.html.plaintext.txt	193	For example know environment broad sense including behavioural factors essential understanding time trends CHD rates Figure 2 longevity
0.31263503.15319409.html.plaintext.txt	194	What known whether single common genetic variations APOE polymorphism important factors add explanation provided conventional environmental risk factors
0.31263503.15319409.html.plaintext.txt	195	Studies APOE longevity reviewed consistently showed effect 2 4 alleles longevity suggest APOE may part play
0.31263503.15319409.html.plaintext.txt	196	However analyses taking simultaneous account genetic environmental factors needed address question
0.31263503.15319409.html.plaintext.txt	197	Conclusion Top Abstract Approaches studying
0.31263503.15319409.html.plaintext.txt	198	Methods Results Discussion Conclusion References Our review leads us following conclusions relation validity assumptions b
0.31263503.15319409.html.plaintext.txt	199	Assumption Initial relative allele frequencies different age groups similar This assumption may hold considerable variation allele frequencies population migration resulted changes population substructure
0.31263503.15319409.html.plaintext.txt	200	Assumption b The risk mortality conferred genotype depend year birth
0.31263503.15319409.html.plaintext.txt	201	This assumption may invalid mortality risk conferred genotype depends interaction environmental behavioural risk factors pattern exposure risk factors closely related year birth
0.31263503.15319409.html.plaintext.txt	202	Whilst studies reviewed provide evidence link APOE longevity problem size effect depends population question probably also time period study spans
0.31263503.15319409.html.plaintext.txt	203	The link size APOE effect relative allele frequency seen review likely result population differences underlying disease susceptibility changes population structure time illustrates impact violating assumptions
0.31263503.15319409.html.plaintext.txt	204	Future case control type studies could improved least including comprehensive data birth origins exposure potential confounding factors
0.31263503.15319409.html.plaintext.txt	205	It also possible address concerns population stratification case control studies carrying genome analysis using methods genomic control structured association
0.31263503.15319409.html.plaintext.txt	206	Cohort studies subject assumptions hence preferable cross sectional design
0.31263503.15319409.html.plaintext.txt	207	Participants selected followed given time period subject age related mortality rate
0.31263503.15319409.html.plaintext.txt	208	The cohort studies carried date looked APOE longevity tend short follow periods typically 5 years49 56 hence provide snapshot overall survival
0.31263503.15319409.html.plaintext.txt	209	These studies reported mixed results documenting null findings APOE 4 longevity5051 others showing negative associations subgroups
0.31263503.15319409.html.plaintext.txt	210	54 56 To address question adequately cohort studies ideally birth cohorts long follow required
0.31263503.15319409.html.plaintext.txt	211	Cross sectional studies longevity assume relative allele frequencies different age cohorts b risk mortality conferred genotypes depend year birth
0.31263503.15319409.html.plaintext.txt	212	Population admixture may result considerable population changes allele frequency time allele frequencies differ substantially population migration high
0.31263503.15319409.html.plaintext.txt	213	Mortality risk conferred genotypes may differ gene question interacts environmental factors vary time place
0.31263503.15319409.html.plaintext.txt	214	Studies apolipoprotein E APOE 4 longevity show effect size estimates associated relative allele frequency control populations hence accurately predicting impact APOE longevity depends validity assumption
0.31263503.15319409.html.plaintext.txt	215	APOE associated coronary heart disease CHD risk one mechanism proposed explain association APOE longevity
0.31263503.15319409.html.plaintext.txt	216	However CHD mortality decreased mortaliy last 30 years largely due environmental behavioural factors hence effect APOE longevity context dependent
0.31263503.15319409.html.plaintext.txt	217	Acknowledgments We would like thank Dr Meena Kumari Dr Mark Pearce comments manuscript also Drs Jonathan Sterne Nicola Welton help statistical analysis using BUGS
0.31263503.15319409.html.plaintext.txt	218	This work funded Co op research grant Medical Research Council UK
0.31263503.15319409.html.plaintext.txt	219	References Top Abstract Approaches studying
0.31263503.15319409.html.plaintext.txt	220	Methods Results Discussion Conclusion References 1 Cournil A Kirkwood TBL
0.31263503.15319409.html.plaintext.txt	221	If would live long choose parents well
0.31263503.15319409.html.plaintext.txt	222	Trends Genet 200117233 35
0.31263503.15319409.html.plaintext.txt	223	2 Hirschhorn JN Lohmueller K Byrne E Hirschhorn K
0.31263503.15319409.html.plaintext.txt	224	A comprehensive review genetic association studies
0.31263503.15319409.html.plaintext.txt	225	3 Heijmans BT Westendorp RGJ Slagboom PE
0.31263503.15319409.html.plaintext.txt	226	Common gene variants mortality extreme longevity humans
0.31263503.15319409.html.plaintext.txt	227	Exp Gerontol 200035865 77
0.31263503.15319409.html.plaintext.txt	228	4 De Benedictis G Tan Q Jeune B et al
0.31263503.15319409.html.plaintext.txt	229	Recent advances human gene longevity association studies
0.31263503.15319409.html.plaintext.txt	230	Mech Ageing Dev 2001122909 20
0.31263503.15319409.html.plaintext.txt	231	Searching genetic determinants human aging longevity opportunities challenges
0.31263503.15319409.html.plaintext.txt	232	Mech Ageing Dev 2002123195 205
0.31263503.15319409.html.plaintext.txt	233	6 Schachter F Cohen D Kirkwood T
0.31263503.15319409.html.plaintext.txt	234	Prospects genetics human longevity
0.31263503.15319409.html.plaintext.txt	235	7 Wilson PWF Schaefer EJ Larson MG Ordovas JM
0.31263503.15319409.html.plaintext.txt	236	Apolipoprotein E alleles risk coronary disease meta analysis
0.31263503.15319409.html.plaintext.txt	237	Arterioscler Thromb Vasc Biol 1996161250 55
0.31263503.15319409.html.plaintext.txt	238	Apolipoprotein E genetic variation Alzheimers disease
0.31263503.15319409.html.plaintext.txt	239	Dement Geriatr Cogn Disord 199910199 209
0.31263503.15319409.html.plaintext.txt	240	9 Ioannidis JPA Ntzani EE Trikalinos TA Contopoulos Ioannidis DG
0.31263503.15319409.html.plaintext.txt	241	Replication validity genetic association studies
0.31263503.15319409.html.plaintext.txt	242	Association study designs complex diseases
0.31263503.15319409.html.plaintext.txt	243	11 Colhoun HM McKeigue Davey Smith G
0.31263503.15319409.html.plaintext.txt	244	Problems reporting genetic associations complex outcomes
0.31263503.15319409.html.plaintext.txt	245	Population stratification spurious allelic association
0.31263503.15319409.html.plaintext.txt	246	The Stationery Office ONS London 2001
0.31263503.15319409.html.plaintext.txt	247	International migration United Kingdom 1975 1999 consistency change implications labour market
0.31263503.15319409.html.plaintext.txt	248	Popul Trends 200110629 38
0.31263503.15319409.html.plaintext.txt	249	Effect interregional migration geographic variability biological social trends Britain
0.31263503.15319409.html.plaintext.txt	250	16 Office National Statistics
0.31263503.15319409.html.plaintext.txt	251	The Health Adult Britain 1841 1994
0.31263503.15319409.html.plaintext.txt	252	Trends mortality Britain 1920 1986
0.31263503.15319409.html.plaintext.txt	253	Ann Nutr Metab 19913553 63
0.31263503.15319409.html.plaintext.txt	254	18 Levi F Lucchini F Negri E La Vecchia C
0.31263503.15319409.html.plaintext.txt	255	Trends mortality cardiovascular cerebrovascular diseases Europe areas world
0.31263503.15319409.html.plaintext.txt	256	Apolipoproteins aging emerging mechanisms
0.31263503.15319409.html.plaintext.txt	257	Ageing Res Rev 20021345 65
0.31263503.15319409.html.plaintext.txt	258	20 Davignon J Bouthillier S Nestruck C Sing CF
0.31263503.15319409.html.plaintext.txt	259	Apolipoprotein E polymorphism atherosclerosis Insight study octogenarians
0.31263503.15319409.html.plaintext.txt	260	Trans Am Clin Climatol Assoc 198799100 10
0.31263503.15319409.html.plaintext.txt	261	21 Schachter F Faure Delanef L Guenot F et al
0.31263503.15319409.html.plaintext.txt	262	Genetic associations human longevity APOE ACE loci
0.31263503.15319409.html.plaintext.txt	263	22 Kervinen K Savolainen MJ Salokannel J et al
0.31263503.15319409.html.plaintext.txt	264	Apolipoprotein E B polymorphisms Longevity factors assessed nonagenarians
0.31263503.15319409.html.plaintext.txt	265	Atheroscerosis 199412689 95
0.31263503.15319409.html.plaintext.txt	266	23 Louhija J Miettinen K Kontula K Tikkanen MJ Miettinen TA Tivlis RS
0.31263503.15319409.html.plaintext.txt	267	Aging genetic variation plasma apolipoproteins
0.31263503.15319409.html.plaintext.txt	268	Relative loss apolipoprotein E4 phenotype Centenarians
0.31263503.15319409.html.plaintext.txt	269	Arterioscler Thromb 1994141084 89
0.31263503.15319409.html.plaintext.txt	270	24 Galinsky D Tysoe C Brayne CE et al
0.31263503.15319409.html.plaintext.txt	271	Analysis apo Eapo C I angiotensin converting enzyme methylenetetrahydrofolate reductase genes candidates affecting human longevity
0.31263503.15319409.html.plaintext.txt	272	Atherosclerosis 1997129177 83
0.31263503.15319409.html.plaintext.txt	273	25 Hirose N Homma S Arai Y et al
0.31263503.15319409.html.plaintext.txt	274	Apolipoprotein E phenotype Japanese centenarians living Tokyo metropolitan area
0.31263503.15319409.html.plaintext.txt	275	Nippon Ronen Igakkai Zasshi 19974267 72
0.31263503.15319409.html.plaintext.txt	276	26 Bader G Zuliani G Kostner GM Fellin R
0.31263503.15319409.html.plaintext.txt	277	Apolipoprotein E polymorphism associated longevity disability sample Italian octo nonagenarians
0.31263503.15319409.html.plaintext.txt	278	27 Jian Gang Z Yong Xing M Chuan Fu W et al
0.31263503.15319409.html.plaintext.txt	279	Apolipoprotein E longevity among Han Chinese population
0.31263503.15319409.html.plaintext.txt	280	Mech Ageing Dev 1998104159 67
0.31263503.15319409.html.plaintext.txt	281	28 Gerdes LU Jeune B Ranberg KA Nybo H Vaupel JW
0.31263503.15319409.html.plaintext.txt	282	Estimation apolipoprotein E genotype specific relative mortality risks distribution genotypes centenarians middle aged men Apolipoprotein E gene frailty gene longevity gene
0.31263503.15319409.html.plaintext.txt	283	Genet Epidemiol 200019202 10
0.31263503.15319409.html.plaintext.txt	284	CO2 QlinktypeDOI CrossRefISIMedline
0.31263503.15319409.html.plaintext.txt	285	29 Rea IM McDowell I McMaster D Smye M Stout R Evans A
0.31263503.15319409.html.plaintext.txt	286	Apolipoprotein E alleles nonagenarian subjects Belfast elderly longitudinal free living ageing study BELFAST
0.31263503.15319409.html.plaintext.txt	287	Mech Ageing Dev 20011221367 72
0.31263503.15319409.html.plaintext.txt	288	30 Blanche H Cabanne L Sahbatou M Thomas G
0.31263503.15319409.html.plaintext.txt	289	A study French Centenarians ACE APOE associated longevity C R Acad Sci III 2001324129 35
0.31263503.15319409.html.plaintext.txt	290	31 Wang X Wang G Yang C Xuan L
0.31263503.15319409.html.plaintext.txt	291	Apolipoprotein E gene polymorphism association human longevity Uygar nationality Xinjiang
0.31263503.15319409.html.plaintext.txt	292	32 Zubenko GS Stiffler S Hughes HB Fatigati MJ Zubenko WN
0.31263503.15319409.html.plaintext.txt	293	Genome survey loci influence successful aging sample characterization method validation initial results Y chromosome
0.31263503.15319409.html.plaintext.txt	294	Am J Geriatr Psychiatry 200210619 30
0.31263503.15319409.html.plaintext.txt	295	33 Choi YH Kim JH Kim DK et al
0.31263503.15319409.html.plaintext.txt	296	Distributions ACE APOE Polymorphisms relations dementia status Korean centenarians
0.31263503.15319409.html.plaintext.txt	297	J Gerontol A Biol Sci Med Sci 200358227 31
0.31263503.15319409.html.plaintext.txt	298	34 Panza F Solfrizzi V Colacicco AM et al
0.31263503.15319409.html.plaintext.txt	299	Apolipoprotein E APOE polymorphism influences serum APOE levels Alzheimers disease patients Centenarians
0.31263503.15319409.html.plaintext.txt	300	35 Schiele F De Bacquer D Vincent Viry M et al
0.31263503.15319409.html.plaintext.txt	301	Apolipoprotein E serum concentration polymorphism six European countries The ApoEurope project
0.31263503.15319409.html.plaintext.txt	302	Atherosclerosis 2000152475 88
0.31263503.15319409.html.plaintext.txt	303	36 Frikke Schmidt R Tybjaerg Hansen A Steffensen R Jensen G Nordestgaard BG
0.31263503.15319409.html.plaintext.txt	304	Apolipoprotein E genotype epsilon 32 women protected epsilon 43 epsilon 44 men susceptible ischemic heart disease
0.31263503.15319409.html.plaintext.txt	305	The Copenhagen city heart study
0.31263503.15319409.html.plaintext.txt	306	J Am Coll Cardiol 2000351192 99
0.31263503.15319409.html.plaintext.txt	307	37 Thomson SG Smith TC Sharp SJ
0.31263503.15319409.html.plaintext.txt	308	Investigating underlying risk source heterogeneity meta analysis
0.31263503.15319409.html.plaintext.txt	309	Statist Med 1997162741 58
0.31263503.15319409.html.plaintext.txt	310	CO2 0linktypeDOI CrossRefISI
0.31263503.15319409.html.plaintext.txt	311	Operating characteristics rank correlation test publication bias
0.31263503.15319409.html.plaintext.txt	312	Biometrics 1994501088 101
0.31263503.15319409.html.plaintext.txt	313	39 Egger M Davey Smith G Schneider M Minder C
0.31263503.15319409.html.plaintext.txt	314	Bias meta analysis detected simple graphical test
0.31263503.15319409.html.plaintext.txt	315	Apolipoprotein E APOE allele distribution world
0.31263503.15319409.html.plaintext.txt	316	Is APOE4 thrifty allele Ann Hum Genet 199963301 10
0.31263503.15319409.html.plaintext.txt	317	41 United Nations Population Division Department Economic Social Affairs
0.31263503.15319409.html.plaintext.txt	318	United Nations Publication 2002
0.31263503.15319409.html.plaintext.txt	319	42 Haddy N De Bacquer D Chemaly MM et al
0.31263503.15319409.html.plaintext.txt	320	The importance plasma apolipoprotein E concentration addition common polymorphism inter individual variation lipid levels results Apo Europe
0.31263503.15319409.html.plaintext.txt	321	Eur J Hum Genet 200210841 50
0.31263503.15319409.html.plaintext.txt	322	Estimating effective population size migration rates genetic samples space time
0.31263503.15319409.html.plaintext.txt	323	44 Lehtinen S Luoma P Lehtimaki T Nayha S Hassi J Nikkari T
0.31263503.15319409.html.plaintext.txt	324	Differences genetic variation apolipoprotein Lapps Finns
0.31263503.15319409.html.plaintext.txt	325	45 Corbo RM Scacchi R Mureddu L Mulas G Alfano G
0.31263503.15319409.html.plaintext.txt	326	Apolipoprotein E polymorphism Italy investigated native plasma simple polyacrylamide gel isoelectric focusing technique
0.31263503.15319409.html.plaintext.txt	327	Comparison frequency data European populations
0.31263503.15319409.html.plaintext.txt	328	Ann Hum Genet 199559197 209
0.31263503.15319409.html.plaintext.txt	329	46 Stengard JH Weiss KM Sing CF
0.31263503.15319409.html.plaintext.txt	330	An ecological study association coronary heart disease mortality rates men relative frequencies common allelic variations gene coding apolipoprotein E
0.31263503.15319409.html.plaintext.txt	331	47 Sing CF Stengard JH Kardia SLR
0.31263503.15319409.html.plaintext.txt	332	Genes environment cardiovascular disease
0.31263503.15319409.html.plaintext.txt	333	Arterioscler Thromb Vasc Biol 2003231190 96
0.31263503.15319409.html.plaintext.txt	334	Mortality differences APOE genotype estimated APOE genotype estimated demographic synthesis
0.31263503.15319409.html.plaintext.txt	335	Genet Epidemiol 200222146 55
0.31263503.15319409.html.plaintext.txt	336	49 Tilvis RS STrandberg TE Juva K
0.31263503.15319409.html.plaintext.txt	337	Apolipoprotein E phenotypes dementia mortality prospective population sample
0.31263503.15319409.html.plaintext.txt	338	J Am Geriatr Soc 199846712 15
0.31263503.15319409.html.plaintext.txt	339	Apolipoprotein E longevity Rotterdam study
0.31263503.15319409.html.plaintext.txt	340	J Am Geriatr Soc 2001491258 59
0.31263503.15319409.html.plaintext.txt	341	51 Louhija J Aguero Torres H Tilvis R
0.31263503.15319409.html.plaintext.txt	342	Survival Finnish centenarians relation apolipoprotein E polymorphism
0.31263503.15319409.html.plaintext.txt	343	J Am Geriatr Soc 2001491007 08
0.31263503.15319409.html.plaintext.txt	344	52 Stengard JH Zerba KE Pekkanen J Ehnholm C Nissinen A Sing CF
0.31263503.15319409.html.plaintext.txt	345	Apolipoprotein E polymorphism predicts death coronary heart disease longitudinal study elderly Finnish men
0.31263503.15319409.html.plaintext.txt	346	53 Stengard JH Pekkanen J Ehnholm C Nissinen A Sing CF
0.31263503.15319409.html.plaintext.txt	347	Genotypes apolipoprotein episilon 4 allele predictors coronary heart disease mortality longitudinal study elderly Finnish men
0.31263503.15319409.html.plaintext.txt	348	54 Corder EH Lannfelt L Vittanen M et al
0.31263503.15319409.html.plaintext.txt	349	Apolipoprotein E genotype determines survival oldest old 85 years older good cognition
0.31263503.15319409.html.plaintext.txt	350	55 Lee JH Tang MX Schupf N et al
0.31263503.15319409.html.plaintext.txt	351	Mortality apolipoprotein E Hispanic African American Caucasian Elders
0.31263503.15319409.html.plaintext.txt	352	Am J Med Genet 2001103121 27
0.31263503.15319409.html.plaintext.txt	353	56 Vogt MT Cauley JA Kuller LH
0.31263503.15319409.html.plaintext.txt	354	Apolipoprotein E phenotype arterial disease mortality among older women study osteoporotic fractures
0.31263503.15319409.html.plaintext.txt	355	Genet Epidemiol 199714147 56
0.31263503.15319409.html.plaintext.txt	356	CO2 KlinktypeDOI CrossRefISIMedline
0.30754375.9787187.html.plaintext.txt	0	Apolipoprotein E 4 Allele Genetic Risk Factor Left Ventricular Failure Homozygous Thalassemia
0.30754375.9787187.html.plaintext.txt	1	By Effrosini Economou Petersen Athanassios Aessopos Athina Kladi Panagiota Flevari Fotis Karabatsos Christina Fragodimitri Peter Nicolaidis Helen Vrettou Dimitris Vassilopoulos Markissia Karagiorga Lagana Dimitrios Th
0.30754375.9787187.html.plaintext.txt	2	From Hellenic Red Cross Hospital Athens Eginition University Hospital Athens Laiko University Hospital Athens Onassis Cardiac Surgery Center Piraeus Aghia Sophia Childrens Hospital Athens Mitera Maternity Hospital Athens Institute Child Health Athens Greece
0.30754375.9787187.html.plaintext.txt	3	ABSTRACT Abstract Introduction Methods Results Discussion References
0.30754375.9787187.html.plaintext.txt	4	In homozygous thalassemia organ damage mainly attributed excessive iron deposition formation oxygen free radicals
0.30754375.9787187.html.plaintext.txt	5	Despite appropriate transfusion chelation therapy low ferritin levels patients still develop organ failure heart failure main cause death
0.30754375.9787187.html.plaintext.txt	6	This study designed determine whether decreased antioxidant activity apolipoprotein E APOE 4 allele could represent genetic risk factor development left ventricular failure LVF thalassemia homozygotes
0.30754375.9787187.html.plaintext.txt	7	A total 251 Greek thalassemia homozygotes studied
0.30754375.9787187.html.plaintext.txt	8	Patients divided three groups group A n 151 cardiac impairment group C n 47 LVF 53 patients LV dilatation normal LV systolic function constituted group B
0.30754375.9787187.html.plaintext.txt	9	DNA obtained patients polymerase chain reaction used analyze polymorphism APOE locus
0.30754375.9787187.html.plaintext.txt	10	The APOE allele frequencies compared Greek control sample 216 healthy blood donors
0.30754375.9787187.html.plaintext.txt	11	Patients cardiac impairment APOE 4 allele frequency 7
0.30754375.9787187.html.plaintext.txt	12	9 different population controls 6
0.30754375.9787187.html.plaintext.txt	13	05 patients LVF significantly higher frequency APOE 4 12
0.30754375.9787187.html.plaintext.txt	14	The APOE 4 allele may represent important genetic risk factor development organ damage homozygous thalassemia
0.30754375.9787187.html.plaintext.txt	15	1998 The American Society Hematology
0.30754375.9787187.html.plaintext.txt	16	INTRODUCTION Abstract Introduction Methods Results Discussion References
0.30754375.9787187.html.plaintext.txt	17	THE HEMOGLOBINOPATHIES common monogenic disorders world population first diseases analyzed recombinant DNA technology
0.30754375.9787187.html.plaintext.txt	18	1 3 More known molecular pathology genetic disease possible trace almost diverse pathophysiologic features back primary molecular defects single genes
0.30754375.9787187.html.plaintext.txt	19	4 In monogenic disorders phenotypic variability expected due allelic heterogeneity although siblings genotype show big phenotypic differences
0.30754375.9787187.html.plaintext.txt	20	The molecular basis difference clinical expression yet fully understood
0.30754375.9787187.html.plaintext.txt	21	Homozygous thalassemia characterized severe hemolytic anemia associated chronic tissue damage disease treatment related organ failure premature death
0.30754375.9787187.html.plaintext.txt	22	Heart failure remains main cause death traditionally attributed iron overload regular transfusions increased iron intestinal absorption ineffective erythropoiesis life span patients
0.30754375.9787187.html.plaintext.txt	23	56 During last two decades striking improvement life quality life expectancy observed mainly due proper transfusion effective chelation therapy prevent secondary hemosiderosis
0.30754375.9787187.html.plaintext.txt	24	Regular chelation therapy deferoxamine mesylate naturally occurring trihydroxamic acid produced Streptomyces pilosus increases urinary fecal iron excretion resulting amelioration cardiac dysfunction89 increased survival
0.30754375.9787187.html.plaintext.txt	25	7 Although many patients benefit therapy others continue organ dysfunction die sometimes despite intensive treatment deferoxamine
0.30754375.9787187.html.plaintext.txt	26	10 It thus hypothesized either deferoxamine therapy effective patients reduced defense mechanisms iron overload
0.30754375.9787187.html.plaintext.txt	27	The present study designed test hypothesis whether postulated genetically determined decreased antioxidant iron binding activity patients homozygous thalassemia could represent independent risk factor development heart failure
0.30754375.9787187.html.plaintext.txt	28	Apolipoprotein E apoE plasma protein known functions cholesterol transport metabolism Alzheimers disease
0.30754375.9787187.html.plaintext.txt	29	1112 The APOE gene located chromosome 19 polymorphism exists APOE locus three common alleles designated 2 3 4 corresponding three isoforms apoE protein
0.30754375.9787187.html.plaintext.txt	30	13 It recently shown apoE physiologic levels isoform specific effects protecting rat neuronal cell line oxidative cell death effects correlated apoEs antioxidant activity vitro assays ranked E2 E3 E4
0.30754375.9787187.html.plaintext.txt	31	14 The demonstrated metal binding ability including iron apoE postulated one mechanism accounting antioxidant properties
0.30754375.9787187.html.plaintext.txt	32	14 We hypothesized decreased antioxidant activity apoE4 thalassemia homozygotes might genetic risk factor development left ventricular failure LVF
0.30754375.9787187.html.plaintext.txt	33	We tested hypothesis comparing frequency APOE allele 4 thalassemia major patients divided three groups according cardiac status 4 frequency Greek control sample
0.30754375.9787187.html.plaintext.txt	34	MATERIALS AND METHODS Abstract Introduction Methods Results Discussion References Subjects
0.30754375.9787187.html.plaintext.txt	35	The subjects 251 thalassemia major patients Greek origin 117 men 134 women followed systematically three major thalassemia treatment units Athens area belonging public health system
0.30754375.9787187.html.plaintext.txt	36	Transfusion therapy started patients age 5 years
0.30754375.9787187.html.plaintext.txt	37	Each patient receiving blood transfusions every 15 25 days maintain hemoglobin level 9 gdL years follow
0.30754375.9787187.html.plaintext.txt	38	All patients receiving chelation therapy subcutaneous deferoxamine
0.30754375.9787187.html.plaintext.txt	39	The therapy initiated patient serum ferritin level reached 2000 ngmL
0.30754375.9787187.html.plaintext.txt	40	To evaluate transfusion therapy hemosiderosis level obtained mean pretransfusion hemoglobin level mean serum ferritin level patient last 2 5 years follow respectively
0.30754375.9787187.html.plaintext.txt	41	Serum ferritin measured two times per year patient enzyme linked immunosorbent assay ELISA method Abbott Chicago IL values rounded nearest 10
0.30754375.9787187.html.plaintext.txt	42	Clinical laboratory cardiac evaluation included medical history clinical examination electrocardiographic ECG well echocardiographic studies
0.30754375.9787187.html.plaintext.txt	43	The echocardiographic examination performed follows two dimensional M mode echocardiograms obtained using instruments 3 MHZ transducer
0.30754375.9787187.html.plaintext.txt	44	A two dimensional study first performed identify overall cardiac anatomy motion
0.30754375.9787187.html.plaintext.txt	45	Long axis parasternal short axis views midventricular level used derive following M mode measurements left ventricular end systolic end diastolic dimensions left atrial right ventricular cavity dimensions thickness interventricular septum posterior left ventricular wall according recommendations American Society Echocardiography
0.30754375.9787187.html.plaintext.txt	46	15 Four two chamber apical views used estimate ventricular systolic diastolic volumes calculated using discs method
0.30754375.9787187.html.plaintext.txt	47	16 Left ventricular ejection fraction LVEF calculated end diastolic volume minus end systolic volume divided end diastolic volume multiplied 100
0.30754375.9787187.html.plaintext.txt	48	The patients divided three groups according severity heart disease based clinical evaluation echocardiographic findings
0.30754375.9787187.html.plaintext.txt	49	Group A patients symptoms signs heart failure echocardiographic study within normal limits
0.30754375.9787187.html.plaintext.txt	50	Group C patients symptoms signs LVF concomitant echocardiographic findings
0.30754375.9787187.html.plaintext.txt	51	These patients exhibited dyspnea exertion New York Heart Association NYHA functional class I IV fulfilled least two major Framingham criteria heart failure diagnosis
0.30754375.9787187.html.plaintext.txt	52	Finally patients group B asymptomatic exhibited LV dilatation LV end diastolic diameter index LVEDDI higher 30 mmm2 without left ventricular systolic dysfunction LV fractional shortening FS higher 28 assessed echocardiographically
0.30754375.9787187.html.plaintext.txt	53	Patients group receive treatment
0.30754375.9787187.html.plaintext.txt	54	Another type heart failure thalassemia major associated right ventricular dilatation
0.30754375.9787187.html.plaintext.txt	55	Patients kind excluded study right ventricular failure thalassemia major due different pathophysiologic reasons
0.30754375.9787187.html.plaintext.txt	56	Genomic DNA extracted EDTA blood samples salting procedure
0.30754375.9787187.html.plaintext.txt	57	19 Genotyping polymorphic APOE alleles done polymerase chain reaction amplification genomic DNA digestion Hha I restriction enzyme agarose gel electrophoresis described previously
0.30754375.9787187.html.plaintext.txt	58	2021 The control sample data APOE genotype available consisted random sample 216 voluntary healthy Greek blood donors
0.30754375.9787187.html.plaintext.txt	59	22 The blood donors 146 men 70 women mean age 35
0.30754375.9787187.html.plaintext.txt	60	6 years range 19 64 years
0.30754375.9787187.html.plaintext.txt	61	We used analysis variance ANOVA multiple groups assess differences regarding echocardiographic measurements three patient groups 2 test compare 4 allele frequency different patient groups population controls
0.30754375.9787187.html.plaintext.txt	62	RESULTS Abstract Introduction Methods Results Discussion References
0.30754375.9787187.html.plaintext.txt	63	From 251 patients studied 151 belonged group A 53 group B 47 group C
0.30754375.9787187.html.plaintext.txt	64	Three cases excluded study presented clinical picture congestive heart failure echocardiographic findings profound right ventricular dilatation good LV function pulmonary hypertension Doppler study
0.30754375.9787187.html.plaintext.txt	65	Hematologic hemosiderosis parameters patients shown Table 1
0.30754375.9787187.html.plaintext.txt	66	No statistically significant differences found hemoglobin ferritin levels patient groups
0.30754375.9787187.html.plaintext.txt	67	Hematologic Characteristics Patients With Thalassemia Major Stratified Cardiac Status
0.30754375.9787187.html.plaintext.txt	68	The cardiologic characteristics three patient groups depicted Table 2
0.30754375.9787187.html.plaintext.txt	69	Twenty eight patients group C severe cardiac failure NYHA class III IV 19 class I II
0.30754375.9787187.html.plaintext.txt	70	All patients groups B C LV dilatation LVEDDI higher 30 mmm2
0.30754375.9787187.html.plaintext.txt	71	Groups A B good LV function significant difference fractional shortening ejection fraction group C Table 2
0.30754375.9787187.html.plaintext.txt	72	All 47 patients group C receiving treatment angiotensin converting enzyme ACE inhibitors diuretics plus minus digitalis
0.30754375.9787187.html.plaintext.txt	73	The 53 patients group B 151 patients group A cardiac failure echocardiographically normal LV function
0.30754375.9787187.html.plaintext.txt	74	Clinical Echocardiographic Characteristics Patients With Thalassemia Major
0.30754375.9787187.html.plaintext.txt	75	Table 3 gives APOE allele frequencies three patient groups well controls
0.30754375.9787187.html.plaintext.txt	76	The APOE 3 allele highest frequency three patient groups 2 allele frequency 5
0.30754375.9787187.html.plaintext.txt	77	4 group C show statistical difference control group
0.30754375.9787187.html.plaintext.txt	78	The APOE 4 allele frequency thalassemia homozygotes without cardiac impairment 7
0.30754375.9787187.html.plaintext.txt	79	9 different frequency population controls 6
0.30754375.9787187.html.plaintext.txt	80	The 4 frequency patients heart failure 12
0.30754375.9787187.html.plaintext.txt	81	8 significantly higher controls 2 4
0.30754375.9787187.html.plaintext.txt	82	32 4 frequency group B patients 12
0.30754375.9787187.html.plaintext.txt	83	Taking patient groups B C together 4 frequency 12
0.30754375.9787187.html.plaintext.txt	84	5 significantly higher controls 2 6
0.30754375.9787187.html.plaintext.txt	85	All thalassemia homozygotes irrespective cardiac diagnosis 4 frequency 9
0.30754375.9787187.html.plaintext.txt	86	8 different population healthy blood donors 2 3
0.30754375.9787187.html.plaintext.txt	87	Four patients homozygous 4 allele three belonged group C one group B
0.30754375.9787187.html.plaintext.txt	88	APOE Allele Frequencies Patients With Thalassemia Major Controls Stratified Cardiac Status
0.30754375.9787187.html.plaintext.txt	89	DISCUSSION Abstract Introduction Methods Results Discussion References
0.30754375.9787187.html.plaintext.txt	90	The severity iron toxicity thalassemia major seems related magnitude body iron burden
0.30754375.9787187.html.plaintext.txt	91	2324 The exact mechanism iron overload toxicity uncertain many years
0.30754375.9787187.html.plaintext.txt	92	Via iron driven Fenton Haber Weiss reactions nontransferrin plasma iron bivalent trivalent form high toxicity formation hydroxyl radicals OH
0.30754375.9787187.html.plaintext.txt	93	25 This leads peroxidative damage membrane lipids proteins
0.30754375.9787187.html.plaintext.txt	94	Imbalance production oxygen free radicals antioxidant defense mechanisms result oxidative stress human disease
0.30754375.9787187.html.plaintext.txt	95	26 In heart imbalance free radicals antioxidant mechanisms manifested impaired function mitochondrial inner membrane respiratory chain resulting abnormal energy metabolism expressed clinically fatal cardiomyopathy
0.30754375.9787187.html.plaintext.txt	96	Apart iron overload recently shown group myocarditis appears involved pathogenesis LVF certain number patients homozygous thalassemia
0.30754375.9787187.html.plaintext.txt	97	27 As shown animal models oxygen free radicals may also contribute pathogenesis infectious myocarditis
0.30754375.9787187.html.plaintext.txt	98	In present study categorized patients three groups according severity heart disease
0.30754375.9787187.html.plaintext.txt	99	The normal cases group A severely affected cases group C clear clinical echocardiographic characteristics easily distinguished
0.30754375.9787187.html.plaintext.txt	100	Patients group B characterized LV dilatation good LV function
0.30754375.9787187.html.plaintext.txt	101	In cases LV left atrial LA dilatation could possibly represent first step LV dysfunction without overt LV decreased contractility compensatory mechanism due anemia
0.30754375.9787187.html.plaintext.txt	102	Some patients eventually develop LVF
0.30754375.9787187.html.plaintext.txt	103	The results functional polymorphism APOE locus study suggest 4 allele may genetic risk factor development LVF organ damage homozygous thalassemia
0.30754375.9787187.html.plaintext.txt	104	It represents first demonstration genetic factor unlinked globin gene cluster contributing clinical manifestations disease
0.30754375.9787187.html.plaintext.txt	105	The 4 allele could represent predictive marker development LVF patients thalassemia major LV dilatation patient group B suggesting closer follow patients
0.30754375.9787187.html.plaintext.txt	106	As APOE 4 frequency found 12
0.30754375.9787187.html.plaintext.txt	107	8 patients homozygous thalassemia LVF obvious genetic environmental factors instance number transfusions iron overload chelation therapy viral myocardial inflammation play role development organ damage
0.30754375.9787187.html.plaintext.txt	108	The fact patients groups B C shown Table 1 either higher ferritin levels transfused inadequately without cardiac impairment supports role APOE 4 allele genetic risk factor LVF development
0.30754375.9787187.html.plaintext.txt	109	Furthermore patients group A 4 allele could still develop LVF
0.30754375.9787187.html.plaintext.txt	110	Additional evidence relationship 4 allele heart disease comes analysis patients homozygous 4 allele three LVF one LV dilatation numbers category small
0.30754375.9787187.html.plaintext.txt	111	The increase 4 allele frequency among patients cardiac disease comes reduction 3 rather 2 allele frequency 2 allele frequency already low Greek population22 factors may influence level allele
0.30754375.9787187.html.plaintext.txt	112	As APOE 4 allele found patients advanced age cardiac impairment presence 4 allele guarantee development LVF thalassemia
0.30754375.9787187.html.plaintext.txt	113	In addition 85 patients LVF carry 4 allele neither necessary prerequisite development LVF
0.30754375.9787187.html.plaintext.txt	114	This equivalent association APOE 4 Alzheimers disease association confirmed almost 100 studies around world
0.30754375.9787187.html.plaintext.txt	115	30 A consensus statement APOE genotyping Alzheimers disease concluded APOE genotyping used adjunct diagnostic tests prospective investigations dementia function APOE genotype needed31 something similar might apply thalassemia
0.30754375.9787187.html.plaintext.txt	116	Allelic variation APOE locus studied many populations
0.30754375.9787187.html.plaintext.txt	117	Significant differences observed Caucasian Chinese Japanese black races
0.30754375.9787187.html.plaintext.txt	118	Also among Caucasian populations significant variation allele frequencies
0.30754375.9787187.html.plaintext.txt	119	32 Average allele frequencies Caucasians show 4 allele frequency 15
0.30754375.9787187.html.plaintext.txt	120	The low 4 frequency Greek population22 agreement gradient found frequency allele Europe supported similar low frequency 7
0.30754375.9787187.html.plaintext.txt	121	33 Our finding association APOE 4 allele LVF Greek thalassemia homozygotes needs confirmation populations using appropriate population controls
0.30754375.9787187.html.plaintext.txt	122	The well known isoform specific influence apoE plasma cholesterol level atherosclerosis32 cannot explain association found APOE allele 4 LVF thalassemia homozygotes atherosclerosis general feature pathophysiology disorder
0.30754375.9787187.html.plaintext.txt	123	It recognized severity monogenic disorder may modified second locus depending genetic background
0.30754375.9787187.html.plaintext.txt	124	34 Any genes involved pathogenic pathway represent candidate modifier genes
0.30754375.9787187.html.plaintext.txt	125	35 The boundaries monogenic polygenic disorders might always clear cut previously thought34 genes gene interactions become known progress Human Genome Project
0.30754375.9787187.html.plaintext.txt	126	The finding increased frequency APOE 4 allele thalassemia homozygotes LVF provides additional evidence theory oxygen free radicals contributing organ damage due recently demonstrated antioxidant iron binding activity apoE
0.30754375.9787187.html.plaintext.txt	127	14 This suggests several genetic loci could potential relevance oxidative damage organs thalassemia
0.30754375.9787187.html.plaintext.txt	128	Such loci include genes modulating genesis oxygen free radicals ie cytochrome C oxidase genes scavenger enzymes superoxide dismutases catalase genes regulating mitochondrial DNA replication structural genes membrane lipoproteins genes involved DNA repair mechanisms
0.30754375.9787187.html.plaintext.txt	129	36 It noteworthy mutant mice lacking Mn superoxide dismutase enzyme suffer neonatal lethality due dilated cardiomyopathy
0.30754375.9787187.html.plaintext.txt	130	37 Other functional polymorphisms genes could examined association organ failure thalassemia
0.30754375.9787187.html.plaintext.txt	131	It also believed genetic susceptibility majority common diseases associated relatively common alleles one several loci
0.30754375.9787187.html.plaintext.txt	132	Submitted September 29 1997 accepted June 30 1998
0.30754375.9787187.html.plaintext.txt	133	Address reprint requests Effrosini Economou Petersen MD Hellenic Red Cross Hospital 4 Alkibiadou GR 10439 Athens Greece
0.30754375.9787187.html.plaintext.txt	134	The publication costs article defrayed part page charge payment
0.30754375.9787187.html.plaintext.txt	135	This article must therefore hereby marked advertisement accordance 18 U
0.30754375.9787187.html.plaintext.txt	136	section 1734 solely indicate fact
0.30754375.9787187.html.plaintext.txt	137	REFERENCES Abstract Introduction Methods Results Discussion References 1
0.30754375.9787187.html.plaintext.txt	138	Kan YW Dozy AM Polymorphism DNA sequence adjacent human globin structural gene Relationship sickle mutation
0.30754375.9787187.html.plaintext.txt	139	Proc Natl Acad Sci USA 755631 1978Abstract 2
0.30754375.9787187.html.plaintext.txt	140	Boehm CD Antonarakis SE Phillips JA Stetten G Kazazian HH Jr Prenatal diagnosis using DNA polymorphisms
0.30754375.9787187.html.plaintext.txt	141	Report 95 pregnancies risk sickle cell disease thalassemia
0.30754375.9787187.html.plaintext.txt	142	N Engl J Med 3081054 1983Abstract 3
0.30754375.9787187.html.plaintext.txt	143	Pirastu M Kan YW Cao A Conner BJ Teplitz RL Wallace RB Prenatal diagnosis thalassemia
0.30754375.9787187.html.plaintext.txt	144	Detection single nucleotide mutation DNA
0.30754375.9787187.html.plaintext.txt	145	N Engl J Med 309284 1983Abstract 4
0.30754375.9787187.html.plaintext.txt	146	Wood WG The hemoglobinopathies Scriver CR Beaudet AL Sly WS Valle D eds The Metabolic Molecular Bases Inherited Disease New York NY McGraw Hill 1995 p 3417 5
0.30754375.9787187.html.plaintext.txt	147	Sapoznikov D Lewis N Rachmilewitz EA Gotsman MS Lewis BS Left ventricular filling emptying patterns anemia due beta thalassemia A computer assisted echocardiographic study
0.30754375.9787187.html.plaintext.txt	148	Cardiology 69276 1982Medline Order article via Infotrieve 6
0.30754375.9787187.html.plaintext.txt	149	Lau KC Li AMC Hui PW Yeung CY Left ventricular function thalassemia major
0.30754375.9787187.html.plaintext.txt	150	Arch Dis Child 641046 1989Abstract 7
0.30754375.9787187.html.plaintext.txt	151	Olivieri NF Nathan DG MacMillan JH Wayne AS Liu PP McGee A Martin M Koren G Cohen AR Survival medically treated patients homozygous thalassemia
0.30754375.9787187.html.plaintext.txt	152	N Engl J Med 331574 1994AbstractFree Full Text 8
0.30754375.9787187.html.plaintext.txt	153	Freeman AP Giles RW Berdoukas VA Walsh WF Choy D Murray PC Early left ventricular dysfunction chelation therapy thalassemia major
0.30754375.9787187.html.plaintext.txt	154	Ann Intern Med 99450 1983Medline Order article via Infotrieve 9
0.30754375.9787187.html.plaintext.txt	155	Wolfe L Olivieri N Sallan D Colan S Rose V Propper R Freedman MH Nathan DG Prevention cardiac disease subcutaneous deferoxamine patients thalassemia major
0.30754375.9787187.html.plaintext.txt	156	N Engl J Med 3121600 1985Abstract 10
0.30754375.9787187.html.plaintext.txt	157	Marcus RE Davies SC Bantock HM Underwood SR Walton S Huehns ER Desferrioxamine improve cardiac function iron overloaded patients thalassaemia major
0.30754375.9787187.html.plaintext.txt	158	Lancet 1392 1984Medline Order article via Infotrieve 11
0.30754375.9787187.html.plaintext.txt	159	Mahley RW Apolipoprotein E Cholesterol transport protein expanding role cell biology
0.30754375.9787187.html.plaintext.txt	160	Science 240622 1988Medline Order article via Infotrieve 12
0.30754375.9787187.html.plaintext.txt	161	Strittmatter WJ Saunders AM Schmechel D Pericak Vance M Enghild J Salvesen GS Roses AD Apolipoprotein E High avidity binding amyloid increased frequency type 4 allele late onset familial Alzheimer disease
0.30754375.9787187.html.plaintext.txt	162	Proc Natl Acad Sci USA 901977 1993Abstract 13
0.30754375.9787187.html.plaintext.txt	163	Zannis VI Breslow JL Utermann G Mahley RW Weisgraber KH Havel RJ Goldstein JL Brown MS Schonfeld G Hazzard WR Blum C Proposed nomenclature apoE isoproteins apoE genotypes phenotypes
0.30754375.9787187.html.plaintext.txt	164	J Lipid Res 23911 1982Medline Order article via Infotrieve 14
0.30754375.9787187.html.plaintext.txt	165	Miyata M Smith JD Apolipoprotein E allele specific antioxidant activity effects cytotoxicity oxidative insults amyloid peptides
0.30754375.9787187.html.plaintext.txt	166	Nat Genet 1455 1996Medline Order article via Infotrieve 15
0.30754375.9787187.html.plaintext.txt	167	Sahn DJ De Maria A Kisslo J Weyman A The committee M mode standardization American Society Echocardiography Results survey echocardiographic measurements
0.30754375.9787187.html.plaintext.txt	168	Circulation 581072 1978Abstract 16
0.30754375.9787187.html.plaintext.txt	169	Schiller NB Shah PM Crawford M DeMaria A Devereux R Fligenbaum H Gutgesell H Reicher N Sahn D Schnittger I Silverman NH Tajih AJ Recommendations quantitation left ventricle two dimensional echocardiography American Society Echocardiography Committee Standards Subcommittee Quantitation Two Dimensional Echocardiography
0.30754375.9787187.html.plaintext.txt	170	J Am Soc Echocardiogr 2358 1989Medline Order article via Infotrieve 17
0.30754375.9787187.html.plaintext.txt	171	Crisaru D Rachmilewitz EA Mosseri M Gotsman M Latair JS Okon E Goldfard A Hasin Y Cardiopulmonary assessment thalassemia major
0.30754375.9787187.html.plaintext.txt	172	Chest 981138 1990Abstract 18
0.30754375.9787187.html.plaintext.txt	173	Aessopos A Stamatelos G Skoumas V Vassilopoulos G Mantzourani M Loukopoulos D Pulmonary hypertension right ventricle failure patients beta thalassemia intermedia
0.30754375.9787187.html.plaintext.txt	174	Chest 10750 1995AbstractFree Full Text 19
0.30754375.9787187.html.plaintext.txt	175	Miller SA Dykes DD Polesky HF A simple salting procedure extracting DNA human nucleated cells
0.30754375.9787187.html.plaintext.txt	176	Nucleic Acids Res 161215 1988Medline Order article via Infotrieve 20
0.30754375.9787187.html.plaintext.txt	177	Wenham PR Price WH Blundell G Apolipoprotein E genotyping one stage PCR
0.30754375.9787187.html.plaintext.txt	178	Lancet 3371158 1991Medline Order article via Infotrieve 21
0.30754375.9787187.html.plaintext.txt	179	Avramopoulos D Mikkelsen M Vassilopoulos D Grigoriadou M Petersen MB Apolipoprotein E allele distribution parents Downs syndrome children
0.30754375.9787187.html.plaintext.txt	180	Lancet 347862 1996Medline Order article via Infotrieve 22
0.30754375.9787187.html.plaintext.txt	181	Sklavounou E Economou Petersen E Karadima G Panas M Avramopoulos D Varsou A Vassilopoulos D Petersen MB Apolipoprotein E polymorphism Greek population
0.30754375.9787187.html.plaintext.txt	182	Clin Genet 52216 1997Medline Order article via Infotrieve 23
0.30754375.9787187.html.plaintext.txt	183	Leon MB Borer JS Bacharach SL Green MV Benz EJ Jr Griffith P Nienhuis AW Detection early cardiac dysfunction patients severe beta thalassemia chronic iron overload
0.30754375.9787187.html.plaintext.txt	184	N Engl J Med 3011143 1979Abstract 24
0.30754375.9787187.html.plaintext.txt	185	Brittenham GM Griffith PM Nienhuis AW McLaren CE Young NS Tucker EE Allen CJ Farrell DE Harris JW Efficacy deferoxamine preventing complications iron overload patients thalassemia major
0.30754375.9787187.html.plaintext.txt	186	N Engl J Med 331567 1994AbstractFree Full Text 25
0.30754375.9787187.html.plaintext.txt	187	Halliwell B The role oxygen radicals human disease particular reference vascular system
0.30754375.9787187.html.plaintext.txt	188	Haemostasis 23118 1993Medline Order article via Infotrievesuppl 1 26
0.30754375.9787187.html.plaintext.txt	189	Kukreja RC Hess ML The oxygen free radical system From equations membrane protein interactions cardiovascular injury protection
0.30754375.9787187.html.plaintext.txt	190	Cardiovasc Res 26641 1992Medline Order article via Infotrieve 27
0.30754375.9787187.html.plaintext.txt	191	Kremastinos DTh Tiniakos G Theodorakis GN Katritsis DG Toutouzas PK Myocarditis thalassemia major A cause heart failure
0.30754375.9787187.html.plaintext.txt	192	Circulation 9166 1995AbstractFree Full Text 28
0.30754375.9787187.html.plaintext.txt	193	Hiraoka Y Kishimoto C Takada H Kurokawa M Ochiai H Shiraki K Sasayama S Role oxygen derived free radicals pathogenesis coxsackievirus B3 myocarditis mice
0.30754375.9787187.html.plaintext.txt	194	Cardiovasc Res 27957 1993Medline Order article via Infotrieve 29
0.30754375.9787187.html.plaintext.txt	195	Suzuki H Matsumori A Matoba Y Kyu BS Tanaka A Fujita J Sasayama S Enhanced expression superoxide dismutase messenger RNA viral myocarditis
0.30754375.9787187.html.plaintext.txt	196	An SH dependent reduction expression myocardial injury
0.30754375.9787187.html.plaintext.txt	197	J Clin Invest 912727 1993Medline Order article via Infotrieve 30
0.30754375.9787187.html.plaintext.txt	198	Roses AD Apolipoprotein E genotyping differential diagnosis prediction Alzheimers disease
0.30754375.9787187.html.plaintext.txt	199	Ann Neurol 386 1995Medline Order article via Infotrieve 31
0.30754375.9787187.html.plaintext.txt	200	National Institute AgingAlzheimers Association Working Group Apolipoprotein E genotyping Alzheimers disease
0.30754375.9787187.html.plaintext.txt	201	Lancet 3471091 1996Medline Order article via Infotrieve 32
0.30754375.9787187.html.plaintext.txt	202	Davignon J Gregg RE Sing CF Apolipoprotein E polymorphism atherosclerosis
0.30754375.9787187.html.plaintext.txt	203	Arteriosclerosis 81 1988Abstract 33
0.30754375.9787187.html.plaintext.txt	204	Cariolou MA Kakkofitou A Manoli P Christou S Karagrigoriou A Middleton L Underexpression apolipoprotein E2 E4 alleles Greek Cypriot population Cyprus
0.30754375.9787187.html.plaintext.txt	205	Genet Epidemiol 12489 1995Medline Order article via Infotrieve 34
0.30754375.9787187.html.plaintext.txt	206	Estivill X Complexity monogenic disease
0.30754375.9787187.html.plaintext.txt	207	Nat Genet 12348 1996Medline Order article via Infotrieve 35
0.30754375.9787187.html.plaintext.txt	208	Houlston RS Tomlinson IPM Modifier genes humans Strategies identification
0.30754375.9787187.html.plaintext.txt	209	Eur J Hum Genet 680 1998Medline Order article via Infotrieve 36
0.30754375.9787187.html.plaintext.txt	210	Martin GM Austad SN Johnson TE Genetic analysis ageing Role oxidative damage environmental stresses
0.30754375.9787187.html.plaintext.txt	211	Nat Genet 1325 1996Medline Order article via Infotrieve 37
0.30754375.9787187.html.plaintext.txt	212	Li Y Huang T T Carlson EJ Melov S Ursell PC Olson JL Noble LJ Yoshimura MP Berger C Chan PH Wallace DC Epstein CJ Dilated cardiomyopathy neonatal lethality mutant mice lacking manganese superoxide dismutase
0.30754375.9787187.html.plaintext.txt	213	Nat Genet 11376 1995Medline Order article via Infotrieve 38
0.30754375.9787187.html.plaintext.txt	214	Brown PO Hartwell L Genomics human diseasevariations variation
0.30754375.9787187.html.plaintext.txt	215	Nat Genet 1891 1998Medline Order article via Infotrieve 1998 American Society Hematology
